,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL,Cancer Type
0,1,NCT00632047,early detection of breast cancer and cervical cancer in women in india,,Unknown status,No Results Available,breast cancer|cervical cancer,other: active surveillance|other: educational intervention|procedure: examination|procedure: long-term screening,"effectiveness of well planned health education programs and low-cost screening methods (e.g., clinical breast exam and visual inspection of the cervix) in reducing the incidence of and mortality due to breast and cervical cancer",tata memorial hospital|national cancer institute (nci),Female,35 Years to 64 Years   (Adult),Phase 2,151538.0,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Screening,CDR0000586791|TATA-1900215717A1,May 1998,December 2015,,"March 10, 2008",,"August 26, 2013","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00632047,breast
1,2,NCT04075058,hypofractionated radiation therapy in patients with breast cancer,HRBC,Completed,No Results Available,breast cancer,radiation: hypofractionated radiation therapy,"local recurrence|acute skin toxicity|cosmetic assessment|quality of life|disease free survival|overall survival|arm edema|late effects- pain, shoulder stiffness|late effects- brachial plexopathy|late effects- lung, cardiac",postgraduate institute of medical education and research,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1070.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HRBC,June 2015,December 2020,December 2020,"August 30, 2019",,"June 23, 2021","['dr budhi singh yadav, chandigarh , india']",,https://ClinicalTrials.gov/show/NCT04075058,breast
2,3,NCT02460744,2-weeks of adjuvant radiotherapy in patients with breast cancer,,Completed,No Results Available,breast cancer,radiation: hypofractionation,acute skin and subcutaneous toxicity assessed using a rtog grading system|cosmetic score analysis using harvard/nsabp/rtog breast cosmesis grading scale,postgraduate institute of medical education and research,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,50.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BHRT,June 2013,October 2014,October 2014,"June 2, 2015",,"June 2, 2015","['dr budhi singh yadav, chandigarh , india']",,https://ClinicalTrials.gov/show/NCT02460744,breast
3,4,NCT03997110,palliative radiation for advanced cervical cancer,RAPPAL,Recruiting,No Results Available,cervical cancer,radiation: short course palliative radiation.|radiation: long course palliative treatment.,"pain relief (numerical pain rating scale will be used)|presence or absence of vaginal bleeding and/or discharge and relief in vaginal bleeding (as reported by the patient)|change in use of analgesics (who ladder)|compliance to therapy|quality of life using eortc qlqc30 questionnaires|quality of life using eortc qlqc-15 pall questionnaires|quality of life using cx-24 questionnaires|acute gastrointestinal and genitourinary toxicities|late gastrointestinal and genitourinary toxicities|overall survival, defined as time from randomization until death due to any cause.|patterns of terminal event (due to local relapse or distant metastasis)",tata memorial hospital|tata memorial centre,Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,230.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH IRB 3157,"June 19, 2020","August 1, 2024","February 1, 2025","June 25, 2019",,"May 2, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03997110,cervic
4,5,NCT00808379,concurrent chemo-radiotherapy versus radiotherapy with boost in locally advanced unresectable rectal cancers,,Unknown status,No Results Available,rectal cancer,drug: chemoradiation|radiation: additional radiation boost to the primary tumor volume,comparison of resectability rate of in the two groups at 6-8 weeks following radiotherapy.|side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.|comparison of pathological downstaging between the two groups who undergo surgery.,tata memorial hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,260,May 2006,February 2009,July 2009,"December 15, 2008",,"December 15, 2008","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00808379,
5,6,NCT02783235,cervical cancer screening : video based tutorials for anms/ashas/phws,,Unknown status,No Results Available,cervical cancer,other: cervical cancer screening,improvement in the post training knowledge about cancer|satisfaction to the video based tutorials,tata memorial hospital,Female,18 Years to 45 Years   (Adult),Not Applicable,50.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,TMH1605 Video Based Tutorials,"January 29, 2018",September 2018,September 2018,"May 26, 2016",,"August 6, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02783235,cervic
6,7,NCT04688086,a prospective study to evaluate clinical performance of thermalytix in detecting breast cancers,,Completed,No Results Available,breast cancer|early detection of cancer,diagnostic test: thermalytix,"sensitivity, specificity, positive predictive value and negative predictive value of thermalytix|sensitivity and specificity of thermalytix for different patient characteristics",niramai health analytix private limited|max healthcare insititute limited,Female,"18 Years to 80 Years   (Adult, Older Adult)",,459.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NIR-THERMA-02,"December 15, 2018","January 6, 2020","January 30, 2020","December 29, 2020",,"September 28, 2021","['max healthcare insititute limited, new delhi, india']",,https://ClinicalTrials.gov/show/NCT04688086,breast
7,8,NCT01276730,advanced cervical cancer trial in india,,Completed,No Results Available,cervical cancer,"drug: interferon, retinoic acid and radiation|drug: cisplatin and radiation",survival|response rate|overall toxicity|determine immune response to human papillomavirus hpv,university of louisville|james graham brown cancer center,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,209.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,464.05,October 2007,August 2015,August 2015,"January 13, 2011",,"December 29, 2017","['chittaranjan national cancer institute, kolkata, india']",,https://ClinicalTrials.gov/show/NCT01276730,cervic
8,9,NCT03110497,single application brachytherapy in cervical cancer,,Unknown status,No Results Available,cervical cancer,radiation: single application multi-fraction brachytherapy,number of participants achieving specified dosimetric constraints|number of participants with adverse events as assessed by ctcae v 4.0|local control rate|percentage inter-fraction dose variation,tata memorial hospital,Female,"Child, Adult, Older Adult",Not Applicable,40.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH-1759|REF/2017/03/013733,"September 17, 2017","April 17, 2019","April 17, 2020","April 12, 2017",,"November 7, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03110497,cervic
9,10,NCT00447746,a comparison between d1 and d2 lymphadenectomy in gastric cancer : a prospective randomized controlled trial,,Unknown status,No Results Available,gastric cancer,procedure: d1 or d2 lymphadenectomy for gastric cancer patients,5 year overall survival|: 5 year disease free survival|: 5 year local recurrence|: postoperative morbidity and mortality rates,tata memorial hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH 262,March 2007,,March 2014,"March 15, 2007",,"March 15, 2007","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00447746,gastric
10,11,NCT03788213,one week versus three week in adjuvant radiotherapy in breast cancer,HYPORTAdjuvant,Recruiting,No Results Available,breast cancer female,radiation: 3 week rt|radiation: 1 week rt,locoregional recurrence rate (lrr)|overall survival (os )|invasive disease free survival ( idfs )|adverse event ( ae )|quality of life ( qol ),"tata medical center|christian medical college, vellore, india|sanjay gandhi postgraduate institute of medical sciences",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,2100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018/TMC/133/IRB/31,"March 26, 2019","March 26, 2029","March 26, 2029","December 27, 2018",,"December 17, 2021","['sanjoy chatterjee, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03788213,breast
11,12,NCT04588909,outcomes of elective colorectal cancer surgery during covid 19 pandemic: implications for cancer care policy,,"Active, not recruiting",No Results Available,colo-rectal cancer,procedure: colorectal resections,early post operative mortality|early post operative complications|incidence of sars cov2 infectivity among health care providers providing direct care to involved patients|rate of hospital acquired sars cov 2 infection among operated patients.,sheri kashmir institute of medical sciences,All,"Child, Adult, Older Adult",,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,73/2020 (Supl 2),"March 23, 2020","September 22, 2020","October 22, 2020","October 19, 2020",,"October 19, 2020","['sher i kashmir institute of medical sciences, srinagar, j&k, india']",,https://ClinicalTrials.gov/show/NCT04588909,
12,13,NCT05258747,"a crossover bioequivalence study of olaparib tablets, 150 mg (lek pharmaceuticals d.d.) and lynparza® (olaparib) tablets 150 mg (astrazeneca pharmaceuticals lp), in patients with brca mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer",,Recruiting,No Results Available,ovarian cancer|breast cancer,"drug: olaparib tablets, 150 mg|drug: lynparza® (olaparib) tablets 150 mg",maximum plasma concentration during the dosing interval at steady state (cmaxss)|area under the plasma concentration versus time curve for one dosing interval at steady state (auc(0-t)ss)|number of adverse events and serious adverse events,sandoz,Female,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,70.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,21-VIN-0166/SAN-0647,"April 7, 2022","February 15, 2023","February 15, 2023","February 28, 2022",,"April 19, 2022","['sandoz investigative site, vijayawada, andhra pradesh, india']",,https://ClinicalTrials.gov/show/NCT05258747,breast ovari
13,14,NCT03909620,utility of ldct in lung cancer screening in a tb endemic region,,Completed,No Results Available,lung cancer,diagnostic test: low-dose computed tomography of chest,positivity rate with ldct screening|rate of detection of lung cancer|false positive rate|proportion of patients requiring additional procedures (imaging/invasive procedures)|proportion of patients developing complications due to additional procedures|change in the 6-item spielberger state-trait anxiety inventory (stai-6) questionnaire score|cost in indian rupees to detect one case of lung cancer by ldct screening|proportion of patients who quit/re-initiated smoking after inclusion in study,postgraduate institute of medical education and research,All,"50 Years to 74 Years   (Adult, Older Adult)",Not Applicable,253.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,NK/5292/DM/760,"May 1, 2019","March 31, 2020","December 31, 2021","April 10, 2019",,"March 29, 2022","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT03909620,
14,15,NCT01769950,choline-pet for evaluating the incidence of nodal metastases among newly diagnosed patients of prostate cancer,ChoPEN,Unknown status,No Results Available,prostate cancer,other: choline-pet,detection of choline-pet detected nodal metastases|comparison of choline-pet and ct for the detection of nodal metastatic disease|comparison of choline-pet and mri for the detection of nodal metastatic disease,bangalore institute of oncology,Male,"Child, Adult, Older Adult",Not Applicable,120.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Choline-Prostate-1,January 2013,January 2014,February 2014,"January 17, 2013",,"January 17, 2013","['healthcare global- bangalore institute of oncology, bengaluru, karnataka, india']",,https://ClinicalTrials.gov/show/NCT01769950,prostat
15,16,NCT03519165,restrictive or individualized goal-directed fluid replacement strategy in ovarian cancer cytoreductive surgery,RIGoROCS,Completed,No Results Available,ovarian cancer,device: ev1000(flotrac system 4.0),postoperative length of stay (los) in hospital in days|cost of treatment|post operative morbidity survey (poms survey)|30 day morbidity and mortality,tata medical center,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,145.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",EC/TMC/56/15,June 2016,June 2019,September 2019,"May 8, 2018",,"January 31, 2020","['tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03519165,ovari
16,17,NCT00128362,sentinel node biopsy and axillary sampling in operable breast cancer,,Terminated,No Results Available,cancer of the breast,procedure: radio-guided sentinel node biopsy|procedure: axillary sampling,comparison of methodologies in predicting status of axillary lymph nodes|number of lymph nodes identified by sentinel node biopsy and axillary sampling|number of times the sentinel node is found within the sampled nodes|false negative rate by each method|negative predictive value for each method,tata memorial hospital|indian council of medical research,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,478.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,TMH/115/2003|No.5/13/66/2003-NCD-III,September 2005,December 2011,,"August 9, 2005",,"June 24, 2014","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00128362,breast
17,18,NCT01133067,telephonic contact and subsequent physical follow up treated lung cancer patients,TELE001,Completed,Has Results,lung cancer,,concurrence between the telephonic interview and the physician assessment|cost analysis,tata memorial hospital,All,"18 Years to 90 Years   (Adult, Older Adult)",,200.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PROJECT NO 754,July 2010,July 2016,July 2016,"May 28, 2010","August 7, 2018","August 7, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01133067,
18,19,NCT03005743,image based brachytherapy in locally advanced cervical cancers - a randomized controlled trial,COMBAT-Cx,Recruiting,No Results Available,cervical cancer,radiation: magnetic resonance image based brachytherapy|radiation: conventional radiograph based brachytherapy,local control|late toxicities|pelvic control rates|distant failure rates|progression free & cause specific survival|overall survival|quality of life questionnaire eortc qlq c30|quality life questionnaire eortc qlq cx24,tata memorial hospital,Female,"Child, Adult, Older Adult",Not Applicable,1050.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH-1587,December 2016,December 2021,December 2023,"December 29, 2016",,"January 23, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03005743,cervic
19,20,NCT00193726,estrogen priming to increase the efficacy of adjuvant chemotherapy in operable breast cancer,,Terminated,No Results Available,breast cancer,drug: tab premarin (ethinyl estradiol)|drug: placebo,disease free survival|overall survival,sudeep gupta|tata memorial hospital,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,273.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",122 of 2003,July 2005,"March 30, 2012","March 30, 2012","September 19, 2005",,"September 20, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193726,breast
20,21,NCT00193778,assessing impact of loco-regional treatment on survival in metastatic breast cancer at presentation,,Completed,No Results Available,cancer of the breast,procedure: surgery for breast cancer|other: no loco-regional treatment,"overall survival|progression free survival|changes in vegf, bfgf, angiostatin and endostatin",tata memorial hospital,Female,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,350.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH/153/2004,February 2005,"July 30, 2020","July 30, 2020","September 19, 2005",,"October 8, 2020","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193778,breast
21,22,NCT01935466,"risk of bladder cancer in type 2 diabetes patients with pioglitazone therapy ""probe""",PROBE-PIO,Completed,No Results Available,bladder cancer,drug: pioglitazone,bladder cancer rate,postgraduate institute of medical education and research,Male,"50 Years and older   (Adult, Older Adult)",,6107.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PROBEPIO,July 2013,October 2021,October 2021,"September 5, 2013",,"January 25, 2022","['deptt of endocrinology, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT01935466,bladder
22,23,NCT00772824,study of the effect of glutamine supplementation on chemotherapy induced toxicities in breast cancer patients,,Completed,No Results Available,breast cancer,dietary supplement: glutamine|dietary supplement: iv glutamine,reduction in toxicity|serum level of creatinine kinase and ldh,banaras hindu university,Female,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,23.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,GLU_07,December 2007,December 2009,December 2009,"October 15, 2008",,"July 17, 2018","['sir sunder lal hospital, varanasi, up, india']",,https://ClinicalTrials.gov/show/NCT00772824,breast
23,24,NCT04072718,simultaneous integrated boost with volumetric arc radiotherapy in patients with breast cancer,SIBART-BC,Completed,No Results Available,breast cancer,radiation: radiotherapy,acute radiation toxicities|cosmetic score analysis|local control|late toxicity,postgraduate institute of medical education and research,Female,18 Years to 60 Years   (Adult),Phase 2,27.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INT/IEC/2017/127,"August 10, 2017","March 31, 2020","March 31, 2020","August 28, 2019",,"July 14, 2020","['dr budhi singh yadav, chandigarh , india']",,https://ClinicalTrials.gov/show/NCT04072718,breast
24,25,NCT03936933,pharmacodynamic study goserelin 3.6mg injection administered subcutaneously in premenopausal patients with breast cancer,,Recruiting,No Results Available,breast cancer,drug: goserelin acetate 3.6 mg injection|drug: zoladex® 3.6mg injection,to evaluate and compare the pharmacodynamics,eurofarma laboratorios s.a.,Female,18 Years to 59 Years   (Adult),Phase 3,68.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EF 160,"January 1, 2021","December 1, 2022","December 1, 2022","May 3, 2019",,"January 27, 2022","['mahatma gandhi cancer hospital & research institute, visakhapatnam, andhra pradesh, india']",,https://ClinicalTrials.gov/show/NCT03936933,breast
25,26,NCT04249895,comprehensive digital archive of cancer imaging-radiation oncology( chavi-ro ),,Completed,No Results Available,all cancer,,number of patients with complete data safe.,tata medical center,All,"Child, Adult, Older Adult",,500.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,EC/GOVT/24/IRB23,"August 31, 2018","February 28, 2021","February 28, 2021","January 31, 2020",,"December 17, 2021","['sanjoy chatterjee, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT04249895,
26,27,NCT00123669,primary progesterone therapy for operable breast cancer,,Completed,No Results Available,breast neoplasms,drug: 500 mg of depot hydroxy-progesterone,to test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years,"tata memorial hospital|ministry of science and technology, india",Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,1000.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,No. SP/SO/B29/2000,October 1997,"May 29, 2020","May 29, 2020","July 25, 2005",,"July 22, 2020","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00123669,breast
27,28,NCT02804477,validation and assessment of patient adherence to opioids for cancer pain using mmas 8 pain clinic,,Completed,No Results Available,chronic cancer pain,,validation and assessment of adherence to opioids for chronic cancer pain in pain clinic using morisky medication adherence scale 8|relationship of adherence to opioids with demographic characteristics,tata memorial centre,All,"18 Years to 80 Years   (Adult, Older Adult)",,330.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,TataMC 1680,June 2016,November 2016,January 2017,"June 17, 2016",,"April 26, 2017","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02804477,pain
28,29,NCT04351009,sentinel lymph node mapping and analysis in colon cancer using indocyanine green dye,,Recruiting,No Results Available,colon cancer,procedure: sentinel lymph node mapping,detection rate|upstaging rate|accuracy|negative predictive value|aberrant lymph node drainage,"asian institute of gastroenterology, india",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,32.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ICG001,"June 8, 2020","June 30, 2022","June 30, 2022","April 17, 2020",,"January 18, 2022","['asian institute of gastroenterology, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT04351009,colon
29,30,NCT02302105,randomized trial of prostate only or pelvic rt in high risk prostate cancer,POP-RT,"Active, not recruiting",No Results Available,prostate cancer,radiation: igrt,biochemical disease free survival,tata memorial centre,Male,"Child, Adult, Older Adult",Not Applicable,224.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,POP-RT,"November 25, 2011","October 23, 2025","October 23, 2025","November 26, 2014",,"November 23, 2021","['dr vedang murthy, navi-mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02302105,prostat
30,31,NCT03669432,to study the impact of radiation treatment after surgery in patient with locally advanced thyroid cancer.,THYRO-RT,"Active, not recruiting",No Results Available,thyroid cancer stage iv|radiation toxicity,radiation: intensity modulated radiotherapy|procedure: surgery alone,locoregional recurrence|acute toxicity|late toxicity,tata memorial hospital|department of atomic energy,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,72.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1076,July 2013,July 2026,July 2026,"September 13, 2018",,"May 2, 2022","['gouri pantvaidya, mumbai, maharashtra, india']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/32/nct03669432/prot_sap_001.pdf|""informed consent form"", https://clinicaltrials.gov/provideddocs/32/nct03669432/icf_000.pdf",https://ClinicalTrials.gov/show/NCT03669432,thyroid
31,32,NCT05102240,development of clinically high efficient platforms for individualised treatment of cervix cancer,,Not yet recruiting,No Results Available,cervix cancer,,"generation of software for automated target delineation for cervix cancer|development and validation of normal tissue complication plots|identify ""high risk patient population"" that may benefit from intensification of treatment in future","tata memorial hospital|bhabha atomic research centre and indian institute of technology, mumbai.|erasmus medical center",Female,"18 Years to 90 Years   (Adult, Older Adult)",,1800.0,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,TMC IRB 900787|CTRI/2021/08/035810,February 2022,September 2024,September 2024,"November 1, 2021",,"February 14, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05102240,cervix
32,33,NCT03005860,effect of tiva propofol vs sevoflurane anaesthetic on serum biomarkers and on pbmcs in breast cancer surgery,,Unknown status,No Results Available,female breast cancer,"drug: 2,6-diisopropylphenol|drug: fluoromethyl hexafluoroisopropyl ether|drug: fentanyl citrate|drug: atracurium besylate","change in baseline levels versus 24 hour postoperative levels (tpre vs t24h ) of serum hif-1a and vegf-c in both groups.|change in levels of serum biomarkers hif-1a & vegf-c in patients with breast cancer undergoing resection surgery at other time points - intraoperative, at 2hr postoperative. ti, t2h in both groups.|change in levels of serum biomarkers tgf-β, il-17 ifn-g, tnf-a, il-6 and mmp-2 at the four time points in both groups.|measure expression of various lymphocyte subsets (cd3+ t cells, cd4+ helper t cells, cd8+ cytotoxic t cells, γδt cells, nk cells and b cells peripheral blood lymphocytes at four time points",tata memorial centre,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",PN 219,February 2017,January 2018,February 2018,"December 29, 2016",,"January 16, 2017","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03005860,breast
33,34,NCT03936218,goserelin 10.8mg injection in treatment of advanced prostate cancer,,Recruiting,No Results Available,advanced prostate cancer,drug: inj. goserelin (test) subcutaneously|drug: inj. zoladex (reference) subcutaneously,to evaluate and compare the pharmacodynamics of test product against reference product and establish non inferiority.,eurofarma laboratorios s.a.,Male,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,94.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EF 161,"January 1, 2021","December 1, 2022","December 1, 2022","May 3, 2019",,"January 27, 2022","['mahatma gandhi cancer hospital & research institute, visakhapatnam, andhra pradesh, india']",,https://ClinicalTrials.gov/show/NCT03936218,prostat
34,35,NCT01814345,her 2 testing in indian patients with gastric cancer,,Terminated,No Results Available,gastric cancer,,incidence of her2 testing in gastric cancer,tata memorial hospital,All,"18 Years to 90 Years   (Adult, Older Adult)",,100.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,1077|Her 2 in gastric cancer,June 2013,February 2017,February 2017,"March 19, 2013",,"April 27, 2017","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01814345,gastric
35,36,NCT03168880,"a randomized controlled trial of neoadjuvant weekly paclitaxel versus weekly paclitaxel plus weekly carboplatin in women with large operable or locally advanced, triple negative breast cancer",TNBC,"Active, not recruiting",No Results Available,triple negative breast cancer,drug: paclitaxel + carboplatin|drug: paclitaxel only,dfs|os,tata memorial hospital,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,720.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTRI/2012/07/002802,April 2010,"November 30, 2022","November 30, 2024","May 30, 2017",,"April 27, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03168880,breast
36,37,NCT02867865,perioperative therapy preoperative chemotherapy versus chemoradiotherapy in locally advanced gall bladder cancers,POLCAGB,Recruiting,No Results Available,gall bladder cancers,drug: gemcitabine|drug: cisplatin|radiation: chemoradiation|procedure: petcect|procedure: laparoscopy,overall survival|surgical resection rate|progression free survival|number of participants with treatment related serious adverse events|deterioration free rate of quality of life (qol) scores at baseline and three monthly,tata memorial hospital,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,314.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1652,October 2016,August 2021,August 2022,"August 16, 2016",,"November 14, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02867865,bladder
37,38,NCT02139605,"""phase iii randomized trial comparing d2 vs d3 lymphadenectomy with gastric cancer following neoadjuvant chemotherapy",,Recruiting,No Results Available,gastric cancer,procedure: d3 lymphadenectomy,primary endpoint:overall survival|disease-free survival,tata memorial centre,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,400.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,87,"July 5, 2013",July 2025,July 2026,"May 15, 2014",,"April 27, 2022","['dr shailesh vinayak shrikhande, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02139605,gastric
38,39,NCT03797482,a prospective evaluation of the peri-operative hypoxia in breast cancer,Hypoxia,Recruiting,No Results Available,breast cancer female,procedure: intra-operative tumor tissue biopsy,gene expression changes|immunohistochemistry for other markers,tata memorial hospital,Female,"18 Years and older   (Adult, Older Adult)",,500.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Protocol 254,"November 27, 2017","July 30, 2022","November 30, 2022","January 9, 2019",,"April 27, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03797482,breast
39,40,NCT00193752,para-aortic lymph nodal staging & evaluation of treatment outcome by 18f fdg-pet in advanced cancer cervix,,Completed,No Results Available,cancer of cervix,other: pet imaging,"pet scan for para-aortic staging in carcinoma cervix|clinical (figo), mri, and pet - abdomen and pelvis correlation|volumetric correlation of local disease by pet and mri|radiotherapy response evaluation and post therapy surveillance by serial pet scans|overall survival",tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TMH/205/2004/Cx_PET STUDY,September 2005,January 2015,January 2018,"September 19, 2005",,"January 23, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193752,cervix
40,41,NCT03669497,hypo-fractionated radiotherapy in breast cancer,HYPORT-B,Recruiting,No Results Available,breast cancer|advanced breast cancer|metastatic breast cancer,radiation: hypo fractionated whole breast radiotherapy,toxicity (ctcae v 4.03)|response,tata medical center,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC/TMC/108/17,"January 2, 2018","December 2, 2020","January 3, 2023","September 13, 2018",,"December 3, 2021","['sanjoy chatterjee, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03669497,breast
41,42,NCT02161900,randomized controlled trial evaluating the role of exercise in women undergoing treatment for breast cancer,,"Active, not recruiting",No Results Available,non metastatic operable breast cancer,other: yogic and routine exercises,"disease-free survival|quality of life, improvements in overall survival",tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,850.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH Project No. 735,"November 12, 2010","March 31, 2023","April 30, 2025","June 12, 2014",,"May 2, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02161900,breast
42,43,NCT03546023,brief pain inventory to assess cancer pain and quality of life,,Completed,No Results Available,chronic cancer pain,other: patient interview,functional activity measurement using the brief pain inventory (bpi),tata memorial hospital,All,"18 Years and older   (Adult, Older Adult)",,900.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1921,"June 5, 2018","June 4, 2019","June 4, 2019","June 6, 2018",,"September 11, 2019","['tata memorial centre, mumbai, maharashtra, india tata memorial centre, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03546023,pain
43,44,NCT03638622,low-cost enabling technology for image-guided photodynamic therapy (pdt) of oral cancer cancer.,UH3-India,Completed,Has Results,oral cancer,combination product: photodynamic therapy,number of participants with no residual tumor following photodynamic therapy (pdt),massachusetts general hospital|jawaharlal nehru medical college|national cancer institute (nci),All,"21 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015P001855|5UH3CA189901-04,"March 10, 2017","October 12, 2020","October 12, 2020","August 20, 2018","February 21, 2021","February 21, 2021","['j.n. medical college, aligarh muslim university, aligarh, up, india']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/22/nct03638622/prot_sap_001.pdf",https://ClinicalTrials.gov/show/NCT03638622,
44,45,NCT01608451,randomized controlled trial of neo-adjuvant progesterone and vitamin d3 in women with large operable breast cancer and locally advanced breast cancer,,Terminated,No Results Available,locally advanced breast cancer and large operable breast cancer,drug: cholecalciferol|drug: inj. progesterone,"disease-free survival|improvements in overall survival, tumor response",tata memorial hospital,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,800.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Vitamin D3/377/TMH|TMH project No. 377,September 2007,"August 20, 2021","August 20, 2021","May 31, 2012",,"May 2, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01608451,breast
45,46,NCT01118897,tomotherapy in locally advanced gallbladder and pancreatic cancers,,Completed,No Results Available,pancreatic neoplasms malignant|malignant neoplasm of gall bladder non-resectable,radiation: tomotherapy,to assess the feasibility of concurrent chemo-radiation with dose escalated imrt in locally advanced inoperable gallbladder and pancreatic cancers|response to ctrt|r0 resection rate|locoregional control|overall survival,tata memorial hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,60.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 599,December 2008,January 2013,June 2013,"May 7, 2010",,"August 7, 2015","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01118897,skin bladder pancreat
46,47,NCT00750503,workplace tobacco cessation and oral cancer screening study,,Completed,No Results Available,tobacco cessation|oral cancer,behavioral: behavioural and pharmacotherapy for tobacco cessation,"the prevalence of tobacco use and the the change in knowledge, attitude and practices during post intervention. the reasons for initiation and continuation of tobacco consumption habit. the tobacco quit rates.|the prevalence of oral precancerous and cancerous lesions among this group and its correlation with the different forms and frequency of tobacco use.",tata memorial hospital|department of atomic energy,Male,18 Years to 60 Years   (Adult),Phase 3,104.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,458,June 2007,June 2008,August 2008,"September 10, 2008",,"September 10, 2008","['chemical industry, tal. khed, district : ratnagiri, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00750503,
47,48,NCT01429766,a prospective study of variation in breath holding times at various phases of respiration during the course of radiotherapy including the effect of respiratory training in lung cancer patients,,Unknown status,No Results Available,small cell lung cancer|non small cell lung cancer,other: respiratory training,breath holding time in various phases of the respiratory cycle,tata memorial hospital,All,"Child, Adult, Older Adult",Phase 2,100.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,747,June 2010,May 2012,May 2012,"September 7, 2011",,"September 7, 2011","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01429766,
48,49,NCT04842994,trial on intraoperative neuromonitoring (ionm) in thyroid cancer surgery.,ACTION,Recruiting,No Results Available,malignant neoplasm of thyroid gland,device: ionm tube,primary objective assessment (temporary rln palsy)- fol evaluation|acoustic analysis|aerodynamic voice measurement|voice quality assessment,tata memorial hospital,All,"Child, Adult, Older Adult",Not Applicable,448.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,3223,"August 16, 2019",August 2024,August 2024,"April 13, 2021",,"May 5, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT04842994,thyroid skin
49,50,NCT02116920,hpv e6/e7 mrna versus hpv dna as triage for cervical cancer screening,PODBT,Unknown status,No Results Available,cin|cervix cancer,,efficacy outcome measure,"tata memorial hospital|ministry of science and technology, india",Female,"30 Years to 65 Years   (Adult, Older Adult)",,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BT/PR6121/SPD/11/1401/2012,May 2013,May 2016,May 2016,"April 17, 2014",,"April 17, 2014","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02116920,cervix
50,51,NCT04085120,ropivacaine/dexamethasone and 10% lignocaine injection in gpn block for intractable cancer pain,,Unknown status,No Results Available,"cancer, oropharynx|pain, intractable|cancer pain",procedure: 0.75 % ropivacaine/ 4mg/ml dexamethasone injection|procedure: 10% lignocaine injection,pain reduction on the basis of the numeric rating scale (nrs).|brief pain inventory (bpi)- short form|who quality of life-bref|patient global impression of change (pgic)|clinical global impression of change (cgic)|analgesic requirement and rescue analgesic requirement,"all india institute of medical sciences, new delhi",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","IEC-402/07.06.2019, RP-34/2019","August 23, 2019","January 31, 2020","February 28, 2020","September 11, 2019",,"September 11, 2019","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT04085120,pain
51,52,NCT04985253,correlation of predictive accuracy of predict version 2.2 of indian women with operable breast cancer,PREDICT,"Active, not recruiting",No Results Available,operable breast neoplasms,other: prediction of overall survival using web based predictv2.0 portal,"five year overall survival|to compare the observed 5 year overall survival of operable breast cancer patients with the one predicted by predict v2.0v 2.2 for subgroups like age at diagnosis, stage of disease, tumour grade and molecular class (er/pr positive or tnbc)",tata memorial centre,Female,"18 Years to 99 Years   (Adult, Older Adult)",,2780.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,3055,"November 15, 2018","October 18, 2021","July 31, 2022","August 2, 2021",,"May 4, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT04985253,breast
52,53,NCT01785420,pre operative trastuzumab in operable breast cancer,,Recruiting,No Results Available,carcinoma breast stage i|her2 positive breast cancer,drug: trastuzumab|drug: placebo,disease free survival|overall survival|circulating tumour cells in peripheral blood|4.1.3. evaluation of the paraffin blocks for pten loss6-8 and p95erbb2 truncated form of her2,dr rajendra a. badwe|tata memorial hospital,Female,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TMH Project-982,May 2013,April 2025,February 2027,"February 7, 2013",,"April 27, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01785420,breast
53,54,NCT01304199,cancer survivorship issues: a survey of patients in india.aiims study (cansurvive),CANSURVIVE,Unknown status,No Results Available,cancer,,"to study the cancer survivorship experience(as binary responses)|to assess the mental status of cancer survivors|to identify the differences if any, in the cancer survivorship issues by age(less than 50 or greater than 50 years)|to define follow up care for cancer survivors in india.","all india institute of medical sciences, new delhi",All,"18 Years to 75 Years   (Adult, Older Adult)",,200.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IEC/NP-252/2010,January 2011,July 2013,December 2013,"February 25, 2011",,"July 12, 2012","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01304199,
54,55,NCT00128817,concurrent chemoradiation versus surgery with adjuvant therapy in advanced laryngopharyngeal cancers,,Terminated,No Results Available,larynx neoplasms,radiation: concurrent chemoradiation|procedure: laryngectomy + adjuvant radiotherapy/chemoradiotherapy,overall survival at 3 and 5 years|disease free survival at 3 and 5 years|locoregional control rates at 3 and 5 years|patterns of relapse|salvage rates|treatment-related adverse events|completion of treatment|quality of life,"tata memorial hospital|ministry of science and technology, india",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,900.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH/196/2004|DAECTC/Projno 4/2004-2005,May 2005,May 2015,May 2015,"August 10, 2005",,"January 23, 2013","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00128817,
55,56,NCT05250336,tumor-infiltrating lymphocytes and programmed cell death - ligand 1 in breast cancer,,Recruiting,No Results Available,breast cancer|tumor infiltrating lymphocytes|programmed cell death ligand 1,other: observational study,correlation of tils and pdl-1 in various molecular sub-types|pdl-1 expression in patients with triple negative breast cancer (tnbc)|tils and tumor response to treatment|pd-l1 expression and tumor response to treatment,sanjay gandhi postgraduate institute of medical sciences,All,"18 Years to 90 Years   (Adult, Older Adult)",,1000.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,2018-177-IMP-EXP-4,"January 19, 2019","June 30, 2022","September 30, 2022","February 22, 2022",,"February 22, 2022","['sanjay gandhi postgraduate institute of medical sciences, lucknow, uttar pradesh, india']",,https://ClinicalTrials.gov/show/NCT05250336,breast
56,57,NCT02745288,inferior alveolar nerve block for intraoperative analgesia for maxillofacial cancer surgery - rct,,Completed,No Results Available,mandibular neoplasms,procedure: inferior alveolar nerve block,iv fentanyl requirement during primary tumour removal|iv fentanyl requirement during neck dissection and primary tumour removal|maximum change in heart rate from baseline during primary tumour removal|maximum change in blood pressure from baseline during primary tumour removal|need for rescue analgesics or vasoactive agents during primary tumour removal,tata memorial centre,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1648,June 2016,October 2016,October 2016,"April 20, 2016",,"November 22, 2016","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02745288,
57,58,NCT00896155,trial of concurrent versus sequential tamoxifen with radiotherapy in breast cancer patients,CONSET,Unknown status,No Results Available,pulmonary fibrosis|breast cancer,drug: tamoxifen|radiation: radiotherapy,development of lung fibrosis|locoregional failure and distant failure,tata memorial hospital|indian council of medical research,Female,"Child, Adult, Older Adult",Phase 3,260.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,349,December 2008,December 2011,December 2013,"May 11, 2009",,"August 30, 2011","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00896155,breast
58,59,NCT01858571,low dose chemotherapy versus best supportive care in progressive pediatric malignancies,,Completed,No Results Available,malignant childhood neoplasm,drug: low dose chemotherapy,progression free survival|overall survival,"all india institute of medical sciences, new delhi",All,"5 Years to 18 Years   (Child, Adult)",Phase 3,108.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",IEC/NP-63/2013,October 2013,July 2016,January 2017,"May 21, 2013",,"January 25, 2017","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01858571,skin
59,60,NCT00655421,"oral cancer screening in mumbai, india by primary health care workers",,Unknown status,No Results Available,oral cancer|precancerous conditions,other: unaided visual inspection|device: velscope|other: toluidine blue assisted oral examination,"to evaluate the feasibility and efficacy of performance of the three oral cancer screening tests viz. naked eye unaided examination , examination using velscope and after application of toluidine blue by trained primary health workers.|to estimate the test characteristics of each of the three oral cancer screening techniques.","tata memorial hospital|american cancer society, inc.|emory university",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,329.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening,391,April 2008,September 2009,September 2009,"April 9, 2008",,"July 3, 2009","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00655421,
60,61,NCT03022162,prevalence of paclitaxel induced cipn-related pain and cipn in indian patients with breast cancer,,Completed,No Results Available,breast cancer female|neuropathic pain,,prevalence of paclitaxel induced cipn-related pain|prevalence of paclitaxel induced cipn|temporal characteristics and risk factors of cipn-related pain|use of agents offered with an intend to prevent cipn,tata memorial centre,Female,"18 Years and older   (Adult, Older Adult)",,150.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1758,"December 1, 2017","May 31, 2018","May 31, 2018","January 16, 2017",,"October 14, 2020","['anuja bidkar, thane, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03022162,breast pain
61,62,NCT04472845,hypofractionated adjuvant radiotherapy in 1 versus 2 weeks in high-risk patients with breast cancer (hypart).,HYPART,Recruiting,No Results Available,breast cancer|hypofractionation|radiotherapy side effect,radiation: 1 week rt|radiation: 2 week rt,"loco-regional recurrence, change is being assessed|disease-free survival, change is being assessed|overall survival, change is being assessed|acute radiation toxicity|late adverse events, change is being assessed|quality of life(qol), change is being assessed",postgraduate institute of medical education and research,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1018.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HYPART,"March 30, 2021","August 20, 2023","August 20, 2028","July 15, 2020",,"June 25, 2021","['dr budhi singh yadav, chandigarh , india']",,https://ClinicalTrials.gov/show/NCT04472845,breast
62,63,NCT01797770,trial on mechanical bowel preparation in laparoscopic colorectal surgery,MBP,Unknown status,No Results Available,rectal cancer|colon cancer,drug: polyethylene glycol|other: no preparation,anastomotic leak|surgical site infection|intraoperative parameters assessment|bowel recovery|drain removal|re-exploration|hospital stay|readmission,pvs memorial hospital,All,"25 Years to 75 Years   (Adult, Older Adult)",,90.0,Other,Observational,Time Perspective: Prospective,PVS2,January 2012,January 2014,February 2014,"February 22, 2013",,"February 22, 2013","['pvs memorial hospital, kochi, kerala, india']",,https://ClinicalTrials.gov/show/NCT01797770,colon
63,64,NCT04094974,heartrate variability and intraoperative brain conditions in supratentorial tumors,,Completed,No Results Available,supratentorial brain tumors,device: ansiscope,brain relaxation|hemodynamic measurement-heartrate|hemodynamic measurement-bloodpressure,"dyansys, inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",,58.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CS009,"October 12, 2019","October 3, 2020","October 3, 2020","September 19, 2019",,"January 25, 2021","['national institute of mental health and neurosciences, bengaluru, karnataka, india']",,https://ClinicalTrials.gov/show/NCT04094974,brain
64,65,NCT04365647,intra-operative variation in size of brain tumors after craniotomy,,Completed,No Results Available,"brain tumor, primary",,tumor dimension change|tumor distance from dural surface|relationship of tumor size change with other characteristics,sheri kashmir institute of medical sciences,All,"15 Years to 75 Years   (Child, Adult, Older Adult)",,51.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"SKIMS, Soura","March 1, 2018","November 1, 2019","March 31, 2020","April 28, 2020",,"April 28, 2020","['sher-i-kashmir institute of medical sciences, soura, srinagar, jammu and kashmir, india']",,https://ClinicalTrials.gov/show/NCT04365647,brain
65,66,NCT01476670,cerebral blood circulation in patients with posterior fossa brain tumor,,Unknown status,No Results Available,brain tumor,other: monitoring,,"all india institute of medical sciences, new delhi",All,18 Years to 60 Years   (Adult),,20.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CA-CO2-TCD|Posterior fossa tumor - TCD,July 2012,,,"November 22, 2011",,"November 22, 2011","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01476670,brain
66,67,NCT01758146,impact of obesity on the efficacy of endocrine therapy with aromatase inhibitors,,Unknown status,No Results Available,breast cancer,drug: tamoxifen|drug: letrozole,disease free survival|recurrence-free survival .|overall survival (os),postgraduate institute of medical education and research,Female,"45 Years to 80 Years   (Adult, Older Adult)",Phase 3,412.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BMI,January 2012,January 2020,June 2020,"January 1, 2013",,"March 4, 2020","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT01758146,breast
67,68,NCT05144867,stereotactic radiosurgery vs whole brain radiotherapy in breast cancer with brain oligometastasis,SRSvsWBRT,Recruiting,No Results Available,"breast cancer|brain metastases, adult|stereotactic radiosurgery|whole brain radiotherapy",radiation: stereotactic radiosurgery,overall survival|progression free survival (pfs)|quality of life - kps|quality of life - mini mental state,postgraduate institute of medical education and research,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,98.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NK/7784/Study/249,"August 31, 2021","August 31, 2025","August 31, 2026","December 3, 2021",,"December 3, 2021","['dr budhi singh yadav, chandigarh , india']",,https://ClinicalTrials.gov/show/NCT05144867,breast brain
68,69,NCT01145781,trial to evaluate single- and double- freeze cryotherapy in the prevention of cervical neoplasia,,Completed,No Results Available,cervical intraepithelial neoplasia,procedure: cryotherapy,the primary end point is the cure rate at the end of one year|the secondary end points are the rates and the types of side effects and complications,tata memorial hospital,Female,25 Years to 64 Years   (Adult),Not Applicable,440.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,649,January 2010,January 2015,January 2015,"June 17, 2010",,"May 1, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01145781,cervic
69,70,NCT00847717,trial of iib preserving neck dissection,,Completed,No Results Available,oral cancer,procedure: selective neck dissection|procedure: conventional neck dissection,spinal accessary nerve function|neck node failure,banaras hindu university,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,32.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SND_01,August 2007,August 2009,August 2009,"February 19, 2009",,"July 17, 2018","['banaras hindu university, varanasi, up, india']",,https://ClinicalTrials.gov/show/NCT00847717,
70,71,NCT01391065,mr- pet guided biologically optimised interstitial brachytherapy,MR-PET Brachy,Completed,No Results Available,cervical cancer,radiation: mr pet guided brachytherapy,local response in spatial reference to high risk gtv (as identified by functional imaging)|incidence of grade iii rectal and bladder toxicity with biologically dose modulated brachytherapy,tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH-IRB 843,"February 23, 2011",February 2019,"October 4, 2019","July 11, 2011",,"April 7, 2020","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01391065,cervic
71,72,NCT01440621,modafinil in cancer related fatigue,ModCRF,Completed,No Results Available,cancer related fatigue|quality of life,drug: modafinil|drug: pyridoxine,reduction in cancer related fatigue|improvement in quality of life|karnofsky performance status scores|effects of modafinil on systolic and diastolic blood pressure|changes in weight,"indira gandhi medical college, shimla",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,217.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",ModCRF,August 2010,February 2012,February 2012,"September 26, 2011",,"March 23, 2012","['regional cancer centre, shimla, himachal pradesh, india']",,https://ClinicalTrials.gov/show/NCT01440621,
72,73,NCT00193843,oral cancer adjuvant therapy (ocat) trial,,Unknown status,No Results Available,mouth neoplasms,procedure: post-operative chemoradiotherapy / accelerated radiotherapy,local-regional failure|overall survival|treatment related toxicity|protocol compliance|overall treatment time|quality of life: assessment by eortc-qlq-c30 and eortc-h&n-35,tata memorial hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,900.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH/177/2004,June 2005,,June 2017,"September 19, 2005",,"December 26, 2005","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193843,
73,74,NCT02150564,3d ultra sound for resection of brain tumors,SonoRCT,Completed,No Results Available,patients with resectable brain tumors,device: sonowand|procedure: navigation,percentage of patients where gross total resection (gtr) achieved|accuracy of us,tata memorial hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,TMC-ACTREC 101,March 2014,"June 30, 2019","June 30, 2019","May 30, 2014",,"May 9, 2022","['advanced centre for treatment research and education in cancer, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02150564,brain
74,75,NCT05240378,mortality of cancer surgery during sars cov2 pandemic,,Completed,No Results Available,sars cov 2 infection|cancer,other: surgery,30 day mortality|number of participants developing major or minor complications|number of health care worker with sars cov2 infection,banaras hindu university,All,"18 Years to 99 Years   (Adult, Older Adult)",,1576.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Dean/2021/EC/3004,"October 29, 2021","December 31, 2021","January 15, 2022","February 15, 2022",,"March 3, 2022","['banaras hindu university, varanasi, up, india']",,https://ClinicalTrials.gov/show/NCT05240378,
75,76,NCT01179074,role of radiotherapy following oesophageal stenting in cancer,,Completed,No Results Available,oesophageal cancer,procedure: oesophageal stenting with self expandable metal stent|procedure: oesophageal stent followed by external beam radiotherapy,relief of dysphagia|survival,"all india institute of medical sciences, new delhi",All,"Child, Adult, Older Adult",Not Applicable,84.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,SEMSRT-1,April 2007,March 2009,March 2009,"August 11, 2010",,"August 11, 2010","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01179074,esophag
76,77,NCT03923998,adjuvant chemoradiotherapy prior to surgery in stage iva oral cancers,,Completed,No Results Available,squamous cell carcinoma of oral cavity,drug: neoadjuvant chemotherapy|radiation: neoadjuvant radiotherapy|procedure: resection and reconstruction,objective response rate|disease free survival|overall survival|quality of life assessment,indrayani hospital and cancer institute|tata capital limited|grant medical foundation ruby hall clinic,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,8.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OIT415,"March 15, 2016","March 15, 2019","March 15, 2019","April 23, 2019",,"April 23, 2019","['indrayani hospital and cancer institute, pune, maharshtra, india']",,https://ClinicalTrials.gov/show/NCT03923998,skin
77,78,NCT02247999,improving cervical cancer screening among hiv-infected women in india,,Completed,No Results Available,cervical cancer|hiv/aids|hpv|cervical intraepithelial neoplasia|biomarkers,,cervical intraepithelial neoplasia grade ii or more severe,national cancer institute (nci)|national institutes of health clinical center (cc),Female,"18 Years and older   (Adult, Older Adult)",,1000.0,NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,999913037|13-C-N037,"November 28, 2012","October 8, 2020","October 8, 2020","September 25, 2014",,"October 9, 2020","['national institute of epidemiology (nie), chennai, india']",,https://ClinicalTrials.gov/show/NCT02247999,cervic
78,79,NCT03137953,role of imaging to predict the deep surgical margin in gingivobuccal complex tumors,,Unknown status,No Results Available,buccal mucosa cancer|gingival cancer,procedure: clinical evaluation|diagnostic test: radiological imaging,proportion of patients undergoing skin preservation surgeries,healthcare global enterprise ltd.,All,"Child, Adult, Older Adult",Not Applicable,30.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HCG/SX/002/2016,"June 1, 2016","June 30, 2017","June 30, 2017","May 3, 2017",,"May 9, 2017","['healthcare global enterprises ltd, bangalore, karnataka, india']",,https://ClinicalTrials.gov/show/NCT03137953,
79,80,NCT03727126,robotic versus thoracolaparoscopic esophagectomy for esophageal cancer,,Recruiting,No Results Available,esophageal cancer,procedure: robotic esophagectomy|procedure: thoracolaparoscopic esophagectomy,lymph node yield|surgical margin status|complications|icu stay|hospital stay|mortality|duration of surgery|blood loss|conversion rate,gem hospital & research center,All,"Child, Adult, Older Adult",Not Applicable,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GEMBOT,"November 1, 2018","December 31, 2020","January 1, 2021","November 1, 2018",,"October 14, 2020","['gem hospital & research center, chennai, tamil nadu, india gem hospital & research center, coimbatore, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT03727126,esophag
80,81,NCT03386695,acceptability and validity of self sampling for high risk hpv detection among women in maharashtra,HPV,Unknown status,No Results Available,cervical cancer,other: education by pamphlets|other: health education programme,agreement rate between health care personnel collected samples and self collected samples in these two groups.|test characteristics of hpv self sample and health care worker collected sample by hpv hc 2.|acceptability and barriers for self-collection of specimens for hpv dna testing in an urban population.,tata memorial hospital,Female,30 Years to 55 Years   (Adult),Not Applicable,1600.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,TMHPO 1686,September 2018,January 2019,January 2020,"December 29, 2017",,"August 6, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03386695,cervic
81,82,NCT02778308,adjuvant chemotherapy vs no chemotherapy for patients with gallbllader carcinoma,,Completed,No Results Available,gallbladder cancer,drug: gemcitabine + cisplatin,disease free survival|overall survival|blood and lymphatic system adverse events|gastrointestinal system adverse events,govind ballabh pant institute of postgraduate medical education and research,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FI/IEC/MAMC(32)/4/2012/239,January 2012,June 2018,December 2018,"May 19, 2016",,"April 6, 2021","['gipmer, new delhi, india']",,https://ClinicalTrials.gov/show/NCT02778308,bladder
82,83,NCT00409864,endoscopic versus percutaneous drainage for hilar block in gall bladder cancer,,Completed,No Results Available,gallbladder cancer|obstructive jaundice,"procedure: endoscopic biliary stenting, percutaneous biliary stenting","successful drainage: a decrease in bilirubin to less than 75% of the pretreatment value within 7 days|early cholangitis: occurring within 48 hours to 7 days of the procedure as evidenced by fever, leukocytosis and worsening lfts.|quality of life|complications|procedure-related and 30-day mortality|stent patency time will be defined by time to stent occlusion","all india institute of medical sciences, new delhi",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,182.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GIS/1/2003,October 2003,July 2005,December 2005,"December 11, 2006",,"May 26, 2010","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00409864,bladder
83,84,NCT04406844,issues and challenges in cancer patients on active treatment during the covid-19 pandemic,,Recruiting,No Results Available,oncology patients,,oncology patients,max healthcare insititute limited,All,"12 Years to 98 Years   (Child, Adult, Older Adult)",,150.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,Onco_Covid-19,"May 9, 2020","June 30, 2021","June 30, 2021","May 28, 2020",,"July 22, 2020","['max superspeciality hospital, a unit of balaji medical and diagnostic centre, new delhi, india']",,https://ClinicalTrials.gov/show/NCT04406844,
84,85,NCT03003273,"early stoppage versus continuation of antimicrobial therapy in low risk pediatric cancer patients with febrile neutropenia, before recovery of counts: -dalfen study",DALFEN,Terminated,No Results Available,"neutropenia, febrile|pediatric cancer",other: stoppage of antibiotics|other: amoxycillin/clavulanic acid|other: levofloxacin,treatment is considered to be successful if the following is attained without changing the regimen - patient remains afebrile till recovery of anc ≥500 •measure of effect: proportion of patients afebrile in each arm|rate of re-admission,"all india institute of medical sciences, new delhi",All,"3 Years to 18 Years   (Child, Adult)",Phase 3,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IECPG-164,January 2017,December 2018,December 2018,"December 28, 2016",,"February 1, 2019","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT03003273,
85,86,NCT03229603,a pilot study on hpv and cervical cancer screening in mumbai,HPV,Unknown status,No Results Available,hpv infection,other: cluster of 3000 women,"the feasibility of hpv testing as a single visit approach will be summarized using the appropriate descriptive statistics.|overall agreement between clinician-collected versus self-collected samples will be compared using pairwise t tests|the focus group data will be analyzed using constant comparative data analysis to identify thematic components and sub-themes.|the hpv genexpert by health care provider and hpv hc2 samples by health care provider will be compared to study the agreement rates.|documentation of six different genotypes/ genotype families of hpv from cervical tissue samples, which will inform the development of hpv vaccinations specific to the strains of hpv in india.|probe for perceptions about self-collection of vaginal samples to describe acceptability of this process.|fit a predictive model of hpv infection(s).",tata memorial hospital|university of arizona,Female,30 Years to 55 Years   (Adult),Not Applicable,227.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,TMHPO1763,April 2018,April 2018,May 2018,"July 25, 2017",,"December 22, 2017","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03229603,
86,87,NCT01633463,an observational study of pain assessment and treatment adequacy of emergency cancer pain,,Completed,No Results Available,observe pain management practices in emergency department,,,tata memorial hospital,All,"18 Years and older   (Adult, Older Adult)",,100.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,emcap 2011,April 2011,June 2011,June 2011,"July 4, 2012",,"July 4, 2012","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01633463,pain
87,88,NCT01190982,efficacy and safety study of lep-etu to treat metastatic breast cancer,,Completed,No Results Available,breast cancer,drug: lep-etu,assessment of overall response rate (orr) following treatment of lep-etu at 275 mg/m2 dose|lep-etu 275mg/m2 induce progression-free survival assessment,insys therapeutics inc,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LEP-ETU 202,March 2008,December 2011,December 2011,"August 30, 2010",,"August 24, 2012","['indo-american cancer institute and research center, banjara hills, hyderabad, india p.d. hinduja antional hospital & medical research center, mahim, mumbia, india jaslok hospital and research center, mumbai, india']",,https://ClinicalTrials.gov/show/NCT01190982,breast
88,89,NCT02951325,bladder cancer adjuvant radiotherapy trial,BART,Recruiting,No Results Available,bladder cancer|urothelial carcinoma bladder,other: adjuvant rt,improvement in loco-regional relapse free survival (lrfs)|disease free survival (dfs)|overall survival(os)|rt toxicity (acute and late)|qol|patterns of failure,tata memorial centre,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,153.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BART,June 2016,"April 13, 2023","April 13, 2023","November 1, 2016",,"October 7, 2021","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02951325,bladder urotheli
89,90,NCT05099809,registry trial to evaluate the safety and efficacy of hyperthermia in locally advanced cancers,RESHMART,Recruiting,No Results Available,locally advanced malignant neoplasm,other: hyperthermia,locoregional tumour control|disease free survival|overall survival|acute treatment related morbidity|late treatment related morbidity,mahatma gandhi institute of medical sciences,All,"18 Years and older   (Adult, Older Adult)",,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MahatmaIGMS,"December 1, 2021","December 31, 2022","June 30, 2023","October 29, 2021",,"May 5, 2022","['mahatma gandhi institute of medical sciences, sevagram, maharashtra, india mahatma gandhi institute of medical sciences,, sevagram, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05099809,skin
90,91,NCT04546607,evaluation of clinical efficacy and safety of nuvastatic in cancer asthenia,,Completed,No Results Available,asthenia|cancer,other: nuvastatic tm (c5osew5050esa) 1000 mg,to evaluate efficacy of canssufive® nuvastatic (c5osew5050esa) in improving fatigue in patients with solid stage i - iv tumors.|to evaluate the safety and tolerability of canssufive® nuvastatic (c5osew5050esa) in patients with solid stage i - iv tumors.|quality of life (qol)|fatigue severity scale|brief fatigue inventory|vitality subscale of the medical outcome scale short form-36 (sf-36)|f2-isoprostane|the adverse events,natureceuticals sdn bhd,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,110.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EBSB0045011CRA,"September 2, 2017","October 28, 2019","October 31, 2019","September 14, 2020",,"September 16, 2020","['notrox research pvt ltd, bangalore, karnataka, india']",,https://ClinicalTrials.gov/show/NCT04546607,
91,92,NCT00191789,neoadjuvant sequential administration of two gemcitabine combinations in operable breast cancer,,Completed,Has Results,breast cancer,drug: gemcitabine|drug: doxorubicin|drug: cisplatin|procedure: surgery,number of patients with pathological complete response (pathological complete response rate)|summary of deaths during study|progression free survival (pfs)|overall survival|time to treatment failure|number of patients eligible for breast conservation surgery at baseline and number of patients undergoing breast conservation surgery,eli lilly and company,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,65.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7117|B9E-MC-S329,February 2003,April 2009,April 2009,"September 19, 2005","July 22, 2010","July 27, 2010","['for additional information regarding investigative sites for this clinical trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon-fri from 9am to 5pm eastern time (utc/gmt -5 hours, est), or speak with your personal physician., pune, maharashtra, india for additional information regarding investigative sites for this clinical trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon-fri from 9am to 5pm eastern time (utc/gmt -5 hours, est), or speak with your personal physician., vellore, tamil nadu, india for additional information regarding investigative sites for this clinical trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon-fri from 9am to 5pm eastern time (utc/gmt -5 hours, est), or speak with your personal physician., delhi, india']",,https://ClinicalTrials.gov/show/NCT00191789,breast
92,93,NCT01145638,a study of intravenous iron isomaltoside 1000 (monofer®) as mono therapy (without erythropoiesis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with chemotherapy induced anaemia (cia),,Completed,Has Results,non-myeloid malignancies|chemotherapy induced anaemia,drug: iron isomaltoside 1000|drug: iron sulphate,change in hb concentration|change in hemoglobin from baseline to week 24,pharmacosmos a/s,All,"18 Years and older   (Adult, Older Adult)",Phase 3,350.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P-Monofer-CIA-01|EudraCT no. 2009-016727-53,October 2010,April 2014,May 2014,"June 16, 2010","December 3, 2015","December 3, 2015","['apollo hospitals, new delhi, india']",,https://ClinicalTrials.gov/show/NCT01145638,skin
93,94,NCT02074137,evaluation of safety of cabazitaxel (jevtana) in patients with metastatic hormone refractory prostate cancer,,Completed,No Results Available,prostate cancer metastatic,drug: cabazitaxel xrp6258|drug: prednisone|drug: prednisolone,"number of patients with related serious adverse events|evaluation of use of cabazitaxel in terms of treatment duration, number of cycles, dose modifications|radiological overall response (if radiological tumor assessment done) using recist criteria|number of patients with at least 50% decrease in psa",sanofi,Male,"18 Years and older   (Adult, Older Adult)",Phase 4,10.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CABAZL06499|U1111-1131-3161,July 2014,March 2016,March 2016,"February 28, 2014",,"June 2, 2016","['investigational site number 356005, kollkata, india investigational site number 356003, new delhi, india investigational site number 356002, trivandrum, india']",,https://ClinicalTrials.gov/show/NCT02074137,prostat
94,95,NCT00915369,"a clinical trial to study the effects of nanoparticle based paclitaxel drug, which does not contain the solvent cremophor, in advanced breast cancer",,Unknown status,No Results Available,advanced breast cancer,drug: nanoxel (paclitaxel nanoparticle formulation ),"the primary outcomes of the study would be the pharmacokinetic data at all the four dose levels (220, 260, 310 and 375 mg/m2); ability to identify a dose higher than 220 mg/m2 that demonstrate better efficacy and manageable toxicity|evaluation of the effect of paclitaxel nanoparticle formulation on qtc.",fresenius kabi oncology ltd.,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DO/NDR/02/2008/01,March 2009,April 2010,April 2010,"June 8, 2009",,"February 8, 2010","[""nizam's institute of medical sciences, hyderabaad, andhra pradesh, india kidwai memorial institute of oncology, bangalore, karnataka, india searoc cancer center, s k soni hospital, jaipur, rajasthan, india""]",,https://ClinicalTrials.gov/show/NCT00915369,breast
95,96,NCT01917695,study on early stage bulky cervical cancers,,Unknown status,No Results Available,carcinoma cervix,drug: chemotherapy|radiation: external beam radiotherapy|radiation: brachytherapy|procedure: radical hysterectomy,overall and disease free survival|acute adverse reactions and complications|subacute adverse reactions and complications|chronic adverse reactions and complications,rajkumar kottayasamy seenivasagam|government royapettah hospital,Female,18 Years to 60 Years   (Adult),Phase 3,180.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GRHCO-01,August 2013,August 2018,August 2018,"August 7, 2013",,"August 13, 2015","['government royapettah hospital, chennai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT01917695,cervix
96,97,NCT00193765,elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity,,Unknown status,No Results Available,oral cancer,procedure: elective neck dissection in early oral cancer|procedure: therapeutic neck dissection,"overall survival|disease free survival|role of ultrasound examination in routine initial workup of a node negative patient.|role of ultrasonogrphy vs clinical examination in ideal follow up of patient.|correlation between the tumour thickness assessment by surgeon on table , on frozen section and final histopathology.|identify histological prognostic factors in primary that may help identify a sub-set of patients at an increased risk of cervical metastasis.",tata memorial hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,710.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH/131/2003,January 2004,June 2019,June 2019,"September 19, 2005",,"June 16, 2017","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193765,
97,98,NCT02515006,impact of homeopathy for persistent insomnia in patients with cancer,,Completed,No Results Available,chronic insomnia|cancer,other: homeopathy medicine,changes in sleep efficiency on the insomnia severity index|change in anxiety and depression on hospital anxiety depression scale|change in quality of life on short form-36 scale,"adwin life care|center for homeopathy research, india|sonal foundation, india",All,18 Years to 45 Years   (Adult),Not Applicable,160.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Adwin/chr/1121,September 2014,April 2015,June 2015,"August 4, 2015",,"August 4, 2015","['center for homeopathy research, ahmedabad, gujarat, india center for homeopathy research, jaipur, rajasthan, india']",,https://ClinicalTrials.gov/show/NCT02515006,
98,99,NCT00193817,three field radical esophagectomy versus two field esophagectomy - a prospective trial,,Unknown status,No Results Available,cancer of esophagus,procedure: two field vs three field lymphadenectomy,overall survival|disease-free survival|quality of life,tata memorial hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,700.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH 111/IM-2004|DAECTC/Projno 5 / 2004-05,January 2005,,December 2015,"September 19, 2005",,"February 7, 2006","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193817,esophag
99,100,NCT05368116,effectiveness of video assisted self management program on chemotherapy related side effects .,,Completed,No Results Available,cancer patients,other: video assisted self management program|other: standard of care,"knowledge regarding the management of chemotherapy related side effects.|self efficacy in relation to symptom management relevant to chemotherapy for patients with cancer.|severity of side effects including nausea, vomiting, diarrhea, constipation, mucositis, fever, pain ,dry skin and alopecia related distress.","institute of liver and biliary sciences, india",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ILBS-VASMPCa-103,"November 1, 2021","November 14, 2021","December 5, 2021","May 10, 2022",,"May 10, 2022","['institute of liver & biliary sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT05368116,
100,101,NCT03511781,palliative hypofractionated radiotherapy in advanced incurable breast cancer,HYPORT,Completed,No Results Available,carcinoma breast stage iv,radiation: hypofractionated radiotherapy,proportion of patients with ctcae 4.03 defined grade 3 or more toxicity,tata medical center,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC/TMC/31/14,September 2015,October 2020,March 2021,"April 30, 2018",,"December 17, 2021","['tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03511781,breast
101,102,NCT05278052,standard maintenance therapy (smt) vs local consolidative radiation therapy and smt in om-nsclc,TARGET-02,Recruiting,No Results Available,oligometastatic disease|metastatic non small cell lung cancer,radiation: local consolidative radiation therapy|drug: standard maintenance therapy as decided by the treating medical oncologist,overall survival (os)|progression free survival (pfs )|local control rates of treated sites|new distant metastases|health related qol using the eortc-qlq-c30 questionnaire|health related qol using the eortc- lc13 questionnaire|response rates|toxicity using ctc v5.0 (radiotherapy related acute and late toxicity),tata memorial hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,190.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3445|CTRI/2020/04/024761,"April 20, 2020","April 20, 2026","April 20, 2028","March 14, 2022",,"March 14, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05278052,
102,103,NCT03710018,impact of tumor bed localisation on dosimetry boost irradiation in patients undergoing breast conserving surgery,,Unknown status,No Results Available,breast carcinoma,,volume of ptv|ptv coverage by 95% isodose line|cosmesis,tata memorial centre,All,"18 Years to 90 Years   (Adult, Older Adult)",,21.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1860,"July 1, 2017","June 30, 2019","June 30, 2019","October 17, 2018",,"October 17, 2018","['tata memorial hospital, mumbai, maharashtra, india']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/18/nct03710018/prot_sap_000.pdf",https://ClinicalTrials.gov/show/NCT03710018,breast
103,104,NCT00193739,neoadjuvant chemotherapy followed by surgery versus concurrent chemoradiation in carcinoma of the cervix,NACTcervix,Unknown status,No Results Available,cancer of cervix,"drug: nact|procedure: radical abdominal hysterectomy (class iii), bplnd & lower para aortic lymph node sampling|drug: inj.cisplatin|radiation: concurrent chemo radiotherapy",disease free survival|over all survival|rate of distant metastases,tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,635.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,119 of 2003,"September 4, 2003","July 31, 2020","July 31, 2020","September 19, 2005",,"September 20, 2019","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193739,cervix
104,105,NCT05022576,robotic-arm assisted ga-68 psma pet/ct guided transgluteal prostate biopsy,,Completed,No Results Available,prostate cancer,diagnostic test: robotic arm assisted psma pet/ct guided prostate biopsy,the diagnostic yield of the procedure|safety of the procedure,postgraduate institute of medical education and research,Male,"Child, Adult, Older Adult",Not Applicable,78.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,INT/IEC/2019/001994,"January 30, 2019","September 30, 2020","September 30, 2020","August 26, 2021",,"August 26, 2021","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT05022576,prostat
105,106,NCT00391183,palliative biliary stenting on the quality of life of patients with unresectable carcinoma gallbladder with hiliar block.,,Completed,No Results Available,gallbladder cancer,procedure: biliary stenting,improvement in the physical functioning scale (containing five items) of eortc qlq-30 one month after after biliary stenting.|improvements in other functional and social scales and single items of eortc qlq-30|survival|hospital stay|cost of therapy|complications|performance status change,"all india institute of medical sciences, new delhi",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,GE-CAGB/2005,January 2006,December 2012,December 2012,"October 23, 2006",,"July 11, 2013","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00391183,bladder
106,107,NCT03039465,a novel modified tracheo-esophageal voice prosthesis for total laryngectomy patients,TEP,Unknown status,No Results Available,laryngeal cancer|hypopharynx cancer,device: modified trans-esophageal prosthesis,change in voice quality|change in presence / absence of fluid leak,healthcare global enterprise ltd.,All,"Child, Adult, Older Adult",Not Applicable,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HCG/SX/003/2016,"April 18, 2016","December 31, 2017","December 31, 2017","February 1, 2017",,"February 1, 2017","['healthcare global enterprises ltd, bangalore, karnataka, india']",,https://ClinicalTrials.gov/show/NCT03039465,
107,108,NCT05137561,robotic-arm assisted 68 ga psma pet/ct guided prostate biopsy versus mr directed trus guided prostate biopsy,PROBIOP,Recruiting,No Results Available,prostate cancer|prostate neoplasm,procedure: psma pet guided prostate biopsy|procedure: mri directed trus guided prostate biopsy,diagnostic yield of mpmri directed vs pet/ct directed prostate biopsy|diagnostic performance of mpmri directed vs pet/ct directed prostate biopsy|incidence of procedure related complications,postgraduate institute of medical education and research,Male,"45 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NK/7840/MD/624,"October 25, 2021","October 31, 2022","December 31, 2022","November 30, 2021",,"November 30, 2021","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT05137561,prostat
108,109,NCT05158907,patient reported scale vs ctcae grading: a prospective comparator study,PROSE,Recruiting,No Results Available,gastrointestinal cancer,other: patient reported adverse event scale,improvement in detection rate of adverse effects of patient reported adverse effect (ae) scale versus the standard ctcae grading by a physician.|patient compliance to filling the patient reported ae scale.|early intervention using patient reported ae scale and preventing severity of ae in the subsequent chemotherapy cycles.|timely chemotherapy dose adjustments using patient reported adverse effect scale|reduction in cost of cancer care using patient reported ae scale.,tata medical center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,220.0,Other,Interventional,"Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention",2021/TMC/239/IRB50,"November 23, 2021","December 31, 2022","February 28, 2023","December 15, 2021",,"January 13, 2022","['tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT05158907,gastric
109,110,NCT00193804,a trial comparing intensity modulated radiation therapy (imrt) with conventional radiation therapy in stage iib carcinoma cervix,,Completed,No Results Available,cancer of cervix,radiation: imrt,to compare the normal tissue toxicities (acute & late) of standard radiation therapy with imrt|to compare the disease free survivals|to compare the quality of life in both the groups|to compare the overall survivals,tata memorial hospital|varian medical systems,Female,"18 Years to 65 Years   (Adult, Older Adult)",,200.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,TMH/158/2004/Cx_IMRT TRIAL,February 2005,"June 20, 2017","June 30, 2019","September 19, 2005",,"September 16, 2019","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193804,cervix
110,111,NCT02757222,dose escalation versus standard in laryngopharyngeal cancers,INTELHOPE,Recruiting,No Results Available,malignant neoplasm of oropharynx stage iii|malignant neoplasm of larynx stage iii|malignant neoplasm of hypopharynx stage iii|malignant neoplasm of oropharynx stage iva|malignant neoplasm of oropharynx stage ivb|malignant neoplasm of larynx stage iv|malignant neoplasm of hypopharynx stage iva|malignant neoplasm of hypopharynx stage ivb,radiation: escalated dose|radiation: standard dose,"number of patients with grade 3 through grade 5 adverse events that are related to dose escalation, graded according to nci ctcae version 4.0|efficacy (improvement in complete response rates at 2 years) of dose escalation in intermediate and high risk oropharyngeal cancer (opc) patients and in node positive, locally advanced laryngeal and hypopharyngeal cancer patients.",tata medical center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC/TMC/38/14,January 2016,December 2022,December 2022,"May 2, 2016",,"December 17, 2021","['tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT02757222,skin
111,112,NCT04809324,gross examinations versus frozen section for assessment of surgical margins in oral cancers,,Recruiting,No Results Available,oral cavity cancer,procedure: gross examination of the resection specimen|procedure: frozen section,"local recurrence free survival (lrfs) between two arms|accuracy of gross examination|sensitivity, specificity, positive predictive value (ppv) and negative predictive value (npv) of ge and fs for the assessment of surgical margin",dr.pankaj chaturvedi|tata memorial centre,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1206.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",protocol no 3541|CTRI/2021/03/032015,"November 15, 2021",December 2026,June 2028,"March 22, 2021",,"April 27, 2022","['tata memorial hospital, mumbai, maharashtra, india actrec,advanced centre for treatment, research and education in cancer, navi mumbai, raigad, india mahamana pandit madan mohan malaviya cancer centre, varanasi, uttar pradesh, india']",,https://ClinicalTrials.gov/show/NCT04809324,
112,113,NCT05144100,surgery vs chemoradiation for oropharyngeal cancer- a phase ii/iii integrated design randomized control trial,SCOPE,Not yet recruiting,No Results Available,stage iii oropharyngeal (p16-negative) carcinoma ajcc v8|stage iv oropharyngeal (p16-negative) carcinoma ajcc v8,procedure: surgery with or without neck dissection|radiation: radiation|drug: cisplatin based chemotherpay,event free survival.(efs)|overall survival (os)|disease free survival (dfs)|progression free survival (pfs)|locoregional control (lrc)|subjective swallowing function|m.d. anderson dysphagia inventory head and neck cancer-specific quality of life and patietn reproted outcomes (qol and pros)|eortc hn35 head and neck cancer-specific quality of life and patietn reproted outcomes (qol and pros),"tata memorial centre|all india institute of medical sciences, new delhi|amrita institute of medical sciences & research center",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,498.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3582,"December 1, 2021","June 30, 2029","June 30, 2031","December 3, 2021",,"December 3, 2021","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05144100,
113,114,NCT00193791,concomitant chemoradiation in advanced stage carcinoma cervix,CRACx,Completed,No Results Available,cancer of cervix,other: ct + rt,to compare the disease free survivals.|to compare the overall survivals|to compare the distant metastasis rates|to compare the quality of life in both the groups|to compare the normal tissue toxicities (acute & late) of standard radiation therapy with concomitant chemo-radiation.,tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,850.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH/114/2003/CRACX TRIAL,"July 7, 2003",May 2017,December 2017,"September 19, 2005",,"September 17, 2019","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193791,cervix
114,115,NCT05277844,local consolidative radiation therapy plus tki versus tki alone in driver mutated om-nsclc,TARGET-01,Recruiting,No Results Available,oligometastatic disease|non-small cell lung cancer|driver mutation,radiation: local consolidative radiation therapy|drug: tki,progression free survival (pfs)|overall survival (os)|local control rates|health related quality of life using the eortc-qlq-c30 questionnaire|health related quality of life using the eortc-lc13 questionnaire|toxicities using ctc v5.0 (radiotherapy related),tata memorial hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,106.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3338|CTRI/2019/11/021872,"November 11, 2019","November 11, 2023","November 11, 2025","March 14, 2022",,"March 14, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05277844,
115,116,NCT02891460,pilot study to evaluate the clinical response to mitomycin-c in hydrogel (tc-3) administered intravesically in nmibc patients,,Completed,No Results Available,urinary bladder neoplasms|urologic neoplasms|neoplasms|urinary bladder diseases|urologic diseases,device: 40 mg mmc in 40 ml tc-3.|device: 80 mg mmc in 40 ml tc-3.,subject's degree of response at 2-4 weeks post-treatment|adverse events (ae) including serious adverse events (sae)|anesthesia information|blood and urine tests|the degree of pain during treatment|gel clearance and urinary patency|tumor recurrence rate during 12 months post- 2-4 week follow-up visit in complete response (cr) subjects.|lesion mass by time point (screening and 2-4 weeks post-treatment),urogen pharma ltd.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TC-3 /2012 / P2,January 2013,February 2014,March 2015,"September 7, 2016",,"September 8, 2016","['rajiv gandhi cancer institute & research center, delhi, new delhi, india']",,https://ClinicalTrials.gov/show/NCT02891460,bladder
116,117,NCT02350855,impact of nutritional intervention in indian female cancer cachexia patients,,Completed,No Results Available,cachexia|cancer,dietary supplement: improved atta|other: nutritional counseling|behavioral: physical activity counseling,"body weight|mid upper arm circumference (muac)|body fat percentage (bf%)|nutritional status assessment (indian migrant study food frequency questionnaire (ims-ffq), two day 24 hour dietary recall and patient generated subjective global assessment)|physical activity assessment (indian migrant study physical activity questionnaire (ims-paq)|quality of life (qol) assessment (eortc-qlq- c30 questionnaire)|haemoglobin (haemoglobin levels)|serum albumin (serum albumin levels)","university of westminster|all india institute of medical sciences, new delhi",Female,"18 Years and older   (Adult, Older Adult)",Phase 2,62.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,12_13_11,December 2013,July 2014,August 2014,"January 30, 2015",,"January 30, 2015","['all india institute of medical sciences, new delhi, india university of westminster, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT02350855,
117,118,NCT02561143,"effectiveness of nutritional counselling and ""improved atta"" supplementation in cachexic adult indian cancer patients",,Completed,No Results Available,cachexia|cancer,dietary supplement: improved atta|dietary supplement: wheat flour|behavioral: physical activity counseling|other: nutritional counseling,change in body weight at 6 months|change in mid upper arm circumference (muac) at 6 months|change in body fat percentage (bf%) at 6 months|indian migrant study food frequency questionnaire (ims-ffq)|two day 24 hour dietary recall|patient generated subjective global assessment (pgsga)|indian migrant study physical activity questionnaire (ims-paq)|change in quality of life by eortc-qlq- c30 (quality of life questionnaire) at 6 months|change in haemoglobin levels at 6 months|change in serum albumin levels|change in c-reactive protein levels at 6 months,"university of westminster|all india institute of medical sciences, new delhi",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,IEC/NP-339/08.10.2014,April 2015,November 2015,May 2016,"September 25, 2015",,"June 22, 2017","['all india institute of medical sciences, new delhi, india university of westminster, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT02561143,
118,119,NCT00147862,does tranexamic acid administration reduce blood loss during head and neck surgery?,,Completed,No Results Available,head and neck neoplasms,drug: tranexamic acid,"administration of tranexamic acid reduces perioperative blood loss and thus,|requirement for replacement of blood in head and neck surgeries|to observe procoagulant effects leading to complications, if any.|cost effectiveness of the drug in terms of savings on blood transfusion requirements.",tata memorial hospital,All,"Child, Adult, Older Adult",Phase 3,240.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,TMH/185/IM-2004,May 2005,,January 2007,"September 7, 2005",,"February 7, 2007","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00147862,
119,120,NCT01182831,trial comparing two techniques of celiac plexus neurolysis for treatment of pain in carcinoma pancreas,,Unknown status,No Results Available,pancreatic cancer,procedure: percutaneous fluoro guided celiac plexus neurolysis|procedure: eus guided neurolysis,immediate pain relief,"asian institute of gastroenterology, india",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AIG-GIA-201001,January 2010,January 2011,January 2011,"August 17, 2010",,"August 30, 2010","['asian institute of gastroenterology, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT01182831,pancreat
120,121,NCT01124409,evaluation of 3dcrt versus igrt and analysis of early response in head and neck cancer.,,Unknown status,No Results Available,head and neck cancer|carcinoma oropharynx|carcinoma pyriform sinus|carcinoma larynx,radiation: epid verification|radiation: cbct verification,compare the early tumour response between 3dcrt and igrt in head and neck cancer.|to assess and compare early and late toxicities between 3dcrt and igrt in head and neck cancer|to find out the different doses received by target and organs at risk during the various phases of adaptive rt.,"all india institute of medical sciences, new delhi",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,41.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3DIGHNC,December 2009,August 2011,August 2011,"May 17, 2010",,"June 23, 2011","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01124409,brain
121,122,NCT00408018,phase i study of p276-00 in patients with advanced refractory neoplasms,,Terminated,No Results Available,neoplasm,drug: p276-00,"safety assessment by laboratory investigations (hematology,biochemistry, urinalysis), ecg, holter monitoring,physical examination|tumor measurements,pharmacokinetics, maldi- tof to study plasma peptide pattern",piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/02/05,March 2006,August 2008,October 2008,"December 5, 2006",,"January 1, 2009","[""nizam's institute of medicai sciences, hyderabaad, andhra pradesh, india global hospital, hyderabad, andhra pradesh, india tata memorial hospital, mumbai, maharashtra, india""]",,https://ClinicalTrials.gov/show/NCT00408018,
122,123,NCT02142907,evaluation of two boost radiation schedules in post lumpectomy early stage carcinoma breast,,Completed,No Results Available,breast cancer|adverse effect of radiation therapy,,radiation toxicities- acute and early-late|cosmetic outcome and local control iii) local control,postgraduate institute of medical education and research,Female,"20 Years to 75 Years   (Adult, Older Adult)",,100.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,BD,January 2013,January 2020,December 2020,"May 20, 2014",,"June 23, 2021","['dr budhi singh yadav, chandigarh , india']",,https://ClinicalTrials.gov/show/NCT02142907,breast
123,124,NCT04489368,response prediction to neoadjuvant chemoradiation in esophageal cancer using artificial intelligence & machine learning,QARC,"Active, not recruiting",No Results Available,esophageal neoplasm,radiation: neo-adjuvant radiotherapy|drug: neo-adjuvant chemotherapy|procedure: esophagectomy,"develop models to predict pcr based on pre-neoadjuvant imaging modalities|perform a clinical audit of patient outcomes (os, rfs, pcr rate) after new-adjuvant chemoradiation and esophagectomy","dr kundan singh chufal|rajiv gandhi cancer institute & research center, india",All,"18 Years and older   (Adult, Older Adult)",,150.0,Other,Observational,Observational Model: Cohort|Time Perspective: Other,RGCIRC/IRB/80/2020,"January 16, 2020",July 2022,July 2022,"July 28, 2020",,"May 3, 2022","['illawarra cancer care centre, wollongong, australia rajiv gandhi cancer institute & research center, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT04489368,esophag
124,125,NCT02868151,effect of oral vitamin c in assessing the severity of oral mucositis in chemoradiation of head and neck cancers,,Completed,No Results Available,oral mucositis,drug: ascorbic acid|drug: zinc acetate,world health organization criteria of grading oral mucositis.for head and neck cancer patients,panineeya mahavidyalaya institute of dental sciences & research centre|saveetha university|mnj institute of oncology & regional cancer center,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,180.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,ECR/227/INSP/AP/2014,August 2016,December 2017,October 2018,"August 16, 2016",,"March 20, 2019","['mnj institute of oncology & regional cancer center, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT02868151,
125,126,NCT02794337,tace vs tace+sbrt for unresectable hepatocellular cancer,TACE-SBRT,Recruiting,No Results Available,"carcinoma, hepatocellular",radiation: sbrt|procedure: tace|drug: sorafenib,in-field progression free survival|cause specific survival|response assessment after treatment|quality of life assessment of patients over a period of time|toxicity assessment,tata memorial hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,67.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMC IEC III 91,December 2014,January 2024,January 2024,"June 9, 2016",,"April 27, 2022","['advanced centre for treatment, research and education in cancer, tata memorial centre, navi mumbai, maharashtra, india advanced centre of treatment research and education in cancer,tata memorial centre, navi mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02794337,liver
126,127,NCT02818530,correlation between intraocular pressure measurement by tomometer and anterior chamber depth measurement by ultrasound,,Terminated,No Results Available,urological cancer|gastrointestinal cancer|malignant female reproductive system neoplasm,device: iop by tonometer|device: anterior chamber depth measurement by ultrasound,changes in intraocular pressure measured by tonometer|changes in anterior chamber depth measured by ultrasound.|time dependent changes in iop during prolonged steep trendelenberg position.|time dependent changes in anterior chamber depth during prolonged trendelenberg position.,tata memorial centre,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PN 1690,"June 21, 2017","May 7, 2018","May 7, 2018","June 29, 2016",,"May 14, 2018","['sohan lal solanki, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02818530,gastric skin
127,128,NCT00776659,an observational study of indian breast cancer patients receiving adjuvant therapy with aromasin,,Terminated,Has Results,breast neoplasms,other: aromasin,"number of participants with locoregional/distant recurrence of primary breast cancer|number of participants with appearance of second primary or contralateral breast cancer|number of participants who died|number of participants who discontinued aromasin therapy|number of participants with gynecological, cardiac, thromboembolic, musculoskeletal and menopausal adverse events (aes)|change from baseline in high density lipoprotein-cholesterol (hdl-c), low density lipoprotein-cholesterol (ldl-c), total cholesterol and triglycerides at month 6, 12, 18, 24, 30, 36 and 42|change from baseline in bone mineral density (bmd) at month 6, 12, 18, 24, 30, 36 and 42",pfizer,Female,"18 Years to 75 Years   (Adult, Older Adult)",,39.0,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,A5991088,December 2008,September 2012,September 2012,"October 21, 2008","November 19, 2013","November 19, 2013","['pfizer investigational site, bangalore, karnataka, india pfizer investigational site, ludhiana, punjab, india pfizer investigational site, ludhiana, punjab, india pfizer investigational site, lucknow, uttar pradesh, india']",,https://ClinicalTrials.gov/show/NCT00776659,breast
128,129,NCT00855985,anastomotic techniques in pancreaticoduodenectomy,PG/PJ,Unknown status,No Results Available,pancreatic cancer|pancreatic fistula,procedure: type of anastomosis after pancreaticoduodenectomy,pancreatic fistula rate|mortality|hospital stay|need for postoperative intervention|major complication,lakeshore hospital,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,312.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,001,July 2004,October 2011,October 2011,"March 5, 2009",,"September 27, 2011","['lakeshore hospital & research center, cochin, kerala, india']",,https://ClinicalTrials.gov/show/NCT00855985,pancreat
129,130,NCT05022342,study of pik3ca mutations and effectiveness and tolerability outcomes of alpelisib in real-world,SPEAR,Recruiting,No Results Available,breast cancer,other: alpelisib plus fulvestrant,"part a: percentage of patients with tumors harboring a pik3ca mutation|part b: clinical benefit rate (cbr) as measured by recist 1.1|part a: age at early stage (initial) disease, and advanced/metastatic disease diagnosis|part a: clinical characteristics of the disease at early (initial) stage of diagnosis- tnm staging|part a: clinical characteristics of the disease at early (initial) stage of diagnosis - receptor expression|part a: clinical characteristics of advanced / metastatic disease stage - disease free interval (dfi)|part a: clinical characteristics of advanced / metastatic disease stage - number of metastasis|part a: clinical characteristics of advanced / metastatic disease stage - location of metastasis|part a: clinical characteristics of advanced / metastatic disease stage - receptor expression|part a: prior number of lot for the advanced / metastatic disease|part a: prior treatment type|part a: prior treatment sequence by lot|part a: time to next treatment|part a: reason (s) for discontinuation of prior therapy|part a: pik3ca mutation positive patients not prescribed alpelisib|part b: progression free survival (pfs) by recist 1.1|part b: overall response rate (orr) by recist 1.1|partb: duration of response (dor) by recist 1.1|part b: tolerability of alpelisib plus fulvestrant measured by adverse events (aes)|part b: number of patients with laboratory abnormalities",novartis pharmaceuticals|novartis,All,"18 Years to 100 Years   (Adult, Older Adult)",,200.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CBYL719CIN02,"October 27, 2021","September 30, 2025","September 30, 2025","August 26, 2021",,"January 12, 2022","['novartis investigative site, mumbai, maharashtra, india novartis investigative site, bhubaneshwar, orissa, india novartis investigative site, kolkata, west bengal, india novartis investigative site, kolkata, india']",,https://ClinicalTrials.gov/show/NCT05022342,breast
130,131,NCT03518853,short course radiotherapy for localized prostate cancer,SHORT,Completed,No Results Available,adenocarcinoma of prostate,radiation: short-course hypofractionated once-weekly radiation therapy,incidence of acute gastrointestinal and genitourinary toxicity as assessed by national cancer institute(nci) common terminology criteria for adverse events (ctcae) v4.0|biochemical control (with measurement of prostate specific antigen measured in ng/ml)|incidence of late gastrointestinal toxicity as assessed by nci ctcae v4.0|incidence of late genitourinary toxicity as assessed by nci ctcae v4.0|assessing the quality of life by measuring patient reported outcomes using european organization for research and treatment of cancer (eortc) quality of life questionnaire (qlq) c30 questionnaire|assessing the quality of life by measuring patient reported outcomes using european organization for research and treatment of cancer (eortc) quality of life questionnaire (qlq) pr25 questionnaire,tata medical center,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC/TMC/0612|CTRI/2016/02/006671,December 2013,"February 15, 2019","February 15, 2019","May 8, 2018",,"October 14, 2020","['tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03518853,prostat gastric kidney
131,132,NCT05236946,observation or upfront cranial rt in oncogene mutated nsclc with asymptomatic bm: a phase iii rct,,Recruiting,No Results Available,asymptomatic brain metastases|driver mutation positive non-small cell lung cancer,radiation: stereotactic radiosurgery/whole brain radiotherapy|drug: tyrosine kinase inhibitor,intracranial progression free survival at 24 months|overall survival|progression free survival|neurocognition toxicity|toxicity using ctc v5.1|local control,tata memorial hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,190.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTRI/2020/08/027279|IEC/3470,"November 10, 2020",July 2024,July 2026,"February 11, 2022",,"February 11, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05236946,brain
132,133,NCT00193830,high dose rate (hdr) versus low dose rate (ldr) brachytherapy in carcinoma cervix,,Completed,No Results Available,cancer of cervix|cervical cancer|cancer of the cervix|cervix cancer,procedure: high dose rate vs low dose rate brachytherapy,to asses the feasibility of high dose rate brachytherapy|to compare the early and late reactions of high dose rate brachytherapy in contrast with low dose rate brachytherapy.|to compare the over-all survival and disease free survival in the two regimens.,tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,750.0,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH/11062/1996/Cx_HDR STUDY,May 1996,,January 2007,"September 19, 2005",,"May 6, 2015","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00193830,cervix
133,134,NCT01209338,acceptability and feasibility of human papilloma virus vaccine,,Unknown status,No Results Available,cervical cancer,behavioral: health education,"to determine the knowledge, attitude and practice about cervix cancer, human papilloma virus (hpv).|. to identify the barriers and facilitators perceived by women for vaccinating their daughters against hpv infection and cervix cancer.",tata memorial hospital,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),655,November 2009,December 2010,December 2010,"September 27, 2010",,"September 28, 2010","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01209338,cervic
134,135,NCT04889599,a bioequivalence study of docetaxel injection in patients with solid tumours,,Completed,No Results Available,docetaxel|solid tumours|bioequivalence,drug: bh009 (docetaxel injection)|drug: docetaxel injection,cmax of docetaxel injection|auc of docetaxel injection|to evaluate of safety and tolerability of bh009,"zhuhai beihai biotech co., ltd",All,"18 Years and older   (Adult, Older Adult)",Phase 3,46.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,20-VIN-0225,"April 29, 2021","September 17, 2021","September 24, 2021","May 17, 2021",,"January 11, 2022","['hcg city cancer center, andra, india nirmal hospital pvt. ltd, gujrat, india hcg manavata cancer centre, mahara, india']",,https://ClinicalTrials.gov/show/NCT04889599,
135,136,NCT01143922,role of intraoperative ultrasound in gastrointestinal (gi) malignancies,,Unknown status,No Results Available,ultrasonography|gastrointestinal disease|malignancy,,,"all india institute of medical sciences, new delhi",All,"10 Years to 90 Years   (Child, Adult, Older Adult)",,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IOUS,August 2009,,,"June 15, 2010",,"June 15, 2010","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01143922,gastric skin
136,137,NCT04588402,"impact of hpv vaccination on prevention of cervical hpv infection in sikkim, india",HPV-Vac-S,Recruiting,No Results Available,cervical cancer,"biological: the study being observational in nature, there is no intervention. the investigators will only collect cervical samples from married women within a specified age range at different intervals.",the reduction in the point prevalence of genotype-specific hpv infection in women within 7 years of initiation of hpv vaccination compared to that at baseline|the difference in the point prevalence of chlamydia trachomatis infection in women within 7 years of initiation of hpv vaccination compared to that at baseline,"international agency for research on cancer|department of health and family welfare, government of sikkim|sikkim manipal institute|rajiv gandhi centre for biotechnology",Female,18 Years to 22 Years   (Adult),,5500.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SMIMS/IEC/C/2020-09,"October 1, 2020","June 1, 2025","December 31, 2025","October 19, 2020",,"February 17, 2021","['sikkim manipal hospital, gangtok, sikkim, india']",,https://ClinicalTrials.gov/show/NCT04588402,cervic
137,138,NCT01307774,"survey of predictors of human papillomavirus (hpv) vaccination among parents of rural adolescent girls in mysore, india",,Unknown status,No Results Available,human papillomavirus|cervical cancer,,parental acceptability of hpv vaccine|knowledge about hpv and cervical cancer,"purnima madhivanan|florida international university|public health research institute, india",All,18 Years to 55 Years   (Adult),,800.0,Other,Observational,Time Perspective: Cross-Sectional,IISP38250,June 2014,June 2015,December 2015,"March 3, 2011",,"October 29, 2014","['public health research institute of india, mysore, karnataka, india public health research institute of india, mysore, karnataka, india']",,https://ClinicalTrials.gov/show/NCT01307774,
138,139,NCT01762410,clinical study of oral pi3k/mtor inhibitor in patients with advanced refractory solid tumors,,Suspended,No Results Available,advanced refractory solid tumors,drug: p7170,"maximum tolerated dose|number of subject with adverse events|pharmacokinetic profile(cmax,tmax and auc)|activity of p7170 based on selected biomarkers|objective response",piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P7170/70/11,September 2012,November 2015,March 2016,"January 7, 2013",,"September 29, 2014","['usc norris comprehensive cancer center, los angeles, california, united states medanta duke research institute (mdri), gurgaon, haryana, india central india cancer research institute, nagpur, maharashtra, india meenakshi mission hospital & research centre, madurai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT01762410,
139,140,NCT01913275,comparison between endoscopic stenting and cholecystojejunostomy for preoperativedrainage before pancreaticoduodenectomy,,Unknown status,No Results Available,periampullary cancer|pancreatic cancer,procedure: endoscopic stenting|procedure: cholecystojejunostomy,technical success|successful drainage|procedure-related complication: was defined complications directly related to stent insertion/cj|intraoperative assessment|1. procedure-related mortality|2. duration of hospital stay|3. postoperative complication:|a. wound infection|b. intra-abdominal abscess|c. postoperative haemorrhage|d. pancreaticojejunal leak|e. bile leak,"all india institute of medical sciences, new delhi",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,134.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GIS/2/2001,March 2006,December 2013,February 2014,"August 1, 2013",,"August 1, 2013","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01913275,pancreat
140,141,NCT01178736,early detection of cancers in low resource countries,,Unknown status,No Results Available,breast neoplasms|uterine cervical neoplasms|ovarian neoplasms|endometrial neoplasms,procedure: breast cancer screening and diagnosis|procedure: cervical cancer screening and diagnosis|procedure: ovarian cancer screening and diagnosis|procedure: endometrial cancer screening and diagnosis,"the effectiveness of an innovative, low-cost screening and diagnostic methodology|effectiveness of cbe and ultrasonography for breast cancer detection",woman's cancer foundation,Female,30 Years to 64 Years   (Adult),,36000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,WCF-2011-BRA-IND-CAM,March 2011,March 2014,March 2014,"August 10, 2010",,"August 10, 2010","['hospital de cancer de barretos, sao paolo, brazil sihanouk hospital center of hope, hope worldwide cambodia, phnom penh, cambodia manipal healthcare group, goa, india']",,https://ClinicalTrials.gov/show/NCT01178736,breast cervic ovari fibroid
141,142,NCT05320328,radio frequency ablation in unresectable malignant biliary obstruction,MBOP,Recruiting,No Results Available,bile duct neoplasms|gall bladder carcinoma,device: radio frequency ablation,prospectively evaluate the safety and efficacy of combining intraductal radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction.|stent patency at 1 year,"asian institute of gastroenterology, india",All,"18 Years to 75 Years   (Adult, Older Adult)",,50.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RFA,"June 10, 2021","June 10, 2022","December 10, 2022","April 11, 2022",,"April 11, 2022","['asian institute of gastroenterology, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT05320328,bladder biliari
142,143,NCT05038501,prevalence of comorbidities in patients undergoing oncosurgeries at tertiary cancer institute in north india.,oncosurgery,Completed,No Results Available,comorbidities and coexisting conditions,other: to study comorbidities in patients undergoing oncosurgeries,to study coronary artery disease in patients undergoing oncosurgeries|to study diabetes mellitus in patients undergoing oncosurgeries.|to study hypothyroidism in patients undergoing oncosurgeries,"rajiv gandhi cancer institute & research center, india",All,"35 Years to 80 Years   (Adult, Older Adult)",,150.0,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,RGCI \ MK 1967,"July 1, 2021","August 31, 2021","August 31, 2021","September 9, 2021",,"October 4, 2021","['anita kulkarni, delhi, india']",,https://ClinicalTrials.gov/show/NCT05038501,
143,144,NCT03067922,postmastectomy pain syndrome in an indian cancer hospital,,Completed,No Results Available,pain syndrome|mastectomy|quality of life,other: non interventional study,incidence of post mastectomy pain syndrome (pmps)|pain severity|impact on daily function|impact on quality of life,tata memorial centre,Female,"18 Years to 80 Years   (Adult, Older Adult)",,120.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TataMC,"March 6, 2017","March 6, 2018","September 6, 2018","March 1, 2017",,"September 11, 2019","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03067922,pain
144,145,NCT03470948,surgical apgar score after whipple procedure in pancreatic cancer patients,,Terminated,No Results Available,postoperative complications,other: observe postoperative complications,incidence of major postoperative complications and/or death within 30 days of surgery,tata memorial hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",,263.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TataMH,"March 27, 2018","March 26, 2021","March 26, 2021","March 20, 2018",,"April 1, 2021","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03470948,
145,146,NCT00667563,vaccine therapy in preventing hpv in hiv-positive women in india,,Completed,Has Results,cervical cancer|nonneoplastic condition|precancerous condition,"biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|genetic: dna analysis|genetic: polymerase chain reaction|other: cytology specimen collection procedure|procedure: colposcopic biopsy","safety, in terms of grade 3 or 4 adverse events attributed to the vaccine, according to nci ctcae v3.0|number of patients with significant decrease (at the 0.05 significance level) in cd4+ cell count|number of patients with detectable hpv antibodies to hpv 16 at week 28|number of patients with a significant increase in hiv viral load|number of patients with detectable antibodies to hpv-6|number of patients with detectable antibodies to hpv-11|number of patients with detectable antibodies to hpv-18","aids malignancy consortium|national cancer institute (nci)|the emmes company, llc",Female,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,150.0,Other|NIH|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AMC-054|U01CA121947|CDR0000593634,August 2009,November 2012,November 2012,"April 28, 2008","April 11, 2014","February 29, 2016","['yrg care, chennai, india']",,https://ClinicalTrials.gov/show/NCT00667563,cervic
146,147,NCT00715286,neoadjuvant chemotherapy in advanced epithelial ovarian cancer (eoc): a phase iii randomized study,,Unknown status,No Results Available,ovarian carcinoma,other: timing of surgery,to compare the optimal debulking rate in primary surgery group and neoadjuvant chemotherapy group|post operative morbidity,"all india institute of medical sciences, new delhi",Female,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,180.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I473,November 2001,April 2007,June 2009,"July 15, 2008",,"July 15, 2008","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00715286,ovari
147,148,NCT03249766,study of prevalence of ipsilateral shoulder pain in patients after thoracic surgeries,,Completed,No Results Available,lung cancer,other: observational,prevalence of ipsilateral shoulder pain,tata memorial hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",,370.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1900,"August 22, 2017","August 21, 2018","August 21, 2018","August 15, 2017",,"September 25, 2018","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03249766,
148,149,NCT03962595,patient satisfaction survey (pss) in breast clinic,PSS,Unknown status,No Results Available,breast cancer,,linguistic validation of patient satisfaction survey (pss) questionnaires in hindi and marathi.|proportion of patients having mean overall satisfaction score <70|to compare the level of overall patient satisfaction between paid and service patients: percentage of patients having overall score below 75 of the maximum 125,tata memorial centre,All,"18 Years to 70 Years   (Adult, Older Adult)",,340.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,1835,"March 23, 2017","December 31, 2019","December 31, 2019","May 24, 2019",,"May 24, 2019","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03962595,breast
149,150,NCT02803385,comparison of patient controlled & continuous epidural analgesia in thoraco-abdominal surgeries in cancer patients,,Completed,No Results Available,pain,other: continous epidural analgesia|other: patient controlled epidural analgesia,"to compare the pain scores during rest and movement with continuous epidural infusion (cei) vs. patient controlled epidural analgesia (pcea)|to compare patient satisfaction between the two groups using verbal rating scale|to assess the incidence of side effects in both groups including hypotension, motor weakness, pruritus, nausea, vomiting and any other",tata memorial centre,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",1681,July 2016,December 2018,January 2019,"June 17, 2016",,"October 6, 2021","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02803385,pain
150,151,NCT02736604,evaluation of impact of nitrous oxide on ponv in breast surgeries,,Completed,No Results Available,breast cancer,drug: nitrous oxide anesthesia|drug: air anesthesia|device: laryngeal mask airway (lma supreme size 3/4|drug: sevoflurane,incidence and severity of post operative nausea and vomiting|measurement of pain score and analgesic requirements|airway device cuff pressures,tata memorial hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,250.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",project number 1650,May 2016,November 2016,February 2017,"April 13, 2016",,"April 26, 2017","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02736604,breast
151,152,NCT01279135,tomotherapy vs conventional radiation for adjuvant pelvic rt in ca cervix,PARCER,Completed,No Results Available,cancer cervix,radiation: conventional radiation|radiation: tomotherapy based igrt,late bowel toxicity ≥ grade ii|to identify small bowel dose volume characteristics that predict for ≥ grade ii late toxicity|to evaluate acute toxicity difference in two study arms using ctcae version 3.0|preoperative functional imaging features that predict for local and distant recurrence will be identified|to compare quality of life between tomotherapy vs conventional radiotherapy arm using eortc qlq c30|to compare quality of life between tomotherapy vs conventional radiotherapy arm using eortc qlq cx24,tata memorial hospital,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,300.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Project 803,"January 1, 2011","December 30, 2019","January 31, 2020","January 19, 2011",,"June 11, 2020","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01279135,cervix
152,153,NCT00407498,open label phase i study of p276-00 in patients with advanced refractory neoplasms,,Completed,No Results Available,neoplasm,drug: p276-00,"to determine the maximum tolerated dose and dose limiting toxicity of selective cdk inhibitor p276-00 in patients with advanced refractory neoplasms.|to determine the toxic effects, pharmacokinetics and clinical response of this regimen.",piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/01/04,May 2005,March 2008,September 2008,"December 5, 2006",,"January 1, 2009","[""juravinsky cancer centre, hamilton, ontario, canada kingston general hospital, kingston, ontario, canada nizam's institute of medicai sciences, hyderabaad, andhrapradesh, india""]",,https://ClinicalTrials.gov/show/NCT00407498,
153,154,NCT04972630,r21 india pal-care evaluation,,Recruiting,No Results Available,cancer palliative care,behavioral: pal-care|behavioral: control-usual care,average score for quality of life (qol)|palliative care outcomes,"medical university of south carolina|national cancer institute (nci)|tata medical center, kolkata, india",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,90.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",00089815|1R21CA252850-01|2019/GOVT/25/IRB8|2019-3793,"November 1, 2021",July 2022,July 2022,"July 22, 2021",,"November 4, 2021","['tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT04972630,
154,155,NCT01291095,accelerated fractionation radiotherapy (afrt) versus concurrent chemoradiotherapy (crt) in locally advanced head and neck squamous cell carcinoma,,Unknown status,No Results Available,head and neck cancer,drug: cisplatin|radiation: external beam radiotherapy,to compare the loco-regional tumor control rate between afrt & crt in locally advanced head and neck squamous cell carcinomas.|to compare the toxicity between afrt and crt in locally advanced head and neck squamous cell carcinomas|to compare post-therapy quality of life between afrt and crt in locally advanced head and neck squamous cell carcinoma.,"all india institute of medical sciences, new delhi",All,20 Years to 60 Years   (Adult),Phase 2,80.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCTOFAFRTVSCRTINHNSCCAIIMS,February 2011,July 2012,December 2012,"February 8, 2011",,"March 4, 2011","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01291095,
155,156,NCT00889525,study of cabergoline in treatment of corticotroph pituitary tumor,,Completed,No Results Available,cushing's disease|corticotroph adenoma,drug: cabergoline,response in term of mid night cortisol < 5.0 mcg/dl and/or standard two day dexamethasone suppression test < 1.8 mcg/dl,seth gordhandas sunderdas medical college,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC/104/2005,November 2007,,,"April 29, 2009",,"April 29, 2009","['seth gsmc & kem hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00889525,
156,157,NCT01647503,differentially expressed proteins in sporadic parathyroid tumors,,Unknown status,No Results Available,primary hyperparathyroidism|hypercalcemia,,differentially expressed proteins in parathyroid adenomas tissue samples,postgraduate institute of medical education and research,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",,50.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,parathyroid tumorigenesis,July 2012,September 2015,,"July 23, 2012",,"April 16, 2014","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT01647503,thyroid
157,158,NCT00497549,trial comparing side-to-side stapled and hand-sewn esophagogastric anastomosis in neck,,Completed,No Results Available,esophageal cancer,procedure: side-to-side stapled|procedure: hand sewn,anastomotic leakage defined as a radiological defect at the anastomotic site or leakage of swallowed fluid out of the drain site or cervical wound.,"all india institute of medical sciences, new delhi",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,174.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GIS1/2004,July 2004,January 2010,December 2010,"July 6, 2007",,"May 10, 2011","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00497549,esophag
158,159,NCT01464918,safety and efficacy of using master to perform endoscopic submucosal dissection in human,,Unknown status,No Results Available,gastric cancer|colon cancer,"device: endoscopic submucosal dissection (esd) using device, master",total time taken to complete the esd procedure|measure of ease of performing the esd procedure|safety,"national university hospital, singapore|prince of wales hospital, shatin, hong kong|apollo gleneagles hospitals, kolkata",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,7.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E11/058,November 2011,December 2012,December 2012,"November 4, 2011",,"November 4, 2011","['prince of wales hospital, shatin, hong kong, china apollo gleneagles hospitals, kolkata, india national university hospital, singapore, singapore']",,https://ClinicalTrials.gov/show/NCT01464918,gastric colon
159,160,NCT04480619,a study of aip-301 ga-68 positron emission tomography study for imaging of patients with solid tumors: the shiva study,Shiva,Not yet recruiting,No Results Available,pet diagnosis of breast and other neoplasms,diagnostic test: aip-301,specific aims 1: safety and tolerability assessment using aip-301 ga-68 pet/ct imaging in patients with breast neoplasms and other neoplasms: adverse events|specific aims 2: safety and tolerability assessment using aip-301 ga-68 pet/ct imaging in patients with breast neoplasms and other neoplasms: incidence of abnormal vital signs|specific aims 3: safety and tolerability assessment using aip-301 ga-68 pet/ct imaging in patients with breast neoplasms and other neoplasms: incidence of abnormal physical examination|specific aims 4: safety and tolerability assessment using aip-301 ga-68 pet/ct imaging in patients with breast neoplasms and other neoplasms: incidence of abnormal clinical laboratory results|specific aim 1: assess uptake in imaging of tumors to determine the ability of aip-301 ga-68 to localize breast tumors and other neoplasms as determined by pet imaging.|specific aims 2: assess efficacy in imaging of breast tumors and other neoplasms to determine the ability of aip-301 ga-68 to localize cancers as determined by pet imaging.|specific aims 3: assess efficacy in imaging of breast tumors and other neoplasms to determine the ability of aip-301 ga-68 to localize cancers as determined by pet imaging.,"advanced imaging projects, llc|all india institute of medical sciences, new delhi|post graduate institute of medical education and research|university of witwatersrand, south africa|university of lausanne hospital|positron pharma|università degli studi di trieste|us department of veterans affairs",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,210.0,Industry|Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,145314,"August 30, 2020","August 30, 2021","August 30, 2021","July 21, 2020",,"July 21, 2020","['postgraduate institute of medical and research, chandigarh, india all india institute of medical sciences, new delhi, india university of witwatersrand, johannesburg, south africa']",,https://ClinicalTrials.gov/show/NCT04480619,breast
160,161,NCT02664103,study of capecitabine and cyclophosphamide administered as a single pill in patients with advanced breast cancer,METRO-ABC,Completed,No Results Available,breast cancer metastatic,drug: fixed-dose combination of capecitabine and cyclophosphamide sar439281,proportion of patients with adverse events|assessment of pk parameter: maximum concentration (cmax)|assessment of pk parameter: time to reach cmax (tmax)|disease control rate (dcr)|objective response rate (orr)|time to progression (ttp)|proportion of patients compliant with treatment,sanofi,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,2.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAPCYR07568|U1111-1166-1149,"January 23, 2016","November 6, 2017","November 6, 2017","January 26, 2016",,"February 1, 2018","['investigational site number 356009, kollkata, india investigational site number 356002, mumbai, india investigational site number 356007, new delhi, india investigational site number 356008, trivandrum, india investigational site number 356001, vellore, india']",,https://ClinicalTrials.gov/show/NCT02664103,breast
161,162,NCT00931008,study to evaluate sid 530 compared to taxotere,,Completed,No Results Available,non-small cell lung cancer,"drug: sid530, taxotere",to test the bioequivalence of sid530 (test) to taxotere|to evaluate the of safety and tolerability of sid530 as compared to the marketed taxotere.,"sk chemicals co., ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,42.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",SID530_2009,October 2009,January 2011,January 2011,"July 2, 2009",,"January 24, 2013","['advanced clinical research pharma, miami, florida, united states gabrail cancer center, canton, ohio, united states city cancer hospital, vijayawada andhrapradesh, ch. venkatka krishnayya, india kamakshi memorial hospital, no-1, radial road, pallikarani, chennai, tamilnadu, india']",,https://ClinicalTrials.gov/show/NCT00931008,
162,163,NCT01151839,a trial to compare preoperative chemoradiation and surgery versus surgery alone in squamous cell carcinoma of oesophagus,,Unknown status,No Results Available,esophageal neoplasms,procedure: esophagectomy|procedure: neoadjuvant chemoradiation followed by surgery,resectability rate|postoperative morbidity|operative mortality|early disease control|treatment toxicity,"all india institute of medical sciences, new delhi",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IESC/T-186/2010,June 2010,July 2012,,"June 29, 2010",,"July 12, 2010","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01151839,esophag
163,164,NCT05187091,the swoar trial sparing of swallowing and aspiration related organs at risk & submandibular gland with intensity modulated radiotherapy versus standard imrt in head and neck squamous cell carcinomas,SWOAR,Recruiting,No Results Available,head and neck neoplasms|swallowing sparing imrt,radiation: swallowing and submandibular sparing imrt,change in swallowing function post radiotherapy|swallowing assessment|aspiration assessment|acute toxicity|late toxicity assessment by rtog|late toxicity assessment by lent soma|treatment outcome: loco-regional tumor control|treatment outcome: overall survival|quality of life assessment: eortc qlq c-30|quality of life assessment: eortc qlq hn35,"all india institute of medical sciences, new delhi",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,136.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2021/05/043810,"July 11, 2021",June 2023,June 2025,"January 11, 2022",,"January 31, 2022","['nci, aiims, jhajjar, haryana, india']",,https://ClinicalTrials.gov/show/NCT05187091,
164,165,NCT03604939,improving access to control of diseases for women,IMPACD,Completed,No Results Available,cardio-vascular disease|stroke cancer|breast cancer|oral cancer|cervical cancer,"diagnostic test: evaluation of social, cultural and behavioral factors|diagnostic test: evaluation of the feasibility and acceptability of delivery of early detections services",outcomes of the questionnaire survey 1/5|outcomes of the questionnaire survey 2/5|outcomes of the questionnaire survey 3/5|outcomes of the questionnaire survey 4/5|outcomes of the questionnaire survey 5/5|ncd screening study 1/11|ncd screening study 2/11|ncd screening study 3/11|ncd screening study 4/11|ncd screening study 5/11|ncd screening study 6/11|ncd screening study 7/11|ncd screening study 8/11|ncd screening study 9/11|ncd screening study 10/11|ncd screening study 11/11|effect of different participant characteristics on the final diagnosis of hypertension and diabetes using multivariate analysis,"international agency for research on cancer|gbh cancer memorial hospital udaipur, india",Female,30 Years to 60 Years   (Adult),Not Applicable,1200.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,DCA/SCR/2016/01,"January 1, 2017","August 1, 2018","July 1, 2019","July 30, 2018",,"September 5, 2021","['gbh cancer memorial hospital, udaipur, rajasthan, india']",,https://ClinicalTrials.gov/show/NCT03604939,breast
165,166,NCT01351571,an observational study of avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma,,Completed,No Results Available,renal cell cancer,,safety: incidence of adverse events|progression-free survival: time from first drug administration to documented disease progression or death of any cause|overall response rate: complete response or partial response according to recist criteria|overall survival,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",,5.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ML25251,August 2010,August 2011,August 2011,"May 11, 2011",,"October 4, 2017","['aurangabad, india delhi, india']",,https://ClinicalTrials.gov/show/NCT01351571,kidney
166,167,NCT05251168,pet guided bone marrow biopsy vs trephine bone marrow biopsy,,Completed,No Results Available,lymphoma|bone marrow neoplasm,procedure: pet guided bone marrow biopsy|procedure: trephine bone marrow biopsy,comparison results of pet guided bone marrow biopsy with trephine bone marrow biopsy,postgraduate institute of medical education and research,All,"18 Years to 80 Years   (Adult, Older Adult)",,180.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,INT/IEC/2017/1416,"January 1, 2017","December 31, 2018","March 31, 2019","February 22, 2022",,"February 23, 2022","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT05251168,lymphoma
167,168,NCT03671044,a study to evaluate the efficacy and safety of nanosomal docetaxel lipid suspension in triple negative breast cancer patients,,Recruiting,No Results Available,triple negative breast cancer,drug: nanosomal docetaxel lipid suspension (75 mg/m2)|drug: nanosomal docetaxel lipid suspension (100 mg/m2)|drug: taxotere® (100 mg/m2),"proportion of the patients with objective response rate (i.e., cr + pr) as the best overall response rate (i.e., cr + pr) in the test arm (ndls) compared to reference arm (taxotere)|progression free survival (pfs)|to evaluate the overall survival (os) of the patients|incidence of adverse events as assessed by clinical examination, and/or laboratory parameters","jina pharmaceuticals inc.|intas pharmaceuticals, ltd.|lambda therapeutic research ltd.",Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,657.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0063-17,"July 10, 2018","March 31, 2022","May 31, 2022","September 14, 2018",,"July 29, 2020","['columbus regional research institute, llc, columbus, georgia, united states cox medical center, springfield, missouri, united states gabrail cancer center, canton, ohio, united states kailash cancer hospital & research centre, vadodara, gujarat, india']",,https://ClinicalTrials.gov/show/NCT03671044,breast
168,169,NCT05348239,chlorophyllin tablets for urinary bleeding following radiation therapy for cancers of pelvic organs,CLARITY,Recruiting,No Results Available,hemorrhagic cystitis,drug: sodium copper chlorophyllin,assessment of objective response rate (orr) as per ctcae v5.0.|assessment of bladder cancer index (bci) scores.|assessment of treatment failure (tf).|evaluation of treatment failure-free survival.|assessment of quality of life (qol) using eortc -qlq c-30 questionnaire.,"tata memorial centre|bhabha atomic research centre (barc), mumbai",All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,900878,"March 26, 2022","March 31, 2024","March 31, 2024","April 27, 2022",,"April 27, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05348239,
169,170,NCT02081131,pancreatic head and peri-ampullary cancer laparoscopic vs open surgical treatment trial (plot),PLOT,Completed,No Results Available,adenocarcinoma of head of pancreas|cholangio carcinoma|duodenal adenocarcinoma|carcinoma of ampulla of vater,procedure: open surgery|procedure: laparoscopic surgery,hospital stay|blood loss|pathological radicality|operating time|complication rate,gem hospital & research center,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,64.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PLOT|CTRI/2013/09/004016,September 2013,September 2015,September 2015,"March 7, 2014",,"September 15, 2015","['gem hospital & research centre private limited, coimbatore, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT02081131,gastric kidney pancreat
170,171,NCT01387841,effect of yoga in reducing chemotherapy induced nausea and vomiting,,Completed,No Results Available,breast cancer|malignant female reproductive system neoplasm|lymphomas|chemotherapy-induced nausea and vomiting,behavioral: yoga|behavioral: jacobsons pmrt group,effect of yoga on chemotherapy induced nausea and vomiting|quality of life after chemotherapy,bharath charitable cancer hospital and institute|bangalore institute of oncology|central council for research in yoga and naturopathy,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,120.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,Y010810,May 2010,December 2012,January 2013,"July 6, 2011",,"July 24, 2013","['health care global, bangalore, karnataka, india']",,https://ClinicalTrials.gov/show/NCT01387841,breast lymphoma skin
171,172,NCT02985255,role of neo-adjuvant chemotherapy in tongue preservation in locally advanced squamous cell carcinoma of oral tongue,,Unknown status,No Results Available,tongue neoplasms|squamous cell carcinoma|anterior tongue squamous cell carcinoma,drug: docetaxel|drug: cisplatin|drug: 5fu|radiation: radiotherapy|procedure: glossectomy,tongue preservation rate|overall survival|progression free survival|sensitivity and specificity of pet-ct,healthcare global enterprise ltd.,All,"1 Year to 99 Years   (Child, Adult, Older Adult)",Phase 2,30.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCG/SX/001/2016,April 2016,June 2017,June 2017,"December 7, 2016",,"December 7, 2016","['healthcare global enterprises ltd, bangalore, karnataka, india']",,https://ClinicalTrials.gov/show/NCT02985255,skin
172,173,NCT01947062,metronomic cyclophosphamide in combination with standard chemotherapy for squamous cell lung carcinoma,,Unknown status,No Results Available,lung cancer|squamous cell carcinoma of the lung|locally advanced and metastatic squamous cell carcinoma of the lung,drug: intravenous cisplatin & etoposide|drug: intravenous cisplatin & etoposide along with oral cyclophosphamide,progression free survival|response rate,swami rama cancer hospital and research institute,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,60.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MetroCyclo1,October 2013,June 2014,October 2014,"September 20, 2013",,"September 20, 2013","['swami rama cancer hospital & research institute, haldwani, nainital, uttarakhand, india']",,https://ClinicalTrials.gov/show/NCT01947062,skin
173,174,NCT02679443,vitamin supplementation in nsclc patients on pemetrexed based chemotherapy,PEMVITASTART,Completed,No Results Available,lung adenocarcinoma|neutropenia|anemia|thrombocytopenia|nonsquamous nonsmall cell neoplasm of lung,dietary supplement: folate and b12,incidence of any grade hematological toxicity|incidence of grade 3/4 hematological toxicity|number of doses of g-csf administered|number of doses of esas administered|number of prbc transfusions administered|relative dose intensity (rdi) delivered|number of inter-cycle delays (icds),postgraduate institute of medical education and research,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,161.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NK/2376/DM/913,July 2015,December 2016,December 2016,"February 10, 2016",,"April 25, 2017","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT02679443,gastric kidney
174,175,NCT03162198,frequency of circulating tumor cells (ctcs) and amount of cell-free dna (cfdna) in cirrhotic patients with hepatocellular carcinoma (hcc),,Completed,No Results Available,hepatocellular carcinoma,other: cirrhosis with hcc|other: cirrhosis without hcc,number of circulating tumor cells (ctcs) in cirrhotic patients with hepatocellular carcinoma (hcc)|number of cell-free dna (cfdna) in cirrhotic patients with hepatocellular carcinoma (hcc)|number of circulating tumor cells in the peripheral blood of cirrhotic patients in both groups|to study the difference in amount of cfdna in the peripheral blood of cirrhotic patients with and without hcc.|number of circulatory tumor cells with the tumor size of hepatocellular carcinoma.|number of circulatory tumor cells with the tumor number of hepatocellular carcinoma.|number of circulatory tumor cells withbarcelona clinic of liver cancer (bclc) stage of hepatocellular carcinoma.|number of cfdna amount with the tumor size of hepatocellular carcinoma.|number of cfdna amount with the tumor number of hepatocellular carcinoma.|number of cfdna amount with the barcelona clinic of liver cancer (bclc) stage of hepatocellular carcinoma.,"institute of liver and biliary sciences, india",All,"18 Years to 70 Years   (Adult, Older Adult)",,53.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,ILBS-HCC-03,"May 15, 2017","October 31, 2018","October 31, 2018","May 22, 2017",,"October 23, 2019","['institute of liver & biliary sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT03162198,liver
175,176,NCT00840190,a study of selective cyclin dependent kinase inhibitor p1446a-05 in subjects with advanced refractory malignancies,Serenity,Completed,No Results Available,solid tumor|hematologic malignancy,drug: p1446a-05,"to determine the maximum tolerated dose (mtd) and dose limiting toxicities (dlt) of p1446a-05 in subjects with advanced refractory malignancies|1 to evaluate safety and tolerability ,pharmacokinetics of p1446a-05 in study population 2. to evaluate efficacy of p1446a-05 3. to perform exploratory analysis of biomarkers associated with use of p1446a-05 in the study population",piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,29.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P1446A-05/19/08,December 2008,March 2011,September 2011,"February 10, 2009",,"November 21, 2012","['tata memorial centre, mumbai, maharashtra, india ruby hall clinic, pune, maharashtra, india jehangir hospital, pune, maharashtra, india searoc cancer centre,, jaipur, rajasthan, india bhagwan mahaveer cancer hospital, jaipur, rajasthan, india']",,https://ClinicalTrials.gov/show/NCT00840190,skin
176,177,NCT00517959,scrt versus conventional rt in children and young adults with low grade and benign brain tumors,SCRT,Unknown status,No Results Available,low grade gliomas|craniopharyngioma|ependymomas|meningiomas,radiation: stereotactic conformal radiotherapy|radiation: conventional radiotherapy,incidence of neuropsychological and neuroendocrine function in the two arms|progression free and overall survival.,tata memorial hospital|terry fox foundation,All,"3 Years to 25 Years   (Child, Adult)",Phase 3,200.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRT Trial,May 2001,March 2013,June 2017,"August 17, 2007",,"December 11, 2012","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00517959,brain
177,178,NCT01659346,non-selective beta blockers versus evl for primary prophylaxis of esophageal variceal bleeding in patients with hepatocellular carcinoma with portal vein tumour thrombosis.,,Withdrawn,No Results Available,hepatocellular carcinoma with portal vein thrombosis,procedure: endoscopic variceal ligation|drug: carvedilol,first variceal bleeding|death|procedure related complications.|reappearance of esophageal varices in presence of portal vein thrombosis,"institute of liver and biliary sciences, india",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILBS-HCC-01,February 2016,December 2017,December 2017,"August 7, 2012",,"November 17, 2017","['institute of liver & biliary sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01659346,liver
178,179,NCT01779336,clinical study of oral igf-1r inhibitor in subjects with advanced refractory solid tumors,,Suspended,No Results Available,advanced refractory solid tumors,drug: pl225b,"maximum tolerated dose|number of subject with adverse events|pharmacokinetic profile(cmax,tmax and auc)|activity of pl225b based on selected biomarkers|objective response",piramal enterprises limited,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,70.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PL225B/71/11,December 2012,November 2014,December 2014,"January 30, 2013",,"September 29, 2014","['usc norris comprehensive cancer center, los angeles, california, united states central india cancer research institute, nagpur, maharashtra, india curie manavata cancer centre, nashik, maharashtra, india ruby hall clinic, pune, maharashtra, india meenakshi mission hospital and research centre, madurai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT01779336,
179,180,NCT02754115,an audit of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy,,Recruiting,No Results Available,colorectal cancer|ovarian cancer|peritoneal disease,other: hyperthermic intraperitoneal chemotherapy,changes in invasive blood pressure in perioperative period|changes in body temperature in perioperative period|changes in cardiac output in perioperative period|changes in arterial blood gas in perioperative period|length of stay in intensive care unit|mortality,tata memorial centre,All,"18 Years to 70 Years   (Adult, Older Adult)",,400.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PN 1667,April 2016,December 2026,January 2027,"April 28, 2016",,"April 27, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02754115,ovari colon
180,181,NCT02748707,effect of cox-2 and egfr suppression on molecular markers of angiogenesis and proliferation in squamous cell carcinoma of oral cavity - prospective randomized study,ERLO-XIB,"Active, not recruiting",No Results Available,oral squamous cell carcinoma|carcinoma of buccal mucosa|tongue cancers|head and neck cancers,drug: arm1|drug: arm 2|drug: arm 3|other: arm 4,"change in expression of selected biomarkers in tissue samples, assessed by immunohistochemistry (ihc) and pcr|clinical and radiological change in tumor size and appearance",tata memorial hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,64.0,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,830,"August 18, 2015","February 12, 2018",April 2023,"April 22, 2016",,"April 28, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02748707,skin
181,182,NCT00963716,hot and cold biopsy forceps in the diagnosis of endobronchial lesions,,Completed,No Results Available,endobronchial growth|lung cancer,device: hot biopsy forceps|device: cold biopsy forceps,quality of pathological specimen|severity of bleeding,postgraduate institute of medical education and research,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,168.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,Khan-1,November 2007,July 2009,July 2009,"August 21, 2009",,"August 21, 2009","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT00963716,
182,183,NCT00862355,bioequivalence study of sparc147609 in patients with ovarian cancer,,Completed,No Results Available,ovarian carcinoma,drug: sparc147609|drug: reference147609,"90% confidence interval of the relative mean cmax, auc0-t, auc0-∞, of the test and reference product|treatment emergent adverse events",sun pharma advanced research company limited,Female,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,DOX_2I_1476_09,March 2010,December 2010,January 2011,"March 16, 2009",,"May 3, 2019","['sparc site 1, hyderabaad, andhra pradesh, india']",,https://ClinicalTrials.gov/show/NCT00862355,ovari
183,184,NCT04022408,to study the role of liquid based cytology (lbc) for diagnosis and characterization of biliopancreatic tumor s compared with standard cytology and on-site evaluation.,,Unknown status,No Results Available,pancreatobiliary-type carcinoma,diagnostic test: liquid based cytology|diagnostic test: conventional cytology,"sensitivity of lbc for diagnosis of bilio-pancreatic tumors, compared to cytology, on-site evaluation, and cell-block preparation.|comparison of liquid based cytology versus conventional cytology in the diagnosis of tumor with size < 2 cm or > 2 cm|comparison of liquid based cytology versus conventional cytology in the diagnosis of tumor with respect to site of tumor (pancreas biliary tract or gall bladder).","institute of liver and biliary sciences, india",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,ILBS-Biliopancreatic Tumor-01,"July 8, 2019","October 31, 2020","October 31, 2020","July 17, 2019",,"April 8, 2020","['institute of liver & biliary sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT04022408,pancreat
184,185,NCT00921375,safety and efficacy of tuly (rasburicase) in prevention and treatment of malignancy-associated hyperuricemia,,Completed,No Results Available,hyperuricemia,drug: tuly,percentage of reduction in plasma uric acid at 4 hrs after uric acid-lowering therapy|plasma uric acid auc 0-96 hr|incidence of adverse events,virchow group,All,"1 Year to 75 Years   (Child, Adult, Older Adult)",Phase 3,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,VB037/2007|VB037,February 2010,December 2011,January 2012,"June 16, 2009",,"December 12, 2014","['dr. raghunathrao, hyd, andhra pradesh, india']",,https://ClinicalTrials.gov/show/NCT00921375,
185,186,NCT01271673,cohort study to assess the level of compliance in undertaking breast self examination among women attending preventive oncology clinic,,Unknown status,No Results Available,breast self examination,,compliance to breast self examination|association of various socio-demographic factors and the level of compliance to breast self examination,tata memorial hospital,Female,"20 Years to 80 Years   (Adult, Older Adult)",,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,827,November 2010,February 2011,April 2011,"January 7, 2011",,"January 7, 2011","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01271673,breast
186,187,NCT02419742,safety and efficacy of trastuzumab as part of breast cancer treatment regimen,,Completed,No Results Available,breast cancer,drug: carboplatin|drug: cyclophosphamide|drug: docetaxel|drug: doxorubicin|drug: paclitaxel|drug: trastuzumab,percentage of participants experiencing clinically significant changes in cardiac function as determined by left ventricular ejection fraction (lvef) measurements using echocardiography|percentage of participants with adverse events|disease free survival (dfs)|overall survival (os),hoffmann-la roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,109.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML28714,"August 18, 2015","June 24, 2021","June 24, 2021","April 17, 2015",,"August 6, 2021","['yashoda hospital, hyderabad, andhra pradesh, india rajiv gandhi cancer institute & research center, new delhi, delhi, india manipal hospital; department of oncology, bangalore, karnataka, india jehangir clinical development centre pvt. ltd; cancer research room, pune, maharashtra, india max balaji hospital, delhi, india dr. gvn cancer institute; medical oncology, trichy, india']",,https://ClinicalTrials.gov/show/NCT02419742,breast
187,188,NCT01260194,a study of herceptin (trastuzumab) in combination with standard chemotherapy in patients with her positive metastatic gastric cancer,,Terminated,Has Results,gastric cancer,drug: trastuzumab [herceptin],median progression free survival (pfs)|overall survival (os)|percentage of participants with overall tumor response|percentage of participants with clinical benefit response (cbr)|duration of response (dr)|number of participants with adverse events (aes) or serious adverse events (saes)|number of participants with clinically significant change from baseline in laboratory parameters|number of participants with clinically significant change from baseline in left ventricular ejection fraction (lvef)|number of participants with human epidermal growth factor receptor 2 (her2) positive gastric cancer,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 4,4.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML25477,June 2011,January 2015,January 2015,"December 15, 2010","March 14, 2016","November 2, 2016","['new delhi, delhi, india bangalore, karnataka, india bangalore, india nagpur, india noida, india vishakpatnam, india']",,https://ClinicalTrials.gov/show/NCT01260194,gastric
188,189,NCT01766323,palliative morphine with or without concurrent modafinil,,Unknown status,No Results Available,cancer|pain palliation|excessive sleepiness,drug: modafinil|drug: placebo,patient reported sleepiness scores|mood changes,dr. rajendra prasad government medical college,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,200.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,ModMorphine,September 2012,June 2013,August 2013,"January 11, 2013",,"January 11, 2013","['tanda government medical college and hospital, kangra, himachal pradesh, india']",,https://ClinicalTrials.gov/show/NCT01766323,pain
189,190,NCT05245630,comparison of robotic arm-assisted pet/ct-guided lung biopsy with pet fused ct- fluoroscopy-guided lung biopsy,,Completed,No Results Available,lung cancer|lung diseases|adenocarcinoma of lung,procedure: robotic arm assisted pet/ct guided biopsy|procedure: pet fused ct-fluoroscopy guided biopsy,to compare the accuracy ( in percentage) of trans-thoracic percutaneous pet fused ct-fluoroscopy guided lung biopsy and automated robotic arm assisted pet/ct guided lung biopsy|to compare the radiation exposure and complication in the both arms,postgraduate institute of medical education and research,All,"18 Years to 80 Years   (Adult, Older Adult)",,59.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,NK/6832/MD/594,"July 1, 2020","December 31, 2021","January 31, 2022","February 18, 2022",,"February 18, 2022","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT05245630,gastric kidney
190,191,NCT04512729,detection of colonic polyps in india: diagnostic colonoscopy,DoCPI,Recruiting,No Results Available,colonic polyp|colonic adenoma|colonic neoplasms,diagnostic test: colonoscopy,colonic adenoma|risk factors for colonic adenoma,"asian institute of gastroenterology, india",All,"18 Years and older   (Adult, Older Adult)",,4000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DoCPI,"August 4, 2020","November 30, 2020","December 30, 2020","August 13, 2020",,"October 30, 2020","['d nageshwar reddy, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT04512729,colon
191,192,NCT03471572,"study to assess prevalence of brca1 and brca2 mutation among ovarian, primary peritoneal and fallopian tube cancer patients in india",BRCA,Completed,No Results Available,ovarian cancer,,brca1 or brca2 mutation positive status|association between histopathological type and brca 1/brca 2 mutation positive status,astrazeneca,Female,"18 Years to 130 Years   (Adult, Older Adult)",,240.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,D0818R00001,"March 22, 2018","December 21, 2018","December 21, 2018","March 20, 2018",,"December 18, 2019","['research site, bangalore, karnataka, india research site, mumbai, maharashtra, india research site, mumbai, maharashtra, india research site, delhi, new delhi, india research site, delhi, new delhi, india research site, delhi, new delhi, india research site, hyderabad, telangana, india research site, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03471572,ovari
192,193,NCT04330040,prospective multicentre phase-iv clinical trial of olaparib in indian patients with ovarian and metastatic breast cancer,SOLI,"Active, not recruiting",No Results Available,ovarian cancer|breast cancer,drug: olaparib,to assess the safety of olaparib in indian subjects,astrazeneca,Female,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,162.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D0816R00025,"May 30, 2020","July 31, 2022","July 31, 2022","April 1, 2020",,"April 13, 2022","['research site, ahmedabad, india research site, ansari nagar, india research site, bhubaneswar, india research site, chandigarh, india research site, faridabad, india research site, kamrup, india research site, kochi, india research site, kolkata, india research site, kolkata, india research site, madurai, india research site, mumbai, india research site, mumbai, india research site, new delhi, india research site, new delhi, india research site, vellore, india']",,https://ClinicalTrials.gov/show/NCT04330040,breast ovari
193,194,NCT04914195,leuprolide acetate 3.75 mg depot injection for patients with advanced prostate cancer,,Recruiting,No Results Available,advanced prostate adenocarcinoma,drug: leuprolide acetate 3.75 mg/ml,testosterone response rate defined as testosterone values sustained below castration level (0.5 ng/ml or 50 ng/dl) i.e. all testosterone values at and after day 28 until day 57 must be < 0.5 ng/ml or < 50 ng/dl|percentage of subjects who have reached castration level of testosterone at the last visit (day 57)|percentage of breakthrough responses defined as a single total serum testosterone value of >0.5 ng/ml or >50 ng/dl measured after achieving a castration testosterone level|time after first implantation until castration level of testosterone is achieved|percentage of subjects with testosterone values sustained below 0.2 ng/ml or 20 ng/dl at and after day 28 until day 57|change from baseline in luteinizing hormone (lh) levels at day 28 and 57|change from baseline in follicle stimulating hormone (fsh) levels at day 28 and day 57|change from baseline in prostate-specific antigen (psa) at day 57|mean number of days of maintaining testosterone castration levels (mean number of castration days)|mean maximum testosterone concentration during the dosing period after reaching the castration level,bharat serums and vaccines limited,Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,168.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,BSV_LEUPR_18_05,"July 1, 2021",August 2022,December 2022,"June 4, 2021",,"January 25, 2022","['government med ical college & superspeciality hospital nagpur, nagpur, maharashtra, india mv hospital and research center, lucknow, uttar pradesh, india']",,https://ClinicalTrials.gov/show/NCT04914195,prostat gastric kidney
194,195,NCT05348876,a study to learn more about how safe darolutamide is and how well it works under real world conditions when taken in addition to standard androgen deprivation therapy (adt) in indian participants with high-risk non-metastatic castration-resistant prostate cancer (nmcrpc),,Not yet recruiting,No Results Available,non-metastatic castration-resistant prostate cancer,"drug: darolutamide (nubeqa, bay1841788)",number of participants with adverse events (aes) and serious adverse events (saes) and their severity|number of participants with discontinuations of study treatment due to aes|number of participants with dose modifications of study treatment due to aes|number of participants with clinically significant abnormalities in laboratory parameters|number of participants with clinically significant electrocardiograms abnormalities|number of participants with clinically significant physical examination abnormalities|number of participants with clinically significant changes in vital signs|number of participants with changes in eastern cooperative oncology group (ecog) performance status|prostate-specific antigen (psa) percent change from baseline to 16 weeks|psa maximum percent decline from baseline at any time on study treatment|time to initiation of first subsequent antineoplastic therapy|time to initiation of first cytotoxic chemotherapy for prostate cancer,bayer,Male,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21707,"May 9, 2022","June 30, 2023","June 30, 2023","April 27, 2022",,"May 5, 2022","['mnj institute of oncology & regional cancer centre, hyderabad, andhra pradesh, india hcg-city cancer centre, vijayawada, andhra pradesh, india king george hospital, visakhapatnam, andhra pradesh, india dr. rml hospital & pgimer, new delhi, delhi, india all india institute of medical sciences, new delhi, delhi, india muljibhai patel urological hospital, nadiad, gujarat, india surat institute of digestive sciences, surat, gujarat, india kles dr. prabhakar kore hospital & medical research centre, belagavi, karnataka, india fortis hospital bangalore, bengaluru, karnataka, india rajiv gandhi cancer institute & research centre, new delhi, karnataka, india amrita institute of medical sciences, kochi, kerala, india regional cancer centre - thiruvananthapuram, thiruvananthapuram, kerala, india mvr cancer centre and research institute, vellalasseri, kerala, india sujan surgical cancer hospital & amravati cancer foundation, amravati, maharashtra, india tata memorial hospital, mumbai,, maharashtra, india jawaharlal institute of postgraduate medical education and r, gorimedu, pondicherry, india victoria hospital, bangalore, punjab, india dayanand medical college & hospital, ludhiana, punjab, india bhagwan mahaveer cancer hospital & research centre, jaipur, rajasthan, india erode cancer centre, erode, tamil nadu, india post graduate institute of medical education and research, chandigarh, uttar pradesh, india mahamana pandit madan mohan malviya cancer centre, varanasi, uttar pradesh, india netaji subhas chandra bose cancer hospital, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT05348876,prostat
195,196,NCT02679755,"palbociclib in combination with letrozole as treatment of post-menopausal women with hr+, her2- advanced breast cancer",,Completed,Has Results,breast cancer,drug: palbociclib|drug: letrozole,number of participants with treatment-emergent adverse events (all causalities)|number of participants with treatment-emergent adverse events by severity (all causalities)|number of participants with treatment-emergent adverse events (palbociclib-related)|number of participants with treatment-emergent adverse events by severity (palbociclib-related)|number of participants with serious adverse events (all causalities and palbociclib-related)|percentage of participants with complete response and partial response|the objective response rate (orr)|eq-5d health utility index score|change from baseline in eq-5d health utility index score|eq-vas score|change from baseline in eq-vas score,pfizer,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,252.0,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,A5481037,"March 9, 2016","July 25, 2019","July 25, 2019","February 10, 2016","October 5, 2020","August 17, 2021","['benjamin carl forster, north sydney, new south wales, australia dr. alexander maxwell menzies, north sydney, new south wales, australia hps pharmacies - north sydney, north sydney, new south wales, australia mater hospital sydney, north sydney, new south wales, australia professor frances mary boyle, north sydney, new south wales, australia royal north shore hospital - clinical trials pharmacy, st leonards, new south wales, australia royal north shore hospital, dept. of medical oncology, st leonards, new south wales, australia icon cancer care wesley, auchenflower, queensland, australia river city pharmacy, auchenflower, queensland, australia icon cancer care chermside, chermside, queensland, australia icon cancer care south brisbane, south brisbane, queensland, australia icon cancer care, corporate office, south brisbane, queensland, australia icon cancer care southport, southport, queensland, australia flinders medical centre-pharmacy department, bedford park, south australia, australia flinders medical centre, bedford park, south australia, australia monash health, clayton, victoria, australia peter maccallum cancer centre pharmacy, melbourne, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia sunshine hospital, st albans, victoria, australia sunshine hospital pharmacy, st. albans, victoria, australia fiona stanley hospital, murdoch, western australia, australia pharmacy department, murdoch, western australia, australia rajiv gandhi cancer institute and research centre, new delhi, delhi, india dr. b.r.a institute rotary cancer hospital, all india institue of medical sciences, new delhi, delhi, india the gujarat cancer & research institute, m.p shah cancer hospital, ahmedabad, gujarat, india manipal hospital, bangalore, karnataka, india healthcare global enterprises ltd., bangalore, karnataka, india kasturba hospital, manipal, karnataka, india tata memorial centre, tata memorial hospital, mumbai, maharashtra, india meditrina institute of medical sciences, nagpur, maharashtra, india shatabdi hospital, nashik, maharashtra, india deenanath mangeshkar hospital and research center, pune, maharashtra, india sahyadri super speciality hospital, pune, maharashtra, india apollo speciality hospital, chennai, tamilnadu, india']","""study protocol"", https://clinicaltrials.gov/provideddocs/55/nct02679755/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/55/nct02679755/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02679755,breast
196,197,NCT03511378,immunogenicity assessment of peg-filgrastim vs. neulasta® as adjunct to chemotherapy in patients with breast cancer,,Completed,Has Results,breast cancer,drug: lupin's pegfilgrastim|drug: neulasta®,"comparison of cumulative incidence of anti-pegfilgrastim antibodies (binding and neutralizing) to pegfilgrastim between treatment groups at the end of cycle 4 (day 84).|comparison of cumulative incidence of anti-peg antibodies (binding and neutralizing) between treatment groups at the end of cycle 4 (day 84).|comparison of incidence of anti-pegfilgrastim antibodies (binding & neutralizing) to pegfilgrastim between treatment groups on day 10, day 21, day 42, day 63 and day 84|secondary immunogenicity endpoint",lupin ltd.,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,138.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LRP/PegGCSF/2016/004,"March 6, 2018","January 9, 2019","January 9, 2019","April 27, 2018","June 15, 2021","June 15, 2021","['m s patel cancer centre,, gokal, anand, india city cancer center, vijayawada, andhra pradesh, india research & development department, hcg cancer center, ahmedabad, gujarat, india apple hospital, sūrat, gujarat, india nirmal hospital, sūrat, gujarat, india shree himalaya cancer hospital & research institute,, vadodara, gujarat, india kailash cancer hospital & research center, vadodara, gujarat, india adhar health institute, hisar, haryana, india sri venketeshwara hospital, dept of medical oncology, bengaluru, karnataka, india curie manavata cancer centre, mumbai, maharashtra, india government medical college & hospital, nagpur, maharashtra, india sterling hospital, nigdi, maharashtra, india bhaktivedanta hospital & research institute, thāne, maharashtra, india clinical research department, bande, nagpur, india acharya tulsi regional cancer treatment & research institute, bīkaner, rajahstan, india global clinical research services pvt ltd., hyderabad, telangana, india apollo gleneagles hospitals, kolkata, west bengal, india']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/78/nct03511378/prot_sap_000.pdf",https://ClinicalTrials.gov/show/NCT03511378,breast
197,198,NCT03155997,endocrine therapy with or without abemaciclib (ly2835219) following surgery in participants with breast cancer,monarchE,"Active, not recruiting",Has Results,breast cancer,drug: abemaciclib|drug: standard adjuvant endocrine therapy,"invasive disease free survival (idfs)|idfs for participants with ki-67 index ≥20%|distant relapse-free survival (drfs)|overall survival (os)|pharmacokinetics (pk): minimum steady state concentration (cmin,ss) of abemaciclib|change from baseline on the functional assessment of cancer therapy - breast (fact-b)|change from baseline on the functional assessment of cancer therapy - endocrine symptoms (fact-es)|change from baseline on the functional assessment of chronic illness therapy - fatigue (facit-f)|change from baseline on the euroqol five-dimension five-level questionnaire (eq-5d-5l)",eli lilly and company|nsabp foundation inc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,5637.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16338|I3Y-MC-JPCF|2016-004362-26|NSABP B-58,"July 12, 2017","March 16, 2020","June 24, 2029","May 16, 2017","April 9, 2021","January 24, 2022","['university of alabama birmingham, birmingham, alabama, united states southern cancer center, p.c., daphne, alabama, united states banner md anderson cancer center, gilbert, arizona, united states university of arizona cancer center, phoenix, arizona, united states mayo clinic hospital, phoenix, arizona, united states arizona oncology associates, p.c., tempe, arizona, united states arizona oncology associates, p.c., tucson, arizona, united states the university of arizona cancer center, tucson, arizona, united states yuma regional cancer center, yuma, arizona, united states highlands oncology group, fayetteville, arkansas, united states st. bernards medical center, jonesboro, arkansas, united states beverly hills cancer center, beverly hills, california, united states providence st. joseph\'s medical center, burbank, california, united states city of hope national medical center, duarte, california, united states california cancer associates research and excellence (ccare), fresno, california, united states loma linda university school of medicine, loma linda, california, united states cedars sinai medical center, los angeles, california, united states pacific cancer care, monterey, california, united states st. joseph hospital, orange, california, united states university of california, davis - health systems, sacramento, california, united states kaiser permanente medical group, san diego, california, united states univ of california san francisco, san francisco, california, united states california cancer associates in research and excellence, san marcos, california, united states sansum clinic, santa barbara, california, united states dominican hospital, santa cruz, california, united states kaiser permanente, vallejo, california, united states rocky mountain cancer center, denver, colorado, united states yale university school of medicine, new haven, connecticut, united states florida cancer specialists, fort myers, florida, united states university of southern florida school of medicine, gainesville, florida, united states millennium oncology, hollywood, florida, united states mayo clinic-jacksonville, jacksonville, florida, united states miami cancer institute at baptist health, inc., miami, florida, united states ocala oncology, p.a., ocala, florida, united states cancer specialists of north florida -st augustine, saint augustine, florida, united states florida cancer specialists, saint petersburg, florida, united states tallahassee memorial cancer center, tallahassee, florida, united states h lee moffitt cancer center, tampa, florida, united states florida cancer specialists, west palm beach, florida, united states northeast georgia cancer care, llc, athens, georgia, united states northside hospital cancer institute, atlanta, georgia, united states northwest georgia oncology centers, marietta, georgia, united states summit cancer care, savannah, georgia, united states university of hawaii cancer center, honolulu, hawaii, united states john h. stroger hospital of cook county, chicago, illinois, united states rush university medical center, chicago, illinois, united states edward cancer center, naperville, illinois, united states illinois cancer specialists-niles, niles, illinois, united states quincy medical group, quincy, illinois, united states franciscan st. francis health, indianapolis, indiana, united states community howard oncology center, kokomo, indiana, united states cancer center of kansas, wichita, kansas, united states univ of louisville school of medicine, louisville, kentucky, united states lady of the lake physicians\' group, baton rouge, louisiana, united states terrebonne general medical center, houma, louisiana, united states eastern maine medical center, brewer, maine, united states central maine healthcare corporation, lewiston, maine, united states new england cancer specialists - scarborough, scarborough, maine, united states maryland oncology hematology, p.a., columbia, maryland, united states meritus john marsh cancer center, hagerstown, maryland, united states dana farber cancer institute, boston, massachusetts, united states reliant medical group, inc., worcester, massachusetts, united states minnesota oncology/hematology pa, minneapolis, minnesota, united states mayo clinic, rochester, minnesota, united states jackson oncology associates pllc, jackson, mississippi, united states research medical center, kansas city, missouri, united states cancer alliance of nebraska, omaha, nebraska, united states nebraska methodist cancer center, omaha, nebraska, united states ncca- national cancer care alliance, omaha, nebraska, united states oncology hematology west, omaha, nebraska, united states comprehensive cancer centers of nevada, henderson, nevada, united states renown medical group, reno, nevada, united states dartmouth hitchcock medical center, lebanon, new hampshire, united states summit medical group pa, florham park, new jersey, united states newark beth israel medical center, newark, new jersey, united states the valley hospital - luckow pavilion, paramus, new jersey, united states community medical center, toms river, new jersey, united states new york oncology hematology, p.c, albany, new york, united states broome oncology llc, johnson city, new york, united states memorial sloan kettering cancer center, new york, new york, united states weill cornell medical college, new york, new york, united states vassar brothers medical center, poughkeepsie, new york, united states suny at stony brook, stony brook, new york, united states white plains hospital, white plains, new york, united states waverly hematology oncology, cary, north carolina, united states margaret r. pardee memorial hospital, hendersonville, north carolina, united states wake forest university school of medicine, winston-salem, north carolina, united states aultman hospital, canton, ohio, united states university hospitals case medical center, cleveland, ohio, united states cleveland clinic foundation, cleveland, ohio, united states columbus community clinical oncology program, columbus, ohio, united states oncology hematology care inc, fairfield, ohio, united states hematology oncology associates, pc, medford, oregon, united states ohsu knight cancer institute, portland, oregon, united states providence cancer center oncology hematology care, portland, oregon, united states northwest cancer specialists pc, portland, oregon, united states willamette valley cancer institute & research ctr., springfield, oregon, united states abington memorial hospital, abington, pennsylvania, united states st. luke\'s hospital & health network, bethlehem, pennsylvania, united states pinnaclehealth cancer institute, harrisburg, pennsylvania, united states albert einstein healthcare network, philadelphia, pennsylvania, united states allegheny general hospital, pittsburgh, pennsylvania, united states nsabp foundation, pittsburgh, pennsylvania, united states univ of pittsburgh cancer inst. (upci), pittsburgh, pennsylvania, united states wellspan health/york cancer center oncology research, york, pennsylvania, united states mcleod regional medical center, florence, south carolina, united states bon secours saint francis cancer center, greenville, south carolina, united states spartanburg regional medical center, spartanburg, south carolina, united states sanford research/usd, sioux falls, south dakota, united states ut/erlanger oncology & hematology, chattanooga, tennessee, united states sarah cannon research institute scri, chattanooga, tennessee, united states the west clinic, germantown, tennessee, united states indian path community hospital, kingsport, tennessee, united states brig center for cancer care and survivorship, knoxville, tennessee, united states university of tennessee medical center, knoxville, tennessee, united states baptist cancer center, memphis, tennessee, united states sarah cannon cancer center, nashville, tennessee, united states tennessee oncology pllc, nashville, tennessee, united states texas oncology - amarillo, amarillo, texas, united states texas oncology-arlington south, arlington, texas, united states texas oncology cancer center, austin, texas, united states texas oncology - carrollton, carrollton, texas, united states texas oncology - methodist dallas cancer center, dallas, texas, united states texas oncology - medical city dallas, dallas, texas, united states texas oncology - dallas presbyterian hospital, dallas, texas, united states texas oncology-baylor charles a. sammons cancer center, dallas, texas, united states university of texas southwestern medical center at dallas, dallas, texas, united states texas oncology denton, denton, texas, united states texas oncology-el paso cancer treatment center, el paso, texas, united states texas oncology fort worth, fort worth, texas, united states oncology consultants, p.a., houston, texas, united states texas oncology - tyler, longview, texas, united states texas oncology - mcallen, mcallen, texas, united states texas oncology-mckinney, mckinney, texas, united states texas oncology- mesquite, mesquite, texas, united states texas oncology - paris, paris, texas, united states texas oncology-plano east, plano, texas, united states texas oncology-plano west, plano, texas, united states university of texas health science center - san antonio, san antonio, texas, united states texas oncology - san antonio medical center, san antonio, texas, united states texas oncology-sherman, sherman, texas, united states texas oncology - the woodlands, the woodlands, texas, united states us oncology, the woodlands, texas, united states texas oncology cancer care and research center, waco, texas, united states texas oncology-deke slayton cancer center, webster, texas, united states utah cancer specialists, salt lake city, utah, united states university of vermont medical center, burlington, vermont, united states virginia cancer specialists, fairfax, virginia, united states hematology oncology associates of fredericksburg inc., fredericksburg, virginia, united states virginia oncology associates, norfolk, virginia, united states virginia commonwealth university, richmond, virginia, united states oncology and hematology associates of southwest virginia inc, salem, virginia, united states shenandoah oncology, p.c., winchester, virginia, united states swedish medical center, seattle, washington, united states multicare health system, tacoma, washington, united states centro de oncologia e investigacion buenos aires, berazategui, buenos aires, argentina instituto de investigaciones clinicas mar del plata, mar del plata, buenos aires, argentina hospital universitario austral, pilar, buenos aires, argentina fundacion cenit para la investigacion en neurociencias, caba, ciudad autonoma buenos aires, argentina centros de investigaciones cli-nicas. clinica viedma, viedma, rio negro, argentina instituto de oncologia de rosario, rosario, santa fe, argentina centro medico san roque, s.m. de tucuman, tucuman, argentina instituto médico especializado alexander fleming, buenos aires, argentina instituto de investigaciones metabolicas, buenos aires, argentina hospital aleman, capital federal, argentina clinica adventista de belgrano, ciudad autonoma buenos aires, argentina centro oncologico riojano integral, la rioja, argentina sanatorio parque, salta, argentina centro polivalente de asistencia e inv. clinica cer-san juan, san juan, argentina centro para la atencion integral del paciente oncologico, tucuman, argentina chris o\'brien lifehouse, camperdown, new south wales, australia lismore base hospital, lismore, new south wales, australia liverpool hospital, liverpool, new south wales, australia calvary mater newcastle, newcastle, new south wales, australia mater private hospital, north sydney, new south wales, australia st vincent\'s hospital, sydney, new south wales, australia westmead hospital, westmead, new south wales, australia southern medical day care centre, wollongong, new south wales, australia the townsville hospital, douglas, queensland, australia mater adult hospital brisbane, south brisbane, queensland, australia gold coast university hospital, southport, queensland, australia lyell mcewin hospital, elizabeth vale, south australia, australia ashford cancer centre research, kurralta park, south australia, australia launceston general hospital, launceston, tasmania, australia box hill hospital, box hill, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia epworth research institute, richmond, victoria, australia eastern health, maroondah hospital, ringwood east, victoria, australia st john of god hospital - subiaco, subiaco, western australia, australia breast cancer research centre wa, nedlands, australia universitätsklinikum graz, graz, steiermark, austria universitätsklinik innsbruck, innsbruck, tirol, austria ordination dr. hubalek - brustzentrum schwaz, schwaz, tirol, austria universitätsklinikum salzburg, salzburg, austria akh, wien, austria kh hietzing mit neurologischem zentrum rosenhügel, wien, austria jessa ziekenhuis, hasselt, limburg, belgium az nikolaas, campus moerland, sint-niklaas, oost-vlaanderen, belgium vivalia st joseph, arlon, belgium az klina, brasschaat, belgium algemeen ziekenhuis st jan brugge, brugge, belgium cliniques universitaires saint-luc, brussels, belgium universitair ziekenhuis antwerpen, edegem, belgium hopital de jolimont, haine-st.- paul, belgium vzw regional ziekenhuis jan yperman, ieper, belgium az groeninge, kortrijk, belgium universitaire ziekenhuizen leuven - campus gasthuisberg, leuven, belgium centre hospitalier universitaire sart tilman, liege, belgium clinique st joseph, liege, belgium hôpital civil marie curie, lodelinsart, belgium clinique st elisabeth namur, namur, belgium clinique saint pierre ottignies, ottignies, belgium chu dinant godinne - ucl namur, yvoir, belgium instituto do cancer do ceara, fortaleza, ceara, brazil sírio-libanês brasilia-centro de oncologia-asa sul, brasilia, district federal, brazil hospital araujo jorge da assoc. combate ao cancer em goias, goiania, goias, brazil instituto de cancer de londrina, londrina, parana, brazil cionc - centro integrado de oncologia de curitiba, curitiba, paraná, brazil hospital de caridade ijui, ijui, rio grande do sul, brazil hospital são lucas - pucrs - oncology, porto alegre, rio grande do sul, brazil instituto coi de pesquisa educação e gestão, rio de janeiro, rj, brazil hospital bruno born de lajeado, lajeado, rs, brazil fundação pio xii, barretos, sao paulo, brazil hospital de base fac de medicina de sao jose do rio preto, sao jose rio preto, sao paulo, brazil instituto do cancer do estado de sao paulo - icesp, são paulo, sp, brazil hospital das clinicas da fmrp, ribeirao preto, são paulo, brazil faculdade de medicina do abc, santo andré, são paulo, brazil inca - instituto nacional do cancer, rio de janeiro, brazil clinica onco star, sao paulo, brazil soc. beneficente de senhoras hospital sirio libanes-oncology, são paulo, brazil clin. pesq.e centro estudos oncologia ginecológica e mamária, são paulo, brazil ibcc-instituto brasileiro de controle do câncer, são paulo, brazil instituto de assistência médica ao servidor público estadual, são paulo, brazil the ottawa hospital, ottawa, ontario, canada north york general hospital, toronto, ontario, canada humber river regional hospital, toronto, ontario, canada st michaels hospital, toronto, ontario, canada centre hospitalier de l\'universite de montreal, montreal, quebec, canada jewish general hospital, montreal, quebec, canada hopital du sacre-coeur de montreal, montreal, quebec, canada chu de quebec-hopital de saint-sacrement, quebec city, quebec, canada centre hospitalier universitaire de sherbrooke - chus, sherbrooke, quebec, canada the fifth medical center of pla general hospital, beijing, beijing, china fujian medical university union hospital, fuzhou, fujian, china guangdong provincial people\'s hospital, guangzhou, guangdong, china sun yat-sen memorial hospital, sun yat-sen university, guangzhou, guangdong, china the first affiliated hospital, sun-yat sen university, guangzhou, guangdong, china harbin medical university cancer hospital, harbin, heilongjiang, china henan cancer hospital, zhengzhou, henan, china hunan cancer hospital, changsha, hunan, china jiangsu cancer hospital, nanjing, jiangsu, china jiangsu province hospital, nanjing, nanjing, china shandong cancer hospital, jinan, shandong, china zhejiang cancer hospital, hang zhou, zhejiang, china the second affiliated hospital of zhejiang university school of medicine, hangzhou, zhejiang, china beijing cancer hospital, beijing, china ruijin hospital affiliated to shanghai jiao tong university, shanghai, china fudan university shanghai cancer center, shanghai, china masarykuv onkologicky ustav, brno, czech republic, czechia nemocnice horovice, horovice, czechia fakultni nemocnice ostrava, ostrava, czechia multiscan, s.r.o., pardubice, czechia fn plzen lochotin, plzen, czechia thomayerova nemocnice, praha 4 - krc, czechia odense universitetshospital, odense c, syd, denmark aalborg universitets hospital, aalborg, denmark aarhus universitetshospital, aarhus sygehus, aarhus c, denmark sydvestjysk sygehus esbjerg, esbjerg, denmark herlev hospital, herlev, denmark regionshospitalet herning, herning, denmark rigshospitalet, københavn ø, denmark næstved sygehus, næstved, denmark soenderborg sygehus, soenderborg, denmark vejle sygehus, vejle, denmark tampere university hospital tays, tampere, pirkanmaa, finland satakunta central hospital - oncology, pori, satakunta, finland helsinki docrates cancer clinic, helsinki, finland keski-suomen keskussairaala, jyväskylä, finland kuopio university hospital, kuopio, finland päijät-häme central hospital, lahti, finland oulu university hospital - oncology, oulu, finland turku university central hospital, turku, finland vaasa central hospital, vaasa, finland centre jean perrin, clermont ferrand bp 392, cedex 1, france institut sainte catherine, avignon cedex 9, france chu de besancon hopital jean minjoz, besancon cedex, france chru de brest - hôpital morvan, brest, france chu henri mondor, creteil cedex, france centre georges francois leclerc, dijon cedex, france polyclinique de blois, la chaussee saint victor, france centre hospitalier de vendee les oudairies, la roche sur yon, france clinique victor hugo - centre jean bernard, le mans, france centre de lutte contre le cancer leon berard, lyon cedex 08, france centre de cancérologie du grand montpellier, montpellier, france polyclinique de gentilly, nancy, france institut curie, paris cedex 05, france hôpital privé des côtes d\'armor- hpca, plérin, france centre eugene marquis, rennes cedex, france centre henri becquerel, rouen cedex, france institut de cancérologie de l\'ouest centre rené gauducheau, saint herblain cedex, france universitätsklinikum freiburg, freiburg im breisgau, baden-württemberg, germany onkologische schwerpunktpraxis, freiburg im breisgau, baden-württemberg, germany praxis für onkologie, friedrichshafen, baden-württemberg, germany klinikum ludwigsburg, ludwigsburg, baden-württemberg, germany universitätsklinikum tübingen, tübingen, baden-württemberg, germany universitätsklinikum ulm, ulm, baden-württemberg, germany hämatologisch-onkologische praxis augsburg, augsburg, bavaria, germany gesundheitszentrum st. marien amberg, amberg, bayern, germany universitätsklinikum erlangen, erlangen, bayern, germany klinikum der universität münchen, münchen, bayern, germany rotkreuzklinikum münchen - frauenklinik, münchen, bayern, germany klinikum rechts der isar der tu münchen, münchen, bayern, germany agaplesion markus krankenhaus, frankfurt am main, hessen, germany städtische kliniken offenbach am main, offenbach am main, hessen, germany gemeinschaftspraxis für hämatologie und onkologie, langen, hesse, germany franziskus-hospital harderberg, georgsmarienhütte, niedersachsen, germany gynäkologisch-onkologische schwerpunktpraxis am pelikanplatz, hannover, niedersachsen, germany medizinische hochschule hannover, hannover, niedersachsen, germany universitätsklinikum bonn, bonn, nordrhein-westfalen, germany universitätsklinikum düsseldorf, düsseldorf, nordrhein-westfalen, germany kliniken essen-mitte ev. huyssens-stiftung, essen, nordrhein-westfalen, germany helios klinikum krefeld, krefeld, nordrhein-westfalen, germany evangelisches krankenhaus bethesda mönchengladbach ggmbh, mönchengladbach, nordrhein-westfalen, germany universitätsklinikum münster, münster, nordrhein-westfalen, germany st. elisabeth gruppe - marien hospital witten, witten, nordrhein-westfalen, germany universitätsklinikum carl gustav carus, dresden, sachsen, germany universitätsklinikum schleswig-holstein, kiel, schleswig-holstein, germany srh wald-klinikum gera ggmbh, gera, thüringen, germany helios klinikum emil von behring, berlin, germany medizinisches versorgungszentrum onkologischer schwerpunkt am oskar-helene-heim, berlin, germany mammazentrum hamburg brustklinik am krankenhaus jerusalem, hamburg, germany kath. marienkrankenhaus ggmbh, hamburg, germany mvz onkologie barmbek - asklepios klinik barmbek, hamburg, germany university general hospital of patras, patras, achaia, greece metropolitan hospital, neo faliro, athens, greece general hospital of athens \'alexandra\', athens, attica, greece ag. savvas hospital, athens, attica, greece gen onc hosp ag. anargyroi, n. kifissia, attica, greece university general hospital of heraklion, heraklion, crete, greece bioclinic of thessaloniki, thessaloniki, macedonia, greece general hospital of thessaloniki papageorgiou, n. efkarpia, thessaloniki, greece errikos dynan, athens, greece attikon\' university hospital, haidari/athens, greece university hospital of ioannina, ioannina, greece interbalkan medical center, pylaia/thessaloniki, greece euromedica - general clinic of thessaloniki, thessaloniki, greece pamela youde nethersole eastern hospital, hong kong, hong kong queen mary hospital, hong kong, hong kong tuen mun hospital, hong kong, hong kong queen elizabeth hospital, kowloon, hong kong bacs-kiskun megyei korhaz, kecskemet, bacs-kiskun, hungary fovarosi onkormanyzat szent margit korhaza, budapest, hungary magyar honvedseg egeszsegugyi kozpont, budapest, hungary szent imre egyetemi oktatokorhaz, budapest, hungary semmelweis egyetem iii. sz belgyogyaszati klinika, budapest, hungary fovarosi onkormanyzat uzsoki utcai korhaz, budapest, hungary jasz-nagykun-szolnok megyei hetenyi geza korhaz, szolnok, hungary mnj institute of oncology, hyderabad, andhra pradesh, india dr. b. l. kapur memorial hospital, new delhi, delhi, india hcg cancer centre, vadodara, gujarat, india artemis hospital, gurgaon, haryana, india manipal hospital, bangalore, karmnataka, india regional cancer centre, trivandrum, kerala, india tata memorial hospital, mumbai, maharashtra, india hcg manavata cancer centre, nasik, maharashtra, india ruby hall clinic and grant medical foundation, pune, maharashtra, india deenanth mangeshkar hospital and research centre, pune, maharashtra, india apollo speciality hospital, chennai, tamil nadu, india apollo gleneagles hospitals, kolkata, west bengal, india medica superspecialty hospital, kolkata, west bengal, india hcg cancer centre, ahmedabad, india post graduate institute of medical education & research, chandigarh, india soroka medical center, beer sheva, israel rambam medical center, haifa, israel shaare zedek medical center, jerusalem, israel hadassah medical center, jerusalem, israel meir medical center, kfar saba, israel rabin medical center, petach tikva, israel sheba medical center, ramat gan, israel kaplan medical center, rehovot, israel assaf harofeh medical center, zerifin 70300, israel ospedale perrino, brindisi, br, italy azienda ospedaliero universitaria di ferrara, cona, ferrara, italy istituto scientifico romagnolo - studio e la cura dei tumori, meldola, forli, italy istituto clinico humanitas, rozzano, milano, italy istituto tumori fondazione g. pascale irccs, napoli, naples, italy azienda ospedaliera santa maria, terni, tr, italy ospedale bellaria, bologna, italy azienda ospedaliera universitaria ospedale san martino di genova, genova, italy ospedale fatebenefratelli-oftalmico, milano, italy asst monza - presidio ospedaliero di monza, milano, italy azienda ospedaliera universitaria policlinico de modena, modena, italy azienda ospedaliera universitaria federico ii, napoli, italy istituto oncologico veneto, padova, italy azienda ospedaliera di parma, parma, italy i.f.o. istituto nazionale tumori regina elena, roma, italy policlinico ospedale s. andrea, roma, italy azienda ospedaliero-universitaria s.giovanni battista, torino, italy presidio ospedaliero santa chiara, trento, italy aichi cancer center hospital, nagoya, aichi, japan national cancer center hospital east, kashiwa, chiba, japan national hospital organization shikoku cancer center, matsuyama, ehime, japan jcho kurume general hosp, kurume, fukuoka, japan gunma prefectural cancer center, ohta, gunma, japan hiroshima university hospital, hiroshima-shi, hiroshima-ken, japan national hospital organization hokkaido cancer center, sapporo, hokkaido, japan the hospital of hyogo college of medecine, nishinomiya, hyogo, japan university of tsukuba hospital, tsukuba-shi, ibaragi, japan tokai university hospital, isehara, kanagawa, japan st marianna university school of medicine toyoko hospital, kawasaki, kanagawa, japan kanagawa cancer center, yokohama, kanagawa, japan kkr tohoku kosai hospital, aoba-ku, sendai-shi, miyagi, japan kindai university hospital, osaka sayama-shi, osaka, japan saitama medical university international medical center, hidaka, saitama, japan saitama cancer center, kitaadachi-gun, saitama, japan shizuoka cancer center, sunto-gun, shizuoka, japan jichi medical university hospital, shimotsuke, tochigi, japan tochigi cancer center, utsunomiya, tochigi, japan juntendo university hospital, bunkyo-ku, tokyo, japan st. lukes international hospital, chuo-ku, tokyo, japan national cancer center hospital, chuo-ku, tokyo, japan the cancer institute hospital of jfcr, koto-ku, tokyo, japan showa university hospital, shinagawa-ku, tokyo, japan tokyo medical university hospital, shinjuku-ku, tokyo, japan national center for global health and medicine, shinjuku-ku, tokyo, japan chiba cancer center, chiba, japan kyushu cancer center, fukuoka, japan sagara hospital, kagoshima, japan kumamoto university hospital, kumamoto, japan kumamoto shinto general hospital, kumamoto, japan kyoto university hospital, kyoto, japan niigata cancer center hospital, niigata, japan national hospital organization osaka national hospital, osaka, japan osaka international cancer institute, osaka, japan chungbuk national university hospital, cheong ju-city, chung cheong buk-do, korea, republic of soonchunhyang university hospital cheonan, cheonan, chungcheongnam-do, korea, republic of national cancer center, goyang-si, gyeonggi-do, korea, republic of seoul national university bundang hospital, seongnam, gyeonggi-do, korea, republic of dongnam institute of radiological and medical sciences, busan, gyeongsangnam do, korea, republic of gachon university gil medical center, incheon, korea, korea, republic of samsung medical center, seoul, korea, korea, republic of korea university guro hospital, seoul, korea, korea, republic of asan medical center, songpa-gu, seoul, korea, republic of ewha university mokdong hospital, seoul, yangcheon-gu, korea, republic of inje university haeundae paik hospital, busan, korea, republic of kyungpook national university medical center chilgok hospital, daegu, korea, republic of inha university hospital, incheon, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital yonsei university health system, seoul, korea, republic of centro de estudios y prevencion del cancer a.c., tuxtla gutiérrez, chiapas, mexico cimab s.a. de c.v., torreon, coahuila, mexico grupo medico camino s.c., méxico city, distrito federal, mexico health pharma professional research, s.a. de c.v., mexico city, federal district, mexico coi centro oncológico internacional s.a.p.i de c.v., mexico, federal district, mexico hospital civil de guadalajara fray antonio alcalde, guadalajara, jalisco, mexico coi centro oncológico internacional s.a.p.i de c.v., tlajomulco de zuniga, jalisco, mexico cri centro regiomontano de investigacion s.c., monterrey, nuevo leon, mexico christus muguerza clinica vidriera, monterrey, nuevo leon, mexico joaquin gabriel reinoso toledo (consultorios de medicina especializada), monterrey, nuevo león, mexico neurociencias estudios clinicos s.c., culiacan, sinaloa, mexico consultorio centro hemato oncologico privado, san bernardino, toluca, mexico medical care and research, s.a. de c.v., merida, yucatan, mexico centro de atención e investigación clínica en oncología, merida, yucatan, mexico unidad de investigacion en salud de chihuahua s.c., chihuahua, mexico oaxaca site management organization sc, oaxaca, mexico oncológica de puebla, puebla, mexico oncológico potosino, san luis potosí, mexico onze lieve vrouwe gasthuis (olvg), amsterdam, netherlands hagaziekenhuis, den haag, netherlands albert schweitzer ziekenhuis, dordrecht, netherlands universitair medisch centrum maastricht, maastricht, netherlands palmerston north hospital, palmerston north, wanganui, new zealand auckland city hospital, auckland, new zealand waikato hospital, hamilton, new zealand uniwersyteckie centrum kliniczne, gdansk, poland szpital morski im. pck sp. z o.o., gdynia, poland przychodnia lekarska ""komed"", konin, poland centrum terapii wspolczesnej j.m. jasnorzewska s.k.a., lodz, poland centrum onkologii ziemii lubelskiej im. sw. jana z dukli, lublin, poland olsztynski osrodek onkologiczny, olsztyn, poland opolskie centrum onkologii, opole, poland wielkopolskie centrum onkologii im. m. sklodowskiej-curie, poznan, poland magodent szpital onkologiczny elblaska, warszawa, poland narodowy instytut onkologii im. marii sklodowskiej-curie panstwowy instytut, warszawa, poland dolnoslaskie centrum onkologii, wroclaw, poland instituto português de oncologia dr. francisco gentil, coimbra, portugal fundação champalimaud, lisboa, portugal centro hospitalar lisboa norte - hospital de santa maria, lisboa, portugal hospital geral de santo antonio, porto, portugal ipofg - porto, porto, portugal puerto rico hematology/oncology group, bayamon, puerto rico university of puerto rico, san juan, puerto rico centrul de oncologie sf. nectarie srl, craiova, dolj, romania s.c. r.t.c. radiology therapeutic center s.r.l., otopeni, ilfov, romania sc oncopremium team srl, baia mare, maramureș, romania institutul oncologic dr trestioreanu bucuresti, bucuresti, sector 2, romania spitalul clinic filantropia, bucuresti, romania institutul oncologic ""prof. dr. ion chiricuta"" cluj-napoca, cluj-napoca, romania spitalul clinic judetean de urgenta sf.apostol andrei constanta, constanta, romania kazan oncology dispensary, kazan, tatarstan republic, russian federation chelyabinsk regional oncology dispensary, chelyabinsk, russian federation shi kaluga regional hospital, kaluga, russian federation kursk regional oncology dispensary, kursk, russian federation leningrad regional oncology dispensary, leningrad region, russian federation principal military clinical hospital n.a. n. n. burdenko, moscow, russian federation blokhin cancer research center, moscow, russian federation russian oncological research center, moscow, russian federation orenburg regional clinical oncology dispensary, orenburg, russian federation st. petersburg city clinical oncological dispensary, saint-petersburg, russian federation samara regional clinical oncology dispensary, samara, russian federation gou vpo st-petersburg sma n/a mechnikov fed. agen of health, st. petersburg, russian federation fgu research institution of oncology, st. petersburg, russian federation st-petersburg scientifical practical cente spec medical care, st. petersburg, russian federation volgograd regional clinical oncology dispensary, volgograd, russian federation yaroslavl region regional clinical oncology hospital, yaroslavl, russian federation king fahad specialist hospital-dammam, dammam, saudi arabia king faisal specialist hospital & research center, riyadh, saudi arabia king abdulaziz medical city - national guard hospital, riyadh, saudi arabia king fahad medical city, riyadh, saudi arabia national cancer center, singapore, singapore national university hospital, singapore, singapore eastleigh breast care center, pretoria, gauteng, south africa cancercare rondebosch oncology, cape town, south africa cancercare, george, south africa sandton oncology centre, johannesburg, south africa langenhoven drive oncology centre, port elizabeth, south africa mary potter oncology center, pretoria, south africa hospital clinico universitario virgen de la victoria, malaga, andalucia, spain hospital universitario virgen del rocio, sevilla, andalucía, spain hospital universitario central de asturias, oviedo, asturias, spain hospital universitari arnau de vilanova, lleida, cataluña, spain hospital clinico universitario de santiago, santiago de compostela, la coruna, spain hospital fundación alcorcón, alcorcón, madrid, spain hospital universitario quironsalud madrid, pozuelo de alarcon, madrid, spain hospital universitario de canarias, la laguna, santa cruz de tenerife, spain hospital del mar, barcelona, spain hospital quirón salud barcelona-instituto oncológico baselga, barcelona, spain hospital universitari vall d\'hebron, barcelona, spain hospital clinic i provincial, barcelona, spain hospital de la santa creu i sant pau, barcelona, spain hospital reina sofia, cordoba, spain hospital clinico universitario san cecilio, granada, spain complejo hospitalario ciudad de jaen, jaen, spain hospital de la princesa, madrid, spain hospital general universitario gregorio marañon, madrid, spain hospital universitario ramon y cajal, madrid, spain hospital clinico san carlos, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital madrid norte sanchinarro, madrid, spain hospital clinico de salamanca, salamanca, spain hospital universitario virgen macarena, sevilla, spain hospital universitario nuestra señora de valme, sevilla, spain hospital clínico universitario de valencia, valencia, spain hospital quirón salud valencia, valencia, spain hospital universitario miguel servet, zaragoza, spain norrlands universitetssjukhus, umeå, vasterbotten, sweden skånes universitetssjukhus lund, lund, sweden länssjukhuset sundsvall, sundsvall, sweden västmanlands sjukhus västerås, västerås, sweden växjö centrallasarettet, växjö, sweden changhua christian hospital, changhua, taiwan kaohsiung medical university chung-ho memorial hospital, kaohsiung city, taiwan chang gung memorial hospital - kaohsiung, kaohsiung, taiwan tri-service general hospital, neihu taipei, taiwan taipei medical university- shuang ho hospital, new taipei city, taiwan china medical university hospital, taichung city, taiwan mackay memorial hospital, taipei city, taiwan national taiwan university hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan sun yat-sen cancer center, taipei, taiwan chang gung memorial hospital - linkou, taoyuan city, taiwan ankara gulhane training ve research hospital, ankara, kecioren, turkey baskent adana educational hospital, adana, turkey ankara university medicine hospital, ankara, turkey hacettepe university faculty of medicine, ankara, turkey dr.abdurrahman yurtaslan ankara oncology training & res hosp, ankara, turkey akdeniz university medical faculty, antalya, turkey trakya university faculty of medicine, edirne, turkey istanbul university, istanbul, turkey acibadem altunizade hastanesi, istanbul, turkey istanbul medeniyet university medical faculty, istanbul, turkey ege university faculty of medicine, izmir, turkey medical park izmir hospital, izmir, turkey kocaeli university medical faculty hospital, izmit, turkey inonu university medical faculty, malatya, turkey dnipropetrovsk city multifunctional clinical hospital #4 of dnipropetrovsk regional council, dnipro, ukraine commu instit ""krivorizhskiy oncology dispensary"" dnip reg co, kriviy rig, ukraine communal enterprise ""volyn regional medical oncology center"", lutsk, ukraine odesa regional clinical hospital, odesa, ukraine poltava regional clinical oncological dispensary, poltava, ukraine central municipal clinical hospital, uzhhorod, ukraine podilskyi regional center of oncology, vinnytsia, ukraine university hospital of north tees, stockton-on-tees, cleveland, united kingdom royal cornwall hospital, truro, cornwall, united kingdom broomfield hospital, chelmsford, essex, united kingdom north middlesex hospital, london, greater london, united kingdom christie nhs foundation trust, manchester, greater manchester, united kingdom victoria hospital, blackpool, lancashire, united kingdom royal preston hospital, preston, lancashire, united kingdom charing cross hospital, chelsea, london, united kingdom mount vernon hospital, northwood, middlesex, united kingdom nottingham city hospital, nottingham, nottinghamshire, united kingdom western general hospital, edinburgh, scotland, united kingdom musgrove park hospital, taunton, somerset, united kingdom royal surrey county hospital, guildford, surrey, united kingdom guys/st. thomas hospital, london, surrey, united kingdom sarah canon research institute uk, london, surrey, united kingdom royal marsden hospital, sutton, surrey, united kingdom airedale general hospital, keighley, west yorkshire, united kingdom pilgrim hospital, boston, united kingdom churchill hospital, oxford, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/97/nct03155997/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/97/nct03155997/sap_001.pdf",https://ClinicalTrials.gov/show/NCT03155997,breast
198,199,NCT02301962,phase iv panitumumab study in indian subjects with metastatic colorectal cancer,,Unknown status,No Results Available,cancer,drug: panitumumab,number of subjects with adverse event.|progression free survival.|overall response rate.|duration of response.,dr. reddy's laboratories limited|amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,58.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DRL-INDG02-PAN/2018,"July 28, 2015","June 30, 2021","January 31, 2022","November 26, 2014",,"December 16, 2019","['drl investigational site, vijayawada, andhra pradesh, india drl investigational site, mumbai, maharashtra, india drl investigational site, nagpur, maharashtra, india drl investigational site, nashik, maharashtra, india drl investigational site, nashik, maharashtra, india drl investigational site, ludhiāna, punjab, india drl investigational site, jaipur, rajasthan, india drl investigational site, madurai, tamilnadu, india drl investigational site, hyderabad, telangana, india drl investigational site, kolkata, west bengal, india drl investigational site, new delhi, india drl investigational site, new delhi, india']",,https://ClinicalTrials.gov/show/NCT02301962,
199,200,NCT00455533,study to assess effectiveness of giving combination of standard chemotherapy drugs versus combination of standard chemotherapy and new drug ixabepilone when given before surgical removal of early stage breast cancer,,Completed,Has Results,breast cancer,drug: ixabepilone|drug: paclitaxel|drug: cyclophosphamide|drug: doxorubicin,"percentage of participants achieving pathologic complete response (pcr)|percentage of participants achieving pathologic complete response (pcr) in biomarker-defined populations|percentage of participants achieving pathologic complete response (pcr) in 20- and 26-gene model subgroups|percentage of participants achieving clinical objective response|percentage of participants requiring breast conservation surgery|percentage of participants achieving combined pcr and minimal residual cancer burden (rcb) 1|randomized participants with non-missing pcr & biomarker expression (gene [probe set]), to explore whether gene expression patterns for gtse1, isoforms of β-tubulin, kallikreins 5, 6, 10 are differentially predictive of pcr|randomized participants with non-missing pcr & biomarker expression (gene [probe set]) to explore whether gene expression patterns for gtse1, isoforms of β-tubulin, kallikreins 5, 6, 10 are differentially predictive of pcr/rcb1|percentage of participants with pcr and mdr1 immunohistochemistry (ihc) positivity using two pre-specified thresholds|percentage of participants with pcr/rcb1 and mdr1 immunohistochemistry (ihc) positivity using two pre-specified thresholds|percentage of participants with pcr and mdr1 immunohistochemistry (ihc) positivity using two pre-specified thresholds, estrogen-receptor (er) negative participants|prevalence of biomarker based on optimal threshold (biomarker positive participants)|overall safety summary: deaths, serious adverse events (saes), discontinuations due to adverse events (aes), drug-related aes, and most common treatment-related non-hematologic adverse events (tnaes) occuring in >=10% of participants|severity of any drug-related aes and gastrointestinal aes by system organ class|on-study hematology: worst common terminology criteria of adverse events (ctcae version 3) grade per participant in ixabepilone/paclitaxel phase|on-study liver function: worst common terminology criteria of adverse events (ctcae version 3) grade per participant in ixabepilone/paclitaxel phase|on-study renal function: worst common terminology criteria of adverse events (ctcae version 3) grade per participant in ixabepilone/paclitaxel phase|number of participants by dose for ac|number of participants by dose for ixabepilone/paclitaxel|reason for first dose reduction of ac|reason for first dose reduction of ixabepilone/paclitaxel|number of participants with course delay and reason for delay for ac|number of participants with dose delay and reason for dose delay for ixabepilone/paclitaxel",bristol-myers squibb,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,384.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA163-100|EUDRACT 2006-003047-24,October 2007,December 2009,December 2009,"April 3, 2007","April 4, 2011","February 24, 2016","['comprehensive cancer center, palm springs, california, united states northwest oncology & hematology associates, coral spring, florida, united states florida cancer research institute, davie, florida, united states medical specialists of palm beaches, lake worth, florida, united states moffitt cancer center, tampa, florida, united states university medical center, inc, louisville, kentucky, united states university of new mexico cancer center, albuquerque, new mexico, united states albert einstein cancer center, bronx, new york, united states virginia mason medical center, seattle, washington, united states providence cancer center, spokane, washington, united states local institution, capital federal, buenos aires, argentina local institution, capital federal, buenos aires, argentina local institution, buenos aires, argentina local institution, buenos aires, argentina local institution, salzburg, austria local institution, vienna, austria local institution, wien, austria local institution, bordeaux, france local institution, saint herblain, france local institution, duesseldorf, germany local institution, erlangen, germany local institution, jena, germany local institution, new delhi, delhi, india local institution, bangalore, karnataka, india local institution, trivandrum, kerala, india local institution, pune, maharashtra, india local institution, bhopal, india local institution, hyderabad, india local institution, mumbai, india local institution, vellore, india local institution, bologna, italy local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, callao, peru local institution, lima, peru local institution, lima, peru local institution, cebu city, philippines local institution, davao city, philippines local institution, quezon city, philippines local institution, kazan, russian federation local institution, moscow, russian federation local institution, st petersburg, russian federation local institution, singapore, singapore local institution, barcelona, spain local institution, jaen, spain local institution, lleida, spain local institution, taipei, taiwan local institution, taipei, taiwan local institution, nottingham, nottinghamshire, united kingdom local institution, coventry, warwickshire, united kingdom']",,https://ClinicalTrials.gov/show/NCT00455533,breast
200,201,NCT00122746,clinical and experimental studies to improve radiotherapy outcome in aids cancer patients,,Unknown status,No Results Available,cancer of the cervix,radiation: radiotherapy alone|radiation: radiotherapy with cisplatin,3 year recurrence free survival|incidence of grade 3 acute toxicity|pelvic control rates|tumour response at 3 months.|cancer specific survival rates.|overall survival rates.|acute and late toxicities after the treatment.,international atomic energy agency,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,322.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E33022,December 2004,June 2012,,"July 22, 2005",,"October 13, 2011","['dept. of atomic energy, tata memorial centre, mumbai, india johannesburg hospital, johannesburg, south africa ocean road cancer institute, dar es salaam, tanzania radiotherapy centre, kampala, uganda radiotherapy centre, harare, zimbabwe']",,https://ClinicalTrials.gov/show/NCT00122746,cervix
201,202,NCT00099437,comparison of fulvestrant (faslodex™) 250 mg and 500 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer progressing or relapsing after previous endocrine therapy.,CONFIRM,"Active, not recruiting",Has Results,breast cancer,drug: fulvestrant,time to progression (ttp)|objective response rate (orr)|clinical benefit rate (cbr)|duration of response (dor)|duration of clinical benefit (docb)|overall survival (os)|change from randomisation in trial outcome index (toi) over the course of the study|overall survival (os) - follow-up,astrazeneca,Female,"45 Years to 130 Years   (Adult, Older Adult)",Phase 3,736.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D6997C00002,"February 13, 2005","February 27, 2009","December 30, 2022","December 14, 2004","June 15, 2010","February 23, 2022","['research site, casa grande, arizona, united states research site, fountain valley, california, united states research site, new britain, connecticut, united states research site, crystal river, florida, united states research site, fort lauderdale, florida, united states research site, urbana, illinois, united states research site, rosedale, maryland, united states research site, detroit, michigan, united states research site, kansas city, missouri, united states research site, saint louis, missouri, united states research site, voorhees, new jersey, united states research site, greenville, north carolina, united states research site, pasadena, texas, united states research site, west bend, wisconsin, united states research site, brasschaat, belgium research site, brussels, belgium research site, brussels, belgium research site, edegem, belgium research site, gent, belgium research site, hasselt, belgium research site, liège, belgium research site, turnhout, belgium research site, barretos, brazil research site, londrina, brazil research site, porto alegre, brazil research site, recife, brazil research site, salvador, brazil research site, sao paulo, brazil research site, antofagasta, chile research site, santiago, chile research site, santiago, chile research site, bogota, colombia research site, cali, colombia research site, brno, czechia research site, ceske budejovice, czechia research site, pardubice, czechia research site, praha 10, czechia research site, praha 2, czechia research site, praha 8, czechia research site, tabor, czechia research site, v uvalu 84, czechia research site, nyíregyháza, hungary research site, szombathely, hungary research site, székesfehérvár, hungary research site, ansari nagar, india research site, bhopal, india research site, hyderabad, india research site, jaipur, india research site, kolkata, india research site, manipal, india research site, marg jaipur, india research site, mumbai, india research site, pune, india research site, trivandrum, india research site, vellore, india research site, aviano, italy research site, bergamo, italy research site, carpi, italy research site, genova, italy research site, prato, italy research site, reggio emilia, italy research site, varese, italy research site, floriana, malta research site, mexico city, mexico research site, mexico, mexico research site, mexico, mexico research site, białystok, poland research site, poznań, poland research site, łódź, poland research site, ivanovo, russian federation research site, kazan, tatarstan, russian federation research site, kazan, tatarstan, russian federation research site, krasnodar, russian federation research site, lipetsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhniy novgorod, russian federation research site, obninsk, russian federation research site, ryazan, russian federation research site, st-petersburg, russian federation research site, st.-petersburg, russian federation research site, st.petersburg, russian federation research site, yaroslavl, russian federation research site, bardejov, slovakia research site, bratislava, slovakia research site, nitra, slovakia research site, trnava, slovakia research site, a coruña, spain research site, madrid, spain research site, malaga, spain research site, oviedo, spain research site, salamanca, spain research site, sevilla, spain research site, cherkasy, ukraine research site, dnipro, ukraine research site, donetsk, ukraine research site, kyiv, ukraine research site, lviv, ukraine research site, sumy, ukraine research site, ternopil, ukraine research site, uzhhorod, ukraine research site, caracas, venezuela']",,https://ClinicalTrials.gov/show/NCT00099437,breast
202,203,NCT01073865,study to compare zoladex™ 10.8 mg with zoladex 3.6 mg in pre-menopausal women with breast cancer,,Completed,Has Results,breast cancer,drug: zd9393 (zoladex) 10.8 mg|drug: zd9393 (zoladex) 3.6 mg,number of patients with progression-free survival (pfs) at 24 weeks|number of responders at 24 weeks|oestradiol (e2) serum concentrations at 24 weeks,astrazeneca,Female,"20 Years to 130 Years   (Adult, Older Adult)",Phase 3,222.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8666C00001,"February 26, 2010","September 19, 2012","November 20, 2017","February 23, 2010","January 10, 2014","December 12, 2018","['research site, ahmedabad, india research site, bangalore, india research site, bangalore, india research site, chennai, india research site, hubli, india research site, hyderabad, india research site, jaipur, india research site, mumbai, india research site, nagpur, india research site, new delhi, india research site, new delhi, india research site, pune, india research site, pune, india research site, pune, india research site, thiruvananthapuram, india research site, amagasaki-shi, japan research site, chiba, japan research site, chuo-ku, japan research site, fukuoka-shi, japan research site, hamamatsu, japan research site, hiroshima-shi, japan research site, kagoshima-shi, japan research site, kamogawa-shi, japan research site, kitaadachi, japan research site, kumamoto-shi, japan research site, kyoto-shi, japan research site, mitaka-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, osaka-shi, japan research site, osaka, japan research site, sakai-shi, japan research site, sapporo-shi, japan research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon-si, korea, republic of research site, cebu city, philippines research site, iloilo city, philippines research site, lipa city, philippines research site, pasay city, philippines research site, quezon city, philippines research site, quezon city, philippines research site, kaohsiung, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, maharat nakorn ratchasima, thailand research site, songkla, thailand research site, ubonratchathani, thailand']",,https://ClinicalTrials.gov/show/NCT01073865,breast
203,204,NCT00856375,"nktr-102 versus irinotecan in patients with second-line, irinotecan-naïve, kras mutant, colorectal cancer",,Completed,Has Results,colorectal cancer,drug: nktr-102|drug: irinotecan,kaplan-meier estimate of pfs by central radiological review: itt population|kaplan-meier estimate of os: itt population|orr by central radiological review: itt population|dor by central radiological review: itt population|percentage of participants (≥2%) with treatment-emergent adverse events nci-ctcae grade 3 or higher|pk parameters of nktr-102 or irinotecan and respective metabolites,nektar therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,83.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-PIR-03,December 2008,July 2014,December 2014,"March 5, 2009","June 14, 2021","July 12, 2021","['investigator site - peoria, peoria, arizona, united states investigator site - burbank, burbank, california, united states investigator site - los angeles, los angeles, california, united states investigator site - vallejo, vallejo, california, united states investigator site - centralia, centralia, illinois, united states investigator site - louisville, louisville, kentucky, united states investigator site - detroit, detroit, michigan, united states investigator site - buffalo, buffalo, new york, united states investigator site - knoxville, knoxville, tennessee, united states investigator site - antwerp, antwerp, belgium investigator site - celle, celle, germany investigator site - karlsruhe, karlsruhe, germany investigator site - hyderabad, hyderabad, andra pradesh, india investigator site - ahmedabad, ahmedabad, gujarat, india investigator site - bangalore, bangalore, karnatak, india investigator site - bangalore, bangalore, karnatak, india investigator site - kochi, kochi, kerata, india investigator site - mumbai, mumbai, maharashtra, india investigator site - kolkata, kolkata, west benagal, india investigator site - kolkata, kolkata, west bengal, india investigator site - elche, elche, spain investigator site - madrid, madrid, spain investigator site - aberdeen, aberdeen, scotland, united kingdom investigator site - manchester, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00856375,colon
204,205,NCT02103322,comparative bioequivalence study in adult patients suffering from chronic myeloid leukemia & gastrointestinal stromal tumor under fed conditions,,Completed,No Results Available,chronic myeloid leukemia|gastrointestinal stromal tumor,"drug: imatinib mesylate tablets, 400 mg",cmax|auc0-tau|tmax|cmin|cavg|swing|fluctuation rate,"amneal pharmaceuticals, llc|accutest research laboratories (i) pvt. ltd.",All,18 Years to 55 Years   (Adult),Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARL/CT/13/001,February 2014,March 2014,June 2014,"April 3, 2014",,"June 27, 2014","['kailash cancer hospital & research centre, vadodara, gujurat, india srinivasam cancer care hospitals india pvt., bangalore, karnataka, india karnataka caner hospital, bengaluru, karnataka, india lokmaya hospital, pune, maharashtra, india dr. g viswanathan speciality hospitals, tiruchirappalli, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT02103322,gastric blood
205,206,NCT03681548,a study of doxorubicin hydrochloride liposome injection in subjects with ovarian cancer.,,Completed,No Results Available,ovarian cancer recurrent,drug: doxorubicin hydrochloride liposome injection,assessment of bioequivalence using cmax of encapsulated and free doxorubicin in plasma|assessment of bioequivalence using auc (0-t) of encapsulated and free doxorubicin in plasma|assessment of bioequivalence using auc (0-inf) of encapsulated and free doxorubicin in plasma|assessment of bioequivalence using cmax of total doxorubicin in plasma|assessment of bioequivalence using auc (0-t) of total doxorubicin in plasma|assessment of bioequivalence using auc (0-inf) total doxorubicin as secondary analyte|assessment of safety,"ayana pharma ltd.,|lambda therapeutic research ltd.",Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,52.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LC-101-02|0384-18|CTRI/2018/07/014835,"August 29, 2018","February 8, 2019","March 7, 2019","September 24, 2018",,"November 20, 2019","['mnj institute of oncology & regional cancer center, hyderabad, andhra pradesh, india hcg city cancer centre, vijayawada, andhra pradesh, india mahatma gandhi cancer hospital & research institute, visakhapatnam, andhra pradesh, india nirmal hospital pvt. ltd., surat, gujarat, india unique hospital - multispeciality and research institute, sūrat, gujarat, india aman hospital and research center, vadodara, gujarat, india kailash cancer hospital and research center, vadodara, gujarat, india k r hospital, mysore, karnataka, india apex wellness rishikesh hospital, nashik, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india noble hospital pvt ltd., pune, maharashtra, india sparsh hospitals & critical care (p) ltd., bhubaneshwar, odisha, india sri ramachandra medical centre, chennai, tamil nadu, india saveetha medical college & hospital, chennai, tamil nadu, india vgm hospital, coimbatore, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT03681548,ovari
206,207,NCT03243877,"performance of mammoalert™, point of care system, for the screening of breast cancer in women 18 years of age or older",,Unknown status,No Results Available,breast cancer,other: mammoalert screening test,"screening performance (i.e., sensitivity and specificity)|predictive values & likelihood ratios","poc medical systems, inc.",Female,"18 Years and older   (Adult, Older Adult)",,2458.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,POC-BC-0217,"June 17, 2017","November 26, 2017","August 31, 2018","August 9, 2017",,"April 11, 2018","['kims ushalakshmi centre for breast diseases kims hospitals, hyderabad, andhra pradesh, india indo american cancer hospital and research institute, hyderabad, andhra pradesh, india hcg multi specialty hospital hcg cancer center, ahmadabad, gujarat, india manipal hospital, bangalore, karnataka, india amrita institute of medical sciences and research centre, kochi, kerala, india tata medical center, kolkata, west bengal, india maulana azad medical college university of delhi & associated lok nayak hospital, new delhi, india']",,https://ClinicalTrials.gov/show/NCT03243877,breast
207,208,NCT04784715,"trastuzumab deruxtecan (t-dxd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in her2-positive metastatic breast cancer (destiny-breast09)",,Recruiting,No Results Available,breast cancer; her2-positive; metastatic,drug: trastuzumab deruxtecan|drug: placebo|drug: taxane|drug: pertuzumab|drug: trastuzumab,"progression free survival (pfs) by blinded independent central review (bicr) assessment|progression free survival (pfs) by investigator assessment|overall survival (os)|objective response rate (orr) by bicr and investigator assessment|duration of response (dor) by bicr and investigator assessment|time to second progression or death (pfs2) by investigator assessment|health related quality of life (hrqol) using the eortc qlq-c30|time to deterioration in eortc-qlq-c30 scores|health related quality of life (hrqol) using the eortc qlq-br45|serum concentration of trastuzumab deruxtecan and pertuzumab|immunogenicity of trastuzumab deruxtecan, alone or with pertuzumab.|safety and tolerability of trastuzumab deruxtecan, alone or with pertuzumab","astrazeneca|daiichi sankyo, inc.",All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,1134.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D967UC00001,"April 26, 2021","July 24, 2025","December 30, 2029","March 5, 2021",,"January 11, 2022","[""research site, phoenix, arizona, united states research site, tucson, arizona, united states research site, tucson, arizona, united states research site, little rock, arkansas, united states research site, springdale, arkansas, united states research site, duarte, california, united states research site, glendale, california, united states research site, miami, florida, united states research site, arlington heights, illinois, united states research site, louisville, kentucky, united states research site, silver spring, maryland, united states research site, boston, massachusetts, united states research site, detroit, michigan, united states research site, minneapolis, minnesota, united states research site, jackson, mississippi, united states research site, morristown, new jersey, united states research site, albany, new york, united states research site, new york, new york, united states research site, port jefferson station, new york, united states research site, portland, oregon, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, denton, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, shenandoah, texas, united states research site, tyler, texas, united states research site, norfolk, virginia, united states research site, roanoke, virginia, united states research site, seattle, washington, united states research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, capital federal, argentina research site, cipolletti, argentina research site, ciudad autonoma de buenos aire, argentina research site, ciudad de buenos aires, argentina research site, la plata, argentina research site, mar del plata, argentina research site, rosario, argentina research site, rosario, argentina research site, san salvador de jujuy, argentina research site, auchenflower, australia research site, macquarie university, australia research site, st leonards, australia research site, graz, austria research site, innsbruck, austria research site, linz, austria research site, wien, austria research site, brussels, belgium research site, bruxelles, belgium research site, charleroi, belgium research site, edegem, belgium research site, gent, belgium research site, hasselt, belgium research site, leuven, belgium research site, libramont-chevigny, belgium research site, liège, belgium research site, namur, belgium research site, sint-niklaas, belgium research site, barretos, brazil research site, brasília, brazil research site, florianópolis, brazil research site, goiânia, brazil research site, londrina, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, sorocaba, brazil research site, são paulo, brazil research site, calgary, alberta, canada research site, kelowna, british columbia, canada research site, halifax, nova scotia, canada research site, kitchener, ontario, canada research site, north york, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, saskatoon, saskatchewan, canada research site, iloilo city, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, changsha, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, chongqing, china research site, chongqing, china research site, dalian, china research site, guangzhou, china research site, guangzhou, china research site, guiyang, china research site, hangzhou, china research site, hangzhou, china research site, hefei, china research site, hefei, china research site, kunming, china research site, nanjing, china research site, nanjing, china research site, nanning, china research site, shanghai, china research site, shenyang, china research site, shenzhen, china research site, tianjin, china research site, wu han, china research site, wuhan, china research site, wuhan, china research site, xi'an, china research site, xi'an, china research site, xi'an, china research site, yinchuan, china research site, aalborg, denmark research site, copenhagen o, denmark research site, odense c, denmark research site, sønderborg, denmark research site, vejle, denmark research site, avignon, france research site, besancon, france research site, bordeaux, france research site, caen cedex, france research site, le mans, france research site, montpellier, france research site, montpellier, france research site, nice cedex 2, france research site, paris, france research site, pierre benite cedex, france research site, rennes, france research site, saint cloud, france research site, saint herblain, france research site, toulouse cedex 9, france research site, vandoeuvre les nancy, france research site, augsburg, germany research site, berlin, germany research site, berlin, germany research site, bonn, germany research site, dresden, germany research site, erlangen, germany research site, essen, germany research site, essen, germany research site, frankfurt am main, germany research site, frankfurt, germany research site, frankfurt, germany research site, freiburg, germany research site, hamburg, germany research site, heidelberg, germany research site, kiel, germany research site, koblenz am rhein, germany research site, leipzig, germany research site, mainz am rhein, germany research site, mannheim, germany research site, muenster, germany research site, münchen, germany research site, neu-isenburg, germany research site, paderborn, germany research site, rostock, germany research site, troisdorf, germany research site, tübingen, germany research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, győr, hungary research site, kecskemét, hungary research site, miskolc, hungary research site, nyíregyháza, hungary research site, szolnok, hungary research site, veszprém, hungary research site, ahmedabad, india research site, bangalore, india research site, belagavi, india research site, bengaluru, india research site, gurgaon, india research site, mysuru, india research site, nashik, india research site, nashik, india research site, new delhi, india research site, new delhi, india research site, haifa, israel research site, jerusalem, israel research site, petah tikva, israel research site, ramat gan, israel research site, tel-aviv, israel research site, aviano, italy research site, bergamo, italy research site, candiolo, italy research site, genova, italy research site, napoli, italy research site, padova, italy research site, prato, italy research site, akashi-shi, japan research site, bunkyo-ku, japan research site, chiba-shi, japan research site, chuo-ku, japan research site, fukushima-shi, japan research site, hidaka-shi, japan research site, hiroshima-shi, japan research site, hiroshima-shi, japan research site, isehara-shi, japan research site, kagoshima-shi, japan research site, kawasaki-shi, japan research site, kobe-shi, japan research site, koto-ku, japan research site, kurume-shi, japan research site, kyoto-shi, japan research site, matsuyama-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, nishinomiya-shi, japan research site, okayama, japan research site, osaka-shi, japan research site, ota-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shinagawa-ku, japan research site, shinjuku-ku, japan research site, shinjuku-ku, japan research site, shizuoka, japan research site, yokohama-shi, japan research site, cheonan-si, korea, republic of research site, daegu, korea, republic of research site, goyang-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, acapulco, mexico research site, alc. cuauhtémoc, mexico research site, del. cuauhtemoc, mexico research site, estado de méxico, mexico research site, guadalajara jalisco, mexico research site, guadalajara, mexico research site, metepec, mexico research site, mexico, mexico research site, mex, mexico research site, nuevo leon, mexico research site, arequipa, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, baguio city, philippines research site, cebu city, philippines research site, davao city, philippines research site, iloilo city, philippines research site, manila, philippines research site, quezon city, philippines research site, san juan, philippines research site, bucharest, romania research site, bucuresti, romania research site, cluj-napoca, romania research site, constanta, romania research site, floresti, romania research site, iasi, romania research site, timisoara, romania research site, kazan, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhny novgorod, russian federation research site, omsk, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, yaroslavl, russian federation research site, dammam, saudi arabia research site, jeddah, saudi arabia research site, jeddah, saudi arabia research site, makkah, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, cape town, south africa research site, cape town, south africa research site, cape town, south africa research site, george, south africa research site, johannesburg, south africa research site, parktown, south africa research site, port elizabeth, south africa research site, pretoria, south africa research site, rondebosch, south africa research site, barcelona, spain research site, barcelona, spain research site, barcelona, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, majadahonda, spain research site, san sebastian, spain research site, göteborg, sweden research site, stockholm, sweden research site, uppsala, sweden research site, växjö, sweden research site, örebro, sweden research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, adana, turkey research site, ankara, turkey research site, ankara, turkey research site, karsiyaka, turkey research site, malatya, turkey research site, samsun, turkey research site, buckhurst hill, united kingdom research site, edinburgh, united kingdom research site, guildford, united kingdom research site, london, united kingdom research site, london, united kingdom research site, maidstone, united kingdom research site, manchester, united kingdom research site, swansea, united kingdom research site, taunton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04784715,breast
208,209,NCT00999921,effects of tamoxifen in premenopausal women with benign breast disease not at high-risk of developing breast cancer,,Completed,Has Results,benign breast disease|fibrocystic disease of breast|fibroadenoma|mastalgia,drug: tamoxifen|drug: evening primrose oil,number of participants analysed for reduction in lump size ( 60% reduction in lump size considered to be a satisfactory response)|number of participants analysed for reduction in mastalgia (cardiff breast pain score).|number of participants analysed for response of cyclical mastalgia (good response was defined as disappearance of mastalgia),medical college and hospital kolkata,Female,"16 Years and older   (Child, Adult, Older Adult)",Phase 4,256.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,MSVP-107/08,January 2008,August 2014,January 2015,"October 22, 2009","April 29, 2015","May 18, 2015","['department of surgery, medical college, kolkata, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT00999921,breast
209,210,NCT02445586,safety study of pertuzumab (in combination with trastuzumab and docetaxel) in indian participants with breast cancer,,Completed,Has Results,breast cancer,drug: docetaxel|drug: pertuzumab|drug: trastuzumab,"overall number of participants by the number of serious adverse events reported per participant|overall number of participants with serious adverse events by severity (initial and most extreme), according to national cancer institute common terminology criteria for adverse events version 4.03 (nci ctcae v4.03)|number of participants with serious adverse events related to docetaxel|number of participants with serious adverse events related to pertuzumab|number of participants with serious adverse events related to trastuzumab|overall number of participants with serious adverse events by action taken with study drug|overall number of participants with serious adverse events by event outcome|number of participants with hematological abnormalities reported as serious adverse events|number of participants with serum chemistry abnormalities reported as serious adverse events|number of participants with coagulation abnormalities reported as serious adverse events|number of participants who died due to a serious adverse event by cause of death|overall number of participants by the number of non-serious adverse events reported per participant|overall number of participants with non-serious adverse events by severity, according to nci-ctcae v4.03|number of participants with non-serious adverse events related to docetaxel|number of participants with non-serious adverse events related to pertuzumab|number of participants with non-serious adverse events related to trastuzumab|overall number of participants with non-serious adverse events by chemotherapy adjustment with docetaxel and/or trastuzumab|overall number of participants with non-serious adverse events by action taken with pertuzumab|overall number of participants with non-serious adverse events by event outcome|overall number of participants with non-serious adverse events by treatment emergence (teae versus non-teae)|number of participants with hematological abnormalities reported as non-serious adverse events|number of participants with serum chemistry abnormalities reported as non-serious adverse events|number of participants with coagulation abnormalities reported as non-serious adverse events|number of participants with congestive heart failure|change from baseline in left ventricular ejection fraction (lvef) over time|number of participants by left ventricular ejection fraction (lvef) findings over time|number of participants with adverse events leading to treatment discontinuation|overall response rate|number of participants by best overall response|number of participants with disease progression or death or who were censored for progression-free survival analysis|median duration of progression-free survival|probability of participants remaining event-free in progression-free survival from 2 to 32 months|number of participants who died or were censored for overall survival analysis|median duration of overall survival|probability of participants remaining alive in overall survival from 3 to 34 months",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 4,52.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML29282,"August 17, 2015","September 26, 2018","September 26, 2018","May 15, 2015","October 29, 2019","October 29, 2019","['rajiv gandhi cancer institute & research center, new delhi, delhi, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india kokilaben dhirubhai ambani hospital & medical research institute, mumbai, maharashtra, india jehangir clinical development centre pvt. ltd; cancer research room, pune, maharashtra, india christian medical college & hospital; medicine, vellore, tamil nadu, india indo-american cancer hospital & research center, hyderabad, telangana, india tata medical centre; medical oncology, kolkata, west bengal, india m s ramaiah memorial hospital, bangalore, india max balaji hospital, delhi, india']","""study protocol"", https://clinicaltrials.gov/provideddocs/86/nct02445586/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/86/nct02445586/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02445586,breast
210,211,NCT03641560,a safety and efficacy study of enzalutamide in indian patients with progressive metastatic castration-resistant prostate cancer (mcrpc) previously treated with docetaxel-based chemotherapy,,"Active, not recruiting",No Results Available,metastatic castration resistant prostate cancer,drug: enzalutamide|drug: androgen deprivation therapy (adt),safety assessed by incidence of adverse events (aes)|number of participants with laboratory test abnormalities and/or aes|number of participants with physical examination abnormalities and/or aes|number of participants with vital sign abnormalities and/or aes|efficacy assessed by prostate-specific antigen (psa) response rate (≥ 50% reduction from baseline),astellas pharma inc,Male,"18 Years and older   (Adult, Older Adult)",Phase 4,52.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9785-CL-0413,"September 19, 2018","November 30, 2022","November 30, 2022","August 22, 2018",,"April 5, 2022","['site in00002, ahmedabad, india site in00004, hubli, india site in00008, kolkata, india site in00003, nashik, india site in00007, nashik, india site in00010, new delhi, india site in00001, pune, india site in00011, surat, india']",,https://ClinicalTrials.gov/show/NCT03641560,prostat
211,212,NCT02726009,a trial to evaluate safety of firmagon® (degarelix) in indian patients diagnosed with advanced hormone-dependent prostate cancer,,Completed,No Results Available,prostate cancer,drug: degarelix,frequency of adverse events|severity of adverse events|clinically significant changes in laboratory values (hematology and clinical biochemistry)|clinically significant changes in vital signs|cumulative probability of no prostate specific antigen (psa) failure|cumulative probability of progression free survival (pfs)|change in international prostate symptom score (ipss)|change in physician's satisfaction score,ferring pharmaceuticals,Male,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,230.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,000201,May 2016,"May 15, 2020","May 15, 2020","April 1, 2016",,"December 15, 2021","[""s. p medical college and ag of hospitals, bikaner, rajasthan, india krishna institute of medical sciences, secunderabad, telangana, india bodyline hospitals, ahmedabad, india hcg multi specialty hospital, ahmedabad, india shalby hospital, ahmedabad, india healthcare global enterprises limited, bangalore, india kle's dr. prabhakar kore hospital & mrc, belgaum, india apollo speciality hospital, chennai, india rajiv gandhi cancer institute and research centre, delhi, india muljibhai patel urological hospital, gujrat, india chl hospital, indore, india sms medical college & attached hospital's, jaipur, india tata medical center, kolkata, india king's george medical university, lucknow, india kokilaben dhirubhai ambani hospital and medical research institute, mumbai, india tata memorial hospital, mumbai, india government medical college and super specialty hospital, nagpur, india rml & pgimer, new delhi, india aman hospital and research center, vadodara, india""]",,https://ClinicalTrials.gov/show/NCT02726009,prostat
212,213,NCT00387387,"study on pazopanib when given with folfox6 (fluorouracil, oxaliplatin, leucovorin) or capeox (capecitabine, oxaliplatin)",,Completed,No Results Available,"neoplasms, colorectal",drug: pazopanib|drug: folfox 6|drug: capeox,"plasma auc(0-24) of pazopanib on day 1, 14 and 21 plasma auc(0-46) of 5-fu and auc(0-8) of platinum on day 1 plasma auc(0-24) of capecitabine, 5-fu, and platinum on day 1|pharmacokinetic endpoints (auc, c24, cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on day 1. assessment of disease by imaging",glaxosmithkline,All,"21 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VEG105424,"October 20, 2006","August 14, 2009","August 14, 2009","October 13, 2006",,"November 17, 2017","['gsk investigational site, hyderabad, andhra pradesh, india gsk investigational site, parel, india gsk investigational site, cambridge, cambridgeshire, united kingdom gsk investigational site, oxford, oxfordshire, united kingdom gsk investigational site, sutton, surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00387387,colon
213,214,NCT03472053,a study of bio-11006 in the treatment of advanced non-small cell lung cancer,,Completed,No Results Available,non small cell lung cancer stage iiib,drug: bio-11006 plus standard of care|drug: standard of care,progression-free survival|maintenance of body weight|treatment emergent adverse effects,"biomarck pharmaceuticals, ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIO-NSCLC-001,"February 1, 2018","December 30, 2019","December 30, 2019","March 21, 2018",,"May 19, 2020","['vardhman mahavir medical college & hospital, new delhi, delhi, india unique hospital and research institute, surat, gujarat, india aadhar health institute, hisar, hariyana, india hcg manavata cancer center, nashik, maharashtra, india deenanath mangeshkar hospital & research center, pune, maharashtra, india tata memorial hospital, mumbai, maharastra, india navsanjeevani hospital, nashik, maharastra, india chirayu cancer hospital, bhopal, mp, india sparsh hospitals and critical care, bhubaneswar, odisa, india sms medical college & hospital, jaipur, rajasthan, india nehru hospital & post graduate institute of medical education, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT03472053,
214,215,NCT03725475,a study to reveal the patient characteristics and treatment patterns of stage iii non-small-cell lung cancer patients,KINDLE,Completed,No Results Available,non-small-cell lung cancer (nsclc),,overall survival (os)|progression-free survival (pfs),astrazeneca,All,"Child, Adult, Older Adult",,3111.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,D133HR00004,"November 26, 2018","September 30, 2019","September 30, 2019","October 31, 2018",,"October 5, 2020","['research site, buenos aires, argentina research site, rosario, argentina research site, santiago de chile, chile research site, cali, colombia research site, cordoba, colombia research site, medellin, colombia research site, santo domingo, dominican republic research site, anand, india research site, bangalore, india research site, calicut, india research site, chennai, india research site, mohali, india research site, mumbai, india research site, nashik, india research site, new delhi, india research site, odissa, india research site, srinagar, india research site, west bengal, india research site, guadalajara, mexico research site, mexico city, mexico research site, toluca, mexico research site, lima, peru research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkoknoi, thailand research site, dusit, thailand research site, pathumwan, thailand research site, ratchathewi, thailand research site, montevideo, uruguay']",,https://ClinicalTrials.gov/show/NCT03725475,
215,216,NCT02608359,"a post-marketing surveillance to assess safety of abiraterone acetate (zytiga) in indian participants with metastatic, castration resistant prostate cancer",,Recruiting,No Results Available,prostate cancer,drug: abiraterone acetate,the number and type of adverse events reported by the investigator or the patient,johnson & johnson private limited,Male,"18 Years and older   (Adult, Older Adult)",,103.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CR107096|212082PCR4021,"May 31, 2016","May 31, 2022","May 31, 2022","November 18, 2015",,"April 28, 2022","['healthcare global (hcg) hospital, bangalore, india tata memorial hospital, bombay, india rajiv gandhi cancer institute & research centre, delhi, india christian medical, ludhiana, punjab, india p. d. hinduja national hospital and research center, mumbai, india max super specialty, new delhi, india indraprastha apollo hospital, new delhi, india']",,https://ClinicalTrials.gov/show/NCT02608359,prostat
216,217,NCT01201265,a study of bevacizumab in combination with gemcitabine and carboplatin in participants with triple negative metastatic breast cancer,,Completed,Has Results,breast cancer,drug: bevacizumab|drug: carboplatin|drug: gemcitabine,progression-free survival (pfs)|percentage of participants achieving an overall response|percentage of participants achieving a clinical benefit response (cbr)|time to progression (ttp)|overall survival (os)|number of participants with an adverse event (ae)|change from baseline to cycle 6 in european organization for research and treatment of cancer quality of life questionnaire (eortc qlq-30)|change from baseline in systolic blood pressure (sbp)|change from baseline in diastolic blood pressure (dbp),hoffmann-la roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML25420,February 2011,April 2015,April 2015,"September 14, 2010","May 27, 2016","May 27, 2016","['ahmedabad, india bangalore, india bangalore, india delhi, india gandhinagar, india mumbai, india mumbai, india mumbai, india new delhi, india new delhi, india pune, india vellore, india']",,https://ClinicalTrials.gov/show/NCT01201265,breast
217,218,NCT00300950,"safety and efficacy of the therapeutic vaccine gi-4000 in combination with gemcitabine versus placebo for the treatment of non-metastatic, post-resection pancreas cancer",,Completed,No Results Available,pancreas cancer,biological: gi-4000|drug: gemcitabine,recurrence free time and survival,globeimmune,All,"18 Years and older   (Adult, Older Adult)",Phase 2,176.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GI-4000-02,January 2006,February 2015,February 2015,"March 10, 2006",,"April 6, 2015","[""university of alabama at birmingham, birmingham, alabama, united states tower cancer research foundation, beverly hills, california, united states university of california san diego, lajolla, california, united states ucla medical center, los angeles, california, united states georgetown university medical center / lombardi cancer center, washington, district of columbia, united states rush university medical school, chicago, illinois, united states minnesota oncology hematology, pa, minneapolis, minnesota, united states washington university, st. louis, missouri, united states state university of ny at stony brook, stony brook, new york, united states unc lineberger comprehensive cancer center, chapel hill, north carolina, united states ohio state university, columbus, ohio, united states texas oncology, pa, dallas, texas, united states the texas cancer center dallas southwest, dallas, texas, united states baylor college of medicine, houston, texas, united states south texas oncology & hematology, san antonio, texas, united states tyler cancer center, tyler, texas, united states seattle cancer care alliance, seattle, washington, united states froedtert multi-disciplinary cancer clinic, milwaukee, wisconsin, united states psg hospitals, peelamedu, coimbatore, tamil nadu, india sri ramchandra medical college & research institute, ponur, chennai, tamil nadu, india indo american cancer hospital and research centre, hyderabad, india kmc hospital, mangalore, india govt medical colleg & hospital, nagpur, india lake shore hospital & research centre, nettoor, cochin, india g b pan hospital & maulana azad medical college, new delhi, india nizam's institute of medical sciences, panjagutta, hyderaba, india lifeline multispecialty hospital, perungudi, chennai, india regional cancer centre, trivandrum, india""]",,https://ClinicalTrials.gov/show/NCT00300950,pancreat
218,219,NCT00384176,first line metastatic colorectal cancer therapy in combination with folfox,HORIZON III,Completed,Has Results,colorectal cancer,drug: cediranib|drug: bevacizumab|drug: 5-fluorouracil ( in folfox)|drug: leucovorin (in folfox)|drug: oxaliplatin (in folfox),progression free survival|overall survival|objective response rate|duration of response|percentage change in tumour size|time to worsening of health related quality of life (qol) based on the fact colorectal symptom index (fcsi),astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2|Phase 3,1814.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D8480C00013|Eudract Number 2005-003440-66,"August 30, 2006","November 15, 2009","August 19, 2015","October 5, 2006","November 28, 2012","April 14, 2017","['research site, anniston, alabama, united states research site, birmingham, alabama, united states research site, casa grande, arizona, united states research site, tucson, arizona, united states research site, hot springs, arkansas, united states research site, palm springs, california, united states research site, san diego, california, united states research site, fairfield, connecticut, united states research site, stamford, connecticut, united states research site, bay pines, florida, united states research site, fort meyers, florida, united states research site, port st lucie, florida, united states research site, port st. lucie, florida, united states research site, galesburg, illinois, united states research site, park ridge, illinois, united states research site, quincy, illinois, united states research site, layfayette, indiana, united states research site, new albany, indiana, united states research site, alexandria, louisiana, united states research site, layfayette, louisiana, united states research site, hagerstown, maryland, united states research site, ann arbor, michigan, united states research site, ypsilanti, michigan, united states research site, st louis, missouri, united states research site, great falls, montana, united states research site, lincoln, nebraska, united states research site, summit, new jersey, united states research site, fresh meadows, new york, united states research site, northport, new york, united states research site, rochester, new york, united states research site, fayetteville, north carolina, united states research site, new bern, north carolina, united states research site, bismarck, north dakota, united states research site, cincinnati, ohio, united states research site, middletown, ohio, united states research site, zanesville, ohio, united states research site, coos bay, oregon, united states research site, hilton head island, south carolina, united states research site, chattanooga, tennessee, united states research site, knoxville, tennessee, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, white river junction, vermont, united states research site, abingdon, virginia, united states research site, alexandria, virginia, united states research site, armidale, new south wales, australia research site, coffs harbour, new south wales, australia research site, darlinghurst, new south wales, australia research site, hornsby, new south wales, australia research site, kogarah, new south wales, australia research site, port macquarie, new south wales, australia research site, randwick, new south wales, australia research site, st. leonards, new south wales, australia research site, tamworth, new south wales, australia research site, waratah, new south wales, australia research site, south brisbane, queensland, australia research site, ashford, south australia, australia research site, bedford park, south australia, australia research site, woodville south, south australia, australia research site, hobart, tasmania, australia research site, epping, victoria, australia research site, ashford, australia research site, bedford park, australia research site, bendigo, australia research site, box hill, australia research site, camperdown, australia research site, coffs harbour, australia research site, darlinghurst, australia research site, east-melbourne, australia research site, epping, australia research site, herston, australia research site, hobart, australia research site, hornsby, australia research site, kogarah, australia research site, lismore, australia research site, malvern, australia research site, nedlands, australia research site, port macquarie, australia research site, randwick, australia research site, south brisbane, australia research site, st. leonards, australia research site, tamworth, australia research site, waratah, australia research site, wodonga, australia research site, woodville south, australia research site, kundratstrasse 3, vienna, austria research site, innsbruck, austria research site, kundratstrasse 3, austria research site, salzburg, austria research site, wels, austria research site, wien, austria research site, zams, austria research site, bonheiden, belgium research site, brugge, belgium research site, brussels (woluwe-st-lambert), belgium research site, brussels (woluwé-st-lambert), belgium research site, edegem, belgium research site, gent, belgium research site, ghent, belgium research site, kortrijk, belgium research site, leuven, belgium research site, roeselare, belgium research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, surrey, british columbia, canada research site, vancouver, british columbia, canada research site, sydney, nova scotia, canada research site, barrie, ontario, canada research site, newmarket, ontario, canada research site, scarborough, ontario, canada research site, st catharines, ontario, canada research site, sudbury, ontario, canada research site, toronto, ontario, canada research site, york, ontario, canada research site, levis, quebec, canada research site, montreal, quebec, canada research site, montreal, canada research site, quebec, canada research site, brno, czech republic research site, chomutov, czech republic research site, kutna hora, czech republic research site, nova ves pod plesi, czech republic research site, pardubice, czech republic research site, tabor, czech republic research site, alexandria, egypt research site, cairo, egypt research site, helsinki, finland research site, tampere, finland research site, turku, finland research site, vaasa, finland research site, boulogne cedex, france research site, la roche s yon, france research site, marseille cedex 08, france research site, nantes,, france research site, nantes, france research site, paris cedex 15, france research site, paris, france research site, saint gregoire, france research site, dresden, germany research site, essen, germany research site, freiburg, germany research site, halle, germany research site, hannover, germany research site, heidelberg, germany research site, munchen, germany research site, münchen, germany research site, neu-isenburg, germany research site, tubingen, germany research site, tübingen, germany research site, budapest, hungary research site, debrecen, hungary research site, pecs, hungary research site, pécs, hungary research site, szeged, hungary research site, tatabanya, hungary research site, tatabánya, hungary research site, bhopal, madhya pradesh, india research site, pune, maharashtra, india research site, jaipur, rajasthan, india research site, varanasi, uttar prad, india research site, kolkata, w bengal, india research site, bangalore, india research site, bhopal, india research site, chennai, india research site, hyderabad, india research site, jaipur, india research site, kolkata, india research site, mumbai, india research site, pune, india research site, sheikhpura, india research site, holon, israel research site, kfar-saba, israel research site, petah tikva, israel research site, tel aviv, israel research site, tel-hashomer, israel research site, tiberias, israel research site, tzrifin, israel research site, genova, ge, italy research site, rozzano, mi, italy research site, ancona, italy research site, genova, italy research site, napoli, italy research site, roma, italy research site, rozzano, italy research site, riga, latvia research site, floriana, malta research site, valletta, malta research site, cebu city, philippines research site, davao city, philippines research site, molo, philippines research site, quezon city, philippines research site, bytom, poland research site, elblag, poland research site, gdynia, poland research site, krakow, poland research site, kraków, poland research site, lublin, poland research site, poznan, poland research site, poznań, poland research site, rybnik, poland research site, warszawa, poland research site, barnaul, russian federation research site, novosibirsk, russian federation research site, omsk, russian federation research site, tomsk, russian federation research site, tumen, russian federation research site, bratislava, slovakia research site, kosice, slovakia research site, nitra, slovakia research site, presov, slovakia research site, cape town, south africa research site, lyttelton manor, south africa research site, polokwane, south africa research site, port elizabeth, south africa research site, pretoria, south africa research site, cordoba, andalucia, spain research site, zaragoza, aragon, spain research site, oviedo, asturias, spain research site, barcelona, cataluna, spain research site, granollers, cataluna, spain research site, hospitalet de llobregat(barcel, cataluna, spain research site, terrassa(barcelona), cataluna, spain research site, madrid, comunidad de madrid, spain research site, valencia, comunidad valenciana, spain research site, a coruna, galicia, spain research site, a coruña, spain research site, córdoba, spain research site, granollers, spain research site, hospitalet de llobregat(barcel, spain research site, madrid, spain research site, manresa, spain research site, oviedo, spain research site, valencia, spain research site, zaragoza, spain research site, tainan, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, nakhonratchasima, naimuang, thailand research site, chiang mai, thailand research site, rachathewi, thailand research site, songkla, thailand research site, istanbul, goztepe, turkey research site, ankara, turkey research site, izmir, turkey research site, cherkassy, ukraine research site, chernigiv, ukraine research site, chernivtsi, ukraine research site, dnipropetrovsk, ukraine research site, donetsk, ukraine research site, ivano-frankivsk, ukraine research site, kharkiv, ukraine research site, kharkov, ukraine research site, kherson, ukraine research site, kiev, ukraine research site, kyiv, ukraine research site, lugansk, ukraine research site, lviv, ukraine research site, poltava, ukraine research site, simferopol, ukraine research site, sumy, ukraine research site, ternopil, ukraine research site, ternopol, ukraine research site, uzhgorod, ukraine research site, southampton, hampshire, united kingdom research site, maidstone, kent, united kingdom research site, northwood, middlesex, united kingdom research site, sutton, surrey, united kingdom research site, bebington, united kingdom research site, bournemouth, united kingdom research site, bradford, united kingdom research site, guildford, united kingdom research site, ipswich, united kingdom research site, london, united kingdom research site, maidstone, united kingdom research site, newcastle upon tyne, united kingdom research site, newcastle-upon-tyne, united kingdom research site, northwood, united kingdom research site, poole, united kingdom research site, stockport, united kingdom research site, sutton, united kingdom research site, hanoi city, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT00384176,colon
219,220,NCT00704730,efficacy of xl184 (cabozantinib) in advanced medullary thyroid cancer,EXAM,Completed,Has Results,thyroid cancer,drug: xl184|drug: placebo,progression-free survival (pfs)|overall survival (os) with xl184 compared with placebo|objective response rate (orr)|duration of objective response (or): independent radiology committee (irc) determined|biochemical response calcitonin (ctn) %|biochemical response carcinoembryonic antigen (cea) %,exelixis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,330.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",XL184-301,June 2008,October 2011,September 2020,"June 25, 2008","September 9, 2014","April 20, 2021","[""university of alabama at birmingham, comprehensive cancer center, birmingham, alabama, united states tgen clinical research service at scottsdale healthcare, scottsdale, arizona, united states university of arkansas for medical sciences, little rock, arkansas, united states burbank, california, united states ucla, los angeles, california, united states stanford cancer center, stanford, california, united states university of colorado cancer center, aurora, colorado, united states yale university, school of medicine, new haven, connecticut, united states washington cancer institute, washington, district of columbia, united states h. lee moffet cancer center and research institute, tampa, florida, united states university of chicago, chicago, illinois, united states indiana university melvin and bren simon cancer center, indianapolis, indiana, united states university of iowa, iowa city, iowa, united states kansas university medical center, kansas city, kansas, united states johns hopkins university, baltimore, maryland, united states massachusetts general hospital, boston, massachusetts, united states henry ford health system, detroit, michigan, united states mayo clinic, rochester, minnesota, united states capitol comprehensive cancer care clinic and research institute, jefferson city, missouri, united states washington university school of medicine, saint louis, missouri, united states nebraska methodist hospital, omaha, nebraska, united states ohio state university, james cancer hospital, columbus, ohio, united states oregon health & science university, portland, oregon, united states st. luke's hospital & health network, bethlehem, pennsylvania, united states hospital of the university of pennsylvania, philadelphia, pennsylvania, united states hollings cancer center, charleston, south carolina, united states vanderbilt university medical center, nashville, tennessee, united states vermont cancer center at fletcher allen health care, burlington, vermont, united states peninsula cancer institute, newport news, virginia, united states klagenfurt, austria multiple site locations, wien, austria cliniques universitaires st. luc, brussels, belgium universitair ziekenhuis, leuven, belgium brasilia, brazil lajeado, brazil porto alegre, brazil multiple site locations, sao paulo, brazil calgary, alberta, canada toronto, ontario, canada chum - hopital saint-luc, montreal, quebec, canada sherbrooke, quebec, canada santiago, chile odense, denmark angers, france bordeaux, france lyon, france marseille, france reims, france villejuif, france klinik fuer nuklearmedizin des universitaetsklinikums essen, essen, germany gemeinschaftspraxis, heidelberg, germany universitaetsklinikum leipzig, leipzig, germany johannes-gutenberg universitaet mainz, mainz, germany klinikum der ludwig-maximilians-universitaet muenchen, muenchen, germany ludwig-maximilians-universitaet muenchen, muenchen, germany universitaetsklinikum tuebingen, tuebingen, germany universitaetsklinikum wuerzburg, wuerzburg, germany athens, greece kidwai institute of oncology, bangalore, india indo-american cancer institute and research center, hyderabad, india searoc cancer institute, s.k. soni hospital, jaipur, india netaji subhash chandra bose cancer hospital research institute, kolkata, india central india cancer research institute, nagpur, india shatabdi superspeciality hospital, nashik, india all india institute of medical sciences, new dehli, india deenanath mangeshkar hospital & research center, pune, india ruby hall clinic, pune, india haifa, israel jerusalem, israel petach tikva, israel tel aviv, israel florence, italy milan, italy naples, italy pisa, italy rome, italy siena, italy turin, italy multiple site locations, seoul, korea, republic of amsterdam, netherlands groningen, netherlands leiden, netherlands multiple site locations, lima, peru bydgoszcz, poland gliwice, poland pozan, poland szczecin, poland warszawa, poland coimbra, portugal oporto, portugal porto, portugal obninsk, russian federation ufa, russian federation voronezh, russian federation yaroslavl, russian federation riyadh, saudi arabia multiple site locations, barcelona, spain madrid, spain murcia, spain santiago de compostela, spain sevilla, spain valencia, spain gothenburg, sweden lund, sweden uppsala, sweden berne, switzerland geneve, switzerland cardiff, united kingdom glasgow, united kingdom london, united kingdom manchester, united kingdom newcastle upon tyne, united kingdom oxford, united kingdom sheffield, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00704730,thyroid
220,221,NCT05104866,"a phase-3, open-label, randomized study of dato-dxd versus investigator's choice of chemotherapy (icc) in participants with inoperable or metastatic hr-positive, her2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy (tropion-breast01)",,Recruiting,No Results Available,breast cancer,drug: dato-dxd|drug: capecitabine|drug: gemcitabine|drug: eribulin|drug: vinorelbine,progression free survival|overall survival|objective response rate (orr)|duration of response (dor)|progression-free survival by investigator assessment|disease control rate (dcr)|time to first subsequent therapy (tfst)|time to second subsequent therapy (tsst)|time from randomization to second progression or death (pfs2)|clinical outcome assessment- ttd in pain|pharmacokinetics of dato-dxd|immunogenicity|clinical outcome assessment- ttd in physical functioning|clinical outcome assessment- ttd in ghs,"astrazeneca|daiichi sankyo, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,700.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D9268C00001,"October 18, 2021","July 18, 2025","July 18, 2025","November 3, 2021",,"April 22, 2022","[""research site, duarte, california, united states research site, los angeles, california, united states research site, palo alto, california, united states research site, san francisco, california, united states research site, fort myers, florida, united states research site, jacksonville, florida, united states research site, west palm beach, florida, united states research site, atlanta, georgia, united states research site, chicago, illinois, united states research site, columbia, maryland, united states research site, boston, massachusetts, united states research site, boston, massachusetts, united states research site, grand rapids, michigan, united states research site, minneapolis, minnesota, united states research site, jackson, mississippi, united states research site, kansas city, missouri, united states research site, ridgewood, new jersey, united states research site, new york, new york, united states research site, chapel hill, north carolina, united states research site, charlotte, north carolina, united states research site, cleveland, ohio, united states research site, columbus, ohio, united states research site, portland, oregon, united states research site, pittsburgh, pennsylvania, united states research site, providence, rhode island, united states research site, nashville, tennessee, united states research site, nashville, tennessee, united states research site, el paso, texas, united states research site, houston, texas, united states research site, richmond, virginia, united states research site, seattle, washington, united states research site, madison, wisconsin, united states research site, caba, argentina research site, anderlecht, belgium research site, leuven, belgium research site, liège, belgium research site, brasília, brazil research site, jau, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, santa catarina, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são paulo, brazil research site, são paulo, brazil research site, edmonton, alberta, canada research site, vancouver, british columbia, canada research site, halifax, nova scotia, canada research site, north york, ontario, canada research site, montreal, quebec, canada research site, ste-foy, quebec, canada research site, montreal, canada research site, toronto, canada research site, baoding, china research site, beijing, china research site, beijing, china research site, beijing, china research site, bengbu, china research site, changchun, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, dalian, china research site, guangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, jinan, china research site, jinan, china research site, linyi, china research site, nanchang, china research site, nanchang, china research site, nanjing, china research site, nantong, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, shenyang, china research site, tianjin, china research site, xiamen, china research site, xian, china research site, zhengzhou, china research site, bordeaux, france research site, lille cedex, france research site, lyon cedex 08, france research site, montpellier, france research site, plerin, france research site, reims, france research site, toulouse cedex 9, france research site, villejuif, france research site, aschaffenburg, germany research site, bielefeld, germany research site, düsseldorf, germany research site, essen, germany research site, heidelberg, germany research site, homburg, germany research site, leipzig, germany research site, lübeck, germany research site, münchen, germany research site, münchen, germany research site, ravensburg, germany research site, rostock, germany research site, wiesbaden, germany research site, budapest, hungary research site, budapest, hungary research site, győr, hungary research site, miskolc, hungary research site, szekszárd, hungary research site, szolnok, hungary research site, coimbatore, india research site, gulbarga, india research site, gurgaon, india research site, howrah, india research site, hyderabad, india research site, jaipur, india research site, kolkata, india research site, ludhiana, india research site, mumbai, india research site, nashik, india research site, nashik, india research site, rishikesh, india research site, surat, india research site, ancona, italy research site, bologna, italy research site, candiolo, italy research site, firenze, italy research site, meldola, italy research site, milano, italy research site, napoli, italy research site, prato, italy research site, roma, italy research site, chuo-ku, japan research site, fukuoka, japan research site, fukushima-shi, japan research site, hiroshima-shi, japan research site, isehara-shi, japan research site, kagoshima-shi, japan research site, kashiwa, japan research site, kitaadachi-gun, japan research site, koto-ku, japan research site, kyoto-shi, japan research site, matsuyama-shi, japan research site, nagoya-shi, japan research site, nishinomiya-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sapporo-shi, japan research site, shinagawa-ku, japan research site, shinjuku-ku, japan research site, yokohama-shi, japan research site, goyang-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, estado de méxico, mexico research site, nuevo leon, mexico research site, toluca, mexico research site, amsterdam, netherlands research site, amsterdam, netherlands research site, den bosch, netherlands research site, rotterdam, netherlands research site, tilburg, netherlands research site, venlo, netherlands research site, zwolle, netherlands research site, białystok, poland research site, gdansk, poland research site, gdynia, poland research site, konin, poland research site, koszalin, poland research site, poznan, poland research site, rzeszów, poland research site, tomaszów mazowiecki, poland research site, toruń, poland research site, warszawa, poland research site, łódź, poland research site, kazan, russian federation research site, krasnoyarsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, amanzimtoti, south africa research site, cape town, south africa research site, george, south africa research site, johannesburg, south africa research site, port elizabeth, south africa research site, pretoria, south africa research site, pretoria, south africa research site, pretoria, south africa research site, rondebosch, south africa research site, barcelona, spain research site, barcelona, spain research site, bilbao (vizcaya), spain research site, huelva, spain research site, l'hospitalet de llobregat, spain research site, la coruña, spain research site, madrid, spain research site, madrid, spain research site, malaga, spain research site, sevilla, spain research site, valencia, spain research site, kaohsiung, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, blackpool, united kingdom research site, bristol, united kingdom research site, cardiff, united kingdom research site, colchester, united kingdom research site, edinburgh, united kingdom research site, guildford, united kingdom research site, london, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, nottingham, united kingdom research site, sutton, united kingdom research site, truro, united kingdom""]",,https://ClinicalTrials.gov/show/NCT05104866,breast
221,222,NCT01916317,randomized controlled trial to assess blockade of voltage gated sodium channels during surgery in operable breast cancer,,"Active, not recruiting",No Results Available,operable breast cancer,drug: 0.5% lignocaine 60mm,• to assess the in-vivo ability of local anesthetics agents like lignocaine to decrease the dissemination of cancer cells during surgery and improve the disease free interval|• to assess the in-vivo ability of local anesthetics agents like lignocaine on impacting long term survival,"tata memorial hospital|shri siddhivinayak ganpati cancer hospital|kolhapur cancer centre (kcc)|max super speciality hospital|basavatarakam indo- american cancer hospital (biach)|malabar cancer centre (mcc)|north eastern indira gandhi regional institute of health and medical sciences (neigrihms)|all india institute of medical sciences, new delhi|gujarat cancer and research institute (gcri)|sterling multi speciality hospital (smsh)|dr. b barooha cancer institute (bbci)",Female,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH project 902,"December 12, 2011","October 31, 2026","December 31, 2026","August 5, 2013",,"March 22, 2022","['dr. b barooha cancer institute, guwahati, assam, india all india institute of medical science, new delhi, delhi, india gujarat cancer & research institute (gcri), ahmedabad, gujarat, india malabar cancer centre, kannur, kerela, india kolhapur cancer centre pvt ltd, kolhapur, maharashtra, india tata memorial centre mumbai, mumbai, maharashtra, india sterling multi speciality hospital, pune, maharashtra, india shree siddhivinayak ganapti cancer hospital sangli, sangli, maharashtra, india north eastern indira gandhi regional institute of health & medical sciences (neigrihms), shillong, meghalaya, india basavatarakam indo- american cancer hospital, hyderabad, telangana, india max super speciality hospital, delhi, india']",,https://ClinicalTrials.gov/show/NCT01916317,breast
222,223,NCT00864175,open label trial of incb07839 to determine effect and safety of incb007839 plus trastuzumab in her2 positive metastatic breast cancer,,Terminated,No Results Available,breast cancer,drug: incb007839|drug: trastuzumab|drug: docetaxel,overall response rate (complete + partial response) using recist (response evaluation criteria in solid tumor) criteria|to determine the plasma pharmacokinetic (pk) profile of incb007839 and trastuzumab when given in combination,incyte corporation,Female,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,68.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 7839-202,July 2007,June 2011,October 2011,"March 18, 2009",,"January 18, 2018","['visakhapatnam, andhra pradesh, india new delhi, ansari nagar, india mangalore, attavar, india bangalore, karnataka, india hyderabaad, punjagutta, india bangalore, ram nagar, india delhi, rohini, india delhi, vasundhara enclave, india bhopal, india kolkata, india nashik, india pune, india']",,https://ClinicalTrials.gov/show/NCT00864175,breast
223,224,NCT03573960,a study to evaluate the safety and efficacy of lenvatinib in participants with refractory differentiated thyroid cancer,,"Active, not recruiting",No Results Available,thyroid neoplasms,drug: lenvatinib,percentage of participants with grade 3 or higher treatment-emergent adverse events (teaes)|number of dose reductions|time to first dose reduction|objective response rate (orr)|progression-free survival (pfs)|percentage of participants with greater than or equal to (>=) grade 2 other teaes,eisai pharmaceuticals india pvt. ltd|eisai inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7080-M091-507,"April 1, 2018","December 31, 2022","December 31, 2022","June 29, 2018",,"December 10, 2021","[""all india institute of medical sciences, new delhi, delhi, india indraprastha apollo hospital, new delhi, delhi, india shetty's hospital, bangalore, karnataka, india deenanath mangeshkar hospital, pune, maharashtra, india all india institute of medical sciences, bhubaneshwar, odisa, india s. p. medical college & a. g. hospitals, bīkaner, rajasthan, india tata memorial hospital, mumbai, india bl kapoor hospital, new delhi, new delhi, india indrayani hospital, alandi, pune, india city cancer centre, vijayawada, india""]",,https://ClinicalTrials.gov/show/NCT03573960,thyroid
224,225,NCT00299195,a randomized study of sulindac in oral premalignant lesions,,Completed,Has Results,"leukoplakia, oral|benign neoplasms",drug: sulindac|drug: placebo,"- to evaluate the efficacy of sulindac in subjects with early or advanced oral premalignant lesion (opl) by both clinical response (reduction in size of all lesions) and histological response (change in histological grade).|to evaluate the effect of sulindac in modulating the expression of the intermediate biomarkers ki67, p53 proteins and dna ploidy after 24 weeks of treatment of study drug, and again after 8 weeks off study drug.|to evaluate the correlation between baseline cox-2 expression or dna ploidy with clinical response or biomarker modulation|to evaluate the safety of chronic dosing of sulindac in this subject population|to explore the relationship between genetic polymorphisms of genes involved in carcinogenesis and clinical or biomarker response to sulindac","memorial sloan kettering cancer center|amrita institute of sciences, aims, cochin, india|weill medical college of cornell university|regional cancer center(rcc), trivandrum, india|narayana hrudayalaya hospitals",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",04-099,"February 23, 2006","January 6, 2020","January 6, 2020","March 6, 2006","November 19, 2020","November 19, 2020","['memorial sloan kettering cancer center, new york, new york, united states amrita institute of sciences (aims), cochin, india regional cancer center (rcc), trivandrum, india']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/95/nct00299195/prot_sap_000.pdf",https://ClinicalTrials.gov/show/NCT00299195,
225,226,NCT03800134,a study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable non-small cell lung cancer,AEGEAN,Recruiting,No Results Available,non-small cell lung cancer,drug: durvalumab|other: placebo|drug: carboplatin/paclitaxel|drug: cisplatin/gemcitabine|drug: pemetrexed/cisplatin|drug: pemetrexed/carboplatin,pathological complete response (pcr) in modified intent-to-treat (mitt)|event-free survival (efs)|disease-free survival (dfs) in modified resected population|major pathological response (mpr)|overall survival (os)|event-free survival (efs) in pd-l1-tc ≥1% positive patients|pcr in pd-l1-tc ≥1% positive patients|disease-free survival (dfs) in pd-l1-tc ≥1% positive patients|major pathological response (mpr) in pd-l1-tc ≥1% positive patients|overall survival (os) in pd-l1-tc ≥1% positive patients|to assess disease-related symptoms and hrqol (eortc qlq-c30) in patients treated with durva + chemo prior to surgery followed by durva post-surgery compared with placebo + chemo prior to surgery followed by placebo post-surgery|to assess disease-related symptoms and hrqol (eortc qlq-lc13) in patients treated with durva + chemo prior to surgery followed by durva post-surgery compared with placebo + chemo prior to surgery followed by placebo post-surgery|to assess the pk of durvalumab in blood (through concentration)|presence of ada for durvalumab,astrazeneca,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,824.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",D9106C00001,"December 6, 2018","April 30, 2024","April 30, 2024","January 11, 2019",,"May 9, 2022","['research site, phoenix, arizona, united states research site, duarte, california, united states research site, long beach, california, united states research site, orange, california, united states research site, rancho mirage, california, united states research site, san diego, california, united states research site, aurora, colorado, united states research site, boca raton, florida, united states research site, jacksonville, florida, united states research site, orlando, florida, united states research site, tampa, florida, united states research site, boise, idaho, united states research site, chicago, illinois, united states research site, fort wayne, indiana, united states research site, waterloo, iowa, united states research site, wichita, kansas, united states research site, ashland, kentucky, united states research site, lexington, kentucky, united states research site, silver spring, maryland, united states research site, towson, maryland, united states research site, detroit, michigan, united states research site, duluth, minnesota, united states research site, minneapolis, minnesota, united states research site, hastings, nebraska, united states research site, morristown, new jersey, united states research site, bronx, new york, united states research site, buffalo, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, port jefferson station, new york, united states research site, poughkeepsie, new york, united states research site, durham, north carolina, united states research site, salisbury, north carolina, united states research site, winston-salem, north carolina, united states research site, bend, oregon, united states research site, medford, oregon, united states research site, pittsburgh, pennsylvania, united states research site, charleston, south carolina, united states research site, charleston, south carolina, united states research site, sioux falls, south dakota, united states research site, austin, texas, united states research site, fort worth, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, fairfax, virginia, united states research site, fort belvoir, virginia, united states research site, newport news, virginia, united states research site, kennewick, washington, united states research site, kirkland, washington, united states research site, seattle, washington, united states research site, seattle, washington, united states research site, morgantown, west virginia, united states research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, ciudad autonoma de buenos aire, argentina research site, ciudad autónoma de bs. as., argentina research site, cordoba, argentina research site, córdoba, argentina research site, florencio varela, argentina research site, la plata, argentina research site, pergamino, argentina research site, rosario, argentina research site, rosario, argentina research site, san salvador de jujuy, argentina research site, santa rosa, argentina research site, viedma, argentina research site, graz, austria research site, innsbruck, austria research site, rankweil, austria research site, wien, austria research site, wien, austria research site, charleroi, belgium research site, edegem, belgium research site, gent, belgium research site, kortrijk, belgium research site, liège, belgium research site, mons, belgium research site, barretos, brazil research site, belo horizonte, brazil research site, campinas, brazil research site, curitiba, brazil research site, florianópolis, brazil research site, natal, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, santa maria, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, teresina, brazil research site, vitoria, brazil research site, plovdiv, bulgaria research site, plovdiv, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, edmonton, alberta, canada research site, vancouver, british columbia, canada research site, kitchener, ontario, canada research site, london, ontario, canada research site, mississauga, ontario, canada research site, newmarket, ontario, canada research site, thunder bay, ontario, canada research site, windsor, ontario, canada research site, levis, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, saskatoon, saskatchewan, canada research site, quebec, canada research site, santiago de chile, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, temuco, chile research site, viña del mar, chile research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, changsha, china research site, changsha, china research site, changzhou, china research site, chengdu, china research site, guang zhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guiyang, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hefei, china research site, kunming, china research site, linhai, china research site, nanchang, china research site, nanjing, china research site, nanning, china research site, ningbo, china research site, ningbo, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, shenyang, china research site, shenzhen, china research site, shenzhen, china research site, tianjin, china research site, tianjin, china research site, urumqi, china research site, wuhan, china research site, wuhan, china research site, xiamen, china research site, xian, china research site, xintai, china research site, yangzhou, china research site, zhengzhou, china research site, san josé, costa rica research site, san josé, costa rica research site, avignon cedex, france research site, bordeaux, france research site, lyon cedex 08, france research site, nice, france research site, rouen cedex, france research site, toulon cedex 9, france research site, tours, france research site, vantoux, france research site, bielefeld, germany research site, frankfurt am main, germany research site, göttingen, germany research site, immenstadt, germany research site, köln, germany research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, farkasgyepü, hungary research site, gyöngyös - mátraháza, hungary research site, győr, hungary research site, székesfehérvár, hungary research site, törökbálint, hungary research site, ahmedabad, india research site, bangalore, india research site, bangalore, india research site, chandigarh, india research site, coimabatore, india research site, delhi, india research site, erode, india research site, gurgaon, india research site, gurgaon, india research site, hubli, india research site, kolkata, india research site, madurai, india research site, maharashtra, india research site, manipal, india research site, mumbai, india research site, mumbai, india research site, mysuru, india research site, nagpur, india research site, namakkal, india research site, nasik, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, surat, india research site, thane, india research site, vishakhapatnam, india research site, ancona, italy research site, bari, italy research site, bergamo, italy research site, firenze, italy research site, milano, italy research site, milano, italy research site, monza, italy research site, padova, italy research site, roma, italy research site, verona, italy research site, habikino-shi, japan research site, himeji-shi, japan research site, hiroshima-shi, japan research site, hiroshima-shi, japan research site, iwakuni-shi, japan research site, kitaadachi-gun, japan research site, kitakyushu-shi, japan research site, kurashiki shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, okayama-shi, japan research site, osakasayama-shi, japan research site, toyoake-shi, japan research site, wakayama-shi, japan research site, busan, korea, republic of research site, cheongju-si, korea, republic of research site, incheon, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon-si, korea, republic of research site, suwon-si, korea, republic of research site, aguascalientes, mexico research site, chihuahua, mexico research site, guadalajara, mexico research site, monterrey, mexico research site, monterrey, mexico research site, méxico, mexico research site, méxico, mexico research site, pachuca de soto, mexico research site, arnhem, netherlands research site, breda, netherlands research site, nijmegen, netherlands research site, arequipa, peru research site, bellavista, peru research site, chiclayo, peru research site, cusco, peru research site, la libertad, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, san isidro, peru research site, baguio city, philippines research site, davao city, philippines research site, iloilo city, philippines research site, makati, philippines research site, manila, philippines research site, manila, philippines research site, quezon city, philippines research site, san juan, philippines research site, białystok, poland research site, kraków, poland research site, olsztyn, poland research site, otwock, poland research site, poznań, poland research site, szczecin, poland research site, warszawa, poland research site, warszawa, poland research site, warszawa, poland research site, wrocław, poland research site, hato rey central, puerto rico research site, brasov, romania research site, cluj napoca, romania research site, constanta, romania research site, craiova, romania research site, iasi, romania research site, suceava, romania research site, timisoara, romania research site, barnaul, russian federation research site, ekaterinburg, russian federation research site, kazan, russian federation research site, krasnoyarsk, russian federation research site, lipetsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhniy novgorod, russian federation research site, novosibirsk, russian federation research site, obninsk, russian federation research site, obninsk, russian federation research site, omsk, russian federation research site, p. herzen moscow oncology rese, russian federation research site, rostov-on-don, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, st. petersburg, russian federation research site, st. petersburg, russian federation research site, syktyvkar, russian federation research site, tomsk, russian federation research site, tomsk, russian federation research site, yaroslavl, russian federation research site, alicante, spain research site, barcelona, spain research site, barcelona, spain research site, madrid, spain research site, madrid, spain research site, málaga, spain research site, oviedo, spain research site, pamplona, spain research site, san sebastian, spain research site, santiago de compostela (a coruña), spain research site, valencia, spain research site, changhua, taiwan research site, kaohsiung city, taiwan research site, taichung city, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, tainan city, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, chiang rai, thailand research site, khon kaen, thailand research site, lampang, thailand research site, dnipro, ukraine research site, dnipro, ukraine research site, kharkiv region, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, vinnytsia, ukraine research site, zaporizhzhia, ukraine research site, hanoi, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT03800134,
226,227,NCT03839823,study to compare the combination of ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancer,RIGHT Choice,"Active, not recruiting",No Results Available,breast cancer,combination product: docetaxel / capecitabine|combination product: capecitabine / vinorelbine|combination product: paclitaxel / gemcitabine|drug: ribociclib|drug: letrozole or anastrozole|drug: goserelin,"progression free survival|time to treatment failure|overall response rate (orr)|clinical benefit rate|time to response|overall survival|frequency/severity of adverse events, lab abnormalities.|change from baseline in the global health status/qol scale score by using fact-b questionnaire|3-month treatment failure rate",novartis pharmaceuticals|novartis,Female,18 Years to 59 Years   (Adult),Phase 2,225.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011A3201C,"February 25, 2019","April 12, 2022","January 27, 2023","February 15, 2019",,"April 28, 2022","['novartis investigative site, cairo, egypt novartis investigative site, cairo, egypt novartis investigative site, cairo, egypt novartis investigative site, giza, egypt novartis investigative site, hyderabad, andhra pradesh, india novartis investigative site, bangalore, karnataka, india novartis investigative site, pune, maharashtra, india novartis investigative site, kolkata, west bengal, india novartis investigative site, mumbai, india novartis investigative site, new delhi, india novartis investigative site, amman, jordan novartis investigative site, ashrafieh, lebanon novartis investigative site, beirut, lebanon novartis investigative site, beirut, lebanon novartis investigative site, saida, lebanon novartis investigative site, tripoli, lebanon novartis investigative site, johor bahru, johor, malaysia novartis investigative site, kota kinabalu, sabah, malaysia novartis investigative site, kuching, sarawak, malaysia novartis investigative site, kuala lumpur, wilayah persekutuan, malaysia novartis investigative site, pulau pinang, malaysia novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, pushkin saint petersburg, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, riyadh, saudi arabia novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, durban, kwazulu natal, south africa novartis investigative site, pretoria, south africa novartis investigative site, pretoria, south africa novartis investigative site, kaohsiung city, taiwan novartis investigative site, taichung, taiwan novartis investigative site, tainan, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan, taiwan novartis investigative site, songkhla, hat yai, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, chiang mai, thailand novartis investigative site, ankara, turkey novartis investigative site, antalya, turkey novartis investigative site, cankaya ankara, turkey novartis investigative site, istanbul, turkey novartis investigative site, istanbul, turkey novartis investigative site, izmir, turkey novartis investigative site, kecioren ankara, turkey novartis investigative site, malatya, turkey novartis investigative site, hanoi, vietnam']",,https://ClinicalTrials.gov/show/NCT03839823,breast
227,228,NCT00565708,aspirin for dukes c and high risk dukes b colorectal cancers,ASCOLT,"Active, not recruiting",No Results Available,colorectal cancer,other: placebo|drug: acetylsalicylic acid,disease-free survival|overall survival,"national cancer centre, singapore|university of oxford|australasian gastro-intestinal trials group|indox cancer research network",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1587.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CDR0000577892|SINGAPORE-ICR-02|SINGAPORE-ASCOLT,December 2008,December 2025,June 2026,"November 30, 2007",,"September 13, 2021","[""bankstown-lidcombe hospital bankstown cancer centre, bankstown, new south wales, australia macarthur cancer therapy centre, campbelltown, new south wales, australia chris o'brien lifehouse, clinical research centre, camperdown, new south wales, australia coffs harbour health campus north coast cancer institute, coffs harbour, new south wales, australia central coast cancer centre gosford hospital, gosford, new south wales, australia newcastle private hospital, new lambton heights, new south wales, australia orange health service, orange, new south wales, australia port macquarie base hospital north coast cancer institute, port macquarie, new south wales, australia northern cancer institute, st leonards, st leonards, new south wales, australia st vincent's hospital, sydney, new south wales, australia northwest cancer centre tamworth hospital, tamworth, new south wales, australia the tweed hospital, tweed heads, new south wales, australia calvary mater newcastle hospital, waratah, new south wales, australia royal darwin hospital, tiwi, northern territory, australia townsville hospital, douglas, queensland, australia royal brisbane and women's hospital, herston, queensland, australia toowoomba hospital, toowoomba, queensland, australia lyell mcewin hospital, elizabeth vale, south australia, australia royal hobart hospital, hobart, tasmania, australia border medical oncology research unit, albury, victoria, australia ballarat regional integrated cancer centre, ballarat, victoria, australia barwon health andrew love cancer centre, geelong, victoria, australia austin health cancer clinical trials, heidelberg, victoria, australia launceston general hospital, launceston, victoria, australia monash health medical oncology, melbourne, victoria, australia mildura base hospital, mildura, victoria, australia goulburn valley health, shepparton, victoria, australia st john of god healthcare southwest oncology, warrnambool, victoria, australia sir charles gairdner hospital, nedlands, western australia, australia st john of god hospital subiaco, subiaco, western australia, australia beijing university cancer hospital, beijing, beijing, china the first people's hospital of foshan city, foshan, guangdong, china sixth affiliated hospital, guangzhou, guangdong, china guangdong general hospital, guangzhou, guangdong, china sun yat sen university cancer center, guangzhou, guangdong, china zhongshan city people's hospital, zhongshan, guangdong, china jinan central hospital, jinan, shandong, china yantai yuhuangding hospital, yantai, shandong, china the second affiliated hospital of zhejiang university, hangzhou, zhejiang, china queen mary hospital - hong kong, hong kong, china affiliated hospital of nantong university, nantong, china kidwai memorial institute of oncology, bangalore, india g. kuppuswamy naidu memorial hospital, coimbatore, india nizam's institute of medical sciences, hyderabad, india tata memorial hospital, mumbai, india all india institute of medical sciences, new delhi, india regional cancer center, trivandrum, india christian medical college and hospital, vellore, india dharmais cancer hospital, jakarta, indonesia cipto mangunkusumo general hospital, jakarta, indonesia rumah sakit rsup dr. sardjito, yogyakarta, indonesia hallym university sacred heart hospital, anyang-si, gyeonggi-do, korea, republic of severance hospital, seoul, korea, republic of ajou university hospital, suwon-si, korea, republic of sarawak general hospital, kuching, sarawak, malaysia hospital kuala lumpur, kuala lumpur, malaysia university of malaysia medical center, kuala lumpur, malaysia university kebangsaan malaysia medical center, kuala lumpur, malaysia christchurch public hospital, christchurch, new zealand dunedin hospital, dunedin, new zealand king fahad medical city, riyadh, saudi arabia national cancer centre - singapore, singapore, singapore johns hopkins singapore international medical center, singapore, singapore national cancer institute, maharagama, sri lanka shuang ho hospital, taipei, taiwan koo foundation sun yat sen cancer centre, taipei, taiwan taipei medical university hospital, taipei, taiwan wan fang hospital, taipei, taiwan""]",,https://ClinicalTrials.gov/show/NCT00565708,colon
228,229,NCT03822468,"study of 2 ribociclib doses in combination with aromatase inhibitors in women with hr+, her2- advanced breast cancer",AMALEE,"Active, not recruiting",No Results Available,breast cancer,drug: ribociclib|drug: letrozole or anastrozole|drug: goserelin,overall response rate (orr)|δ qtcf at cycle 1 day 15 (at 2h post-dose) (key secondary endpoint)|progression-free survival (pfs)|clinical benefit rate (cbr)|time to response (ttr)|duration of response (dor)|pharmacokinetics (pk) of ribociclib: cmax|pharmacokinetics (pk) of ribociclib: tmax|pharmacokinetics (pk) of ribociclib: auc0 - 24h,novartis pharmaceuticals|novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,376.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011A2207|2018-004234-15,"June 11, 2019","June 11, 2021","December 30, 2025","January 30, 2019",,"May 13, 2022","['southern cancer center pc, mobile, alabama, united states marin cancer care, greenbrae, california, united states rocky mountain cancer centers rocky mountain cancer ctr (50), denver, colorado, united states florida retina institute, orlando, florida, united states emory university school of medicine/winship cancer institute, atlanta, georgia, united states weinberg cancer institute at franklin square hospital, baltimore, maryland, united states nebraska hematology-oncology, p.c., lincoln, nebraska, united states nebraska cancer specialists oncology hematology west, omaha, nebraska, united states comprehensive cancer centers of nevada ccc of nevada henderson (4), las vegas, nevada, united states new york oncology hematology sc, albany, new york, united states montefiore medical center, bronx, new york, united states mount sinai school of medicine cfty720d2306, new york, new york, united states northwest cancer ctr, houston, texas, united states texas oncology, mcallen, texas, united states northwest medical specialties dept.ofnw med. specialties, tacoma, washington, united states novartis investigative site, san juan, argentina novartis investigative site, innsbruck, austria novartis investigative site, linz, austria novartis investigative site, salzburg, austria novartis investigative site, vienna, austria novartis investigative site, edegem, antwerpen, belgium novartis investigative site, namur, belgium novartis investigative site, goiania, go, brazil novartis investigative site, natal, rn, brazil novartis investigative site, florianopolis, santa catarina, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao jose do rio preto, brazil novartis investigative site, plovdiv, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, cambridge, ontario, canada novartis investigative site, valledupar, cesar, colombia novartis investigative site, ibague, tolima, colombia novartis investigative site, bogota, colombia novartis investigative site, bogota, colombia novartis investigative site, monteria, colombia novartis investigative site, san jose, costa rica novartis investigative site, brno, czech republic, czechia novartis investigative site, praha 5, czechia novartis investigative site, helsinki, finland novartis investigative site, tampere, finland novartis investigative site, besancon cedex, france novartis investigative site, caen cedex, france novartis investigative site, clermont ferrand, france novartis investigative site, lyon cedex 08, france novartis investigative site, marseille, france novartis investigative site, montpellier cedex 5, france novartis investigative site, saint herblain cedex, france novartis investigative site, strasbourg, france novartis investigative site, valenciennes, france novartis investigative site, langen, hessen, germany novartis investigative site, augsburg, germany novartis investigative site, berlin, germany novartis investigative site, bonn, germany novartis investigative site, dresden, germany novartis investigative site, dresden, germany novartis investigative site, essen, germany novartis investigative site, tübingen, germany novartis investigative site, weiden, germany novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, szolnok, hungary novartis investigative site, raipur, chhattisgarh, india novartis investigative site, nagpur, maharashtra, india novartis investigative site, bhubaneshwar, orissa, india novartis investigative site, delhii, india novartis investigative site, mumbai, india novartis investigative site, amman, jordan novartis investigative site, kaunas, ltu, lithuania novartis investigative site, vilnius, lithuania novartis investigative site, trujillo, la libertad, peru novartis investigative site, san borja, lima, peru novartis investigative site, san isidro, lima, peru novartis investigative site, san miguel, lima, peru novartis investigative site, arequipa, peru novartis investigative site, lisbon, portugal novartis investigative site, loures, portugal novartis investigative site, porto, portugal novartis investigative site, arkhangelsk, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, st-petersburg, russian federation novartis investigative site, cape town, south africa novartis investigative site, johannesburg, south africa novartis investigative site, parktown, south africa novartis investigative site, stockholm, sweden novartis investigative site, stockholm, sweden novartis investigative site, uppsala, sweden novartis investigative site, bangkok, thailand novartis investigative site, chiang mai, thailand']",,https://ClinicalTrials.gov/show/NCT03822468,breast
229,230,NCT00294996,trial of myocet in metastatic breast cancer,,Unknown status,No Results Available,breast cancer,drug: myocet,progression-free survival|overall survival|safety,sopherion therapeutics,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,363.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STM01-102,January 2006,,,"February 22, 2006",,"March 31, 2009","['scripps cancer center clinical research, san diego, california, united states university of colorado, aurora, colorado, united states northwest hematology/oncology associates, coral springs, florida, united states osceola cancer center, kissimmee, florida, united states um/sylvester cancer center, plantation, florida, united states john b. amos cancer center, columbus, georgia, united states clintell, inc, skokie, illinois, united states hutchinson clinic p.a., hutchinson, kansas, united states western maryland health system, cumberland, maryland, united states brody school of medicine @ ecu, greenville, north carolina, united states aultman hospital cancer center, canton, ohio, united states hematology oncology consultants, inc., columbus, ohio, united states vita hematology oncology, bethlehem, pennsylvania, united states hematology & oncology associates of nepa, dunmore, pennsylvania, united states pa oncology hematology asso, philadelphia, pennsylvania, united states m. francisco gonzalez, columbia, south carolina, united states sioux valley clinic, sioux falls, south dakota, united states tennessee cancer specialists, knoxville, tennessee, united states centro oncologico de excelencia, buenos aires, argentina hospital enrique tornú, buenos aires, argentina hospital interzonal gral de agudos "" evita"", buenos aires, argentina hospital profesor a. posadas, buenos aires, argentina santorio municipal dr. j. mendez, buenos aires, argentina unidad oncologica del neuquen, neuquen, argentina caici instituto, santa fe, argentina centro oncologico rosario, santa fe, argentina isis clinica especializada, santa fe, argentina ceten, villa dominico, argentina dr. leon richard oncology centre, moncton, new brunswick, canada qeii health sciences centre, halifax, nova scotia, canada london regional cancer centre/london health science centre, london, ontario, canada the ottawa hospital regional cancer center, ottawa, ontario, canada princess margaret hospital, toronto, ontario, canada chum hospital notre-dame, montreal, quebec, canada mcgill university, montreal, quebec, canada allan blair cancer centre, regina, saskatchewan, canada saskatoon cancer centre, saskatoon, saskatchewan, canada hopital du st. sacrement, quebec, canada u.k charité, campus mitte, berlin, germany universitätsklinikum magdeburg, magdeburg, germany gemeinschaftspraxis gynäkologie & geburtshilfe, mannheim, germany frauenklinik von roten kreuz, münchen, germany klinikum offenbach, offenbach, germany üniversitäts klinikum tübingen, tübingen, germany dr. horst schmidt kliniken, wiesbaden, germany gujarat cancer research institute, asarwa, gujarat, india kidwai memorial institute of oncology, bangalore, india manipal hospital, bangalore, india apollo specialty hospitals, chennai, chennai, india nizam\'s institute of medical science, hyderabaad, india smsmedicalcollegehospital,, jaipur, india lakeshore hospital and research centre ltd, kerala, india himadri cancer welfare trusr, kolkata, india orchid nursing home,, kolkata, india ruby hall clinic, maharashtra, india tata memorial hospital, maharashtra, india kasturba medical college,, mangalore, india jaslok hospital and research centre, mumbai, india batra hospital & medical research center, new delhi, india indraprastha apollo hospitals, new delhi, india safdarjung hospital & vardhaman mahaveer medical college, new delhi, india fortis hospital, noida, india azienda ospedialera pugliese-ciaccio, catanzaro, italy clinica oncologica ospedale, chieti, italy dimi - università di genova, genova, italy arnas civico. presidio ospedaliero m. ascoli, palermo, italy oncologia medica, pavia, italy day hospital oncologico,, roma, italy istituto clinico humanitas, rozzano, italy sp sk nr1 ack amg, gdańsk, poland centrum onkologii - instytut marii skłodowskiej-curie oddział gliwice, gliwice, poland samodzielny publiczny szpital, lublin, poland zakład opieki zdrowotnej mswia, olsztyn, poland szpital wojewódzki im. św. łukasza, tarnow, poland centrum onkologii - instytut im. marii skłodowskiej-curie, warszawa, poland wojskowy instytut medyczny, warszawa, poland sp zoz szpital wojewódzki, zielona gora, poland regionalny ośrodek onkologiczny, łódź, poland regionalny szpital specjalistyczny, świdnica, poland nstituto português de oncologia francisco gentil, lisbon, portugal non-state health care insitution ""n.a. semashko central clinical hospital #2"" of the ""russian railways"" joint stock company, moscow, russian federation state institution ""n.n. blokhin russian oncology scientific center"" of the russian academy of medical sciences, moscow, russian federation state science institution ""p.a. hertzen moscow oncology research institute"" of the federal agency of health care and social development, moscow, russian federation state health care institution ""regional clinical oncology dispensary"", ryazan, russian federation municipal health care institution of the city of sochi ""oncology dispensary"", sochi, russian federation st. petersburg state health care institution ""city clinical oncology dispensary"", st petersberg, russian federation state science institution ""prof. n.n. petrov research institute of oncology"" of the federal agency of health care and social development, st petersberg, russian federation research institute of pulmonology affiliated with state educational institution ""st. petersburg state medical university n.a. academician i.p. pavlov"" of the federal agency of health care and social development, st. petersberg, russian federation state health care institution ""leningrad regional oncology dispensary"", st. petersburg, russian federation state health care institution of the yaroslavl region ""yaroslavl regional oncology dispensary"", yaroslavl, russian federation hospital de la santa creu i sant pau, barcelona, spain hospital universitario vall d\'hebron, barcelona, spain hospital universitari arnau de vilanova de lleida, lleida, spain hospital 12 de octubre, madrid, spain hospital son dureta, palma de mallorca, spain hospital clínico universitario de salamanca, salamanca, spain hospital virgen macarena, sevilla, spain hospital mutua de terrassa, terrassa, spain hospital clínico universitario de valencia, valencia, spain hospital general universitario de valencia, valencia, spain hospital clínico universitario lozano blesa, zaragoza, spain broomfield hospital, broomfield, united kingdom christie hospital nhs trust, cardiff, united kingdom guy\'s hospital, london, united kingdom royal free hospital, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00294996,breast
230,231,NCT01989676,a study of pf-05280014 [trastuzumab-pfizer] or herceptin® [trastuzumab-eu] plus paclitaxel in her2 positive first line metastatic breast cancer treatment (reflections b327-02),,Completed,Has Results,metastatic breast cancer,biological: pf-05280014|drug: paclitaxel|biological: herceptin®,objective response rate (orr) derived from central radiology assessments: itt population|one-year progression-free survival (pfs) rate derived from central radiology assessments: itt population|duration of response (dor) per central radiology assessments: itt population|overall survival: itt population|serum peak concentration of pf-05280014 at selected cycles: pharmacokinetics (pk) population|serum peak concentration of trastuzumab-eu at selected cycles: pk population|serum trough (pre-dose) concentration of pf-05280014 at selected cycles: pk population|serum trough (pre-dose) concentration of trastuzumab-eu at selected cycles: pk population|number of participants with positive anti-drug antibodies (ada) sample: safety population|number of participants with positive neutralizing antibodies (nab) prior to treatment: safety population,pfizer,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,707.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B3271002|REFLECTIONS B327-02|2013-001352-34,"February 24, 2014","August 24, 2016","June 27, 2020","November 21, 2013","January 23, 2018","July 6, 2021","['cancer center of central connecticut, plainville, connecticut, united states cancer center of central connecticut, southington, connecticut, united states florida cancer research institute, boca raton, florida, united states florida cancer research institute, plantation, florida, united states coiba - centro de oncologia e investigacion buenos aires, berazategui, buenos aires, argentina instituto de oncologia de rosario, rosario, santa fe, argentina centro medico san roque, san miguel de tucuman, tucuman, argentina sanatorio de la providencia, c.a.b.a, argentina crio - centro regional integrado de oncologia, fortaleza, ce, brazil associacao de combate ao cancer em goias - hospital araujo jorge, goiania, go, brazil liga paranaense de combate ao cancer - hospital erasto gaertner, curitiba, parana, brazil instituto do cancer de londrina - hospital do cancer de londrina - hcl, londrina, parana, brazil hospital bruno born (sociedade beneficencia e caridade de lajeado), lajeado, rio grande do sul, brazil associacao hospital de caridade ijui, ijui, rs, brazil centro de pesquisa em oncologia - uniao brasileira de educacao e assistencia, porto alegre, rs, brazil centro de novos tratamentos itajai - clinica de neoplasias litoral, itajai, santa catarina, brazil fundacao pio xii - hospital de cancer de barretos, barretos, sao paulo, brazil centro de pesquisas oncologicas de santa catarina - cepon, florianopolis, sc, brazil centro de novos tratamentos itajai - clinica de neoplasias litoral, itajai, sc, brazil cepho - centro de estudos e pesquisas de hematologia e oncologia - faculdade de medicina do abc, santo andre, sp, brazil cepho - centro de estudos e pesquisas de hematologia e oncologia - faculdade de medicina do abc, santo andre, sp, brazil clinica alemana de temuco, temuco, region de la araucania, chile centro de investigacion clinica sim, temuco, region de la araucania, chile administrative office, temuco, region de la araucania, chile fresenius kabi chile therapia iv, santiago, rm, chile hospital clinico vina del mar, vina del mar, v region, chile instituto oncologico, clinica renaca, vina del mar, v region, chile hospital naval almirante nef, v region, chile instituto oncologico clinica renaca, v region, chile onkologicka klinika vfn a 1. lf uk, fakultni poliklinika, praha 2, czechia general hospital of chania ""o agios georgios"", chania, crete, greece interbalkan european medical center, pylaia, thessaloniki, greece general hospital of athens ""hippokration"", athens, greece bacs-kiskun megyei korhaz, onkoradiologiai kozpont, kecskemet, hungary borsod-abauj-zemplen megyei korhaz, es egyetemi oktatokorhaz, klinikai onkologiai es sugarterapias, miskolc, hungary jasz-nagykun-szolnok megyei hetenyi geza korhaz - rendelointezet, megyei onkologiai kozpont, szolnok, hungary markusovszky egyetemi oktatokorhaz, szombathely, hungary department of medicine new block, visakhapatnam, andhra pradesh, india manipal hospital, bengaluru, karnataka, india manipal centre for clinical research, manipal, karnataka, india tata memorial centre, tata memorial hospital, mumbai, maharashtra, india shatabdi super speciality hospital, nashik, maharashtra, india advanced centre for treatment research and education in cancer (actrec), navi mumbai, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india sahyadri clinical research & development centre, pune, maharashtra, india sahyadri speciality hospital, pune, maharashtra, india acharya harihar regional cancer center, cuttack, odisha, india acharya tulsi regional cancer treatment and research institute, bikaner, rajasthan, india meenakshi mission hospital and research centre, madurai, tamil nadu, india mnj institute of oncology & regional cancer center, hyderabad, telangana, india national hospital organization nagoya medical center, nagoya, aichi, japan national hospital organization kyushu cancer center, fukuoka-shi, fukuoka, japan japan community health care organization kurume general hospital, kurume-city, fukuoka, japan hokkaido university hospital, sapporo, hokkaido, japan kumamoto university hospital, kumamoto-city, kumamoto, japan saitama cancer center hospital, kitaadachi-gun, saitama, japan tokyo metropolitan cancer and infectious diseases center komagome hospital, bunkyo-ku, tokyo, japan national hospital organization tokyo medical center, meguro-ku, tokyo, japan showa university hospital, shinagawa-ku, tokyo, japan chiba cancer center, chiba, japan hakuaikai medical corporation sagara hospital, kagoshima, japan niigata cancer center hospital, niigata, japan nakanoshima osaka breast clinic, osaka, japan osaka breast clinic, osaka, japan shizuoka general hospital, shizuoka, japan chungbuk national university hospital, cheongju-si, chungcheongbuk-do, korea, republic of ulsan university hospital, ulsan, korea, korea, republic of pusan national university hospital, busan, korea, republic of kyungpook national university chilgok hospital, daegu, korea, republic of national cancer centre, goyang-si, korea, republic of korea university anam hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of korea university guro hospital, seoul, korea, republic of p.stradins clinical university hospital, riga, latvia instituto nacional de cancerologia, mexico city, distrito federal, mexico consultorio dentro de la torre medica dalinde (oncologia medica), mexico, distrito federal, mexico inter hosp s.a. de c.v. ""centro medico dalinde"", mexico, distrito federal, mexico oaxaca site management organization s.c., oaxaca, mexico cancerologia de queretaro s.c., queretaro, mexico hospital militar central, lima, peru innpares, lima, peru resocentro, lima, peru clinica anglo americana, lima, peru instituto de oncologia y radioterapia de la clinica ricardo palma, lima, peru radiologos s.r.l., lima, peru instituto nacional de enfermedades neoplasicas, lima, peru siglo xxi, lima, peru resocentro, lima, peru siglo xxi, lima, peru cebu doctors\' university hospital, cebu city, cebu, philippines cardinal santos medical center, san juan city, mentro manila, philippines manila doctors hospital, manila, metro manila, philippines veterans memorial medical center, quezon city, metro manila, philippines university of philippines manila-philippine general hospital, manila, ncr, philippines the medical city, pasig city, ncr, philippines st. luke\'s medical center, quezon city, ncr, philippines the research institute at perpetual succor hospital, cebu city, region vii, philippines manila doctors hospital, manila, philippines copernicus podmiot leczniczy sp. z o.o. wojewodzkie centrum onkologii, gdansk, poland szpitale pomorskie sp. z o.o. oddzial onkologii i radioterapii, gdynia, poland centrum terapii wspolczesnej, lodz, poland spzoz msw z warminsko-mazurskim centrum onkologii w olsztynie, oddzial kliniczny chemioterapii, olsztyn, poland mrukmed. lekarz beata madej mruk i partner. sp. p. oddzial nr 1 w rzeszowie, rzeszow, poland magodent sp. z o.o. oddzial onkologii klinicznej/chemioterapii, warszawa, poland hospital de braga, braga, portugal hospital cuf descobertas, lisboa, portugal institutul oncologic prof. dr. ion chiricuta, cluj-napoca, cluj, romania s.c. medisprof s.r.l, cluj-napoca, cluj, romania centrul de oncologie sf. nectarie, craiova, dolj, romania sc oncolab srl, oncologie, craiova, jud dolj, romania spitalul universitar de urgenta, departamentul oncologie medicala, bucuresti, romania spitalul clinic judetean de urgenta sibiu, sibiu, romania spitalul judetean de urgenta ""sf.ioan cel nou"", sectia oncologie, suceava, romania spitalul clinic municipal de urgenta timisoara, sectia clinica oncologie medicala, timisoara, romania republic clinical hospital of emergency care, grozny, chechenkaya republic, russian federation state healthcare institution kursk regional oncological dispensary of the healthcare committee, kislino settlement, kursk, russian federation state budgetary healthcare institution ""leningrad regional oncological dispensary"", kuzmolovo, vsevolozhskiy, leningrad region, russian federation fsbsi russian cancer research center n.a. n.n.blokhin, moscow, nap, russian federation gbuz of perm region ""perm regional oncology dispensary"", perm, nap, russian federation federal state budgetary institution ¿national medical research oncology centre named after n.n., saint-petersburg, pos.pesochny, russian federation state healthcare institution, republican clinical oncology dispensary of the ministry of, ufa, republic of bashkortostan, russian federation gbuz republican clinical hospital n.a. g.f. kuvatova, ufa, republic of baskortostan, russian federation republican clinical oncology dispensary of the ministry of healthcare of baskortostan republic, ufa, republic of baskortostan, russian federation state budgetary healthcare institution \'\'republic oncological dispensary\'\', petrozavodsk, republic of karelia, russian federation state budget institution of healthcare of mordovia republic ""republic oncology dispensary"", saransk, republic of mordovia, russian federation rostov research institute of oncology, rostov-on-don, rostov region, russian federation private medical institution euromedservice, pushkin, saint petersburg, russian federation saint-petersburg clinical research center of specialized types of medical care (oncology), poselok pesochny, saint-petersburg, russian federation llc medekspert, kislovodsk, stavropol region, russian federation federal state budgetary healthcare institution of ""clinical hospital #101 of federal medical and, lermontov, stavropol region, russian federation centre of specialized kinds of medical care of pyatigorsk city, pyatigorsk, stavropol region, russian federation state budgetary healthcare institution of stavropol region pyatigorsk oncology dispensary, pyatigorsk, stavropol region, russian federation llc novaya clinica, pyatigorsk, stavropol region, russian federation pyatigorsk city hospital #2, pyatigorsk, stavropol region, russian federation stavropol regional hospital for war veterans, pyatigorsk, stavropol region, russian federation state budgetary healthcare institution volgograd regional clinical oncology dispensary, volzhskiy, volgograd region, russian federation gbuz arkhangelsk regional clinical oncological dispensary, arkhangelsk, russian federation state budgetary healthcare institution ""chelyabinsk regional clinical oncological dispensary"", chelyabinsk, russian federation ""regional budgetary healthcare institution """"ivanovo regional oncology dispensary"""""", ivanovo, russian federation sbih of kaluga region ""kaluga regional clinical oncology dispensary"", kaluga, russian federation gbuz ""regional oncology dispensary #2"", magnitogorsk, russian federation federal state budgetary institution ""russian oncological scientific center n.a. n.n. blokhin"" of, moscow, russian federation llc vitamed, moscow, russian federation llc vitamed, moscow, russian federation state budgetary healthcare institution ""nizhniy novgorod regional oncological dispensary"", nizhniy novgorod, russian federation ""bih of omsk region """"clinical oncological dispensary"""""", omsk, russian federation budgetary institution of healthcare of orel region ""orel oncological dispensary"", orel, russian federation sbei hpe ryazsmu of moh of the russian federation based on sbi of ryazan region ""regional clinical, ryazan, russian federation sbei of hpe ""first saint petersburg state medical university, saint petersburg, russian federation sbi ""north-western state medical university n.a. i. i. mechnikov"" of the moh of the russian, saint-petersburg, russian federation non-state healthcare agency road clinical hospital plc russian railways, saint-petersburg, russian federation saint-petersburg state budgetary healthcare institution ""oncological dispensary of moscow district"", saint-petersburg, russian federation non-state healthcare institution ""road clinical hospital at saratov ii station"", saratov, russian federation state budgetary healthcare institution of stavropol region ""stavropol regional clinical oncology, stavropol, russian federation institute for oncology and radiology of serbia, belgrade, serbia military medical academy, belgrade, serbia clinic of oncology-clinical center nis, nis, serbia oncology institute of vojvodina, sremska kamenica, serbia onkologicky ustav sv. alzbety, s.r.o., bratislava, slovakia narodny onkologicky ustav, bratislava, slovakia gvi oncology, langenhoven drive oncology centre, port elizabeth, eastern cape, south africa wits clinical research, joannesburg, gauteng, south africa the medical oncology centre of rosebank, johannesburg, gauteng, south africa sandton oncology centre, johannesburg, gauteng, south africa *department of medical oncology, university of pretoria & steve biko academic hospitals complex, pretoria, gauteng, south africa eastleigh breast care centre, pretoria, gauteng, south africa cape town oncology trials, kraaifontein, western cape, south africa gvi rondebosch oncology centre-rondebosch medical centre, rondebosch, western cape, south africa national cancer institute, ratchathewi, bangkok, thailand udonthani cancer hospital, amphur muang, udonthani, thailand faculty of medicine, chulongkorn university, medical oncology unit, bangkok, thailand baskent university school of medicine adana hospital, adana, turkey hacettepe universitesi tip fakultesi, ankara, turkey uludag universitesi tip fakultesi ic hastaliklari anabilim dali, bursa, turkey dicle university medical faculty, diyarbakir, turkey gaziantep university medical faculty, gaziantep, turkey istanbul universitesi onkoloji enstitusu, istanbul, turkey municipal institution ""chernivtsi regional clinical oncology center"", outpatient department, chernivtsi, ukraine municipal non-profit enterprise city clinical hospital no.4of dnipro regional council, department of, dnipro, ukraine si institute of medical radiology n.a.s.p. ilrygoriev of national academy of medical science of, kharkiv, ukraine communal non-profit enterprise ""regional center of oncology"", kharkiv, ukraine khmelnytskyi regional oncologic dispensary, khmelnytskyi, ukraine municipal enterprise \'kryvyi rih oncology dispensary of dnipropetrovsk regional council\', kryvyi rih, ukraine municipal non-profit enterprise of kyiv regional council ""kyiv regional oncology dispensary"", kyiv, ukraine lviv state oncologic regional treatment and diagnostic center, lviv, ukraine municipal institution odesa regional clinical hospital, mammology center, odesa, ukraine zakarpattia regional clinical oncological center, uzhgorod, ukraine municipal non-profit enterprise podilsk regional oncology centre of vinnytsia regional council, vinnytsia, ukraine']",,https://ClinicalTrials.gov/show/NCT01989676,breast
231,232,NCT03564938,regorafenib in indian patients with metastatic colorectal cancer (mcrc).,,Recruiting,No Results Available,metastatic colorectal cancer,"drug: regorafenib (stivarga, bay73-4506)","number of adverse events|changes in eastern cooperative oncology group performance status (ecog ps)|percentage of participants with change in worst grades for hematological and biochemical toxicities according to ctcae version 4.03, based on laboratory measurements|change in body weight (kg)|change in systolic / diastolic bp (mmhg)|change in heart rate (beats/min)|disease control rate (dcr)|overall response rate (orr)|progression free survival (pfs)|overall survival (os)",bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19214,"July 30, 2018","April 2, 2023","April 2, 2023","June 21, 2018",,"April 26, 2022","['apollo research foundation, hyderabad, andhra pradesh, india hcg-city cancer centre, vijayawada, andhra pradesh, india sir ganga ram hospital, new-delhi, delhi, india the gujarat cancer & research institute, ahmedabad, gujarat, india healthcare center global hospital, ahmedabad, gujarat, india manipal hospital, bangalore, karnataka, india healthcare global enterprises ltd, bengaluru, karnataka, india amrita institute of medical sciences, kochi, kerala, india tata memorial hospital, mumbai, maharashtra, india jaslok hospital and research centre, mumbai, maharashtra, india sushrut hospital & research centre, mumbai, maharashtra, india jehangir hospital, pune, maharashtra, india fortis hospital, west-mumbai, maharashtra, india sparsh hospital & critical care, bhubaneswar, orissa, india shalby hospital, jaipur, rajasthan, india apollo speciality hospitals, madurai, tamil n?du, india ipgme & r / sskm hospital, kolkata, west bengal, india health point hospital, kolkata, west bengal, india indraprastha apollo hospital, new delhi, india']",,https://ClinicalTrials.gov/show/NCT03564938,colon
232,233,NCT00718354,overall survival of inoperable gastric/gastrooesophageal cancer subjects on treating with lmwh + chemotherapy(ct) vs standard ct,GASTRANOX,Completed,No Results Available,gastric cancer|gastroesophageal cancer,drug: enoxaparin|drug: standard chemotherapy,"event free survival (efs) - composite endpoint of overall survival plus free of symptomatic vte .|incidence of svte overall survival major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. serious adverse events, all reported adverse events hit",thrombosis research institute,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,740.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,TRI0702,July 2008,January 2010,August 2010,"July 18, 2008",,"May 13, 2015","['mahatma gandhi cancer hospital & research institute ,1/7 m.v.p. colony, - ,, ., vishakhapattanam, andhra pradesh, india mahavir cancer sansthan,phulwari sharif, patna, bihar, india gujarat cancer research institute, civil hospital campus,asarwa, ,, ahmedabad, gujarat,, india department of radiotherapy,s.s.g. hospital, -, baroda,vadodara, gujarat,, india gokula curie cancer centre,m.s.ramaiah memorial hospital,msr nagar, msrit post, bangalore, karnataka, india madhavan j.p., trivandrum, kerala,, india mgm medical college & my hospital,, indore, m.p, india curie manavta cancer centre, opp.hotel sandeep naka,nashik, mumbai, maharashtra,, india ruby hall clinic,cancer building,40 sassoon road, , ,, pune, maharashtra, india cancer hospital & research institute, cancer hill, gwalior, mp, india acharya tulsi regional cancer treatment & research institute, bikaner, up, india b.p.poddar hospital & medical research ltd,71/1, humayun kabir sarani,, block-g, new alipore, kolkata, west bangol, india biswajit sanyal, calcutta, west bengal, india chittaranjan national cancer institute,37, s.p.mukhurjee road, kolkata, west bengal, india dr. bra irch,all india institute of medical sciences,ansari nagar,, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00718354,gastric esophag
233,234,NCT03109249,pharmacokinetic study of sparc1613 and reference1613 in subjects with locally recurrent or metastatic breast cancer,,Completed,No Results Available,recurrent or metastatic breast cancer,drug: sparc1613|drug: reference1613,maximum observed concentration (cmax),sun pharma advanced research company limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,142.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLR_16_13,"January 14, 2017","October 4, 2018","October 4, 2018","April 12, 2017",,"May 3, 2019","['sparc site 40, visakhapatnam, andhra pradesh, india sparc site 20, ahmedabad, gujarat, india sparc site 39, ahmedabad, gujarat, india sparc site 38, karamsad, gujarat, india sparc site 27, surat, gujarat, india sparc site 35, surat, gujarat, india sparc site 24, vadodara, gujarat, india sparc site 13, bangalore, karnataka, india sparc site 41, bangalore, karnataka, india sparc site 28, bangalore, karnataka, india sparc site 22, belgaum, karnataka, india sparc site 7, mangalore, karnataka, india sparc site 25, aurangabad, maharashtra, india sparc site 23, aurangabad, maharashtra, india sparc site 2, mumbai, maharashtra, india sparc site 12, nagpur, maharashtra, india sparc site 34, nashik, maharashtra, india sparc site 37, nashik, maharashtra, india sparc site 18, pune, maharashtra, india sparc site 4, pune, maharashtra, india sparc site 9, aurangabad, marashtra, india sparc site 15, khorda, orissa, india sparc site 42, chennai, tamil nadu, india sparc site 32, madurai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT03109249,breast
234,235,NCT01077154,study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (d-care),,Terminated,Has Results,breast cancer,drug: placebo|drug: denosumab,bone metastasis-free survival (bmfs)|disease-free survival (dfs)|disease-free survival (dfs) in the postmenopausal subset|overall survival|distant recurrence-free survival,"amgen|daiichi sankyo, inc.",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,4509.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20060359|2009-011299-32,"June 2, 2010","August 31, 2017","March 26, 2018","February 26, 2010","October 3, 2018","September 28, 2021","[""research site, birmingham, alabama, united states research site, tucson, arizona, united states research site, jonesboro, arkansas, united states research site, alhambra, california, united states research site, anaheim, california, united states research site, beverly hills, california, united states research site, campbell, california, united states research site, fresno, california, united states research site, fullerton, california, united states research site, la verne, california, united states research site, lancaster, california, united states research site, long beach, california, united states research site, los angeles, california, united states research site, los angeles, california, united states research site, los angeles, california, united states research site, northridge, california, united states research site, redondo beach, california, united states research site, santa barbara, california, united states research site, santa maria, california, united states research site, torrance, california, united states research site, denver, colorado, united states research site, grand junction, colorado, united states research site, new haven, connecticut, united states research site, boynton beach, florida, united states research site, coral springs, florida, united states research site, fort lauderdale, florida, united states research site, hollywood, florida, united states research site, jacksonville, florida, united states research site, melbourne, florida, united states research site, athens, georgia, united states research site, niles, illinois, united states research site, indianapolis, indiana, united states research site, cedar rapids, iowa, united states research site, hutchinson, kansas, united states research site, wichita, kansas, united states research site, paducah, kentucky, united states research site, annapolis, maryland, united states research site, baltimore, maryland, united states research site, bethesda, maryland, united states research site, columbia, maryland, united states research site, boston, massachusetts, united states research site, danvers, massachusetts, united states research site, ann arbor, michigan, united states research site, detroit, michigan, united states research site, edina, minnesota, united states research site, minneapolis, minnesota, united states research site, saint louis park, minnesota, united states research site, jackson, mississippi, united states research site, jefferson city, missouri, united states research site, lincoln, nebraska, united states research site, henderson, nevada, united states research site, lebanon, new hampshire, united states research site, denville, new jersey, united states research site, hackensack, new jersey, united states research site, east setauket, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, nyack, new york, united states research site, asheville, north carolina, united states research site, high point, north carolina, united states research site, cincinnati, ohio, united states research site, columbus, ohio, united states research site, tulsa, oklahoma, united states research site, hershey, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, pawtucket, rhode island, united states research site, charleston, south carolina, united states research site, columbia, south carolina, united states research site, hilton head island, south carolina, united states research site, sioux falls, south dakota, united states research site, chattanooga, tennessee, united states research site, germantown, tennessee, united states research site, nashville, tennessee, united states research site, abilene, texas, united states research site, corpus christi, texas, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, el paso, texas, united states research site, garland, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, plano, texas, united states research site, san antonio, texas, united states research site, san antonio, texas, united states research site, tyler, texas, united states research site, richlands, virginia, united states research site, richmond, virginia, united states research site, roanoke, virginia, united states research site, seattle, washington, united states research site, seattle, washington, united states research site, tacoma, washington, united states research site, quilmes, buenos aires, argentina research site, quilmes, buenos aires, argentina research site, san martin, buenos aires, argentina research site, neuquen, neuquã©n, argentina research site, provincia de santa fe, santa fe, argentina research site, san miguel de tucuman, tucuman, argentina research site, camperdown, new south wales, australia research site, caringbah, new south wales, australia research site, kogarah, new south wales, australia research site, tweed heads, new south wales, australia research site, wahroonga, new south wales, australia research site, bedford park, south australia, australia research site, bentleigh east, victoria, australia research site, east melbourne, victoria, australia research site, fitzroy, victoria, australia research site, footscray, victoria, australia research site, frankston, victoria, australia research site, heidelberg, victoria, australia research site, malvern, victoria, australia research site, parkville, victoria, australia research site, richmond, victoria, australia research site, ringwood east, victoria, australia research site, warrnambool, victoria, australia research site, wodonga, victoria, australia research site, perth, western australia, australia research site, subiaco, western australia, australia research site, antwerpen, belgium research site, bonheiden, belgium research site, brugge, belgium research site, brussel, belgium research site, bruxelles, belgium research site, bruxelles, belgium research site, edegem, belgium research site, gent, belgium research site, hasselt, belgium research site, kortrijk, belgium research site, leuven, belgium research site, libramont, belgium research site, liã¨ge, belgium research site, namur, belgium research site, oostende, belgium research site, ottignies, belgium research site, sint-niklaas, belgium research site, tournai, belgium research site, wilrijk, belgium research site, yvoir, belgium research site, salvador, bahia, brazil research site, salvador, bahia, brazil research site, curitiba, paranã¡, brazil research site, londrina, paranã¡, brazil research site, porto alegre, rio grande do sul, brazil research site, porto alegre, rio grande do sul, brazil research site, porto alegre, rio grande do sul, brazil research site, itajaã-, santa catarina, brazil research site, barretos, sã£o paulo, brazil research site, santo andre, sã£o paulo, brazil research site, sao paulo, sã£o paulo, brazil research site, sã£o paulo, brazil research site, sã£o paulo, brazil research site, plovdiv, bulgaria research site, rousse, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, stara zagora, bulgaria research site, varna, bulgaria research site, veliko tarnovo, bulgaria research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, kelowna, british columbia, canada research site, victoria, british columbia, canada research site, moncton, new brunswick, canada research site, st. john's, newfoundland and labrador, canada research site, sydney, nova scotia, canada research site, barrie, ontario, canada research site, brampton, ontario, canada research site, kingston, ontario, canada research site, kitchener, ontario, canada research site, ottawa, ontario, canada research site, sault ste. marie, ontario, canada research site, sudbury, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, greenfield park, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, sherbrooke, quebec, canada research site, quebec, canada research site, temuco, cautã-n, chile research site, vina del mar, valparaã-so, chile research site, santiago, chile research site, brno, czechia research site, brno, czechia research site, chomutov, czechia research site, horovice, czechia research site, hradec kralove, czechia research site, olomouc, czechia research site, praha 10, czechia research site, praha 10, czechia research site, praha 4, czechia research site, praha 5, czechia research site, praha 8, czechia research site, herning, denmark research site, vejle, denmark research site, viborg, denmark research site, ã…rhus c, denmark research site, angers, france research site, bordeaux cedex, france research site, dijon, france research site, grenoble, france research site, hyã¨res, france research site, le mans, france research site, lille, france research site, monaco, france research site, nantes cedex 2, france research site, paris, france research site, pierre-benite, france research site, saint priest en jarez cedex, france research site, strasbourg cedex, france research site, villejuif cedex, france research site, berlin, germany research site, berlin, germany research site, bonn, germany research site, bottrop, germany research site, erlangen, germany research site, frankfurt, germany research site, kiel, germany research site, koblenz, germany research site, mannheim, germany research site, mã¼nchen, germany research site, mã¼nchen, germany research site, mã¼nchen, germany research site, recklinghausen, germany research site, rostock, germany research site, trier, germany research site, tã¼bingen, germany research site, athens, greece research site, athens, greece research site, heraklion, greece research site, patra, greece research site, thessaloniki, greece research site, thessaloniki, greece research site, hong kong, hong kong research site, new territories, hong kong research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, gyor, hungary research site, nyiregyhaza, hungary research site, pecs, hungary research site, szeged, hungary research site, szekesfehervar, hungary research site, szolnok, hungary research site, zalaegerszeg, hungary research site, hyderabad, andhra pradesh, india research site, bangalore, karnataka, india research site, ahmednagar, maharashtra, india research site, aurangabad, maharashtra, india research site, miraj, maharashtra, india research site, mumbai, maharashtra, india research site, mumbai, maharashtra, india research site, nashik, maharashtra, india research site, nashik, maharashtra, india research site, pune, maharashtra, india research site, jaipur, rajasthan, india research site, chennai, tamil nadu, india research site, madurai, tamil nadu, india research site, cork, ireland research site, dublin, ireland research site, dublin, ireland research site, dublin, ireland research site, limerick, ireland research site, waterford, ireland research site, ashkelon, israel research site, haifa, israel research site, jerusalem, israel research site, kfar sava, israel research site, petah tikva, israel research site, poria eylit, israel research site, rehovot, israel research site, tel aviv, israel research site, tel aviv, israel research site, ancona, italy research site, bari, italy research site, brescia, italy research site, meldola fc, italy research site, milano, italy research site, monza (mb), italy research site, palermo, italy research site, parma, italy research site, san giovanni rotondo fg, italy research site, treviglio (bg), italy research site, varese, italy research site, nagoya-shi, aichi, japan research site, nagoya-shi, aichi, japan research site, matsuyama-shi, ehime, japan research site, fukuoka-shi, fukuoka, japan research site, kitakyushu-shi, fukuoka, japan research site, kurume-shi, fukuoka, japan research site, kure-shi, hiroshima, japan research site, akashi-shi, hyogo, japan research site, kagoshima-shi, kagoshima, japan research site, isehara-shi, kanagawa, japan research site, kumamoto-shi, kumamoto, japan research site, kyoto-shi, kyoto, japan research site, miyazaki-shi, miyazaki, japan research site, niigata-shi, niigata, japan research site, kurashiki-shi, okayama, japan research site, osaka-shi, osaka, japan research site, osaka-shi, osaka, japan research site, suita-shi, osaka, japan research site, hidaka-shi, saitama, japan research site, kitaadachi-gun, saitama, japan research site, suntou-gun, shizuoka, japan research site, shimotsuke-shi, tochigi, japan research site, utsunomiya-shi, tochigi, japan research site, chuo-ku, tokyo, japan research site, tokyo, japan research site, tokyo, japan research site, tokyo, japan research site, tokyo, japan research site, goyang-si, gyeonggi-do, korea, republic of research site, incheon, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, daugavpils, latvia research site, liepaja, latvia research site, riga, latvia research site, kota bharu, kelantan, malaysia research site, subang jaya, selangor (incl. putrajaya), malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, mexico city, distrito federal, mexico research site, mexico city, distrito federal, mexico research site, mexico, distrito federal, mexico research site, leon, guanajuato, mexico research site, pachuca de soto, hidalgo, mexico research site, monterrey, nuevo leã³n, mexico research site, queretaro, querã©taro, mexico research site, san luis potosi, san luis potosã-, mexico research site, colima, mexico research site, distrito federal, mexico research site, durango, mexico research site, toluca, mexico research site, amsterdam, netherlands research site, bergen op zoom, netherlands research site, breda, netherlands research site, capelle aan den ijssel, netherlands research site, den haag, netherlands research site, dordrecht, netherlands research site, hoofddorp, netherlands research site, leiden, netherlands research site, nieuwegein, netherlands research site, rotterdam, netherlands research site, rotterdam, netherlands research site, schiedam, netherlands research site, sittard-geleen, netherlands research site, tiel, netherlands research site, tilburg, netherlands research site, venlo, netherlands research site, lima, peru research site, lima, peru research site, lima, peru research site, cebu city, philippines research site, manila, philippines research site, manila, philippines research site, metro manila, philippines research site, quezon city, philippines research site, gdansk, poland research site, gdansk, poland research site, krakow, poland research site, olsztyn, poland research site, poznan, poland research site, rzeszow, poland research site, szczecin, poland research site, lisboa, portugal research site, lisboa, portugal research site, porto, portugal research site, porto, portugal research site, santa maria da feira, portugal research site, bucharest, romania research site, craiova, romania research site, sibiu, romania research site, suceava, romania research site, timisoara, romania research site, barnaul, russian federation research site, chelyabinsk, russian federation research site, ivanovo, russian federation research site, kazan, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, belgrade, serbia research site, nis, serbia research site, bardejov, slovakia research site, kosice, slovakia research site, michalovce, slovakia research site, poprad, slovakia research site, presov, slovakia research site, spisska nova ves, slovakia research site, trebisov, slovakia research site, ljublijana, slovenia research site, maribor, slovenia research site, groenkloof, gauteng, south africa research site, johannesburg, gauteng, south africa research site, cape town, south africa research site, pietermaritzburg, south africa research site, port elizabeth, south africa research site, pretoria, south africa research site, pretoria, south africa research site, cã¡diz, andalucã-a, spain research site, cã³rdoba, andalucã-a, spain research site, jaã©n, andalucã-a, spain research site, mã¡laga, andalucã-a, spain research site, sevilla, andalucã-a, spain research site, zaragoza, aragã³n, spain research site, santander, cantabria, spain research site, badalona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, girona, cataluã±a, spain research site, lleida, cataluã±a, spain research site, sabadell, cataluã±a, spain research site, elche, comunidad valenciana, spain research site, valencia, comunidad valenciana, spain research site, valencia, comunidad valenciana, spain research site, a coruã±a, galicia, spain research site, a coruã±a, galicia, spain research site, alcorcã³n, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, putzu city, chiayi, taiwan research site, keelung city, keelung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, ankara, turkey research site, ankara, turkey research site, bornova-izmir, turkey research site, ä°zmir, turkey research site, bebington, united kingdom research site, birmingham, united kingdom research site, brighton, united kingdom research site, bristol, united kingdom research site, cambridge, united kingdom research site, dorset, united kingdom research site, guildford, united kingdom research site, leeds, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, manchester, united kingdom research site, newcastle, united kingdom research site, peterborough, united kingdom research site, plymouth, united kingdom research site, poole, united kingdom research site, portsmouth, united kingdom research site, sheffield, united kingdom research site, truro, united kingdom""]","""study protocol"", https://clinicaltrials.gov/provideddocs/54/nct01077154/prot_000.pdf|""statistical analysis plan: sap 3.0"", https://clinicaltrials.gov/provideddocs/54/nct01077154/sap_001.pdf|""statistical analysis plan: sap 3.0 addendum"", https://clinicaltrials.gov/provideddocs/54/nct01077154/sap_002.pdf",https://ClinicalTrials.gov/show/NCT01077154,breast
235,236,NCT04511533,dacomitinib for treatment of patients in india with metastatic non small cell lung cancer with egfr activating mutations,,"Active, not recruiting",No Results Available,metastatic non small cell lung cancer,drug: dacomitinib,incidence of adverse events (aes)|confirmed objective response rate (orr) as assessed by the investigator using response evaluation criteria in solid tumor (recist) version 1.1|confirmed duration of response (dor) as assessed by the investigator using response evaluation criteria in solid tumor (recist) version 1.1,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,17.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A7471064,"August 27, 2020","October 18, 2022","October 18, 2022","August 13, 2020",,"January 24, 2022","['rajiv gandhi cancer institute and research centre, new delhi, delhi, india the gujarat cancer and research institute, ahmedabad, gujarat, india hemato oncology clinic ahmedabad pvt. ltd, ahmedabad, gujarat, india gujarat hospital - gastro and vascular centre, surat, gujarat, india artemis hospital, gurugram, haryana, india national cancer institute, nagpur, maharashtra, india apex wellness hospital, nashik, maharashtra, india grant medical foundation, ruby hall clinic, pune, maharashtra, india sahyadri clinical research and development center, pune, maharashtra, india sahyadri super speciality hospital, pune, maharashtra, india bhaktivedanta hospital and research institute, thane, maharashtra, india yashoda hospital, hyderabad, telangana state, india netaji subhas chandra bose cancer hospital, kolkata, west bengal, india tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT04511533,
236,237,NCT00457691,study of folfiri chemotherapy with or without sunitinib in patients with metastatic colorectal cancer,,Completed,Has Results,metastatic colorectal cancer,drug: 5 fluorouracil|drug: irinotecan|drug: levo- leucovorin|drug: sunitinib|drug: placebo,progression-free survival (pfs)|overall survival (os)|number of participants with overall confirmed objective response|duration of response (dr)|change from baseline in monroe dunaway (md) anderson symptom assessment inventory of gastrointestinal symptoms (mdasi-gi) symptom intensity score|change from baseline in mdasi-gi symptom interference score|change from baseline in european quality of life (euroqol) eq-5d self-report questionnaire|change from baseline in euroqol (eq) visual analog scale (vas) (eq-vas),pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,768.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A6181122,June 2007,March 2010,March 2010,"April 6, 2007","June 3, 2011","March 30, 2015","['pfizer investigational site, la plata, buenos aires, argentina pfizer investigational site, santa fe, argentina pfizer investigational site, wollongong, new south wales, australia pfizer investigational site, east bentleigh, victoria, australia pfizer investigational site, frankston, victoria, australia pfizer investigational site, fremantle, western australia, australia pfizer investigational site, st. poelten, austria pfizer investigational site, wien, austria pfizer investigational site, bruxelles, belgium pfizer investigational site, bruxelles, belgium pfizer investigational site, gent, belgium pfizer investigational site, leuven, belgium pfizer investigational site, liege, belgium pfizer investigational site, sarajevo, bosnia and herzegovina pfizer investigational site, goiânia, go, brazil pfizer investigational site, curitiba, pr, brazil pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, santo andré, sp, brazil pfizer investigational site, ruse, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, stara zagora, bulgaria pfizer investigational site, varna, bulgaria pfizer investigational site, oshawa, ontario, canada pfizer investigational site, ottawa, ontario, canada pfizer investigational site, santiago, rm, chile pfizer investigational site, santiago, rm, chile pfizer investigational site, medellin, antioquia, colombia pfizer investigational site, pasto, narino, colombia pfizer investigational site, nicosia, cyprus pfizer investigational site, brno, czech republic pfizer investigational site, nova ves pod plesi, czech republic pfizer investigational site, pribram, czech republic pfizer investigational site, berlin, germany pfizer investigational site, bochum, germany pfizer investigational site, esslingen, germany pfizer investigational site, frankfurt, germany pfizer investigational site, halle, germany pfizer investigational site, hannover, germany pfizer investigational site, moenchengladbach, germany pfizer investigational site, oldenburg, germany pfizer investigational site, regensburg, germany pfizer investigational site, hong kong, hong kong pfizer investigational site, kowloon, hong kong pfizer investigational site, tuen mun, new territories, hong kong pfizer investigational site, budapest, hungary pfizer investigational site, budapest, hungary pfizer investigational site, budapest, hungary pfizer investigational site, debrecen, hungary pfizer investigational site, debrecen, hungary pfizer investigational site, bangalore, karnataka, india pfizer investigational site, mumbai, maharashtra, india pfizer investigational site, mumbai, maharashtra, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, vellore, tamil nadu, india pfizer investigational site, dublin 24, ireland pfizer investigational site, dublin, ireland pfizer investigational site, dublin, ireland pfizer investigational site, galway, ireland pfizer investigational site, goyang-si, gyeonggi-do, korea, republic of pfizer investigational site, daegu, korea, republic of pfizer investigational site, incheon, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, mexico, df, mexico pfizer investigational site, acapulco, guerrero, mexico pfizer investigational site, ciudad obregon, sonora, mexico pfizer investigational site, forde, norway pfizer investigational site, tonsberg, norway pfizer investigational site, warszawa, poland pfizer investigational site, warszawa, poland pfizer investigational site, warszawa, poland pfizer investigational site, porto, portugal pfizer investigational site, porto, portugal pfizer investigational site, santa maria da feira, portugal pfizer investigational site, évora, portugal pfizer investigational site, cluj-napoca, cluj, romania pfizer investigational site, moscow, russian federation pfizer investigational site, moscow, russian federation pfizer investigational site, saint petersburg, russian federation pfizer investigational site, saint petersburg, russian federation pfizer investigational site, st. petersburg, russian federation pfizer investigational site, belgrade, serbia pfizer investigational site, sremska kamenica, serbia pfizer investigational site, singapore, singapore pfizer investigational site, singapore, singapore pfizer investigational site, bratislava, slovakia pfizer investigational site, bratislava, slovakia pfizer investigational site, observatory, south africa pfizer investigational site, panorama, south africa pfizer investigational site, parktown, south africa pfizer investigational site, port elizabeth, south africa pfizer investigational site, sandton, south africa pfizer investigational site, elche, alicante, spain pfizer investigational site, santander, cantabria, spain pfizer investigational site, mostoles, madrid, spain pfizer investigational site, alicante, spain pfizer investigational site, barcelona, spain pfizer investigational site, madrid, spain pfizer investigational site, sevilla, spain pfizer investigational site, zaragoza, spain pfizer investigational site, goteborg, sweden pfizer investigational site, stockholm, sweden pfizer investigational site, uppsala, sweden pfizer investigational site, changhua, taiwan pfizer investigational site, chiayi county, taiwan pfizer investigational site, kaohsiang hsien, taiwan pfizer investigational site, kaohsiung, taiwan pfizer investigational site, kwei-shan, taoyuan, taiwan pfizer investigational site, taichung, taiwan pfizer investigational site, tainan, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, rachathevee, bangkok, thailand pfizer investigational site, muang, chiang mai, thailand pfizer investigational site, muang, khon kaen, thailand pfizer investigational site, bangkok, thailand pfizer investigational site, cherkasy, ukraine pfizer investigational site, dnipropetrovsk, ukraine pfizer investigational site, kyiv, ukraine pfizer investigational site, lviv, ukraine pfizer investigational site, uzhgorod, ukraine pfizer investigational site, northwood, middlesex, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00457691,colon
237,238,NCT03830866,study of durvalumab with chemoradiotherapy for women with locally advanced cervical cancer (calla),CALLA,"Active, not recruiting",No Results Available,locally advanced cervical cancer,biological: durvalumab|drug: cisplatin|drug: carboplatin|radiation: external beam radiation therapy (ebrt) + brachytherapy,the efficacy of durvalumab + soc ccrt compared to placebo + soc ccrt in terms of progression-free survival (pfs)|the efficacy of durvalumab + soc ccrt compared to placebo + soc ccrt as assessed by the time from the date of randomization until death due to any cause in terms of overall survival (os)|the efficacy of durvalumab + soc ccrt compared to placebo + soc ccrt as assessed by proportion of patients with a complete response at the first tumor assessment after chemoradiotherapy in terms of complete response (cr) rate|the efficacy of durvalumab + soc ccrt compared to placebo + soc ccrt as assessed by the number (%) of patients with at least one visit response of complete response (cr) or partial response (pr) in terms of objective response rate (orr)|the efficacy of durvalumab + soc ccrt compared to placebo + soc ccrt as assessed by time from detection of cr until the date of disease progression in terms of duration of response (dor) in patients with a complete response (cr)|disease-related symptoms and health related quality of life (hrqol) in patients treated with durvalumab + soc ccrt compared with placebo + soc ccrt as assessed by the change from baseline in disease-related symptoms and hrqol|to further assess the efficacy of durvalumab + soc ccrt compared with placebo + soc ccrt in terms of proportion of patients alive and progression-free at 3 years (pfs 3 year).|the efficacy of durvalumab + soc ccrt compared with placebo + soc ccrt in terms of pfs in pd-l1 positive patients|the efficacy of durvalumab + soc ccrt compared with placebo + soc ccrt in terms of os in pd-l1 positive patients,astrazeneca,Female,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,770.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D9100C00001,"February 15, 2019","January 20, 2022","June 30, 2023","February 5, 2019",,"April 18, 2022","['research site, phoenix, arizona, united states research site, la jolla, california, united states research site, orange, california, united states research site, fort myers, florida, united states research site, miami, florida, united states research site, augusta, georgia, united states research site, ann arbor, michigan, united states research site, bronx, new york, united states research site, lake success, new york, united states research site, cleveland, ohio, united states research site, cleveland, ohio, united states research site, cleveland, ohio, united states research site, nashville, tennessee, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, spring, texas, united states research site, barretos, brazil research site, fortaleza, brazil research site, londrina, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, antofagasta, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, temuco, chile research site, temuco, chile research site, viña del mar, chile research site, changchun, china research site, changsha, china research site, chengdu, china research site, chongqing, china research site, guangzhou, china research site, hangzhou, china research site, hefei, china research site, hefei, china research site, shanghai, china research site, shenyang, china research site, shenyang, china research site, tianjin, china research site, wuhan, china research site, wuhan, china research site, budapest, hungary research site, debrecen, hungary research site, győr, hungary research site, kaposvár, hungary research site, szeged, hungary research site, ahmedabad, india research site, coimbatore, india research site, gurgaon, india research site, madurai, india research site, mumbai, india research site, nagpur, india research site, nasik, india research site, new delhi, india research site, vishakhapatnam, india research site, fukuoka-shi, japan research site, kagoshima-shi, japan research site, koto-ku, japan research site, kyoto-shi, japan research site, nakazu-gun, japan research site, osaka-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shinjuku-ku, japan research site, toon-shi, japan research site, yokohama-shi, japan research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, alc. cuauhtémoc, mexico research site, deleg. tlalpan, mexico research site, guadalajara jalisco, mexico research site, guadalajara, mexico research site, mérida, mexico research site, san luis potosí, mexico research site, veracruz, mexico research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, baguio city, philippines research site, cebu, philippines research site, iloilo, philippines research site, makati, philippines research site, manila, philippines research site, quezon city, philippines research site, bialystok, poland research site, gdańsk, poland research site, gliwice, poland research site, lublin, poland research site, łódź, poland research site, arkhangelsk, russian federation research site, chelyabinsk, russian federation research site, kaluga, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, novosibirsk, russian federation research site, parktown, south africa research site, port elizabeth, south africa research site, taichung, taiwan research site, tainan city, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan']",,https://ClinicalTrials.gov/show/NCT03830866,cervic
238,239,NCT03583944,"a study to evaluate safety, tolerability and efficacy of eribulin mesylate in treating adult females with locally advanced or metastatic breast cancer",,Completed,No Results Available,breast neoplasms,drug: eribulin mesylate,number of participants reporting one or more treatment-emergent adverse events (teaes) and serious adverse events (saes)|number of participants with teaes related to laboratory parameters|objective tumor response|objective response rate (orr),eisai inc.,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7389-M065-401,"March 28, 2018","June 28, 2019","June 28, 2019","July 12, 2018",,"November 27, 2019","[""sir ganga ram hospital, new delhi, delhi, india hemato-oncology clinic vedanta institute of medical sciences, ahmedabad, gujarat, india healthcare global enterprises ltd, bangalore, karnataka, india srinivasam cancer care multispecialty hospitals india pvt ltd, bangalore, karnataka, india kr hospital mysore medical college, mysore, karnataka, india tata memorial hospital department of oncology, mumbai, maharashtra, india hcg nchri cancer centre, nagpur, maharashtra, india lokmanya hospital, pune, maharashtra, india all india institute of medical sciences, bhubaneswar, orissa, india deep hospital, ludhiana, punjab, india sawai man singh hospital, jaipur, rajasthan, india mnj institute of oncology and regional cancer centre, hyderabad, telangana, india j.k.cancer institute, kanpur, uttar pradesh, india king george's medical university,(erstwhile chhatrapati shahuji maharaj medical university), lucknow, uttar pradesh, india ajanta research centre, ajanta hospital & ivf centre, lucknow, uttar pradesh, india nilratan sircar medical college and hospital, kolkata, west bengal, india netaji subhash chandra bose cancer institute, kolkata, west bengal, india ipgme&r s.s.k.m hospital, kolkata, west bengal, india""]",,https://ClinicalTrials.gov/show/NCT03583944,breast
239,240,NCT04332549,to assess the bioavailability and safety of paclitaxel injection concentrate for suspension in subjects with locally recurrent or metastatic breast cancer,,Withdrawn,No Results Available,metastatic breast cancer|locally recurrent cancer,drug: pics (reconstitution method 1 or 2),"maximum observed plasma concentration plasma|area under the plasma concentration versus time curve, from time 0 to the last measurable concentration|area under the plasma concentration versus time curve from time 0 to infinity|incidence of treatment-emergent adverse events",sun pharma advanced research company limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,0.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SDO-006-20-01,"April 27, 2020","January 28, 2021","January 28, 2021","April 2, 2020",,"June 1, 2020","['sparc site 12, visakhapatnam, andhra pradesh, india sparc site 21, ahmadabad, gujarat, india sparc site 22, sūrat, gujarat, india sparc site 4, bangalore, karnataka, india sparc site 10, bangalore, karnataka, india sparc site 18, bangalore, karnataka, india sparc site 13, bangalore, karnataka, india sparc site 9, aurangabad, maharashtra, india sparc site 8, kolhāpur, maharashtra, india sparc site 2, nagpur, maharashtra, india sparc site 1, nagpur, maharashtra, india sparc site 17, nagpur, maharashtra, india sparc site 3, nashik, maharashtra, india sparc site 19, nashik, maharashtra, india sparc site 15, pune, maharashtra, india sparc site 16, pune, maharashtra, india sparc site 5, pune, maharashtra, india sparc site 11, sāngli, maharashtra, india sparc site 20, khorda, orissa, india sparc site 14, madurai, tamil nadu, india sparc site 7, lucknow, uttar pradesh, india sparc site 6, gujrat, vadodara, india']",,https://ClinicalTrials.gov/show/NCT04332549,breast
240,241,NCT00626548,a phase iii trial of zd4054 (zibotentan) (endothelin a antagonist) in non-metastatic hormone resistant prostate cancer,ENTHUSE M0,Terminated,Has Results,prostate cancer,drug: zd4054|drug: palcebo,overall survival|progression free survival|health related quality of life|time to prostate-specific antigen (psa) progression|time to symptomatic progression,astrazeneca,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,2577.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D4320C00015,January 2008,January 2011,May 2011,"February 29, 2008","June 1, 2012","September 3, 2012","[""research site, tucson, arizona, united states research site, greenbrae, california, united states research site, los angeles, california, united states research site, san diego, california, united states research site, san francisco, california, united states research site, denver, colorado, united states research site, norwich, connecticut, united states research site, washington, district of columbia, united states research site, boca raton, florida, united states research site, miami, florida, united states research site, ocala, florida, united states research site, port st. lucie, florida, united states research site, atlanta, georgia, united states research site, macon, georgia, united states research site, kansas city, kansas, united states research site, new orleans, louisiana, united states research site, baltimore, maryland, united states research site, rockville, maryland, united states research site, minneapolis, minnesota, united states research site, lincoln, nebraska, united states research site, las vegas, nevada, united states research site, brooklyn, new york, united states research site, chapel hill, north carolina, united states research site, bismarck, north dakota, united states research site, canton, ohio, united states research site, cincinnati, ohio, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, charleston, south carolina, united states research site, mystle beach, south carolina, united states research site, raleigh, south carolina, united states research site, memphis, tennessee, united states research site, nashville, tennessee, united states research site, san antonio, texas, united states research site, burlington, vermont, united states research site, seattle, washington, united states research site, wenatchee, washington, united states research site, milwaukee, wisconsin, united states research site, ciudad autonoma de buenos aires, buenos aires, argentina research site, rosario, santa fe, argentina research site, santa fe, argentina research site, darlinghurst, new south wales, australia research site, hornsby, new south wales, australia research site, westmead, new south wales, australia research site, wollongong, new south wales, australia research site, wodonga, victoria, australia research site, nedlands, western australia, australia research site, sydney, australia research site, graz, austria research site, innsbruck, austria research site, wels, austria research site, (wilrijk) antwerpen, belgium research site, brussels, belgium research site, edegem, belgium research site, gent, belgium research site, kortrijk, belgium research site, leuven, belgium research site, liege, belgium research site, goiania, goias, brazil research site, belo horizonte, minas gerais, brazil research site, curitiba, parana, brazil research site, londrina, pr, brazil research site, porto alegre, rio grande do sul, brazil research site, rio de janeiro, rj, brazil research site, santo andre, sao paulo, brazil research site, sao paulo, brazil research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, vancouver, british columbia, canada research site, victoria, british columbia, canada research site, winnipeg, manitoba, canada research site, burlington, ontario, canada research site, hamilton, ontario, canada research site, kingston, ontario, canada research site, kitchener, ontario, canada research site, london, ontario, canada research site, north york, ontario, canada research site, oakville, ontario, canada research site, toronto, ontario, canada research site, greenfeild park, quebec, canada research site, montreal, quebec, canada research site, point-claire, quebec, canada research site, quebec city, quebec, canada research site, sherbrooke, quebec, canada research site, la serena, chile research site, santiago, chile research site, temuco, chile research site, vina del mar, chile research site, nanjing, jiangsu, china research site, hangzhou, zhejiang, china research site, beijing, china research site, chongqing, china research site, guangzhou city, china research site, hubei, china research site, jiangsu, china research site, shanghai, china research site, shanxi, china research site, tianjin, china research site, zejiang, china research site, bogota, colombia research site, medellin, colombia research site, brno, czech republic research site, hradec kralove, czech republic research site, jablonec nad nisou, czech republic research site, kromeriz, czech republic research site, olomouc, czech republic research site, prague 2, czech republic research site, prague 4, czech republic research site, prague 6, czech republic research site, praha, czech republic research site, usti nad labem, czech republic research site, aalborg, denmark research site, frederiksberg, denmark research site, herlev, denmark research site, holstebro, denmark research site, kobenhavn, denmark research site, odense, denmark research site, roskilde, denmark research site, helsinki, finland research site, joensuu, finland research site, oulu, finland research site, seinajoki, finland research site, tampere, finland research site, caen cedex, france research site, creteil, france research site, lille, france research site, lyon cedex 03, france research site, lyon, france research site, marseille, france research site, montpellier, france research site, orleans cedex, france research site, paris, france research site, pierre benite cedex, france research site, poitiers cedex, france research site, reims cedex, france research site, reims, france research site, rennes cedex 9, france research site, rouen, france research site, suresnes, france research site, toulouse, france research site, vandoeuvre-les-nancy cedex, france research site, villejuif, france research site, augsburg, germany research site, bad ems, germany research site, berlin, germany research site, bonn, germany research site, borken, germany research site, chemnitz, germany research site, emmendingen, germany research site, fuerth, germany research site, gelsenkirchen-buer, germany research site, germering, germany research site, goettingen, germany research site, holzminden, germany research site, kirchheim/teck, germany research site, leipzig, germany research site, lubeck, germany research site, mannheim, germany research site, muehlacker, germany research site, muehlheim an der ruhr, germany research site, muenchen-planegg, germany research site, muenchen, germany research site, muenster, germany research site, reutlingen, germany research site, rostock, germany research site, tuebingen, germany research site, waltshut-tiengen, germany research site, wuppertal, germany research site, budapest, hungary research site, debrecen, hungary research site, gyor, hungary research site, miskolc, hungary research site, nyiregyhaza, hungary research site, szeged, hungary research site, szekesfehervar, hungary research site, ahmedabad, gujarat, india research site, nadiad, gujarat, india research site, kochi, kerala, india research site, pune, maharashtra, india research site, chennai, tamil nadu, india, india research site, lucknow, uttar pradesh, india research site, kolkota, west bengal, india research site, new delhi, india research site, dublin 7, ireland research site, dublin 8, ireland research site, dublin, ireland research site, be'er sheva, israel research site, be'er-ya'akov, israel research site, haifa, israel research site, holon, israel research site, jeruslaem, israel research site, petah-tikva, israel research site, tel-hashomer - ramat gan, israel research site, ancona, italy research site, bari, italy research site, bergamo, italy research site, bologna, italy research site, catania, italy research site, como, italy research site, firenze, italy research site, genova, italy research site, messina, italy research site, milano, italy research site, pisa, italy research site, rome, italy research site, terni, italy research site, varese, italy research site, hirosaki-city, aomori, japan research site, chiba-city, chiba, japan research site, narashino-city, chiba, japan research site, matsuyama-city, ehime, japan research site, fukuoka-city, fukuoka, japan research site, maebashi-city, gunma, japan research site, otake-city, hiroshima, japan research site, sapporo-city, hokkaido, japan research site, kobe-city, hyogo, japan research site, ibaraki-machi, ibaraki, japan research site, mito-city, ibaraki, japan research site, tsukuba-city, ibaraki, japan research site, kita-gun, kagawa, japan research site, sagamihara-city, kanagawa, japan research site, kamigyo-ku, kyoto, japan research site, kyoto-city, kyoto, japan research site, sendai-city, miyagi, japan research site, ueda-city, nagano, japan research site, kashihara, nara, japan research site, oita-city, oita, japan research site, kurashiki, okayama, japan research site, osaka-city, osaka, japan research site, osaka-sayama-city, osaka, japan research site, suita-city, osaka, japan research site, wako-city, saitama, japan research site, hamamatsu-city, shizuoka, japan research site, sunto-gun, shizuoka, japan research site, bunkyo-ku, tokyo, japan research site, fuchu_city, tokyo, japan research site, itabashi-ku, tokyo, japan research site, meguro-ku, tokyo, japan research site, minato-ku, tokyo, japan research site, mitaka-city, tokyo, japan research site, shinjuku-ku, tokyo, japan research site, kyoto, japan research site, nagasaki, japan research site, bundang-gu, seongnam-si, gyeonggi-do, korea, republic of research site, seo-gu, pusan, korea, republic of research site, gangnam-gu, seoul, korea, republic of research site, seodaemun-gu, seoul, korea, republic of research site, seongbuk-gu, seoul, korea, republic of research site, songpa-gu, seoul, korea, republic of research site, liepaja, latvia research site, riga, latvia research site, distrito federal, ciudad de mexico, mexico research site, mexico df, distrito federal, mexico research site, amsterdam, netherlands research site, arnhem, netherlands research site, eindhoven, netherlands research site, hertogenbosch, netherlands research site, nijmegen, netherlands research site, rotterdam, netherlands research site, tilburg, netherlands research site, tonsberg, norway research site, trondheim, norway research site, arequipa, peru research site, bellavista, peru research site, jesus maria, peru research site, lima, peru research site, gdynia, poland research site, kielce, poland research site, koscierzyna, poland research site, szczecin, poland research site, warszawa, poland research site, wroclaw, poland research site, coimbra, portugal research site, porto, portugal research site, timisoara, timis, romania research site, bucuresti, romania research site, cluj-napoca, romania research site, omsk, omsk region, russian federation research site, izhevsk, russia, russian federation research site, tomsk, tomsk region, russian federation research site, barnaul, russian federation research site, kursk, russian federation research site, moscow, russian federation research site, sochi, russian federation research site, st.petersburg, russian federation research site, voronezh, russian federation research site, belgrade, serbia research site, nis, serbia research site, novi sad, serbia research site, observatory, cape town, south africa research site, tygerberg, cape town, south africa research site, overport, durban, south africa research site, parktown, johannesburg, south africa research site, pietermaritzburg, south africa research site, pretoria, south africa research site, elche, alicante, spain research site, barakaldo, bizkaia, spain research site, bilbao, vizcaya, spain research site, a corunna, spain research site, barcelona, spain research site, madrid, spain research site, sevilla, spain research site, valencia, spain research site, gothenburg, sweden research site, helsingborg, sweden research site, jonkoping, sweden research site, orebro, sweden research site, stockholm, sweden research site, uppsala, sweden research site, aarau, switzerland research site, ch-4031 basel, switzerland research site, locarno, switzerland research site, zuerich, switzerland research site, taipei, taiwan research site, ankara, turkey research site, istanbul, turkey research site, izmir, turkey research site, reading, berkshire, united kingdom research site, cottingham, east yorkshire, united kingdom research site, stevenage, hertfordshire, united kingdom research site, maidstone, kent, united kingdom research site, guildford, surrey, united kingdom research site, cambridge, united kingdom research site, coventry, united kingdom research site, glasgow, united kingdom research site, huddersfield, united kingdom research site, liverpool, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, newcastle upon tyne, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00626548,prostat
241,242,NCT00617669,a phase iii trial of zd4054 (zibotentan) (endothelin a antagonist) and docetaxel in metastatic hormone resistant prostate cancer,ENTHUSE M1C,Completed,Has Results,prostate cancer,drug: docetaxel|drug: zd4054|drug: placebo,overall survival|progression free survival|incidence of skeletal related events|time to prostate-specific antigen (psa) progression|time to pain progression|pain response|health related quality of life|psa response,astrazeneca,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,1494.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D4320C00033,January 2008,May 2011,July 2011,"February 18, 2008","May 31, 2012","September 10, 2012","['research site, greenbrae, california, united states research site, san diego, california, united states research site, norwich, connecticut, united states research site, washington, district of columbia, united states research site, fort myers, florida, united states research site, gainsville, florida, united states research site, ocala, florida, united states research site, portugalt st. lucie, florida, united states research site, rockville, maryland, united states research site, minneapolis, minnesota, united states research site, lincoln, nebraska, united states research site, omaha, nebraska, united states research site, chapel hill, north carolina, united states research site, durham, north carolina, united states research site, winston-salem, north carolina, united states research site, canton, ohio, united states research site, cincinnati, ohio, united states research site, pittsburgh, pennsylvania, united states research site, charleston, south carolina, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, san antonio, texas, united states research site, richmond, virginia, united states research site, seattle, washington, united states research site, milwaukee, wisconsin, united states research site, bahia blanca, buenos aires, argentina research site, buenos aires, argentina research site, santa fe, argentina research site, darlinghurst, new south wales, australia research site, st leonards, new south wales, australia research site, wollongong, new south wales, australia research site, redcliffe, queensland, australia research site, ashford, south australia, australia research site, footscray, victoria, australia research site, wodonga, victoria, australia research site, perth, western australia, australia research site, subiaco, western australia, australia research site, fortaleza, ceara/ la, brazil research site, goiania, goias/ la, brazil research site, goiania, goias, brazil research site, belo horizonte, minas germanyais, brazil research site, curitiba, parana/ brazil, brazil research site, londrina, pr, brazil research site, portugalto alegre, rio grande do sul/ la, brazil research site, rio de janeiro, rj, brazil research site, ribeirao preto, sao paulo/ la, brazil research site, santo andre, sao paulo, brazil research site, sao paulo, brazil research site, winnipeg, manitoba, canada research site, halifax, nova scotia, canada research site, london, ontario, canada research site, toronto, ontario, canada research site, quebec city, quebec, canada research site, sherbrooke, quebec, canada research site, brno, czechoslovakia republic, czech republic research site, jablonec nad nisou, czech republic research site, kromeriz, czech republic research site, olomouc, czech republic research site, prague 2, czech republic research site, prague 6, czech republic research site, usti nad labem, czech republic research site, helsinki, finland research site, joensuu, finland research site, seinajoki, finland research site, la roche sur yon, francence, france research site, marseille, francence, france research site, paris, francence, france research site, reims, francence, france research site, villejuif, francence, france research site, paris, france research site, saint herblain, france research site, hannover, germanymany, germany research site, berlin, germany research site, bonn, germany research site, dresden, germany research site, emmendingen, germany research site, kirchheim-teck, germany research site, leipzig, germany research site, luebeck, germany research site, muenster, germany research site, tuebingen, germany research site, wuppertal, germany research site, budapest, hungaryary, hungary research site, gyor, hungaryary, hungary research site, miskolc, hungaryary, hungary research site, ny regyh za, hungaryary, hungary research site, szeged, hungaryary, hungary research site, bangalore, karnataka, india research site, trivandrum, kerala, india research site, bhopal, madhya pradesh, india research site, pune, maharashtra, india research site, bikaner, rajasthan, india research site, jaipur, rajasthan, india research site, vellore, tamil nadu, india research site, kolkata, west bengal, india research site, kolkota, west bengal, india research site, delhi, india research site, new delhi, india research site, genoa, italy research site, lugo (ra), italy research site, rome, italy research site, cheongju, chungbuk, korea, republic of research site, ilsandong-gu, goyang-si, gyeonggi-do, korea, republic of research site, nowon-gu, seoul, korea, republic of research site, seodaemun-gu, seoul, korea, republic of research site, songpa-gu, seoul, korea, republic of research site, nijmegen, netherlands research site, cercado de arequipa, arequipa, peru research site, cercado, arequipa, peru research site, callao, peru research site, lima, peru research site, lublin, polandand, poland research site, swidnica, polandand, poland research site, warszaa, polandand, poland research site, koscierzyna, poland research site, wroclaw, poland research site, coimbra, portugaltugal, portugal research site, portugalto, portugaltugal, portugal research site, bucharest, romania research site, sibiu, romania research site, timisoara, romania research site, barnaul, russiasia, russian federation research site, izhevsk, russiasia, russian federation research site, kursk, russiasia, russian federation research site, sochi, russiasia, russian federation research site, voronezh, russiasia, russian federation research site, belgrade, serbiabia, serbia research site, beograd, serbiabia, serbia research site, nis, serbiabia, serbia research site, panorama, cape town, south africa research site, tygerberg, cape town, south africa research site, overport, durban, south africa research site, bloemfontein, south africa research site, port elizabeth, south africa research site, madrid, spain research site, valencia, spain research site, stockholm, sweden research site, uppsala, sweden research site, aarau, switzerland research site, locarno, switzerland research site, sursee, switzerland research site, kaohsiung, taiwanwan, taiwan research site, taiwanpei, taiwanwan, taiwan research site, reading, berkshire, united kingdom research site, westgate road, newcastle upon tyne, united kingdom research site, london, united kingdom research site, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00617669,prostat
242,243,NCT00554229,a phase iii trial of zd4054 (zibotentan) (endothelin a antagonist) in hormone resistant prostate cancer with bone metastases,ENTHUSE M1,Completed,Has Results,prostate cancer,drug: zd4054|drug: placebo,overall survival|progression free survival|time to use of opiates|incidence of skeletal related events|bone metastases formation|health related quality of life|time to prostate-specific antigen (psa) progression|time to pain progression|time to initiation of chemotherapy|pharmacokinetic characteristics of zd4054,astrazeneca,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,896.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D4320C00014|2007-003227-20,November 2007,July 2010,August 2011,"November 6, 2007","May 31, 2012","February 8, 2016","[""research site, tucson, arizona, united states research site, greenbrae, california, united states research site, los angeles, california, united states research site, palm springs, california, united states research site, san mateo, california, united states research site, norwich, connecticut, united states research site, washington, district of columbia, united states research site, gainsville, florida, united states research site, port st.lucie, florida, united states research site, des moines, iowa, united states research site, canton, ohio, united states research site, pittsburgh, pennsylvania, united states research site, nashville, tennessee, united states research site, salt lake city, utah, united states research site, burlington, vermont, united states research site, norfolk, virginia, united states research site, seattle, washington, united states research site, wheeling, west virginia, united states research site, milwaukee, wisconsin, united states research site, buenos aires, buenos aires province, argentina research site, santa fe, santa fe province, argentina research site, hornsby, new south wales, australia research site, st leonards, new south wales, australia research site, redcliffe, queensland, australia research site, ashford, south australia, australia research site, subiaco, western australia, australia research site, graz, austria research site, wels, austria research site, brussels, belgium research site, gent, belgium research site, kortrijk, belgium research site, leuven, belgium research site, fortaleza, ceara, brazil research site, goiania, goias, brazil research site, belo horizonte, minas gerais, brazil research site, curitiba, parana, brazil research site, porto alegre, rio grande do sul, brazil research site, ribeirao preto, sao paulo, brazil research site, santo andre, sao paulo, brazil research site, sao paulo, brazil research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, vancouver, british columbia, canada research site, kentville, nova scotia, canada research site, barrie, ontario, canada research site, burlington, ontario, canada research site, hamilton, ontario, canada research site, kitchener, ontario, canada research site, london, ontario, canada research site, mississauga, ontario, canada research site, north york, ontario, canada research site, oakville, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, granby, quebec, canada research site, laval, quebec, canada research site, montreal, quebec, canada research site, point-claire, quebec, canada research site, quebec city, quebec, canada research site, quebec, canada research site, haidian district, beijing, china research site, xi cheng district, beijing, china research site, xicheng district, beijing, china research site, wuhan, hubei, china research site, nanjing, jiangsu, china research site, pudong new area, shanghai, china research site, shanghai, shanghai, china research site, xuhui district, shanghai, china research site, xi'an, shanxi, china research site, prague 4, prague, czech republic research site, prague 6, prague, czech republic research site, brno, czech republic research site, olomouc, czech republic research site, usti nad labem, czech republic research site, aalborg, denmark research site, aarhus, denmark research site, herlev, denmark research site, kobenhavn, denmark research site, joensuu, finland research site, kajaanintie, finland research site, tampere, finland research site, montpellier, france research site, paris, france research site, poitiers cedex, france research site, suresnes, france research site, toulouse, france research site, villejuif, france research site, planegg, muenchen, germany research site, kirchheim, teck, germany research site, augsburg, germany research site, bad gegeberg, germany research site, berlin, germany research site, emmendingen, germany research site, leipzig, germany research site, luebeck, germany research site, mannheim, germany research site, muenchen, germany research site, reutlingen, germany research site, hong kong, hong kong research site, shatin, hong kong research site, tuen mun, hong kong research site, budapest, hungary research site, debrecen, hungary research site, miskolc, hungary research site, nyiregyhaza, hungary research site, szeged, hungary research site, rohini, delhi, india research site, trivandrum, kerala, india research site, bhopal, madhya pradesh, india research site, mumbai, maharashtra, india research site, chandigarh, punjab, india research site, ludhiana, punjab, india research site, bikaner, rajasthan, india research site, jaipur, rajasthan, india research site, kolkota, west bengal, india research site, gujarat, india research site, new delhi, india research site, milan, italy research site, rome, italy research site, asahi-city, chiba, japan research site, chiba-city, chiba, japan research site, narashino-city, chiba, japan research site, matsuyama-city, ehime, japan research site, fukuoka-city, fukuoka, japan research site, maebashi-city, gunma, japan research site, otake-city, hiroshima, japan research site, sapporo-city, hokkaido, japan research site, kobe-city, hyogo, japan research site, tsukuba-city, ibaraki, japan research site, kita-gun, kagawa, japan research site, sagamihara-city, kanagawa, japan research site, kyoto-city, kyoto, japan research site, sendai-city, miyagi, japan research site, oita-city, oita, japan research site, osaka-city, osaka, japan research site, osaka-sayama-city, osaka, japan research site, suita-city, osaka, japan research site, wako-city, saitama, japan research site, hamamatsu-city, shizuoka, japan research site, sunto-gun, shizuoka, japan research site, bunkyo-ku, tokyo, japan research site, fuchu_city, tokyo, japan research site, itabashi-ku, tokyo, japan research site, meguro-ku, tokyo, japan research site, mitaka-city, tokyo, japan research site, shinjuku-ku, tokyo, japan research site, nagasaki, japan research site, heungduk-gu cheongju, chungbuk, korea, republic of research site, seongnam-si, gyeonggi-do, korea, republic of research site, seo-gu, pusan, korea, republic of research site, gangnam-gu, seoul, korea, republic of research site, songpa-gu, seoul, korea, republic of research site, metepec, estado de mexico, mexico research site, distrito federal ciudad, mexico research site, mexico city, mexico research site, amsterdam, netherlands research site, eindhoven, netherlands research site, groningen, netherlands research site, nijmegen, netherlands research site, bialystok, poland research site, koscierzyna, poland research site, krakow, poland research site, rzeszow, poland research site, warszawa, poland research site, wroclaw, poland research site, coimbra, portugal research site, lisboa, portugal research site, porto, portugal research site, stary oskol, belgorodskaya region, russian federation research site, barnaul, russian federation research site, izhevsk, russian federation research site, kursk, russian federation research site, moscow, russian federation research site, sochi, russian federation research site, st. petersgurg, russian federation research site, voronezh, russian federation research site, belgrade, serbia research site, nis, serbia research site, novi sad, serbia research site, singapore, singapore research site, tygerberg, cape town, south africa research site, bloemfontein, south africa research site, pietermaritzburg, south africa research site, port elizabeth, south africa research site, goteborg, sweden research site, gothenburg, sweden research site, stockholm, sweden research site, basel, switzerland research site, bern, switzerland research site, locarno, switzerland research site, sursee, switzerland research site, kaohsiung, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, reading, berkshire, united kingdom research site, cambridge, cambridgeshire, united kingdom research site, maidstone, kent, united kingdom research site, huddersfield, yorkshire, united kingdom research site, london, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00554229,prostat
243,244,NCT00915018,study evaluating neratinib plus paclitaxel vs trastuzumab plus paclitaxel in erbb-2 positive advanced breast cancer,NEFERTT,Completed,Has Results,breast cancer,drug: neratinib|drug: trastuzumab|drug: paclitaxel,progression-free survival|objective response rate|duration of response|clinical benefit rate|symptomatic or progressive central nervous system (cns) lesions,"puma biotechnology, inc.",Female,"18 Years and older   (Adult, Older Adult)",Phase 2,479.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3144A2-3005 / B1891005,"August 21, 2009",August 2013,"June 28, 2018","June 5, 2009","November 6, 2017","August 22, 2018","['ventura county hematology-oncology specialists, oxnard, california, united states redwood regional medical group, santa rosa, california, united states cancer center of central connecticut, plainville, connecticut, united states palm beach institute of hematology and oncology, boynton beach, florida, united states north broward medical center cancer center, deerfield beach, florida, united states broward general medical center, fort lauderdale, florida, united states mid florida cancer centers, orange city, florida, united states florida cancer research institute, plantation, florida, united states hematology oncology associates of treasure coast, port saint lucie, florida, united states phoebe cancer center, albany, georgia, united states dublin hematology and oncology care, dublin, georgia, united states clintell, skokie, illinois, united states presence hematology and oncology, skokie, illinois, united states springfield clinic, springfield, illinois, united states christus st. frances cabrini hospital, alexandria, louisiana, united states hematology oncology services, metairie, louisiana, united states park nicollet institute, saint louis park, minnesota, united states missouri cancer associates, columbia, missouri, united states washington university school of medicine siteman cancer center, saint louis, missouri, united states st. john\'s medical research institute, springfield, missouri, united states the valley hospital, luckow pavilion office of oncology clinical trials, paramus, new jersey, united states gaston hematology and oncology associates, gastonia, north carolina, united states summa health system hospitals, akron, ohio, united states warren cancer research foundation, tulsa, oklahoma, united states samaritan hematology and oncology consultants, corvallis, oregon, united states pawtucket memorial hospital, pawtucket, rhode island, united states medical university of south carolina hollings cancer center, charleston, south carolina, united states santee hematology oncology, sumter, south carolina, united states tenessee cancer specialists, knoxville, tennessee, united states family cancer care, memphis, tennessee, united states texas oncology, bedford, texas, united states el paso cancer treatment center, el paso, texas, united states texas oncology-allison cancer center, midland, texas, united states southlake oncology, southlake, texas, united states utah cancer specialists, salt lake city, utah, united states charleston area medical center, health, education, and research institute, charleston, west virginia, united states the queen elizabeth hospital, north adelaide, south australia, australia royal melbourne hospital, parkville, victoria, australia affinity research limited, nassau, cb, bahamas n.n. aleksandrov national cancer center of belarus, lesnoy, minsk region, belarus institution gomel regional clinical oncology dispensary, gomel, belarus institution of healthcare grodno regional clinical hospital, grodno, belarus healthcare institution vitebsk regional clinical oncology dispensary, vitebsk, belarus institut jules bordet, brussels, belgium district dispensary for oncology diseases internal unit- plovdiv eood, plovdiv, bulgaria district dispensary for oncology diseases internal unit- sofia eood, sofia, bulgaria specialised hospital of activetreatment in oncology, clinic of chemotherapy, sofia, bulgaria hopital charles, lemoyne le centre intégré de cancérologie de la montérégie, greenfield park, quebec, canada centre hospitalier régional de trois-rivières, trois-rivieres, quebec, canada sun yat-sen university cancer center, guangzhou, guangdong, china southern medical university nanfang hospital, guangzhou, guangdong, china zhejiang cancer hospital, hangzhou, zhejiang, china cancer hospital, chinese academy of medical sciences, beijing, china peking union medical college hospital of chinese academy of medical sciences, beijing, china the hospital affiliated academy military medical science, chinese people\'s liberation army, beijing, china chinese people\'s liberation army general hospital, beijing, china fudan university shanghai cancer center, shanghai, china tianjin cancer hospital, tian jin, china clinical hospital osijek, department of radiotherapy and oncology, osijek, croatia university hospital for tumors, zagreb, croatia rigshospitalet, copenhagen, onkologisk klinik, copenhagen, denmark hôpital henri-mondor, creteil, france centre leon berard departement de cancerologie medicale, lyon, france centre val d\'aurelle, montpellier, france hopital hotel dieu, service d\'oncologie medicale, bat b2, 5ieme, paris, france hopital la pitie-salpetriere, paris, france groupe hospitalier paris saint joseph, oncologie medicale, paris, france service d\'oncologie et de radiotherapie, polyclinique francheville, perigueux, france clinique armoricaine de radiologie, st. brieuc, france centre de radiothérapie, clinique sainte anne, service d\'oncologie libérale, strasbourg, france chu strasbourg departement oncologie & hematologie hopital civil, strasbourg, france chu bretonneau, centre henry kaplan, tours, france sozialstiftung bamberg klinik fuer haematologie und internistische onkologie, bamberg, germany pamela youde nethersole eastern hospital, chai wan, hong kong queen mary hospital, hong kong, hong kong unimed medical institute, comprehensive centre for breast diseases, wanchai, hong kong semmelweis egyetem radiologiai és onkoterapias klinika, budapest, hungary fovarosi onkormanyzat szent imre korhaz klinikai onkologiai profil, budapest, hungary orszagos onkologiai intezet ""b"" belgyogyaszati osztaly, budapest, hungary kaposi mor oktato korhoz onkologiai centrum, kaposvar, hungary bacs-kiskun megyei onkormanyzat korhaza onkoradiologiai kozpont, kecskemet, hungary borsod-abaúj-zemplén megyei kórház és egyetemi oktató kórház, miskolc, hungary szegedi tudomanyegyetem onkoterapias klinika, szeged, hungary institute rotary cancer hospital, aiims, new delhi, delhi, india jawaharlal nehru cancer hospital, bhopal, madhya pradesh, india tata memorial centre, mumbai, maharashtra, india central india cancer research institute, nagpur, maharashtra, india curie manavata cancer centre, nashik, maharashtra, india shatabdi super speciality hospital, nashilk, maharashtra, india deenanath mangeshkar hospital and research centre, pune, maharashtra, india searoc cancer center, jaipur, rajasthan, india meenakshi mission hospital and research centre, madurai, tamil nadu, india b p poddar and medical research ltd., kolkata, west bengal, india kaplan medical center, rehovot, israel sourasky medical center, tel aviv, israel assaf harofeh medical center, zerifin, israel policlinico di modena oncologia ed ematologia, modena, italy fondazione salvatore maugeri, pavia, italy policlinico universitario campus bio-medico, roma, italy ospedale san pietro fatebenefratelli, roma, italy ospedale san giovanni battista-molinette, torino, italy hyogo cancer center, hyogo, akashi-shi, japan national hospital organization beppu medical center, oita, beppu-shi, japan tokyo metropolitan cancer and infectious disease center, komagome hospital, tokyo, bunkyo-ku, japan chiba cancer center, chiba, chiba-shi, japan national hospital organization kyushu cancer center, fukuoka, fukuoka-shi, japan national hospital organization mito medical center, ibaraki, higashiibaraki-gun, japan hiroshima university hospital, hiroshima, hiroshima-shi, japan hakuaikai medical corporation sagara hospital, kagoshima, kagoshima-city, japan national cancer center hospital east, chiba, kashiwa-shi, japan saitama cancer center, saitama, kitaadachi-gun, japan kumamoto municipal hospital, kumamoto, kumamoto-city, japan kurume daiichi social insurance hospital, fukuoka, kurume-shi, japan national hospital organization shikoku cancer center, ehime, matsuyama-city, japan iwate medical university hospital, iwate, morioka-shi, japan aichi cancer center, aichi, nagoya-shi, japan national hospital organization nagoya medical center, aichi, nagoya, japan niigata cancer center hospital, niigata, niigata-shi, japan osaka medical center for cancer and cardiovascular diseases, osaka, osaka-shi, japan national hospital organization osaka national hospital, osaka, osaka-shi, japan national hospital organization hokkaido cancer center, hokkaido, sapporo-shi, japan tohoku university hospital, miyagi, sendai-city, japan tenri hospital, nara, tenri-shi, japan kanagawa cancer center, kanagawa, yokohama-city, japan hiroshima city hospital, hiroshima, japan national hospital organization kure medical center and chugoku cancer center, hiroshima, japan kobe city medical center general hospital, hyogo, japan shinko hospital, hyogo, japan kumamoto university hospital, kumamoto, japan tazuke kofukai medical research institute kitano hospital, osaka, japan osaka university hospital, osaka, japan jichi medical university hospital, tochigi, japan toranomon hospital, tokyo, japan national hospital organization tokyo medical center, tokyo, japan national cancer center, center for breast cancer, goyang-si, gyeonggi-do, korea, republic of samsung medical center, seoul, korea, korea, republic of asan medical center, seoul, korea, korea, republic of korea university guro hospital, seoul, korea, korea, republic of yonsei university health system severance hospital, seoul, seoul/korea, korea, republic of piejuras hospital, liepajas oncological clinic, liepaja, latvia pauls stradiņš clinical university hospital, riga, latvia riga eastern university hospital, riga, latvia hospital of lithuanian university of health sciences, kaunas, lithuania nacionalinis vezio institutas, vilniaus universiteto onkologijos institutas, vilnius, lithuania university malaya medical centre, kuala lumpur, malaysia sir anthony oncology center, floriana, malta samodzielny publiczny zaklad opieki zdrowotnej szpital wojewodzki oddzial, jelenia gora, dolnoslaskie, poland magodent, warszawa, mazowieckie, poland opolskie centrum onkologii, opole, opolskie, poland zakład opieki zdrowotnej msw z warmińsko, mazurskim centrum onkologii, olsztyn, warminsko-mazurskie, poland białostockie centrum onkologii, bialystok, poland hospital da luz servico de oncologia medica, lisboa, portugal institutul oncologic prof. dr. ion chiricuţă, cluj-napoca, cluj, romania sc oncolab s.r.l., craiova, dolj, romania spitalul universitar de urgenta bucuresti, bucuresti, romania institute of oncology and radiology of serbia, belgrade, serbia clinical centre nis clinic of oncology, nis, serbia national university hospital, national cancer institute, singapore, singapore national cancer centre singapore, singapore, singapore gvi oncology, port elizabeth, eastern cape, south africa the medical oncology centre of rosebank, johannesburg, gauteng, south africa university of witwatersrand oncology, donald gordon medical centre, johannesburg, gauteng, south africa sandton oncology centre, johannesburg, gauteng, south africa eastleigh breast care centre, pretoria, gauteng, south africa westridge medical centre, durban, kwazulu natal, south africa gvi oncology, kraaifontein, western cape, south africa hospital universitari arnau de vilanova, lleida, cataluna, spain complejo hospitalario universitario santiago de compostela, santiago de compostela, galicia, spain hospital son llàtzer, palma, illes balears, spain hospital universitario fundación alcorcón, alcorcon, madrid, spain hospital puerta de hierro, majadahonda, madrid, spain hospital universitario infanta cristina, parla, madrid, spain hospital madrid norte sanchinarro centro integral oncológico clara campal ensayos clínicos, sanchinarro, madrid, spain hospital costa del sol, marbella, malaga, spain hospital de cruces, baracaldo, vizcaya, spain centro oncologico md anderson, madrid, spain hospital universitario ramón y cajal, madrid, spain hospital universitario 12 de octubre, madrid, spain tumor center hirslanden medical center, aarau, switzerland spital sts ag onkologiezentrum thun - berner oberland, thun, switzerland kantonsspital winterthur medizinische onkologie, winterthur, switzerland chang gung medical foundation, linkou branch, taoyuan, taiwan ege universitesi tip fakultesi tulay aktas onkoloji hastanesi, bornova, izmir, turkey komunalnyy zaklad cherkasskyy oblasnyy onkologichnyy dyspanser, cherkassy, ukraine chernivtsi regional oncology centre outpatient department bukovynian state medical university department of oncology and radiology, chernivtsi, ukraine city multifield clinical hospital, dnipropetrovsk, ukraine donetsk regional antitumor center department of pretumor diseases and tumor treatment, donetsk, ukraine s.p. grigoreva institute of medical radiology department of chemotherapy, kharkiv, ukraine national institute of cancer department of conseravtive methods of treatment, kyiv, ukraine volyn regional oncological center, lutsk, ukraine state oncological regional treatment and diagnostic center, lviv, ukraine mariupil oncological center, mariupil, ukraine sumy regional clinical oncology centre, sumy, ukraine guy\'s and st thomas nhs foundation trust management offices 4th floor bermondsey wing guy\'s hospital, london, united kingdom nottingham university hospital, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT00915018,breast
244,245,NCT04538742,a phase 1b/2 study of t-dxd combinations in her2-positive metastatic breast cancer,DB-07,Recruiting,No Results Available,metastatic breast cancer,drug: trastuzumab deruxtecan|drug: durvalumab|drug: paclitaxel|drug: pertuzumab|drug: tucatinib,occurrence of adverse events (aes)- part 1|occurrence of serious adverse events (saes)- part 1|occurrence of adverse events (aes)- part 2|occurrence of serious adverse events (saes)- part 2|objective response rate (orr)- part 1 and part 2|progression free survival (pfs)- part 1 and part 2|progression free survival 2 (pfs2)- part 2|duration of response (dor)- part 2|overall survival (os)- part 2|serum concentration of trastuzumab deruxtecan (t-dxd)|serum concentration of durvalumab|serum concentration of pertuzumab|plasma concentration of paclitaxel|plasma concentration of tucatinib|immunogenicity of trastuzumab deruxtecan|immunogenicity of durvalumab|immunogenicity of pertuzumab,"astrazeneca|daiichi sankyo company, limited",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,450.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D967JC00001,"December 28, 2020","April 30, 2025","April 30, 2025","September 4, 2020",,"May 9, 2022","[""research site, west hollywood, california, united states research site, fort myers, florida, united states research site, saint petersburg, florida, united states research site, baton rouge, louisiana, united states research site, saint paul, minnesota, united states research site, basking ridge, new jersey, united states research site, middletown, new jersey, united states research site, montvale, new jersey, united states research site, commack, new york, united states research site, harrison, new york, united states research site, long island city, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, uniondale, new york, united states research site, durham, north carolina, united states research site, cincinnati, ohio, united states research site, columbus, ohio, united states research site, providence, rhode island, united states research site, nashville, tennessee, united states research site, fort worth, texas, united states research site, fairfax, virginia, united states research site, melbourne, australia research site, barretos, brazil research site, belo horizonte, brazil research site, natal, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sorocaba, brazil research site, edmonton, alberta, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, quebec, canada research site, toronto, canada research site, dijon, france research site, villejuif cedex, france research site, berlin, germany research site, bottrop, germany research site, düsseldorf, germany research site, erlangen, germany research site, halle, germany research site, münchen, germany research site, münchen, germany research site, recklinghausen, germany research site, würzburg, germany research site, gurgaon, india research site, madurai, india research site, mumbai, india research site, mumbai, india research site, rohini, india research site, bologna, italy research site, milan, italy research site, napoli, italy research site, rome, italy research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, bydgoszcz, poland research site, koszalin, poland research site, lublin, poland research site, rzeszów, poland research site, warszawa, poland research site, łódź, poland research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, sankt-peterburg, russian federation research site, barcelona, spain research site, l'hospitalet de llobregat, spain research site, madrid, spain research site, madrid, spain research site, sevilla, spain research site, hualien, taiwan research site, tainan, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan research site, ankara, turkey research site, edirne, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, buckhurst hill, united kingdom research site, cambridge, united kingdom research site, glasgow, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, oxford, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04538742,breast
245,246,NCT00898287,safety and efficacy study of p276-00 in combination with gemcitabine in patients with advanced pancreatic cancer,SAVIOR,Completed,No Results Available,pancreatic cancer,drug: p276-00|drug: gemcitabine,to determine the maximum tolerated dose (mtd) of p276-00 administered along with gemcitabine.|to evaluate pharmacokinetic parameters of p276-00.|to determine clinical benefit response to p276-00 in combination with gemcitabine in patients with cancer of pancreas.|to determine objective tumor response rate to p276-00 in combination with gemcitabine in patients with cancer of pancreas.|to characterize toxicities of p276-00 in combination with gemcitabine.,piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,23.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/28/08,May 2009,December 2010,,"May 12, 2009",,"January 20, 2012","['central india cancer research institute, nagpur, ajayonco@hotmail.com, india global hospital, hyderabaad, andhra pradesh, india curie manavata cancer centre, nashik, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india sri ramachandra medical centre, chennai, tamil nadu, india lifeline mutispecilaity hospital, chennai, tamil nadu, india meenakshi mission hospital & reasearch centre, madurai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT00898287,pancreat
246,247,NCT00849667,efficacy and safety of morab-003 in subjects with platinum-sensitive ovarian cancer in first relapse,,Completed,No Results Available,ovarian cancer,drug: morab-003 (farletuzumab)|drug: 0.9% saline,"progression-free survival using by recist|overall survival, ca-125 pfs, gcig pfs, length of first versus second remission, tumor response,serologic response (ca-125), quality of life, resource utilization and pk ddi substudy.",morphotek,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,1100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MORAb003-004,April 2009,December 2012,April 2013,"February 24, 2009",,"July 20, 2015","['university of alabama at birmingham, birmingham, alabama, united states oncology specialties, pc, huntsville, alabama, united states arizona hematology & oncology associates, phoenix, arizona, united states st. joseph\'s hospital, barrow neurology clinics, phoenix, arizona, united states arizona oncology associates, tucson, arizona, united states arizona cancer center, tucson, arizona, united states providence st. joseph medical center, burbank, california, united states california cancer care, inc., greenbrae, california, united states university of california san diego, la jolla, california, united states university of california los angeles medical center, los angeles, california, united states gynecologic oncology associates, newport beach, california, united states university of california davis cancer center, sacramento, california, united states stanford university, stanford, california, united states university of colorado, aurora, colorado, united states catholic health initiatives, colorado springs, colorado, united states denver health and hospital authority, denver, colorado, united states hematology oncology p.c., stamford, connecticut, united states washington hospital center, washington, district of columbia, united states palm beach institute of hematology and oncology, boynton beach, florida, united states university cancer institute, boynton beach, florida, united states gainsville hematology oncology associates, gainesville, florida, united states baptist cancer institute, jacksonville, florida, united states jupiter medical center physician\'s group, jupiter, florida, united states hematology/oncology associates, lake worth, florida, united states lakeland regional cancer center, lakeland, florida, united states florida hospital, orlando, florida, united states sarasota memorial healthcare system, sarasota, florida, united states gulfcoast oncology, st. petersburg, florida, united states oncology-hematology associates of w. broward p.a., tamarac, florida, united states palm beach cancer institute, west palm beach, florida, united states medical college of georgia, augusta, georgia, united states memorial health university medical center, savannah, georgia, united states kaiser permanente - moanalua medical center, honolulu, hawaii, united states kapi\'olani medical center for women and children, honolulu, hawaii, united states medical & surgical specialists, llc, galesburg, illinois, united states ingalls memorial hospital, harvey, illinois, united states loyola university chicago, maywood, illinois, united states midwest cancer research group, skokie, illinois, united states central dupage hospital, winfield, illinois, united states st. francis hospital & health centers, indianapolis, indiana, united states st. vincent gynecologic oncology, indianapolis, indiana, united states central baptist hospital, lexington, kentucky, united states university of louisville, louisville, kentucky, united states norton healthcare, louisville, kentucky, united states hematology & oncology specialists, metairie, louisiana, united states john hopkins university, balitmore, maryland, united states mercy medical center, baltimore, maryland, united states greater baltimore medical center, baltimore, maryland, united states weinberg cancer institute at franklin square, baltimore, maryland, united states center for cancer and blood disorders, bethesda, maryland, united states frederick memorial hospital, frederick, maryland, united states barbara ann kamanos cancer center, detroit, michigan, united states henry ford health system, detroit, michigan, united states saint mary\'s health care, grand rapids, michigan, united states sparrow regional cancer center, lansing, michigan, united states park nicollet institute, st. louis park, minnesota, united states saint francis memorial health center, grand island, nebraska, united states good samaritan hospital cancer center, kearney, nebraska, united states the center for cancer and hematologic disease, camden, new jersey, united states hematology-oncolgy associates of nnj-pa, denville, new jersey, united states john theurer cancer center at hackensack university mc, hackensack, new jersey, united states morristown memorial hospital, morristown, new jersey, united states cooper cancer institute, voorhees, new jersey, united states university of new mexico cancer center, albuquerque, new mexico, united states roswell park cancer institute, buffalo, new york, united states arena oncology associates, lake success, new york, united states columbia university medical center, new york, new york, united states suny upstate medical university, syracuse, new york, united states carolinas medical center, charlotte, north carolina, united states presbyterian hospital, charlotte, north carolina, united states duke university medical center, durham, north carolina, united states piedmont hematology & oncology, winston-salem, north carolina, united states catholic health initiatives, cincinnati, ohio, united states university hospitals of cleveland, cleveland, ohio, united states metrohealth medical center, cleveland, ohio, united states miami valley hospital, dayton, ohio, united states kettering medical center, kettering, ohio, united states signal point clinical research center, llc, middletown, ohio, united states cancer care associates, tulsa, oklahoma, united states providence oncology & hematology care, portland, oregon, united states kaiser permanente northwest, portland, oregon, united states oregon health & science university, portland, oregon, united states willamette valley cancer center, springfield, oregon, united states abington memorial hospital, abington, pennsylvania, united states st. luke\'s hospital, bethlehem, pennsylvania, united states oncology hematology associates, dubois, pennsylvania, united states gettysburg cancer center, gettysburg, pennsylvania, united states magee-womens hospital of upmc, pittsburgh, pennsylvania, united states western pennsylvania hospital, pittsburgh, pennsylvania, united states medical university of south carolina, charleston, south carolina, united states chattanooga\'s program in women\'s oncology, chattanooga, tennessee, united states vanderbilt university medical center, nashville, tennessee, united states texas oncology, pa, austin, texas, united states texas oncology, p.a., bedford, texas, united states texas oncology, pa, dallas, texas, united states baylor sammons cancer center, dallas, texas, united states international beneficence clinical research, l.l.c., harlingen, texas, united states university of texas health science center at houston medical school, houston, texas, united states south texas oncology and hematology, pa, san antonio, texas, united states scott and white memorial hospital, temple, texas, united states us oncology research, wichita falls, texas, united states northern utah associates, ogden, utah, united states utah cancer specialists, salt lake city, utah, united states northern virginia pelvic surgery associates, annandale, virginia, united states peninsula cancer institute - riverside gynecology oncology, newport news, virginia, united states harrison bremerton hematology and oncology, bremerton, washington, united states providence everett medical center, everett, washington, united states cancer care northwest-south, spokane, washington, united states northwest cancer specialists, pc, vancouver, washington, united states aurora health care, west allis, wisconsin, united states hospital zonal especializado en oncología de lanús, buenos aires, argentina consultorios medicos privados sa, buenos aries, argentina fundación sanatorio güemes, caba, argentina clinica universitaria reina fabiola, códoba, argentina instituto medico platense, la plata, argentina centro oncologico riojano integral (cori), la rioja, argentina hospital bocalandro, loma hermosa, argentina centro oncologico integral, mar del plata, argentina cer instituto medico, quilmes, argentina centro médico san roque, san miguel de tucuman, argentina centro medico de alta complejidad cemac, san salvador de jujuy, argentina isis centro especializado de luce sa, santa fe, argentina tweed hospital, tweed heads, new south wales, australia westmead hospital, westmead, new south wales, australia the royal brisbane and women\'s hospital, herston, queensland, australia mater adult hospital, south brisbane, queensland, australia north adelaide oncology clinical trials, north adelaide, south australia, australia sir charles gairdner hospital, nedlands, western australia, australia landeskrankenhaus villach, villach, austria kaiser-franz-josef spital, wien, austria krankenhaus wien-hietzing, wien, austria institut jules bordet, bruxelles, belgium cliniques universitaires saint-luc, bruxelles, belgium uz gent, gent, belgium az groeninge - campus maria\'s voorzienigheid, kortrijk, belgium uz leuven, leuven, belgium chu de liège, liège, belgium sint-augustinuskliniek, wilrijk, belgium fundação pio xii - hospital de câncer de barretos, barretos, brazil instituto de pesquisas clínicas para estudos multicêntricos, caxias do sul, brazil santa casa da misericórdia de curitiba, curitiba, brazil instituto do câncer do ceará - icc, fortaleza, brazil hosp. araujo jorge, goiania, brazil associação hospital de caridade ijuí, ijuí, brazil clinica de neoplasias litoral, itajai, brazil hospital amaral carvalho, jaú, brazil liga norte-riograndense contra o câncer, natal, brazil irmandade santa casa de misericórdia de porto alegre, porto alegre, brazil clínica de oncologia de porto alegre s/s ltda, porto alegre, brazil instituto ribeirãopretano de combate ao câncer, ribeirão preto, brazil inca - instituto nacional do câncer, rio de janeiro - rj, brazil clínica oncologistas associados, rio de janeiro, brazil hospital santa izabel - santa casa de misericordia da bahia, salvador, brazil clínica amo - assistência multidiciplinar em oncologia, salvador, brazil centro de estudos de oncologia da fmabc, santo andré, brazil saúde abc serviços médicos hospitalares ltda, santo andré, brazil instituto do câncer arnaldo vieira de carvalho, são paulo, brazil certo oncologia, são paulo, brazil hospital premier, são paulo, brazil tom baker cancer centre, calgary, alberta, canada cancer center for the southern interior, kelowna, british columbia, canada british columbia cancer agency, surrey, british columbia, canada bcca, vancouver, british columbia, canada the moncton hospital, moncton, new brunswick, canada ottawa hospital, ottawa, ontario, canada instituto de terapias oncologicas, santiago, chile instituto clínico oncológico del sur, temuco, chile instituto oncologico ltda., viña del mar, chile centre régional de lutte contre le cancer paul papin, angers cedex 9, france centre hospitalier louis pasteur, le coudray, france institut paoli calmettes, marseille, france hôpital saint louis, paris cedex 10, france institut jean godinot - centre de lutte contre le cancer, reims, france helios klinikum berlin-buch, berlin-buch, germany charité - universitätsmedizin berlin, berlin, germany klinikum chemnitz ggmbh, chemnitz, germany marien-hospital akademisches lehrkrankenhaus, düsseldorf, germany frauenarztpraxis dr. med. gröll de rivera, ebersberg, germany universitätsklinikum essen, essen, germany krankenhaus nordwest, frankfurt, germany universitätsklinikum freiburg, freiburg, germany kath. marienkrankenhaus ggmbh, hamburg, germany universität heidelberg, heidelberg, germany st. vincentius kliniken karlsruhe, karlsruhe, germany universitätsklinik magdeburg, magdeburg, germany universitätsmedizin der johannes gutenberg-universität mainz, mainz, germany klinikum der universität münchen - innenstadt, münchen, germany rotkreuzklinikum münchen, münchen, germany klinikum südstadt rostock, rostock, germany klinikum traunstein, traunstein, germany university general hospital of heraklion, heraklion, crete, greece alexandra hospital, athens, greece general oncology hospital kifissias ""oi agioi anargyroi"", athens, greece university general hospital of patras, patras, greece papageorgiou general hospital, thessaloniki, greece queen mary hospital, pokfulam, islands, hong kong tuen mun hospital, tuen mun, hong kong semmelweis egyetem, budapest, hungary semmelweis egyetem, budapest, hungary petz aladár megyei oktató kórház, gyor, hungary bács-kiskun megyei önkormányzat kórháza, kecskemét, hungary borsod-abaúj-zemplén megyei kórház és egyetemi oktató kórház, miskolc, hungary jász-nagykun-szolnok megyei hetényi géza kórház-rendelöintézet, szolnok, hungary veszprém megyei önkormányzat csolnoky ferenc kórház-rendelöintézet, veszprém, hungary apollo hospitals international limited, gandhinagar, gujarat, india kidwai memorial institute of oncology, bangalore, karnataka, india jawaharlal nehru cancer hospital & research centre, bhopal, madhya pradesh, india jehangir, clinical development centre, pune, maharashtra, india ruby hall clinic, pune, maharashtra, india dr. kamakshi memorial hospital, chennai, tamil nadu, india chittaranjan national cancer institute, kolkata, west bengal, india m.s ramaiah medical college and teaching hospital ethical review board, bangalore, india amrita institute of medical sciences and research centre, cochin, india mnj institute of oncology and regional cancer centre, hyderabaad, india sk soni hospital, jaipur, india bhagwan mahaveer cancer hospital and research centre, jaipur, india lakeshore hospital, kochi, india tata memorial hospital, mumbai, india shatabdi superspeciality hospital, nashik, india curie manavata cancer centre, nasik, india all india institute of medical sciences, new delhi, india regional cancer centre, trivandrum, india rambam medical center, haifa, israel linn medical center, clalit health services, haifa, israel wolfson centre, holon, israel shaare zedek medical center, jerusalem, israel hadassah university hospital ein kerem, jerusalem, israel meir medical center, kfar saba, israel rabin medical center, petach tikva, israel the chaim sheba medical center, ramat-gan, israel kaplan medical center, rehovot, israel assaf harofe medical center, zerifin, israel centro di riferimento oncologico, aviano, pordenone, italy azienda ospedaliera santi antonio, biagio e cesare arrigo, alessandria, italy azienda ospedaliero-universitaria di bologna - policlinico s.orsola-malpighi, bologna, italy istituto ospedaliero fondazione poliambulanza, brescia, italy centro di ricerca e formazione ad alta tecnologia nelle scienze biomediche, campobasso, italy azienda ospedaliera cannizzaro, catania, italy humanitas centro catanese di oncologia, catania, italy azienda ospedaliera sant\'anna, como, italy ospedale di faenza, faenza, italy azienda ospedaliera universitaria san martino, genova, italy presidio ospedaliero vito fazzi, lecce, italy ospedale mater salutis ulss 21 della regione veneto, legnago, italy istituto scientifico romagnolo per lo studio e la cura dei tumori - irst, meldola, italy fondazione irccs cà granda ospedale maggiore policlinico, milano, italy fondazione centro san raffaele del monte tabor, milano, italy istituto nazionale dei tumori, milano, italy azienda ospedaliera niguarda cà granda, milano, italy istituto nazionale per lo studio e la cura dei tumori ""fondazione giovanni pascale"", napoli, italy ospedale sacro cuore don calabria, negrar, italy istituto oncologico veneto, padova, italy ospedale santa maria della misericordia di perugia, perugia, italy ospedale santa maria delle croci, ravenna, italy arcispedale santa maria nuova, reggio emilia, italy azienda policlinico umberto i, roma, italy policlinico universitario ""a. gemelli"", roma, italy azienda ospedaliero-universitaria di udine, udine, italy akashi, japan amagasaki, japan chiba, japan fukuoka, japan hidaka, japan hiroshima, japan kagoshima, japan kashiwa, japan kawasaki, japan koto-ku, japan kumamoto, japan kure, japan kurume, japan matsuyama, japan minato-ku, japan morioka, japan nagoya, japan nakano-ku, japan niigata, japan okayama, japan osakasayama, japan osaka, japan sapporo, japan sendai, japan shinjuku-ku, japan sunto-gun, japan tsukuba, japan tsu, japan yamagata, japan yonago, japan national cancer center, gyeonggi-do, korea, republic of gachon university gil medical center, in cheon, korea, republic of cheil general hospital & women\'s healthcare center, seoul, korea, republic of seoul national univercity hospital, seoul, korea, republic of severance hospital, yonsei university college of medicine, seoul, korea, republic of samsung medical center, seoul, korea, republic of asan medical center, seoul, korea, republic of union medica quirurgica de colima, colima, mexico triva investigaciones medicas sociedad anónima de capital variable, morelia, mexico hospital regional de veracruz, veracruz, mexico vu medisch centrum, amsterdam, netherlands albert schweitzer ziekenhuis, dordrecht, netherlands academisch ziekenhuis maastricht, maastricht, netherlands orbis medisch centrum, sittard-geleen, netherlands perpetual succour hospital, cebu city, cebu, philippines cebu gynecologic cancer care clinic, cebu, philippines manila doctors hospital, manila, philippines san juan de dios hospital, pasay city, philippines st. luke\'s medical center, quezon city, philippines national kidney and transplant institute, quezon city, philippines bialostockie centrum onkologii, bialystok, poland wojewodzkie centrum onkologii, gdansk, poland centrum onkologii, instytut im. m. sklodowskiej-curie oddzial w gliwicach, gliwice, poland wojewodzki szpital specjalistyczny im. m. kopernika w lodzi, lodz, poland centrum onkologii ziemi lubelskiej, lublin, poland zaklad opieki zdrowotnej mswia z warminsko-mazurskim centrum onkologii, olsztyn, poland olsztynski osrodek onkologiczny ""kopernik"" sp. z o.o., olsztyn, poland wielkopolskie centrum onkologii, poznan, poland szpital kliniczny przemienienia panskiego uniwersytetu medycznego im. karola marcinkowskiego w pozna, poznan, poland spzoz wojewodzki szpital specjalistyczny nr 3, rybnik, poland samodzielny publiczny szpital kliniczny nr 2 pam w szczecinie, szczecin, poland wojskowy instytut medyczny, warszawa, poland hospitais da universidade de coimbra, coimbra, portugal instituto português de oncologia francisco gentil, centro regional de oncologia de coimbra, epe, coimbra, portugal instituto portugues de oncologia de lisboa francisco gentil (ipolfg, epe), lisboa, portugal instituto portugues de oncologia do porto francisco gentil (ipopfg, epe), porto, portugal hospital de são joão, porto, portugal kursk regional oncology centre, kursk, russian federation russian oncology research center named after n.n. blokhin, moscow, russian federation russian oncology research center, moscow, russian federation moscow research oncology institute n.a. p.a.gertsen, moscow, russian federation medical radiology research center of rams, obninsk, russian federation ryazan regional clinical oncology dispensary, ryazan, russian federation city clinical oncology dispensary, st. petersburg, russian federation republican clinical oncology center of bashkortostan republic ministry of healthcare, ufa, russian federation national university hospital, singapore, singapore national cancer centre, singapore, singapore kk women\'s and children\'s hospital, singapore, singapore hospital universitario reina sofia, córdoba, andalucía, spain hospital virgen del rocio, sevilla, andalucía, spain hospital son llatzer, palma de mallorca, baleares, spain hospital universitario vall d\'hebron, barcelona, cataluna, spain hospital clinic i provincial, barcelona, cataluña, spain hospital de mataró, mataró, cataluña, spain corporació sanitaria parc taulí, sabadell, cataluña, spain hospital mutua de terrassa, terrassa, cataluña, spain hospital general universitario de elche, elche, comunidad valenciana, spain fundación instituto valenciano de oncología, valencia, comunidad valenciana, spain fundacion hospital alcorcon, alcorcón, madrid, communidad de, spain hospital general universitario gregorio marañon, madrid, madrid, communidad de, spain hospital universitario ramón y cajal, madrid, madrid, communidad de, spain hospital 12 de octubre, madrid, madrid, communidad de, spain hospital clinico san carlos, madrid, spain universität zürich, zürich, switzerland national cheng kung university hosptial, tainan, taiwan national taiwan university hospital, taipei, taiwan mackay memorial hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan tri-service general hospital, taipei, taiwan chang gung memorial hospital, taoyuan, taiwan municipal institution of cherkasy regional counsil ""cherkasy regional oncology dispensary"", cherkasy, ukraine chernivtsi regional clinical oncology dispansery, chernivtsi, ukraine kiev city oncology hospital, kyiv, ukraine volyn regional oncology dispensary, lutsk, ukraine belfast city hospital, belfast, united kingdom velindre hospital, cardiff, united kingdom university hospital coventry, coventry, united kingdom ninewells hospital, dundee, united kingdom beatson oncology centre, glasgow, united kingdom leicester royal infirmary, leicester, united kingdom royal marsden hospital, london, united kingdom hammersmith hospital, london, united kingdom derriford hospital, plymouth, united kingdom poole hospital nhs trust, poole, united kingdom weston park hospital, sheffield, united kingdom clatterbridge centre for oncology, wirral, united kingdom new cross hospital, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00849667,ovari
247,248,NCT02763566,a study of abemaciclib (ly2835219) in participants with breast cancer,MONARCH plus,"Active, not recruiting",Has Results,breast cancer,drug: abemaciclib|drug: anastrozole|drug: letrozole|drug: placebo|drug: fulvestrant,"progression free survival (pfs) (abemaciclib + nsai & placebo nsai)|progression free survival (pfs) (abemaciclib + fulvestrant and placebo + fulvestrant arms)|overall survival (os)|percentage of participants with best overall response (bor) of complete response (cr) or partial response (pr) [objective response rate (orr)]|duration of response (dor)|percentage of participants who exhibit stable disease (sd) or cr or pr [disease control rate (dcr)]|percentage of participants with best overall response of cr, pr, or sd with duration of sd for at least 6 months [clinical benefit rate (cbr)]|change from randomization in symptom burden on the european organization for research and treatment of cancer quality of life questionnaire-c30 (eortc qlq-c30)|pharmacokinetics (pk): area under the concentration curve of abemaciclib, its metabolites (m2 & m20)",eli lilly and company,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,463.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15530|I3Y-CR-JPBQ,"December 5, 2016","March 29, 2019","February 28, 2023","May 5, 2016","March 30, 2020","October 27, 2021","[""hospital de caridade ijui, ijui, rio grande do sul, brazil instituto do câncer - hospital mãe de deus center/aesc, porto alegre, rio grande do sul, brazil fundação pio xii, barretos, sao paulo, brazil hospital de base fac de medicina de sao jose do rio preto, sao jose rio preto, sao paulo, brazil instituto do cancer do estado de sao paulo - icesp, sao paulo, brazil clin. pesq.e centro estudos oncologia ginecológica e mamária, são paulo, brazil afflilated hospital of bengbu medical college, bengbu, anhui, china the 307th hospital of chinese people's liberation army, beijing, beijing, china fujian provincial cancer hospital, fuzhou, fujian, china fujian province hospital, fuzhou, fujian, china affiliated cancer hospital of guangxi medical university, nan ning, guang xi, china guangdong province people's hospital, guangzhou, guangdong, china sun yat-sen memorial hospital, sun yat-sen university, guangzhou, guangdong, china the fourth hospital of hebei medical university, shijiazhuang, hebei, china harbin medical university caner hospital, harbin, heilongjiang, china henan cancer hospital, zhengzhou, henan, china wu han tongji hospital, wuhan city, hubei, china wuhan union (xiehe) hospital, wuhan, hubei, china hu bei cancer hospital, wuhan, hubei, china hunan province tumor hospital, changsha, hunan, china jilin province tumor hospital, chang chun, ji lin, china nanjing drum tower hosp affiliated hosp of nanjing univ med, nanjing, jiangsu, china jiangsu province cancer hospital, nanjing, jiangsu, china dalian med. univ. no 2 affiliate hospital, dalian, liao ning, china liaoning cander hospital&institute, shenyang, liaoning, china the first hospital of china medical university, shenyang, liaoning, china the first affiliated hospital with nanjing medical universit, nanjing, nanjing, china first affiliated hospital of medical college, xi'an jiaotong, xi'an, shaanxi, china zhejiang cancer hospital, hang zhou, zhejiang, china second affiliate hospital of zhejiang medical university, hangzhou, zhejiang, china beijing tumor hospital, beijing, china shanghai tumor hospital, shanghai, china shanghai first people's hospital, shanghai, china tianjin medical university cancer institute & hospital, tianjin, china dr. b. l. kapur memorial hospital, new delhi, delhi, india the gujarat cancer & research institute (gcri), ahmedabad, gujarat, india m s ramaiah medical college hospital, bangalore, karnataka, india healthcare global enterprises limited (hcg), bangalore, karnataka, india tata memorial hospital, mumbai, maharashtra, india jehangir hospital, pune, maharashtra, india christian medical college and hospital, vellore, tamil nadu, india medica superspecialty hospital, kolkata, west bengal, india the medical oncology centre of rosebank, johannesburg, gauteng, south africa eastleigh breast care center, pretoria, gauteng, south africa sandton oncology centre, johannesburg, south africa""]","""study protocol"", https://clinicaltrials.gov/provideddocs/66/nct02763566/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/66/nct02763566/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02763566,breast
248,249,NCT00667251,chemotherapy and lapatinib or trastuzumab in treating women with her2/neu-positive metastatic breast cancer,,"Active, not recruiting",Has Results,breast cancer,biological: trastuzumab|drug: docetaxel|drug: lapatinib ditosylate|drug: paclitaxel,"progression-free survival|overall survival|time to cns metastases at the time of first progression|cns metastases at the time of progression (itt)|cns metastases at the time of progression (her2+)|overall objective response rate (complete or partial) itt|overall objective response rate (complete or partial) her2/neu+|clinical benefit response rate (itt)|clinical benefit response rate (her2/neu+))|quality of life as measured by the eortc qlq-c30 global score from baseline to 12 weeks|effects of changes in biomarkers on clinical outcomes|economic evaluation, including health utilities, as measured by the eq-5d questionnaire, and healthcare utilization",novartis pharmaceuticals|ncic clinical trials group|novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,652.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,108919|CLAP016A2303|CAN-NCIC-MA31|2007-004568-27|CDR0000594764|EGF108919,"October 7, 2008","August 1, 2012","December 31, 2022","April 28, 2008","June 18, 2014","March 10, 2022","['novartis investigative site, anchorage, alaska, united states novartis investigative site, tucson, arizona, united states novartis investigative site, hot springs, arkansas, united states novartis investigative site, berkeley, california, united states novartis investigative site, highland, california, united states novartis investigative site, montebello, california, united states novartis investigative site, colorado springs, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, greenwich, connecticut, united states novartis investigative site, southington, connecticut, united states novartis investigative site, stamford, connecticut, united states novartis investigative site, trumbull, connecticut, united states novartis investigative site, waterbury, connecticut, united states novartis investigative site, kissimmee, florida, united states novartis investigative site, loxahatchee groves, florida, united states novartis investigative site, new port richey, florida, united states novartis investigative site, augusta, georgia, united states novartis investigative site, lawrenceville, georgia, united states novartis investigative site, savannah, georgia, united states novartis investigative site, post falls, idaho, united states novartis investigative site, chicago, illinois, united states novartis investigative site, oak lawn, illinois, united states novartis investigative site, evansville, indiana, united states novartis investigative site, goshen, indiana, united states novartis investigative site, indianapolis, indiana, united states novartis investigative site, munster, indiana, united states novartis investigative site, new albany, indiana, united states novartis investigative site, towson, maryland, united states novartis investigative site, wheaton, maryland, united states novartis investigative site, bozeman, montana, united states novartis investigative site, grand island, nebraska, united states novartis investigative site, kearney, nebraska, united states novartis investigative site, kearney, nebraska, united states novartis investigative site, denville, new jersey, united states novartis investigative site, parsippany, new jersey, united states novartis investigative site, cooperstown, new york, united states novartis investigative site, greensboro, north carolina, united states novartis investigative site, canton, ohio, united states novartis investigative site, wooster, ohio, united states novartis investigative site, portland, oregon, united states novartis investigative site, pittsburgh, pennsylvania, united states novartis investigative site, columbia, south carolina, united states novartis investigative site, memphis, tennessee, united states novartis investigative site, chesapeake, virginia, united states novartis investigative site, salem, virginia, united states novartis investigative site, bellevue, washington, united states novartis investigative site, kirkland, washington, united states novartis investigative site, mount vernon, washington, united states novartis investigative site, seattle, washington, united states novartis investigative site, sequim, washington, united states novartis investigative site, tacoma, washington, united states novartis investigative site, wenatchee, washington, united states novartis investigative site, milwaukee, wisconsin, united states novartis investigative site, capital federal, buenos aires, argentina novartis investigative site, capital federal, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, la plata, buenos aires, argentina novartis investigative site, cipolletti, río negro, argentina novartis investigative site, viedma, río negro, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, santa fe, argentina novartis investigative site, tucuman, argentina novartis investigative site, garran, australian capital territory, australia novartis investigative site, liverpool, new south wales, australia novartis investigative site, north sydney, new south wales, australia novartis investigative site, tweed heads, new south wales, australia novartis investigative site, woolloongabba, queensland, australia novartis investigative site, adelaide, south australia, australia novartis investigative site, bedford park, south australia, australia novartis investigative site, kurralta park, south australia, australia novartis investigative site, hobart, tasmania, australia novartis investigative site, box hill, victoria, australia novartis investigative site, fitzroy, victoria, australia novartis investigative site, wodonga, victoria, australia novartis investigative site, subiaco, western australia, australia novartis investigative site, gent, belgium novartis investigative site, jette, belgium novartis investigative site, liege, belgium novartis investigative site, namur, belgium novartis investigative site, edmonton, alberta, canada novartis investigative site, kelowna, british columbia, canada novartis investigative site, surrey, british columbia, canada novartis investigative site, vancouver, british columbia, canada novartis investigative site, victoria, british columbia, canada novartis investigative site, winnipeg, manitoba, canada novartis investigative site, moncton, new brunswick, canada novartis investigative site, saint john, new brunswick, canada novartis investigative site, barrie, ontario, canada novartis investigative site, hamilton, ontario, canada novartis investigative site, kingston, ontario, canada novartis investigative site, london, ontario, canada novartis investigative site, newmarket, ontario, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, sault ste. marie, ontario, canada novartis investigative site, st catharines, ontario, canada novartis investigative site, sudbury, ontario, canada novartis investigative site, thunder bay, ontario, canada novartis investigative site, charlottetown, prince edward island, canada novartis investigative site, montreal, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, regina, saskatchewan, canada novartis investigative site, saskatoon, saskatchewan, canada novartis investigative site, quebec, canada novartis investigative site, angers, france novartis investigative site, bordeaux, france novartis investigative site, bordeaux, france novartis investigative site, caen cedex 05, france novartis investigative site, marseille cedex 9, france novartis investigative site, metz-tessy, france novartis investigative site, nantes cedex, france novartis investigative site, paris, france novartis investigative site, strasbourg, france novartis investigative site, heidelberg, baden-wuerttemberg, germany novartis investigative site, stuttgart, baden-wuerttemberg, germany novartis investigative site, coburg, bayern, germany novartis investigative site, eggenfelden, bayern, germany novartis investigative site, fuerth, bayern, germany novartis investigative site, regensburg, bayern, germany novartis investigative site, rosenheim, bayern, germany novartis investigative site, weiden, bayern, germany novartis investigative site, fuerstenwalde, brandenburg, germany novartis investigative site, frankfurt, hessen, germany novartis investigative site, fulda, hessen, germany novartis investigative site, lich, hessen, germany novartis investigative site, goslar, niedersachsen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, leer, niedersachsen, germany novartis investigative site, bielefeld, nordrhein-westfalen, germany novartis investigative site, bonn, nordrhein-westfalen, germany novartis investigative site, coesfeld, nordrhein-westfalen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, koeln, nordrhein-westfalen, germany novartis investigative site, porta westfalica, nordrhein-westfalen, germany novartis investigative site, troisdorf, nordrhein-westfalen, germany novartis investigative site, velbert, nordrhein-westfalen, germany novartis investigative site, witten, nordrhein-westfalen, germany novartis investigative site, koblenz, rheinland-pfalz, germany novartis investigative site, saarbruecken, saarland, germany novartis investigative site, halle, sachsen-anhalt, germany novartis investigative site, dresden, sachsen, germany novartis investigative site, luebeck, schleswig-holstein, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, brandenburg, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, bangalore, india novartis investigative site, nagpur, india novartis investigative site, pune, india novartis investigative site, beer-sheva, israel novartis investigative site, holon, israel novartis investigative site, petah-tikva, israel novartis investigative site, poriya, israel novartis investigative site, ramat gan, israel novartis investigative site, aviano (pn), friuli-venezia-giulia, italy novartis investigative site, roma, lazio, italy novartis investigative site, sora (fr), lazio, italy novartis investigative site, genova, liguria, italy novartis investigative site, lecce, puglia, italy novartis investigative site, sassari, sardegna, italy novartis investigative site, prato (po), toscana, italy novartis investigative site, chieti, italy novartis investigative site, aichi, japan novartis investigative site, chiba, japan novartis investigative site, ehime, japan novartis investigative site, kagoshima, japan novartis investigative site, kanagawa, japan novartis investigative site, osaka, japan novartis investigative site, osaka, japan novartis investigative site, saitama, japan novartis investigative site, saitama, japan novartis investigative site, shizuoka, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, gyeonggi-do, korea, republic of novartis investigative site, gyeonggi-do, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, songpa-gu, seoul, korea, republic of novartis investigative site, cuernavaca, morelos, mexico novartis investigative site, ciudad obregon, sonora, mexico novartis investigative site, mexico city, mexico novartis investigative site, amsterdam, netherlands novartis investigative site, delft, netherlands novartis investigative site, dordrecht, netherlands novartis investigative site, maastricht, netherlands novartis investigative site, gdansk, poland novartis investigative site, lodz, poland novartis investigative site, olsztyn, poland novartis investigative site, olsztyn, poland novartis investigative site, plock, poland novartis investigative site, rzeszow, poland novartis investigative site, warszawa, poland novartis investigative site, warszawa, poland novartis investigative site, arkhangelsk, russian federation novartis investigative site, ivanovo, russian federation novartis investigative site, kazan, russian federation novartis investigative site, kirov, russian federation novartis investigative site, lipetsk, russian federation novartis investigative site, moscow, russian federation novartis investigative site, ryazan, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, stavropol, russian federation novartis investigative site, ufa,, russian federation novartis investigative site, ufa, russian federation novartis investigative site, alcorcon, spain novartis investigative site, alicante, spain novartis investigative site, badalona, spain novartis investigative site, barcelona, spain novartis investigative site, elche, spain novartis investigative site, girona, spain novartis investigative site, jaen, spain novartis investigative site, la coruna, spain novartis investigative site, lugo, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, majadahonda (madrid), spain novartis investigative site, pozuelo de alarcon (madrid), spain novartis investigative site, sevilla, spain novartis investigative site, valencia, spain novartis investigative site, changhua, taiwan novartis investigative site, taichung, taiwan novartis investigative site, tainan county, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, bangkok, thailand novartis investigative site, chiangmai, thailand novartis investigative site, dnepropetrovsk, ukraine novartis investigative site, dnipropetrovsk, ukraine novartis investigative site, lviv, ukraine novartis investigative site, sumy, ukraine novartis investigative site, bournemouth, united kingdom novartis investigative site, brighton, united kingdom novartis investigative site, chelmsford, united kingdom novartis investigative site, cheltenham, united kingdom novartis investigative site, colchester, united kingdom novartis investigative site, cottingham, hull, united kingdom novartis investigative site, derby, united kingdom novartis investigative site, edmonton, united kingdom novartis investigative site, guildford, united kingdom novartis investigative site, harrogate, united kingdom novartis investigative site, huddersfield, united kingdom novartis investigative site, london, united kingdom novartis investigative site, newcastle upon tyne, united kingdom novartis investigative site, norwich, united kingdom novartis investigative site, nottingham, united kingdom novartis investigative site, oxford, united kingdom novartis investigative site, poole, dorset, united kingdom novartis investigative site, sheffield, united kingdom novartis investigative site, shrewsbury, united kingdom novartis investigative site, sutton, united kingdom novartis investigative site, whitchurch, cardiff, united kingdom novartis investigative site, york, united kingdom']",,https://ClinicalTrials.gov/show/NCT00667251,breast
249,250,NCT03256916,radiosensitizing effect of nelfinavir in locally advanced carcinoma of cervix,NELCER,Recruiting,No Results Available,"carcinoma cervix,stage iii",drug: nelfinavir|drug: cisplatin|radiation: pelvic ebrt and brachytherapy,improvement in 3 year disease free survival|change in locoregional control rates at 3 years|overall survival at 5 years|incidence of grade 3/4 adverse events|changes in akt levels in the tumor|change in tumour hypoxia using multifunctional pet/ mri.|interindividual variability of volume of distribution|interindividual variability of clearance of nelfinavir.|interindividual variability of clearence of nelfinavir,tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,348.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMH Project 1543,"January 16, 2018","September 30, 2025","September 30, 2025","August 22, 2017",,"February 21, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03256916,cervix
250,251,NCT03433313,efficacy and safety study of eg12014 compared with herceptin in subjects with her2 positive early breast cancer,,Unknown status,No Results Available,breast cancer,drug: eg12014|drug: herceptin,determination of pathologic complete response (pcr) at time of surgery|pcr at the time of surgery|event-free survival (efs) up to end of study (eos)|overall response (or) prior to surgery|overall survival (os) up to end of study (eos)|incidence of aes|evaluation of immunogenicity of eg12014 and herceptin|measure serum trastuzumab concentration,"eirgenix, inc.",Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,800.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EGC002|2017-003973-33,"October 16, 2018","November 3, 2020","January 11, 2022","February 14, 2018",,"April 6, 2020","['detroit clinical research center, farmington hills, michigan, united states aultman hospital, cancer center, canton, ohio, united states brest regional oncology center, brest, belarus gomel regional clinical oncology center, gomel, belarus n.n. aleksandrov republican research oncology and medical radiology center, lesnoy, belarus minsk city clinical oncology center, minsk, belarus mogilev regional oncology center, mogilev, belarus vitebsk regional clinical oncology center, vitebsk, belarus medical research limited society, temuco, chile oncocentro apys, viña del mar, chile clinic life foundation, medellín, colombia rodrigo botero sas, medellín, colombia ltd high-tech hospital medcenter, batumi, georgia jsc ""evex hospitals, kutaisi, georgia ltd acad. f. todua medical center - ltd research institute of clinical medicine, tbilisi, georgia ltd aversi clinic, tbilisi, georgia ltd cancer research centre, tbilisi, georgia ltd health house, tbilisi, georgia ltd institute of clinical oncology, tbilisi, georgia ltd s.khechinashvili university hospital, tbilisi, georgia malkhaz katsiashvili multiprofile emergency medicine center, tbilisi, georgia cytecare cancer hospitals, bengaluru, india king george\'s medical university, department of endocrine surgery, shatabdi phase ii, lucknow, india tata memorial centre, mumbai, india hcg nchri cancer centre, nagpur, india christian medical college, department of medical oncology, vellore, india keimyung university - dongsan medical center, daegu, korea, republic of arkhangelsk clinical oncology center, arkhangel\'sk, russian federation chelyabinsk regional clinical oncology and nuclear medicine center, chelyabinsk, russian federation evimed, llc, chelyabinsk, russian federation ivanovo regional oncology center, ivanovo, russian federation republican clinical oncology center, kazan, russian federation krasnoyarsk a.i. kryzhanovsky regional oncology center, krasnoyarsk, russian federation kursk regional clinical oncology center, kursk, russian federation n.n. blokhin national medical oncology research center, moscow, russian federation national medical research center for radiology, moscow, russian federation vitamed"" llc, moscow, russian federation a.f.tsyb medical radiology research center, obninsk, russian federation clinical oncology center, omsk, russian federation pyatigorsk interdistrict oncology center, pyatigorsk, russian federation rostov oncology research institute, rostov-on-don, russian federation regional clinical oncology center, ryazan\', russian federation av medical group, saint petersburg, russian federation city clinical oncology center, saint petersburg, russian federation clinic ""mart"", saint petersburg, russian federation i.i. mechnikov north-western state medical university, saint petersburg, russian federation leningrad regional oncology center (outpatient department), saint petersburg, russian federation leningrad regional oncology center (surgery department), saint petersburg, russian federation n.n. petrov national medical research center of oncology, saint petersburg, russian federation oncology center of moskovskiy district, saint petersburg, russian federation private medical institution ""evromedservis"", department of oncology, saint petersburg, russian federation st. petersburg clinical research and practical center for specialized types of medical care (oncology), saint petersburg, russian federation republican oncology center, saransk, russian federation oncology center #2, sochi, russian federation tomsk national research medical center, tomsk, russian federation regional clinical oncology center, veliky novgorod, russian federation volgograd regional clinical oncology center, volgograd, russian federation gvi oncology, cape gate oncology centre, cape town, south africa the oncology centre, durban, south africa medical oncology centre of rosebank, johannesburg, south africa little company of mary medical center, department of oncology, pretoria, south africa university of pretoria, department of medical oncology, pretoria, south africa kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan china medical university hospital, taichung, taiwan national taiwan university hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan tri-service general hospital, taipei, taiwan linkou chang gung memorial hospital, taoyuan, taiwan chernihiv regional oncology center, chernihiv, ukraine chernivtsi regional clinical oncology center, chernivtsi, ukraine clinical oncology center, dnipro, ukraine dnipropetrovsk city multispecialty clinical hospital #4, department of chemotherapy, dnipro, ukraine prikarpattia clinical oncology center, ivano-frankivsk, ukraine communal non-profit enterprise ""regional center of oncology"", kharkiv, ukraine state institution: s.p. hryhoriev institute of medical radiology under the ukrainian academy of medical sciences, department of clinical oncology and hematology, kharkiv, ukraine khmelnytskyi regional oncology center, khmelnytskyi, ukraine kryvyi rih oncology center, department of chemotherapy, kryvyi rih, ukraine kyiv city clinical hospital #2, kyiv, ukraine kyiv regional oncology center, department of mastology, kyiv, ukraine medical center ""verum"", kyiv, ukraine medical center of first private clinic, kyiv, ukraine volyn regional oncology center, department of chemotherapy, luts\'k, ukraine public institution under lviv regional council: lviv regional treatment and diagnostics oncology center, department of chemotherapy, lviv, ukraine mariupol oncology center, mariupol, ukraine odesa regional clinical hospital, center for mastology, department of thoracic surgery, odesa, ukraine odesa regional oncology center, odesa, ukraine ternopil regional clinical oncology center, department of chemotherapy, ternopil\', ukraine central city clinical hospital, department of oncology and radiology, uzhhorod, ukraine zakarpattia regional clinical oncology center, department of chemotherapy, uzhhorod, ukraine podillia regional oncology center, vinnytsia, ukraine zhytomyr regional oncology center, zhytomyr, ukraine']",,https://ClinicalTrials.gov/show/NCT03433313,breast
251,252,NCT04494425,"study of trastuzumab deruxtecan (t-dxd) vs investigator's choice chemotherapy in her2-low, hormone receptor positive, metastatic breast cancer",DB-06,Recruiting,No Results Available,advanced or metastatic breast cancer,drug: trastuzumab deruxtecan|drug: capecitabine|drug: paclitaxel|drug: nab-paclitaxel,"progression free survival (pfs) - in hr+, her2-low populaton|overall survival (os) - in hr+, her2-low population|progression free survival (pfs) - in intent to treat (itt) population (her2-low and her2 ihc >0<1+)|overall survival - in intent to treat (itt) population (her2-low and her2 ihc >0<1+)|objective response rate (orr) in hr+, her-2 low populaton|duration of response (dor) - in hr+, her-2 low populaton|progression free survival by investigator assessment - in the hr+, her2-low population|objective response rate (orr) in the itt population|duration of response (dor) - in the itt population|pfs2 by investigator assessment, time to first subsequent therapy (tfst) and time to second subsequent treatment or death (tsst) - in hr+, her2-low and the itt population|safety and tolerability of drugs; number of adverse events (aes)|serum concentration of trastuzumab deruxtecan|immunogenicity of trastuzumab deruxtecan|health-related quality of life - eortc-qlq-c30|time to deterioration in eortc-qlq-c30 scores|health-related quality of life - eortc qlq-br45","astrazeneca|daiichi sankyo company, limited 3-5-1 nihonbashihoncho, chuo-ku, tokyo",All,"18 Years to 105 Years   (Adult, Older Adult)",Phase 3,850.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D9670C00001,"July 24, 2020","June 30, 2023","October 30, 2025","July 31, 2020",,"April 21, 2022","[""research site, birmingham, alabama, united states research site, scottsdale, arizona, united states research site, springdale, arkansas, united states research site, duarte, california, united states research site, los angeles, california, united states research site, san marcos, california, united states research site, santa rosa, california, united states research site, aurora, colorado, united states research site, lakewood, colorado, united states research site, washington, district of columbia, united states research site, jacksonville, florida, united states research site, kansas city, kansas, united states research site, louisville, kentucky, united states research site, bethesda, maryland, united states research site, boston, massachusetts, united states research site, boston, massachusetts, united states research site, ann arbor, michigan, united states research site, detroit, michigan, united states research site, rochester, minnesota, united states research site, saint louis, missouri, united states research site, camden, new jersey, united states research site, summit, new jersey, united states research site, voorhees, new jersey, united states research site, bronx, new york, united states research site, rochester, new york, united states research site, westbury, new york, united states research site, columbus, ohio, united states research site, pittsburgh, pennsylvania, united states research site, providence, rhode island, united states research site, germantown, tennessee, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, dallas, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, kingwood, texas, united states research site, spring, texas, united states research site, norfolk, virginia, united states research site, issaquah, washington, united states research site, seattle, washington, united states research site, madison, wisconsin, united states research site, milwaukee, wisconsin, united states research site, berazategui, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, ciudad autonoma de buenos aire, argentina research site, ciudad de buenos aires, argentina research site, cordoba, argentina research site, la plata, argentina research site, mar del plata, argentina research site, rosario, argentina research site, rosario, argentina research site, rosario, argentina research site, salta, argentina research site, san miguel de tucumán, argentina research site, san salvador de jujuy, argentina research site, adelaide, australia research site, auchenflower, australia research site, birtinya, australia research site, concord, australia research site, darlinghurst, australia research site, fitzroy, australia research site, frankston, australia research site, hobart, australia research site, melbourne, australia research site, murdoch, australia research site, south brisbane, australia research site, st leonards, australia research site, waratah, australia research site, graz, austria research site, innsbruck, austria research site, wien, austria research site, wien, austria research site, anderlecht, belgium research site, bruges, belgium research site, bruxelles, belgium research site, charleroi, belgium research site, edegem, belgium research site, gent, belgium research site, hasselt, belgium research site, leuven, belgium research site, liège, belgium research site, namur, belgium research site, roeselare, belgium research site, sint-niklaas, belgium research site, wilrijk, belgium research site, barretos, brazil research site, belo horizonte, brazil research site, fortaleza, brazil research site, natal, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sorocaba, brazil research site, são paulo, brazil research site, são paulo, brazil research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, vancouver, british columbia, canada research site, toronto, ca, canada research site, london, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, sherbrooke, quebec, canada research site, baoding, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changchun, china research site, changsha, china research site, changsha, china research site, changsha, china research site, changzhou, china research site, chengdu, china research site, chongqing, china research site, dalian, china research site, foshan, china research site, fuzhou, china research site, fuzhou, china research site, fuzhou, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, haerbin, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hefei, china research site, jinan, china research site, lanzhou, china research site, lanzhou, china research site, linyi, china research site, nanchang, china research site, nanchang, china research site, nanchang, china research site, nanjing, china research site, nanning, china research site, qingdao, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, shenyang, china research site, suzhou, china research site, tianjin, china research site, urumqi, china research site, wuhan, china research site, wuxi, china research site, xi'an, china research site, xi'an, china research site, xi'an, china research site, zhengzhou, china research site, aalborg, denmark research site, aarhus, denmark research site, copenhagen ø, denmark research site, naestved, denmark research site, odense c, denmark research site, vejle, denmark research site, avignon cedex 09, france research site, besançon, france research site, bordeaux, france research site, brest, france research site, caen cedex 05, france research site, dijon, france research site, le mans, france research site, marseille, france research site, montpellier, france research site, nice, france research site, paris, france research site, pierre benite, france research site, plerin sur mer, france research site, rennes, france research site, saint herblain cedex, france research site, saint-cloud, france research site, tours, france research site, villejuif cedex, france research site, berlin, germany research site, dresden, germany research site, freiburg, germany research site, hamburg, germany research site, hannover, germany research site, leipzig, germany research site, münchen, germany research site, münchen, germany research site, münster, germany research site, tübingen, germany research site, velbert, germany research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, győr, hungary research site, kaposvár, hungary research site, kecskemét, hungary research site, miskolc, hungary research site, nyíregyháza, hungary research site, szolnok, hungary research site, tatabánya, hungary research site, veszprém, hungary research site, amritsir, india research site, bangalore, india research site, bangalore, india research site, bengaluru, india research site, calicut, india research site, hyderabad, india research site, kolkata, india research site, kolkata, india research site, mumbai, india research site, mumbai, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, thiruvananthapuram, india research site, haifa, israel research site, jerusalem, israel research site, jerusalem, israel research site, kfar-saba, israel research site, petah tikva, israel research site, ramat gan, israel research site, tel-aviv, israel research site, aviano, italy research site, bergamo, italy research site, candiolo, italy research site, cona, italy research site, genova, italy research site, livorno, italy research site, messina, italy research site, milano, italy research site, milano, italy research site, milan, italy research site, napoli, italy research site, padova, italy research site, parma, italy research site, perugia, italy research site, prato, italy research site, rozzano, italy research site, tricase, lecce, italy research site, udine, italy research site, akashi-shi, japan research site, bunkyo-ku, japan research site, chiba-shi, japan research site, chuo-ku, japan research site, fukuoka-shi, japan research site, gifu-shi, japan research site, hidaka-shi, japan research site, hiroshima-shi, japan research site, isehara, japan research site, kagoshima-shi, japan research site, kashiwa, japan research site, kawasaki-shi, japan research site, kitaadachi-gun, japan research site, koto-ku, japan research site, matsuyama-shi, japan research site, nagoya-shi, japan research site, nagoya, japan research site, naha-shi, japan research site, niigata-shi, japan research site, nishinomiya-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sagamihara-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shinagawa-ku, japan research site, shinjuku-ku, japan research site, shizuoka, japan research site, tsu-shi, japan research site, yokohama-shi, japan research site, daegu, korea, republic of research site, goyang-si, korea, republic of research site, incheon, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, alc. cuauhtémoc, mexico research site, cdmx, mexico research site, guadalajara jalisco, mexico research site, guadalajra, mexico research site, león, mexico research site, mexico city, mexico research site, mexico city, mexico research site, mexico, d.f., mexico research site, monterrey, mexico research site, méxico, mexico research site, nuevo leon, mexico research site, tuxtla gutierrez, mexico research site, amsterdam, netherlands research site, breda, netherlands research site, hengelo, netherlands research site, leeuwarden, netherlands research site, rotterdam, netherlands research site, sittard-geleen, netherlands research site, bydgoszcz, poland research site, koszalin, poland research site, kraków, poland research site, lublin, poland research site, rzeszów, poland research site, warszawa, poland research site, wroclaw, poland research site, łódź, poland research site, łódź, poland research site, lisboa, portugal research site, lisboa, portugal research site, lisboa, portugal research site, lisboa, portugal research site, lisboa, portugal research site, loures, portugal research site, porto, portugal research site, arkhangelsk, russian federation research site, kaluga, russian federation research site, kazan, russian federation research site, krasnodar, russian federation research site, krasnodar, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, sankt-peterburg, russian federation research site, sochi, russian federation research site, yaroslavl, russian federation research site, ar riyāḑ, saudi arabia research site, dammam, saudi arabia research site, jeddah, saudi arabia research site, jeddah, saudi arabia research site, makkah, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, bukit merah, singapore research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, barcelona, spain research site, barcelona, spain research site, barcelona, spain research site, cordoba, spain research site, el palmar, spain research site, la coruña, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, san sebastián, spain research site, sevilla, spain research site, valencia, spain research site, göteborg, sweden research site, stockholm, sweden research site, umeå, sweden research site, uppsala, sweden research site, växjö, sweden research site, örebro, sweden research site, taichung, taiwan research site, tainan, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, birmingham, united kingdom research site, cambridge, united kingdom research site, cardiff, united kingdom research site, colchester, united kingdom research site, coventry, united kingdom research site, edinburgh, united kingdom research site, exeter, united kingdom research site, glasgow, united kingdom research site, guildford, united kingdom research site, leeds, united kingdom research site, leicester, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, northwood, united kingdom research site, plymouth, united kingdom research site, truro, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04494425,breast
252,253,NCT01783444,a phase ii study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in advance breast cancer.,BOLERO-6,Completed,Has Results,breast cancer,drug: capecitabine|drug: exemestane|drug: everolimus,progression free survival (pfs) - everolimus plus exemestane versus everolimus alone|progression free survival (pfs) - everolimus plus exemestane versus capecitabine alone|overall survival (os)|overall response rate (orr)|clinical benefit rate (cbr)|time to eastern cooperative oncology group (ecog) performance deterioration|time to 10% definitive deterioration in the global health status / quality of life|mean change in treatment satisfaction questionnaire for medication (tsqm) between week 3 and 12,novartis pharmaceuticals|novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,309.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRAD001Y2201|2012-003757-28,"February 26, 2013","July 2, 2018","July 30, 2018","February 5, 2013","February 26, 2021","February 26, 2021","[""university of california at los angeles mattel children's hospital, los angeles, california, united states sharp memorial hospital sharpclinicaloncologyresearch, san diego, california, united states florida cancer specialists dept of oncology (2), fort myers, florida, united states florida cancer specialists fl cancer specialists, fort myers, florida, united states lahey clinic dept of lahey clinic (2), burlington, massachusetts, united states new england hematology/ oncology associates, p.c. sc, newton, massachusetts, united states glacier view research institute - cancer sc, kalispell, montana, united states trinitas comprehensive cancer center sc, elizabeth, new jersey, united states hackensack university medical center dept of oncology, hackensack, new jersey, united states rutgers-new jersey medical school sc, newark, new jersey, united states oncology hematology care inc oncology hematology care 2, cincinnati, ohio, united states oklahoma cancer specialists and research institute oklahoma cancer specialists, tulsa, oklahoma, united states chattanooga oncology and hematology assoicates, pc chattanooga oncology, chattanooga, tennessee, united states the jones clinic sc, germantown, tennessee, united states university of tennessee sc, knoxville, tennessee, united states sarah cannon research institute sc (2), nashville, tennessee, united states the center for cancer and blood disorders dept. of the ctr for c & bd, fort worth, texas, united states university of virginia health systems sc-4, charlottesville, virginia, united states northwest medical specialties dept of onc, tacoma, washington, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, posadas, misiones, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, rio negro, viedma, argentina novartis investigative site, cordoba, argentina novartis investigative site, randwick, new south wales, australia novartis investigative site, wahroonga, new south wales, australia novartis investigative site, malvern, victoria, australia novartis investigative site, parkville, victoria, australia novartis investigative site, liege, belgium novartis investigative site, salvador, ba, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, natal, rn, brazil novartis investigative site, passo fundo, rs, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, aarhus, denmark novartis investigative site, copenhagen, denmark novartis investigative site, næstved, denmark novartis investigative site, odense c, denmark novartis investigative site, roskilde, denmark novartis investigative site, vejle, denmark novartis investigative site, budapest, hun, hungary novartis investigative site, debrecen, hungary novartis investigative site, tatabanya, hungary novartis investigative site, hyderabad, andhra pradesh, india novartis investigative site, pune, maharashtra, india novartis investigative site, kolkatta, west bengal, india novartis investigative site, mumbai, india novartis investigative site, limerick, co limerick, ireland novartis investigative site, dublin 4, ireland novartis investigative site, galway, ireland novartis investigative site, ashrafieh, lebanon novartis investigative site, beirut, lebanon novartis investigative site, beirut, lebanon novartis investigative site, hazmieh, lebanon novartis investigative site, saida, lebanon novartis investigative site, kota kinabalu, sabah, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, jesus maria, lima, peru novartis investigative site, san borja, lima, peru novartis investigative site, surquillo, lima, peru novartis investigative site, arequipa, peru novartis investigative site, arkhangelsk, russian federation novartis investigative site, moscow, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, sevilla, andalucia, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, eskilstuna, sweden novartis investigative site, joenkoeping, sweden novartis investigative site, stockholm, sweden novartis investigative site, uppsala, sweden novartis investigative site, vasteras, sweden novartis investigative site, vaxjo, sweden novartis investigative site, songkhla, hat yai, thailand novartis investigative site, muang lopburi, lopburi, thailand novartis investigative site, muang, thailand novartis investigative site, adana, turkey novartis investigative site, istanbul, turkey novartis investigative site, izmir, turkey novartis investigative site, east kilbride, united kingdom novartis investigative site, middlesborough, united kingdom novartis investigative site, nottingham, united kingdom""]","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/44/nct01783444/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/44/nct01783444/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01783444,breast
253,254,NCT04961996,"a study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in participants with estrogen receptor-positive, her2-negative early breast cancer (lidera breast cancer)",,Recruiting,No Results Available,early breast cancer,drug: giredestrant|drug: endocrine therapy of physician's choice|drug: lhrh agonist,"invasive disease-free survival (idfs), excluding second primary non-breast cancers|overall survival|invasive disease-free survival (idfs), including second primary non-breast cancers|disease-free survival (dfs)|distant recurrence-free interval (drfi)|locoregional recurrence-free interval (lrrfi)|mean physical functioning scale score at specified timepoints, assessed using the european organisation for the research and treatment of cancer quality of life questionnaire (eortc qlq-c30)|change from baseline in the mean physical functioning scale score at specified timepoints, assessed using the eortc qlq-c30|mean role functioning scale score at specified timepoints, assessed using the eortc qlq-c30|change from baseline in the mean role functioning scale score at specified timepoints, assessed using the eortc qlq-c30|mean global health status/quality of life (qol) scale score at specified timepoints, assessed using the eortc qlq-c30|change from baseline in the mean global health status/quality of life (qol) scale score at specified timepoints, assessed using the eortc qlq-c30|change from baseline in the eq 5d-5l index-based score at specified timepoints|change from baseline in the eq 5d-5l visual analogue scale (vas) score at specified timepoints|incidence and severity of adverse events, with severity determined according to national cancer institute common terminology criteria for adverse events, version 5.0 (nci-ctcae v5.0)|plasma concentrations of giredestrant at specified timepoints",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,4100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO42784|2021-000129-28,"August 27, 2021","December 19, 2025","November 21, 2033","July 14, 2021",,"May 2, 2022","['southern cancer center, daphne, alabama, united states cbcc global research inc., at comprehensive blood and cancer center, bakersfield, california, united states cancer and blood specialty clinic, fountain valley, california, united states sansum clinic, santa barbara, california, united states ucla hematology/oncology, santa monica, california, united states st joseph heritage healthcare, santa rosa, california, united states torrance memorial physician network/cancer care, torrance, california, united states valley breast care and women\'s health center, van nuys, california, united states rocky mountain cancer centers (longmont) - usor, longmont, colorado, united states stamford hospital; clincal trials office - 1st fl - bennett cancer cente, stamford, connecticut, united states memorial healthcare system - memorial regional hospital, hollywood, florida, united states mount sinai comprehensive cancer center, miami beach, florida, united states university of illinois at chicago, chicago, illinois, united states joliet oncology hematology associates, ltd., joliet, illinois, united states cancer center of kansas - kingman, kingman, kansas, united states lahey clinic med ctr, lexington, kentucky, united states maryland oncology hematology (bethesda) - usor, bethesda, maryland, united states massachusetts general hospital; lurie center for autism, lexington, massachusetts, united states st. vincent frontier cancer center, billings, montana, united states comprehensive cancer centers of nevada, las vegas, nevada, united states hunterdon hematology oncology, flemington, new jersey, united states rutgers cancer institute of new jersey, new brunswick, new jersey, united states oncology hematology care inc, cincinnati, ohio, united states oncology associates of oregon, p.c.; willamette valley cancer institute, springfield, oregon, united states northwest cancer specialists, p.c., tigard, oregon, united states texas oncology, p.a. - el paso; west, el paso, texas, united states texas oncology (flower mound) - usor, flower mound, texas, united states texas oncology-fort worth cancer center, fort worth, texas, united states nebraska cancer specialists, fort worth, texas, united states texas oncology (mcallen) - usor, mcallen, texas, united states texas oncology mckinney, mckinney, texas, united states usor - texas oncology - san antonio northeast, san antonio, texas, united states texas oncology (tyler) - usor, tyler, texas, united states texas oncology (waco) - usor, waco, texas, united states virginia oncology associates, norfolk, virginia, united states fundación cenit para la investigación en neurociencias, buenos aires, argentina border medical oncology research unit, albury, new south wales, australia bankstown-lidcombe hospital, bankstown, new south wales, australia campbelltown hospital; macarthur cancer therapy centre, campbelltown, new south wales, australia kinghorn cancer centre; pharmacy department, darlinghurst, new south wales, australia mater hospital; patricia ritchie centre for cancer care and research, north sydney, new south wales, australia westmead hospital; pharmacy distribution centre, northmead, new south wales, australia north coast cancer institute - port macquarie, port macquarie, new south wales, australia nepean cancer care centre, sydney, new south wales, australia wesley medical centre; clinic for haematology and oncology, auchenflower, queensland, australia cairns hospital; renal services, crains, queensland, australia princess alexandra hospital, woolloongabba, queensland, australia st andrews medical centre, adelaide, south australia, australia flinders medical centre, bedford park, south australia, australia adelaide cancer centre, kurralta park, south australia, australia icon cancer care hobart, hobart, tasmania, australia victorian breast and oncology care, east melbourne, victoria, australia frankston hospital; oncology/haematology, frankston, victoria, australia sunshine hospital, st albans, victoria, australia south west oncology, warrnambool, victoria, australia ballarat oncology & haematology, wendouree, victoria, australia lkh-universitätsklinikum klinikum graz, graz, austria medizinische universitat innsbruck; department of internal medicine, pneumology centre, innsbruck, austria lkh rankweil, interne e, rankweil, austria universitätsklinikum salzburg, salzburg, austria universitätsklinikum st. pölten; klinische abteilung für innere medizin 1, st. pölten, austria oö. gesundheits- und spitals-ag/lkh steyr, steyr, austria klinikum wels-grieskirchen gmbh, wels, austria institute jules bordet; med onc & translational rsch, belgium, belgium cliniques universitaires saint-luc, bruxelles, belgium grand hopital de charleroi asbl, charleroi, belgium uz antwerpen, edegem, belgium chu sart tilman; immunologie & transplantation, liege, belgium centre hospitalier chrétien montlégia, liège, belgium hospital mae de deus, porto alegre, rs, brazil clinica de pesquisas e centro de estudos oncologia ginecologica e mamaria ltda, são paulo, sp, brazil tom baker cancer centre-calgary, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada british columbia cancer agency, vancouver, british columbia, canada the moncton hospital, moncton, new brunswick, canada sault area hospital, sault ste. marie, ontario, canada centre integre universitaire de sante et de services sociaux du saguenay lac saint jean, chicoutimi, quebec, canada hopital charles le moyne, greenfield park, quebec, canada mcgill university health center, montreal, quebec, canada st-jérome medical research, inc., saint-jerome, quebec, canada centre hospitalier universitaire de sherbrooke, sherbrooke, quebec, canada chu de quebec-universite laval, quebec, canada biocinetic spa, peñalolen, chile centro de estudios clínicos saga spa, providencia, chile fundacion arturo lopez perez; quimioterapia, providencia, chile oncovida - santiago, providencia, chile servicios médicos urumed spa, rancagua, chile meditek ltda, santiago, chile sociedad de investigaciones medicas ltda (sim), temuco, chile oncocentro apys; oncología, vina del mar, chile centro de investigaciones clinicas viña del mar, viña del mar, chile union hospital tongji medical college huazhong university of science and technology, wuhan city, china consultorio oncologico-hospital metropolitano linc, moravia, costa rica instituto de investigación en ciencias médicas s.a., san jose, costa rica centro de cáncer y hematología, san josé, costa rica consultorio oncologico-hospital metropolitano san, san josé, costa rica oncotech s.a., san josé, costa rica university hospital centre split, split, croatia general hospital varazdin, varazdin, croatia nemocnice agel novy jicin a.s.; oddeleni radioterapie a onkologie, novy jicin, czechia fakultni nemocnice olomouc, olomouc, czechia fakultni nemocnice v motole, praha 5, czechia fakultni nemocnice kralovske vinohrady, praha, czechia fakultni thomayerova nemocnice; onkologicke oddeleni, praha, czechia helsingin yliopistollinen keskussairaala, helsinki, finland kuopion yliopistollinen sairaala, kuopio, finland tampereen yliopistollinen sairaala, tampere, finland turun yliopistollinen keskussairaala, turku, finland high technology hospital medcenter ltd, batumi, georgia evex clinics, saint nikolozi medical centre, kutaisi, georgia research institute of clinical medicine, tbilisi, georgia institute of clinical oncology ltd, tbilisi, georgia tbilisi oncological center, ltd, tbilisi, georgia ltd tim, tbilisi institute of medicine, tbilisi, georgia s khechinashvili university clinic ltd, tbilisi, georgia universitätsklinikum aachen aör - medizinische fakultät der rwth, aachen, germany hämatologisch/onkologische gemeinschaftspraxis; dres. brudler/heinrich/bangerter, augsburg, germany ambulantes tumorzentrum spandau, berlin, germany lübecker onkologische schwerpunktpraxis, bonn, germany marienhospital bottrop, bottrop, germany klinikum chemnitz ggmbh, chemnitz, germany carl-thiem-klinikum ggmbh, cottbus, germany kliniken essen mitte evang. huyssens stiftung/knappschaft gmbh, essen, germany centrum fur hamatologie und onkologie bethanien, frankfurt, germany franziskus-hospital harderberg, georgsmarienhutte, germany srh wald-klinikum gera; brustzentrum ostthüringen, gera, germany martin luther universitat halle wittenberg, halle, germany mammazentrum hamburg am krankenhaus jerusalem, hamburg, germany gynäkologisch onkologische praxis hannover, hannover, germany vincentius-diakonissen-kliniken gag, karlsruhe, germany facharztpraxis für gynäkologie und geburtshilfe pd dr. med. christian kurbacher, lübeck, germany universitätsmedizin der johannes gutenberg-universität mainz, mainz, germany klinikum mannheim gmbh universitätsklinikum, mannheim, germany universitäts-frauenklinik, marburg, germany praxis fuer gynaekologische onkologie prof. dr. me, mönchengladbach, germany hämatologie und onkologie ravensburg / wangen, ravensburg, germany caritasklinikum saarbruecken st theresia, saarbrücken, germany leopoldina krankenhaus schweinfurt, schweinfurt, germany praxis fur haematologie und internistische onkologie, velbert, germany university of athens medical school - regional general hospital alexandra, athens, greece sotiria chest hospital of athens, athens, greece general oncology hospital kifissias ""oi agioi anargyroi"", athens, greece aretaieio hospital of athens, athina, greece metropolitan general hospital, cholargos, greece metropolitan hospital first oncology clinic, faliro, greece metropolitan hospital fourth oncology clinic, faliro, greece university general hospital of heraklion, herakleion, greece university general hospital of ioannina, ioannina, greece university general hospital of larissa, larissa, greece iaso obstetrics gynecology clinic, marousi, greece medical center of athens, marousi, greece olympion clinic, patras, greece university general hospital of patras, patras, greece bioclinic thessaloniki, thessaloniki, greece interbalkan medical center of thessaloniki, thessaloniki, greece euromedica ppds, thessaloniki, greece papageorgiou general hospital of thessaloniki, thessaloniki, greece celan s.a., ciudad de guatemala, guatemala integra cancer institute, ciudad de guatemala, guatemala oncomedica, guatemala, guatemala clínica médica especializada en hematología, guatemala, guatemala queen mary hospital, hong kong, hong kong tolna megyei balassa jános kórház, budapest, hungary uzsoki utcai korhaz, budapest, hungary borsod-abauj-zemplen megyei korhaz es egyetemi oktato korhaz, miskolc, hungary szent borbala korhaz, tatabánya, hungary yashoda hospital, hyderabad, andhra pradesh, india state cancer institute, indira gandhi institute of medical sciences (igims), patna, bihar, india gujarat cancer & research inst., ahmadabad city, gujarat, india hemato oncology clinic ahmedabad pvt ltd, ahmadabad, gujarat, india nirmal hospital, surat, gujarat, india kiran hospital multi super speciality hospital and research center, surat, gujarat, india himalaya cancer hospital & research institute, vadodara, gujarat, india kailash cancer hospital and research center, vadodara, gujarat, india tata memorial hospital, mumbai, maharashtra, india hcg nchri cancer center, nagpur, maharashtra, india shalinitai meghe medical college and hospital, nagpur, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india chopda medicare & research centre pvt. ltd, nashik, maharashtra, india apex wellness hospital, nashik, maharashtra, india lokmanya holistic cancer care and research center (lmrc), pune, maharashtra, india sparsh hospitals & critical care (p) ltd., bhubaneswar, odisha, india erode cancer centre, erode, tamil nadu, india asirvatham speciality hospital, madurai, tamil nadu, india institute of post graduate medical education and research (ipgmer) and sskm hospital, kolkata, west bengal, india fortis hospital, mohali, india bon secours hospital; oncology, cork, ireland beaumont hospital; clinical research and education centre, smurfit building, dublin, ireland st vincents university hospital, dublin, ireland galway university hospital, galway, ireland waterford regional hospital; department of medical oncology, waterford, ireland shamir medical center assaf harofeh, beer jacob, israel soroka university medical centre, beer sheva, israel sheba medical center - ppds, ramat gan, israel tel-aviv sourasky medical center, tel aviv, israel azienda ospedaliera universitaria senese, siena, abruzzo, italy azienda ospedaliera di rilievo nazionale e di alta specialita san giuseppe moscati, avellino, campania, italy istituto nazionale per lo studio e la cura dei tumori fondazione g. pascale, napoli, campania, italy istituto nazionale tumori regina elena, roma, lazio, italy ospedale san raffaele s.r.l. - ppds, milano, lombardia, italy asst grande ospedale metropolitano niguarda - presidio ospedaliero ospedale niguarda ca\' granda, milano, lombardia, italy irccs ospedale sacro cuore don calabria, negrar, veneto, italy st. luke\'s international hospital, chuo, japan fukushima medical university hospital, fukushima, japan hiroshima university hospital, hiroshima, japan national hospital organization hokkaido cancer center, hokkaido, japan social medical corporation hakuaikai sagara hospital, kagoshima, japan tokai university hospital, kanagawa, japan kumamoto university hospital, kumamoto, japan national hospital organization osaka national hospital, osaka, japan osaka international cancer institute, osaka, japan saitama cancer center, saitama, japan the cancer institute hospital of japanese foundation for cancer research, tokyo, japan chungbuk national university hospital, cheongju-si, korea, republic of soon chun hyang university cheonan hospital, dongnam-gu, cheonan-si, korea, republic of national cancer centre, gyeonggi-do, korea, republic of cha bundang medical center, gyeonggi-do, korea, republic of gachon university gil medical center, incheon, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of asan medical center - ppds, seoul, korea, republic of samsung medical center - ppds, seoul, korea, republic of korea university guro hospital, seoul, korea, republic of the catholic university of korea seoul st. mary\'s hospital, seoul, korea, republic of ajou university hospital, suwon city, korea, republic of ulsan university hosiptal, ulsan, korea, republic of riga east clinical university hospital latvian oncology centre, riga, latvia pauls stradins clinical university hospital, rīga, latvia centro de investigación en artritis y osteoporosis - ppds, mexicali, baja california, mexico health pharma professional research, cdmx, mexico city (federal district), mexico centro de investigacion clinica de oaxaca, oaxaca de juárez, oaxaca, mexico neurociencias estudios clinicos s.c., culiacán, sinaloa, mexico accelerium s. de r.l. de c.v., monterrey, mexico cancerologia de queretaro, queretaro, mexico oncológico potosino, san luis potosí, mexico metro davao medical and research center, davao city, philippines university of santo tomas hospital; pharmacy, manila, philippines cardinal santos medical center; department of internal medicine, section of endocrinology, manila, philippines east avenue medical center; breast care center, quezon city, philippines st. luke\'s medical center - quezon city, quezon city, philippines regionalny szpital specjalistyczny im. w. bieganskiego; oddzial neurologiczny, grudziądz, poland centrum terapii wspolczesnej j.m.jasnorzewska spolka komandytowo-akcyjna, lodz, poland centrum medyczna ostroleka - pratia - ppds, ostrołęka, poland narodowy instytut onkologii im. marii skłodowskiej-curie - państwowy instytut badawczy, warszawa, poland hospital senhora da oliveira - guimaraes, e.p.e, guimarães, portugal champalimaud cancer center, lisboa, portugal hospital da luz, lisboa, portugal centro hospitalar lisboa norte, e.p.e. - hospital de santa maria; servicos farmaceuticos, lisboa, portugal hospital beatriz angelo, loures, portugal centro hospitalar do porto - hospital de santo antónio; oncologia, porto, portugal instituto portugues de oncologia do porto francisco gentil epe, porto, portugal centro hospitalar de vila nova de gaia / espinho e.p.e, vila nova de gaia, portugal centro hospitalar trás os montes e alto douro epe, vila real, portugal spitalul clinic de obstetrica si ginecologie filantropia; sectorul 1 bucurești, bucurești, romania prof dr i chiricuta institute of oncology; oncology department, cluj-napoca, romania medisprof srl, cluj-napoca, romania affidea romania srl, constanţa, romania onco clinic consult sa, craiova, romania oncology center sf. nectarie, craiova, romania institutul regional de oncologie iasi, iasi, romania timisoara emergency county clinical hospital, timişoara, romania leningrad regional oncology dispensary, kuzmolovsky, sankt petersburg, russian federation spbgu medical and diagnostic center of the clinic of high medical technology n a n i pirogov, saint petersburg, sankt petersburg, russian federation private healthcare institution clinical hospital rzhd medicine, st. petersburg, sankt petersburg, russian federation llc av medical grupp, st. petersburg, sankt petersburg, russian federation institute of oncology ljubljana, ljubljana, slovenia cancercare rondebosch oncology, cape town, south africa sandton oncology medical group (pty) ltd, city of johannesburg, south africa west rand oncology centre; flora clinic, floracliffe, south africa excellentis clinical trial consultants; clinical research, george, south africa langenhoven drive oncology centre, port elizabeth, south africa wilgers oncology centre, pretoria, south africa eastleigh breast care centre, pretoria, south africa hospital general universitario de elche, elche, alicante, spain hospital universitario reina sofia; servicio de farmacia, córdoba, cordoba, spain hospital son llatzer, palma de mallorca, islas baleares, spain chus - h. clinico u. de santiago, santiago de compostela, la coruña, spain hospital universitario fundación alcorcón, alcorcon, madrid, spain hospital universitario puerta de hierro - majadahonda, majadahonda, madrid, spain clinica universidad navarra; servicio de farmacia, pamplona, navarra, spain complejo hospitalario de navarra; servicio de farmacia, pamplona, navarra, spain hospital nuestra senora de valme, seville, sevilla, spain hospital universitario virgen macarena, seville, sevilla, spain hospital universitario basurto, bilbao, vizcaya, spain hospital general universitario de alicante, alicante, spain hospital del mar, barcelona, spain clinica tres torres, barcelona, spain hospital universitario quiron dexeus, barcelona, spain hospital clinic de barcelona, barcelona, spain hospital universitario clínico san cecilio, granada, spain hospital universitario virgen de las nieves, granada, spain hospital universitario de jaen, jaen, spain hospital universitario la paz, madrid, spain hospital universitario infanta leonor, madrid, spain centro oncologioco md anderson internacional; servicio de farmacia, madrid, spain hospital ruber internacional, madrid, spain hospital universitario virgen del rocío, sevilla, spain hospital universitari i politecnic la fe de valencia, valencia, spain länssjukhuset ryhov, jönköping, sweden skaraborgs sjukhus skoevde, dept of surgery, skoevde, sweden södersjukhuset, stockholm, sweden sundsvalls sjukhus, sundsvall, sweden akademiska sjukhuset, uppsala, sweden universitätsspital basel, basel, switzerland luzerner kantonsspital luks; studienzentrale onkologie, luzern, switzerland hirslanden klinik st. anna brustzentrum/chirurgie, luzern, switzerland kantonsspital st. gallen, st. gallen, switzerland kantonsspital winterthur medizin pneumologie, winterthur, switzerland brust-zentrum zürich ag seefeldstrasse 214 zürich, zürich, switzerland koo foundation sun yat-sen cancer center, beitou dist., taiwan mackay memorial hospital-tamsui branch, new taipei city, taiwan china medical university hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan taipei veterans general hospital, taipei city, taiwan national taiwan university hospital, taipei, taiwan taichung veterans general hospital, xitun dist., taiwan siriraj hospital, mahidol university, bangkok, thailand medical center of llc mriya med-service, kryvyi rih, kherson governorate, ukraine municipal non-profit enterprise odessa regional clinical hospital of odessa regional council, odesa, kherson governorate, ukraine communal non-profit enterprise chernihiv medical center of modern oncology of crc, chernihiv, kiev governorate, ukraine regional municipal non-commercial enterprise bukovynian clinical oncology center, chernivtsi, kiev governorate, ukraine medical center llc ""harmony of beauty"", kyiv, kiev governorate, ukraine clinic verum expert llc, kyiv, kiev governorate, ukraine treatment and diagnostic center of llc specialized clinic prognosis optima, kyiv, kiev governorate, ukraine communal nonprofit enterprise kyiv city clinical oncological center, kyiv, kiev governorate, ukraine municipal non-profit enterprise zhytomyr regional oncology dispensary of zhytomyr regional council, zhytomyr, kiev governorate, ukraine medical clinical research center of medical center llc health clinic, vinnytsia, podolia governorate, ukraine the municipal enterprise volyn regional medical oncology centre of the volyn regional council, lutsk, volhynian governorate, ukraine dnipropetrovsk state medical academy, dnipropterovsk, ukraine kyiv regional oncological dispensary, kyiv, ukraine']",,https://ClinicalTrials.gov/show/NCT04961996,breast
254,255,NCT00525408,a study of mycobacterium w plus docetaxel for hormone refractory metastatic prostate cancer,HRPC,Terminated,No Results Available,hormone refractory prostate cancer,biological: mycobacterium w.|drug: docetaxel,"median survival time|time to tumor progression|hematological toxicity, psa levels, quality of life",cadila pharnmaceuticals,Male,"18 Years and older   (Adult, Older Adult)",Phase 2,134.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR-60/1260,November 2007,January 2013,January 2013,"September 5, 2007",,"March 12, 2012","['v.m. medical college & safdarjang hospital, new delhi, delhi, india rajiv gandhi cancer institute & research center, rohini, delhi, india kidwai memorial institute of oncology, bangalore, karnataka, india kasturba hospital,, manipal, karnataka, india regional cancer centre, trivandrum, kerala, india choithram hospital & research centre, indore, madhya pradesh, india seth g.s. medical college & kem hospital, parel, mumbai, india lokmanya tilak municipal medical college & general hospital, sion, mumbai, india patel hospital pvt. ltd., jalandhar, punjab, india christian medical college, ludhiana, ludhiana, punjab, india s.p. medical college & a. g. of hospitals, bikaner, rajashthan, india christian medical college, vellore, tamil nadu, india chatrapati sahuji mahraj medical university, lucknow, uttar pradesh, india post graduate institute of medical education and research, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT00525408,prostat
255,256,NCT02658734,a study of trastuzumab emtansine in indian patients with human epidermal growth factor receptor 2 (her2)-positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane,,Completed,Has Results,"her2 positive breast cancer, metastatic breast cancer, locally advanced breast cancer",drug: trastuzumab emtansine,"severity of adverse events|percentage of participants with adverse events|percentage of participants with serious adverse events (saes)|severity of saes as per the national cancer institute common terminology criteria for adverse events (nci-ctcae), version 4.03|percentage of participants with non-serious adverse events of special interest|laboratory results abnormalities|percentage of participants with adverse events leading to discontinuation of study medication|percentage of participants with adverse events leading to modification of study medication|percentage of participants with adverse events leading to interruption of study medication|exposure to study drug|percentage of participants with drug-induced liver injury meeting hy's law criteria|percentage of participants with congestive heart failure|change in left ventricular ejection fraction (lvef) as measured by echocardiogram|overall response rate (orr)|progression-free survival (pfs)|overall survival (os)",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 4,70.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,ML29662,"November 1, 2016","December 14, 2019","December 14, 2019","January 20, 2016","February 9, 2021","April 2, 2021","['indraprastha apollo hospitals, new delhi, delhi, india rajiv gandhi cancer inst.&research center; medical oncology, new delhi, delhi, india max super speciality hospital; medical oncology, north west delhi, delhi, india apollo hospitals international limited, gandhinagar, gujarat, india manipal hospital; department of oncology, bangalore, karnataka, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india jehangir hospital, pune, maharashtra, india christian medical college & hospital; medicine, vellore, tamil nadu, india healthcare global enterprises limited, bangalore, india artemis health institute, gurgaon, india fortis memorial research institute; department of medical oncology & haematology, gurgaon, india sir gangaram hospital; medical oncology, new delhi, india max super speciality hospital, new delhi, india']","""study protocol"", https://clinicaltrials.gov/provideddocs/34/nct02658734/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/34/nct02658734/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02658734,breast
256,257,NCT01095003,trial of vinflunine plus capecitabine in advanced breast cancer,,Completed,Has Results,breast cancer,drug: vinflunine plus capecitabine|drug: capecitabine,progression free survival|overall survival|overall response rate (orr)|disease control rate|duration of response,pierre fabre medicament,Female,"21 Years and older   (Adult, Older Adult)",Phase 3,770.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,L00070 IN 305 B0|2008-004171-21,May 2009,December 2011,October 2015,"March 29, 2010","September 13, 2019","April 28, 2022","['buenos aires, argentina quilmes, argentina rosario, argentina san martin, argentina tucuman, argentina gomel, belarus grodno, belarus minsk, belarus vitebsk, belarus bruxelles, belgium liège, belgium curitiba, brazil porto alegre, brazil santo andre, brazil sao paulo, brazil plovdiv, bulgaria sofia, bulgaria stara zagora, bulgaria brno, czechia jihlava, czechia tallinn, estonia angers, france caen, france dijon, france le mans, france lorient, france lyon, france montpellier, france nantes, france saint-brieuc, france saint-cloud, france saint-herblain, france tours, france villejuif, france budapest, hungary szekesfehervar, hungary szolnok, hungary aurangabad, india bangalore, india bhopal, india calcutta, india calicut, india jaipur, india mumbai, india patna, india pune, india trivandrum, india avellino, italy cagliari, italy cremona, italy fabriano, italy milano, italy monza, italy padova, italy pisa, italy rozzano, italy verona, italy chihuahua, mexico leon, mexico mexico city, mexico saltillo, mexico bialystok, poland gdansk, poland krakow, poland lodz, poland lubin, poland warsawa, poland arkhangelsk, russian federation chelyabinsk, russian federation moscow, russian federation ryazan, russian federation saratov, russian federation st-petersburg, russian federation stavropol, russian federation tambov, russian federation ufa, russian federation vladimir, russian federation volgograd, russian federation nis, serbia sremska kamenica, serbia durban, south africa kimberley, south africa pretoria, south africa sandton, south africa barcelona, spain lleida, spain madrid, spain oviedo, spain valencia, spain genolier, switzerland lausanne, switzerland winterthur, switzerland taipei, taiwan taoyuan, taiwan cherkasy, ukraine dnipropetrovsk, ukraine donetsk, ukraine khmelnytskyï, ukraine kyiv, ukraine simferopol, ukraine belfast, united kingdom chelmsford, united kingdom keighley, united kingdom london, united kingdom nottingham, united kingdom peterborough, united kingdom portsmouth, united kingdom sheffield, united kingdom southend-on-sea, united kingdom sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01095003,breast
257,258,NCT00093002,fulvestrant (faslodex™) as a treatment in postmenopausal women with estrogen receptor positive breast cancer,,Completed,No Results Available,breast cancer,drug: fulvestrant,"anti-proliferative effect after 4 weeks of treatment.|safety, tolerability, tumor response and pharmacokinetics after 4 weeks of treatment.",astrazeneca,Female,"Child, Adult, Older Adult",Phase 2,179.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9238IL/0065|D6997C00003,June 2004,,July 2007,"September 29, 2004",,"June 12, 2008","['research site, little rock, arkansas, united states research site, boston, massachusetts, united states research site, winchester, massachusetts, united states research site, albuquerque, new mexico, united states research site, hershey, pennsylvania, united states research site, nashville, tennessee, united states research site, laredo, texas, united states research site, innsbruck, austria research site, salzburg, austria research site, vienna, austria research site, wien, austria research site, barretos, brazil research site, florianopolis, brazil research site, goiamia, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, santo andre, brazil research site, sao paulo, brazil research site, berlin, germany research site, hannover, germany research site, magdeburg, germany research site, munchen, germany research site, rostock, germany research site, bangalore, india research site, hyderabaad, india research site, new delhi, india research site, pune, india research site, trivandrum, india research site, birmingham, united kingdom research site, bournemouth, united kingdom research site, dundee, united kingdom research site, edinburgh, united kingdom']",,https://ClinicalTrials.gov/show/NCT00093002,breast
258,259,NCT00338286,a study of epoetin alfa plus standard supportive care versus standard supportive care only in anemic patients with metastatic breast cancer receiving standard chemotherapy,,Completed,Has Results,breast cancer|neoplasm metastasis,other: standard supportive care (packed rbc transfusion)|drug: epoetin alfa + packed rbc transfusion,progression free survival|overall survival|time to tumor progression|overall response rate (orr)|percentage of participants with suspected thrombotic vascular events (tves),"janssen research & development, llc",Female,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,2098.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR005143|EPOANE3010|2005-001817-17,"March 2, 2006","July 7, 2014","January 31, 2017","June 20, 2006","March 24, 2016","March 19, 2018","['anaheim, california, united states gainesville, florida, united states miami, florida, united states new port richey, florida, united states rockledge, florida, united states hazard, kentucky, united states alexandria, louisiana, united states marrero, louisiana, united states jackson, mississippi, united states lake success, new york, united states staten island, new york, united states philadelphia, pennsylvania, united states corpus christi, texas, united states houston, texas, united states buenos aires, argentina capital federal, argentina ciudad autonoma de buenos airess, argentina cordoba, argentina la plata, argentina mendoza, argentina quilmes, argentina rosario, argentina santa fe, argentina barretos, brazil curitiba, brazil goiânia/go, brazil ijuí, brazil jau, brazil piracicaba, brazil porto alegre, brazil ribeirão preto/sp, brazil santo andre, brazil sao paulo, brazil são josé do rio preto, brazil são paulol, brazil plovdiv, bulgaria rousse, bulgaria sofia, bulgaria stara zagora, bulgaria varna, bulgaria arica, chile santiago, chile temuco, chile valdivia, chile valparaiso, chile bogota, colombia floridablanca-santander, colombia monteria, colombia cuenca, ecuador guayaquil, ecuador portoviejo, ecuador quito, ecuador batumi, georgia tbilisi, georgia tblisi, georgia new territories, hong kong ahmedabad, india andra pradesh, india bangalore n/a, india bangalore, india bhopal, india cochin, india delhi, india hyderabad, india jaipur, india karnad, india kerala, india kolkata, india mangalore, india mumbai, india nashik, india new delhi, india pune, india tamil nadu na, india tamil nadu, india thiruvananthapuram, india uttar pradesh, india vellore, india bandung, indonesia jakarta, indonesia semarang, indonesia yogyakarta, indonesia bitola, macedonia, the former yugoslav republic of skopje, macedonia, the former yugoslav republic of georgetown, malaysia kelantan, malaysia kuala lumpur, malaysia nilai, malaysia tanjung bunga, malaysia chihuahua, mexico guerrero, mexico leon, mexico merida, mexico morelia, mexico puebla, mexico san luis potosi, mexico sinaloa, mexico zapopan, mexico cebu, philippines davao city, philippines iloilo city, philippines manila, philippines quezon city, philippines białystok, poland gdansk, poland gliwice, poland katowice n/a, poland kraków, poland lodz, poland olsztyn, poland poznan, poland wroclaw, poland brasov, romania bucuresti, romania cluj-napoca, romania iasi, romania onesti, romania sibiu, romania suceava, romania timisoara, romania arkhangelsk, russian federation balashikha, russian federation belgorod, russian federation chelyabinsk, russian federation ekaterinburg, russian federation engels saratov region, russian federation ivanovo, russian federation kazan, russian federation krasnodar, russian federation leningrad region, russian federation lipetsk, russian federation magnitogorsk, russian federation moscow, russian federation novosibirsk, russian federation obninsk, russian federation orenburg, russian federation perm, russian federation pyatigorsk, russian federation ryazan, russian federation smolensk, russian federation st petersburg, russian federation st. petersburg, russian federation tyumen, russian federation ufa, russian federation voronezh, russian federation bloemfontein, south africa cape town, south africa durban, south africa johannesburg, south africa klerksdorp, south africa port elizabeth n/a, south africa pretoria, south africa changhua, taiwan chiayi, taiwan hualien, taiwan kaohsiung, taiwan taichung, taiwan tainan, taiwan taipei 112, taiwan taipei, taiwan tao-yuan, taiwan cherkassy, ukraine chernihiv, ukraine chernivtsi, ukraine dnepropetrovsk, ukraine donetsk, ukraine ivano-francovsk, ukraine kharkiv, ukraine kiev, ukraine lviv, ukraine odessa, ukraine poltava, ukraine sumy, ukraine uzhgorod, ukraine vinnitsa, ukraine vinnytsia, ukraine zaporozhye, ukraine']",,https://ClinicalTrials.gov/show/NCT00338286,breast
259,260,NCT04736199,darolutamide in addition to adt versus adt in metastatic hormone-sensitive prostate cancer,ARANOTE,Recruiting,No Results Available,prostatic neoplasms,"drug: darolutamide (nubeqa, bay1841788)|drug: placebo|other: androgen deprivation therapy (adt)",radiological progression-free survival (rpfs)|overall survival (os)|time to castration-resistant prostate cancer (crpc)|time to initiation of subsequent antineoplastic therapy|time to psa progression|psa undetectable rates (<0.2 ng/ml)|time to pain progression|number of participants with adverse events as a measure of safety,"bayer|orion corporation, orion pharma",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,555.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",21140|2020-003093-48,"February 23, 2021","March 27, 2024","September 26, 2025","February 3, 2021",,"April 22, 2022","['macquarie university hospital, macquarie university, new south wales, australia northern cancer institute, st leonards, new south wales, australia nepean hospital, sydney, new south wales, australia cancer research south australia, south terrace, south australia, australia peninsula oncology centre, frankston, victoria, australia austin health, heidelberg, australia assistência multidisciplinar em oncologia (amo), salvador, bahia, brazil hosp. araujo jorge da associação de combate ao câncer, goiânia, goiás, brazil hospital da universidade federal de minas gerais, belo horizonte, minas gerais, brazil cetus oncologia hospital dia, belo horizonte, minas gerais, brazil liga paranaense de combate ao cancer-hosp erasto gaertner, curitiba, parana, brazil liga norte riograndense contra o câncer, natal, rio grande do norte, brazil unidade de pesquisas clinicas em oncologia, pelotas, rio grande do sul, brazil irmandade santa casa de misericordia de porto alegre, porto alegre, rio grande do sul, brazil hospital ernesto dornelles, porto alegre, rio grande do sul, brazil hospital mae de deus, porto alegre, rio grande do sul, brazil hospital nossa senhora da conceição, porto alegre, rio grande do sul, brazil hospital de clínicas de porto alegre, porto alegre, rio grande do sul, brazil fundação pio xii - hospital de câncer de barretos, barretos, sao paulo, brazil hospital de base da fundação f m s j rio preto, são josé do rio preto, sao paulo, brazil urobrasil, são paulo, sao paulo, brazil ibcc - instituto brasileiro de controle do cancer, são paulo, sao paulo, brazil inst. de assistência médica ao sérvidor público estadual, são paulo, sao paulo, brazil instituto coi de educação e pesquisa, rio de janeiro, brazil exdeo clinical research inc., abbotsford, british columbia, canada g. kenneth jansz medicine professional corporation, burlington, ontario, canada centre integre de sante et de services sociaux de ioutaouais, gatineau, quebec, canada ciusss de l\'estrie- centre haute-yamaska, granby, quebec, canada centre de recherche du chum, montreal, quebec, canada centro oncológico del norte, antofagasta, araucanía, chile centro de investigación clínica del sur, temuco, araucanía, chile sociedad clinical research chile spa, valdivia, los lagos, chile centro de estudios clínicos saga spa, providencia, santiago, chile oncocentro, viña del mar, valparaíso, chile fundación arturo lópez perez, santiago, chile oncovida, santiago, chile hospital clínico de la pontificia univ. católica de chile, santiago, chile uromed, santiago, chile anhui provincial hospital, hefei, anhui, china fujian medical university union hospital, fuzhou, fujian, china the first affiliated hospital of xiamen university, xiamen, fujian, china sun yat-sen university cancer center, guangzhou, guangdong, china guangzhou first people hospital, guangzhou, guangdong, china cancer hospital chinese academy of medical sciences,shenzhen, shenzhen, guangdong, china tongji hosp. of tongji med coll, huazhong uni of sci & tech., wuhan, hubei, china zhongnan hospital ,wuhan university, wuhan, hubei, china hubei cancer hospital, wuhan, hubei, china hunan cancer hospital, changsha, hunan, china nj drum tower hospital, the affil hos of nj univ med school, nanjing, jiangsu, china nantong tumor hospital, nantong, jiangsu, china the 2nd affiliated hospital of soochow university, suzhou, jiangsu, china 1st hospital of jilin university, changchun, jilin, china liaoning cancer hospital and institute, shengyang, liaoning, china the first affiliated hospital of xi\'an jiaotong university, xi\'an, shaanxi, china yantai yuhuangding hospital, yantai, shandong, china sichuanacademyofmedicalsciences&sichuanprovincialpeople\'shos, chengdu, sichuan, china sichuan university west china hospital, chengdu, sichuan, china yunnan cancer hospital, kunming, yunnan, china the 1st affiliated hospital of zhejiang university, hangzhou, zhejiang, china zhejiang provincial people\'s hospital, hangzhou, zhejiang, china ningbo first hospital, ningbo, zhejiang, china the first affiliated hospital of wenzhou medical university, wenzhou, zhejiang, china cancer hospital, chinese academy of medical sciences, beijing, china beijing friendship hospital, capital medical university, beijing, china peking university third hospital, beijing, china beijing cancer hospital, beijing, china beijing hospital, beijing, china huashan hospital, fudan university, shanghai, china xinhua hos affiliated to sh jiaotong uni school of medicine, shanghai, china shanghai fifth people\'s hospital,fudan university, shanghai, china docrates klinikka, helsinki, finland hus, meilahden sairaala, helsinki, finland oulun yliopistollinen sairaala, oulu, finland seinäjoen keskussairaala, seinäjoki, finland tampereen yliopistollinen sairaala, keskussairaala, tampere, finland mahatma gandhi cancer hospital & research institute, vishakapatnam, andhra pradesh, india all india institute of medical sciences, new delhi, delhi, india the gujarat cancer & research institute, ahmedabad, gujarat, india hcg cancer centre - ahmedabad, ahmedabad, gujarat, india cancer care clinic - vadodara, vadodara, gujarat, india kles dr. prabhakar kore hospital & medical research centre, belagavi, karnataka, india healthcare global enterprises ltd, bengaluru, karnataka, india amrita institute of medical sciences, kochi, kerala, india regional cancer centre - thiruvananthapuram, thiruvananthapuram, kerala, india tata memorial hospital, mumbai,, maharashtra, india jaslok hospital and research centre, mumbai, maharashtra, india sushrut hospital & research centre, mumbai, maharashtra, india curie manavata cancer centre, nashik, maharashtra, india jehangir hospital, pune, maharashtra, india sparsh hospital & critical care, bhubaneswar, orissa, india christian medical center & hospital, ludhiana, punjab, india sms medical college & attached hospitals, jaipur, rajasthan, india meenakshi mission hospital & research centre, madurai, tamil n?du, india apollo specialty hospital- teynampet, chennai, tamil nadu, india tata medical center, kolkata, india rajiv gandhi cancer institute & research centre, new delhi, india daugavpils regional hospital, daugavpils, latvia rakus hospital gailezers, riga, latvia uro ltd., riga, latvia p. stradins clinical university hospital, riga, latvia vidzemes hospital, valmiera, latvia the hospital of lithuanian university of health sciencesluhs, kaunas, lithuania pi klaipedos university hospital, klaipeda, lithuania national cancer institute, vilnius, lithuania vilnius university hospital santaros klinikos, vilnius, lithuania canterbury urology research trust, christchurch, new zealand waikato hospital, hamilton, new zealand urology waikato, hamilton, new zealand tauranga urology research limited, tauranga, new zealand hospital guillermo almenara irigoyen, la victoria, lima, peru aliada, san isidro, lima, peru hospital militar luis arias schreiber, lima, peru clínica el golf, lima, peru arkhangelsk clinical oncology dispensary, arkhangelsk, russian federation ltd ""evimed"", chelyabinsk, russian federation chelyabinsk regional oncology dispensary, chelyabinsk, russian federation ivanovo regional oncology dispensary, ivanovo, russian federation republican clinical oncology dispensary, kazan, russian federation russian oncological scientific center n.a. n.n. blokhin rams, moscow, russian federation research centre of x-ray and radiology, moscow, russian federation volga district med center fmba, nizhny novgorod, russian federation medical center ""avicenna"", novosibirsk, russian federation llc reafan, novosibirsk, russian federation clinical oncological dispensary of omsk region, omsk, russian federation gbuz rm ""republican oncology dispensary"", saransk, russian federation st. petersburg clinical hospital of ras, st. petersburg, russian federation av medical group, st. petersburg, russian federation russian scientific radiology and surgery technologies center, st. petersburg, russian federation scientific research instutute of oncology n.a. n.n. petrov, st. petersburg, russian federation multi-field clinical medical center ""medical city"", tyumen, russian federation republican clinical oncology dispensary, ufa, russian federation vologda regional hospital, vologda, russian federation sverdlovsk regional clinical hospital #1, yekaterinburg, russian federation cancercare langenhoven, port elizabeth, eastern cape, south africa east rand medical research unit, johannesburg, gauteng, south africa university of pretoria, clinical research unit, pretoria, gauteng, south africa groote schuur hospital, cape town, western cape, south africa cape town oncology trials, cape town, south africa corporació sanitària parc taulí, sabadell, barcelona, spain fundación hospital alcorcón, alcorcón, madrid, spain hospital fundació puigvert, barcelona, spain hospital san pedro de alcántara, cáceres, spain hospital universitario puerta del mar, cádiz, spain hospital universitario 12 de octubre, madrid, spain hospital virgen de la victoria, málaga, spain hospital universitario virgen del rocío, sevilla, spain changhua christian hospital, changhua, taiwan kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan taichung veterans general hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan taipei veterans general hospital, taipei, taiwan cherkasy oncological dispensary, cherkasy, ukraine city dnipropetrovsk multi- field clinical hosp. 4 dsma, dnipro, ukraine kyiv city hospital #3, kyiv, ukraine kyiv regional oncological dispensary, kyiv, ukraine']",,https://ClinicalTrials.gov/show/NCT04736199,prostat
260,261,NCT04760288,a study of pralsetinib versus standard of care (soc) for treatment of ret-mutated medullary thyroid cancer (mtc).,AcceleRET-MTC,Not yet recruiting,No Results Available,thyroid cancer,drug: pralsetinib|drug: cabozantinib|drug: vandetanib,progression-free survival (pfs)|time-to-treatment failure (ttf)|objective response rate (orr)|overall survival (os)|percentage of participants with adverse events (aes)|duration of response (dor)|disease control rate (dcr)|clinical benefit rate (cbr)|time to deterioration of function|quality of life (qol)|acceptability and palatability of pralsetinib capsules,hoffmann-la roche,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,198.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CO42865|2020-005269-15,"July 1, 2022","April 15, 2026","April 15, 2028","February 18, 2021",,"May 4, 2022","['the lundquist institute for biomedical innovation at harbor-ucla medical cente, torrance, california, united states instituto de investigaciones metabolicas (idim), ciudad autonoma de buenos aires, argentina centro médico privado cemaic, córdoba, argentina instituto medico de la fundacion estudios clinicos, rosario, argentina sanatorio britanico de rosario, rosario, argentina centro de investigación clínica - clínica viedma, viedma, argentina macquarie university hospital, macquarie park, new south wales, australia royal north shore hospital, st. leonards, new south wales, australia ashford cancer center research, kurralta park, south australia, australia the alfred hospital;clinical trial pharmacy, melbourne, victoria, australia medizinische universität graz; klinische abteilung für allgemeine hno, graz, austria cetus hospital dia oncologia, uberaba, mg, brazil hospital de clinicas de porto alegre (hcpa) - ppds, porto alegre, pa, brazil irmandade da santa casa de misericordia de porto alegre, porto alegre, rs, brazil fundação pio xii hospital de câncer de barretos, barretos, sp, brazil instituto do câncer do estado de são paulo octávio frias de oliveira, são paulo, sp, brazil multiprofile hospital for active treatment uni hospital; department of medicinal oncology, panagyurishte, bulgaria complex oncology center plovdiv; department of medical oncology and oncology diseases in pneumology, plovdiv, bulgaria university multiprofile hospital for active treatment ""sveti ivan rilski"" ead; clinical hematology, sofia, bulgaria tom baker cancer centre; dept of pathology, calgary, alberta, canada cross cancer institute; clinical trials, edmonton, alberta, canada mcgill university health center; glen-cedars cancer centre, oncology pharmacy, montreal, quebec, canada centre hospitalier universitaire de sherbrooke; pharmacie de chimiotherapie, sherbrooke, quebec, canada clinical hospital centre osijek; hematology, osijek, croatia clinical hospital sestre milosrdnice, zagreb, croatia klinicki bolnicki centar zagreb, zagreb, croatia odense universitetshospital, onkologisk afdeling, klinisk forsknings enhed, odense c, denmark hôtel dieu -angers; pharmacie / secteur essais cliniques, angers, france edog - institut bergonie - ppds, bordeaux, france centre hospitalier universitaire lyon; institut hématologique et d\'oncologie pédiatrique, lyon, france chu nantes, nantes, france centre antoine lacassagne centre régional de lutte contre le cancer, nice, france hopital cochin, paris, france institut curie; pharmacie, paris, france hôpital saint-louis, paris, france icans, strasbourg, france institut universitaire de cancer de toulouse oncopole; iuct- oncopole, toulouse, france attikon university general hospital, ahens, greece university of athens medical school - regional general hospital alexandra, athens, greece kianous stavros, thessaloniki, greece semmelweis egyetem, ii. belgyógyászati klinika, budapest, hungary debreceni egyetem klinikai kozpont, debrecen, hungary szegedi tudomanyegyetem szent-gyorgyi albert klinikai kozpont, szeged, hungary panchshil hospital, ahmadabad city, gujarat, india unity hospital-surat, surat city, gujarat, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india hcg nchri cancer center, nagpur, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india sparsh hospitals & critical care (p) ltd., bhubaneswar, odisha, india dayanand medical college and hospital, ludhiana, punjab, india hadassah medical center, jerusalem, israel c.h. regional reina sofia - ppds, cordoba, calabria, italy national cancer center, goyang-si, korea, republic of seoul national university hospital, seoul, korea, republic of samsung medical center - ppds, seoul, korea, republic of vu medisch centrum, amsterdam, netherlands saint louis university hospital of sacred heart, baguio city, philippines st. luke\'s medical center - quezon city, quezon city, philippines centrum onkologii-instytut im. marii skłodowskiej curie; i klinika radioterapii i chemioterapii, gliwice, poland centrum onkologii instytut im. marii sklodowskiej-curie w krakowie - apteka/pharmacy; pharmacy, warszawa, poland instituto português de oncologia de lisboa francisco gentil, e.p.e., lisbon, portugal instituto portugues de oncologia do porto francisco gentil epe, porto, portugal institutul national de endocrinologie ""c. i. parhon""; sectorul 1 bucurești, bucuresti, romania prof dr i chiricuta institute of oncology; oncology department, cluj-napoca, romania onco clinic consult sa, craiova, romania chus - h. clinico u. de santiago, santiago de compostela, la coruña, spain clinica universidad navarra; servicio de farmacia, pamplona, navarra, spain hospital universitario vall d\'hebron, barcelona, spain hospital clinic de barcelona, barcelona, spain md anderson cancer center madrid - españa; servicio de farmacia, madrid, spain hospital universitario ramon y cajal, madrid, spain hospital universitario hm sanchinarro - ciocc; farmacia - ensayos clínicos, madrid, spain hospital regional universitario de malaga, malaga, spain hospital universitario virgen del rocio, sevilla, spain phramongkutklao hospital, bangkok, thailand siriraj hospital, mahidol uni ; division of rheumatology, dept. of medicine, bangkok, thailand chulalongkorn university hospital; hematology, pathum wan, thailand si institute for general and urgent surgery n.a. v.t.zaitseva of nams of ukraine, kharkiv, kharkiv governorate, ukraine municipal non-profit enterprise ""city clinical hospital # 4"" of dnipro city council - ppds, dnipro, kiev governorate, ukraine ukr. scientific practical center of endocrine surgery,transplantation of endocrine organs&tissues, kyiv, kiev governorate, ukraine clinic verum expert llc, kyiv, kiev governorate, ukraine treatment and diagnostic center of llc specialized clinic prognosis optima, kyiv, kiev governorate, ukraine st bartholomew\'s hospital, london, united kingdom guys hospital; guys cancer center, london, united kingdom the christie nhs foundation trust, manchester, united kingdom the royal marsden nhs foundation trust - royal marsden hospital (rmh) - sutton, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT04760288,thyroid
261,262,NCT03176238,"study in post-menopausal women with hormone receptor positive, her2-negative advanced breast cancer",EVEREXES,Completed,Has Results,post menopausal breast cancer,drug: everolimus|drug: exemestane,summary of number of participants with treatment emergent adverse events (teae) - all grades|percentage of participants response rates (best overall and overall)|percentage of participants clinical benefit rate|progression free survival (pfs)|percent of participants event-free probability estimates of deterioration of eastern cooperative oncology group (ecog) performance status,novartis pharmaceuticals|novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,235.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRAD001JIC06,"March 29, 2013","January 29, 2019","January 29, 2019","June 5, 2017","April 7, 2020","April 7, 2020","['novartis investigative site, garran, australian capital territory, australia novartis investigative site, caringbah, new south wales, australia novartis investigative site, liverpool, new south wales, australia novartis investigative site, box hill, victoria, australia novartis investigative site, heidelberg, victoria, australia novartis investigative site, ringwood east, victoria, australia novartis investigative site, st albans, victoria, australia novartis investigative site, karamsad, gujarat, india novartis investigative site, nashik, maharashtra, india novartis investigative site, pune, maharashtra, india novartis investigative site, cuttack, orissa, india novartis investigative site, bandung, indonesia novartis investigative site, jakarta, indonesia novartis investigative site, jogyakarta, indonesia novartis investigative site, semarang, indonesia novartis investigative site, amman, jordan novartis investigative site, suwon, gyeonggi-do, korea, republic of novartis investigative site, gyeonggi do, korea, korea, republic of novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, seocho gu, korea, republic of novartis investigative site, busan, korea, republic of novartis investigative site, jeollanam-do, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, taegu, korea, republic of novartis investigative site, kuala lumpur, mys, malaysia novartis investigative site, kota kinabalu, sabah, malaysia novartis investigative site, kuala lumpur, wilayah persekutuan, malaysia novartis investigative site, casablanca, morocco novartis investigative site, rabat, morocco novartis investigative site, cape town, western cape, south africa novartis investigative site, george, western cape, south africa novartis investigative site, western cape, south africa novartis investigative site, new taipei city, twn, taiwan novartis investigative site, changhua, taiwan novartis investigative site, kaohsiung city, taiwan novartis investigative site, kaoshiung, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, chiang mai, thailand novartis investigative site, ariana, tunisia novartis investigative site, ankara, turkey novartis investigative site, ankara, turkey novartis investigative site, ankara, turkey novartis investigative site, gaziantep, turkey novartis investigative site, izmir, turkey novartis investigative site, kartal, turkey novartis investigative site, pendik / istanbul, turkey novartis investigative site, ho chi minh, vietnam']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/38/nct03176238/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/38/nct03176238/prot_001.pdf",https://ClinicalTrials.gov/show/NCT03176238,breast
262,263,NCT04711252,a comparative study of azd9833 plus palbociclib versus anastrozole plus palbociclib in patients with er-positive her2 negative breast cancer who have not received any systemic treatment for advanced disease.,SERENA-4,Recruiting,No Results Available,er-positive her2-negative breast cancer,drug: azd9833|drug: anastrozole|drug: anastrozole placebo|drug: azd9833 placebo|drug: palbociclib|drug: luteinizing hormone-releasing hormone (lhrh) agonist,progression-free survival (pfs) assessed by the investigator as defined by response evaluation criteria in solid tumors (recist) version 1.1|overall survival (os)|second progression-free survival (pfs2)|objective response rate (orr) assessed by the investigator as defined by recist version 1.1|duration of response (dor) assessed by the investigator as defined by recist version 1.1|time to chemotherapy (ttc)|time to first subsequent anti-cancer therapy (tfst)|clinical benefit rate at 24 weeks (cbr24)|time to second subsequent therapy (tsst)|plasma concentration of azd9833 at specified timepoints|change from baseline in eortc qlq-c30 scale scores|change from baseline in eortc qlq-br45 scale scores,astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,1402.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D8532C00001|2020-002276-12,"January 28, 2021","November 10, 2025","February 12, 2029","January 15, 2021",,"May 6, 2022","[""research site, mobile, alabama, united states research site, springdale, arkansas, united states research site, harbor city, california, united states research site, lone tree, colorado, united states research site, fort myers, florida, united states research site, jacksonville, florida, united states research site, west palm beach, florida, united states research site, evergreen park, illinois, united states research site, urbana, illinois, united states research site, edgewood, kentucky, united states research site, lexington, kentucky, united states research site, baton rouge, louisiana, united states research site, baltimore, maryland, united states research site, silver spring, maryland, united states research site, boston, massachusetts, united states research site, detroit, michigan, united states research site, rochester, minnesota, united states research site, hattiesburg, mississippi, united states research site, jackson, mississippi, united states research site, hackensack, new jersey, united states research site, syracuse, new york, united states research site, asheville, north carolina, united states research site, fargo, north dakota, united states research site, cincinnati, ohio, united states research site, cincinnati, ohio, united states research site, portland, oregon, united states research site, greenville, south carolina, united states research site, greenville, south carolina, united states research site, west columbia, south carolina, united states research site, rapid city, south dakota, united states research site, sioux falls, south dakota, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, houston, texas, united states research site, tyler, texas, united states research site, fairfax, virginia, united states research site, everett, washington, united states research site, kennewick, washington, united states research site, renton, washington, united states research site, morgantown, west virginia, united states research site, feldkirch, austria research site, salzburg, austria research site, wien, austria research site, wien, austria research site, anderlecht, belgium research site, edegem, belgium research site, gent, belgium research site, leuven, belgium research site, liège, belgium research site, sint-niklaas, belgium research site, panagyurishte, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, edmonton, alberta, canada research site, vancouver, british columbia, canada research site, kitchener, ontario, canada research site, london, ontario, canada research site, sudbury, ontario, canada research site, montreal, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, bengbu, china research site, changchun, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, chengdu, china research site, chongqing, china research site, dalian, china research site, guangzhou, china research site, guangzhou, china research site, guiyang, china research site, haikou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hefei, china research site, jinan, china research site, lanzhou, china research site, linyi, china research site, nanchang, china research site, nanjing, china research site, qingdao, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, tianjin, china research site, urumqi, china research site, wuhan, china research site, wuhan, china research site, xi'an, china research site, zhengzhou, china research site, horovice, czechia research site, hradec kralove, czechia research site, novy jicin, czechia research site, olomouc, czechia research site, praha 10, czechia research site, praha 4, czechia research site, praha 5, czechia research site, besancon cedex, france research site, bordeaux, france research site, brest cedex, france research site, caen cedex 05, france research site, dijon, france research site, le mans, france research site, lille, france research site, montpellier, france research site, pierre benite cedex, france research site, plerin sur mer, france research site, saint-cloud, france research site, vandoeuvre les nancy, france research site, villejuif cedex, france research site, berlin, germany research site, bottrop, germany research site, dessau-roblau, germany research site, essen, germany research site, freiburg, germany research site, mönchengladbach, germany research site, münchen, germany research site, regensburg, germany research site, velbert, germany research site, wuerzburg, germany research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, győr, hungary research site, miskolc, hungary research site, nyíregyháza, hungary research site, szekszárd, hungary research site, tatabánya, hungary research site, zalaegerszeg, hungary research site, ahmedabad, india research site, calicut, india research site, faridabad, india research site, gurgaon, india research site, karamsad, india research site, kolkata, india research site, madurai, india research site, mumbai, india research site, nagpur, india research site, nashik, india research site, nashik, india research site, new delhi, india research site, rohini, india research site, bergamo, italy research site, genova, italy research site, modena, italy research site, napoli, italy research site, novara, italy research site, padova, italy research site, parma, italy research site, prato, italy research site, roma, italy research site, rozzano, italy research site, chiba-shi, japan research site, chuo-ku, japan research site, chuo-ku, japan research site, fukushima-shi, japan research site, hidaka-shi, japan research site, hirakata-shi, japan research site, isehara-shi, japan research site, kitaadachi-gun, japan research site, koto-ku, japan research site, kumamoto-shi, japan research site, kurashiki shi, japan research site, kurume-shi, japan research site, kyoto-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, nishinomiya-shi, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, ota-shi, japan research site, sagamihara-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shimotsuke-shi, japan research site, shinagawa-ku, japan research site, shinjuku-ku, japan research site, suita-shi, japan research site, takasaki-shi, japan research site, tsu-shi, japan research site, tsukuba-shi, japan research site, yokohama-shi, japan research site, busan, korea, republic of research site, daegu, korea, republic of research site, goyang-si, korea, republic of research site, incheon, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, george town, malaysia research site, johor bahru, malaysia research site, kuala lumpur, malaysia research site, kuala lumpur, malaysia research site, kuching, malaysia research site, selangor, malaysia research site, del. cuauhtemoc, mexico research site, estado de méxico, mexico research site, la paz, mexico research site, metepec, mexico research site, mexico, mexico research site, mex, mexico research site, monterrey, mexico research site, puebla, mexico research site, drammen, norway research site, oslo, norway research site, gdynia, poland research site, konin, poland research site, koszalin, poland research site, lublin, poland research site, olsztyn, poland research site, rzeszów, poland research site, skórzewo, poland research site, łódź, poland research site, braga, portugal research site, guimarães, portugal research site, lisboa, portugal research site, lisboa, portugal research site, lisboa, portugal research site, lisboa, portugal research site, loures, portugal research site, porto, portugal research site, porto, portugal research site, porto, portugal research site, vila nova de gaia, portugal research site, kaluga, russian federation research site, kislino village, ryshkovsky ru, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, bratislava, slovakia research site, bratislava, slovakia research site, košice, slovakia research site, prešov, slovakia research site, trencin, slovakia research site, žilina, slovakia research site, barcelona, spain research site, barcelona, spain research site, jaén, spain research site, lleida, spain research site, madrid, spain research site, madrid, spain research site, malaga, spain research site, pamplona, spain research site, sevilla, spain research site, valencia, spain research site, basel, switzerland research site, bern, switzerland research site, zürich, switzerland research site, kaohsiung, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, adana, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, i̇stanbul, turkey research site, izmir, turkey research site, izmir, turkey research site, kayseri, turkey research site, birmingham, united kingdom research site, cambridge, united kingdom research site, colchester, united kingdom research site, leeds, united kingdom research site, northwood, united kingdom research site, nottingham, united kingdom research site, surrey, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04711252,breast
263,264,NCT05113251,"trastuzumab deruxtecan (t-dxd) alone or in sequence with thp, versus standard treatment (ddac-thp), in her2-positive early breast cancer",,Recruiting,No Results Available,breast neoplasms|breast cancer|her2-positive early breast cancer,drug: trastuzumab deruxtecan|drug: paclitaxel|drug: trastuzumab|drug: pertuzumab|drug: doxorubicin|drug: cyclophosphamide,rate of pathologic complete response (pcr)|event-free survival|invasive disease-free survival (idfs)|overall survival,"astrazeneca|daiichi sankyo, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,624.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D967RC00001,"October 25, 2021","February 5, 2024","June 26, 2026","November 9, 2021",,"April 8, 2022","['research site, birmingham, alabama, united states research site, beverly hills, california, united states research site, glendale, california, united states research site, orange, california, united states research site, denver, colorado, united states research site, grand junction, colorado, united states research site, new haven, connecticut, united states research site, fort myers, florida, united states research site, miami, florida, united states research site, saint petersburg, florida, united states research site, tallahassee, florida, united states research site, west palm beach, florida, united states research site, fort wayne, indiana, united states research site, lexington, kentucky, united states research site, louisville, kentucky, united states research site, shreveport, louisiana, united states research site, scarborough, maine, united states research site, baltimore, maryland, united states research site, towson, maryland, united states research site, detroit, michigan, united states research site, minneapolis, minnesota, united states research site, billings, montana, united states research site, omaha, nebraska, united states research site, las vegas, nevada, united states research site, east brunswick, new jersey, united states research site, summit, new jersey, united states research site, commack, new york, united states research site, durham, north carolina, united states research site, cincinnati, ohio, united states research site, pittsburgh, pennsylvania, united states research site, greenville, south carolina, united states research site, germantown, tennessee, united states research site, knoxville, tennessee, united states research site, nashville, tennessee, united states research site, fort worth, texas, united states research site, ogden, utah, united states research site, salt lake city, utah, united states research site, burlington, vermont, united states research site, fairfax, virginia, united states research site, midlothian, virginia, united states research site, richmond, virginia, united states research site, tacoma, washington, united states research site, innsbruck, austria research site, salzburg, austria research site, wien, austria research site, wien, austria research site, goiânia, brazil research site, ijuí, brazil research site, natal, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, são paulo, brazil research site, são paulo, brazil research site, vitoria, brazil research site, panagyurishte, bulgaria research site, pleven, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, edmonton, alberta, canada research site, victoria, british columbia, canada research site, sault ste. marie, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, sherbrooke, quebec, canada research site, montreal, canada research site, quebec, canada research site, beijing, china research site, beijing, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, chongqing, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, hangzhou, china research site, hefei, china research site, kunming, china research site, nanchang, china research site, nanjing, china research site, nanning, china research site, qingdao, china research site, shanghai, china research site, shenyang, china research site, tianjin, china research site, wuhan, china research site, wuhan, china research site, zhengzhou, china research site, aschaffenburg, germany research site, augsburg, germany research site, berlin, germany research site, erlangen, germany research site, hamburg, germany research site, heidelberg, germany research site, kiel, germany research site, leipzig, germany research site, muenster, germany research site, mönchengladbach, germany research site, münchen, germany research site, offenbach am main, germany research site, tübingen, germany research site, gurgaon, india research site, ludhiana, india research site, manipal, india research site, mumbai, india research site, mumbai, india research site, nasik, india research site, new delhi, india research site, new delhi, india research site, raipur, india research site, rishikesh, india research site, thiruvananthapuram, india research site, vadodara, india research site, bologna, italy research site, candiolo, italy research site, livorno, italy research site, napoli, italy research site, negrar, italy research site, padova, italy research site, rome, italy research site, chuo-ku, japan research site, hidaka-shi, japan research site, hiroshima-shi, japan research site, kawasaki-shi, japan research site, koto-ku, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, osaka-shi, japan research site, ota-shi, japan research site, shinjuku-ku, japan research site, goyang-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, arequipa, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, bacolod, philippines research site, baguio city, philippines research site, cebu city, philippines research site, cebu city, philippines research site, davao city, philippines research site, davao city, philippines research site, iloilo, philippines research site, legazpi city, philippines research site, manila, philippines research site, quezon city, philippines research site, quezon city, philippines research site, san juan, philippines research site, biała podlaska, poland research site, bydgoszcz, poland research site, koszalin, poland research site, lublin, poland research site, rzeszów, poland research site, rzeszów, poland research site, warszawa, poland research site, wroclaw, poland research site, łódź, poland research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, dammam, saudi arabia research site, jeddah, saudi arabia research site, jeddah, saudi arabia research site, riyadh, saudi arabia research site, barcelona, spain research site, madrid, spain research site, madrid, spain research site, sevilla, spain research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, tainan, taiwan research site, taipei 112, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, hat yai, thailand research site, khon kaen, thailand']",,https://ClinicalTrials.gov/show/NCT05113251,breast
264,265,NCT01419197,a study of trastuzumab emtansine in comparison with treatment of physician's choice in participants with her2-positive breast cancer who have received at least two prior regimens of her2-directed therapy,TH3RESA,Completed,Has Results,breast cancer,drug: trastuzumab emtansine|drug: treatment of physician's choice,progression-free survival|overall survival|percentage of participants with an objective response|duration of the objective response|6-month and 1-year survival|time to pain symptom progression|change from baseline in the eortc qlq-bm22 pain score on day 1 of each cycle|overall survival (final analysis)|6-month and 1-year survival (final analysis),hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,602.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TDM4997g|BO25734|2011-000509-29,September 2011,February 2013,August 2015,"August 18, 2011","May 5, 2014","October 12, 2016","['tucson, arizona, united states hot springs, arkansas, united states hayward, california, united states highland, california, united states oakland, california, united states roseville, california, united states sacramento, california, united states san diego, california, united states san francisco, california, united states san jose, california, united states santa clara, california, united states south san francisco, california, united states stockton, california, united states vallejo, california, united states walnut creek, california, united states west hollywood, california, united states denver, colorado, united states trumbull, connecticut, united states newark, delaware, united states washington, district of columbia, united states coral springs, florida, united states deerfield beach, florida, united states fort myers, florida, united states jacksonville, florida, united states plantation, florida, united states marietta, georgia, united states post falls, idaho, united states chicago, illinois, united states chicago, illinois, united states maywood, illinois, united states fort wayne, indiana, united states sioux city, iowa, united states wichita, kansas, united states scarborough, maine, united states bethesda, maryland, united states columbia, maryland, united states boston, massachusetts, united states boston, massachusetts, united states boston, massachusetts, united states detroit, michigan, united states minneapolis, minnesota, united states saint louis, missouri, united states omaha, nebraska, united states new brunswick, new jersey, united states bronx, new york, united states lake success, new york, united states charlotte, north carolina, united states columbus, ohio, united states portland, oregon, united states philadelphia, pennsylvania, united states charleston, south carolina, united states chattanooga, tennessee, united states nashville, tennessee, united states nashville, tennessee, united states dallas, texas, united states fort worth, texas, united states san antonio, texas, united states richmond, virginia, united states seattle, washington, united states kogarah, new south wales, australia south brisbane, queensland, australia frankston, victoria, australia perth, western australia, australia leuven, belgium wilrijk, belgium salvador, ba, brazil goiania, go, brazil rio de janeiro, rj, brazil porto alegre, rs, brazil itajai, sc, brazil sao paulo, sp, brazil moncton, new brunswick, canada toronto, ontario, canada regina, saskatchewan, canada saskatoon, saskatchewan, canada quebec, canada brno, czech republic hradec kralove, czech republic olomouc, czech republic praha 2, czech republic praha 5, czech republic angers, france bordeaux, france caen, france lyon, france montpellier cedex 5, france nantes, france nice, france nimes, france paris, france reims cedex, france rouen, france st-priest-en-jarez, france strasbourg, france toulouse, france toulouse, france tours, france villejuif, france bielefeld, germany hamburg, germany hamburg, germany hannover, germany kiel, germany mainz, germany münchen, germany ravensburg, germany recklinghausen, germany stuttgart, germany trier, germany troisdorf, germany budapest, hungary budapest, hungary gyula, hungary kecskemet, hungary miskolc, hungary szeged, hungary szolnok, hungary bangalore, india chennai, india kolkata, india new delhi, india pune, india pune, india beer sheva, israel hafia, israel jerusalem, israel petach tikva, israel ramat-gan, israel rehovot, israel tel aviv, israel potenza, basilicata, italy napoli, campania, italy genova, liguria, italy bergamo, lombardia, italy brescia, lombardia, italy milano, lombardia, italy milano, lombardia, italy biella, piemonte, italy cona (ferrara), veneto, italy kyunggi-do, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of oslo, norway bialystok, poland bydgoszcz, poland gdansk, poland lublin, poland poznan, poland warszawa, poland moscow, russian federation samara, russian federation stavropol, russian federation kosice, slovakia poprad, slovakia la coruna, la coruña, spain bilbao, vizcaya, spain barcelona, spain barcelona, spain madrid, spain madrid, spain madrid, spain malaga, spain murcia, spain sevilla, spain valencia, spain umea, sweden uppsala, sweden örebro, sweden bern, switzerland zürich, switzerland bangkok, thailand bangkok, thailand bangkok, thailand brighton, united kingdom guildford, united kingdom london, united kingdom maidstone, united kingdom nottingham, united kingdom sheffield, united kingdom stoke-on-trent, united kingdom westcliffe-on-sea, united kingdom wirral, united kingdom']",,https://ClinicalTrials.gov/show/NCT01419197,breast
265,266,NCT03125902,a study of atezolizumab and paclitaxel versus placebo and paclitaxel in participants with previously untreated locally advanced or metastatic triple negative breast cancer (tnbc),IMpassion131,"Active, not recruiting",Has Results,triple-negative breast cancer,"drug: atezolizumab (mpdl3280a), an engineered anti-pdl1 antibody|drug: atezolizumab placebo|drug: paclitaxel","progression-free survival (pfs) assessed using response evaluation criteria in solid tumors version 1.1 (recist v1.1) in the subpopulation with programmed death-ligand 1 (pd-l1)-positive tumour status|progression-free survival (pfs) assessed using response evaluation criteria in solid tumors version 1.1 (recist v1.1) in the intent-to-treat (itt) population|overall survival (os) in the pd-l1-positive subpopulation|overall survival (os) in the itt population|percentage of participants who are alive at 12 and 18 months|time to deterioration (ttd) in global health status/ health related quality of life (hrqol) in the pro evaluable population|percentage of participants who are alive without progression event at month 12 assessed using recist v1.1|percentage of participants with objective response assessed using recist v1.1 in the pd-l1-positive population (confirmed, investigator-assessed )|percentage of participants with objective response assessed using recist v1.1 in the pd-l1-positive population (unconfirmed, investigator-assessed)|percentage of participants with objective response assessed using recist v1.1 in the response-evaluable population (confirmed, investigator-assessed )|percentage of participants with objective response assessed using recist v1.1 in the response-evaluable population (unconfirmed, investigator-assessed )|duration of objective response (dor) assessed using recist v1.1 in dor-evaluable population (unconfirmed)|percentage of participants with clinical benefit assessed using recist v1.1 in response-evaluable population|minimum observed serum concentration (cmin) of atezolizumab in pk evaluable population|maximum observed serum concentration (cmax) of atezolizumab in pk-evaluable population|minimum observed plasma concentration (cmin) of paclitaxel|maximum observed plasma concentration (cmax) of paclitaxel|percentage of participants with adverse events (aes) and serious aes (saes)|percentage of participants with anti-drug antibodies' (adas) against atezolizumab in ada evaluable population|overall survival by pd-l1 status, intent to treat population|progression free survival by pd-l1 status, intent to treat population|duration of confirmed response (c-dor) in (c-dor)-evaluable population",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,651.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MO39196|2016-004024-29,"August 25, 2017","November 15, 2019","June 30, 2022","April 24, 2017","January 7, 2021","May 16, 2022","[""stanford cancer center, stanford, california, united states florida cancer specialists; department of oncology, fort myers, florida, united states florida cancer specialist, north region, saint petersburg, florida, united states northwest georgia oncology centers pc - marietta, marietta, georgia, united states hca midwest health, kansas city, missouri, united states the valley hospital, paramus, new jersey, united states magee-woman's hospital, pittsburgh, pennsylvania, united states tennessee oncology; sarah cannon research institute, nashville, tennessee, united states centro oncologico riojano integral (cori), la rioja, argentina santa casa de misericordia de salvador, salvador, ba, brazil centro de pesquisas clinicas em oncologia - cpco, cachoeiro de itapemirim, es, brazil hospital araujo jorge; departamento de ginecologia e mama, goiania, go, brazil hospital sao lucas - pucrs, porto alegre, rs, brazil hospital nossa senhora da conceicao, porto alegre, rs, brazil hospital perola byington, sao paulo, sp, brazil tom baker cancer centre-calgary, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada kingston general hospital, kingston, ontario, canada grand river hospital, kitchener, ontario, canada london regional cancer centre, london, ontario, canada sunnybrook odette cancer centre, toronto, ontario, canada mcgill university; glen site; oncology, montreal, quebec, canada hopital du saint sacrement, quebec city, quebec, canada centre hospitalier universitaire de sherbrooke - hopital fleurimont, sherbrooke, quebec, canada cancer hospital chinese academy of medical sciences., beijing, china beijing union hospital, beijing, china west china hospital, sichuan university; department of breast, chengdu, china sun yat-sen memorial hospital, guangzhou, china harbin medical university cancer hospital, harbin, china shandong cancer hospital, jinan, china jiangsu province hospital (the first affiliated hospital with nanjing medical university), nanjing city, china jiangsu cancer hospital, nanjing city, china fudan university shanghai cancer center, shanghai city, china shanghai jiao tong university school of medicine (sjtusm) - ruijin hospital (guangci hospital), shanghai, china liaoning cancer hospital & institute, shenyang, china hebei medical university fourth hospital;(tumor hospital of hebei province), shijiazhuang, china tianjin medical university cancer institute & hospital, tianjing, china the second affiliated hospital of xi'an jiao tong university, xi'an city, china first affiliated hospital of medical college of xi'an jiaotong university, xi'an, china zhejiang cancer hospital, zhejiang, china henan cancer hospital, zhengzhou, china clinical hospital centre zagreb, zagreb, croatia fakultni nemocnice hradec kralove; dept of radiotherapy & oncology, hradec kralove, czechia fakultni nemocnice olomouc; onkologicka klinika, olomouc, czechia fakultni nemocnice ostrava; klinika onkologicka fno a lf ou, ostrava-poruba, czechia fakultni poliklinika vseobecne fakultni niemocnice; onkologicka klinika, praha 2, czechia clinique sainte catherine; hopital de semaine, avignon, france hopital jean minjoz; oncologie, besancon, france polyclinique bordeaux nord aquitaine, bordeaux, france hopital morvan, brest, france chd les oudairies, la roche sur yon, france centre oscar lambret; senologie, lille, france centre leon berard; departement oncologie medicale, lyon, france centre d'oncologie de gentilly; oncology, nancy, france hopital caremeau; hematologie oncologie, nimes, france hopital tenon, paris, france institut curie; oncologie medicale, paris, france hopital saint louis, service d oncologie medicale, paris, france ch pitie salpetriere; oncologie medicale, paris, france centre eugene marquis; service d'oncologie, rennes, france centre paul strauss; oncologie medicale, strasbourg, france institut claudius regaud; departement oncologie medicale, toulouse, france institut gustave roussy; sitep, villejuif cedex, france ambulantes tumorzentrum spandau; dres. benno mohr und uwe peters, berlin, germany onkologische schwerpunktpraxis bielefeld, bielefeld, germany klinikum essen-mitte ev. huyssens-stiftung / knappschafts gmbh; klinik für senologie / brustzentrum, essen, germany hopa im struensee-haus, dres. erik engel, wiebke hollburg, hamburg, germany nationales centrum für tumorerkrankungen (nct) ; gyn. onk. frauenklinik; uniklinikum heidelberg, heidelberg, germany st. elisabeth krankenhaus köln gmbh; gynäkologie und geburtshilfe, koeln, germany universitätsmedizin mainz; klinik u. poliklinik f. geburtshilfe u. frauenheilkunde, mainz, germany onkonet marburg gmbh, marburg, germany klinik & poliklinik für frauenheilkunde und geburtshilfe, campus innenstadt, münchen, germany gemeinschaftspraxis für hämatologie und onkologie, münster, germany klinikum ernst von bergmann; frauenklinik, potsdam, germany dres. helmut forstbauer, carsten ziske und kollegen; onkologische schwerpunktpraxis, troisdorf, germany universitätsklinik tübingen; frauenklinik, tübingen, germany anticancer hospital ag. savas ; 2nd dept. of oncology - internal medicine, athens, greece aretaieion university hospital; oncology unit, athens, greece agioi anargyroi cancer hospital; 2nd oncology dept., kifisia, greece papageorgiou general hospital; medical oncology, thessaloniki, greece yashoda hospital, hyderabad, andhra pradesh, india indraprastha apollo hospitals, new delhi, delhi, india rajiv gandhi cancer inst.&research center; medical oncology, new delhi, delhi, india max super speciality hospital; medical oncology, north west delhi, delhi, india manipal hospital; department of oncology, bangalore, karnataka, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india jehangir hospital, pune, maharashtra, india tata medical centre; medical oncology, kolkata, west bengal, india apollo speciality hospital, chennai, india max balaji hospital, delhi, india apollo gleneagles hospitals, kolkata, india dr. b l kapur memorial hospital; blk cancer centre, new delhi, india hadassah ein karem hospital; oncology dept, jerusalem, israel rabin mc; davidof center - oncology institute, petach tikva, israel sheba medical center, ramat gan, israel rambam health corporation; oncology institute, rambam, israel kaplan medical center, rehovot, israel tel aviv sourasky medical ctr; oncology, tel aviv, israel assaf harofeh; oncology, zerifin, israel fondazione università g. d'annunzio; clinical research center (crc); centro studi (cesi), chieti, abruzzo, italy presidio ospedaliero s. giovanni di dio; u.o. di oncologia, frattamaggiore, campania, italy azienda ospedaliera universitaria federico ii, napoli, campania, italy istituto nazionale tumori fondazione g. pascale, napoli, campania, italy azienda ospedaliero - universitaria di modena policlinico, modena, emilia-romagna, italy universita campus bio-medico di roma (ucbm), roma, lazio, italy irccs istituto regina elena (ifo); oncologia medica b, roma, lazio, italy azienda policlinico umberto i, roma, lazio, italy a.o. universitaria s. martino di genova, genova, liguria, italy azienda socio sanitaria territoriale papa giovanni xxiii (presidio papa giovanni xxiii), bergamo, lombardia, italy asst degli spedali civili di brescia, brescia, lombardia, italy hospital san raffaele, milano, lombardia, italy fondazione irccs istituto nazionale dei tumori, milano, lombardia, italy ieo istituto europeo di oncologia;divisione oncologia medica, milano, lombardia, italy irccs istituto clinico humanitas; oncologia, rozzano, lombardia, italy fondazione del piemonte per l'oncologia ircc di candiolo, candiolo, piemonte, italy ospedale s. vincenzo; oncologia medica, taormina, sicilia, italy azienda ospedaliero-universitaria careggi; sod radioterapia, firenze, toscana, italy ospedale civile; unita operativa di oncologia medica, livorno, toscana, italy iov - istituto oncologico veneto - irccs; oncologia medica ii, padova, veneto, italy gunma prefectural cancer center, gunma, japan hiroshima city hiroshima citizens hospital, hiroshima, japan sagara hospital, kagoshima, japan kanagawa cancer center, kanagawa, japan tokai university hospital, kanagawa, japan niigata cancer center hospital, niigata, japan naha-nishi clinic, okinawa, japan osaka international cancer institute, osaka, japan saitama cancer center, saitama, japan the cancer institute hospital of jfcr, tokyo, japan centre hospitalier universitaire mohamed vi; oncologie-hématologie, marrakech, morocco institut national d'oncologie sidi mohammed ben abdellah; anatomopathologie, rabat, morocco prof. dr. i. chiricuta institute of oncology, cluj napoca, romania centrul de oncologie sfantul nectarie, craiova, romania petrov research inst. of oncology, pesochny, leningrad, russian federation russian oncology research center n.a. n.n. blokhin, moscow, russian federation king fahad specialist hospital; oncology, dammam, saudi arabia international medical center (imc), jeddah, saudi arabia king fahad medical city; gastroentrology, riyadh, saudi arabia narodny onkologicky ustav; oddelenie klinickej onkologie a, bratislava, slovakia poko poprad; department of oncology, poprad, slovakia wilgers oncology centre, pretoria, south africa private oncology centre, pretoria, south africa sandton oncology medical group, sandton, south africa complejo hospitalario universitario a coruña (chuac); servicio de oncologia, a coruña, la coruña, spain hospital clínic i provincial; servicio de hematología y oncología, barcelona, spain hospital universitario de fuenlabrada; servicio de oncologia, madrid, spain hospital universitario virgen macarena; servicio de oncologia, sevilla, spain hospital universitario virgen del rocio; servicio de oncologia, sevilla, spain adana baskent university medical faculty; oncology, adana, turkey ankara city hospital, ankara, turkey uludag university medical faculty; internal medicine, bursa, turkey dicle uni medical faculty; internal medicine, diyarbakir, turkey trakya universitesi tip fakultesi, medikal onkoloji bilim dali, balkan yerleskesi, edirne, turkey izmir ataturk training and research hospital, izmir, turkey kocaeli university faculty of medicine; medical oncology, izmit, turkey goztepe prof.dr. suleyman yalcin city hospital; clinical oncology, kadiköy, turkey guys and st thomas nhs foundation trust, guys hospital, london, united kingdom christie hospital, manchester, united kingdom mount vernon cancer centre, northwood, united kingdom k hospital, hanoi, vietnam hochiminh city oncology hospital, hochiminh city, vietnam""]","""study protocol"", https://clinicaltrials.gov/provideddocs/02/nct03125902/prot_001.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/02/nct03125902/sap_000.pdf",https://ClinicalTrials.gov/show/NCT03125902,breast
266,267,NCT00929240,a study of avastin (bevacizumab) + xeloda (capecitabine)as maintenance therapy in patients with her2-negative metastatic breast cancer,,Completed,Has Results,breast cancer,drug: bevacizumab [avastin]|drug: capecitabine [xeloda],"percentage of participants with disease progression or death (maintenance phase data cutoff october 4, 2013)|progression free survival (maintenance phase data cutoff october 4, 2013)|percentage of participants with best overall confirmed objective response of cr or pr per recist 1.0 (maintenance phase data cutoff october 4, 2013)|percentage of participants with clinical benefit (cr, pr and sd) per recist 1.0 (data cutoff october 4, 2013)|percentage of participants who died (maintenance phase data cutoff october 4, 2013)|overall survival (maintenance phase data cutoff october 4, 2013)|percentage of participants expected to be alive after 1 and 2 years on treatment (maintenance phase data cutoff october 4, 2013)|percentage of participants with pd or death due to pd (maintenance phase data cutoff october 4, 2013)|time to progression (maintenance phase data cutoff october 4, 2013)|quality of life assessed as change from baseline in global health status using the european organization for research and treatment of cancer quality of life questionnaire - 30 (eortc qlq - c30) (maintenance phase data cutoff october 4, 2013)|percentage of participants with best overall confirmed objective response of cr or pr per recist 1.0 (initial treatment phase)|percentage of participants with clinical benefit (cr, pr and sd) per recist 1.0 (initial treatment phase)",hoffmann-la roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,287.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO22223|2008-006872-31,July 2009,June 2014,June 2014,"June 26, 2009","March 3, 2015","March 3, 2015","['fortaleza, ce, brazil belo horizonte, mg, brazil rio de janeiro, rj, brazil ijui, rs, brazil porto alegre, rs, brazil jau, sp, brazil santo andre, sp, brazil sao paulo, sp, brazil sao paulo, sp, brazil beijing, china beijing, china beijing, china hangzhou, china hangzhou, china shanghai, china alexandria, egypt cairo, egypt amiens, france angers, france besancon, france bobigny, france dijon, france hyeres, france le coudray, france lille, france paris, france paris, france perigueux, france rodez, france st priest en jarez, france strasbourg, france hong kong, hong kong hong kong, hong kong bangalore, india hyderabad, india mumbai, india mumbai, india new delhi, india new delhi, india napoli, campania, italy trieste, friuli-venezia giulia, italy genova, liguria, italy saronno, lombardia, italy brindisi, puglia, italy antella (fi), toscana, italy bydgoszcz, poland wroclaw, poland dammam, saudi arabia jeddah, saudi arabia jeddah, saudi arabia alcoy, alicante, spain sabadell, barcelona, barcelona, spain alcazar de s. juan, ciudad real, spain barakaldo, vizcaya, spain jaen, spain malaga, spain toledo, spain valencia, spain ankara, turkey ankara, turkey antalya, turkey istanbul, turkey sıhhiye, ankara, turkey']",,https://ClinicalTrials.gov/show/NCT00929240,breast
267,268,NCT01764022,a safety and efficacy study of bcd-022 with paclitaxel compared to herceptin with paclitaxel in her2+ metastatic breast cancer patients,,Completed,Has Results,human epithelial receptor (her)-2 positive breast cancer,drug: trastuzumab|drug: paclitaxel,overall response rate|area under the curve after the first test drug administration|complete response rate|partial response rate|stabilization rate|progression rate|treatment postponed due to ae/sae|treatment discontinuation due to ae/sae|occurrence of neutralizing anti-trastuzumab antibodies|cmax after the first test drug administration|tmax after the first test drug administration|t1/2 after the first test drug administration|cmax after the sixth test drug administration|tmax after the sixth test drug administration,biocad,Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,225.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCD-022-02,October 2012,March 2015,December 2017,"January 9, 2013","October 24, 2016","November 29, 2018","['brest region clinical oncology dispensary, brest, belarus gomel region clinical oncology dispensary, gomel, belarus grodno regional hospital, grodno, belarus vitebsk state medical university of order of peoples\' friendship, vitebsk, belarus hcg bangalore institute of oncology, bangalore, india m.s.ramaiah memorial hospital, bangalore, india narayana hrudayalaya hospitals, bangalore, india state health institution of moscow ""moscow city oncology hospital #62 of moscow board of health"", stepanovskoye, moscow region, russian federation arkhangelsk district clinical oncology dispensary, arkhangelsk, russian federation non-governmental healthcare institution ""railway clinical hospital on the chelyabinsk station of jsc russian railways"", chelyabinsk, russian federation state-financed health institution ""chelyabinsk region clinical oncology dispansary"", chelyabinsk, russian federation state-financed health institution ""republican clinical oncology hospital"", izhevsk, russian federation institution of russian academy of medical sciences ""russian cancer research center named after n.n. blokhin"", moscow, russian federation federal state institution ""moscow institute of cancer research named after p.a. hertsen"" ministry of health of russian federation, moscow, russian federation regional state health institution ""orlov oncology dispansary"", orel, russian federation state health institution ""region oncology dispansary"", penza, russian federation perm region oncology dispensary, perm, russian federation federal government budgetary institution ""rostov institute of cancer research"" of ministry of health of russian federation, rostov-on-don, russian federation saint petersburg city clinical oncology center, saint petersburg, russian federation state-financed health institution ""samara region clinical oncology dispansary"", samara, russian federation oncology dispensary 2, sochi, russian federation military medical academy named after s.m. kirov, st.petersburg, russian federation n.n.petrov oncology research center, st.petersburg, russian federation russian scientific center of radiology and surgery technologies, st.petersburg, russian federation state-financed health institution ""stavropol region clinical oncology dispansary"", stavropol, russian federation republican clinical oncology dispensary of ministry of health republic bashkortostan, ufa, russian federation volgograd district oncology dispensary №1, volgograd, russian federation donetsk city oncology dispensary, donetsk, ukraine donetsk regional antitumor center, donetsk, ukraine kharkiv regional clinical oncology center, kharkiv, ukraine kryvyi rih oncology dispensary, kryvyi rih, ukraine lviv regional state cancer diagnostics and treatment center, lviv, ukraine city hospital №2, makiivka, ukraine poltava regional clinical oncology dispensary, poltava, ukraine zakarpatskyi regional clinical oncology center, uzhhorod, ukraine vinnytsia regional clinical oncology dispensary, vinnytsia, ukraine']",,https://ClinicalTrials.gov/show/NCT01764022,breast
268,269,NCT01491737,a study of pertuzumab in combination with trastuzumab plus an aromatase inhibitor in participants with metastatic human epidermal growth factor receptor 2 (her2)-positive and hormone receptor-positive advanced breast cancer,PERTAIN,Completed,Has Results,breast cancer,drug: pertuzumab|drug: trastuzumab|drug: aromatase inhibitor|drug: induction chemotherapy,"progression-free survival (pfs)|overall survival (os)|overall response rate (orr)|clinical benefit rate (cbr)|duration of response (dor)|time to response (ttr)|change from baseline in health-related quality of life as determined by european quality of life 5-dimension (eq-5d) visual analog scale (vas) scores|overview of the number of participants with adverse events, severity determined according to nci-ctcae version 4.03|number of participants who died over the course of the study by reported cause of death and time of death relative to first or last dose of study treatment|change from baseline in left ventricular ejection fraction (lvef) values over the course of the study",hoffmann-la roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,258.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO27775|2011-002132-10,"February 17, 2012","March 17, 2016","November 14, 2019","December 14, 2011","June 7, 2017","October 28, 2020","['university of alabama at birmingham, birmingham, alabama, united states ironwood cancer tx & rsch ctrs, chandler, arizona, united states genesis cancer center, hot springs, arkansas, united states comprehensive blood & ca ctr; research, bakersfield, california, united states rocky mountain cancer center - denver, denver, colorado, united states norwalk hospital, norwalk, connecticut, united states advanced medical specialties, miami, florida, united states georgia cancer specialists - northside, atlanta, georgia, united states northwest georgia oncology centers, a service of wellstar cobb hospital, marietta, georgia, united states cancer center of kansas, wichita, kansas, united states crescent city rsrch cnsrtm, llc, marrero, louisiana, united states weinberg ca inst franklin sq, baltimore, maryland, united states center for cancer and blood disorders, bethesda, maryland, united states washington university school of medicine; internal medicine - renal, saint louis, missouri, united states hematology oncology associates; carol g. simon ctr, morristown, new jersey, united states cooper hospital; hematology & oncology, voorhees, new jersey, united states ns-long island jewish hlth sys, lake success, new york, united states prohealth care associates llp, lake success, new york, united states upmc cancer centers, pittsburgh, pennsylvania, united states baylor college of medicine; lester & sue smith breast ctr, houston, texas, united states scott and white hospital; cancer center, temple, texas, united states instituto do cancer do estado de sao paulo - icesp, sao paulo, sp, brazil hospital perola byington, sao paulo, sp, brazil inst. brasileiro de controle ao cancer; oncologia clinica / quimioterapia, sao paulo, sp, brazil hospital sao jose, são paulo, sp, brazil hopital jean minjoz; oncologie, besancon, france clinique tivoli; sce radiotherapie, bordeaux, france hopital morvan; oncologie - radiotherapie, brest, france centre jean perrin; oncologie, clermont ferrand, france clinique de la sauvegarde; chimiotherapie, lyon, france centre catherine de sienne; chimiotherapie, nantes, france centre antoine lacassagne; hopital de jour a2, nice, france ch de senlis; medecine 2, senlis, france clinique pasteur; oncologie medicale, toulouse, france centre alexis vautrin; oncologie medicale, vandoeuvre-les-nancy, france indraprastha apollo hospitals, new delhi, delhi, india bangalore institute of oncology, bangalore, karnataka, india jaslok hospital & research centre; medical oncology, mumbai, maharashtra, india apollo speciality hospital, chennai, india ruby hall clinic, pune, india istituto nazionale tumori fondazione g. pascale, napoli, campania, italy università degli studi federico ii; clinica di oncologia medica, napoli, campania, italy azienda ospedaliero-universitaria s.orsola-malpighi; unità operativa oncologia medica, bologna, emilia-romagna, italy ospedale regionale di parma; divisione di oncologia medica, parma, emilia-romagna, italy a.o. santa maria degli angeli; u.o di oncologia medica, pordenone, friuli-venezia giulia, italy ospedale s.s. trinità nuovo; divisione oncologia, sora, lazio, italy casa di cura multimedica ospedale di castellanza; uo senologia medica, castellanza, lombardia, italy irccs istituto nazionale dei tumori (int);s.c. medicina oncologica 1, milano, lombardia, italy irccs fondazione maugeri; oncologia medica i, pavia, lombardia, italy irccs ist. tumori giovanni paolo ii; dipartimento oncologia medica, bari, puglia, italy ospedale antonio perrino; oncologia medica, brindisi, puglia, italy ospedale vito fazzi; div. oncoematologia, lecce, puglia, italy az ospedaliera nuovo garibaldi quartiere nesima; oncologia medica, catania, sicilia, italy a.o. careggi; radioterapia, firenze, toscana, italy ospedale misericordia e dolce; oncologia medica, prato, toscana, italy hospital universitari germans trias i pujol; servicio de oncologia, badalona, barcelona, spain hospital provincial de castellon; servicio de oncologia, castellon de la plana, castellon, spain hospital universitario reina sofia; servicio de oncologia, córdoba, cordoba, spain iinstituto oncologico de san sebastian, oncologikoa; servicio de oncologia, san sebastian, guipuzcoa, spain hospital de donostia; servicio de oncologia medica, san sebastian, guipuzcoa, spain hospital del mar; servicio de oncologia, barcelona, spain hospital de san pedro de alcantara, caceres, spain complejo hospitalario universitario a coruña (chuac, materno infantil), oncología, la coruña, spain centro oncológico gallego josé antonio quiroga y piñeiro, servicio de oncologia, la coruña, spain hospital universitari arnau de vilanova de lleida; servicio de oncologia, lerida, spain hospital ramon y cajal; servicio de oncologia, madrid, spain hospital universitario clínico san carlos; servicio de oncologia, madrid, spain hospital universitario virgen de arrixaca; servicio de oncologia, murcia, spain hospital universitario virgen macarena; servicio de oncologia, sevilla, spain hospital clinico universitario de valencia; servicio de onco-hematologia, valencia, spain hospital universitario miguel servet; servicio oncologia, zaragoza, spain hacettepe uni medical faculty hospital; oncology dept, ankara, turkey ankara city hospital, ankara, turkey ege uni medical faculty hospital; oncology dept, izmir, turkey inonu university medical faculty turgut ozal medical center medical oncology department, malatya, turkey brighton and sussex univ hosp, brighton, united kingdom university hospital coventry; oncology department, coventry, united kingdom beatson west of scotland cancer centre, glasgow, united kingdom queen elizabeth hospital, london, united kingdom queen alexandra hospital, portsmouth, portsmouth, united kingdom scarborough general hospital, scarborough, united kingdom weston park hospital; cancer clinical trials centre, sheffield, united kingdom']",,https://ClinicalTrials.gov/show/NCT01491737,breast
269,270,NCT04541706,lorlatinib in alk inhibitor treated unresectable advanced/recurrent alk-positive non small cell lung cancer patients in india,,"Active, not recruiting",No Results Available,advanced non-small cell lung cancer,drug: lorlatinib,incidence of adverse events (aes)|percentage of participants with objective responses based on investigators' assessments|percentage of participants with intracranial objective responses based on investigators' assessments|duration of response(dor)|intracranial duration of response (ic-dor),pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,111.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B7461030,"August 27, 2020","July 11, 2022","July 11, 2022","September 9, 2020",,"June 21, 2021","['rajiv gandhi cancer institute and research centre, new delhi, delhi, india the gujarat cancer and research institute, ahmedabad, gujarat, india hemato oncology clinic ahmedabad pvt. ltd, ahmedabad, gujarat, india artemis hospital, gurugram, haryana, india national cancer institute, nagpur, maharashtra, india apex wellness hospital, nashik, maharashtra, india grant medical foundation, ruby hall clinic, pune, maharashtra, india sahyadri clinical research and development center, pune, maharashtra, india sahyadri super speciality hospital, pune, maharashtra, india bhaktivedanta hospital and research institute, thane, maharashtra, india yashoda hospital, hyderabad, telangana state, india tata medical center, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT04541706,
270,271,NCT00077857,a study to assess capecitabine (xeloda®) in patients with locally advanced or metastatic breast cancer,,Completed,Has Results,breast cancer,drug: capecitabine (xeloda®)|drug: docetaxel (taxotere®),time to progression of disease or death|percentage of participants with best overall response being complete response (cr) or partial response (pr)|time to overall response|duration of overall response|time to treatment failure|overall survival|number of participants with adverse events and serious adverse events,hoffmann-la roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,470.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NO16853,July 2003,March 2010,March 2010,"February 16, 2004","May 10, 2013","May 10, 2013","['birmingham, alabama, united states hoover, alabama, united states tucson, arizona, united states berkeley, california, united states poway, california, united states boca raton, florida, united states fort lauderdale, florida, united states inverness, florida, united states jacksonville, florida, united states miami shores, florida, united states port saint lucie, florida, united states tamarac, florida, united states skokie, illinois, united states urbana, illinois, united states beech grove, indiana, united states des moines, iowa, united states overland park, kansas, united states houma, louisiana, united states baltimore, maryland, united states baltimore, maryland, united states frederick, maryland, united states rockville, maryland, united states boston, massachusetts, united states detroit, michigan, united states kalamazoo, michigan, united states jefferson city, missouri, united states st joseph, missouri, united states paramus, new jersey, united states summit, new jersey, united states williamsville, new york, united states canton, ohio, united states mayfield heights, ohio, united states allentown, pennsylvania, united states kingston, pennsylvania, united states charleston, south carolina, united states columbia, south carolina, united states collierville, tennessee, united states knoxville, tennessee, united states austin, texas, united states houston, texas, united states colchester, vermont, united states abingdon, virginia, united states walla walla, washington, united states mostar, bosnia and herzegovina sarajevo, bosnia and herzegovina tuzla, bosnia and herzegovina beijing, china beijing, china bengbu, china dalian, china dalian, china hangzhou, china shanghai, china tianjin, china pardubice, czech republic praha, czech republic praha, czech republic praha, czech republic tabor, czech republic ahmedabad, india bangalore, india bangalore, india cochin, india hyderabad, india hyderabad, india hyderabad, india jaipur, india kolkata, india ludhiana, india manipal, india mumbai, india new delhi, india trivandrum, india vellore, india poznan, poland wroclaw, poland chelyabinsk, russian federation ivanovo, russian federation kazan, russian federation kazan, russian federation moscow, russian federation moscow, russian federation omsk, russian federation ryazan, russian federation samara, russian federation st petersburg, russian federation st petersburg, russian federation yaroslavl, russian federation bloemfontein, south africa durban, south africa polokwane, south africa bangkok, thailand chiang mai, thailand khon kaen, thailand']",,https://ClinicalTrials.gov/show/NCT00077857,breast
271,272,NCT00829166,a study of trastuzumab emtansine versus capecitabine + lapatinib in participants with her2-positive locally advanced or metastatic breast cancer,EMILIA,Completed,Has Results,breast cancer,drug: trastuzumab emtansine|drug: lapatinib|drug: capecitabine,percentage of participants with pd or death as assessed by an independent review committee (irc)|progression-free survival (pfs) as assessed by an irc (co-primary endpoint)|percentage of participants who died: second interim analysis|overall survival: second interim analysis (co-primary endpoint)|percentage of participants who died: final analysis|overall survival: final analysis|percentage of participants who were alive at year 1|percentage of participants who were alive at year 2|percentage of participants with pd or death as assessed by the investigator|pfs as assessed by the investigator|percentage of participants with objective response (or) as assessed by an irc|duration of objective response (dor) as assessed by an irc|percentage of participants with clinical benefit as assessed by an irc|percentage of participants with treatment failure|time to treatment failure|percentage of participants with symptom progression|time to symptom progression,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,991.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO21977|TDM4370g,February 2009,July 2012,September 2015,"January 26, 2009","April 23, 2013","October 31, 2016","['chandler, arizona, united states tucson, arizona, united states anaheim, california, united states anaheim, california, united states bakersfield, california, united states baldwin park, california, united states bellflower, california, united states duarte, california, united states fontana, california, united states hayward, california, united states irvine, california, united states la jolla, california, united states la mesa, california, united states loma linda, california, united states long beach, california, united states los angeles, california, united states los angeles, california, united states los angeles, california, united states los angeles, california, united states montebello, california, united states newport beach, california, united states oakland, california, united states panorama city, california, united states riverside, california, united states roseville, california, united states sacramento, california, united states san diego, california, united states san diego, california, united states san francisco, california, united states san jose, california, united states santa clara, california, united states santa maria, california, united states santa monica, california, united states south san francisco, california, united states thousand oaks, california, united states vallejo, california, united states walnut creek, california, united states woodland hills, california, united states fort collins, colorado, united states norwalk, connecticut, united states norwich, connecticut, united states stamford, connecticut, united states washington, district of columbia, united states boca raton, florida, united states fernandina beach, florida, united states fort myers, florida, united states ft. lauderdale, florida, united states hollywood, florida, united states jacksonville, florida, united states jacksonville, florida, united states jacksonville, florida, united states jacksonville, florida, united states kissimmee, florida, united states lakeland, florida, united states miami, florida, united states miami, florida, united states miami, florida, united states orange park, florida, united states pembroke pines, florida, united states athens, georgia, united states atlanta, georgia, united states atlanta, georgia, united states atlanta, georgia, united states atlanta, georgia, united states carrolton, georgia, united states cartersville, georgia, united states decatur, georgia, united states douglasville, georgia, united states macon, georgia, united states marietta, georgia, united states boise, idaho, united states meridian, idaho, united states nampa, idaho, united states post falls, idaho, united states twin falls, idaho, united states chicago, illinois, united states decatur, illinois, united states effingham, illinois, united states joliet, illinois, united states morris, illinois, united states peoria, illinois, united states skokie, illinois, united states zion, illinois, united states bettendorf, iowa, united states wichita, kansas, united states paducah, kentucky, united states covington, louisiana, united states lafayette, louisiana, united states marrero, louisiana, united states metairie, louisiana, united states new orleans, louisiana, united states kittery, maine, united states wells, maine, united states york, maine, united states baltimore, maryland, united states baltimore, maryland, united states bethesda, maryland, united states rockville, maryland, united states boston, massachusetts, united states boston, massachusetts, united states boston, massachusetts, united states boston, massachusetts, united states burlington, massachusetts, united states peabody, massachusetts, united states brownstown, michigan, united states dearborn, michigan, united states detroit, michigan, united states detroit, michigan, united states saint joseph, michigan, united states west bloomfield, michigan, united states edina, minnesota, united states maplewood, minnesota, united states minneapolis, minnesota, united states saint louis park, minnesota, united states saint paul, minnesota, united states st. louis park, minnesota, united states joplin, missouri, united states kansas city, missouri, united states saint louis, missouri, united states saint peters, missouri, united states st. louis, missouri, united states st. peters, missouri, united states missoula, montana, united states omaha, nebraska, united states henderson, nevada, united states cherry hill, new jersey, united states hackensack, new jersey, united states morristown, new jersey, united states parsippany, new jersey, united states voorhees, new jersey, united states santa fe, new mexico, united states brockport, new york, united states canandaigua, new york, united states fresh meadows, new york, united states geneva, new york, united states greece, new york, united states lake success, new york, united states mount kisco, new york, united states rochester, new york, united states stony brook, new york, united states charlotte, north carolina, united states durham, north carolina, united states hickory, north carolina, united states kinston, north carolina, united states washington, north carolina, united states cleveland, ohio, united states cleveland, ohio, united states columbus, ohio, united states columbus, ohio, united states columbus, ohio, united states middletown, ohio, united states newark, ohio, united states sandusky, ohio, united states portland, oregon, united states philadelphia, pennsylvania, united states philadelphia, pennsylvania, united states pittsburgh, pennsylvania, united states pittsburgh, pennsylvania, united states east providence, rhode island, united states columbia, south carolina, united states north charleston, south carolina, united states memphis, tennessee, united states nashville, tennessee, united states austin, texas, united states bryan, texas, united states cypress, texas, united states dallas, texas, united states el paso, texas, united states houston, texas, united states shenandoah, texas, united states temple, texas, united states fairfax, virginia, united states gig harbor, washington, united states lakewood, washington, united states puyallup, washington, united states tacoma, washington, united states milwaukee, wisconsin, united states wausau, wisconsin, united states banja luka, bosnia and herzegovina sarajewo, bosnia and herzegovina belo horizonte, brazil curitiba, brazil goiania, brazil itajai, brazil jau, brazil joao pessoa, brazil porto alegre - rs, brazil porto alegre, brazil porto alegre, brazil porto alegre, brazil rio de janeiro, brazil rio de janeiro, brazil santo andre, brazil sao paulo, brazil sao paulo, brazil plovdiv, bulgaria sofia, bulgaria sofia, bulgaria varna, bulgaria calgary, alberta, canada edmonton, alberta, canada kelowna, british columbia, canada vancouver, british columbia, canada halifax, nova scotia, canada ottawa, ontario, canada sudbury, ontario, canada toronto, ontario, canada greenfield park, quebec, canada montreal, quebec, canada montreal, quebec, canada montreal, quebec, canada bogota, colombia bogota, colombia monteria, colombia herlev, denmark københavn, denmark odense, denmark helsinki, finland tampere, finland turku, finland avignon, france bordeaux, france brest, france caen, france dijon, france la roche sur yon, france montpellier, france paris, france saint brieuc, france saint herblain, france vandoeuvre-les-nancy, france aschaffenburg, germany berlin, germany berlin, germany berlin, germany bonn, germany dortmund, germany freiburg, germany fuerstenwalde, germany hamburg, germany karlsruhe, germany kiel, germany offenbach, germany stralsund, germany hong kong, hong kong bangalore, india gurgaon, india kolkata, india new delhi, india pune, india aviano, italy bologna, italy candiolo, italy genova, italy meldola, italy milano, italy milano, italy napoli, italy negrar, italy pisa, italy reggio emilia, italy roma, italy rozzano, italy sassari, italy terni, italy kyunggi-do, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of acapulco, mexico oaxaca, mexico toluca, mexico newtown, new zealand palmerston north, new zealand diliman, quezon city, philippines quezon city, luzon, philippines bialystok, poland gdansk, poland krakow, poland lublin, poland opole, poland poznan, poland warszawa, poland coimbra, portugal lisboa, portugal porto, portugal kemerovo, russian federation moscow, russian federation st petersburg, russian federation singapore, singapore singapore, singapore ljubljana, slovenia barcelona, spain córdoba, spain lerida, spain madrid, spain madrid, spain santander, spain sevilla, spain valencia, spain zaragoza, spain eskilstuna, sweden gaelve, sweden goteborg, sweden luzern, switzerland st. gallen, switzerland kaohsung, taiwan taichung, taiwan taichung, taiwan taipei, taiwan taoyuan, taiwan bournemouth, united kingdom cardiff, united kingdom denbigh, united kingdom london, united kingdom london, united kingdom manchester, united kingdom new castle upon tyne, united kingdom northwood, united kingdom poole, united kingdom preston, united kingdom romford, united kingdom sutton, united kingdom weston super mare, united kingdom']",,https://ClinicalTrials.gov/show/NCT00829166,breast
272,273,NCT04942054,a study in patients with advanced breast cancer,,Not yet recruiting,No Results Available,her2-negative breast cancer|advanced breast cancer|hormone receptor-positive breast cancer,drug: part 1|drug: part 2|drug: part 3,incidence of dose limiting toxicities at each dose levels (part 1 only)|incidence and severity of adverse events with each dose level|evaluation of cmax (part 1 and part 2)|evaluation of tmax (part 1 and part 2)|evaluation of auc (part 1 and part 2)|tumour response,sun pharma advanced research company limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,141.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCO-120-19-22,"May 15, 2022",January 2024,January 2024,"June 28, 2021",,"May 9, 2022","[""hoag memorial hospital presbyterian, newport beach, california, united states the university of chicago, chicago, illinois, united states michigan center of medical research, farmington hills, michigan, united states narayana multispeciality hospital, ahmedabad, gujarat, india healthcare global enterprises ltd, bangalore, karnataka, india amrita institute of medical sciences (aims), kochi, kerala, india prince aly khan hospital, mumbai, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india lmmf's deenanath mangeshkar hospital & research centre, pune, maharashtra, india noble hospital pvt. ltd.,, pune, maharashtra, india meenakshi mission hospital, madurai, tamil nadu, india""]",,https://ClinicalTrials.gov/show/NCT04942054,breast
273,274,NCT01134666,an observational study to evaluate the safety and efficacy of folfiri / folfox plus cetuximab as first-line therapy in patients with kras wild-type metastatic colorectal cancer,,Terminated,No Results Available,colorectal neoplasms,drug: cetuximab,safety and tolerability evaluated based on the incidence and severity of aes.|response rate,"merck kgaa, darmstadt, germany|merck ltd., india",All,"Child, Adult, Older Adult",,165.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,EMR 062202-517,"November 30, 2009","July 31, 2013","August 5, 2014","June 2, 2010",,"June 9, 2017","[""indo- american cancer institute & research centre, hyderabad, andhra pradesh, india nvs ramakrishna's clinic, hyderabad, andhra pradesh, india dr. nikhil's clinic, secunderabad, andhra pradesh, india nikhil gharyalpatil's clinic, secunderabad, andhra pradesh, india ravi kumar's clinic, hyderabad, andrapradesh, india ambaa hospitals, hyderabad, andrapradesh, india swarna sai hospital, hyderabad, andrapradesh, india manipal centre for clinical research, mangalore, bangalore, india medical college calicut, kerala, calicut, india hemato oncology clinic, ahmedabad, gujarat, india kattimani oncology clinic, hubli, karnataka, india skims, srinagar, kashmir, india s. k. i. m. s., srinagar, kashmir, india dr. t. p. sahoo's clinic, bhopal, madhya pradesh, india bnd onco centre, mumbai, maharashtra, india joy hospital, mumbai, maharashtra, india ruby hall clinic, pune, maharashtra, india grace nursing home, aizwal, mizoram, india lilavati hospital, bandra, mumbai, india s.l.raheja hospital, mahim, mumbai, india apollo cancer institute, delhi, new delhi, india rajiv gandhi cancer institute & research, delhi, new delhi, india fortis escorts hospital, amritsar, punjab, india dr. rajeev bedi's clinic, chandigarh, punjab, india d.m.c hospital, ludhiana, punjab, india ivy hospital, mohali, punjab, india cancer clinic, jaipur, rajasthan, india sms hospital, jaipur, rajasthan, india bhagwan mahaveer cancer hospital, jaipur, rajasthan, india bhagwan mahaveer cancer hospital & research centre, jaipur, rajasthan, india vyas cancer care, jodhpur, rajasthan, india tc 14/ 764 sreemangalam, trivandrum, tamilnadu, india shati gopal hospital, ghaziabad, uttar pradesh, india annapurna medical and cancer relief society, lucknow, uttar pradesh, india chittaranjan national cancer institute, kolkata, west bengal, india apollo gleneagles cancer hospital, kolkata, west bengal, india nothern railway central hospital, delhi, india indraprastha apollo hospital, delhi, india shanti mukand hospital, delhi, india dharamshila cancer hospital & research centre, delhi, india""]",,https://ClinicalTrials.gov/show/NCT01134666,colon
274,275,NCT00191854,"gemcitabine combinations in metastatic breast cancer (mbc), 1st line",,Completed,Has Results,breast cancer,drug: gemcitabine|drug: paclitaxel|drug: carboplatin|drug: cisplatin,best overall response|number of participants with a time to treatment failure (tttf) event|progression free survival (pfs)|duration of response|overall survival,eli lilly and company,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,147.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7451|B9E-AA-S355,March 2005,August 2008,November 2009,"September 19, 2005","August 31, 2009","March 2, 2010","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santo andré, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sao paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beijing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hangzhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nan jing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wu han, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kolkata, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ludhiana, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pune, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cuernavaca, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mexico city, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., villahermosa, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., antalya, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gaziantep, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kayseri, turkey']",,https://ClinicalTrials.gov/show/NCT00191854,breast
275,276,NCT04493853,capivasertib+abiraterone as treatment for patients with metastatic hormone-sensitive prostate cancer and pten deficiency,CAPItello-281,Recruiting,No Results Available,hormone-sensitive prostate cancer,drug: capivasertib|other: placebo|drug: abiraterone acetate,"radiographic progression-free survival (rpfs)|overall survival (os)|time to start of first subsequent therapy or death (tfst)|symptomatic skeletal event-free survival (sse-fs)|time to pain progression (ttpp)|time to psa progression|time to castration resistance (ttcr)|fatigue intensity, severity and interference domains assessed by the brief fatigue inventory (bfi)|overall pain severity and pain interference as assessed by bpi-sf questionnaire|disease-related symptoms and hrqol using the functional assessment of cancer therapy - prostate cancer (fact-p) questionnaire|progression-free survival after next-line treatment (pfs2)|plasma concentration of capivasertib pre-dose|plasma concentration of capivasertib 1h post-dose|plasma concentration of capivasertib 4h post-dose",astrazeneca,Male,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,1000.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D361BC00001,"July 13, 2020","November 11, 2024","November 11, 2025","July 30, 2020",,"May 16, 2022","[""research site, anchorage, alaska, united states research site, anchorage, alaska, united states research site, tucson, arizona, united states research site, tucson, arizona, united states research site, little rock, arkansas, united states research site, la jolla, california, united states research site, orange, california, united states research site, san diego, california, united states research site, denver, colorado, united states research site, lakewood, colorado, united states research site, fort myers, florida, united states research site, miami, florida, united states research site, pensacola, florida, united states research site, west palm beach, florida, united states research site, chicago, illinois, united states research site, geneva, illinois, united states research site, lisle, illinois, united states research site, iowa city, iowa, united states research site, fairway, kansas, united states research site, louisville, kentucky, united states research site, baltimore, maryland, united states research site, baltimore, maryland, united states research site, bethesda, maryland, united states research site, towson, maryland, united states research site, detroit, michigan, united states research site, grand rapids, michigan, united states research site, troy, michigan, united states research site, bozeman, montana, united states research site, lebanon, new hampshire, united states research site, englewood, new jersey, united states research site, bronx, new york, united states research site, rochester, new york, united states research site, syracuse, new york, united states research site, asheville, north carolina, united states research site, durham, north carolina, united states research site, winston-salem, north carolina, united states research site, cincinnati, ohio, united states research site, columbus, ohio, united states research site, lancaster, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, charleston, south carolina, united states research site, myrtle beach, south carolina, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, houston, texas, united states research site, irving, texas, united states research site, salt lake city, utah, united states research site, norfolk, virginia, united states research site, roanoke, virginia, united states research site, seattle, washington, united states research site, madison, wisconsin, united states research site, berazategui, argentina research site, buenos aires, argentina research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, la plata, argentina research site, mendoza, argentina research site, rosario, argentina research site, rosario, argentina research site, san salvador de jujuy, argentina research site, birtinya, australia research site, darlinghurst, australia research site, kingswood, australia research site, orange, australia research site, richmond, australia research site, south brisbane, australia research site, wollongong, australia research site, graz, austria research site, linz, austria research site, salzburg, austria research site, anderlecht, belgium research site, brussels, belgium research site, gent, belgium research site, kortrijk, belgium research site, liège, belgium research site, wilrijk, belgium research site, barretos, brazil research site, belem, brazil research site, belo horizonte, brazil research site, curitiba, brazil research site, florianópolis, brazil research site, fortaleza, brazil research site, joinville, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, rio de janeiro, brazil research site, santa maria, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, pleven, bulgaria research site, plovdiv, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, abbotsford, british columbia, canada research site, kelowna, british columbia, canada research site, vancouver, british columbia, canada research site, toronto, ca, canada research site, winnipeg, manitoba, canada research site, moncton, new brunswick, canada research site, brampton, ontario, canada research site, oshawa, ontario, canada research site, toronto, ontario, canada research site, chicoutimi, quebec, canada research site, montreal, quebec, canada research site, montreal, canada research site, quebec, canada research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, temuco, chile research site, viña del mar, chile research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changchun, china research site, changsha, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, chengdu, china research site, chongqing, china research site, chongqing, china research site, chongqing, china research site, fuzhou, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guiyang, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, he fei, china research site, jinan, china research site, kunming, china research site, nanchang, china research site, nanjing, china research site, nanjing, china research site, nantong, china research site, ningbo, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shengyang, china research site, shenyang, china research site, suzhou, china research site, tianjin, china research site, urumqi, china research site, wenzhou, china research site, wuhan, china research site, wuhan, china research site, wuhan, china research site, xi'an, china research site, xiamen, china research site, yantai, china research site, zhengzhou city, china research site, zhengzhou, china research site, brno, czechia research site, horovice, czechia research site, hradec kralove, czechia research site, hradec kralove, czechia research site, kromeriz, czechia research site, nachod, czechia research site, olomouc, czechia research site, praha 10, czechia research site, praha 8, czechia research site, praha, czechia research site, praha, czechia research site, besançon cedex, france research site, bordeaux, france research site, marseille, france research site, montpellier, france research site, nice, france research site, paris cedex 14, france research site, pierre benite, france research site, quimper cedex, france research site, rennes cedex 9, france research site, strasbourg, france research site, suresnes, france research site, villejuif cedex, france research site, berlin, germany research site, duisburg, germany research site, emmendingen, germany research site, hamburg, germany research site, herne, germany research site, mettmann, germany research site, münster, germany research site, nürnberg, germany research site, nürtingen, germany research site, wesel, germany research site, hong kong, hong kong research site, hongkong, hong kong research site, lai chi kok, hong kong research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, győr, hungary research site, nyíregyháza, hungary research site, szolnok, hungary research site, ahmedabad, india research site, bangalore, india research site, bangalore, india research site, bangalore, india research site, chandigarh, india research site, faridabad, india research site, gurgaon, india research site, kanpur, india research site, kochi, india research site, kolkata, india research site, madurai, india research site, manipal, india research site, meerut, india research site, mohali, india research site, mumbai, india research site, nagpur, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, rohini, india research site, thiruvananthapuram, india research site, haifa, israel research site, jerusalem, israel research site, kfar saba, israel research site, petach-tikva, israel research site, ramat gan, israel research site, zerifin, israel research site, bunkyo-ku, japan research site, chiba-shi, japan research site, chuo-ku, japan research site, fukuoka, japan research site, hamamatsu-shi, japan research site, hirakata-shi, japan research site, hirosaki-shi, japan research site, hiroshima-shi, japan research site, isehara-shi, japan research site, kanazawa-shi, japan research site, kashihara-shi, japan research site, kashiwa, japan research site, kawagoe-shi, japan research site, kisarazu-shi, japan research site, kita-gun, japan research site, kobe-shi, japan research site, kumamoto-shi, japan research site, kyoto-shi, japan research site, maebashi-shi, japan research site, miyazaki-city, japan research site, morioka-shi, japan research site, nagakute-shi, japan research site, nagano-shi,, japan research site, nagasaki-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, natori-shi, japan research site, omihachiman-shi, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, ota shi, japan research site, sagamihara-shi, japan research site, sapporo-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shinjuku-ku, japan research site, toon-shi, japan research site, tsu-shi, japan research site, ube-shi, japan research site, yokohama-shi, japan research site, yokosuka-shi, japan research site, yufu-shi, japan research site, daegu, korea, republic of research site, goyang-si, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, culiacan, mexico research site, culiacan, mexico research site, guadalajara, mexico research site, guadalajara, mexico research site, mexico city, mexico research site, monterrey, mexico research site, nuevo leon, mexico research site, puebla, mexico research site, amsterdam, netherlands research site, den haag, netherlands research site, hilversum, netherlands research site, roosendaal, netherlands research site, sittard-geleen, netherlands research site, tilburg, netherlands research site, utrecht, netherlands research site, callao, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, san isidro, peru research site, baguio city, philippines research site, cebu city, philippines research site, davao city, philippines research site, iloilo city, philippines research site, iloilo city, philippines research site, quezon city, philippines research site, quezon city, philippines research site, san juan, philippines research site, bialystok, poland research site, biała podlaska, poland research site, bielsko-biała, poland research site, bydgoszcz, poland research site, gdańsk, poland research site, koszalin, poland research site, lublin, poland research site, olsztyn, poland research site, opole, poland research site, poznań, poland research site, rzeszow, poland research site, słupsk, poland research site, toruń, poland research site, toruń, poland research site, warszawa, poland research site, wroclaw, poland research site, wroclaw, poland research site, łódź, poland research site, arkhangelsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, novisibirsk, russian federation research site, novosibirsk, russian federation research site, saint-petersburg, russian federation research site, st. petersburg, russian federation research site, st.petersburg, russian federation research site, tomsk, russian federation research site, yaroslavl, russian federation research site, bratislava, slovakia research site, bratislava, slovakia research site, martin, slovakia research site, nitra, slovakia research site, presov, slovakia research site, sala, slovakia research site, trencin, slovakia research site, amanzimtoti, south africa research site, cape town, south africa research site, johannesburg, south africa research site, johannesburg, south africa research site, johannesburg, south africa research site, kraaifontein, south africa research site, parow, south africa research site, port elizabeth, south africa research site, pretoria, south africa research site, pretoria, south africa research site, badalona (barcelona), spain research site, barcelona, spain research site, las palmas de gran canaria, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, oviedo, spain research site, santander, spain research site, sevilla, spain research site, kaohsiung, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, hat yai, thailand research site, lampang, thailand research site, muang, thailand research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, antalya, turkey research site, eskisehir, turkey research site, istanbul, turkey research site, izmir, turkey research site, izmir, turkey research site, kayseri, turkey research site, cambridge, united kingdom research site, guildford, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, newcastle upon tyne, united kingdom research site, plymouth, united kingdom research site, southampton, united kingdom research site, sutton, united kingdom research site, whitchurch, united kingdom research site, ha noi, vietnam research site, hanoi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam""]",,https://ClinicalTrials.gov/show/NCT04493853,prostat
276,277,NCT03017885,post marketing surveillance of nintedanib in indian patients with non-small cell lung cancer (nsclc) after first-line therapy,,Recruiting,No Results Available,non-small cell lung cancer,,incidence of all adverse drug reactions (adrs) in nintedanib & docetaxel treated patients|incidence of all serious adverse events (saes) in nintedanib & docetaxel treated patients|percentage of patients who require nintedanib dose reductions and discontinuations due to adverse events.,boehringer ingelheim,All,"18 Years and older   (Adult, Older Adult)",,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Other,1199-0272,"February 28, 2017","October 8, 2022","October 8, 2022","January 11, 2017",,"May 4, 2022","['zydus hospitals and healthcare research pvt. ltd, anand, india narayana hrudyalaya, bangalore, india manipal hospitals, bengaluru, india hcg hospital, bengaluru, india sparsh hospitals and critical care, bhubaneshwar, india action cancer hospital, delhi, delhi, india apollo health city hospital, hyderabad, india yashoda hospitals, hyderabad, india chittaranjan national cancer institute, kolkata, india kasturba medical college and hospital, mangalore, india rajiv gandhi cancer institute and research centre, new delhi, india srm institute of medical science, vadapalani, india']",,https://ClinicalTrials.gov/show/NCT03017885,
277,278,NCT01001377,aspecct: a study of panitumumab efficacy and safety compared to cetuximab in patients with kras wild-type metastatic colorectal cancer,,Completed,Has Results,metastatic colorectal cancer,drug: cetuximab|drug: panitumumab,overall survival|progression-free survival|objective response|duration of response|time to response|time to treatment failure|change from baseline in euroqol 5 dimension (eq-5d) health state index score|change from baseline in euroqol 5 dimension (eq-5d) visual analog scale (vas)|change from baseline in national comprehensive cancer network functional assessment of cancer therapy colorectal symptom index (nccn fcsi ) symptoms score|change from baseline in nccn fcsi physical well-being scale score|change from baseline in nccn fcsi functional well-being scale score|number of participants with adverse events (aes),amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1010.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20080763|ASPECCT|2009-010715-32,"February 2, 2010","February 5, 2013","March 7, 2017","October 26, 2009","March 24, 2014","December 26, 2018","['research site, stockton, california, united states research site, boynton beach, florida, united states research site, wichita, kansas, united states research site, temple, texas, united states research site, ogden, utah, united states research site, liverpool, new south wales, australia research site, st leonards, new south wales, australia research site, wahroonga, new south wales, australia research site, wollongong, new south wales, australia research site, woodville south, south australia, australia research site, ballarat, victoria, australia research site, box hill, victoria, australia research site, epping, victoria, australia research site, footscray, victoria, australia research site, heidelberg, victoria, australia research site, parkville, victoria, australia research site, edegem, belgium research site, sofia, bulgaria research site, sofia, bulgaria research site, edmonton, alberta, canada research site, halifax, nova scotia, canada research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, harbin, heilongjiang, china research site, changsha, hunan, china research site, nanjing, jiangsu, china research site, changchun, jilin, china research site, xi an, shaanxi, china research site, shanghai, shanghai, china research site, chengdu, sichuan, china research site, chongqing, sichuan, china research site, hangzhou, zhejiang, china research site, hangzhou, zhejiang, china research site, beijing, china research site, beijing, china research site, beijing, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, tianjin, china research site, horovice, czechia research site, nova ves pod plesi, czechia research site, olomouc, czechia research site, praha 10, czechia research site, pribram, czechia research site, znojmo, czechia research site, besançon cedex, france research site, montbéliard, france research site, saint brieuc, france research site, saint herblain, france research site, villejuif cedex, france research site, kowloon, hong kong research site, new territories, hong kong research site, hyderabad, andhra pradesh, india research site, hyderabad, andhra pradesh, india research site, kochi, kerala, india research site, ahmednagar, maharashtra, india research site, nagpur, maharashtra, india research site, nashik, maharashtra, india research site, nashik, maharashtra, india research site, pune, maharashtra, india research site, jaipur, rajasthan, india research site, chennai, tamil nadu, india research site, kolkata, west bengal, india research site, beer sheva, israel research site, jerusalem, israel research site, kfar saba, israel research site, ramat gan, israel research site, rehovot, israel research site, ancona, italy research site, cesena, italy research site, cremona, italy research site, faenza ra, italy research site, genova, italy research site, lugo, italy research site, meldola fc, italy research site, ravenna, italy research site, rimini, italy research site, torino, italy research site, goyang-si, gyeonggi-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, daugavpils, latvia research site, riga, latvia research site, riga, latvia research site, kaunas, lithuania research site, vilnius, lithuania research site, kota bharu, kelantan, malaysia research site, kota kinabalu, sabah, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, rotterdam, netherlands research site, lima, peru research site, lima, peru research site, lima, peru research site, cebu city, philippines research site, manila, philippines research site, quezon city, philippines research site, elblag, poland research site, gdansk, poland research site, jelenia gora, poland research site, poznan, poland research site, szczecin, poland research site, warszawa, poland research site, warszawa, poland research site, warszawa, poland research site, bucharest, romania research site, sibiu, romania research site, moscow, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, nis, serbia research site, sremska kamenica, serbia research site, singapore, singapore research site, singapore, singapore research site, bardejov, slovakia research site, bratislava, slovakia research site, nitra, slovakia research site, groenkloof, gauteng, south africa research site, johannesburg, gauteng, south africa research site, kraaifontein, western cape, south africa research site, johannesburg, south africa research site, port elizabeth, south africa research site, göteborg, sweden research site, linköping, sweden research site, lund, sweden research site, uppsala, sweden research site, västerås, sweden research site, växjö, sweden research site, putzu city, chiayi, taiwan research site, keelung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, belfast, united kingdom research site, bristol, united kingdom research site, cardiff, united kingdom research site, guildford, united kingdom research site, leicester, united kingdom research site, london, united kingdom research site, maidstone, united kingdom research site, manchester, united kingdom research site, oxford, united kingdom research site, sutton, united kingdom research site, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01001377,colon
278,279,NCT04801186,retrospective study to describe the real-world treatment patterns and associated clinical outcomes in patients with metastatic castration-resistant prostates cancer,REMPRO,Recruiting,No Results Available,metastatic castration-resistant prostates cancer,,describe the real-world treatment patterns in patients with mcrpc|demographic and clinico-pathological profile|survival outcomes associated with different treatment regimens used for mcrpc|assess the real-world effectiveness|brca1/2 and hrrm status,astrazeneca,Male,"18 Years and older   (Adult, Older Adult)",,1920.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,D0817R00037,"September 28, 2021","June 30, 2022","June 30, 2022","March 16, 2021",,"April 25, 2022","['research site, melbourne, australia research site, bogota, colombia research site, raml station, alexandria, egypt research site, ramsis, cairo, egypt research site, cairo, egypt research site, cairo, egypt research site, new delhi, delhi, india research site, ahmedabad, gujarat, india research site, faridabad, haryana, india research site, bangalore, karnataka, india research site, srinagar, kashmir, india research site, mumbai, maharashtra, india research site, bhubhaneshwar, odisha, india research site, hyderabad, telangana, india research site, kolkata, west bengal, india research site, delhi, india research site, goyang-si, gyeonggi, korea, republic of research site, seongnam-si, gyeonggi, korea, republic of research site, gangnam-gu, seoul, korea, republic of research site, jongno-gu, seoul, korea, republic of research site, seocho-gu, seoul, korea, republic of research site, seodaemun-gu, seoul, korea, republic of research site, kuwait, kuwait research site, lima, peru research site, doha, qatar research site, dammam, saudi arabia research site, jeddah, saudi arabia research site, makkah, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, istanbul, turkey research site, abu dhabi, united arab emirates research site, dubai, united arab emirates']",,https://ClinicalTrials.gov/show/NCT04801186,prostat
279,280,NCT04873362,a study evaluating the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for participants with her2-positive breast cancer at high risk of recurrence following preoperative therapy,Astefania,Recruiting,No Results Available,breast cancer,drug: atezolizumab|drug: trastuzumab emtansine|drug: placebo|drug: trastuzumab,"invasive disease-free survival (idfs)|idfs including second primary non-breast invasive cancer|disease-free survival (dfs)|overall survival (os)|distant recurrence-free interval (drfi)|number of participants with clinically meaningful deterioration in global health status/quality of life (ghs/qol) physical, role, and cognitive function|mean absolute scores in ghs/qol, physical, role, and cognitive function, as assessed using the eortc qlq-c30|mean change from baseline scores in ghs/qol, physical, role, and cognitive function, as assessed using the eortc qlq-c30|percentage of participants with adverse events (aes) according to national cancer institute common terminology criteria for adverse events version 5.0 (nci ctcae v5.0)|maximum serum concentrations (cmax) for atezolizumab|cmax for trastuzumab emtansine|cmax for total trastuzumab|cmax for dm1|minimum serum concentrations (cmin) for atezolizumab|percentage of participants with anti-drug antibodies (adas) to atezolizumab|percentage of participants with adas to trastuzumab emtansine",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1700.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WO42633|2020-003681-40,"May 4, 2021","December 18, 2025","October 26, 2034","May 5, 2021",,"May 10, 2022","['alabama oncology, alabaster, alabama, united states roy and patricia disney family cancer center- providence saint joseph medical center, burbank, california, united states california cancer associate for research & excellence, fresno, california, united states glendale adventist medical ctr, glendale, california, united states ucla medical center, santa monica, california, united states innovation clinical research institute, whittier, california, united states cancer specialists; north florida ;jacksonville (ac skinner pkwy), jacksonville, florida, united states florida cancer specialists, west palm beach, florida, united states university cancer & blood center, llc; research, athens, georgia, united states northwest georgia oncology centers, a service of wellstar cobb hospital, carrollton, georgia, united states elmhurst memorial healthcare, elmhurst, illinois, united states edward cancer center naperville, naperville, illinois, united states edward cancer center plainfield, plainfield, illinois, united states university of iowa, iowa city, iowa, united states pontchartrain cancer center, covington, louisiana, united states new england cancer specialists, scarborough, maine, united states university of maryland medical center, baltimore, maryland, united states mercy medical center, baltimore, maryland, united states henry ford health system; dept of transplantation surgery, detroit, michigan, united states jackson oncology associates, pllc, jackson, mississippi, united states central care cancer center; nc, bolivar, missouri, united states md anderson cancer center at cooper, camden, new jersey, united states the valley hospital, paramus, new jersey, united states cooper cancer institute, voorhees, new jersey, united states mount sinai medical center, new york, new york, united states great lakes cancer center, williamsville, new york, united states messino cancer centers, asheville, north carolina, united states providence health & services - oregon, portland, oregon, united states abramson cancer center; univ of pennsylvania; clinical research unit, philadelphia, pennsylvania, united states lankenau hospital, wynnewood, pennsylvania, united states charleston oncology, p .a, charleston, south carolina, united states avera cancer institute, sioux falls, south dakota, united states scri tennessee oncology chattanooga, chattanooga, tennessee, united states the west clinic; west cancer center, germantown, tennessee, united states thompson cancer survival center, knoxville, tennessee, united states tennessee oncology; sarah cannon research institute, nashville, tennessee, united states joe arrington cancer research & treatment center, lubbock, texas, united states hematology oncology associates of fredericksburg, inc., fredericksburg, virginia, united states virginia oncology associates - new port news, newport news, virginia, united states virginia oncology associates, norfolk, virginia, united states virginia cancer institute, richmond, virginia, united states virginia oncology associates - virginia beach, virginia beach, virginia, united states providence regional cancer partnership, everett, washington, united states kadlec regional medical center, kennewick, washington, united states northwest medical specialties, tacoma, washington, united states macarthur cancer therapy centre, campbelltown, new south wales, australia kinghorn cancer centre; st vincents hospital, darlinghurst, new south wales, australia royal north shore hospital; department of medical oncology, st leonards, new south wales, australia princess alexandra hospital; cancer trials unit, woolloongabba, queensland, australia peter maccallum cancer centre; medical oncology, melbourne, victoria, australia tiroler landeskrankenanstalten ges.m.b.h.; abt. für gynäkologie, innsbruck, austria ordensklinikum linz barmherzige schwestern; interne 1 - hämato-onkologie, linz, austria lkh salzburg - univ. klinikum salzburg; iii. medizinische abt., salzburg, austria akh - medizinische universität wien; department of oncology, vienna, austria cliniques universitaires st-luc, bruxelles, belgium jessa zkh (campus virga jesse), hasselt, belgium clinique st. elizabeth, namur, belgium hospital sao rafael - hsr, salvador, ba, brazil crio - centro regional integrado de oncologia, fortaleza, ce, brazil hospital araujo jorge; departamento de ginecologia e mama, goiania, go, brazil hospital nossa senhora da conceicao, porto alegre, rs, brazil hospital de base de sao jose do rio preto, sao jose do rio preto, sp, brazil clinica de pesquisa e centro de estudos em oncologia ginecologica e mamaria ltda, sao paulo, sp, brazil koc plovdiv; first medical oncology department, plovdiv, bulgaria medical center ""nadezhda clinical"" eood; medical oncology department, sofia, bulgaria university multiprofile hospital for active treatment tsaritsa yoanna - isul ead, sofia, bulgaria sichuan cancer hospital, chengdu city, china west china hospital - sichuan university, chengdu city, china chongqing cancer hospital, chongqing, china the first affilicated hospital, sun yat-sen university, guangzhou city, china guangdong provincial people\'s hospital; breast, guangzhou city, china sun yat-sen memorial hospital, guangzhou, china harbin medical university cancer hospital, harbin, china zhongshan hospital fudan university, shanghai, china tianjin medical university cancer institute & hospital, tianjing, china union hospital tongji medical college huazhong university of science and technology, wuhan city, china first affiliated hospital of medical college of xi\'an jiaotong university, xi\'an, china zhejiang cancer hospital, zhejiang, china henan cancer hospital, zhengzhou, china masarykův onkologický ústav; klinika komplexní onkologické péče, brno, czechia fakultni nemocnice hradec kralove; dept of radiotherapy & oncology, hradec kralove, czechia nemocnice agel novy jicin a.s.; oddeleni radioterapie a onkologie, novy jicin, czechia fakultni nemocnice olomouc; onkologicka klinika, olomouc, czechia fakultni poliklinika vseobecne fakultni niemocnice; onkologicka klinika, praha 2, czechia thomayerova nemocnice; onkologicka klinika 1. lf uk a tn, praha 4 - krc, czechia fakultni nemocnice v motole; onkologicka klinika 2. lf uk a fn motol, praha 5, czechia herlev hospital; afdeling for kræftbehandling, herlev, denmark vejle sygehus; onkologisk afdeling, vejle, denmark institut sainte catherine, avignon, france chru besançon, besançon, france polyclinique bordeaux nord aquitaine, bordeaux, france hopital morvan, brest, france centre francois baclesse; comite sein, caen, france groupe hospitalier public du sud de l\'oise ghpso; oncologie, creil cedex 1, france clcc leon berard lyon, lyon, france centre hospitalier uni ire caremeau; radiotherapie & oncologie, nimes, france groupe hospitalier diaconesses, paris, france institut curie; oncologie medicale, paris, france pole regional de cancerologie, poitiers, france hopital rene huguenin, institut curie; service d\'oncologie médicale., saint-cloud, france klinikum augsburg; frauenklinik, augsburg, germany gemeinschaftspraxis für hämatologie und onkologie dr. reichert/dr.janssen, aurich, germany hochtaunus-kliniken ggmbh; krankenhaus bad homburg; frauenklinik, bad homburg vdh, germany hochwaldkrankenhaus; abt.gynäkologie geburtshilfe u.senologie, bad nauheim, germany onkologische schwerpunktpraxis kurfürstendamm, berlin, germany vivantes klinikum am urban; zentrum für brusterkrankungen, berlin, germany städtisches klinikum dessau, dessau-roßlau, germany frauenarztpraxis dr. apel, dr. kolpin, erfurt, germany universitätsklinikum erlangen; frauenklinik, erlangen, germany klinikum essen-mitte ev. huyssens-stiftung / knappschafts gmbh; klinik für senologie / brustzentrum, essen, germany agaplesion markus-krankenhaus, frankfurt, germany klinik johann wolfgang von goethe uni; klinik für frauenheilkunde und geburtshilfe, frankfurt, germany praxis für interdisziplinäre onkologie und hämatologie gbr, freiburg, germany st. barbara-klinik hamm-heessen gmbh; frauenklinik, hamm, germany diakovere henriettenstift, frauenklinik, hannover, germany städtisches klinikum karlsruhe ggmbh; frauenklinik, karlsruhe, germany uni-klinikum campus kiel klinik für gynäkologie und geburtshilfe, kiel, germany universitätsklinikum leipzig; klinik und poliklinik für frauenheilkunde, leipzig, germany städtische klinik lüneburg; frauenklinik, lüneburg, germany klinik & poliklinik für frauenheilkunde und geburtshilfe, campus innenstadt, münchen, germany sana klinikum offenbach gmbh; klinik für gynäkologie & geburtshilfe, offenbach, germany klinikum ernst von bergmann; frauenklinik, potsdam, germany leopoldina krankenhaus der stadt schweinfurt gmbh, schweinfurt, germany johanniter-krankenhaus genthin-stendal; klinik für frauenheilkunde & geburtshilfe, stendal, germany metropolitan general hospital, cholargos, greece university general hospital of heraklion, crete, greece university hospital of larissa;department of medical oncology, larissa, greece metropolitan hospital; 2nd oncology clinic, piraeus, greece euromedical general clinic of thessaloniki; oncology department, thessaloniki, greece queen mary hospital; surgery, hong kong, hong kong pamela youde nethersole eastern hospital; clinical oncology, hong kong, hong kong tuen mun hospital; clinical oncology, hong kong, hong kong honvédelmi minisztérium állami egészségügyi központ; onkológiai osztály; oncology department, budapest, hungary orszagos onkologiai intezet; b belgyogyaszati osztaly, budapest, hungary debreceni egyetem klinikai kozpont ; department of oncology, debrecen, hungary borsod-abauj-zemplen megyei korhaz es egyetemi oktato korhaz; onkologiai osztaly, miskolc, hungary rajiv gandhi cancer institute & research center, new delhi, delhi, india max super speciality hospital; medical oncology, north west delhi, delhi, india hemato oncology clinic ahmedabad pvt ltd, ahmadabad, gujarat, india manipal hospital; department of oncology, bangalore, karnataka, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india sahyadri super specialty hospital hadapsar, pune, maharashtra, india tata medical centre; medical oncology, kolkata, west bengal, india christian med clg & hspt, vellore, india aorn\'s.g.moscati; oncologia, avellino, campania, italy u.o.c. oncologia medica senologica, napoli, campania, italy università degli studi federico ii; clinica di oncologia medica, napoli, campania, italy policlinico s.orsola-malpighi; istituto oncologia r. addarii, bologna, emilia-romagna, italy a.o. universitaria policlinico di modena; oncologia, modena, emilia-romagna, italy irccs centro di riferimento oncologico (cro), aviano, friuli-venezia giulia, italy asu fc s. m. della misericordia; oncologia, udine, friuli-venezia giulia, italy policlinico universitario agostino gemelli, roma, lazio, italy asst degli spedali civili di brescia; oncologia medica, brescia, lombardia, italy ospedale san raffaele; medical oncology, milano, lombardia, italy irccs istituto nazionale dei tumori (int);s.c. medicina oncologica 1, milano, lombardia, italy ospedale civile - livorno, livorno, toscana, italy azlenda ospendaliero-universitaria pisana; c.o. oncologia 2, pisa, toscana, italy university of eastern piedmont - maggiore della carità university hospital, novara, umbria, italy irccs istituto oncologico veneto (iov); oncologia medica seconda, padova, veneto, italy kyungpook national university medical center, daegu, korea, republic of national cancer center, goyang-si, korea, republic of seoul national university bundang hospital, seongnam-si, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of gangnam severance hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of seoul st mary\'s hospital, seoul, korea, republic of korea university guro hospital, seoul, korea, republic of investigacion oncofarmaceutica, la paz, baja california sur, mexico health pharma professional research, cdmx, mexico city (federal district), mexico centro medico dalinde, cdmx, mexico city (federal district), mexico christus muguerza clinica vidriera, monterrey, nuevo leon, mexico centro de investigacion clinica de oaxaca, oaxaca de juárez, oaxaca, mexico instituto nacional de cancerologia; oncology; tumores mamarios, distrito federal, mexico auckland city hospital, cancer and blood research, auckland, new zealand tauranga hospital, clinical trials unit; bop clinical school, tauranga, new zealand bialostockie centrum onkologii; oddzial onkologii klinicznej, bialystok, poland uniwersyteckie centrum kliniczne; klinika onkologii i radioterapii, gdańsk, poland narodowy instytut onkologii odział w gliwicach; centrum diagnostyki i leczenia chorób piersi, gliwice, poland szpital uniwersytecki w krakowie, oddział kliniczny kliniki onkologii, kraków, poland wielkopolskie centrum onkologii; oddzial chemioterapii, poznan, poland centrum onkologii instytut im.m. sklodowskiej-curie; klin. nowot. piersii i chirurgii rekonstruk, warszawa, poland hospital cuf tejo; oncologia médica e hematologia, lisboa, portugal hospital de santa maria; servico de oncologia medica, lisboa, portugal hospital beatriz angelo; departamento de oncologia, loures, portugal centro hospitalar do porto - hospital de santo antónio; oncologia, porto, portugal ipo do porto; servico de oncologia medica, porto, portugal filantropia clinical hospital; medical oncology, bucuresti, romania prof.dr. alexandru trestioreanu, the oncology institute; medical oncology i, bucuresti, romania amethyst cluj; medical oncology, cluj county, romania cluj-napoca emergency clinical county hospital; medical oncology, cluj-napoca, romania institutul oncologic prof. dr. ion chiricuta cluj-napoca; radioterapie i - oncologie, cluj-napoca, romania sf. nectarie oncology center; medical oncology, craiova, romania oncomed srl, timisoara, romania republican clinical oncological dispensary of the ministry of healthcare; chemotherapy department, kazan, karelija, russian federation fsbi""national medical research center of oncology named after n.n.petrov"" mhrf, st petersburg, leningrad, russian federation medsi clinical hospital on pyatnitsky highway; department of antitumor drug therapy, moscow, moskovskaja oblast, russian federation sbih ""moscow clinical scientific and practical center named after a.s. loginov of dhm"", moskva, moskovskaja oblast, russian federation nizhny novgorod regional clinical oncology center, nizhny novgorod, niznij novgorod, russian federation medical clinic ""ab medical group"", saint petersburg, sankt petersburg, russian federation sbih kaluga region clinical oncology dispensary, kaluga, russian federation krasnoyarsk regional oncology dispensary n.a. krizhanovsky; chemotherapy, krasnoyarsk, russian federation oncology dispensary#1; out-patient oncology dept, moscow, russian federation fsbi russian oncology research center n.a. blokhin of moh rf, moscow, russian federation llc medical and sanitary unit ""clinician"", novosibirsk, russian federation s-pb clinical scientific practical center of specialized kinds of medical care (oncological), saint-petersburg, russian federation sbi of healthcare samara regional clinical oncology dispensary, samara, russian federation sbi of healthcare leningrad regional oncology dispensary, st petersburg, russian federation regional oncology dispensary, tomsk, russian federation regional clinical oncology hospital, yaroslavl, russian federation national cancer centre; medical oncology, singapore, singapore hospital general universitario de elche; servicio de oncologia, elche, alicante, spain hospital universitari germans trias i pujol; servicio de oncologia, badalona, barcelona, spain corporacio sanitaria parc tauli; servicio de oncologia, sabadell, barcelona, spain complejo hospitalario universitario a coruña (chuac); servicio de oncologia, a coruña, la coruña, spain complejo hospitalario universitario de santiago (chus) ; servicio de oncologia, santiago de compostela, la coruña, spain hospital quiron de madrid; servicio de oncologia, pozuelo de alarcon, madrid, spain hospital alvaro cunqueiro; servicio de oncologia, vigo, pontevedra, spain hospital universitario de canarias;servicio de oncologia, la laguna, tenerife, spain hospital de basurto; servicio de oncologia, bilbao, vizcaya, spain hospital del mar; servicio de oncologia, barcelona, spain vall d´hebron institute of oncology (vhio), barcelona, barcelona, spain hospital clinic barcelona; servicio de oncologia, barcelona, spain hospital universitario clínico san cecilio; servicio de oncologia, granada, spain complejo hospitalario de jaen-hospital universitario medico quirurgico; servicio de oncologia, jaen, spain hospital general universitario gregorio marañon; servicio de oncologia, madrid, spain hospital ramon y cajal; servicio de oncologia, madrid, spain hospital clinico san carlos; servicio de oncologia, madrid, spain hospital universitario la paz; servicio de oncologia, madrid, spain hospital clinico universitario virgen de la victoria; servicio de oncologia, malaga, spain hospital clinico universitario de salamanca; servicio de oncologia, salamanca, spain hospital universitario virgen macarena; servicio de oncologia, sevilla, spain hospital universitario virgen del rocio; servicio de oncologia, sevilla, spain hospital clínico universitario de valencia; servicio de oncología, valencia, spain hospital universitario dr. peset; servicio de oncologia, valencia, spain hospital universitario miguel servet; servicio oncologia, zaragoza, spain china medical university hospital; surgery, taichung, taiwan national cheng kung uni hospital; dept of hematology and oncology, tainan, taiwan national taiwan university hospital ; dept of surgery & hepatitis research center, taipei 100, taiwan taipei veterans general hospital; department of clinical trial pharmacy, taipei, taiwan mackay memorial hospital; dept of surgery, taipei, taiwan chulalongkorn hospital; medical oncology, bangkok, thailand ramathibodi hospital; dept of med.-div. of med. onc, bangkok, thailand srinagarind hospital; department of surgery, khon kaen, thailand songklanagarind hospital; department of surgery, songkla, thailand adana baskent university hospital; medical oncology, adana, turkey hacettepe university medical faculty, ankara, turkey ankara city hospital, ankara, turkey memorial ankara hastanesi, ankara, turkey antalya training and research hospital ; oncology department, antalya, turkey ege university medical faculty; medical oncology department, bornova, i̇̇zmi̇r, turkey dicle university faculty of medicine, diyarbakir, turkey trakya universitesi tip fakultesi, medikal onkoloji bilim dali, balkan yerleskesi, edirne, turkey istanbul faculty of medicine, istanbul, turkey istanbul university cerrahpasa faculty of medicine, istanbul, turkey katip celebi university ataturk training and research hospital; oncology, izmir, turkey medeniyet university goztepe training and research hospital., kadiköy, turkey inonu university medical faculty of medicine; medical oncology department, malatya, turkey acıbadem altunizade hastanesi; oncology, üsküdar, turkey uzhgorod central city clinical hospital, uzhhorod, katerynoslav governorate, ukraine municipal noncommercial institution regional center of oncology, kharkiv, kharkiv governorate, ukraine municipal non profit enterprise of sumy regional council sumy regional clinical oncology disp, sumy, kholm governorate, ukraine mi ""clinical oncological dispensary"" of dnipro reg council; chemotherapy department, dnipro, kiev governorate, ukraine innovacia cancer center, liutizh, kiev governorate, ukraine ci dnipropetrovsk cmch #4 of dnipropetrovsk rc si dnipropetrovsk ma of mohu ch of oncology and mr, dnipropetrovsk, ukraine municipal institution kirovograd regional oncology dispensary, kirovograd, ukraine kyiv city clinical oncological center, kyiv, ukraine belfast city hospital, belfast, united kingdom blackpool victoria hospital, blackpool, united kingdom bradford royal infirmary; oncology department, bradford, united kingdom royal sussex county hospital, brighton, united kingdom velindre cancer centre; clinical trials unit, cardiff, united kingdom cheltenham general hospital, cheltenham, united kingdom royal cornwall hospital; dept of clinical oncology, cornwall, united kingdom raigmore hospital, inverness, united kingdom barts & london school of med; medical oncology, london, united kingdom university college london hospital, london, united kingdom royal free hospital, london, united kingdom royal marsden hospital - london, london, united kingdom christie hospital nhs trust, manchester, united kingdom nottingham city hospital, nottingham, united kingdom royal preston hospital, preston, united kingdom glan clywd hospital, rhyl, united kingdom royal marsden hospital - surrey, surrey, united kingdom walsall manor hospital, walsall, united kingdom']",,https://ClinicalTrials.gov/show/NCT04873362,breast
280,281,NCT02278120,"study of efficacy and safety in premenopausal women with hormone receptor positive, her2-negative advanced breast cancer",MONALEESA-7,"Active, not recruiting",Has Results,advanced metastatic breast cancer,drug: lee011|drug: tamoxifen|drug: letrozole|drug: anastrozole|drug: goserelin|drug: lee011 placebo,progression free survival (pfs) per investigator's assessment|overall survival (os)|overall response rate (orr) per local assessment|clinical benefit rate (cbr)|safety and tolerability of lee011|time to response (ttr) per local investigator's assessment|duration of response (dor) per investigator's assessment - patients with confirmed complete response (cr) or partial response (pr)|time to definitive deterioration of the ecog ps from baseline|time to 10% deterioration in the global health status/qol scale score of the eortc qlq-c30|change from baseline in the global health status/qol scale score of the eortc qlq-c30,novartis pharmaceuticals|novartis,Female,18 Years to 59 Years   (Adult),Phase 3,672.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLEE011E2301|2014-001931-36,"November 20, 2014","August 21, 2017","June 30, 2022","October 29, 2014","February 26, 2019","February 18, 2022","[""comprehensive blood and cancer center sc-2, bakersfield, california, united states university of california at los angeles dept of onc, los angeles, california, united states comprehensive cancer center at saint joseph hospital sc, denver, colorado, united states danbury hospital sc, danbury, connecticut, united states florida cancer specialists onc dept, fort myers, florida, united states florida cancer specialists sc-2, fort myers, florida, united states memorial cancer institute sc, hollywood, florida, united states university of miami univ miami 2, miami, florida, united states northwest georgia oncology centers nw georgia oncology, marietta, georgia, united states moanalua medical center. attn: oncology dept sc, honolulu, hawaii, united states university of chicago sc-3, chicago, illinois, united states norton cancer institute sc, louisville, kentucky, united states sidney kimmel comprehensive cancer center johns hopkins med dept of onc., baltimore, maryland, united states massachusetts general hospital onc dept, boston, massachusetts, united states university of michigan comprehensive cancer center onc dept, ann arbor, michigan, united states washington university school of medicine sc, saint louis, missouri, united states meridian health systems sc, neptune, new jersey, united states university of new mexico hospital sc-2, albuquerque, new mexico, united states clinical research alliance, lake success, new york, united states duke university medical center duke (sc), durham, north carolina, united states penn state university milton s hershey medical center, hershey, pennsylvania, united states bon secours cancer center sc, greenville, south carolina, united states erlanger medical center sc, chattanooga, tennessee, united states tennessee oncology tennessee oncology (3), nashville, tennessee, united states the center for cancer and blood disorders sc, fort worth, texas, united states methodist hospital / methodist cancer center dept of oncology, houston, texas, united states university of texas md anderson cancer center sc-5, houston, texas, united states cancer therapy and research center ut health science center sc-4, san antonio, texas, united states brooke army medical center sc, san antonio, texas, united states northern utah cancer associates, ogden, utah, united states bon secours virginia health system, midlothian, virginia, united states providence regional cancer partnership, everett, washington, united states kadlec clinic hematology and oncology kadlec clinic hematology & onc, kennewick, washington, united states northwest medical specialties dept of onc, tacoma, washington, united states university of wisconsin / paul p. carbone comp cancer center univ wisc 3, madison, wisconsin, united states novartis investigative site, cordoba, argentina novartis investigative site, jujuy, argentina novartis investigative site, la rioja, argentina novartis investigative site, waratah, new south wales, australia novartis investigative site, box hill, victoria, australia novartis investigative site, heidelberg, victoria, australia novartis investigative site, murdoch, western australia, australia novartis investigative site, nedlands, western australia, australia novartis investigative site, bruxelles, belgium novartis investigative site, leuven, belgium novartis investigative site, namur, belgium novartis investigative site, wilrijk, belgium novartis investigative site, londrina, pr, brazil novartis investigative site, ijuí, rs, brazil novartis investigative site, passo fundo, rs, brazil novartis investigative site, barretos, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, são paulo, sp, brazil novartis investigative site, sofia, bulgaria novartis investigative site, varna, bulgaria novartis investigative site, edmonton, alberta, canada novartis investigative site, vancouver, british columbia, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, quebec, canada novartis investigative site, bogota, colombia novartis investigative site, monteria, colombia novartis investigative site, strasbourg cedex, cedex, france novartis investigative site, caen cedex, france novartis investigative site, lille cedex, france novartis investigative site, lyon cedex, france novartis investigative site, montpellier cedex 5, france novartis investigative site, paris, france novartis investigative site, rouen cedex 1, france novartis investigative site, toulouse cedex 9, france novartis investigative site, muehlhausen, thueringen, germany novartis investigative site, bonn, germany novartis investigative site, dresden, germany novartis investigative site, erlangen, germany novartis investigative site, essen, germany novartis investigative site, esslingen, germany novartis investigative site, kiel, germany novartis investigative site, leipzig, germany novartis investigative site, muenchen, germany novartis investigative site, offenbach, germany novartis investigative site, ravensburg, germany novartis investigative site, ulm, germany novartis investigative site, thessaloniki, gr, greece novartis investigative site, heraklion crete, greece novartis investigative site, hong kong, hong kong novartis investigative site, kowloon, hong kong novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, szeged, hungary novartis investigative site, szolnok, hungary novartis investigative site, bangalore, karnataka, india novartis investigative site, nashik, maharashtra, india novartis investigative site, kolkatta, west bengal, india novartis investigative site, mumbai, india novartis investigative site, l'aquila, aq, italy novartis investigative site, benevento, bn, italy novartis investigative site, bologna, bo, italy novartis investigative site, cremona, cr, italy novartis investigative site, catania, ct, italy novartis investigative site, meldola, fc, italy novartis investigative site, cona, fe, italy novartis investigative site, genova, ge, italy novartis investigative site, lecce, le, italy novartis investigative site, lucca, lu, italy novartis investigative site, macerata, mc, italy novartis investigative site, milano, mi, italy novartis investigative site, perugia, pg, italy novartis investigative site, prato, po, italy novartis investigative site, pavia, pv, italy novartis investigative site, roma, rm, italy novartis investigative site, candiolo, to, italy novartis investigative site, terni, tr, italy novartis investigative site, udine, ud, italy novartis investigative site, napoli, italy novartis investigative site, bundang gu, gyeonggi do, korea, republic of novartis investigative site, gyeonggi do, korea, korea, republic of novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, el chouf, lbn, lebanon novartis investigative site, ashrafieh, lebanon novartis investigative site, beirut, lebanon novartis investigative site, beirut, lebanon novartis investigative site, beirut, lebanon novartis investigative site, saida, lebanon novartis investigative site, johor bahru, johor, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, metepec, edo. de méxico, mexico novartis investigative site, leon, guanajuato, mexico novartis investigative site, monterrey nuevo leon, monterrey, mexico novartis investigative site, gdansk, poland novartis investigative site, konin, poland novartis investigative site, lisboa, portugal novartis investigative site, lisboa, portugal novartis investigative site, lisboa, portugal novartis investigative site, porto, portugal novartis investigative site, porto, portugal novartis investigative site, arkhangelsk, russian federation novartis investigative site, saint petersburg, russian federation novartis investigative site, riyadh, saudi arabia novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, elche, alicante, spain novartis investigative site, almeria, andalucia, spain novartis investigative site, malaga, andalucia, spain novartis investigative site, sabadell, barcelona, spain novartis investigative site, sant joan despi, barcelona, spain novartis investigative site, badalona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, santiago de compostela, galicia, spain novartis investigative site, mallorca, islas baleares, spain novartis investigative site, alcorcon, madrid, spain novartis investigative site, san sebastian, pais vasco, spain novartis investigative site, baracaldo, vizcaya, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, geneve, switzerland novartis investigative site, new taipei city, twn, taiwan novartis investigative site, changhua, taiwan novartis investigative site, kaohsiung city, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan, taiwan novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, istanbul, tur, turkey novartis investigative site, adana, turkey novartis investigative site, ankara, turkey novartis investigative site, diyarbakir, turkey novartis investigative site, edirne, turkey novartis investigative site, izmir, turkey novartis investigative site, al ain abu dhabi, united arab emirates""]","""study protocol"", https://clinicaltrials.gov/provideddocs/20/nct02278120/prot_001.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/20/nct02278120/sap_000.pdf",https://ClinicalTrials.gov/show/NCT02278120,breast
281,282,NCT00022672,a study to evaluate the efficacy and safety of herceptin® (trastuzumab) in combination with arimidex® (anastrozole) an aromatase inhibitor compared to arimidex® alone in patients with metastatic breast cancer,,Completed,Has Results,breast cancer,drug: trastuzumab (herceptin®)|drug: anastrazole (arimidex®),progression free survival (pfs)|percentage of participants with clinical benefit|duration of response at 24 months|time to response at 24 months|overall survival at 24 months|percentage of participants with two-year survival|percentage of participants with overall tumor response at 24 months|percentage of participants with best tumor response at 24 months|percentage of participants with eastern cooperative oncology group (ecog) performance status at final visit compared to baseline|duration of response at end of study|time to response at end of study|percentage of participants with overall tumor response at end of study|percentage of participants with best tumor response at end of study|number of participants with adverse events,"hoffmann-la roche|genentech, inc.",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,208.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO16216,January 2001,October 2009,October 2009,"January 27, 2003","June 13, 2013","June 13, 2013","['phoenix, arizona, united states little rock, arkansas, united states los angeles, california, united states vallejo, california, united states gainsville, florida, united states miami, florida, united states plantation, florida, united states chicago, illinois, united states chicago, illinois, united states kansas city, kansas, united states scarborough, maine, united states detroit, michigan, united states omaha, nebraska, united states hackensack, new jersey, united states albuquerque, new mexico, united states santa fe, new mexico, united states rochester, new york, united states cincinnati, ohio, united states cleveland, ohio, united states hershey, pennsylvania, united states box hill, australia darlinghurst, australia waratah, australia porto alegre, brazil plovdiv, bulgaria sofia, bulgaria stara zagora, bulgaria calgary, alberta, canada edmonton, alberta, canada victoria, british columbia, canada winnipeg, manitoba, canada oshawa, ontario, canada toronto, ontario, canada toronto, ontario, canada montreal, quebec, canada quebec city, quebec, canada beijing, china beijing, china shanghai, china shanghai, china wuhan, china avignon, france nice, france frankfurt, germany kiel, germany münchen, germany trier, germany hong kong, hong kong budapest, hungary ahmedabad, india bangalore, india chennai, india cuttack, india ludhiana, india mumbai, india new delhi, india new delhi, india new delhi, india haifa, israel haifa, israel petach tikva, israel ramat-gan, israel rehovot, israel tel aviv, israel genova, italy vilnius, lithuania guadalajara, mexico mexico city, mexico amsterdam, netherlands rotterdam, netherlands trondheim, norway bialystok, poland bydgoszcz, poland gliwice, poland krakow, poland lodz, poland szczecin, poland warszawa, poland warszawa, poland barnaul, russian federation izhevsk, russian federation kazan, russian federation krasnodar, russian federation moscow, russian federation moscow, russian federation moscow, russian federation moscow, russian federation moscow, russian federation st petersburg, russian federation st petersburg, russian federation st petersburg, russian federation ufa, russian federation floracliffe, south africa pretoria, south africa barcelona, spain córdoba, spain girona, spain madrid, spain madrid, spain madrid, spain mataro, spain reus, spain valencia, spain boras, sweden gaelve, sweden stockholm, sweden örebro, sweden taipei, taiwan taoyuan, taiwan ankara, turkey ankara, turkey istanbul, turkey istanbul, turkey izmir, turkey shhiye, ankara, turkey kiev, ukraine kiev, ukraine lvov, ukraine odessa, ukraine sumy, ukraine zaporozhye, ukraine cardiff, united kingdom edinburgh, united kingdom guildford, united kingdom ipswich, united kingdom london, united kingdom london, united kingdom manchester, united kingdom merseyside, united kingdom newcastle upon tyne, united kingdom southampton, united kingdom swansea, united kingdom']",,https://ClinicalTrials.gov/show/NCT00022672,breast
282,283,NCT01151215,study of anastrozole +/- azd8931 in postmenopausal women with endocrine therapy naive breast cancer,MINT,Terminated,Has Results,neoplasms|breast neoplasms|breast cancer,drug: azd8931|drug: anastrozole|drug: placebo,progression free survival as evaluated by response evaluation criteria in solid tumors (recist) 1.1|compare the overall survival in patients treated with azd8931 in combination with anastrozole versus anastrozole alone,astrazeneca,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,482.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D0102C00004,June 2010,January 2013,January 2013,"June 28, 2010","May 8, 2014","July 25, 2014","['research site, lake success, new york, united states research site, belo horizonte, brazil research site, goiânia, brazil research site, ijuí, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, são paulo, brazil research site, vancouver, british columbia, canada research site, ottawa, ontario, canada research site, montreal, quebec, canada research site, brno, czech republic research site, olomouc, czech republic research site, praha 2, czech republic research site, praha 4, czech republic research site, helsinki, finland research site, tampere, finland research site, turku, finland research site, bangalore, india research site, hyderabad, india research site, mumbai, india research site, pune, india research site, trivandrum, india research site, vellore, india research site, niigata-shi, japan research site, osaka-shi, japan research site, ota-shi, japan research site, sapporo-shi, japan research site, seoul, korea, republic of research site, durango, mexico research site, juchitan, mexico research site, merida, mexico research site, monterrey, mexico research site, callao, peru research site, lima, peru research site, piura, peru research site, iloilo city, philippines research site, lipa city, philippines research site, pasay city, philippines research site, quezon city, philippines research site, białystok, poland research site, elbląg, poland research site, kraków, poland research site, warszawa, poland research site, kuzmolovsky, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, durban, south africa research site, pretoria, south africa research site, taipei, taiwan research site, bangkok, thailand research site, songkla, thailand research site, dnipropetrovsk, ukraine research site, lviv, ukraine research site, birmingham, united kingdom research site, bournemouth, united kingdom research site, coventry, united kingdom research site, leicester, united kingdom research site, london, united kingdom research site, nottingham, united kingdom research site, surrey, united kingdom research site, wythenshawe, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT01151215,breast
283,284,NCT04416633,"study to access safety of durvalumab in indian adult patients with locally advanced, nsclc and urothelial cancer",,Recruiting,No Results Available,unresectable non-small cell lung cancer (nsclc) and urothelial cancer,drug: durvalumab,to assess the safety of durvalumab among locally advanced unresectable non-small cell lung carcinoma and metastatic urothelial carcinoma,astrazeneca,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,200.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D133HC00003,"November 30, 2021","March 31, 2023","March 31, 2023","June 4, 2020",,"May 5, 2022","['research site, ansari nagar, india research site, bhubaneswar, india research site, faridabad, india research site, gurgaon, india research site, kolkata, india research site, kolkata, india research site, new delhi, india research site, new delhi, india research site, west bengal, india']",,https://ClinicalTrials.gov/show/NCT04416633,urotheli
284,285,NCT01133990,folfiri alone versus folfiri plus bevacizumab versus folfiri plus e7820 as second-line therapy in patients with locally advanced or metastatic colorectal cancer,,Completed,No Results Available,colorectal cancer,drug: foliri|drug: foliri plus e7820|drug: folfiri plus bevacizumab,safety parameter: adverse events|safety parameter: concomitant meds|safety parameter: lab tests|safety parameter: ecgs|efficacy parameter,eisai inc.|pharmabio development inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7820-701|2009-016015-37,April 2010,January 2011,January 2011,"May 31, 2010",,"May 29, 2013","['rocky mountain cancer center - midtown, denver, colorado, united states summit medical group, berkeley heights, new jersey, united states hematology oncology associates sj p.a., mount holly, new jersey, united states university of north carolina at chapel hill, chapel hill, north carolina, united states university of texas southwestern medical center, dallas, texas, united states northwest medical specialties, pllc, tacoma, washington, united states north coast cancer institute, coffs harbour, new south wales, australia sydney haematology & oncology clinic, hornsby, new south wales, australia calvary mater newcastle, waratah, new south wales, australia royal brisbane and women\'s hospital, herston, queensland, australia royal hobart hospital, hobart, south australia, australia queen elizabeth hospital, woodville south, south australia, australia box hill hospital, box hill, victoria, australia the austin hospital, epping, victoria, australia newcastle private hospital, merewether, australia jawaharlal nehru cancer hospital and research centre, bhopal, madhya pradesh, india searoc cancer hosptial, jaipur, rajasthan, india gujarat cancer & research institute, ahmedabad, india kidwai institute of oncology, bangalore, india m. s. ramaiah memorial hospital, bangalore, india subodh mitra cancer hospital and research centre, kolkata, india shatabdi hospital, nashik, india deenanath mangeshkar hospital and research center, pune, india noble hospital, pune, india christian medical college, vellore, india cch #2 n.a. n. a. semashko of llc ""russian railways"", moscow, russian federation city mariinskaya hospital, st petersburg, russian federation scientific research oncology institute named after n.n. petr, st petersburg, russian federation yaroslav regional clinical oncology hospital, yaroslav, russian federation mun. multifield clin.hosp.#4,dept. of chemotherapy, dsmu, dnipropetrovsk, ukraine donetsk regional anticancer centre, donetsk, ukraine city clinical hospital #2, kharkiv, ukraine the st.inst. ""s.p.grigoriev med. rad.inst. of ams of ukr."", kharkiv, ukraine uzhgorod centr.city cl.hosp.,city onc.center, unmu,fac.of pg, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT01133990,colon
285,286,NCT03562819,study to evaluate concordance of detecting egfr (epidermal growth factor receptor) mutation by circulating tumour free dna versus tissues biopsy in nsclc (non-small cell lung cancer).,CONCORDANCE,Completed,No Results Available,nsclc (non-small cell lung cancer),,determine the level of concordance between egfr mutation status|assess the frequency of t790m mutation among study patients.,astrazeneca,All,"Child, Adult, Older Adult",,268.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,D5161R00003,"August 16, 2018","June 7, 2019","June 7, 2019","June 20, 2018",,"June 5, 2020","['reserch site, punjab, chandigarh, india research site, new delhi, delhi, india research site, new delhi, delhi, india research site, new delhi, delhi, india research site, bengaluru, karnataka, india research site, kerala, kozhikode, india research site, mumbai, maharashtra, india research site, mumbai, maharashtra, india research site, maharashtra, mumbai, india research site, bhubaneswar, odisha, india research site, hyderabad, telanagana, india research site, kolkata, west bangal, india research site, kolkata, west bengal, india research site, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03562819,
286,287,NCT02437318,study assessing the efficacy and safety of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer which progressed on or after aromatase inhibitor treatment.,SOLAR-1,"Active, not recruiting",Has Results,breast cancer,drug: fulvestrant|drug: alpelisib|drug: alpelisib placebo,progression-free survival (pfs) per investigator assessment in the pik3ca mutant cohort|overall survival (os) for patients with pi3kca mutant status|overall response rate (orr)|time to definitive deterioration of eastern cooperative oncology group (ecog) performance status|safety and tolerability of alpelisib in combination with fulvestrant|time to 10% deterioration in the global health status/quality of life (qol) scale score of the eortc qlq-c30|plasma concentration-time profile of alpelisib given in combinatio with fulvestrant and appropriate pharmacokinetics (pk) parameters|pfs based on radiology assessments and using recist 1.1 criteria|clinical benefit rate (cbr)|change in the global health status/(qol) scale score of the eortc qlq-c30|summary statistics of fulvestrant and alpelisib plasma concentrations|pfs for patients with pik3ca non-mutant status|os for patients with pik3ca non-mutant status,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,572.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CBYL719C2301|2015-000340-42,"July 23, 2015","June 12, 2018","July 1, 2022","May 7, 2015","August 13, 2019","December 14, 2021","[""ironwood cancer and research centers chandler 2, chandler, arizona, united states mayo clinic - arizona, scottsdale, arizona, united states highlands oncology group, fayetteville, arkansas, united states beverly hills cancer center, beverly hills, california, united states city of hope national medical center, duarte, california, united states scripps clinic sc, la jolla, california, united states kaiser permanente - california southern, san diego, california, united states university of california san francisco, san francisco, california, united states florida cancer specialists fl cancer specialists, fort myers, florida, united states florida cancer specialists-north sc, saint petersburg, florida, united states rush university medical center rush uni medical center, chicago, illinois, united states north shore university health system northshore university, evanston, illinois, united states edward cancer center sc, naperville, illinois, united states fort wayne medical oncology/hematology, inc. dept.of fort wayne med onc/hem, fort wayne, indiana, united states st. francis health comprehensive cancer center sc, topeka, kansas, united states mercy medical center sc-2, baltimore, maryland, united states massachusetts general hospital updated regulatory, boston, massachusetts, united states lahey clinic, burlington, massachusetts, united states detroit clinical research center, owosso, michigan, united states st. luke's cancer institute sc, kansas city, missouri, united states st vincent frontier cancer center, billings, montana, united states rutgers cancer institute of new jersey sc-2, new brunswick, new jersey, united states university hospitals of cleveland seidman cancer center sc, cleveland, ohio, united states good samaritan regional medical center good samaritan reg med ctr, corvallis, oregon, united states lancaster general hospital, lancaster, pennsylvania, united states prisma health upstate sc-2, greenville, south carolina, united states avera cancer sc, sioux falls, south dakota, united states tennessee oncology sc-3, nashville, tennessee, united states texas oncology pa dallas presbyterian hospital sc-1, dallas, texas, united states el paso, texas oncology, el paso, texas, united states cancer therapy and research center ut health science center institutefordrugdevelopment(4), san antonio, texas, united states us oncology p a, tyler, texas, united states virginia cancer specialists sc, fairfax, virginia, united states wenatchee valley medical center sc-2, wenatchee, washington, united states novartis investigative site, berazategui, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, rio negro, viedma, argentina novartis investigative site, la rioja, argentina novartis investigative site, wahroonga, new south wales, australia novartis investigative site, wooloongabba, queensland, australia novartis investigative site, elizabeth vale, south australia, australia novartis investigative site, melbourne, victoria, australia novartis investigative site, linz, austria novartis investigative site, vienna, austria novartis investigative site, edegem, antwerpen, belgium novartis investigative site, jette, brussel, belgium novartis investigative site, sint niklaas, vlaams brabant, belgium novartis investigative site, bruxelles, belgium novartis investigative site, libramont, belgium novartis investigative site, ottignies, belgium novartis investigative site, verviers, belgium novartis investigative site, natal, rn, brazil novartis investigative site, lajeado, rs, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao jose do rio preto, brazil novartis investigative site, sao paulo, brazil novartis investigative site, plovdiv, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, varna, bulgaria novartis investigative site, varna, bulgaria novartis investigative site, calgary, alberta, canada novartis investigative site, cambridge, ontario, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, quebec, canada novartis investigative site, temuco, araucania, chile novartis investigative site, santiago, chile novartis investigative site, vina del mar, chile novartis investigative site, hradec kralove, czech republic, czechia novartis investigative site, praha 4, czech republic, czechia novartis investigative site, zlin, czech republic, czechia novartis investigative site, prague 8, czechia novartis investigative site, marseille cedex 20, bouches du rhone, france novartis investigative site, angers cedex 02, france novartis investigative site, avignon cedex, france novartis investigative site, caen cedex, france novartis investigative site, clermont-ferrand, france novartis investigative site, creteil, france novartis investigative site, la roche sur yon cedex 9, france novartis investigative site, le chesnay, france novartis investigative site, levallois-perret, france novartis investigative site, lyon cedex 08, france novartis investigative site, montpellier, france novartis investigative site, nimes, france novartis investigative site, rouen cedex 1, france novartis investigative site, saint-herblain cédex, france novartis investigative site, toulouse cedex 9, france novartis investigative site, villejuif cedex, france novartis investigative site, recklinghausen, north rhine-westphalia, germany novartis investigative site, leipzig, sachsen, germany novartis investigative site, luebeck, schleswig-holstein, germany novartis investigative site, aschaffenburg, germany novartis investigative site, frankfurt, germany novartis investigative site, friedrichshafen, germany novartis investigative site, hannover, germany novartis investigative site, homburg, germany novartis investigative site, kiel, germany novartis investigative site, mainz, germany novartis investigative site, potsdam, germany novartis investigative site, rostock, germany novartis investigative site, ulm, germany novartis investigative site, velbert, germany novartis investigative site, thessaloniki, gr, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, hong kong, hong kong novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, nyiregyhaza, hungary novartis investigative site, szekszard, hungary novartis investigative site, vijayawada, andhra pradesh, india novartis investigative site, nagpur - maharashtra, maharashtra, india novartis investigative site, mumbai, india novartis investigative site, beer-sheva, israel novartis investigative site, haifa, israel novartis investigative site, petach tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, tel aviv, israel novartis investigative site, ancona, an, italy novartis investigative site, chieti, ch, italy novartis investigative site, meldola, fc, italy novartis investigative site, milano, mi, italy novartis investigative site, palermo, pa, italy novartis investigative site, padova, pd, italy novartis investigative site, pontedera, pi, italy novartis investigative site, aviano, pn, italy novartis investigative site, rionero in vulture, pz, italy novartis investigative site, roma, rm, italy novartis investigative site, sassari, ss, italy novartis investigative site, savona, sv, italy novartis investigative site, torino, to, italy novartis investigative site, negrar, vr, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, matsuyama, ehime, japan novartis investigative site, maebashi city, gunma, japan novartis investigative site, sapporo-city, hokkaido, japan novartis investigative site, akashi, hyogo, japan novartis investigative site, kagoshima-city, kagoshima, japan novartis investigative site, isehara, kanagawa, japan novartis investigative site, yokohama-city, kanagawa, japan novartis investigative site, kumamoto city, kumamoto, japan novartis investigative site, osaka-city, osaka, japan novartis investigative site, osaka-city, osaka, japan novartis investigative site, kitaadachi-gun, saitama, japan novartis investigative site, chuo ku, tokyo, japan novartis investigative site, minato ku, tokyo, japan novartis investigative site, bundang gu, gyeonggi do, korea, republic of novartis investigative site, gyeonggi do, korea, korea, republic of novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, ashrafieh, lebanon novartis investigative site, beirut, lebanon novartis investigative site, saida, lebanon novartis investigative site, monterrey, n.l., monterrey, mexico novartis investigative site, san luis potosi, mexico novartis investigative site, venray, ce, netherlands novartis investigative site, terneuzen, netherlands novartis investigative site, san borja, lima, peru novartis investigative site, surquillo, lima, peru novartis investigative site, lima, peru novartis investigative site, floresti, cluj, romania novartis investigative site, craiova, dolj, romania novartis investigative site, iasi, romania novartis investigative site, arkhangelsk, russian federation novartis investigative site, ryazan, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, sevilla, andalucia, spain novartis investigative site, jerez, cadiz, spain novartis investigative site, badalona, catalunya, spain novartis investigative site, barcelona, cataluña, spain novartis investigative site, alicante, comunidad valenciana, spain novartis investigative site, castellon, comunidad valenciana, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, badajoz, extremadura, spain novartis investigative site, caceres, extremadura, spain novartis investigative site, santiago de compostela, galicia, spain novartis investigative site, palma de mallorca, islas baleares, spain novartis investigative site, pozuelo de alarcon, madrid, spain novartis investigative site, el palmar, murcia, spain novartis investigative site, la laguna, santa cruz de tenerife, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, gavle, sweden novartis investigative site, oerebro, sweden novartis investigative site, vasteras, sweden novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, bangkok, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, plymouth, devon, united kingdom novartis investigative site, leicester, united kingdom novartis investigative site, london, united kingdom""]","""study protocol"", https://clinicaltrials.gov/provideddocs/18/nct02437318/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/18/nct02437318/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02437318,breast
287,288,NCT03703297,"study of durvalumab + tremelimumab, durvalumab, and placebo in limited stage small-cell lung cancer in patients who have not progressed following concurrent chemoradiation therapy",ADRIATIC,"Active, not recruiting",No Results Available,small cell lung cancer,drug: durvalumab|drug: tremelimumab|other: placebo,"progression-free survival (pfs)|overall survival (os)|objective response rate (orr)|progression-free survival pfs|progression-free survival at 18 months (pfs18)|progression-free survival at 24 months (pfs24)|time to death or distant metastasis (ttdm)|proportion of patients alive at 24 months (os24)|proportion of patients alive at and 36 months (os36)|time from randomization to second progression (pfs2)|to assess symptoms and health-related qol in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the eortc qlq-c30 v3|to assess the pk of durvalumab and tremelimumab in blood (peak trough concentration)|presence of anti-drug antibodies (ada) for durvalumab and tremelimumab (confirmatory results: positive or negative)|pd-l1 expression in tumor and/or immune cells relative to response/efficacy outcomes (pfs, os & orr).|to assess symptoms and health-related qol in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the eortc qlq-lc13",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,730.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D933QC00001,"September 27, 2018","May 10, 2024","May 10, 2024","October 11, 2018",,"March 7, 2022","['research site, tucson, arizona, united states research site, santa rosa, california, united states research site, new haven, connecticut, united states research site, fort myers, florida, united states research site, orange city, florida, united states research site, saint petersburg, florida, united states research site, marietta, georgia, united states research site, hines, illinois, united states research site, fort wayne, indiana, united states research site, muncie, indiana, united states research site, lexington, kentucky, united states research site, annapolis, maryland, united states research site, baltimore, maryland, united states research site, towson, maryland, united states research site, boston, massachusetts, united states research site, detroit, michigan, united states research site, grand rapids, michigan, united states research site, minneapolis, minnesota, united states research site, summit, new jersey, united states research site, new hyde park, new york, united states research site, chapel hill, north carolina, united states research site, fargo, north dakota, united states research site, portland, oregon, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, sioux falls, south dakota, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, nashville, tennessee, united states research site, dallas, texas, united states research site, kennewick, washington, united states research site, tacoma, washington, united states research site, charleston, west virginia, united states research site, huntington, west virginia, united states research site, milwaukee, wisconsin, united states research site, caba, argentina research site, caba, argentina research site, ciudadela, argentina research site, córdoba, argentina research site, la plata, argentina research site, mar del plata, argentina research site, rosario, argentina research site, san salvador de jujuy, argentina research site, aalst, belgium research site, anderlecht, belgium research site, bruxelles, belgium research site, hasselt, belgium research site, roeselare, belgium research site, edmonton, alberta, canada research site, toronto, ca, canada research site, winnipeg, manitoba, canada research site, hamilton, ontario, canada research site, london, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, bengbu, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, chongqing, china research site, chongqing, china research site, fuzhou, china research site, hangzhou, china research site, hefei, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, shenyang, china research site, tianjin, china research site, wuhan, china research site, wuhan, china research site, wuhan, china research site, yangzhou, china research site, zhengzhou, china research site, brno, czechia research site, olomouc, czechia research site, ostrava, czechia research site, praha 2, czechia research site, praha, czechia research site, berlin, germany research site, freiburg, germany research site, gauting, germany research site, gerlingen, germany research site, heidelberg, germany research site, köln, germany research site, mainz, germany research site, münster, germany research site, oldenburg, germany research site, regensburg, germany research site, wuerzburg, germany research site, bangalore, india research site, bengaluru, india research site, chennai, india research site, gurgaon, india research site, kolkata, india research site, brescia, italy research site, milano, italy research site, milano, italy research site, orbassano, italy research site, parma, italy research site, roma, italy research site, rozzano, italy research site, terni, italy research site, bunkyo-ku, japan research site, chuo-ku, japan research site, fukuoka-shi, japan research site, iwakuni-shi, japan research site, kashiwa, japan research site, koto-ku, japan research site, kurume-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, osakasayama, japan research site, sakai-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, sunto-gun, japan research site, tokushima-shi, japan research site, ube-shi, japan research site, changwon-si, korea, republic of research site, cheongju-si, korea, republic of research site, daegu, korea, republic of research site, goyang-si, korea, republic of research site, gyeongsangnam-do, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon-si, korea, republic of research site, amsterdam, netherlands research site, den bosch, netherlands research site, groningen, netherlands research site, harderwijk, netherlands research site, hengelo, netherlands research site, gdańsk, poland research site, olsztyn, poland research site, poznań, poland research site, tomaszów mazowiecki, poland research site, warszawa, poland research site, wroclaw, poland research site, kazan, russian federation research site, kirov, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, obninsk, russian federation research site, omsk, russian federation research site, ufa, russian federation research site, volgograd, russian federation research site, barcelona, spain research site, barcelona, spain research site, las palmas de gran canaria, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, oviedo, spain research site, sevilla, spain research site, valencia, spain research site, zaragoza, spain research site, hsinchu, taiwan research site, kaohsiung city, taiwan research site, keelung city, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan research site, yunlin, taiwan research site, adana, turkey research site, ankara, turkey research site, ankara, turkey research site, antalya, turkey research site, edirne, turkey research site, istanbul, turkey research site, izmir, turkey research site, konya, turkey research site, samsun, turkey research site, manchester, united kingdom research site, truro, united kingdom research site, hanoi, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT03703297,
288,289,NCT04607421,a study of encorafenib plus cetuximab with or without chemotherapy in people with previously untreated metastatic colorectal cancer,,Recruiting,No Results Available,neoplasms,drug: encorafenib|drug: cetuximab|drug: oxaliplatin|drug: irinotecan|drug: leucovorin|drug: 5-fu|drug: capecitabine|drug: bevacizumab,"safety lead-in study: incidence of dose limiting toxicities (dlts)|phase 3: progression free survival, by blinded independent review|safety lead-in: incidence of adverse events|safety lead-in: incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms|safety lead-in: incidence of dose interruptions, dose modifications and discontinuations due to adverse events|safety lead-in: overall response rate by investigator|safety lead-in: duration of response by investigator|safety lead-in:progression free survival by investigator|safety lead-in: time to response by investigator|safety lead-in: overall survival|phase 3: overall survival and progression free survival by blinded independent review|phase 3: overall response rate by blinded independent review and by investigator|phase 3: duration of response by blinded independent review and by investigator|phase 3: time to response by blinded independent review and by investigator|phase 3: progression free survival by investigator|phase 3: progression free survival 2 by investigator|phase 3: incidence of adverse events|phase 3: incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms|phase 3: change from baseline in the european organization for research and treatment of cancer (eortc) quality of life questionnaire (eortc qlq-c30)|phase 3: change from baseline in the euroqol-5d-5l (eq-5d-5l) questionnaire|phase 3: change from baseline in the patient global impression of severity (pgis)|phase 3: change from baseline in the patient global impression of change (pgic) questionnaires|phase 3: confirm the msi-status in tumor tissue|phase 3: determine the correlation between cfdna genetic alterations and clinical outcome|safety lead-in: maximum plasma concentration of encorafenib, lhy746, irinotecan and sn-38|safety lead-in: area under the plasma concentration time curve of encorafenib, lhy746, irinotecan and sn-38|safety lead-in: time to maximim plasma concentration time curve of encorafenib, lhy746, irinotecan and sn-38|safety lead-in: maximum plasma concentration of encorafenib, lhy746 and oxaliplatin|safety lead-in: area under the plasma concentration time curve of encorafenib, lhy746 and oxaliplatin|safety lead-in: clearance of irinotecan, sn-38 and oxaliplatin|safety lead-in: time to maximim plasma concentration time curve of encorafenib, lhy746 and oxaliplatin|phase 3: trough concentrations of encorafenib and its metabolite lhy746","pfizer|ono pharmaceutical co. ltd|merck kgaa, darmstadt, germany",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,765.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,C4221015|2020-001288-99,"December 21, 2020","September 16, 2024","November 15, 2026","October 29, 2020",,"May 12, 2022","['mayo clinic - phoenix oncology pharmacy, phoenix, arizona, united states mayo clinic hospital, phoenix, arizona, united states mayo clinic in arizona - scottsdale, scottsdale, arizona, united states tower hematology oncology medical group (tho), beverly hills, california, united states keck hospital of usc, los angeles, california, united states lac & usc medical center, los angeles, california, united states usc / norris comprehensive cancer center, los angeles, california, united states usc/norris comprehensive cancer center / investigational drug services, los angeles, california, united states usc/norris comprehensive cancer center, los angeles, california, united states cedars- sinai medical center, los angeles, california, united states cedars-sinai medical center, samuel oschin comprehensive cancer institute, los angeles, california, united states cedars-sinai medical center, los angeles, california, united states keck hospital of usc pasadena, pasadena, california, united states torrance memorial medical center (tmmc), torrance, california, united states georgetown university medical center, washington, district of columbia, united states medstar georgetown university hospital, washington, district of columbia, united states mount sinai comprehensive cancer center, aventura, aventura, florida, united states sylvester comprehensive cancer center- the lennar foundation medical center, coral gables, florida, united states holy cross hospital - michael and dianne bienes comprehensive cancer center, fort lauderdale, florida, united states mayo clinic florida, jacksonville, florida, united states mount sinai comprehensive cancer center, miami beach, florida, united states mount sinai medical center, miami beach, florida, united states sylvester comprehensive cancer center, miami, florida, united states baptist hospital of miami, miami, florida, united states miami cancer institute, miami, florida, united states orlando health cancer institute, orlando, florida, united states orlando health, inc., orlando, florida, united states orlando health, inc, orlando, florida, united states brcr medical center inc., plantation, florida, united states lewis cancer & research pavilion at st joseph\'s/candler health system, savannah, georgia, united states lewis cancer & research pavilion pharmacy, savannah, georgia, united states st. joseph\'s/candler health system, inc., savannah, georgia, united states summit cancer care, p.c., savannah, georgia, united states summit cancer care, savannah, georgia, united states st. joseph\'s/candler health system, inc., savannah, georgia, united states ochsner clinic foundation research pharmacy, new orleans, louisiana, united states ochsner clinic foundation, new orleans, louisiana, united states university of michigan hospitals, ann arbor, michigan, united states university of michigan, ann arbor, michigan, united states mayo clinic rochester, rochester, minnesota, united states mayo clinic, rochester, minnesota, united states siteman cancer center - west county, creve coeur, missouri, united states siteman cancer center - north county, florissant, missouri, united states barnes- jewish hospital, saint louis, missouri, united states washington university school of medicine, saint louis, missouri, united states siteman cancer center - south county, saint louis, missouri, united states siteman cancer center - st peters, saint peters, missouri, united states st vincent healthcare, billings, montana, united states st. vincent frontier cancer center, billings, montana, united states oncology hematology west pc dba nebraska cancer specialists, omaha, nebraska, united states oncology hematology west pc dba nebraska cancer specialists, omaha, nebraska, united states oncology hematology west pc dba nebraska cancer specialists, omaha, nebraska, united states oncology hematology west, pc dba nebraska cancer specialists - ip storage, omaha, nebraska, united states oncology hematology west pc dba nebraska cancer specialists, papillion, nebraska, united states memorial sloan kettering cancer center - basking ridge, basking ridge, new jersey, united states summit medical group, berkeley heights, new jersey, united states summit medical group, florham park, new jersey, united states memorial sloan kettering cancer center- monmouth, middletown, new jersey, united states memorial sloan kettering cancer center- bergen, montvale, new jersey, united states north shore hematology oncology assoc. p.c. dba ny cancer and blood specialists, babylon, new york, united states north shore hematology oncology assoc. p.c. dba ny cancer and blood specialists, bronx, new york, united states memorial sloan kettering cancer center commack, commack, new york, united states memorial sloan kettering cancer center - westchester, harrison, new york, united states memorial sloan kettering cancer center, new york, new york, united states north shore hematology oncology assoc. p.c. dba ny cancer and blood specialists, new york, new york, united states memorial sloan kettering cancer center - main campus, new york, new york, united states north shore hematology oncology assoc. p.c. dba ny cancer and blood specialists, patchogue, new york, united states north shore hematology oncology assoc. p.c. dba ny cancer and blood specialists, port jefferson station, new york, united states north shore hematology oncology assoc. p.c. dba ny cancer and blood specialists, riverhead, new york, united states memorial sloan kettering cancer center- nassau, uniondale, new york, united states carolinas medical center, charlotte, north carolina, united states carolinas medical center investigational drug services, charlotte, north carolina, united states levine cancer institute, charlotte, north carolina, united states atrium health mercy, charlotte, north carolina, united states atrium health pineville, charlotte, north carolina, united states levine cancer institute - southpark, charlotte, north carolina, united states atrium health university city, charlotte, north carolina, united states levine cancer institute university city, charlotte, north carolina, united states atrium health cabarrus, concord, north carolina, united states levine cancer institute - concord, concord, north carolina, united states atrium health union, monroe, north carolina, united states investigational drug service, the ohio state university wexner medical center, columbus, ohio, united states the ohio state university james cancer hospital and solove research institute, columbus, ohio, united states stefanie spielman comprehensive breast cancer, columbus, ohio, united states martha morehouse medical plaza, columbus, ohio, united states university of oklahoma health sciences center, ou health stephenson cancer center, oklahoma city, oklahoma, united states providence cancer institute franz clinic, portland, oregon, united states providence portland medical center, portland, oregon, united states providence onc and heme care clinic - westside, portland, oregon, united states providence oncology and hematology care clinic - westside, portland, oregon, united states providence st vincent medical center, portland, oregon, united states providence st. vincent medical center, portland, oregon, united states upmc hillman cancer center investigational drug service, pittsburgh, pennsylvania, united states upmc hillman cancer center, pittsburgh, pennsylvania, united states vanderbilt health clinic at walgreens clarksville, clarksville, tennessee, united states vanderbilt health clinic at walgreens cool springs, franklin, tennessee, united states vanderbilt health clinic at walgreens gallatin, gallatin, tennessee, united states the west clinic. pllc. dba west cancer center, germantown, tennessee, united states vanderbilt health clinic at walgreens hendersonville, hendersonville, tennessee, united states vanderbilt health clinic at walgreens hermitage, hermitage, tennessee, united states vanderbilt health clinic at walgreens la vergne, la vergne, tennessee, united states vanderbilt health clinic at walgreens lebanon, lebanon, tennessee, united states the west clinic pllc dba west cancer center, memphis, tennessee, united states vanderbilt health clinic at walgreens murfreesboro, murfreesboro, tennessee, united states vanderbilt health clinic at walgreens belle meade, nashville, tennessee, united states vanderbilt health clinic at walgreens nippers corner, nashville, tennessee, united states vanderbilt health clinic at walgreens donelson, nashville, tennessee, united states vanderbilt health clinic at walgreens hart lane, nashville, tennessee, united states vanderbilt health clinic at walgreens bellevue, nashville, tennessee, united states vanderbilt-ingram cancer center, nashville, tennessee, united states henry-joyce cancer center, nashville, tennessee, united states vanderbilt oncology ids pharmacy, nashville, tennessee, united states vanderbilt health clinic at walgreens smyrna, smyrna, tennessee, united states the university of texas md anderson cancer center, houston, texas, united states the university of texas md anderson cancer center, houston, texas, united states vcu health system, investigational drug service pharmacy, richmond, virginia, united states virginia commonwealth university massey cancer center, richmond, virginia, united states seattle cancer care alliance, seattle, washington, united states university of washington medical center, seattle, washington, united states university of wisconsin clinical science center, madison, wisconsin, united states centro medico san roque, san miguel de tucumán, tucumán, argentina centro medico san roque, tucuman, tucumán, argentina liverpool hospital, liverpool, new south wales, australia slade pharmacy, mount kuring-gai, new south wales, australia genesiscare - north shore, st leonards, new south wales, australia northern cancer institute, st leonards, new south wales, australia royal brisbane & women\'s hospital, herston, queensland, australia princess alexandra hospital, woolloongabba, queensland, australia the queen elizabeth hospital, adelaide, south australia, australia monash health, clayton, victoria, australia peninsula health, frankston, victoria, australia austin health, heidelberg, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia the alfred hospital, melbourne, victoria, australia université libre de bruxelles - hôpital erasme, brussels, bruxelles-capitale, région de, belgium cliniques universitaires saint-luc, brussels, bruxelles-capitale, région de, belgium grand hôpital de charleroi, charleroi, hainaut, belgium chr verviers east belgium, verviers, liège, belgium az groeninge campus kennedylaan, kortrijk, west-vlaanderen, belgium zna middelheim, antwerpen, belgium uz leuven, leuven, belgium centre hospitalier universitaire de liège - domaine universitaire du sart tilman, liège, belgium clínica de neoplasias litoral, itajaí, santa catarina, brazil medical school famerp-hb-funfarme_do not use - duplicate facility, sao jose do rio preto, são paulo, brazil fundação faculdade regional de medicina de são josé do rio preto, são josé do rio preto, são paulo, brazil mhat uni hospital ood, panagyurishte, pazardzhik, bulgaria mhat ""dr. tota venkova"" ad, gabrovo, bulgaria complex oncology center - plovdiv eood, plovdiv, bulgaria mhat central onco hospital, plovdiv, bulgaria medical center nadezhda clinical eood, sofia, bulgaria university multiprofile hospital for active treatment sofiamed, sofia, bulgaria cross cancer institute, edmonton, alberta, canada kingston health sciences centre-kingston general hospital site, kingston, ontario, canada london regional cancer program, london health sciences centre, london, ontario, canada centre intégré de santé et de services sociaux (cisss) de laval / hôpital de la cité-de-la-sant, laval, quebec, canada jewish general hospital, montreal, quebec, canada anhui provincial cancer hospital, hefei, anhui, china beijing cancer hospital, beijing, beijing, china affiliated tumor hospital of guangxi medical university, nanning, guangxi, china henan provincial people\'s hospital, zhengzhou, henan, china the second xiangya hospital of central south university, changsha, hunan, china the third xiangya hospital of central south university, changsha, hunan, china nanjing drum tower hospital the affiliated hospital of nanjing university medical school, nanjing, jiangsu, china shengjing hospital of china medical university, shenyang, liaoning, china jinan central hospital, jinan, shandong, china shanghai jiaotong university school of medicine ruijin hospital, shanghai, shanghai, china shanghai general hospital, shanghai, shanghai, china sichuan province cancer hospital, chengdu, sichuan, china the second affiliated hospital of college of medicine, zhejiang university, hangzhou, zhejiang, china peking university first hospital, beijing, china fudan university shanghai cancer center, shanghai, china shengjing hospital of china medical university, shenyang, china shengjing hospital of china medical university, shenyang, china fakultní nemocnice brno bohunice, brno, brno-město, czechia fakultni nemocnice hradec kralove, hradec kralove, hradec králové, czechia fakultni thomayerova nemocnice, prague, praha 4, czechia fakultni nemocnice v motole, praha 5, czechia fakultni nemocnice bulovka, praha 8, czechia rigshospitalet, copenhagen, denmark odense university hospital, odense c, denmark docrates syöpäsairaala, helsinki, nyland, finland tampereen yliopistollinen sairaala, tampere, pirkanmaa, finland helsinki university central hospital, helsinki, finland oulu university hospital, oulu, finland turku university hospital, turku, finland muenchen klinik neuperlach, klinik fuer haematologie und onkologie, muenchen, bayern, germany institut für klinisch onkologische forschung, frankfurt, hessen, germany radiologie berlin, berlin - charlottenburg, germany onkologische schwerpunktpraxis kurfuerstendamm, berlin, germany waage apotheke, berlin, germany helios klinikum berlin buch gmbh, berlin, germany helios klinikum berlin-buch, berlin, germany technische universität dresden, medizinische fakultät carl gustav carus, dresden, germany universitätsklinikum carl gustav carus dresden, dresden, germany facharztzentrum eppendorf, hamburg, germany zytoservice deutschland gmbh, standort-hamburg-jenfeld, hamburg, germany radiologie im israelitischen krankenhaus, hamburg, germany klinikum oldenburg aör, oldenburg, germany klinikum oldenburg aör, oldenburg, germany rajiv gandhi cancer institute and research centre, new delhi, delhi, india tata memorial hospital, mumbai, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india sahyadri speciality hospital, pune, maharashtra, india bhakti vedanta hospital and research institute, thane, maharashtra, india r k birla cancer center, sms hospital, jaipur, rajasthan, india sawai man singh medical college hospital (sms hospital), jaipur, rajasthan, india azienda ospedaliera universitaria di cagliari - presidio policlinico universitario ""d.casula"", monserrato (ca), cagliari, italy irccs casa sollievo della sofferenza, san giovanni rotondo, foggia, italy asst grande ospedale metropolitano niguarda, milan, milano, italy fondazione del piemonte per l\'oncologia - istituto di candiolo irccs, candiolo, torino, italy azienda ospedaliero universitaria san luigi gonzaga, orbassano, torino, italy istituto europeo di oncologia irccs, milano, italy irccs istituto oncologico veneto (iov), padova, italy chiba cancer center, chiba-shi, chiba, japan national cancer center hospital east, kashiwa, chiba, japan national hospital organization shikoku cancer center, matsuyama, ehime, japan hokkaido university hospital, sapporo, hokkaido, japan kanazawa university hospital, kanazawa, ishikawa, japan st. marianna university hospital, kawasaki, kanagawa, japan st. marianna university school of medicine hospital, kawasaki, kanagawa, japan kanagawa cancer center, yokohama, kanagawa, japan aichi cancer center hospital, nagoya, nagoya, aichi, japan osaka prefectural hospital organization osaka international cancer institute, osaka-shi, osaka, japan kindai university hospital, osakasayama, osaka, japan osaka university hospital, suita, osaka, japan osaka medical and pharmaceutical university hospital, takatsuki, osaka, japan saitama medical university international medical center, hidaka-city, saitama, japan saitama prefectural cancer center, ina-machi, saitama, japan shizuoka cancer center, nagaizumi, shizuoka, japan national cancer center hospital, chuo-ku, tokyo, japan japanese foundation for cancer research, koto-ku, tokyo, japan national hospital organization kyushu cancer center, fukuoka, japan national hospital organization - osaka national hospital - institute for clinical research, osaka, japan keio university hospital, tokyo, japan national cancer center, goyang-si, gyeonggi-do, korea, republic of kyungpook national university hospital, daegu, taegu-kwangyǒkshi, korea, republic of dong-a university hospital, busan, korea, republic of kyungpook national university chilgok hospital, daegu, korea, republic of gachon university gil medical center, incheon, korea, republic of chonnam national university hwasun hospital pharmacy, jeonnam, korea, republic of chonnam national university hwasun hospital, jeonnam, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of centro de investigacion clinica de oaxaca, oaxaca, mexico maastricht umc+, maastricht, limburg, netherlands nederlands kanker instituut - antoni van leeuwenhoek (nki-avl), amsterdam, noord-holland, netherlands maastricht university medical center, maastricht, netherlands universitair medisch centrum utrecht, utrecht, netherlands tauranga hospital, tauranga, bay of plenty, new zealand auckland city hospital, auckland, new zealand sørlandet sykehus kristiansand, kristiansand, norway oslo universitetssykehus, radiumhospitalet, oslo, norway oslo universitetssykehus ullevål, oslo, norway przychodnia lekarska komed, konin, wielkopolskie, poland szpital specjalistyczny podkarpacki ósrodek onkologiczny w brzozowie, brzozow, poland wojewodzki szpital specjalistyczny nr 4 w bytomiu oddzial onkologii, bytom, poland wojewodzki szpital specjalistyczny nr 4 w bytomiu oddzial onkologii, bytom, poland copernicus pl sp. z. o. o. wojewodzkie centrum onkologii w gdansku ambulatoryjna, gdansk, poland copernicus podmiot leczniczy sp. z o.o. wojewodzkie centrum onkologii, gdansk, poland przychodnia lekarska komed, konin, poland regional specialised hospital no. 4 in bytom, bytom, śląskie, poland sbi ""city clinical hospital №1, nalchik, kabardino-balkarian republic, russian federation state budget institution of healthcare of mordovia republic ""republic oncology dispensary"", saransk, republic of mordovia, russian federation private medical institution ""euromedservice"", pushkin, saint-petersburg, russian federation private medical institution ""euromedservice"", pushkin, sankt-peterburg, russian federation gbuz, chelyabinsk, russian federation kaluga regional clinical oncology center, kaluga, russian federation fsaei he i.m sechenov first msmu moh russia (sechenovskiy university),, moscow, russian federation bhi of omsk region ""clinical oncology dispensary"", omsk, russian federation bhi of omsk region ""clinical oncology dispensary"", omsk, russian federation state budgetary healthcare institution ""orenburg regional clinical oncological dispensary"", orenburg, russian federation llc ""eurocityclinic"", saint petersburg, russian federation llc ""medicina severnoy stolitsy"", saint-petersburg, russian federation llc ""severo-zapadny medical center"", saint-petersburg, russian federation private healthcare institution ""clinical hospital ""rzd-medicine"" of st. petersburg, saint-petersburg, russian federation fsbi ""russian scientific center for radiology and surgical technologies n.a. academician a.m. granov, st. petersburg, russian federation sahi republican clinical oncology dispensary under the ministry of health, republic of bashkortostan, ufa, russian federation shi yr regional clinical oncology hospital, yaroslavl, russian federation shi yr regional clinical oncology hospital, yaroslavl, russian federation shi yr regional clinical oncology hospital, yaroslav, russian federation fakultna nemocnica s poliklinikou f. d. roosevelta banska bystrica, banska bystrica, slovakia vychodoslovensky onkologicky ustav, a.s., kosice, slovakia poko poprad s.r.o., poprad, slovakia cancercare rondebosch oncology, rondebosch, cape town, south africa cancercare langenhoven drive oncology centre, port elizabeth, eastern cape, south africa cancercare langenhoven drive oncology centre, port elizabeth, eastern cape, south africa cape town oncology trials, cape town, western cape, south africa gvi oncology, cape town, western cape, south africa complejo hospitalario universitario santiago de compostela, santiago de compostela, a coruña, spain hospital general universitario de elche, elche, alicante, spain ico l\'hospitalet (hospital duran i reynals), hospitalet de llobregat, barcelona, spain hospital universitario vall d\'hebron, barcelona, spain hospital clinic barcelona, barcelona, spain hospital general universitario gregorio marañon, madrid, spain hospital universitario ramon y cajal, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital universitario virgen del rocio, sevilla, spain hospital clinico universitario de valencia, valencia, spain hospital general universitario de valencia, valencia, spain hospital universitario miguel servet, zaragoza, spain akademiska sjukhuset, uppsala, uppsala län [se-03], sweden norrlands universitetssjukhus, umeå, västerbottens län [se-24], sweden sahlgrenska universitetssjukhuset, göteborg, västra götalands län [se14], sweden västmanlands sjukhus västerås, västerås, sweden kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan china medical university hospital, taichung, taiwan national cheng-kung university hospital, tainan, taiwan chi mei hospital, liouying, tainan, taiwan national taiwan university hospital, taipei, taiwan taipei medical university hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan chang gung medical foundation-linkou branch, taoyuan, taiwan medical and diagnostic center of medix-ray international group llc israeli oncology hospital ""lisod"", pliuty village, kyiv region, obuhovskiy district, ukraine municipal non-profit enterprise ""city clinical hospital #4"" of dnipro city council, dnipro, ukraine precarpathian nuclear medicine center, limited liability company, ivano-frankivsk, ukraine ivano-frankivsk national medical university, ivano-frankivsk, ukraine mnpe ""prykarpatski clinical oncological center"" of ivano-frankivsk regional council"", ivano-frankivsk, ukraine municipal non-profit enterprise ""city clinical hospital #2 named after o.o.shalimov"", kharkiv, ukraine communal non-profit enterprise ""regional center of oncology"", kharkiv, ukraine communal enterprise ""kryvyi rih oncology dispensary"" of dnipropetrovsk regional council, kryvyi rih, ukraine si ""insitute of neurosurgery n.a.acad. a.p., kyiv, ukraine si ""insitute of neurosurgery n.a.acad. a.p., kyiv, ukraine municipal non-profit enterprise of kyiv regional council ""kyiv regional clinical hospital"", kyiv, ukraine municipal non-profit enterprise ""zaporizhzhia regional antitumor center"" zaporizhzhia regional, zaporizhzhia, ukraine freeman hospital, newcastle upon tyne, high heaton, united kingdom hammersmith hospital, imperial college healthcare nhs trust, london, united kingdom charing cross hospital, imperial college healthcare nhs trust, london, united kingdom churchill hospital - oncology, oxford, united kingdom']",,https://ClinicalTrials.gov/show/NCT04607421,
289,290,NCT01028495,a safety and efficacy study of rx-0201 plus gemcitabine in metastatic pancreatic cancer,,Completed,No Results Available,metastatic pancreatic cancer,drug: rx-0201 plus gemcitabine,"survival|tumor response|toxicity and safety parameters|karnofsky performance scale, clinical laboratory assessment, and molecular markers","rexahn pharmaceuticals, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,31.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RX-0201-P2-A-07,May 2009,July 2012,August 2012,"December 9, 2009",,"September 12, 2019","['baptist cancer institute, jacksonville, florida, united states orchard healthcare research inc., skokie, illinois, united states texas oncology, austin, texas, united states texas oncology, p.a., mcallen, texas, united states jawaharlal nehru cancer hospital and research centre, bhopal, kerala, india meenakshi mission hospital and research center, madurai-625020, india central india cancer research institute, maharashtra, india shatabdi superspeciality hospital, maharashtra, india rajiv gandhi cancer institute and research center, rohini new- delhi, india king george hospital, visakhapatanam, a.p, india']",,https://ClinicalTrials.gov/show/NCT01028495,pancreat
290,291,NCT00920816,axitinib (ag-013736) for the treatment of metastatic renal cell cancer,,Completed,Has Results,kidney neoplasms,drug: axitinib (ag-013736)|drug: sorafenib,progression free survival (pfs): first-line participants|progression free survival (pfs): second-line participants|percentage of participants with objective response (or): first-line participants|percentage of participants with objective response (or): second-line participants|duration of response (dr): first-line participants|duration of response (dr): second-line participants|overall survival (os): first-line participants|overall survival (os): second-line participants,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,492.0,Industry,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,A4061051|2010-018585-23,"August 25, 2009","July 27, 2012","April 29, 2021","June 15, 2009","February 4, 2014","May 6, 2022","['advanced medical specialties, miami, florida, united states advanced medical specialties, miami, florida, united states illinois cancer specialists, arlington heights, illinois, united states illinois cancer specialists, niles, illinois, united states indiana university health central indiana cancer centers, carmel, indiana, united states indiana university health central indiana cancer centers, fishers, indiana, united states indiana university health central indiana cancer centers, greenfield, indiana, united states indiana university health central indiana cancer centers, indianapolis, indiana, united states indiana university health central indiana cancer centers, indianapolis, indiana, united states missouri cancer associates, columbia, missouri, united states nebraska methodist hospital, omaha, nebraska, united states comprehensive cancer centers of nevada, henderson, nevada, united states us oncology west region, henderson, nevada, united states comprehensive cancer centers of nevada, henderson, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states hematology-oncology associates of northern nj, pa, morristown, new jersey, united states hematology-oncology associates of northern nj, pa, parsippany, new jersey, united states new york oncology hematology, pc, albany, new york, united states new york oncology hematology, pc, albany, new york, united states new york oncology hematology, pc, latham, new york, united states new york oncology hematology, pc, rexford, new york, united states new york oncology hematology, pc, troy, new york, united states raleigh hematology oncology associates, cary, north carolina, united states raleigh hematology oncology associates, raleigh, north carolina, united states raleigh hematology oncology associates, raleigh, north carolina, united states northwest cancer specialists, pc, portland, oregon, united states northwest cancer specialists, pc, portland, oregon, united states northwest cancer specialists, pc, portland, oregon, united states northwest cancer specialists, pc, tualatin, oregon, united states penn state milton s. hershey medical center, penn state cancer institute, hershey, pennsylvania, united states medical university of south carolina university hospital, charleston, south carolina, united states medical university of south carolina, charleston, south carolina, united states texas oncology- amarillo, amarillo, texas, united states texas oncology-beaumont, mamie mcfaddin ward cancer center, beaumont, texas, united states texas oncology- bedford, bedford, texas, united states texas oncology- baylor charles a. sammons cancer center, dallas, texas, united states texas oncology- fort worth 12th avenue, fort worth, texas, united states texas oncology- southwest fort worth, fort worth, texas, united states investigational products center (lpc), fort worth, texas, united states us oncology research and clinical pharmacy, fort worth, texas, united states texas oncology - grapevine, grapevine, texas, united states cancer care centers of south texas, kerrville, texas, united states texas oncology- mcallen south second street, mcallen, texas, united states texas oncology- midland allison cancer center, midland, texas, united states cancer care centers of south texas, san antonio, texas, united states cancer care centers of south texas, san antonio, texas, united states texas oncology-deke slayton cancer center, webster, texas, united states texas oncology-weslaco, weslaco, texas, united states oncology and hematology associates of southwest virginia, inc., dba blue ridge cancer care, christiansburg, virginia, united states oncology and hematology associates of southwest virginia, inc., dba blue ridge cancer care, low moor, virginia, united states oncology and hematology associates of southwest virginia, inc., dba blue ridge cancer care, roanoke, virginia, united states oncology and hematology associates of southwest virginia, inc., dba blue ridge cancer care, salem, virginia, united states oncology and hematology associates of southwest virginia, inc., dba blue ridge cancer care, wytheville, virginia, united states northwest cancer specialists, pc, vancouver, washington, united states northwest cancer specialists, pc, vancouver, washington, united states wenatchee valley medical center, wenatchee, washington, united states clinic of oncology, banja luka, bosnia and herzegovina institute of oncology, university hospital center sarajevo, sarajevo, bosnia and herzegovina university clinical center tuzla, clinic for oncology, hematology and radiotherapy, tuzla, bosnia and herzegovina spetsializirana bolnitsa za aktivno lechenie po onkologiya, ead, klinika po himioterapiya, sofia, bulgaria sbaloz d-r marko markov-varna, varna, bulgaria instituto clinico oncologico del sur, temuco, cautin, chile instituto clinico oncologico del sur, temuco, ix region, chile instituto de terapias oncologicas providencia, providencia, santiago, chile private office, santiago, chile cancer institute and hospital ,chinese academy of medical sciences, beijing, beijing, china chinese pla general hospital, haidian district, beijing, china the fuzhou general hospital, pla nanjing military area command, fuzhou, fujian, china nanfang hospital, guangzhou, guang dong, china urology department, sun yet-sen university cancer center, guangzhou, guangdong, china nanjing bayi hospital, nanjing, jiangsu, china the oncology department, jiangsu province hospital, nanjing, jiangsu, china jilin provincial cancer hospital, changchun, jilin, china urology department, 1st hospital of china medical university, shen yang, liao ning, china xijing hospital, the fourth military medical university,oncology department, xi\'an, shaanxi, china urology department, renji hospital,shanghai jiao tong university school of medicine, shanghai, shanghai, china west china hospital of sichuan university, chengdu, sichuan, china sir run run shaw hospital of college of medicine of zhejiang university, center for oncology, hangzhou, zhejiang, china department of urology,peking university first hospital, beijing, china beijing cancer hospital/department of renal cancer and melanoma, beijing, china south-western hospital, 3rd military medical university, chongqing, china jiangsu cancer hospital, nanjing, china fudan university, cancer hospital, department of urology, shanghai, china tianjin oncology hospital,biology treatment department, tianjin, china urology department, the second hospital of tianjin medical university, tianjin, china bibi general hospital and cancer centre,, hyderabad, andhra pradesh, india chinmaya mission hospital, bangalore, karnataka, india sri venkateshwara hospital, bangalore, karnataka, india nu hospitals, bangalore, karnataka, india cancer care clinic and hospitals, nagpur, maharashtra, india shatabdi superspeciality hospital, nashik, maharashtra, india curie manavata cancer centre, nashik, maharashtra, india deenanath mangeshkar hospital and research centre, pune, maharashtra, india sahyadri speciality hospital, pune, maharashtra, india shettys hospital, bangalore, india university malaya medical centre, kuala lumpur, malaysia instituto nacional de ciencias medicas y nutricion salvador zubiran, mexico, df, mexico hospital general de mexico o.d., mexico city, distrito federal, mexico centro hemato-oncologico privado, toluca, estado de mexico, mexico centenario hospital miguel hidalgo, aguascalientes, mexico oaxaca site management organization, oaxaca, mexico rm. 3227 doctors clinic, annex ii bldg., national kidney & transplant institute, quezon city, diliman, philippines st. lukes medical center, quezon city, metro manila, philippines university of the east ramon magsaysay memorial medical center, quezon city, metro manila, philippines makati medical center, makati city, philippines room 805, committee on research room, manila doctors hospital, manila, philippines oncomed srl, timisoara, jud. timis, romania institutul oncologic ""prof.dr.i.chiricuta"" cluj-napoca, cluj-napoca, romania institutul oncologic \'\'prof.dr. i. chiricuta\'\' cluj napoca, cluj-napoca, romania moscow state healthcare institution oncology clinical dispensary #1, moscow, russian federation p.a. herzen moscow oncology research institute,, moscow, russian federation gbu ro ""ryazan regional clinical oncology dispensary"", ryazan, russian federation fgbou vo ""ryazan state medical university named after academician i.p.pavlov"", ryazan, russian federation fgbou vo ""first saint-petersburg state medical university n.a. i.p.pavlov"", saint-petersburg, russian federation republican clinical oncology dispensary of the ministry of health of bashkortostan republic, ufa, russian federation gvi oncology, port elizabeth, south africa taichung veterans general hospital, taichung, taiwan taipei veterans general hospital, taipei, taiwan kp dnipropetrovska oblasna klinichna likarnia im. i.i. mechnykova"" dnipropetrovskoi oblasnoi rady,, dnipro, ukraine komunalne nekomertsiine pidpryiemstvo kharkivskoi oblasnoi rady oblasnyi medychnyi klinichnyi tsentr, kharkiv, ukraine du instytut urolohii namn ukrainy, viddil onkourolohii, knp kyivskyi miskyi klinichnyi onkolohichnyi, kyiv, ukraine komunalne nekomertsiine pidpryiemstvo lvivskoi oblasnoi rady lvivskyi onkolohichnyi rehionalnyi, lviv, ukraine si ""zaporizhzhya medical academy of postgraduate education of the ministry of health of ukraine"", zaporizhzhya, ukraine']",,https://ClinicalTrials.gov/show/NCT00920816,kidney
291,292,NCT03032679,pain and impact of chronic pain on function after total knee replacements,,Completed,No Results Available,"pain, postoperative|pain, chronic|osteogenic sarcoma|knee arthropathy",other: non interventional study,pain severity in the immediate post-operative period following oncologic tkrs|the proportion of patients who continue to have pain at 4 and 6 months post surgery(cpsp)|• to identify the type of pain (neuropathic component) persisting at 4 and 6 months after tkr|impact of the pain on daily function,tata memorial centre,All,"18 Years to 99 Years   (Adult, Older Adult)",,139.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1780,"February 2, 2017","June 30, 2020","August 31, 2020","January 26, 2017",,"October 8, 2020","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03032679,pain sarcoma
292,293,NCT01254279,early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen,,Completed,No Results Available,prostate cancer metastatic,drug: cabazitaxel,to provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen|to document safety of cabazitaxel in these patients,sanofi,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,984.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CABAZ_C_05331|2010-021128-92|U1111-1115-2476,December 2010,December 2014,December 2014,"December 6, 2010",,"January 21, 2015","[""investigational site number 036004, box hill, australia investigational site number 036020, campbelltown, australia investigational site number 036001, camperdown, australia investigational site number 036002, camperdown, australia investigational site number 036011, douglas, australia investigational site number 036019, nambour, australia investigational site number 036023, north adelaide, australia investigational site number 036008, parkville, australia investigational site number 036005, perth, australia investigational site number 036003, port macquarie, australia investigational site number 036025, randwick, australia investigational site number 036009, south brisbane, australia investigational site number 036022, south brisbane, australia investigational site number 036017, southport, australia investigational site number 036012, st leonards, australia investigational site number 036010, sydney, australia investigational site number 036013, sydney, australia investigational site number 036014, sydney, australia investigational site number 036016, tweed heads, australia investigational site number 036024, wendouree, australia investigational site number 036007, westmead, australia investigational site number 036015, wodonga, australia investigational site number 040-004, linz, austria investigational site number 040-005, salzburg, austria investigational site number 040-003, vienna, austria investigational site number 040-002, wien, austria investigational site number 056002, brugge, belgium investigational site number 056007, bruxelles, belgium investigational site number 056003, haine st paul, belgium investigational site number 056005, liège, belgium investigational site number 056004, ottignies, belgium investigational site number 056001, roeselare, belgium investigational site number 056006, tournai, belgium investigational site number 070003, banja luka, bosnia and herzegovina investigational site number 070001, sarajevo, bosnia and herzegovina investigational site number 070002, zenica, bosnia and herzegovina investigational site number 100004, plovdiv, bulgaria investigational site number 100001, sofia, bulgaria investigational site number 100003, sofia, bulgaria investigational site number 100002, sofia, bulgaria investigational site number 124012, kitchener, canada investigational site number 124009, laval, canada investigational site number 124004, london, canada investigational site number 124007, moncton, canada investigational site number 124001, montreal, canada investigational site number 124011, montreal, canada investigational site number 124010, quebec, canada investigational site number 124003, toronto, canada investigational site number 124002, toronto, canada investigational site number 124006, winnipeg, canada investigational site number 191-001, zagreb, croatia investigational site number 203001, brno, czech republic investigational site number 208-001, cph ø, denmark investigational site number 208-002, herlev, denmark investigational site number 208-003, odense, denmark investigational site number 246002, helsinki, finland investigational site number 246001, seinäjoki, finland investigational site number 348001, budapest, hungary investigational site number 348002, szolnok, hungary investigational site number 348003, szombathely, hungary investigational site number 348004, veszprém, hungary investigational site number 356004, chennai, india investigational site number 356006, gurgaon, india investigational site number 356001, new delhi, india investigational site number 356002, new delhi, india investigational site number 356005, trivandrum, india investigational site number 372004, cork, ireland investigational site number 372003, dublin 24, ireland investigational site number 372001, dublin 7, ireland investigational site number 372002, dublin 7, ireland investigational site number 380-001, arezzo, italy investigational site number 380-011, aviano, italy investigational site number 380-025, bari, italy investigational site number 380-007, bergamo, italy investigational site number 380-015, bologna, italy investigational site number 380-021, fano, italy investigational site number 380-012, firenze, italy investigational site number 380-003, genova, italy investigational site number 380-005, genova, italy investigational site number 380-014, lecce, italy investigational site number 380-023, messina, italy investigational site number 380-018, milano, italy investigational site number 380-022, milano, italy investigational site number 380-006, napoli, italy investigational site number 380-010, napoli, italy investigational site number 380-027, napoli, italy investigational site number 380-004, orbassano, italy investigational site number 380-017, padova, italy investigational site number 380-002, parma, italy investigational site number 380-009, roma, italy investigational site number 380-008, roma, italy investigational site number 380-024, rozzano, italy investigational site number 380-020, san giovanni rotondo, italy investigational site number 380-013, sassari, italy investigational site number 380-016, taormina, italy investigational site number 398001, almaty, kazakhstan investigational site number 398003, shymkent, kazakhstan investigational site number 442001, niederkorn, luxembourg investigational site number 458002, georgetown, malaysia investigational site number 458001, kuala lumpur, malaysia investigational site number 458003, kuching, malaysia investigational site number 484002, durango, mexico investigational site number 484006, irapuato, mexico investigational site number 484005, toluca, mexico investigational site number 484001, zapopan, mexico investigational site number 608001, manila, philippines investigational site number 616-001, gdansk, poland investigational site number 620002, coimbra, portugal investigational site number 620003, lisboa, portugal investigational site number 620004, lisboa, portugal investigational site number 620001, porto, portugal investigational site number 620005, setúbal, portugal investigational site number 642001, bucharest, romania investigational site number 642002, cluj-napoca, romania investigational site number 642003, timisoara, romania investigational site number 688001, belgrade, serbia investigational site number 688002, belgrade, serbia investigational site number 702002, singapore, singapore investigational site number 702001, singapore, singapore investigational site number 703001, bratislava, slovakia investigational site number 703002, kosice, slovakia investigational site number 724018, barcelona, spain investigational site number 724019, barcelona, spain investigational site number 724023, castellón de la plana, spain investigational site number 724020, córdoba, spain investigational site number 724025, elche, spain investigational site number 724017, granada, spain investigational site number 724006, guadalajara, spain investigational site number 724011, l'hospitalet de llobregat, spain investigational site number 724002, la coruña, spain investigational site number 724010, león, spain investigational site number 724003, madrid, spain investigational site number 724012, madrid, spain investigational site number 724007, madrid, spain investigational site number 724008, manresa, spain investigational site number 724021, málaga, spain investigational site number 724009, oviedo, spain investigational site number 724022, pamplona, spain investigational site number 724005, san cristóbal de la laguna - sta. cruz de tenerife, spain investigational site number 724016, santander, spain investigational site number 724015, santiago de compostela, spain investigational site number 724024, sevilla, spain investigational site number 724004, terrassa, spain investigational site number 724013, valencia, spain investigational site number 724014, valencia, spain investigational site number 724001, zaragoza, spain investigational site number 752-002, umeå, sweden investigational site number 752-001, uppsala, sweden investigational site number 005, kaohsiung hsien,, taiwan investigational site number 004, taichung, taiwan investigational site number 002, taipei, taiwan investigational site number 003, taipei, taiwan investigational site number 001, tao yuan hsien, taiwan investigational site number 826011, birmingham, united kingdom investigational site number 826002, bristol, united kingdom investigational site number 826003, glasgow, united kingdom investigational site number 826013, leeds, united kingdom investigational site number 826009, london, united kingdom investigational site number 826012, manchester, united kingdom investigational site number 826005, nottingham, united kingdom investigational site number 826008, preston, united kingdom investigational site number 826001, sutton, united kingdom investigational site number 826007, torquay, united kingdom investigational site number 826006, whitechurch, united kingdom investigational site number 826004, wirral, united kingdom""]",,https://ClinicalTrials.gov/show/NCT01254279,prostat
293,294,NCT01238107,a clinical study with mt-102 in subjects with cancer cachexia,,Completed,No Results Available,cancer cachexia,drug: mt-102,demonstrate the effect of a 10mg / bd dose of mt-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage iii and stage iv colorectal or non-small cell lung cancer,psioxus therapeutics ltd|veeda oncology,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,87.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MT-102-2001,April 2011,May 2013,May 2013,"November 10, 2010",,"September 10, 2014","[""charite hospital virchow-klinikum campus, berlin, germany kumaran hospital private ltd, kilpauk, chennai, india dr kamakshi memorial hospital, pallikaranai, chennai, india vedanta institute of medical science, ahmedabad, gujarat, india shree krishna hopsital, anand, gujarat, india kailash cancer hospital & research centre, goraj, gujarat, india tata memorial hopsital, mumbai, maharashtra, india curie manavta cancer centre, nashik, maharashtra, india shatabdi super speciality hospital, nashik, maharashtra, india noble hopsital, pune, india hospital sultahan bahiyah, alor setar, kedha, malaysia hospital universiti sains malaysia, kubang kerian, kelantan, malaysia hospital universiti kebangsaan malaysia, cheras, kuala lumpur, malaysia universiti malaya medical, jalan baharu, kuala lumpur, malaysia tuanku ja'afar hospital, seremban, negeri sembilan, malaysia international islamic university malaysia, kuantan, pahang, malaysia penang general hopsital, pulau pinang, penang, malaysia hospital umum sarawak, kuching, sarawak, malaysia""]",,https://ClinicalTrials.gov/show/NCT01238107,
294,295,NCT00511459,phase 2 study of amg 386 plus paclitaxel with or without bevacizumab as first line therapy in her2-negative breast cancer patients,,Completed,No Results Available,locally recurrent and metastatic breast cancer,drug: amg 386 placebo|drug: amg 386|drug: bevacizumab|drug: paclitaxel,progression-free survival (pfs)|objective response (or)|duration of response (dor)|time to response|overall survival|time to progression (ttp)|incidence of aes and significant laboratory changes|amg 386 pharmakokinetic parameters|incidence of the occurrence of anti-amg 386 antibody formation,amgen,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,228.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20060341,July 2007,August 2010,May 2014,"August 3, 2007",,"October 29, 2015","['research site, litchfield park, arizona, united states research site, tucson, arizona, united states research site, hot springs, arkansas, united states research site, little rock, arkansas, united states research site, campbell, california, united states research site, los angeles, california, united states research site, murrieta, california, united states research site, santa maria, california, united states research site, new haven, connecticut, united states research site, stamford, connecticut, united states research site, orlando, florida, united states research site, robbinsdale, minnesota, united states research site, henderson, nevada, united states research site, lebanon, new hampshire, united states research site, nashua, new hampshire, united states research site, edison, new jersey, united states research site, mountain lakes, new jersey, united states research site, asheville, north carolina, united states research site, charlotte, north carolina, united states research site, hershey, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, columbia, south carolina, united states research site, richardson, texas, united states research site, san antonio, texas, united states research site, sugar land, texas, united states research site, ogden, utah, united states research site, kurralta park, south australia, australia research site, epping, victoria, australia research site, fitzroy, victoria, australia research site, footscray, victoria, australia research site, malvern, victoria, australia research site, perth, western australia, australia research site, innsbruck, austria research site, wels, austria research site, wien, austria research site, leuven, belgium research site, liege, belgium research site, wilrijk, belgium research site, herlev, denmark research site, helsinki, finland research site, la roche sur yon cedex 9, france research site, lyon, france research site, marseille, france research site, montpellier cedex 5, france research site, paris cedex 20, france research site, paris cedex 5, france research site, toulouse cedex, france research site, vandoeuvre les nancy, france research site, gyula, hungary research site, kaposvar, hungary research site, szombathely, hungary research site, veszprem, hungary research site, bangalore, karnataka, india research site, miraj, maharashtra, india research site, mumbai, maharashtra, india research site, nagpur, maharashtra, india research site, pune, maharashtra, india research site, jaipur, rajasthan, india research site, jaipur, rajasthan, india research site, maastricht, netherlands research site, gdansk, poland research site, lubin, poland research site, poznan, poland research site, warszawa, poland research site, warszawa, poland research site, wroclaw, poland research site, jaã©n, andalucã-a, spain research site, sabadell, cataluã±a, spain research site, santiago de compostela, galicia, spain research site, madrid, spain research site, guildford, united kingdom research site, leicester, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, northwood, united kingdom research site, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT00511459,breast
295,296,NCT04707196,a study of abemaciclib in indian women with advanced breast cancer,,Recruiting,No Results Available,breast neoplasms|neoplasm metastasis,drug: abemaciclib|drug: nonsteroidal aromatase inhibitor (nsai)|drug: fulvestrant,percentage of participants experiencing at least one treatment emergent adverse event (serious or non-serious)|percentage of participants who discontinue from study treatment due to adverse events,eli lilly and company,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17782|I3Y-IN-JPEC,"February 22, 2021","March 3, 2023","March 3, 2023","January 13, 2021",,"May 11, 2022","['mnj institute of oncology, hyderabad, andhra pradesh, india nirmal hospital pvt ltd., surat, gujarat, india unique hospital multispecialty & research institute, surat, gujarat, india anand multispeciality hospital, vadodara, gujarat, india kailash cancer hospital & research centre (kchrc), waghodia, gujarat, india hcg cancer centre, kalinga rao road, bengaluru, karnataka, india regional cancer centre, trivandrum, kerala, india srj-cbcc cancer hospital, indore, madhya pradesh, india kingsway hospital, nagpur, maharashtra, india meditrina institute of medical sciences, nagpur, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india ruby hall clinic and grant medical foundation, pune, maharashtra, india apollo gleneagles hospitals kolkata, kolkata, west bengal, india max superspeciality hospital, chandigarh, india rajiv gandhi cancer institute & research center, delhi, india']",,https://ClinicalTrials.gov/show/NCT04707196,breast
296,297,NCT01337154,first line study of tamibarotene in combination for advanced non-small cell lung cancer,,Terminated,No Results Available,stage iiib non-small cell lung cancer with pleural effusion|stage iv non-small cell lung cancer,drug: tamibarotene|drug: placebo,progression-free survival|objective response rate|overall survival|assessment of quality of life,cytrx,All,"18 Years and older   (Adult, Older Adult)",Phase 2,140.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAMI-P2-NSCLC-01,April 2011,June 2013,June 2013,"April 18, 2011",,"June 28, 2013","[""desert hematology oncology medical group, inc., rancho mirage, california, united states kansas city cancer center, kansas city, kansas, united states hackensack university medical center, hackensack, new jersey, united states department of medical oncology, specialized hospital for active treatment of oncological diseases, sofia, bulgaria medical oncology clinic, multiprofile hospital for active treatment, varna, bulgaria department of medical oncology, complex oncology center, veliko tarnovo, bulgaria nizam's institute of medical sciences, hyderabad, andhra pradesh, india m s patel cancer centre, shree krishna hospital, anand, gujarat, india curie manavata cancer centre, nashik, maharashtra, india shatabdi super speciality hospital, nashik, maharashtra, india noble hospital, pune, maharashtra, india dr. kamakshi memorial hospital, chennai, pallikaranai, india g kuppuswamy naidu memorial hospital, valvadi narayanaswamy cancer centre, coimbatore, pappanaickenpalayam, india orchid nursing home, kolkata, west bengal, india instituto nacional de cancerologia, mexico city, mexico state medical institution: arkhangelsk regional clinical oncology center, arkhangelsk, russian federation state therapeutical and prophylatic institution: chelyabinsk regional clinical oncology center, chelyabinsk, russian federation state medical instituion kursk regional oncology center, kursk, russian federation non-state medical institution: central clinical hospital #2, moscow, russian federation st. petersburg state healthcare institution: city clinical oncology center, saint-pertersburg, russian federation public institution: dnipropetrovsk city multispeciality clinical hospital #4, dnipropetrovsk, ukraine public clinical treatment and prophylaxis instituion: donetsk regional antitumor center, donetsk, ukraine ivano-frankivsk regional oncology center, ivano-frankivsk, ukraine public healthcare instituion: kharkiv regional clinical oncology center, kharkiv, ukraine kyiv city clinical oncology center, kyiv, ukraine zakarpattia regional clinical oncology center, uzhhorod, ukraine""]",,https://ClinicalTrials.gov/show/NCT01337154,
297,298,NCT00687817,study of bavituximab plus paclitaxel and carboplatin in patients with non-small cell lung cancer,,Completed,No Results Available,non-small cell lung cancer,drug: bavituximab plus paclitaxel and carboplatin,"overall response (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small-cell lung cancer|time to tumor progression, duration of response, overall survival and safety",peregrine pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,49.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PPHM 0701,June 2008,July 2010,July 2010,"June 2, 2008",,"March 24, 2011","[""apollo hospital, bannerghatta rd., banglore, india kidwai hospital, munigowda road, banglore, india m s ramaiah hospital, new bel rd, banglore, india bangalore institute of oncology speciality centre, sampangi ram nagar, banglore, india nizam's institute of medical sciences, panjagutta, hyderabad, india yashoda hospital, somajiguda, hyderabad, india rcc medical college, trivandrum, kerala, india orchid nursing home, phoolanbhaghan, kolkata, india ruby hall clinic, pune, india""]",,https://ClinicalTrials.gov/show/NCT00687817,
298,299,NCT01828099,ldk378 versus chemotherapy in previously untreated patients with alk rearranged non-small cell lung cancer,,"Active, not recruiting",Has Results,non-small cell lung cancer,drug: ceritinib|drug: pemetrexed|drug: cisplatin|drug: carboplatin,progression free survival (pfs) by blinded independent review committee (birc)|overall survival (os)|overall response rate (orr)|duration of response (dor)|disease control rate (dcr)|time to response (ttr)|patient reported outcomes,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,376.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLDK378A2301|2013-000319-26,"July 9, 2013","June 24, 2016","December 14, 2023","April 10, 2013","September 21, 2017","December 7, 2021","[""novartis investigative site, woolloongabba, queensland, australia novartis investigative site, heidelberg, victoria, australia novartis investigative site, auckland, australia novartis investigative site, salzburg, austria novartis investigative site, wien, austria novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, natal, rn, brazil novartis investigative site, itajai, sc, brazil novartis investigative site, barretos, sp, brazil novartis investigative site, sao jose do rio preto, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, beijing, beijing, china novartis investigative site, chongqing, chongqing, china novartis investigative site, guangzhou, guangdong, china novartis investigative site, chang chun, jilin, china novartis investigative site, changchun, jilin, china novartis investigative site, shanghai, shanghai, china novartis investigative site, xi'an, shanxi, china novartis investigative site, chengdu, sichuan, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, beijing, china novartis investigative site, chongqing, china novartis investigative site, guang dong province, china novartis investigative site, tianjin, china novartis investigative site, monteria, colombia novartis investigative site, herlev, denmark novartis investigative site, odense c, denmark novartis investigative site, toulon cedex 9, val de marne, france novartis investigative site, villejuif cedex, villejuif, france novartis investigative site, caen, france novartis investigative site, grenoble, france novartis investigative site, lille cedex, france novartis investigative site, limoges cedex, france novartis investigative site, paris cedex 10, france novartis investigative site, pierre benite cedex, france novartis investigative site, rennes, france novartis investigative site, strasbourg cedex, france novartis investigative site, gottingen, germany novartis investigative site, heidelberg, germany novartis investigative site, tübingen, germany novartis investigative site, ulm, germany novartis investigative site, wiesbaden, germany novartis investigative site, heraklion crete, greece novartis investigative site, hyderabad, andhra pradesh, india novartis investigative site, bangalore, karnataka, india novartis investigative site, nashik, maharashtra, india novartis investigative site, jaipur, rajasthan, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, kolkata, west bengal, india novartis investigative site, delhi, india novartis investigative site, mumbai, india novartis investigative site, dublin 4, ireland novartis investigative site, bergamo, (bg), italy novartis investigative site, ancona, an, italy novartis investigative site, genova, ge, italy novartis investigative site, monza, mb, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, rozzano, mi, italy novartis investigative site, perugia, pg, italy novartis investigative site, pisa, pi, italy novartis investigative site, aviano, pn, italy novartis investigative site, parma, pr, italy novartis investigative site, reggio emilia, re, italy novartis investigative site, roma, rm, italy novartis investigative site, roma, rm, italy novartis investigative site, orbassano, to, italy novartis investigative site, udine, ud, italy novartis investigative site, napoli, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, kashiwa, chiba, japan novartis investigative site, akashi, hyogo, japan novartis investigative site, hirakata-city, osaka, japan novartis investigative site, osaka-city, osaka, japan novartis investigative site, koto ku, tokyo, japan novartis investigative site, niigata, japan novartis investigative site, bundang gu, gyeonggi do, korea, republic of novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, ashrafieh, lebanon novartis investigative site, saida, lebanon novartis investigative site, guadalajara, jalisco, mexico novartis investigative site, maastricht, az, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, breda, netherlands novartis investigative site, groningen, netherlands novartis investigative site, leiden, netherlands novartis investigative site, oslo, norway novartis investigative site, szczecin, poland novartis investigative site, warszawa, poland novartis investigative site, porto, portugal novartis investigative site, moscow, russian federation novartis investigative site, saint petersburg, russian federation novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, granada, andalucia, spain novartis investigative site, sevilla, andalucia, spain novartis investigative site, oviedo, asturias, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, hospitalet de llobregat, catalunya, spain novartis investigative site, badajoz, extremadura, spain novartis investigative site, la coruna, galicia, spain novartis investigative site, reus, tarragona, spain novartis investigative site, barcelona, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, linkoping, sweden novartis investigative site, lund, sweden novartis investigative site, stockholm, sweden novartis investigative site, uppsala, sweden novartis investigative site, taipei, taiwan, roc, taiwan novartis investigative site, kuei-shan chiang, taoyuan/ taiwan roc, taiwan novartis investigative site, kaohsiung city, taiwan novartis investigative site, taichung city, taiwan novartis investigative site, taichung, taiwan novartis investigative site, taipei, taiwan novartis investigative site, songkhla, hat yai, thailand novartis investigative site, khon kaen, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, ankara, sihhiye, turkey novartis investigative site, istanbul, turkey novartis investigative site, leeds, west yorkshire, united kingdom novartis investigative site, birmingham, united kingdom novartis investigative site, london, united kingdom novartis investigative site, manchester, united kingdom""]",,https://ClinicalTrials.gov/show/NCT01828099,
299,300,NCT00374322,tykerb evaluation after chemotherapy (teach): lapatinib versus placebo in women with early-stage breast cancer,,Completed,Has Results,"neoplasms, breast",drug: lapatinib|other: placebo,"number of participants (par.) with any recurrence of the initial disease, second primary cancer, contralateral breast cancer, or death (disease-free survival [dfs])|number of participants who died (overall survival)|percentage of participants with the indicated period of recurrence-free survival (time to first recurrence)|percentage of participants with the indicated period of distant recurrence-free survival (time to distant recurrence)|time to central nervous system (cns) recurrence|number of participants with cns recurrence|modified disease-free survival (mdfs)|number of participants with any recurrence of the initial disease, contralateral breast cancer, or death (disease-free survival [dfs])|change from baseline in short form-36 version 2 (sf-36 v2) scores for the physical component summary (pcs)|change from baseline in sf-36 v2 scores for the mental component summary (mcs)|change from baseline in the sf-36 v2 domain scores for physical functioning (pf), role-physical (rp), bodily pain (bp), general health (gh), vitality (vt), social functioning (sf), role-emotional (re), and mental health (mh)|number of participants with hematology values outside the reference range for the indicated parameters|number of participants with clinical chemistry values outside the reference range for the indicated parameters|number of participants with non-laboratory toxicities of the indicated toxicity grades|number of participants experiencing primary or secondary cardiac events|number of participants with the indicated electrocardiogram (ecg) findings",glaxosmithkline,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,3166.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EGF105485,August 2006,September 2011,July 2013,"September 11, 2006","August 18, 2014","August 18, 2014","[""gsk investigational site, tuscaloosa, alabama, united states gsk investigational site, phoenix, arizona, united states gsk investigational site, sedona, arizona, united states gsk investigational site, tucson, arizona, united states gsk investigational site, fayetteville, arkansas, united states gsk investigational site, jonesboro, arkansas, united states gsk investigational site, little rock, arkansas, united states gsk investigational site, anaheim, california, united states gsk investigational site, bakersfield, california, united states gsk investigational site, gilroy, california, united states gsk investigational site, la jolla, california, united states gsk investigational site, la verne, california, united states gsk investigational site, palm springs, california, united states gsk investigational site, rancho mirage, california, united states gsk investigational site, denver, colorado, united states gsk investigational site, fairfield, connecticut, united states gsk investigational site, norwalk, connecticut, united states gsk investigational site, torrington, connecticut, united states gsk investigational site, washington, district of columbia, united states gsk investigational site, washington, district of columbia, united states gsk investigational site, boca raton, florida, united states gsk investigational site, boynton beach, florida, united states gsk investigational site, gainesville, florida, united states gsk investigational site, new port richey, florida, united states gsk investigational site, ocala, florida, united states gsk investigational site, orlando, florida, united states gsk investigational site, plantation, florida, united states gsk investigational site, port st. lucie, florida, united states gsk investigational site, augusta, georgia, united states gsk investigational site, marietta, georgia, united states gsk investigational site, chicago, illinois, united states gsk investigational site, chicago, illinois, united states gsk investigational site, joliet, illinois, united states gsk investigational site, park ridge, illinois, united states gsk investigational site, indianapolis, indiana, united states gsk investigational site, ames, iowa, united states gsk investigational site, sioux city, iowa, united states gsk investigational site, wichita, kansas, united states gsk investigational site, louisville, kentucky, united states gsk investigational site, marrero, louisiana, united states gsk investigational site, scarborough, maine, united states gsk investigational site, bethesda, maryland, united states gsk investigational site, boston, massachusetts, united states gsk investigational site, danvers, massachusetts, united states gsk investigational site, newton, massachusetts, united states gsk investigational site, kalamazoo, michigan, united states gsk investigational site, duluth, minnesota, united states gsk investigational site, edina, minnesota, united states gsk investigational site, minneapolis, minnesota, united states gsk investigational site, robbinsdale, minnesota, united states gsk investigational site, columbia, missouri, united states gsk investigational site, kansas city, missouri, united states gsk investigational site, saint louis, missouri, united states gsk investigational site, st. joseph, missouri, united states gsk investigational site, st. louis, missouri, united states gsk investigational site, hooksett, new hampshire, united states gsk investigational site, cherry hill, new jersey, united states gsk investigational site, morristown, new jersey, united states gsk investigational site, paramus, new jersey, united states gsk investigational site, sparta, new jersey, united states gsk investigational site, albany, new york, united states gsk investigational site, east setauket, new york, united states gsk investigational site, mount kisco, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, rochester, new york, united states gsk investigational site, charleston, north carolina, united states gsk investigational site, gastonia, north carolina, united states gsk investigational site, greensboro, north carolina, united states gsk investigational site, hickory, north carolina, united states gsk investigational site, cleveland, ohio, united states gsk investigational site, cleveland, ohio, united states gsk investigational site, columbus, ohio, united states gsk investigational site, middletown, ohio, united states gsk investigational site, drexel hill, pennsylvania, united states gsk investigational site, philadelphia, pennsylvania, united states gsk investigational site, charleston, south carolina, united states gsk investigational site, chattanooga, tennessee, united states gsk investigational site, germantown, tennessee, united states gsk investigational site, memphis, tennessee, united states gsk investigational site, austin, texas, united states gsk investigational site, austin, texas, united states gsk investigational site, bedford, texas, united states gsk investigational site, dallas, texas, united states gsk investigational site, dallas, texas, united states gsk investigational site, dallas, texas, united states gsk investigational site, duncanville, texas, united states gsk investigational site, el paso, texas, united states gsk investigational site, fort worth, texas, united states gsk investigational site, houston, texas, united states gsk investigational site, houston, texas, united states gsk investigational site, round rock, texas, united states gsk investigational site, san antonio, texas, united states gsk investigational site, tyler, texas, united states gsk investigational site, waco, texas, united states gsk investigational site, ogden, utah, united states gsk investigational site, chesapeake, virginia, united states gsk investigational site, fairfax, virginia, united states gsk investigational site, richland, virginia, united states gsk investigational site, kirkland, washington, united states gsk investigational site, seattle, washington, united states gsk investigational site, vancouver, washington, united states gsk investigational site, yakima, washington, united states gsk investigational site, capital federal, buenos aires, argentina gsk investigational site, ciudad autonoma de buenos aires, buenos aires, argentina gsk investigational site, ciudad autonoma de buenos aires, buenos aires, argentina gsk investigational site, córdoba, córdova, argentina gsk investigational site, neuquen, neuquén, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, ciudad autónoma de buenos aires, argentina gsk investigational site, quilmes, argentina gsk investigational site, san miguel de tucumán, argentina gsk investigational site, santa fe, argentina gsk investigational site, campbelltown, new south wales, australia gsk investigational site, darlinghurst, new south wales, australia gsk investigational site, kogarah, new south wales, australia gsk investigational site, liverpool, new south wales, australia gsk investigational site, north sydney, new south wales, australia gsk investigational site, douglas, queensland, australia gsk investigational site, herston, queensland, australia gsk investigational site, redcliffe, queensland, australia gsk investigational site, south brisbane, queensland, australia gsk investigational site, bedford park, south australia, australia gsk investigational site, elizabeth vale, south australia, australia gsk investigational site, woodville, south australia, australia gsk investigational site, box hill, victoria, australia gsk investigational site, east melbourne, victoria, australia gsk investigational site, fitzroy, victoria, australia gsk investigational site, footscray, victoria, australia gsk investigational site, heidelberg, victoria, australia gsk investigational site, parkville, victoria, australia gsk investigational site, ringwood east, victoria, australia gsk investigational site, wodonga, victoria, australia gsk investigational site, nedlands, western australia, australia gsk investigational site, perth, western australia, australia gsk investigational site, bruxelles, belgium gsk investigational site, belo horizonte, minas gerais, brazil gsk investigational site, porto alegre, rio grande do sul, brazil gsk investigational site, porto alegre, rio grande do sul, brazil gsk investigational site, santo andre, são paulo, brazil gsk investigational site, rio de janeiro, brazil gsk investigational site, são paulo, brazil gsk investigational site, st. john's, newfoundland and labrador, canada gsk investigational site, halifax, nova scotia, canada gsk investigational site, barrie, ontario, canada gsk investigational site, brampton, ontario, canada gsk investigational site, kingston, ontario, canada gsk investigational site, london, ontario, canada gsk investigational site, mississauga, ontario, canada gsk investigational site, oshawa, ontario, canada gsk investigational site, ottawa, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, greenfield park, quebec, canada gsk investigational site, montreal, quebec, canada gsk investigational site, saskatoon, saskatchewan, canada gsk investigational site, quebec, canada gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, viña del mar, valparaíso, chile gsk investigational site, guangzhou, guangdong, china gsk investigational site, wuhan, hubei, china gsk investigational site, jinan, shandong, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, shanghai, china gsk investigational site, tianjin, china gsk investigational site, osijek, croatia gsk investigational site, pula, croatia gsk investigational site, rijeka, croatia gsk investigational site, split, croatia gsk investigational site, zagreb, croatia gsk investigational site, brno, czech republic gsk investigational site, prague 2, czech republic gsk investigational site, praha 8, czech republic gsk investigational site, aalborg, denmark gsk investigational site, copenhagen, denmark gsk investigational site, esbjerg, denmark gsk investigational site, herlev, denmark gsk investigational site, naestved, denmark gsk investigational site, odense, denmark gsk investigational site, roskilde, denmark gsk investigational site, vejle, denmark gsk investigational site, angers, france gsk investigational site, besançon, france gsk investigational site, bordeaux, france gsk investigational site, caen cedex 05, france gsk investigational site, clermont ferrand, france gsk investigational site, colmar cedex, france gsk investigational site, dijon cedex, france gsk investigational site, lille cedex, france gsk investigational site, lille, france gsk investigational site, lyon cedex 08, france gsk investigational site, lyon, france gsk investigational site, marseille cedex 09, france gsk investigational site, montbeliard, france gsk investigational site, montpellier cedex 5, france gsk investigational site, nantes cedex, france gsk investigational site, nice cedex 2, france gsk investigational site, paris cedex 15, france gsk investigational site, reims, france gsk investigational site, rennes, france gsk investigational site, saint grégoire, france gsk investigational site, saint-cloud, france gsk investigational site, saint-herblain, france gsk investigational site, strasbourg, france gsk investigational site, toulouse cedex 3, france gsk investigational site, toulouse cedex 9, france gsk investigational site, tourcoing, france gsk investigational site, vandoeuvre-les-nancy, france gsk investigational site, villejuif cedex, france gsk investigational site, villejuif, france gsk investigational site, freiburg, baden-wuerttemberg, germany gsk investigational site, heidelberg, baden-wuerttemberg, germany gsk investigational site, konstanz, baden-wuerttemberg, germany gsk investigational site, mannheim, baden-wuerttemberg, germany gsk investigational site, mayen, baden-wuerttemberg, germany gsk investigational site, mutlangen, baden-wuerttemberg, germany gsk investigational site, rheinfelden, baden-wuerttemberg, germany gsk investigational site, schwetzingen, baden-wuerttemberg, germany gsk investigational site, singen, baden-wuerttemberg, germany gsk investigational site, stuttgart, baden-wuerttemberg, germany gsk investigational site, stuttgart, baden-wuerttemberg, germany gsk investigational site, tuebingen, baden-wuerttemberg, germany gsk investigational site, ulm, baden-wuerttemberg, germany gsk investigational site, amberg, bayern, germany gsk investigational site, aschaffenburg, bayern, germany gsk investigational site, bayreuth, bayern, germany gsk investigational site, deggendorf, bayern, germany gsk investigational site, ebersberg, bayern, germany gsk investigational site, eggenfelden, bayern, germany gsk investigational site, erlangen, bayern, germany gsk investigational site, fuerth, bayern, germany gsk investigational site, kempten, bayern, germany gsk investigational site, krumbach, bayern, germany gsk investigational site, marktredwitz, bayern, germany gsk investigational site, memmingen, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, rehling, bayern, germany gsk investigational site, rosenheim, bayern, germany gsk investigational site, roth, bayern, germany gsk investigational site, schwandorf, bayern, germany gsk investigational site, weiden, bayern, germany gsk investigational site, cottbus, brandenburg, germany gsk investigational site, fuerstenwalde, brandenburg, germany gsk investigational site, frankfurt am main, hessen, germany gsk investigational site, frankfurt, hessen, germany gsk investigational site, frankfurt, hessen, germany gsk investigational site, frankfurt, hessen, germany gsk investigational site, kassel, hessen, germany gsk investigational site, kassel, hessen, germany gsk investigational site, wiesbaden, hessen, germany gsk investigational site, guestrow, mecklenburg-vorpommern, germany gsk investigational site, goslar, niedersachsen, germany gsk investigational site, hannover, niedersachsen, germany gsk investigational site, hildesheim, niedersachsen, germany gsk investigational site, salzgitter, niedersachsen, germany gsk investigational site, bochum, nordrhein-westfalen, germany gsk investigational site, bonn, nordrhein-westfalen, germany gsk investigational site, duesseldorf, nordrhein-westfalen, germany gsk investigational site, duisburg, nordrhein-westfalen, germany gsk investigational site, duisburg, nordrhein-westfalen, germany gsk investigational site, essen, nordrhein-westfalen, germany gsk investigational site, herne, nordrhein-westfalen, germany gsk investigational site, hilden, nordrhein-westfalen, germany gsk investigational site, koeln, nordrhein-westfalen, germany gsk investigational site, koeln, nordrhein-westfalen, germany gsk investigational site, muelheim, nordrhein-westfalen, germany gsk investigational site, porta westfalica, nordrhein-westfalen, germany gsk investigational site, recklinghausen, nordrhein-westfalen, germany gsk investigational site, troisdorf, nordrhein-westfalen, germany gsk investigational site, velbert, nordrhein-westfalen, germany gsk investigational site, witten, nordrhein-westfalen, germany gsk investigational site, koblenz, rheinland-pfalz, germany gsk investigational site, mainz, rheinland-pfalz, germany gsk investigational site, homburg/saar, saarland, germany gsk investigational site, neunkirchen, saarland, germany gsk investigational site, saarbruecken, saarland, germany gsk investigational site, blankenburg, sachsen-anhalt, germany gsk investigational site, halle, sachsen-anhalt, germany gsk investigational site, magdeburg, sachsen-anhalt, germany gsk investigational site, magdeburg, sachsen-anhalt, germany gsk investigational site, stendal, sachsen-anhalt, germany gsk investigational site, chemnitz, sachsen, germany gsk investigational site, dresden, sachsen, germany gsk investigational site, kauschwitz, sachsen, germany gsk investigational site, neustadt, sachsen, germany gsk investigational site, spremberg, sachsen, germany gsk investigational site, zittau, sachsen, germany gsk investigational site, zwickau, sachsen, germany gsk investigational site, kiel, schleswig-holstein, germany gsk investigational site, luebeck, schleswig-holstein, germany gsk investigational site, eisenach, thueringen, germany gsk investigational site, jena, thueringen, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, bremen, germany gsk investigational site, bremen, germany gsk investigational site, hamburg, germany gsk investigational site, hamburg, germany gsk investigational site, hamburg, germany gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, chania, greece gsk investigational site, heraklion, crete, greece gsk investigational site, hong kong, hong kong gsk investigational site, shatin, hong kong gsk investigational site, wanchai, hong kong gsk investigational site, budapest, hungary gsk investigational site, budapest, hungary gsk investigational site, győr, hungary gsk investigational site, kaposvár, hungary gsk investigational site, kistarcsa, hungary gsk investigational site, pécs, hungary gsk investigational site, szeged, hungary gsk investigational site, chennai, india gsk investigational site, hyderabad, india gsk investigational site, jaipur, india gsk investigational site, mumbai, india gsk investigational site, new delhi, india gsk investigational site, pune, india gsk investigational site, ashkelon, israel gsk investigational site, haifa, israel gsk investigational site, jerusalem, israel gsk investigational site, kfar saba, israel gsk investigational site, ramat gan, israel gsk investigational site, rehovot, israel gsk investigational site, tel aviv, israel gsk investigational site, avellino, campania, italy gsk investigational site, piacenza, emilia-romagna, italy gsk investigational site, genova, liguria, italy gsk investigational site, sassari, sardegna, italy gsk investigational site, perugia, umbria, italy gsk investigational site, negrar (verona), veneto, italy gsk investigational site, goyang-si, gyeonggi-do, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, songpa-gu, seoul, korea, republic of gsk investigational site, liepaja, latvia gsk investigational site, riga, latvia gsk investigational site, riga, latvia gsk investigational site, kaunas, lithuania gsk investigational site, klaipeda, lithuania gsk investigational site, vilnius, lithuania gsk investigational site, mérida, yucatán, mexico gsk investigational site, chihuahua, mexico gsk investigational site, df., mexico gsk investigational site, mexico city, mexico gsk investigational site, méxico d.f., mexico gsk investigational site, auckland, new zealand gsk investigational site, christchurch, new zealand gsk investigational site, hamilton, new zealand gsk investigational site, lima, peru gsk investigational site, lima, peru gsk investigational site, lima, peru gsk investigational site, baguio city, benguet, philippines gsk investigational site, cebu, philippines gsk investigational site, pasig city, philippines gsk investigational site, quezon city, philippines gsk investigational site, bydgoszcz, poland gsk investigational site, krakow, poland gsk investigational site, olsztyn, poland gsk investigational site, olsztyn, poland gsk investigational site, torun, poland gsk investigational site, warszawa, poland gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, ryazan, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, yaroslavl, russian federation gsk investigational site, banska bystrica, slovakia gsk investigational site, bardejov, slovakia gsk investigational site, bratislava, slovakia gsk investigational site, nitra, slovakia gsk investigational site, tygerberg, western province, south africa gsk investigational site, athlone park, amanzimtoti, south africa gsk investigational site, groenkloof, south africa gsk investigational site, kraaifontein, south africa gsk investigational site, overport, south africa gsk investigational site, parktown, south africa gsk investigational site, port elizabeth, south africa gsk investigational site, sandton, south africa gsk investigational site, saxonwold, johannesburg, south africa gsk investigational site, alcorcon, spain gsk investigational site, barcelona, spain gsk investigational site, barcelona, spain gsk investigational site, cáceres, spain gsk investigational site, girona, spain gsk investigational site, jaén, spain gsk investigational site, lerida, spain gsk investigational site, llobregat, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, mataró, spain gsk investigational site, orense, spain gsk investigational site, palma de mallorca, spain gsk investigational site, palma de mallorca, spain gsk investigational site, santa cruz de tenerife, spain gsk investigational site, santander, spain gsk investigational site, santiago de compostela, spain gsk investigational site, valencia, spain gsk investigational site, zaragoza, spain gsk investigational site, dnepropetrovsk, ukraine gsk investigational site, kyiv, ukraine gsk investigational site, lvov, ukraine gsk investigational site, uzhgorod, ukraine gsk investigational site, chelmsford, essex, united kingdom gsk investigational site, manchester, lancashire, united kingdom gsk investigational site, sutton, surrey, united kingdom gsk investigational site, bournemouth, united kingdom gsk investigational site, edgbaston, birmingham, united kingdom gsk investigational site, glasgow, united kingdom gsk investigational site, lindley, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, maidstone, united kingdom gsk investigational site, manchester, united kingdom gsk investigational site, newcastle upon tyne, united kingdom gsk investigational site, nottingham, united kingdom gsk investigational site, sheffield, united kingdom gsk investigational site, shrewsbury, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00374322,breast
300,301,NCT00680940,a study of mycobacterium w in combination with paclitaxel plus cisplatin in advanced non small cell lung cancer,NSCLC,Completed,No Results Available,non small cell lung cancer,drug: paclitaxel & cisplatin|biological: mycobacterium w.,"overall survival time of patients, quality of life|response rate, hematological toxicity",cadila pharnmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,221.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR-60/7260,June 2008,December 2010,December 2010,"May 20, 2008",,"August 7, 2012","['gujarat cancer & research institute, new civil hospital campus, asarwa, ahmedabad, india regional cancer center, indira gandhi medical college, shimla, himachal pradesh, india mnj institute of oncology, regional cancer centre, red hills, hyderabad, india malabar institute of medical science (mims), calicut, kerala, india b.p. poddar hospital and medical research ltd., new alipore, kolkata, india choithram hospital and research centre, indore, madhya pradesh, india regional cancer centre, indira gandhi institute of medical science, sheikhpura, patna, india patel hospital pvt. ltd, jalandhar, punjab, india acharya tulsi regional cancer treatment & research institute, bikaner, rajasthan, india v.n. cancer center, gknm hospital, coimbatore, tamilnadu, india netaji subash chandra bose cancer research institute, kolkata, west bangal, india bankura sammilani medical college, gobindnagar, west bengal, india institute of post graduate medical education & research, kolkata, west bengal, india chittaranjan national cancer institute, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT00680940,
301,302,NCT01412957,comparison of survival benefit of panitumumab with supportive care to best supportive care alone in patients with metastatic colorectal cancer,,Completed,Has Results,metastatic colorectal cancer,other: best supportive care (bsc)|drug: panitumumab,overall survival|progression-free survival|overall survival in participants with wild-type ras|progression free survival (pfs) in participants with wild-type ras|objective response rate|objective response rate in participants with wild-type ras|number of participants with adverse events (aes)|maximum post-baseline change from baseline in corrected qt (qtc) interval,amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,377.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20100007|2010-022951-49,November 2011,June 2014,November 2016,"August 9, 2011","April 8, 2016","March 15, 2017","['research site, curitiba, paraná, brazil research site, natal, rio grande do norte, brazil research site, ijui, rio grande do sul, brazil research site, porto alegre, rio grande do sul, brazil research site, greenfield park, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, québec, quebec, canada research site, trois-rivières, quebec, canada research site, quebec, canada research site, temuco, cautín, chile research site, vina del mar, valparaíso, chile research site, fuzhou, fujian, china research site, fuzhou, fujian, china research site, shijiazhuang, hebei, china research site, nanjing, jiangsu, china research site, changchun, jilin, china research site, shenyang, liaoning, china research site, xi an, shaanxi, china research site, xi an, shaanxi, china research site, beijing, china research site, chongqing, china research site, chongqing, china research site, shanghai, china research site, osijek, croatia research site, pula, croatia research site, rijeka, croatia research site, split, croatia research site, zagreb, croatia research site, tallinn, estonia research site, tartu, estonia research site, athens, greece research site, chania, greece research site, hyderabad, andhra pradesh, india research site, visakhapatnam, andhra pradesh, india research site, bangalore, karnataka, india research site, kochi, kerala, india research site, mumbai, maharashtra, india research site, nashik, maharashtra, india research site, nashik, maharashtra, india research site, pune, maharashtra, india research site, chennai, tamil nadu, india research site, goyang-si, gyeonggi-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, daugavpils, latvia research site, riga, latvia research site, riga, latvia research site, kaunas, lithuania research site, vilnius, lithuania research site, nilai, negri sembilan, malaysia research site, georgetown, pinang, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, mexico city, distrito federal, mexico research site, mexico, distrito federal, mexico research site, cuernavaca, morelos, mexico research site, oaxaca, mexico research site, davao city, davao, philippines research site, cebu city, philippines research site, manila, philippines research site, manila, philippines research site, pasay city, philippines research site, bucharest, romania research site, bucharest, romania research site, cluj-napoca, romania research site, cluj-napoca, romania research site, cluj-napoca, romania research site, craiova, romania research site, craiova, romania research site, lasi, romania research site, ploiesti, romania research site, suceava, romania research site, timisoara, romania research site, belgrade, serbia research site, nis, serbia research site, sremska kamenica, serbia']",,https://ClinicalTrials.gov/show/NCT01412957,colon
302,303,NCT01160601,study of paclitaxel/carboplatin with or without bavituximab in previously untreated non small-cell lung cancer,,Completed,No Results Available,non-squamous non-small cell lung cancer,drug: paclitaxel / carboplatin|drug: bavituximab,objective response rate,peregrine pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,86.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PPHM 1001,June 2010,June 2013,September 2013,"July 12, 2010",,"April 19, 2017","['ironwood cancer and research center, chandler, arizona, united states baptist clinical research, jonesboro, arkansas, united states american institute of research, whittier, california, united states baptist cancer institute, jacksonville, florida, united states community hospital, munster, indiana, united states cedar valley medical specialists, pc, waterloo, iowa, united states southeast nebraska cancer center, lincoln, nebraska, united states dartmouth hitchcock medical center, lebanon, new hampshire, united states the center for cancer and hematologic disease, cherry hill, new jersey, united states san juan oncology associates, farmington, new mexico, united states presbyterian hospital, charlotte, north carolina, united states gabrail cancer center, canton, ohio, united states the christ hospital cancer center research, cincinnati, ohio, united states signal point clinical research center, llc, middletown, ohio, united states gettysburg cancer center, gettysburg, pennsylvania, united states hematology-oncology of knoxville/mercy medical center, knoxville, tennessee, united states delta hematology oncology associates, pc, portsmouth, virginia, united states jsc a.gvamichava national oncology center, tbilisi, georgia medulla chemotherapy and immunotherapy clinic, tbilisi, georgia bibi general hospital & cancer centre, hyderabad, andhra pradesh, india mahavir cancer sansthan, patna, bihar, india o.p. jindal institute of cancer & research, hisar, haryana, india bangalore institute of oncology specialty centre, bangalore, karnataka, india kodlikeri memorial hospital, aurangabad, maharashtra, india cancer care clinic, nagpur, maharashtra, india shatabdi superspecialty hospital, nashik, maharashtra, india ruby hall clinic, pune, maharashtra, india sms medical college hospital, jaipur, rajasthan, india state institution of healthcare ""pyatigorsk oncology dispensary"", pyatigorsk, stavropol territory, russian federation state institution of healthcare of yaroslavl region ""regional clinical oncology hospital"", yaroslavl, yaroslavl region, russian federation state medical preventive institution ""chelyabinsk regional clinical oncology"", chelyabinsk, russian federation state institution of healthcare "" ivanovo regional oncology dispensary "", ivanovo, russian federation institution of russian academy of medical science ""russian oncology scientific centre named after n. n. blokhina ramn"", moscow, russian federation state educational institution of higher professional education ""saint-petersburg state medical university named after academician i.p. pavlov of federal agency of healthcare and social development"", saint-petersburg, russian federation state institution of healthcare ""tula regional oncology dispensary"", tula, russian federation city multi-field clinical hospital # 4, department of chemotherapy; dnipropetrovsk state medical academy, chair of oncology and medical radiology;, dnipropetrovsk, ukraine municipal clinical medical and prophylactic institution ""donetsk regional antineoplastic center"", onco-chemotherapy department #1, donetsk, ukraine state institution ""institute of medical radiology named after s.p. grygoryev of ams of ukraine"", department of chemotherapy, kharkiv, ukraine kyiv city oncology hospital, thoracal department, kyiv, ukraine uzhgorod central city clinical hospital, city oncology center, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT01160601,
303,304,NCT04655469,personal health train for radiation oncology in india and the netherlands,TRAIN,"Active, not recruiting",No Results Available,head and neck carcinoma,,overall survival|recurrence|distant metastases|treatment-related adverse events,maastricht radiation oncology,All,"18 Years and older   (Adult, Older Adult)",,2000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,629.002.212,"April 10, 2020","April 10, 2022","February 1, 2024","December 7, 2020",,"December 7, 2020","['healthcare global, bengaluru, karnataka, india tata memorial hospital, mumbai, maharashtra, india maastro, maastricht, limburg, netherlands']",,https://ClinicalTrials.gov/show/NCT04655469,
304,305,NCT01138163,study of bavituximab plus docetaxel in patients with locally advanced or metastatic non-squamous non small-cell lung cancer,,Completed,No Results Available,non-small-cell lung cancer,drug: docetaxel plus bavituximab or placebo,objective response rate,peregrine pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,121.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PPHM 0902,June 2010,October 2012,May 2013,"June 7, 2010",,"April 19, 2017","['ironwood cancer and research center, chandler, arizona, united states south bay hematology oncology, campbell, california, united states medical oncology care associates, orange, california, united states american institute of research, whittier, california, united states the center for hematology-oncology/boca raton community hospital, inc, boca raton, florida, united states florida cancer specialists, fort myers, florida, united states georgia cancer specialists, pc, atlanta, georgia, united states northwest georgia oncology centers, pc, marietta, georgia, united states rush university medical center, chicago, illinois, united states cedar valley medical specialists, pc, waterloo, iowa, united states jewish hospital, louisville, kentucky, united states frederick memorial hospital regional cancer therapy center, frederick, maryland, united states nebraska hematology oncology, pc, lincoln, nebraska, united states hanover medical specialists, pa, wilmington, north carolina, united states the christ hospital cancer center research, cincinnati, ohio, united states oncology/ hematology care, inc, cincinnati, ohio, united states dayton clinical oncology program, dayton, ohio, united states pennsylvania state hershey cancer institute, hershey, pennsylvania, united states south carolina oncology associates, columbia, south carolina, united states sarah cannon research institute, llc, nashville, tennessee, united states coastal bend cancer center, corpus christi, texas, united states mary crowley cancer research centers, dallas, texas, united states university of texas southwestern medical center, dallas, texas, united states university of utah hospitals and clinics, huntsman cancer institute, salt lake city, utah, united states jsc a.gvamichava national oncology center, tbilisi, georgia medulla chemotherapy and immunotherapy clinic, tbilisi, georgia bibi general hospital & cancer centre, hyderabad, andhra pradesh, india nizam\'s institute of medical sciences, hyderabad, andra pradesh, india mahavir cancer sansthan, patna, bihar, india o.p. jindal institute of cancer & research, hisar, haryana, india bangalore institute of oncology specialty centre, bangalore, karnataka, india kidwai memorial institute of oncology, bangalore, karnataka, india bharath hospital and institute of oncology, mysore, karnataka, india kodlikeri memorial hospital, aurangabad, maharashtra, india cancer care clinic, nagpur, maharashtra, india shatabdi superspecialty hospital, nashik, maharashtra, india ruby hall clinic, pune, maharashtra, india sms medical college hospital, jaipur, rajasthan, india chhatrapati shahuji maharaj medical university, lucknow, uttar pradesh, india shanti mukund hospital curie cancer center, delhi, india all india institute of medical sciences, delhi, india state medical preventive institution ""chelyabinsk regional clinical oncology"", chelyabinsk, russian federation state institution of healthcare "" ivanovo regional oncology dispensary "", ivanovo, russian federation institution of russian academy of medical science ""russian oncology scientific centre named after n. n. blokhina ramn"", moscow, russian federation state educational institution of higher professional education ""saint-petersburg state medical university named after academician i.p. pavlov of federal agency of healthcare and social development"", saint petersburg, russian federation state institution of healthcare ""pyatigorsk oncology dispensary"", stavropol\', russian federation state institution of healthcare ""tula regional oncology dispensary"", tula, russian federation state institution of healthcare of yaroslavl region ""regional clinical oncology hospital"", yaroslavl, russian federation city multi-field clinical hospital # 4, department of chemotherapy; dnipropetrovsk state medical academy, chair of oncology and medical radiology;, dnipropetrovsk, ukraine municipal clinical medical and prophylactic institution ""donetsk regional antineoplastic center"", onco-chemotherapy, donetsk, ukraine state institution ""institute of medical radiology named after s.p. grygoryev of ams of ukraine"", department of chemotherapy, kharkiv, ukraine kyiv city oncology hospital, thoracal department, kyiv, ukraine uzhgorod central city clinical hospital, city oncology center, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT01138163,
305,306,NCT04035486,a study of osimertinib with or without chemotherapy as 1st line treatment in patients with mutated epidermal growth factor receptor non-small cell lung cancer (flaura2),FLAURA2,"Active, not recruiting",No Results Available,non-small cell lung cancer,drug: osimertinib|drug: pemetrexed/carboplatin|drug: pemetrexed/cisplatin,progression-free survival (pfs)|overall survival (os)|landmark overall survival (los)|objective response rate (orr)|duration of response (dor)|depth of response|disease control rate (dcr) by investigator|progression free survival 2 (pfs2)|change from baseline and time to deterioration in european organization for research and treatment of cancer quality of life questionnaire - core 30 items (eortc qlq-c30)|change from baseline and time to deterioration in european organization for research and treatment of cancer quality of life questionnaire - lung cancer 13 items (eortc qlq-lc13)|concordance of epidermal growth factor receptor mutation status between the local epidermal growth factor receptor mutation test and the central cobas® epidermal growth factor receptor mutation test v2 results from tumor samples with evaluable results|progression-free survival (pfs) by investigator by plasma epidermal growth factor receptor mutation status.|plasma concentration of osimertinib when given with or without chemotherapy|plasma concentration of metabolite az5104 when osimertinib is given with or without chemotherapy,astrazeneca,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 3,587.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5169C00001,"July 2, 2019","April 3, 2023","June 3, 2026","July 29, 2019",,"April 18, 2022","[""research site, bellflower, california, united states research site, fullerton, california, united states research site, la jolla, california, united states research site, los angeles, california, united states research site, santa monica, california, united states research site, santa rosa, california, united states research site, west hollywood, california, united states research site, whittier, california, united states research site, orlando, florida, united states research site, tampa, florida, united states research site, kansas city, kansas, united states research site, louisville, kentucky, united states research site, boston, massachusetts, united states research site, henderson, nevada, united states research site, albany, new york, united states research site, canton, ohio, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, blacksburg, virginia, united states research site, fairfax, virginia, united states research site, vancouver, washington, united states research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, ciudad autonoma de buenos aire, argentina research site, ciudad de buenos aires, argentina research site, cordoba, argentina research site, santa fe, argentina research site, camperdown, australia research site, chermside, australia research site, elizabeth vale, australia research site, heidelberg, australia research site, kogarah, australia research site, melbourne, australia research site, barretos, brazil research site, florianópolis, brazil research site, londrina, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, vitoria, brazil research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, toronto, ontario, canada research site, santiago, chile research site, santiago, chile research site, temuco, chile research site, viña del mar, chile research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, chongqing, china research site, guangzhou, china research site, haikou, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, jinan, china research site, nanjing, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, urumqi, china research site, wuhan, china research site, xi'an, china research site, zhengzhou, china research site, olomouc, czechia research site, ostrava - vitkovice, czechia research site, praha 5, czechia research site, praha, czechia research site, bordeaux cedex, france research site, lyon, france research site, montpellier, france research site, villejuif cedex, france research site, bangalore, india research site, belagavi, india research site, gurgaon, india research site, kolkata, india research site, new delhi, india research site, pune, india research site, bunkyo-ku, japan research site, bunkyo-ku, japan research site, fukuoka, japan research site, hidaka-shi, japan research site, himeji-shi, japan research site, iwakuni-shi, japan research site, kanazawa, japan research site, kashiwa, japan research site, koto-ku, japan research site, osaka-shi, japan research site, sakai-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, sunto-gun, japan research site, yokohama-shi, japan research site, cheongju-si, korea, republic of research site, goyang-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, arequipa, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, san isidro, peru research site, cebu city, philippines research site, davao city, philippines research site, iloilo city, philippines research site, las pinas, philippines research site, legazpi city, philippines research site, quezon city, philippines research site, quezon city, philippines research site, moscow, russian federation research site, moscow, russian federation research site, murmansk, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, syktyvkar, russian federation research site, banska bystrica, slovakia research site, bratislava, slovakia research site, kosice, slovakia research site, poprad, slovakia research site, johannesburg, south africa research site, port elizabeth, south africa research site, rondebosch, south africa research site, changhua, taiwan research site, hualien city, taiwan research site, kaohsiung city, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, muang, thailand research site, cambridge, united kingdom research site, leicester, united kingdom research site, liverpool, united kingdom research site, maidstone, united kingdom research site, manchester, united kingdom research site, hanoi, vietnam research site, ho chi minh, vietnam""]",,https://ClinicalTrials.gov/show/NCT04035486,
306,307,NCT00480025,gsk1572932a antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer,,Terminated,Has Results,"lung cancer, non-small cell",biological: gsk1572932a antigen-specific cancer immunotherapeutic|biological: placebo control,"person year rate (pyar) as regards disease-free survival (dfs) in the overall population|person year rate (pyar) as regards disease-free survival (dfs) in the no-ct population|person year rate (pyar) as regards disease-free survival (dfs) in the ct population|person year rate (pyar) as regards overall-survival (os) in the overall population|person year rate (pyar) as regards overall-survival (os) in the no-ct population|person year rate (pyar) as regards overall-survival (os) in the ct population|person year rate (pyar) as regards lung-cancer specific survival (lcss) in the overall population|person year rate (pyar) as regards lung-cancer specific survival (lcss) in the no-ct population|person year rate (pyar) as regards lung-cancer specific survival (lcss) in the ct population|kaplan-meier estimate (kme) of 2, 3, 4 and 5-year as regards disease-free survival (dfs) in the overall population|kaplan-meier estimate (kme) of 2, 3, 4 and 5-year as regards disease-free survival (dfs) in the no-ct population|kaplan-meier estimate (kme) of 2, 3, 4 and 5-year as regards disease-free survival (dfs) in the ct population|person year rate (pyar) as regards disease-free specific survival (dfss) in the overall population|person year rate (pyar) as regards disease-free specific survival (dfss) in the no-ct population|person year rate (pyar) as regards disease-free specific survival (dfss) in the ct population|number of subjects seropositive for anti-melanoma antigen (mage)-a3 antibodies (anti-mage-a3 s+)|number of humoral responders as regards anti-melanoma antigen (mage)-a3 antibodies (anti-mage-a3 hr)|number of subjects seropositive for anti-protein d (pd) antibodies (anti-pd s+)|number of humoral responders as regards anti-protein d (pd) antibodies (anti-pd hr)|health-related quality of life (hql) scores|number of patients with abnormal alanine aminotransferase (alt) values by maximum grade|number of patients with abnormal alanine aspartate aminotransferase (ast) values by maximum grade|number of patients with abnormal alkaline phosphatase (alkp) values by maximum grade|number of patients with abnormal bilirubin (bil) values by maximum grade|number of patients with abnormal creatinine (crea) values by maximum grade|number of patients with abnormal haemoglobin (hgb) values by maximum grade|number of patients with abnormal leukocytes (leu) values by maximum grade|number of patients with abnormal lymphocytes (lym) values by maximum grade|number of patients with abnormal neutrophils (neu) values by maximum grade|number of patients with abnormal platelets (pla) values by maximum grade|number of patients with any adverse events (aes) and with aes by maximum grade reported - up to data lock point (dlp)|number of patients with serious adverse events (saes) - up to data lock point (dlp)",glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2278.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",109493|2007-001283-73,"October 4, 2007","December 6, 2013","September 23, 2014","May 30, 2007","January 30, 2019","December 22, 2020","[""gsk investigational site, birmingham, alabama, united states gsk investigational site, mobile, alabama, united states gsk investigational site, mobile, alabama, united states gsk investigational site, phoenix, arizona, united states gsk investigational site, scottsdale, arizona, united states gsk investigational site, scottsdale, arizona, united states gsk investigational site, tucson, arizona, united states gsk investigational site, fayetteville, arkansas, united states gsk investigational site, fort smith, arkansas, united states gsk investigational site, jonesboro, arkansas, united states gsk investigational site, bakersfield, california, united states gsk investigational site, beverly hills, california, united states gsk investigational site, burbank, california, united states gsk investigational site, duarte, california, united states gsk investigational site, fresno, california, united states gsk investigational site, greenbrae, california, united states gsk investigational site, la jolla, california, united states gsk investigational site, la jolla, california, united states gsk investigational site, los angeles, california, united states gsk investigational site, montebello, california, united states gsk investigational site, orange, california, united states gsk investigational site, palm springs, california, united states gsk investigational site, palo alto, california, united states gsk investigational site, pleasant hill, california, united states gsk investigational site, rancho mirage, california, united states gsk investigational site, sacramento, california, united states gsk investigational site, sacramento, california, united states gsk investigational site, san diego, california, united states gsk investigational site, san diego, california, united states gsk investigational site, san francisco, california, united states gsk investigational site, santa rosa, california, united states gsk investigational site, stanford, california, united states gsk investigational site, vallejo, california, united states gsk investigational site, west hollywood, california, united states gsk investigational site, aurora, colorado, united states gsk investigational site, colorado springs, colorado, united states gsk investigational site, danbury, connecticut, united states gsk investigational site, torrington, connecticut, united states gsk investigational site, waterbury, connecticut, united states gsk investigational site, newark, delaware, united states gsk investigational site, washington, district of columbia, united states gsk investigational site, boca raton, florida, united states gsk investigational site, boynton beach, florida, united states gsk investigational site, deerfield beach, florida, united states gsk investigational site, fort lauderdale, florida, united states gsk investigational site, hollywood, florida, united states gsk investigational site, jacksonville, florida, united states gsk investigational site, ocala, florida, united states gsk investigational site, orlando, florida, united states gsk investigational site, orlando, florida, united states gsk investigational site, stuart, florida, united states gsk investigational site, tampa, florida, united states gsk investigational site, west palm beach, florida, united states gsk investigational site, alpharetta, georgia, united states gsk investigational site, athens, georgia, united states gsk investigational site, atlanta, georgia, united states gsk investigational site, atlanta, georgia, united states gsk investigational site, atlanta, georgia, united states gsk investigational site, augusta, georgia, united states gsk investigational site, macon, georgia, united states gsk investigational site, marietta, georgia, united states gsk investigational site, savannah, georgia, united states gsk investigational site, honolulu, hawaii, united states gsk investigational site, coeur d'alene, idaho, united states gsk investigational site, chicago, illinois, united states gsk investigational site, chicago, illinois, united states gsk investigational site, chicago, illinois, united states gsk investigational site, decatur, illinois, united states gsk investigational site, evanston, illinois, united states gsk investigational site, harvey, illinois, united states gsk investigational site, park ridge, illinois, united states gsk investigational site, peoria, illinois, united states gsk investigational site, springfield, illinois, united states gsk investigational site, evansville, indiana, united states gsk investigational site, indianapolis, indiana, united states gsk investigational site, indianapolis, indiana, united states gsk investigational site, munster, indiana, united states gsk investigational site, new albany, indiana, united states gsk investigational site, waterloo, iowa, united states gsk investigational site, ashland, kentucky, united states gsk investigational site, hazard, kentucky, united states gsk investigational site, lexington, kentucky, united states gsk investigational site, louisville, kentucky, united states gsk investigational site, owensboro, kentucky, united states gsk investigational site, alexandria, louisiana, united states gsk investigational site, metairie, louisiana, united states gsk investigational site, shreveport, louisiana, united states gsk investigational site, annapolis, maryland, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, bethesda, maryland, united states gsk investigational site, silver spring, maryland, united states gsk investigational site, towson, maryland, united states gsk investigational site, boston, massachusetts, united states gsk investigational site, boston, massachusetts, united states gsk investigational site, boston, massachusetts, united states gsk investigational site, worcester, massachusetts, united states gsk investigational site, worcester, massachusetts, united states gsk investigational site, ann arbor, michigan, united states gsk investigational site, bay city, michigan, united states gsk investigational site, detroit, michigan, united states gsk investigational site, detroit, michigan, united states gsk investigational site, flint, michigan, united states gsk investigational site, grand rapids, michigan, united states gsk investigational site, lansing, michigan, united states gsk investigational site, lapeer, michigan, united states gsk investigational site, southfield, michigan, united states gsk investigational site, minneapolis, minnesota, united states gsk investigational site, minneapolis, minnesota, united states gsk investigational site, rochester, minnesota, united states gsk investigational site, saint louis park, minnesota, united states gsk investigational site, saint louis park, minnesota, united states gsk investigational site, kansas city, missouri, united states gsk investigational site, kansas city, missouri, united states gsk investigational site, saint louis, missouri, united states gsk investigational site, springfield, missouri, united states gsk investigational site, billings, montana, united states gsk investigational site, grand island, nebraska, united states gsk investigational site, omaha, nebraska, united states gsk investigational site, henderson, nevada, united states gsk investigational site, lebanon, new hampshire, united states gsk investigational site, long branch, new jersey, united states gsk investigational site, paramus, new jersey, united states gsk investigational site, armonk, new york, united states gsk investigational site, buffalo, new york, united states gsk investigational site, east syracuse, new york, united states gsk investigational site, flushing, new york, united states gsk investigational site, mineola, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, syracuse, new york, united states gsk investigational site, chapel hill, north carolina, united states gsk investigational site, charlotte, north carolina, united states gsk investigational site, charlotte, north carolina, united states gsk investigational site, durham, north carolina, united states gsk investigational site, durham, north carolina, united states gsk investigational site, greenville, north carolina, united states gsk investigational site, akron, ohio, united states gsk investigational site, canton, ohio, united states gsk investigational site, cincinnati, ohio, united states gsk investigational site, cincinnati, ohio, united states gsk investigational site, columbus, ohio, united states gsk investigational site, dayton, ohio, united states gsk investigational site, tulsa, oklahoma, united states gsk investigational site, bend, oregon, united states gsk investigational site, portland, oregon, united states gsk investigational site, bethlehem, pennsylvania, united states gsk investigational site, danville, pennsylvania, united states gsk investigational site, lancaster, pennsylvania, united states gsk investigational site, langhorne, pennsylvania, united states gsk investigational site, philadelphia, pennsylvania, united states gsk investigational site, philadelphia, pennsylvania, united states gsk investigational site, philadelphia, pennsylvania, united states gsk investigational site, pittsburgh, pennsylvania, united states gsk investigational site, pittsburgh, pennsylvania, united states gsk investigational site, sayre, pennsylvania, united states gsk investigational site, wilkes-barre, pennsylvania, united states gsk investigational site, willow grove, pennsylvania, united states gsk investigational site, providence, rhode island, united states gsk investigational site, providence, rhode island, united states gsk investigational site, charleston, south carolina, united states gsk investigational site, charleston, south carolina, united states gsk investigational site, columbia, south carolina, united states gsk investigational site, greenville, south carolina, united states gsk investigational site, spartanburg, south carolina, united states gsk investigational site, sumter, south carolina, united states gsk investigational site, chattanooga, tennessee, united states gsk investigational site, cookeville, tennessee, united states gsk investigational site, knoxville, tennessee, united states gsk investigational site, knoxville, tennessee, united states gsk investigational site, memphis, tennessee, united states gsk investigational site, memphis, tennessee, united states gsk investigational site, nashville, tennessee, united states gsk investigational site, amarillo, texas, united states gsk investigational site, dallas, texas, united states gsk investigational site, dallas, texas, united states gsk investigational site, dallas, texas, united states gsk investigational site, grapevine, texas, united states gsk investigational site, houston, texas, united states gsk investigational site, houston, texas, united states gsk investigational site, round rock, texas, united states gsk investigational site, tyler, texas, united states gsk investigational site, ogden, utah, united states gsk investigational site, salt lake city, utah, united states gsk investigational site, fairfax, virginia, united states gsk investigational site, roanoke, virginia, united states gsk investigational site, everett, washington, united states gsk investigational site, seattle, washington, united states gsk investigational site, seattle, washington, united states gsk investigational site, seattle, washington, united states gsk investigational site, spokane, washington, united states gsk investigational site, tacoma, washington, united states gsk investigational site, vancouver, washington, united states gsk investigational site, madison, wisconsin, united states gsk investigational site, milwaukee, wisconsin, united states gsk investigational site, c.a.b.a., buenos aires, argentina gsk investigational site, ciudad autonoma de buenos aires, buenos aires, argentina gsk investigational site, ciudad autónoma de buenos aires, buenos aires, argentina gsk investigational site, cordoba, córdova, argentina gsk investigational site, cipolletti, río negro, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, quilmes, argentina gsk investigational site, santa fe, argentina gsk investigational site, tucuman, argentina gsk investigational site, garran, australian capital territory, australia gsk investigational site, camperdown, new south wales, australia gsk investigational site, tweed heads, new south wales, australia gsk investigational site, waratah, new south wales, australia gsk investigational site, westmead, new south wales, australia gsk investigational site, chermside, queensland, australia gsk investigational site, south brisbane, queensland, australia gsk investigational site, woolloongabba, queensland, australia gsk investigational site, adelaide, south australia, australia gsk investigational site, hobart, tasmania, australia gsk investigational site, box hill, victoria, australia gsk investigational site, fitzroy, victoria, australia gsk investigational site, heidelberg, victoria, australia gsk investigational site, richmond, victoria, australia gsk investigational site, nedlands, western australia, australia gsk investigational site, perth, western australia, australia gsk investigational site, graz, austria gsk investigational site, innsbruck, austria gsk investigational site, linz, austria gsk investigational site, linz, austria gsk investigational site, salzburg, austria gsk investigational site, vienna, austria gsk investigational site, vienna, austria gsk investigational site, wels, austria gsk investigational site, antwerpen, belgium gsk investigational site, brussels, belgium gsk investigational site, bruxelles, belgium gsk investigational site, charleroi, belgium gsk investigational site, duffel, belgium gsk investigational site, edegem, belgium gsk investigational site, genk, belgium gsk investigational site, hasselt, belgium gsk investigational site, jette, belgium gsk investigational site, leuven, belgium gsk investigational site, liège, belgium gsk investigational site, namur, belgium gsk investigational site, belo horizonte, minas gerais, brazil gsk investigational site, porto alegre, rio grande do sul, brazil gsk investigational site, barretos, são paulo, brazil gsk investigational site, santo andré, são paulo, brazil gsk investigational site, rio de janeiro, brazil gsk investigational site, são paulo, brazil gsk investigational site, são paulo, brazil gsk investigational site, são paulo, brazil gsk investigational site, calgary, alberta, canada gsk investigational site, edmonton, alberta, canada gsk investigational site, surrey, british columbia, canada gsk investigational site, halifax, nova scotia, canada gsk investigational site, hamilton, ontario, canada gsk investigational site, london, ontario, canada gsk investigational site, newmarket, ontario, canada gsk investigational site, scarborough, ontario, canada gsk investigational site, st catherines, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, greenfield park, quebec, canada gsk investigational site, montreal, quebec, canada gsk investigational site, montreal, quebec, canada gsk investigational site, montreal, quebec, canada gsk investigational site, montreal, quebec, canada gsk investigational site, québec, canada gsk investigational site, guangzhou, guangdong, china gsk investigational site, guangzhou, guangdong, china gsk investigational site, nanning, guangxi, china gsk investigational site, wuhan, hubei, china gsk investigational site, nanjing, jiangsu, china gsk investigational site, changchun, jilin, china gsk investigational site, chengdu, sichuan, china gsk investigational site, hangzhou, zhejiang, china gsk investigational site, hangzhou, zhejiang, china gsk investigational site, beijing, china gsk investigational site, changsha, china gsk investigational site, guangzhou, china gsk investigational site, harbin, china gsk investigational site, shanghai, china gsk investigational site, shanghai, china gsk investigational site, shanghai, china gsk investigational site, tianjin, china gsk investigational site, wuhan, china gsk investigational site, brno, czechia gsk investigational site, ostrava, czechia gsk investigational site, plzen, czechia gsk investigational site, praha 5, czechia gsk investigational site, praha 8, czechia gsk investigational site, usti nad labem, czechia gsk investigational site, tallinn, estonia gsk investigational site, tartu, estonia gsk investigational site, helsinki, finland gsk investigational site, oulu, finland gsk investigational site, tampere, finland gsk investigational site, turku, finland gsk investigational site, angers cedex 9, france gsk investigational site, bayonne, france gsk investigational site, beauvais, france gsk investigational site, bethune cedex, france gsk investigational site, bordeaux, france gsk investigational site, brest cedex, france gsk investigational site, bron, france gsk investigational site, caen, france gsk investigational site, elbeuf, france gsk investigational site, lille, france gsk investigational site, lille, france gsk investigational site, limoges cedex, france gsk investigational site, lorient cedex, france gsk investigational site, lyon cedex 08, france gsk investigational site, lyon, france gsk investigational site, lyon, france gsk investigational site, marseille cedex 20, france gsk investigational site, meaux, france gsk investigational site, metz, france gsk investigational site, montpellier, france gsk investigational site, mulhouse cedex, france gsk investigational site, nantes, france gsk investigational site, nice, france gsk investigational site, nîmes, france gsk investigational site, paris cedex 20, france gsk investigational site, paris cedex 5, france gsk investigational site, paris, france gsk investigational site, paris, france gsk investigational site, paris, france gsk investigational site, perpignan, france gsk investigational site, périgueux cedex, france gsk investigational site, reims, france gsk investigational site, rennes cedex 09, france gsk investigational site, rouen, france gsk investigational site, saint herblain, france gsk investigational site, saint-priest en jarez, france gsk investigational site, saint-quentin, france gsk investigational site, st grégoire, france gsk investigational site, toulon cedex 09, france gsk investigational site, toulouse cedex 9, france gsk investigational site, vannes, france gsk investigational site, villefranche sur saône, france gsk investigational site, freiburg, baden-wuerttemberg, germany gsk investigational site, heidelberg, baden-wuerttemberg, germany gsk investigational site, ulm, baden-wuerttemberg, germany gsk investigational site, villingen-schwenningen, baden-wuerttemberg, germany gsk investigational site, wangen, baden-wuerttemberg, germany gsk investigational site, augsburg, bayern, germany gsk investigational site, bayreuth, bayern, germany gsk investigational site, ebensfeld, bayern, germany gsk investigational site, gauting, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, regensburg, bayern, germany gsk investigational site, regensburg, bayern, germany gsk investigational site, rosenheim, bayern, germany gsk investigational site, wuerzburg, bayern, germany gsk investigational site, frankfurt/oder, brandenburg, germany gsk investigational site, darmstadt, hessen, germany gsk investigational site, frankfurt/main, hessen, germany gsk investigational site, frankfurt, hessen, germany gsk investigational site, frankfurt, hessen, germany gsk investigational site, fulda, hessen, germany gsk investigational site, immenhausen, hessen, germany gsk investigational site, offenbach, hessen, germany gsk investigational site, greifswald, mecklenburg-vorpommern, germany gsk investigational site, rostock, mecklenburg-vorpommern, germany gsk investigational site, braunschweig, niedersachsen, germany gsk investigational site, hannover, niedersachsen, germany gsk investigational site, oldenburg, niedersachsen, germany gsk investigational site, ostercappeln, niedersachsen, germany gsk investigational site, bielefeld, nordrhein-westfalen, germany gsk investigational site, bielefeld, nordrhein-westfalen, germany gsk investigational site, bochum, nordrhein-westfalen, germany gsk investigational site, bonn, nordrhein-westfalen, germany gsk investigational site, essen, nordrhein-westfalen, germany gsk investigational site, essen, nordrhein-westfalen, germany gsk investigational site, hemer, nordrhein-westfalen, germany gsk investigational site, herne, nordrhein-westfalen, germany gsk investigational site, koeln, nordrhein-westfalen, germany gsk investigational site, koeln, nordrhein-westfalen, germany gsk investigational site, luedenscheid, nordrhein-westfalen, germany gsk investigational site, moers, nordrhein-westfalen, germany gsk investigational site, muenster, nordrhein-westfalen, germany gsk investigational site, muenster, nordrhein-westfalen, germany gsk investigational site, mulheim, nordrhein-westfalen, germany gsk investigational site, neuss, nordrhein-westfalen, germany gsk investigational site, oberhausen, nordrhein-westfalen, germany gsk investigational site, porta westfalica, nordrhein-westfalen, germany gsk investigational site, troisdorf, nordrhein-westfalen, germany gsk investigational site, velbert, nordrhein-westfalen, germany gsk investigational site, waldbrol, nordrhein-westfalen, germany gsk investigational site, koblenz, rheinland-pfalz, germany gsk investigational site, mainz, rheinland-pfalz, germany gsk investigational site, trier, rheinland-pfalz, germany gsk investigational site, homburg, saarland, germany gsk investigational site, halle (saale), sachsen-anhalt, germany gsk investigational site, halle, sachsen-anhalt, germany gsk investigational site, weissenfels, sachsen-anhalt, germany gsk investigational site, dresden, sachsen, germany gsk investigational site, leipzig, sachsen, germany gsk investigational site, leipzig, sachsen, germany gsk investigational site, zwickau, sachsen, germany gsk investigational site, grosshansdorf, schleswig-holstein, germany gsk investigational site, kiel, schleswig-holstein, germany gsk investigational site, luebeck, schleswig-holstein, germany gsk investigational site, bad berka, thueringen, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, bremen, germany gsk investigational site, hamburg, germany gsk investigational site, hamburg, germany gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, chania, greece gsk investigational site, heraklion, greece gsk investigational site, larissa, greece gsk investigational site, marousi, greece gsk investigational site, neo faliro, greece gsk investigational site, patra, greece gsk investigational site, piraeus, greece gsk investigational site, pylaia, greece gsk investigational site, thessaloniki, greece gsk investigational site, thessaloniki, greece gsk investigational site, kowloon, hong kong gsk investigational site, shatin, hong kong gsk investigational site, budapest, hungary gsk investigational site, budapest, hungary gsk investigational site, deszk, hungary gsk investigational site, gyula, hungary gsk investigational site, győr, hungary gsk investigational site, miskolc, hungary gsk investigational site, mátraháza, hungary gsk investigational site, nyíregyháza, hungary gsk investigational site, pozva, hungary gsk investigational site, pécs, hungary gsk investigational site, szombathely, hungary gsk investigational site, székesfehérvár, hungary gsk investigational site, ahmedabad, india gsk investigational site, ahmedabad, india gsk investigational site, bangalore, india gsk investigational site, hyderabad, india gsk investigational site, mumbai, india gsk investigational site, mumbai, india gsk investigational site, mumbai, india gsk investigational site, dublin, ireland gsk investigational site, dublin, ireland gsk investigational site, dublin, ireland gsk investigational site, galway, ireland gsk investigational site, beer-sheva, israel gsk investigational site, haifa, israel gsk investigational site, jerusalem, israel gsk investigational site, kfar saba, israel gsk investigational site, ramat gan, israel gsk investigational site, zrifin, israel gsk investigational site, napoli, campania, italy gsk investigational site, bologna, emilia-romagna, italy gsk investigational site, meldola (fc), emilia-romagna, italy gsk investigational site, modena, emilia-romagna, italy gsk investigational site, parma, emilia-romagna, italy gsk investigational site, ravenna, emilia-romagna, italy gsk investigational site, rimini, emilia-romagna, italy gsk investigational site, udine, friuli-venezia-giulia, italy gsk investigational site, roma, lazio, italy gsk investigational site, roma, lazio, italy gsk investigational site, roma, lazio, italy gsk investigational site, genova, liguria, italy gsk investigational site, genova, liguria, italy gsk investigational site, lecco, lombardia, italy gsk investigational site, milano, lombardia, italy gsk investigational site, milano, lombardia, italy gsk investigational site, monza, lombardia, italy gsk investigational site, rozzano (mi), lombardia, italy gsk investigational site, novara, piemonte, italy gsk investigational site, orbassano (to), piemonte, italy gsk investigational site, torino, piemonte, italy gsk investigational site, bari, puglia, italy gsk investigational site, monserrato, sardegna, italy gsk investigational site, palermo, sicilia, italy gsk investigational site, pisa, toscana, italy gsk investigational site, siena, toscana, italy gsk investigational site, perugia, umbria, italy gsk investigational site, legnago, veneto, italy gsk investigational site, padova, veneto, italy gsk investigational site, aichi, japan gsk investigational site, chiba, japan gsk investigational site, ehime, japan gsk investigational site, fukuoka, japan gsk investigational site, fukuoka, japan gsk investigational site, hiroshima, japan gsk investigational site, hyogo, japan gsk investigational site, kanagawa, japan gsk investigational site, niigata, japan gsk investigational site, osaka, japan gsk investigational site, osaka, japan gsk investigational site, shizuoka, japan gsk investigational site, tokyo, japan gsk investigational site, tokyo, japan gsk investigational site, tokyo, japan gsk investigational site, kyunggi-do, korea, republic of gsk investigational site, seongnam-si, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, amsterdam, netherlands gsk investigational site, harderwijk, netherlands gsk investigational site, heerlen, netherlands gsk investigational site, leeuwarden, netherlands gsk investigational site, nieuwegein, netherlands gsk investigational site, oslo, norway gsk investigational site, oslo, norway gsk investigational site, trondheim, norway gsk investigational site, bialystok, poland gsk investigational site, bydgoszcz, poland gsk investigational site, bydgoszcz, poland gsk investigational site, checiny, poland gsk investigational site, gdansk, poland gsk investigational site, glucholazy, poland gsk investigational site, krakow, poland gsk investigational site, lodz, poland gsk investigational site, lodz, poland gsk investigational site, lublin, poland gsk investigational site, poznan, poland gsk investigational site, rzeszow, poland gsk investigational site, szczecin, poland gsk investigational site, warszawa, poland gsk investigational site, wroclaw, poland gsk investigational site, zakopane, poland gsk investigational site, chelyabinsk, russian federation gsk investigational site, kazan, russian federation gsk investigational site, kursk, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, stavropol, russian federation gsk investigational site, ufa,, russian federation gsk investigational site, singapore, singapore gsk investigational site, singapore, singapore gsk investigational site, barcelona, spain gsk investigational site, barcelona, spain gsk investigational site, barcelona, spain gsk investigational site, granada, spain gsk investigational site, granada, spain gsk investigational site, leganes, spain gsk investigational site, lerida, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, málaga, spain gsk investigational site, oviedo, spain gsk investigational site, sabadell, spain gsk investigational site, san sebastian de los reyes, spain gsk investigational site, santander, spain gsk investigational site, santiago de compostela, spain gsk investigational site, sevilla, spain gsk investigational site, sevilla, spain gsk investigational site, valencia, spain gsk investigational site, valencia, spain gsk investigational site, lund, sweden gsk investigational site, stockholm, sweden gsk investigational site, uppsala, sweden gsk investigational site, aarau, switzerland gsk investigational site, basel, switzerland gsk investigational site, bern, switzerland gsk investigational site, bruderholz, switzerland gsk investigational site, thun, switzerland gsk investigational site, zuerich, switzerland gsk investigational site, kaohsiung, taiwan gsk investigational site, taichung, taiwan gsk investigational site, taichung, taiwan gsk investigational site, tainan, taiwan gsk investigational site, taipei, taiwan gsk investigational site, taipei, taiwan gsk investigational site, taoyuan, taiwan gsk investigational site, bangkok, thailand gsk investigational site, bangkok, thailand gsk investigational site, chiang mai, thailand gsk investigational site, hat yai, thailand gsk investigational site, dnipropetrovsk, ukraine gsk investigational site, donetsk, ukraine gsk investigational site, kharkiv, ukraine gsk investigational site, kyiv, ukraine gsk investigational site, kyiv, ukraine gsk investigational site, kyiv, ukraine gsk investigational site, lviv, ukraine gsk investigational site, odesa, ukraine gsk investigational site, simferopol, ukraine gsk investigational site, uzhgorod, ukraine gsk investigational site, vinnytsia, ukraine gsk investigational site, cambridge, cambridgeshire, united kingdom gsk investigational site, wythenshawe, greater manchester, united kingdom gsk investigational site, leicester, leicestershire, united kingdom gsk investigational site, edinburgh, midlothian, united kingdom gsk investigational site, sutton, surrey, united kingdom gsk investigational site, aberdeen, united kingdom gsk investigational site, bebington, united kingdom gsk investigational site, belfast, united kingdom gsk investigational site, birmingham, united kingdom gsk investigational site, cambridge, united kingdom gsk investigational site, dundee, united kingdom gsk investigational site, glasgow, united kingdom gsk investigational site, inverness, united kingdom gsk investigational site, leeds, united kingdom gsk investigational site, liverpool, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, maidstone, united kingdom gsk investigational site, sheffield, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00480025,
307,308,NCT04172675,a study of erdafitinib versus investigator choice of intravesical chemotherapy in participants who received bacillus calmette-guérin (bcg) and recurred with high risk non-muscle-invasive bladder cancer (nmibc),,Recruiting,No Results Available,urinary bladder neoplasms,drug: erdafitinib|drug: investigator choice (gemcitabine)|drug: investigator choice (mitomycin c),recurrence-free survival (rfs)|time to disease worsening|time to progression|disease-specific survival|overall survival|recurrence-free survival|recurrence-free survival 2 (rfs2)|rfs by central histopathologic review|plasma concentration of erdafitinib|number of participants with adverse events|change from baseline in patient's global impression of severity (of cancer) (pgis)|change from baseline in patient's global impression of change (of cancer) (pgic)|change from baseline in european organisation for research and treatment of cancer quality-of-life questionnaire (eortc qlq) -c30|change from baseline in eortc qlq- non-muscle-invasive bladder cancer (nmibc) 24|change from baseline in euroqol european quality of life - 5 dimensions-5 levels (eq-5d-5l),"janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,280.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR108699|2019-002449-39|42756493BLC2003,"February 28, 2020","October 26, 2022","August 11, 2027","November 21, 2019",,"April 27, 2022","[""urological associates of southern arizona, p.c., tucson, arizona, united states usc institute of urology, los angeles, california, united states the urology center of colorado, denver, colorado, united states foothills urology - golden off, golden, colorado, united states urological research network, hialeah, florida, united states tampa general hospital, tampa, florida, united states emory university - winship cancer institute, atlanta, georgia, united states northwestern university, chicago, illinois, united states simmons cancer institute, springfield, illinois, united states university of kansas, westwood, kansas, united states university of kentucky, lexington, kentucky, united states lcmc health, metairie, louisiana, united states regional urology, shreveport, louisiana, united states mi medicine, ann arbor, michigan, united states university of missouri, columbia, missouri, united states albany medical college, albany, new york, united states montefiore medical center, bronx, new york, united states nyu langone health, new york, new york, united states strong memorial hospital university of rochester, rochester, new york, united states great lakes physician pc d/b/a western new york urology associates, sanborn, new york, united states levine cancer institute, charlotte, north carolina, united states the urology group, cincinnati, ohio, united states the ohio state university- james cancer hospital, columbus, ohio, united states oregon health & science university, portland, oregon, united states midlantic urology, bala-cynwyd, pennsylvania, united states lancaster urology, lancaster, pennsylvania, united states university of pittsburgh medical center - cancer centers, pittsburgh, pennsylvania, united states urology associates, nashville, tennessee, united states ut southwestern medical center, dallas, texas, united states university of washington, seattle, washington, united states william s. middleton memorial va, madison, wisconsin, united states medical college of wisconsin-froedtert hospital, milwaukee, wisconsin, united states hospital sirio libanes, buenos aires, argentina hospital britanico de buenos aires, buenos aires, argentina cemic saavedra, ciudad autonoma de buenos aires, argentina hospital italiano de buenos aires, ciudad autonoma de, argentina cemaic - centro privado de especialidades medicas ambulatorias e investigacion clinica, cordoba, argentina centro urologico profesor bengio, cordoba, argentina hospital privado de cordoba, cordoba, argentina flinders medical centre, bedford park, australia st. vincent's hospital sydney, darlinghurst, australia macquarie university, macquarie university, australia peter maccallum cancer centre, melbourne, australia newcastle private hospital, new lambton heights, australia icon cancer care, south brisbane, australia sydney adventist hospital, wahroonga, australia princess alexandra hospital, woolloongabba, australia cliniques universitaires saint luc, brussel, belgium az maria middelares, gent, belgium uz leuven, leuven, belgium chu sart-tilman, liege, belgium algemeen ziekenhuis delta, roeselare, belgium hospital erasto gaertner, curitiba, brazil oncocentro ceará, fortaleza, brazil hospital araújo jorge da associação de combate ao câncer em goiás, goiânia, brazil liga norte riograndense contra o cancer, natal, brazil irmandade da santa casa de misericordia de porto alegre, porto alegre, brazil hospital nossa senhora da conceicao, porto alegre, brazil instituto de medicina integral professor fernando figueira, recife, brazil hospital das clinicas da faculdade de medicina da usp de ribeirao preto, ribeirão preto, brazil centro de tratamento de tumores botafogo - cttb, rio de janeiro, brazil instituto coi de pesquisa, educacao e gestao, rio de janeiro, brazil faculdade de medicina do abc, santo andré, brazil instituto do cancer do estado de sao paulo icesp, sao paulo, brazil hospital do servidor publico estadual, sao paulo, brazil hospital sirio libanes, são paulo, brazil nanjing drum tower hospital, nanjing, china fudan university shanghai cancer center, shanghai, china renji hospital, shanghai jiaotong university school of medicine, shanghai, china tongji hospital, tongji medical college of huazhong university of science and technology, wuhan, china fakultni nemocnice u sv. anny v brne, brno, czechia krajská nemocnice liberec, liberec, czechia urologicka klinika fnol, olomouc, czechia vseobecna fakultni nemocnice v praze, praha 2, czechia fakultni nemocnice v motole, praha 5, czechia hôpital pellegrin chu bordeaux, bordeaux, france chu gabriel-montpied, clermont ferrand, france hopital huriez, lille, france hôpital edouard herriot, lyon cedex 03, france institut paoli calmettes, marseille cedex 9, france hôpital universitaire pitié-salpêtrière, paris, france groupe hospitalier diaconesses croix saint simon, paris, france hopital bichat claude bernard, paris, france chu de poitiers, poitiers, france chu rennes - hopital pontchaillou, rennes cedex, france hopital charles nicolle, rouen, france chp saint gregoire, saint gregoire, france institut universitaire du cancer toulouse oncopole, toulouse, france centre hospitalier universitaire de nancy - hôpital central, vandœuvre-lès-nancy cedex, france gustave roussy, villejuif cedex, france gfo kliniken rhein berg, bergisch-gladbach, germany urologicum duisburg, duisburg, germany praxis dr. med. stefan carl, emmendingen, germany klinikum herne - urologie, herne, germany universitätsklinikum schleswig holstein campus lübeck, lubeck, germany klinikum rechts der isar - iii. med. klinik und poliklinik, muenchen, germany universitaetsklinikum muenster, muenster, germany praxisklinik urologie rhein/ruhr - germany, mülheim an der ruhr, germany mvz urologie 24 ggmbh, nuernberg, germany studienpraxis urologie drs. feyerabend, nuertingen, germany curos - uberörtliche urologische gemeinschaftspraxis, wesseling, germany health care global enterprises pvt ltd, bangalore, india s.p.medical college &amp; ag of hospitals, bikaner, india rajiv gandhi cancer institute & research centre, delhi, india health care global enterprises, jaipur, india tata medical center, kolkata, india king george's medical university, lucknow, india meenakshi mission hospital and research center, madhurai, india tata memorial hospital, mumbai, india muljibhai patel urological hospital, nadiad, india cimet's inamdar multispeciality hospital, pune, india generale regionale f. miulli, acquaviva delle fonti, italy ospedale regionale umberto parini, aosta, italy fondazione istituto g. giglio, cefalu, italy ospedale civile di guastalla, guastalla, italy azienda ospedaliera ''vito fazzi'', lecce, italy uoc oncologia ospedale provinciale di macerata, macerata, italy fondazione irccs istituto nazionale dei tumori, milano, italy irccs ospedale san raffaele, milan, italy humanitas centro catanese di oncologia, misterbianco/catania, italy fondazione g. pascale - istituto nazionale tumori irccs, napoli, italy azienda ospedaliera sant andrea, roma, italy azienda ospedaliera universitaria integrata verona, verona, italy juntendo university hospital, bunkyo-ku, japan tokyo medical and dental university hospital, bunkyo-ku, japan asahi general hospital, chiba, japan hakodate goryokaku hospital, hakodate, japan saitama medical university international medical center, hidaka, japan hitachi general hospital, hitachi, japan st.marianna university hospital, kanagawa, japan nagoya university hospital, nagoya, japan johas osaka rosai hospital, osaka, japan gunma prefectural cancer center, ota, japan osaka medical and pharmaceutical university hospital, takatsuki, japan toranomon hospital, tokyo, japan the cancer institute hospital of jfcr, tokyo, japan fujita health university hospital, toyoake, japan university of tsukuba hospital, tsukuba-city, japan yokohama city university medical center, yokohama, japan pusan national university hospital, busan, korea, republic of chungbuk national university hospital, cheongju, korea, republic of kyungpook national university chilgok hospital, daegu, korea, republic of national cancer center, goyang-si, korea, republic of chonnam national university hwasun hospital, jeollanam-do, korea, republic of korea university medical center (kumc) - korea university anam hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of kangbuk samsung hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of samsung medical center, seoul, korea, republic of uniwersyteckie centrum kliniczne, gdańsk, poland pratia mcm krakow, krakow, poland wojewodzkie wielospecjalistyczne centrum onkologii i traumatologii im. m. kopernika w lodzi, lodz, poland crc sp. z o.o., poznan, poland kliniczny szpital wojewodzki nr 1 w rzeszowie, rzeszow, poland samodzielny publiczny szpital kliniczny nr 2 pum, szczecin, poland city clinic sp. z o.o., warszawa, poland medical concierge centrum medyczne, warszawa, poland uniwersytecki szpital kliniczny, wroclaw, poland dolnoslaskie centrum onkologii, wroclaw, poland fundacion puigvert, barcelona, spain hosp. clinic i provincial de barcelona, barcelona, spain hosp. univ. ramon y cajal, madrid, spain hosp. univ. 12 de octubre, madrid, spain hosp. univ. la paz, madrid, spain corporacio sanitari parc tauli, sabadell, spain hosp. univ. marques de valdecilla, santander, spain instituto valenciano de oncologia, valencia, spain kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan national taiwan university hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan chang gung memorial hospital- linkou, taoyuan county, taiwan royal surrey county hospital nhs trust, guildford, united kingdom university college london hospitals, london, united kingdom the christie nhs foundation trust - christie hospital, manchester, united kingdom south tees hospital nhs foundation trust-the james cook university hospital, middlesborough, united kingdom universirty of sheffield teaching hospitals nhs trust, sheffield, united kingdom lister hospital, stevenage, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04172675,bladder
308,309,NCT01239732,a study of the addition of avastin (bevacizumab) to carboplatin and paclitaxel therapy in patients with ovarian cancer,,Completed,Has Results,ovarian cancer,drug: paclitaxel|drug: bevacizumab|drug: carboplatin,percentage of participants with at least one adverse event (ae)|progression-free survival (pfs)|percentage of participants achieving best overall response of complete response (cr) or partial response (pr) according to recist version 1.0|percentage of participants achieving an overall response by 50% carcinoma antigen 125 (ca-125) response criteria|percentage of participants achieving an overall response by recist version 1.0 and/or 50% ca-125 response criteria|duration of objective response (dor)|overall survival (os)|biological progression-free interval,hoffmann-la roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,1021.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO22923|2010-019525-34,December 2010,March 2015,March 2015,"November 11, 2010","June 10, 2016","June 10, 2016","['buenos aires, argentina buenos aires, argentina buenos aires, argentina rosario, argentina tucuman, argentina graz, austria graz, austria innsbruck, austria ried-innkreis, austria salzburg, austria steyr, austria villach, austria wien, austria wien, austria salvador, ba, brazil fortaleza, ce, brazil goiania, go, brazil curitiba, pr, brazil rio de janeiro, rj, brazil porto alegre, rs, brazil porto alegre, rs, brazil piracicaba, sp, brazil sao paulo, sp, brazil sao paulo, sp, brazil sao paulo, sp, brazil sao paulo, sp, brazil sofia, bulgaria varna, bulgaria veliko tarnovo, bulgaria calgary, alberta, canada ottawa, ontario, canada toronto, ontario, canada montreal, quebec, canada quebec, canada aalborg, denmark roskilde, denmark vejle, denmark cairo, egypt tanta, egypt tallinn, estonia tallinn, estonia tartu, estonia amiens, france bordeaux, france brest, france caen, france clermont ferrand, france grenoble, france lille, france lyon, france marseille, france mougins, france paris, france paris, france paris, france paris, france paris, france paris, france reims cedex, france strasbourg, france toulouse, france villejuif, france athens, greece athens, greece athens, greece heraklion, crete, greece larissa, greece patras, greece thessaloniki, greece hong kong, hong kong hong kong, hong kong budapest, hungary budapest, hungary debrecen, hungary pecs, hungary szeged, hungary bangalore, india bangalore, india hyderabad, india jaipur, india kochi, india new delhi, india pune, india dublin, ireland afula, israel beer sheva, israel haifa, israel haifa, israel holon, israel jerusalem, israel jerusalem, israel kfar saba, israel petach tikva, israel ramat gan, israel rehovot, israel tel aviv, israel napoli, campania, italy bologna, emilia-romagna, italy meldola, emilia-romagna, italy roma, lazio, italy roma, lazio, italy genova, liguria, italy brescia, lombardia, italy milano, lombardia, italy milano, lombardia, italy monza, lombardia, italy saronno, lombardia, italy novara, piemonte, italy torino, piemonte, italy torino, piemonte, italy palermo, sicilia, italy firenze, toscana, italy pisa, toscana, italy perugia, umbria, italy terni, umbria, italy shuwaikh, kuwait daugavpils, latvia riga, latvia riga, latvia kaunas, lithuania klaipeda, lithuania vilnius, lithuania bitola, macedonia, the former yugoslav republic of skopje, macedonia, the former yugoslav republic of distrito federal, mexico oaxaca, mexico toluca, mexico alkmaar, netherlands amsterdam, netherlands apeldoorn, netherlands blaricum, netherlands breda, netherlands capelle a/d ijssel, netherlands den haag, netherlands den haag, netherlands deventer, netherlands dordrecht, netherlands eindhoven, netherlands leidschendam, netherlands rotterdam, netherlands sittard-geleen, netherlands utrecht, netherlands bydgoszcz, poland warszawa, poland porto, portugal bucuresti, romania cluj napoca, romania iasi, romania barnaul, russian federation moscow, russian federation obninsk, kaluzhskaya region, russian federation saint-petersburg, russian federation stavropol, russian federation ufa, russian federation dammam, saudi arabia belgrade, serbia nis, serbia bratislava, slovakia kosice, slovakia ljubljana, slovenia maribor, slovenia durban, south africa johannesburg, south africa sandton, south africa elda, alicante, spain oviedo, asturias, spain llerena (badajoz), badajoz, spain manresa, barcelona, spain cádiz, cadiz, spain jerez de la frontera, cadiz, spain san sebastian de los reyes, guipuzcoa, spain san sebastian, guipuzcoa, spain palma de mallorca, islas baleares, spain palma de mallorca, islas baleares, spain santiago de compostela, la coruña, spain las palmas de gran canaria, las palmas, spain leganes, madrid, spain reus, tarragona, spain la laguna, tenerife, spain santa cruz de tenerife, tenerife, spain san juan, valencia, spain barakaldo, vizcaya, spain bilbao, vizcaya, spain albacete, spain alicante, spain badajoz, spain barcelona, spain barcelona, spain barcelona, spain barcelona, spain burgos, spain caceres, spain castellon, spain ciudad real, spain cordoba, spain girona, spain granada, spain guadalajara, spain jaen, spain la coruña, spain lugo, spain madrid, spain madrid, spain madrid, spain madrid, spain madrid, spain madrid, spain madrid, spain malaga, spain malaga, spain navarra, spain salamanca, spain segovia, spain sevilla, spain sevilla, spain toledo, spain valencia, spain valencia, spain valencia, spain valencia, spain valladolid, spain zaragoza, spain eskilstuna, sweden falun, sweden karlstad, sweden umeå, sweden uppsala, sweden örebro, sweden aarau, switzerland baden, switzerland bellinzona, switzerland bern, switzerland genève 14, switzerland zürich, switzerland taipei city, taiwan taipei city, taiwan taoyuan hsien, taiwan ankara, turkey ankara, turkey diyarbakir, turkey istanbul, turkey montevideo, uruguay']",,https://ClinicalTrials.gov/show/NCT01239732,ovari
309,310,NCT00678392,axitinib (ag 013736) as second line therapy for metastatic renal cell cancer,,Completed,Has Results,kidney neoplasms,drug: axitinib (ag-013736)|drug: sorafenib,progression-free survival (pfs)|overall survival (os)|objective response rate (orr)|duration of response (dr)|percentage of participants with treatment-emergent adverse events (aes) and serious adverse events (saes)|percentage of participants with adverse events (aes) by severity|percentage of participants with treatment-related adverse events (aes) and serious adverse events (saes)|number of participants with clinically significant laboratory abnormalities: hematology|number of participants with clinically significant laboratory abnormalities: biochemistry|number of participants with clinically significant laboratory abnormalities: urinalysis|functional assessment of cancer therapy kidney symptom index-15 (fksi-15) score|functional assessment of cancer therapy kidney symptom index-disease related symptoms (fksi-drs) score|euro quality of life questionnaire- 5 dimension (eq-5d): health state profile utility score|euro quality of life questionnaire- 5 dimension (eq-5d): visual analog scale (vas),pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,723.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A4061032|AXIS TRIAL|2008-001451-21|AXIS,"September 3, 2008","August 31, 2010","February 25, 2016","May 15, 2008","March 27, 2012","January 9, 2019","['east valley hematology and oncology medical group, burbank, california, united states maurice berkowtiz, md, burbank, california, united states agajanian institute of oncology and hematology, downey, california, united states los angeles hematology/oncology medical group, glendale, california, united states los angeles hematology/oncology medical group, los angeles, california, united states lac-usc medical center, los angeles, california, united states usc norris cancer hospital and clinics, los angeles, california, united states kenmar research institute, los angeles, california, united states metropolitan hematology/oncology medical group, los angeles, california, united states ronald regan ucla medical center, los angeles, california, united states ucla, los angeles, california, united states agajanian institute of oncology and hematology, montebello, california, united states brian leberthon, md, a medical corporation, west covina, california, united states agajanian institute of oncology and hematology, whittier, california, united states rocky mountain cancer centers, aurora, colorado, united states university of colorado cancer center, aurora, colorado, united states university of colorado denver: division of medical oncology, aurora, colorado, united states rocky mountain cancer centers, boulder, colorado, united states rocky mountain cancer centers, colorado springs, colorado, united states rocky mountain cancer centers, llp, denver, colorado, united states rocky mountain cancer centers, denver, colorado, united states rocky mountain cancer centers, lakewood, colorado, united states rocky mountain cancer centers, littleton, colorado, united states rocky mountain cancer centers, lone tree, colorado, united states rocky mountain cancer centers, longmont, colorado, united states rocky mountain cancer centers, parker, colorado, united states rocky mountain cancer centers, thornton, colorado, united states georgetown university hospital, lombardi cancer center, washington, district of columbia, united states georgetown university medical center, washington, district of columbia, united states florida cancer specialists, bonita springs, florida, united states florida cancer specialists, bradenton, florida, united states florida cancer specialists, cape coral, florida, united states florida cancer specialists, cape coral, florida, united states university of miami sylvester at deerfield beach, deerfield beach, florida, united states florida cancer specialists, englewood, florida, united states florida cancer specialists, fort myers, florida, united states florida cancer specialists, fort myers, florida, united states florida cancer specialists, fort myers, florida, united states florida cancer specialists, fort myers, florida, united states university of miami hospital and clinics, miami, florida, united states florida cancer specialists, naples, florida, united states florida cancer specialists, naples, florida, united states m.d. anderson cancer center orlando, orlando, florida, united states orlando regional medical center, orlando, florida, united states florida cancer specialists, port charlotte, florida, united states florida cancer specialists, sarasota, florida, united states florida cancer specialists, sarasota, florida, united states florida cancer specialists, venice, florida, united states florida cancer specialists, venice, florida, united states peachtree hematology-oncology consultants, p.c., atlanta, georgia, united states chattanooga oncology and hematology associates, pc, ringgold, georgia, united states mountain states tumor institute, boise, idaho, united states mountain states tumor institute, fruitland, idaho, united states mountain states tumor institute, meridian, idaho, united states mountain states tumor institute, nampa, idaho, united states mountain states tumor institute, twin falls, idaho, united states loyola university chicago cardinal bernardin cancer center, maywood, illinois, united states cental indiana cancer centers, carmel, indiana, united states central indiana cancer centers, fishers, indiana, united states cental indiana cancer centers, greenfield, indiana, united states central indiana cancer centers, indianapolis, indiana, united states central indiana cancer centers, indianapolis, indiana, united states massachusetts general hospital, boston, massachusetts, united states beth israel deaconess medical center, boston, massachusetts, united states university of michigan health system, ann arbor, michigan, united states karmanos cancer institute, detroit, michigan, united states weisberg cancer treatment center, farmington hills, michigan, united states university of minnesota medical center fairview, minneapolis, minnesota, united states missouri cancer associates, columbia, missouri, united states st. john\'s mercy medical center, saint louis, missouri, united states st. john\'s mercy, david c. pratt cancer center, saint louis, missouri, united states st. john\'s mercy medical center, washington, missouri, united states comprehensive cancer centers of nevada, henderson, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states nevada cancer institute, las vegas, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states hackensack university medical center, hackensack, new jersey, united states the cancer center at hackensack university medical center - the hillcrest building, hackensack, new jersey, united states the cancer center at hackensack university medical center, hackensack, new jersey, united states montefiore medical center, bronx, new york, united states memorial sloan kettering cancer center - sidney kimmel center, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states department of medicine msg @ suny hsc @ syrcacuse, inc., oneida, new york, united states department of medicine msg @ suny hsc @ syracuse, inc., oswego, new york, united states suny upstate medical university, syracuse, new york, united states department of medicine msg @ suny hsc @ syracuse, inc, syracuse, new york, united states raleigh hematology oncology associates, dba, cary, north carolina, united states duke university medical center, durham, north carolina, united states investigational chemotherapy services, durham, north carolina, united states albermarie hospitals, elizabeth city, north carolina, united states virginia oncology associates, elizabeth city, north carolina, united states raleigh hematology oncology associates, p.c., raleigh, north carolina, united states case western reserve university, cleveland, ohio, united states cleveland clinic foundation, cleveland, ohio, united states ohio state university arthur g. james cancer hospital and richard j. solove research institute, columbus, ohio, united states ohio state university, columbus, ohio, united states james care in kenny, columbus, ohio, united states monarch, mayfield heights, ohio, united states lake university - ireland cancer center (luicc), mentor, ohio, united states uhhs - chagrin highlands, orange village, ohio, united states uhhs - westlake, westlake, ohio, united states oncology associates of oregon, p.c., eugene, oregon, united states willamette valley cancer institute and research center, springfield, oregon, united states penn state milton s. hershey medical center, hershey, pennsylvania, united states fox chase cancer center, philadelphia, pennsylvania, united states medical university of south carolina, charleston, south carolina, united states cancer centers of the carolinas, easley, south carolina, united states cancer centers of the carolinas, greenville, south carolina, united states hematology and oncology associates of sc, llc - eastside medical center, greenville, south carolina, united states cancer centers of the carolinas, seneca, seneca, south carolina, united states cancer centers of the carolinas, spartanburg, south carolina, united states chattanooga oncology and hematology associates, pc, chattanooga, tennessee, united states chattanooga oncology hematology associates p.c., chattanooga, tennessee, united states tennessee oncology, pllc, franklin, tennessee, united states vanderbilt-ingram cancer center-cool springs, franklin, tennessee, united states tennessee oncology, pllc, gallatin, tennessee, united states tennessee oncology, pllc, hermitage, tennessee, united states chattanooga oncology & hematology associates, hixson, tennessee, united states tennessee oncology, pllc, lebanon, tennessee, united states tennessee oncology, pllc, murfreesboro, tennessee, united states sarah cannon research institute, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states vanderbilt-ingram cancer center, nashville, tennessee, united states vanderbilt university medical center, nashville, tennessee, united states tennessee oncology, pllc, smyrna, tennessee, united states texas oncology - austin midtown, austin, texas, united states texas oncology - central midtown, austin, texas, united states texas oncology - austin central, austin, texas, united states texas oncology - south austin, austin, texas, united states texas oncolgoy - austin north, austin, texas, united states texas oncology - austin northwest, austin, texas, united states texas oncology, p.a., bedford, texas, united states texas oncology - cedar park, cedar park, texas, united states texas oncology - baylor charles a. sammons cancer center, dallas, texas, united states investigation products center (ipc), fort worth, texas, united states investigational products center (ipc), fort worth, texas, united states us oncology research and clinical pharmacy, fort worth, texas, united states genitourinary cancer center, houston, texas, united states the university of texas md anderson cancer center, houston, texas, united states texas oncology - seton williamson, round rock, texas, united states texas oncology - round rock, round rock, texas, united states texas oncology, p.a., tyler, texas, united states deke slayton cancer center, webster, texas, united states texas oncology - clear lake, webster, texas, united states virginia cancer specialists, pc, arlington, virginia, united states virginia oncology associates, chesapeake, virginia, united states virginia cancer specialists, pc, fairfax, virginia, united states virginia cancer specialists, pc, gainesville, virginia, united states virginia oncology associates, hampton, virginia, united states virginia cancer specialists, pc, leesburg, virginia, united states virginia oncology associates, newport news, virginia, united states virginia oncology associates, norfolk, virginia, united states virginia oncology associates, virginia beach, virginia, united states virginia cancer specialists, pc, woodbridge, virginia, united states virginia mason medical center, section of hematology/oncology, seattle, washington, united states seattle cancer care alliance, seattle, washington, united states university of washington medical center, seattle, washington, united states the canberra hospital, medical oncology, garran, australian capital territory, australia ashford cancer centre research, kurralta park, south australia, australia ballarat oncology & haematology services, ballarat, victoria, australia peter maccallum cancer centre, east melbourne, victoria, australia heidelberg repatriation hospital, austin health, heidelberg west, victoria, australia austin hospital, austin health, heidelberg, victoria, australia med. abt. kh barmherzige brueder wien, krankenhaus der barmherzigen brueder wien, wien, austria universitaets-klinik fuer innere medizin i, wien, austria clinica oncologistas associados, rio de janeiro, rj, brazil irmandade da santa casa de misericordia de porto alegre (iscmpa) - hospital santa rita, porto alegre, rs, brazil fundacao pio xii hospital de cancer de barretos, barretos, sp, brazil fundacao antonio prudente, sao paulo, sp, brazil tom baker cancer centre, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada british columbia cancer agency - cancer centre for the southern interior, kelowna, british columbia, canada dr. leon richard oncology centre, moncton, new brunswick, canada dr. h. bliss murphy cancer centre, st. john\'s, newfoundland and labrador, canada rsm durham regional cancer centre lakeridge health oshawa, oshawa, ontario, canada cancer institute and hospital, chinese academy of medical sciences, beijing, chaoyang district, china the department of medical oncology, pla cancer center, nanjing bayi hospital, nanjing, jiangsu, china beijing cancer hospital, beijing, p.r., china xijing hospital, the fourth military medical university, xi\'an, shaanxi, china sun yet-sen university cancer center, guangzhou, china urology department, renji hospital,shanghai jiao tong university school of medicine, shanghai, china tianjin oncology hospital,biology treatment department, tianjin, china centre leon berard, lyon, cedex 08, france hopital saint-andré, bordeaux cedex, france hôpital henri mondor, creteil cedex, france institut paoli-calmettes, marseille cedex 09, france hopital europeen georges pompidou, paris cedex 15, france centre eugene marquis, rennes, france centre rene gauducheau - service oncologie medicale, st herblain cedex, france chru de tours - hopital bretonneau, tours cedex 1, france centre alexis vautrin, vandoeuvre les nancy, france institut gustave roussy / service d\'immunotherapie, villejuif cedex, france rwth aachen, urologische klinik, aachen, germany charite - universitaetsmedizin berlin, campus benjamin franklin, berlin, germany innere klinik und poliklinik fuer tumorforschung, universitaetsklinikum essen, essen, germany klinikum region hannover krankenhaus siloah, hannover, germany klinikum der johannes-gutenberg-universitaet, iii. medizinische klinik und poliklinik, mainz, germany ludwig-maximilians-universitaet muenchen, klinikum grosshadern urologische klinik und poliklinik, muenchen, germany klinikum oldenburg ggmbh, klinik fuer innere medizin ii onkologie / haematologie, oldenburg, germany alexandra university hospital / oncology dept., athens, attiki, greece ""theagenio""cancer hospital / 3rd. dept. of clinical oncology, thessaloniki, macedonia, greece fortis memorial research institute, gurgaon, haryana, india amrita institute of medical sciences, kochi, kerala, india dept. of medical oncology, tata memorial hospital, mumbai, maharashtra, india christian medical college & hospital, ludhiana, punjab, india bhagwan mahaveer cancer hospital and research center, jaipur, rajasthan, india oncology department, dublin 24, ireland uoc oncologia medica, ospedale san donato, arezzo, italy centro di riferimento oncologico, istituto nazionale tumori, irccs, aviano (pn), italy dipartimento dei laboratori diagnositici e per le terapie cellulari, aviano (pn), italy azienda ospedaliera spedali civili di brescia, unita\' operativa oncologia medica, brescia, italy struttura complessa di oncologia, cremona, italy uoc oncologia medica b, irccs ao universitaria san martino, genova, italy fondazione irccs, istituto nazionale dei tumori, sc oncologia medica 2, milano, italy divisione di oncologia, aorn antonio cardarelli, napoli, italy istituto per lo studio e la cura dei tumori fondazione pascale, napoli, italy unita\' operativa oncologia medica 2, regione del veneto, padova, italy irccs policlinico san matteo, pavia, italy struttura complessa di oncologia medica a, roma, italy azienda ospedaliera san camillo forlanini, oncologia medica, padiglione flajani, i piano, roma, italy uo di oncologia ed ematologia, istituto clinico humanitas, rozzano (mi), italy sapporo medical university school of medicine, sapporo-shi, hokkaido, japan hokkaido university hospital, sapporo, hokkaido, japan university of tsukuba, graduate school of comprehensive human sciences, department of urology, tsukuba, ibaraki, japan kinki university hospital, osakasayama, osaka, japan hamamatsu university school of medicine, hamamatsu-city, shizuoka, japan shizuoka cancer center, sunto-gun, shizuoka, japan tokyo women\'s medical university medical center east, department of urology, arakawa-ku, tokyo, japan national cancer center hospital, chuo-ku, tokyo, japan nihon university itabashi hospital, itabashi-ku, tokyo, japan keio university hospital, shinjuku-ku, tokyo, japan tokyo women\'s medical university hospital, shinjuku-ku, tokyo, japan yamaguchi university hospital, ube-shi, yamaguchi, japan akita university hospital, akita, japan chiba cancer center, chiba, japan kyushu university hospital, fukuoka, japan kumamoto university hospital, kumamoto, japan tokushima university, tokushima, japan yamagata university hospital, yamagata, japan national cancer center, urologic oncology clinic, center for specific organs cancer, goyang-si, gyeonggi-do, korea, republic of dong-a university medical center, department of medicine, division of hemato-oncology, busan, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of catholic university of korea, seoul st. mary\'s hospital, department of oncology, seoul, korea, republic of centrum medyczne hcp, poznan, wielkopolska, poland wielkopolskie centrum onkologii im.marii sklodowskiej-curie, poznan, wielkopolska, poland wojewodzkie centrum onkologii, gdansk, poland klinika onkologii, szpital kliniczny przemienienia panskiego uniwersytetu medycznego, poznan, poland pracownia tomografii komputerowej, poznan, poland klinika onkologii, wojskowy instytut medyczny, warszawa, poland klinika urologii i onkologii urologicznej, wroclaw, poland medical radiology research center of the minzdravsotsrazvitiya of russia, obninsk, kaluga region, russian federation cancer research center named after n.n. blokhin, biotherapy department, moscow, russian federation cancer research center named after n.n.blokhin, chemotherapy department, moscow, russian federation russian research center of roentgenology and radiology, moscow, russian federation the main clinical hospital of the ministry of internal affairs of russian federation, moscow, russian federation moscow research institute of oncology p.a. herzen, moscow, russian federation city clinical oncology dispensary, st. petersburg, russian federation national cancer centre singapore, singapore, singapore onkologicky ustav sv. alzbety, bratislava, slovakia narodny onkologicky ustav, bratislava, slovakia nemocnica s poliklinikou zilina, zilina, slovakia institut catala d\'oncologia l\'hospitalet, l\'hospitalet de llobregat, barcelona, spain clinica universitaria de navarra, pamplona, navarra, spain hospital de navarra, pamplona, navarra, spain hospital vall d¿hebron, barcelona, spain hospital universitario ramon y cajal, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital clinico universitario virgen de la victoria, malaga, spain hospital universitario virgen macarena, sevilla, spain hospital universitario miguel servet, zaragoza, spain universitetssjukhuset, onkologiska kliniken, linkoping, sweden norrlands universitetssjukhus, onkologkliniken, umea, sweden onkologkliniken, vaxjo, sweden chang gung medical foundation-kaohsiung branch, kaohsiung hsien, taiwan taichung veterans general hospital, department of surgery, taichung, taiwan department of oncology, national taiwan university hospital, taipei, taiwan chang gung medical foundation-linkou branch, taoyuan, taiwan royal marsden hospital, london, england, united kingdom mount vernon cancer centre, northwood, middlesex, united kingdom clatterbridge centre for oncology nhs foundation trust, bebington, wirral, united kingdom university of birmingham, cruk institute for cancer studies, birmingham, united kingdom royal bournemouth & poole hospitals, bournemouth, united kingdom bristol haematology and oncology centre, bristol, united kingdom addenbrooke\'s hospital, cambridge, united kingdom the beatson west of scotland cancer centre, glasgow, united kingdom department of medical oncology, st. bartholomew\'s hospital, london, united kingdom university department of medical oncology/oxford cancer centre, oxford, united kingdom royal marsden hospital nhs foundation trust, surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00678392,kidney
310,311,NCT02546908,a registry of participants with prostate cancer in asia,,Completed,No Results Available,prostatic neoplasms,other: no intervention,"overall survival (os)|prostate cancer (pc)-related mortality (pm)|metastasis-free survival (mfs)|progression-free survival (pfs)|time to prostate-specific antigen (psa) progression (ttpp)|european quality of life-5 dimensions, 5 levels (eq-5d-5l) score|functional assessment of cancer therapy for prostate cancer (fact-p) score","janssen research & development, llc",Male,"21 Years and older   (Adult, Older Adult)",,3644.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CR107351|NOPRODPCR4001,"September 9, 2015","September 1, 2020","September 1, 2020","September 11, 2015",,"September 22, 2020","['beijing, china guangzhou, china hangzhou, china shanghai, china shenyang, china sichuan, china su zhou, china wuhan, china bangalore, india delhi, india mumbai, india new delhi, india chiba, japan hirosaki, japan ikoma, japan kobe, japan koshigaya, japan matsuyama, japan osaka-sayama, japan suita, japan seoul, korea, republic of kuala lumpur n/a, malaysia kuala lumpur, malaysia kuching, malaysia pulau pinang, malaysia singapore, singapore kaohsiung, taiwan tainan, taiwan taipei, taiwan bangkok, thailand chiang mai, thailand songkla, thailand']",,https://ClinicalTrials.gov/show/NCT02546908,prostat
311,312,NCT00707304,safety and efficacy of talactoferrin in previously treated patients with non-small cell lung cancer,FORTIS-M,Completed,No Results Available,non small cell lung cancer,drug: talactoferrin|drug: placebo,overall survival|progression free survival|objective response and disease stablization rate|safety and tolerability,agennix,All,"18 Years and older   (Adult, Older Adult)",Phase 3,742.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LF-0207,November 2008,March 2011,August 2012,"June 30, 2008",,"August 21, 2012","['desert oasis cancer center, casa grande, arizona, united states arizona oncology associates, tucson, arizona, united states university of colorado hospital, aurora, colorado, united states pasco pinellas cancer center, new port richey, florida, united states emory university, atlanta, georgia, united states rush university medical center, chicago, illinois, united states cancer care specialists of central illinois, decatur, illinois, united states cancer care & hematology specialists of chicagoland, niles, illinois, united states central indiana cancer centers, greenfield, indiana, united states kansas city cancer center, llc, overland park, kansas, united states nci, ccr, the waren grant magnuson clinical center, bethesda, maryland, united states newland medical associates, southfield, michigan, united states minnesota oncology and hematology, pa, minneapolis, minnesota, united states washington university school of medicine, st. louis, missouri, united states southeast nebraska cancer center, lincoln, nebraska, united states nh oncology-hematology, pa, hooksett, new hampshire, united states montefiore medical center, bronx, new york, united states university of rochester medical center, rochester, new york, united states alamance regional medical center, burlington, north carolina, united states duke university medical center, durham, north carolina, united states rex cancer center, raleigh, north carolina, united states legacy pharma research, bismarck, north dakota, united states signal point clinical research center, middletown, ohio, united states kaiser group health, portland, oregon, united states texas oncology, dallas, texas, united states texas oncology, fort worth, texas, united states tyler cancer center, tyler, texas, united states oncology & hematology associates of southwest virginia, inc., dba blue ridge cancer care, salem, virginia, united states cancer care northwest, spokane, washington, united states campbelltown hospital, campbelltown, new south wales, australia port macquarie base hospital, port macquarie, new south wales, australia townsville hospital, townsville, queensland, australia the queen elisabeth hospital, woodville south, south australia, australia epworth healthcare, richmond, victoria, australia ddodiu-plovdiv, eood, aleksandur stamboliyski, plovdiv, bulgaria umhat \'dr. georgi stranski\', ead, pleven, bulgaria ddodiu-plovdiv, eood, plovdiv, bulgaria ddodiu - sofia district eood, sofia, bulgaria umhat \'tsaritsa yoanna - isul\', ead, sofia, bulgaria cross cancer institute, edmonton, alberta, canada mount sinai hospital, toronto, ontario, canada hôtel-dieu de lévis, lévis, quebec, canada gerald bronfman centre for clinical research in oncology, montreal, quebec, canada fakultni nemocnice na bulovce, budinova, praha, czech republic institut onkologie a rehabilitace na plesi, nova ves pod plesi, czech republic vitkovicka nemocnice a.s., ostrava, czech republic fakultni nemocnice ostrava, ostrava, czech republic pardubicka krajska nemocnice, a.s., pardubice, czech republic fakultni nemocnice kralovske vinohrady, praha, czech republic fakultni nemocnice v motole, s.p., praha, czech republic oblastni nemocnice pribram, a.s., pribram, czech republic nemocnice tabor, a.s., tabor, czech republic hopital cardiologique, chru lille, lille, cedex, france chu pontchaillou, rennes, cedex, france crlcc rené gauducheau, saint-herblain, cedex, france clcc paul strauss, strasbourg, cedex, france hopital larrey, toulouse, cedex, france centre catherine de sienne, eric tabarly, nantes, france chu angers, angers cedex, france hopital morvan, brest, france centre francois baclesse, caen cedex, france centre d\'oncology de gentilly, cedex, france centre hospitalier du mans, le mans cedex, france centre léon berard, lyon, france hopital sainte marguerite, marseille cedex 9, france hôpital saint-antoine, paris, france centre hospitalier lyon sud, pierre bénite cedex, france hopital maison blanche, reims, france chu de nancy, hopital de brabois, vandoeuvre les nancy, france praxis fuer interdisziplinaere onkologie, freiburg, bw, germany universitaetsklinikum mannheim, mannheim, bw, germany universitaetsklinikum erlangen - ps, erlangen, by, germany asklepios fachkliniken muenchen-gauting, gauting, by, germany klinikum rechts der isar der tu muenchen, muenchen, by, germany gemeinschaftspraxis fuer haematologie onkologie, wiesbaden, he, germany universitaetsklinikum goettingen, goettingen, ni, germany st. johannes hospital - ps, dortmund, nw, germany krankenhaus grosshansdorf, woehrendamm, sh, germany staedt. krankenhaus martha-maria halle-doelau ggmbh, halle, st, germany zentralklinik bad berka, bad berka, th, germany thoraxklinik-heidelberg ggmbh, heidelberg, germany general hospital of chania \'ag. georgios\', mournies, crete, greece university hospital of larissa, mezourlo, larissa, greece university general hospital of patras, rion, patras, greece general hospital of athens ""sotiria"", athens, greece university hospital of heraklio, crete, greece general hospital of thessaloniki ""g. papanikolaou"", thessaloniki, greece miskolc megyei jogu varos onkormanyzat miskolci egeszsegugyi, csabai kapu, miskolc, hungary fejer megyei szent gyorgy korhaz, seregelyesi, szekesfehervar, hungary semmelweis egyetem, budapest, hungary orszagos koranyi tbc es pulmonologiai intezet, budapest, hungary borsod-abauj-zemplen megyei korhaz es egyetemi oktato korhaz, miskolc, hungary szabolcs-szatmar bereg megyei josa andras oktato korhaz, nyiregyháza, hungary torokbalinti tudogyogyintezet, torokbalint, hungary zala megyei korhaz, zalaegerszeg, hungary king george hospital, vishakhapattanam, andhhra pradesh, india apollo hospital, hyderabad, andhra pradesh, india indo-american cancer institute and research center, hyderabad, andhra pradesh, india kidwai institute of oncology, bangalore, karnataka, india m. s. ramaiah memorial hospital, bangalore, karnataka, india a.j. medical college hosptial, mangalore, karnataka, india tata memorial hospital, mumbai, maharashtra, india p.d. hinduja nat. hospital & med. research centre, mumbai, maharashtra, india kaushalya medical foundation trust hospital, mumbai, maharashtra, india cancer care clinic, nagpur, maharashtra, india shatabdi hospital, nashik, maharashtra, india deenanath mangeshkar hospital and research center, pune, maharashtra, india searoc cancer hospital, jaipur, rajasthan, india mahaveer cancer hospital and research centre, jaipur, rajasthan, india dr. kamakshi memorial hospital pvt ltd, chennai, tamilnadu, india christian medical college hospital, vellore, tamilnadu, india azienda ospedaliero universitaria ospedali riuniti umberto i, ancona, an, italy istituto per la ricerca e la cura del cancro, candiolo, candiolo/to, italy ospedale versilia, lido di camaiore, lu, italy istituto nazionale tumori, milano, mi, italy azienda ospedaliera san gerardo, monza, mi, italy azienda ospedaliera san camillo forlanini, roma,, rm, italy ospedale mater salutis, legnago, vr, italy cro centro di riferimento oncologico di aviano, aviano, italy azienda ospedaliera istituti ospitalieri di cremona, cremona, italy chonnam national university hwasun hospital, hwasun up, chonnam, korea, republic of national cancer center, ilsandong-gu, goyang, korea, republic of seoul national university bundang hospital, seongnam-si, gyeonggi-do,, korea, republic of samsung medical center, gangnam-gu, seoul, korea, republic of seoul national university hospital, jongno-gu, seoul, korea, republic of korea university anam hospital, seongbuk-gu, seoul, korea, republic of asan medical center, songpa-gu, seoul, korea, republic of the catholic university of korea st. vincent\'s hospital, paldal-gu, suwon gyeonggi-do, korea, republic of dr. anna levcenko gp and internist practice, daugavpils, latvia piejuras hospital, liepaja, latvia riga eastern clinical university hospital, riga, latvia p. stradina clinical university hospital, riga, latvia nilai cancer institute (nci cancer hospital), negeri sembilan, darul khusus, malaysia lam wah ee hospital, pulau pinang, georgetown,, malaysia hospital universiti sains malaysia, kubang kerian, kelantan, malaysia hospital tengku ampuan afzan, kuantan, pahang, malaysia manila doctors hospital, manila, philippines lung center of the philippines, quezon city, philippines st. luke\'s medical center, quezon city, philippines akademickie centrum kliniczne - szpital am w gdansku, gdansk, poland nzoz vesalius, krakow, poland miedziowe centrum zdrowia s.a., lubin, poland nzoz olsztynski osr. onkologiczny ""kopernik"" sp.z o.o, olsztyn, poland specjalistyczny szpital im. prof. a. sokolowskiego, szczecin, poland centrum onkologii-instytut im. m. sklodowskiej curie, warszawa, poland institutul oncologic ""prof. dr. ion chiricuta"" cluj-napoca, str. republicii nr. 34-36, cluj-napoca, romania spitalul judetean de urgenta ""dr. constantin opris"", baia mare, romania spitalul judetean de urgenta braila, braila, romania s.c. ianuli med consult s.r.l., bucuresti, romania institutul oncologic ""prof. dr. ion chiricuta"" cluj-napoca, cluj-napoca, romania spitalul judetean de urgenta ""sf. ioan cel nou"" suceava, suceava, romania oncology dispensary #2 of krasnodar region, dagomysskaya str., sochi, russian federation arkhangelsk regional clinical oncology dispensary, arkhangelsk, russian federation shi altay regional oncology dispensary, barnaul, russian federation cch #2 n.a. n. a. semashko of llc ""russian railways"", moscow, russian federation city clinical hospital #1, novosibirsk, russian federation perm territorial oncology dispensary, perm, russian federation seihpe ""saint petersburg smu roszdrav n.a. i.i.pavlov"", st. petersburg, russian federation national cancer centre, hospital drive, singapore parkway cancer centre, mount elizabeth, singapore medical oncology centre, napier road, singapore john hopkins singapore international medical centre, singapore, singapore h mutua de terrassa, barcelona, spain hu virgen de las nieves, granada, spain fundacion jimenez diaz, madrid, spain hgu la paz, madrid, spain clinica universitaria de navarra, pamplona, spain changhua christian hospital, changhua, taiwan kaohsiung veterans general hospital, kaohsiung,, taiwan taichung veterans general hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan taipei veterans general hospital, taipei, taiwan chang-gung memorial hospital, linkou branch, toayuan, taiwan gazi university medical faculty, ankara, turkey gaziantep university medical faculty, gaziantep, turkey istanbul bilim university medical fac., istanbul, turkey ege university medical faculty, izmir, turkey bristol haematology & oncology centre, bristol, brist, united kingdom guy\'s & st thomas\' nhs foundation trust, london, gt lon, united kingdom christie hospital, manchester, gt man, united kingdom southampton general hospital, southampton, hants, united kingdom castle hill hospital, cottingham hull, hull, united kingdom university hospital of south manchester nhs foundation trust wythenshawe hospital, wythenshawe, manchester, united kingdom singleton hospital, swansea,, s glam,, united kingdom university hospital of north staffordshire, stoke on trent, staffs, united kingdom wolverhampton new cross hospital, wolverhampton, staffs, united kingdom beatson west of scotland cancer centre, glasgow, strath, united kingdom ninewells hospital, dundee, tays, united kingdom university hospital of coventry and warwickshire, coventry, warwks, united kingdom']",,https://ClinicalTrials.gov/show/NCT00707304,
312,313,NCT02477124,a see and treat paradigm for cervical pre-cancer,,Terminated,No Results Available,cervical pre-cancer,device: transvaginal digital colposcope (tvdc)|other: standard of care screening,"concordance of the tvdc to standard of care, as measured by weighted kappa statistic",duke university,Female,"25 Years and older   (Adult, Older Adult)",Not Applicable,514.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Pro00052865,September 2015,March 2020,March 2020,"June 22, 2015",,"January 26, 2022","['duke university medical center, durham, north carolina, united states aiims, new delhi, india la liga contra el cancer, lima, peru kilimanjaro christian medical centre, moshi, tanzania university teaching hospital, lusaka, zambia']",,https://ClinicalTrials.gov/show/NCT02477124,cervic
313,314,NCT01041404,toga study - a study of herceptin (trastuzumab) in combination with chemotherapy compared with chemotherapy alone in patients with her2-positive advanced gastric cancer,,Completed,Has Results,gastric cancer,drug: trastuzumab|drug: fluorouracil|drug: cisplatin|drug: capecitabine,overall survival (os) - percentage of participants with an event|overall survival - time to event|progression-free survival (pfs) - percentage of participants with an event|progression-free survival - time to event|time to progression (ttp) - percentage of participants with an event|time to progression - time to event|percentage of participants with confirmed complete response (cr) or partial response (pr) determined by response evaluation criteria in solid tumors (recist)|duration of response - percentage of participants with an event|duration of response|percentage of participants with clinical benefit|european organisation for the research and treatment of cancer (eortc) quality of life questionnaire-core 30 (qlq c-30) questionnaire scores|eortc quality of life questionnaire-stomach cancer specific (qlq sto22) questionnaire scores|pain intensity scores as assessed by visual analog scale (vas)|percentage of participants with a change in analgesic medication during the study|body weight (kilograms [kg]) at bl|percentage of participants with change from baseline in body weight by percentage change in weight|steady state trastuzumab area under the concentration (auc)|trastuzumab minimum serum concentration (cmin)|trastuzumab maximum serum concentration (cmax),hoffmann-la roche|chugai pharmaceutical,All,"18 Years and older   (Adult, Older Adult)",Phase 3,584.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO18255,September 2005,June 2010,June 2010,"December 31, 2009","November 5, 2014","November 5, 2014","['adelaide, australia kurralta park, australia melbourne, australia milton, australia perth, australia sydney, australia leuven, belgium barretos, brazil rio de janeiro, brazil sao paulo, brazil sao paulo, brazil beijing, china beijing, china beijing, china beijing, china guangdong, china guangzhou, china jiangsu, china nanjing, china shanghai, china shanghai, china shanghai, china shanghai, china shanghai, china shanghai, china suzhou, china wuhan, china san jose, costa rica san josé, costa rica herlev, denmark odense, denmark tampere, finland brest, france caen, france colmar, france lille, france marseille, france reims, france rouen, france strasbourg, france heidelberg, germany mainz, germany münchen, germany trier, germany witten, germany guatemala city, guatemala hyderabad, india kochi, india mumbai, india new delhi, india ancona, italy firenze, italy napoli, italy parma, italy roma, italy udine, italy aichi, japan chiba, japan ehime, japan fukuoka, japan hyogo, japan nagano, japan osaka, japan osaka, japan saitama, japan saitama, japan shizuoka, japan tochigi, japan tokyo, japan tokyo, japan tokyo, japan yamagata, japan buchun, korea, republic of bundang city, korea, republic of daegu, korea, republic of goyang-si, korea, republic of pusan, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of guadalajara, mexico merida, mexico mexico city, mexico mexico city, mexico monterrey, mexico panama city, panama callao, peru lima, peru lima, peru braga, portugal coimbra, portugal faro, portugal guimaraes, portugal lisboa, portugal lisboa, portugal porto, portugal porto, portugal porto, portugal chelyabinsk, russian federation ekaterinburg, russian federation ivanovo, russian federation kazan, russian federation moscow, russian federation moscow, russian federation moscow, russian federation moscow, russian federation ryazan, russian federation samara, russian federation st petersburg, russian federation st petersburg, russian federation st petersburg, russian federation ufa, russian federation yaroslavl, russian federation cape town, south africa cape town, south africa durban, south africa barcelona, spain barcelona, spain barcelona, spain girona, spain madrid, spain valencia, spain valencia, spain changhua, taiwan kaohsiung, taiwan taipei, taiwan istanbul, turkey istanbul, turkey izmir, turkey izmir, turkey shhiye, ankara, turkey birmingham, united kingdom denbigh, united kingdom dundee, united kingdom glasgow, united kingdom manchester, united kingdom weston super mare, united kingdom wirral, united kingdom wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01041404,gastric
314,315,NCT03521154,a global study to assess the effects of osimertinib following chemoradiation in patients with stage iii unresectable non-small cell lung cancer (laura),LAURA,"Active, not recruiting",No Results Available,non small cell lung cancer (stage iii),drug: osimertinib 80mg/40mg|drug: placebo osimertinib 80mg/40mg,progression-free survival (pfs)|pfs in patients with egfr ex19del or l858r mutation|pfs in patients with egfr mutations ex19del or l858r detectable in plasma-derived ctdna|time to cns pfs|overall survival (os)|objective response rate (orr)|duration of response (dor)|disease control rate (dcr)|tumor shrinkage|time to death or distant metastases (ttdm)|time to treatment discontinuation|second progression free survival on a subsequent treatment (pfs2)|time to first subsequent therapy (tfst)|time to second subsequent therapy (tsst)|patients reported disease-related symptoms and hrqol by eortc qlq-lc13 and eortc qlq-30 questionnaires|incidence of adverse events (aes)|plasma concentrations of osimertinib and azd5104,astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,197.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D5160C00048,"July 19, 2018","January 31, 2023","June 29, 2026","May 11, 2018",,"May 16, 2022","['research site, duarte, california, united states research site, atlanta, georgia, united states research site, florham park, new jersey, united states research site, salt lake city, utah, united states research site, madison, wisconsin, united states research site, ciudad autónoma de bs. as., argentina research site, ciudad autónoma de bs. as., argentina research site, mar del plata, argentina research site, rosario, argentina research site, san salvador de jujuy, argentina research site, barretos, brazil research site, campinas, brazil research site, curitiba, brazil research site, florianópolis, brazil research site, fortaleza, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, guangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, jinan, china research site, linhai, china research site, nanjing, china research site, shanghai, china research site, shanghai, china research site, urumqi, china research site, wuhan, china research site, wuhan, china research site, budapest, hungary research site, budapest, hungary research site, gyöngyös - mátraháza, hungary research site, pécs, hungary research site, bangalore, india research site, gurgaon, india research site, hubli, india research site, karamsad, india research site, kolkata, india research site, nasik, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, hiroshima-shi, japan research site, kanazawa-shi, japan research site, kashiwa, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, nishinomiya-shi, japan research site, osaka-shi, japan research site, osakasayama, japan research site, sakai-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shinjuku-ku, japan research site, sunto-gun, japan research site, yokohama-shi, japan research site, cheongju-si, korea, republic of research site, incheon, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, george town, malaysia research site, kuala lumpur, malaysia research site, selangor, malaysia research site, mérida, mexico research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, san isidro, peru research site, kazan, russian federation research site, kostroma, russian federation research site, moscow, russian federation research site, novisibirsk, russian federation research site, obninsk, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, ufa, russian federation research site, barcelona, spain research site, madrid, spain research site, madrid, spain research site, málaga, spain research site, san sebastián, spain research site, sevilla, spain research site, valencia, spain research site, kaohsiung, taiwan research site, taichung city, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, lampang, thailand research site, mueang, thailand research site, adana, turkey research site, adapazari, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, hanoi city, vietnam research site, hanoi, vietnam research site, hcmc, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT03521154,
315,316,NCT00430781,pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer,,Completed,Has Results,"neoplasms, uterine cervix|metastatic cervical cancer",drug: pazopanib (gw786034)|drug: lapatinib (gw572016),"progression-free survival (pfs) in interim analysis|progression-free survival (pfs) in final analysis|overall survival|clinical benefit response|response|time to response|duration of response|safety and tolerability of pazopanib, lapatinib and the combination of pazopanib and lapatinib",glaxosmithkline,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,228.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VEG105281,November 2006,July 2008,July 2011,"February 2, 2007","March 14, 2011","May 8, 2015","['gsk investigational site, los angeles, california, united states gsk investigational site, orange, california, united states gsk investigational site, stanford, california, united states gsk investigational site, augusta, georgia, united states gsk investigational site, boston, massachusetts, united states gsk investigational site, albuquerque, new mexico, united states gsk investigational site, new york, new york, united states gsk investigational site, cleveland, ohio, united states gsk investigational site, columbus, ohio, united states gsk investigational site, oklahoma city, oklahoma, united states gsk investigational site, chattanooga, tennessee, united states gsk investigational site, dallas, texas, united states gsk investigational site, capital federal, buenos aires, argentina gsk investigational site, ciudad autonoma de buenos aires, buenos aires, argentina gsk investigational site, neuquen, neuquén, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, tucuman, tucumán., argentina gsk investigational site, quilmes, argentina gsk investigational site, santa fe, argentina gsk investigational site, brussel, belgium gsk investigational site, bruxelles, belgium gsk investigational site, gent, belgium gsk investigational site, leuven, belgium gsk investigational site, roeselare, belgium gsk investigational site, calgary, alberta, canada gsk investigational site, vancouver, british columbia, canada gsk investigational site, hamilton, ontario, canada gsk investigational site, toronto, ontario, canada gsk investigational site, montréal, quebec, canada gsk investigational site, tallinn, estonia gsk investigational site, tartu, estonia gsk investigational site, bordeaux, france gsk investigational site, caen cedex, france gsk investigational site, lille cedex, france gsk investigational site, marseille cedex 09, france gsk investigational site, strasbourg, france gsk investigational site, villejuif, france gsk investigational site, muenchen, bayern, germany gsk investigational site, saarbruecken, saarland, germany gsk investigational site, halle, sachsen-anhalt, germany gsk investigational site, magdeburg, sachsen-anhalt, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, ahemdabad, india gsk investigational site, mangalore, india gsk investigational site, new delhi, india gsk investigational site, trivandrum, india gsk investigational site, cork, ireland gsk investigational site, dublin, ireland gsk investigational site, napoli, campania, italy gsk investigational site, milano, lombardia, italy gsk investigational site, campobasso, molise, italy gsk investigational site, bari, puglia, italy gsk investigational site, mexico city, mexico gsk investigational site, barcelona, spain gsk investigational site, barcelona, spain gsk investigational site, la laguna (santa cruz de tenerife), spain gsk investigational site, madrid, spain gsk investigational site, marid, spain gsk investigational site, pamplona, spain gsk investigational site, bangkok, thailand gsk investigational site, chiang mai, thailand gsk investigational site, khon kaen, thailand']",,https://ClinicalTrials.gov/show/NCT00430781,cervic cervix fibroid
316,317,NCT03098030,dinutuximab and irinotecan versus irinotecan to treat subjects with relapsed or refractory small cell lung cancer,,Completed,Has Results,small cell lung cancer,biological: dinutuximab|drug: irinotecan|drug: topotecan,overall survival (os)|progression-free survival (pfs)|objective response rate (orr)|clinical benefit rate (cbr),united therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,483.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIV-SCLC-301,"June 1, 2017","January 27, 2020","March 26, 2020","March 31, 2017","December 9, 2020","December 9, 2020","['alaska clinical research center, anchorage, alaska, united states cancer treatment centers of america - western regional medical center, goodyear, arizona, united states innovative clinical research institute, tucson, arizona, united states genesis cancer center, hot springs, arkansas, united states usc norris comprehensive cancer center, los angeles, california, united states va palo alto health care system, palo alto, california, united states olive view - ucla, sylmar, california, united states innovative clinical research institute, whittier, california, united states hartford hospital, hartford, connecticut, united states eastern connecticut hematology and oncology assoc, norwich, connecticut, united states alpha oncology research llc, debary, florida, united states 21st century oncology, jacksonville, florida, united states comprehensive hematology oncology, saint petersburg, florida, united states winship cancer institute, emory university, atlanta, georgia, united states northwest georgia oncology centers, p.c., marietta, georgia, united states baptist health floyd cancer center, new albany, indiana, united states physicians\' clinic of iowa hematology and oncology, cedar rapids, iowa, united states kentucky cancer clinic, hazard, kentucky, united states university of kentucky, lexington, kentucky, united states 21st century oncology, louisville, kentucky, united states cox health medical, springfield, missouri, united states billings clinic cancer center, billings, montana, united states st. vincent frontier cancer center, billings, montana, united states the university of new mexico comprehensive cancer center, albuquerque, new mexico, united states uh cleveland medical center, cleveland, ohio, united states cancer treatment centers of america at southwestern rmc, tulsa, oklahoma, united states kaiser permanente northwest center for health research crss, portland, oregon, united states fox chase cancer center office of clinical research, philadelphia, pennsylvania, united states cancer treatment centers of america at eastern regional medical center, philadelphia, pennsylvania, united states charleston oncology, charleston, south carolina, united states spartanburg medical center/gibbs cancer center and research institute, spartanburg, south carolina, united states prairie lakes health care, watertown, south dakota, united states center for biomedical research, knoxville, tennessee, united states texas health physicians group, arlington, texas, united states plano cancer institute, plano, texas, united states the university of texas health science center at tyler, office of clinical studies, tyler, texas, united states vista oncology (shelton office), shelton, washington, united states united hospital center, bridgeport, west virginia, united states camden clark medical center / regional cancer center, parkersburg, west virginia, united states university of wisoncsin - carbone cancer ctr, madison, wisconsin, united states mid north coast cancer institute coff habour health campus, coffs harbour, new south wales, australia mater misericordiae limited and mater medical research institute limited, south brisbane, queensland, australia royal adelaide hospital, adelaide, south australia, australia ballarat health services, ballarat, victoria, australia medical oncology department, specialized hospital for active treatment of oncology sveti mina eood - blagoevgrad, blagoevgrad, bulgaria department of medical oncology, complex oncology center - burgas eood, burgas, burgas, bulgaria medical oncology department, multiprofile hospital for active treatment - dobrich ad, dobrich, dobrich, bulgaria medical oncology department, multiprofile hospital for active treatment - dr. tota venkova ad, gabrovo, gabrovo, bulgaria medical oncology department, multiprofile hospital for active treatment - uni hospital ood, panagiurishte, panagyurishte, bulgaria clinic of oncology, umhat dr. georgi stranski - pleven, pleven, bulgaria clinic of oncology, umhat pulmed, plovdiv, bulgaria first department of medical oncology, gastroenterology and pulmology, complex oncology center - plovdiv eood, plovdiv, bulgaria first department for medical oncology, multiprofile hospital for active treatement serdika eood, sofia, sofia, bulgaria medical oncology clinic, multiprofile hospital for active treatment (mhat) for female\'s health - nadezhda ood, sofia, sofia, bulgaria medical oncology department, university multiprofile hospital for active treatment sv. ivan rilski ead, sofia, sofia, bulgaria clinic for chemotherapy, specialized hospital for active treatment in oncology ead, sofia, sofia, bulgaria clinic of oncology, umhat sofiamed, sofia, bulgaria clinic of oncology, mhat sveta marina, varna, bulgaria cross cancer institute - clinical trials unit, edmonton, alberta, canada horizon health network - the moncton hosoital, moncton, new brunswick, canada princess margaret cancer centre, toronto, ontario, canada windsor regional hospital cancer program, windsor, ontario, canada mcgill university health center, montréal, quebec, canada l\'institut universitaire de cardiologie et de pneumologie de quebec, québec, quebec, canada hopital nord, marseille, alpes-côte d\'azur, france institut regional du cancer de montpellier, montpellier, occitanie, france institut de cancérologie de l\'ouest - centre paul papin, angers, pays de la loire, france clinique victor hugo, le mans, pays de la loire, france urcot : unité de recherche commune en oncologie thoracique service de pneumologie de l\'hôpital de la croix-rousse, bron, rhône-alpes, france urcot : unité de recherche commune en oncologie thoracique service de pneumologie de l\'hôpital de la croix-rousse, lyon, rhône-alpes, france service de pneumologie aiguë et cancérologie thoracique centre hospitalier lyon-sud, pierre bénite, rhône-alpes, france chu brest, brest, france centre françois baclesse, caen, france chi créteil, créteil, france institut paoli-calmettes, service dòncologie médicale, marseille, france institut de cancérologie de l\'ouest - centre rené gauducheau, saint-herblain, france centre paul strauss, strasbourg, france nouvel hôpital civil de strasbourg, strasbourg, france ltd high technology hospital medcenter, batumi, georgia ltd \'\'accad. f. todua medical center-research institute of clinical medicine\'\', tbilisi, georgia high technology medical center, university clinic, tbilisi, georgia institute of clinical oncology, tbilisi, georgia multiprofile clinic consillium medulla, tbilisi, georgia princess margaret hospital, kowloon, hong kong queen elizabeth hospital, kowloon, hong kong queen mary hospital, pokfulam, hong kong hetenyi geza hospital, szolnok, jasz-nagykun-szolnok, hungary koranyi national institute of pulmonology - horváth, budapest, hungary koranyi national institute of tbc and pulmonology, budapest, hungary korányi national institute, budapest, hungary semmelweis egyetem aok pulmonologiai klinika, budapest, hungary veszprém megyei tüdőgyógyintézet, farkasgyepű, hungary matrai gyogyintezet, matrahaza, hungary borsod-abaúj-zemplén megyei központi kórház és egyetemi oktatókórház, semmelweis tagkórház, tüdőgyógyászati osztály, miskolc, hungary komarom-esztergom megyei onkorm. szent borbala korhaza, tatabanya, hungary tudogyogyintezet torokbalint, torokbalint, hungary zala megyei szent rafael korhaz, zalaegerszeg, hungary sri venkateshwara hospitals, bangalore, karnataka, india kles dr prabhakar kore hospital & mrc, nehru nagar, karnataka, india jaslok hospital & research center, mumbai, maharashtra, india deenanath mangeshkar hospital, pune, maharashtra, india grant medical foundation ruby hall clinic, pune, maharashtra, india birla cancer centre, sms hospital, jaipur, rajasthan, india healthcare global (hcg) towers, bangalore, india bhagawan mahaveer cancer hospital, jaipur, india dipartimento di oncologia, arnas garibaldi, catania, italy istituto nazionale dei tumori, milan, italy istituto europeo di oncologia (ieo), milano, milan, italy ospedale santa maria della misericordia, perugia, perugia, italy radiation oncology, campus bio-medico university, rome, italy division of medical oncology and immunotherapy, department of oncology, university hospital of siena, siena, italy a.o.u. san luigi gonzaga, orbassano (torino), torino, italy kosin university gospel hospital, busan, korea, republic of chungbuk national university hospital, chungcheongbuk-do, korea, republic of kyungpook national university medical center, daegu, korea, republic of kyungpook university chilgok hospital, daegu, korea, republic of keimyung university dongsan medical centre, daegu, korea, republic of chungnam national university hospital, daejeon, korea, republic of cha bundang medical center, gyeonggi-do, korea, republic of seoul national university bundang hospital, gyeonggi-do, korea, republic of pusan national university yangsan hospital, gyeongsangnam-do, korea, republic of inha university hospital, incheon, korea, republic of chonnam national university hwasun hospital, jeonnam, korea, republic of gachon universtiy gil medical center, namdong, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university boramae medical center, seoul, korea, republic of ulsan university hospital, ulsan, korea, republic of wonju severance christian hospital, wonju-si, gangwon-do, korea, republic of hospital of lithuanian university of health sciences (lsmu) kauno klinikos, kaunas, lithuania national cancer institute, vilnius, lithuania vilnius university hospital santaros klinikos, vilnius, lithuania hospital kuala lumpur, kuala lumpur, malaysia department of medicine, faculty of medicine, kuala lumpur, malaysia hospital umum sarawak, kuching, malaysia national cancer institute, putrajaya, malaysia cebu doctors university hospital, cebu city, philippines davao doctors hospital, davao city, philippines manila doctors hospital, manila, philippines st. luke\'s medical center - quezon city, quezon city, philippines st. luke\'s medical centre, quezon city, philippines szpital specjalistyczny w prabutach sp. z o.o, prabuty, pomeranian voivodeship, poland samodzielny publiczny zespół gruźlicy i chorób płuc w olsztynie, olsztyn, warminsko-mazurskie, poland samodzielny specjalistyczny zespółzakładów opieki zdrowotnej im. dr. teodora dunina, mrozy, poland mazowieckie centrum leczenia chorob pluc i gruzlicy, otwock, poland szpital chorób płuc im św. józefa w pilchowicach, pilchowice, poland wielkopolskie centrum pulmonologii i torakochirurgii im. eugenii i janusza zeylandów, poznań, poland centrum onkologii-instytut im. sklodowskiej-curie, warszawa, poland wojskowy instytut medyczny, warszawa, poland centrum terapii wspolczesnej j.m. jasnorzewska sp. komandytowo-akcyjna, łódź, łódź voivodeship, poland oncopremium team ltd, baia-mare, romania institute of oncology prof. dr. i.chiricuta cluj-napoca, cluj-napoca, romania medisprof ltd, cluj-napoca, romania sc oncolab ltd, craiova, romania sc oncology center sf. nectarie ltd, craiova, romania emergency county hospital satu-mare, medical oncology clinic, satu-mare, romania emergency hospital ,sf. ioan cel nou\', suceava, romania oncocenter oncology clinic ltd, timisoara, romania state budgetary healthcare institution of arkhangelsk region arkhangelsk clinical oncology dispensary, arkhangelsk, russian federation state budgetary healthcare institution of sverdlovsk region, sverdlovsk regional oncology dispensary, ekaterinburg, russian federation region budgetary healthcare institution, kursk regional clinical oncology dispensary of healthcare committee of kursk region, kursk, russian federation federal state budgetary institution, natiоnal medical research center of oncology n.a. n.n. blokhin of ministry of healthcare of the russian federation, moscow, russian federation state budgetary healthcare institution of moscow, moscow city oncology hospital #62 of moscow healthcare department, moscow, russian federation state budgetary healthcare institution of arkhangelsk region ""arkhangelsk clinical oncology dispensary"", moscow, russian federation state budgetary healthcare institution of novosibirsk region, сity clinical hospital #1, novosibirsk, russian federation state budgetary healthcare institution of novosibirsk region, novosibirsk regional oncology dispensary, novosibirsk, russian federation budgetary healthcare institution of omsk region, clinical oncology dispensary, omsk, russian federation state budgetary healthcare institution, orenburg regional clinical oncology dispensary, orenburg, russian federation center of palliative care-devita llc, saint petersburg, russian federation state budgetary healthcare institution, leningrad regional clinical hospital, saint-petersburg, russian federation bioeq, llc, saint-petersburg, russian federation federal state budgetary institution, scientific research institute of oncology n.a. petrov, saint-petersburg, russian federation state budgetary healthcare institution, saint-petersburg clinical scientific practical center of specialized kinds of medical care (oncological), saint-petersburg, russian federation saint-petersburg state budgetary healthcare institution, city clinical oncology dispensary, saint-petersburg, russian federation state budgetary healthcare institution, samara regional clinical oncology dispensary, samara, russian federation state budgetary healthcare institution of yaroslavl region, regional oncology hospital, yaroslavl, russian federation st. jacob´s hospital bardejov - department of clinical oncology, bardejov, slovakia faculty hospital zilina, žilina, slovakia hospital general universitario de elche, elche, alicante, spain hospital universitario marqués de valdecilla, santander, cantabria, spain chu a coruña, coruña, galicia, spain hospital universitario puerta de hierro, majadahonda, madrid, spain complejo hospitalario de navarra, pamplona, navarra, spain hospital general de alicante, alicante, spain hospital quirón dexeus, barcelona, spain hospital universitari vall d´hebron, barcelona, spain hospital universitario reina sofia, córdoba, spain instituto catalán de oncología (ico) - josep trueta, girona, spain hospital universitario lucus augusti, lugo, spain hospital general universitário gregorio marañón, madrid, spain hospital universitario la paz, madrid, spain hospital universitario madrid norte sanchinarro, madrid, spain h. m. puerta del sur (h. móstoles), madrid, spain hospital regional de málaga (h. carlos haya), málaga, spain complexo hospitalario universitario de ourense (chuo), ourense, spain hospital virgen de los lirios alcoy, planta, spain corporació sanitària parc taulí, sabadell, spain hospital universitario virgen de valme, sevilla, spain hospital universitario y politécnico de la fe, valencia, spain hospital álvaro cunqueiro, vigo, spain hospital lozano blesa, zaragoza, spain e-da hospital, kaohsiung city, taiwan e-da hospital, kaohsiung city, taiwan kaohsiung chang gung memorial hospital, kaohsiung city, taiwan chung shan medical university hospital, taichung city, taiwan chi mei hospital, liouying, tainan city, taiwan chang-gung memorial hospital, linkou, taoyuan city, taiwan king chulalongkorn memorial hospital, bangkok, thailand national cancer institute of thailand, bangkok, thailand siriraj hopsital, bangkok, thailand maharaj nakorn chiang mai hospital, chiang mai, thailand srinagarind hospital, khon kaen, thailand naresuan university hospital, phitsanulok, thailand songklanagarind hospital, songkhla, thailand municipal non-profit enterprise ""city clinical hospital #4"" of dnipro city council,"" municipal institution ""multifield dnipropetrovsk city hospital #4"" of dnipropetrovsk regional council, department of chemotherapy, dnipro, dnipropetrovsk, ukraine municipal nonprofit institution ""cental municipal clinical hospital"" of uzhgorod city council, municipal oncology centre, uzhgorod, zakarpattia, ukraine regional communal nonprofit enterprise, municipal institution chernivtsi regional clinical oncology dispensary, surgery department, state higher educational establishment of ukraine, bukovinian state medical university, department of onc and radiology, chernivtsi, ukraine communal non-profit enterprise ""kyiv city clinical oncology center"" of executive body of kyiv city council, kyiv city clinical oncology center by main department of health protection kyiv, hospital of day stay for oncology patients, kiev, ukraine municipal nonprofit institution ""odessa regional oncology dispensary"" of odessa regional council, municipal institution odesa regional oncology dispensary, hospital of day stay (unit of dispensary-polyclinic department), odessa, ukraine municipal nonprofit institution ""podilsky regional oncology center"" of vinnytsa city council, podilsky regional oncology сenter, department of chemotherapy, vinnitsya, ukraine princess alexandra hospital, harlow, essex, united kingdom royal marsden hospital, chelsea, london, united kingdom st james\' institute of oncology, leeds, united kingdom st bartholomew\'s hospital, london, united kingdom royal free hospital, london, united kingdom guy\'s and st thomas\' nhs foundation trust, london, united kingdom royal marsden hospital, sutton, united kingdom']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/30/nct03098030/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/30/nct03098030/prot_001.pdf",https://ClinicalTrials.gov/show/NCT03098030,
317,318,NCT04269200,durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer,DUO-E,Recruiting,No Results Available,endometrial neoplasms,drug: olaparib|biological: durvalumab|drug: durvalumab placebo|drug: olaparib placebo|drug: carboplatin|drug: paclitaxel,progression free survival (pfs) for arm b vs arm a|progression free survival (pfs) for arm c vs arm a|second progression (pfs2)|overall survival (os)|objective response rate (orr)|duration of response (dor)|time to first subsequent therapy (tfst)|time to second subsequent therapy (tsst)|time to discontinuation or death (tdt)|the pharmacokinetics (pk) of durvalumab will be determined after steady state doses|safety and tolerability of drugs by assessment of aes/saes|the immunogenicity of durvalumab as determined by concentration of anti-drug antibodies (ada) to durvalumab,astrazeneca|the gynecologic oncology group (gog) foundation inc|the european network for gynaecological oncological trial groups (engot),Female,"18 Years to 150 Years   (Adult, Older Adult)",Phase 3,699.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D9311C00001|2019-004112-60|GOG-3041|ENGOT-EN10,"May 21, 2020","September 26, 2023","March 5, 2025","February 13, 2020",,"May 13, 2022","[""research site, tucson, arizona, united states research site, concord, california, united states research site, la jolla, california, united states research site, long beach, california, united states research site, san francisco, california, united states research site, santa barbara, california, united states research site, aurora, colorado, united states research site, new haven, connecticut, united states research site, newark, delaware, united states research site, fort lauderdale, florida, united states research site, gainesville, florida, united states research site, tampa, florida, united states research site, savannah, georgia, united states research site, honolulu, hawaii, united states research site, arlington heights, illinois, united states research site, chicago, illinois, united states research site, chicago, illinois, united states research site, hinsdale, illinois, united states research site, indianapolis, indiana, united states research site, ames, iowa, united states research site, louisville, kentucky, united states research site, baton rouge, louisiana, united states research site, scarborough, maine, united states research site, boston, massachusetts, united states research site, saint paul, minnesota, united states research site, jackson, mississippi, united states research site, las vegas, nevada, united states research site, lebanon, new hampshire, united states research site, camden, new jersey, united states research site, paramus, new jersey, united states research site, teaneck, new jersey, united states research site, brooklyn, new york, united states research site, johnson city, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, poughkeepsie, new york, united states research site, pinehurst, north carolina, united states research site, cleveland, ohio, united states research site, cleveland, ohio, united states research site, cleveland, ohio, united states research site, columbus, ohio, united states research site, dayton, ohio, united states research site, oklahoma city, oklahoma, united states research site, tulsa, oklahoma, united states research site, eugene, oregon, united states research site, portland, oregon, united states research site, tigard, oregon, united states research site, pittsburgh, pennsylvania, united states research site, willow grove, pennsylvania, united states research site, providence, rhode island, united states research site, sioux falls, south dakota, united states research site, chattanooga, tennessee, united states research site, germantown, tennessee, united states research site, knoxville, tennessee, united states research site, bedford, texas, united states research site, dallas, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, sugar land, texas, united states research site, tyler, texas, united states research site, webster, texas, united states research site, fairfax, virginia, united states research site, norfolk, virginia, united states research site, seattle, washington, united states research site, morgantown, west virginia, united states research site, madison, wisconsin, united states research site, milwaukee, wisconsin, united states research site, bedford park, australia research site, campbelltown, australia research site, clayton, australia research site, kogarah, australia research site, malvern, australia research site, melbourne, australia research site, nedlands, australia research site, port macquarie, australia research site, sydney, australia research site, bruges, belgium research site, bruxelles, belgium research site, charleroi, belgium research site, gent, belgium research site, hasselt, belgium research site, kortrijk, belgium research site, leuven, belgium research site, libramont-chevigny, belgium research site, liège, belgium research site, belo horizonte, brazil research site, belo horizonte, brazil research site, curitiba, brazil research site, passo fundo, brazil research site, pelotas, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, calgary, alberta, canada research site, moncton, new brunswick, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, chicoutimi, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changchun, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, chengdu, china research site, chongqing, china research site, chongqing, china research site, dalian, china research site, dalian, china research site, guangdong, china research site, guangzhou, china research site, haikou, china research site, harbin, china research site, hefei, china research site, kunming, china research site, nanjing, china research site, nanning, china research site, shanghai, china research site, shenyang, china research site, taiyuan, china research site, tianjin, china research site, wuhan, china research site, wuhan, china research site, zhanjiang, china research site, zhengzhou, china research site, zhengzhou, china research site, zhengzhou, china research site, barranquilla, colombia research site, bogota, colombia research site, bogota, colombia research site, bogota, colombia research site, bogota, colombia research site, cali, colombia research site, cali, colombia research site, medellin, colombia research site, medellín, colombia research site, monteria, colombia research site, pereira, colombia research site, rionegro, colombia research site, tallinn, estonia research site, tartu, estonia research site, berlin, germany research site, berlin, germany research site, bonn, germany research site, chemnitz, germany research site, dresden, germany research site, frankfurt am main, germany research site, karlsruhe, germany research site, konstanz, germany research site, leipzig, germany research site, athens, greece research site, chaidari, greece research site, marousi, greece research site, thessaloniki, greece research site, hkg, hong kong research site, hong kong, hong kong research site, hong kong, hong kong research site, tun mun, hong kong research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, győr, hungary research site, szolnok, hungary research site, bangalore, india research site, bangalore, india research site, hisar, india research site, ludhiana, india research site, mumbai, india research site, mysuru, india research site, nagpur, india research site, nashik, india research site, new delhi, india research site, pune, india research site, be'er ya'akov, israel research site, hadera, israel research site, jerusalem, israel research site, nahariya, israel research site, tel aviv, israel research site, chuo-ku, japan research site, kashiwa-shi, japan research site, koto-ku, japan research site, kurume-shi, japan research site, kyoto-shi, japan research site, matsuyama-shi, japan research site, minato-ku, japan research site, nagoya-shi, japan research site, nakagami-gun, japan research site, niigata-shi, japan research site, osaka-shi, japan research site, osaka, japan research site, sapporo-shi, japan research site, shinjuku-ku, japan research site, sunto-gun, japan research site, toon-shi, japan research site, tsu-shi, japan research site, yokohama-shi, japan research site, goyang-si, korea, republic of research site, gyeongsangnam-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon, korea, republic of research site, kaunas, lithuania research site, vilnius, lithuania research site, vilnius, lithuania research site, aguascalientes, mexico research site, ciudad de mexico, mexico research site, durango, mexico research site, guadalajara, mexico research site, mexico, mexico research site, monterrey, mexico research site, oaxaca, mexico research site, queretaro, mexico research site, san luis potosi, mexico research site, veracruz, mexico research site, gdansk, poland research site, lublin, poland research site, olsztyn, poland research site, olsztyn, poland research site, wroclaw, poland research site, łódź, poland research site, anzorey, russian federation research site, chelyabinsk, russian federation research site, kazan, tatarstan, russian federation research site, krasnodar, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moskva, russian federation research site, saransk, russian federation research site, sochi, russian federation research site, st petersburg, russian federation research site, st. petersburg, russian federation research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, barcelona, spain research site, barcelona, spain research site, el palmar, spain research site, girona, spain research site, jaén, spain research site, madrid, spain research site, madrid, spain research site, mallorca, spain research site, sevilla, spain research site, vigo, spain""]",,https://ClinicalTrials.gov/show/NCT04269200,
318,319,NCT00606502,study of pralatrexate vs. erlotinib for non-small cell lung cancer after at least 1 prior platinum-based treatment,,Completed,Has Results,non-small cell lung cancer,drug: pralatrexate|drug: erlotinib|dietary supplement: vitamin b12|dietary supplement: folic acid,overall survival (os) of patients receiving pralatrexate vs. erlotinib|response rate (rr) to treatment of patients receiving pralatrexate vs. erlotinib|progression-free survival (pfs) of patients receiving pralatrexate vs. erlotinib|adverse events of patients receiving pralatrexate vs. erlotinib,"spectrum pharmaceuticals, inc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,201.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDX-012|2007-004673-26,January 2008,"June 24, 2010","June 24, 2010","February 4, 2008","January 20, 2011","March 5, 2021","['comprehensive blood and cancer center, bakersfield, california, united states sharp memorial hospital, san diego, california, united states hematology oncology associates of the treasure coast, port saint lucie, florida, united states northwestern university feinberg school of medicine, chicago, illinois, united states university of kansas cancer center, westwood, kansas, united states donald berdeaux, great falls, montana, united states summit medical group, berkeley heights, new jersey, united states hematology and oncology associates south jersey, mount holly, new jersey, united states new york oncology hematology-oncology associates, p.c., latham, new york, united states memorial sloan-kettering cancer center, new york, new york, united states new bern cancer care, new bern, north carolina, united states signal point clinical research center, middletown, ohio, united states baptist regional cancer center, knoxville, tennessee, united states cancer therapy and research center, san antonio, texas, united states providence everett medical center, everett, washington, united states instituto medico especializado alexander fleming, buenos aires, cuidad de buenos aires, argentina policlinica privada - instituto de medicina nuclear, bahia blanca, provincia de buenos aires, argentina hospital britanico, capital federal, argentina centro oncologico rosario, rosario, argentina isis clinica especializada, santa fe, argentina caipo (centero para la atencion integral del paciente oncologico), tucuman, argentina associação hospital de caridade de ijuí, ijui, rs, brazil hospital de clínicas de porto alegre, porto alegre, rs, brazil clinionco - clínica de oncologia de porto alegre, porto alegre, rs, brazil fundação pio xii - hospital do câncer de barretos, barretos, sp, brazil biocancer s.a., belo horizonte, brazil instituto do cancer - arnaldo vieira de carvalho, sao paulo, brazil masarykuv onkologicky ustav, brno, czechia palacký university medical school and teaching hospital, olomouc, czechia vitkovicka nemocnice, a. s., ostrava, czechia fakultni nemocnice na bulovce, praha 8, czechia fakultni nemocnice v motole, praha, czechia nemocnice na homolce, praha, czechia national koranyi tbc and pulmonology institute, budapest, pest, hungary jósa andrás teaching hospital, nyiregyhaza, szabolcs-szatmár-bereg, hungary vas county markusovszky hospital, szombathely, vas, hungary zala county hospital, zalaegerszeg, zala, hungary matrai allami gyogyintezet, matrahaza, hungary komarom-esztergom megyei onkorm. szent borbala korhaza, tatabánya, hungary mnj radium hospital and radium institute of oncology and regional cancer centre, hyderabaad, andhra pradesh, india indo american cancer institute and research center, hyderabad, andhra pradesh, india kidwai memorial institute of oncology, bangalore, karnataka, india regional cancer center, trivandrum, kerala, india tata memorial hospital, mumbai, maharashtra, india jehangir clinical development centre pvt ltd, pune, mahara, india b.p. poddar cancer institute, kolkata, west bengal, india dharmashila cancer hospital & research centre, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00606502,
319,320,NCT01168973,a study of chemotherapy and ramucirumab versus chemotherapy alone in second line non-small cell lung cancer (nsclc) participants who received prior first line platinum-based chemotherapy,,Completed,Has Results,non-small cell lung cancer,biological: ramucirumab|drug: placebo (for ramucirumab)|drug: docetaxel,overall survival|progression-free survival (pfs) time|percentage of participants achieving an objective response (objective response rate)|percentage of participants achieving disease control (disease control rate)|maximum improvement on lung cancer symptom scale (lcss)|change from baseline to 30-day follow-up visit on european quality of life questionnaire-5 dimension (eq-5d) health state scores|maximum and minimum serum concentrations (cmax and cmin) of ramucirumab|number of participants with anti-ramucirumab antibodies,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1253.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13852|I4T-MC-JVBA|2010-021297-11|CP12-1027|CTRI/2011/08/001942,December 2010,December 2013,August 2016,"July 23, 2010","December 29, 2014","September 25, 2019","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., phoenix, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sedona, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fayetteville, arkansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., alhambra, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., duarte, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fresno, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fullerton, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., la jolla, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., long beach, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., los angeles, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., northridge, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., redondo beach, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa barbara, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa monica, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., denver, colorado, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., waterbury, connecticut, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jacksonville, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., miami, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ocala, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., orlando, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., augusta, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lawrenceville, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., macon, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., savannah, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., springfield, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bloomington, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cedar rapids, iowa, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., iowa city, iowa, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., overland park, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ashland, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mount sterling, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., baton rouge, louisiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., metairie, louisiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bethesda, maryland, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chevy chase, maryland, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., boston, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., danvers, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., framingham, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., newton, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ann arbor, michigan, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbia, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., joplin, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., billings, montana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., henderson, nevada, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., reno, nevada, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lebanon, new hampshire, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., portsmouth, new hampshire, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., albuquerque, new mexico, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bronx, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., latham, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new york, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., durham, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., raleigh, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fargo, north dakota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbus, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tulsa, oklahoma, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., abington, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kingston, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., philadelphia, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., charleston, south carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sioux falls, south dakota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chattanooga, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., abilene, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., amarillo, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beaumont, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bedford, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dallas, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., el paso, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fort worth, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lewisville, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mcallen, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mesquite, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., midland, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., odessa, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., paris, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san antonio, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san antonio, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sherman, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sugar land, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., the woodlands, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tyler, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., webster, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita falls, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., christiansburg, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fairfax, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., newport news, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., richmond, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lacey, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., spokane, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wenatchee, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madison, wisconsin, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., buenos aires, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., córdoba, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., la rioja, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rosario, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tucumain, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., viedma, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., graz, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., grimmenstein, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vienna, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wels, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barretos, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., belo horizonte, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., goiania, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., porto alegre, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., são paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edmonton, alberta, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., moncton, new brunswick, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sainte-foy, quebec, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., grenoble, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lille, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lyon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nice, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., strasbourg, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toulouse, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vandoeuvre les nancy, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., augsburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bad soden, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bielefeld, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dresden, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankfurt, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gerlingen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., großhansdorf, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., halle, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heidelberg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., immenhausen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oldenburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ulm, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., villingen-schwenningen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chania, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kifissia, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., patras, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., budapest, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gyula, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., matrahaza, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nyiregyhaza, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pécs, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., szekesfehervar, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cuttack, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jaipur, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kochin, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madurai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pune, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., haifa, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jerusalem, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kfar saba, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., petah tikva, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., safed, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tel-aviv, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., livorno, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., monza, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., novara, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., padova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., palermo, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., parma, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pisa, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., incheon, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., suwon-city, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guadalajara, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mexico city, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., amsterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., arnhem, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., harderwijk, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., s-hertogenbosch, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zwolle, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., grafton, new zealand for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wellington, new zealand for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oslo, norway for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tromsø, norway for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gdansk, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gdynia, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., glucholazy, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., krakow, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lodz, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., opole, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., otwock, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poznan, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bayamon, puerto rico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bucharest, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cluj-napoca, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., iasi, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., moscow, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint petersburg, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., stavropol, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barcelona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., girona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., las palmas de gran canaria, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mataró, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pamplona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pozuelo de alarcon, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., eskilstuna, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., linkoping, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lund, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., solna, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., basel, switzerland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bern, switzerland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fribourg, switzerland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., luzern, switzerland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zurich, switzerland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kaohsiung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kuei shan hsiang, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., neihu taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., niao sung hsiang, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taichung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ankara, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., istanbul, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., izmir, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kayseri, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cottingham, east yorkshire, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., london, greater london, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., preston, lancashire, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wythenshawe, manchester, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., scunthorpe, north lincolnshire, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., glasgow, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., coventry, west midlands, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wolverhampton, west midlands, united kingdom']",,https://ClinicalTrials.gov/show/NCT01168973,
320,321,NCT01996241,evaluation of an intervention for adolescent girls in karnataka,Samata,Completed,Has Results,secondary school entry and completion|child marriage,"behavioral: multi-level, structural and norms-based intervention",number of participants completing secondary school [sit 10th standard exam]|number of participants married [by trial end line]|number of participants entering into 8th standard [start secondary school]|number of participants passing 10th standard [pass 10th standard exam]|number of participants having sexual debut [by trial end line]|number of participants married and co-habiting with husband [by trial end line],karnataka health promotion trust|university of manitoba|london school of hygiene and tropical medicine,Female,13 Years to 15 Years   (Child),Not Applicable,2457.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",111/2013,January 2014,"December 31, 2017","December 31, 2017","November 27, 2013","September 25, 2019","October 15, 2019","['bagalkot and bijapur districts, bagalkot, karnataka, india']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/41/nct01996241/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/41/nct01996241/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01996241,
321,322,NCT04742192,"non-interventional, prospective study to determine prevalence of egfr mutations in non-small cell lung cancer",EARLY-EGFR,Recruiting,No Results Available,non-small cell lung cancer,,overall proportion of patients with egfrm|proportion of egfrm in pathologic stage|proportion of patients with the egfrm types|proportion of patients who were prescribed modalities,astrazeneca,All,"18 Years and older   (Adult, Older Adult)",,550.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,D5161R00028,"March 4, 2021","November 30, 2022","November 30, 2022","February 8, 2021",,"May 11, 2022","['research site, buenos aires, argentina research site, rosario - santa fe, argentina research site, santiago de chile, chile research site, santiago de chile, chile research site, bogotá, colombia research site, montería -cordoba, colombia research site, san jose, costa rica research site, santo domingo, dominican republic research site, alexandria, egypt research site, cairo, egypt research site, tanta, egypt research site, kashmir, india research site, kolkata, india research site, mumbai, india research site, mumbai, india research site, new delhi, india research site, new delhi, india research site, kuwait city, kuwait research site, cdmx, mexico research site, guadalajara, mexico research site, monterrey, mexico research site, lima, peru research site, lima, peru research site, cebu city, philippines research site, cebu city, philippines research site, iliolo city, philippines research site, makati, philippines research site, manila, philippines research site, quezon city, philippines research site, quezon city, philippines research site, taguig city, philippines research site, singapore, singapore research site, bangkok, thailand research site, muang, thailand research site, hanoi, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT04742192,
322,323,NCT00538863,long-term safety and efficacy study of fentanyl sublingual spray for the treatment of breakthrough cancer pain,,Completed,Has Results,cancer|pain,drug: fentanyl sublingual spray,percentage of patients that experienced 1 or more adverse events,insys therapeutics inc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,319.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,INS-06-007,December 2007,October 2010,October 2010,"October 3, 2007","October 11, 2013","October 11, 2013","['huntsville, alabama, united states winfield, alabama, united states glendale, arizona, united states scottsdale, arizona, united states laguna hills, california, united states loma linda, california, united states los gatos, california, united states san mateo, california, united states bradenton, florida, united states lake worth, florida, united states miami, florida, united states winter park, florida, united states newnan, georgia, united states chicago, illinois, united states skokie, illinois, united states zion, illinois, united states elkhart, indiana, united states bethesda, maryland, united states southfield, michigan, united states edina, minnesota, united states jefferson city, missouri, united states great falls, montana, united states kalispell, montana, united states missoula, montana, united states voorhees, new jersey, united states flat rock, north carolina, united states winston-salem, north carolina, united states canton, ohio, united states dayton, ohio, united states eugene, oregon, united states altoona, pennsylvania, united states danville, pennsylvania, united states lemoyne, pennsylvania, united states kingsport, tennessee, united states bellaire, texas, united states dallas, texas, united states fort worth, texas, united states port sam houston, texas, united states tacoma, washington, united states appleton, wisconsin, united states oakville, ontario, canada montreal, quebec, canada saskatoon, saskatchewan, canada quebec, canada ahmedabad, india bangalore, india bhopal, india hyderabad, india jaipur, india mumbai, india nasik, india pune, india']",,https://ClinicalTrials.gov/show/NCT00538863,pain
323,324,NCT00300781,study evaluating hki-272 (neratinib) in subjects with advanced breast cancer,,Completed,Has Results,breast neoplasms|neoplasms,drug: neratinib,16-week progression free survival|objective response rate|clinical benefit rate|duration of response,"puma biotechnology, inc.",Female,"18 Years and older   (Adult, Older Adult)",Phase 2,136.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3144A1-201 / B1891012,"August 4, 2006",April 2008,"January 30, 2018","March 9, 2006","September 13, 2017","August 14, 2018","[""university of colorado hospital, aurora, colorado, united states midwestern regional medical center, zion, illinois, united states louisiana state university, shreveport, louisiana, united states the cancer center at gbmc, baltimore, maryland, united states oncology care associates, bethesda, maryland, united states beth israel deaconess medical center, boston, massachusetts, united states dana farber cancer institute, boston, massachusetts, united states boston university medical center, boston, massachusetts, united states faulkner hospital, boston, massachusetts, united states norris cotton cancer center dartmouth hitchcock medical center, lebanon, new hampshire, united states the cancer institute of new jersey, new brunswick, new jersey, united states the cleveland clinic taussig cancer center, cleveland, ohio, united states virginia mason medical center, seattle, washington, united states institut jules bordet unite du chimiotherapie, brussels, belgium university hospital gasthuisberg, leuven, belgium st-augustinus ziekenhuis oncology department, wilrijk, belgium the hospital affiliated academy military medical science, chinese people's liberation army, beijing, beijing, china no. 81 hospital of chinese people's liberation army, nanjing, jiangsu, china cancer hospital peking union medical college, beijing, china chinese people's liberation army general hospital, beijing, china institut gustave roussy service de pathologie mammaire, villejuif cedex, france jehangir clinical development centre, pune, maharashtra, india deenanath mangeshkar hospital, pune, maharashtra, india nizam's institute of medical sciences, hyderabad, panjagutta, india tata memorial centre, mumbai, parel, india hospital regional lic. adolfo lopez mateos oncología médica, mexico city, mexico arke estudios clínicos s.a. de c.v., mexico city, mexico hospital de especialidades mig, mexico city, mexico n.n. blokhin russian cancer research center of rams, moscow, russian federation medical radiological research center of rams, department of radiation and surgical methods, obninsk, russian federation city oncology dispensary, saint petersburg, russian federation city hospital n 31 oncology haematology dept. for adults, saint petersburg, russian federation breast tumor department, n.n. petrov research institute of oncology, saint-petersburg, russian federation""]",,https://ClinicalTrials.gov/show/NCT00300781,breast
324,325,NCT00527735,phase ii study for previously untreated subjects with non small cell lung cancer (nsclc) or small cell lung cancer (sclc),,Completed,Has Results,"lung cancer|small cell lung cancer|carcinoma, non-small-cell lung",drug: ipilimumab|drug: placebo|drug: paclitaxel|drug: carboplatin,"immune-related progression-free survival (irpfs) in participants with nonsmall-cell lung cancer (nsclc) per immune-related response criteria (irrc)|progression-free survival (pfs) in participants with nsclc per modified world health organization (mwho) criteria|overall survival in participants with nsclc|best overall response rate (borr) per mwho criteria in participants with nsclc and sclc|immune-related best overall response rate (irborr) per irrc in participants with nsclc and small-cell lung cancer (sclc)|immune-related disease control rate (irdcr) per irrc and disease control rate (dcr) per mwho criteria in participants with nsclc and sclc|immune-related duration of response (irdor) per irrc and dor per mwho criteria in participants with nsclc and sclc|number of participants with nsclc who have death as outcome, serious adverse events (saes), drug-related saes, adverse events (aes), aes leading to discontinuation, and drug-related aes by worst common terminology criteria (ctc) grade|percentage of participants with nsclc who have abnormalities in on-study hematology laboratory test results by worst ctc grade|irpfs in participants with sclc per irrc|number of participants with nsclc who have abnormalities in on-study liver function test results by worst ctc grade|number of participants with nsclc who had abnormalities in vital sign measurements and physical examination findings|percentage of participants with nsclc who have abnormalities in pancreatic enzyme clinical laboratory test results by worst ctc grade|number of participants with nsclc who have positive human antihuman antibody (haha) status postbaseline|number of participants with sclc with death as outcome, serious adverse events (saes), drug-related saes, adverse events (aes), aes leading to discontinuation, drug-related aes by worst ctc grade|number of participants with sclc who have abnormalities in on-study hematology laboratory test results by worst ctc grade|number of participants with sclc who have abnormalities in liver function test results by worst ctc grade|percentage of participants with sclc who have abnormalities in pancreatic enzyme and other clinical laboratory test results by worst ctc grade|progression-free survival (pfs) in participants with sclc per mwho criteria|number of participants with sclc who had abnormalities in vital sign measurements and physical examination findings|number of participants with sclc who have positive haha status postbaseline|overall survival in participants with sclc",bristol-myers squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 2,334.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CA184-041,February 2008,October 2009,December 2011,"September 11, 2007","July 16, 2012","July 18, 2018","['birmingham hematology & oncology assoc. llc, birmingham, alabama, united states mayo clinic, scottsdale, arizona, united states acrc/arizona clinical research center, inc., tucson, arizona, united states compassionate cancer care medical group, corona, california, united states compassionate cancer care medical group, inc., fountain valley, california, united states the angeles clinic & research institute, inc, los angeles, california, united states oncology care medical associates, montebello, california, united states compassionate cancer care medical group, riverside, california, united states sharp clinical oncology research, san diego, california, united states m d anderson cancer center- orlando, orlando, florida, united states georgia cancer specialists, atlanta, georgia, united states university of chicago medical center, chicago, illinois, united states local institution, park ridge, illinois, united states kentucky cancer clinic, hazard, kentucky, united states the john r. marsh cancer center, hagerstown, maryland, united states massachusetts general hospital, boston, massachusetts, united states the cancer center, minneapolis, minnesota, united states nevada cancer institute, las vegas, nevada, united states dartmouth-hitchcock medical center, lebanon, new hampshire, united states local institution, new york, new york, united states cmc-northeast/ northeast oncology associates, concord, north carolina, united states gabrail cancer center, canton, ohio, united states hematology oncology consultants, inc, columbus, ohio, united states st. mary medical center, langhorne, pennsylvania, united states guthrie clinical research, sayre, pennsylvania, united states santee hematology/oncology, sumter, south carolina, united states southwest cancer treatment and research center, lubbock, texas, united states local institution, belfort, france local institution, caen, france local institution, marseille cedex 9, france local institution, rennes cedex 9, france local institution, bochum, germany local institution, coswig, germany local institution, ebensfeld, germany local institution, grosshansdorf, germany local institution, halle (saale), germany local institution, hamburg, germany local institution, koeln, germany local institution, leipzig, germany local institution, mainz, germany local institution, muenchen, germany local institution, hyderabad, andhra pradesh, india local institution, navrangpura, ahmedabad, gujarat, india local institution, manipal, karnataka, india local institution, trivandrum, kerala, india local institution, vellore, india local institution, genova, italy local institution, siena, italy local institution, torino, italy local institution, gdansk, poland local institution, krakow, poland local institution, olsztyn, poland local institution, szczecin, poland local institution, arkhangelsk, russian federation local institution, chelyabinsk, russian federation local institution, ivanovo, russian federation local institution, moscow, russian federation local institution, moscow, russian federation local institution, moscow, russian federation local institution, pyatigorsk, russian federation local institution, saint-petersburg, russian federation local institution, sochi, russian federation local institution, st. petersburg, russian federation local institution, st. petersburg, russian federation local institution, st. petersburg, russian federation local institution, st. petersburg, russian federation local institution, dnipropetrovsk, ukraine local institution, donetsk, ukraine local institution, kharkov, ukraine local institution, lviv, ukraine local institution, ternopol, ukraine local institution, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT00527735,
325,326,NCT02299505,pharmacokinetic and safety study of lower doses of ceritinib taken with a low-fat meal versus 750 mg of ceritinib in the fasted state in adult patients with (alk-positive) metastatic non-small cell lung cancer (nsclc),,Completed,No Results Available,non-small cell lung cancer,drug: ceritinib,plasma concentration of ceritinib|safety profile|objective response rate (orr)|duration of response (dor),novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,306.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLDK378A2112|2014-004001-32,"April 9, 2015","June 16, 2016","March 6, 2020","November 24, 2014",,"February 9, 2022","['highlands oncology group, fayetteville, arkansas, united states loma linda university, loma linda, california, united states goshen center for cancer care iu health - sc, indianapolis, indiana, united states maryland oncology hematology, p.a. sc-2, rockville, maryland, united states essex oncology of north jersey pa sc, belleville, new jersey, united states greenville health system sc, greenville, south carolina, united states utah cancer specialists dept.of utah cancer spec. (3), salt lake city, utah, united states novartis investigative site, grafton, auckland, australia novartis investigative site, auckland, australia novartis investigative site, wien, austria novartis investigative site, wien, austria novartis investigative site, edegem, belgium novartis investigative site, natal, rn, brazil novartis investigative site, passo fundo, rs, brazil novartis investigative site, porto alegre, rs, brazil novartis investigative site, itajai, sc, brazil novartis investigative site, barretos, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sofia, bulgaria novartis investigative site, edmonton, alberta, canada novartis investigative site, hamilton, ontario, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, monteria, colombia novartis investigative site, brno, czechia novartis investigative site, regensburg, bavaria, germany novartis investigative site, berlin, germany novartis investigative site, koeln, germany novartis investigative site, wuerzburg, germany novartis investigative site, athens, gr, greece novartis investigative site, athens, greece novartis investigative site, hyderabad, andhra pradesh, india novartis investigative site, bangalore, karnataka, india novartis investigative site, nashik, maharashtra, india novartis investigative site, kolkata, west bengal, india novartis investigative site, delhi, india novartis investigative site, bergamo, bg, italy novartis investigative site, bologna, bo, italy novartis investigative site, brescia, bs, italy novartis investigative site, meldola, fc, italy novartis investigative site, san giovanni rotondo, fg, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, aviano, pn, italy novartis investigative site, roma, rm, italy novartis investigative site, verona, vr, italy novartis investigative site, novara, italy novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, ashrafieh, lebanon novartis investigative site, kuching, sarawak, malaysia novartis investigative site, pulau pinang, malaysia novartis investigative site, nieuwegein, netherlands novartis investigative site, gdansk, poland novartis investigative site, konin, poland novartis investigative site, tarnobrzeg, poland novartis investigative site, st petersburg, russian federation novartis investigative site, sevilla, andalucia, spain novartis investigative site, pamplona, navarra, spain novartis investigative site, san sebastian, pais vasco, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, taichung, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan, taiwan novartis investigative site, hat yai, songkla, thailand novartis investigative site, bangkok, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, talas / kayseri, turkey novartis investigative site, wirral, merseyside, united kingdom novartis investigative site, newcastle upon tyne, newcastle, united kingdom']",,https://ClinicalTrials.gov/show/NCT02299505,
326,327,NCT04351555,a study of osimertinib with or without chemotherapy versus chemotherapy alone as neoadjuvant therapy for patients with egfrm positive resectable non-small cell lung cancer,NeoADAURA,Recruiting,No Results Available,non-small cell lung cancer,drug: osimertinib|drug: cisplatin|drug: carboplatin|drug: placebo|drug: pemetrexed,major pathological response (mpr)|pathological complete response (pcr)|event-free survival (efs)|overall survival (os)|disease free survival (dfs)|downstaging|difference between treatment arms in change from baseline in eortc qlq-c30 (european organisation for research and treatment of cancer quality of life questionnaire - core 30 items)|concordance of egfrm status between tumour tissue dna and patient-matched plasma-derived ctdna|corcordance of egfr mutation status between the local and central cobas egfr mutation test results from baseline tumour samples|pk plasma concentrations of osimertinib|difference between treatment arms in change from baseline in eortc qlq-lc13 (european organisation for research and treatment of cancer quality of life questionnaire - lung cancer 13 items),astrazeneca,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,328.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D516AC00001,"December 16, 2020","March 26, 2024","March 29, 2029","April 17, 2020",,"March 31, 2022","['research site, birmingham, alabama, united states research site, birmingham, alabama, united states research site, scottsdale, arizona, united states research site, duarte, california, united states research site, los angeles, california, united states research site, san francisco, california, united states research site, santa monica, california, united states research site, santa rosa, california, united states research site, new haven, connecticut, united states research site, washington, district of columbia, united states research site, miami, florida, united states research site, chicago, illinois, united states research site, boston, massachusetts, united states research site, ann arbor, michigan, united states research site, detroit, michigan, united states research site, columbia, missouri, united states research site, lebanon, new hampshire, united states research site, commack, new york, united states research site, new york, new york, united states research site, stony brook, new york, united states research site, cleveland, ohio, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, fairfax, virginia, united states research site, seattle, washington, united states research site, milwaukee, wisconsin, united states research site, linz, austria research site, vienna, austria research site, wien, austria research site, barretos, brazil research site, belo horizonte, brazil research site, belo horizonte, brazil research site, bento goncalves, brazil research site, florianópolis, brazil research site, fortaleza, brazil research site, ibirapuera, brazil research site, jau, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, santa maria, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, panagyurishte, bulgaria research site, pleven, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, antofagasta, chile research site, la serena, chile research site, las condes, chile research site, providencia, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, talca, chile research site, viña del mar, chile research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, chongqing, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hefei, china research site, linhai, china research site, nanchang, china research site, nanjing, china research site, nantong, china research site, shandong, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shenzhen, china research site, suzhou, china research site, urumqi, china research site, wanzhou, china research site, wenzhou, china research site, xiamen, china research site, yangzhou, china research site, zhengzhou, china research site, berlin, germany research site, bielefeld, germany research site, essen, germany research site, esslingen a.n., germany research site, freiburg, germany research site, gauting, germany research site, georgsmarienhuette, germany research site, gerlingen, germany research site, halle, germany research site, hamburg, germany research site, heidelberg, germany research site, homburg, germany research site, köln, germany research site, oldenburg, germany research site, regensburg, germany research site, rheinland-pfalz, germany research site, würzburg, germany research site, bangalore, india research site, belagavi, india research site, chennai, india research site, coimabatore, india research site, kolkata, india research site, manipal, india research site, mumbai, india research site, mumbai, india research site, namakkal, india research site, new delhi, india research site, new delhi, india research site, haifa, israel research site, jerusalem, israel research site, kfar saba, israel research site, petah tikva, israel research site, ramat gan, israel research site, bari, italy research site, monza, italy research site, orbassano, italy research site, padova, italy research site, roma, italy research site, roma, italy research site, rozzano, italy research site, varese, italy research site, akashi-shi, japan research site, bunkyo-ku, japan research site, bunkyo-ku, japan research site, chiba-shi, japan research site, hiroshima-shi, japan research site, kashiwa, japan research site, koto-ku, japan research site, kyoto-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sakai-shi, japan research site, sendai-shi, japan research site, shinjuku-ku, japan research site, sunto-gun, japan research site, yokohama-shi, japan research site, daegu, korea, republic of research site, daegu, korea, republic of research site, daejeon, korea, republic of research site, gyeongsangnam-do, korea, republic of research site, hwasun-gun, korea, republic of research site, incheon, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, aguascalientes, mexico research site, d.f, mexico research site, mexico city, mexico research site, mexico city, mexico research site, la libertad, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, białystok, poland research site, olsztyn, poland research site, otwock, poland research site, szczecin, poland research site, warszawa, poland research site, warszawa, poland research site, warszawa, poland research site, wrocław, poland research site, kazan, russian federation research site, krasnoyarsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhniy novgorod, russian federation research site, obninsk, russian federation research site, perm, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, st. petersburg, russian federation research site, tomsk, russian federation research site, yaroslavl, russian federation research site, singapore, singapore research site, barcelona, spain research site, barcelona, spain research site, madrid, spain research site, majadahonda, spain research site, málaga, spain research site, bellinzona, switzerland research site, bern, switzerland research site, geneva, switzerland research site, zürich, switzerland research site, taichung, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, tainan city, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, khon kaen, thailand research site, pathumthani, thailand research site, pathumwan, thailand research site, phisanulok, thailand research site, ankara, turkey research site, ankara, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, malatya, turkey research site, birmingham, united kingdom research site, liverpool, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, hanoi, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT04351555,
327,328,NCT00448305,endotag-1 in triple receptor negative breast cancer patients,,Completed,No Results Available,breast neoplasms,drug: endotag-1 + paclitaxel|drug: endotag-1|drug: paclitaxel,4-month progression free survival (pfs) rate|median progression free survival (pfs) time|tumor response|4-month survival rate|median overall survival time|pain assessment|clinical benefit assessment via quality of life (qol)scale|adverse events|laboratory values|dose variations,medigene,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,143.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT 4002|EudraCT-Nr. 2006-002221-23,January 2007,February 2010,March 2011,"March 16, 2007",,"January 5, 2012","['institut jules bordet - centre des tumeurs de l\'université libre de bruxelles, brussels, belgium chu brugmann, brussels, belgium uz antwerpen, edegem, belgium chu liège, liège, belgium centre oscar lambret, lille, france cente antoine lacassagne, nice, france institut curie, paris, france hôpital de jour centre henri kaplan, tours, france institut gustave roussy, villejuif, france vedanta institute of medical science, ahmedabad, india bangalore institute of oncology, bangalore, india searoc cancer center, jaipur, india lakeshore hospital, kochin, india deenanath mangeshkar hospital, pune, india kaushalya medical foundation, thane, india wojewodzkie centrum onkologii, gdansk, poland centrum onkologii instytut im. m. sklodowskiej-curie, gliwice, poland instytut im. m. sklodowskiej-curie, lublin, poland nzoz grupowa specjalistyczna, olsztyn, poland klinika onkologii adadmii medycznej, poznan, poland institute of oncology ""prof. dr. al. trestioreanu"", bucharest, romania institute of oncology ""prof. dr. i. chiricuta"", cluj napoca, romania center of medical oncology, iasi, romania emergency county hospital sibiu, sibiu, romania oncology clinic ""oncomed"", timisoara, romania dnepropetrovsk state medical acedamy, dnepropetrovsk, ukraine institute of medical radiology of acedamy of medical sciences, kharkov, ukraine department of abdominal surgery, kiev, ukraine institut of oncology, kiev, ukraine surgical department, kiev, ukraine rivne regional oncological dispensary, rovno, ukraine sumy reginal oncology center, sumy, ukraine regional clinical oncological dispensary, uzhorod, ukraine']",,https://ClinicalTrials.gov/show/NCT00448305,breast
328,329,NCT03296163,a study comparing mb02 and avastin® in subjects with stage iiib/iv non-squamous non-small cell lung cancer (nsclc),STELLA,Completed,Has Results,non-small cell lung cancer,drug: mb02 (bevacizumab biosimilar drug)|drug: eu-approved avastin®|drug: carboplatin|drug: paclitaxel,objective response rate (orr) at week 18|progression-free survival (pfs)|overall survival (os)|incidence of treatment-emergent adverse events (teaes)|immunogenicity assessments (anti-drug antibodies [ada] and neutralizing antibodies [nab]),mabxience s.a,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,627.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MB02-C-02-17,"February 6, 2018","July 3, 2019","February 27, 2020","September 28, 2017","March 26, 2021","April 26, 2021","['medradius, maceió, al, brazil instituto do câncer do ceará - icc, fortaleza, ce, brazil centro brasileiro de radioterapia oncologia e mastologia, goiânia, go, brazil hospital erasto gaertner - paranaense de combate ao câncer, curitiba, pr, brazil instituto nacional de cancer- inca, rio de janeiro, rj, brazil centro de pesquisa e educação da serra gaúcha (cepesg), caxias do sul, rs, brazil ipcem universidade de caxias do sul, caxias do sul, rs, brazil hospital de caridade de ijuí, ijuí, rs, brazil instituto do câncer - hospital são vicente de paulo, passo fundo, rs, brazil hospital são lucas da pucrs, pôrto alegre, rs, brazil hospital de câncer de barretos, barretos, sp, brazil hospital de base de são josé do rio preto, são josé do rio prêto, sp, brazil centro de pesquisa do instituto brasileiro de controle do câncer - ibcc, são paulo, sp, brazil instituto de ensino e pesquisa são lucas, são paulo, sp, brazil hospital santa marcelina, sao paulo, brazil central hospital plovdiv, plovdiv, bulgaria acıbadem city clinic cancer center umhat, sofia, bulgaria specialized hospital for active treatment of oncology diseases sofia district eood, sofia, bulgaria fundación arturo lópez pérez - instituto oncológico falp, santiago, chile health & care spa, santiago, chile instituto clinico oncologico del sur icos, temuco, chile oncocentro apys, viña del mar, chile cancer center of adjara autonomous republic, batumi, georgia acad. f . todua medical center-research institute of clinical medicine, tbilisi, georgia consilium medulla, tbilisi, georgia institute of clinical oncology, tbilisi, georgia ltd aversi clinic, tbilisi, georgia ltd cancer research centre, tbilisi, georgia tbilisi state medical universitys first university clinic, tbilisi, georgia general hospital of athens ""ippokratio"", athens, greece sotiria general hospital for chest diseases, athens, greece university general hospital of larissa, lárisa, greece agioi anargyroi general oncological hospital of kifissia, néa kifisiá, greece general hospital of thessaloniki ""george papanikolaou"", thessaloníki, greece national koranyi institute of tb and pulmonology, budapest, hungary országos korányi pulmonológiai intézet (okpi), budapest, hungary csongrád megyei önkormányzat mellkasi betegségek szakkórháza, deszk, hungary veszprém megyei tüdőgyógyinzézet, farkasgyepű, hungary borsod-abaúj-zemplén megyei központi kórház és egyetemi oktatókórház, miskolc, hungary zydus hospital, ahmedabad, india action cancer hospital, delhi, india aadhar health institute, hisar, india nims - nizam\'s institute of medical sciences, hyderabad, india ganadhipati purushottam shekhawati hospital research centre, jaipur, india pvs hospital pvt ltd, kerola, india apollo gleneagles hospital, kolkata, india netaji subhas chandra bose cancer research institute, kolkata, india shatabdi super speciality hospital, nashik, india deenanath mangeshkar hospital & research center, pune, india nirmal hospital pvt. ltd., surat, india kiran super multispeciality hospital, sūrat, india shree himalaya cancer hospital research institute, vadodara, india queen\'s nri hospital gurudwara lane, visakhapatnam, india notre dame de secours, jbaïl, lebanon hospital pulau pinang, george town, pulau pinang, malaysia institut perubatan dan pergigian termaju universiti sains malaysia, kepala batas, malaysia hospital kuala lumpur, kuala lumpur, malaysia pusat perubatan universiti kebangsaan malaysia, kuala lumpur, malaysia university malaya medical centre, kuala lumpur, malaysia hospital umum sarawak, kuching, malaysia national cancer institute, putrajaya, malaysia instituto nacional de cancerologia, mexico city, mexico hospital universitario dr. jose eleuterio gonzález, monterrey, mexico sultan qaboos university hospital, muscat, oman baguio general hospital & medical center, baguio, philippines cebu doctors university hospital - cduh, cebu, philippines perpetual succour hospital - psh, cebu, philippines de la salle university medical center - dlsumc, dasmariñas, philippines davao doctors hospital - ddh, davao, philippines makati medical center, makati city, philippines philippine general hospital - pgh, manila, philippines the medical city, pasig, philippines st. luke\'s medical center - global city, taguig, philippines sbhi arkhangelsk region - arkhangelsk clinical oncological dispensary, arkhangel\'sk, russian federation regional state budgetary healthcare institution ""belgorod oncology dispensary"", belgorod, russian federation state budget healthcare institution ivanovo regional oncology dispensary, ivanovo, russian federation kaluga regional clinical oncology center, kaluga, russian federation republic clinical oncology dispensary, kazan\', russian federation kursk republican clinical oncology dispensary, kursk, russian federation ""vitamed"" llc, moscow, russian federation moscow city oncology hospital no 62, moscow, russian federation n. n. blokhin russian cancer research center, moscow, russian federation university headache clinic llc, moscow, russian federation federal budget healthcare institution ""volga district medical centre"" under federal medical and biological agency, novgorod, russian federation gbuz of sk pyatigorsk oncology dispensary, pyatigorsk, russian federation ryazan regional clinical oncology dispensary, ryazan\', russian federation city clinical oncology dispensary, saint petersburg, russian federation guz ""leningrad regional clinical hospital"", saint petersburg, russian federation state budgetary healthcare institution ""samara regional clinical oncology dispensary"", samara, russian federation chc bezanijska kosa, belgrade, serbia institute of oncology and radiology of serbia (iors), belgrade, serbia clinical center kragujevac, kragujevac, serbia clinical center nis (clinic for pulmonary diseases), niš, serbia institute for pulmonary diseases of vojvodina, sremska kamenica, serbia hospital universitario puerta de hierro majadahonda, madrid, spain bangkok international hospital and wattanosod hospital, bangkok, thailand chiang mai university (cmu) - maharaj nakhon chiang mai hospital nakorn chiang mai hospital, chiang mai, thailand chiang rai prachanukroh hospital, chiang rai, thailand songklanagarind hospital, hat yai, thailand buddhachinaraj hospital, phitsanulok, thailand istanbul medeniyet university medical faculty, i̇stanbul, turkey suat seren chest diseases hospital, i̇zmir, turkey municipal institution cherkasy regional oncology dispensary of cherkasy regional council, cherkasy, ukraine public higher education insititution of ukraine ""bukovinian state medical university"", chernivtsi, ukraine multifield clinical hospital no.4, dnepropetrovsk, ukraine clinical oncology dispensary, dnipro, ukraine state institution ""grigoriev institute for medical radiology national academy of medical science of ukraine"", kharkiv, ukraine state institution ""v.t. zaycev institute of general and urgent surgery of national academy medical sciences of ukraine"", kharkiv, ukraine medical and diagnostic centre private enterprise of private manufacturing company ""acinus"", kropyvnytskyi, ukraine municipal institution ""kryviy rih oncology dispensary"" of dnipropetrovsk regional council, kryvyi rih, ukraine national cancer institute, kyiv, ukraine national institute of cancer, kyiv, ukraine lviv state oncology regional treatment and diagnostic center, l\'viv, ukraine healthcare facility ""volyn regional oncological dispensary"", luts\'k, ukraine odessa regional clinical oncology dispensary, odessa, ukraine uzhgorod national university, uzhgorod, ukraine vinnytsia regional clinical oncology dispensary, vinnytsya, ukraine communal institution ""zaporizhzhya regional clinical oncological dispensary"" of zaporizhzhya regional council, zaporizhzhya, ukraine']","""study protocol"", https://clinicaltrials.gov/provideddocs/63/nct03296163/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/63/nct03296163/sap_001.pdf",https://ClinicalTrials.gov/show/NCT03296163,
329,330,NCT03447769,brief title: study of efficacy and safety of canakinumab as adjuvant therapy in adult subjects with stages ajcc/uicc v. 8 ii-iiia and iiib (t>5cm n2) completely resected non-small cell lung cancer acronym: canopy-a,Canopy-A,"Active, not recruiting",No Results Available,non-small cell lung cancer,drug: canakinumab|drug: placebo,"disease free survival (dfs) by local investigator|overall survival (os)|disease free survival (dfs) by local investigator in pd-l1 subgroups|disease free survival (dfs) by local investigator in cd8 subgroups|overall survival (os) by local investigator in pd-l1 subgroups|overall survival (os) by local investigator in cd8 subgroups|lung cancer specific survival (lcss)|area under the plasma concentration-time curve from time zero to the last quantifiable concentration (auclast) of canakinumab|maximum observed plasma concentration (cmax) of canakinumab|trough concentration (cmin) of canakinumab|anti-drug antibody (ada) prevalence at baseline|anti-drug antibody (ada) incidence|time to definitive 10 point deterioration symptom scores of pain,cough and dyspnea per eortc qlq-lc13 questionnaire|time to definitive 10 point deterioration of global health status/qol, shortness of breath and pain per eortc qlq-c30 questionnaire|time to first 10 point deterioration for symptom scores of pain, cough and dyspnea per eortc qlq-lc13 questionnaire|time to first 10 point deterioration of global health status/qol, shortness of breath and pain per eortc qlq-c30 questionnaire|utility scores of the eq-5d-5l",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1382.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CACZ885T2301|2017-004011-39,"March 16, 2018","August 31, 2023","September 15, 2025","February 27, 2018",,"May 2, 2022","['highlands oncology group, fayetteville, arkansas, united states cancer and blood specialty clinic, los alamitos, california, united states university of california at los angeles, los angeles, california, united states va palo alto health care system crlx030a2301, palo alto, california, united states sansum clinic, santa barbara, california, united states rocky mountain cancer centers denver-mdtn(bone&marrowtransp), denver, colorado, united states florida cancer specialists, fort myers, florida, united states advanced medical specialties drug ship - 2, miami, florida, united states florida cancer affiliates of ocala, ocala, florida, united states florida cancer specialists north, saint petersburg, florida, united states florida cancer specialists panhandle, tallahassee, florida, united states florida cancer specialists, west palm beach, florida, united states rush university medical center cldt600aus06, chicago, illinois, united states cancer center of kansas dept.ofcancerctr.ofkansas, wichita, kansas, united states va nebraska-western iowa health care system, omaha, nebraska, united states louis stokes cleveland department of veterans affairs mc, cleveland, ohio, united states oncology associates of oregon, pc, eugene, oregon, united states chattanooga oncology and hematology associates pc chattanooga oncology, chattanooga, tennessee, united states sarah cannon research institute, nashville, tennessee, united states va north texas health care system, dallas, texas, united states texas oncology mamiemcfaddenwardctr, dallas, texas, united states virginia cancer specialists fairfax northern virginia, fairfax, virginia, united states oncology and hematology associates of southwest virginia inc, salem, virginia, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, mar del plata, buenos aires, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, rosario, sante fe, argentina novartis investigative site, cordoba, argentina novartis investigative site, graz, austria novartis investigative site, klagenfurt, austria novartis investigative site, krems, austria novartis investigative site, vienna, austria novartis investigative site, teresina, piaui, brazil novartis investigative site, londrina, pr, brazil novartis investigative site, barretos, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, edmonton, alberta, canada novartis investigative site, moncton, new brunswick, canada novartis investigative site, halifax, nova scotia, canada novartis investigative site, hamilton, ontario, canada novartis investigative site, montreal, quebec, canada novartis investigative site, quebec, canada novartis investigative site, santiago, chile novartis investigative site, santiago, chile novartis investigative site, hefei, anhui, china novartis investigative site, beijing, beijing, china novartis investigative site, chongqing, chongqing, china novartis investigative site, guangzhou, guangdong, china novartis investigative site, shenzhen, guangdong, china novartis investigative site, zhanjing, guangong, china novartis investigative site, zunyi, guizhou, china novartis investigative site, zhengzhou, henan, china novartis investigative site, nanjing, jiangsu, china novartis investigative site, suzhou, jiangsu, china novartis investigative site, chang chun, jilin, china novartis investigative site, shenyang, liaoning, china novartis investigative site, jinan, shandong, china novartis investigative site, shanghai, shanghai, china novartis investigative site, shanghai, shanghai, china novartis investigative site, xi an, shanxi, china novartis investigative site, shenyang, shengyang, china novartis investigative site, chengdu, sichuan, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, beijing, china novartis investigative site, changsha, china novartis investigative site, chengdu, china novartis investigative site, fujian, china novartis investigative site, tianjin, china novartis investigative site, tianjin, china novartis investigative site, bogota, colombia novartis investigative site, ostrava vitkovice, czechia novartis investigative site, prague 2, czechia novartis investigative site, marseille cedex 20, bouches du rhone, france novartis investigative site, le mans, cedex 09, france novartis investigative site, montpellier cedex 5, herault, france novartis investigative site, amiens, france novartis investigative site, angers cedex 9, france novartis investigative site, avignon cedex, france novartis investigative site, bayonne, france novartis investigative site, brest, france novartis investigative site, bron, france novartis investigative site, clermont-ferrand, france novartis investigative site, creteil, france novartis investigative site, la rochelle, france novartis investigative site, la seyne sur mer, france novartis investigative site, lille, france novartis investigative site, paris, france novartis investigative site, paris, france novartis investigative site, pessac, france novartis investigative site, poitiers, france novartis investigative site, saint-herblain cédex, france novartis investigative site, strasbourg cedex, france novartis investigative site, suresnes, france novartis investigative site, toulouse, france novartis investigative site, batumi, georgia novartis investigative site, tbilisi, georgia novartis investigative site, tbilisi, georgia novartis investigative site, tbilisi, georgia novartis investigative site, tbilisi, georgia novartis investigative site, tbilisi, georgia novartis investigative site, heidelberg, baden-württemberg, germany novartis investigative site, gauting, bayern, germany novartis investigative site, bochum, nordrhein westfalen, germany novartis investigative site, velbert, north rhine-westphalia, germany novartis investigative site, aachen, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, chemnitz, germany novartis investigative site, dresden, germany novartis investigative site, erfurt, germany novartis investigative site, essen, germany novartis investigative site, georgsmarienhuette, germany novartis investigative site, gera, germany novartis investigative site, gerlingen, germany novartis investigative site, grosshansdorf, germany novartis investigative site, halle (saale), germany novartis investigative site, koeln, germany novartis investigative site, leipzig, germany novartis investigative site, minden, germany novartis investigative site, muenchen, germany novartis investigative site, nuernberg, germany novartis investigative site, solingen, germany novartis investigative site, ulm, germany novartis investigative site, wuerzburg, germany novartis investigative site, athens, attica, greece novartis investigative site, athens, gr, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, thessaloniki, greece novartis investigative site, hong kong, hong kong novartis investigative site, kowloon, hong kong novartis investigative site, tuen mun, hong kong novartis investigative site, torokbalint, pest, hungary novartis investigative site, veszprem, hungary novartis investigative site, reykjavik, iceland novartis investigative site, mumbai, maharashtra, india novartis investigative site, mumbai, maharashtra, india novartis investigative site, nashik, maharashtra, india novartis investigative site, kolkata, west bengal, india novartis investigative site, delhi, india novartis investigative site, mumbai, india novartis investigative site, dublin 9, d9, ireland novartis investigative site, haifa, israel novartis investigative site, holon, israel novartis investigative site, ancona, an, italy novartis investigative site, bari, ba, italy novartis investigative site, meldola, fc, italy novartis investigative site, monza, mb, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, padova, pd, italy novartis investigative site, aviano, pn, italy novartis investigative site, ravenna, ra, italy novartis investigative site, roma, rm, italy novartis investigative site, orbassano, to, italy novartis investigative site, perugia, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, nagoya, aichi, japan novartis investigative site, hirosaki, aomori, japan novartis investigative site, matsuyama, ehime, japan novartis investigative site, iizuka-city, fukuoka, japan novartis investigative site, asahikawa-city, hokkaido, japan novartis investigative site, sapporo city, hokkaido, japan novartis investigative site, himeji, hyogo, japan novartis investigative site, kanazawa-city, ishikawa, japan novartis investigative site, shiwa-gun, iwate, japan novartis investigative site, yokohama-city, kanagawa, japan novartis investigative site, yokohama-city, kanagawa, japan novartis investigative site, natori, miyagi, japan novartis investigative site, hirakata-city, osaka, japan novartis investigative site, osaka-city, osaka, japan novartis investigative site, sakai, osaka, japan novartis investigative site, hidaka-city, saitama, japan novartis investigative site, sunto gun, shizuoka, japan novartis investigative site, bunkyo ku, tokyo, japan novartis investigative site, chuo ku, tokyo, japan novartis investigative site, minato ku, tokyo, japan novartis investigative site, wakayama-city, wakayama, japan novartis investigative site, ube-city, yamaguchi, japan novartis investigative site, fukuoka, japan novartis investigative site, osaka, japan novartis investigative site, amman, jordan novartis investigative site, cheongju si, chungcheongbuk do, korea, republic of novartis investigative site, jeollanam-do, korea, korea, republic of novartis investigative site, seoul, korea, korea, republic of novartis investigative site, busan, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, ashrafieh, lebanon novartis investigative site, beirut, lebanon novartis investigative site, saida, lebanon novartis investigative site, tripoli, lebanon novartis investigative site, kuching, sarawak, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, pulau pinang, malaysia novartis investigative site, monterrey, nuevo leon, mexico novartis investigative site, bergen, norway novartis investigative site, drammen, norway novartis investigative site, oslo, norway novartis investigative site, tromsø, norway novartis investigative site, panama city, panama novartis investigative site, san borja, lima, peru novartis investigative site, surquillo, lima, peru novartis investigative site, makati city, philippines novartis investigative site, krakow, ma3opolska, poland novartis investigative site, konin, poland novartis investigative site, olsztyn, poland novartis investigative site, poznan, poland novartis investigative site, rzeszow, poland novartis investigative site, warszawa, poland novartis investigative site, lisboa, portugal novartis investigative site, matosinhos, portugal novartis investigative site, porto, portugal novartis investigative site, floresti, cluj, romania novartis investigative site, bucuresti, romania novartis investigative site, cluj-napoca, romania novartis investigative site, iasi, romania novartis investigative site, arkhangelsk, russian federation novartis investigative site, kaliningrad, russian federation novartis investigative site, moscow, russian federation novartis investigative site, obninsk, russian federation novartis investigative site, omsk, russian federation novartis investigative site, pushkin saint petersburg, russian federation novartis investigative site, ryazan, russian federation novartis investigative site, saint petersburg, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, yaroslavl, russian federation novartis investigative site, ljubljana, slovenia novartis investigative site, cordoba, andalucia, spain novartis investigative site, sevilla, andalucia, spain novartis investigative site, santander, cantabria, spain novartis investigative site, badalona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, hospitalet de llobregat, catalunya, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, santiago de compostela, galicia, spain novartis investigative site, la laguna, santa cruz de tenerife, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, bern, switzerland novartis investigative site, fribourg, switzerland novartis investigative site, geneve 14, switzerland novartis investigative site, taichung, taiwan roc, taiwan novartis investigative site, changhua, taiwan novartis investigative site, hualien, taiwan novartis investigative site, kaohsiung city, taiwan novartis investigative site, kaohsiung, taiwan novartis investigative site, taichung, taiwan novartis investigative site, taichung, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan, taiwan novartis investigative site, songkhla, hat yai, thailand novartis investigative site, khon kaen, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, chaingmai, thailand novartis investigative site, ankara, yenimahalle, turkey novartis investigative site, adana, turkey novartis investigative site, istanbul, turkey novartis investigative site, izmir, turkey novartis investigative site, pendik / istanbul, turkey novartis investigative site, cambridge, cambrigdeshire, united kingdom novartis investigative site, truro, cornwall, united kingdom novartis investigative site, cheltenham, gloucestershire, united kingdom novartis investigative site, wirral, merseyside, united kingdom novartis investigative site, ipswich, suffolk, united kingdom novartis investigative site, guildford, surrey, united kingdom novartis investigative site, birmingham, united kingdom novartis investigative site, bristol, united kingdom novartis investigative site, leicester, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, nottingham, united kingdom novartis investigative site, oxford, united kingdom novartis investigative site, preston, united kingdom novartis investigative site, stoke-on-trent, united kingdom novartis investigative site, hanoi, vietnam']",,https://ClinicalTrials.gov/show/NCT03447769,
330,331,NCT00940251,"evaluation of safety and efficacy of mersina, an ayurvedic formulation: a double blind, placebo controlled study in type 2 diabetic patients with secondary failure to oral drugs",,Completed,No Results Available,antihyperglycemic effect in type 2 diabetic patients with secondary failure to oral hypoglycemic agents,drug: mersina,"antidiabetic activity|improvement in metabolic, insulin level, hba1c,kidney and lipid profile",jyoti clinical and pathological laboratory,All,30 Years to 60 Years   (Adult),Phase 2,26.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MER1,September 2008,October 2008,November 2008,"July 15, 2009",,"July 15, 2009","['jyoti clinical and pathological laboratory, shirpur, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00940251,
331,332,NCT00625664,larotaxel + cisplatin versus gemcitabine + cisplatin in first line treatment of locally advanced/metastatic urothelial tract or bladder cancer,CILAB,Completed,No Results Available,urinary bladder neoplasms,drug: larotaxel (xrp9881)|drug: gemcitabine|drug: cisplatin,"overall survival defined as the time interval from the date of randomization to the date of death due to any cause|radiological tumor assessments (ct/mri)|adverse events, laboratory assessments, vital signs, physical examinations, and ecog performance status",sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,337.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC6668|EUDRACT: 2007-001943-23,February 2008,February 2011,February 2011,"February 28, 2008",,"May 5, 2016","['sanofi-aventis investigational site number 840068, anchorage, alaska, united states sanofi-aventis investigational site number 840035, berkeley, california, united states sanofi-aventis investigational site number 840012, burbank, california, united states sanofi-aventis investigational site number 840029, la jolla, california, united states sanofi-aventis investigational site number 840046, los angeles, california, united states sanofi-aventis investigational site number 840003, sacramento, california, united states sanofi-aventis investigational site number 840005, san bernardino, california, united states sanofi-aventis investigational site number 840033, san diego, california, united states sanofi-aventis investigational site number 840031, denver, colorado, united states sanofi-aventis investigational site number 840032, stamford, connecticut, united states sanofi-aventis investigational site number 840034, washington, district of columbia, united states sanofi-aventis investigational site number 840021, washington, district of columbia, united states sanofi-aventis investigational site number 840001, boca raton, florida, united states sanofi-aventis investigational site number 840048, boynton beach, florida, united states sanofi-aventis investigational site number 840049, jacksonville, florida, united states sanofi-aventis investigational site number 840061, lakeland, florida, united states sanofi-aventis investigational site number 840060, athens, georgia, united states sanofi-aventis investigational site number 840030, boise, idaho, united states sanofi-aventis investigational site number 840024, maywood, illinois, united states sanofi-aventis investigational site number 840062, peoria, illinois, united states sanofi-aventis investigational site number 840039, goshen, indiana, united states sanofi-aventis investigational site number 840054, kansas city, kansas, united states sanofi-aventis investigational site number 840057, paducah, kentucky, united states sanofi-aventis investigational site number 840004, metarie, louisiana, united states sanofi-aventis investigational site number 840045, baltimore, maryland, united states sanofi-aventis investigational site number 840006, detroit, michigan, united states sanofi-aventis investigational site number 840026, lansing, michigan, united states sanofi-aventis investigational site number 840047, st. joseph, michigan, united states sanofi-aventis investigational site number 840009, hackensack, new jersey, united states sanofi-aventis investigational site number 840044, lake success, new york, united states sanofi-aventis investigational site number 840013, new york, new york, united states sanofi-aventis investigational site number 840050, new york, new york, united states sanofi-aventis investigational site number 840056, rochester, new york, united states sanofi-aventis investigational site number 840015, syracuse, new york, united states sanofi-aventis investigational site number 840041, chapel hill, north carolina, united states sanofi-aventis investigational site number 840007, charlotte, north carolina, united states sanofi-aventis investigational site number 840019, sylvania, ohio, united states sanofi-aventis investigational site number 840020, bethlehem, pennsylvania, united states sanofi-aventis investigational site number 840065, dunmore, pennsylvania, united states sanofi-aventis investigational site number 840058, woonsocket, rhode island, united states sanofi-aventis investigational site number 840052, charleston, south carolina, united states sanofi-aventis investigational site number 840002, knoxville, tennessee, united states sanofi-aventis investigational site number 840008, houston, texas, united states sanofi-aventis investigational site number 840018, houston, texas, united states sanofi-aventis investigational site number 840017, lubbock, texas, united states sanofi-aventis investigational site number 840016, san antonio, texas, united states sanofi-aventis investigational site number 840064, temple, texas, united states sanofi-aventis investigational site number 840010, woodlands, texas, united states sanofi-aventis investigational site number 840036, seattle, washington, united states sanofi-aventis investigational site number 840011, madison, wisconsin, united states sanofi-aventis investigational site number 840025, marshfield, wisconsin, united states sanofi-aventis investigational site number 840038, milwaukee, wisconsin, united states sanofi-aventis investigational site number 032002, buenos aires, argentina sanofi-aventis investigational site number 032003, ciudad de buenos aires, argentina sanofi-aventis investigational site number 032004, mendoza, argentina sanofi-aventis investigational site number 032005, rosario, argentina sanofi-aventis investigational site number 032001, santa fe, argentina sanofi-aventis investigational site number 036002, adelaide, australia sanofi-aventis investigational site number 036003, bedford park, australia sanofi-aventis investigational site number 036004, st leonards, australia sanofi-aventis investigational site number 056005, aalst, belgium sanofi-aventis investigational site number 056001, bruxelles, belgium sanofi-aventis investigational site number 056002, bruxelles, belgium sanofi-aventis investigational site number 056004, ottignies, belgium sanofi-aventis investigational site number 056003, wilrijk, belgium sanofi-aventis investigational site number 056006, yvoir, belgium sanofi-aventis investigational site number 076006, barretos, brazil sanofi-aventis investigational site number 076004, florianopolis, brazil sanofi-aventis investigational site number 076001, porto alegre, brazil sanofi-aventis investigational site number 076003, porto alegre, brazil sanofi-aventis investigational site number 076002, rio de janeiro, brazil sanofi-aventis investigational site number 076007, sao paulo, brazil sanofi-aventis investigational site number 076005, sao paulo, brazil sanofi-aventis investigational site number 124007, edmonton, canada sanofi-aventis investigational site number 124001, london, canada sanofi-aventis investigational site number 124006, montreal, canada sanofi-aventis investigational site number 124003, quebec, canada sanofi-aventis investigational site number 124002, weston, canada sanofi-aventis investigational site number 152001, santiago, chile sanofi-aventis investigational site number 250006, avignon, france sanofi-aventis investigational site number 250003, bordeaux cedex, france sanofi-aventis investigational site number 250005, hyeres, france sanofi-aventis investigational site number 250011, le mans, france sanofi-aventis investigational site number 250004, lyon, france sanofi-aventis investigational site number 250012, perpignan, france sanofi-aventis investigational site number 250007, poitiers cedex, france sanofi-aventis investigational site number 250008, saint herblain, france sanofi-aventis investigational site number 250009, strasbourg, france sanofi-aventis investigational site number 250001, suresnes, france sanofi-aventis investigational site number 356003, bangalore, india sanofi-aventis investigational site number 356007, kolkata, india sanofi-aventis investigational site number 356004, new delhi, india sanofi-aventis investigational site number 356001, new delhi, india sanofi-aventis investigational site number 356002, vellore, india sanofi-aventis investigational site number 356005, vishakhapatnam, india sanofi-aventis investigational site number 376005, haifa, israel sanofi-aventis investigational site number 376004, kfar saba, israel sanofi-aventis investigational site number 376003, petah-tikva, israel sanofi-aventis investigational site number 376002, tel aviv, israel sanofi-aventis investigational site number 376007, tel hashomer, israel sanofi-aventis investigational site number 376001, tzrifin, israel sanofi-aventis investigational site number 380004, bari, italy sanofi-aventis investigational site number 380003, lecce, italy sanofi-aventis investigational site number 380005, meldola, italy sanofi-aventis investigational site number 380006, pavia, italy sanofi-aventis investigational site number 380002, perugia, italy sanofi-aventis investigational site number 380001, roma, italy sanofi-aventis investigational site number 380008, viterbo, italy sanofi-aventis investigational site number 484003, aguascalientes, mexico sanofi-aventis investigational site number 484007, chihuahua, mexico sanofi-aventis investigational site number 484005, chihuahua, mexico sanofi-aventis investigational site number 484004, monterrey, mexico sanofi-aventis investigational site number 528005, amsterdam, netherlands sanofi-aventis investigational site number 528002, arnhem, netherlands sanofi-aventis investigational site number 528006, hoofddorp, netherlands sanofi-aventis investigational site number 528003, maastricht, netherlands sanofi-aventis investigational site number 528004, nijmegen, netherlands sanofi-aventis investigational site number 528001, sittard-geleen, netherlands sanofi-aventis investigational site number 528007, zwolle, netherlands sanofi-aventis investigational site number 616002, poznan, poland sanofi-aventis investigational site number 616004, rybnik, poland sanofi-aventis investigational site number 616001, warszawa, poland sanofi-aventis investigational site number 616005, wroclaw, poland sanofi-aventis investigational site number 643009, chelyabinsk, russian federation sanofi-aventis investigational site number 643010, kursk, russian federation sanofi-aventis investigational site number 643006, moscow, russian federation sanofi-aventis investigational site number 643008, moscow, russian federation sanofi-aventis investigational site number 643004, moscow, russian federation sanofi-aventis investigational site number 643005, moscow, russian federation sanofi-aventis investigational site number 643001, obninsk, russian federation sanofi-aventis investigational site number 643003, saint-petersburg, russian federation sanofi-aventis investigational site number 643007, saint-petersburg, russian federation sanofi-aventis investigational site number 643002, st-petersburg, russian federation sanofi-aventis investigational site number 643011, st-petersburg, russian federation sanofi-aventis investigational site number 710008, bloemfontein, south africa sanofi-aventis investigational site number 710003, cape town, south africa sanofi-aventis investigational site number 710001, cape town, south africa sanofi-aventis investigational site number 710007, durban, south africa sanofi-aventis investigational site number 710009, durban, south africa sanofi-aventis investigational site number 710006, port elizabeth, south africa sanofi-aventis investigational site number 710005, pretoria, south africa sanofi-aventis investigational site number 724006, badalona, spain sanofi-aventis investigational site number 724001, barcelona, spain sanofi-aventis investigational site number 724004, barcelona, spain sanofi-aventis investigational site number 724008, barcelona, spain sanofi-aventis investigational site number 724002, barcelona, spain sanofi-aventis investigational site number 724003, madrid, spain sanofi-aventis investigational site number 724010, oviedo, spain sanofi-aventis investigational site number 724013, palma de mallorca, spain sanofi-aventis investigational site number 724007, palma de mallorca, spain sanofi-aventis investigational site number 724009, pamplona, spain sanofi-aventis investigational site number 724011, santiago de compostela, spain sanofi-aventis investigational site number 724012, zaragoza, spain sanofi-aventis investigational site number 752001, umeå, sweden sanofi-aventis investigational site number 752002, uppsala, sweden sanofi-aventis investigational site number 792002, ankara, turkey sanofi-aventis investigational site number 792003, ankara, turkey sanofi-aventis investigational site number 792004, ankara, turkey sanofi-aventis investigational site number 792006, istanbul, turkey sanofi-aventis investigational site number 792001, istanbul, turkey']",,https://ClinicalTrials.gov/show/NCT00625664,bladder
332,333,NCT03775486,study of durvalumab+olaparib or durvalumab after treatment with durvalumab and chemotherapy in patients with lung cancer (orion),ORION,"Active, not recruiting",No Results Available,non-small cell lung cancer nsclc,drug: durvalumab|drug: placebo for olaparib|drug: olaparib|drug: nab-paclitaxel+carboplatin|drug: gemcitabine+carboplatin|drug: pemetrexed+carboplatin|drug: gemcitabine+cisplatin|drug: pemetrexed+cisplatin,progression-free survival|overall survival|objective response rate|duration of response|pfs in homologous recombination repair related gene mutation (hrrm) population|concentration of durvalumab|change from baseline and time to deterioration in european organisation for research and treatment of cancer (eortc) quality of life questionnaire (qlq)-lung cancer (lc)13|change from baseline and time to deterioration in eortc quality of life questionnaire (qlq) qlq-c30|presence of anti-drug antibodies (ada) for durvalumab|'number of participants with treatment-related adverse events as assessed by common terminology criteria for adverse events (ctcae),astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,401.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D9102C00001|2018-003460-30,"December 21, 2018","January 11, 2021","June 2, 2022","December 14, 2018",,"April 26, 2022","[""research site, bonita springs, florida, united states research site, saint petersburg, florida, united states research site, tallahassee, florida, united states research site, west palm beach, florida, united states research site, kansas city, missouri, united states research site, bethlehem, pennsylvania, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, houston, texas, united states research site, aalst, belgium research site, leuven, belgium research site, roeselare, belgium research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, deszk, hungary research site, farkasgyepü, hungary research site, törökbálint, hungary research site, ahmedabad, india research site, ahmedabad, india research site, jamnagar, india research site, kochi, india research site, mysuru, india research site, nashik, india research site, nashik, india research site, pune, india research site, thiruvananthapuram, india research site, chuo-ku, japan research site, kanazawa-shi, japan research site, kurume-shi,, japan research site, matsuyama-shi, japan research site, nagoya-shi, japan research site, sendai-shi, japan research site, sunto-gun, japan research site, ube-shi, japan research site, dongjakgu, korea, republic of research site, goyang-si, korea, republic of research site, seodaemun-gu, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suweonsi paldalgu, korea, republic of research site, chihuahua, mexico research site, culiacan, mexico research site, san luis potosí, mexico research site, blaricum, netherlands research site, harderwijk, netherlands research site, tilburg, netherlands research site, białystok, poland research site, poznan, poland research site, prabuty, poland research site, łódź, poland research site, arkhangelsk, russian federation research site, chelyabinsk, russian federation research site, kursk, russian federation research site, moscow, russian federation research site, nal'chik, russian federation research site, p. herzen moscow oncology rese, russian federation research site, sochi, russian federation research site, st. petersburg, russian federation research site, yaroslavl, russian federation research site, dnipro, ukraine research site, kharkiv region, ukraine research site, kirovohrad, ukraine research site, odesa, ukraine research site, uzhhorod, ukraine research site, zaporizhzhia, ukraine research site, dundee, united kingdom research site, hull, united kingdom""]",,https://ClinicalTrials.gov/show/NCT03775486,
333,334,NCT04211337,a study of selpercatinib (ly3527723) in participants with ret-mutant medullary thyroid cancer,LIBRETTO-531,Recruiting,No Results Available,medullary thyroid cancer,drug: selpercatinib|drug: cabozantinib|drug: vandetanib,"progression free survival (pfs) by bicr|treatment failure-free survival (tffs) by blinded independent committee review (bicr)|overall response rate (orr): percentage of participants with complete response (cr) or partial response (pr) by bicr|duration of response (dor) by bicr|overall survival (os)|pfs2 by investigator|comparative tolerability: percentage of time with high side effect bother based on the functional assessment of cancer therapy-side effects (fact-gp5)|the concordance of the local lab and the central lab ret results: percentage of participants with ret-positive specimens as called by the central lab, which is also ret-positive as called by a local lab (positive percent agreement)","loxo oncology, inc.|eli lilly and company",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,400.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17478|J2G-MC-JZJB|2019-001978-28,"February 11, 2020","May 20, 2024","November 13, 2026","December 26, 2019",,"April 19, 2022","[""university of alabama at birmingham, birmingham, alabama, united states mayo clinic hospital, phoenix, arizona, united states city of hope national medical center, duarte, california, united states ucla medical center, los angeles, california, united states university of california, davis - health systems, sacramento, california, united states ucsf medical center at mission bay, san francisco, california, united states los angeles biomedical research institute at harbor - ucla medical, torrance, california, united states mayo clinic in florida, jacksonville, florida, united states emory university, atlanta, georgia, united states university of chi med center, chicago, illinois, united states massachusetts general hospital, boston, massachusetts, united states university of michigan, ann arbor, michigan, united states mayo clinic, rochester, minnesota, united states washington university medical school, saint louis, missouri, united states memorial sloan kettering cancer center, new york, new york, united states university of cincinnati cancer institute, cincinnati, ohio, united states ohio state university medical center, columbus, ohio, united states university of pennsylvania hospital, philadelphia, pennsylvania, united states thomas jefferson university, philadelphia, pennsylvania, united states university of texas md anderson cancer center, houston, texas, united states university of wisconsin-madison hospital and health clinic, madison, wisconsin, united states chris o'brien lifehouse, camperdown, new south wales, australia royal north shore hospital, st. leonards, new south wales, australia peter maccallum cancer centre, melbourne, victoria, australia the alfred hospital, melbourne, victoria, australia sir charles gairdner hospital, nedlands, western australia, australia universitair ziekenhuis antwerpen, edegem, belgium centre hospitalier universitaire sart tilman, liege, belgium oncocentro bh, belo horizonte, minas gerais, brazil hospital de cancer de londrina, londrina, paraná, brazil hospital de clinicas de porto alegre, porto alegre, rio grande do sul, brazil instituto de educação, pesquisa e gestão em saúde, rio de janeiro, rj, brazil fundação pio xii - hospital de câncer de barretos, barretos, sao paulo, brazil clinica onco star, sao paulo, sp, brazil hospital puc-campinas, campinas, são paulo, brazil hospital das clinicas da fmrp, ribeirão preto, são paulo, brazil inca hospital do câncer iii, rio de janeiro, brazil oncoclinicas rio de janeiro s.a., rio de janeiro, brazil soc. beneficente de senhoras hospital sirio libanes-oncology, sao paolo, brazil icesp - instituto do câncer do estado de são paulo, sao paulo, brazil centro paulista de oncologia, são paulo, brazil london health science centre - victoria hospital, london, ontario, canada princess margaret hospital, toronto, ontario, canada anhui provincial hospital, hefei, anhui, china beijing tongren hospital affiliated to capital medical unive, beijing, beijing, china the first affiliated hospital of fujian medical university, fujian, fuzhou, china gansu province cancer hospital, lanzhou, gansu, china sun yat-sen university cancer center, guangzhou, guangdong, china harbin medical university cancer hospital, harbin, heilongjiang, china henan cancer hospital, zhengzhou, henan, china hunan cancer hospital, changsha, hunan, china jilin cancer hospital, chang chun, ji lin, china nanjing drum tower hospital the affiliated hospital of nanjing university medical school, nanjing, jiangsu, china jinan central hospital, jinan, shandong, china fudan university shanghai cancer center, shanghai, shanghai, china west china hospital of sichuan university, cheng du, sichuan, china first affiliated hospital of kunming medical university, kunming, yunnan, china zhejiang provincial people's hospital, hangzhou, zhejiang, china sir run run shaw hospital, hangzhou, zhejiang, china zhejiang cancer hospital, hangzhou, zhejiang, china chongqing cancer hospital, chongqing, china tianjin medical university cancer institute and hospital, tianjin, china fakultni nemocnice brno, brno, czechia fakultni nemocnice olomouc, olomouc, czechia fakultni nemocnice v motole, praha 5, czechia assistance publique hôpitaux de marseille - hôpital nord, marseille, bouches-du-rhône, france centre georges françois leclerc, dijon, côte-d'or, france centre hospitalier universitaire d'angers, angers, maine-et-loire, france centre jean perrin - centre régional de lutte contre le cancer d'auvergne, clermont-ferrand, puy-de-dôme, france centre leon berard, lyon, rhône-alpes, france institut bergonié - centre régional de lutte contre le cancer de bordeaux et sud ouest, bordeaux, france centre françois baclesse, caen cedex 5, france hôpital c. huriez, lille, france hopital pitie salpetriere -unité thyroïde-tumeurs endocrines, paris- cedex 13, france institut de cancérologie strasbourg europe, strasbourg, france institut claudius regaud, toulouse cedex 9, france gustave roussy, villejuif cedex, france klinikum der universität münchen großhadern, münchen, bayern, germany universitätsklinikum würzburg a. ö. r., würzburg, bayern, germany medizinische hochschule hanover, hannover, niedersachsen, germany universitätsmedizin johannes gutenberg universität mainz, mainz, rheinland-pfalz, germany charité campus mitte, berlin, germany universitaetsklinikum essen, essen, germany studiengesellschaft hämato-onkologie hamburg - prof laack & partner, hamburg, germany otto-von-guericke-universität, magdeburg, germany alexandra general hospital of athens, athens, attikí, greece university general hospital of heraklion, heraklion, irakleío, greece european interbalkan medical center, thessaloniki, thessaloníki, greece regional cancer centre, trivandrum, kerala, india hcg manavata cancer centre, nashik, maharashtra, india ruby hall clinic and grant medical foundation, pune, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india apollo gleneagles hospitals kolkata, kolkata, west bengal, india postgraduate institute of medical education & research, chandigarh, india hadassah medical center, jerusalem, israel rabin medical center, petach tikva, israel sheba medical center, ramat gan, israel istituto nazionale dei tumori, milano, lombardie, italy ospedale san luca, irccs istituto auxologico, milano, milan, italy polic.umberto i -univ. la sapienza, roma, rome, italy a.o.u. senese policlinico santa maria alle scotte, siena, si, italy istituto oncologico veneto irccs, padova, veneto, italy ospedale garibaldi-nesima, catania, italy azienda ospedaliera universitaria federico ii, napoli, italy azienda ospedlaliero-univeristaria pisana, stabilimento ospedaliero di cisanello, pisa, italy i.f.o. istituto nazionale tumori regina elena, roma, italy azienda ospedaliero-universitaria s.giovanni battista, torino, italy aichi cancer center hospital, nagoya, aichi, japan national cancer center hospital east, kashiwa, chiba, japan hokkaido university hospital, sapporo, hokkaido, japan kobe university hospital, kobe, hyogo, japan yokohama city university hospital, yokohama, kanagawa, japan osaka university hospital, suita, osaka, japan japanese foundation for cancer research, koto, tokyo, japan national hospital organization kyushu medical center, fukuoka, japan national cancer center, goyang-si, gyeonggi-do, korea, republic of seoul national university bundang hospital, seongnam-si, gyeonggi-do, korea, republic of chonnam national university hwasun hospital, hwasun-gun, jeollanam do, korea, republic of seoul national university hospital, seoul, seoul, korea, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of samsung medical center, seoul, korea, republic of nederlands kanker instituut - antoni van leeuwenhoek, amsterdam, netherlands university medical center groningen, groningen, netherlands leids universitair medisch centrum, leiden, netherlands maastricht umc+, maastricht, netherlands erasmus medisch centrum, rotterdam, netherlands narodowy instytut onkologii im. marii skłodowskiej-curie, gliwice, poland swietokrzyskie centrum onkologii, samodzielny publiczny zaklad opieki zdrowotnej, kielce, poland national medical research center of radiology obninsk, obninsk, kaluga region, russian federation clinic of advanced medical technologies n. a. nicolay i. pirogov (policlinic, hospital), saint-petersburg, northwestern federal district, russian federation llc evimed, chelyabinsk, russian federation blokhin cancer research center, moscow, russian federation national medical research center of endocrinology of ministry of health dept, moscow, russian federation saint-petersburg city clinical oncology dispensary, saint-petersburg, russian federation hospital universitario virgen de la victoria, malaga, andalucia, spain hospital universitari vall d'hebron, barcelona, barcelona [barcelona], spain hospital universitari de girona dr. josep trueta, girona, barcelona, spain hospital universitario ramón y cajal, madrid, madrid, comunidad de, spain clinica universidad de navarra, pamplona, navarra, spain clinica universitaria de navarra, pamplona, navarra, spain institut catala d'oncologia, barcelona, spain hospital general universitario gregorio marañon, madrid, spain hospital clinico san carlos, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital universitario la paz, madrid, spain hospital universitario miguel servet, zaragoza, spain china medical university hospital, taichung, taiwan national cheng-kung uni. hosp., tainan, taiwan national taiwan university hospital, taipei, taiwan gartnavel general hospital, glasgow, glasgow city, united kingdom university college hospital - london, london, greater london, united kingdom royal marsden nhs trust, london, greater london, united kingdom velindre cancer centre, cardiff, south glamorgan, united kingdom weston park hospital, sheffield, south yorkshire, united kingdom royal marsden hospital, sutton, surrey, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04211337,thyroid
334,335,NCT01230710,a study of tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer following 4 cycles of platinum-based chemotherapy without disease progression,,Completed,Has Results,non-small cell lung cancer,drug: erlotinib,percentage of participants with progression-free survival at week 52|progression-free survival (pfs)|overall survival|percentage of participants with a complete response (cr) or a partial response (pr)|percentage of participants with disease control,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 4,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML25478,March 2011,September 2013,September 2013,"October 29, 2010","March 30, 2015","March 30, 2015","['bangalore, india chennai, india delhi, india hyderabad, india jaipur, india kolkata, india nasik, india']",,https://ClinicalTrials.gov/show/NCT01230710,
335,336,NCT03191786,a study of atezolizumab compared with a single-agent chemotherapy in treatment naïve participants with locally advanced or recurrent or metastatic non-small cell lung cancer who are deemed unsuitable for platinum-doublet chemotherapy,IPSOS,"Active, not recruiting",No Results Available,non-small cell lung cancer,"drug: atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody|drug: vinorelbine|drug: gemcitabine","overall survival|percentage of participants who are alive at specified timepoints|percentage of participants with objective response, as determined by the investigator using response evaluation criteria in solid tumors (recist) version 1.1 (v1.1)|progression-free survival (pfs), as determined by the investigator using recist v1.1|duration of response, as determined by the investigator using recist v1.1|percentage of participants with adverse events (aes)|change from baseline in european organisation for research and treatment of cancer quality of life questionnaire - core 30 (eortc-qlq-c30) score|change from baseline in eortc qlq supplementary lung cancer module 13 (eortc qlq-lc13) score|time to deterioration in patient-reported lung cancer symptoms as assessed by eortc qlq-c30 score|time to deterioration in patient-reported lung cancer symptoms as assessed by eortc qlq-lc13 score|overall survival in participants with pd-l1 positive status|progression-free survival (pfs), as determined by the investigator using recist v1.1 in participants with pd-l1 positive status",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,453.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO29872|2015-004105-16,"September 11, 2017","May 31, 2022","July 31, 2022","June 19, 2017",,"February 16, 2022","['fundación cenit para la investigación en neurociencias, buenos aires, argentina hospital privado de comunidad, mar del plata, argentina centro de investigacion; clinica - clinica viedma s.a., viedma, argentina uz brussel, brussel, belgium grand hôpital de charleroi notre dame, charleroi, belgium uz leuven gasthuisberg, leuven, belgium hospital sao lucas - pucrs, porto alegre, rs, brazil hospital nossa senhora da conceicao, porto alegre, rs, brazil instituto do cancer do estado de sao paulo - icesp, sao paulo, sp, brazil umhat dr georgi stranski; clinic of chemotherapy, pleven, bulgaria complex oncology center (coc)-plovidiv, plovdiv, bulgaria bcca-vancouver cancer centre, vancouver, british columbia, canada regional health authority a vitalite health network, moncton, new brunswick, canada ottawa hospital research institute, ottawa, ontario, canada princess margaret cancer center, toronto, ontario, canada jewish general hospital, montreal, quebec, canada beijing cancer hospital, beijing, china hu nan provincial cancer hospital, changsha, china the second affiliated hospital of zhejiang university school of medicine, hangzhou city, china anhui provincial hospital, hefei, china shanghai chest hospital, shanghai, china tianjin cancer hospital, tianjin, china union hospital of tongji medical college, dept. of cancer center; cancer center, wuhan, china fundacion cardioinfantil, bogota, colombia fundación centro de investigación clínica cic, medellin, colombia oncomedica s.a., monteria, colombia oncólogos de occidente, pereira, colombia fakultni nemocnice olomouc; pneumologicka klinika, olomouc, czechia odense universitetshospital, onkologisk afdeling r, odense c, denmark evang. lungenklinik berlin klinik für pneumologie, berlin, germany lungenclinic großhansdorf gmbh, großhansdorf, germany krankenhaus martha-maria halle-doelau ggmbh; klinik fuer innere medizin ii, halle, germany fachklinik für lungenerkrankungen, immenhausen, germany klinikum der philipps-universität marburg, marburg, germany asklepios klinik münchen-gauting, münchen-gauting, germany universitätsklinikum regensburg; klinik und poliklinik für innere medizin ii, pneumologie, regensburg, germany universitätsklinikum tübingen; innere medizin viii, medizinische onkologie und pneumologie, tübingen, germany indraprastha apollo hospitals, new delhi, delhi, india rajiv gandhi cancer inst.&research center; medical oncology, new delhi, delhi, india healthcare global cancer centre; medical oncology, ahmedabad, gujarat, india kailash cancer hospital and research center, vadodara, gujarat, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india kokilaben dhirubhai ambani hospital & medical research institute; department of rheumatologz, mumbai, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india indo-american cancer hospital & research center, hyderabad, telangana, india tata medical center; department of medical oncology, kolkata, west bengal, india p.d. hinduja nat. hospital & med. research centre, mahim (west), india max super speciality hospital, new delhi, india grant medical foundation, ruby hall clinic, pune, india mater misericordiae university hospital - institute for cancer research, dublin, ireland university hospital limerick - clinical trials department, limerick, ireland ospedale provinciale santa maria delle croci; oncologia medica, ravenna, emilia-romagna, italy azienda ospedaliera san camillo forlanini; u.o.c. pneumologia ad indirizzo oncologico 1, roma, lazio, italy azienda ospedaliera san gerardo di monza, monza mi, lombardia, italy kazakh scientific research institution of oncology and radiology; chemotherapy department, almaty, kazakhstan almaty cancer hospital; chemotherapy department, almaty, kazakhstan centre hospitalier de luxembourg, luxembourg, luxembourg health pharma professional research, cdmx, mexico city (federal district), mexico oncologico potosino, san luis potosí, san luis potosi, mexico centro estatal de cancerologia de chihuahua; oncology, chihuahua, mexico mazowieckie centrum leczenia chorob pluc i gruzlicy; oddzial iii, otwock, poland narod.inst.onkol. im. m.sklodowskiej - curie-panst.inst.bad; klinika nowot.pluca i klatki piers, warszawa, poland chuc - unidade de pneumologia oncológica; hospital de dia de oncologia edificio sao jeronimo, coimbra, portugal ipo do porto; servico de oncologia medica, porto, portugal institutul oncologic prof. dr. ion chiricuta cluj napoca; oncologie medicala, cluj napoca, romania centrul de radioterapie amethyst, floresti, romania oncocenter timisoara, timişoara, romania specializovana nemocnica sv. svorada zobor, n.o., nitra, slovakia fakultna nemocnica trnava, trnava, slovakia complejo hospitalario universitario de santiago (chus) ; servicio de oncologia, santiago de compostela, la coruña, spain hospital de cruces; servicio de oncologia, bilbao, vizcaya, spain institut catala d oncologia hospital duran i reynals, barcelona, spain hospital universitario de la princesa; servicio de oncologia, madrid, spain hospital universitario clínico san carlos; servicio de oncologia, madrid, spain hospital clinico universitario virgen de la victoria; servicio de oncologia, malaga, spain hospital general universitario j.m morales meseguer; servicio de oncologia, murcia, spain hospital universitario virgen macarena; servicio de oncologia, sevilla, spain hospital arnau de vilanova (valencia) servicio de oncologia, valencia, spain ospedale regionale di bellinzona medizin onkologie, bellinzona, swaziland spital sts ag - spital thun medizin onkologie; medizinische klinik, thun, switzerland kantonsspital winterthur; medizinische onkologie, winterthur, switzerland clatterbridge cancer centre, bebington, united kingdom birmingham heartlands hospital; department of haematology, birmingham, united kingdom royal cornwall hospital; dept of clinical oncology, cornwall, united kingdom new victoria hospital, glasgow, united kingdom uclh - clinical trials pharmacy b&d centre, london, united kingdom christie hospital nhs trust; medical oncology, manchester, united kingdom york district hospital; haematology/oncology department, york, united kingdom bach mai hospital, hanoi, vietnam cho ray hospital, hochiminh city, vietnam']",,https://ClinicalTrials.gov/show/NCT03191786,
336,337,NCT03875235,durvalumab or placebo in combination with gemcitabine/cisplatin in patients with 1st line advanced biliary tract cancer (topaz-1),TOPAZ-1,"Active, not recruiting",No Results Available,biliary tract neoplasms,drug: durvalumab|drug: placebo,"overall survival|pfs according to recist 1.1 using investigator assessment|orr according to recist 1.1 using investigator assessment|dor according to recist 1.1 using investigator assessment|eortc qlq-c30 and eortc qlq-bil21|pfs, orr, dor, and dcr according to recist 1.1 using investigator assessments and os by pd-l1 expression|serum concentration of durvalumab (peak and trough concentration)|tiered results of adas for durvalumab",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,810.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D933AC00001,"April 16, 2019","August 11, 2021","March 31, 2025","March 14, 2019",,"April 20, 2022","['research site, los angeles, california, united states research site, orange, california, united states research site, washington, district of columbia, united states research site, fort myers, florida, united states research site, saint petersburg, florida, united states research site, westwood, kansas, united states research site, louisville, kentucky, united states research site, burlington, massachusetts, united states research site, saint louis, missouri, united states research site, chapel hill, north carolina, united states research site, portland, oregon, united states research site, philadelphia, pennsylvania, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, seattle, washington, united states research site, buenos aires, argentina research site, buenos aires, argentina research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, rosario, argentina research site, san salvador de jujuy, argentina research site, burgas, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, puerto montt, chile research site, santiago, chile research site, temuco, chile research site, viña del mar, chile research site, baoding, china research site, beijing, china research site, beijing, china research site, bengbu, china research site, chongqing, china research site, foshan, china research site, guangzhou, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, hefei, china research site, jinan, china research site, nanchang, china research site, nanjing, china research site, shandong, china research site, shanghai, china research site, shenyang, china research site, suzhou, china research site, xian, china research site, zhengzhou, china research site, zhuhai, china research site, clichy, france research site, dijon cedex, france research site, montpellier cedex 5, france research site, nice, france research site, paris cedex 12, france research site, pessac, france research site, poitiers, france research site, hong kong, hong kong research site, hong kong, hong kong research site, hongkong, hong kong research site, kowloon, hong kong research site, gurgaon, india research site, kolkata, india research site, mumbai, india research site, new delhi, india research site, faenza, italy research site, firenze, italy research site, milano, italy research site, napoli, italy research site, roma, italy research site, verona, italy research site, chuo-ku, japan research site, kashiwa, japan research site, kitaadachi-gun, japan research site, mitaka-shi, japan research site, osaka-shi, japan research site, suita-shi, japan research site, wakayama-shi, japan research site, yokohama-shi, japan research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, gdańsk, poland research site, kościerzyna, poland research site, olsztyn, poland research site, poznan, poland research site, warszawa, poland research site, wrocław, poland research site, łódź, poland research site, barnaul, russian federation research site, kostroma, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, omsk, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, chiayi, taiwan research site, kaohsiung, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, muang, thailand research site, sisaket, thailand research site, ankara, turkey research site, istanbul, turkey research site, izmir, turkey research site, mersin, turkey research site, bristol, united kingdom research site, cambridge, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, oxford, united kingdom research site, romford, united kingdom research site, sheffield, united kingdom']",,https://ClinicalTrials.gov/show/NCT03875235,biliari
337,338,NCT00445458,a phase 1/2 study of hki-272 (neratinib) in combination with paclitaxel (taxol) in subjects with solid tumors and breast cancer,,Completed,Has Results,advanced breast cancer|advanced malignant solid tumors|breast neoplasms,drug: hki-272|drug: paclitaxel,dose limiting toxicity incidence of neratinib in combination with paclitaxel|maximum tolerated dose|objective response rate|maximum plasma concentration of neratinib|area under the concentration-time curve 0-24,"puma biotechnology, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,110.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3144A1-203 / B1891014,"September 11, 2007",May 2011,"February 7, 2018","March 9, 2007","May 9, 2018","July 26, 2018","[""scripps, clinic general, la jolla, california, united states moores uc san diego cancer center, la jolla, california, united states sharp memorial hospital, san diego, california, united states boston university medical center, boston, massachusetts, united states mid-michigan physicians-hos division, lansing, michigan, united states oncology care associates, saint joseph, michigan, united states columbia university medical center, new york, new york, united states ctrc at the university of texas health science center, san antonio, texas, united states institut jules bordet unite du chimiotherapie, brussels, belgium universitair ziekenhuis gent, gent, belgium az groeninge campus maria's voorzienigheid (mv), kortrijk, belgium oncologisch centrum gza - location st augustinus, wilrijk, belgium princess margaret hospital university health network, toronto, ontario, canada the hospital affiliated academy military medical science, chinese people's liberation army, beijing, beijing, china chinese people's liberation army general hospital, beijing, beijing, china tianjin cancer hospital, tianjin, tianjin, china tianjin union medicine center department of oncology, tianjin, tianjin, china cancer hospital, chinese academy of medical sciences, beijing, china peking union medical college hospital of chinese academy of medical sciences, beijing, china unimed medical institute, hong kong, hong kong department of medicine, queen mary hospital, hong kong, hong kong department of surgery queen mary hospital, hong kong, hong kong jehangir clinical development centre, jehangir hospital premises, pune, maharashtra, india m.m.f. joshi hospital & ratna memorial hospital, pune, maharashtra, india tata memorial hospital, mumbai, parel, india birla cancer centre, s.m.s. medical college & hospital, jaipur, rajasthan, india yonsei university health system - severance hospital, seoul, korea, republic of asan medical center, division of oncology, department of internal medicine, seoul, korea, republic of wojewodzki szpital specjalistyczny im. ludwika rydygiera, oddzial onkologii, krakow, poland oddzial chemioterapii centrum onkologii ziemii lubelskiej, lublin, poland city multifield clinical hospital #4 department of chemotherapy, dnipropetrovs'k state medical academy, chair of oncology and medical radiology, dnipropetrovsk, ukraine state oncological regional treatment and diagnostic center department of chemotherapy, lviv, ukraine""]",,https://ClinicalTrials.gov/show/NCT00445458,breast skin
338,339,NCT00415194,a study for patients with head and neck cancer,,Completed,Has Results,head and neck neoplasms,drug: pemetrexed|drug: cisplatin|drug: placebo,overall survival (os)|progression-free survival (pfs)|percent of participants with a tumor response (response rate)|duration of response (dor)|time to treatment worsening in functional assessment of cancer therapy - head and neck cancer (fact-h&n) total score|correlation between biomarkers and treatment effect,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,795.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",8431|H3E-MC-JMHR,December 2006,March 2010,March 2010,"December 22, 2006","April 6, 2011","June 28, 2011","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., orange, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., orlando, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., st. petersburg, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., atlanta, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chicago, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beech grove, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., louisville, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ann arbor, michigan, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., st louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., stony brook, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chapel hill, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oklahoma city, oklahoma, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., north smithfield, rhode island, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., buenos aires, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., s.m. de tucuman, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa fé, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tucumain, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., antwerp, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edegem, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., belo horizonte, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rio de janeiro, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guang zhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nanning, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shanghai, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wu han, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aarhus, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., odense, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., avignon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tours, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., berlin, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., erlangen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., essen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankfurt, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hannover, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heidelberg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., leipzig, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., luebeck, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., budapest, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nyiregyhaza, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bhopal, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hyderabaad, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jaipur, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kochin, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kolkata, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., patna, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pune, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., confreria, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., genova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., milano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., padova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., daegu, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hwasun-gun, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pusan, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., durango, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mexico city, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., michoacan, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., monterrey, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., roma sur, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toluca, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., amsterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nijmegen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gdansk, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., krakow, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., olsztyn, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., warsaw, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san juan, puerto rico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bucharest, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cluj-napoca, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oradea, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., targu mures, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barnaul, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chelyabinsk, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., moscow, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., murmansk, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint petersburg, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bloemfontein, south africa for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., durban, south africa for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., parktown, south africa for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barcelona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., murcia, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pamplona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sevilla, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., valencia, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., changhua, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hualien, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liouying/tainan, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan']",,https://ClinicalTrials.gov/show/NCT00415194,
339,340,NCT00363415,study of pemetrexed and carboplatin compared with etoposide carboplatin to treat extensive-stage small cell lung cancer,,Completed,Has Results,small cell lung cancer,drug: pemetrexed|drug: etoposide|drug: carboplatin,overall survival|overall survival (subgroups)|progression free survival|change from baseline to each cycle in functional assessment of cancer therapy - lung (fact-l)|overall survival (subgroups: ldh<=upper limit of normal and history of brain metastases=yes),eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,908.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9691|H3E-MC-JMHO,August 2006,June 2008,June 2008,"August 15, 2006","October 6, 2009","October 28, 2009","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., huntsville, alabama, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., anchorage, alaska, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fayetteville, arkansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., burbank, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., la jolla, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., los angeles, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mission hills, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., orange, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poway, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fort myers, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jacksonville, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., miami, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., orlando, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chicago, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., springfield, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lexington, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., louisville, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., scarborough, maine, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., boston, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., detroit, michigan, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kansas city, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., st louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lincoln, nebraska, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sparta, new jersey, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., albuquerque, new mexico, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa fe, new mexico, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chapel hill, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., concord, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cincinnati, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbus, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zanesville, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., portland, oregon, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dunmore, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., east stroudsburg, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ephrata, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., media, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., philadelphia, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wilkes-barre, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., charleston, south carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbia, south carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chattanooga, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., knoxville, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nashville, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., austin, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dallas, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fort worth, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., houston, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san antonio, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., richmond, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., everett, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madison, wisconsin, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bahia blanca, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., buenos aires, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mar del plata, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rosario, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tucumain, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., camperdown, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., coffs harbour, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., port macquarie, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wollongong, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brisbane, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chermisdie, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., redcliffe, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., south brisbane, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., townsville, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., adelaide, south australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., woodville, south australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hobart, tasmania, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankston, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., geelong, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wodonga, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., graz, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., linz, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wien, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brussels, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edegem, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., leuven, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liege, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liège, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., florianópolis, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fortaleza, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jau, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sao paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beijing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guang zhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shanghai, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brest, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., caen, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., clichy, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., grenoble, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lille, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lyon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., marseille, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., montpellier, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., borstel, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., freiburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gauting, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., großhansdorf, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hamburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heidelberg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hemer, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kassel, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., köln, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nürnberg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., regensburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rostock, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., stralsund, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heraklion, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., marousi attikis, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pylaia/thessaloniki, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., deszk, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pecs, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., szekesfehervar, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., szombathely, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., torokbalint, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zalaegerszeg, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ahmedabad, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kolkata, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ludhiana, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pune, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bergamo, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., livorno, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., monteforte irpino, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., orbassano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., parma, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ravenna, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san sisto, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., amsterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., arnhem, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., den bosch, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., groningen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., harderwijk, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heerlen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., auckland, new zealand for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., christchurch, new zealand for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wellington, new zealand for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gdansk, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., krakow-nowa huta, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., otwock, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., szczecin-zdunowo, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zabrze-biskupice, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., coimbra, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lisbon, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., porto, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa maria da feira, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vila nova de gaia, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san juan, puerto rico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bucharest, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cluj-napoca, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chelyabinsk, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., engels, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kazan, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., murmansk, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint petersburg, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., stavropol, russian federation for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cape town, south africa for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., durban, south africa for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., parktown, south africa for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., alicante, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., badalona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barakaldo, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barcelona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zaragoza, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., niao sung hsiang, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taichung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., besevler/ankara, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gaziantep, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., istanbul, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., izmir, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., samsun, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bristol, avon, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., truro, cornwall, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chelmsford, essex, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aberdeen, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., glasgow, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., birmingham, west midlands, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wolverhampton, west midlands, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00363415,
340,341,NCT01185314,to study the changes in protein in lung cells of asian patients with advanced non-small cell lung cancer (nsclc),PIONEER,Completed,No Results Available,non small cell lung cancer,procedure: testing for mutation status,egfr mutation status of asian patients with advanced nsclc,astrazeneca,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,1270.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,D7913L00086,September 2010,July 2011,July 2011,"August 19, 2010",,"August 8, 2011","['research site, beijing, beijing, china research site, guangzhou, guangdong, china research site, shijiazhuang, hebei, china research site, zhengzhou, henan, china research site, wuhan, hubei, china research site, changchun, jilin, china research site, shenyang, liaoning, china research site, jinan, shandong, china research site, shanghai, shanghai, china research site, taiyuan, shanxi, china research site, chengdu, sichuan, china research site, tianjin, tianjin, china research site, hong kong, hong kong research site, rohini, delhi, india research site, vadodara, gujarat, india research site, kochi, kerala, india research site, mumbai, maharashtra, india research site, pune, maharashtra, india research site, chennai, india research site, kolkata, india research site, cebu city, philippines research site, manila city, philippines research site, pasay city, philippines research site, quezon city, philippines research site, taguig city, philippines research site, chiayi, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, bangkok, thailand research site, chiang mai, thailand research site, songkla, thailand research site, hanoi, vietnam research site, ho chi minh city, vietnam']",,https://ClinicalTrials.gov/show/NCT01185314,
341,342,NCT01101334,study of erlotinib with or without investigational drug (cs-7017) in subjects with advanced non-small cell lung cancer,,Completed,Has Results,advanced non-small cell lung cancer (nsclc),drug: cs-7017|drug: erlotinib,summary of analysis of progression-free survival following administration of cs-7017 and erlotinib in participants with advanced non-small cell lung cancer who failed first line therapy|analysis of overall survival following administration of cs-7017 and erlotinib in participants with advanced non-small cell lung cancer who failed first line therapy|overall response rate following administration of cs-7017 and erlotinib in participants with advanced non-small cell lung cancer who failed first line therapy|summary of treatment-emergent adverse events (teaes) occurring in ≥10% of participants following administration of cs-7017 and erlotinib in participants with advanced non-small cell lung cancer who failed first line therapy,"daiichi sankyo, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CS7017-A-U204,March 2010,April 2013,April 2013,"April 9, 2010","June 16, 2020","June 16, 2020","[""dhha, denver, colorado, united states gabrail cancer center, canton, ohio, united states providence regional medical center everett, everett, washington, united states zentrum fur pneumologie und thoraxchirurgie, gauting, germany king george hospital, visakhapatnam, andhra pradesh, india vedanta institute of medical sciences, ahmedabad, gujarat, india kodlikeri memorial hospital, aurangabad, maharashtra, india tata memorial hospital, mumbai, maharashtra, india noble hospital, pune, maharastra, india apollo speciality hospital, chennai, tamil nadu, india meenakshi mission hospital, madurai, tamil nadu, india orchid nursing home, kolkata, west bengal, india st. vincent's hospital, gyeonggi-do, korea, republic of hwasun hospital, jeonnam, korea, republic of severance hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of asan medical center, seoul, korea, republic of""]",,https://ClinicalTrials.gov/show/NCT01101334,
342,343,NCT00550173,a study for non-smoker patients with nonsquamous non-small cell lung cancer,,Completed,Has Results,non-small-cell lung cancer,drug: pemetrexed|drug: erlotinib,"progression-free survival (pfs)|percentage of participants with a tumor response of complete response (cr) or partial response (pr) [tumor response rate (trr)]|overall survival (os)|number of participants with adverse events|percentage of participants with cr, pr, and stable disease (sd) - disease control rate (dcr)|time to worsening of symptoms (tws) on lung cancer symptoms scale (lcss)|number of participants with mutated or non-mutated epidermal growth factor receptor (egfr) genotype status|probability of os at 12 months",eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,247.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10725|H3E-MC-S103,November 2007,January 2012,January 2012,"October 29, 2007","February 13, 2013","February 13, 2013","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barretos, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ijui, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., são paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beijing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nanning, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shanghai, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sha tin, hong kong for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ahmedabad, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bhopal, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hyderabaad, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jaipur, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kochin, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kolkata, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madurai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mohali, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vishakhapatnam, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jin-ju-si, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., suwon-city, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., changhua, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taichung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tao-yuan, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poole, dorset, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chelmsford, essex, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aberdeen, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guildford, surrey, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00550173,
343,344,NCT00347919,pazopanib plus lapatinib compared to lapatinib alone in subjects with advanced or metastatic breast cancer,,Completed,Has Results,"neoplasms, breast",drug: pazopanib (gw786034) 400 mg|drug: lapatinib (gw572016) 1500 mg|drug: lapatinib (gw572016) 1000 mg|drug: pazopanib (gw786034) 800 mg,percentage of participants with progressive disease at week 12 in cohort 1|overall survival for cohort 1|response at week 12 for cohort 1 and cohort 2|duration of response in cohort 1|time to response (complete or partial response) in cohort 1 and cohort 2|percentage of participants with progressive disease at week 12,glaxosmithkline,Female,"21 Years and older   (Adult, Older Adult)",Phase 2,189.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VEG20007,July 2006,August 2008,March 2015,"July 4, 2006","February 21, 2011","February 25, 2016","['gsk investigational site, jonesboro, arkansas, united states gsk investigational site, alhambra, california, united states gsk investigational site, bakersfield, california, united states gsk investigational site, fullerton, california, united states gsk investigational site, long beach, california, united states gsk investigational site, los angeles, california, united states gsk investigational site, northridge, california, united states gsk investigational site, oxnard, california, united states gsk investigational site, redondo beach, california, united states gsk investigational site, santa barbara, california, united states gsk investigational site, santa maria, california, united states gsk investigational site, indianapolis, indiana, united states gsk investigational site, metairie, louisiana, united states gsk investigational site, henderson, nevada, united states gsk investigational site, bronx, new york, united states gsk investigational site, akron, ohio, united states gsk investigational site, dallas, texas, united states gsk investigational site, lubbock, texas, united states gsk investigational site, san antonio, texas, united states gsk investigational site, edmonton, alberta, canada gsk investigational site, halifax, nova scotia, canada gsk investigational site, weston, ontario, canada gsk investigational site, besançon, france gsk investigational site, hyeres, france gsk investigational site, lille cedex, france gsk investigational site, lyon cedex 03, france gsk investigational site, marseille cedex bp 156, france gsk investigational site, paris cedex 5, france gsk investigational site, strasbourg, france gsk investigational site, budapest, hungary gsk investigational site, budapest, hungary gsk investigational site, győr, hungary gsk investigational site, bangalore, india gsk investigational site, delhi, india gsk investigational site, jaipur, india gsk investigational site, mumbai, india gsk investigational site, pune, india gsk investigational site, pune, india gsk investigational site, trivandrum, india gsk investigational site, haifa, israel gsk investigational site, jerusalem, israel gsk investigational site, petach tikva, israel gsk investigational site, ramat gan, israel gsk investigational site, rehovot, israel gsk investigational site, tel aviv, israel gsk investigational site, incheon, korea, republic of gsk investigational site, seodaemun-gu, seoul, korea, republic of gsk investigational site, songpa-gu, seoul, korea, republic of gsk investigational site, suwon, kyonggi-do, korea, republic of gsk investigational site, bandar tun razak, cheras, malaysia gsk investigational site, petaling jaya, malaysia gsk investigational site, merida, yucatán, mexico gsk investigational site, mexico city, mexico gsk investigational site, islamabad, pakistan gsk investigational site, karachi, pakistan gsk investigational site, lahore, pakistan gsk investigational site, lahore, pakistan gsk investigational site, multan, pakistan gsk investigational site, callao, peru gsk investigational site, lima, peru gsk investigational site, lima, peru gsk investigational site, elblag, poland gsk investigational site, kielce, poland gsk investigational site, kraków, poland gsk investigational site, olsztyn, poland gsk investigational site, olsztyn, poland gsk investigational site, warszawa, poland gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, singapore, singapore gsk investigational site, bangkok, thailand gsk investigational site, chelmsford, essex, united kingdom gsk investigational site, manchester, lancashire, united kingdom gsk investigational site, sutton, surrey, united kingdom gsk investigational site, birmingham, united kingdom gsk investigational site, glasgow, united kingdom gsk investigational site, ipswich, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, nottingham, united kingdom gsk investigational site, plymouth, united kingdom']",,https://ClinicalTrials.gov/show/NCT00347919,breast
344,345,NCT00537381,an efficacy and safety study of intetumumab (cnto 95) in participants with metastatic hormone refractory prostate cancer,,Completed,Has Results,prostatic neoplasms,drug: docetaxel|drug: prednisone|biological: intetumumab|drug: placebo,progression-free survival (pfs)|number of participants with best overall response (or)|number of participants with prostate specific antigen (psa) response|overall survival|percent change from baseline in 'c-telopeptide of type i collagen (ctx)' marker concentration|percent change from baseline in 'n-telopeptide of type i collagen (ntx)' marker concentration|percent change from baseline in 'vascular endothelial growth factor (vegf)' marker concentration,"centocor, inc.",Male,"18 Years and older   (Adult, Older Adult)",Phase 2,131.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR013249|C1034T08|2006-005766-39,May 2007,November 2009,November 2009,"October 1, 2007","May 20, 2013","June 20, 2013","['birmingham, alabama, united states los angeles, california, united states san bernardino, california, united states wichita, kansas, united states shreveport, louisiana, united states charleston, south carolina, united states n charleston, south carolina, united states graz, austria wels n/a, austria wien, austria antwerpen, belgium brasschaat, belgium brussel, belgium doornik, belgium haine-saint-paul, la louviere, belgium leuven, belgium liÿge, belgium ottignies, belgium roeselare, belgium wilrijk, belgium aschaffenburg, germany berlin, germany freiburg, germany kirchheim, germany köln, germany marburg, germany münchen, germany tübingen, germany ahmedabad, india bangalore, india chennai, india mumbai, india new delhi, india pune, india apeldoorn, netherlands den haag, netherlands leiden, netherlands maastricht, netherlands nijmegen, netherlands bydgoszcz, poland gdansk, poland inowroclaw, poland koscierzyna, poland lodz, poland lublin, poland ekaterinburg, russian federation moscow n/a, russian federation moscow region, russian federation moscow, russian federation st petersburg, russian federation st-petersburg leningrad, russian federation voronezh, russian federation yaroslavl, russian federation johannesburg gauteng, south africa pretoria gauteng, south africa pretoria, south africa cambridge, united kingdom leicester, united kingdom lincoln, united kingdom london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00537381,prostat
345,346,NCT00949910,an expanded access program of tarceva (erlotinib) in participants with advanced non-small cell lung cancer (nsclc),,Completed,Has Results,non-small cell lung cancer,drug: erlotinib,percentage of participants with objective response according to response evaluation criteria in solid tumors (recist)|percentage of participants with disease control according to recist|percentage of participants by best overall response according to recist|percentage of participants with death or disease progression according to recist|progression-free survival (pfs) according to recist|percentage of participants who died|overall survival (os),hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 4,6586.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO18109|2004-000564-28|INC-9042,November 2004,April 2009,April 2009,"July 31, 2009","October 4, 2016","October 5, 2016","[""tirana, albania buenos aires, argentina buenos aires, argentina buenos aires, argentina buenos aires, argentina buenos aires, argentina córdoba, argentina la plata, argentina salta, argentina santa fe, argentina adelaide, australia camperdown, australia chermside, australia frankston, australia fremantle, australia geelong, australia kurralta park, australia malvern, australia melbourne, australia melbourne, australia perth, australia st. leonards, australia sydney, australia sydney, australia tugun, australia waratah, australia wodonga, australia wollongong, australia bludesch, austria grimmenstein, austria innsbruck, austria klagenfurt, austria kufstein, austria leoben, austria linz, austria linz, austria natters, austria oberpullendorf, austria salzburg, austria wels, austria wien, austria wien, austria wien, austria wien, austria wien, austria zams, austria aalst, belgium antwerpen, belgium antwerpen, belgium antwerpen, belgium arlon, belgium baudour, belgium blankenberge, belgium borgerhout, belgium boussu, belgium brasschaat, belgium bruxelles, belgium bruxelles, belgium bruxelles, belgium bruxelles, belgium bruxelles, belgium charleroi, belgium edegem, belgium genk, belgium gent, belgium gilly, belgium godinne, belgium gosselies, belgium haine-saint-paul, belgium hasselt, belgium kortrijk, belgium libramont, belgium liege, belgium mons, belgium namur, belgium oostende, belgium ottignies, belgium oudenaarde, belgium roeselare, belgium sint-niklaas, belgium tielt, belgium tournai, belgium turnhout, belgium wilrijk, belgium banja luka, bosnia and herzegovina sarajevo, bosnia and herzegovina belo horizonte, brazil belo horizonte, brazil belo horizonte, brazil belo horizonte, brazil brasilia, brazil brasilia, brazil campinas, brazil campinas, brazil caxias do sul, brazil curitiba, brazil curitiba, brazil curitiba, brazil fortaleza, brazil fortaleza, brazil fortaleza, brazil ijui, brazil jaú, brazil joao pessoa, brazil porto alegre, brazil porto alegre, brazil porto alegre, brazil porto alegre, brazil recife, brazil ribeirao preto, brazil rio de janeiro, brazil rio de janeiro, brazil rio de janeiro, brazil rio de janeiro, brazil salvador, brazil salvador, brazil salvador, brazil santos, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sao paulo, brazil sorocaba, brazil plovdiv, bulgaria sofia, bulgaria sofia, bulgaria sofia, bulgaria varna, bulgaria santiago, chile beijing, china beijing, china beijing, china beijing, china chengdu, china guangzhou, china guangzhou, china hangzhou, china harbin, china nanjing, china shanghai, china shanghai, china shanghai, china tianjin, china wuhan, china bogota, colombia cali, colombia zagreb, croatia brno, czech republic hradec kralove, czech republic olomouc, czech republic plzen, czech republic praha, czech republic guayaquil, ecuador quito, ecuador cairo, egypt giza, egypt giza, egypt tallin, estonia tartu, estonia haemeenlinna, finland helsinki, finland helsinki, finland joensuu, finland kuopio, finland oulu, finland pori, finland tampere, finland turku, finland vaasa, finland amberg, germany augsburg, germany aurich, germany bad berka, germany berlin, germany berlin, germany berlin, germany bonn, germany celle, germany dortmund, germany dresden, germany essen, germany flensburg, germany frankfurt am main, germany frankfurt, germany freiburg, germany gauting, germany gerlingen, germany giessen, germany grosshansdorf, germany halle (saale), germany hamburg, germany hamburg, germany heidelberg, germany herne, germany homburg/saar, germany kassel, germany koblenz, germany köln, germany köln, germany leipzig, germany leverkusen, germany lostau, germany löwenstein, germany lübeck, germany mainz, germany mannheim, germany minden, germany muenchen, germany mönchengladbach, germany münchen, germany münchen, germany neuruppin, germany nürnberg, germany oldenburg, germany osnabrück, germany rostock, germany saarbruecken, germany trier, germany ulm, germany wangen, germany wiesbaden, germany wuerselen, germany wuppertal, germany athens, greece athens, greece athens, greece haidari, greece heraklion, greece neo faliro, greece thessaloniki, greece thessaloniki, greece thessaloniki, greece guatemala city, guatemala hong kong, hong kong hong kong, hong kong budapest, hungary budapest, hungary budapest, hungary deszk, hungary kecskemet, hungary mátraháza, hungary nyíregyháza, hungary pecs, hungary torokbalint, hungary bangalore, india new delhi, india new delhi, india pune, india vellore, india jakarta, indonesia cork, ireland dublin, ireland dublin, ireland dublin, ireland dublin, ireland galway, ireland ashkelon, israel beer sheva, israel haifa, israel haifa, israel holon, israel jerusalem, israel jerusalem, israel kfar saba, israel nahariya, israel petach tikva, israel ramat-gan, israel rehovot, israel safed, israel tel aviv, israel zerifin, israel ancona, italy avellino, italy aviano, italy bari, italy benevento, italy bergamo, italy bollate, italy bologna, italy bologna, italy brescia, italy candiolo, italy catania, italy catanzaro, italy cosenza, italy cuneo, italy fabriano, italy feltre - bl, italy firenze, italy genova, italy la spezia, italy lido di camaiore, italy livorno, italy meldola, italy messina, italy milano, italy milano, italy milano, italy mirano, italy modena, italy napoli, italy napoli, italy nuoro, italy orbassano, italy palermo, italy palermo, italy parma, italy pavia, italy perugia, italy pescara, italy pisa, italy rionero in vulture, italy roma, italy roma, italy roma, italy roma, italy roma, italy roma, italy salerno, italy salerno, italy san giovanni rotondo, italy sassari, italy siena, italy sondrio, italy taormina, italy torino, italy trento, italy udine, italy bundang city, korea, republic of busan, korea, republic of cheonan, korea, republic of daegu, korea, republic of daegu, korea, republic of daegu, korea, republic of daejeon, korea, republic of gwangju, korea, republic of iksan, korea, republic of incheon, korea, republic of kyunggi-do, korea, republic of pusan, korea, republic of pusan, korea, republic of pusan, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of suwon, korea, republic of riga, latvia riga, latvia kaunas, lithuania vilnius, lithuania kuala lumpur, malaysia acapulco, mexico chihuahua, mexico chihuahua, mexico guadalajara, mexico guadalajara, mexico juarez, mexico leon, mexico leon, mexico matamoros, mexico merida, mexico merida, mexico mexicali, mexico mexico city, mexico mexico city, mexico mexico city, mexico mexico city, mexico mexico city, mexico mexico city, mexico mexico city, mexico mexico city, mexico mexico city, mexico mexico city, mexico monterrey, mexico monterrey, mexico monterrey, mexico monterrey, mexico obregon, mexico obregon, mexico puebla, mexico san luis potosi, mexico tampico, mexico tijuana, mexico toluca, mexico torreon, mexico zapopan, mexico 's hertogenbosch, netherlands alkmaar, netherlands amersfoort, netherlands amstelveen, netherlands amsterdam, netherlands amsterdam, netherlands amsterdam, netherlands amsterdam, netherlands amsterdam, netherlands arnhem, netherlands assen, netherlands beverwijk, netherlands boxmeer, netherlands breda, netherlands capelle ad yssel, netherlands den haag, netherlands drachten, netherlands eindhoven, netherlands enschede, netherlands groningen, netherlands groningen, netherlands haarlem, netherlands harderwijk, netherlands heerlen, netherlands helmond, netherlands hengelo, netherlands hoofddorp, netherlands leiden, netherlands leiderdorp, netherlands maastricht, netherlands nieuwegein, netherlands nijmegen, netherlands roermond, netherlands rotterdam, netherlands sliedrecht, netherlands veldhoven, netherlands venlo, netherlands vlaardingen, netherlands vlissingen, netherlands zaandam, netherlands zwolle, netherlands christchurch, new zealand hamilton, new zealand palmerston north, new zealand wellington, new zealand panama city, panama callao, peru lima, peru lima, peru lima, peru gdansk, poland lublin, poland olsztyn, poland poznan, poland warszawa, poland warszawa, poland wroclaw, poland zabrze, poland lisboa, portugal porto, portugal setubal, portugal são martinho do bispo, portugal vila nova de gaia, portugal alba iulia, romania baia mare, romania bucharest, romania bucharest, romania bucharest, romania cluj napoca, romania oradea, romania sibiu, romania suceava, romania timisoara, romania barnaul, russian federation kazan, russian federation kazan, russian federation krasnodar, russian federation krasnodar, russian federation moscow, russian federation moscow, russian federation moscow, russian federation obninsk, russian federation samara, russian federation smolensk, russian federation st petersburg, russian federation st petersburg, russian federation stavropol, russian federation tumen, russian federation ufa, russian federation volgograd, russian federation riyadh, saudi arabia belgrade, serbia novi sad, serbia banska bystrica, slovakia bratislava, slovakia kosice, slovakia nitra, slovakia poprad, slovakia ljubljana, slovenia falun, sweden goeteborg, sweden göteborg, sweden linkoeping, sweden lund, sweden malmoe, sweden stockholm, sweden uppsala, sweden aarau, switzerland aarau, switzerland baden, switzerland chur, switzerland locarno, switzerland luzern, switzerland zürich, switzerland changhua, taiwan kaohsiung, taiwan kaohsiung, taiwan kaohsiung, taiwan taichung, taiwan taichung, taiwan tainan, taiwan tainan, taiwan taipei, taiwan taipei, taiwan taipei, taiwan taipei, taiwan taipei, taiwan taoyuan, taiwan bangkok, thailand bangkok, thailand bangkok, thailand ankara, turkey ankara, turkey ankara, turkey ankara, turkey istanbul, turkey istanbul, turkey istanbul, turkey izmir, turkey izmir, turkey shhiye, ankara, turkey montevideo, uruguay caracas, venezuela caracas, venezuela""]",,https://ClinicalTrials.gov/show/NCT00949910,
346,347,NCT00409188,cancer vaccine study for unresectable stage iii non-small cell lung cancer (start),START,Completed,Has Results,non-small cell lung cancer,biological: tecemotide (l-blp25)|drug: single low dose cyclophosphamide|drug: placebo,"overall survival|time to symptom progression (ttsp) as measured by the lung cancer symptom scale (lcss)|time to progression (ttp)|one-, two- and three-year survival rate|number of participants with treatment emergent adverse events and injection site reactions","emd serono|merck kgaa, darmstadt, germany",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1513.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EMR 63325-001,January 2007,April 2012,April 2015,"December 8, 2006","November 20, 2015","November 20, 2015","['saint edward mercy medical center, fort smith, arkansas, united states pacific cancer medical center, anaheim, california, united states glendale adventist medical center, glendale, california, united states norris cancer hospital, los angeles, california, united states cedars-sinai outpatient cancer center at the samuel oschin comprehensive cancer institute, los angeles, california, united states clinical trials and research associates, inc., montebello, california, united states desert hematology oncology medical group, inc, rancho mirage, california, united states stockton hematology oncology medical group, inc., stockton, california, united states university of colorado cancer center, denver, colorado, united states pasco hernando oncology associates p.a, brooksville, florida, united states university of miami, sylvester comprehensive cancer center, miami, florida, united states pasco hernando oncology associates, pa, new port richey, florida, united states florida hospital memorial system, ormond beach, florida, united states southern illinois hematology/oncology, centralia, illinois, united states rush university medical center, chicago, illinois, united states joliet oncology-hematology associates, ltd., joliet, illinois, united states kentucky cancer center, hazard, kentucky, united states leonard j. chabert medical center, houma, louisiana, united states hematology and oncology specialists, llc, metarie, louisiana, united states sinai hospital of baltimore, baltimore, maryland, united states university of maryland, marlene and steward greenbaum cancer center, baltimore, maryland, united states lahey clinic, burlington, massachusetts, united states oncology care associates, saint joseph, michigan, united states university of minnesota physicians, masonic cancer center, minneapolis, minnesota, united states saint louis university cance center, saint louis, missouri, united states deaconess billings clinic, billings, montana, united states big sky oncology, sletten cancer institute, great falls, montana, united states nebraska cancer care, llc, hastings, nebraska, united states southeast nebraska cancer center, lincoln, nebraska, united states st. vincents comprehensive cancer center, new york, new york, united states hematology oncology associates of rockland, nyack, new york, united states univ. of north carolina at chapel hill, lineberger comprehensive cancer center, chapel hill, north carolina, united states carolinas hematology-oncology, charlotte, north carolina, united states hanover medical specialts pa, wilmington, north carolina, united states gabrail cancer center, canton, ohio, united states university hospitals of cleveland, cleveland, ohio, united states signal point clinical research center, llc, middletown, ohio, united states southwestern regional medical center, tulsa, oklahoma, united states southwestern regional medical center, tulsa, oklahoma, united states providence portland medical center, portland, oregon, united states univ. of pennsylvania abramson cancer center, philadelphia, pennsylvania, united states fox chase cancer center, philadelphia, pennsylvania, united states the jones clinic, pc, germantown, tennessee, united states center for oncology research, dallas, texas, united states john peter smith center for cancer care, fort worth, texas, united states the center for cancer and blood disorders, fort worth, texas, united states cancer therapy & research center, institute for drug development, san antonio, texas, united states fairfax-northern virginia hematology oncology, pc, fairfax, virginia, united states wheeling hospital, wheeling, west virginia, united states hospital italiano regional del sur, bahia blanca, buenos aires, argentina paliar, capital, buenos aires, buenos aires, argentina corporacion medica general san martin, san martin, buenos aires, argentina centro oncologico de roario, rosario, santa fe, argentina centro de educacion medica e investigaciones clinicas ""norberto quirno"" (cemic), ciudad autonoma de buenos aires, argentina instituto especializado alexander fleming, ciudad autonoma de buenos aires, argentina sociedad intaliana de beneficencia en buenos aires, hospital italiano, ciudad autonoma de buenos aires, argentina clinica universitaria reina fabiola, cordoba, argentina research site, tandil, argentina research site, nedlands, western australia, australia research site, bankstown, nsw, australia research site, camperdown, australia research site, heidelberg, australia research site, kingswood, australia research site, saint leonards, australia research site, woolloongabba, australia research site, graz, styria, austria research site, linz, upper austria, austria research site, inssbruck, austria research site, salzburg, austria research site, wein, venna, austria research site, wels, austria research site, wien, austria research site, brasschaat, belgium research site, brussels, belgium research site, haine-saint paul, belgium research site, leuven, belgium research site, liege, belgium research site, mechelen, belgium nugieo de oncologia da bahia, salvador, bahia, brazil hospital das clinicas da faculdade de medinina de univeridade, são paulo, de ao paulo, brazil hospital lifecenter, belo horizonte, minas gerais, brazil hospital nossa senhora da conceicao, centro de pesquisas medicas e ensaios clinicos, porto alegre, rio grande do sol, brazil associacao hospital de caridade ijui, ijuí, rio grande do sul, brazil hospital de clinicas de porto alegre, dept. de endocrinologia, porto alegre, rio grande do sul, brazil hospital sao lucas-pucrs, porto alegre, rio grande do sul, brazil research site, porto algre, rio grande do sul, brazil centro de oncologia de campinas - occ, campinas, sao paulo, brazil fundacao hospital amaral carvalho, jau, sao paulo, brazil instituto de oncologia de sorocaba, sorocaba, sao paulo, brazil research site, ondina-salvdor, brazil instituto nacional do cancer - inca, rio de janeriro, brazil instituto do cancer arnaldo vieira de caralho-onco-pneumonia, sao paulo, brazil santa casa de misericordia de sao paulo, sao paulo, brazil tom baker cancer center, calgary, alberta, canada cross cancer institue, edmonton, alberta, canada frazer valley cancer center, surrey, british columbia, canada british columbia cancer agency, vancouver, british columbia, canada vancouver island cancer center, victoria, british columbia, canada cancer care manitoba, winnipeg, manitoba, canada capital district health authority, halifax, nova scotia, canada cape breton districk health authority cancer care, sydney, nova scotia, canada juravinski cancer center, hamilton, ontario, canada niagara health system, saint catharines, ontario, canada thunder bay regional health science center northwestern ontario regional center, thunder bay, ontario, canada mount sinai hospital, toronto, ontario, canada princess margaret hospital, toronto, ontario, canada windsor regional cancer center, windsor, ontario, canada hopital notre dame, montreal, quebec, canada jewish general hospital, montreal, quebec, canada hopital laval, sainte-foy, quebec, canada research site, beijing, china research site, guangzhou, china research site, shanghai, china research site, hradec králové, czech republic research site, ostrava-poruba, czech republic research site, prague, czech republic research site, praha 2, czech republic research site, praha, czech republic research site, usti nad labem, czech republic research site, herlev, denmark research site, odense c, denmark research site, besancon, franche-comte, france research site, pierre-benite cedex, rhone-alpes, france research site, beuvry, france research site, brest, france research site, caen, france research site, chauny, france research site, marseille cedex, france research site, marseille, france research site, nancy, france research site, nantes-saint herblain, france research site, paris cedex 15, france research site, perpignan, france research site, poitiers cedex, france research site, strasbourg cedex, france research site, essen, nordrhein-westfalen, germany research site, hemer, nordrhein-westfalen, germany research site, mainz, rheinland-pfalz, germany research site, homburg, saar, germany research site, berlin, germany research site, coswig, germany research site, essen, germany research site, frankfurt am main, germany research site, freiburg, germany research site, gauting, germany research site, großhansdorf, germany research site, hamburg, germany reseach site, heidelberg, germany research site, kassel, germany research site, kiel, germany research site, koln, germany research site, leipzig, germany research site, magdeburg, germany research site, mainz, germany research site, minden, germany research site, muchen, germany research site, münchen, germany research site, oldenburg, germany research site, rostock, germany research site, maroussi, athens, greece research site, athens, attica, greece research site, thessaloniki, nea efkarpia, greece research site, athens, greece research site, chidari, athens, greece research site, heraklion, greece research site, shatin, new territories, hong kong research site, hong kong, hong kong research site, budapest, hungary research site, mátraháza, hungary research site, nyíregyháza, hungary research site, tatabayana, hungary research site, chennai, india research site, hyderabad, india research site, mumbai, india research site, new delhi, india research site, vellore, india research site, dublin, ireland research site, tel hashomer, tel avir, israel research site, beer sheva, israel research site, haifa, israel research site, jerusalem, israel research site, kfar saba, israel research site, petach tikva, israel research site, tel aviv, israel research site, zerifin, israel research site, candiolo, torino, italy research site, avelino, italy research site, bologna, italy research site, carpi, italy research site, chieti, italy research site, forli, italy research site, genova, italy research site, meldola, italy research site, milano, italy research site, napoli, italy research site, orbassano-torino, italy research site, palermo, italy research site, parma, italy research site, rome, italy research site, rozzano-milano, italy research site, sassari, italy research site, trento, italy research site, goyang-si, gyeonggi-do, korea, republic of research site, seoul, gyeonggi-do, korea, republic of research site, seoul, korea, republic of consultorio del, morelia, michoacan, mexico centro oncologico de chihuahua, chihuahua, mexico instituto nacional de cancerologia (incan), mexico city, mexico research site, amsterdam, noord-holland, netherlands research site, amsterdam, netherlands research site, eindhoven, netherlands research site, hoofdrop, netherlands research site, tilburg, netherlands research site, zwolle, netherlands research site, warszawa, mazowieckie, poland research site, bialystok, poland research site, bydgoszcz, poland research site, bytom, poland research site, gdynia, poland research site, kraków, poland genova, lodz, poland research site, olsztyn, poland research site, otwock, poland research site, poznan, poland research site, torun, poland research site, warsaw, poland genova, warszawa, poland research site, wroclaw, poland research site, zabrze, poland genova, coimbra, portugal genova, lisboa, portugal genova, porto, portugal genova, santa maria de feira, portugal research site, bucharest, romania research site, bucuresti, romania research site, cluj-napoca, romania research site, iasi, romania research site, sibiu, romania research site, suceava, romania research site, timisoara, romania reseaerch site, kazan, tatarstan, russian federation research site, yaroslavl, yaroslavlr, russian federation research site, barnaul, russian federation genova, chelaybinsk, russian federation research site, ivanovo, russian federation research site, kazan, russian federation research site, moscow, russian federation research site, obninsk, russian federation research site, saint petersburg, russian federation research site, tomsk, russian federation research site, voronezh, russian federation research site, singapore, singapore research site, bratislava, slovakia research site, kosice, slovakia research site, nitra, slovakia research site, mataro, barcelona, spain research site, barakaldo, bilbao, spain research site, donostia-san sebastian, guipuzcoa, spain research site, a coruna, spain research site, alicante, spain research site, barcelona, spain research site, burgos, spain research site, girona, spain research site, jaen, spain research site, lugo, spain research site, madrid, spain research site, malaga, spain research site, gävle, sweden research site, göteborg, sweden research site, lund, sweden research site, stockholm, sweden research site, umea, sweden research site, uppsala, sweden research site, basel, switzerland research site, geneve, switzerland research site, genève, switzerland research site, winterthur, switzerland research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, cornwall, united kingdom research site, edinburgh, united kingdom research site, glasgow, united kingdom research site, guildford, united kingdom research site, inverness, united kingdom research site, leeds, united kingdom research site, leicester, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, southampton, united kingdom research site, surrey, united kingdom research site, torquay, united kingdom research site, wirral, united kingdom']",,https://ClinicalTrials.gov/show/NCT00409188,
347,348,NCT00686959,chemotherapy and radiation in treating participants with stage 3 non-small cell lung cancer,PROCLAIM,Completed,Has Results,non small cell lung cancer,drug: pemetrexed|drug: cisplatin|drug: etoposide|drug: vinorelbine|drug: paclitaxel|drug: carboplatin|radiation: thoracic radiation therapy (trt),"overall survival|progression-free survival (pfs)|objective response rate (complete response [cr] + partial response [pr])|survival rates at 1, 2, and 3 years|first site of disease failure in terms of relapse|percentage of participants with a post baseline swallowing diary score >=4",eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,598.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11514|H3E-MC-JMIG,September 2008,October 2014,November 2014,"May 30, 2008","November 26, 2015","June 28, 2016","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., birmingham, alabama, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., scottsdale, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tucson, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fayetteville, arkansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., duarte, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fountain valley, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., la jolla, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new haven, connecticut, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hollywood, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tampa, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., west palm beach, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., marietta, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., thomasville, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chicago, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., quincy, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., evansville, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., indianapolis, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new albany, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., westwood, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., louisville, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbia, maryland, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fairhaven, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ann arbor, michigan, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kansas city, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., st louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bronx, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new york, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fargo, north dakota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cincinnati, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., charleston, south carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chattanooga, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nashville, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bedford, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dallas, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., longview, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., odessa, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san marcos, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sherman, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sugar land, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., the woodlands, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita falls, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., burlington, vermont, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., spokane, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vancouver, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., morgantown, west virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madison, wisconsin, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., buenos aires, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wollongong, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., launceston, tasmania, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankston, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., antwerp, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edegem, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gent, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gilly, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., haine-st.- paul, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., leuven, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., namur, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., turnhout, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barretos, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., curitiba, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., porto alegre, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rio de janeiro, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., são paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edmonton, alberta, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., london, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., newmarket, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toronto, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., montreal, quebec, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beijing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guang zhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jinan, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shanghai, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sichuan, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wu han, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bayonne, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lille, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., paris, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pierre benite, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., erlangen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankfurt, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hannover, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hemer, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., immenhausen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., köln, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mainz, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mannheim, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oldenburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rheine, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ulm, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., patras, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hyderabaad, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jaipur, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kolkata, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madurai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dublin, ireland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., incheon, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., suwon-city, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., amsterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., breda, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., s-hertogenbosch, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lisbon, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa maria da feira, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vila franca de xira, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., alicante, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., badalona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., elche, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hospitalet de llobregat, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., majadahonda, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pamplona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., terrassa, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kaohsiung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kuei shan hsiang, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taichung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fatih, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gaziantep, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., izmir, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., melikgazi, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., umuttepe, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edgbaston, birmingham, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., london, greater london, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edinburgh, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00686959,
348,349,NCT01125566,lux-breast 1: bibw 2992 (afatinib) in her2-positive metastatic breast cancer patients after one prior herceptin treatment,,Completed,Has Results,breast neoplasms,drug: bibw 2992|drug: trastuzumab|drug: vinorelbine,progression-free survival (pfs)|overall survival (os)|best recist assessment|objective response (or),boehringer ingelheim,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,508.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.75|2009-015476-98,"June 22, 2010","June 8, 2013","July 6, 2018","May 18, 2010","August 21, 2014","July 18, 2019","['achieve clinical research, llc, birmingham, alabama, united states ironwood cancer and research centers, chandler, arizona, united states robert a. moss md, facp, inc, fountain valley, california, united states st. jude heritage healthcare, fullerton, california, united states university of california, los angeles, california, united states cancer care associates medical group, inc, redondo beach, california, united states santa barbara hematology oncology medical group, inc, santa barbara, california, united states central coast medical oncology corporation, santa maria, california, united states north shore cancer research associates, skokie, illinois, united states cedar valley cancer center, waterloo, iowa, united states pro health care associated, lake success, new york, united states hope women\'s cancer center, asheville, north carolina, united states thomas jefferson university, philadelphia, pennsylvania, united states utah cancer specialists cancer center, salt lake city, utah, united states instituto medico de asistencia e investigaciones s. a., buenos aires, argentina hospital britanico, capital federal, argentina sanatorio de la provodencia, ciudad autonoma de bs as, argentina sanatorio parque, rosario, argentina port macquarie base hospital (pmbh), port macquarie, new south wales, australia st vincent\'s hospital melbourne, fitzroy, victoria, australia peninsula haematology & oncology, frankston, victoria, australia maroondah hospital, ringwood east, victoria, australia mount medical centre, perth, western australia, australia ordensklinikum linz gmbh - barmherzige schwestern, linz, austria kaiser franz josef spital vienna, wien, austria grodno regional clinical hospital, grodno, belarus n. n. alexandrov national cancer center of belarus, minsk region, belarus public health inst. minsk city clinical oncology dispensary, minsk, belarus vitebsk regional clinical oncology dispensary, vitebsk, belarus brussels - hosp jules bordet, bruxelles, belgium edegem - univ uz antwerpen, edegem, belgium liège - hosp st-joseph, liège, belgium centro de pesquisas clínicas em oncología, cachoeiro de itapemirim, brazil hospital santa cruz, curitiba, brazil associacao hospital de caridade de ijui, ijui, brazil associação hospitalar moinhos de vento, porto alegre, brazil irmandade da santa casa de misericórdia de porto alegre, porto alegre, brazil centro de novos tratamentos clinionco, porto alegre, brazil instituto nacional do câncer - inca, rio de janeiro, brazil faculdade de medicina do abc, santo andré, brazil centro de referência da saude da mulher-hosp perola byington, sao paulo, brazil bc cancer agency - vancouver, vancouver, british columbia, canada dr. leon richard oncology centre, moncton, new brunswick, canada grand river regional cancer centre, kitchener, ontario, canada the ottawa hospital, ottawa, ontario, canada princess margaret cancer centre, toronto, ontario, canada hopital notre-dame du chum, montreal, quebec, canada chu de quebec-universite laval research centre, quebec, canada instituto clínico oncológico del sur - icos, temuco, chile cancer hospital of chinese academy of medical science, beijing, china peking union medical college hospital, beijing, china peking university people\'s hospital, beijing, china 307 hospital of pla, beijing, china chinese pla general hospital, beijing, china first hospital of jilin university, changchun, china west china hospital, chengdu, china fujian provincial tumor hospital, fuzhou, china sun yat-sen university cancer center, guangzhou, china guangdong provincial people\'s hospital, guangzhou, china nanfang hosptial, guangzhou, china the third affiliated hospital of harbin medical university, haerbin, china the first affiliated hospital, zhejiang university, hangzhou, china zhejiang cancer hospital, hangzhou, china qilu hospital, shangdong university, jinan, china the 81th hospital of pla, nanjing, china ruijin hospital, shanghai jiao tong university school of medicine, shanghai, china fudan university shanghai cancer center, shanghai, china tianjin medical university cancer institute and hospital, tianjin, china wuhan union hospital, wuhan, china hospital ceske budejovice, ceske budejovice, czechia university hospital olomouc, olomouc, czechia general faculty hospital, prague, prague 2, czechia medicon a.s., praha 4, praha 4, czechia el manial specialized hospital, cairo, egypt oncology centre- mansoura university, mansoura, egypt hop amiens-picardie sud, amiens cedex 1, france ctr p papin, onco, angers, angers cedex 9, france hop jean minjoz, besançon cedex, france cli bordeaux nord aquitaine, bordeaux, france ctr j perrin, onco, clermont-ferrand, clermont-ferrand cedex, france hop victor hugo, le mans, france ctr catherine de sienne, nantes, france hop saint-louis, paris, france ins jean godinot, onco, reims, reims, france ctr eugène marquis, rennes cedex, france ctr rené huguenin, st cloud, france ctr paul strauss, strasbourg cedex, france universitätsklinikum aachen, aör, aachen, germany medizinisches zentrum bonn, bonn, germany onkodok gbr, bottrop, germany donauisar klinikum deggendorf-dingolfing-landau gku, deggendorf, germany universitätsklinikum erlangen, erlangen, germany kliniken essen - mitte ggmbh, essen, germany gynäk.-onkol. gem.praxis, dr. uleer, hildesheim, hildesheim, germany universitätsklinikum köln (aör), köln, germany st. elisabeth-krankenhaus, köln, germany universitätsklinikum magdeburg aör, magdeburg, germany klinikum der universität münchen - campus innenstadt, münchen, germany klinikum rechts der isar der technischen universität münchen, münchen, germany onkologische praxis oldenburg, oldenburg, germany universitätsfrauenklinik am klinikum südstadt, rostock, germany facharzt für innere medizin, wuppertal, germany gujarat cancer and research institute, ahmedabad, india sujan surgical cancer hospital, amravati, india kidwai memoraial institute of oncology, bangalore, india sri venkateshwara hospital, bengaluru, india dr. rai memorial cancer centre, chennai, india bibi general hospital and cancer centre, hyderabad, india orchid nursing home, kolkata, india natinal cancer institute, maharagama, india central india cancer research institute, nagpur, india curie manavata cancer centre, nashik, india jehangir hospital oncology department, pune, india k.e.m hospital, pune, india king george hospital, visakhapatnam, india beaumont hospital, dubliin 9, ireland st vincent\'s university hospital, dublin 4, ireland mater misericordiae university hospital, dublin 7, ireland st james\'s hospital, dublin 8, ireland rambam medical center, haifa, israel shaare zedek medical center, jerusalem 91031, jerusalem, israel meir medical center, kfar saba, israel the chaim sheba medical center tel hashomer, tel hashomer, israel sourasky medical center, tel-aviv, israel azienda ospedaliera universitaria arcispedale sant\'anna, ferrara, italy istituto europeo di oncologia, milan, italy p.o. monserrato, monserrato (ca), italy tokai university hospital, kanagawa, isehara, japan osaka medical center for cancer and cardiovascular diseases, osaka, osaka, japan national cancer center hospital, tokyo, chuo-ku, japan national cancer center, goyang, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of asan medical center, seoul, korea, republic of p. stradins clinical univ. hospital, oncology clinic, riga, latvia riga east univ. hospital, oncology centre, riga, latvia hammoud hospital university medical centre (hhumc), lebanon, lebanon hospital of lithuanian univ.of healthsciences kauno klinikos, kaunas, lithuania national cancer institute, vilnius, vilnius, lithuania hospital de jesus, colonia centro, mexico albert schweitzerziekenhuis, dordrecht, netherlands máxima medisch centrum, locatie eindhoven, eindhoven, netherlands zuyderland medisch centrum, geleen, netherlands zuyderland medisch centrum, heerlen, netherlands metc academisch ziekenhuis maastricht/universiteit van maastricht, maastricht, netherlands isala zwolle, zwolle, netherlands hospital nacional adolfo guevara velasco, cusco, peru clinica san judas tadeo, lima, peru instituto oncologico miraflores s.a., miraflores, peru clinica peruano americana de trujillo, trujillo, peru bialystock\'s oncology center, bialystok, poland wojewodzki specialist hospital no. 4, bytom, bytom, poland university clinical center, gdansk, gdansk, poland provincial specialist m. kopernik hospital, lodz, poland ziemia lubelska oncological center, lublin, lublin, poland oncology centre of olsztyn ""kopernik"" sp. z.o.o., olsztyn, poland wielkopolskie oncology centre n.a. maria sklodowska-courie, poznan, poland military medical institute, warsaw, poland instituto português de oncologia de coimbra francisco gentil, coimbra, portugal chuc, epe - chc-maternidade bissaya barreto, coimbra, portugal ipo lisboa francisco gentil, epe, lisboa, portugal centro hospitalar são joão,epe, porto, portugal ipo porto francisco gentil, epe, porto, portugal st.auton.heal.inst.""rep.clin.onc.disp.of moh of rep. tatarstan"", kazan, russian federation n.a. semashko central clinical hospital, moscow, moscow, russian federation guz ""regional clinical oncology dispensary"", ryazan, russian federation regional clinical oncology dispensary, saint petersburg, russian federation national university hospital, singapore, singapore national cancer centre, singapore, singapore johns hopkins singapore international medical center, singapore, singapore st. jacobs hosp.outpat.pneumology&phthisiology dept,bardejov, bardejov, slovakia national institute of oncology, bratislava, bratislava, slovakia poko policlinic dept. of clinical oncology, poprad, slovakia institute of oncology ljubljana, ljubljana, slovenia wcr cmjah clinical trial site, johannesburg, south africa medical oncology centre of rosebank, johannesburg, south africa gvi oncology medi clinic, kraaifontein, south africa langenhoven drive oncology centre, port elizabeth, south africa wilgers oncology, pretoria, south africa rondebosch oncology centre, rondebosch, cape town, south africa hospital del mar, barcelona, spain hospital universitari dexeus, barcelona, spain hospital vall d\'hebron, barcelona, spain complejo hospitalario universitario insular - materno infantil, las palmas de gran canaria, spain hospital clínico san carlos, madrid, spain hospital clínico de santiago, santiago de compostela, spain hospital virgen de la salud, toledo, spain hospital arnau de vilanova, valencia, spain shatabdi superspeciality hospital, maharashtra, sri lanka chang-hua christian hospital, changhua, taiwan kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan kaohsiung veterans general hospital, kaohsiung, taiwan taichung veterans general hospital, taichung, taiwan nckuh, tainan, taiwan national taiwan university hospital, taipei, taiwan mackay memorial hospital, taipei, taiwan taipe veterans general hospital, taipei, taiwan koo foundation sun yet-sen cancer center, taipei, taiwan chang gung memorial hospital(taoyuan), taoyuan county, taiwan hacettepe universitesi tip fakultesi, ic hastaliklari abd, ankara, turkey ege universitesi tip fakultesi tibbi onkoloji bilim dali, izmir, turkey ninewells hospital & medical school, dundee, united kingdom guy\'s hospital, london, united kingdom the royal marsden hospital, sutton, united kingdom queen elizabeth hospital, woolwich, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT01125566,breast
349,350,NCT00806286,study of carboplatin/paclitaxel with or without investigational drug (cs-7017) in subjects with metastatic non-small cell lung cancer,,Completed,Has Results,metastatic non-small cell lung cancer,drug: cs7017 tablets|drug: paclitaxel|drug: carboplatin|drug: placebo tablets,percentage of participants with progression-free survival at 18 weeks following administration of carboplatin/paclitaxel with or without cs-7017 in chemotherapy-naïve participants with metastatic non-small cell lung cancer|percentage of participants with progression-free survival based on radiologic and clinical assessments and death after carboplatin/paclitaxel with or without cs-7017 in chemotherapy-naïve participants with metastatic non-small cell lung cancer|summary of kaplan-meier analysis of overall survival following administration of carboplatin/paclitaxel with or without cs-7017 in chemotherapy-naïve participants with metastatic non-small cell lung cancer|number of participants with best overall tumor response and objective response rate following administration of carboplatin/paclitaxel with or without cs-7017 in chemotherapy-naïve participants with metastatic non-small cell lung cancer|number of participants with treatment-emergent adverse events related to cs-7017/placebo following administration of carboplatin/paclitaxel with or without cs-7017 in chemotherapy-naïve participants with metastatic non-small cell lung cancer,"daiichi sankyo, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,111.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CS7017-A-U202,December 2008,January 2012,August 2012,"December 10, 2008","May 13, 2020","May 13, 2020","['university colorado cancer center, aurora, colorado, united states georgetown univ. medical center, washington, district of columbia, united states southern illinois hematology/oncology, centralia, illinois, united states rush university medical center, chicago, illinois, united states michiana hematology-oncology, south bend, indiana, united states harbor view cancer center, baltimore, maryland, united states massachusetts general hospital, boston, massachusetts, united states signal point clinical research center, middletown, ohio, united states penn state milton hershey cancer center, hershey, pennsylvania, united states eastern virginia medical school, norfolk, virginia, united states kidwai memorial institute of oncology, bangalore, karnataka, india pentagon research, aundh, maharashtra, india shatabdi super specialty hospital, nashik, mumbai naka, india hemato-oncology clinic, vedanta, gujarat, navrangpura, ahmedabad, india meenakshi mission hospital, madurai, tamil nadu, india orchid nursing home, kolkata, west bengal, india apollo specialty hospital, chennai, india ruby hall clinic, pune, india noble hospital, pune, india oddzial chemioterapii zoz mswia, olsztyn, poland oddzial onkologii klinicznej z pododdzialem dziennej chemioterapii, poznan, poland specjalistyczny szpital im. prof. alfresa sokolowskiego, szczecin, poland oncomed srl, timisoara, judet timis, romania spitalul municipal ploiesti, ploiesti, prahova, romania institutul oncologic prof. dr. alexandru trestioreanu, bucuresti, romania institutul oncologic prof. dr. ion chiricuta, cluj-napoca, romania institutul oncologic prof. dr. ion chiricuta, cluj-napoca, romania centrul de oncologie medicala, iasi, romania']",,https://ClinicalTrials.gov/show/NCT00806286,
350,351,NCT00789373,a study of induction and maintenance treatment of advanced non-squamous non-small cell lung cancer,,Completed,Has Results,non-small cell lung cancer,drug: pemetrexed|drug: cisplatin|drug: placebo|other: best supportive care,investigator-assessed objective progression-free survival (pfs)|independently-assessed objective progression-free survival (pfs)|overall survival (os)|change from baseline in the euroqol instrument (eq-5d) index score|change from baseline in euroqol instrument (eq-5d) visual analog scale (vas)|percentage of participants with hospitalizations due to adverse events or requiring transfusion (resource utilization)|percentage of participants with a non-serious adverse event (ae) during maintenance phase|percentage of participants with serious adverse events during maintenance phase|percentage of participants with objective tumor response (response rate) during maintenance phase of study up to primary data cut-off|percentage of participants with independently-assessed objective tumor response (response rate) during maintenance phase up to primary data cut-off,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,939.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12560|H3E-EW-S124|CTRI/2009/091/000113,November 2008,June 2010,November 2017,"November 11, 2008","July 18, 2011","December 14, 2018","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., adelaide, south australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankston, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wendouree, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aalst, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brussels, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., genk, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gilly, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liege, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sint niklaas, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., espoo, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., helsinki, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tampere, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., turku, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., avignon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dijon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., le mans cedex 1, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., montpellier, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nantes, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., paris, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vandoeuvre les nancy, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vandoeuvre-les-nancy, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankfurt, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gerlingen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., großhansdorf, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hamburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heidelberg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ulm, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chania, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., neo faliro, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., patras, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bhopal, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madurai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., patna, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., avellino, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aviano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., genova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lido di camaiore, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., monza, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pisa, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., reggio emilia, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., udine, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ede, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., groningen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., harderwijk, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heerlen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poznan, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., warsaw, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., coimbra, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lisbon, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vila franca de xira, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bucharest, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cluj-napoca, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oradea, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., manresa, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sabadell, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sevilla, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., valencia, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zaragoza, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bornova, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sihhiye, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zeytinburnu, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aberdeen, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guildford, surrey, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., birmingham, west midlands, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., newcastle, united kingdom']",,https://ClinicalTrials.gov/show/NCT00789373,
351,352,NCT00682981,a phase i/ii study of carboplatin and etoposide with or without obatoclax in extensive-stage small cell lung cancer (es-sclc),,Completed,No Results Available,extensive-stage small cell lung cancer,drug: obatoclax|drug: carboplatin/etoposide,"determine the recommended phase ii dose of obatoclax administered as a 3-hour or 24-hour infusion for 3 consecutive days in phase i, and response rate in phase ii.","gemin x|cephalon|teva branded pharmaceutical products r&d, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,218.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GEM017,May 2008,November 2011,November 2011,"May 23, 2008",,"July 21, 2016","['clearview cancer institute, huntsville, alabama, united states northwest alabama cancer center, muscle shoals, alabama, united states mayo clinic-arizona, scottsdale, arizona, united states arizona clinical research center, tucson, arizona, united states city of hope and beckman research institute, duarte, california, united states university of california-san diego moores cancer center, lajolla, california, united states georgetown university hospital-lombardi comprehensive cancer center, washington, district of columbia, united states integrated community oncology network, jacksonville, florida, united states university of miami-sylvester cancer center, miami, florida, united states florida cancer institute, new port richey, florida, united states h. lee moffitt cancer center, tampa, florida, united states northwest georgia oncology centers, marietta, georgia, united states university of chicago, chicago, illinois, united states iowa blood and cancer center, plc, cedar rapids, iowa, united states cancer center of kansas, wichita, kansas, united states james brown cancer center, louisville, kentucky, united states center for cancer and blood disorders, bethesda, maryland, united states kalamazoo hematology and oncology, kalamazoo, michigan, united states mid ohio oncology/hematology, inc., columbus, ohio, united states cancer care associates-oklahoma city, oklahoma city, oklahoma, united states cancer care associates-tulsa, tulsa, oklahoma, united states university of pennsylvania abramson cancer center, philadelphia, pennsylvania, united states greater philadelphia cancer and hematology specialists, philadelphia, pennsylvania, united states cancer centers of the carolinas, greenville, south carolina, united states mcleod cancer & blood center, johnson city, tennessee, united states the west clinic, memphis, tennessee, united states baylor, dallas, texas, united states ut southwestern medical center at dallas, dallas, texas, united states tyler cancer center, tyler, texas, united states peninsula cancer institute, newport news, virginia, united states virginia oncology associates, norfolk, virginia, united states wheeling hospital, wheeling, west virginia, united states mhat ""dr. tota venkova"", gabrovo, bulgaria district dispensary for cancer diseases, plovdiv, plovdiv, bulgaria district dispensary for oncology diseases, sofia city, sofia, bulgaria specialized hospital for active treatment in oncology, sofia, bulgaria tom baker cancer centre, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada mcgill university, montreal, quebec, canada regional hospital kladno, kladno, czech republic hospital kutna hora, kutna hora, czech republic university hospital olomouc, olomouc, czech republic faculty hospital ostrava, ostrava-poruba, czech republic university hospital na bulovce, prague, czech republic national institute of tuberculosis & pulmonology, budapest, hungary semmelweis university medical school, budapest, budapest, hungary university of debrecen medical and health science centre, debrecen, hungary csongrad county council\'s hospital for chest diseases, deszk, hungary bacs-kiskun county hospital, kecskemet, hungary state hospital matrahaza, matrahaza, hungary clinfan ltd. smo tolna county hospital, szekszard, hungary pest county hospital, torokbalint, hungary vedanta institute of medical sciences, ahmedabad, gujarat, india kailash cancer hospital and research centre, goraj, gujarat, india jawaharlal nehru cancer hospital and research centre, bhopal, madhya pradesh, india curie manavata cancer centre, nashik, maharashtra, india noble hospital, pune, maharashtra, india dr. kamakshi memorial hospital, chennai, tamal nadu, india galaxy cancer institute, pushpanjali crosslay hospital, ghaziabad, uttar pradesh, india orchid nursing home, kolkata, west bengal, india wojewodzki szpital specjalistyczny im. k. dluskiego, bialystok, poland spz gruzlicy i chorob pluc, olsztyn, poland mazowieckie centrum leczenia chorob pluc i gruzlicy, otwock, poland specjalistyczny szpital im prof alfreda sokolowskiego, szczecin-zdunowo, poland wojewodzki szpital chorob pluc, wodzislaw slaski, poland prof. dr. ion chiricuta oncology institute cluj napoca, cluj, romania oncology medical centre scm, iasi, romania emergency clinical county hospital oradea, oradea, romania center for pulmonary diseases, clinic for internal medicine, kragujevac, serbia institute for pulmonary diseases of vojvodina, sremska kamenica, serbia northern ireland cancer centre queens university belfast, belfast, northern ireland, united kingdom royal bournemouth hospital, dorset, united kingdom nottingham university hospital, nottingham, united kingdom weston park hospital, sheffield, united kingdom royal surrey county hospital, surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00682981,
352,353,NCT04975308,"a study of imlunestrant, investigator's choice of endocrine therapy, and imlunestrant plus abemaciclib in participants with er+, her2- advanced breast cancer",EMBER-3,Recruiting,No Results Available,breast neoplasms|neoplasm metastasis,drug: imlunestrant|drug: exemestane|drug: fulvestrant|drug: abemaciclib,"progression free survival (pfs)|overall survival (os)|objective response rate (orr): percentage of participants who achieve a confirmed best overall response of complete response (cr) or partial response (pr)|duration of response (dor)|clinical benefit rate (cbr): percentage of participants who achieve a best overall response of cr, pr or stable disease for greater than or equal to (≥) 24 weeks|pfs by estrogen receptor 1 gene (esr1) mutation status in plasma|patient reported outcomes (pro): time to worsening of ""worst pain""|pharmacokinetics (pk): steady state plasma concentrations of imlunestrant|pk: steady state plasma concentrations of imlunestrant and abemaciclib",eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,800.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18175|J2J-OX-JZLC|2021-000079-35,"October 4, 2021","June 13, 2023","September 13, 2026","July 23, 2021",,"April 19, 2022","['ironwood cancer & research centers, chandler, arizona, united states banner md anderson cancer center, gilbert, arizona, united states university of california, davis - health systems, sacramento, california, united states sharp memorial hospital, san diego, california, united states banner md anderson cancer center at north colorado medical center, greeley, colorado, united states rocky mountain cancer center, lone tree, colorado, united states banner md anderson cancer center at mckee medical center, loveland, colorado, united states florida cancer specialists, fort myers, florida, united states univ of florida school of medicine, gainesville, florida, united states florida cancer specialists, saint petersburg, florida, united states florida cancer specialists, west palm beach, florida, united states kaiser permanente moanalua medical center, honolulu, hawaii, united states rush university medical center, chicago, illinois, united states university of chi med center, chicago, illinois, united states minnesota oncology/hematology pa, coon rapids, minnesota, united states broome oncology, binghamton, new york, united states columbia university medical center, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states aultman hospital, canton, ohio, united states zangmeister cancer center, columbus, ohio, united states willamette valley cancer institute & research ctr., eugene, oregon, united states avera cancer institute, sioux falls, south dakota, united states sarah cannon research institute scri, nashville, tennessee, united states texas oncology - austin central, austin, texas, united states texas oncology - carrollton, carrollton, texas, united states texas oncology - methodist charlton cancer center, dallas, texas, united states texas oncology - medical city dallas, dallas, texas, united states texas oncology - dallas presbyterian hospital, dallas, texas, united states texas oncology-baylor charles a. sammons cancer center, dallas, texas, united states texas oncology - denison, denison, texas, united states texas oncology denton, denton, texas, united states texas oncology fort worth, fort worth, texas, united states texas oncology - willowbrook, houston, texas, united states texas oncology - mckinney, mckinney, texas, united states texas oncology - paris, paris, texas, united states texas oncology-plano east, plano, texas, united states texas oncology - san antonio medical center, san antonio, texas, united states texas oncology - the woodlands, the woodlands, texas, united states us oncology, the woodlands, texas, united states utah cancer specialists, salt lake city, utah, united states university of vermont medical center, burlington, vermont, united states blue ridge cancer care, salem, virginia, united states fundación cenit para la investigación en neurociencias, caba, ba, argentina instituto de investigaciones clínicas mar del plata, mar del plata, buenos aires, argentina ciprec, caba, ciudad autónoma de buenos aire, argentina clinica viedma, viedma, río negro, argentina instituto argentino de diagnóstico y tratamiento (iadt), buenos aires, argentina cent priva especiali médicas ambulatorias inve clin cemaic, cordoba, argentina instituto san marcos, san juan, argentina sanatorio norte, santiago del estero, argentina st vincent\'s hospital, darlinghurst, new south wales, australia princess alexandra hospital, brisbane, queensland, australia cancer research sa, adelaide, south australia, australia box hill hospital, box hill, victoria, australia universitätsklinikum graz, graz, steiermark, austria private practice - dr. hubalek, schwaz, tirol, austria medizinische universität wien, vienna, wien, austria universitätsklinikum salzburg, salzburg, austria imelda general hospital, bonheiden, antwerpen, belgium uz brussel, brussels, bruxelles-capitale, région de, belgium uz gent, gent, oost-vlaanderen, belgium az nikolaas, sint-niklaas, oost-vlaanderen, belgium az groeninge campus kennedylaan, kortrijk, west-vlaanderen, belgium institut jules bordet, brussels-capital, belgium universitaire ziekenhuizen leuven - campus gasthuisberg, leuven, belgium hospital de cancer de londrina, londrina, paraná, brazil faculdade de medicina do abc, santo andre, sp, brazil icesp - instituto do câncer do estado de são paulo, são paulo, brazil clínica de pesquisa e centro de estudos em ginecologia oncológica e mamária ltda, são paulo, brazil ibcc - instituto brasileiro de controle do câncer, são paulo, brazil afflilated hospital of bengbu medical college, bengbu, anhui, china beijing hospital, beijing, beijing, china the fifth medical center of pla general hospital, beijing, beijing, china beijing cancer hospital, beijing, beijing, china sun yat-sen university cancer centre, guangzhou, guangdong, china harbin medical university cancer hospital, harbin, heilongjiang, china the first affiliated hospital of henan university of science &technology, luoyang, henan, china people\'s hospital of henan province, zhengzhou, henan, china renmin hospital of wuhan university, wuhan, hubei, china hubei cancer hospital, wuhan, hubei, china the first people\'s hospital of changde city, changde, hunan, china hunan provincial people\'s hospital, changsha, hunan, china xiangya hospital central south university, changsha, hunan, china hunan cancer hospital, changsha, hunan, china the third hospital of nanchang, nanchang, jiangxi, china the first hospital of jilin university, changchun, jilin, china the second hospital of jilin university, changchun, jilin, china jiangsu province hospital, nanjing, nanjing, china the first affiliated hospital of xi\'an jiaotong university, xi\'an, shaanxi, china jinan central hospital, jinan, shandong, china yantai yuhuangding hospital, yantai, shandong, china tianjin medical university cancer institute and hospital, tianjin, tianjin, china xinjiang medical university cancer hospital - urumqi, urumqi, xinjiang, china the first affiliated hospital, zhejiang university, hangzhou, zhejiang, china sir run run shaw hospital, hangzhou, zhejiang, china zhejiang cancer hospital, hangzhou, zhejiang, china hwa mei hospital university of chinese academy of sciences, ningbo, zhejiang, china sichuan cancer hospital, chengdu, china jining medical university - affiliated hospital, jining, china wu han tongji hospital, wuhan, china thomayerova nemocnice, praha, praha 4 - krč, czechia nemocnice na bulovce, prague, praha 8, czechia nemocnice horovice, horovice, czechia fakultni nemocnice kralovske vinohrady, praha 10, czechia oblastní nemocnice příbram, a.s., pribram, czechia institut de cancérologie strasbourg europe (icans), strasbourg, alsace, france centre de cancérologie du grand montpellier, montpellier, languedoc-roussillon, france centre hospitalier de la côte basque, bayonne, pyrénées-atlantiques, france polyclinique de blois, la chaussee saint victor, france clinique victor hugo - centre jean bernard, le mans, france institut curie, paris, france institut curie, saint-cloud, île-de-france, france klinikum ludwigsburg, ludwigsburg, baden-württemberg, germany universitätsklinikum erlangen, erlangen, bayern, germany rotkreuzklinikum münchen - frauenklinik (gemeinnützige gmbh), münchen, bayern, germany klinikum der universität münchen großhadern, münchen, bayern, germany agaplesion markus krankenhaus, frankfurt, hessen, germany gynäkologisch-onkologische praxis am pelikanplatz, hannover, niedersachsen, germany kliniken essen-mitte, evangelische huyssens-stiftung, essen, nordrhein-westfalen, germany evangelisches krankenhaus bethesda mönchengladbach, mönchengladbach, nordrhein-westfalen, germany universitaetsklinikum schleswig-holstein campus kiel, kiel, schleswig-holstein, germany ostholstein onkologie, oldenburg in holstein, schleswig-holstein, germany agios savvas regional cancer hospital, athens, attikí, greece alexandra general hospital of athens, athens, attikí, greece university general hospital of heraklion, heraklion, irakleío, greece euromedica general clinic of thessaloniki, thessaloniki, thessaloníki, greece european interbalkan medical center, thessaloniki, thessaloníki, greece general hospital of thessaloniki papageorgiou, thessaloniki, greece maulana azad medical college, new delhi, delhi, india hcg-bangalore, bengaluru, karnataka, india regional cancer centre - thiruvananthapuram, thiruvananthapuram, kerala, india hcg cancer centre, mumbai, maharashtra, india government medical college and hospital - nagpur, nagpur, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india yashoda hospitals, hyderabad, telangana, india university of naples federico ii, naples, campania, italy istituto nazionale tumori irccs fondazione pascale, napoli, campania, italy cro-irccs, aviano, friuli-venezia giulia, italy fondazione policlinico universitario agostino gemelli, roma, lazio, italy fondazione irccs istituto nazionale dei tumori, milan, lombardia, italy azienda ospedaliera universitaria careggi, firenze, toscana, italy ospedale san martino, genova, italy istituto europeo di oncologia irccs, milano, italy azienda ospedaliero universitaria, modena, italy istituto oncologico veneto irccs, padova, italy nagoya university hospital, nagoya, aichi, japan chiba cancer center, chiba-shi, chiba, japan kurume general hospital, kurume, fukuoka, japan gunma prefectural cancer center, ota, gunma, japan national hospital organization hokkaido cancer center, sapporo, hokkaido, japan hyogo cancer center, akashi, hyogo, japan university of tsukuba hospital, tsukuba-shi, ibaragi, japan st. marianna university hospital, kawasaki, kanagawa, japan kanagawa cancer center, yokohama, kanagawa, japan niigata cancer center hospital, niigata-shi, niigata, japan juntendo university hospital, bunkyo-ku, tokyo, japan national cancer center hospital, chuo-ku, tokyo, japan national hospital organization kyushu cancer center, fukuoka, japan hiroshima city hospital, hiroshima, japan sagara hospital, kagoshima, japan kumamoto shinto general hospital, kumamoto, japan osaka international cancer institute, osaka, japan shizuoka prefectural general hospital, shizuoka, japan soon chun hyang university cheonan hospital, cheonan-si, chungcheongnam-do [chungnam], korea, republic of gachon university gil hospital, namdong-gu, incheon-gwangyeoksi [incheon], korea, republic of severance hospital, yonsei university health system, seoul, korea, korea, republic of ajou university hospital, suwon-si, kyǒnggi-do, korea, republic of yeungnam univeristy medical center, gyeongsan-si, kyǒngsangbuk-do, korea, republic of dong-a university hospital, busan, pusan-kwangyǒkshi, korea, republic of asan medical center, seoul, seoul-teukbyeolsi [seoul], korea, republic of gangnam severance hospital, seoul, seoul-teukbyeolsi [seoul], korea, republic of seoul national university hospital, seoul, seoul-teukbyeolsi [seoul], korea, republic of kangbuk samsung hospital, seoul, seoul-teukbyeolsi [seoul], korea, republic of samsung medical center, seoul, seoul-teukbyeolsi [seoul], korea, republic of centro de investigación clínica de alta especialidad, torreón, coahuila, mexico grupo medico camino sc, mexico city, distrito federal, mexico christus muguerza clinica vidriera (christus muguerza sistemas hospitalarios s.a. de c.v.), monterrey nuevo león, c.p., monterrey, mexico coi centro oncológico intl. s.a.p.i. de c.v._ s.f., paso de las lomas, mx, mexico private practice - dr. joaquin reinoso, monterrey, nuevo león, mexico centro medico zambrano helion, san pedro garza garcia, nuevo león, mexico unidad de investigación en salud, chihuahua, mexico oaxaca site management organization, oaxaca, mexico unidad médica onco-hematológica, puebla, mexico medische centrum leeuwarden, leeuwarden, fryslân, netherlands maastricht umc+, maastricht, limburg, netherlands haga ziekenhuis locatie leyweg, den haag, zuid-holland, netherlands fed state budgetary inst ""n.n. blokhin med center of oncology"" mhrf, moscow, moskva, russian federation n.n.petrov research institute of oncology, st. petersburg, peterburg, russian federation volgograd regional clinical cancer clinic no.1, volgograd, volgogradskaya oblast\', russian federation shi kaluga regional hospital, kaluga, russian federation hospital universitari vall d\'hebron, barcelona, barcelona [barcelona], spain hospital de la santa creu i sant pau, barcelona, catalunya [cataluña], spain hospital universitari arnau de vilanova, lleida, cataluña, spain hospital universitario ramón y cajal, madrid, madrid, comunidad de, spain hospital universitario de canarias, san cristobal de la laguna, santa cruz de tenerife, spain hospital universitario san cecilio, granada, spain hospital clinico san carlos, madrid, spain hospital universitario virgen macarena, sevilla, spain hospital universitario virgen del rocio, sevilla, spain hospital clínico universitario de valencia, valencia, spain hospital quirón salud valencia, valencia, spain chi mei hospital - liouying branch, tainan city, tainan, taiwan taichung veterans general hospital, taichung, taiwan national cheng-kung uni. hosp., tainan, taiwan national taiwan university hospital, taipei, taiwan koo foundation sun yat-sen cancer center, taipei, taiwan acibadem altunizade hospital, üsküdar / stanbul, i̇stanbul, turkey ege university medicine of faculty, bornova, i̇zmir, turkey baskent university dr. turgut noyan research and training center, adana, turkey university of health sciences,gulhane school of medicine, ankara, turkey memorial ankara hastanesi, ankara, turkey ankara city hospital, ankara, turkey hacettepe universitesi, ankara, turkey abdurrahman yurtaslan ankara oncology, education and research hospital, ankara, turkey akdeniz university medical faculty, antalya, turkey dicle üniversitesi, diyarbakir, turkey trakya university, edirne, turkey medipol mega university hospital, istanbul, turkey acıbadem maslak hastanesi, i̇stanbul, turkey tc saglik bakanligi goztepe prof. dr. suleyman yalcin sehir hastanesi, istanbul, turkey i̇nönü üniversitesi turgut özal tıp merkezi, malatya, turkey mersin university, mersin, turkey mi kryvyi rih oncology dispensary of dnipropetrovsk regional council; chemotherapy department, kryvyi rih, dnipropetrovska oblast, ukraine cnpe ""regional center of oncology"", kharkiv, kharkivska oblast, ukraine municipal non-profit enterprise\'odesa regional clinical hospital\'of odesa regional council, odesa, odeska oblast, ukraine communal noncommercial enterprise ""podillia regional oncology center of vinnytsia regional council"", vinnytsia, vinnytska oblast, ukraine municipal enterprise ""volyn regional medical oncology centre"" of the volyn regional council, lutsk, volynska oblast, ukraine uzhgorod central city clinical hospital, uzhhorod, zakarpatska oblast, ukraine']",,https://ClinicalTrials.gov/show/NCT04975308,breast
353,354,NCT03853655,adjuvant radiotherapy in early stage oral cancers,AREST,Recruiting,No Results Available,cancer of mouth|cancer of the tongue|cancer of the head and neck|buccal mucosa cancer|floor of mouth carcinoma,radiation: post-operative adjuvant radiotherapy,loco-regional recurrence free survival|disease free survival|overall survival,tata memorial hospital|national cancer grid,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,392.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1713,"August 2, 2018","August 1, 2023","September 30, 2026","February 25, 2019",,"May 4, 2022","['dr. b barooah cancer institute, guwahati, assam, india hcg hospital, ahmedabad, gujarat, india kailash cancer hospital and research centre, goraj, gujarat, india sree sankara cancer hospital, bangalore, karnataka, india mazumdar shaw medical centre, bangalore, karnataka, india malabar cancer centre, kannur, kerala, india amrita institute of medical sciences, kochi, kerala, india tata memorial centre, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03853655,
354,355,NCT02136927,bioavailability study of sparc1210 and reference1210 in subjects with metastatic breast cancer,,Terminated,No Results Available,breast cancer,drug: sparc1210|drug: reference1210,maximum observed concentration (cmax),sun pharma advanced research company limited,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLR_12_10,August 2014,April 2016,April 2016,"May 13, 2014",,"May 3, 2019","['sparc site 12, hyderabad, andhra pradesh, india sparc site 9, hyderabad, andhra pradesh, india sparc site 6, new delhi, delhi, india sparc site 2, goraj, gujarat, india sparc site 8, cochin, kerala, india sparc site 11, mumbai, maharashtra, india sparc site 5, nagpur, maharashtra, india sparc site 4, nashik, maharashtra, india sparc site 1, pune, maharashtra, india sparc site 3, pune, maharashtra, india sparc site 10, chennai, tamil nadu, india sparc site 7, madurai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT02136927,breast
355,356,NCT01566240,induction chemotherapy plus chemoradiation as first line treatment for locally advanced cervical cancer,INTERLACE,Recruiting,No Results Available,cervical cancer,drug: paclitaxel|drug: carboplatin|radiation: radiotherapy|drug: cisplatin,"overall survival|progression free survival|adverse events (ae) as assessed by the common terminology criteria for adverse events v4.03|quality of life (uk and ireland only) as assessed by eortc qlq-c30, qlq-cx24 and eq-5d|patterns of first relapse (local and/or systemic)","university college, london|cancer research uk",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCL 11/0034|2011-001300-35|C37815/A12832,September 2012,August 2022,May 2026,"March 29, 2012",,"April 29, 2021","[""chittaranjan national cancer institute (cnci), kolkata, india saroj gupta cancer centre and research institute, kolkata, india istituto europeo di oncologia, milan, lombardy, italy instituto nacional de cancerologia (incan), mexico city, mexico north devon district hospital, barnstaple, devon, united kingdom university college london hospital, london, greater london, united kingdom weston park hospital, sheffield, south yorkshire, united kingdom belfast city hospital, belfast, united kingdom pilgrim hospital, boston, united kingdom royal sussex county hospital, brighton, united kingdom velindre cancer centre, cardiff, united kingdom cheltenham general hospital, cheltenham, united kingdom royal derby hospital, derby, united kingdom royal devon and exeter nhs foundation trust, exeter, united kingdom beatson woscc, glasgow, united kingdom gloucester royal hospital, gloucester, united kingdom grantham and district hospital, grantham, united kingdom castle hill hospital, hull, united kingdom leicester royal infirmary, leicester, united kingdom lincoln county hospital, lincoln, united kingdom guy's and st thomas' nhs foundation trust, london, united kingdom imperial college healthcare nhs trust, london, united kingdom st bart's hospital, london, united kingdom the christie nhs foundation trust, manchester, united kingdom james cook university hospital, middlesbrough, united kingdom northampton general hospital, northampton, united kingdom norfolk and norwich university hospital, norwich, united kingdom nottingham university hospitals nhs trust, nottingham, united kingdom derriford hospital, plymouth, united kingdom southampton general hospital, southampton, united kingdom royal stoke university hospital, stoke-on-trent, united kingdom torbay hospital, torquay, united kingdom royal cornwall hospital, truro, united kingdom the clatterbridge cancer centre, wirral, united kingdom new cross hospital, wolverhampton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT01566240,cervic
356,357,NCT03853551,osimertinib study in indian patients,,Completed,Has Results,non small cell lung cancer (nsclc),drug: osimertinib,safety of osimertinib,astrazeneca,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,60.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5161C00005,"April 18, 2019","April 15, 2020","April 15, 2020","February 25, 2019","June 3, 2021","June 3, 2021","['research site, hyderabad, india research site, hyderabad, india research site, kolkata, india research site, mumbai, india research site, mumbai, india research site, new dehli, india research site, new delhi, india']","""study protocol"", https://clinicaltrials.gov/provideddocs/51/nct03853551/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/51/nct03853551/sap_001.pdf",https://ClinicalTrials.gov/show/NCT03853551,
357,358,NCT00102804,pemetrexed and best supportive care versus placebo and best supportive care in non-small cell lung cancer (nsclc),,Completed,Has Results,non-small cell lung cancer,drug: pemetrexed|drug: placebo|other: best supportive care,progression-free survival (pfs) time|overall survival (os) time|time to objective progressive disease (tpd)|time to worsening of symptoms (tws)|percentage of participants with a complete response (cr) or partial response (pr) (objective tumor response rate)|number of participants with adverse events (aes)|maximum improvement over baseline in individual symptom scores and quality of life using the lcss,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,663.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",5122|H3E-MC-JMEN,March 2005,August 2007,December 2013,"February 2, 2005","December 29, 2014","December 29, 2014","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., portsmouth, new hampshire, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pittsburgh, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dallas, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., marshfield, wisconsin, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bankstown, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., coffs harbour, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kogarah, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., port macquarie, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nambour, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., townsville, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ashford, south australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankston, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vienna, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ijui, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sao paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sofia, bulgaria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., varna, bulgaria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beijing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dalian, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guang zhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hangzhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ji nan, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nan jing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shanghai, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zagreb, croatia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brno, czech republic for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ostrava-poruba, czech republic for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., prague, czech republic for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hamburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hamm, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hannover, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., magdeburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ulm, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chania, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mosdos, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., szombathely, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., banglagore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jaipur, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., p.o ernakulam, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bari, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bologna, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., genova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., livorno, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., messina, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., padova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pisa, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rozzano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., amsterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ede, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zutphen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zwolle, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poznan, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., warsaw, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cluj-napoca, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oradea, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., alcoi, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., alcorcon, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barcelona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., granada, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mataró, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., murcia, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., palma de mallorca, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa cruz de tenerife, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ankara, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., izmir, turkey']",,https://ClinicalTrials.gov/show/NCT00102804,
358,359,NCT01160211,"a study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, her2+ metastatic breast cancer",,"Active, not recruiting",Has Results,"neoplasms, breast",drug: lapatinib|drug: trastuzumab|drug: aromatase inhibitor,"pfs of lapatinib+trastuzumab+ai combination vs. trastuzumab+ai combination|median kaplan meier estimates for pfs of lapatinib+trastuzumab+ai combination vs. trastuzumab+ai combination|pfs of trastuzumab/ai vs. lapatinib/ai and trastuzumab/lapatinib/ai vs. lapatinib/ai|overall survival (os) events of lapatinib+trastuzumab+ai vs. trastuzumab+ai and lapatinib+ai vs. trastuzumab+ai|overall response rate (orr; complete or partial response) in lapatinib+trastuzumab+ai vs. trastuzumab+ai and lapatinib+ai vs. trastuzumab+ai|clinical benefit rate (cbr; complete response, partial response, or stable disease for at least 6 months) in lapatinib+trastuzumab+ai vs. trastuzumab+ai and lapatinib+ai vs. trastuzumab+ai|duration of response in lapatinib+trastuzumab+ai vs. trastuzumab+ai and lapatinib+ai vs. trastuzumab+ai|changes in the quality of life (qol) status relative to baseline fact-b overall and subscale scores at last on-treatment assessment|time to response in lapatinib+trastuzumab+ai vs. trastuzumab+ai and lapatinib+ai vs. trastuzumab+ai",novartis pharmaceuticals|glaxosmithkline|novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,369.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,114299|2010-019577-16|CLAP016A2307,"May 5, 2011","March 11, 2016","May 2, 2023","July 12, 2010","July 15, 2019","August 31, 2021","['novartis investigative site, la jolla, california, united states novartis investigative site, pleasant hill, california, united states novartis investigative site, hollywood, florida, united states novartis investigative site, miami, florida, united states novartis investigative site, augusta, georgia, united states novartis investigative site, lawrenceville, georgia, united states novartis investigative site, chicago, illinois, united states novartis investigative site, goshen, indiana, united states novartis investigative site, waterloo, iowa, united states novartis investigative site, grand rapids, michigan, united states novartis investigative site, minneapolis, minnesota, united states novartis investigative site, billings, montana, united states novartis investigative site, omaha, nebraska, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, cary, north carolina, united states novartis investigative site, dayton, ohio, united states novartis investigative site, germantown, tennessee, united states novartis investigative site, houston, texas, united states novartis investigative site, tacoma, washington, united states novartis investigative site, milwaukee, wisconsin, united states novartis investigative site, berazategui, buenos aires, argentina novartis investigative site, capital federal, buenos aires, argentina novartis investigative site, ciudad aut6noma de buenos aires, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, la plata, buenos aires, argentina novartis investigative site, viedma, río negro, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, ciudad autonoma de buenos aires, argentina novartis investigative site, cordoba, argentina novartis investigative site, la rioja, argentina novartis investigative site, quilmes, argentina novartis investigative site, san miguel de tucuman, argentina novartis investigative site, box hill, victoria, australia novartis investigative site, wodonga, victoria, australia novartis investigative site, adelaide, australia novartis investigative site, douglas, australia novartis investigative site, ringwood east, australia novartis investigative site, tweed heads, australia novartis investigative site, leuven, belgium novartis investigative site, liege, belgium novartis investigative site, namur, belgium novartis investigative site, fortaleza, ceará, brazil novartis investigative site, goiania, goiás, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, barretos, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, rio de janeiro, brazil novartis investigative site, plovdiv, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, varna, bulgaria novartis investigative site, calgary, alberta, canada novartis investigative site, fuzhou, fujian, china novartis investigative site, guangzhou, guangdong, china novartis investigative site, changchun, jilin, china novartis investigative site, harbin, china novartis investigative site, shanghai, china novartis investigative site, monteria, colombia novartis investigative site, osijek, croatia novartis investigative site, pula, croatia novartis investigative site, zagreb, croatia novartis investigative site, besancon, france novartis investigative site, le mans, france novartis investigative site, lille, france novartis investigative site, montpellier cedex 5, france novartis investigative site, nancy, france novartis investigative site, paris cedex 20, france novartis investigative site, heidelberg, baden-wuerttemberg, germany novartis investigative site, tuebingen, baden-wuerttemberg, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, regensburg, bayern, germany novartis investigative site, rosenheim, bayern, germany novartis investigative site, fuerstenwalde, brandenburg, germany novartis investigative site, rostock, mecklenburg-vorpommern, germany novartis investigative site, goslar, niedersachsen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, aachen, nordrhein-westfalen, germany novartis investigative site, bottrop, nordrhein-westfalen, germany novartis investigative site, troisdorf, nordrhein-westfalen, germany novartis investigative site, velbert, nordrhein-westfalen, germany novartis investigative site, halle, sachsen-anhalt, germany novartis investigative site, kiel, schleswig-holstein, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, athens, greece novartis investigative site, chania, greece novartis investigative site, heraklion, greece novartis investigative site, perioxi dragana, alexandroupolis, greece novartis investigative site, hong kong, hong kong novartis investigative site, kowloon, hong kong novartis investigative site, pokfulam, hong kong novartis investigative site, tuen mun, hong kong novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, gyor, hungary novartis investigative site, gyula, hungary novartis investigative site, kaposvar, hungary novartis investigative site, miskolc, hungary novartis investigative site, nyiregyhaza, hungary novartis investigative site, pecs, hungary novartis investigative site, szeged, hungary novartis investigative site, szolnok, hungary novartis investigative site, veszprem, hungary novartis investigative site, zalaegerszeg, hungary novartis investigative site, bangalore, india novartis investigative site, chennai, india novartis investigative site, delhi, india novartis investigative site, nagpur, india novartis investigative site, new delhi, india novartis investigative site, pune, india novartis investigative site, surat, india novartis investigative site, dublin 7, ireland novartis investigative site, dublin, ireland novartis investigative site, dublin, ireland novartis investigative site, dublin, ireland novartis investigative site, galway, ireland novartis investigative site, haifa, israel novartis investigative site, jerusalem, israel novartis investigative site, petah-tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, rehovot, israel novartis investigative site, tel aviv, israel novartis investigative site, parma, emilia-romagna, italy novartis investigative site, piacenza, emilia-romagna, italy novartis investigative site, monza, lombardia, italy novartis investigative site, pavia, lombardia, italy novartis investigative site, rozzano (mi), lombardia, italy novartis investigative site, san giovanni rotondo, italy novartis investigative site, aichi, japan novartis investigative site, chiba, japan novartis investigative site, ehime, japan novartis investigative site, kagoshima, japan novartis investigative site, osaka, japan novartis investigative site, osaka, japan novartis investigative site, saitama, japan novartis investigative site, saitama, japan novartis investigative site, shizuoka, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, gyeonggi-do, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, vilnius, lithuania novartis investigative site, lorenskog, norway novartis investigative site, miraflores, lima, peru novartis investigative site, san borja, lima, peru novartis investigative site, san isidro, lima, peru novartis investigative site, arequipa, peru novartis investigative site, lima, peru novartis investigative site, trujillo, peru novartis investigative site, makati city, philippines novartis investigative site, quezon city, philippines novartis investigative site, konin, poland novartis investigative site, lubin, poland novartis investigative site, otwock, poland novartis investigative site, warszawa, poland novartis investigative site, warszawa, poland novartis investigative site, wieliszew, poland novartis investigative site, wroclaw, poland novartis investigative site, coimbra, portugal novartis investigative site, evora, portugal novartis investigative site, lisboa, portugal novartis investigative site, lisbon, portugal novartis investigative site, porto, portugal novartis investigative site, san juan, puerto rico novartis investigative site, san juan, puerto rico novartis investigative site, bucharest, romania novartis investigative site, bucuresti, romania novartis investigative site, timisoara, romania novartis investigative site, arkhangelsk, russian federation novartis investigative site, kazan, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, ryazan, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, tver, russian federation novartis investigative site, belgrade, serbia novartis investigative site, kragujevac, serbia novartis investigative site, sremska kamenica, serbia novartis investigative site, singapore, singapore novartis investigative site, cape town, south africa novartis investigative site, durban, south africa novartis investigative site, port elizabeth, south africa novartis investigative site, pretoria, south africa novartis investigative site, saxonwold, johannesburg, south africa novartis investigative site, barcelona, spain novartis investigative site, barcelona, spain novartis investigative site, castellon, spain novartis investigative site, cordoba, spain novartis investigative site, la coruna, spain novartis investigative site, madrid, spain novartis investigative site, santa cruz de tenerife, spain novartis investigative site, changhua, taiwan novartis investigative site, kaohsiung hsien, taiwan novartis investigative site, taipei city, taiwan novartis investigative site, ankara, turkey novartis investigative site, izmir, turkey novartis investigative site, chernivtsi, ukraine novartis investigative site, dnipropetrovsk, ukraine novartis investigative site, kharkiv, ukraine novartis investigative site, khmelnytskyi, ukraine novartis investigative site, lyutizh, ukraine novartis investigative site, sumy, ukraine novartis investigative site, uzhgorod, ukraine novartis investigative site, vinnitsia, ukraine novartis investigative site, chelmsford, essex, united kingdom novartis investigative site, birmingham, west midlands, united kingdom novartis investigative site, huddersfield, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, maidstone, united kingdom novartis investigative site, manchester, united kingdom novartis investigative site, nottingham, united kingdom novartis investigative site, peterborough, united kingdom novartis investigative site, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01160211,breast
359,360,NCT00744497,randomized study comparing docetaxel plus dasatinib to docetaxel plus placebo in castration-resistant prostate cancer,READY,Completed,Has Results,prostatic neoplasms,drug: placebo|drug: dasatinib|drug: docetaxel|drug: prednisone,overall survival: time from randomization to date of death|percentage of participants with an objective tumor response by modified response evaluation criteria in solid tumors (recist)|time to first skeletal-related event (sre)|percentage of participants with a reduction in urinary n-telopeptide (untx) level from baseline|progression-free survival (pfs)|time to prostate specific antigen (psa) progression|percentage of participants with a reduction in pain intensity from baseline,bristol-myers squibb,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,1930.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CA180-227|2008-000701-11,October 2008,August 2012,July 2015,"September 1, 2008","February 6, 2014","October 17, 2016","['university of south alabama / mitchell cancer institute, mobile, alabama, united states southern cancer center, mobile, alabama, united states alaska clinical research center, llc, anchorage, alaska, united states highlands oncology group, fayetteville, arkansas, united states compassionate cancer care medical group, inc., corona, california, united states desert hematology oncology medical group, rancho mirage, california, united states compassionate cancer care medical group inc, riverside, california, united states sharp clinical oncology research, san diego, california, united states va san diego healthcare system, san diego, california, united states edward alexson, md, inc., santa ana, california, united states connecticut oncology group, middletown, connecticut, united states va connecticut healthcare system, west haven, connecticut, united states gwinnett hospital system inc., lawrenceville, georgia, united states university of chicago, chicago, illinois, united states midwestern regional medical center, zion, illinois, united states fort wayne medical oncology and hematology inc, fort wayne, indiana, united states cancer center of kansas, wichita, kansas, united states maine center for cancer medicine, scarborough, maine, united states tufts medical center, boston, massachusetts, united states jackson oncology associates, pllc, jackson, mississippi, united states north mississippi hematology and oncology associates, ltd, tupelo, mississippi, united states new york oncology hematology, pc, albany, new york, united states new york oncology hematology, pc, albany, new york, united states samuel s. stratton vamc, albany, new york, united states roswell park cancer institute, buffalo, new york, united states memorial sloan kettering cancer center, new york, new york, united states duke university medical center, durham, north carolina, united states piedmont hematology oncology associates, pllc, winston-salem, north carolina, united states summa health system, akron, ohio, united states mid ohio oncology/hematology, inc,dba, columbus, ohio, united states providence portland med ctr, portland, oregon, united states regional hemetology oncology, pc, langhorne, pennsylvania, united states upmc cancer pavilion, pittsburgh, pennsylvania, united states va pittsburgh healthcare system, pittsburgh, pennsylvania, united states associates in hematology & oncology, p.c., upland, pennsylvania, united states the miriam hospital, providence, rhode island, united states cancer centers of the carolinas, greenville, south carolina, united states boston baskin cancer foundation, memphis, tennessee, united states cancer specialists of south texas, pa, corpus christi, texas, united states the university of texas md anderson cancer center, houston, texas, united states providence regional cancer system, lacey, washington, united states university of washington, seattle, washington, united states dean hematology and oncology clinic, madison, wisconsin, united states local institution, caba, buenos aires, argentina local institution, capital federal, buenos aires, argentina local institution, capital federal, buenos aires, argentina local institution, capital federal, buenos aires, argentina local institution, la plata, buenos aires, argentina local institution, ramos mejia, buenos aires, argentina local institution, cipolletti, rio negro, argentina local institution, rosario, santa fe, argentina local institution, rosario, santa fe, argentina local institution, san miguel de tucuman, tucuman, argentina local institution, buenos aires, argentina local institution, buenos aires, argentina local institution, buenos aires, argentina local institution, cordaba, argentina local institution, coffs harbour, new south wales, australia local institution, lismore, new south wales, australia local institution, port macquarie, new south wales, australia local institution, sydney, new south wales, australia local institution, douglas, queensland, australia local institution, milton, queensland, australia local institution, kurralta park, south australia, australia local institution, hobart, tasmania, australia local institution, frankston, victoria, australia local institution, ringwood, victoria, australia local institution, fremantle, western australia, australia local institution, salvador, bahia, brazil local institution, porto alegre, rio grande do sul, brazil local institution, barretos, sao paulo, brazil local institution, campinas, sao paulo, brazil local institution, jau, sao paulo, brazil local institution, santo andre, sao paulo, brazil local institution, rio de janeiro, brazil local institution, rio de janeiro, brazil local institution, edmonton, alberta, canada local institution, abbottsford, british columbia, canada local institution, moncton, new brunswick, canada local institution, ottawa, ontario, canada local institution, owen sound, ontario, canada local institution, sudbury, ontario, canada local institution, thunder bay, ontario, canada local institution, greenfield park, quebec, canada local institution, montreal, quebec, canada local institution, montreal, quebec, canada local institution, rimouski, quebec, canada local institution, sherbrooke, quebec, canada local institution, regina, saskatchewan, canada local institution, saskatoon, saskatchewan, canada local institution, brno, czech republic local institution, hradec kralove, czech republic local institution, praha 2, czech republic local institution, praha 8, czech republic local institution, turku, finland local institution, vaasa, finland local institution, avignon, france local institution, besancon cedex, france local institution, caen, france local institution, creteil, france local institution, paris, france local institution, st genis laval, france local institution, strasbourg, france local institution, aachen, germany local institution, berlin, germany local institution, erlangen, germany local institution, essen, germany local institution, kirchheim, germany local institution, markkleeberg, germany local institution, athens, greece local institution, budapest, hungary local institution, kecskemet, hungary local institution, zalaegerszeg, hungary local institution, trivandrum, kerala, india local institution, mumbai, maharashtra, india local institution, pune, maharashtra, india local institution, pune, maharashtra, india local institution, ahmedabad, india local institution, jaipur, india local institution, kolkata, india local institution, kolkatta, india local institution, dublin 7, dublin, ireland local institution, tallaght, dublin, ireland local institution, cork, ireland local institution, dublin, ireland local institution, arezzo, italy local institution, genova, italy local institution, lecce, italy local institution, milan, italy local institution, napoli, italy local institution, perugia, italy local institution, roma, italy local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, tijuana, baja california, mexico local institution, df, distrito federal, mexico local institution, mexico d.f., distrito federal, mexico local institution, tlalpan, distrito federal, mexico local institution, tlalpan, distrito federal, mexico local institution, huixquilucan, estado de mexico, mexico local institution, toluca, estado de mexico, mexico local institution, guadalajara, jalisco, mexico local institution, zapopan, jalisco, mexico local institution, monterrey, nuevo leon, mexico local institution, mexico, queretaro, mexico local institution, stavanger, norway local institution, callao, peru local institution, lima, peru local institution, lima, peru local institution, lima, peru local institution, lima, peru local institution, lima, peru local institution, bialystok, poland local institution, lodz, poland local institution, warszawa, poland local institution, baia mare, romania local institution, cluj napoca, romania local institution, timisoara, timis, romania local institution, moscow, russian federation local institution, moscow, russian federation local institution, st petersburg, russian federation local institution, st petersburg, russian federation local institution, bloemfontein, free state, south africa local institution, pretoria, gauteng, south africa local institution, saxonwold, gauteng, south africa local institution, barcelona, spain local institution, barcelona, spain local institution, barcelona, spain local institution, gijon, spain local institution, madrid, spain local institution, madrid, spain local institution, madrid, spain local institution, santander, spain local institution, sevilla, spain local institution, valencia, spain local institution, kungalv, sweden local institution, sundsvall, sweden local institution, uppsala, sweden local institution, vaxjo, sweden local institution, cardiff, glamorgan, united kingdom local institution, london, middlesex, united kingdom local institution, sutton, surrey, united kingdom local institution, leeds, west yorkshire, united kingdom local institution, essex, united kingdom']",,https://ClinicalTrials.gov/show/NCT00744497,prostat
360,361,NCT00830180,open label extension in cancer patients,,Completed,Has Results,neoplasms|bone metastases,biological: anti-ngf ab,"change from parent study (a4091003 [nct00545129]) baseline in brief pain inventory-short form (bpi-sf) average pain score for at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from a4091029 baseline in bpi-sf average pain score at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from parent study (a4091003 [nct00545129]) baseline in bpi-sf worst pain score at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from study a4091029 baseline in bpi-sf worst pain score at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from parent study (a4091003 [nct00545129]) baseline in bpi-sf least pain score at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from study a4091029 baseline in bpi-sf least pain score at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from parent study (a4091003 [nct00545129]) baseline in bpi-sf score for right now pain at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from study a4091029 baseline in bpi-sf score for right now pain at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from parent study (a4091003 [nct00545129]) baseline in bpi-sf score for pain interference with function (composite score) weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from study a4091029 baseline in bpi-sf score for pain interference with function (composite score) at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from parent study (a4091003 [nct00545129]) baseline in bpi-sf item scores for pain interference at weeks 4, 8, 16, 24, 40, 48, 56 and 64|change from study a4091029 baseline in bpi-sf item scores for pain interference at weeks 4, 8, 16, 24, 40, 48, 56 and 64",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,41.0,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,A4091029|2008-005182-66|CANCER PAIN OL EXTENSION,"October 29, 2009","February 14, 2013","February 14, 2013","January 27, 2009","February 2, 2021","April 5, 2021","['ucsd center for pain medicine, la jolla, california, united states ucsd medical center - thornton hospital, la jolla, california, united states ucsd periman ambulatory care center, la jolla, california, united states ucsd moores cancer center, la jolla, california, united states wk river cities clinical research center, shreveport, louisiana, united states huntsman cancer institute, salt lake city, utah, united states nuhr zentrum, senftenberg, austria clinic of oncology, banja luka, bosnia and herzegovina general hospital varazdin, varazdin, croatia fejer megyei szt. gyorgy korhaz - rendelointezet/aneszteziologiai es intenziv betegellato osztaly, szekesfehervar, hungary central india cancer research institute central india cancer research institute, nagpur, maharashtra, india shatabdi super speciality hospital, nashik, maharashtra, india chhatrapati shahuji maharaj medical university, lucknow, uttar pradesh, india severance hospital, yonsei university college of medicine, seodaemun-gu, seoul, korea, republic of samsung medical center, division of hematology-oncology, department of medicine, seoul, korea, republic of latvian oncology centre, riga, latvia niepubliczny zaklad opieki zdrowotnej, bydgoszcz, poland hospicjum im ks eugeniusza dutkiewicza sac w gdansku, gdansk, poland **poradnia medycyny paliatywnej, hospicjum palium, poznan, poland wielkopolskie centrum onkologii im. marii sklodowskiej-curie, poznan, poland nzoz zespol opieki domowej polskiego towarzystwa opieki paliatywnej, wloclawek, poland fakultna nemocina s poliklinikou fd roosevelta banska bystrica, banska bystrica, slovakia narodny onkologicky ustav, bratislava, slovakia']",,https://ClinicalTrials.gov/show/NCT00830180,
361,362,NCT01204749,"trinova-1: a study of amg 386 or placebo, in combination with weekly paclitaxel chemotherapy, as treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancer",,Completed,No Results Available,fallopian tube cancer|ovarian cancer|primary peritoneal cancer,drug: amg 386|drug: amg 386 placebo|drug: paclitaxel,progression-free survival|overall survival|objective response rate|duration of response|ca-125 response rate per gynecologic cancer intergroup (gcig) and change in ca-125|incidence of adverse events and significant laboratory abnormalities|pharmacokinetics of amg 386 (cmax and cmin)|incidence of the occurrence of anti-amg 386 antibody formation|patient reported health related quality of life (hrqol) and ovarian cancer related symptoms using functional assessment of cancer therapy - ovary questionnaire (fact-o)|overall health status using euroqol(eq-5d),amgen,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,919.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20090508,November 2010,March 2013,December 2016,"September 17, 2010",,"December 15, 2016","['research site, phoenix, arizona, united states research site, los angeles, california, united states research site, san diego, california, united states research site, stanford, california, united states research site, englewood, colorado, united states research site, danbury, connecticut, united states research site, new haven, connecticut, united states research site, hollywood, florida, united states research site, orlando, florida, united states research site, honolulu, hawaii, united states research site, honolulu, hawaii, united states research site, boise, idaho, united states research site, peoria, illinois, united states research site, skokie, illinois, united states research site, metairie, louisiana, united states research site, baltimore, maryland, united states research site, baltimore, maryland, united states research site, boston, massachusetts, united states research site, boston, massachusetts, united states research site, lebanon, new hampshire, united states research site, hackensack, new jersey, united states research site, brightwaters, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, charlotte, north carolina, united states research site, charlotte, north carolina, united states research site, winston salem, north carolina, united states research site, abington, pennsylvania, united states research site, chattanooga, tennessee, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, ogden, utah, united states research site, tacoma, washington, united states research site, milwaukee, wisconsin, united states research site, milwaukee, wisconsin, united states research site, new lambton heights, new south wales, australia research site, greenslopes, queensland, australia research site, bendigo, victoria, australia research site, bentleigh east, victoria, australia research site, footscray, victoria, australia research site, malvern, victoria, australia research site, parkville, victoria, australia research site, edegem, belgium research site, leuven, belgium research site, namur, belgium research site, porto alegre, rio grande do sul, brazil research site, porto alegre, rio grande do sul, brazil research site, itajaã-, santa catarina, brazil research site, ribeirao preto, sã£o paulo, brazil research site, rio de janeiro, brazil research site, sã£o paulo, brazil research site, gabrovo, bulgaria research site, plovdiv, bulgaria research site, sofia, bulgaria research site, stara zagora, bulgaria research site, varna, bulgaria research site, calgary, alberta, canada research site, vancouver, british columbia, canada research site, london, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, sherbrooke, quebec, canada research site, quebec, canada research site, temuco, cautã-n, chile research site, valparaiso, valparaã-so, chile research site, zagreb, croatia research site, brno, czech republic research site, brno, czech republic research site, praha 2, czech republic research site, praha 5, czech republic research site, tallinn, estonia research site, tartu, estonia research site, amiens, france research site, angers, france research site, avignon cedex 2, france research site, bayonne, france research site, besancon cedex, france research site, bordeaux cedex, france research site, bordeaux cedex, france research site, brest cedex 2, france research site, dijon, france research site, le mans, france research site, lille cedex, france research site, lyon, france research site, marseille cedex 05, france research site, marseille cedex 09, france research site, marseille, france research site, montpellier cedex 5, france research site, nancy, france research site, nantes cedex 2, france research site, nice cedex 2, france research site, orlã©ans cedex 2, france research site, paris cedex 15, france research site, pã©rigueux cedex, france research site, reims cedex, france research site, saint grã©goire cedex, france research site, saint herblain, france research site, strasbourg, france research site, villejuif cedex, france research site, athens, greece research site, heraklion, greece research site, larissa, greece research site, patra, greece research site, thessaloniki, greece research site, hong kong, hong kong research site, hyderabad, andhra pradesh, india research site, mumbai, maharashtra, india research site, nashik, maharashtra, india research site, pune, maharashtra, india research site, pune, maharashtra, india research site, haifa, israel research site, holon, israel research site, kefar sava, israel research site, tel hashomer, israel research site, tel-aviv, israel research site, benevento, italy research site, catania, italy research site, cosenza (cs), italy research site, genova, italy research site, milano, italy research site, milano, italy research site, napoli, italy research site, padova, italy research site, potenza, italy research site, roma, italy research site, roma, italy research site, nagoya-city, aichi, japan research site, fukuoka-shi, fukuoka, japan research site, kure-city, hiroshima, japan research site, sapporo-city, hokkaido, japan research site, tsukuba-city, ibaraki, japan research site, morioka-city, iwate, japan research site, niigata-city, niigata, japan research site, osakasayama-city, osaka, japan research site, hidaka-shi, saitama, japan research site, suntou-gun, shizuoka, japan research site, chuo-ku, tokyo, japan research site, yonago-city, tottori, japan research site, kurume-city, japan research site, tokyo, japan research site, tokyo, japan research site, tokyo, japan research site, goyang-si, gyeonggi-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, daugavpils, latvia research site, riga, latvia research site, riga, latvia research site, johor bahru, johor, malaysia research site, kota bahru, kelantan, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, mexico city, distrito federal, mexico research site, mexico city, distrito federal, mexico research site, san luis potosi, san luis potosã-, mexico research site, distrito federal, mexico research site, lima, peru research site, lima, peru research site, bydgoszcz, poland research site, gdansk, poland research site, lodz, poland research site, lublin, poland research site, poznan, poland research site, warszawa, poland research site, coimbra, portugal research site, guimaraes, portugal research site, lisboa, portugal research site, porto, portugal research site, porto, portugal research site, santa maria da feira, portugal research site, bucharest, romania research site, bucharest, romania research site, cluj napoca, romania research site, suceava, romania research site, targu mures, romania research site, ivanovo, russian federation research site, krasnodar, russian federation research site, moscow, russian federation research site, obninsk, russian federation research site, pyatigorsk, russian federation research site, saint petersburg, russian federation research site, ufa, russian federation research site, voronezh, russian federation research site, ljubljana, slovenia research site, groenkloof, gauteng, south africa research site, johannesburg, gauteng, south africa research site, kraaifontein, western cape, south africa research site, observatory, south africa research site, port elizabeth, south africa research site, pretoria, south africa research site, cã³rdoba, andalucã-a, spain research site, huelva, andalucã-a, spain research site, mã¡laga, andalucã-a, spain research site, sevilla, andalucã-a, spain research site, palma de mallorca, baleares, spain research site, salamanca, castilla leã³n, spain research site, badalona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, elche, comunidad valenciana, spain research site, valencia, comunidad valenciana, spain research site, santiago de compostela, galicia, spain research site, vigo, galicia, spain research site, san sebastiã¡n, paã-s vasco, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, umeã¥, sweden research site, uppsala, sweden research site, baden, switzerland research site, bellinzona, switzerland research site, chur, switzerland research site, geneva 14, switzerland research site, zurich, switzerland research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, northwood, united kingdom research site, nottingham, united kingdom research site, poole, united kingdom research site, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01204749,ovari
362,363,NCT00235898,clinical trial in patients with metastatic colorectal cancer,,Completed,No Results Available,colon cancer|rectal cancer,drug: cofactor|drug: 5-fu|drug: leucovorin,,"mast therapeutics, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-CoFactor,May 2005,March 2008,,"October 12, 2005",,"August 25, 2008","[""global hospital, hyderabad, andhra pradesh, india department of medical oncology, nizam's institute of medical sciences, hyderabad, andhra pradesh, india kasturba medical college, mangalore, attavar, india department of medical oncology, deenanath mangeshkar hospital and research centre, pune, erandawane, india department of medical oncology, kidwai memorial institute of oncology, bangalore, karnataka, india department of oncology, christian medical college, vellore, tamil nadu, india manipal hospital, bangalore, india sms medical college hospital, jaipur, india department of medical oncology, dayanad medical college and hospital, ludhiana, india department of medical oncology, jaslok hospital and research centre, mumbai, india colorectal cancer clinic, centrum cancer clinic onkologii-instytut im m. skladowskiej-curie, roentgena, warszawa, poland department and clinic for oncology and radiotherapy, gdansk, poland department for oncology and radiotherapy, szpital morski im. pck, gdynia redlowo, poland oncological chemotherapy clinic, regionalny osrodek onkologiczny, lodz, poland oncological chemotherapy department centrum onkologii ziemi, lublin, poland clinical oncology department, wojewodski szpital zespolony, torun, poland gastroenterology and hepatology department, fundeni clinical institute, bucharest, romania professor of dr. alexandru trestioreanu, institute of oncology ii, bucharest, romania department of medical oncology and radiotherapy ii, cluj-napoca, romania medical oncology department, county hospital sibiu, sibiu, romania clinical center of serbia, belgrade, serbia institute of oncology and radiology serbia, belgrade, serbia chc bezanijska, belgrade, serbia chc kragujevac, kragujevac, serbia clinic centre nis, nis, serbia clinic for internal medicine, institute for oncology sremska, sremska kamenica, serbia general hospital djordje joanovic, zrenjanin, serbia haematology/lung/gi cancer services, harlow, essex, united kingdom oncology research, north middlesex university hospital, middlesex, london, united kingdom beatson oncology centre, glasgow, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00235898,colon
363,364,NCT02365597,an efficacy and safety study of erdafitinib (jnj-42756493) in participants with urothelial cancer,,Recruiting,No Results Available,urothelial cancer,drug: erdafitinib|drug: midazolam|drug: metformin,percentage of participants with best overall response|progression-free survival|duration of response|overall survival|number of participants with adverse events (aes) and serious adverse events (saes)|percentage of participants with biomarker assessment|plasma concentration of erdafitinib|plasma clearance of erdafitinib|volume of distribution of erdafitinib|plasma concentration of midazolam and its metabolite (1-oh-midazolam)|plasma concentration of metformin,"janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,236.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR105065|42756493BLC2001|2014-002408-26,"April 22, 2015","June 30, 2022","June 30, 2022","February 19, 2015",,"April 27, 2022","[""mayo clinic arizona, scottsdale, arizona, united states arizona oncology associates, pc - nahoa, sedona, arizona, united states university of arizona cancer center, tucson, arizona, united states marin cancer care inc., greenbrae, california, united states cedars sinai medical center - pediatric infectious disease, los angeles, california, united states ronald reagan ucla medical center, los angeles, california, united states university of california irvine, orange, california, united states university of california - davis medical center, sacramento, california, united states stanford university medical center, stanford, california, united states rocky mountain cancer center, aurora, colorado, united states georgetown univ. medical center - lombardi cancer center, washington, district of columbia, united states northwestern university feinberg school of medicine, chicago, illinois, united states university of chicago, chicago, illinois, united states the university of iowa - division of hematology, oncology and blood & marrow transplantation, iowa city, iowa, united states norton cancer institute, louisville, kentucky, united states univ of michigan medical center, ann arbor, michigan, united states karmanos cancer institute - wayne state university, detroit, michigan, united states minnesota oncology, minneapolis, minnesota, united states nebraska cancer specialists, omaha, nebraska, united states comprehensive cancer centers of nevada, las vegas, nevada, united states rutgers cancer institute of new jersey, new brunswick, new jersey, united states weill medical college of cornell university, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states levine cancer institute, charlotte, north carolina, united states hematology oncology associates, pc, medford, oregon, united states northwest cancer specialists pc, tualatin, oregon, united states penn state milton s. hershey medical ctr., hershey, pennsylvania, united states university of pittsburgh medical center (upmc), pittsburgh, pennsylvania, united states carolina urologic research center, myrtle beach, south carolina, united states scri - sarah cannon research institute, nashville, tennessee, united states texas oncology-dallas presbyterian hospital, dallas, texas, united states texas oncology - sammons cancer center, dallas, texas, united states ut southwestern medical center, dallas, texas, united states texas oncology-denton south, denton, texas, united states texas oncology-memorial city, houston, texas, united states university of texas md anderson cancer center, houston, texas, united states virginia oncology associates, hampton, virginia, united states university of wisconsin school of medicine and public health, madison, wisconsin, united states lkh-univ. klinikum graz, graz, austria krankenhaus der barmherzigen schwestern linz, linz, austria krankenhaus der barmherzigen brüder, vienna, austria medical university vienna, vienna, austria o.l.v. ziekenhuis, aalst, belgium cliniques universitaires saint luc, brussel, belgium clinique notre dame, charleroi, belgium u.z. gent, gent, belgium gza ziekenhuizen- campus st augustinus, wilrijk, belgium ico, site paul papin, angers cedex, france institut bergonié, bordeaux, france centre francois baclesse, caen cédex 05, france centre georges-françois leclerc, dijon, france centre leon bérard, lyon, france aphm hopital timone, marseille, france centre antoine lacassagne, nice cedex 2, france institut de cancérologie du gard, nîmes, france hospital saint-louis, paris cedex 10, france hopital europeen georges-pompidou, paris cedex 15, france i.c.o. rené gauducheau, saint herblain cedex, france hopital foch, suresnes, france institut universitaire du cancer toulouse - oncopole, toulouse cedex 09, france institut universitaire du cancer toulouse oncopole, toulouse, france gustave roussy, villejuif cedex, france vivantes klinikum am urban, abt. fur kardiologie, berlin, germany waldkrankenhaus st. marien -urologische universitätsklinik-, erlangen, germany kliniken essen-mitte; evangelische huyssens-stiftung, essen, germany goethe universität frankfurt, frankfurt, germany universitatsklinikum freiburg, freiburg, germany universitätsmedizin greifswald, greifswald, germany georg-august-universitaet goettingen - innere medizin - haematologie, onkologie, göttingen, germany asklepios klinik altona, hamburg, germany medizinische hochschule hannover;klinik f. urologie u. urologische onkologie, hannover, germany university hospital heidelberg, heidelberg, germany klinikum rechts der isar der tu muenchen, muenchen, germany university hospital muenster, dpt. of urology, muenster, germany caritas krankenhaus st. josef - innere medizin ii, regensburg, germany klinikum st. elisabeth, straubing, germany kliniken nordoberpfalz, klinik für urologie, weiden/opf, germany health care global enterprises pvt ltd, bangalore, india post graduate institute of medical education & research (pgimer), chandigarh, india advanced centre for treatment, research and education in cancer (actrec), kharghar, navi mumbai, india netaji subhas chandra bose cancer research institute, kolkata, india bhaktivedanta hospital & research institute, mira road (east), india kokilaben dhirubhai ambani hosp. & med. research inst, mumbai, india muljibhai patel urological hospital, nadiad, india soroka medical center, beer sheba, israel asaf harofe medical center, beer yaakov, israel rambam medical center, haifa, israel meir medical center, kfar-saba, israel rabin medical center - bellins, petah tikva, israel sourasky medical center, tel aviv sourasky med ctr, tel-aviv, israel unità operativa di oncologia medica, arezzo, italy oncologia-irccs irst, meldola, italy fondazione irccs istituto nazionale dei tumori, milano, italy oncologia medica a - ist naz tumori g pascale, napoli, italy ospedale maggiore della carità, novara, italy oncologia medica azienda sanitaria ospedaliera san luigi gonzaga, orbassano, italy istituto oncologico veneto - irccs, padova, italy oncologia medica - azienda ospedaliero universitaria di parma, parma, italy azienda ospedaliero universitaria pisana, pisa, italy azienda ospedaliera san camillo - roma, roma, italy uoc di oncologia medica università cattolica del sacro cuore policlinico universitario a. gemelli, roma, italy university hospital umberto i, rome, italy istituto clinico humanitas uo di emodinamica e cradiologia interventistica, rozzano, italy oncologia medica-città della salute e della scienza di torino, torino, italy azienda ospedaliero - universitaria ospedali riuniti, torrette di ancona, italy chungnam national university hospital - dept. of internal medicine, daejeon, korea, republic of national cancer center, goyangsi, korea, republic of gachon university gil medical center, incheon, korea, republic of severance hospital, seoul, korea, republic of asan medical center (amc), seoul, korea, republic of samsung medical center, seoul, korea, republic of arensia exploratory medicine, chisinau, moldova, republic of spitalul clinic de urologie prof. dr. theodor burghele, bucharest, romania spitalul clinic sf. maria, bucharest, romania institutul clinic fundeni, bucuresti, romania arensia exploratory medicine - romania, bucuresti, romania institutul oncologic ''prof dr. ion chiricuta'' cluj-napoca, cluj-napoca, romania oncolab, craiova, romania institutul regional de oncologie iasi, iasi, romania spitalul clinic municipal de urgenta timisoara; sectia oncologie, timisoara, romania altai regional oncology dispensary, barnaul, russian federation cancer research center, moscow n/a, russian federation scientific research institute of urology, moscow, russian federation hertzen oncology research institute, moscow, russian federation clinical oncology dispensary, omsk, russian federation pyatigorsk regional oncology dispensary, pyatigorsk, russian federation leningradski regional oncological dispensary, saint-petersburg, russian federation russian scientific center of radiology and surgical technologies, sankt-peterburg, russian federation bashkiria state medical university, ufa, russian federation hospital universitari germans trias i pujol, badalona, spain hospital universitario vall d'hebron, barcelona, spain hospital clinic de barcelona, barcelona, spain hosp. univ. de la princesa, madrid, spain hospital u. gregorio marañón, madrid, spain fundacion jimenez diaz, madrid, spain hosp. univ. ramon y cajal, madrid, spain hosp. univ. 12 de octubre, madrid, spain hospital universitario la paz, madrid, spain centro integral oncológico clara campal, madrid, spain hosp. virgen de la victoria, málaga, spain clinica universitaria de navarra, pamplona, spain corporacio sanitari parc tauli, sabadell, spain hosp. univ. marques de valdecilla, santander, spain hosp. clinico univ. de santiago, santiago de compostela, spain hospital virgen del rocío, sevilla, spain hosp. clinico univ. de valencia, valencia, spain taichung veterans general hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan national taiwan university hospital, taipei, taiwan chang gung memorial hospital- linkou, taoyuan, taiwan hacettepe university medical faculty, ankara, turkey trakya university medical faculty, edirne, turkey istanbul universitesi cerrahpasa tip fakultesi ic hastaliklari anabilim dali medikal onkoloji bd, istanbul, turkey goztepe prof. dr. suleyman yalcin sehir hastanesi, istanbul, turkey royal blackburn hospital, blackburn, united kingdom ninewells hospital, dundee, united kingdom queens hospital, essex, united kingdom charing cross hospital, london, united kingdom derriford hospital, plymouth, united kingdom royal marsden hospital, sutton, united kingdom clatterbridge centre for oncology, wirral, united kingdom""]",,https://ClinicalTrials.gov/show/NCT02365597,urotheli
364,365,NCT00312377,zactima (an anti-egfr / anti-vegf agent) combined with docetaxel compared to docetaxel in non-small cell lung cancer,ZODIAC,Completed,Has Results,non-small cell lung cancer|lung cancer,drug: docetaxel|drug: vandetanib,progression-free survival (pfs) in the overall population|progression-free survival (pfs) in the female population|overall survival (os) in the overall population|overall survival (os) in the female population|objective response rate (orr)|disease control rate (dcr)|duration of response (dor)|time to deterioration of disease-related symptoms (tds) by functional assessment of cancer therapy - lung (fact-l) lung cancer subscale (lcs).|time to deterioration of disease-related symptoms (tds) by fact-l pulmonary symptom index (psi),"genzyme, a sanofi company|sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1690.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D4200C00032|6474IL/0032|2005-004749-32,May 2006,August 2008,March 2014,"April 10, 2006","May 24, 2011","September 30, 2016","['research site, fullerton, california, united states research site, los angeles, california, united states research site, northridge, california, united states research site, colorado springs, colorado, united states research site, norwalk, connecticut, united states research site, ocala, florida, united states research site, marietta, georgia, united states research site, joliet, illinois, united states research site, park ridge, illinois, united states research site, hutchinson, kansas, united states research site, louisville, kentucky, united states research site, boston, massachusetts, united states research site, ann arbor, michigan, united states research site, st. louis, missouri, united states research site, henderson, nevada, united states research site, albany, new york, united states research site, armonk, new york, united states research site, new york, new york, united states research site, durham, north carolina, united states research site, hickory, north carolina, united states research site, portland, oregon, united states research site, austin, texas, united states research site, houston, texas, united states research site, ogden, utah, united states research site, alexandria, virginia, united states research site, salem, virginia, united states research site, vancouver, washington, united states research site, bahía blanca, argentina research site, capital federal, argentina research site, ciudad de buenos aires, argentina research site, mendoza, argentina research site, rosario, argentina research site, graz, austria research site, grimmenstein, austria research site, innsbruck, austria research site, linz, austria research site, wels, austria research site, wien, austria research site, brussels (jette), belgium research site, brussels (woluwé-st-lambert), belgium research site, edegem, belgium research site, genk, belgium research site, liege, belgium research site, fortaleza, brazil research site, goiânia, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, edmonton, alberta, canada research site, moncton, new brunswick, canada research site, halifax, nova scotia, canada research site, kitchener, ontario, canada research site, london, ontario, canada research site, toronto, ontario, canada research site, laval, quebec, canada research site, quebec, canada research site, beijing, china research site, chongqing, china research site, guangzhou, china research site, nanjing, china research site, shanghai, china research site, wuhan, china research site, herlev, denmark research site, københavn ø, denmark research site, odense, denmark research site, roskilde, denmark research site, vejle, denmark research site, bordeaux cedex, france research site, boulogne billancourt, france research site, caen cedex, france research site, dijon, france research site, nancy, france research site, paris, france research site, pierre benite cedex, france research site, saint herblain, france research site, bad berka, germany research site, berlin, germany research site, essen, germany research site, großhansdorf, germany research site, halle, germany research site, hamburg, germany research site, heidelberg, germany research site, köln, germany research site, oldenburg, germany research site, ulm, germany research site, wiesbaden, germany research site, athens, greece research site, heraklion, greece research site, ahmedabad, india research site, chennai, india research site, hyderabad, india research site, kolkata, india research site, new delhi, india research site, pune, india research site, vellore, india research site, jakarta timur, indonesia research site, yogyakarta, indonesia research site, ancona, italy research site, avellino, italy research site, bologna, italy research site, genova, italy research site, mantova, italy research site, napoli, italy research site, orbassano, italy research site, parma, italy research site, perugia, italy research site, pisa, italy research site, reggio emilia, italy research site, akashi-shi, japan research site, fukuoka-shi, japan research site, fukuoka, japan research site, isehara-shi, japan research site, kobe-shi, japan research site, koto-ku, japan research site, kumamoto-shi, japan research site, matsuyama-shi, japan research site, nagoya-shi, japan research site, okayama-shi, japan research site, okazaki-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sakai-shi, japan research site, sapporo-shi, japan research site, shinjuku-ku, japan research site, sunto-gun, japan research site, toyonaka, japan research site, ube-shi, japan research site, utsunomiya-shi, japan research site, yokohama-shi, japan research site, seoul, korea, republic of research site, kubang kerian, malaysia research site, nilai, malaysia research site, penang, malaysia research site, durango, mexico research site, morelia, mexico research site, toluca, mexico research site, amsterdam, netherlands research site, den bosch, netherlands research site, groningen, netherlands research site, maastricht, netherlands research site, coimbra, portugal research site, funchal, portugal research site, lisboa, portugal research site, porto, portugal research site, vila nova de gaia, portugal research site, singapore, singapore research site, a coruña, spain research site, alicante, spain research site, madrid, spain research site, málaga, spain research site, zaragoza, spain research site, chiang mai, thailand research site, ankara, turkey research site, istanbul, turkey research site, izmir, turkey research site, hanoi city, vietnam research site, ho chi minh city, vietnam']",,https://ClinicalTrials.gov/show/NCT00312377,
365,366,NCT01360554,archer 1009 : a study of dacomitinib (pf-00299804) vs. erlotinib in the treatment of advanced non-small cell lung cancer,ARCHER 1009,Completed,Has Results,non-small cell lung cancer,drug: dacomitinib (pf-00299804)|drug: active comparator (erlotinib)|drug: placebo erlotinib|drug: placebo pf00299804,"progression-free survival (pfs) per independent radiologic review.|progression-free survival (pfs) per independent radiologic review in kras wild-type (wt) participants.|pfs based on investigator review.|pfs based on investigator review in kras-wt participants.|overall survival (os).|os in kras-wt participants.|best overall response (bor) per independent radiologic review.|bor per investigator review.|duration of response (dr) based on independent radiologic review.|dr based on investigator review.|trough concentrations (ctrough) of dacomitinib.|trough concentrations (ctrough) of pf-05199265.|time to deterioration (ttd) in pain, dyspnea, fatigue or cough patient reported disease symptoms.|mean and difference in mean in functioning and global quality of life (qol) as assessed by the european organization for the research and treatment of cancer quality of life questionnaire core 30 (eortc-qlq-c30)|mean and difference in mean in qlq-c30 symptoms as assessed by the eortc-qlq-c30.|mean and difference in mean in lung cancer symptom scores as assessed by the eortc qlq- lc13.|mean and difference in mean of the euroqol-5 dimensions (eq-5d) visual analogue scale (vas) score",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,878.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A7471009|2010-022656-22,"June 16, 2011","September 30, 2013","September 14, 2015","May 25, 2011","May 24, 2017","May 24, 2017","[""university of alabama at birmingham, birmingham, alabama, united states university of alabama at birmingham, birmingham, alabama, united states university of alabama at birmingham, birmingham, alabama, united states northwest alabama cancer center, florence, alabama, united states university of south alabama mitchell cancer institute, mobile, alabama, united states university of south alabama medical center, mobile, alabama, united states northwest alabama cancer center, muscle shoals, alabama, united states ironwood physicians p c dba ironwood cancer & research centers, chandler, arizona, united states ironwood physicians p.c. dba ironwood cancer and research centers, chandler, arizona, united states ironwood physicians p.c. dba ironwood cancer and research centers, gilbert, arizona, united states desert oncology associates dba ironwood cancer and research centers, mesa, arizona, united states ironwood physicians p.c. dba ironwood cancer and research centers, mesa, arizona, united states highlands oncology group pa, fayetteville, arkansas, united states highlands oncology group, pa, rogers, arkansas, united states central hematology oncology medical group inc., alhambra, california, united states ucla hematology oncology-alhambra, alhambra, california, united states city of hope, duarte, california, united states st. jude heritage healthcare, fullerton, california, united states drug management only, los angeles, california, united states drug managerrent only:, los angeles, california, united states ucla west medical pharmacy, los angeles, california, united states administrative address: ucla hematology oncology-clinical research unit (cru), los angeles, california, united states drug shipment address: ronald reagan ucla medical center, drug information center, los angeles, california, united states regulatory management only:, los angeles, california, united states regulatory management:, los angeles, california, united states ronald reagan ucla medical center, los angeles, california, united states tori central administration, los angeles, california, united states westwood bowyer clinic, peter morton medical building, los angeles, california, united states ucla/pasadena healthcare hematology-oncology, pasadena, california, united states central hematology oncology medical group, inc., pasadena, california, united states cancer care associates medical group inc., redondo beach, california, united states central coast medical oncology corporation, santa maria, california, united states ucla hematology oncology-parkside, santa monica, california, united states ucla hematology oncology-santa monica, santa monica, california, united states ucla santa monica medical center & orthopedic hospital, santa monica, california, united states city of hope south pasadena cancer center, south pasadena, california, united states ucla/santa clarita valley cancer center, valencia, california, united states ucla cancer center, westlake village, california, united states norwalk hospital, norwalk, connecticut, united states florida hospital, orlando, florida, united states cancer institute of florida, orlando, florida, united states hematology and oncology consultants, p.a., orlando, florida, united states investigational drug services, florida hospital, orlando, florida, united states hematology oncology associates of the treasure coast, port saint lucie, florida, united states emory university hospital midtown, atlanta, georgia, united states emory clinic, atlanta, georgia, united states emory university hospital, atlanta, georgia, united states winship cancer institute of emory university, atlanta, georgia, united states northwest georgia oncology centers, p.c., austell, georgia, united states northwest georgia oncology centers, p.c., carrollton, georgia, united states northwest georgia oncology centers, pc, cartersville, georgia, united states john b. amos cancer center, columbus, georgia, united states atlanta cancer care, decatur, georgia, united states georgia cancer specialists, decatur, georgia, united states the cancer center at dekalb medical, decatur, georgia, united states northwest georgia oncology centers, p.c., douglasville, georgia, united states suburban hematology-oncology associates, p.c., duluth, georgia, united states northeast georgia medical center, gainesville, georgia, united states oncology specialists of north georgia, llc, gainesville, georgia, united states the longstreet clinic cancer center, gainesville, georgia, united states suburban hematology-oncology associates, p.c., lawrenceville, georgia, united states northwest georgia oncology centers, p.c., marietta, georgia, united states suburban hematology-oncology associates, p.c., snellville, georgia, united states illinois cancer specialists, arlington heights, illinois, united states ingalls memorial hospital - in-patient pharmacy, harvey, illinois, united states ingalls memorial hospital, harvey, illinois, united states monroe medical associates, harvey, illinois, united states illinois cancer specialists, niles, illinois, united states monroe medical associates, tinley park, illinois, united states deaconess clinic downtown, evansville, indiana, united states monroe medical associates, munster, indiana, united states cedar valley medical specialists, p.c., waterloo, iowa, united states kentucky cancer clinic, hazard, kentucky, united states university medical center, inc., louisville, kentucky, united states university medical center, inc, louisville, kentucky, united states baptist hospital east, louisville, kentucky, united states karmanos cancer institute, detroit, michigan, united states karmanos cancer institute at farmington hills, farmington hills, michigan, united states north mississippi hematology and oncology associates, ltd., starkville, mississippi, united states north mississippi hematology and oncology associates, ltd.,, tupelo, mississippi, united states siteman cancer center-west county, creve coeur, missouri, united states barnes jewish hospital, saint louis, missouri, united states washington university school of medicine-ids pharmacy, saint louis, missouri, united states siteman cancer center-st. peters, saint peters, missouri, united states dartmouth-hitchcock medical center /mary hitchcock memorial hospital, lebanon, new hampshire, united states oncology and hematology specialists, p.a., denville, new jersey, united states stony brook university-cancer center, stony brook, new york, united states carolina oncology specialists pa, hickory, north carolina, united states carolina oncology specialists pa, lenoir, north carolina, united states mercy clinic oklahoma communities, inc. - mercy clinic oncology/hematology - norman, norman, oklahoma, united states mercy physicians of oklahoma-communities, inc. - mercy clinic oncology/hematology - mcauley, oklahoma city, oklahoma, united states mercy hospital oklahoma city - oncology infusion, oklahoma city, oklahoma, united states good samaritan hospital samaritan ambulatory infusion services, corvallis, oregon, united states samaritan hematology & oncology consultants, corvallis, oregon, united states samaritan pharmacy services, corvallis, oregon, united states samaritan north lincoln hospital, lincoln city, oregon, united states samaritan pacific communities hospital, newport, oregon, united states guthrie clinic, limited, sayre, pennsylvania, united states robert packer hospital, sayre, pennsylvania, united states texas oncology-longview cancer center, longview, texas, united states texas oncology-tyler, tyler, texas, united states texas oncology - waco, waco, texas, united states kadlec clinic hematology and oncology, kennewick, washington, united states kadlec medical center, richland, washington, united states outpatient imaging center, richland, washington, united states seattle cancer care alliance, seattle, washington, united states university of washington medical center, seattle, washington, united states sozialmedizinisches zentrum baumgartner hoehe - otto wagner spital und pflegezentrum, vienna, austria institut jules bordet, brussels, belgium laboratoire de la porte de hall, brussels, belgium grand hopital de charleroi oncologie-hematologie, charleroi, belgium chu ambroise parre- service biologie clinique, mons, belgium heilig hart ziekenhuis roeselare-menen, roeselare, belgium tumour hospital of guangxi zhuang autonomous region, nanning, guangxi, china union hospital, tongji medical college of huazhong university of science & technology/cancer center, wuhan, hubei, china jilin provincial cancer hospital, changchun, jilin, china west china hospital of sichuan university, chengdu, sichuan, china shanghai pulmonary hospital, shanghai, china aalborg sygehus syd, aalborg, denmark helsingin yliopistollinen sairaala, meilahden kolmiosairaala, keuhkosairauksien poliklinikka, helsinki, finland satakunnan keskussairaala/keuhkosairauksien osasto a4, pori, finland centre georges francois leclerc, dijon, france hopital albert michallon, grenoble cedex 09, france hôpital paris saint joseph, paris, france chu de poitiers, poitiers cedex, france institut de cancerologie de louest - rene gauducheau, saint herblain cedex, france universitaetsklinikum aachen, aachen, germany asklepios fachkliniken muenchen-gauting, gauting, germany lungenfachklinik immenhausen, immenhausen, germany universitaetsmedizin der johannes gutenberg-universitaet, mainz, germany krankenhaus bethanien, medizinische klinik iii, moers, germany university hospital of larissa, larissa, thessaly, greece sotiria general hospital of athens, athens, greece university hospital of heraklion, heraklion, greece semmelweis egyetem pulmonologiai klinika, budapest, hungary debreceni egyetem orvos- es egeszsegtudomanyi centrum, debrecen, hungary veszprem megyei onkormanyzat tudogyogyintezete, farkasgyepu, hungary pandy kalman megyei korhaz, aktiv tudogyogyaszat, gyula, hungary josa andras oktatokorhaz egeszsegugyi szolgaltato nonprofit kft., nyiregyhaza, hungary zala megyei korhaz, pulmonologiai osztaly, zalaegerszeg-pozva, hungary vedanta institute of medical sciences, ahmedabad, gujarat, india manipal hospital, bangalore, karnataka, india tata memorial centre, mumbai, maharashtra, india ruby hall clinic, pune, maharastra, india st vincent's university hospital, dublin, leinster, ireland beaumont hospital, dublin, leinster, ireland st. james hospital, dublin, ireland oncology department, waterford, ireland aichi cancer center central hospital /thoracic oncology, nagoya, aichi, japan national cancer center hospital east, kashiwa, chiba, japan national hospital organization shikoku cancer center, matsuyama-city, ehime, japan national hospital organization asahikawa medical center, asahikawa, hokkaido, japan hyogo cancer center, akashi, hyogo, japan kanazawa university hospital, kanazawa city, ishikawa, japan kanagawa cardiovascular and respiratory center, yokohama, kanagawa, japan tohoku university hospital, sendai, miyagi, japan kurashiki central hospital, kurashiki, okayama, japan okayama university hospital, okayama-city, okayama, japan national hospital organization kinki-chuo chest medical center, sakai-shi, osaka-fu, japan osaka city general hospital department of clinical oncology, osaka-city, osaka, japan kinki university hospital, osakasayama-shi, osaka, japan shizuoka cancer center, sunto-gun, shizuoka, japan national cancer center hospital, chuo-ku, tokyo, japan national hospital organization, yamaguchi-ube medical center, ube-shi, yamaguchi, japan national hp. org. kyushu medical center, fukuoka, japan national hospital organization kyushu cancer center/department of thoracic oncology, fukuoka, japan kyushu university hospital respiratory medicine, fukuoka, japan the cancer institute hospital of jfcr, koto-ku, tokyo, japan seoul national university hospital, seoul, korea, republic of samsung medical center, clinical trial center, seoul, korea, republic of asan medical center, department of oncology, seoul, korea, republic of oaxaca site management organization, oaxaca, mexico mazowieckie centrum leczenia chorob pluc i gruzlicy, otwock, mazowieckie, poland zoz all-medi, otwock, mazowieckie, poland centrum onkologii-instytut im. marii sklodowskiej-curie, warsaw, mazowieckie, poland nukleomed, warsaw, mazowieckie, poland city hospital #2 krasnodar multi-field diagnostic and treatment association, krasnodar, krasnodarskij kraj, russian federation oncology center # 2, sochi, krasnodarskij kraj, russian federation federal state healthcare clinical hospital #101 of the federal biomedical agency, pyatigorsk, stavropolskij kraj, russian federation pyatigorsk oncology center, pyatigorsk, russian federation clinic of hospital surgery, saint-petersburg, russian federation military medical academy n.a. s.m.kirov, saint-petersburg, russian federation city clinical oncology dispensary, saint-petersburg, russian federation st.-petersburg state medical university i.p.pavlov of roszdrav, saint-petersburg, russian federation research institute of pulmonology, saint-petersburg, russian federation russian scientific center of radiology and surgical technologies, saint-petersburg, russian federation city clinical oncology dispensary, saint-petersburg, russian federation samara regional clinical oncology dispensary, samara, russian federation univerzitna nemocnica bratislava, klinika pneumologie a ftizeologie i- oddelenie klinickej onkologie, bratislava, slovakia specializovana nemocnica sv. svorada zobor, n.o., nitra, slovakia fakultna nemocnica s poliklinikou, nove zamky, slovakia wcr: wits clinical research, parktown,johannesburg, gauteng, south africa gvi oncology clinical research unit, kraaifontein, western cape, south africa department of oncotherapy, bloemfontein, south africa gvi oncology, port elizabeth, south africa hospital general universitario de elche - edificio uiae, elche, alicante, spain hospital universitari germans trias i pujol, badalona, barcelona, spain hospital provincial de castellon - servicio de oncologia, castellón, castellon, spain hospital de la santa creu i sant pau - pharmacy, barcelona, spain hospital de la santa creu i sant pau - agdac, barcelona, spain hospital de la santa creu i sant pau - anatomia patológica, barcelona, spain hospital de la santa creu i sant pau - diagnostic per la imatge i med. nuclear, barcelona, spain hospital de la santa creu i sant pau - hospital de día, barcelona, spain hospital de la santa creu i sant pau, barcelona, spain hospital provincial de castellon (farmacia), castellon, spain hospital universitario 12 de octubre-radiology, madrid, spain hospital universitario 12 de octubre01, madrid, spain hospital universitario madrid sanchinarro, madrid, spain hospital universitario virgen del rocio. hospital general planta baja. servicio de oncologia., sevilla, spain kpe/onkologikliniken, karlstad, sweden karolinska universitetssjukhuset, stockholm, sweden kantonsspital aarau, aarau, switzerland istituto oncologico della svizzera italiana, bellinzona, switzerland hopitaux universitaires de geneve, geneve 14, switzerland ospedale regionale di locarno la carita, locarno, switzerland kantonsspital st. gallen, st. gallen, switzerland kent oncology centre, maidstone, kent, united kingdom new cross hospital - royal wolverhampton hospital nhs trust, wolverhampton, west midlands, united kingdom north middlesex nhs trust, edmonton, united kingdom leicester royal infirmary, leicester, united kingdom cancer clinical trials unit, london, united kingdom christie hospital nhs trust, department of medical oncology, manchester, united kingdom christie hospital nhs trust, manchester, united kingdom lung and melanoma research team, manchester, united kingdom""]",,https://ClinicalTrials.gov/show/NCT01360554,
366,367,NCT01424566,a two-part study of sativex® oromucosal spray for relieving uncontrolled persistent pain in patients with advanced cancer,,Completed,Has Results,pain|advanced cancer,drug: nabiximols|drug: placebo (ga-0034),change from randomization baseline in mean nrs average pain at end of treatment|percent improvement from eligibility baseline in mean nrs average pain score at end of treatment|change from randomization baseline in mean nrs worst pain at end of treatment|change from randomization baseline in mean sleep disruption nrs at end of treatment|subject global impression of change at last visit (up to day 36 of the double-blind period)|physician global impression of change at last visit (up to day 36 of the double-blind period)|patient satisfaction questionnaire at last visit (up to day 36 of the double-blind period)|change from randomization baseline in daily total opioid use (morphine equivalent) at end of treatment|change from randomization baseline in daily maintenance opioid dose (morphine equivalent) at end of treatment|change from randomization baseline in daily break-through opioid dose (morphine equivalent) at end of treatment|change from randomization baseline in nrs constipation at last visit (up to day 36 of the double-blind period),"jazz pharmaceuticals|otsuka pharmaceutical development & commercialization, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,406.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GWCA1103|2010-022905-17,"June 29, 2012","July 10, 2015","December 28, 2015","August 29, 2011","April 23, 2018","April 23, 2018","['east melbourne, australia parkville, australia shumen, bulgaria varna, bulgaria vratsa, bulgaria lunen, germany stadtroda, germany wetzlar, germany budapest, hungary deszk, hungary komárom, hungary nyíregyháza, hungary szikszó, hungary bangalore, india jaipur, india pune, india ashkelon, israel beer sheva, israel haifa, israel jerusalem, israel ramat gan, israel zerifin, israel garbagnate milanese, italy piacenza, italy torino, italy klaipeda, lithuania siauliai, lithuania vilnius, lithuania bydgoszcz, poland czeladź, poland gdansk, poland gliwice, poland klodzko, poland opole, poland ostrowiec swietokrzyski, poland poznan, poland warszawa, poland warszawa, poland wloclawek, poland alba iulia, romania baia mare, romania braila, romania bucuresti, romania focșani, romania oradea, romania satu mare, romania sibiu, romania suceava, romania cadiz, spain granada, spain madrid, spain salamanca, spain sevilla, spain changhua city, taiwan taichung, taiwan tainan city, taiwan taipei, taiwan taipei, taiwan taipei, taiwan taipei, taiwan bury saint edmunds, united kingdom edinburgh, united kingdom glasgow, united kingdom manchester, united kingdom norwich, united kingdom']",,https://ClinicalTrials.gov/show/NCT01424566,pain
367,368,NCT00089999,lapatinib in chemotherapy-naive or metastatic breast cancer,,Completed,Has Results,"neoplasms, breast",drug: lapatinib,"number of participants with a best overall response (or) of confirmed complete response (cr) or partial response (pr), as assessed by the independent review committee (irc)|number of participants with a best overall response (or) of confirmed complete response (cr) or partial response (pr), as assessed by the investigator|percentage of participants with clinical benefit (cr or pr or stable disease [sd] for at least 24 weeks), as assessed by the irc and investigator|time to response, as assessed by the irc and investigator|duration of response (dor), as assessed by the irc and investigator|progression-free survival, as assessed by the irc and investigator|time to treatment failure, as assessed by irc and investigator|number of participants with any adverse event (ae) or serious adverse event (sae)",glaxosmithkline,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,138.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EGF20009,June 2004,March 2008,March 2008,"August 23, 2004","August 29, 2014","February 28, 2017","['gsk investigational site, hollywood, florida, united states gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, pokfulam, hong kong gsk investigational site, delhi, india gsk investigational site, hyderabad, andhra pradesh, india gsk investigational site, pune, india gsk investigational site, bandar tun razak, cheras, malaysia gsk investigational site, kubang kerian, malaysia gsk investigational site, tanjong bungah, malaysia gsk investigational site, tanjong bungah, malaysia gsk investigational site, ixtaltepec / espinal, oaxaca, mexico gsk investigational site, merida, yucatán, mexico gsk investigational site, mexico, mexico gsk investigational site, karachi, pakistan gsk investigational site, karachi, pakistan gsk investigational site, karachi, pakistan gsk investigational site, lahore, pakistan gsk investigational site, rawalpindi, pakistan gsk investigational site, callao, peru gsk investigational site, lima, peru gsk investigational site, lima, peru gsk investigational site, lima, peru gsk investigational site, bydogoszcz, poland gsk investigational site, krakow, poland gsk investigational site, olsztyn, poland gsk investigational site, singapore, singapore gsk investigational site, singapore, singapore gsk investigational site, taipei, taiwan gsk investigational site, taipei, taiwan']",,https://ClinicalTrials.gov/show/NCT00089999,breast
368,369,NCT01457846,efficacy and safety of azd4547 versus paclitaxel in patients with advanced gastric or gastro-oesophageal cancer,SHINE,Terminated,Has Results,gastro-oesophageal junction cancer|gastric cancer,drug: azd4547|drug: paclitaxel,median progression free survival|overall survival : number of patients who had died at dco (data cut off)|objective response rate|percentage change from baseline at week 8 in target lesion size|percentage of patients without progressive disease at 8 weeks,astrazeneca,All,"25 Years to 130 Years   (Adult, Older Adult)",Phase 2,960.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D2610C00004,November 2011,August 2013,February 2015,"October 24, 2011","March 7, 2017","March 7, 2017","['research site, brussels (anderlecht), belgium research site, brussels (woluwé-st-lambert), belgium research site, leuven, belgium research site, liege, belgium research site, plovdiv, bulgaria research site, sofia, bulgaria research site, vratza, bulgaria research site, fredericton, new brunswick, canada research site, toronto, ontario, canada research site, brno, czech republic research site, olomouc, czech republic research site, praha 2, czech republic research site, saint cloud, france research site, villejuif, france research site, hamburg, germany research site, mainz, germany research site, budapest, hungary research site, debrecen, hungary research site, nyíregyháza, hungary research site, bangalore, india research site, chennai, india research site, hyderabad, india research site, nagpur, india research site, pune, india research site, vellore, india research site, ancona, italy research site, milano, italy research site, pisa, italy research site, roma, italy research site, chiba-shi, japan research site, chuo-ku, japan research site, koto-ku, japan research site, nagoya-shi, japan research site, sapporo-shi, japan research site, takatsuki-shi, japan research site, anyang-si, korea, republic of research site, daegu, korea, republic of research site, hwasun-gun, korea, republic of research site, jeonju-si, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, brasov, romania research site, cluj napoca, romania research site, a coruña, spain research site, barcelona, spain research site, madrid, spain research site, oviedo, spain research site, santander, spain research site, sevilla, spain research site, keelung, taiwan research site, taichung, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, kharkiv, ukraine research site, lviv, ukraine research site, aberdeen, united kingdom research site, london, united kingdom research site, maidstone, united kingdom research site, manchester, united kingdom research site, sutton, united kingdom research site, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01457846,esophag
369,370,NCT01763645,a safety and efficacy study of bcd-021 with paclitaxel and carboplatin compared to avastin with paclitaxel and carboplatin in non-small cell lung cancer,,Completed,Has Results,non-small cell lung cancer,drug: bevacizumab|drug: paclitaxel|drug: carboplatin,overall response rate|area under the curve after the first test drug administration|complete response rate|partial response rate|stabilization rate|progression rate|occurrence of anti-bevacizumab antibodies,biocad,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BCD-021-02,October 2012,November 2014,November 2014,"January 9, 2013","October 24, 2016","March 30, 2018","['brest regional clinical dispensary, brest, belarus gomel regional clinical oncology dispensary, gomel, belarus grodno regional clinical hospital, grodno, belarus vitebsk regional clinical oncology dispensary, vitebsk, belarus hcg bangalore institute of oncology, bangalore, india m.s.ramaiah memorial hospital, bangalore, india narayana hrudayalaya hospitals, bangalore, india arkhangelsk district clinical oncology dispensary, arkhangelsk, russian federation non-governmental healthcare institution ""railway clinical hospital on the chelyabinsk station of jsc russian railways"", chelyabinsk, russian federation state-financed health institution ""chelyabinsk region clinical oncology dispansary"", chelyabinsk, russian federation state healthcare facility ""kursk regional oncology dispensary"", kursk, russian federation state health institution of moscow ""moscow city oncology hospital #62 of moscow board of health"", moscow region, russian federation institution of russian academy of medical sciences ""russian cancer research center named after n.n. blokhin"", moscow, russian federation federal state institution ""moscow institute of cancer research named after p.a. hertsen"" ministry of health of russian federation, moscow, russian federation murmansk regional oncology dispensary, murmansk, russian federation nizhny novgorod region state budgetary healthcare facility ""clinical diagnostics center"", nizhny novgorod, russian federation state healthcare facility ""nizhny novgorod regional oncology dispensary"", nizhny novgorod, russian federation city clinical hospital №1, novosibirsk, russian federation regional state health institution ""orlov oncology dispansary"", orel, russian federation state health institution ""region oncology dispansary"", penza, russian federation perm region oncology dispensary, perm, russian federation federal government budgetary institution ""rostov institute of cancer research"" of ministry of health of russian federation, rostov-on-don, russian federation saint petersburg city clinical oncology center, saint petersburg, russian federation state-financed health institution ""samara region clinical oncology dispansary"", samara, russian federation oncology dispensary 2, sochi, russian federation st. petersburg state medical university n.a. i. p. pavlov, st. petersburg, russian federation st. petersburg research and practice center for secondary care in oncology, st. petersburg, russian federation n.n.petrov oncology research center, st.petersburg, russian federation military medical academy named after s.m. kirov, st.petersburg, russian federation russian scientific center of radiology and surgery technologies, st.petersburg, russian federation state-financed health institution ""stavropol region clinical oncology dispansary"", stavropol, russian federation volgograd district oncology dispensary №1, volgograd, russian federation volgograd regional oncology dispensary №3, volgograd, russian federation state health institution ""voronezh region clinical oncology dispansary"", voronezh, russian federation donetsk city oncology dispensary, donetsk, ukraine donetsk regional antitumor center, donetsk, ukraine kharkiv regional clinical oncology center, kharkiv, ukraine kryvyi rih oncology dispensary, kryvyi rih, ukraine lviv state regional cancer diagnostic and treatment center, lviv, ukraine city hospital № 2, makiivka, ukraine poltava regional clinical oncology dispensary, poltava, ukraine zakarpatskyi clinical oncology dispensary, uzhhorod, ukraine vinnytsia regional clinical oncology dispensary, vinnytsia, ukraine zaporizhia regional clinical oncology dispensary, zaporizhia, ukraine']",,https://ClinicalTrials.gov/show/NCT01763645,
370,371,NCT00630110,phase 1/2 study of vascular disrupting agent npi-2358 + docetaxel in patients with advanced non-small cell lung cancer,,Completed,No Results Available,cancer,drug: docetaxel|drug: npi-2358 + docetaxel,"compare overall survival of patients treated with docetaxel to patients treated with docetaxel + npi-2358|compare response rate, duration of response, 6-month survival, progression free survival and safety.|pharmacokinetics","nereus pharmaceuticals, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,172.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NPI-2358-101,February 2008,June 2011,June 2011,"March 6, 2008",,"August 16, 2011","['mayo clinic, scottsdale, arizona, united states san diego pacific oncology & hematology associates, encinitas, california, united states university san diego moores cancer center, san diego, california, united states kaiser permanente, san diego, california, united states premiere oncology, santa monica, california, united states massachusetts general hospital, boston, massachusetts, united states karmanos cancer institute, detroit, michigan, united states university texas health science center at san antonio (ctrc), san antonio, texas, united states policlinica privada instituto de medicina nuclear, bahia blanca, argentina hospital britanico, capital federal, argentina instituto oncologico de cordoba, cordoba, argentina clinica universitaria privada reina fabiola, cordoba, argentina caici centro de asistencia e investigacion clinica integral, rosario, argentina hospital del centrenario, rosario, argentina mater adult hospital, south brisbane, queensland, australia bendigo health care group, bendigo, victoria, australia sir charles gairdner hospital, nedlands, western australia, australia fundacap pip xii hospital do cancer de barretos, barretos, brazil hospital erasto gaertner liga do combate as cancer, curitiba, brazil associacao hospital de caridade ijui, ijui, brazil hospital sao lucas, porte alegre, brazil hospital de clinicas de porto alegre, porto alegre, brazil clinionco-clinica de oncologia de porto alegre, porto alegre, brazil hosp.das clinicas da univ.de sao paulo, sao paulo, brazil instituto do cancer aenaldo vieira de carvahlo, sao paulo, brazil instituto nacional del cancer oncology, santiago, chile hospital carlos van buren, valparaiso, chile chittaranjan national cancer institute, kolkata, w. bengal, india kidwai memorial institute of oncology, bangalore, india apollo speciality hospital, chennai, india apollo hospital, hyderabad, india searoc cancer centre s.k. soni hospital, jaipur, india subodh mitra cancer hospital & research centre, kolkata, india tata memorial hospital, mumbai, india ruby hall clinic, pune, india andhra medical college, vishakhapatnam, india']",,https://ClinicalTrials.gov/show/NCT00630110,
371,372,NCT04821622,study of talazoparib with enzalutamide in men with ddr gene mutated mcspc,,Recruiting,No Results Available,prostate cancer,drug: talazoparib plus enzalutamide|drug: placebo plus enzalutamide,"radiological progression-free survival|overall survival|objective response in measurable soft tissue disease|duration of response in measurable soft tissue disease|prostate specific antigen (psa) response|time to psa progression|time to initiation of antineoplastic therapy|time to first symptomatic skeletal event|opiate use for prostate cancer pain|incidence of adverse events|pharmacokinetic assessment of talazoparib|pharmacokinetic assessment of enzalutamide and its metabolite|relationship between ctdna burden and outcome|patient-reported outcomes in pain symptoms - change from baseline|patient-reported outcomes in pain symptoms - time to deterioration|patient-reported outcomes in cancer specific general health status - change from baseline|patient-reported outcomes in cancer specific global health status/qol - change from baseline|patient-reported outcomes in cancer specific global health status/qol - time to definitive deterioration|patient-reported outcomes in cancer specific symptoms - time to definitive deterioration|patient-reported outcome: cancer specific functioning, and symptoms - change from baseline",pfizer|astellas pharma inc,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,550.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C3441052|TALAPRO-3|2021-000248-23,"May 12, 2021","December 11, 2024","April 10, 2027","March 29, 2021",,"May 16, 2022","['university of alabama at birmingham, birmingham, alabama, united states university of alabama at birmingham, birmingham, alabama, united states arizona institute of urology, pllc, tucson, arizona, united states arkansas urology, little rock, arkansas, united states arkansas urology research clinic, sherwood, arkansas, united states beverly hills cancer center, beverly hills, california, united states adventist health glendale, glendale, california, united states va long beach healthcare system, long beach, california, united states medstar georgetown university hospital, washington, district of columbia, united states washington cancer institute at medstar washington hospital center, washington, district of columbia, united states adventhealth medical group hematology and oncology, orlando, florida, united states investigational drug services, advent health orlando, orlando, florida, united states investigational drug services, orlando, florida, united states northwest georgia oncology centers, a service of wellstar cobb hospital, austell, georgia, united states wellstar cobb hospital, austell, georgia, united states northwest georgia oncology centers, a service of tanner medical center villa rica, carrollton, georgia, united states west georgia infusion center, a service of tanner medical center villa rica, carrollton, georgia, united states northwest georgia oncology centers, a service of wellstar cobb hospital, cartersville, georgia, united states northwest georgia oncology centers, a service of wellstar cobb hospital, douglasville, georgia, united states northwest georgia oncology centers, a service of wellstar cobb hospital, marietta, georgia, united states comprehensive urologic care, sc, lake barrington, illinois, united states mid-illinois hematology & oncology associates, ltd, normal, illinois, united states henry ford health system, detroit, michigan, united states revive research institute, inc., farmington hills, michigan, united states revive research institute inc., sterling heights, michigan, united states david c. pratt cancer center, saint louis, missouri, united states new jersey cancer care, p.a., belleville, new jersey, united states premier medical group of the hudson valley pc, poughkeepsie, new york, united states clinical research solutions, middleburg heights, ohio, united states providence cancer institute clackamas clinic, clackamas, oregon, united states providence cancer institute newberg clinic, newberg, oregon, united states providence newberg medical center, newberg, oregon, united states providence cancer institute franz clinic, portland, oregon, united states providence portland medical center, portland, oregon, united states providence oncology and hematology care clinic - westside, portland, oregon, united states providence st. vincent medical center, portland, oregon, united states keystone urology specialists, lancaster, pennsylvania, united states carolina urologic research center, myrtle beach, south carolina, united states parkway surgery center, myrtle beach, south carolina, united states bristol regional medical center, bristol, tennessee, united states ballad health cancer care - kingsport, kingsport, tennessee, united states holston valley hospital and medical center, kingsport, tennessee, united states indian path community hospital, kingsport, tennessee, united states urology clinics of north texas, dallas, texas, united states kelsey research foundation, houston, texas, united states oncology consultants, p.a., houston, texas, united states oncology consultants, p.a., houston, texas, united states kelsey-seybold clinic, houston, texas, united states houston metro urology, houston, texas, united states oncology consultants p.a., houston, texas, united states urology san antonio, san antonio, texas, united states texas oncology-deke slayton cancer center, webster, texas, united states huntsman cancer institute - university of utah, salt lake city, utah, united states coiba, berazategui, buenos aires, argentina centro de investigacion pergamino sa - clinica pergamino sa, pergamino, buenos aires, argentina centro de investigaciones clínicas - clínica viedma, viedma, río negro, argentina centro medico san roque, san miguel de tucuman, tucuman, argentina centro oncologico korben, caba, argentina instituto médico especializado alexander fleming, caba, argentina centro medico privado cemaic, córdoba, argentina chris o\'brien lifehouse, camperdown, new south wales, australia southern medical day care centre, wollongong, new south wales, australia gallipoli medical research foundation, greenslopes private hospital, brisbane, queensland, australia gold coast university hospital, southport, queensland, australia the queen elizabeth hospital, woodville south, south australia, australia epworth freemasons-epworth healthcare, east melbourne, victoria, australia cabrini hospital, malvern, victoria, australia western health, sunshine hospital, st albans, victoria, australia onze lieve vrouw ziekenhuis aalst, aalst, belgium institut jules bordet, anderlecht, belgium cliniques universitaires saint-luc, brussels, belgium az (algemeen ziekenhuis) maria middelares, gent, belgium az (algemeen ziekenhuis) sint-lucas, gent, belgium az (algemeen ziekenhuis) groeninge, kortrijk, belgium chu de liege, liege, belgium zna jan palfijn, merksem, belgium multiprofile hospital for active treatment - uni hospital ood, panagyurishte, bulgaria complex oncology center - plovdiv eood, plovdiv, bulgaria independent medical-diagnostic laboratory ""medisken"" eood, plovdiv, bulgaria university multiprofile hospital for active treatment sveti georgi ead, plovdiv, bulgaria acibadem city clinic university multiprofile hospital for active treatment tokuda ead, sofia, bulgaria university multiprofile hospital for active treatment ""sv. ivan rilski"" ead, sofia, bulgaria acibadem city clinic university multiprofile hospital for active treatment eood, sofia, bulgaria complex oncology center - stara zagora ltd., stara zagora, bulgaria mri smdlod ""mediscan"" ltd, stara zagora, bulgaria umhat ""prof. dr. stoyan kirkovich"", stara zagora, bulgaria prostate cancer centre, calgary, alberta, canada centre of applied urology research, nova scotia health authority, halifax, nova scotia, canada london health sciences centre, london, ontario, canada the ottawa hospital cancer center, ottawa, ontario, canada university health network-princess margaret cancer centre, toronto, ontario, canada ciusss- saguenay-lac-saint-jean, chicoutimi, quebec, canada urology south shore research, greenfield park, quebec, canada chum - centre hospitalier de l\'université de montréal, montreal, quebec, canada jewish general hospital, montreal, quebec, canada mcgill university health center, montreal, quebec, canada the first affiliated hospital of anhui medical university, hefei, anhui, china peking university first hospital, beijing, beijing, china lanzhou university second hospital, lanzhou, gansu, china the first affiliated hospital of guangzhou medical university, guangzhou, guangdong, china henan cancer hospital, zhengzhou, henan, china union hospital, tongji medical college of huazhong university of science & technology, wuhan, hubei, china tongji hospital, tongji medical college,huazhong university of science and technology, wuhan, hubei, china hubei cancer hospital, wuhan, hubei, china hunan cancer hospital, changsha, hunan, china the third xiangya hospital of central south university, changsha, hunan, china zhongda hospital southeast university, nanjing, jiangsu, china nantong tumor hospital, nantong, jiangsu, china the second affiliated hospital of soochow university, suzhou, jiangsu, china the first hospital of jilin university, changchun, jilin, china the first affiliated hospital of xi\'an jiaotong university, xi\'an, shaanxi, china fudan university cancer hospital, shanghai, shanghai, china west china hospital of sichuan university, chengdu, sichuan, china the second hospital of tianjin medical university, tianjin, tianjin, china zhejiang provincial people\'s hospital, hangzhou, zhejiang, china ningbo first hospital, ningbo, zhejiang, china the first affiliated hospital of wenzhou medical university, wenzhou, zhejiang, china the first affiliated hospital chongqing medical university, chongqing, china fakultni nemocnice olomouc, olomouc, czechia fakultni nemocnice ostrava, ostrava - poruba, czechia fakultni nemocnice kralovske vinohrady, praha 10, czechia fakultni nemocnice motol, praha 5, czechia fakultni nemocnice bulovka, praha 8- liben, czechia helsinki university hospital, helsinki, finland docrates cancer center, helsinki, finland kuopio university hospital, kuopio, finland oulun yliopistollinen sairaala, oulu, finland tampere university hospital, tampere, finland turku university hospital, turku, finland chu morvan de brest, brest, bretagne, france hopital henri mondor, creteil, ile de france, france clinique belharra, bayonne, france chu morvan de brest, brest, france clinique victor hugo, le mans, france hopital prive le bois, lille, france hopital bichat - claude bernard, paris cedex 18, france hopital bichat - claude bernard, paris, france hopital lyon sud, pierre-benite, france institut jean godinot, reims cedex, france chp saint-grégoire, saint gregoire, france hopitaux universitaires de strasbourg - icans (institut de cancerologie strasbourg europe), strasbourg, france gustave roussy, villejuif cedex, france urologische gemeinschaftspraxis wesel, wesel, nordrhein-westfalen, germany urologicum duisburg, duisburg, germany universitaetsklinikum frankfurt, frankfurt, germany universitaetsklinik heidelberg, heidelberg, germany uro-/onkologisches zentrum, leipzig, germany studienpraxis urologie, nuertingen, germany universitaetsklinikum tuebingen, tuebingen, germany péterfy kórház-rendelőintézet és manninger jenő országos traumatológiai intézet, budapest, hungary országos onkológiai intézet, budapest, hungary uzsoki utcai korhaz, budapest, hungary jahn ferenc del-pesti korhaz es rendelointezet, budapest, hungary borsod-abaúj-zemplén megyei központi kórház és egyetemi oktatókórház, miskolc, hungary soproni erzsebet oktato korhaz es rehabilitacios intezet, sopron, hungary indraprastha apollo hospital, new delhi, delhi, india rajiv gandhi cancer institute and research centre, new delhi, delhi, india gujarat gastro and vascular hospital, surat, gujarat, india artemis hospital, gurugram, haryana, india medanta- the medicity hospital, gurugram, haryana, india bhakti vedanta hospital and research institute, mumbai, thane, maharashtra, india sahyadri clinical research & development centre, pune, maharashtra, india sahyadri super speciality hospital, pune, maharashtra, india valentis cancer hospital, meerut, uttar pradesh, india netaji subhas chandra bose cancer hospital, kolkata, west bengal, india azienda ospedaliero-universitaria policlinico s. orsola malpighi, bologna, bo, italy asst cremona, cremona, cr, italy istituto romagnolo per lo studio dei tum.ori ""dino amadori"" (irst), meldola, fc, italy fondazione casa sollievo della sofferenza, san giovanni rotondo, fg, italy istituto nazionale tumori irccs fondazione g. pascale - napoli, napoli, naples, italy ospedale santa chiara, trento, tn, italy aou san luigi gonzaga, orbassano, to, italy ospedale san donato, arezzo, italy irccs istituto tumori ""giovanni paolo ii"" di bari, bari, italy asst degli spedali civili de brescia, brescia, italy azienda ospedaliera universitaria integrata verona, verona, italy nagoya university hospital, nagoya, aichi, japan hirosaki university school of medicine & hospital, hirosaki, aomori, japan chiba cancer center, chiba-shi, chiba, japan national cancer center hospital east, kashiwa, chiba, japan national hospital organization shikoku cancer center, matsuyama, ehime, japan national hospital organization kyushu cancer center, fukuoka-shi, fukuoka, japan national hospital organization kure medical center and chugoku cancer center, kure, hiroshima, japan national hospital organization hokkaido cancer center, sapporo, hokkaido, japan hokkaido university hospital, sapporo, hokkaido, japan kanazawa university hospital, kanazawa, ishikawa, japan yokohama city university medical center, yokohama, kanagawa, japan yokosukakyosai, yokosuka, kanagawa, japan osaka international cancer institute, osaka-shi, osaka, japan kindai university hospital, osakasayama, osaka, japan osaka university hospital, suita, osaka, japan hamamatsu university school of medicine university hospital, hamamatsu, shizuoka, japan national hospital organization tokyo medical center, meguro-ku, tokyo, japan keio university hospital, shinjuku-ku, tokyo, japan kagoshima university hospital, kagoshima, japan national hospital organization kumamoto medical center, kumamoto, japan tokushima university hospital, tokushima, japan yamagata university hospital, yamagata, japan national cancer center, goyang-si, gyeonggi-do, korea, republic of chonnam national university hwasun hospital, hwasun-gun, jeollanam-do, korea, republic of seoul national university bundang hospital, seongnam, kyǒnggi-do, korea, republic of samsung medical center, seoul, seoul-teukbyeolsi, korea, republic of kyungpook national university chilgok hospital, daegu, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of gangnam severance hospital, yonsei university health system, seoul, korea, republic of the catholic university of korea seoul st. mary\'s hospital, seoul, korea, republic of josé luis gonzález trujillo (consultorio privado), león, guanajuato, mexico axis heilsa s. de r.l. de c.v., monterrey, nuevo león, mexico hospital universitario ""dr. jose eleuterio gonzalez"", monterrey, nuevo león, mexico centro de investigacion clinica de oaxaca, oaxaca, mexico meander medisch centrum, amersfoort, utrecht, netherlands hagziekenhuis, den haag, zuid-holland, netherlands moscow research oncology institute n.a p.a. gertsen (mroi n.a p.a. gertsen), obninsk, kaluga region, russian federation mrrc n.a. a.f. tsyb - branch of fsbi ""nmrc of radiology"" minzdrav russia, obninsk, kaluga region, russian federation state budget institution of healthcare of mordovia republic ""republic oncology dispensary"", saransk, republic of mordovia, russian federation private medical institution ""euromedservice"", pushkin, saint-petersburg, russian federation limited liability company ""4d ultrasound clinic"" (llc ""4d ultrasound clinic""), pyatigorsk, stavropol region, russian federation state budgetary healthcare institution of arkhangelsk region, arkhangelsk, russian federation evimed llc, chelyabinsk, russian federation sbih ""chelyabinsk regional clinical centre of oncology and nuclear medicine"", chelyabinsk, russian federation regional budgetary healthcare institution ""ivanovskiy regional oncology dispensary"" (rbhi ""ivrod""), ivanovo, russian federation federal state budgetary institution ""russian research center of roentgenology and radiology"" of, moscow, russian federation branch of the limited liability company ""hadassah medical ltd."", moscow, russian federation federal state budgetary institution ""central clinical hospital with ambulance"", moscow, russian federation moscow research oncology institute n.a p.a. gertsen (mroi n.a p.a. gertsen), moscow, russian federation bhi of omsk region ""clinical oncological dispensary"", omsk, russian federation llc ""medicina severnoy stolitsy"", saint-petersburg, russian federation llc ""severo-zapadny medical center"", saint-petersburg, russian federation private institution educational organization of higher education ""medical university ""reaviz"", samara, russian federation sahi republican clinical oncology dispensary under the ministry of health, republic of bashkortostan, ufa, russian federation budgetary healthcare institution of vologda region ""vologda regional clinical hospital"", vologda, russian federation budgetary healthcare institution of vologda region ""vologda regional clinical hospital"", vologda, russian federation state budgetary institution of healthcare of yaroslavl region ""regional clinical oncology hospital"", yaroslavl, russian federation fakultna nemocnica s poliklinikou f.d. roosevelta banska bystrica, banska bystrica, slovakia narodny onkologicky ustav, bratislava, slovakia vychodoslovensky onkologicky ustav, a.s., kosice, slovakia uroexam, spol. s r.o., nitra, slovakia poko poprad s.r.o., poprad, slovakia milab s.r.o., presov, slovakia privatna urologicka ambulancia, s.r.o., trencin, slovakia sandton oncology medical group (pty) ltd, johannesburg, gauteng, south africa clinical research unit, university of pretoria, pretoria, gauteng, south africa hospital general universitario de elche, elche, alicante, spain hospital universitario central de asturias, oviedo, asturias, spain hospital germans trias i pujol, badalona, barcelona [barcelona], spain althaia, xarxa assistencial universitària de manresa, manresa, barcelona, spain hospital universitario lucus augusti, lugo, galicia, spain hospital universitario puerta de hierro, majadahonda, madrid, spain hospital universitario virgen de la arrixaca, el palmar, murcia, spain complejo hospitalario de navarra, pamplona, navarra, spain fundaciã³n instituto valenciano de oncologã-a, valencia, valenciana, comunitat, spain hospital universitari vall d\'hebron, barcelona, spain hospital clínic de barcelona, barcelona, spain hospital universitario reina sofía, cordoba, spain hospital universitario gregorio marañón, madrid, spain md anderson cancer center, madrid, spain hospital clinico san carlos, madrid, spain hospital universitario virgen de la macarena, sevilla, spain hospital politecnic universitari la fe, valencia, spain kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan taichung veterans general hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan national taiwan university hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan linkou chang gung memorial hospital, taoyuan city, taiwan adana city training and research hospital, adana, turkey ankara university faculty of medicine, ankara, turkey ankara city hospital, ankara, turkey trakya university medical faculty, edirne, turkey goztepe prof. dr. suleyman yalcin city hospital, istanbul, turkey inonu university, faculty of medicine, malatya, turkey mi kryvyi rih oncology dispensary of dnipropetrovsk regional council; chemotherapy department, kryviy rih, dnipropetrovska oblast, ukraine medical & diagnostic center of lisod-israeli oncological hosp ""medx-ray international group"", pliuty village, kyiv region, ukraine asklepion medical center, khodosivka, kyivska oblast, ukraine national cancer institute, kyiv, kyivska oblast, ukraine municipal ent ""dnipropetrovsk regional clinical hosp (i.i.mechnikov dnipropetrovsk regional council), dnipro, ukraine municipal non-profit enterprise ""city clinical hospital #4"" of dnipro city council, dnipro, ukraine communal non-profit enterprise ""regional clinical hospital of ivano-frankivsk regional council"", ivano-frankivsk, ukraine municipal non-commercial enterprise of kharkiv regional council regional medical clinical center of, kharkiv, ukraine communal non-profit enterprise ""regional center of oncology"", kharkiv, ukraine comm noncommerc entp lviv reg council ""lviv oncological regional therapeutical and diagnostic cntr, lviv, ukraine maidstone and tunbridge wells nhs trust, maidstone, kent, united kingdom lancashire teaching hospitals nhs foundation trust, preston, lancashire, united kingdom nhs lothian, edinburgh, midlothian, united kingdom royal devon and exeter nhs foundation trust, exeter, united kingdom nhs greater glasgow and clyde, glasgow, united kingdom the royal marsden nhs foundation trust, london, united kingdom imperial college healthcare nhs trust, london, united kingdom the christie nhs foundation trust, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT04821622,prostat
372,373,NCT00793546,study evaluating bosutinib-exemestane combination vs exemestane alone in post menopausal women with breast cancer,,Terminated,Has Results,advanced breast cancer,drug: bosutinib|drug: exemestane|drug: exemestane,progression free survival (pfs) based on independent radiologist|percentage of participants with treatment-emergent adverse events (aes) and serious adverse events (saes)|progression free survival (pfs) based on investigator|percentage of participants with objective response|overall survival (os)|duration of response (dr)|functional assessment of cancer therapy-breast cancer (fact-b)|euro quality of life (eq-5d)- health state profile utility score|euro quality of life (eq-5d)- visual analog scale (vas)|maximum observed plasma concentration (cmax)|time to reach maximum observed plasma concentration (tmax)|area under the curve from time zero to last quantifiable concentration [auc (0-24)],pfizer,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,42.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3160A6-2206|B1871009,February 2009,June 2010,June 2010,"November 19, 2008","November 4, 2012","November 4, 2012","['pfizer investigational site, lake worth, florida, united states pfizer investigational site, joliet, illinois, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, detroit, michigan, united states pfizer investigational site, new brunswick, new jersey, united states pfizer investigational site, new york, new york, united states pfizer investigational site, bethlehem, pennsylvania, united states pfizer investigational site, philadelphia, pennsylvania, united states pfizer investigational site, philadelphia, pennsylvania, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, south brisbane, queensland, australia pfizer investigational site, brussels, belgium pfizer investigational site, leuven, belgium pfizer investigational site, liege, belgium pfizer investigational site, wilrijk, belgium pfizer investigational site, kelowna, british columbia, canada pfizer investigational site, beijing, china pfizer investigational site, hong kong, hong kong pfizer investigational site, budapest, hungary pfizer investigational site, mumbai, maharashtra, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, olsztyn, poland pfizer investigational site, lynnwood, gauteng, south africa pfizer investigational site, barcelona, spain pfizer investigational site, madrid, spain pfizer investigational site, valencia, spain pfizer investigational site']",,https://ClinicalTrials.gov/show/NCT00793546,breast
373,374,NCT02603432,a study of avelumab in patients with locally advanced or metastatic urothelial cancer (javelin bladder 100),,"Active, not recruiting",Has Results,urothelial cancer,biological: avelumab|other: best supportive care|biological: following the planned interim analysis for this study: avelumab,"overall survival (os)|progression-free survival (pfs) as assessed by blinded independent central review (bicr)|progression-free survival (pfs) as assessed by investigator|percentage of participants with objective response (or) as assessed by blinded independent central review (bicr)|percentage of participants with objective response as assessed by investigator|time to tumor response (ttr) as assessed by blinded independent central review (bicr)|time to tumor response (ttr) as assessed by investigator|duration of response (dor) as assessed by blinded independent central review (bicr)|duration of response (dor) as assessed by investigator|percentage of participants with disease control (dc) as assessed by blinded independent central review (bicr)|percentage of participants with disease control (dc) as assessed by investigator|number of participants with treatment-emergent adverse events (aes) graded based on, national cancer institute common terminology criteria (nci-ctcae), version 4.03|number of participants with laboratory abnormalities greater than or equal to (>=) grade 3 (g3), based on national cancer institute common terminology criteria (nci-ctcae), version 4.03|change from baseline in vital signs - blood pressure at day 1 of cycle 2, 3, 4, 5, 6, 7 and end of treatment (eot) visit|change from baseline in vital signs - pulse rate at day 1 of cycle 2, 3, 4, 5, 6, 7 and end of treatment (eot) visit|maximum plasma concentration (cmax) of avelumab|predose plasma concentration (ctrough) of avelumab|number of participants with anti-drug antibodies (ada) against avelumab by never and ever positive status|number of ada ever positive participants for each serum of ada titers for avelumab|number of participants with neutralizing antibodies (nab) against avelumab by never positive and ever positive status|number of participants with programmed death receptor-1 ligand 1 (pd-l1) biomarker expression in tumor tissue as assessed by immunohistochemistry (ihc)|number of participants with cluster of differentiation 8 (cd8) t lymphocytes (cytotoxic t lymphocytes)|change from baseline in national comprehensive cancer network- functional assessment of cancer therapy (nccn-fact) bladder symptom index- 18 (fblsi-18) score at day 1 of cycle 6|time to deterioration (ttd) based on national comprehensive cancer network- functional assessment of cancer therapy (nccn-fact) bladder symptom index- 18 (fblsi-18) disease related symptoms-physical subscale (drs-p) scores|change from baseline in european quality of life-5 dimensions-5 levels (eq-5d-5l) overall health utility score at cycle 6|change from baseline in european quality of life-5 dimensions-5 levels (eq-5d-5l) - visual analog scale (vas) score at cycle 6",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,700.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B9991001|2015-003262-86|JAVELIN BLADDER 100,"April 25, 2016","October 21, 2019","June 3, 2022","November 11, 2015","December 17, 2020","January 20, 2022","['anschutz cancer center pavilion pharmacy, aurora, colorado, united states university of colorado cancer center, aurora, colorado, united states university of colorado denver, cto (ctrc), aurora, colorado, united states university of colorado hospital - anschutz inpatient pavilion (aip), aurora, colorado, united states university of colorado hospital - anschutz outpatient pavilion (aop), aurora, colorado, united states smilow cancer hospital at yale new haven, new haven, connecticut, united states smilow cancer hospital at yale-new haven, new haven, connecticut, united states massachusetts general hospital, boston, massachusetts, united states university of minnesota medical center, minneapolis, minnesota, united states university of minnesota, minneapolis, minnesota, united states cleveland clinic taussing cancer center, cleveland, ohio, united states cleveland clinic foundation, cleveland, ohio, united states inova schar cancer institute infusion pharmacy, fairfax, virginia, united states inova schar cancer institute, fairfax, virginia, united states seattle cancer care alliance, seattle, washington, united states seattle cancer care alliance, seattle, washington, united states university of washington medical center, seattle, washington, united states centro de investigacion pergamino s.a., pergamino, buenos aires, argentina fundación cenit para la investigación en neurociencias, caba, argentina gp diagnostico srl, la rioja, argentina hospital regional dr. enrique vera barros, la rioja, argentina instituto del diagnostico, la rioja, argentina centro oncologico riojano integral (cori), la rioja, argentina chris o\'brien lifehouse, camperdown, new south wales, australia concord hospital, concord, new south wales, australia dubbo base hospital, dubbo, new south wales, australia ramsay pharmacy, kogarah, new south wales, australia st george private hospital, kogarah, new south wales, australia epic pharmacy, lismore, new south wales, australia north coast radiology st vincents, lismore, new south wales, australia northern rivers pathology service, lismore, new south wales, australia st vincent\'s pathology lismore, lismore, new south wales, australia macquarie university hospital pharmacy, macquarie university, new south wales, australia macquarie university, macquarie university, new south wales, australia the murwillumbah hospital, murwillubah, new south wales, australia the tweed hospital pharmacy department, tweed heads, new south wales, australia the tweed hospital, tweed heads, new south wales, australia icon cancer care wesley, auchenflower, queensland, australia river city pharmacy, auchenflower, queensland, australia oncology pharmacy, birtinya, queensland, australia sunshine coast university hospital, birtinya, queensland, australia icon cancer care chermside, chermside, queensland, australia the townsville hospital, douglas, queensland, australia slade health, geebung, queensland, australia icon cancer care south brisbane, south brisbane, queensland, australia icon cancer care, south brisbane, queensland, australia icon cancer care southport, southport, queensland, australia flinders medical centre, bedford park, south australia, australia sa pharmacy, level 3 pharmacy, bedford park, south australia, australia adelaide cancer centre, kurralta park, south australia, australia ashford cancer centre research, kurralta park, south australia, australia cancer care sa pty ltd, kurralta park, south australia, australia icon cancer care sa trading as icon pharmacy adelaide, kurralta park, south australia, australia the queen elizabeth hospital, woodville south, south australia, australia bhs diagnostic services, ballarat, victoria, australia lake imaging, ballarat, victoria, australia ballarat oncology & haematology services, ballarat, victoria, australia box hill hospital, box hill, victoria, australia eastern health clinical school, box hill, victoria, australia monash medical centre, clayton, victoria, australia monash cancer centre, east bentleigh, victoria, australia moorabbin radiology, east bentleigh, victoria, australia ballarat day procedure centre, wendouree, victoria, australia ballarat oncology & haematology services, wendouree, victoria, australia nova pharmacy, wendouree, victoria, australia fiona stanley hospital, murdoch, western australia, australia st john of god murdoch hospital, murdoch, western australia, australia slade health, mount waverley, australia macquarie heart, new south wales, australia az klina - apotheek, brasschaat, belgium az klina, brasschaat, belgium hôpital erasme, brussels, belgium hôpital erasme, bruxelles, belgium uz gent, gent, belgium uz gent, ghent, belgium az groeninge, kortrijk, belgium chu de liège, liège, belgium gza sint-augustinus, wilrijk, belgium hospital da bahia, salvador, ba, brazil cenob centro de oncologia da bahia s/s ltda. / oncovida, salvador, ba, brazil hospital mãe de deus/aesc, porto alegre, rio grande do sul, brazil instituto nacional de câncer - inca, rio de janeiro, rj, brazil associação hospital de caridade ijuí / hospital de caridade de ijuí, ijuí, rs, brazil associação educadora são carlos - aesc / hospital mãe de deus, porto alegre, rs, brazil associação educadora são carlos - aesc / hospital mãe de deus - ambulatório quimioterapia, porto alegre, rs, brazil associação educadora são carlos - aesc / hospital mãe de deus - centro de abastecimento farmaceu, porto alegre, rs, brazil associação educadora são carlos - aesc / hospital mãe de deus - farmácia oncológica, porto alegre, rs, brazil associação educadora são carlos - aesc / hospital mãe de deus, porto alegre, rs, brazil uniao brasileira de educacao e assistencia / hospital sao lucas da pucrs, porto alegre, rs, brazil fundação fpio xii barretos, barretos, sp, brazil fundação pio xii barretos, barretos, sp, brazil fundacao faculdade regional de medicina de sao jose do rio preto, sao jose do rio preto, sp, brazil fundacao faculdade de medicina / instituto do cancer do estado de sao paulo - icesp, sao paulo, sp, brazil hospital alemao oswaldo cruz, sao paulo, sp, brazil hospital das clinicas da faculdade de medicina da usp - hcfmusp, sao paulo, sp, brazil centro integrado de pesquisa clinica - cip, são josé do rio preto, sp, brazil sociedade beneficente de senhoras hospital sírio libanês, são paulo, sp, brazil hospital israelita albert einstein - sp, são paulo, sp, brazil sociedade beneficente de senhoras hospital sírio libanês/ instituo sirio libanes de ensino e pesqu, são paulo, brazil william osler health system, brampton, ontario, canada princess margaret cancer centre, toronto, ontario, canada chum - centre hospitalier de l\'universite de montreal, montréal, quebec, canada fakultni nemocnice u sv. anny v brne, brno, ceska republika, czechia fakultni nemocnice brno, brno, czechia fakultni nemocnice u sv. anny v brne, brno, czechia fakultni nemocnice u sv.anny v brne, brno, czechia nemocnice horovice, nh hospital a.s., horovice, czechia nemocnice horovice, horovice, czechia aalborg universitetshospital syd, aalborg, denmark aalborg universitetshospital, aalborg, denmark sygehusapoteket aalborg, aalborg, denmark aarhus universitetshospital, aarhus c, denmark aarhus universitetshospital, aarhus n, denmark ct-klinikken a/s, aarhus n, denmark rigshospitalet, onkologisk klinik, afsnit 5073, copenhagen oe, denmark herlev hospital, herlev, denmark herlev og gentofte hospital, herlev, denmark klinik for klinisk fysiologi,nuklearmedicin og pet, københavn ø, denmark rigshospitalet, københavn ø, denmark odense universitetshospital, odense c, denmark odense universitetshospital, odense, denmark groupe hospitalier pitie saleptriere, paris, cedex 13, france institut de cancérologie de l\'ouest - site paul papin, angers cedex 02, france institut de cancérologie de l\'ouest - site paul papin, angers, france centre d\'oncologie et de radiothérapie du pays-basque, bayonne, france clinique capio belharra, bayonne, france hôpital jean minjoz, besancon cedex, france chu besançon, besançon, france hôpital henri mondor, créteil cedex, france hôpital privé toulon-hyères - clinique sainte marguerite, hyères, france clinique victor hugo, le mans, france centre oscar lambret, lille cedex, france centre oscar lambret, lille, france centre leon berard, lyon cedex 8, france centre léon berard, lyon cedex 8, france hopital la conception, marseille cedex 5, france institut paoli calmettes, marseille cedex 9, france institut paoli calmettes, marseille, france hopital de la timone, marseille, france hopital de la timone, marseille, france chu nimes - institut de cancerologie du gard, nimes cedex 9, france chu nimes, nimes cedex 9, france chu nimes - hopital caremeau, nimes, france groupe hospitalier pitié salpêtrière, paris cedex 13, france groupe hospitalier pitié salpêtrière, paris, france centre eugene marquis, rennes cedex, france centre henri becquerel, rouen cedex 1, france chu de rouen - hôpital charles nicolle, rouen, france chu de rouen, rouen, france institut de cancérologie de l\'ouest - centre rené gauducheau, saint herblain cedex, france centre de radiothérapie - clinique sainte anne, strasbourg, france clinique sainte anne, strasbourg, france hopital foch, suresnes, france institut gustave roussy, villejuif cedex, france institut gustave roussy, villejuif, france medical center of athens, marousi, athens, greece metropolitan general hospital, athens, pc, greece sotiria general chest disease hospital, athens, greece alexandra general hospital, oncology department, athens, greece university general hospital of patras, division of oncology, patra, greece euromedica general clinic of thessaloniki, thessaloniki, greece department of clinical oncology, hong kong, hong kong kaposvári egyetem egészségügyi centrum, kaposvár, hungary somogy megyei kaposi mór oktató kórház, kaposvár, hungary dr ram manohar lohia (rml) hospital & pgi mer, new delhi, delhi, india cims cancer, care institute of medical sciences, cims hospital, ahmedabad, gujarat, india sahyadri super speciality hospital, pune, maharashtra, india apollo hospitals, hyderabad, telangana, india medica superspecialty hospital, kolkata, west bengal, india rajiv gandhi cancer institute and research centre, delhi, india hadassah university hospital, kiryat hadassah, jerusalem, israel the chaim sheba medical center, tel-hashomer, ramat - gan, israel assaf harofe mc, beer yaakov, israel rambam health care campus, haifa, israel the chaim sheba medical center, ramat - gan, israel farmacia ospedaliera, candiolo, (torino), italy aou ospedali riuniti di ancona, torrette, ancona, italy u.o. anatomia patologica, forli, forli-cesena, italy u.o. radiologia, forli, forli-cesena, italy u.o.s. medicina nucleare, forli, forli-cesena, italy farmacia oncologica, meldola, forli-cesena, italy istituto scientifico romagnolo per lo studio e la cura dei tumori, meldola, forli-cesena, italy u.o.c. farmacia, genova, genoa, italy irccs ospedale policlinico san martino, genova, liguria, italy farmacia studi clinici, rozzano, milan, italy istituto clinico humanitas, rozzano, milan, italy ausl della romagna - ravenna, presidio ospedaliero di faenza, faenza, ravenna, italy presidio ospedaliero di lugo, lugo, ravenna, italy fondazione del piemonte per l\'oncologia - irccs candiolo, candiolo, torino, italy farmacia ospedaliera, arezzo, italy presidio ospedaliero san donato, arezzo, italy centro di riferimento oncologico - irccs, aviano (pn), italy s.o.c. di farmacia, aviano (pn), italy azienda ospedaliero-universitaria policlinico s.orsola malpighi, bologna, italy u.o. farmacia clinica - ids, bologna, italy fondazione irccs istituto nazionale dei tumori, milan, italy sc farmacia, milan, italy instituto europeo di oncologia, milan, italy servizio di farmacia, milan, italy azienda ospedaliera di rilievo nazionale ""a. cardarelli"", naples, italy uosc farmacia, naples, italy istituto nazionale per lo studio e la cura dei tumori, irccs fondazione giovanni pascale, napoli, italy s.c. farmacia ospedaliera, napoli, italy a.o.u. pisana ospedale s. chiara, pisa, italy presidio ospedaliero di ravenna, ravenna, italy servizio farmacia ospedaliera - farmacia oncologica, ravenna, italy azienda ospedaliera san camillo forlanini_oncologia medica, rome, italy u.o.c. farmacia, rome, italy azienda ospedaliera s. maria di terni, terni, italy s.c. farmacia interna, terni, italy nagoya university hospital, nagoya, aichi, japan hirosaki university school of medicine & hospital, hirosaki, aomori, japan national hospital organization shikoku cancer center, matsuyama, ehime, japan gunma prefectural cancer center, ota, gunma, japan national hospital organization hokkaido cancer center, sapporo,, hokkaido, japan hokkaido university hospital, sapporo, hokkaido, japan kobe city medical center general hospital, kobe-city, hyogo, japan tsukuba medical center hospital, tsukuba, ibaraki, japan iwate medical university hospital, shiwa-gun, iwate, japan national hospital organization sagamihara national hospital, sagamihara, kanagawa, japan kanagawa cancer center, yokohama, kanagawa, japan kindai university hospital, osakasayama, osaka, japan saitama medical university international medical center, hidaka, saitama, japan dokkyo medical university saitama medical center, koshigaya, saitama, japan hamamatsu university school of medicine, university hospital, hamamatsu, shizuoka, japan nihon university itabashi hospital, itabashi-ku, tokyo, japan the cancer institute hospital of jfcr, koto-ku, tokyo, japan keio university hospital, shinjuku-ku, tokyo, japan yamaguchi university hospital, ube, yamaguchi, japan chiba cancer center, chiba, japan national hospital organization kyushu cancer center, fukuoka, japan kyushu university hospital, fukuoka, japan hiroshima city hiroshima citizens hospital, hiroshima, japan kagoshima university hospital, kagoshima, japan national hospital organization kumamoto medical center, kumamoto, japan niigata university medical & dental hospital, niigata, japan osaka city university hospital, osaka, japan tokushima university hospital, tokushima, japan yamagata university hospital, yamagata, japan national cancer center - clinical trial pharmacy, goyang-si, gyeonggi-do, korea, republic of national cancer center urology center for prostate cancer, goyang-si, gyeonggi-do, korea, republic of seoul national university bundang hospital, clinical pharmacy, seongnam-si, gyeonggido, korea, republic of seoul national university bundang hospital, seongnam-si, gyeonggido, korea, republic of chungnam national university hospital, clinical pharmacy, daejeon, korea, republic of chungnam national university hospital, daejeon, korea, republic of severance hospital yonsei university health system, seoul, korea, republic of asan medical center - clinical trial pharmacy, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center clinical trial pharmacy, seoul, korea, republic of samsung medical center, seoul, korea, republic of instituto nacional de cancerologia, mexico, ciudad de mexico, mexico phylasis clinicas research s. de r.l. de c.v., cuautitlan izcalli, estado de mexico, mexico centro de investigación clínica de leon s.c., leon, guanajuato, mexico hospital médica campestre (administradora hospitalaria s.a de c.v.), león, guanajuato, mexico rijnstate arnhem, arnhem, netherlands ziekenhuis rijnstate, arnhem, netherlands st apotheek der haarlemse ziekenhuizen, haarlem, netherlands spaarne gasthuis, hoofddorp, netherlands maastricht university medical center, maastricht, netherlands radboud university medical center, nijmegen, netherlands radboudumc, nijmegen, netherlands auckland city hospital pharmacy, grafton, auckland, new zealand auckland city hospital, grafton, auckland, new zealand christchurch hospital, christchurch, new zealand waikato hospital, hamilton, new zealand akershus university hospital, lorenskog, norway sykehusapoteket hf 23 lørenskog, lorenskog, norway sykehusapoteket hf 23 lørenskog, nordbyhagen, norway sykehusapoteket lorenskog, nordbyhagen, norway bildediagnostisk avdeling, nordbyhagen, norway stavanger university hospital, stavanger, norway centralny szpital kliniczny mswia, warszawa, masovian, poland centrum onkologii ziemi lubelskiej im. sw. jana z dukli, lublin, poland lecznice citomed sp. z o.o., torun, poland wojewodzki szpital zespolony im. l. rydygiera w toruniu szpital obserwacyjno-zakazny, torun, poland wojewodzki szpital zespolony im. l. rydygiera w toruniu, torun, poland wojewodzki szpital zespolony im. l. rydygiera, szpital specjalistyczny dla dzieci i doroslych, torun, poland instituto português de oncologia de coimbra francisco gentil, epe, coimbra, portugal hospital da luz coimbra, sa, coimbra, portugal centro hospitalar de lisboa central, e.p.e. - hospital de santo antónio dos capuchos, lisboa, portugal hospital cuf descobertas, sa, lisboa, portugal dr. campos costa - consultório de tomografia computorizada, s.a., porto, portugal instituto português de oncologia do porto francisco gentil, epe, porto, portugal centro hospitalar de são joão, epe, porto, portugal dr. campos costa - consultório de tomografia computorizada, s.a.- matosinhos, senhora da hora, portugal centro hospitalar de trás-os-montes e alto douro, epe, vila real, portugal state budgetary healthcare insti. republican clinical oncology dispensary of the moh of bashk. rep., ufa, bashkortostan republic, russian federation federal state budgetary institution ""national medical research radiology center"" moh rf, obninsk, kaluzhskaya region, russian federation private medical institution ""evromedservice"", pushkin, saint petersburg, russian federation principal military clinical hospital n.a. n.n. burdenko, moscow, russian federation moscow research oncology institute named after p. a. gertsen, moscow, russian federation bhi of omsk region ""clinical oncological dispensary"", omsk, russian federation fgbih ""clinical hospital #122 n.a. l.g. sokolov of federal medico-biological agency"", st. petersburg, russian federation non-state healthcare institution ""railway clinical hospital jsc rzhd"", st. petersburg, russian federation fsbei he ""first st. petersburg state medical university n. a. academician l.p pavlov"" moh rf, st. petersburg, russian federation fsbei he ""first st. petersburg state medical university n.a. academician i.p pavlov"" moh rf, st. petersburg, russian federation fsbei he ""first st. petersburg state medical university n.a. academician i.p pavlov"", st. petersburg, russian federation ""ramsay diagnostics rus"", llc, st. petersburg, russian federation fsbi ""russian scientific center for radiology and surgical technologies n.a. academician a.m. granov, st. petersburg, russian federation hospital orkli, llc, st. petersburg, russian federation mart, llc, st. petersburg, russian federation shi yr ""regional clinical oncology hospital"", yaroslavl, russian federation institute for oncology and radiology of serbia, belgrade, serbia clinical centre nis, clinic of oncology, nis, serbia oncology institute of vojvodina, sremska kamenica, serbia c.h. univ. santiago de compostela, santiago de compostela, a coruña, spain hospital comarcal general de elda de virgen de la salud, elda, alicante, spain hospital universitario central de asturias, oviedo, asturias, spain hospital universitario germans trias i pujol, badalona, barcelona, spain institut catalá d\'oncología - hospital duran i reynals, l´hospitalet de llobregat, barcelona, spain institut catalá d\'oncología, l´hospitalet de llobregat, barcelona, spain althaia. xarxa assistencial universitaria de manresa, manresa, barcelona, spain corporacio sanitaria parc tauli, sabadell, barcelona, spain hospital general universitario de elche, elche, comunidad valenciana, spain hospital clinico universitario de valencia, valencia, comunidad valenciana, spain c. h. universitario de vigo- hospital álvaro cunqueiro, vigo, galicia, spain c.h. universitario de vigo- hospital meixoeiro, vigo, galicia, spain hospital universitario infanta sofia, san sebastian de los reyes, madrid, spain hospital universitario infanta sofia, san sebastián de los reyes, madrid, spain clinica universidad de navarra, pamplona, navarra, spain complejo hospitalario de navarra, pamplona, navarra, spain hospital vithas internacional medimar, alicante, spain hospital universitario infanta cristina, badajoz, spain hospital del mar, barcelona, spain hospital quiron of barcelona, barcelona, spain hospital quirón de barcelona, barcelona, spain hospital de la santa creu i sant pau_oncology department, barcelona, spain hospital de la santa creu i sant pau, barcelona, spain cetir grup medic, barcelona, spain cetir, centre mèdic, s.l, barcelona, spain hospital universitario vall d\'hebron, barcelona, spain hospital clinic de barcelona, barcelona, spain hospital universitario reina sofia, cordoba, spain hospital universitario reina sofía, cordoba, spain institut catala d\'oncologia, gerona, spain institut diagnostic de la lmatge, gerona, spain hospital universitario lucus augusti, lugo, spain fundacion maria rafols para la investigacion del diagnostico de la imagen, madrid, spain gabinete radiologico doctor pita, madrid, spain hospital general universitario gregorio marañon, madrid, spain hospital ruber internacional, madrid, spain hospital ruber international, madrid, spain hospital universitario ramón y cajal, madrid, spain hospital clinico san carlos, madrid, spain hospital clínico san carlos, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital universitario la paz, madrid, spain hospital universitario hm sanchinarro - ciocc, madrid, spain hospital universitario virgen del rocio, sevilla, spain instituto valenciano de oncología, valencia, spain hospital clínico universitario de valencia, valencia, spain hospital clinico universitario de valencia, valencia, spain apl, stockholm, sweden karolinska university hospital, stockholm, sweden clinical trial pharmacy, china medical university hospital, taichung, taiwan china medical university hospital, taichung, taiwan department of pharmacy, national cheng kung university hospital, tainan, taiwan national cheng kung university hospital, tainan, taiwan investigational drug services, national taiwan university hospital, taipei, taiwan national taiwan university hospital, taipei, taiwan koo foundation sun yat-sen cancer center, taipei, taiwan chang gung memorial hospital, linkou, taoyuan, taiwan chemotherapy pharmacy, chang gung memorial hospital, linkou, taoyuan, taiwan royal united hospitals bath nhs foundation trust, bath, united kingdom st bartholomew \'s hospital, barts health nhs trust, london, united kingdom st. bartholomew\'s hospital, barts health nhs trust, london, united kingdom guy\'s & st. thomas\' nhs foundation trust, london, united kingdom guy\'s and st thomas\' nhs foundation trust, guy\'s hospital, london, united kingdom churchill hospital, oxford university hospitals nhs trust, oxford, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/32/nct02603432/prot_002.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/32/nct02603432/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02603432,urotheli
374,375,NCT03682068,"study of durvalumab given with chemotherapy, durvalumab in combination with tremelimumab given with chemotherapy, or chemotherapy in patients with unresectable urothelial cancer",NILE,Recruiting,No Results Available,unresectable locally advanced urothelial cancer|metastatic urothelial cancer,drug: durvalumab|drug: tremelimumab|drug: cisplatin + gemcitabine|drug: carboplatin + gemcitabine,"overall survival (os)|overall survival at 24 months (os24)|progression free survival (pfs)|alive and progression free survival at 12 months (apf12)|objective response rate (orr)|duration of response (dor)|disease control rate (dcr)|time from randomization to second (pfs2)|to assess disease-related symptoms, physical functioning, and other health-related quality of life",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,1292.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D933SC00001,"September 27, 2018","June 30, 2023","October 30, 2025","September 24, 2018",,"April 15, 2022","[""research site, birmingham, alabama, united states research site, bakersfield, california, united states research site, fountain valley, california, united states research site, fullerton, california, united states research site, los angeles, california, united states research site, los angeles, california, united states research site, salinas, california, united states research site, santa barbara, california, united states research site, santa maria, california, united states research site, truckee, california, united states research site, new haven, connecticut, united states research site, washington, district of columbia, united states research site, orlando, florida, united states research site, chicago, illinois, united states research site, fort wayne, indiana, united states research site, kansas city, kansas, united states research site, louisville, kentucky, united states research site, new orleans, louisiana, united states research site, grand rapids, michigan, united states research site, bozeman, montana, united states research site, livingston, new jersey, united states research site, neptune, new jersey, united states research site, bronx, new york, united states research site, new hyde park, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, rochester, new york, united states research site, philadelphia, pennsylvania, united states research site, sioux falls, south dakota, united states research site, germantown, tennessee, united states research site, fort worth, texas, united states research site, buenos aires, argentina research site, buenos aires, argentina research site, ciudad de buenos aires, argentina research site, ciudad de buenos aires, argentina research site, rosario, argentina research site, box hill, australia research site, elizabeth vale, australia research site, kogarah, australia research site, macquarie university, australia research site, murdoch, australia research site, orange, australia research site, south brisbane, australia research site, st albans, australia research site, belo horizonte, brazil research site, curitiba, brazil research site, fortaleza, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, rio de janeiro, brazil research site, salvador, brazil research site, santa maria, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, burgas, bulgaria research site, pleven, bulgaria research site, plovdiv, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, vancouver, british columbia, canada research site, hamilton, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, sherbrooke, quebec, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, chongqing, china research site, chongqing, china research site, dalian, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, jinan, china research site, jinan, china research site, nanchang, china research site, nanjing, china research site, nanjing, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, suzhou, china research site, tianjin, china research site, tianjin, china research site, urumqi, china research site, wuhan, china research site, wuhan, china research site, xi'an, china research site, xiamen, china research site, zhengzhou, china research site, brno, czechia research site, hradec kralove, czechia research site, olomouc, czechia research site, ostrava, czechia research site, praha 2, czechia research site, praha 8, czechia research site, praha, czechia research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, gyula, hungary research site, győr, hungary research site, kecskemét, hungary research site, szolnok, hungary research site, ahmedabad, india research site, ahmedabad, india research site, bangalore, india research site, calicut, india research site, gurgaon, india research site, hubli, india research site, hyderabad, india research site, kolkata, india research site, mangalore, india research site, mysuru, india research site, nagpur, india research site, nasik, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, pune, india research site, vadodara, india research site, haifa, israel research site, jerusalem, israel research site, kfar saba, israel research site, petach-tikva, israel research site, ramat gan, israel research site, arezzo, italy research site, catania, italy research site, milano, italy research site, milano, italy research site, napoli, italy research site, orbassano, italy research site, parma, italy research site, pavia, italy research site, roma, italy research site, san giovanni rotondo, italy research site, terni, italy research site, verona, italy research site, bunkyo-ku, japan research site, chuo-ku, japan research site, fukuoka-shi, japan research site, hirosaki-shi, japan research site, kanazawa-shi, japan research site, kita-gun, japan research site, koshigaya-shi, japan research site, koto-ku, japan research site, kumamoto-shi, japan research site, kumamoto-shi, japan research site, kyoto-shi, japan research site, miyazaki-city, japan research site, nagasaki-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, shinjuku-ku, japan research site, suita-shi, japan research site, toyama-shi, japan research site, tsukuba-shi, japan research site, yokohama-shi, japan research site, yokohama-shi, japan research site, goyang-si, korea, republic of research site, incheon, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon-si, korea, republic of research site, bacolod, philippines research site, baguio city, philippines research site, cebu, philippines research site, davao city, philippines research site, iloilo city, philippines research site, legazpi city, philippines research site, makati, philippines research site, manila, philippines research site, quezon city, philippines research site, quezon city, philippines research site, bialystok, poland research site, gdańsk, poland research site, grudziądz, poland research site, koszalin, poland research site, kraków, poland research site, lublin, poland research site, olsztyn, poland research site, poznan, poland research site, radom, poland research site, warszawa, poland research site, warszawa, poland research site, wroclaw, poland research site, łódź, poland research site, ivanovo, russian federation research site, krasnoyarsk, russian federation research site, lipetsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhniy novgorod, russian federation research site, nizhniy novgorod, russian federation research site, omsk, russian federation research site, rostov-on-don, russian federation research site, ryazan, russian federation research site, saint-petersburg, russian federation research site, st. petersburg, russian federation research site, st. petersburg, russian federation research site, st.-petersburg,, russian federation research site, st.petersburg, russian federation research site, tyumen, russian federation research site, vologda, russian federation research site, barcelona, spain research site, barcelona, spain research site, barcelona, spain research site, lugo, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, malaga, spain research site, santander, spain research site, sevilla, spain research site, taichung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, khon kaen, thailand research site, lampang, thailand research site, mueang, thailand research site, songkla, thailand research site, adana, turkey research site, adapazari, turkey research site, ankara, turkey research site, edirne, turkey research site, istanbul, turkey research site, izmir, turkey research site, ha noi, vietnam research site, hanoi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam""]",,https://ClinicalTrials.gov/show/NCT03682068,urotheli
375,376,NCT04469127,a study of aip-303 in her2 positive breast cancer and/or metastatic breast cancer patients,Heroine01,Not yet recruiting,No Results Available,her2 positive breast cancer,drug: aip-303,specific aim 1|specific aim 2|specific aim 3|specific aim 4|specific aim 5|specific aim 6,"advanced imaging projects, llc|all india institute of medical sciences, new delhi|university of lausanne|university of witwatersrand, south africa|postgraduate institute of medical and research|positronpharma|università degli studi di trieste|us department of veterans affairs",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,150.0,Industry|Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,145358,"August 30, 2020","August 30, 2021","August 30, 2021","July 13, 2020",,"July 22, 2020","['department of veterans affairs, iowa city, iowa, united states positronpharma, santiago, chile all india institute of medical sciences, new delhi, dehli, india postgraduate institute of medical and research, chandigarh, india università degli studi di trieste, cremona, italy university of witwatersrand, johannesburg, south africa university of lausanne, lausanne, switzerland']",,https://ClinicalTrials.gov/show/NCT04469127,breast
376,377,NCT03337724,"a study of ipatasertib in combination with paclitaxel as a treatment for participants with pik3ca/akt1/pten-altered, locally advanced or metastatic, triple-negative breast cancer or hormone receptor-positive, her2-negative breast cancer",IPATunity130,"Active, not recruiting",No Results Available,breast cancer,drug: ipatasertib|drug: paclitaxel|drug: placebo,progression-free survival (pfs)|objective response rate (orr)|duration of response (dor)|clinical benefit rate (cbr)|overall survival (os)|global health status (ghs)/health-related quality of life (hrqol) score|time to deterioration in pain|incidence and severity of adverse events (aes)|changes in vital signs|changes in targeted laboratory results|plasma concentration of ipatasertib and its metabolite (g-037720),hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,580.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CO40016|2017-001548-36,"January 6, 2018","December 22, 2022","December 22, 2022","November 9, 2017",,"May 9, 2022","[""ucsd moores cancer center, la jolla, california, united states usc norris cancer center, los angeles, california, united states usc norris cancer center; usc oncology hematology newport beach, newport beach, california, united states kaiser permanente - oakland, oakland, california, united states kaiser permanente - roseville, roseville, california, united states kaiser permanente sacramento medical center, sacramento, california, united states uc davis; comprehensive cancer center, sacramento, california, united states kaiser permanente - san francisco (2238 geary), san francisco, california, united states ucsf comprehensive cancer ctr, san francisco, california, united states k. permanente - san jose, san jose, california, united states kaiser permanente - san leandro, san leandro, california, united states k. permanente - santa clara, santa clara, california, united states kaiser permanente - south san francisco, south san francisco, california, united states kaiser permanente - vallejo, vallejo, california, united states k. permanente - walnut creek, walnut creek, california, united states memorial regional hospital, hollywood, florida, united states mount sinai comprehensive cancer center, miami beach, florida, united states uf health cancer center at orlando health, orlando, florida, united states memorial hospital west, pembroke pines, florida, united states university of maryland, baltimore, maryland, united states mercy medical center, baltimore, maryland, united states johns hopkins sidney kimmel comprehensive cancer center, baltimore, maryland, united states memorial sloan kettering cancer center at westchester, harrison, new york, united states memorial sloan kettering, new york, new york, united states west clinic, germantown, tennessee, united states texas oncology, p.a., dallas, texas, united states ut southwestern medical center; simmons comprehensive cancer center, simmons pharmacy, dallas, texas, united states oncology consultants pa, houston, texas, united states fundación cenit para la investigación en neurociencias, buenos aires, argentina hosp provincial d. centenarios; oncology dept, rosario, argentina chris o'brien lifehouse, camperdown, new south wales, australia calvary mater newcastle; medical oncology, waratah, new south wales, australia westmead hospital; medical oncology, wentworthville, new south wales, australia mater hospital; cancer services, south brisbane, queensland, australia cabrini medical centre; oncology, malvern, victoria, australia fiona stanley hospital; fsh cancer centre clinical trials unit, bull creek, western australia, australia cliniques universitaires st-luc, bruxelles, belgium ghdc site notre dame, charleroi, belgium uz leuven gasthuisberg, leuven, belgium santa casa de misericordia de salvador, salvador, ba, brazil hospital araujo jorge; departamento de ginecologia e mama, goiania, go, brazil hospital do câncer de londrina, londrina, pr, brazil instituto nacional de cancer - inca; oncologia, rio de janeiro, rj, brazil hospital sao lucas - pucrs, porto alegre, rs, brazil hospital nossa senhora da conceicao, porto alegre, rs, brazil faculdade de medicina do abc - fmabc, santo andre, sp, brazil hospital perola byington, sao paulo, sp, brazil british columbia cancer agency (bcca) - vancouver cancer centre, vancouver, british columbia, canada jewish general hospital, montreal, quebec, canada sociedad de investigaciones medicas ltda (sim), temuco, chile clinica cimca, san josé, costa rica icimed instituto de investigación en ciencias médicas, san josé, costa rica masarykův onkologický ústav; klinika komplexní onkologické péče, brno, czechia fakultni nemocnice olomouc; onkologicka klinika, olomouc, czechia chu besançon - hôpital jean minjoz, besançon cedex, france polyclinique bordeaux nord aquitaine, bordeaux, france centre georges francois leclerc; oncologie 3, dijon, france icm; medecine b3, montpellier cedex 5, france centre catherine de sienne, nantes, france aphp - hospital saint louis, paris, france institut jean godinot; oncologie medicale, reims cedex, france onkologische schwerpunktpraxis kurfürstendamm, berlin, germany praxis für interdisziplinäre onkologie und hämatologie gbr, freiburg, germany universitätsklinikum hamburg-eppendorf; frauenklinik, hamburg, germany universitätsklinikum des saarlandes; klinik f. frauenheilkunden und geburtshilfe, homburg/saar, germany praxis dr.med. katja ziegler-löhr, köln, germany dres. andreas köhler und roswitha fuchs, langen, germany mühlenkreiskliniken; johannes wesling klinikum minden; klinik für frauenheilkunde und geburtshilfe, minden, germany oncologianova gmbh - gesellschaft für innovationen in der onkologie, recklinghausen, germany universitätsfrauen- und poliklinik am klinikum suedstadt, rostock, germany universitätsklinikum würzburg; frauenklinik, würzburg, germany anticancer hospital ag savas; 1st dept of internal medicine, athens, greece agioi anargyroi; 3rd dept. of medical oncology, athens, greece euromedical general clinic of thessaloniki; oncology department, thessaloniki, greece orszagos onkologial intezet; onkologiai osztaly x, budapest, hungary borsod-abauj-zemplen megyei korhaz es egyetemi oktato korhaz; onkologiai osztaly, miskolc, hungary szegedi tudomanyegyetem, aok, szent-gyorgyi albert klinikai kozpont, onkoterapias klinika, szeged, hungary hetenyi geza county hospital; onkologiai kozpont, szolnok, hungary zala county hospital icu, zalaegerszeg, hungary indraprastha apollo hospitals, new delhi, delhi, india rajiv gandhi cancer inst.&research center; medical oncology, new delhi, delhi, india istituto nazionale tumori irccs fondazione g. pascale;u.o.c. oncologia medica senologica, napoli, campania, italy azienda ospedaliero-universitaria s.orsola-malpighi; unità operativa oncologia medica, bologna, emilia-romagna, italy irccs centro di riferimento oncologico (cro); dipartimento di oncologia medica, aviano, friuli-venezia giulia, italy ospedale santa maria annunziata; oncologia, bagno a ripoli, toscana, italy iov - istituto oncologico veneto - irccs; oncologia medica ii, padova, veneto, italy aichi cancer center hospital, aichi, japan national cancer center hospital east, chiba, japan national hospital organization kyushu cancer center;breast oncology, fukuoka, japan fukushima medical university hospital, fukushima, japan hyogo college of medicine hospital, hyogo, japan st. marianna university hospital, kanagawa, japan kanagawa cancer center, kanagawa, japan tokai university hospital, kanagawa, japan kumamoto shinto general hospital, kumamoto, japan niigata cancer center hospital, niigata, japan okayama university hospital, okayama, japan national hospital organization osaka national hospital, osaka, japan kinki university hospital, faculty of medicine; surgery, osaka, japan saitama cancer center, breast oncology, saitama, japan shizuoka cancer center, shizuoka, japan national cancer center hospital, tokyo, japan st. luke's international hospital, tokyo, japan the cancer institute hospital of jfcr, tokyo, japan showa university hospital; breast surgery, tokyo, japan national cancer center, goyang-si, korea, republic of inha university hospital, incheon, korea, republic of seoul national university bundang hospital, seongnam-si, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of centro medico dalinde, cdmx, mexico city (federal district), mexico centro médico zambrano hellion, monterrey, nuevo leon, mexico merida   investigacion clinica, mérida, yucatan, mexico consultorio de medicina especializada; dentro de condominio san francisco, mexico city, mexico clinical hospital; oncology department, bitola, north macedonia phi university clinic of radiotherapy and oncology; breast malignancy, skopje, north macedonia phi university clinic of radiotherapy and oncology; malignant diseases of thorax, skopje, north macedonia centro medico monte carmelo, arequipa, peru hospital daniel alcides carrion, callao, peru clínica san gabriel; unidad de investigación oncológica de la clínica san gabriel, lima, peru hospital nacional cayetano heredia; ocología; servicio de hematología oncología médica, lima, peru oncosalud sac; oncología, lima, peru instituto nacional de enfermedades neoplasicas, lima, peru clinica ricardo palma, san isidro, peru instituto regional de enfermedades neoplasicas - iren norte, trujillo, peru narodowy inst.onkol.im.sklodowskiej-curie panstw.inst.bad gliwice; iii klin. radioter. i chemioter., gliwice, poland narodowy instytut onkologii im. m.sklodowskiej-curie; klinika nowotworow piersi i chirurgii rekonstr, warszawa, poland instyt. centrum zdrowia matki polki; klinika chirurgii onk. chorób piersi z podod. onko klinicznej, łódź, poland arkhangelsk regional clinical oncology dispensary, arkhangelsk, arhangelsk, russian federation moscow city oncology hospital #62, moscovskaya oblast, moskovskaja oblast, russian federation blokhin cancer research center; combined treatment, moskva, moskovskaja oblast, russian federation ivanovo regional oncology dispensary, ivanovo, russian federation sbih kaluga region clinical oncology dispensary, kaluga, russian federation clinical oncology dispensary of ministry of health of tatarstan, kazan, russian federation federal state institution, moscow research oncology institute n.a. p.a. hertzen; oncourology, moscow, russian federation fsi rostov research oncological institute of moh and sd of rf; pad, rostov-on-don, russian federation s-pb clinical scientific practical center of specialized kinds of medical care (oncological), saint-petersburg, russian federation national university hospital; national university cancer institute, singapore (ncis), singapore, singapore national cancer centre; medical oncology, singapore, singapore institute of oncology ljubljana, ljubljana, slovenia medical oncology centre of rosebank; oncology, johannesburg, south africa hospital provincial de castellon; servicio de oncologia, castellon de la plana, castellon, spain hospital universitario reina sofia; servicio de oncologia, córdoba, cordoba, spain complejo hospitalario universitario de santiago (chus) ; servicio de oncologia, santiago de compostela, la coruña, spain hospital universitario puerta de hierro; servicio de oncologia, majadahonda, madrid, spain hospital del mar; servicio de oncologia, barcelona, spain vall d´hebron institute of oncology (vhio), barcelona, barcelona, spain hospital clinic barcelona; servicio de oncologia, barcelona, spain hospital de donostia; servicio de oncologia, guipuzcoa, spain hospital ramon y cajal; servicio de oncologia, madrid, spain hospital de madrid norte sanchinarro- centro integral oncologico clara campal; servicio de oncologia, madrid, spain hospital universitario virgen del rocio; servicio de oncologia, sevilla, spain hospital clinico universitario; oncologia, valencia, spain chi mei medical center liou ying campus, liuying township, taiwan koo foundation sun yat-sen cancer center; hemato-oncology, taipei city, taiwan veterans general hospital; department of general surgery, taipei, taiwan national taiwan uni hospital; general surgery, taipei, taiwan ankara city hospital, ankara, turkey dicle uni medical faculty; internal medicine, diyarbakir, turkey medipol university mf; oncology department, istanbul, turkey prof. dr. cemil tascioglu city hospital; med onc, istanbul, turkey katip celebi university ataturk training and research hospital; oncology, izmir, turkey sakarya university medical school; medical oncology, sakarya, turkey chemotherapy si dnipropetrovsk ma of mohu, dnipropetrovsk, ukraine kyiv city clinical oncological center, day hospital department for oncological patients, kiev, ukraine national cancer institute moh of ukraine, kiev, ukraine lviv state oncological regional treatment and diagnostic center, lviv, ukraine velindre cancer centre, cardiff, united kingdom university hospital coventry; oncology department, coventry, united kingdom the beatson west of scotland cancer centre; cancer clinical trials unit, glasgow, united kingdom royal marsden hospital - london, london, united kingdom derriford hospital, plymouth, united kingdom royal stoke university hospital, stoke-on-trent, united kingdom royal marsden hospital; dept of medical oncology, sutton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT03337724,breast
377,378,NCT02941926,study to assess the safety and efficacy of ribociclib (lee011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hr+ her2- abc,COMPLEEMENT-1,"Active, not recruiting",Has Results,breast cancer,drug: ribociclib|drug: letrozole|drug: goserelin|drug: leuprolide,number of participants with adverse events (aes) and serious aes (saes) during treatment with ribociclib + letrozole in the core phase|time-to-progression (ttp) based on investigator's assessment (core phase)|overall response rate (orr) based on investigator's assessment (core phase)|clinical benefit rate (cbr) based on investigator's assessment (core phase)|change from baseline in functional assessment of cancer therapy - breast (fact-b) score (core phase)|number of participants with aes and saes in the extension phase|percentage of participants with clinical benefit (extension phase),novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3246.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011A2404|2016-003467-19,"November 30, 2016","November 8, 2019","September 5, 2022","October 21, 2016","May 9, 2022","May 9, 2022","[""alaska cancer research and education center, anchorage, alaska, united states ironwood cancer and research centers, chandler, arizona, united states arizona oncology associates, phoenix, arizona, united states arizona oncology associates arizona oncology assoc. (2), tucson, arizona, united states highlands oncology group, fayetteville, arkansas, united states beverly hills cancer center, beverly hills, california, united states pacific shores medical group sc, long beach, california, united states usc norris cancer center, los angeles, california, united states university of california irvine uc irvine (11), orange, california, united states ventura county hematology and oncology, oxnard, california, united states pcr oncology, pismo beach, california, united states california pacific medical center onc dept, san francisco, california, united states centura health research center centura health research center, denver, colorado, united states poudre valley hospital poudre valley health system, fort collins, colorado, united states valley view hospital cancer center, glenwood springs, colorado, united states florida cancer research institute dept of oncology, davie, florida, united states foundation for sickle cell disease research, hollywood, florida, united states watson clinic center for research 1730 location, lakeland, florida, united states mid florida hematology and oncology center, orange city, florida, united states summit cancer care summit cancer care (sc), savannah, georgia, united states john d archbold memorial hospital john d. archbold mem hosp (4), thomasville, georgia, united states saint alphonsus regional medical center, boise, idaho, united states stroger cook county hospital division of hematology & onc, chicago, illinois, united states joliet oncology-hematology associates presence cancer center, joliet, illinois, united states mid illinois hematology oncology mid illinois hema/onc (3), normal, illinois, united states alpha med physician group, llc, tinley park, illinois, united states indiana university health goshen center for cancer sc, goshen, indiana, united states northwest oncology, munster, indiana, united states june e. nylan cancer center, sioux city, iowa, united states university of kansas cancer center university of kansas med ctr 9, kansas city, kansas, united states sarah cannon at overland park regional medical center, overland park, kansas, united states john ochsner heart and vascular institute clinical trials, new orleans, louisiana, united states mercy oncology / hematology center sc, portand, maine, united states greater baltimore medical center cancer center greater baltimore medical ctr, baltimore, maryland, united states maryland oncology hematology, p.a. columbia, rockville, maryland, united states kaiser permanente, rockville, maryland, united states medical faculty assc inc medical faculty assc., inc. (2, washington dc, maryland, united states jackson oncology associates, jackson, mississippi, united states nebraska hematology-oncology, p.c., lincoln, nebraska, united states nebraska cancer specialists oncology hematology west, omaha, nebraska, united states comprehensive cancer centers of nevada ccc of nevada henderson (4), las vegas, nevada, united states trinitas comprehensive cancer center, elizabeth, new jersey, united states englewood hospital and medical center, englewood, new jersey, united states the valley hospital / luckow pavillion, paramus, new jersey, united states somerset hematology oncology associates somerset hematolgy onc -mi, somerset, new jersey, united states new mexico cancer care alliance, albuquerque, new mexico, united states san juan oncology associates, farmington, new mexico, united states eastchester center for cancer care, bronx, new york, united states clinical research alliance, lake success, new york, united states oncology speciialists of charlotte, charlotte, north carolina, united states aultman hospital, canton, ohio, united states the christ hospital cancer center research program linder research center, cincinnati, ohio, united states university hospitals of cleveland seidman cancer center cleveland medical center, cleveland, ohio, united states cleveland clinic cleveland clinic (5), cleveland, ohio, united states dayton physicians, kettering, ohio, united states oklahoma cancer specialists and research institute sc-2, tulsa, oklahoma, united states oregon health and science university sc-5, portland, oregon, united states mcleod center for cancer treatment and research, florence, south carolina, united states carolina blood and cancer care of south carolina, rock hill, south carolina, united states northwest cancer ctr millennium oncology - fl, houston, texas, united states cancer therapy and research center ut health science center, san antonio, texas, united states hope cancer center of east texas, tyler, texas, united states virginia oncology associates, norfolk, virginia, united states peacehealth st joseph medical center, bellingham, washington, united states providence regional medical centre of everett, everett, washington, united states kadlec clinic hematology and oncology, kennewick, washington, united states valley medical center research valley medical center, renton, washington, united states virginia mason medical center-oncology sc, seattle, washington, united states northwest medical specialties dept.ofnw med. specialties, tacoma, washington, united states columbia st mary s hospital of milwaukee st. mary's hospital ozaukee, milwaukee, wisconsin, united states cheyenne regional medical center cheyenne regional med ctr (3), cheyenne, wyoming, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, san miguel de tucuman, tucuman, argentina novartis investigative site, la rioja, argentina novartis investigative site, innsbruck, tyrol, austria novartis investigative site, graz, austria novartis investigative site, leoben, austria novartis investigative site, rankweil, austria novartis investigative site, salzburg, austria novartis investigative site, vienna, austria novartis investigative site, vienna, austria novartis investigative site, wien, austria novartis investigative site, sint niklaas, vlaams brabant, belgium novartis investigative site, antwerp, belgium novartis investigative site, bonheiden, belgium novartis investigative site, brugge, belgium novartis investigative site, brussels, belgium novartis investigative site, brussel, belgium novartis investigative site, bruxelles, belgium novartis investigative site, charleroi, belgium novartis investigative site, genk, belgium novartis investigative site, gent, belgium novartis investigative site, hasselt, belgium novartis investigative site, kortrijk, belgium novartis investigative site, leuven, belgium novartis investigative site, liege, belgium novartis investigative site, luxembourg, belgium novartis investigative site, mons, belgium novartis investigative site, namur, belgium novartis investigative site, roeselare, belgium novartis investigative site, verviers, belgium novartis investigative site, wilrijk, belgium novartis investigative site, gabrovo, bulgaria novartis investigative site, plovdiv, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, calgary, alberta, canada novartis investigative site, edmonton, alberta, canada novartis investigative site, kelowna, british columbia, canada novartis investigative site, surrey, british columbia, canada novartis investigative site, vancouver, british columbia, canada novartis investigative site, winnipeg, manitoba, canada novartis investigative site, moncton, new brunswick, canada novartis investigative site, halifax, nova scotia, canada novartis investigative site, barrie, ontario, canada novartis investigative site, cambridge, ontario, canada novartis investigative site, hamilton, ontario, canada novartis investigative site, kingston, ontario, canada novartis investigative site, kitchener, ontario, canada novartis investigative site, london, ontario, canada novartis investigative site, newmarket, ontario, canada novartis investigative site, north york, ontario, canada novartis investigative site, oshawa, ontario, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, sault ste marie, ontario, canada novartis investigative site, sudbury, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, greenfield park, quebec, canada novartis investigative site, laval, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, sherbrooke, quebec, canada novartis investigative site, regina, saskatchewan, canada novartis investigative site, saskatoon, saskatchewan, canada novartis investigative site, quebec, canada novartis investigative site, santiago, chile novartis investigative site, brno, czech republic, czechia novartis investigative site, liberec, czech republic, czechia novartis investigative site, prague 8, czech republic, czechia novartis investigative site, zlin, czech republic, czechia novartis investigative site, hradec kralove, cze, czechia novartis investigative site, olomouc, cze, czechia novartis investigative site, brno, czechia novartis investigative site, ceske budejovice, czechia novartis investigative site, pardubice, czechia novartis investigative site, prague 5, czechia novartis investigative site, praha 10, czechia novartis investigative site, praha 4, czechia novartis investigative site, praha, czechia novartis investigative site, copenhagen, denmark novartis investigative site, vejle, denmark novartis investigative site, helsinki, finland novartis investigative site, oulu, finland novartis investigative site, tampere, finland novartis investigative site, nice cedex 2, alpes maritimes, france novartis investigative site, dijon cedex, cote d or, france novartis investigative site, limoges cedex, haute vienne, france novartis investigative site, saint-cloud, hauts de seine, france novartis investigative site, tours cedex 9, indre et loire, france novartis investigative site, reims cedex, marne, france novartis investigative site, albi, france novartis investigative site, angers cedex 02, france novartis investigative site, avignon cedex, france novartis investigative site, besancon cedex, france novartis investigative site, bobigny cedex, france novartis investigative site, bordeaux cedex, france novartis investigative site, bordeaux, france novartis investigative site, caen cedex, france novartis investigative site, clermont-ferrand, france novartis investigative site, colmar cedex, france novartis investigative site, corbeil essonnes, france novartis investigative site, creteil, france novartis investigative site, le mans cedex, france novartis investigative site, lille cedex, france novartis investigative site, limoges, france novartis investigative site, lyon cedex 08, france novartis investigative site, lyon cedex, france novartis investigative site, marseille, france novartis investigative site, mont de marsan cedex, france novartis investigative site, montpellier cedex 5, france novartis investigative site, montpellier, france novartis investigative site, nancy, france novartis investigative site, nantes cedex, france novartis investigative site, paris cedex 10, france novartis investigative site, paris cedex 13, france novartis investigative site, paris, france novartis investigative site, paris, france novartis investigative site, paris, france novartis investigative site, pierre benite cedex, france novartis investigative site, plerin sur mer, france novartis investigative site, périgueux cédex, france novartis investigative site, reims, france novartis investigative site, rouen cedex 1, france novartis investigative site, saint herblain cedex, france novartis investigative site, strasbourg cedex, france novartis investigative site, strasbourg cedex, france novartis investigative site, toulon la seyne sur mer, france novartis investigative site, troyes, france novartis investigative site, vandoeuvre-les-nancy cedex, france novartis investigative site, ioannina, gr, greece novartis investigative site, thessaloniki, gr, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, patras, greece novartis investigative site, thessaloniki, greece novartis investigative site, hong kong, hong kong novartis investigative site, kowloon, hong kong novartis investigative site, pokfulam, hong kong novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, szeged, hungary novartis investigative site, hyderabad, andhra pradesh, india novartis investigative site, tamil nadu, chennai, india novartis investigative site, new delhi, delhi, india novartis investigative site, admedabad, gujarat, india novartis investigative site, bangalore, karnataka, india novartis investigative site, nashik, maharashtra, india novartis investigative site, pune, maharashtra, india novartis investigative site, jaipur, rajasthan, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, kolkata, west bengal, india novartis investigative site, delhi, india novartis investigative site, beer-sheva, israel novartis investigative site, haifa, israel novartis investigative site, jerusalem, israel novartis investigative site, petach tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, tel aviv, israel novartis investigative site, alessandria, al, italy novartis investigative site, ancona, an, italy novartis investigative site, l'aquila, aq, italy novartis investigative site, arezzo, ar, italy novartis investigative site, asti, at, italy novartis investigative site, avellino, av, italy novartis investigative site, bari, ba, italy novartis investigative site, bergamo, bg, italy novartis investigative site, treviglio, bg, italy novartis investigative site, benevento, bn, italy novartis investigative site, bologna, bo, italy novartis investigative site, bologna, bo, italy novartis investigative site, brindisi, br, italy novartis investigative site, brescia, bs, italy novartis investigative site, brescia, bs, italy novartis investigative site, monserrato, ca, italy novartis investigative site, cuneo, cn, italy novartis investigative site, cremona, cr, italy novartis investigative site, catania, ct, italy novartis investigative site, cona, fe, italy novartis investigative site, san giovanni rotondo, fg, italy novartis investigative site, firenze, fi, italy novartis investigative site, genova, ge, italy novartis investigative site, grosseto, gr, italy novartis investigative site, lecco, lc, italy novartis investigative site, livorno, li, italy novartis investigative site, lucca, lu, italy novartis investigative site, monza, mb, italy novartis investigative site, macerata, mc, italy novartis investigative site, messina, me, italy novartis investigative site, taormina, me, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, rozzano, mi, italy novartis investigative site, modena, mo, italy novartis investigative site, nuoro, nu, italy novartis investigative site, palermo, pa, italy novartis investigative site, palermo, pa, italy novartis investigative site, padova, pd, italy novartis investigative site, pisa, pi, italy novartis investigative site, aviano, pn, italy novartis investigative site, prato, po, italy novartis investigative site, parma, pr, italy novartis investigative site, fano, pu, italy novartis investigative site, pavia, pv, italy novartis investigative site, reggio calabria, rc, italy novartis investigative site, reggio emilia, re, italy novartis investigative site, roma, rm, italy novartis investigative site, roma, rm, italy novartis investigative site, roma, rm, italy novartis investigative site, roma, rm, italy novartis investigative site, roma, rm, italy novartis investigative site, salerno, sa, italy novartis investigative site, siena, si, italy novartis investigative site, sassari, ss, italy novartis investigative site, savona, sv, italy novartis investigative site, trento, tn, italy novartis investigative site, candiolo, to, italy novartis investigative site, torino, to, italy novartis investigative site, terni, tr, italy novartis investigative site, udine, ud, italy novartis investigative site, saronno, va, italy novartis investigative site, mirano, ve, italy novartis investigative site, negrar, vr, italy novartis investigative site, verona, vr, italy novartis investigative site, viterbo, vt, italy novartis investigative site, napoli, italy novartis investigative site, napoli, italy novartis investigative site, novara, italy novartis investigative site, amman, jordan novartis investigative site, ashrafieh, lebanon novartis investigative site, beirut, lebanon novartis investigative site, saida, lebanon novartis investigative site, tanjong bungah, penang, malaysia novartis investigative site, petaling jaya, selangor, malaysia novartis investigative site, kuala lumpur, wilayah persekutuan, malaysia novartis investigative site, putrajaya, wilayah persekutuan, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, monterrey, nuevo león, mexico novartis investigative site, ciudad de mexico, mexico novartis investigative site, mexico city, mexico novartis investigative site, maastricht, az, netherlands novartis investigative site, venray, ce, netherlands novartis investigative site, apeldoorn, dz, netherlands novartis investigative site, arnhem, netherlands novartis investigative site, beverwijk, netherlands novartis investigative site, breda, netherlands novartis investigative site, delft, netherlands novartis investigative site, den bosch, netherlands novartis investigative site, den haag, netherlands novartis investigative site, dordrecht, netherlands novartis investigative site, ede, netherlands novartis investigative site, eindhoven, netherlands novartis investigative site, enschede, netherlands novartis investigative site, goes, netherlands novartis investigative site, groningen, netherlands novartis investigative site, hilversum, netherlands novartis investigative site, hoofddorp, netherlands novartis investigative site, leeuwarden, netherlands novartis investigative site, roermond, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, sittard-geleen, netherlands novartis investigative site, utrecht, netherlands novartis investigative site, zutphen, netherlands novartis investigative site, zwolle, netherlands novartis investigative site, gralum, norway novartis investigative site, oslo, norway novartis investigative site, oslo, norway novartis investigative site, stavanger, norway novartis investigative site, muscat, oman novartis investigative site, panama city, panama novartis investigative site, taguig city, metro manila, philippines novartis investigative site, las pinas, philippines novartis investigative site, san juan city, philippines novartis investigative site, zory, slaskie, poland novartis investigative site, bydgoszcz, poland novartis investigative site, bytom, poland novartis investigative site, gdansk, poland novartis investigative site, krakow, poland novartis investigative site, lublin, poland novartis investigative site, opole, poland novartis investigative site, rzeszow, poland novartis investigative site, warszawa, poland novartis investigative site, wroclaw, poland novartis investigative site, braga, portugal novartis investigative site, guimaraes, portugal novartis investigative site, lisboa, portugal novartis investigative site, lisboa, portugal novartis investigative site, lisboa, portugal novartis investigative site, lisboa, portugal novartis investigative site, porto, portugal novartis investigative site, porto, portugal novartis investigative site, porto, portugal novartis investigative site, leningrad region, russia, russian federation novartis investigative site, kazan, tatarstan republic, russian federation novartis investigative site, chelyabinsk, russian federation novartis investigative site, irkutsk, russian federation novartis investigative site, kaluga, russian federation novartis investigative site, krasnoyarsk, russian federation novartis investigative site, moscow rerion balashiha, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, rostov-na-donu, russian federation novartis investigative site, samara, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, ufa, russian federation novartis investigative site, yaroslavl, russian federation novartis investigative site, dammam, saudi arabia novartis investigative site, makkah, saudi arabia novartis investigative site, riyadh, saudi arabia novartis investigative site, riyadh, saudi arabia novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, banska bystrica, slovak republic, slovakia novartis investigative site, kosice, slovakia novartis investigative site, poprad, slovakia novartis investigative site, ljubljana, slovenia novartis investigative site, maribor, slovenia novartis investigative site, elche, alicante, spain novartis investigative site, almeria, andalucia, spain novartis investigative site, cordoba, andalucia, spain novartis investigative site, granada, andalucia, spain novartis investigative site, huelva, andalucia, spain novartis investigative site, jaen, andalucia, spain novartis investigative site, malaga, andalucia, spain novartis investigative site, sevilla, andalucia, spain novartis investigative site, sevilla, andalucia, spain novartis investigative site, sevilla, andalucia, spain novartis investigative site, sabadell, barcelona, spain novartis investigative site, jerez, cadiz, spain novartis investigative site, toledo, castilla la mancha, spain novartis investigative site, salamanca, castilla y leon, spain novartis investigative site, lerida, cataluna, spain novartis investigative site, badalona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, girona, catalunya, spain novartis investigative site, hospitalet de llobregat, catalunya, spain novartis investigative site, barcelona, cataluña, spain novartis investigative site, alicante, comunidad valenciana, spain novartis investigative site, alicante, comunidad valenciana, spain novartis investigative site, castellon, comunidad valenciana, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, badajoz, extremadura, spain novartis investigative site, caceres, extremadura, spain novartis investigative site, la coruna, galicia, spain novartis investigative site, santiago de compostela, galicia, spain novartis investigative site, palma de mallorca, islas baleares, spain novartis investigative site, las palmas de gran canarias, las palmas de gran canaria, spain novartis investigative site, el palmar, murcia, spain novartis investigative site, pamplona, navarra, spain novartis investigative site, bilbao, pais vasco, spain novartis investigative site, san sebastian, pais vasco, spain novartis investigative site, vigo, pontevedra, spain novartis investigative site, la laguna, santa cruz de tenerife, spain novartis investigative site, reus, tarragona, spain novartis investigative site, barcelona, spain novartis investigative site, burgos, spain novartis investigative site, granollers, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, murcia, spain novartis investigative site, valencia, spain novartis investigative site, zaragoza, spain novartis investigative site, gothenburg, sweden novartis investigative site, orebro, sweden novartis investigative site, stockholm, sweden novartis investigative site, uppsala, sweden novartis investigative site, vaxjo, sweden novartis investigative site, taichung, taiwan novartis investigative site, tainan, taiwan novartis investigative site, taipei, taiwan novartis investigative site, songkhla, hat yai, thailand novartis investigative site, khon kaen, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, chiang mai, thailand novartis investigative site, peterborough, cambridgeshire, united kingdom novartis investigative site, truro, cornwall, united kingdom novartis investigative site, portsmouth, hants, united kingdom novartis investigative site, maidstone, kent, united kingdom novartis investigative site, york, north yorkshire, united kingdom novartis investigative site, aberdeen, scotland, united kingdom novartis investigative site, ipswich, suffolk, united kingdom novartis investigative site, guildford, surrey, united kingdom novartis investigative site, sutton, surrey, united kingdom novartis investigative site, bristol, united kingdom novartis investigative site, cardiff, united kingdom novartis investigative site, east sussex, united kingdom novartis investigative site, edinburgh, united kingdom novartis investigative site, exeter, united kingdom novartis investigative site, glasgow, united kingdom novartis investigative site, leeds, united kingdom novartis investigative site, leicester, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, manchester, united kingdom novartis investigative site, newcastle upon tyne, united kingdom novartis investigative site, nottingham, united kingdom novartis investigative site, oxford, united kingdom novartis investigative site, plymouth, united kingdom novartis investigative site, preston, united kingdom novartis investigative site, sheffield, united kingdom novartis investigative site, stoke-on-trent, united kingdom""]","""study protocol"", https://clinicaltrials.gov/provideddocs/26/nct02941926/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/26/nct02941926/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02941926,breast
378,379,NCT03763604,named patient use program to provide abemaciclib (ly2835219) for the treatment of metastatic breast cancer,,Available,No Results Available,metastatic breast cancer,drug: abemaciclib,,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",,,Industry,Expanded Access:Individual Patients,,17088|I3Y-MC-Y001,,,,"December 4, 2018",,"May 5, 2022","[""liverpool hospital, liverpool, new south wales, australia liverpool hospital, liverpool, new south wales, australia mater private hospital, north sydney, new south wales, australia north west cancer centre, north tamworth, new south wales, australia st vincent's hospital sydney, sydney, new south wales, australia st vincent's hospital sydney, sydney, new south wales, australia st vincent's hospital sydney, sydney, new south wales, australia westmead hospital, westmead, new south wales, australia wollongong hospital, wollongong, new south wales, australia royal adelaide hospital, adelaide, south australia, australia adelaide oncology and haematology, calvary central districts hospital, elizabeth vale, south australia, australia icon cancer centre - hobart, hobart, tasmania, australia royal hobart hospital, hobart, tasmania, australia box hill hospital outpatients, box hill, victoria, australia epworth eastern hospital, box hill, victoria, australia melbourne cancer care, brighton, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia dr. zimet private room, richmond, victoria, australia slade pharmacy epworth hospital, richmond, victoria, australia goulburn valley health, shepparton, victoria, australia goulburn valley health, shepparton, victoria, australia icon cancer care - the wesley medical centre, auchenflower, australia northern beaches hospital, freches forest, australia northern beaches hospital, freches forest, australia northern beaches hospital, freches forest, australia south coast district hospital, victor harbor, australia tom baker cancer center, calgary, alberta, canada tom baker cancer center, calgary, alberta, canada tom baker cancer center, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada bc cancer vancouver, vancouver, british columbia, canada british columbia cancer agency - vancouver island, victoria, british columbia, canada british columbia cancer agency - vancouver island, victoria, british columbia, canada british columbia cancer agency - vancouver island, victoria, british columbia, canada grand river regional cancer centre, kitchener, ontario, canada the ottawa hospital, ottawa, ontario, canada the ottawa hospital, ottawa, ontario, canada algoma district cancer program, sault ste. marie, ontario, canada unity health toronto, st. michael's hospital, toronto, ontario, canada chul du chu de québec, québec city, quebec, canada allan blair cancer centre, regina, saskatchewan, canada saskatoon cancer centre, saskatoon, saskatchewan, canada cairo oncology center (cairo cure), mohandeseen, cairo, egypt apollo cancer institute, apollo speciality hospital, teynampet, chennai, india indraprastha apollo hospital, new delhi, india azienda ospedaliera universitaria policlinico tor vergata, torre, roma, italy istituto oncologico veneto irccs, padova, veneto, italy ospedale di circolo e fondazione macchi, varese, italy national cancer center, ilsandong-gu, goyang-si gyeonggi-do, korea, republic of national cancer center, ilsandong-gu, goyang-si gyeonggi-do, korea, republic of national cancer center, goyang-si, gyeonggi-do, korea, republic of inha university hospital, incheon, incheon-gwangyeoksi [incheon], korea, republic of st. mary's hospital, gyeonggi-do, korea, korea, republic of st. mary's hospital, gyeonggi-do, korea, korea, republic of gachon university gil hospital, namdong-gu, incheon, korea, korea, republic of gachon university gil hospital, namdong-gu, incheon, korea, korea, republic of seoul st. mary's hospital, seoul, korea, korea, republic of national cancer center, goyang-si, kyǒnggi-do, korea, republic of seoul national university hospital, seoul, seoul, korea, korea, republic of seoul national university hospital, seoul, seoul, korea, korea, republic of seoul national university hospital, seoul, seoul, korea, korea, republic of severance hospital, yonsei university health system, seoul, seoul-teukbyeolsi [seoul], korea, republic of samsung medical center, seoul, seoul-teukbyeolsi [seoul], korea, republic of samsung medical center, seoul, seoul-teukbyeolsi [seoul], korea, republic of samsung medical center, seoul, seoul-teukbyeolsi [seoul], korea, republic of ewha university mokdong hospital, seoul, yangcheon-gu, korea, republic of chungbuk national university hospital, chungcheongbuk-do, korea, republic of kyungpook national university medical center chilgok hospital, daegu, korea, republic of korea university anam hospital, seoul, korea, republic of korea university anam hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of gangnam severance hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of pantai hospital sungai petani, sungai petani, kedah, malaysia gleneagles penang, georgetown, penang, malaysia penang adventist hospital, georgetown, penang, malaysia penang adventist hospital, georgetown, penang, malaysia mount miriam cancer hospital, tanjung bungah, penang, malaysia mount miriam cancer hospital, tanjung bungah, penang, malaysia beacon hospital, off jalan templer, petaling jaya, malaysia beacon hospital, off jalan templer, petaling jaya, malaysia pantai hospital penang, bayan baru, pulau pinang, malaysia loh guan lye specialists' centre, georgetown, pulau pinang, malaysia hospital umum sarawak, kuching, sarawak, malaysia subang jaya medical centre, petaling jaya, selangor, malaysia pantai hospital kuala lumpur, kuala lumpur, wilayah persekutuan, malaysia pantai hospital kuala lumpur, kuala lumpur, wilayah persekutuan, malaysia hospital kuala lumpur, kuala lumpur, malaysia universiti malaya medical centre, kuala lumpur, malaysia university malaya medical centre, kuala lumpur, malaysia institut kanser negara, putrajaya, malaysia elizabeth au oncology, singapore, singapore vincent pallotti hospital, pinelands, cape town, south africa flora clinic, floracliff, gauteng, south africa olivedale clinic, johannesburg, gauteng, south africa netcare linksfield hospital, johannesburg, gauteng, south africa donald gordon medical center, johannesburg, gauteng, south africa donald gordon medical center, johannesburg, gauteng, south africa wits donald gordon clinical trial center, johannesburg, gauteng, south africa the medical oncology centre of rosebank, johannesburg, gauteng, south africa the medical oncology centre of rosebank, johannesburg, gauteng, south africa sandton oncology, morningside, gauteng, south africa dgmc oncology, parktown, gauteng, south africa amanzimtoti oncology centre, durban, kwazulu-natal, south africa hopelands cancer centre hilton, hilton, kzn, south africa hopelands cancer centre hilton, hilton, kzn, south africa abraham oncology, richards bay, kzn, south africa gvi oncology, george, western cape, south africa dr pirjol and szpak inc. oncology pratice, amanzimtoti, south africa cancercare rondebosch oncology, cape town, south africa hospital virgen de los lirios, alcoy, alicante, spain hospital universitario puerta del mar, cádiz, andalucía, spain hospital universitario virgen de la victoria, malaga, andalucía, spain hospital universitari vall d'hebron, barcelona, barcelona [barcelona], spain hospital universitari vall d'hebron, barcelona, barcelona [barcelona], spain hospital universitari vall d'hebron, barcelona, barcelona [barcelona], spain hospital universitari vall d'hebron, barcelona, barcelona [barcelona], spain hospital universitari general de catalunya, sant cugat del vallès, barcelona [barcelona], spain hospital universitari de girona dr. josep trueta, girona, barcelona, spain hospital duran i reynals, hospitalet de llobregat, barcelona, spain hospital duran i reynals, hospitalet de llobregat, barcelona, spain hospital duran i reynals, hospitalet de llobregat, barcelona, spain institut catala d'oncologia, l'hospitalet de llobregat, barcelona, spain institut catala d'oncologia, l'hospitalet de llobregat, barcelona, spain corporacion sanitaria parc tauli, sabadell, barcelona, spain corporacion sanitaria parc tauli, sabadell, barcelona, spain corporacion sanitaria parc tauli, sabadell, barcelona, spain hospital germans trias i pujol, badalona, catalunya [cataluña], spain hospital germans trias i pujol, badalona, catalunya [cataluña], spain hospital universitario de canarias, tenerife, la laguna, spain hospital universitario de canarias, tenerife, la laguna, spain hospital universitario de canarias, tenerife, la laguna, spain hospital universitario ramón y cajal, madrid, madrid, comunidad de, spain hospital la zarzuela, aravaca, madrid, spain hospital de mostoles, mostoles, madrid, spain hospital de mostoles, mostoles, madrid, spain hospital universitario virgen de la arrixaca, el palmar, murcia, spain hospital universitario son espases, palma de mallorca, palma de mallorca(baleares), spain h. san francisco de borja (h. gandia), gandia, valencia, spain hospital lluis alcanyis, xativa, valencia, spain hospital de basurto, bilbao, vizcaya, spain hospital general de albacete, albacete, spain hospital quironsalud barcelona- end, barcelona, spain hospital quirón salud barcelona-instituto oncológico baselga, barcelona, spain hospital quirón salud barcelona-instituto oncológico baselga, barcelona, spain hospital universitari dexeusa, barcelona, spain instituto oncologico dr rosell (ior), barcelona, spain hospital universitari vall d'hebron, barcelona, spain hospital arquitecto marcide (área sanitaria de ferrol), coruña, spain hospital universitario san cecilio, granada, spain hospital universitario san cecilio, granada, spain cl. universitaria navarra, madrid, spain centro oncológico md anderson, madrid, spain hospital ruber internacional, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital madrid norte sanchinarro, madrid, spain hospital madrid norte sanchinarro, madrid, spain hospital infanta cristina, madrid, spain hospital universitario de salamanca - complejo asistencial universitario de salamanca, salamanca, spain hospital universitario de salamanca - complejo asistencial universitario de salamanca, salamanca, spain fundación instituto valenciano de oncología, valencia, spain fundación instituto valenciano de oncología, valencia, spain fundación instituto valenciano de oncología, valencia, spain fundación instituto valenciano de oncología, valencia, spain hospital clinico universitario valencia, valencia, spain hospital clínico universitario de valencia, valencia, spain hospital arnau de vilanova valencia, valencia, spain hospital doctor peset, valencia, spain hospital de sagunto, valencia, spain idcq hospitales y sanidad, s.l.u. (hospital quirón zaragoza), zaragoza, spain hospital universitario miguel servet, zaragoza, spain hospital universitario miguel servet, zaragoza, spain hospital universitario miguel servet, zaragoza, spain hospital universitario zaragoza, zaragoza, spain hospital universitario zaragoza, zaragoza, spain universitätsspital basel, basel, basel stadt, switzerland hôpital de la tour, la tour hôpital privé sa, meyrin, geneva, switzerland tumorzentrum zetup rapperswil-jona, rapperswil, saint gallen, switzerland tumor- und brustzentrum zetup sankt gallen, st. gallen, saint gallen, switzerland cantonal hospital st.gallen, st.gallen, sankt gallen, switzerland oncologia varini calderoni christinat, lugano, ticino, switzerland hôpitaux universitaires de genève, geneva, switzerland hug-hôpitaux universitaires de genève, genève, switzerland luzerner kantonsspital, luzern, switzerland onkozentrum zürich ag, zürich, switzerland onkozentrum zürich ag, zürich, switzerland chiayi chang gung memorial hospital, putzu city, chiayi county, taiwan chiayi chang gung memorial hospital, putzu city, chiayi county, taiwan chiayi chang gung memorial hospital, putzu city, chiayi county, taiwan kaohsiung chang gung memorial hospital, niaosong dist, kaohsiung city, taiwan tri-service general hospital, taipei city, taipei, taiwan national taiwan university hospital yunlin branch, zhongzheng district, taipei, taiwan national taiwan university hospital yunlin branch, zhongzheng district, taipei, taiwan mackay memorial hospital, new taipei city, tamsui district, taiwan taichung tzu chi hospital, taichung, tanzi district, taiwan saint paul's hospital, taoyuan, taoyuan district, taiwan kaohsiung municipal siaogang hospital, kaohsiung city, taiwan kaohsiung medical university hospital, kaohsiung, taiwan china medical university hospital, taichung, taiwan china medical university hospital, taichung, taiwan china medical university hospital, taichung, taiwan china medical university hospital, taichung, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan taipei veterans general hospital, taipei city, taiwan national taiwan university hospital, taipei, taiwan national taiwan university hospital, taipei, taiwan national taiwan university hospital, taipei, taiwan national taiwan university hospital, taipei, taiwan mackay memorial hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan koo foundation sun yan-sen cancer center, taipei, taiwan far eastern memorial hospital, taipei, taiwan far eastern memorial hospital, taipei, taiwan national taiwan university hospital yunlin branch, yunlin county, douliu city, taiwan maharaj nakorn chiang mai hospital, muang chiangmai, chiangmai, thailand rajavithi hospital, bangkok, ratchathewi district, thailand songklanagarind hospital, hat yai, songkhla, thailand king chulalongkorn memoiral hospsital, bangkok, thailand ramathibodi hopsital, bangkok, thailand addenbrookes hospital, cambridge, cambridgeshire, united kingdom loom dene, radlett, hertfordshire, united kingdom northern centre for cancer treatment, newcastle upon tyne, tyne and wear, united kingdom""]",,https://ClinicalTrials.gov/show/NCT03763604,breast
379,380,NCT00399035,"cediranib (azd2171, recentin™) in addition to chemotherapy in patients with untreated metastatic colorectal cancer",HORIZON II,Completed,Has Results,metastatic colorectal cancer,"drug: cediranib|drug: folfox (5-fluorouracil, leucovorin, oxaliplatin)|drug: xelox (capecitabine and oxaliplatin)|drug: cediranib placebo",progression-free survival|overall survival|overall response rate|best percentage change in tumour size|duration of response|rate of resection of liver metastases|time to wound healing complications,astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,1254.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D8480C00051|EUDRACT No 2006-001194-14|HORIZON II,November 2006,March 2010,August 2016,"November 14, 2006","October 30, 2012","December 28, 2016","['research site, buenos aires city, argentina research site, capital federal, argentina research site, ciudad de buenos aires, argentina research site, córdoba, argentina research site, resistencia, argentina research site, rosario, argentina research site, santa fe, argentina research site, ashford, australia research site, camperdown, australia research site, heidelberg, australia research site, hornsby, australia research site, liverpool, australia research site, waratah, australia research site, wodonga, australia research site, curitiba, brazil research site, goiânia, brazil research site, jaú, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, salvador, brazil research site, santo andré, brazil research site, sao paulo, brazil research site, são paulo, brazil research site, plovdiv, bulgaria research site, sofia, bulgaria research site, stara zagora, bulgaria research site, varna, bulgaria research site, veliko tarnovo, bulgaria research site, vratza, bulgaria research site, beijing, china research site, changchun, china research site, chengdu, china research site, chongqing, china research site, fuzhou, china research site, guangzhou, china research site, hangzhou, china research site, nanjing, china research site, nanning, china research site, shanghai, china research site, tianjin, china research site, brno, czech republic research site, ceske budejovice, czech republic research site, cheb, czech republic research site, jicin, czech republic research site, jihlava, czech republic research site, olomouc, czech republic research site, ostrava, czech republic research site, praha 6, czech republic research site, pribram - zdabor, czech republic research site, sumperk, czech republic research site, zlin, czech republic research site, znojmo, czech republic research site, essen, germany research site, freiburg, germany research site, goslar, germany research site, hamburg, germany research site, hildesheim, germany research site, mannheim, germany research site, budapest, hungary research site, debrecen, hungary research site, györ, hungary research site, kecskemét, hungary research site, nyíregyháza, hungary research site, szombathely, hungary research site, zalaegerszeg, hungary research site, hyderabad, india research site, trivandrum, india research site, goyang-si, korea, republic of research site, seoul, korea, republic of research site, cebu city, philippines research site, davao city, philippines research site, iloilo, philippines research site, quezon city, philippines research site, quezon, philippines research site, bydgoszcz, poland research site, gdańsk, poland research site, gliwice, poland research site, kraków, poland research site, olsztyn, poland research site, toruń, poland research site, wrocław, poland research site, bellinzona, switzerland research site, lausanne, switzerland research site, locarno, switzerland research site, zürich, switzerland research site, tainan, taiwan research site, taipei, taiwan research site, aberdeen, united kingdom research site, belfast, united kingdom research site, leicester, united kingdom research site, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00399035,colon
380,381,NCT00725387,combined f-18 naf and f-18 fdg pet/ct for evaluation of malignancy,,Completed,No Results Available,neoplasms,,percent of patients with evidence of new lesions on combined f-18/f-18 fdg pet/ct.,stanford university,All,"18 Years and older   (Adult, Older Adult)",,214.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,VAR0024|98043|SU-07232008-1266,August 2007,December 2018,June 2019,"July 30, 2008",,"September 18, 2019","['stanford university school of medicine, stanford, california, united states aalborg hospital, aalborg, denmark apollo hospital, chennai, india coimbra university hospital, coimbra, portugal pretoria academic hospital, pretoria, south africa']",,https://ClinicalTrials.gov/show/NCT00725387,
381,382,NCT01183780,a study in second line metastatic colorectal cancer,,Completed,Has Results,colorectal cancer,biological: ramucirumab|biological: placebo|drug: irinotecan|drug: folinic acid|drug: 5-fluorouracil,overall survival (os)|progression-free survival (pfs) time|percentage of participants achieving an objective response (objective response rate)|change from baseline in european organisation for research and treatment of cancer [eortc] qlq-c30 global health status|change from baseline in euroqol- 5d (eq-5d)|percentage of participants with treatment-emergent anti-ramucirumab antibodies|observed maximum concentration (cmax) and observed minimum concentration (cmin) of ramucirumab,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1072.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13856|I4T-MC-JVBB|CP12-0920|2010-021037-32|CTRI/2011/07/001900,"December 2, 2010","July 17, 2014","June 20, 2016","August 18, 2010","July 15, 2015","September 25, 2019","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sedona, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tucson, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fayetteville, arkansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., little rock, arkansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., duarte, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., escondido, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fresno, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., greenbrae, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., la jolla, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rancho cucamonga, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san diego, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., denver, colorado, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., waterbury, connecticut, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., boynton beach, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fort lauderdale, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fort myers, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., miami, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ocala, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., port saint lucie, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint petersburg, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., titusville, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., augusta, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., macon, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., marietta, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., thomasville, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., honolulu, hawaii, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., harvey, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., peoria, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., warrenville, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., goshen, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., indianapolis, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., muncie, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bethesda, maryland, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbia, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., billings, montana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., las vegas, nevada, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cherry hill, new jersey, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hackensack, new jersey, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., morristown, new jersey, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., albuquerque, new mexico, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bronx, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hudson, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., jamaica, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new york, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., raleigh, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cincinnati, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbus, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tulsa, oklahoma, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bend, oregon, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., portland, oregon, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kingston, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., philadelphia, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., willow grove, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbia, south carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nashville, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., abilene, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., arlington, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beaumont, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bedford, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dallas, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., denton, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., flower mound, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fort worth, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., garland, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mcallen, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., odessa, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., paris, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., round rock, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san antonio, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sherman, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sugar land, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., temple, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., the woodlands, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tyler, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., waco, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., webster, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita falls, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ogden, utah, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., salt lake city, utah, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fairfax, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., newport news, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., richmond, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., winchester, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kennewick, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seattle, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., spokane valley, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., milwaukee, wisconsin, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., buenos aires, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., caba, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rosario, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa fe, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tucumain, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., viedma, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liverpool, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., randwick, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., st. leonards, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wodonga, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wollongong, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., woolloongabba, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bedford park, south australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., elizabeth vale, south australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., innsbruck, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., krems, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vienna, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bonheiden, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brussels, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., charleroi, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edegem, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., haine-st.- paul, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., leuven, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liège, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ijui, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., itajai, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rio de janeiro, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., salvador, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sao jose do rio preto, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., são paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brno, czechia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pardubice, czechia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., prague, czechia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., copenhagen, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., odense, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., helsinki, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tampere, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bordeaux, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., la chaussee saint victor, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., le mans, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nantes, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., paris, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poitiers, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., strasbourg, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., augsburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., balingen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bamberg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dresden, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankfurt, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., halle, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hamburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lübeck, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., munich, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mönchengladbach, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., weiden, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chania, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ioannina, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., budapest, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kecskemet, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kochin, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kolkata, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beer sheva, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., haifa, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tel hashomer, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tel-aviv, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., genova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., livorno, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., macerata, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., padova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., reggio emilia, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aichi, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chiba, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ehime, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fukuoka, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gifu, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hokkaido, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hyogo, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kanagawa, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kochi, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., osaka, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saitama, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shizuoka, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tochigi, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tokyo, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., anyang, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., goyang-si, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., incheon, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., suwon-city, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., breda, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., deventer, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., eindhoven, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., groningen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sittard - geleen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., coimbra, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., porto, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bayamon, puerto rico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bucharest, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cluj-napoca, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., iasi, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oradea, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ljubljana, slovenia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., barcelona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oviedo, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pamplona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sabadell, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sevilla, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., valencia, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., stockholm, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., uppsala, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kaohsiung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kuei shan hsiang, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taichung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tainan, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan']",,https://ClinicalTrials.gov/show/NCT01183780,colon
382,383,NCT04232384,"comparison of ""roll-over' technique with standard abdominal paracentesis in suspected peritoneal carcinomatosis",ROLLON,Terminated,No Results Available,ascites|peritoneal carcinomatosis|peritoneum neoplasm|tuberculous peritonitis,procedure: standard paracentesis|procedure: roll over paracentesis,yield of malignant cells|cellularity of the smear of the smear,postgraduate institute of medical education and research,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,71.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,NK/6111/DM/055,"June 15, 2020","July 1, 2021","July 1, 2021","January 18, 2020",,"March 17, 2022","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT04232384,
383,384,NCT00076024,ag-013736 in combination with docetaxel versus docetaxel alone for patients with metastatic breast cancer,,Completed,Has Results,breast neoplasms,drug: placebo|drug: docetaxel|drug: ag-013736 (axitinib),time to tumor progression (ttp)|percentage of participants with objective response (or) for phase 2 (double-blind)|percentage of participants with objective response (or) for phase 2 (open-label)|duration of response (dr) for phase 2 (double-blind)|duration of response (dr) for phase 2 (open-label),pfizer,Female,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,174.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A4061010,February 2004,January 2007,November 2008,"January 14, 2004","March 16, 2012","June 26, 2012","['pfizer investigational site, tucson, arizona, united states pfizer investigational site, tucson, arizona, united states pfizer investigational site, berkeley, california, united states pfizer investigational site, montebello, california, united states pfizer investigational site, monterey park, california, united states pfizer investigational site, san francisco, california, united states pfizer investigational site, san gabriel, california, united states pfizer investigational site, whittier, california, united states pfizer investigational site, jacksonville beach, florida, united states pfizer investigational site, jacksonville, florida, united states pfizer investigational site, jacksonville, florida, united states pfizer investigational site, jacksonville, florida, united states pfizer investigational site, melbourne, florida, united states pfizer investigational site, orange park, florida, united states pfizer investigational site, palatka, florida, united states pfizer investigational site, st. augustine, florida, united states pfizer investigational site, chicago, illinois, united states pfizer investigational site, chicago, illinois, united states pfizer investigational site, zion, illinois, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, ann arbor, michigan, united states pfizer investigational site, stony brook, new york, united states pfizer investigational site, cleveland, ohio, united states pfizer investigational site, corvallis, oregon, united states pfizer investigational site, edmonton, alberta, canada pfizer investigational site, ottawa, ontario, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, novy jicin, czech republic pfizer investigational site, praha 8, czech republic pfizer investigational site, berlin, germany pfizer investigational site, essen, germany pfizer investigational site, frankfurt, germany pfizer investigational site, freiburg, germany pfizer investigational site, hamburg, germany pfizer investigational site, bangalore, karnataka, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, napoli, italy pfizer investigational site, roma, italy pfizer investigational site, roma, italy pfizer investigational site, roma, italy pfizer investigational site, rozzano (mi), italy pfizer investigational site, taormina, me, italy pfizer investigational site, hospitalet de llobregat, barcelona, spain pfizer investigational site, sabadell, barcelona, spain pfizer investigational site, girona, spain pfizer investigational site, madrid, spain pfizer investigational site, madrid, spain pfizer investigational site, malaga, spain pfizer investigational site, valencia, spain pfizer investigational site, valencia, spain pfizer investigational site, southampton, hampshire, united kingdom pfizer investigational site, rickmansworth, middlesex, united kingdom pfizer investigational site, nottingham, nottinghamshire, united kingdom pfizer investigational site, sheffield, yorkshire, united kingdom']",,https://ClinicalTrials.gov/show/NCT00076024,breast
384,385,NCT00099294,study of the efficacy and safety of glufosfamide compared with best supportive care in metastatic pancreatic cancer,,Completed,No Results Available,pancreatic cancer,drug: glufosfamide,overall survival|objective tumor response rate|duration of objective tumor response rate|progression-free survival|6 month and 12 month survival|serum ca 19-9|pain intensity|performance status,threshold pharmaceuticals|ppd,All,"18 Years and older   (Adult, Older Adult)",Phase 3,300.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TH-CR-302,September 2004,January 2007,January 2007,"December 10, 2004",,"April 30, 2009","['augusta oncology associates, los angeles, california, united states kenmar research institute, los angeles, california, united states mile high oncology, denver, colorado, united states northwestern connecticut oncology - hematology associates, torrington, connecticut, united states palm beach institute of hematology and oncology, boynton beach, florida, united states hematology/oncology of the north shore, skokie, illinois, united states fort wayne medical oncology/hem, fort wayne, indiana, united states norton healthcare center, louisville, kentucky, united states west michigan cancer center, kalamazoo, michigan, united states hattiesburg clinic oncology, hattiesburg, mississippi, united states columbia comprehensive cancer care clinic, columbia, missouri, united states bond clinic, rolla, missouri, united states deaconess billings clinic, billings, montana, united states office of clinical trials, paramus, new jersey, united states new mexico oncology hematology consultants, albuquerque, new mexico, united states hanover medical specialists, wilmington, north carolina, united states vita hematology oncology pc, bethlehem, pennsylvania, united states the family cancer center , pllc, collierville, tennessee, united states center for oncology research and treatment, dallas, texas, united states jps center for cancer care, fort worth, texas, united states northern utah associates, ogden, utah, united states cancer outreach association, abingdon, virginia, united states marshfield clinic research foundation, marshfield, wisconsin, united states hospital interzonal general de agudos, buenos aires, argentina hospital posadas, buenos aires, argentina policlinica privada instituto de medicina nuclear, buenos aires, argentina hospital udaondo, buenos aires, argentina hospital alvarez, buenos aires, argentina hospital churruca - visca, buenos aires, argentina instituto medico alexander fleming, buenos aires, argentina instituto caici, santa fe, argentina fundacao pio xii - hospital de cancer de barretos, barretos, brazil fundação pio xii - hospital de câncer de barretos, barretos, brazil hospital vera cruz - clinica de oncologia, belo horizonte, brazil hospital luxemburgo, belo horizonte, brazil hospital de clínicas da ufpr, curitiba, brazil associacao de combate ao cancer em goias, hospital araujo jorge, setor de oncologia clinica, goiania, brazil hospital nossa senhora da conceicao, porto alegre, brazil instituto nacional do cancer - inca, rio de janeiro, brazil clinica de oncologia medica s/c ltda, sao paulo, brazil hospital do cancer - ac camargo, sao paulo, brazil grupo paulista oncologia integrada, são paulo, brazil department of chemotherapy dr. georgi stranski general hospital of pleven university, pleven, bulgaria first internal department plovdiv regional oncology center with in-patient department, plovdiv, bulgaria department of chemotherapy sofia regional oncology center, sofia, bulgaria chemotherapy clinic queen joanna general hospital, sofia, bulgaria haematology and oncology clinic military medical academy, sofia, bulgaria chemotherapy clinic specialized oncology hospital, sofia, bulgaria department of chemotherapy veliko tarnovo regional oncology center, tarnovo, bulgaria department of medicinal oncotherapy and palliative care dr. marko markov regional oncology center, varna, bulgaria fakultni nemocnice brno oddeleni klinicke onkologie, brno, czech republic masarykuv onkologicky ustav, brno, czech republic krajska nemocnice pardubice,oddeleni radiacni onkologie, kyjevska, czech republic onkologicka klinika, fakultni nemocnice olomouc, olomouc, czech republic onkologicke oddeleni, batova krajska nemocnice zlin, zlin, czech republic national institute of oncology, budapest, hungary szent imre korhaz onkologia, budapest, hungary szent lászló kórház, onkológia, budapest, hungary vaszary kolos korhaz, esztergom, hungary petz aladar county hospital, department of oncology, gyor, hungary baranya megyei korhaz onkologial osztaly, rakoczi, hungary bangalore institute of oncology, bangalore, india curie centre of oncology, bangalore, india radhakrishan birla cancer centre, jaipur, india jaslok hospital and research centre, mumbai, india sir ganga ram hospital, new delhi, india hospital universitario ""dr. angel leano"", zapopan, jalisco, mexico hospital y clinica oca s.a. de c.v., monterrey, nl, mexico hospital central ""dr. ignacio morones prieto"" departamento de radioterapia., san luis potosi, slp, mexico hospital regional issste ""merida"", merida, yucatan, mexico centro estatal de cancerologia, chihuahua, mexico hospital clinica del parque, chihuahua, mexico centro medico issemym, metepec, mexico hospital general ""5 de diciembre"" issste, mexicali, mexico hospital regional de especialidades no. 30 imss, mexicali, mexico hospital de oncologia centro medico, mexico, df, mexico instituto nacional de ciencias medicas u nutricion ""salvador zubiran"", mexico, df, mexico fundeni clinical institute, bucharest, romania trestioreanu institute of oncology, bucharest, romania ""i. chiricuta"" institute of oncology, cluj-napoca, romania craiova emergency clinical county hospital, craiova, romania timisoara city hospital, timisoara, romania institute of medical radiology, russian academy of medical science, obninsk, kaluzhskaya region, russian federation cheliabinsk regional oncology center, cheliabinsk, russian federation irkutsk regional oncology center, irkutsk, russian federation clinical oncology center, kazan, russian federation krasnodar city oncology center, krasnodar, russian federation blokhin cancer research center, dept of clinical pharmacology and chemotherapy, moscow, russian federation central clinical hospital of the presidentof the russian federation, moscow, russian federation hertzen research institute of oncology, moscow, russian federation central clinical hospital of the ministru of transport n.a. semashko, moscow, russian federation orenburg, regional oncology center, orenburg, russian federation samara oncology center, samara, russian federation st. petersburg, central research institute of radiology, st. petersburg, russian federation medical academy of postgraduate education, st. petersburg, russian federation st. petersburg oncology center, st. petersburg, russian federation mechnikov state medical academy, st.petersburg, russian federation voronezh regional clinical oncology center, voronezh, russian federation yaroslavl regional oncology center, yaroslavl, russian federation dnepropetrovsk city clinical hospital, dnepropetrovsk, ukraine donetsk regional antitumor center, donetsk, ukraine state communal healthcare institution: kharkov regional clinical oncological center, kharkov, ukraine institute of oncology under the academy of medical sciences of ukraine, kiev, ukraine kiev municipal clinical hospital #10, kiev center for biliary, biliary tracts and pancreas surgery, kiev, ukraine krivoy rog city oncology center, krivoy rog, ukraine lugansk regional clinical oncological center, lugansk, ukraine nikolaev regional oncology centre, nikolaev, ukraine odessa regional clinical hospital, odessa, ukraine vinnitsa regional clinical oncology center, vinnitsa, ukraine zaporozhye medical academy of postgraduate education, zaporozhye, ukraine zhitomir regional clinical hospital n.a. o.f. gerbachevsky, zhitomir, ukraine']",,https://ClinicalTrials.gov/show/NCT00099294,pancreat
385,386,NCT01516307,trial of active immunotherapy with globo h-klh (opt-822) in metastatic breast cancer subjects,,Completed,No Results Available,metastatic breast cancer,biological: opt-822/opt-821(30 μg/100 μg)|biological: phosphate buffer saline (pbs)|drug: cyclophosphamide,progression free survival (pfs)|overall survival (os),"obi pharma, inc",Female,"21 Years and older   (Adult, Older Adult)",Phase 2,349.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OPT-822-001,December 2011,August 2016,August 2019,"January 24, 2012",,"September 16, 2020","[""the university of alabama at birmingham (uab), birmingham, alabama, united states st. jude heritage healthcare, virginia k. crosson cancer center, fullerton, california, united states university of california, san diego (ucsd), la jolla, california, united states university of california, irvine (uci), orange, california, united states university of california, san francisco (ucsf), san francisco, california, united states coastal integrative cancer care, san luis obispo, california, united states central coast medical oncology corporation, santa maria, california, united states university of california, los angeles (ucla), santa monica, california, united states memorial regional hospital, hollywood, florida, united states university of chicago medical center, chicago, illinois, united states weill cornell medical college, new york, new york, united states hope women's cancer center, asheville, north carolina, united states university of texas md anderson cancer center, houston, texas, united states unimed medical institute, hong-kong, china hcg, bangalore institute of oncology, bengaluru, india curie manavata cancer centre, mumbai, india pusan national university hospital, busan-si, korea, republic of dong-a university hospital, busan, korea, republic of inha university hospital, chungcheongbuk-do, korea, republic of national cancer center, chungcheongbuk-do, korea, republic of kyungpook national university medical center, daegu, korea, republic of yeungnam university medical center, daegu, korea, republic of asan medical center, seoul, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university hospital ,, seoul, korea, republic of seoul st. mary's hospital, seoul, korea, republic of severance hospital, seoul, korea, republic of changhua christian hospital, changhua, taiwan kaohsiung medical university hospital, kaohsiung city, taiwan kaohsiung veterans general hospital, kaohsiung city, taiwan chang gung memorial hospital-ks, kaohsiung, taiwan chang gung memorial hospital -linkou, linkou, taiwan mackay memorial hospital, new taipei city, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan chi mei medical center, tainan city, taiwan national cheng kung university hospital, tainan, taiwan koo foundation sun yat-sen cancer center, taipei city, taiwan taipei veterans general hospital, taipei city, taiwan chang gung memorial hospital-taipei, taipei, taiwan national taiwan university hospital, taipei, taiwan shuang-ho hospital, taipei, taiwan tri-service general hospital, taipei, taiwan""]",,https://ClinicalTrials.gov/show/NCT01516307,breast
386,387,NCT00384735,an adequate cost effective follow up protocol for bone & soft tissue sarcomas - a prospective randomized trial,TOSS,Completed,No Results Available,sarcoma,,overall survival|disease free survival,terry fox foundation|tata memorial hospital,All,"1 Year to 65 Years   (Child, Adult, Older Adult)",,500.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TOSS,"January 1, 2006","June 30, 2010","December 31, 2015","October 6, 2006",,"October 8, 2020","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00384735,sarcoma
387,388,NCT03556358,"trial to compare the safety, efficacy and immunogenicity of tx05 with herceptin® in her2+ early breast cancer",,Completed,Has Results,breast cancer|breast neoplasms|her2-positive breast cancer|stage ii breast cancer|stage iiia breast cancer,biological: tx05 (trastuzumab)|biological: herceptin®|drug: paclitaxel|drug: epirubicin|drug: cyclophosphamide,proportion of subjects in each treatment arm who achieve pathologic complete response (pcr)|objective response rate (orr),"tanvex biopharma usa, inc.",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,809.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TX05-03,"June 28, 2018","November 27, 2020","February 4, 2021","June 14, 2018","January 14, 2022","January 14, 2022","[""tanvex investigational site 1008, lesnoy, minsk region, belarus tanvex investigational site 1007, babruysk, mogilev region, belarus tanvex investigational site 1003, gomel, belarus tanvex investigational site 1006, grodno, belarus tanvex investigational site 1002, minsk, belarus tanvex investigational site 1005, mogilev, belarus tanvex investigational site 1001, vitebsk, belarus tanvex investigational site 4001, temuco, chile tanvex investigational site 4002, viña del mar, chile tanvex investigational site 5006, batumi, georgia tanvex investigational site 5002, batumi, georgia tanvex investigational site 5003, tbilisi, georgia tanvex investigational site 5001, tbilisi, georgia tanvex investigational site 5005, tbilisi, georgia tanvex investigational site 5012, tbilisi, georgia tanvex investigational site 5013, tbilisi, georgia tanvex investigational site 5004, tbilisi, georgia tanvex investigational site 5010, tbilisi, georgia tanvex investigational site 5011, tbilisi, georgia tanvex investigational site 5008, tbilisi, georgia tanvex investigational site 5009, tbilisi, georgia tanvex investigational site 5007, tbilisi, georgia tanvex investigational site 6003, budapest, hungary tanvex investigational site 6007, budapest, hungary tanvex investigational site 6005, debrecen, hungary tanvex investigational site 6006, győr, hungary tanvex investigational site 6004, miskolc, hungary tanvex investigational site 6001, pécs, hungary tanvex investigational site 7007, nashik, maharashtra, india tanvex investigational site 7015, pune, maharashtra, india tanvex investigational site 7003, pune, maharashtra, india tanvex investigational site 7004, pune, maharashtra, india tanvex investigational site 7002, bīkaner, rajasthan, india tanvex investigational site 7010, madurai, tamil nadu, india tanvex invesitgational site 7033, ahmedabad, india tanvex investigational site 7019, bangalore, india tanvex investigational site 7037, bangalore, india tanvex investigational site 7022, belgaum, india tanvex investigational site 7034, chandigarh, india tanvex investigational site 7013, coimbatore, india tanvex investigational site 7024, gurgaon, india tanvex investigational site 7045, hyderabad, india tanvex investigational site 7036, hyderabad, india tanvex investigational site 7009, jaipur, india tanvex investigational site 7039, kolkata, india tanvex investigational site 7040, kolkata, india tanvex investigational site 7006, kolkata, india tanvex investigational site 7005, lucknow, india tanvex investigational site 7012, manipala, india tanvex investigational site 7041, model town, india tanvex investigational site 7031, naka, india tanvex investigational site 7001, nashik, india tanvex investigational site 7042, trichy, india tanvex investigational site 7018, vadodara, india tanvex investigational site 7017, vijayawada, india tanvex investigational site 2102, monterrey, nuevo león, mexico tanvex investigational site 2117, aguascalientes, mexico tanvex investigational site 2109, aguascalientes, mexico tanvex investigational site 2116, cancun, mexico tanvex investigational site 2111, ciudad de mexico, mexico tanvex investigational site 2104, cuauhtemoc, mexico tanvex investigational site 2114, cuauhtémoc, mexico tanvex investigational site 2101, cuautitlán izcalli, mexico tanvex investigational site 2113, mexico, mexico tanvex investigational site 2103, monterrey, mexico tanvex investigational site 2106, oaxaca, mexico tanvex investigational site 2112, san luis potosí, mexico tanvex investigational site 2110, tequisquiapan, mexico tanvex investigational site 2108, zapopan, mexico tanvex investigational site 1104, chiclayo, lambayeque, peru tanvex investigational site 1112, lima cercado, lima, peru tanvex investigational site 1108, san borja, lima, peru tanvex investigational site 1113, san borja, lima, peru tanvex investigational site 1101, arequipa, peru tanvex investigational site 1107, arequipa, peru tanvex investigational site 1110, lima, peru tanvex investigational site 1105, san isidro, peru tanvex investigational site 1102, san isidro, peru tanvex investigational site 1109, surquillo, peru tanvex investigational site 1103, trujillo, peru tanvex investigational site 1210, santo tomas, batangas, philippines tanvex investigational site 1203, cebu city, cebu, philippines tanvex investigational site 1204, cebu city, cebu, philippines tanvex investigational site 1211, cebu city, cebu, philippines tanvex investigational site 1208, quezon city, manila, philippines tanvex investigational site 1207, manila, metro manila, philippines tanvex investigational site 1206, bacolod city, negros occidental, philippines tanvex investigational site 1212, davao city, philippines tanvex investigational site 1214, makati city, philippines tanvex investigational site 1201, manila, philippines tanvex investigational site 1209, quezon city, philippines tanvex investigational site 1213, quezon city, philippines tanvex investigational site 1529, krasnodar, krasnodar region, russian federation tanvex investigational site 1513, sochi, krasnodar region, russian federation tanvex investigational site 1509, omsk, omsk region, russian federation tanvex investigational site 1522, ufa, republic of bashkortostan, russian federation tanvex investigational site 1510, pushkin, saint petersburg, russian federation tanvex investigational site 1511, novosibirsk, siberia, russian federation tanvex investigational site 1519, pyatigorsk, stavropol region, russian federation tanvex investigational site 1518, tomsk, tomsk region, russian federation tanvex investigational site 1535, arkhangel'sk, russian federation tanvex investigational site 1531, belgorod, russian federation tanvex investigational site 1538, chelyabinsk, russian federation tanvex investigational site 1520, ivanovo, russian federation tanvex investigational site 1515, izhevsk, russian federation tanvex investigational site 1502, kaluga, russian federation tanvex investigational site 1540, kazan, russian federation tanvex investigational site 1512, krasnoyarsk, russian federation tanvex investigational site 1505, kursk, russian federation tanvex investigational site 1530, moscow, russian federation tanvex investigational site 1536, moscow, russian federation tanvex investigational site 1514, moscow, russian federation tanvex investigational site 1507, moscow, russian federation tanvex investigational site 1503, omsk, russian federation tanvex investigational site 1537, orenburg, russian federation tanvex investigational site 1521, rostov-na-donu, russian federation tanvex investigational site 1516, saint petersburg, russian federation tanvex investigational site 1517, saint petersburg, russian federation tanvex investigational site 1523, saint petersburg, russian federation tanvex investigational site 1525, saint petersburg, russian federation tanvex investigational site 1506, saint petersburg, russian federation tanvex investigational site 1526, saint petersburg, russian federation tanvex investigational site 1501, saint petersburg, russian federation tanvex investigational site 1524, saint-petersburg, russian federation tanvex investigational site 1508, saransk, russian federation tanvex investigational site 1533, tomsk, russian federation tanvex investigational site 1534, yaroslavl, russian federation tanvex investigational site 1808, chernihiv, ukraine tanvex investigational site 1821, chernivtsi, ukraine tanvex investigational site 1803, dnepropetrovsk, ukraine tanvex investigational site 1824, dnipro, ukraine tanvex investigational site 1820, kherson, ukraine tanvex investigational site 1812, khmelnytskyi, ukraine tanvex investigational site 1815, kiev, ukraine tanvex investigational site 1811, kiev, ukraine tanvex investigational site 1802, kiev, ukraine tanvex investigational site 1814, kirovogrado, ukraine tanvex investigational site 1819, kropyvnytskyi, ukraine tanvex investigational site 1804, kryvyi rih, ukraine tanvex investigational site 1809, kyiv, ukraine tanvex investigational site 1810, odesa, ukraine tanvex investigational site 1806, sumy, ukraine tanvex investigational site 1822, ternopil', ukraine tanvex investigational site 1818, vinnitsya, ukraine tanvex investigational site 1813, zaporizhzhia, ukraine tanvex investigational site 1823, úzhgorod, ukraine""]","""study protocol"", https://clinicaltrials.gov/provideddocs/58/nct03556358/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/58/nct03556358/sap_001.pdf",https://ClinicalTrials.gov/show/NCT03556358,breast
388,389,NCT02472964,"study of efficacy and safety of myl1401o + taxane vs herceptin©+ taxane for 1st line, met. br. ca.",HERiTAge,Completed,Has Results,breast cancer,biological: trastuzumab|biological: myl- 1401o|drug: paclitaxel|drug: docetaxel,primary endpoint : compare best overall response rate (orr) (according to response evaluation criteria in solid tumor [recist] 1.1 criteria) at week 24 of myl-1401o plus taxane versus herceptin® plus taxane in the itt1 population,mylan inc.|mylan gmbh|viatris inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MYL-Her 3001|2011-001965-42,July 2012,March 2016,August 2018,"June 16, 2015","October 30, 2018","February 14, 2022","['mylan investigational site, barretos, brazil mylan investigational site, brasilia, brazil mylan investigational site, goiania, brazil mylan investigational site, ijui, brazil mylan investigational site, jau, brazil mylan investigational site, joinville, brazil mylan investigational site, morumbi, brazil mylan investigational site, porto alegre, brazil mylan investigational site, salvador,, brazil mylan investigational site, santo andre, brazil mylan investigational site, sao paulo, brazil mylan investigational site, sorocaba, brazil mylan investigational site, santiago, chile mylan investigational site, temuco, chile mylan investigational site, batumi, georgia mylan investigational site, tblisi, georgia mylan investigational site, budapest, hungary mylan investigational site, debrecen, hungary mylan investigational site, gyod, hungary mylan investigational site, gyula, hungary mylan investigational site, miskolc, hungary mylan investigational site, nyiregyhaza, hungary mylan investigational site, szekszard, hungary mylan investigational site, szolnok, hungary mylan investigational site, ahmedabad, india mylan investigational site, bangalore, india mylan investigational site, chennai, india mylan investigational site, gurgaon, india mylan investigational site, hyderabad, india mylan investigational site, jaipur, india mylan investigational site, karamsad, india mylan investigational site, madurai, india mylan investigational site, mumbai, india mylan investigational site, nashik, india mylan investigational site, pune, india mylan investigational site, surat, india mylan investigational site, vijaywada, india mylan investigational site, daugavpils, latvia mylan investigational site, leipaja, latvia mylan investigational site, riga, latvia mylan investigational site, arequipa, peru mylan investigational site, lima, peru mylan investigational site, surquillo, peru mylan investigational site, brasov, romania mylan investigational site, bucharest, romania mylan investigational site, bucuresti, romania mylan investigational site, cluj- napoca, romania mylan investigational site, constanta, romania mylan investigational site, craiva, romania mylan investigational site, filimon sirbu, romania mylan investigational site, iasi, romania mylan investigational site, oradea, romania mylan investigational site, timisoara, romania mylan investigational site, arkhangelsk, russian federation mylan investigational site, ivanovo, russian federation mylan investigational site, kazan, russian federation mylan investigational site, kursk, russian federation mylan investigational site, moscow, russian federation mylan investigational site, rostov-on-don, russian federation mylan investigational site, ryazan, russian federation mylan investigational site, samara, russian federation mylan investigational site, st. petersburg, russian federation mylan investigational site, belgrade, serbia mylan investigational site, kamenica, serbia mylan investigational site, sremska, serbia mylan investigational site, bardejov, slovakia mylan investigational site, kosice, slovakia mylan investigational site, nove zamky, slovakia mylan investigational site, trnava, slovakia mylan investigator site, bloemfontein, south africa mylan investigator site, durban, south africa mylan investigational site, george, south africa mylan investigational site, johannesburg, south africa mylan investigator site, kraaifontein, south africa mylan investigational site, port elizabeth, south africa mylan investigational site, pretoria, south africa mylan investigational site, vereeniging, south africa mylan investigator site, bangkok, thailand mylan investigator site, chiang mai, thailand mylan investigator site, phitsanulok, thailand mylan investigator site, rajthavee, thailand mylan investigator site, songkla, thailand mylan investigator site, ankara, turkey mylan investigator site, istanbul, turkey mylan investigator site, izmir, turkey mylan investigator site, kocaeli, turkey mylan investigator site, cherkassy, ukraine mylan investigator site, chernivtsi, ukraine mylan investigator site, dnipropetrovsk, ukraine mylan investigator site, lutsk, ukraine mylan investigator site, lviv, ukraine mylan investigator site, sumy, ukraine mylan investigator site, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT02472964,breast
389,390,NCT00507429,study of combretastatin and paclitaxel/carboplatin in the treatment of anaplastic thyroid cancer,FACT,Terminated,Has Results,anaplastic thyroid cancer,drug: ca4p|drug: paclitaxel|drug: carboplatin,overall survival|to determine progression free survival|to determine percentage of 1 year survival,mateon therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OXC4T4-302,August 2007,October 2011,November 2011,"July 26, 2007","June 9, 2014","June 9, 2014","['usc/norris comprehensive cancer center, los angeles, california, united states university of colorado cancer center, aurora, colorado, united states yale university, school of medicine, new haven, connecticut, united states winship cancer institute, emory university, atlanta, georgia, united states sidney kimmel comprehensive cancer care center at john hopkins, baltimore, maryland, united states university of minnesota otolaryngology department, minneapolis, minnesota, united states ireland cancer center/division od hematology, cleveland, ohio, united states oregon health and science university, portland, oregon, united states university of texas m.d. anderson cancer center, houston, texas, united states west virginia university, morgantown, west virginia, united states belarus national medical university, minsk, belarus regional oncology dispensary with inpatient sector, plodiv, bulgaria specialized hospital for active treatment of oncology, sofia, bulgaria universtiy multiprofile hospital, isui, clinic of oncotherapy, sofia, bulgaria university hospital, cairo, cairo, egypt mediciti hospital, hyderabaad, andhra pradesh, india all india institute of medical sciences, new delhi, delhi, india apollo cancer institute, new delhi, delhi, india kidwai memorial hospital, bangalore, karnataka, india shirdi sai baba cancer hospital, manipal, karnataka, india tata memorial centre, mumbai, maharashtra, india ruby hall clinic, pune, maharashtra, india christian medial college, vellore, tamil nadu, india telaviv sourasky medical center, head and neck service division of oncology, tel-aviv, israel lo studio e la cura, milano, italy int napoli fondazione pascale, napoli, italy istituto oncologico veneto (iov) - irccs, padova, italy azienda ospedaliero - universitaria pisana, pisa, italy zaklad medyczny nuklearnej i endykrynologii, gliwice, poland klinika nowotworow glowy i szyji, warszawa, poland institutul oncologic, cluj-napoca, romania sc meditech srl, craiova, romania centr of medical oncology, iasi, romania clinical county hospital sibiu, sibiu, romania emergency clinical county hospital ""sf. loan cel nou"", suceava, romania city clinical oncology dispensary, saint petersburg, russian federation ukrainian academy of medical science, lomonosova 33/43, kiev, ukraine regional clinical oncology dispensary, lvov, ukraine beatson oncology centre, gartnavel general hospital, glasgow, scotland, united kingdom royal marsden hospital and institute of cancer research, london, united kingdom southampton hospital oncology centre, southampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00507429,thyroid
390,391,NCT00858364,anemia treatment for advanced non-small cell lung cancer (nsclc) patients receiving chemotherapy,,Terminated,Has Results,non-small cell lung cancer|anemia|cancer|lung cancer,drug: darbepoetin alfa|drug: placebo,overall survival (os)|progression-free survival (pfs)|percentage of participants with a red blood cell transfusion or hemoglobin ≤ 8.0 g/dl from week 5 to end of the efficacy treatment period|number of participants with adverse events of special interest|percentage of participants with an objective tumor response|number of participants who developed neutralizing antibodies to darbepoetin alfa|percentage of participants with a red blood cell transfusion or hemoglobin ≤ 8.0 g/dl from week 1 to end of the efficacy treatment period|change from baseline in hemoglobin to end of efficacy treatment period,amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2549.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",20070782|2007-005792-34,"July 17, 2009","June 7, 2017","June 7, 2017","March 9, 2009","July 6, 2018","July 6, 2018","['research site, anniston, alabama, united states research site, birmingham, alabama, united states research site, anchorage, alaska, united states research site, tucson, arizona, united states research site, fayetteville, arkansas, united states research site, hot springs, arkansas, united states research site, jonesboro, arkansas, united states research site, little rock, arkansas, united states research site, anaheim, california, united states research site, arcadia, california, united states research site, berkeley, california, united states research site, burbank, california, united states research site, downey, california, united states research site, fountain valley, california, united states research site, fresno, california, united states research site, fresno, california, united states research site, la verne, california, united states research site, lancaster, california, united states research site, long beach, california, united states research site, los angeles, california, united states research site, los angeles, california, united states research site, los angeles, california, united states research site, merced, california, united states research site, mission hills, california, united states research site, montebello, california, united states research site, oxnard, california, united states research site, palm springs, california, united states research site, pismo beach, california, united states research site, pomona, california, united states research site, redlands, california, united states research site, saint helena, california, united states research site, salinas, california, united states research site, san diego, california, united states research site, santa rosa, california, united states research site, simi valley, california, united states research site, soquel, california, united states research site, torrance, california, united states research site, vallejo, california, united states research site, west covina, california, united states research site, denver, colorado, united states research site, denver, colorado, united states research site, englewood, colorado, united states research site, bridgeport, connecticut, united states research site, southington, connecticut, united states research site, washington, district of columbia, united states research site, washington, district of columbia, united states research site, boynton beach, florida, united states research site, boynton beach, florida, united states research site, coral springs, florida, united states research site, daytona beach, florida, united states research site, fort lauderdale, florida, united states research site, holiday, florida, united states research site, hollywood, florida, united states research site, jacksonville, florida, united states research site, kissimmee, florida, united states research site, lake worth, florida, united states research site, lakeland, florida, united states research site, lecanto, florida, united states research site, miami, florida, united states research site, new port richey, florida, united states research site, new port richey, florida, united states research site, orange city, florida, united states research site, orlando, florida, united states research site, pembroke pines, florida, united states research site, rockledge, florida, united states research site, tamarac, florida, united states research site, the villages, florida, united states research site, titusville, florida, united states research site, weston, florida, united states research site, albany, georgia, united states research site, augusta, georgia, united states research site, stockbridge, georgia, united states research site, thomasville, georgia, united states research site, chicago, illinois, united states research site, chicago, illinois, united states research site, galesburg, illinois, united states research site, gurnee, illinois, united states research site, mount vernon, illinois, united states research site, skokie, illinois, united states research site, indianapolis, indiana, united states research site, michigan city, indiana, united states research site, muncie, indiana, united states research site, council bluffs, iowa, united states research site, dubuque, iowa, united states research site, iowa city, iowa, united states research site, sioux city, iowa, united states research site, waterloo, iowa, united states research site, hutchinson, kansas, united states research site, wichita, kansas, united states research site, ashland, kentucky, united states research site, hazard, kentucky, united states research site, louisville, kentucky, united states research site, louisville, kentucky, united states research site, morehead, kentucky, united states research site, mount sterling, kentucky, united states research site, paducah, kentucky, united states research site, paducah, kentucky, united states research site, alexandria, louisiana, united states research site, lafayette, louisiana, united states research site, marrero, louisiana, united states research site, new orleans, louisiana, united states research site, ruston, louisiana, united states research site, shreveport, louisiana, united states research site, lewiston, maine, united states research site, rockport, maine, united states research site, baltimore, maryland, united states research site, baltimore, maryland, united states research site, baltimore, maryland, united states research site, bethesda, maryland, united states research site, chevy chase, maryland, united states research site, cumberland, maryland, united states research site, frederick, maryland, united states research site, hagerstown, maryland, united states research site, towson, maryland, united states research site, westminster, maryland, united states research site, attleboro, massachusetts, united states research site, boston, massachusetts, united states research site, boston, massachusetts, united states research site, brockton, massachusetts, united states research site, cambridge, massachusetts, united states research site, worcester, massachusetts, united states research site, clarkston, michigan, united states research site, grand rapids, michigan, united states research site, kalamazoo, michigan, united states research site, southfield, michigan, united states research site, southgate, michigan, united states research site, willmar, minnesota, united states research site, biloxi, mississippi, united states research site, hattiesburg, mississippi, united states research site, jackson, mississippi, united states research site, tupelo, mississippi, united states research site, columbia, missouri, united states research site, jefferson city, missouri, united states research site, kansas city, missouri, united states research site, kansas city, missouri, united states research site, saint louis, missouri, united states research site, saint louis, missouri, united states research site, springfield, missouri, united states research site, great falls, montana, united states research site, kalispell, montana, united states research site, grand island, nebraska, united states research site, omaha, nebraska, united states research site, omaha, nebraska, united states research site, henderson, nevada, united states research site, north las vegas, nevada, united states research site, manchester, new hampshire, united states research site, sparta, new jersey, united states research site, teaneck, new jersey, united states research site, vineland, new jersey, united states research site, albuquerque, new mexico, united states research site, santa fe, new mexico, united states research site, albany, new york, united states research site, brooklyn, new york, united states research site, buffalo, new york, united states research site, glens falls, new york, united states research site, goshen, new york, united states research site, lake success, new york, united states research site, latham, new york, united states research site, nyack, new york, united states research site, poughkeepsie, new york, united states research site, staten island, new york, united states research site, staten island, new york, united states research site, syracuse, new york, united states research site, valhalla, new york, united states research site, asheboro, north carolina, united states research site, asheville, north carolina, united states research site, burlington, north carolina, united states research site, concord, north carolina, united states research site, durham, north carolina, united states research site, goldsboro, north carolina, united states research site, greenville, north carolina, united states research site, hendersonville, north carolina, united states research site, hickory, north carolina, united states research site, high point, north carolina, united states research site, huntersville, north carolina, united states research site, kinston, north carolina, united states research site, pinehurst, north carolina, united states research site, raleigh, north carolina, united states research site, washington, north carolina, united states research site, bismarck, north dakota, united states research site, akron, ohio, united states research site, columbus, ohio, united states research site, dayton, ohio, united states research site, massillon, ohio, united states research site, middletown, ohio, united states research site, port clinton, ohio, united states research site, sylvania, ohio, united states research site, wooster, ohio, united states research site, oklahoma city, oklahoma, united states research site, tulsa, oklahoma, united states research site, bethlehem, pennsylvania, united states research site, gettysburg, pennsylvania, united states research site, langhorne, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, upland, pennsylvania, united states research site, willow grove, pennsylvania, united states research site, wynnewood, pennsylvania, united states research site, pawtucket, rhode island, united states research site, providence, rhode island, united states research site, woonsocket, rhode island, united states research site, aiken, south carolina, united states research site, charleston, south carolina, united states research site, charleston, south carolina, united states research site, columbia, south carolina, united states research site, hilton head island, south carolina, united states research site, myrtle beach, south carolina, united states research site, sumter, south carolina, united states research site, aberdeen, south dakota, united states research site, sioux falls, south dakota, united states research site, watertown, south dakota, united states research site, johnson city, tennessee, united states research site, knoxville, tennessee, united states research site, memphis, tennessee, united states research site, memphis, tennessee, united states research site, nashville, tennessee, united states research site, abilene, texas, united states research site, amarillo, texas, united states research site, austin, texas, united states research site, beaumont, texas, united states research site, bedford, texas, united states research site, bryan, texas, united states research site, corpus christi, texas, united states research site, corpus christi, texas, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, el paso, texas, united states research site, el paso, texas, united states research site, fort worth, texas, united states research site, garland, texas, united states research site, harlingen, texas, united states research site, houston, texas, united states research site, irving, texas, united states research site, longview, texas, united states research site, mcallen, texas, united states research site, mesquite, texas, united states research site, midland, texas, united states research site, paris, texas, united states research site, richardson, texas, united states research site, round rock, texas, united states research site, san antonio, texas, united states research site, san antonio, texas, united states research site, sherman, texas, united states research site, southlake, texas, united states research site, sugar land, texas, united states research site, temple, texas, united states research site, the woodlands, texas, united states research site, tyler, texas, united states research site, tyler, texas, united states research site, waco, texas, united states research site, webster, texas, united states research site, wichita falls, texas, united states research site, ogden, utah, united states research site, white river junction, vermont, united states research site, christiansburg, virginia, united states research site, fairfax, virginia, united states research site, lynchburg, virginia, united states research site, newport news, virginia, united states research site, portsmouth, virginia, united states research site, bremerton, washington, united states research site, burien, washington, united states research site, edmonds, washington, united states research site, seattle, washington, united states research site, spokane, washington, united states research site, spokane, washington, united states research site, spokane, washington, united states research site, tacoma, washington, united states research site, vancouver, washington, united states research site, yakima, washington, united states research site, green bay, wisconsin, united states research site, janesville, wisconsin, united states research site, milwaukee, wisconsin, united states research site, quilmes, buenos aires, argentina research site, quilmes, buenos aires, argentina research site, cordoba, córdoba, argentina research site, ciudad autónoma de buenos aires, distrito federal, argentina research site, ciudad autónoma de buenos aires, distrito federal, argentina research site, san salvador de jujuy, jujuy, argentina research site, rosario, santa fe, argentina research site, rosario, santa fe, argentina research site, san miguel de tucuman, tucuman, argentina research site, buenos aires, argentina research site, la rioja, argentina research site, santa fe, argentina research site, steyr, austria research site, wien, austria research site, ieper, belgium research site, libramont, belgium research site, liège, belgium research site, namur, belgium research site, ottignies, belgium research site, salvador, bahia, brazil research site, salvador, bahia, brazil research site, fortaleza, ceará, brazil research site, fortaleza, ceará, brazil research site, brasilia, distrito federal, brazil research site, cachoeiro de itapemirim, espírito santo, brazil research site, campo grande, mato grosso do sul, brazil research site, belo horizonte, minas gerais, brazil research site, belo horizonte, minas gerais, brazil research site, belo horizonte, minas gerais, brazil research site, belo horizonte, minas gerais, brazil research site, curitba, paraná, brazil research site, curitiba, paraná, brazil research site, curitiba, paraná, brazil research site, londrina, paraná, brazil research site, belem, pará, brazil research site, ijui, rio grande do sul, brazil research site, passo fundo, rio grande do sul, brazil research site, pelotas, rio grande do sul, brazil research site, porto alegre, rio grande do sul, brazil research site, porto alegre, rio grande do sul, brazil research site, porto alegre, rio grande do sul, brazil research site, itajaí, santa catarina, brazil research site, ribeirao preto, são paulo, brazil research site, santo andre, são paulo, brazil research site, santo andre, são paulo, brazil research site, sao jose dos campos, são paulo, brazil research site, sao paulo, são paulo, brazil research site, rio de janeiro, brazil research site, rio de janeiro, brazil research site, rio de janeiro, brazil research site, são paulo, brazil research site, são paulo, brazil research site, plovdiv, bulgaria research site, rousse, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, varna, bulgaria research site, moncton, new brunswick, canada research site, oshawa, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, saint-jerome, quebec, canada research site, temuco, cautín, chile research site, renaca, valparaíso, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, beijing, beijing, china research site, chongqing, chongqing, china research site, fuzhou, fujian, china research site, fuzhou, fujian, china research site, lanzhou, gansu, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, zhongshan, guangdong, china research site, haikou, hainan, china research site, haikou, hainan, china research site, shijiazhuang, hebei, china research site, harbin, heilongjiang, china research site, wuhan, hubei, china research site, wuhan, hubei, china research site, changsha, hunan, china research site, nanjing, jiangsu, china research site, nanjing, jiangsu, china research site, suzhou, jiangsu, china research site, nanchang, jiangxi, china research site, changchun, jilin, china research site, changchun, jilin, china research site, dalian, liaoning, china research site, shenyang, liaoning, china research site, shenyang, liaoning, china research site, xi an, shaanxi, china research site, jinan, shandong, china research site, chengdu, sichuan, china research site, chengdu, sichuan, china research site, urumqi, xinjiang, china research site, kunming, yunnan, china research site, kunming, yunnan, china research site, hangzhou, zhejiang, china research site, hangzhou, zhejiang, china research site, hangzhou, zhejiang, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, chongqing, china research site, chongqing, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, rijeka, croatia research site, zagreb, croatia research site, benesov u prahy, czechia research site, horovice, czechia research site, kutna hora, czechia research site, kyjov, czechia research site, nova ves pod plesi, czechia research site, praha 4, czechia research site, praha 8, czechia research site, pribram, czechia research site, bad berka, germany research site, bad saarow, germany research site, bamberg, germany research site, grosshansdorf, germany research site, halle (saale), germany research site, hemer, germany research site, köln-merheim, germany research site, köln, germany research site, moers, germany research site, münchen, germany research site, münchen, germany research site, münchen, germany research site, münster, germany research site, ulm, germany research site, athens, greece research site, athens, greece research site, athens, greece research site, chania, greece research site, larissa, greece research site, nea kifissia, athens, greece research site, piraeus, greece research site, thessaloniki, greece research site, hong kong, hong kong research site, kowloon, hong kong research site, new territories, hong kong research site, new delhi, delhi, india research site, panaji, goa, india research site, ahmedabad, gujarat, india research site, bangalore, karnataka, india research site, belgaum, karnataka, india research site, mangalore, karnataka, india research site, kochi, kerala, india research site, bhopal, madhya pradesh, india research site, ahmednagar, maharashtra, india research site, aurangabad, maharashtra, india research site, miraj, maharashtra, india research site, mumbai, maharashtra, india research site, nashik, maharashtra, india research site, nashik, maharashtra, india research site, nashik, maharashtra, india research site, pune, maharashtra, india research site, pune, maharashtra, india research site, pune, maharashtra, india research site, thane, maharashtra, india research site, jaipur, rajasthan, india research site, jaipur, rajasthan, india research site, chennai, tamil nadu, india research site, madurai, tamil nadu, india research site, lucknow, uttar pradesh, india research site, kolkata, west bengal, india research site, kolkata, west bengal, india research site, bangalore, india research site, dublin, ireland research site, dublin, ireland research site, jerusalem, israel research site, kefar saba, israel research site, poria eylit, israel research site, rehovot, israel research site, tel aviv, israel research site, catania, italy research site, faenza ra, italy research site, grosseto, italy research site, lecce, italy research site, legnago vr, italy research site, lugo ra, italy research site, meldola fc, italy research site, messina, italy research site, milano, italy research site, napoli, italy research site, ravenna, italy research site, reggio calabria, italy research site, san giovanni rotondo fg, italy research site, nagoya-shi, aichi, japan research site, fukui-shi, fukui, japan research site, chikushino-shi, fukuoka, japan research site, kurume-shi, fukuoka, japan research site, amagasaki-shi, hyogo, japan research site, kobe-shi, hyogo, japan research site, kobe, hyogo, japan research site, nishinomiya-shi, hyogo, japan research site, kanazawa, ishikawa, japan research site, sagamihara-shi, kanagawa, japan research site, okayama-shi, okayama, japan research site, osaka-shi, osaka, japan research site, osaka-shi, osaka, japan research site, bunkyo-ku, tokyo, japan research site, shinjuku-ku, tokyo, japan research site, yonago-shi, tottori, japan research site, kyoto, japan research site, cheongju-si, chungcheongbuk-do, korea, republic of research site, daegu, korea, republic of research site, gwangju, korea, republic of research site, seongnam-si, gyeonggi-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon, gyeonggi-do, korea, republic of research site, ulsan, korea, republic of research site, esch-sur-alzette, luxembourg research site, luxembourg, luxembourg research site, kota bharu, kelantan, malaysia research site, kuantan, pahang, malaysia research site, georgetown, pinang, malaysia research site, kota kinabalu, sabah, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, kuala lumpur, wilayah persekutuan, malaysia research site, saltillo, coahuila, mexico research site, mexico city, distrito federal, mexico research site, mexico city, distrito federal, mexico research site, mexico city, distrito federal, mexico research site, mexico, distrito federal, mexico research site, mexico, distrito federal, mexico research site, mexico, distrito federal, mexico research site, leon, guanajuato, mexico research site, guadalajara, jalisco, mexico research site, zapopan, jalisco, mexico research site, monterrey, nuevo león, mexico research site, queretaro, querétaro, mexico research site, san luis potosi, san luis potosí, mexico research site, merida, yucatán, mexico research site, chihuahua, mexico research site, colima, mexico research site, oaxaca, mexico research site, puebla, mexico research site, breda, netherlands research site, eindhoven, netherlands research site, rotterdam, netherlands research site, tilburg, netherlands research site, davao city, davao, philippines research site, baguio city, philippines research site, cebu city, philippines research site, makati city, philippines research site, manila, philippines research site, manila, philippines research site, metro manila, philippines research site, pasig city, metromanila, philippines research site, quezon city, philippines research site, quezon city, philippines research site, bydgoszcz, poland research site, glucholazy, poland research site, konin, poland research site, krakow, poland research site, krakow, poland research site, lomza, poland research site, olsztyn, poland research site, olsztyn, poland research site, rzeszow, poland research site, szczecin, poland research site, warszawa, poland research site, san juan, puerto rico research site, san juan, puerto rico research site, cluj napoca, romania research site, craiova, romania research site, lasi, romania research site, sibiu, romania research site, suceava, romania research site, timisoara, romania research site, arkhangelsk, russian federation research site, barnaul, russian federation research site, belgorod, russian federation research site, ivanovo, russian federation research site, kirov, russian federation research site, krasnodar, russian federation research site, kursk, russian federation research site, lipetsk, russian federation research site, moscow, russian federation research site, nizhniy novgorod, russian federation research site, novosibirsk, russian federation research site, obninsk, russian federation research site, omsk, russian federation research site, orenburg, russian federation research site, penza, russian federation research site, pyatigorsk, russian federation research site, saint-petersburg, russian federation research site, samara, russian federation research site, saratov, russian federation research site, stavropol, russian federation research site, tula, russian federation research site, tver, russian federation research site, ufa, russian federation research site, ulyanovsk, russian federation research site, voronezh, russian federation research site, yaroslavl, russian federation research site, belgrade, serbia research site, gornji matejevac, serbia research site, kragujevac, serbia research site, sremska kamenica, serbia research site, golnik, slovenia research site, pohorje, slovenia research site, umhlanga, kwazulu-natal, south africa research site, bloemfontein, south africa research site, johannesburg, south africa research site, overport, south africa research site, polokwane, south africa research site, granada, andalucía, spain research site, las palmas de gran canaria, canarias, spain research site, barcelona, cataluña, spain research site, alicante, comunidad valenciana, spain research site, benidorm, comunidad valenciana, spain research site, valencia, comunidad valenciana, spain research site, pontevedra, galicia, spain research site, aarau, switzerland research site, aarau, switzerland research site, chur, switzerland research site, sursee, switzerland research site, zurich, switzerland research site, changhua, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, tainan, taiwan research site, tainan, taiwan research site, chernihiv, ukraine research site, chernivtsi, ukraine research site, dnipropetrovsk, ukraine research site, kirovograd, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, lutsk, ukraine research site, lviv, ukraine research site, sumy, ukraine research site, uzhgorod, ukraine research site, vinnytsia, ukraine research site, bebington, united kingdom research site, dorechester, united kingdom research site, dorset, united kingdom research site, liverpool, united kingdom research site, manchester, united kingdom']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/64/nct00858364/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/64/nct00858364/prot_001.pdf",https://ClinicalTrials.gov/show/NCT00858364,
391,392,NCT00356525,chemotherapy treatment in re-occurring non small cell lung cancer (nsclc) after previous chemotherapy and surgical removal of the nsclc tumor,,Terminated,Has Results,lung neoplasms,drug: pemetrexed|drug: gemcitabine|drug: carboplatin|drug: pemetrexed,objective tumor response|overall survival|time to progressive disease|duration of response|time to treatment failure,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,41.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9934|H3E-US-S082,September 2006,June 2008,April 2009,"July 26, 2006","July 29, 2009","August 17, 2010","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., miami, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., evanston, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., omaha, nebraska, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chapel hill, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chattanooga, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nashville, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., houston, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., caxias do sul, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., porto alegre, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santo andre, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india']",,https://ClinicalTrials.gov/show/NCT00356525,
392,393,NCT01932125,"an interventional study of avastin (bevacizumab) in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer",,Recruiting,No Results Available,ovarian neoplasms|peritoneal neoplasms|fallopian tube neoplasms,drug: bevacizumab,safety: incidence of adverse events|progression-free survival|overall survival|overall response rate (complete response + partial response)|clinical benefit rate (complete response + partial response + stable disease),hoffmann-la roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML28446,"December 5, 2018","August 31, 2023","August 31, 2023","August 30, 2013",,"May 3, 2022","['city cancer centre, vijayawada, andhra pradesh, india sir gangaram hospital, new delhi delhi, delhi, india rajiv gandhi cancer inst.&research center; medical oncology, new delhi, delhi, india shalby hospital limited, ahmedabad, gujarat, india manipal hospital; department of oncology, bangalore, karnataka, india hcg nmr cancer centre, hubli, karnataka, india regional cancer centre; dept of oncology, trivandrum, kerala, india marthwada regional cancer center & research institute, aurangabad, maharashtra, india mumbai oncocare center; medical oncology, mumbai, maharashtra, india hcg nchri cancer center, nagpur, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india curie manavata cancer centre, nashik, maharashtra, india sahyadri speciality hospital, pune city, maharashtra, india jehangir clinical development centre pvt. ltd; cancer research room, pune, maharashtra, india peerless hospitex hospital and research center ltd., kolkata, west bengal, india apollo hospitals international ltd, ahmedabad, india healthcare global enterprises limited; medical oncology, bangalore, india fortis malar hospital, chennai, india apollo speciality hospital, chennai, india sri ramchandra medical centre, chennai, india bharat cancer hospital & research institute-nirali memorial radiation centre, gujarat, india basavatarakam indo-american cancer hospital & research institute, hyderabad, india apollo gleneagles hospitals, kolkata, india batra hospital & medical research centre, new delhi, india grant medical foundation, ruby hall clinic, pune, india nirmal hospital pvt. ltd.; department of oncology, surat, india']",,https://ClinicalTrials.gov/show/NCT01932125,ovari
393,394,NCT00573131,efficacy and safety of oncogel™ added to chemotherapy and radiation before surgery in subjects with esophageal cancer,,Terminated,Has Results,esophageal cancer|adenocarcinoma of the esophagus|squamous cell carcinoma,drug: oncogel (paclitaxel gel)|drug: cisplatin|drug: 5-fu|radiation: radiation therapy|procedure: esophageal resection,overall tumor response at the primary tumor site based on measurement of primary tumor volume (excluding involved lymph nodes) by spiral ct,boston scientific corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,137.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PR016-CLN-pro003,January 2008,November 2010,November 2010,"December 13, 2007","May 16, 2014","May 11, 2022","[""university of california san diego, san diego, california, united states rush university medical center, chicago, illinois, united states university of chicago medical center, chicago, illinois, united states indiana university medical center, indianapolis, indiana, united states university of kansas medical center, kansas city, kansas, united states thomas jefferson university, philadelphia, pennsylvania, united states baylor university medical center, dallas, texas, united states digestive health specialists of tyler, texas, tyler, texas, united states university hospital brno, brno, czechia hospital jablonec nad nisou, jablonec nad nisou, czechia university hospital olomouc, olomouc, czechia university hospital motol, praha, czechia massaryk's hospital in usti nad labem, usti nad labem, czechia kidwai memorial institute of oncology, bangalore, karnataka, india amrita institute of medical sciences, kochi, kerala, india bombay hospital & medical research centre, mumbai, maharashtra, india deenanath mangeshkar hospital, erandwane, pune, india meenakshi mission hospital and research centre, madurai, tamil nadu, india samodzielny publiczny szpital kliniczny, lublin, poland samodzielnego publicznego szpitala klinicznego, szczecin, poland""]",,https://ClinicalTrials.gov/show/NCT00573131,gastric kidney esophag
394,395,NCT00193934,magnetic resonance imaging (mri) staging of cervix cancer,,Completed,No Results Available,cancer of the uterine cervix,,"assess the prognostic significance, with respect to overall survival, of the factors, figo stage. overall survival is defined as the date of registration to date of death from any cause.","trans tasman radiation oncology group|peter maccallum cancer centre, australia",Female,"18 Years and older   (Adult, Older Adult)",,109.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,TROG 04.02,January 2006,May 2014,"May 15, 2014","September 19, 2005",,"July 12, 2017","['washington university school of medicine, saint louis, missouri, united states liverpool hospital, liverpool, new south wales, australia calvary mater newcastle, newcastle, new south wales, australia royal north shore hospital, sydney, new south wales, australia westmead hospital, wentworthville, new south wales, australia royal brisbane hospital, herston, queensland, australia north queensland oncology service, townsville, queensland, australia premion - tugun, tugun, queensland, australia royal adelaide hospital, adelaide, south australia, australia peter maccallum cancer centre, melbourne, victoria, australia tata memorial hospital, mumbai, india meenakshi mission hospital, tamil nadu, india auckland hospital, auckland, new zealand christchurch hospital, christchurch, new zealand dunedin hospital, dunedin, new zealand national university hospital, singapore, singapore']",,https://ClinicalTrials.gov/show/NCT00193934,cervix fibroid
395,396,NCT01104584,efficacy and safety of gadobutrol 1.0 molar (gadovist) for breast magnetic resonance imaging (mri),GEMMA 2,Completed,Has Results,breast cancer,"drug: gadobutrol (gadavist, gadovist, bay86-4875)","difference of sensitivity for detection of full extent of malignant breast disease using cmrm vs umrm per reader|sensitivity for detection of full extent of malignant breast disease using cmrm vs umrm per reader|breast level specificity of cmrm for non-malignant breasts by reader|breast level specificity of cmrm based on malignant breasts|percentage difference of participants whose index cancers were detected using cmrm vs umrm, cmrm vs xrm, and cmrm vs cmrm+xrm|percentage difference of participants whose additional index cancers were detected using cmrm vs umrm, cmrm vs xrm, and cmrm vs cmrm+xrm|difference of confidence in diagnosis for breast region diagnosis using cmrm vs umrm, cmrm+xrm vs umrm+xrm and cmrm+xrm vs xrm by reader, participant level",bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,460.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,91782|2009-009598-90,May 2010,September 2011,January 2012,"April 15, 2010","November 11, 2014","November 11, 2014","['tucson, arizona, united states oakland, california, united states englewood, colorado, united states chicago, illinois, united states new york, new york, united states columbus, ohio, united states providence, rhode island, united states san antonio, texas, united states tacoma, washington, united states buenos aires, ciudad auton. de buenos aires, argentina buenos aires, ciudad auton. de buenos aires, argentina buenos aires, ciudad auton. de buenos aires, argentina hamilton, ontario, canada toronto, ontario, canada toronto, ontario, canada montreal, quebec, canada erlangen, bayern, germany münchen, bayern, germany frankfurt, hessen, germany greifswald, mecklenburg-vorpommern, germany göttingen, niedersachsen, germany göttingen, niedersachsen, germany bochum, nordrhein-westfalen, germany münster, nordrhein-westfalen, germany münster, nordrhein-westfalen, germany gera, thüringen, germany berlin, germany mumbai, maharashtra, india delhi, india mumbai, india eindhoven, ej, netherlands maastricht, netherlands nijmegen, netherlands bydgoszcz, poland gliwice, poland krakow, poland szczecin, poland warszawa, poland sabadell, barcelona, spain alzira, valencia, spain barcelona, spain cordoba, spain girona, spain taichung, taiwan taipei, taiwan taipei, taiwan taipei, taiwan taizung, taiwan']",,https://ClinicalTrials.gov/show/NCT01104584,breast
396,397,NCT04482309,a phase 2 study of t-dxd in patients with selected her2 expressing tumors,DPT02,Recruiting,No Results Available,"bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, rare tumors",drug: trastuzumab deruxtecan,"objective response rate (orr)|duration of response (dor)|disease control rate (dcr)|progression free survival (pfs)|proportion of patients alive and progression-free at 6 months and 12 months|overall survival (os)|proportion of patients alive at 6 and 12 months|occurrence of adverse events (aes) and serious adverse events (saes)|pharmacokinetics (pk) assessed by serum concentration of t-dxd, total anti-her2 antibody and maaa-1181|the immunogenicity of t-dxd assessed by the presence of adas for t-dxd","astrazeneca|daiichi sankyo co., ltd.",All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,280.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D967VC00001,"August 18, 2020","May 31, 2023","May 31, 2023","July 22, 2020",,"May 11, 2022","['research site, burbank, california, united states research site, duarte, california, united states research site, fullerton, california, united states research site, la jolla, california, united states research site, los angeles, california, united states research site, santa rosa, california, united states research site, chicago, illinois, united states research site, muncie, indiana, united states research site, boston, massachusetts, united states research site, detroit, michigan, united states research site, saint louis, missouri, united states research site, middletown, new jersey, united states research site, commack, new york, united states research site, harrison, new york, united states research site, new york, new york, united states research site, rochester, new york, united states research site, durham, north carolina, united states research site, columbus, ohio, united states research site, portland, oregon, united states research site, nashville, tennessee, united states research site, houston, texas, united states research site, fairfax, virginia, united states research site, seattle, washington, united states research site, auchenflower, australia research site, camperdown, australia research site, heidelberg, australia research site, kogarah, australia research site, nedlands, australia research site, randwick, australia research site, brussels, belgium research site, bruxelles, belgium research site, gent, belgium research site, leuven, belgium research site, liège, belgium research site, yvoir, belgium research site, barretos, brazil research site, belo horizonte, brazil research site, curitiba, brazil research site, fortaleza, brazil research site, natal, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, santa maria, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, vitória, brazil research site, edmonton, alberta, canada research site, kelowna, british columbia, canada research site, hamilton, ontario, canada research site, london, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, canada research site, quebec, canada research site, brno, czechia research site, hradec kralove, czechia research site, olomouc, czechia research site, ostrava, czechia research site, praha 10, czechia research site, praha 5, czechia research site, praha 8, czechia research site, gurgaon, india research site, kolkata, india research site, madurai, india research site, mumbai, india research site, mumbai, india research site, nasik, india research site, rohini, india research site, milan, italy research site, milan, italy research site, napoli, italy research site, roma, italy research site, rome, italy research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, amsterdam, netherlands research site, delft, netherlands research site, den haag, netherlands research site, groningen, netherlands research site, bydgoszcz, poland research site, gdańsk, poland research site, gliwice, poland research site, kraków, poland research site, poznan, poland research site, warszawa, poland research site, arkhangelsk, russian federation research site, kaluga, russian federation research site, kazan, tatarstan, russian federation research site, krasnoyarsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, murmansk, russian federation research site, nizhnii novgorod, russian federation research site, nizhniy novgorod, russian federation research site, novosibirsk, russian federation research site, omsk, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, yaroslavl, russian federation research site, barcelona, spain research site, barcelona, spain research site, córdoba, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, valencia, spain research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, muang, thailand research site, muang, thailand research site, ongkharak, thailand research site, sisaket, thailand research site, glasgow, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, northwood middlesex, united kingdom research site, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT04482309,cervic ovari bladder pancreat biliari
397,398,NCT00410761,an efficacy study comparing zd6474 to placebo in medullary thyroid cancer,,"Active, not recruiting",Has Results,thyroid cancer,drug: zd6474 (vandetanib),progression-free survival(pfs)|objective response rate (orr)|disease control rate (dcr)|duration of response (dor)|overall survival (os)|biochemical response calcitonin (ctn)|biochemical response carcinoembryonic antigen (cea)|time to worsening of pain (twp),"genzyme, a sanofi company|sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 3,437.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D4200C00058|2005-005077-29|LPS14811,"November 30, 2006","July 31, 2009","December 31, 2022","December 13, 2006","March 26, 2012","November 1, 2021","['investigational site number 3, little rock, arkansas, united states investigational site number 8, san francisco, california, united states investigational site number 9, aurora, colorado, united states investigational site number 11, new haven, connecticut, united states investigational site number 15, jacksonville, florida, united states investigational site number 18, chicago, illinois, united states investigational site number 17, lexington, kentucky, united states investigational site number 2, boston, massachusetts, united states investigational site number 7, detroit, michigan, united states investigational site number 14, rochester, minnesota, united states investigational site number 10, saint louis, missouri, united states investigational site number 6, cincinnati, ohio, united states investigational site number 22, portland, oregon, united states investigational site number 19, charleston, south carolina, united states investigational site number 13, houston, texas, united states investigational site number 21, burlington, vermont, united states investigational site number 1001, st leonards, australia investigational site number 1901, wien, austria investigational site number 1101, bruxelles, belgium investigational site number 1102, leuven, belgium investigational site number 2301, porto alegre, brazil investigational site number 2302, ribeirão preto, brazil investigational site number 1203, calgary, canada investigational site number 1202, london, canada investigational site number 1201, moncton, canada investigational site number 1204, sherbrooke, canada investigational site number 1205, toronto, canada investigational site number 3601, praha 5, czechia investigational site number 2701, odense c, denmark investigational site number 2802, bordeaux cedex, france investigational site number 2803, lyon cedex 8, france investigational site number 2801, villejuif, france investigational site number 2002, essen, germany investigational site number 2001, halle, germany investigational site number 2005, würzburg, germany investigational site number 1601, pécs, hungary investigational site number 1401, mumbai, india investigational site number 1402, vellore, india investigational site number 2506, catania, italy investigational site number 2502, milano, italy investigational site number 2503, napoli, italy investigational site number 2501, pisa, italy investigational site number 2505, roma, italy investigational site number 2504, siena, italy investigational site number 1501, seoul, korea, republic of investigational site number 2403, cd. madero, mexico investigational site number 2402, mexico city, mexico investigational site number 2404, méxico, mexico investigational site number 2902, groningen, netherlands investigational site number 2901, utrecht, netherlands investigational site number 1701, gliwice, poland investigational site number 1702, poznan, poland investigational site number 1703, warszawa, poland investigational site number 2602, coimbra, portugal investigational site number 2601, lisboa, portugal investigational site number 1801, bucarest, romania investigational site number 3301, obninsk, russian federation investigational site number 3402, belgrade, serbia investigational site number 3401, belgrad, serbia investigational site number 3003, madrid, spain investigational site number 3001, madrid, spain investigational site number 3002, pamplona, spain investigational site number 3102, stockholm, sweden investigational site number 3101, uppsala, sweden investigational site number 2101, basel, switzerland investigational site number 2102, bern, switzerland']",,https://ClinicalTrials.gov/show/NCT00410761,thyroid
398,399,NCT00674973,a biomarker identification trial of tarceva (erlotinib) in patients with advanced pancreatic cancer,,Completed,Has Results,pancreatic cancer,drug: erlotinib|drug: placebo,progression-free survival|percentage of participants with best overall response rate|percentage of participants with disease control rate (dcr)|overall survival|number of participants with adverse events (aes),hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,207.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BO21129|2007-003738-40,June 2008,December 2010,March 2015,"May 8, 2008","April 26, 2016","June 17, 2016","['kogarah, new south wales, australia st. leonards, new south wales, australia sydney, new south wales, australia box hill, victoria, australia salvador, bahia, ba, brazil belo horizonte, mg, brazil curitiba, pr, brazil ijui, rs, brazil porto alegre, rs, brazil porto alegre, rs, brazil porto alegre, rs, brazil jau, sp, brazil sao paulo, sp, brazil sao paulo, sp, brazil gabrovo, bulgaria pleven, bulgaria plovdiv, bulgaria sofia, bulgaria sofia, bulgaria sofia, bulgaria vratsa, bulgaria vratza, bulgaria zagreb, croatia bochum, germany dresden, germany esslingen, germany greifswald, germany hamburg, germany köln, germany saarbruecken, germany ulm, germany hong kong, hong kong hong kong, hong kong bangalore, india chennai, india jaipur, india kochi, india kolkata, india ludhiana, india mumbai, india new delhi, india pune, india vellore, india bologna, emilia-romagna, italy udine, friuli-venezia giulia, italy riga, latvia kaunas, lithuania vilnius, lithuania vilnius, lithuania kuala lumpur, malaysia penang, malaysia monterrey, mexico arequipa, peru chiclayo, peru san isidro, peru bucharest, romania cluj napoca, romania craiova (dolj county), romania irkutsk, russian federation kazan, russian federation krasnodar, russian federation moscow, russian federation st petersburg, russian federation st petersburg, russian federation singapore, singapore ljubljana, slovenia kiev, ukraine london, united kingdom london, united kingdom london, united kingdom london, united kingdom sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00674973,pancreat
399,400,NCT03567798,thrombocytopenia induced by chemotherapy,papayaleaf,Completed,No Results Available,thrombocytopenia,dietary supplement: uplat|other: placebo,increase in the platelet counts from baseline levels to the end of therapy.,socrates school of health,All,18 Years to 55 Years   (Adult),Not Applicable,60.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SPL/UP/2017/01,"July 18, 2017","November 20, 2017","November 20, 2017","June 26, 2018",,"June 27, 2018","['north east cancer centre hospital and research institute, guwahati, assam, india']",,https://ClinicalTrials.gov/show/NCT03567798,
400,401,NCT00825955,comparison of brivanib and best supportive care to placebo for treatment of liver cancer for those subjects who have failed sorafenib treatment,BRISK PS,Completed,No Results Available,liver cancer,drug: brivanib|other: placebo|procedure: best supportive care,"to compare overall survival of subjects with advanced hcc who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (bsc) to those receiving placebo plus bsc|to compare time to progression (ttp) (investigator assessed using modified response evaluation criteria in solid tumors (recist) for hcc criteria)|to compare the independent radiological review committee (irrc) assessed objective response rate (orr) and disease control rate (dcr) using modified recist for hcc criteria|to assess duration of response, duration of disease control and time to response|to assess safety profile of brivanib. safety will be assessed by the number of adverse events (aes), serious adverse events (saes), periodic data monitoring committee (dmc) review",bristol-myers squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,587.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CA182-034|EUDRACT #: 2008-005084-34,"February 17, 2009","November 15, 2011","August 25, 2017","January 21, 2009",,"October 9, 2019","['mayo clinic arizona, scottsdale, arizona, united states univ of ark for med sci, little rock, arkansas, united states loma linda university cancer center, loma linda, california, united states richard finn, m.d., los angeles, california, united states sharp clinical oncology research, san diego, california, united states pacific hematology oncology associates, san francisco, california, united states uf health clinical research center, gainesville, florida, united states james graham brown cancer center, louisville, kentucky, united states 3912 taubman center, ann arbor, michigan, united states henry ford health system irb, detroit, michigan, united states mayo clinic, rochester, minnesota, united states mount sinai school of medicine, new york, new york, united states columbia university medical center, new york, new york, united states ohio state university, columbus, ohio, united states oregon health & sci univ, portland, oregon, united states university of pennsylvania, philadelphia, pennsylvania, united states university of texas, houston, texas, united states the university of texas health science center, san antonio, texas, united states mcguire dvamc, richmond, virginia, united states local institution, capital federal, buenos aires, argentina local institution, rosario, santa fe, argentina local institution, bruxelles, belgium local institution, salvador - ba, bahia, brazil local institution, salvador, bahia, brazil local institution, porto alegre, rio grande do sul, brazil local institution, sao paulo, brazil local institution, calgary, alberta, canada local institution, vancouver, british columbia, canada local institution, toronto, ontario, canada local institution, beijing, beijing, china local institution, guangzhou, guangdong, china local institution, guanzhou, guangdong, china local institution, nanning, guangxi, china local institution, wuhan, hubei, china local institution, nanjing, jiangsu, china local institution, tianjing, tianjin, china local institution, hangzhou, zhejiang, china local institution, bordeaux, france local institution, creteil cedex, france local institution, grenoble cedex 09, france local institution, lille cedex, france local institution, lyon cedex 04, france local institution, montpellier cedex 5, france local institution, montpellier cedex, france local institution, paris cedex, france local institution, paris, france local institution, paris, france local institution, rennes, france local institution, toulouse cedex 09, france local institution, vandoeuvre cedex, france local institution, villejuif, france local institution, berlin, germany local institution, frankfurt, germany local institution, freiburg, germany local institution, halle, germany local institution, hannover, germany local institution, mainz, germany local institution, ulm, germany local institution, wuerzburg, germany local institution, kifisia, greece local institution, thessaloniki, greece local institution, hong kong, hong kong local institution, kochi, kerala, india local institution, chennai, india local institution, kolkata, india local institution, new delhi, india local institution, ancona, italy local institution, meldola (fc), italy local institution, milano, italy local institution, milano, italy local institution, napoli, italy local institution, padova, italy local institution, pisa, italy local institution, chiba-shi, chiba, japan local institution, kashiwa-shi, chiba, japan local institution, ogaki-shi, gifu, japan local institution, yokohama, kanagawa, japan local institution, kochi-shi, kochi, japan local institution, kyoto-shi, kyoto, japan local institution, tsu-shi, mie, japan local institution, higashinari-ku, osaka, japan local institution, osaka-sayama-shi, osaka, japan local institution, osaka-shi, osaka, japan local institution, osaka-shi, osaka, japan local institution, sunto-gun, shizuoka, japan local institution, bunkyo-ku, tokyo, japan local institution, chuo-ku, tokyo, japan local institution, musashino-shi, tokyo, japan local institution, toyama city, toyama, japan local institution, shimonoseki-shi, yamaguchi, japan local institution, nishinomiya-shi, japan local institution, busan, korea, republic of local institution, daegu, korea, republic of local institution, gyeonggi-do, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, d.f., distrito federal, mexico local institution, toluca, estado de mexico, mexico local institution, cuernavaca, morelos, mexico local institution, san juan, puerto rico local institution, moscow, russian federation local institution, moscow, russian federation local institution, moscow, russian federation local institution, barcelona, spain local institution, madrid, spain local institution, oviedo, spain local institution, taichung, taiwan local institution, tainan, taiwan local institution, taipei, taiwan local institution, taipei, taiwan local institution, taoyuan hsien, taiwan']",,https://ClinicalTrials.gov/show/NCT00825955,liver
401,402,NCT00364351,efficacy trial comparing zd6474 with erlotinib in nsclc after failure of at least one prior chemotherapy,,Completed,Has Results,non small cell lung cancer,drug: vandetanib|drug: erlotinib,progression-free survival (pfs)|overall survival (os)|objective response rate (orr)|disease control rate (dcr)|time to deterioration of disease-related symptoms (tds) by eortc quality of life questionnaire - pain|time to deterioration of disease-related symptoms (tds) by eortc quality of life questionnaire - dyspnoea|time to deterioration of disease-related symptoms (tds) by eortc quality of life questionnaire - cough,"genzyme, a sanofi company|sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1574.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D4200C00057|EUDRACT No. 2006-000259-16,August 2006,September 2008,November 2016,"August 15, 2006","May 24, 2011","January 25, 2018","['research site, berkeley, california, united states research site, los angeles, california, united states research site, santa rosa, california, united states research site, boynton beach, florida, united states research site, fort myers, florida, united states research site, jacksonville, florida, united states research site, port saint lucie, florida, united states research site, wichita, kansas, united states research site, lexington, kentucky, united states research site, louisville, kentucky, united states research site, metairie, louisiana, united states research site, baltimore, maryland, united states research site, columbia, missouri, united states research site, saint louis, missouri, united states research site, latham, new york, united states research site, hickory, north carolina, united states research site, canton, ohio, united states research site, cincinnati, ohio, united states research site, greenville, south carolina, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, amarillo, texas, united states research site, garland, texas, united states research site, webster, texas, united states research site, fairfax, virginia, united states research site, norfolk, virginia, united states research site, richmond, virginia, united states research site, burien, washington, united states research site, yakima, washington, united states research site, ciudad de buenos aires, argentina research site, córdoba, argentina research site, gonnet, argentina research site, ramos mejía, argentina research site, rosario, argentina research site, santa fe, argentina research site, ashford, australia research site, bedford park, australia research site, chermside, australia research site, geelong, australia research site, hornsby, australia research site, kogarah, australia research site, malvern, australia research site, prahran, australia research site, wodonga, australia research site, belo horizonte, brazil research site, caxias do sul, brazil research site, curitiba, brazil research site, goiânia, brazil research site, porto alegre, brazil research site, santo andré, brazil research site, sao paulo, brazil research site, kelowna, british columbia, canada research site, vancouver, british columbia, canada research site, winnipeg, manitoba, canada research site, oshawa, ontario, canada research site, ottawa, ontario, canada research site, sault ste. marie, ontario, canada research site, thunder bay, ontario, canada research site, toronto, ontario, canada research site, york, ontario, canada research site, charlottetown, prince edward island, canada research site, laval, quebec, canada research site, montreal, quebec, canada research site, beijing, china research site, dalian, china research site, hangzhou, china research site, nanjing, china research site, nanning, china research site, shanghai, china research site, shenyang, china research site, wuhan, china research site, herlev, denmark research site, københavn ø, denmark research site, næstved, denmark research site, caen, france research site, clermont ferrand, france research site, marseille, france research site, paris cedex 12, france research site, rennes cedex 9, france research site, vesoul cedex, france research site, großhansdorf, germany research site, göttingen, germany research site, hannover, germany research site, heidelberg, germany research site, karlsruhe, germany research site, löwenstein, germany research site, mainz, germany research site, mönchengladbach, germany research site, ulm, germany research site, hong kong, hong kong research site, bangalore, india research site, karnataka, india research site, new delhi, india research site, pune, india research site, trivandrum, india research site, bandung, indonesia research site, jakarta, indonesia research site, solo, indonesia research site, ancona, italy research site, avellino, italy research site, catania, italy research site, genova, italy research site, mantova, italy research site, milano, italy research site, orbassano, italy research site, parma, italy research site, perugia, italy research site, roma, italy research site, rozzano, italy research site, seoul, korea, republic of research site, juchitan, mexico research site, monterrey, mexico research site, morelia, mexico research site, puebla, mexico research site, saltillo, mexico research site, zacatecas, mexico research site, harderwijk, netherlands research site, nieuwegein, netherlands research site, rotterdam, netherlands research site, zwolle, netherlands research site, bergen, norway research site, haugesund, norway research site, kristiansand, norway research site, oslo, norway research site, stavanger, norway research site, tromsø, norway research site, trondheim, norway research site, cebu city, philippines research site, davao city, philippines research site, manila, philippines research site, pasay city, philippines research site, quezon city, philippines research site, elche(alicante), spain research site, jaén, spain research site, madrid, spain research site, mataró(barcelona), spain research site, málaga, spain research site, pamplona, spain research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, bangkok, thailand research site, chiang mai, thailand research site, lampang, thailand research site, songkla, thailand research site, birmingham, united kingdom research site, cambridge, united kingdom research site, leicester, united kingdom research site, liverpool, united kingdom research site, nottingham, united kingdom research site, sheffield, united kingdom research site, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00364351,
402,403,NCT00669565,safety and efficacy study of bavituximab plus paclitaxel and carboplatin to treat breast cancer,,Completed,No Results Available,carcinoma breast stage iv,drug: bavituximab,the primary objective of this study is to determine the overall response rate (cr+pr),peregrine pharmaceuticals,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,46.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PPHM 0702,July 2008,July 2010,August 2010,"April 30, 2008",,"March 24, 2011","[""rajalakshmi multispecialty hospital, bangalore, india bangalore institute of oncology, banglore, india apollo specialty hospitals, chennai, india nizam's institute of medical sciences, hyderabaad, india regional cancer center, kerala, india medical college hospital, kolkata, india bharath hospital and institite of oncology, mysore, india curie manavata cancer center, nashik, india ruby hall clinic, pune, india""]",,https://ClinicalTrials.gov/show/NCT00669565,breast
403,404,NCT02576431,a study to test the effect of the drug larotrectinib in adults and children with ntrk-fusion positive solid tumors,NAVIGATE,Recruiting,No Results Available,solid tumors harboring ntrk fusion,"drug: bay2757556 (larotrectinib, vitrakvi)","best overall response rate by irc|best overall response rate by investigator|duration of response (dor) by irc|duration of response (dor) by investigator|clinical benefit rate (cbr)|progression-free survival (pfs) after larotrectinib|overall survival time|progression-free survival (pfs) after past cancer therapy|number of subjects with adverse events|number of subjects with serious adverse events|number of subjects with treatment-related adverse events|severity of adverse events|severity of serious adverse events|severity of treatment-related adverse events|duration of adverse events|duration of serious adverse events|duration of treatment-related adverse events|number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration|severity of safety-relevant changes in clinical parameters or vital signs after drug administration|proportion of patients with any tumor regression (i.e., measured as shrinkage of target lesions) as a best response|concordance coefficient",bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,204.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20289|LOXO-TRK-15002|2015-003582-28,"September 30, 2015","August 15, 2023","August 29, 2025","October 15, 2015",,"May 6, 2022","['stanford cancer center, palo alto, california, united states ucla-santa monica medical center, santa monica, california, united states memorial hospital west, pembroke, florida, united states university of chicago, chicago, illinois, united states massachusetts general hospital, boston, massachusetts, united states dana-farber cancer institute, boston, massachusetts, united states dartmouth hitchock medical center, lebanon, new hampshire, united states memorial sloan-kettering cancer center, new york, new york, united states university of north carolina hospitals, chapel hill, north carolina, united states wake forest baptist health, winston-salem, north carolina, united states cleveland clinic, cleveland, ohio, united states thomas jefferson university, philadelphia, pennsylvania, united states fox chase cancer center, philadelphia, pennsylvania, united states avera cancer institute, sioux falls, south dakota, united states vanderbilt university medical center, nashville, tennessee, united states university of texas md anderson cancer center, houston, texas, united states inova schar cancer institute, fairfax, virginia, united states university of washington, seattle, washington, united states west virginia university, morgantown, west virginia, united states centro medico austral, buenos aires, ciudad auton. de buenos aires, argentina hospital británico, buenos aires, ciudad auton. de buenos aires, argentina instituto medico especializado alexander fleming, buenos aires, ciudad auton. de buenos aires, argentina centro estudios médicos e invest. clínicas ""dr. n. quirno"", buenos aires, ciudad auton. de buenos aires, argentina hospital alemán, buenos aires, ciudad auton. de buenos aires, argentina fundación cenit para la investigación en neurociencias, caba, ciudad auton. de buenos aires, argentina instituto de oncología de rosario, rosario, santa fe, argentina centro médico san roque, san miguel de tucumán, tucuman, argentina macquarie university hospital, macquarie university, new south wales, australia royal darwin hospital, tiwi, northern territory, australia st john of god healthcare, subiaco, western australia, australia sir charles gairdner hospital, nedlands, australia institut jules bordet/jules bordet instituut, anderlecht, belgium hosp. araujo jorge da associação de combate ao câncer, goiânia, goiás, brazil cenantron centro avançado de tratamento oncológico, ltda., belo horizonte, minas gerais, brazil associação hospital de caridade de ijuí, ijuí, rio grande do sul, brazil irmandade santa casa de misericordia de porto alegre, porto alegre, rio grande do sul, brazil fundação pio xii - hospital de câncer de barretos, barretos, sao paulo, brazil hospital de base da fundação f m s j rio preto, são josé do rio preto, sao paulo, brazil instituto do câncer do estado de são paulo, são paulo, sao paulo, brazil clín. de pesq. e centro de estudos em onco gineco mamária, são paulo, sao paulo, brazil real e benemérita associação portuguesa de beneficência, são paulo, sao paulo, brazil ibcc - instituto brasileiro de controle do cancer, são paulo, sao paulo, brazil instituto nacional do câncer - inca - hc ii, rio de janeiro, brazil inca - hospital do cancer iii, rio de janeiro, brazil oncoclínicas rio de janeiro s.a, rio de janeiro, brazil hospital sirio libanes, sao paulo, brazil tom baker cancer centre, calgary, alberta, canada juravinski cancer centre-mcmaster medical unit, hamilton, ontario, canada london regional cancer program, london health sciences ctr, london, ontario, canada sir mortimer b. davis jewish general hospital, montreal, quebec, canada sun yat-sen university cancer center, guangzhou, guangdong, china sichuan university west china hospital, chengdu, sichuan, china beijing cancer hospital, beijing, china zhongshan hospital, fudan university, shanghai, china instituto nacional de cancerología, bogotá, cundinamarca, colombia oncomédica s.a., montería, córdoba, colombia fundación oftalmológica de santander carlos ardila lule, floridablanca, santander, colombia masarykuv onkologicky ustav, brno, czechia fakultni nemocnice hradec kralove, hradec kralove, czechia fakultni nemocnice olomouc, olomouc, czechia fakultni thomayerova nemocnice, praha 4, czechia finsen centre, copenhagen, denmark hopital jean minjoz, besancon, france institut bergonié - unicancer nouvelle aquitaine, bordeaux cedex, france hôpital saint andré - bordeaux, bordeaux, france centre léon bérard, lyon cedex, france centre antoine lacassagne, nice cedex 2, france hôpital saint louis, paris, france hopital saint antoine - paris, paris, france hôpital de la pitié-salpétrière, paris, france centre hospitalier lyon sud, pierre benite, france hôpital de la milétrie, poitiers cedex, france hôpital guillaume et rené laennec - nantes, saint herblain, france institut de cancérologie de l\'ouest - saint herblain, saint herblain, france icans - institut de cancérologie de strasbourg europe, strasbourg, france universitätsklinikum heidelberg, heidelberg, baden-württemberg, germany heinrich-heine-universität düsseldorf, düsseldorf, nordrhein-westfalen, germany universitätsklinikum essen, essen, nordrhein-westfalen, germany charité comprehensive cancer center (cccc), berlin, germany agios savvas anticancer hospital of athens, athens, greece laiko general hospital of athens, athens, greece general hospital of athens ""alexandra"", athens, greece general oncology hospital of kifissia agioi anargyroi, kifissia / athens, greece university general hospital of patra, patra, greece mh egeszsegugyi kozpont, budapest, hungary orszagos onkologiai intezet, budapest, hungary debreceni egyetem klinikai kozpont, debrecen, hungary bacs-kiskun megyei korhaz, kecskemet, hungary all india institute of medical sciences, new delhi, delhi, india tata memorial hospital, mumbai,, maharashtra, india kokilaben dhirubhai ambani hospital & medical research insti, mumbai, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india jawaharlal institute of postgraduate medical education and r, gorimedu, pondicherry, india chittaranjan national cancer institute, kolkata, west bengal, india st vincents university hospital, dublin, ireland a.o.r.n. san giuseppe moscati, avellino, campania, italy a.o.u. di bologna policlinico s.orsola malpighi, bologna, emilia-romagna, italy a.s.u. friuli centrale - a. regionale coordinamento salute, udine, friuli-venezia giulia, italy irccs istituti fisioterapici ospitalieri - ifo, roma, lazio, italy fondazione policlinico universitario agostino gemelli irccs, roma, lazio, italy irccs ospedale policlinico san martino, genova, liguria, italy istituto clinico humanitas - humanitas mirasole s.p.a., milano, lombardia, italy irccs istituto europeo di oncologia s.r.l. (ieo), milano, lombardia, italy asst grande ospedale metropolitano niguarda, milano, lombardia, italy istituto oncologico veneto irccs (iov), padova, veneto, italy nagoya university hospital, nagoya, aichi, japan national cancer center hospital east, kashiwa, chiba, japan hokkaido university hospital, sapporo, hokkaido, japan the cancer institute hospital of jfcr, koto-ku, tokyo, japan seoul national university hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of korea university anam hospital, seoul, korea, republic of oslo universitetssykehus hf radiumhospitalet, oslo, norway wojskowy instytut medyczny, warszawa, poland fundacao champalimaud, lisboa, portugal chuln - hospital santa maria, lisboa, portugal chup - hospital santo antonio, porto, portugal ipo porto, porto, portugal arkhangelsk clinical oncology dispensary, arkhangelsk, russian federation ltd ""evimed"", chelyabinsk, russian federation republican clinical oncology dispensary, kazan, russian federation moscow clinical scientific centre n.a.loginov, moscow, russian federation russian oncological scientific center n.a. n.n. blokhin rams, moscow, russian federation 1st moscow state medical university n.a. i.m.sechenov, moscow, russian federation moscow scient. res. institute of oncology n.a p.a. hertzen, moscow, russian federation city oncological hospital #62, moscow, russian federation clinical diagnostical center, nizhny novgorod, russian federation st. petersburg clinical onc. cent. of spec. types of care, st. petersburg, russian federation national cancer center singapore, singapore, singapore onkologicky ustav svatej alzbety, s.r.o., bratislava, slovakia narodny onkologicky ustav, bratislava, slovakia institut català d\'oncologia hospitalet, hospitalet de llobregat, barcelona, spain hospital universitario ""marqués de valdecilla"", santander, cantabria, spain hospital del mar, barcelona, spain ciutat sanitària i universitaria de la vall d\'hebron, barcelona, spain hospital clínic i provincial de barcelona, barcelona, spain hospital general universitario gregorio marañón, madrid, spain fundacion jimenez diaz (clinica de la concepcion), madrid, spain centro integral oncológico clara campal, madrid, spain hospital clínico universitario de valencia, valencia, spain hospital general universitario de valencia, valencia, spain karolinska universitetssjukhuset i solna, stockholm, sweden chang gung memorial hospital kaohsiung, kaohsiung, taiwan national taiwan university hospital, taipei, taiwan tri-service general hospital, taipei, taiwan ankara sehir hastanesi, ankara, turkey trakya univ. tip fak., edirne, turkey istanbul universitesi istanbul tip fakultesi, istanbul, turkey istanbul universitesi cerrahpasa-cerrahpasa tip fakultesi, istanbul, turkey tc saglik bakanligi goztepe profdr suleyman yalcin sehir has, istanbul, turkey izmir katip celebi universitesi ataturk egitim ve arastirma, izmir, turkey erciyes universitesi tip fakultesi, kayseri, turkey national cancer institute, kiev, ukraine southampton general hospital, southampton, hampshire, united kingdom beatson west of scotland cancer centre, glasgow, united kingdom institute of cancer-barts and the london school of medicine, london, united kingdom university college hospital, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT02576431,
404,405,NCT00424255,study of adjuvant lapatinib in high-risk head and neck cancer subjects after surgery,,Completed,Has Results,"neoplasms, head and neck",drug: lapatinib|radiation: chemoradiation|other: placebo,disease free survival (dfs)|overall survival (os)|disease specific survival (dss)|time to locoregional recurrence (ttlr)|time to distant relapse (ttdr)|number of participants with a second primary tumor|extent of exposure|number of participants with any adverse event (ae) or serious adverse event (sae)|number of participants with the indicated chemistry toxicities by maximum toxicity grade (g3 and g4) at the worst-case on-therapy visit|number of participants with the indicated hematological toxicities by maximum toxicity grade (g3 and g4) at the worst-case on-therapy visit|number of participants with on-therapy and follow-up late radiation morbidity events|change from baseline in blood pressure at the indicated time points|change from baseline in heart rate at the indicated time points|change from baseline in body temperature at the indicated time points|change from baseline in body weight at the indicated time points|number of participants with abnormal 12-lead electrocardiogram (ecg) findings at the indicated time points|number of participants with the indicated eastern cooperative oncology group (ecog) performance status value|change from baseline in quality of life status as assessed by the functional assessement of cancer therapy-head and neck (fact-h&n) questionnaire|change from baseline in quality of life status as assessed by the euroqol-5d (eq-5d) scale|number of participants with the indicated biomarker expression status|number of participants with the indicated worst-case on-therapy left ventricular ejection fraction (lvef) change from baseline,glaxosmithkline,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,688.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EGF102988,December 2006,March 2013,November 2013,"January 19, 2007","February 11, 2014","July 18, 2014","['gsk investigational site, springfield, illinois, united states gsk investigational site, saint louis, missouri, united states gsk investigational site, new york, new york, united states gsk investigational site, chapel hill, north carolina, united states gsk investigational site, lubbock, texas, united states gsk investigational site, ciudad autonoma de buenos aires, buenos aires, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, quilmes, argentina gsk investigational site, santa fe, argentina gsk investigational site, innsbruck, austria gsk investigational site, rankweil, austria gsk investigational site, salzburg, austria gsk investigational site, vienna, austria gsk investigational site, vienna, austria gsk investigational site, edmonton, alberta, canada gsk investigational site, halifax, nova scotia, canada gsk investigational site, london, ontario, canada gsk investigational site, sherbrooke, quebec, canada gsk investigational site, quebec, canada gsk investigational site, guangzhou, guangdong, china gsk investigational site, wuhan, hubei, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, fuzhou, china gsk investigational site, shanghai, china gsk investigational site, tianjin, china gsk investigational site, zagreb, croatia gsk investigational site, zagreb, croatia gsk investigational site, brno, czech republic gsk investigational site, olomouc, czech republic gsk investigational site, ostrava - poruba, czech republic gsk investigational site, praha 8, czech republic gsk investigational site, tallinn, estonia gsk investigational site, angers cedex 09, france gsk investigational site, annecy, france gsk investigational site, caen, france gsk investigational site, colmar, france gsk investigational site, ferolles-attilly, france gsk investigational site, la roche sur yon, france gsk investigational site, lille, france gsk investigational site, lyon, france gsk investigational site, montpellier cedex 5, france gsk investigational site, paris, france gsk investigational site, reims, france gsk investigational site, saint cloud, france gsk investigational site, strasbourg, france gsk investigational site, toulouse, france gsk investigational site, villejuif cedex, france gsk investigational site, heidelberg, baden-wuerttemberg, germany gsk investigational site, karlsruhe, baden-wuerttemberg, germany gsk investigational site, essen, nordrhein-westfalen, germany gsk investigational site, halle, sachsen-anhalt, germany gsk investigational site, dresden, sachsen, germany gsk investigational site, leipzig, sachsen, germany gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, haidari, athens, greece gsk investigational site, neo faliro, greece gsk investigational site, peiraius, greece gsk investigational site, hong kong, hong kong gsk investigational site, kowloon, hong kong gsk investigational site, budapest, hungary gsk investigational site, budapest, hungary gsk investigational site, szombathely, hungary gsk investigational site, kochi, india gsk investigational site, mumbai, india gsk investigational site, mumbai, india gsk investigational site, pune, india gsk investigational site, trivandrum, india gsk investigational site, galway, ireland gsk investigational site, rathgar, dublin, ireland gsk investigational site, napoli, campania, italy gsk investigational site, genova, liguria, italy gsk investigational site, milano, lombardia, italy gsk investigational site, milano, lombardia, italy gsk investigational site, pavia, lombardia, italy gsk investigational site, venezia, veneto, italy gsk investigational site, manila, philippines gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, ufa,, russian federation gsk investigational site, bratislava, slovakia gsk investigational site, kosice, slovakia gsk investigational site, barcelona, spain gsk investigational site, barcelona, spain gsk investigational site, cordoba, spain gsk investigational site, gerona, spain gsk investigational site, granada, spain gsk investigational site, huesca, spain gsk investigational site, lerida, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, murcia, spain gsk investigational site, orense, spain gsk investigational site, santander, spain gsk investigational site, santiago de compostela, spain gsk investigational site, sevilla, spain gsk investigational site, valencia, spain gsk investigational site, zaragoza, spain gsk investigational site, bangkok, thailand gsk investigational site, bangkok, thailand gsk investigational site, chiangmai, thailand gsk investigational site, cambridge, cambridgeshire, united kingdom gsk investigational site, northwood, middlesex, united kingdom gsk investigational site, edinburgh, midlothian, united kingdom gsk investigational site, brighton, sussex east, united kingdom gsk investigational site, guildford, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, newcastle upon tyne, united kingdom gsk investigational site, sheffield, united kingdom gsk investigational site, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00424255,
405,406,NCT04884360,d9319c00001- 1l oc mono global rct,MONO-OLA1,Recruiting,No Results Available,ovarian cancer,drug: olaparib|other: matching placebo,superiority of olaparib as maintenance treatment relative to placebo by assessment of pfs in participants with stage iii/iv ovarian cancer with a brcawt hrd positive tumour and a cr/pr following standard 1st line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of pfs in participants with stage iii/iv ovarian cancer with a brcawt tumour and a cr/pr following standard 1st line platinum-based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of os in participants with stage iii/iv ovarian cancer with a brcawt hrd positive tumour and a cr/pr following standard first line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of os in participants with stage iii/iv ovarian cancer with a brcawt tumour and a cr/pr following standard first-line platinum-based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of tfst in participants with a brcawt hrd positive tumour and a cr or pr following standard first-line platinum-based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of tfst in participants with a brcawt tumour and a cr or pr following standard first line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of pfs2 in participants with a brcawt hrd positive tumour and a cr or pr following standard first-line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of pfs2 in participants with a brcawt tumour and a cr or pr following standard first-line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of tsst in participants with a brcawt hrd positive tumour and a cr or pr following standard first-line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of tsst in participants with a brcawt tumour and a cr or pr following standard first-line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of time to tdt in participants with a brcawt hrd positive tumour and a cr/pr following standard first-line platinum based chemotherapy treatment.|to demonstrate superiority of olaparib as maintenance treatment relative to placebo by assessment of time to tdt in participants with a brcawt tumour and a cr or pr following standard first-line platinum based chemotherapy treatment.|superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by recist 1.1/ca 125/death in participants with a brcawt hrd positive tumour and a cr/pr following 1st line platinum based chemotherapy|superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by recist 1.1/ca 125/death in participants with a brcawt tumour and a cr/pr following first-line platinum based chemotherapy.|assess health-related quality of life in participants treated with olaparib compared with placebo in participants with a brcawt hrd positive tumour and a cr or pr following standard first-line platinum based chemotherapy treatment|assess health-related quality of life in participants treated with olaparib compared with placebo in participants with brcawt tumour and a cr or pr following standard first-line platinum based chemotherapy treatment,astrazeneca,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D9319C00001,"May 31, 2021","July 2, 2024","July 2, 2025","May 13, 2021",,"April 14, 2022","[""research site, santiago, chile research site, santiago, chile research site, temuco, chile research site, temuco, chile research site, viña del mar, chile research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, chengdu, china research site, chongqing, china research site, guangzhou, china research site, guangzhou, china research site, guiyang, china research site, haikou, china research site, haikou, china research site, hangzhou, china research site, hangzhou, china research site, hefei, china research site, hefei, china research site, jiaxing, china research site, jining, china research site, lanzhou, china research site, linyi, china research site, nanjing, china research site, qingdao, china research site, qingdao, china research site, rui'an, china research site, shanghai, china research site, shanghai, china research site, shengyang, china research site, shenzhen, china research site, shijiazhuang, china research site, suzhou, china research site, tianjin, china research site, tianjin, china research site, urumqi, china research site, wenzhou, china research site, wenzhou, china research site, wuhan, china research site, wuhan, china research site, wulumuqi, china research site, wuxi, china research site, xiamen, china research site, xianyang, china research site, xuzhou, china research site, xuzhou, china research site, yanji, china research site, zibo, china research site, zunyi, china research site, barranquilla, colombia research site, bogota, colombia research site, bogotá, colombia research site, bogotá, colombia research site, ibague, colombia research site, medellin, colombia research site, medellín, colombia research site, gurgaon, india research site, jaipur, india research site, kolkata, india research site, kolkata, india research site, madurai, india research site, namakkal, india research site, nashik, india research site, nasik, india research site, new delhi, india research site, new delhi, india research site, arequipa, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, san isidro, peru research site, bialystok, poland research site, gdynia, poland research site, gliwice, poland research site, grzepnica, poland research site, poznań, poland research site, szczecin, poland research site, arkhangelsk, russian federation research site, chelyabinsk, russian federation research site, ekaterinburg, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhniy novgorod, russian federation research site, obninsk, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, sankt-peterburg, russian federation research site, st petersburg, russian federation research site, tomsk, russian federation research site, tomsk, russian federation research site, adana, turkey research site, ankara, turkey research site, istanbul, turkey research site, izmir, turkey research site, samsun, turkey research site, chernihiv, ukraine research site, dnipro, ukraine research site, ivano-frankivsk, ukraine research site, kharkiv, ukraine research site, kryvyi rih, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, zaporizhzhia, ukraine research site, ha noi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam""]",,https://ClinicalTrials.gov/show/NCT04884360,ovari
406,407,NCT02953340,spi-2012 vs pegfilgrastim in management of neutropenia in breast cancer participants with docetaxel and cyclophosphamide,,Completed,Has Results,neutropenia|breast cancer,drug: spi-2012|drug: pegfilgrastim|drug: docetaxel|drug: cyclophosphamide,"duration of severe neutropenia (dsn) in cycle 1|time to absolute neutrophil count (anc) recovery in cycle 1|depth of anc nadir in cycle 1|number of participants with febrile neutropenia (fn) in cycle 1|duration of severe neutropenia (dsn) in cycles 2, 3 and 4|number of participants with neutropenic complications in cycle 1|number of participants with febrile neutropenia in cycles 2, 3 and 4|relative dose intensity (rdi) of tc chemotherapy|number of participants with treatment emergent adverse events (teaes) and serious adverse events (saes), and death|number of participants with clinically significant laboratory abnormalities","spectrum pharmaceuticals, inc",All,"18 Years and older   (Adult, Older Adult)",Phase 3,237.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPI-GCF-302|2016-003469-24,"May 10, 2017","June 8, 2018","May 6, 2019","November 2, 2016","March 2, 2022","March 2, 2022","['acrc/ arizona clinical research center inc., tucson, arizona, united states yuma regional cancer center, yuma, arizona, united states genesis cancer center, hot springs, arkansas, united states nea baptist clinic   fowler family center for cancer care, jonesboro, arkansas, united states pacific cancer medical center, inc., anaheim, california, united states compassionate care research group, inc., fountain valley, california, united states california cancer associates for research and excellence inc., fresno, california, united states pacific shores medical group, long beach, california, united states los angeles hematology oncology medical group, los angeles, california, united states desert regional medical center, palm springs, california, united states emad ibrahim, md, inc., redlands, california, united states innovative clinical research institute/ the oncology institute of hope and innovation, whittier, california, united states denver health & hospital authority, denver, colorado, united states pasco pinellas cancer center, holiday, florida, united states lakes research, llc, miami lakes, florida, united states mid-florida hematology and oncology centers, orange city, florida, united states millennium oncology, pembroke pines, florida, united states brcr medical center inc, plantation, florida, united states pinellas hematology and oncology, saint petersburg, florida, united states bond & steele clinic, pa., winter haven, florida, united states john b. amos cancer center, columbus, georgia, united states cancer center of middle georgia, dublin, georgia, united states dwight d. eisenhower army medical center, fort gordon, georgia, united states saint alphonsus regional medical center, boise, idaho, united states oncology specialists, sc, park ridge, illinois, united states fpn oncology and hematology specialists, indianapolis, indiana, united states commonwealth hematology-oncology, psc, danville, kentucky, united states pontchartrain cancer center, covington, louisiana, united states quest research institute, royal oak, michigan, united states coborn cancer center, saint cloud, minnesota, united states hattiesburg clinic hematology/oncology, hattiesburg, mississippi, united states freeman health systems, joplin, missouri, united states st. vincent frontier cancer center, billings, montana, united states chi health st francis, st francis cancer treatment center, grand island, nebraska, united states waverly hematology oncology, cary, north carolina, united states gaston hematology & oncology associates, pc, gastonia, north carolina, united states aultman hospital, canton, ohio, united states the christ hospital cancer center, cincinnati, ohio, united states st. elizabeth youngstown hospital jacbcc/oncology/ mercy health youngstown llc, youngstown, ohio, united states carolina blood and cancer care associates, rock hill, south carolina, united states the west clinic, pc, d/b/a west cancer center, germantown, tennessee, united states chi st joseph health cancer center, bryan, texas, united states envision cancer center, llc, laredo, texas, united states texas oncology, pa- mcallen south 2nd street, mcallen, texas, united states hope cancer center of east texas, tyler, texas, united states delta hematology/oncology associates, portsmouth, virginia, united states providence regional center partnership, everett, washington, united states northwest medical specialties, pllc, tacoma, washington, united states west virginia university, morgantown, west virginia, united states cisss de la montérégie-centre, longueuil, quebec, canada jewish general hospital, montreal, quebec, canada magyar honvedseg egeszsegugyi kozpont, onkologiai osztaly, budapest, hungary szent imre egyetemi oktatokorhaz, klinikai onkologiai osztaly, budapest, hungary orszagos onkologiai intezet, """"b"""" belgyogyaszati onkologiai osztaly, budapest, hungary borsod-abauj-zemplen megyei korhaz es egyetemi okato korhaz, klinikai onkologiai es sugarterapias centrum, miskolc, hungary szabolcs-szatmar-bereg megyei korhazak, egyetemi oktato korhaz, onkoradiologiai osztaly, nyíregyháza, hungary tolna megyei balassa janos korhaz, klinikai onkologiai osztaly, szekszard, hungary kem hospital research centre, pune, maharashtra, india christian medical college, vellore, tamil nadu, india samsung medical center, irwon-ro, gangnam-gu seoul, korea, republic of wonju severance christian hospital, ilsan-ro, gangwon-do, korea, republic of national cancer center, iisan-ro, gyeonggi-do, korea, republic of cha bundang medical center, yatap-ro, gyeonggi-do, korea, republic of seoul national university hospital, daehwa-ro, jongno-gu seoul, korea, republic of inha university hospital, inhang-ro, jung-guincheon, korea, republic of korea university anam hospital, inchon-ro, seongbuk-guseoul, korea, republic of severance hospital, yonsei-ro, seoul, korea, republic of bialostockie centrum onkologii im. marii sklodowskiej-curie oddzial onkologii klinicznej im. ewy pileckiej z pododdzialem chemioterapii dziennej, bialystok, poland regionalny szpital specjalistyczny im. dr wladyslawa bieganskiego oddział onkologii klinicznej, grudziadz, poland instytut centrum zdrowia matki polki klinika chirurgii onkologicznej i chorob piersi z pododdzialem onkologii klinicznej, lodz, poland pracownia leku cytotoksycznego szpitala klinicznego przemienienia panskiego um im. karola marcinkowskiego w poznaniu, poznan, poland szpital rejonowy im. dr. jozefa rostka w raciborzu dzienny oddzial chemioterapii, racibórz, poland mrukmed. lekarz beata madej mruk i partner. spolka partnerska oddzial nr 1 w rzeszowie, rzeszow, poland zachodniopomorskie centrum onkologii osrodek innowacyjnosci, rozwoju i badan klinicznych, szczecin, poland']","""study protocol"", https://clinicaltrials.gov/provideddocs/40/nct02953340/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/40/nct02953340/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02953340,breast
407,408,NCT01172548,safety and efficacy evaluation of two year imatinib treatment in adjuvant gastrointestinal stromal tumor (gist),INV555,Completed,No Results Available,gastrointestinal stromal tumors,drug: imatinib mesylate,recurrence free survival rate|compare recurrence free survival rate to historical controls|compare overall survival to historical controls|compare time to recurrence to historical controls|adverse events|treatment compliance - tracking if the patient is coming to visits as per visit schedule in protocol,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,132.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CSTI571BIC08,August 2008,March 2014,March 2014,"July 29, 2010",,"May 31, 2017","['novartis investigative site, alger, algeria novartis investigative site, cairo, egypt novartis investigative site, mansoura, egypt novartis investigative site, ahmedabad, gujrat, india novartis investigative site, pune, maharashtra, india novartis investigative site, mumbai, india novartis investigative site, new delhi, india novartis investigative site, amman, jordan novartis investigative site, beirut, lebanon novartis investigative site, kazan, tatarstan republic, russian federation novartis investigative site, ekaterinburg, russian federation novartis investigative site, irkutsk, russian federation novartis investigative site, kursk, russian federation novartis investigative site, omsk, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, riyadh, saudi arabia novartis investigative site, parktown, south africa novartis investigative site, tainan 704, taiwan roc, taiwan novartis investigative site, taipei, taiwan, roc, taiwan novartis investigative site, lin-ko, taiwan novartis investigative site, niaosong township, taiwan novartis investigative site, taichung, taiwan novartis investigative site, taipei, taiwan novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, songkla, thailand novartis investigative site, tunis, tunisia novartis investigative site, ankara, turkey']",,https://ClinicalTrials.gov/show/NCT01172548,gastric
408,409,NCT02992574,trial evaluating role of post mastectomy radiotherapy in women with node negative early breast cancer,PMRT-NNBC,Recruiting,No Results Available,breastcancer,radiation: post mastectomy radiation therapy,disease free survival|chest wall recurrence|regional recurrence|metastasis-free survival|overall survival|acute morbidity of radiotherapy|late morbidity of radiotherapy|quality of life,tata memorial centre,Female,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1022.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1602|CTRI/2016/12/007532,"May 27, 2016",December 2028,December 2028,"December 14, 2016",,"June 13, 2018","['max super speciality hospital(a unit of devki devi foundation), new delhi, delhi, india all india institute of medical sciences, new delhi, delhi, india kolhapur cancer centre pvt ltd, kolhapur, maharashtra, india tata memorial centre, mumbai, maharashtra, india bhagwan mahaveer cancer hospital and research centre, jaipur, rajasthan, india post graduate institute of medical education & research, chandigarh, india max super speciality hospital, shalimar bagh, delhi, india']",,https://ClinicalTrials.gov/show/NCT02992574,breast
409,410,NCT04513522,a study to evaluate the safety and efficacy of nivolumab with ipilimumab in participants with untreated advanced kidney cancer conducted in india,CheckMate 7C9,Recruiting,No Results Available,kidney neoplasms,biological: nivolumab|biological: ipilimumab,incidence of high-grade immune-mediated adverse events (imaes) assessed using common terminology criteria for adverse events (ctcae) v4.0 grade 3 to 4 and grade 5|time to onset of all high grade immune-mediated adverse events (imaes) assessed using common terminology criteria for adverse events (ctcae) v4.0 grade 3 to grade 5|time to resolution of all high grade imaes assessed using ctcae v4.0 grade 3 to grade 5|percentage of participants who received immune modulating medication in all high grade imaes assessed using ctcae v4.0 grade 3 to grade 5|objective response rate (orr) using response evaluation criteria in solid tumors (recist) 1.1|time to response (ttr) using recist 1.1|duration of response (dor) using recist 1.1,bristol-myers squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA209-7C9,"December 17, 2020","December 29, 2023","December 30, 2023","August 14, 2020",,"April 28, 2022","['local institution - 0011, trivandrum, kerala, india local institution - 0006, bangalore, india local institution - 0017, delhi, india local institution - 0002, karnataka, india local institution - 0019, kolkata, india local institution, mumbai, india local institution - 0016, mumbai, india local institution - 0013, mumbai, india local institution - 0007, new delhi, india local institution - 0012, pune, india']",,https://ClinicalTrials.gov/show/NCT04513522,kidney
410,411,NCT05048797,"a study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for unresectable, locally advanced/metastatic non-small cell lung cancer with her2 mutations",,Recruiting,No Results Available,locally advanced or metastatic non-small cell lung cancer,drug: trastuzumab deruxtecan|drug: cisplatin|drug: carboplatin|drug: pembrolizumab|drug: pemetrexed,"progression free survival (pfs) by blinded independent central review (bicr)|overall survival (os)|progression free survival (pfs) by investigator assessment|objective response rate (orr)|duration of response (dor)|time to second progression or death (pfs2)|landmark analysis of pfs (pfs12)|landmark analysis of os (os24)|central nervous system (cns) - progression free survival (pfs)|safety and tolerability of t-dxd versus standard of care treatment|pharmacokinetics (pk) of t-dxd, total anti-her2 antibody and dxd in serum|immunogenicity of t-dxd|patient-reported pulmonary symptoms associated with non-small cell lung cancer|patient-reported tolerability of t-dxd described using symptomatic aes|patient-reported tolerability of t-dxd described using overall side-effect bother|patient-reported tolerability of t-dxd described using physical function","astrazeneca|daiichi sankyo, inc.",All,"18 Years to 123 Years   (Adult, Older Adult)",Phase 3,264.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D967SC00001,"October 28, 2021","January 17, 2025","March 1, 2027","September 17, 2021",,"April 26, 2022","[""research site, anchorage, alaska, united states research site, duarte, california, united states research site, los angeles, california, united states research site, los angeles, california, united states research site, orange, california, united states research site, san francisco, california, united states research site, santa rosa, california, united states research site, boston, massachusetts, united states research site, ann arbor, michigan, united states research site, new brunswick, new jersey, united states research site, new york, new york, united states research site, canton, ohio, united states research site, columbus, ohio, united states research site, pittsburgh, pennsylvania, united states research site, kennewick, washington, united states research site, milwaukee, wisconsin, united states research site, graz, austria research site, innsbruck, austria research site, linz, austria research site, wien, austria research site, gent, belgium research site, hasselt, belgium research site, leuven, belgium research site, barretos, brazil research site, blumenau, brazil research site, brasília, brazil research site, natal, brazil research site, salvador, brazil research site, sao paulo, brazil research site, são paulo, brazil research site, uberlândia, brazil research site, vancouver, british columbia, canada research site, brampton, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, fuzhou, china research site, guangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, jinan, china research site, kunming, china research site, kunming, china research site, linhai, china research site, nanchang, china research site, nanjing, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, shenyang, china research site, shenzhen, china research site, wenzhou, china research site, wu han, china research site, wuhan, china research site, xi'an, china research site, xiamen, china research site, yangzhou, china research site, zhengzhou city, china research site, vejle, denmark research site, bordeaux, france research site, dijon, france research site, le mans cedex, france research site, lyon, france research site, marseille cedex, france research site, nantes, france research site, rennes cedex 9, france research site, toulouse cedex 9, france research site, villejuif cedex, france research site, berlin-zehlendorf, germany research site, dresden, germany research site, erfurt, germany research site, heidelberg, germany research site, immenhausen, germany research site, köln, germany research site, mainz, germany research site, mannheim, germany research site, münchen, germany research site, oldenburg, germany research site, ravensburg, germany research site, würzburg, germany research site, hong kong, hong kong research site, shatin, hong kong research site, bangalore, india research site, hyderabad, india research site, mumbai, india research site, mumbai, india research site, nasik, india research site, rohini, india research site, milan, italy research site, monza, italy research site, orbassano, italy research site, parma, italy research site, roma, italy research site, verona, italy research site, chuo-ku, japan research site, fukuoka-shi, japan research site, kashiwa, japan research site, matsuyama-shi, japan research site, niigata-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, sunto-gun, japan research site, yokohama-shi, japan research site, yonago-shi, japan research site, cheongju-si, korea, republic of research site, goyang-si, korea, republic of research site, gyeonggi-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, cdmx, mexico research site, culiacán, mexico research site, guadalajara jalisco, mexico research site, merida, mexico research site, mexico city, mexico research site, oaxaca, mexico research site, san luis potosí, mexico research site, amsterdam, netherlands research site, groningen, netherlands research site, leiden, netherlands research site, nijmegen, netherlands research site, gdańsk, poland research site, olsztyn, poland research site, przemysl, poland research site, warszawa, poland research site, l'hospitalet de llobregat, spain research site, madrid, spain research site, malaga, spain research site, valencia, spain research site, kaohsiung, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, edirne, turkey research site, istanbul, turkey research site, izmir, turkey research site, kadıkoy/istanbul, turkey""]",,https://ClinicalTrials.gov/show/NCT05048797,
411,412,NCT00373113,a clinical trial comparing efficacy and safety of sunitinib and capecitabine,,Terminated,Has Results,breast neoplasms,drug: capecitabine|drug: sunitinib malate,progression-free survival (pfs)|time to tumor progression (ttp)|number of participants with overall response (or)|duration of response (dr)|time to tumor response (ttr)|overall survival (os)|european organization for research and treatment of cancer (eortc) quality of life questionnaire (eortc qlq-c30)|eortc qlq breast cancer module (br23),pfizer,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,482.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A6181107,November 2006,October 2009,June 2011,"September 7, 2006","November 18, 2010","June 25, 2012","['pfizer investigational site, bahia blanca, prov. de buenos aires, argentina pfizer investigational site, viedma, rio negro, argentina pfizer investigational site, rosario, santa fé, argentina pfizer investigational site, buenos aires, argentina pfizer investigational site, buenos aires, argentina pfizer investigational site, cordoba, argentina pfizer investigational site, tucuman, argentina pfizer investigational site, darlinghurst, new south wales, australia pfizer investigational site, herston, queensland, australia pfizer investigational site, adelaide, south australia, australia pfizer investigational site, heidelberg, victoria, australia pfizer investigational site, parkville, victoria, australia pfizer investigational site, perth, western australia, australia pfizer investigational site, curitiba, pr, brazil pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, porto alegre, rs, brazil pfizer investigational site, porto alegre, rs, brazil pfizer investigational site, são paulo, sp, brazil pfizer investigational site, são paulo, sp, brazil pfizer investigational site, sofia, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, stara zagora, bulgaria pfizer investigational site, halifax, nova scotia, canada pfizer investigational site, halifax, nova scotia, canada pfizer investigational site, halifax, nova scotia, canada pfizer investigational site, london, ontario, canada pfizer investigational site, toronto, ontario, canada pfizer investigational site, quebec, canada pfizer investigational site, temuco, ix región, chile pfizer investigational site, medellin, antioquia, colombia pfizer investigational site, bogotá, cundinamarca, colombia pfizer investigational site, bayonne, france pfizer investigational site, besancon, france pfizer investigational site, clermont ferrand, france pfizer investigational site, lille, france pfizer investigational site, neuilly sur seine, france pfizer investigational site, nice, france pfizer investigational site, rennes cedex, france pfizer investigational site, berlin, germany pfizer investigational site, frankfurt, germany pfizer investigational site, freiburg, germany pfizer investigational site, jena, germany pfizer investigational site, kiel, germany pfizer investigational site, leer, germany pfizer investigational site, luebeck, germany pfizer investigational site, magdeburg, germany pfizer investigational site, mainz, germany pfizer investigational site, meiningen, germany pfizer investigational site, muenchen, germany pfizer investigational site, offenburg, germany pfizer investigational site, tuebingen, germany pfizer investigational site, hong kong, hong kong pfizer investigational site, kowloon, hong kong pfizer investigational site, tuen mun, hong kong pfizer investigational site, wan chai,, hong kong pfizer investigational site, navrangpura / ahmedabad, gujarat, india pfizer investigational site, bangalore, karnataka, india pfizer investigational site, ludhiana, punjab, india pfizer investigational site, jaipur, rajasthan, india pfizer investigational site, lucknow, uttar pradesh, india pfizer investigational site, firenze, italy pfizer investigational site, milano, italy pfizer investigational site, napoli, italy pfizer investigational site, reggio emilia, italy pfizer investigational site, nagoya, aichi, japan pfizer investigational site, matsuyama-shi, ehime, japan pfizer investigational site, kitakyushu-city, fukuoka, japan pfizer investigational site, suita, osaka, japan pfizer investigational site, kita-adachi-gun, saitama, japan pfizer investigational site, bunkyo-ku, tokyo, japan pfizer investigational site, chuo-ku, tokyo, japan pfizer investigational site, fukuoka, japan pfizer investigational site, osaka, japan pfizer investigational site, goyang-si, gyeonggi-do, korea, republic of pfizer investigational site, daegu, korea, republic of pfizer investigational site, incheon, korea, republic of pfizer investigational site, pusan, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, mexico, df, mexico pfizer investigational site, toluca, estado de mexico, mexico pfizer investigational site, acapulco, guerrero, mexico pfizer investigational site, morelia, michoacan, mexico pfizer investigational site, ciudad obregon, sonora, mexico pfizer investigational site, chihuahua, mexico pfizer investigational site, puebla, mexico pfizer investigational site, lima, peru pfizer investigational site, lima, peru pfizer investigational site, quezon city, philippines pfizer investigational site, quezon city, philippines pfizer investigational site, quezon city, philippines pfizer investigational site, san juan city, philippines pfizer investigational site, singapore, singapore pfizer investigational site, singapore, singapore pfizer investigational site, parktown, south africa pfizer investigational site, sandton, south africa pfizer investigational site, mataro, barcelona, spain pfizer investigational site, sabadell, barcelona, spain pfizer investigational site, santander, cantabria, spain pfizer investigational site, alcorcon, madrid, spain pfizer investigational site, bilbao, vizcaya, spain pfizer investigational site, cordoba, spain pfizer investigational site, gerona, spain pfizer investigational site, jaen, spain pfizer investigational site, la coruña, spain pfizer investigational site, las palmas de gran canaria, spain pfizer investigational site, madrid, spain pfizer investigational site, madrid, spain pfizer investigational site, malaga, spain pfizer investigational site, salamanca, spain pfizer investigational site, changhua, taiwan pfizer investigational site, kaohsiung, taiwan pfizer investigational site, tainan, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taoyuan, taiwan pfizer investigational site, ankara, turkey pfizer investigational site, istanbul, turkey pfizer investigational site, cardiff, south wales, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, nottingham, united kingdom pfizer investigational site, somerset, united kingdom']",,https://ClinicalTrials.gov/show/NCT00373113,breast
412,413,NCT03519971,study of durvalumab given with chemoradiation therapy in patients with unresectable non-small cell lung cancer,,"Active, not recruiting",No Results Available,non-small cell lung cancer,drug: durvalumab|other: placebo|drug: cisplatin/ etoposide|drug: carboplatin/ paclitaxel|drug: pemetrexed/ cisplatin|drug: pemetrexed/ carboplatin|radiation: radiation,progression-free survival (pfs)|overall survival (os)|objective response rate (orr)|overall survival at 24 months|rate of complete response|duration of response (dor)|disease control rate (dcr)|time from randomization to second progression pfs2|time to death or distant metastasis (ttdm)|presence of ada for durvalumab in combination with crt|to assess symptoms and health-related qol in patients treated with durvalumab + soc crt compared with placebo + soc crt using eortc qlq-c30 v3|to assess symptoms and health-related qol in patients treated with durvalumab + soc crt compared with placebo + soc crt using qlq-lc13|to assess the pk of durvalumab in blood (peak trough concentration) when in combination with crt,astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,328.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",D933KC00001,"March 29, 2018","June 30, 2022","November 13, 2023","May 9, 2018",,"February 17, 2022","['research site, barretos, brazil research site, curitiba, brazil research site, florianópolis, brazil research site, fortaleza, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, ribeirão preto, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, brno, czechia research site, ostrava, czechia research site, praha 2, czechia research site, budapest, hungary research site, budapest, hungary research site, gyula, hungary research site, győr, hungary research site, törökbálint, hungary research site, bangalore, india research site, chennai, india research site, gurgaon, india research site, karamsad, india research site, mumbai, india research site, nasik, india research site, new delhi, india research site, vadodara, india research site, bunkyo-ku, japan research site, fukuoka-shi, japan research site, koto-ku, japan research site, kyoto, japan research site, nagoya-shi, japan research site, osakasayama, japan research site, sendai-shi, japan research site, yokohama-shi, japan research site, busan, korea, republic of research site, chungcheongbuk-do, korea, republic of research site, gyeongsangnam-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, aguascalientes, mexico research site, guadalajara, mexico research site, mexico city, mexico research site, mérida, mexico research site, méxico, mexico research site, orizaba, mexico research site, la libertad, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, cebu city, philippines research site, denver, philippines research site, iloilo city, philippines research site, iloilo, philippines research site, makati, philippines research site, manila, philippines research site, quezon city, philippines research site, bydgoszcz, poland research site, elbląg, poland research site, gdańsk, poland research site, olsztyn, poland research site, warszawa, poland research site, arkhangelsk, russian federation research site, chelyabinsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, omsk, russian federation research site, rostov-on-don, russian federation research site, saint-petersburg, russian federation research site, bangkok, thailand research site, bangkok, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, mueang, thailand research site, ankara, turkey research site, ankara, turkey research site, antalya, turkey research site, diyarbakir, turkey research site, istanbul, turkey research site, izmir, turkey research site, hanoi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT03519971,
413,414,NCT03631199,study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous nsclc subjects,CANOPY-1,"Active, not recruiting",No Results Available,non-small cell lung cancer,drug: canakinumab|drug: canakinumab matching placebo|drug: pembrolizumab|drug: carboplatin|drug: cisplatin|drug: paclitaxel|drug: nab-paclitaxel|drug: pemetrexed,"safety run-in part: incidence of dose limiting toxicities (dlts)|double-blind, randomized, placebo-controlled part: progression free survival (pfs) per investigator assessment using recist v1.1|double-blind, randomized, placebo-controlled part: overall survival (os) per investigator assessment using recist v1.1|safety run-in part: overall response rate (orr) per investigator assessment using recist v1.1|double-blind, randomized, placebo-controlled part : overall response rate (orr) per investigator assessment using recist v1.1|safety run-in part: disease control rate (dcr) per investigator assessment using recist v1.1|double-blind, randomized, placebo-controlled part : disease control rate (dcr) per investigator assessment using recist v1.1|safety run-in part: duration of response (dor) per investigator assessment using recist v1.1|double-blind, randomized, placebo-controlled part : duration of response (dor) per investigator assessment using recist v1.1|double-blind, randomized, placebo-controlled part only: time to response (ttr) per investigator assessment using recist v1.1|safety run-in part: antidrug antibodies (ada) of canakinumab|double-blind, randomized, placebo-controlled part : antidrug antibodies (ada) of canakinumab|safety run-in part: antidrug antibodies (ada) of pembrolizumab|double-blind, randomized, placebo-controlled part : antidrug antibodies (ada) of pembrolizumab|safety run-in part: serum canakinumab concentration|double-blind, randomized, placebo-controlled part : serum canakinumab concentration|safety run-in part: serum pembrolizumab concentration|double-blind, randomized, placebo-controlled part : serum pembrolizumab concentration|safety run-in part: plasma pemetrexed concentration|double-blind, randomized, placebo-controlled part : : plasma pemetrexed concentration|safety run-in part: plasma cisplatin concentration|double-blind, randomized, placebo-controlled part: plasma cisplatin concentration|safety run-in part: plasma carboplatin concentration|double-blind, randomized, placebo-controlled part: plasma carboplatin concentration|safety run-in part: plasma paclitaxel concentration|double-blind, randomized, placebo-controlled part: plasma paclitaxel concentration|double-blind, randomized, placebo-controlled part: plasma nab-paclitaxel concentration|double-blind, randomized, placebo-controlled part only :time to definitive 10 point deterioration symptom scores of pain, cough and dyspnea per qlq-lc13 questionnaire|double-blind, randomized, placebo-controlled part only: time to definitive deterioration in global health status/qol, shortness of breath and pain per qlq-c30 questionnaire|double-blind, randomized, placebo-controlled part only: change from baseline in score as per the eq-5d-5l questionnaire",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,673.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CACZ885U2301|2018-001547-32,"December 21, 2018","August 9, 2021","September 22, 2022","August 15, 2018",,"May 3, 2022","[""pacific shores medical group, long beach, california, united states usc kenneth norris comprehensive cancer center, los angeles, california, united states advent health cancer institute, orlando, florida, united states dana farber cancer institute, boston, massachusetts, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, buenos aires, argentina novartis investigative site, westmead, new south wales, australia novartis investigative site, wooloongabba, queensland, australia novartis investigative site, melbourne, victoria, australia novartis investigative site, murdoch, western australia, australia novartis investigative site, linz, oberoesterreich, austria novartis investigative site, salzburg, austria novartis investigative site, barretos, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, edmonton, alberta, canada novartis investigative site, brampton, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, temuco, region de la araucania, chile novartis investigative site, santiago, chile novartis investigative site, harbin, heilongjiang, china novartis investigative site, wuhan, hubei, china novartis investigative site, wuhan, hubei, china novartis investigative site, changsha, hunan, china novartis investigative site, changchun, jilin, china novartis investigative site, xi'an, shanxi, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, beijing, china novartis investigative site, valledupar, cesar, colombia novartis investigative site, brno, czech republic, czechia novartis investigative site, prague 2, czech republic, czechia novartis investigative site, brno - bohunice, czechia novartis investigative site, ostrava vitkovice, czechia novartis investigative site, herning, denmark novartis investigative site, oulu, finland novartis investigative site, marseille cedex 20, bouches du rhone, france novartis investigative site, lyon cedex, france novartis investigative site, montpellier, france novartis investigative site, paris, france novartis investigative site, saint herblain, france novartis investigative site, berlin, germany novartis investigative site, dresden, germany novartis investigative site, essen, germany novartis investigative site, georgsmarienhuette, germany novartis investigative site, gerlingen, germany novartis investigative site, gottingen, germany novartis investigative site, halle (saale), germany novartis investigative site, heidelberg, germany novartis investigative site, koeln, germany novartis investigative site, koeln, germany novartis investigative site, leipzig, germany novartis investigative site, muenchen, germany novartis investigative site, athens, gr, greece novartis investigative site, athens, greece novartis investigative site, kowloon, hong kong novartis investigative site, veszprem, hungary novartis investigative site, reykjavik, iceland novartis investigative site, hyderabad, andhra pradesh, india novartis investigative site, gurgaon, haryana, india novartis investigative site, pune, maharashtra, india novartis investigative site, jaipur, rajasthan, india novartis investigative site, hyderabad, telangana, india novartis investigative site, kolkata, west bengal, india novartis investigative site, avellino, av, italy novartis investigative site, genova, ge, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, rozzano, mi, italy novartis investigative site, modena, mo, italy novartis investigative site, padova, pd, italy novartis investigative site, perugia, pg, italy novartis investigative site, parma, pr, italy novartis investigative site, orbassano, to, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, sapporo city, hokkaido, japan novartis investigative site, himeji, hyogo, japan novartis investigative site, yokohama-city, kanagawa, japan novartis investigative site, sakai, osaka, japan novartis investigative site, sunto gun, shizuoka, japan novartis investigative site, chuo ku, tokyo, japan novartis investigative site, ube-city, yamaguchi, japan novartis investigative site, osaka, japan novartis investigative site, gyeonggi do, korea, korea, republic of novartis investigative site, seoul, seocho gu, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, ashrafieh, lebanon novartis investigative site, saida, lebanon novartis investigative site, kuantan, pahang, malaysia novartis investigative site, kuching, sarawak, malaysia novartis investigative site, kuala lumpur, wilayah persekutuan, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, groningen, netherlands novartis investigative site, groningen, netherlands novartis investigative site, drammen, norway novartis investigative site, taguig city, metro manila, philippines novartis investigative site, makati city, philippines novartis investigative site, quezon city, philippines novartis investigative site, san juan city, philippines novartis investigative site, gliwice, poland novartis investigative site, poznan, poland novartis investigative site, tomaszw mazowiecki, poland novartis investigative site, lisboa, portugal novartis investigative site, porto, portugal novartis investigative site, craiova, dolj, romania novartis investigative site, cluj-napoca, romania novartis investigative site, arkhangelsk, russian federation novartis investigative site, omsk, russian federation novartis investigative site, pushkin saint petersburg, russian federation novartis investigative site, saint petersburg, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, bratislava, slovakia novartis investigative site, partizanske, slovakia novartis investigative site, johannesburg, south africa novartis investigative site, granada, andalucia, spain novartis investigative site, malaga, andalucia, spain novartis investigative site, badalona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, las palmas de gran canarias, las palmas de gran canaria, spain novartis investigative site, san sebastian, pais vasco, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, zaragoza, spain novartis investigative site, stockholm, sweden novartis investigative site, basel, switzerland novartis investigative site, kaohsiung city, taiwan novartis investigative site, tainan, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan, taiwan novartis investigative site, songkhla, hat yai, thailand novartis investigative site, khon kaen, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, ankara, turkey novartis investigative site, edirne, turkey novartis investigative site, istanbul, turkey novartis investigative site, high heaton, newcastle upon tyne, united kingdom novartis investigative site, london, united kingdom novartis investigative site, manchester, united kingdom novartis investigative site, plymouth, united kingdom novartis investigative site, hanoi, vietnam""]",,https://ClinicalTrials.gov/show/NCT03631199,
414,415,NCT01903018,a study to assess radiation induced mucositis in patients of head and neck cancer administered chemo-radiation with or without p276-00,,Completed,No Results Available,radiation induced mucositis in head and neck cancer,drug: p276-00|radiation: radiation therapy|drug: cisplatin,number of severe radiation induced mucositis (who grade >=3)|time to onset of severe rim (who grade ≥ 3)|duration of severe rim (who grade>=3)|progression-free survival (pfs)|overall survival (os),piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 2,73.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,P276-00/64/11,July 2012,March 2014,September 2014,"July 19, 2013",,"September 4, 2014","['bharat cancer hospital & research institute, surat, gujarat, india sri venkateshwara hospitals, bangalore, karnataka, india mazumdar shaw cancer center, bangalore, karnataka, india tata memorial hospital, mumbai, maharashtra, india curie manavta cancer centre, nashik, maharashtra, india ruby hall clinic, pune, maharashtra, india meenakshi mission hosp. & res. centre, madurai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT01903018,
415,416,NCT00482014,"a study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with radiation therapy followed by pemetrexed in patients with inoperable non-small-cell lung cancer",,Completed,Has Results,non-small-cell lung cancer,drug: pemetrexed|drug: cisplatin|drug: carboplatin|radiation: radiation therapy,phase 1 - maximum tolerated dose (mtd) of carboplatin|phase 1 - maximum tolerated dose (mtd) of cisplatin|phase 2 - survival probability at 2 years|phase 1 - pharmacology toxicity: number of participants with dose limiting toxicities (dlts)|phase 1 - percentage of participants with complete response or partial response (response rate)|phase 2 - pharmacology toxicity: number of participants with adverse events|phase 2 - time to progression|phase 2 - median survival|phase 2 - percentage of participants with complete response or partial response (response rate),eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,120.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9031|H3E-US-S047,May 2007,October 2011,October 2011,"June 4, 2007","November 27, 2012","November 27, 2012","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., los angeles, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wichita, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., st louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., las vegas, nevada, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., burlington, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., corpus christi, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dallas, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., temple, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india']",,https://ClinicalTrials.gov/show/NCT00482014,
416,417,NCT01856478,lux-head&neck 3: afatinib (bibw2992) versus methotrexate for the treatment of recurrent and/or metastatic head and neck squamous cell cancer after platinum based chemotherapy,,"Active, not recruiting",No Results Available,head and neck neoplasms,drug: methotrexate|drug: afatinib,"progression free survival (pfs), defined as the time from the date of randomization to the date of progression evaluated according to recist 1.1 or to the date of death, whichever occurs first|overall survival (os), defined as the time from the date of randomization to the date of death (regardless of the cause of death)|objective response defined as complete response (cr) or partial response (pr) determined by recist 1.1 according to the best response to study medication|health related quality of life (hrqol) will be assessed based on patient-reported questionaires",boehringer ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,340.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.161|1200-0161,"May 23, 2013","August 22, 2018","October 31, 2022","May 17, 2013",,"May 4, 2022","[""beijing chao-yang hospital, beijing, china cancer hospital of chinese academy of medical science, beijing, china navy general hospital, beijing, china peking union medical college hospital, beijing, china affiliated toumor hospital of bengbu medical college, bengbu, china first hospital of jilin university, changchun, china the second people's hospital of sichuan, chengdu, china west china hospital, chengdu, china sun yat-sen university cancer center, guangzhou, china the third affiliated hospital of harbin medical university, haerbin, china zhejiang cancer hospital, hangzhou, china the 81th hospital of pla, nanjing, china renji hospital shanghai jiaotong univesrity school of medicine, shanghai, china shanghai changzheng hospital, shanghai, china shanghai ninth people's hospital, shanghai, china fudan university shanghai cancer center, shanghai, china shanghai ninth people's hospital, shanghai, china wuhan union hospital, wuhan, china tongji hospital, tongji university, wuhan, china alexandria university hospital, alexandria, egypt national cancer institute, cairo university, cairo, egypt mansoura university faculty of medicine, dakahlia, egypt pamela youde nethersole eastern hospital, hong kong, hong kong queen mary hospital, hongkong, hong kong prince of wales hospital, shatin, hong kong sujan surgical cancer hospital, amravati, india pristine hospital, bengaluru, india acharya tulsi regional cancer treatment & research institute, bikaner, india rajiv gandhi government general hospital, chennai, india m n j institute of oncology and regional cancer centre, hyderabad, india geetanjali medical college and hospital, jaipur, india j k cancer institute, kanpur, india b. p .poddar hospital & medical research ltd., kolkata, west bengal, india king george medical university, lucknow, india government medical college & hospital, nagpur, india shatabdi hospital, nashik, nasik, india ruby hall clinic, pune, india noble hospital pvt ltd, pune, india national cancer center, goyang, korea, republic of severance hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of the catholic university of korea, seoul st.mary's hospital, seoul, korea, republic of asan medical center, seoul, korea, republic of perpetual succour hospital (cebu), cebu city, philippines st. luke's medical center, quezon city, philippines keelung chang gung memorial lover's lake branch, keelung city, taiwan taichung veterans general hospital, taichung, taiwan national taiwan university hospital, taipei, taiwan tri-service general hospital, taipei, taiwan maharaj nakom chiangmai hospital, chiang mai, thailand srinagarind hospital, muang, thailand naresuan university hospital, phitsanulok, thailand songklanagarind hospital, songkla, thailand""]",,https://ClinicalTrials.gov/show/NCT01856478,
417,418,NCT00490139,altto (adjuvant lapatinib and/or trastuzumab treatment optimisation) study; big 2-06/n063d,ALTTO,Completed,Has Results,"neoplasms, breast",drug: lapatinib|biological: trastuzumab,disease-free survival (dfs)|overall survival (os)|time to recurrence|time to distant recurrence|time to central nervous system recurrence|dfs ignoring non-breast second primary malignancies,novartis pharmaceuticals|north central cancer treatment group|national cancer institute (nci)|breast international group|canadian cancer trials group|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,8382.0,Industry|Other|NIH,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106708|CLAP016B2301|2006-000562-36,"May 16, 2007","December 6, 2013","July 1, 2021","June 22, 2007","August 18, 2014","July 23, 2021","[""novartis investigative site, mobile, alabama, united states novartis investigative site, anchorage, alaska, united states novartis investigative site, fairbanks, alaska, united states novartis investigative site, phoenix, arizona, united states novartis investigative site, tucson, arizona, united states novartis investigative site, tucson, arizona, united states novartis investigative site, jonesboro, arkansas, united states novartis investigative site, berkeley, california, united states novartis investigative site, burlingame, california, united states novartis investigative site, castro valley, california, united states novartis investigative site, duarte, california, united states novartis investigative site, fairfield, california, united states novartis investigative site, fremont, california, united states novartis investigative site, fresno, california, united states novartis investigative site, glendale, california, united states novartis investigative site, greenbrae, california, united states novartis investigative site, la jolla, california, united states novartis investigative site, la jolla, california, united states novartis investigative site, loma linda, california, united states novartis investigative site, martinez, california, united states novartis investigative site, marysville, california, united states novartis investigative site, monterey, california, united states novartis investigative site, mountain view, california, united states novartis investigative site, murrieta, california, united states novartis investigative site, oakland, california, united states novartis investigative site, oakland, california, united states novartis investigative site, orange, california, united states novartis investigative site, palm springs, california, united states novartis investigative site, palo alto, california, united states novartis investigative site, pismo beach, california, united states novartis investigative site, pleasanton, california, united states novartis investigative site, sacramento, california, united states novartis investigative site, san francisco, california, united states novartis investigative site, san francisco, california, united states novartis investigative site, san francisco, california, united states novartis investigative site, san leandro, california, united states novartis investigative site, vallejo, california, united states novartis investigative site, aurora, colorado, united states novartis investigative site, boulder, colorado, united states novartis investigative site, colorado springs, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, edwards, colorado, united states novartis investigative site, englewood, colorado, united states novartis investigative site, fort collins, colorado, united states novartis investigative site, fort collins, colorado, united states novartis investigative site, glenwood springs, colorado, united states novartis investigative site, grand junction, colorado, united states novartis investigative site, greeley, colorado, united states novartis investigative site, lone tree, colorado, united states novartis investigative site, longmont, colorado, united states novartis investigative site, loveland, colorado, united states novartis investigative site, montrose, colorado, united states novartis investigative site, pueblo, colorado, united states novartis investigative site, thornton, colorado, united states novartis investigative site, wheat ridge, colorado, united states novartis investigative site, hartford, connecticut, united states novartis investigative site, new haven, connecticut, united states novartis investigative site, stamford, connecticut, united states novartis investigative site, torrington, connecticut, united states novartis investigative site, dover, delaware, united states novartis investigative site, milford, delaware, united states novartis investigative site, washington, district of columbia, united states novartis investigative site, washington, district of columbia, united states novartis investigative site, boca raton, florida, united states novartis investigative site, fort lauderdale, florida, united states novartis investigative site, fort myers, florida, united states novartis investigative site, hollywood, florida, united states novartis investigative site, jacksonville, florida, united states novartis investigative site, jacksonville, florida, united states novartis investigative site, jupiter, florida, united states novartis investigative site, lakeland, florida, united states novartis investigative site, miami beach, florida, united states novartis investigative site, new port richey, florida, united states novartis investigative site, ocala, florida, united states novartis investigative site, orange park, florida, united states novartis investigative site, orlando, florida, united states novartis investigative site, orlando, florida, united states novartis investigative site, titusville, florida, united states novartis investigative site, weston, florida, united states novartis investigative site, athens, georgia, united states novartis investigative site, atlanta, georgia, united states novartis investigative site, atlanta, georgia, united states novartis investigative site, augusta, georgia, united states novartis investigative site, augusta, georgia, united states novartis investigative site, austell, georgia, united states novartis investigative site, columbus, georgia, united states novartis investigative site, decatur, georgia, united states novartis investigative site, fort gordon, georgia, united states novartis investigative site, gainesville, georgia, united states novartis investigative site, lawrenceville, georgia, united states novartis investigative site, marietta, georgia, united states novartis investigative site, riverdale, georgia, united states novartis investigative site, rome, georgia, united states novartis investigative site, savannah, georgia, united states novartis investigative site, valdosta, georgia, united states novartis investigative site, 'aiea, hawaii, united states novartis investigative site, honolulu, hawaii, united states novartis investigative site, honolulu, hawaii, united states novartis investigative site, honolulu, hawaii, united states novartis investigative site, honolulu, hawaii, united states novartis investigative site, lihue, hawaii, united states novartis investigative site, wailuku, hawaii, united states novartis investigative site, boise, idaho, united states novartis investigative site, boise, idaho, united states novartis investigative site, alton, illinois, united states novartis investigative site, aurora, illinois, united states novartis investigative site, berwyn, illinois, united states novartis investigative site, bloomington, illinois, united states novartis investigative site, canton, illinois, united states novartis investigative site, carthage, illinois, united states novartis investigative site, chicago, illinois, united states novartis investigative site, chicago, illinois, united states novartis investigative site, eureka, illinois, united states novartis investigative site, evanston, illinois, united states novartis investigative site, galesburg, illinois, united states novartis investigative site, harvey, illinois, united states novartis investigative site, havana, illinois, united states novartis investigative site, highland park, illinois, united states novartis investigative site, hopedale, illinois, united states novartis investigative site, joliet, illinois, united states novartis investigative site, joliet, illinois, united states novartis investigative site, kankakee, illinois, united states novartis investigative site, kewanee, illinois, united states novartis investigative site, la grange, illinois, united states novartis investigative site, libertyville, illinois, united states novartis investigative site, macomb, illinois, united states novartis investigative site, maywood, illinois, united states novartis investigative site, moline, illinois, united states novartis investigative site, monmouth, illinois, united states novartis investigative site, mount vernon, illinois, united states novartis investigative site, naperville, illinois, united states novartis investigative site, niles, illinois, united states novartis investigative site, normal, illinois, united states novartis investigative site, oak lawn, illinois, united states novartis investigative site, ottawa, illinois, united states novartis investigative site, park ridge, illinois, united states novartis investigative site, pekin, illinois, united states novartis investigative site, pekin, illinois, united states novartis investigative site, peoria, illinois, united states novartis investigative site, peoria, illinois, united states novartis investigative site, peoria, illinois, united states novartis investigative site, peoria, illinois, united states novartis investigative site, peoria, illinois, united states novartis investigative site, peru, illinois, united states novartis investigative site, princeton, illinois, united states novartis investigative site, rockford, illinois, united states novartis investigative site, skokie, illinois, united states novartis investigative site, spring valley, illinois, united states novartis investigative site, springfield, illinois, united states novartis investigative site, urbana, illinois, united states novartis investigative site, warrenville, illinois, united states novartis investigative site, winfield, illinois, united states novartis investigative site, beech grove, indiana, united states novartis investigative site, elkhart, indiana, united states novartis investigative site, fort wayne, indiana, united states novartis investigative site, indianapolis, indiana, united states novartis investigative site, indianapolis, indiana, united states novartis investigative site, kokomo, indiana, united states novartis investigative site, la porte, indiana, united states novartis investigative site, michigan city, indiana, united states novartis investigative site, mishawaka, indiana, united states novartis investigative site, muncie, indiana, united states novartis investigative site, richmond, indiana, united states novartis investigative site, south bend, indiana, united states novartis investigative site, south bend, indiana, united states novartis investigative site, ames, iowa, united states novartis investigative site, bettendorf, iowa, united states novartis investigative site, cedar rapids, iowa, united states novartis investigative site, cedar rapids, iowa, united states novartis investigative site, des moines, iowa, united states novartis investigative site, des moines, iowa, united states novartis investigative site, des moines, iowa, united states novartis investigative site, des moines, iowa, united states novartis investigative site, mason city, iowa, united states novartis investigative site, ottumwa, iowa, united states novartis investigative site, sioux city, iowa, united states novartis investigative site, sioux city, iowa, united states novartis investigative site, waterloo, iowa, united states novartis investigative site, waterloo, iowa, united states novartis investigative site, anthony, kansas, united states novartis investigative site, chanute, kansas, united states novartis investigative site, dodge city, kansas, united states novartis investigative site, el dorado, kansas, united states novartis investigative site, fort scott, kansas, united states novartis investigative site, independence, kansas, united states novartis investigative site, kansas city, kansas, united states novartis investigative site, kingman, kansas, united states novartis investigative site, lawrence, kansas, united states novartis investigative site, liberal, kansas, united states novartis investigative site, newton, kansas, united states novartis investigative site, olathe, kansas, united states novartis investigative site, overland park, kansas, united states novartis investigative site, overland park, kansas, united states novartis investigative site, overland park, kansas, united states novartis investigative site, parsons, kansas, united states novartis investigative site, prairie village, kansas, united states novartis investigative site, pratt, kansas, united states novartis investigative site, salina, kansas, united states novartis investigative site, shawnee mission, kansas, united states novartis investigative site, topeka, kansas, united states novartis investigative site, topeka, kansas, united states novartis investigative site, wellington, kansas, united states novartis investigative site, wichita, kansas, united states novartis investigative site, wichita, kansas, united states novartis investigative site, wichita, kansas, united states novartis investigative site, winfield, kansas, united states novartis investigative site, louisville, kentucky, united states novartis investigative site, baton rouge, louisiana, united states novartis investigative site, baton rouge, louisiana, united states novartis investigative site, houma, louisiana, united states novartis investigative site, new orleans, louisiana, united states novartis investigative site, new orleans, louisiana, united states novartis investigative site, portland, maine, united states novartis investigative site, scarborough, maine, united states novartis investigative site, baltimore, maryland, united states novartis investigative site, baltimore, maryland, united states novartis investigative site, bethesda, maryland, united states novartis investigative site, easton, maryland, united states novartis investigative site, frederick, maryland, united states novartis investigative site, hagerstown, maryland, united states novartis investigative site, silver spring, maryland, united states novartis investigative site, towson, maryland, united states novartis investigative site, westminster, maryland, united states novartis investigative site, boston, massachusetts, united states novartis investigative site, boston, massachusetts, united states novartis investigative site, boston, massachusetts, united states novartis investigative site, boston, massachusetts, united states novartis investigative site, burlington, massachusetts, united states novartis investigative site, gloucester, massachusetts, united states novartis investigative site, hyannis, massachusetts, united states novartis investigative site, lowell, massachusetts, united states novartis investigative site, peabody, massachusetts, united states novartis investigative site, adrian, michigan, united states novartis investigative site, ann arbor, michigan, united states novartis investigative site, ann arbor, michigan, united states novartis investigative site, ann arbor, michigan, united states novartis investigative site, battle creek, michigan, united states novartis investigative site, big rapids, michigan, united states novartis investigative site, byron center, michigan, united states novartis investigative site, dearborn, michigan, united states novartis investigative site, detroit, michigan, united states novartis investigative site, detroit, michigan, united states novartis investigative site, escanaba, michigan, united states novartis investigative site, flint, michigan, united states novartis investigative site, flint, michigan, united states novartis investigative site, grand rapids, michigan, united states novartis investigative site, iron mountain, michigan, united states novartis investigative site, jackson, michigan, united states novartis investigative site, kalamazoo, michigan, united states novartis investigative site, kalamazoo, michigan, united states novartis investigative site, lansing, michigan, united states novartis investigative site, livonia, michigan, united states novartis investigative site, monroe, michigan, united states novartis investigative site, muskegon, michigan, united states novartis investigative site, pontiac, michigan, united states novartis investigative site, port huron, michigan, united states novartis investigative site, saginaw, michigan, united states novartis investigative site, saint joseph, michigan, united states novartis investigative site, saint joseph, michigan, united states novartis investigative site, southfield, michigan, united states novartis investigative site, traverse city, michigan, united states novartis investigative site, warren, michigan, united states novartis investigative site, albert lea, minnesota, united states novartis investigative site, alexandria, minnesota, united states novartis investigative site, bemidji, minnesota, united states novartis investigative site, burnsville, minnesota, united states novartis investigative site, coon rapids, minnesota, united states novartis investigative site, duluth, minnesota, united states novartis investigative site, edina, minnesota, united states novartis investigative site, fergus falls, minnesota, united states novartis investigative site, fridley, minnesota, united states novartis investigative site, hutchinson, minnesota, united states novartis investigative site, litchfield, minnesota, united states novartis investigative site, mankato, minnesota, united states novartis investigative site, maplewood, minnesota, united states novartis investigative site, minneapolis, minnesota, united states novartis investigative site, minneapolis, minnesota, united states novartis investigative site, minneapolis, minnesota, united states novartis investigative site, robbinsdale, minnesota, united states novartis investigative site, saint cloud, minnesota, united states novartis investigative site, saint louis park, minnesota, united states novartis investigative site, saint paul, minnesota, united states novartis investigative site, saint paul, minnesota, united states novartis investigative site, shakopee, minnesota, united states novartis investigative site, waconia, minnesota, united states novartis investigative site, willmar, minnesota, united states novartis investigative site, woodbury, minnesota, united states novartis investigative site, jackson, mississippi, united states novartis investigative site, keesler air force base, mississippi, united states novartis investigative site, pascagoula, mississippi, united states novartis investigative site, bolivar, missouri, united states novartis investigative site, cape girardeau, missouri, united states novartis investigative site, cape girardeau, missouri, united states novartis investigative site, independence, missouri, united states novartis investigative site, joplin, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, lee's summit, missouri, united states novartis investigative site, liberty, missouri, united states novartis investigative site, saint joseph, missouri, united states novartis investigative site, saint joseph, missouri, united states novartis investigative site, saint louis, missouri, united states novartis investigative site, saint louis, missouri, united states novartis investigative site, saint louis, missouri, united states novartis investigative site, saint louis, missouri, united states novartis investigative site, springfield, missouri, united states novartis investigative site, springfield, missouri, united states novartis investigative site, springfield, missouri, united states novartis investigative site, billings, montana, united states novartis investigative site, bozeman, montana, united states novartis investigative site, butte, montana, united states novartis investigative site, great falls, montana, united states novartis investigative site, havre, montana, united states novartis investigative site, helena, montana, united states novartis investigative site, kalispell, montana, united states novartis investigative site, missoula, montana, united states novartis investigative site, missoula, montana, united states novartis investigative site, missoula, montana, united states novartis investigative site, grand island, nebraska, united states novartis investigative site, lincoln, nebraska, united states novartis investigative site, omaha, nebraska, united states novartis investigative site, omaha, nebraska, united states novartis investigative site, omaha, nebraska, united states novartis investigative site, omaha, nebraska, united states novartis investigative site, omaha, nebraska, united states novartis investigative site, omaha, nebraska, united states novartis investigative site, las vegas, nevada, united states novartis investigative site, concord, new hampshire, united states novartis investigative site, exeter, new hampshire, united states novartis investigative site, hooksett, new hampshire, united states novartis investigative site, keene, new hampshire, united states novartis investigative site, laconia, new hampshire, united states novartis investigative site, lebanon, new hampshire, united states novartis investigative site, manchester, new hampshire, united states novartis investigative site, portsmouth, new hampshire, united states novartis investigative site, hackensack, new jersey, united states novartis investigative site, hamilton, new jersey, united states novartis investigative site, livingston, new jersey, united states novartis investigative site, marlton, new jersey, united states novartis investigative site, morristown, new jersey, united states novartis investigative site, mount holly, new jersey, united states novartis investigative site, neptune, new jersey, united states novartis investigative site, new brunswick, new jersey, united states novartis investigative site, pomona, new jersey, united states novartis investigative site, princeton, new jersey, united states novartis investigative site, ridgewood, new jersey, united states novartis investigative site, somerville, new jersey, united states novartis investigative site, sparta, new jersey, united states novartis investigative site, summit, new jersey, united states novartis investigative site, vineland, new jersey, united states novartis investigative site, voorhees, new jersey, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, las cruces, new mexico, united states novartis investigative site, bronx, new york, united states novartis investigative site, bronx, new york, united states novartis investigative site, bronx, new york, united states novartis investigative site, buffalo, new york, united states novartis investigative site, clifton springs, new york, united states novartis investigative site, cooperstown, new york, united states novartis investigative site, east syracuse, new york, united states novartis investigative site, elmhurst, new york, united states novartis investigative site, jamaica, new york, united states novartis investigative site, lake success, new york, united states novartis investigative site, manhasset, new york, united states novartis investigative site, mineola, new york, united states novartis investigative site, new hyde park, new york, united states novartis investigative site, new york, new york, united states novartis investigative site, new york, new york, united states novartis investigative site, new york, new york, united states novartis investigative site, new york, new york, united states novartis investigative site, new york, new york, united states novartis investigative site, rochester, new york, united states novartis investigative site, rochester, new york, united states novartis investigative site, rochester, new york, united states novartis investigative site, stony brook, new york, united states novartis investigative site, syracuse, new york, united states novartis investigative site, utica, new york, united states novartis investigative site, chapel hill, north carolina, united states novartis investigative site, fayetteville, north carolina, united states novartis investigative site, gastonia, north carolina, united states novartis investigative site, goldsboro, north carolina, united states novartis investigative site, hendersonville, north carolina, united states novartis investigative site, kinston, north carolina, united states novartis investigative site, raleigh, north carolina, united states novartis investigative site, rutherfordton, north carolina, united states novartis investigative site, statesville, north carolina, united states novartis investigative site, washington, north carolina, united states novartis investigative site, winston-salem, north carolina, united states novartis investigative site, bismarck, north dakota, united states novartis investigative site, fargo, north dakota, united states novartis investigative site, grand forks, north dakota, united states novartis investigative site, minot, north dakota, united states novartis investigative site, beachwood, ohio, united states novartis investigative site, bellefontaine, ohio, united states novartis investigative site, bowling green, ohio, united states novartis investigative site, canton, ohio, united states novartis investigative site, canton, ohio, united states novartis investigative site, chillicothe, ohio, united states novartis investigative site, cincinnati, ohio, united states novartis investigative site, cincinnati, ohio, united states novartis investigative site, cleveland, ohio, united states novartis investigative site, cleveland, ohio, united states novartis investigative site, clyde, ohio, united states novartis investigative site, columbia, ohio, united states novartis investigative site, columbus, ohio, united states novartis investigative site, columbus, ohio, united states novartis investigative site, columbus, ohio, united states novartis investigative site, columbus, ohio, united states novartis investigative site, columbus, ohio, united states novartis investigative site, dayton, ohio, united states novartis investigative site, dayton, ohio, united states novartis investigative site, dayton, ohio, united states novartis investigative site, dayton, ohio, united states novartis investigative site, dayton, ohio, united states novartis investigative site, delaware, ohio, united states novartis investigative site, elyria, ohio, united states novartis investigative site, findlay, ohio, united states novartis investigative site, franklin, ohio, united states novartis investigative site, greenville, ohio, united states novartis investigative site, independence, ohio, united states novartis investigative site, kettering, ohio, united states novartis investigative site, lambertville, ohio, united states novartis investigative site, lima, ohio, united states novartis investigative site, marietta, ohio, united states novartis investigative site, maumee, ohio, united states novartis investigative site, maumee, ohio, united states novartis investigative site, mayfield heights, ohio, united states novartis investigative site, newark, ohio, united states novartis investigative site, oregon, ohio, united states novartis investigative site, sandusky, ohio, united states novartis investigative site, springfield, ohio, united states novartis investigative site, springfield, ohio, united states novartis investigative site, sylvania, ohio, united states novartis investigative site, tiffin, ohio, united states novartis investigative site, toledo, ohio, united states novartis investigative site, toledo, ohio, united states novartis investigative site, toledo, ohio, united states novartis investigative site, toledo, ohio, united states novartis investigative site, toledo, ohio, united states novartis investigative site, troy, ohio, united states novartis investigative site, wauseon, ohio, united states novartis investigative site, westerville, ohio, united states novartis investigative site, wilmington, ohio, united states novartis investigative site, wooster, ohio, united states novartis investigative site, wright-patterson air force base, ohio, united states novartis investigative site, xenia, ohio, united states novartis investigative site, zanesville, ohio, united states novartis investigative site, oklahoma city, oklahoma, united states novartis investigative site, oklahoma city, oklahoma, united states novartis investigative site, oklahoma city, oklahoma, united states novartis investigative site, tulsa, oklahoma, united states novartis investigative site, coos bay, oregon, united states novartis investigative site, eugene, oregon, united states novartis investigative site, gresham, oregon, united states novartis investigative site, hillsboro, oregon, united states novartis investigative site, klamath falls, oregon, united states novartis investigative site, milwaukie, oregon, united states novartis investigative site, portland, oregon, united states novartis investigative site, portland, oregon, united states novartis investigative site, portland, oregon, united states novartis investigative site, portland, oregon, united states novartis investigative site, portland, oregon, united states novartis investigative site, portland, oregon, united states novartis investigative site, tualatin, oregon, united states novartis investigative site, abington, pennsylvania, united states novartis investigative site, bethlehem, pennsylvania, united states novartis investigative site, bryn mawr, pennsylvania, united states novartis investigative site, butler, pennsylvania, united states novartis investigative site, danville, pennsylvania, united states novartis investigative site, ephrata, pennsylvania, united states novartis investigative site, hazleton, pennsylvania, united states novartis investigative site, hershey, pennsylvania, united states novartis investigative site, kingston, pennsylvania, united states novartis investigative site, lancaster, pennsylvania, united states novartis investigative site, langhorne, pennsylvania, united states novartis investigative site, lewistown, pennsylvania, united states novartis investigative site, media, pennsylvania, united states novartis investigative site, nashville, pennsylvania, united states novartis investigative site, paoli, pennsylvania, united states novartis investigative site, philadelphia, pennsylvania, united states novartis investigative site, philadelphia, pennsylvania, united states novartis investigative site, philadelphia, pennsylvania, united states novartis investigative site, philadelphia, pennsylvania, united states novartis investigative site, phoenixville, pennsylvania, united states novartis investigative site, pottstown, pennsylvania, united states novartis investigative site, sayre, pennsylvania, united states novartis investigative site, scranton, pennsylvania, united states novartis investigative site, sellersville, pennsylvania, united states novartis investigative site, state college, pennsylvania, united states novartis investigative site, state college, pennsylvania, united states novartis investigative site, west reading, pennsylvania, united states novartis investigative site, wilkes-barre, pennsylvania, united states novartis investigative site, wilkes-barre, pennsylvania, united states novartis investigative site, wynnewood, pennsylvania, united states novartis investigative site, providence, rhode island, united states novartis investigative site, providence, rhode island, united states novartis investigative site, providence, rhode island, united states novartis investigative site, warwick, rhode island, united states novartis investigative site, anderson, south carolina, united states novartis investigative site, charleston, south carolina, united states novartis investigative site, columbia, south carolina, united states novartis investigative site, greenville, south carolina, united states novartis investigative site, mount pleasant, south carolina, united states novartis investigative site, spartanburg, south carolina, united states novartis investigative site, aberdeen, south dakota, united states novartis investigative site, rapid city, south dakota, united states novartis investigative site, sioux falls, south dakota, united states novartis investigative site, sioux falls, south dakota, united states novartis investigative site, sioux falls, south dakota, united states novartis investigative site, chattanooga, tennessee, united states novartis investigative site, chattanooga, tennessee, united states novartis investigative site, franklin, tennessee, united states novartis investigative site, germantown, tennessee, united states novartis investigative site, jackson, tennessee, united states novartis investigative site, knoxville, tennessee, united states novartis investigative site, knoxville, tennessee, united states novartis investigative site, knoxville, tennessee, united states novartis investigative site, nashville, tennessee, united states novartis investigative site, nashville, tennessee, united states novartis investigative site, nashville, tennessee, united states novartis investigative site, abilene, texas, united states novartis investigative site, amarillo, texas, united states novartis investigative site, austin, texas, united states novartis investigative site, austin, texas, united states novartis investigative site, austin, texas, united states novartis investigative site, austin, texas, united states novartis investigative site, beaumont, texas, united states novartis investigative site, bedford, texas, united states novartis investigative site, cedar park, texas, united states novartis investigative site, dallas, texas, united states novartis investigative site, dallas, texas, united states novartis investigative site, fort sam houston, texas, united states novartis investigative site, fort worth, texas, united states novartis investigative site, houston, texas, united states novartis investigative site, lackland air force base, texas, united states novartis investigative site, longview, texas, united states novartis investigative site, mcallen, texas, united states novartis investigative site, mesquite, texas, united states novartis investigative site, midland, texas, united states novartis investigative site, paris, texas, united states novartis investigative site, round rock, texas, united states novartis investigative site, round rock, texas, united states novartis investigative site, san antonio, texas, united states novartis investigative site, san antonio, texas, united states novartis investigative site, san marcos, texas, united states novartis investigative site, sherman, texas, united states novartis investigative site, sugar land, texas, united states novartis investigative site, tyler, texas, united states novartis investigative site, waco, texas, united states novartis investigative site, wichita falls, texas, united states novartis investigative site, salt lake city, utah, united states novartis investigative site, berlin, vermont, united states novartis investigative site, burlington, vermont, united states novartis investigative site, saint johnsbury, vermont, united states novartis investigative site, charlottesville, virginia, united states novartis investigative site, danville, virginia, united states novartis investigative site, fredericksburg, virginia, united states novartis investigative site, hampton, virginia, united states novartis investigative site, norfolk, virginia, united states novartis investigative site, richmond, virginia, united states novartis investigative site, roanoke, virginia, united states novartis investigative site, auburn, washington, united states novartis investigative site, bellingham, washington, united states novartis investigative site, bremerton, washington, united states novartis investigative site, burien, washington, united states novartis investigative site, centralia, washington, united states novartis investigative site, federal way, washington, united states novartis investigative site, kennewick, washington, united states novartis investigative site, kirkland, washington, united states novartis investigative site, mount vernon, washington, united states novartis investigative site, olympia, washington, united states novartis investigative site, port angeles, washington, united states novartis investigative site, poulsbo, washington, united states novartis investigative site, puyallup, washington, united states novartis investigative site, renton, washington, united states novartis investigative site, seattle, washington, united states novartis investigative site, seattle, washington, united states novartis investigative site, seattle, washington, united states novartis investigative site, seattle, washington, united states novartis investigative site, seattle, washington, united states novartis investigative site, seattle, washington, united states novartis investigative site, spokane, washington, united states novartis investigative site, spokane, washington, united states novartis investigative site, tacoma, washington, united states novartis investigative site, tacoma, washington, united states novartis investigative site, tacoma, washington, united states novartis investigative site, vancouver, washington, united states novartis investigative site, vancouver, washington, united states novartis investigative site, wenatchee, washington, united states novartis investigative site, charleston, west virginia, united states novartis investigative site, huntington, west virginia, united states novartis investigative site, wheeling, west virginia, united states novartis investigative site, chippewa falls, wisconsin, united states novartis investigative site, eau claire, wisconsin, united states novartis investigative site, eau claire, wisconsin, united states novartis investigative site, green bay, wisconsin, united states novartis investigative site, green bay, wisconsin, united states novartis investigative site, la crosse, wisconsin, united states novartis investigative site, madison, wisconsin, united states novartis investigative site, manitowoc, wisconsin, united states novartis investigative site, marinette, wisconsin, united states novartis investigative site, marshfield, wisconsin, united states novartis investigative site, milwaukee, wisconsin, united states novartis investigative site, minocqua, wisconsin, united states novartis investigative site, oconto falls, wisconsin, united states novartis investigative site, oshkosh, wisconsin, united states novartis investigative site, rhinelander, wisconsin, united states novartis investigative site, rice lake, wisconsin, united states novartis investigative site, stevens point, wisconsin, united states novartis investigative site, sturgeon bay, wisconsin, united states novartis investigative site, weston, wisconsin, united states novartis investigative site, wisconsin rapids, wisconsin, united states novartis investigative site, casper, wyoming, united states novartis investigative site, sheridan, wyoming, united states novartis investigative site, berazategui, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, ciudad autonoma de buenos aires, argentina novartis investigative site, mendoza, argentina novartis investigative site, quilmes, argentina novartis investigative site, santa fe, argentina novartis investigative site, tucuman, argentina novartis investigative site, camperdown, new south wales, australia novartis investigative site, coffs harbour, new south wales, australia novartis investigative site, concord, new south wales, australia novartis investigative site, kingswood, new south wales, australia novartis investigative site, liverpool, new south wales, australia novartis investigative site, north sydney, new south wales, australia novartis investigative site, port macquarie, new south wales, australia novartis investigative site, randwick, new south wales, australia novartis investigative site, taree, new south wales, australia novartis investigative site, tweed heads, new south wales, australia novartis investigative site, wagga wagga, new south wales, australia novartis investigative site, waratah, new south wales, australia novartis investigative site, westmead, new south wales, australia novartis investigative site, nambour, queensland, australia novartis investigative site, south brisbane, queensland, australia novartis investigative site, woolloongabba, queensland, australia novartis investigative site, adelaide, south australia, australia novartis investigative site, bedford park, south australia, australia novartis investigative site, woodville, south australia, australia novartis investigative site, hobart, tasmania, australia novartis investigative site, box hill, victoria, australia novartis investigative site, east bentleigh, victoria, australia novartis investigative site, east melbourne, victoria, australia novartis investigative site, fitzroy, victoria, australia novartis investigative site, footscray, victoria, australia novartis investigative site, frankston, victoria, australia novartis investigative site, heidelberg, victoria, australia novartis investigative site, melbourne, victoria, australia novartis investigative site, parkville, victoria, australia novartis investigative site, ringwood east, victoria, australia novartis investigative site, wendouree, victoria, australia novartis investigative site, bunbury, western australia, australia novartis investigative site, nedlands, western australia, australia novartis investigative site, subiaco, western australia, australia novartis investigative site, campbelltown, australia novartis investigative site, lismore, australia novartis investigative site, murdoch, australia novartis investigative site, guessing, austria novartis investigative site, linz, austria novartis investigative site, rankweil, austria novartis investigative site, salzburg, austria novartis investigative site, steyr, austria novartis investigative site, vienna, austria novartis investigative site, villach, austria novartis investigative site, wien, austria novartis investigative site, wolfsberg, austria novartis investigative site, aalst, belgium novartis investigative site, antwerpen, belgium novartis investigative site, bonheiden, belgium novartis investigative site, brasschaat, belgium novartis investigative site, brugge, belgium novartis investigative site, brussels, belgium novartis investigative site, brussels, belgium novartis investigative site, brussel, belgium novartis investigative site, bruxelles, belgium novartis investigative site, bruxelles, belgium novartis investigative site, bruxelles, belgium novartis investigative site, charleroi, belgium novartis investigative site, edegem, belgium novartis investigative site, genk, belgium novartis investigative site, gent, belgium novartis investigative site, haine saint paul, belgium novartis investigative site, hasselt, belgium novartis investigative site, huy, belgium novartis investigative site, kortrijk, belgium novartis investigative site, leuven, belgium novartis investigative site, liege, belgium novartis investigative site, mons, belgium novartis investigative site, namur, belgium novartis investigative site, roeselare, belgium novartis investigative site, sint-niklaas, belgium novartis investigative site, tournai, belgium novartis investigative site, turnhout, belgium novartis investigative site, verviers, belgium novartis investigative site, wilrijk, belgium novartis investigative site, yvoir, belgium novartis investigative site, salvador, bahía, brazil novartis investigative site, belo horizonte, minas gerais, brazil novartis investigative site, porte alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, jau, são paulo, brazil novartis investigative site, santo andre, são paulo, brazil novartis investigative site, rio de janeiro, brazil novartis investigative site, shumen, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, varna, bulgaria novartis investigative site, kelowna, british columbia, canada novartis investigative site, vancouver, british columbia, canada novartis investigative site, moncton, new brunswick, canada novartis investigative site, saint john, new brunswick, canada novartis investigative site, barrie, ontario, canada novartis investigative site, london, ontario, canada novartis investigative site, sault ste. marie, ontario, canada novartis investigative site, st catharines, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, charlottetown, prince edward island, canada novartis investigative site, montreal, quebec, canada novartis investigative site, sherbrooke, quebec, canada novartis investigative site, regina, saskatchewan, canada novartis investigative site, saskatoon, saskatchewan, canada novartis investigative site, temuco, región de la araucania, chile novartis investigative site, valdivia, región de los lagos, chile novartis investigative site, santiago, región metro de santiago, chile novartis investigative site, santiago, región metro de santiago, chile novartis investigative site, santiago, región metro de santiago, chile novartis investigative site, santiago, región metro de santiago, chile novartis investigative site, valparaiso, valparaíso, chile novartis investigative site, vina del mar, valparaíso, chile novartis investigative site, arica, chile novartis investigative site, guangzhou, guangdong, china novartis investigative site, beijing, china novartis investigative site, beijing, china novartis investigative site, shanghai, china novartis investigative site, tianjin, china novartis investigative site, varazdin, croatia novartis investigative site, zagreb, croatia novartis investigative site, zagreb, croatia novartis investigative site, brno, czechia novartis investigative site, brno, czechia novartis investigative site, brno, czechia novartis investigative site, ceske budejovice, czechia novartis investigative site, chomutov, czechia novartis investigative site, jihlava, czechia novartis investigative site, novy jicin, czechia novartis investigative site, olomouc, czechia novartis investigative site, pardubice, czechia novartis investigative site, praha 10, czechia novartis investigative site, praha 2, czechia novartis investigative site, praha 4, czechia novartis investigative site, praha 5, czechia novartis investigative site, praha 8, czechia novartis investigative site, usti nad labem, czechia novartis investigative site, aalborg, denmark novartis investigative site, arhus c, denmark novartis investigative site, esbjerg, denmark novartis investigative site, herlev, denmark novartis investigative site, hilleroed, denmark novartis investigative site, koebenhavn oe, denmark novartis investigative site, naestved, denmark novartis investigative site, odense, denmark novartis investigative site, roskilde, denmark novartis investigative site, vejle, denmark novartis investigative site, viborg, denmark novartis investigative site, tallinn, estonia novartis investigative site, tartu, estonia novartis investigative site, angers cedex 2, france novartis investigative site, annecy, france novartis investigative site, avignon, france novartis investigative site, bayonne, france novartis investigative site, bethune, france novartis investigative site, bordeaux, france novartis investigative site, brive la gaillarde, france novartis investigative site, bron, france novartis investigative site, caen cedex 05, france novartis investigative site, caen, france novartis investigative site, clermont ferrand, france novartis investigative site, coudekerque branche, france novartis investigative site, dijon cedex, france novartis investigative site, dijon, france novartis investigative site, draguignan, france novartis investigative site, grenoble cedex 9, france novartis investigative site, grenoble cedex, france novartis investigative site, hyeres, france novartis investigative site, la seyne sur mer, france novartis investigative site, le chesnay, france novartis investigative site, le havre, france novartis investigative site, le mans, france novartis investigative site, lille, france novartis investigative site, lyon, france novartis investigative site, lyon, france novartis investigative site, lyon, france novartis investigative site, marseille cedex 09, france novartis investigative site, marseille cedex 5, france novartis investigative site, marseille, france novartis investigative site, metz cedex 01, france novartis investigative site, mont de marsan, france novartis investigative site, montauban, france novartis investigative site, montbeliard, france novartis investigative site, mulhouse, france novartis investigative site, nancy, france novartis investigative site, nice cedex 2, france novartis investigative site, nimes cedex 9, france novartis investigative site, paris cedex 10, france novartis investigative site, paris cedex 14, france novartis investigative site, paris cedex 5, france novartis investigative site, perigueux, france novartis investigative site, perin sur mer, france novartis investigative site, perpignan, france novartis investigative site, reims, france novartis investigative site, rouen cedex 1, france novartis investigative site, rouen, france novartis investigative site, saint gregoire, france novartis investigative site, saint jean, france novartis investigative site, saint-cloud, france novartis investigative site, saint-herblain, france novartis investigative site, saint-martin boulogne, france novartis investigative site, saint-priest en jarez cedex, france novartis investigative site, strasbourg, france novartis investigative site, strasbourg, france novartis investigative site, toulouse, france novartis investigative site, toulouse, france novartis investigative site, tours cedex, france novartis investigative site, valenciennes, france novartis investigative site, vandoeuvre-les-nancy, france novartis investigative site, villejuif cedex, france novartis investigative site, aalen, baden-wuerttemberg, germany novartis investigative site, baden-baden, baden-wuerttemberg, germany novartis investigative site, boeblingen, baden-wuerttemberg, germany novartis investigative site, emmendingen, baden-wuerttemberg, germany novartis investigative site, esslingen, baden-wuerttemberg, germany novartis investigative site, freiburg, baden-wuerttemberg, germany novartis investigative site, goeppingen, baden-wuerttemberg, germany novartis investigative site, heidelberg, baden-wuerttemberg, germany novartis investigative site, heidelberg, baden-wuerttemberg, germany novartis investigative site, karlsruhe, baden-wuerttemberg, germany novartis investigative site, karlsruhe, baden-wuerttemberg, germany novartis investigative site, karlsruhe, baden-wuerttemberg, germany novartis investigative site, konstanz, baden-wuerttemberg, germany novartis investigative site, loerrach, baden-wuerttemberg, germany novartis investigative site, ludwigsburg, baden-wuerttemberg, germany novartis investigative site, mannheim, baden-wuerttemberg, germany novartis investigative site, mannheim, baden-wuerttemberg, germany novartis investigative site, mutlangen, baden-wuerttemberg, germany novartis investigative site, ostfildern, baden-wuerttemberg, germany novartis investigative site, ravensburg, baden-wuerttemberg, germany novartis investigative site, reutlingen, baden-wuerttemberg, germany novartis investigative site, rheinfelden, baden-wuerttemberg, germany novartis investigative site, schwaebisch hall, baden-wuerttemberg, germany novartis investigative site, schwetzingen, baden-wuerttemberg, germany novartis investigative site, sigmaringen, baden-wuerttemberg, germany novartis investigative site, stuttgart, baden-wuerttemberg, germany novartis investigative site, stuttgart, baden-wuerttemberg, germany novartis investigative site, tuebingen, baden-wuerttemberg, germany novartis investigative site, tuttlingen, baden-wuerttemberg, germany novartis investigative site, ulm, baden-wuerttemberg, germany novartis investigative site, villingen-schwenningen, baden-wuerttemberg, germany novartis investigative site, ansbach, bayern, germany novartis investigative site, aschaffenburg, bayern, germany novartis investigative site, augsburg, bayern, germany novartis investigative site, bad reichenhall, bayern, germany novartis investigative site, bayreuth, bayern, germany novartis investigative site, coburg, bayern, germany novartis investigative site, dachau, bayern, germany novartis investigative site, deggendorf, bayern, germany novartis investigative site, donauwoerth, bayern, germany novartis investigative site, ebersberg, bayern, germany novartis investigative site, eggenfelden, bayern, germany novartis investigative site, erlangen, bayern, germany novartis investigative site, forchheim, bayern, germany novartis investigative site, freising, bayern, germany novartis investigative site, fuerth, bayern, germany novartis investigative site, garmisch-partenkirchen, bayern, germany novartis investigative site, kempten, bayern, germany novartis investigative site, kronach, bayern, germany novartis investigative site, landshut, bayern, germany novartis investigative site, landshut, bayern, germany novartis investigative site, marktredwitz, bayern, germany novartis investigative site, memmingen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, muhr, bayern, germany novartis investigative site, munchen, bayern, germany novartis investigative site, nuernberg, bayern, germany novartis investigative site, nuernberg, bayern, germany novartis investigative site, regensburg, bayern, germany novartis investigative site, rosenheim, bayern, germany novartis investigative site, roth, bayern, germany novartis investigative site, schwandorf, bayern, germany novartis investigative site, traunstein, bayern, germany novartis investigative site, waldmuenchen, bayern, germany novartis investigative site, weiden, bayern, germany novartis investigative site, fuerstenwalde, brandenburg, germany novartis investigative site, koenigs wusterhausen, brandenburg, germany novartis investigative site, luckenwalde, brandenburg, germany novartis investigative site, ludwigsfelde, brandenburg, germany novartis investigative site, bremerhaven, bremen, germany novartis investigative site, bad soden, hessen, germany novartis investigative site, frankfurt am main, hessen, germany novartis investigative site, frankfurt, hessen, germany novartis investigative site, frankfurt, hessen, germany novartis investigative site, frankfurt, hessen, germany novartis investigative site, fulda, hessen, germany novartis investigative site, hanau, hessen, germany novartis investigative site, kassel, hessen, germany novartis investigative site, kassel, hessen, germany novartis investigative site, limburg, hessen, germany novartis investigative site, marburg, hessen, germany novartis investigative site, offenbach, hessen, germany novartis investigative site, wiesbaden, hessen, germany novartis investigative site, wiesbaden, hessen, germany novartis investigative site, wiesbaden, hessen, germany novartis investigative site, greifswald, mecklenburg-vorpommern, germany novartis investigative site, guestrow, mecklenburg-vorpommern, germany novartis investigative site, rostock, mecklenburg-vorpommern, germany novartis investigative site, schwerin, mecklenburg-vorpommern, germany novartis investigative site, stralsund, mecklenburg-vorpommern, germany novartis investigative site, aurich, niedersachsen, germany novartis investigative site, braunschweig, niedersachsen, germany novartis investigative site, celle, niedersachsen, germany novartis investigative site, cuxhaven, niedersachsen, germany novartis investigative site, georgsmarienhuette, niedersachsen, germany novartis investigative site, goettingen, niedersachsen, germany novartis investigative site, goslar, niedersachsen, germany novartis investigative site, hameln, niedersachsen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, leer, niedersachsen, germany novartis investigative site, oldenburg, niedersachsen, germany novartis investigative site, oldenburg, niedersachsen, germany novartis investigative site, osnabrueck, niedersachsen, germany novartis investigative site, rotenburg (wuemme), niedersachsen, germany novartis investigative site, stade, niedersachsen, germany novartis investigative site, stadthagen, niedersachsen, germany novartis investigative site, vechta, niedersachsen, germany novartis investigative site, westerstede, niedersachsen, germany novartis investigative site, bergisch gladbach, nordrhein-westfalen, germany novartis investigative site, bielefeld, nordrhein-westfalen, germany novartis investigative site, bochum, nordrhein-westfalen, germany novartis investigative site, bochum, nordrhein-westfalen, germany novartis investigative site, bonn, nordrhein-westfalen, germany novartis investigative site, bonn, nordrhein-westfalen, germany novartis investigative site, bonn, nordrhein-westfalen, germany novartis investigative site, duesseldorf, nordrhein-westfalen, germany novartis investigative site, duesseldorf, nordrhein-westfalen, germany novartis investigative site, duisburg, nordrhein-westfalen, germany novartis investigative site, eschweiler, nordrhein-westfalen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, gummersbach, nordrhein-westfalen, germany novartis investigative site, hamm-heessen, nordrhein-westfalen, germany novartis investigative site, herne, nordrhein-westfalen, germany novartis investigative site, koeln, nordrhein-westfalen, germany novartis investigative site, koeln, nordrhein-westfalen, germany novartis investigative site, koeln, nordrhein-westfalen, germany novartis investigative site, krefeld, nordrhein-westfalen, germany novartis investigative site, leverkusen, nordrhein-westfalen, germany novartis investigative site, minden, nordrhein-westfalen, germany novartis investigative site, moenchengladbach, nordrhein-westfalen, germany novartis investigative site, muelheim, nordrhein-westfalen, germany novartis investigative site, muenster, nordrhein-westfalen, germany novartis investigative site, muenster, nordrhein-westfalen, germany novartis investigative site, olpe, nordrhein-westfalen, germany novartis investigative site, porta westfalica, nordrhein-westfalen, germany novartis investigative site, solingen, nordrhein-westfalen, germany novartis investigative site, troisdorf, nordrhein-westfalen, germany novartis investigative site, velbert, nordrhein-westfalen, germany novartis investigative site, wesel, nordrhein-westfalen, germany novartis investigative site, witten, nordrhein-westfalen, germany novartis investigative site, wuerselen, nordrhein-westfalen, germany novartis investigative site, wuppertal, nordrhein-westfalen, germany novartis investigative site, wuppertal, nordrhein-westfalen, germany novartis investigative site, wuppertal, nordrhein-westfalen, germany novartis investigative site, ludwigshafen, rheinland-pfalz, germany novartis investigative site, mainz, rheinland-pfalz, germany novartis investigative site, trier, rheinland-pfalz, germany novartis investigative site, homburg/saar, saarland, germany novartis investigative site, landstuhl, saarland, germany novartis investigative site, neunkirchen, saarland, germany novartis investigative site, saarbruecken, saarland, germany novartis investigative site, aschersleben, sachsen-anhalt, germany novartis investigative site, halle, sachsen-anhalt, germany novartis investigative site, halle, sachsen-anhalt, germany novartis investigative site, magdeburg, sachsen-anhalt, germany novartis investigative site, magdeburg, sachsen-anhalt, germany novartis investigative site, stendal, sachsen-anhalt, germany novartis investigative site, weissenfels, sachsen-anhalt, germany novartis investigative site, chemnitz, sachsen, germany novartis investigative site, dresden, sachsen, germany novartis investigative site, dresden, sachsen, germany novartis investigative site, hoyerswerda, sachsen, germany novartis investigative site, leipzig, sachsen, germany novartis investigative site, leipzig, sachsen, germany novartis investigative site, radebeul, sachsen, germany novartis investigative site, rodewisch, sachsen, germany novartis investigative site, schkeuditz, sachsen, germany novartis investigative site, torgau, sachsen, germany novartis investigative site, zittau, sachsen, germany novartis investigative site, zwickau, sachsen, germany novartis investigative site, bad oldesloe, schleswig-holstein, germany novartis investigative site, flensburg, schleswig-holstein, germany novartis investigative site, geesthacht, schleswig-holstein, germany novartis investigative site, heide, schleswig-holstein, germany novartis investigative site, itzehoe, schleswig-holstein, germany novartis investigative site, kiel, schleswig-holstein, germany novartis investigative site, kiel, schleswig-holstein, germany novartis investigative site, luebeck, schleswig-holstein, germany novartis investigative site, neumuenster, schleswig-holstein, germany novartis investigative site, rendsburg, schleswig-holstein, germany novartis investigative site, erfurt, thueringen, germany novartis investigative site, gera, thueringen, germany novartis investigative site, jena, thueringen, germany novartis investigative site, meiningen, thueringen, germany novartis investigative site, muehlhausen, thueringen, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, brandenburg, germany novartis investigative site, bremen, germany novartis investigative site, bremen, germany novartis investigative site, friedrichshafen, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, hamburg, germany novartis investigative site, wuerzburg, germany novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, athens, greece novartis investigative site, heraklion,crete, greece novartis investigative site, patra, greece novartis investigative site, thessaloniki, greece novartis investigative site, kowloon, hong kong novartis investigative site, tuen mun, hong kong novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, gyor, hungary novartis investigative site, szeged, hungary novartis investigative site, szombathely, hungary novartis investigative site, gurgaon, india novartis investigative site, hyderabad, india novartis investigative site, kolkatta (w.b.), india novartis investigative site, mangalore, india novartis investigative site, mumbai, india novartis investigative site, nagpur, india novartis investigative site, new delhi, india novartis investigative site, new delhi, india novartis investigative site, trivandrum, india novartis investigative site, dublin, ireland novartis investigative site, dublin, ireland novartis investigative site, dublin, ireland novartis investigative site, galway, ireland novartis investigative site, limerick, ireland novartis investigative site, sligo, ireland novartis investigative site, tallaght, dublin, ireland novartis investigative site, wilton, cork, ireland novartis investigative site, beer-sheva, israel novartis investigative site, haifa, israel novartis investigative site, holon, israel novartis investigative site, jerusalem, israel novartis investigative site, kfar saba, israel novartis investigative site, netanya, israel novartis investigative site, ramat gan, israel novartis investigative site, rehovot, israel novartis investigative site, tel aviv, israel novartis investigative site, potenza, basilicata, italy novartis investigative site, avellino, campania, italy novartis investigative site, carpi (mo), emilia-romagna, italy novartis investigative site, lugo (ravenna), emilia-romagna, italy novartis investigative site, meldola (fc), emilia-romagna, italy novartis investigative site, ravenna, emilia-romagna, italy novartis investigative site, rimini, emilia-romagna, italy novartis investigative site, aviano (pn), friuli-venezia-giulia, italy novartis investigative site, udine, friuli-venezia-giulia, italy novartis investigative site, roma, lazio, italy novartis investigative site, roma, lazio, italy novartis investigative site, roma, lazio, italy novartis investigative site, viterbo, lazio, italy novartis investigative site, genova, liguria, italy novartis investigative site, alzano lombardo (bg), lombardia, italy novartis investigative site, bergamo, lombardia, italy novartis investigative site, brescia, lombardia, italy novartis investigative site, brescia, lombardia, italy novartis investigative site, cremona, lombardia, italy novartis investigative site, lecco, lombardia, italy novartis investigative site, mantova, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, monza, lombardia, italy novartis investigative site, pavia, lombardia, italy novartis investigative site, rozzano (mi), lombardia, italy novartis investigative site, san fermo della battaglia (co), lombardia, italy novartis investigative site, saronno (va), lombardia, italy novartis investigative site, treviglio (bg), lombardia, italy novartis investigative site, varese, lombardia, italy novartis investigative site, fano (pesaro urbino), marche, italy novartis investigative site, fermo (ap), marche, italy novartis investigative site, asti, piemonte, italy novartis investigative site, biella, piemonte, italy novartis investigative site, candiolo (to), piemonte, italy novartis investigative site, brindisi, puglia, italy novartis investigative site, lecce, puglia, italy novartis investigative site, monserrato (ca), sardegna, italy novartis investigative site, sassari, sardegna, italy novartis investigative site, palermo, sicilia, italy novartis investigative site, palermo, sicilia, italy novartis investigative site, ragusa, sicilia, italy novartis investigative site, firenze, toscana, italy novartis investigative site, firenze, toscana, italy novartis investigative site, lido di camaiore (lu), toscana, italy novartis investigative site, livorno, toscana, italy novartis investigative site, montepulciano (siena, toscana, italy novartis investigative site, pisa, toscana, italy novartis investigative site, poggibonsi (siena), toscana, italy novartis investigative site, prato, toscana, italy novartis investigative site, trento, trentino-alto adige, italy novartis investigative site, chieti, italy novartis investigative site, cosenza, italy novartis investigative site, aichi, japan novartis investigative site, chiba, japan novartis investigative site, ehime, japan novartis investigative site, fukuoka, japan novartis investigative site, ibaraki, japan novartis investigative site, kanagawa, japan novartis investigative site, kyoto, japan novartis investigative site, osaka, japan novartis investigative site, osaka, japan novartis investigative site, saitama, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, gyeonggi-do, korea, republic of novartis investigative site, incheon, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, suwon-si, gyeonggi-do, korea, republic of novartis investigative site, kubang kerian, malaysia novartis investigative site, sarawak, malaysia novartis investigative site, toluca, estado de méxico, mexico novartis investigative site, merida, yucatán, mexico novartis investigative site, chihuahua, mexico novartis investigative site, mexico city, mexico novartis investigative site, mexico d.f., mexico novartis investigative site, mexico df, mexico novartis investigative site, amersfoort, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, arnhem, netherlands novartis investigative site, blaricum, netherlands novartis investigative site, delft, netherlands novartis investigative site, den haag, netherlands novartis investigative site, den haag, netherlands novartis investigative site, eindhoven, netherlands novartis investigative site, gouda, netherlands novartis investigative site, hoofddorp, netherlands novartis investigative site, leeuwarden, netherlands novartis investigative site, leiden, netherlands novartis investigative site, leidschendam, netherlands novartis investigative site, purmerend, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, sittard-geleen, netherlands novartis investigative site, tilburg, netherlands novartis investigative site, utrecht, netherlands novartis investigative site, hamilton, new zealand novartis investigative site, palmerston north, new zealand novartis investigative site, wellington, new zealand novartis investigative site, forde, norway novartis investigative site, oslo, norway novartis investigative site, oslo, norway novartis investigative site, tromso, norway novartis investigative site, karachi, pakistan novartis investigative site, karachi, pakistan novartis investigative site, lahore, pakistan novartis investigative site, lahore, pakistan novartis investigative site, rawalpindi, pakistan novartis investigative site, callao, peru novartis investigative site, lima, peru novartis investigative site, lima, peru novartis investigative site, lima, peru novartis investigative site, cebu, philippines novartis investigative site, quezon city, philippines novartis investigative site, sampaloc manila, philippines novartis investigative site, san juan, philippines novartis investigative site, bydgoszcz, poland novartis investigative site, elblag, poland novartis investigative site, gdansk, poland novartis investigative site, gdansk, poland novartis investigative site, gliwice, poland novartis investigative site, krakow, poland novartis investigative site, krakow, poland novartis investigative site, olsztyn, poland novartis investigative site, olsztyn, poland novartis investigative site, opole, poland novartis investigative site, rzeszow, poland novartis investigative site, szczecin, poland novartis investigative site, warszawa, poland novartis investigative site, wroclaw, poland novartis investigative site, bucharest, romania novartis investigative site, bucharest, romania novartis investigative site, bucuresti, romania novartis investigative site, cluj-napoca, romania novartis investigative site, iasi, romania novartis investigative site, arkhangelsk, russian federation novartis investigative site, chelyabinsk, russian federation novartis investigative site, irkutsk, russian federation novartis investigative site, kazan, russian federation novartis investigative site, kirov, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, novosibirsk, russian federation novartis investigative site, omsk, russian federation novartis investigative site, orenburg, russian federation novartis investigative site, ryazan, russian federation novartis investigative site, samara, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, voronezh, russian federation novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, bratislava, slovakia novartis investigative site, bratislava, slovakia novartis investigative site, kosice, slovakia novartis investigative site, poprad, slovakia novartis investigative site, rimavska sobota, slovakia novartis investigative site, zilina, slovakia novartis investigative site, ljubljana, slovenia novartis investigative site, capital park, south africa novartis investigative site, groenkloof, pretoria, 0001, south africa novartis investigative site, johannesburg, south africa novartis investigative site, observatory, south africa novartis investigative site, panorama, south africa novartis investigative site, parktown, south africa novartis investigative site, pretoria, south africa novartis investigative site, pretoria, south africa novartis investigative site, saxonwold, johannesburg, south africa novartis investigative site, alcoy/alicante, spain novartis investigative site, barakaldo (vizcaya), spain novartis investigative site, barcelona, spain novartis investigative site, burgos, spain novartis investigative site, cadiz, spain novartis investigative site, castellon, spain novartis investigative site, cordoba, spain novartis investigative site, coria, spain novartis investigative site, elda, spain novartis investigative site, granada, spain novartis investigative site, hospitalet de llobregat (barcelona), spain novartis investigative site, huesca, spain novartis investigative site, la laguna (santa cruz de tenerife), spain novartis investigative site, lerida, spain novartis investigative site, lugo, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, malaga, spain novartis investigative site, mataro, spain novartis investigative site, mostoles (madrid), spain novartis investigative site, murcia, spain novartis investigative site, murcia, spain novartis investigative site, palma de mallorca, spain novartis investigative site, palma de mallorca, spain novartis investigative site, pamplona, spain novartis investigative site, salamanca, spain novartis investigative site, san sebastian, spain novartis investigative site, santander, spain novartis investigative site, santiago, spain novartis investigative site, segovia, spain novartis investigative site, sevilla, spain novartis investigative site, sevilla, spain novartis investigative site, tarrasa, barcelona, spain novartis investigative site, toledo, spain novartis investigative site, valencia, spain novartis investigative site, valencia, spain novartis investigative site, zamora, spain novartis investigative site, zaragoza, spain novartis investigative site, aarau, switzerland novartis investigative site, basel, switzerland novartis investigative site, bellinzona, switzerland novartis investigative site, bern, switzerland novartis investigative site, chur, switzerland novartis investigative site, lausanne, switzerland novartis investigative site, locarno, switzerland novartis investigative site, st gallen, switzerland novartis investigative site, thun, switzerland novartis investigative site, zuerich, switzerland novartis investigative site, zurich, switzerland novartis investigative site, kaohsiung, taiwan novartis investigative site, taichung, taiwan novartis investigative site, tainan county, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, chiangmai, thailand novartis investigative site, hatyai, songkhla, thailand novartis investigative site, khon kaen, thailand novartis investigative site, phitsanulok, thailand novartis investigative site, chernivtsi, ukraine novartis investigative site, donetsk, ukraine novartis investigative site, ivano-frankivsk, ukraine novartis investigative site, kharkiv, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, lviv, ukraine novartis investigative site, simferopol, ukraine novartis investigative site, uzhgorod, ukraine novartis investigative site, uzhorod, ukraine novartis investigative site, chelmsford, essex, united kingdom novartis investigative site, epping, essex, united kingdom novartis investigative site, prittlewell chase, essex, united kingdom novartis investigative site, nottingham, gloucestershire, united kingdom novartis investigative site, canterbury, kent, united kingdom novartis investigative site, manchester, lancashire, united kingdom novartis investigative site, preston, lancashire, united kingdom novartis investigative site, northwood, middlesex, united kingdom novartis investigative site, edinburgh, midlothian, united kingdom novartis investigative site, headington, oxford, oxfordshire, united kingdom novartis investigative site, ashford, united kingdom novartis investigative site, blackpool, united kingdom novartis investigative site, bournemouth, united kingdom novartis investigative site, brighton, united kingdom novartis investigative site, cheltenham, united kingdom novartis investigative site, cottingham, united kingdom novartis investigative site, dorchester, united kingdom novartis investigative site, exeter, united kingdom novartis investigative site, grimsby, united kingdom novartis investigative site, guildford, united kingdom novartis investigative site, gwynedd, united kingdom novartis investigative site, ipswich, united kingdom novartis investigative site, lancaster, united kingdom novartis investigative site, leeds, united kingdom novartis investigative site, lindley, huddersfield, united kingdom novartis investigative site, liverpool, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, maidstone, united kingdom novartis investigative site, margate, united kingdom novartis investigative site, newcastle upon tyne, united kingdom novartis investigative site, nottingham, united kingdom novartis investigative site, plymouth, united kingdom novartis investigative site, poole, dorset, united kingdom novartis investigative site, portsmouth, united kingdom novartis investigative site, romford, united kingdom novartis investigative site, sheffield, united kingdom novartis investigative site, shrewsbury, united kingdom novartis investigative site, southport, united kingdom novartis investigative site, st helens, united kingdom novartis investigative site, stoke on trent, united kingdom novartis investigative site, sutton, united kingdom novartis investigative site, swansea, united kingdom novartis investigative site, whitchurch, cardiff, united kingdom novartis investigative site, worthing, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00490139,breast
418,419,NCT00676507,phase iii lucanix™ vaccine therapy in advanced non-small cell lung cancer (nsclc) following front-line chemotherapy,STOP,Completed,No Results Available,lung neoplasm|carcinoma non-small cell lung cancer stage iiia|carcinoma non-small cell lung cancer stage iiib|carcinoma non-small cell lung cancer stage iv,biological: lucanix™|other: placebo comparator,compare the overall survival of subjects with stage iii or iv non-small cell lung cancer treated with belagenpumatucel-l (lucanix™) vs placebo.|evaluate the progression free survival (pfs) of subjects treated with lucanix™ compared to treatment within the best support care control group.|evaluate the quality of life (qol) as determined by the lung cancer symptom scale (lcss) compared to treatment within the best supportive care control group.|evaluate the time-to-progression of subjects treated with lucanix™ compared to treatment within the best supportive care control group.|evaluate the best overall tumor response in subjects treated with lucanix™ compared to treatment in the best supportive care control group.|evaluate the response duration in subjects treated with lucanix™ compared to the best supportive care control group.|evaluate the rate of cns metastases development in subjects treated with lucanix™ as compared to the best supportive care control group.|adverse events of subjects treated with lucanix™ will be compared to subjects in the best supportive care control group.,novarx corporation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,532.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NR001-03|BB-IND 8868,July 2008,January 2013,January 2013,"May 13, 2008",,"May 8, 2015","[""southern cancer center, mobile, alabama, united states alaska regional hospital, anchorage, alaska, united states mayo clinic cancer center, scottsdale, arizona, united states clopton clinic hematology/oncology, jonesboro, arkansas, united states comprehensive blood and cancer center, bakersfield, california, united states university of california, san diego, la jolla, california, united states ucla pasadena oncology, pasadena, california, united states cancer care associates, redondo, california, united states innovative research center of california, san diego, california, united states sansum clinic, santa barbara, california, united states santa barbara hematology oncology medical group, inc., santa barbara, california, united states central coast medical oncology corporation, santa maria, california, united states ucla cancer center, santa monica, california, united states ucla cancer center-valencia, valencia, california, united states ucla cancer center, westlake village, california, united states university of colorado health science center, aurora, colorado, united states pasco hernando oncology associates, p.a., brooksville, florida, united states medical specialist of palm beaches, lake worth, florida, united states ocala oncology, ocala, florida, united states space coast medical center, titusville, florida, united states atlanta cancer care, roswell, georgia, united states kootenai cancer center, coeur d'alene, idaho, united states st. francis medical group oncology and hematology specialists, indianapolis, indiana, united states iowa blood and cancer center, cedar rapids, iowa, united states james graham brown cancer center, louisville, kentucky, united states hematology oncology life center, alexandria, louisiana, united states national cancer institute center for cancer research, medical oncology branch, bethesda, maryland, united states henry ford health system, detroit, michigan, united states university of minnesota medical center, minneapolis, minnesota, united states mayo clinic cancer center, rochester, minnesota, united states university of tennessee cancer institute, southaven, mississippi, united states comprehensive cancer centers of nevada, henderson, nevada, united states comprehensive cancer centers of nevada, henderson, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states cancer center at hackensack university medical center, hackensack, new jersey, united states eastchester center for cancer care, bronx, new york, united states richmond university medical center, staten island, new york, united states allergy partners of west north carolina, asheville, north carolina, united states cancer care of wnc, asheville, north carolina, united states gabrail cancer center research llc, canton, ohio, united states optim oncology, midwest city, oklahoma, united states cancer center of the carolinas, greenville, south carolina, united states university of tennessee cancer institute, bartlett, tennessee, united states university of tennessee cancer institute, germantown, tennessee, united states university of tennessee cancer institute, memphis, tennessee, united states texas cancer center abilene, texas oncology p.a., abilene, texas, united states mary crowley cancer research centers, dallas, texas, united states allison cancer center, texas oncology, p.a., midland, texas, united states tyler cancer center, texas oncology, tyler, texas, united states seattle cancer care alliance/fred hutchinson cancer res ctr/univ. of washington med ctr, seattle, washington, united states davis memorial cancer care center, elkins, west virginia, united states marshfield clinic weston center, weston, wisconsin, united states university of alberta cross cancer institute, edmonton, alberta, canada princess margaret hospital, toronto, ontario, canada orszagos koranyi tbc es pulmonologiai intezet, budapest, hungary semmelweis egyetem pulmonológiai klinika, budapest, hungary országos korányi tbc és pulmonológiai intézet, budapest, hungary csongrád megyei önkormányzat mellkasi betegségek szakkórháza, deszk, hungary szabolcs-szatmár-bereg megyei önkormányzat jósa andrás oktató kórháza, nyíregyháza, hungary fejér megyei szent györgy kórház, székesfehérvár, hungary pest megyei tüdőgyógyintézet, törökbálint, hungary gujarat cancer hospital and research institute, ahmedabad, india searoc cancer center, s.k., jaipur, india tata memorial hospital, mumbai, india noble hospital, pune, india ziekenhuis groep twente - locatie twenteborg ziekenhuis, almelo, netherlands academisch medisch centrum, amsterdam, netherlands antoni van leeuwenhoek ziekenhuis, amsterdam, netherlands universitair medisch centrum maastricht, maastricht, netherlands akademickie centrum kliniczne szpital akademii medycznej w gdansku, gdansk, poland samodzielny publiczny szpital kliniczny nr 4, lublin, poland wielkopolskie centrum pulmunologii i torakochirurgii, poznan, poland centrum onkologii - instytut im.marii sklodowskiej-curie, warsaw, poland dolnoslaskie centrum chorob pluc, wroclaw, poland klinicko-bolnicki centar bezanijska kosa, belgrade, serbia klinicki centar nis, nis, serbia institute for pulmonary disease sremska kamenica, sremska kamenica, serbia clatterbridge centre for oncology, bebington, wirral, united kingdom ninewells hospital and medical school, dundee, united kingdom the beatson west of scotland cancer centre, glasgow, united kingdom guy's hospital, london, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00676507,
419,420,NCT00353496,study of lanreotide autogel in non-functioning entero-pancreatic endocrine tumours,CLARINET,Completed,Has Results,endocrine tumors,drug: lanreotide (autogel formulation)|drug: placebo,progression-free survival (pfs)|percentage of patients alive & without disease progression|pharmacokinetic profile of lanreotide|change in the global health status quality of life assessment|percentage of patients with a greater than or equal to 50% decrease in plasma chromogranin a (cga) levels|percentage of patients still alive based on available overall survival data,ipsen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,264.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2-55-52030-726|2005-004904-35,June 2006,April 2013,April 2013,"July 18, 2006","February 18, 2015","March 6, 2015","[""cedars-sinai outpatient cancer center, los angeles, california, united states university of iowa, iowa city, iowa, united states the john hopkins hospital, baltimore, maryland, united states dana farber cancer institute, boston, massachusetts, united states memorial sloan-kettering cancer center, new york, new york, united states providence portland medical center, portland, oregon, united states md anderson cancer center, houston, texas, united states university of wisconsin school of medicine and public health, madison, wisconsin, united states university hospital, vienna, austria uz antwerpen, antwerpen, belgium ucl saint luc, bruxelles, belgium uz gent, gent, belgium fakultni nemocnice na, bulovce, prague, czech republic fekultni nemocnice olomouc, olomouc, czech republic general faculty, praha, czech republic sygehus hospital, aarhus, denmark rigshospitalet, copenhagen, denmark hôpital a. paré, boulogne billancourt, france hôpital beaujon, clichy, france cac oscar lambret, lille, france hôpital edouard herriot, lyon, france chu la timone, marseille, france hôpital r. debré, reims, france chi frejus st raphael, st raphael, france hôpital rangueil, toulouse, france unité de gastro enterologie igr, villejuif, france charite hospital, berlin, germany university hospital, erlangen, germany university hospital, lubeck, germany gutenberg university hospital, mainz, germany university hospital, munchen, germany lukas hospital, neuss, germany global hospital, hyderabad, india tata memorial hospital, mumbai, india centro di refierimiento oncologica, aviano, italy azienda malpighi, bologna, italy insct, milano, italy university of naples, naples, italy hospital s. chiara, pisa, italy azienda san giovanni battista, torino, italy umc gronigen, gronigen, netherlands erasmu mc, rotterdam, netherlands umc utrecht, utrecht, netherlands centrum onkologii-instytut im. marii sklodowskiej - curie, oddzial w gliwicach, zaklad medycyny nuklearnej i endokrynologii onkologicznej ul., gliwice, poland katedra i klinika endokrynologii przemiany materii i chorob wewnetrznych uniwersytetu medycznego w poznaniu, poznan, poland samodzielny publiczny centralny szpital kliniczny, katedra i klinika chorob wewnetrznych i endokrynologii ul. banacha 1 a, warszawa, poland szpital bielanski im. ks. jerzego popieluszki, samodzielny publiczny zaklad opieki zdrowotnej, klinika endokrynologii centrum medycznego ksztalcenia podyplomowego, warszawa, poland zaklad diagnosttyki radiologicznej, centralny szpital klincny, ministrerstwa spraw wewnetrznych i administratracji w warzawie, warszawa, poland silesian medical university, zabrze, poland narodny onkologicky ustav, bratislava, slovakia, slovakia vychodoslovensky onkologicky ustav, rastislavova, slovakia, slovakia hospital vall d'hebron, barcelona, spain institut catala oncologia, barcelona, spain hospital g. maranon, madrid, spain hospital la paz, madrid, spain hospital nuestra senora de la candelaria, tenerife, spain sahlgrenska hospital, goteborg, sweden karolinska university hospital, stockholm, sweden university hospital, uppsala, sweden basingstoke and north hampshire hospital, basingstoke, united kingdom royal victoria hospital, belfast, united kingdom university hospital wales, cardiff, united kingdom western general hospital, edinburgh, united kingdom beatson west of scotland cancer centre, glasgow, united kingdom st james hospital, leeds, united kingdom leicester royal infirmary, leicester, united kingdom royal free hospital, london, united kingdom st bartholomew's hospital, london, united kingdom qmc, nottingham, united kingdom churchill hospital, oxford, united kingdom royal hallamshire hospital, sheffield, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00353496,
420,421,NCT01345669,lux-head&neck 2: a phase iii trial of afatinib (bibw 2992) versus placebo for the treatment of head and neck squamous cell cancer after treatment with chemo-radiotherapy,,Terminated,Has Results,head and neck neoplasms,drug: placebo|drug: afatinib,disease free survival (dfs)|disease free survival (dfs) rate at 2 years|percentage of patient deaths (overall survival (os))|patients with improved health related quality of life (hrqol)|time to deterioration in health related quality of life (hrqol)|health related quality of life (hrqol) scores over time,boehringer ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,617.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1200.131|2011-000392-14,"October 17, 2011","September 12, 2016","September 12, 2016","May 2, 2011","October 23, 2017","December 7, 2017","['1200.131.00171 boehringer ingelheim investigational site, little rock, arkansas, united states 1200.131.00181 boehringer ingelheim investigational site, orange, california, united states 1200.131.00177 boehringer ingelheim investigational site, aurora, colorado, united states 1200.131.00185 boehringer ingelheim investigational site, new haven, connecticut, united states 1200.131.00173 boehringer ingelheim investigational site, baltimore, maryland, united states 1200.131.00176 boehringer ingelheim investigational site, boston, massachusetts, united states 1200.131.00182 boehringer ingelheim investigational site, omaha, nebraska, united states 1200.131.00175 boehringer ingelheim investigational site, lebanon, new hampshire, united states 1200.131.00179 boehringer ingelheim investigational site, stony brook, new york, united states 1200.131.00188 boehringer ingelheim investigational site, the bronx, new york, united states 1200.131.10200 boehringer ingelheim investigational site, winston-salem, north carolina, united states 1200.131.00172 boehringer ingelheim investigational site, philadelphia, pennsylvania, united states 1200.131.00184 boehringer ingelheim investigational site, san antonio, texas, united states 1200.131.00198 boehringer ingelheim investigational site, spokane valley, washington, united states 1200.131.00183 boehringer ingelheim investigational site, wenatchee, washington, united states 1200.131.05451 boehringer ingelheim investigational site, ciudad autonoma de bs as, argentina 1200.131.05457 boehringer ingelheim investigational site, cordoba, argentina 1200.131.05458 boehringer ingelheim investigational site, san miguel de tucuman, argentina 1200.131.05452 boehringer ingelheim investigational site, santa fe, argentina 1200.131.05453 boehringer ingelheim investigational site, villa dominico, argentina 1200.131.06151 boehringer ingelheim investigational site, wooloongabba, queensland, australia 1200.131.04353 boehringer ingelheim investigational site, leoben, austria 1200.131.04357 boehringer ingelheim investigational site, linz, austria 1200.131.04355 boehringer ingelheim investigational site, salzburg, austria 1200.131.04351 boehringer ingelheim investigational site, wien, austria 1200.131.04359 boehringer ingelheim investigational site, wien, austria 1200.131.03259 boehringer ingelheim investigational site, brussel, belgium 1200.131.03256 boehringer ingelheim investigational site, charleroi, belgium 1200.131.03255 boehringer ingelheim investigational site, hasselt, belgium 1200.131.03253 boehringer ingelheim investigational site, kortrijk, belgium 1200.131.03252 boehringer ingelheim investigational site, liège, belgium 1200.131.03254 boehringer ingelheim investigational site, liège, belgium 1200.131.03258 boehringer ingelheim investigational site, namur, belgium 1200.131.05554 boehringer ingelheim investigational site, barretos, brazil 1200.131.05555 boehringer ingelheim investigational site, jau, brazil 1200.131.05557 boehringer ingelheim investigational site, passo fundo, brazil 1200.131.05553 boehringer ingelheim investigational site, porto alegre, brazil 1200.131.05551 boehringer ingelheim investigational site, sao paulo, brazil 1200.131.05556 boehringer ingelheim investigational site, sao paulo, brazil 1200.131.00152 boehringer ingelheim investigational site, vancouver, british columbia, canada 1200.131.00157 boehringer ingelheim investigational site, toronto, ontario, canada 1200.131.00151 boehringer ingelheim investigational site, windsor, ontario, canada 1200.131.00153 boehringer ingelheim investigational site, montreal, quebec, canada 1200.131.00154 boehringer ingelheim investigational site, montreal, quebec, canada 1200.131.00155 boehringer ingelheim investigational site, montreal, quebec, canada 1200.131.05652 boehringer ingelheim investigational site, vina de mar, chile 1200.131.05651 boehringer ingelheim investigational site, vina del mar, chile 1200.131.04254 boehringer ingelheim investigational site, brno, czechia 1200.131.04253 boehringer ingelheim investigational site, praha 5, czechia 1200.131.04251 boehringer ingelheim investigational site, praha 8, czechia 1200.131.04551 boehringer ingelheim investigational site, københavn ø, denmark 1200.131.2052 boehringer ingelheim investigational site, alexandria, egypt 1200.131.35851 boehringer ingelheim investigational site, turku, finland 1200.131.03353 boehringer ingelheim investigational site, le havre, france 1200.131.03362 boehringer ingelheim investigational site, marseille cedex 5, france 1200.131.03359 boehringer ingelheim investigational site, nice cedex 2, france 1200.131.03365 boehringer ingelheim investigational site, orléans cedex 2, france 1200.131.03355 boehringer ingelheim investigational site, pierre-bénite, france 1200.131.03367 boehringer ingelheim investigational site, rouen, france 1200.131.03370 boehringer ingelheim investigational site, saint cloud, france 1200.131.03354 boehringer ingelheim investigational site, saint herblain cedex, france 1200.131.03369 boehringer ingelheim investigational site, saint priest en jarez, france 1200.131.03366 boehringer ingelheim investigational site, salouel, france 1200.131.03356 boehringer ingelheim investigational site, tours, france 1200.131.03357 boehringer ingelheim investigational site, villejuif cedex, france 1200.131.04954 boehringer ingelheim investigational site, essen, germany 1200.131.04961 boehringer ingelheim investigational site, freiburg, germany 1200.131.04953 boehringer ingelheim investigational site, hannover, germany 1200.131.04956 boehringer ingelheim investigational site, jena, germany 1200.131.04959 boehringer ingelheim investigational site, kaiserslautern, germany 1200.131.04951 boehringer ingelheim investigational site, leipzig, germany 1200.131.04957 boehringer ingelheim investigational site, rostock, germany 1200.131.04964 boehringer ingelheim investigational site, trier, germany 1200.131.04963 boehringer ingelheim investigational site, ulm, germany 1200.131.04962 boehringer ingelheim investigational site, villingen-schwenningen, germany 1200.131.03054 boehringer ingelheim investigational site, chaidari, greece 1200.131.03052 boehringer ingelheim investigational site, thessaloniki, greece 1200.131.03651 boehringer ingelheim investigational site, budapest, hungary 1200.131.03652 boehringer ingelheim investigational site, budapest, hungary 1200.131.03656 boehringer ingelheim investigational site, budpest, hungary 1200.131.03654 boehringer ingelheim investigational site, debrecen, hungary 1200.131.03655 boehringer ingelheim investigational site, kecskemet, hungary 1200.131.09178 boehringer ingelheim investigational site, ahmadabad, india 1200.131.09165 boehringer ingelheim investigational site, bangalore, india 1200.131.09152 boehringer ingelheim investigational site, bikaner, india 1200.131.09163 boehringer ingelheim investigational site, chennai, india 1200.131.09173 boehringer ingelheim investigational site, chennai, india 1200.131.09179 boehringer ingelheim investigational site, delhi, india 1200.131.09170 boehringer ingelheim investigational site, gurgaon, india 1200.131.09180 boehringer ingelheim investigational site, hyderabad, india 1200.131.09172 boehringer ingelheim investigational site, jaipur, india 1200.131.09176 boehringer ingelheim investigational site, karamsad,anand, gujarat, india 1200.131.09162 boehringer ingelheim investigational site, madurai, tamil nadu, india 1200.131.09175 boehringer ingelheim investigational site, mazagaon, mumbai, india 1200.131.09151 boehringer ingelheim investigational site, new delhi, india 1200.131.09164 boehringer ingelheim investigational site, pune, india 1200.131.09159 boehringer ingelheim investigational site, vishakapatnam, india 1200.131.97251 boehringer ingelheim investigational site, haifa, israel 1200.131.97253 boehringer ingelheim investigational site, petach tikva, israel 1200.131.03957 boehringer ingelheim investigational site, confreria (cn), italy 1200.131.03951 boehringer ingelheim investigational site, milano, italy 1200.131.03955 boehringer ingelheim investigational site, milano, italy 1200.131.03960 boehringer ingelheim investigational site, milano, italy 1200.131.08156 boehringer ingelheim investigational site, aichi, nagoya, japan 1200.131.08153 boehringer ingelheim investigational site, chiba, kashiwa, japan 1200.131.08151 boehringer ingelheim investigational site, hokkaido, sapporo, japan 1200.131.08161 boehringer ingelheim investigational site, hyogo, akashi, japan 1200.131.08157 boehringer ingelheim investigational site, hyogo, kobe, japan 1200.131.08159 boehringer ingelheim investigational site, kanagawa, isehara, japan 1200.131.08164 boehringer ingelheim investigational site, miyagi, natori, japan 1200.131.08160 boehringer ingelheim investigational site, osaka, osaka, japan 1200.131.08155 boehringer ingelheim investigational site, shizuoka, sunto-gun, japan 1200.131.08152 boehringer ingelheim investigational site, tochigi, shimotsuke, japan 1200.131.08163 boehringer ingelheim investigational site, tokyo, koto-ku, japan 1200.131.08154 boehringer ingelheim investigational site, tokyo, meguro-ku, japan 1200.131.05252 boehringer ingelheim investigational site, mexico, mexico 1200.131.03152 boehringer ingelheim investigational site, amsterdam, netherlands 1200.131.03153 boehringer ingelheim investigational site, leiden, netherlands 1200.131.03151 boehringer ingelheim investigational site, rotterdam, netherlands 1200.131.35155 boehringer ingelheim investigational site, almada, portugal 1200.131.35154 boehringer ingelheim investigational site, coimbra, portugal 1200.131.35153 boehringer ingelheim investigational site, lisboa, portugal 1200.131.35151 boehringer ingelheim investigational site, porto, portugal 1200.131.35152 boehringer ingelheim investigational site, évora, portugal 1200.131.00759 boehringer ingelheim investigational site, moscow, russian federation 1200.131.00753 boehringer ingelheim investigational site, omsk, russian federation 1200.131.00760 boehringer ingelheim investigational site, pyatigorsk, russian federation 1200.131.00761 boehringer ingelheim investigational site, pyatigorsk, russian federation 1200.131.00763 boehringer ingelheim investigational site, st. petersburg, russian federation 1200.131.00755 boehringer ingelheim investigational site, ufa, russian federation 1200.131.00762 boehringer ingelheim investigational site, ufa, russian federation 1200.131.03451 boehringer ingelheim investigational site, barcelona, spain 1200.131.03454 boehringer ingelheim investigational site, barcelona, spain 1200.131.03463 boehringer ingelheim investigational site, girona, spain 1200.131.03452 boehringer ingelheim investigational site, hospitalet de llobregat, spain 1200.131.03459 boehringer ingelheim investigational site, lugo, spain 1200.131.03457 boehringer ingelheim investigational site, madrid, spain 1200.131.03464 boehringer ingelheim investigational site, madrid, spain 1200.131.03465 boehringer ingelheim investigational site, madrid, spain 1200.131.03456 boehringer ingelheim investigational site, málaga, spain 1200.131.03462 boehringer ingelheim investigational site, málaga, spain 1200.131.03455 boehringer ingelheim investigational site, pamplona, spain 1200.131.03460 boehringer ingelheim investigational site, pozuelo de alarcón, madrid, spain 1200.131.03466 boehringer ingelheim investigational site, sevilla, spain 1200.131.03458 boehringer ingelheim investigational site, zaragoza, spain 1200.131.03461 boehringer ingelheim investigational site, ávila, spain 1200.131.04652 boehringer ingelheim investigational site, göteborg, sweden 1200.131.04651 boehringer ingelheim investigational site, stockholm, sweden 1200.131.04151 boehringer ingelheim investigational site, basel, switzerland 1200.131.04152 boehringer ingelheim investigational site, bern, switzerland 1200.131.03854 boehringer ingelheim investigational site, kharkiv, ukraine 1200.131.03851 boehringer ingelheim investigational site, kiev, ukraine 1200.131.04456 boehringer ingelheim investigational site, denbighshire, united kingdom 1200.131.04455 boehringer ingelheim investigational site, edinburgh, united kingdom 1200.131.04459 boehringer ingelheim investigational site, exeter, united kingdom 1200.131.04460 boehringer ingelheim investigational site, glasgow, united kingdom 1200.131.04453 boehringer ingelheim investigational site, leicester, united kingdom 1200.131.04451 boehringer ingelheim investigational site, london, united kingdom 1200.131.04452 boehringer ingelheim investigational site, manchester, united kingdom 1200.131.04454 boehringer ingelheim investigational site, sheffield, united kingdom 1200.131.04458 boehringer ingelheim investigational site, sutton, united kingdom 1200.131.04457 boehringer ingelheim investigational site, whitchurch, cardiff, united kingdom']",,https://ClinicalTrials.gov/show/NCT01345669,
421,422,NCT00465491,study of picoplatin efficacy after relapse,SPEAR,Unknown status,No Results Available,small cell lung cancer,drug: picoplatin|other: best supportive care,overall survival|objective response rate|disease control rate|duration of response|progression-free survival,poniard pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,399.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0601,April 2007,May 2009,,"April 25, 2007",,"April 14, 2009","['consultorios privados, buenos aires, argentina clinica constituyentes, buenos aires, argentina ceten centro de estudio y tratamiento de enfermedades neoplasicas, buenos aires, argentina iadt (insttituto argentino de diagnostico y tratamiento s.a.), buenos aires, argentina centro oncologico, buenos aires, argentina instituto alexander fleming, buenos aires, argentina paliar, buenos aires, argentina ionc, cordoba, argentina centro oncologico de rosario, santa fe, argentina isis clinica especializada, santa fe, argentina centro medico san roque, tucuman, argentina gomel regional oncological dispensary, gomel, belarus institution of healthcare ""grodno regional clinical hospital, grodno, belarus minsk city clinical oncology dispensary, minsk, belarus research institute of oncology and medical radiology named by n.n. aleksandrov, minsk, belarus vitebsk regional oncology dispensary, vitebsk, belarus clinic for lung diseases, clinical center, banja luka, banja luka, bosnia and herzegovina clinic of pulmonary diseases podhrastovi, sarajevo, bosnia and herzegovina multiprofile hospital for active treatment, dr. tota venkova, gabrovo, bulgaria university multifunctional hospital for active treatment ""dr. georgi stranski"", pleven, bulgaria district dispensary for cancer diseases with inpatient hospital plovdiv, plovdiv, bulgaria regional oncodispensary with inpatient sector, rousse, bulgaria inter-district dispensary for cancer diseases w/inpatient hospital, shumen, bulgaria regional oncodispensary with inpatient sector-sofia district, sofia, bulgaria inter-district dispensary for cancer disease w/inpatient hospital ""dr. marko markov"", varna, varna, bulgaria multiprofile hospital for active treatment ""st. marina"", varna, bulgaria instituto nacional de cancer, santiago, chile clinical hospital, dubrovnik, croatia clinical hospital, osijek, croatia clinical hospital split, split, croatia clinic for pulmonary diseses ""jordanovac"", zagreb, croatia st. george county hospital, fejer county, hungary university of szeged, szeged, hungary general rehablitation and medicinal bath hospital, szombathely, hungary gujrat cancer research institute, asarwa, ahmadabad, india kidwai memorial institute of oncology, bangalore, karnataka, india lakeshore hospital and research center, kochin, kerala, india shatabdi superspeciality hospital, nasik, maharashtra, india curie centre of oncology, bangalore, india jawaharlal nehru cancer hospital and research centre, bhopal, india apollo speciality hospital, chennai, india mnj institute of oncology, hyderabaad, india indo american institute of oncology, hyderabaad, india yashoda group of hospitals, hyderabad, india searoc cancer center, jaipur, india institute of post graduate medical education and research, kolkata, india orchid nursing home, kolkata, india king george medical university, lucknow, india kmc (karturba medical college) hospital, manipal, india jaslok hospital and research centre, mumbai, india tata memorial centre, mumbai, india sir ganga ram hospital, new delhi, india rajiv gandhi cancer institute, delhi, new delhi, india mahaveer cancer sansthan, patna, india jahangir hospital and research centre, pune, india smt. vasantben r. desai cancer research center, rajkot, india regional cancer centre, trivandrum, india king george hospital, vishakhapatnam, india daugavas hospital, daugavpils, latvia paul stradins clincial university hospital, riga, latvia special hospital for pulmonary diseases, niksic, montenegro dolnoslaskie centre of lung diseases, wroclaw, dolnoslaskie, poland silesian medical university in katowice, zabrze, dolny slask, poland kujawsko-pomorski centre of pulmonology, bydgoszcz, poland nmp, memorial voyvodship hospital, czestochowa, poland dr. bieganski memorial regional specialsitic hospital, grudziadz, poland regional hospital, department of pulmonary diseases and chemotherapy, krakow, poland independent public group for tuberculosis and lung disease in olsztyn, olsztyn, poland conservative outpatient oncology department, voyevodship hospital in plock, plock, poland department of clinical oncology, wielkopolskie centre of lung diseases and tuberculosis, poznan, poland department of pulmonology, voyvodship specialsitic hospital in radom, radom, poland sp zoz voyevodship specialistic hospital #3, rybnik, poland department of chemotherapy, prof. a. sokolowski memorial specialistic hospital in szczecin, szczecin, poland department of clinical oncology, sp zoz, yoyvodship specialistic hospital, torun, poland prof. dr. ion chiricuta, institute of oncology cluj-napoca, cluj-napoca, cluj, romania baia mare ""constantin opris"" county emergency hospital, baia mare, maramures county, romania ianuli medconsult srl, bucharest, romania bucharest institute of oncology, bucharest, romania prof. dr. ion chircuta, oncology institute, cluj-napoca, romania clinical emergency county hospital constanta, constanta, romania medical oncology center iasi, iasi, romania schuller municipal hospital ploiesti-medical oncology department, ploiesti, romania clinical county hospital, sibiu, romania sf. loan cel nou, emergency county hospital, suceava, romania oncomed, timisoara, romania buryatia republican oncology center, ulan-ude, buryatia, russian federation regional oncology center, birobidzhan, jewish republic, russian federation republican oncology center of the ministry of healthcare of karelia republic, petrozavodsk, karelia republic, russian federation komi republican oncology center, syktyvkar, komi republic, russian federation clinical oncology center, kazan, tatarstan republic, russian federation kazan oncology center, kazan, tatarstan republic, russian federation arkhangelsk regional clinical oncology center, arkhangelsk, russian federation altai regional oncology center, barnaul, russian federation chelyabinsk regional oncology center, chelyabinsk, russian federation city hospital #1, cherepovets, russian federation chita regional oncology center, chita, russian federation sverdlovsk regional oncology center, ekaterinburg, russian federation regional oncology center, engels, russian federation regional oncology center, irkutsk, russian federation ivanovo regional oncology center, ivanovo, russian federation republican clinical oncology center of the republic of udmurtia, izhevsk, russian federation kaluga regional oncology center, kaluga, russian federation regional clinical oncology center, khabarovsk, russian federation regional clinical oncology center, kirov, russian federation city oncology center, komsomolsk-na-amure, russian federation krasnodar clinical oncology, krasnodar, russian federation regional clinical hospital #1, krasnodar, russian federation kurst regional oncology center, kurst, russian federation lipetsk regional oncology center, lipetsk, russian federation magnitogorsk clinical oncology hospital, magnitogorsk, russian federation blokhin russian oncology research center, moscow, russian federation central clinical hospital and outpatient unit of the medical center under the russian presidential administration, moscow, russian federation semashko central clinical hospital #2 under russian railways, moscow, russian federation novorossiysk oncology center, novorossiysk, russian federation city clinical hospital #1, novosibirsk, russian federation medical radiology research center under rams, obnninsk, russian federation orel oncology center, orel, russian federation orenburg regional clinical oncology center, orenburg, russian federation regional oncology center, penza, russian federation pyatigorsk affiliate of stavropol regional clinical oncology center, pyatigorsk, russian federation ogarev mordovian state university, saransk, russian federation state higher education institution saratov state medical university under the federal agency for healthcare and social development, saratov, russian federation oncology center, sochi, russian federation st. petersburg city multifield hospital #2, st. petersburg, russian federation st. petersburg pavlov state medical university, st. petersburg, russian federation pavlov st. petersburg state medical university, pulmonology research institute, st. petersburg, russian federation city clinical oncology center, thoracic oncology department #6, st. petersburg, russian federation tambov regional oncology center, tambov, russian federation tomsk regional oncology center, tomsk, russian federation tula regional oncology center, tula, russian federation ufa, republican oncology center, ufa, russian federation primorsky regional oncology center, vladivostok, russian federation volgograd regional clinical oncology center#1, volograd, russian federation voronezh regional clinical oncology center, voronezh, russian federation regional clinical oncology hospital, yaroslavl, russian federation republican of clinical hospital, mariy-el republican, yoshkar-ola, russian federation clinic for pulmonary diseases and tbc, knez selo, serbia institute for pulmonary diseases of vijvodina, vijvodina, serbia volyn regional oncology center, lutsk, ukraine public treatment and prevention institution mariupol city interdistrict oncology center, mariupol, ukraine sumy regional oncology center, sumy, ukraine ternopol regional clinical oncology center, ternopol, ukraine zaporozhye regional clinical oncology center, zaporozhye, ukraine']",,https://ClinicalTrials.gov/show/NCT00465491,
422,423,NCT00263588,lapatinib for brain metastases in erbb2-positive breast cancer,,Completed,Has Results,"neoplasms, breast",drug: lapatinib,"the number of participants with central nervous system (cns) best overall response|the percentage of participants with central nervous system (cns) objective response rate - response rate (cr + pr)|percentage of participants with improvement in neurological signs and symptoms (nss) measured using the neurological examination worksheet|percentage of subjects with a cns objective response or improvement in baseline neurological signs and symptoms (nss)|duration of central nervous system (cns) objective response|percentage of patients with cns disease control (complete response, partial response or stable disease) at 6 months of lapatinib therapy|time to progression (ttp) at any site|overall survival (os)|summary of site of first progression|primary cause of death",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,242.0,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF105084|CLAP016A2202|2005-003944-68,"December 2, 2005","September 25, 2007","March 15, 2018","December 9, 2005","December 12, 2019","December 12, 2019","['novartis investigative site, san francisco, california, united states novartis investigative site, vallejo, california, united states novartis investigative site, denver, colorado, united states novartis investigative site, washington, district of columbia, united states novartis investigative site, boca raton, florida, united states novartis investigative site, jacksonville, florida, united states novartis investigative site, indianapolis, indiana, united states novartis investigative site, indianapolis, indiana, united states novartis investigative site, sioux city, iowa, united states novartis investigative site, kansas city, kansas, united states novartis investigative site, boston, massachusetts, united states novartis investigative site, ann arbor, michigan, united states novartis investigative site, minneapolis, minnesota, united states novartis investigative site, saint louis, missouri, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, santa fe, new mexico, united states novartis investigative site, new york, new york, united states novartis investigative site, chapel hill, north carolina, united states novartis investigative site, philadelphia, pennsylvania, united states novartis investigative site, pittsburgh, pennsylvania, united states novartis investigative site, nashville, tennessee, united states novartis investigative site, dallas, texas, united states novartis investigative site, houston, texas, united states novartis investigative site, tyler, texas, united states novartis investigative site, seattle, washington, united states novartis investigative site, yakima, washington, united states novartis investigative site, north sydney, new south wales, australia novartis investigative site, herston, queensland, australia novartis investigative site, south brisbane, queensland, australia novartis investigative site, box hill, victoria, australia novartis investigative site, ringwood east, victoria, australia novartis investigative site, perth, western australia, australia novartis investigative site, adelaide, australia novartis investigative site, salzburg, austria novartis investigative site, vienna, austria novartis investigative site, bruxelles, belgium novartis investigative site, vancouver, british columbia, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, weston, ontario, canada novartis investigative site, dijon cedex, france novartis investigative site, paris cedex 05, france novartis investigative site, paris, france novartis investigative site, toulouse cedex, france novartis investigative site, muenchen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, frankfurt am main, hessen, germany novartis investigative site, neo faliro, greece novartis investigative site, bangalore, india novartis investigative site, mumbai, india novartis investigative site, reggio emilia, emilia-romagna, italy novartis investigative site, milano, lombardia, italy novartis investigative site, perugia, umbria, italy novartis investigative site, aichi, japan novartis investigative site, saitama, japan novartis investigative site, saitama, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, tokyo, japan novartis investigative site, olsztyn, poland novartis investigative site, warszawa, poland novartis investigative site, barcelona, spain novartis investigative site, madrid, spain novartis investigative site, uppsala, sweden novartis investigative site, geneve, switzerland novartis investigative site, locarno, switzerland novartis investigative site, tainan county, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, manchester, lancashire, united kingdom novartis investigative site, brighton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00263588,breast
423,424,NCT00680901,"logic - lapatinib optimization study in erbb2 (her2) positive gastric cancer: a phase iii global, blinded study designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib",,"Active, not recruiting",Has Results,"neoplasms, gastrointestinal tract",drug: lapatinib|drug: placebo|drug: capecitabine|drug: oxaliplatin,"overall survival|overall survival in all randomized participants|progression free survival (pfs)|number of participants with a response of confirmed complete response (cr) or confirmed partial response (pr)|number of participants with clinical benefit (cb)|time to response (ttr)|duration of response (dor)|number of participants with any non-serious adverse event (ae: occurring in >=5% participants in any treatment arm) or any serious adverse event (sae)|number of participants with adverse events of the indicated severity, per the national cancer institute (nci) common terminology criteria in adverse events (ctcae)|mean change in scores on the european organization for research and treatment of cancer (eortc) quality of life (qol) questionnaire core 30 (qlq-c30) from baseline to week 36|mean change in scores on the eortc quality of life (qol) questionnaire of stomach 22 (qlq-sto22) from baseline to week 36|mean change in scores on the questionnaire euroqol-5 dimensions (eq-5d) from baseline to week 36|number of participants with a worst-case on therapy grade 3 or grade 4 for the indicated clinical chemistry parameters|number of participants with a worst-case on therapy grade 3 or grade 4 for the indicated hematology parameters",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,545.0,Industry,Interventional,"Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EGF110656|2007-005725-29|CLAP016C2301,"June 4, 2008","September 24, 2012","December 31, 2022","May 20, 2008","October 29, 2013","March 10, 2022","[""novartis investigative site, alhambra, california, united states novartis investigative site, fullerton, california, united states novartis investigative site, la verne, california, united states novartis investigative site, northridge, california, united states novartis investigative site, oxnard, california, united states novartis investigative site, redondo beach, california, united states novartis investigative site, santa maria, california, united states novartis investigative site, santa monica, california, united states novartis investigative site, terre haute, indiana, united states novartis investigative site, henderson, nevada, united states novartis investigative site, ciudad aut6noma de buenos aires, buenos aires, argentina novartis investigative site, quilmes, buenos aires, argentina novartis investigative site, neuquen, neuquén, argentina novartis investigative site, cipolletti, río negro, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, ciudad autonoma de buenos aires, argentina novartis investigative site, la rioja, argentina novartis investigative site, santa fe, argentina novartis investigative site, tucuman, argentina novartis investigative site, belo horizonte, minas gerais, brazil novartis investigative site, belo horizonte, minas gerais, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, florianopolis, santa catarina, brazil novartis investigative site, barretos, são paulo, brazil novartis investigative site, jau, são paulo, brazil novartis investigative site, santo andre, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, rio de janeiro, brazil novartis investigative site, edmonton, alberta, canada novartis investigative site, vancouver, british columbia, canada novartis investigative site, saint john, new brunswick, canada novartis investigative site, london, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, montreal, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, temuco, región de la araucania, chile novartis investigative site, santiago, región metro de santiago, chile novartis investigative site, vina del mar, valparaíso, chile novartis investigative site, santiago, chile novartis investigative site, hefei, anhui, china novartis investigative site, guangzhou, guangdong, china novartis investigative site, ha er bin, heilongjiang, china novartis investigative site, nanjing, jiangsu, china novartis investigative site, changchun, jilin, china novartis investigative site, chengdu, sichuan, china novartis investigative site, beijing, china novartis investigative site, beijing, china novartis investigative site, beijing, china novartis investigative site, fuzhou, china novartis investigative site, hangzhou, china novartis investigative site, qingdao, china novartis investigative site, shanghai, china novartis investigative site, shanghai, china novartis investigative site, tianjin, china novartis investigative site, tallinn, estonia novartis investigative site, tartu, estonia novartis investigative site, pokfulam, hong kong novartis investigative site, tuen mun, hong kong novartis investigative site, gyor, hungary novartis investigative site, kaposvar, hungary novartis investigative site, kecskemet, hungary novartis investigative site, miskolc, hungary novartis investigative site, pecs, hungary novartis investigative site, szeged, hungary novartis investigative site, szolnok, hungary novartis investigative site, calcutta, india novartis investigative site, coimbatore, india novartis investigative site, kochi, india novartis investigative site, kochi, india novartis investigative site, kolkata, india novartis investigative site, nagpur, india novartis investigative site, new delhi, india novartis investigative site, parel, india novartis investigative site, pune, india novartis investigative site, trivandrum, india novartis investigative site, beer-sheva, israel novartis investigative site, haifa, israel novartis investigative site, jerusalem, israel novartis investigative site, petah-tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, rehovot, israel novartis investigative site, tel aviv, israel novartis investigative site, zrifin, israel novartis investigative site, l'aquila, abruzzo, italy novartis investigative site, rionero in vulture (pz), basilicata, italy novartis investigative site, cesena, emilia-romagna, italy novartis investigative site, meldola (fc), emilia-romagna, italy novartis investigative site, modena, emilia-romagna, italy novartis investigative site, parma, emilia-romagna, italy novartis investigative site, piacenza, emilia-romagna, italy novartis investigative site, rimini, emilia-romagna, italy novartis investigative site, udine, friuli-venezia-giulia, italy novartis investigative site, roma, lazio, italy novartis investigative site, roma, lazio, italy novartis investigative site, roma, lazio, italy novartis investigative site, genova, liguria, italy novartis investigative site, bergamo, lombardia, italy novartis investigative site, treviglio (bg), lombardia, italy novartis investigative site, pesasro, marche, italy novartis investigative site, bari, puglia, italy novartis investigative site, firenze, toscana, italy novartis investigative site, macerata, italy novartis investigative site, busan, korea, republic of novartis investigative site, daegu, korea, republic of novartis investigative site, hwasun, korea, republic of novartis investigative site, seodaemun-gu, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, suwon, kyonggi-do, korea, republic of novartis investigative site, suwon, korea, republic of novartis investigative site, acapulco, guerrero, mexico novartis investigative site, mexico city, mexico novartis investigative site, oaxaca, mexico novartis investigative site, amsterdam, netherlands novartis investigative site, leeuwarden, netherlands novartis investigative site, nijmegen, netherlands novartis investigative site, callao, peru novartis investigative site, lima, peru novartis investigative site, lima, peru novartis investigative site, gdansk, poland novartis investigative site, krakow, poland novartis investigative site, olsztyn, poland novartis investigative site, olsztyn, poland novartis investigative site, plock, poland novartis investigative site, poznan, poland novartis investigative site, rybnik, poland novartis investigative site, slupsk, poland novartis investigative site, szczecin, poland novartis investigative site, torun, poland novartis investigative site, warszawa, poland novartis investigative site, warszawa, poland novartis investigative site, san juan, puerto rico novartis investigative site, chelyabinsk, russian federation novartis investigative site, kirov, russian federation novartis investigative site, kursk, russian federation novartis investigative site, moscow, russian federation novartis investigative site, omsk, russian federation novartis investigative site, ryazan, russian federation novartis investigative site, saratov, russian federation novartis investigative site, sochi, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, stavropol, russian federation novartis investigative site, ufa,, russian federation novartis investigative site, tainan, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan county, taiwan novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, hatyai, songkhla, thailand novartis investigative site, ankara, turkey novartis investigative site, gaziantep, turkey novartis investigative site, trabzon, turkey novartis investigative site, cherkasy, ukraine novartis investigative site, chernivtsi, ukraine novartis investigative site, dnepropetrovsk, ukraine novartis investigative site, dnipropetrovsk, ukraine novartis investigative site, donetsk, ukraine novartis investigative site, ivano-frankivsk, ukraine novartis investigative site, kharkiv, ukraine novartis investigative site, kryvyi rih, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, lutsk,, ukraine novartis investigative site, lviv, ukraine novartis investigative site, odessa, ukraine novartis investigative site, plyuty, ukraine novartis investigative site, simferopil, ukraine novartis investigative site, simferopol, ukraine novartis investigative site, sumy, ukraine novartis investigative site, ternopil, ukraine novartis investigative site, uzhgorod, ukraine novartis investigative site, vinnitsia, ukraine novartis investigative site, zaporizhzhia, ukraine""]",,https://ClinicalTrials.gov/show/NCT00680901,gastric
424,425,NCT04919226,lutetium 177lu-edotreotide versus best standard of care in well-differentiated aggressive grade-2 and grade-3 gastroenteropancreatic neuroendocrine tumors (gep-nets) - compose,COMPOSE,Recruiting,No Results Available,neuroendocrine tumors,drug: 177lu-edotreotide (peptide receptor radionuclide therapy) prrt|drug: captem (capecitabine and temozolomide)|other: amino-acid solution|drug: everolimus|drug: folfox (folinic acid + fluorouracil + oxaliplatin),progression-free survival|overall survival,itm solucin gmbh,All,"18 Years and older   (Adult, Older Adult)",Phase 3,202.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DP-1111-02CT,"December 21, 2021",September 2024,September 2026,"June 9, 2021",,"April 28, 2022","[""washington university alvin j. siteman cancer center, saint louis, missouri, united states memorial sloan-kettering cancer center, new york, new york, united states university of texas md anderson cancer center, houston, texas, united states peter maccallum cancer centre, melbourne, victoria, australia haut-leveque hospital, department of hepatogastroenterology and digestive tract oncology, pessac, bordeaux, france nantes university hospital center - hotel dieu hospital, nantes, cedex, france edouard herriot hospital, medical oncology unit, lyon, france iuct oncopole - institut universitaire du cancer de toulouse, toulouse, france all india institute of medical sciences, nuclear medicine, new delhi, delhi, india hcg cancer centre, medical oncology, bangalore, karnataka, india vu medical center (vumc), department of medical oncology, amsterdam, netherlands university hospital vall d'hebron, department of medical oncology, barcelona, spain ico hospitalet, catalan institute of oncology, barcelona, spain university hospital 12 de octubre, department of gastroenterology, madrid, spain central university hospital de asturias (huca), iuopa - universitary institute of oncology, oviedo, spain university hospital complex of santiago (chus), santiago de compostela, spain university and polytechnic hospital la fe, endocrinology, valencia, spain uppsala university hospital, department of oncology, uppsala, sweden""]",,https://ClinicalTrials.gov/show/NCT04919226,
425,426,NCT00694382,evaluation of ave5026 in the prevention of venous thromboembolism in cancer patients undergoing chemotherapy,SAVE-ONCO,Completed,No Results Available,venous thromboembolism|cancer,drug: semuloparin sodium|drug: placebo (for semuloparin),percentage of participants who experienced venous thromboembolism event [vte] or vte-related death|time-to-first occurrence of vte or vte-related death (cumulative incidence function)|percentage of participants who required the initiation of curative anticoagulant or thrombolytic treatment after vte assessment|percentage of participants who experienced clinically relevant bleedings|overall survival [os],sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3212.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",EFC6521|2007-007943-29,June 2008,November 2010,November 2010,"June 10, 2008",,"January 23, 2013","[""investigational site number 840006, birmingham, alabama, united states investigational site number 840007, casa grande, arizona, united states investigational site number 840060, tucson, arizona, united states investigational site number 840050, fountain valley, california, united states investigational site number 840072, fullerton, california, united states investigational site number 840037, indian wells, california, united states investigational site number 840069, la verne, california, united states investigational site number 840009, long beach, california, united states investigational site number 840001, oceanside, california, united states investigational site number 840011, rancho mirage, california, united states investigational site number 840029, west covina, california, united states investigational site number 840005, norwich, connecticut, united states investigational site number 840064, torrington, connecticut, united states investigational site number 840038, woodbridge, connecticut, united states investigational site number 840052, washington, district of columbia, united states investigational site number 840025, washington, district of columbia, united states investigational site number 840074, clearwater, florida, united states investigational site number 840019, jacksonville, florida, united states investigational site number 840051, rockledge, florida, united states investigational site number 840073, sarasota, florida, united states investigational site number 840070, roswell, georgia, united states investigational site number 840016, park ridge, illinois, united states investigational site number 840028, quincy, illinois, united states investigational site number 840008, skokie, illinois, united states investigational site number 840033, goshen, indiana, united states investigational site number 840010, indianapolis, indiana, united states investigational site number 840014, louisville, kentucky, united states investigational site number 840048, mount sterling, kentucky, united states investigational site number 840047, metairie, louisiana, united states investigational site number 840032, ruston, louisiana, united states investigational site number 840042, bethesda, maryland, united states investigational site number 840066, easton, maryland, united states investigational site number 840059, tupelo, mississippi, united states investigational site number 840024, rochester, new york, united states investigational site number 840031, syracuse, new york, united states investigational site number 840020, durham, north carolina, united states investigational site number 840021, durham, north carolina, united states investigational site number 840026, high point, north carolina, united states investigational site number 840046, bismarck, north dakota, united states investigational site number 840003, middletown, ohio, united states investigational site number 840022, sylvania, ohio, united states investigational site number 840075, east providence, rhode island, united states investigational site number 840067, beaumont, texas, united states investigational site number 840004, el paso, texas, united states investigational site number 840034, houston, texas, united states investigational site number 840035, sugar land, texas, united states investigational site number 840063, kennewick, washington, united states investigational site number 840018, tacoma, washington, united states investigational site number 032006, buenos aires, argentina investigational site number 032003, capital federal, argentina investigational site number 032004, rosario, argentina investigational site number 032005, san miguel de tucuman, argentina investigational site number 032007, tucuman, argentina investigational site number 036004, adelaide, australia investigational site number 036002, bedford park, australia investigational site number 036001, box hill, australia investigational site number 036009, lismore, australia investigational site number 036007, perth, australia investigational site number 036006, ringwood east, australia investigational site number 036008, westmead, australia investigational site number 036003, woodville, australia investigational site number 036005, woolloongabba, australia investigational site number 040002, graz, austria investigational site number 040003, wien, austria investigational site number 040004, wien, austria investigational site number 112002, gomel, belarus investigational site number 112003, minsk, belarus investigational site number 112001, minsk, belarus investigational site number 112004, vitebsk, belarus investigational site number 056008, bonheiden, belgium investigational site number 056011, brussels, belgium investigational site number 056005, gent, belgium investigational site number 056010, haine-saint-paul, belgium investigational site number 056006, kortrijk, belgium investigational site number 056009, liège, belgium investigational site number 056004, merksem, belgium investigational site number 056003, oostende, belgium investigational site number 056012, ottignies, belgium investigational site number 056002, sint niklaas, belgium investigational site number 076002, belo horizonte, brazil investigational site number 076022, curitiba, brazil investigational site number 076015, curitiba, brazil investigational site number 076012, florianopolis, brazil investigational site number 076001, fortaleza, brazil investigational site number 076009, goiania, brazil investigational site number 076007, goiania, brazil investigational site number 076016, goiania, brazil investigational site number 076024, ijui, brazil investigational site number 076003, joinville, brazil investigational site number 076010, londrina, brazil investigational site number 076026, passo fundo, brazil investigational site number 076027, passo fundo, brazil investigational site number 076023, porto alegre, brazil investigational site number 076020, porto alegre, brazil investigational site number 076014, salvador, brazil investigational site number 076018, salvador, brazil investigational site number 076011, santo andre, brazil investigational site number 076006, sao jose dos campos, brazil investigational site number 076008, sao paulo, brazil investigational site number 076017, sao paulo, brazil investigational site number 076004, taguatinga, brazil investigational site number 100001, rousse, bulgaria investigational site number 100003, varna, bulgaria investigational site number 124008, greenfield park, canada investigational site number 124007, kelowna, canada investigational site number 124010, moncton, canada investigational site number 124003, montreal, canada investigational site number 124002, ottawa, canada investigational site number 124009, owen sound, canada investigational site number 124006, rimouski, canada investigational site number 124013, saint john, canada investigational site number 124001, sherbrooke, canada investigational site number 124012, victoria, canada investigational site number 124011, weston, canada investigational site number 152002, temuco, chile investigational site number 156014, beijing, china investigational site number 156008, beijing, china investigational site number 156022, beijing, china investigational site number 156031, changchun, china investigational site number 156021, chengdu, china investigational site number 156019, chongqing, china investigational site number 156003, dalian, china investigational site number 156025, guangzhou, china investigational site number 156026, hangzhou, china investigational site number 156030, nanning, china investigational site number 156029, qingdao, china investigational site number 156024, shanghai, china investigational site number 156028, shanghai, china investigational site number 156020, shanghai, china investigational site number 156011, shanghai, china investigational site number 156013, shantou, china investigational site number 156012, suzhou, china investigational site number 156004, xi'an, china investigational site number 156009, xi'an, china investigational site number 156027, yinchuan, china investigational site number 170010, bogota, colombia investigational site number 170005, manizales, colombia investigational site number 170002, medellin, colombia investigational site number 170006, medellin, colombia investigational site number 170007, medellín, colombia investigational site number 170008, monteria, colombia investigational site number 170004, pereira, colombia investigational site number 191006, pula, croatia investigational site number 191005, rijeka, croatia investigational site number 191007, varazdin, croatia investigational site number 191003, zadar, croatia investigational site number 191008, zagreb, croatia investigational site number 191001, zagreb, croatia investigational site number 191004, zagreb, croatia investigational site number 203004, hradec kralove, czech republic investigational site number 203008, kolin, czech republic investigational site number 203007, nova ves pod plesi, czech republic investigational site number 203003, praha 5, czech republic investigational site number 208001, herlev, denmark investigational site number 233001, tallinn, estonia investigational site number 246001, turku, finland investigational site number 250002, antibes, france investigational site number 250010, colmar, france investigational site number 250020, gap, france investigational site number 250005, lille cedex, france investigational site number 250025, lille cedex, france investigational site number 250012, lille cedex, france investigational site number 250003, lyon, france investigational site number 250001, marseille, france investigational site number 250024, montpellier cedex, france investigational site number 250006, paris cedex 10, france investigational site number 250027, paris cedex 10, france investigational site number 250004, paris cedex 14, france investigational site number 250021, reims, france investigational site number 250019, rouen, france investigational site number 250017, saint gregoire, france investigational site number 250014, vandoeuvre les nancy, france investigational site number 276012, augsburg, germany investigational site number 276025, berlin, germany investigational site number 276016, berlin, germany investigational site number 276002, berlin, germany investigational site number 276029, berlin, germany investigational site number 276004, bochum, germany investigational site number 276014, dresden, germany investigational site number 276009, dresden, germany investigational site number 276030, essen, germany investigational site number 276005, frankfurt am main, germany investigational site number 276032, gauting, germany investigational site number 276038, halle/saale, germany investigational site number 276034, halle, germany investigational site number 276037, hamburg, germany investigational site number 276007, hannover, germany investigational site number 276006, köln, germany investigational site number 276020, leer, germany investigational site number 276010, leipzig, germany investigational site number 276017, magdeburg, germany investigational site number 276011, mannheim, germany investigational site number 276003, minden, germany investigational site number 276021, münchen, germany investigational site number 276019, münchen, germany investigational site number 276015, münchen, germany investigational site number 276013, neumünster, germany investigational site number 276022, oldenburg, germany investigational site number 276035, paderborn, germany investigational site number 276031, passau, germany investigational site number 276023, rosenheim, germany investigational site number 276008, singen, germany investigational site number 276024, westerstede, germany investigational site number 300004, athens, greece investigational site number 300003, heraklion, greece investigational site number 300002, thessaloniki, greece investigational site number 344001, hong kong, hong kong investigational site number 348005, budapest, hungary investigational site number 348006, budapest, hungary investigational site number 348009, budapest, hungary investigational site number 348004, budapest, hungary investigational site number 348010, farkasgyepu, hungary investigational site number 348001, gyula, hungary investigational site number 348012, mátraháza, hungary investigational site number 348003, sopron, hungary investigational site number 348008, szikszó, hungary investigational site number 348011, szolnok, hungary investigational site number 348007, zalaegerszeg, hungary investigational site number 356006, bangalore, india investigational site number 356008, bangalore, india investigational site number 356009, bhopal, india investigational site number 356018, chennai, india investigational site number 356020, chennai, india investigational site number 356019, coimbatore, india investigational site number 356015, hyderabad, india investigational site number 356025, hyderabad, india investigational site number 356011, jaipur, india investigational site number 356014, kochi, india investigational site number 356003, kolkata, india investigational site number 356013, kolkata, india investigational site number 356017, kolkata, india investigational site number 356005, madurai, india investigational site number 356016, miraj, india investigational site number 356001, mumbai, india investigational site number 356023, nagpur, india investigational site number 356002, new delhi, india investigational site number 356004, pune, india investigational site number 356024, pune, india investigational site number 356012, vishakhapatnam, india investigational site number 360002, bandung, indonesia investigational site number 360001, denpasar, indonesia investigational site number 360004, medan, indonesia investigational site number 372004, dublin 7, ireland investigational site number 372003, dublin, ireland investigational site number 372002, dublin, ireland investigational site number 376003, jerusalem, israel investigational site number 376004, kfar saba, israel investigational site number 376001, nahariya, israel investigational site number 376006, petah-tikva, israel investigational site number 376007, tzrifin, israel investigational site number 380005, castellanza, italy investigational site number 380014, cattolica, italy investigational site number 380007, cesena, italy investigational site number 380015, cremona, italy investigational site number 380009, faenza, italy investigational site number 380012, lecce, italy investigational site number 380006, lugo, italy investigational site number 380001, meldola, italy investigational site number 380011, parma, italy investigational site number 380020, perugia, italy investigational site number 380013, ravenna, italy investigational site number 380016, rimini, italy investigational site number 380004, sondrio, italy investigational site number 380010, sora, italy investigational site number 380008, taormina, italy investigational site number 380019, terni, italy investigational site number 380003, treviglio, italy investigational site number 380017, udine, italy investigational site number 410008, daegu, korea, republic of investigational site number 410007, seoul, korea, republic of investigational site number 410001, seoul, korea, republic of investigational site number 410002, seoul, korea, republic of investigational site number 410006, seoul, korea, republic of investigational site number 410005, seoul, korea, republic of investigational site number 410003, seoul, korea, republic of investigational site number 410009, seoul, korea, republic of investigational site number 410004, suwon, korea, republic of investigational site number 428002, liepaja, latvia investigational site number 428003, riga, latvia investigational site number 428001, riga, latvia investigational site number 440001, kaunas, lithuania investigational site number 440002, vilnius, lithuania investigational site number 458001, kota kinabalu, malaysia investigational site number 458003, kuala lumpur, malaysia investigational site number 458004, penang, malaysia investigational site number 458005, penang, malaysia investigational site number 484002, acapulco, mexico investigational site number 484006, aguascalientes, mexico investigational site number 484007, durango, mexico investigational site number 484008, mérida, mexico investigational site number 484012, puebla, mexico investigational site number 484003, toluca, mexico investigational site number 484010, xalapa, mexico investigational site number 528006, den haag, netherlands investigational site number 528004, groningen, netherlands investigational site number 528005, helmond, netherlands investigational site number 528001, hoofddorp, netherlands investigational site number 528003, rotterdam, netherlands investigational site number 578001, oslo, norway investigational site number 604012, arequipa, peru investigational site number 604004, callao, peru investigational site number 604011, callao, peru investigational site number 604001, cercado, peru investigational site number 604002, chiclayo, peru investigational site number 604008, lima, peru investigational site number 604007, lima, peru investigational site number 604009, lima, peru investigational site number 604005, lima, peru investigational site number 604006, lima, peru investigational site number 604010, lima, peru investigational site number 604003, lima, peru investigational site number 616009, bialystok, poland investigational site number 616008, bielsko-biala, poland investigational site number 616006, gliwice, poland investigational site number 616004, krakow, poland investigational site number 616003, lubin, poland investigational site number 616019, olsztyn, poland investigational site number 616021, otwock, poland investigational site number 616010, poznan, poland investigational site number 616001, prabuty, poland investigational site number 616014, rybnik, poland investigational site number 616005, rzeszow, poland investigational site number 616013, torun, poland investigational site number 616018, warszawa, poland investigational site number 616002, warszawa, poland investigational site number 616015, wroclaw, poland investigational site number 620003, aveiro, portugal investigational site number 620009, guimarães, portugal investigational site number 620004, lisboa, portugal investigational site number 620008, matosinhos, portugal investigational site number 620007, porto, portugal investigational site number 620002, setúbal, portugal investigational site number 642004, brasov, romania investigational site number 642002, bucuresti, romania investigational site number 642001, cluj napoca, romania investigational site number 642006, cluj-napoca, romania investigational site number 642010, iasi, romania investigational site number 642003, suceava, romania investigational site number 642008, timisoara, romania investigational site number 643024, berdsk, russian federation investigational site number 643006, chelyabinsk, russian federation investigational site number 643001, kazan, russian federation investigational site number 643004, krasnoyarsk, russian federation investigational site number 643010, obninsk, russian federation investigational site number 643005, omsk, russian federation investigational site number 643022, pyatigorsk, russian federation investigational site number 643023, rostov-on-don, russian federation investigational site number 643020, saratov, russian federation investigational site number 643019, smolensk, russian federation investigational site number 643021, sochi, russian federation investigational site number 643014, st-petersburg, russian federation investigational site number 643015, st-petersburg, russian federation investigational site number 643011, st-petersburg, russian federation investigational site number 643009, st.petersburg, russian federation investigational site number 643008, tomsk, russian federation investigational site number 643016, tula, russian federation investigational site number 643018, tyumen, russian federation investigational site number 643012, ufa, russian federation investigational site number 643007, vladivostok, russian federation investigational site number 643017, voronezh, russian federation investigational site number 643003, yaroslavl, russian federation investigational site number 688002, belgrade, serbia investigational site number 688004, belgrade, serbia investigational site number 688007, kragujevac, serbia investigational site number 688005, nis, serbia investigational site number 703003, trnava, slovakia investigational site number 705003, golnik, slovenia investigational site number 705002, maribor, slovenia investigational site number 710003, durban, south africa investigational site number 710002, durban, south africa investigational site number 724008, barakaldo, spain investigational site number 724010, barakaldo, spain investigational site number 724004, barcelona, spain investigational site number 724006, islas baleares, spain investigational site number 724011, lérida, spain investigational site number 724001, madrid, spain investigational site number 724007, madrid, spain investigational site number 724013, madrid, spain investigational site number 724012, madrid, spain investigational site number 724005, orense, spain investigational site number 724003, puerto de sagunto, spain investigational site number 724002, valencia, spain investigational site number 752003, göteborg, sweden investigational site number 752005, mora, sweden investigational site number 752002, uppsala, sweden investigational site number 752001, växjö, sweden investigational site number 756006, aarau, switzerland investigational site number 756004, winterthur, switzerland investigational site number 158004, changhua, taiwan investigational site number 804008, cherkasy, ukraine investigational site number 804009, chernivtsi, ukraine investigational site number 804002, dnipropetrovsk, ukraine investigational site number 804006, donetsk, ukraine investigational site number 804005, krivoy rog, ukraine investigational site number 804001, lutsk, ukraine investigational site number 804010, lviv, ukraine investigational site number 804011, sumy, ukraine investigational site number 804004, ternopil, ukraine investigational site number 826016, bangor, united kingdom investigational site number 826010, brighton, united kingdom investigational site number 826015, coventry, united kingdom investigational site number 826013, dundee, united kingdom investigational site number 826007, hull, united kingdom investigational site number 826002, lincoln, united kingdom investigational site number 826017, lincoln, united kingdom investigational site number 826005, manchester, united kingdom investigational site number 826004, norwich, united kingdom investigational site number 826009, peterborough, united kingdom investigational site number 826011, portsmouth, united kingdom investigational site number 826001, shrewsbury, united kingdom investigational site number 826014, wirral, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00694382,
426,427,NCT00553358,neo altto (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study,Neo ALTTO,Completed,Has Results,"neoplasms, breast",drug: lapatinib|biological: trastuzumab|drug: paclitaxel,number of participants with pathological complete response (pcr) at the time of surgery|number of participants with overall response at week 6|overall response at the time of surgery|number of participants with negative lymph nodes at the time of surgery|number of participants with actual indicated surgery|mean change from baseline in tumor size at week 6 and at surgery|number of participants starting paclitaxel before completing 6 weeks of treatment with either lapatinib or trastuzumab|event-free survival (efs) - median clinical follow-up|event-free survival (efs) - events and censoring|overall survival (os) - median survival follow-up|overall survival (os) - deaths and censoring|assess associations between locoregional pathological complete response (pcr) and event-free survival (efs) - median clinical follow-up (efs landmark population)|assess associations between locoregional pathological complete response (pcr) and event-free survival (efs) - number of participants with efs events (efs landmark population)|assess associations between locoregional pathological complete response (pcr) and and overall survival (os) - median clinical follow-up (os landmark population)|assess associations between locoregional pathological complete response (pcr) and and overall survival (os) - number of participants who died (os landmark population)|to assess safety via a comparison of the three treatment arms - to measure on-treatment primary cardiac endpoints|metabolic response rate determined by positron emission tomography/computed tomography (pet/ct)|percentage of participants with the indicated biomarker expression - pik3ca.|percentage of participants with the indicated biomarker expression - pten.|ratio (95% ci) of geometric means in p95her2 expression in hr positive patients with pcr vs no pcr|percentage of participants with circulating tumor cells (ctc) in the bloodstream,novartis pharmaceuticals|breast international group|solti breast cancer research group|novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,455.0,Industry|Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106903|2006-000564-81|CLAP016B2302,"January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","['novartis investigative site, berazategui, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, quilmes, argentina novartis investigative site, santa fe, argentina novartis investigative site, tucuman, argentina novartis investigative site, brussels, belgium novartis investigative site, brussel, belgium novartis investigative site, bruxelles, belgium novartis investigative site, gent, belgium novartis investigative site, leuven, belgium novartis investigative site, namur, belgium novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, santo andre, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, montreal, quebec, canada novartis investigative site, brno, czechia novartis investigative site, novy jicin, czechia novartis investigative site, praha 10, czechia novartis investigative site, bayonne, france novartis investigative site, bordeaux, france novartis investigative site, le mans, france novartis investigative site, levallois-perret, france novartis investigative site, paris, france novartis investigative site, reims, france novartis investigative site, strasbourg, france novartis investigative site, strasbourg, france novartis investigative site, toulouse, france novartis investigative site, villejuif cedex, france novartis investigative site, freiburg, baden-wuerttemberg, germany novartis investigative site, karlsruhe, baden-wuerttemberg, germany novartis investigative site, fuerth, bayern, germany novartis investigative site, nuernberg, bayern, germany novartis investigative site, fuerstenwalde, brandenburg, germany novartis investigative site, frankfurt am main, hessen, germany novartis investigative site, rostock, mecklenburg-vorpommern, germany novartis investigative site, stralsund, mecklenburg-vorpommern, germany novartis investigative site, celle, niedersachsen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, dortmund, nordrhein-westfalen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, koeln, nordrhein-westfalen, germany novartis investigative site, witten, nordrhein-westfalen, germany novartis investigative site, halle, sachsen-anhalt, germany novartis investigative site, kiel, schleswig-holstein, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, hong kong, hong kong novartis investigative site, kowloon, hong kong novartis investigative site, wanchai, hong kong novartis investigative site, budapest, hungary novartis investigative site, bangalore, india novartis investigative site, hyderabad, india novartis investigative site, mumbai, india novartis investigative site, nagpur, india novartis investigative site, new delhi, india novartis investigative site, new delhi, india novartis investigative site, pune, india novartis investigative site, roma, lazio, italy novartis investigative site, genova, liguria, italy novartis investigative site, lecco, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, monza, lombardia, italy novartis investigative site, sondrio, lombardia, italy novartis investigative site, trento, trentino-alto adige, italy novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, songpa-gu, seoul, korea, republic of novartis investigative site, vilnius, lithuania novartis investigative site, oslo, norway novartis investigative site, oslo, norway novartis investigative site, karachi, pakistan novartis investigative site, lima, peru novartis investigative site, lima, peru novartis investigative site, bucharest, romania novartis investigative site, bucharest, romania novartis investigative site, bucuresti, romania novartis investigative site, cluj-napoca, romania novartis investigative site, moscow, russian federation novartis investigative site, ryazan, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, pretoria, gauteng, south africa novartis investigative site, athlone park, amanzimtoti, south africa novartis investigative site, capital park, south africa novartis investigative site, parktown, south africa novartis investigative site, barcelona, spain novartis investigative site, girona, spain novartis investigative site, lerida, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, mataro, spain novartis investigative site, santiago de compostela, spain novartis investigative site, sevilla, spain novartis investigative site, toledo, spain novartis investigative site, torrevieja (alicante), spain novartis investigative site, valencia, spain novartis investigative site, goteborg, sweden novartis investigative site, changhua, taiwan novartis investigative site, tainan, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, chernivtsi, ukraine novartis investigative site, dnipropetrovsk, ukraine novartis investigative site, kharkiv, ukraine novartis investigative site, kiev, ukraine novartis investigative site, krivoy rog, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, lviv, ukraine novartis investigative site, odessa, ukraine novartis investigative site, simferopol, ukraine novartis investigative site, epping, essex, united kingdom novartis investigative site, bournemouth, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT00553358,breast
427,428,NCT04251533,study assessing the efficacy and safety of alpelisib + nab-paclitaxel in subjects with advanced tnbc who carry either a pik3ca mutation or have pten loss,EPIK-B3,Recruiting,No Results Available,triple negative breast neoplasms,drug: alpelisib|drug: placebo|drug: nab-paclitaxel,progression-free survival (pfs) per investigator assessment in study part a|progression-free survival (pfs) per investigator assessment in study part b2|overall response rate (orr) based on local radiology assessments in subjects with measurable disease at baseline in study part b1|overall survival (os) in study part a|overall survival (os) in study part b2|overall response rate (orr) with confirmed response in study part a|overall response rate (orr) with confirmed response in study part b2|clinical benefit rate (cbr) with confirmed response in study part a|clinical benefit rate (cbr) with confirmed response in study part b1|clinical benefit rate (cbr) with confirmed response in study part b2|time to response (ttr) in study part a|time to response (ttr) in study part b1|time to response (ttr) in study part b2|duration of response (dor) with confirmed response in study part a|duration of response (dor) with confirmed response in study part b1|duration of response (dor) with confirmed response in study part b2|overall survival (os) in study part b1|progression-free survival (pfs) per investigator assessment in study part b1|plasma concentrations of alpelisib - part a|plasma concentrations of alpelisib - part b1|plasma concentrations of alpelisib -part b2|plasma concentrations of paclitaxel - part a|plasma concentrations of paclitaxel - part b1|change from baseline in the global health status/quality of life (qol) scale score of the european organization for research and treatment of cancer quality of life questionnaire 30-item core module (eortc qlq-c30) in study part a|change from baseline in the global health status/qol scale score of the eortc qlq-c30 in study part b2|time to 10% definitive deterioration in the global health status/qol scale score of the eortc qlq-c30 in study part a|time to 10% definitive deterioration in the global health status/qol scale score of the eortc qlq-c30 in study part b2|pfs based on local radiology assessments using recist 1.1 criteria for subjects by pik3ca mutation status measured in baseline ctdna in study part a|pfs based on local radiology assessments using recist 1.1 criteria for subjects by pik3ca mutation status measured in baseline ctdna in study part b2|time to definitive deterioration of the eastern cooperative oncology group (ecog) performance status (ps) from baseline in study part a|time to definitive deterioration of the ecog performance status from baseline in study part b2,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,566.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CBYL719H12301|2019-002637-11,"June 8, 2020","June 19, 2023","January 9, 2026","February 5, 2020",,"May 3, 2022","[""comprehensive blood and cancer center dept. of cbcc (2), bakersfield, california, united states cancer and blood specialty clinic, los alamitos, california, united states usc norris cancer center, los angeles, california, united states university of california at los angeles santa monica location, los angeles, california, united states cancer care associates medical group center, redondo beach, california, united states florida cancer specialists dept of oncology (2), fort myers, florida, united states florida cancer specialists fl cancer specialists, fort myers, florida, united states florida cancer specialists onc dept, fort myers, florida, united states florida cancer affiliates of ocala, ocala, florida, united states university of illinois cancer center at chicago, chicago, illinois, united states fort wayne medical oncology/hematology, inc. jefferson blvd, fort wayne, indiana, united states university of kansas hospital and medical center deptofuofkansas cancercenter-2, kansas city, kansas, united states hematology and oncology clinic sc, baton rouge, louisiana, united states sinai hospital of baltimore dept of sinai hospital - 2, baltimore, maryland, united states mayo clinic rochester mayo - roch., rochester, minnesota, united states park nicollet institute dept onc, saint louis park, minnesota, united states research medical center hca midwest division, kansas city, missouri, united states comprehensive cancer centers of nevada ccc of nevada (1), las vegas, nevada, united states new york oncology hematology, p.c., albany, new york, united states cleveland clinic foundation taussig cancer center, cleveland, ohio, united states university of pittsburgh cancer institute cancer pavilion, 5th floor, pittsburgh, pennsylvania, united states chattanooga oncology and hematology associates pc tennessee oncology chattanooga, chattanooga, tennessee, united states tennessee oncology tennessee oncology (3), nashville, tennessee, united states texas oncology, p.a. austin, bedford, texas, united states texas oncology pa dallas presbyterian hospital sc, dallas, texas, united states texas oncology texas oncology - denton, dallas, texas, united states us oncology us oncology associates, dallas, texas, united states el paso, texas oncology, el paso, texas, united states texas oncology houston memorial city sc, houston, texas, united states university of texas md anderson cancer center, houston, texas, united states cancer care centers of south texas hoast ccc of so. tx- san antonio, san antonio, texas, united states us oncology p a, tyler, texas, united states virginia oncology associates, norfolk, virginia, united states northwest medical specialties northwest medical - puyallup, tacoma, washington, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, buenos aires, caba, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, rio negro, viedma, argentina novartis investigative site, darlinghurst, new south wales, australia novartis investigative site, melbourne, victoria, australia novartis investigative site, murdoch, western australia, australia novartis investigative site, nedlands, western australia, australia novartis investigative site, innsbruck, tyrol, austria novartis investigative site, leoben, austria novartis investigative site, salzburg, austria novartis investigative site, vienna, austria novartis investigative site, vienna, austria novartis investigative site, caxias do sul, rs, brazil novartis investigative site, barretos, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, plovdiv, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, varna, bulgaria novartis investigative site, hefei, anhui, china novartis investigative site, chongqing, chongqing, china novartis investigative site, guangzhou, guangdong, china novartis investigative site, guiyang, guizhou, china novartis investigative site, shijiazhuang, hebei, china novartis investigative site, harbin, heilongjiang, china novartis investigative site, wuhan, hubei, china novartis investigative site, changsha, hunan, china novartis investigative site, nanjing, jiangsu, china novartis investigative site, nanchang, jiangxi, china novartis investigative site, chang chun, jilin, china novartis investigative site, shengyang, liaoning, china novartis investigative site, jinan, shandong, china novartis investigative site, xian, shanxi, china novartis investigative site, chengdu, sichuan, china novartis investigative site, tianjin, tianjin, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, beijing, china novartis investigative site, dalian, china novartis investigative site, qingdao, china novartis investigative site, shanghai, china novartis investigative site, shenyang, china novartis investigative site, rionegro, antioquia, colombia novartis investigative site, ibague, tolima, colombia novartis investigative site, bogota, colombia novartis investigative site, bogota, colombia novartis investigative site, split, hrv, croatia novartis investigative site, zagreb, croatia novartis investigative site, saint-cloud, hauts de seine, france novartis investigative site, angers cedex 02, france novartis investigative site, besancon cedex, france novartis investigative site, clermont ferrand, france novartis investigative site, creteil, france novartis investigative site, dijon, france novartis investigative site, le mans, france novartis investigative site, metz, france novartis investigative site, nimes cedex 9, france novartis investigative site, paris cedex 10, france novartis investigative site, poitiers, france novartis investigative site, reims, france novartis investigative site, saint-herblain cédex, france novartis investigative site, villejuif cedex, france novartis investigative site, ravensburg, baden-wuerttemberg, germany novartis investigative site, muenchen, bavaria, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, velbert, north rhine-westphalia, germany novartis investigative site, luebeck, schleswig-holstein, germany novartis investigative site, berlin, germany novartis investigative site, bonn, germany novartis investigative site, dresden, germany novartis investigative site, erlangen, germany novartis investigative site, hamburg, germany novartis investigative site, heidelberg, germany novartis investigative site, leipzig, germany novartis investigative site, mannheim, germany novartis investigative site, rostock, germany novartis investigative site, tübingen, germany novartis investigative site, ulm, germany novartis investigative site, wuerzburg, germany novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, kecskemet, hungary novartis investigative site, tatabanya, hungary novartis investigative site, faridabad, haryana, india novartis investigative site, mumbai, maharashtra, india novartis investigative site, mumbai, maharashtra, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, hyderabad, telangana, india novartis investigative site, hyderabad, telangana, india novartis investigative site, kolkata, west bengal, india novartis investigative site, be'er sheva, israel novartis investigative site, ramat gan, israel novartis investigative site, tel aviv, israel novartis investigative site, ancona, an, italy novartis investigative site, brindisi, br, italy novartis investigative site, meldola, fc, italy novartis investigative site, genova, ge, italy novartis investigative site, monza, mb, italy novartis investigative site, messina, me, italy novartis investigative site, rionero in vulture, pz, italy novartis investigative site, roma, rm, italy novartis investigative site, roma, rm, italy novartis investigative site, torino, to, italy novartis investigative site, napoli, italy novartis investigative site, amman, jordan novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, el chouf, lbn, lebanon novartis investigative site, ashrafieh, lebanon novartis investigative site, beirut, lebanon novartis investigative site, petaling jaya, selangor, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, tuxtla gutierrez, chiapas, mexico novartis investigative site, ciudad de mexico, distrito federal, mexico novartis investigative site, monterrey, nuevo leon, mexico novartis investigative site, oslo, norway novartis investigative site, stavanger, norway novartis investigative site, tromsoe, norway novartis investigative site, trujillo, la libertad, peru novartis investigative site, lima, peru novartis investigative site, gdynia, poland novartis investigative site, opole, poland novartis investigative site, poznan, poland novartis investigative site, rzeszow, poland novartis investigative site, bucharest, romania novartis investigative site, cluj napoca, romania novartis investigative site, cluj-napoca, romania novartis investigative site, constanta, romania novartis investigative site, craiova, romania novartis investigative site, ploiesti, romania novartis investigative site, arkhangelsk, russian federation novartis investigative site, chelyabinsk, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, pushkin saint petersburg, russian federation novartis investigative site, bratislava, slovak republic, slovakia novartis investigative site, bratislava, slovakia novartis investigative site, kosice, slovakia novartis investigative site, ljubljana, slovenia novartis investigative site, port elizabeth, western cape, south africa novartis investigative site, johannesburg, south africa novartis investigative site, pretoria, south africa novartis investigative site, almeria, andalucia, spain novartis investigative site, sabadell, barcelona, spain novartis investigative site, alicante, comunidad valenciana, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, badajoz, extremadura, spain novartis investigative site, palma de mallorca, islas baleares, spain novartis investigative site, ferrol, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, santa cruz de tenerife, spain novartis investigative site, valencia, spain novartis investigative site, aarau, switzerland novartis investigative site, bern, switzerland novartis investigative site, lausanne, switzerland novartis investigative site, zurich, switzerland novartis investigative site, kaoshiung, taiwan novartis investigative site, taichung, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan, taiwan novartis investigative site, istanbul, turkey novartis investigative site, istanbul, turkey novartis investigative site, nottingham, united kingdom novartis investigative site, oxford, united kingdom novartis investigative site, swansea, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04251533,breast
428,429,NCT00387127,lapatinib versus placebo given concurrently with cisplatin and radiotherapy in patients with unresected head and neck cancer,,Completed,Has Results,"neoplasms, head and neck",drug: lapatinib oral tablets|drug: radiotherapy|drug: cisplatin chemotherapy,"number of participants (par.) with complete response (cr), as assessed by independent radiological review|number of participants with cr, as assessed by the investigator|progression-free survival (pfs), as assessed by the investigator|overall survival (os)|number of participants who died due to progressive disease|disease-specific survival|number of participants with loco-regional recurrence of initial disease|loco-regional control|number of participants with distant recurrence of initial disease|distant relapse|number of participants with overall response (or), as assessed by the investigator|number of participants positive and negative for the expression of biomarkers in tumor tissue: human epidermal growth factor receptor (her)-1, her2, her3, her4, p16, and transforming growth factor (tgf-alpha)|plasma proteome analysis|analysis of deoxyribonucleic acid (dna) and ribonucleic acid (rna) from tumor samples|number of participants negative and positive for human papilloma virus (hpv) infection, as determined from tumor samples|number of participants positive and negative for biomarker her1/erbb1 categorized in the indicated independent review panel-assessed tumor responses by expression of biomarkers from tumor tissue: sensitivity analysis - 0 versus (1, 2, 3)|number of participants positive and negative for biomarker her1/erbb1 categorized in the indicated independent review panel-assessed tumor responses by expression of biomarkers from tumor tissues: sensitivity analysis - 0, 1, 2 versus 3",glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EGF105884,November 2006,June 2009,January 2014,"October 12, 2006","January 5, 2015","June 25, 2015","['gsk investigational site, minneapolis, minnesota, united states gsk investigational site, kansas city, missouri, united states gsk investigational site, charlotte, north carolina, united states gsk investigational site, hamilton, ontario, canada gsk investigational site, sherbrooke, quebec, canada gsk investigational site, quebec, canada gsk investigational site, lens, france gsk investigational site, lille, france gsk investigational site, lyon, france gsk investigational site, paris cedex 15, france gsk investigational site, vandoeuvre-les-nancy, france gsk investigational site, budapest, hungary gsk investigational site, győr, hungary gsk investigational site, ahemdabad, india gsk investigational site, mumbai, india gsk investigational site, thiruvananthapuram, india gsk investigational site, amsterdam, netherlands gsk investigational site, leiden, netherlands gsk investigational site, lima, peru gsk investigational site, lima, peru gsk investigational site, barcelona, spain gsk investigational site, madrid, spain gsk investigational site, cambridge, cambridgeshire, united kingdom gsk investigational site, northwood, middlesex, united kingdom gsk investigational site, coventry, united kingdom gsk investigational site, leeds, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, newcastle upon tyne, united kingdom gsk investigational site, sheffield, united kingdom']",,https://ClinicalTrials.gov/show/NCT00387127,
429,430,NCT02364999,a comparative study of pf-06439535 plus paclitaxel-carboplatin and bevacizumab plus paclitaxel-carboplatin patients with advanced non-squamous nsclc,,Completed,Has Results,non-small cell lung cancer,drug: bevacizumab-pfizer|drug: bevacizumab-eu|drug: paclitaxel|drug: carboplatin,objective response rate (orr) by week 19|number of participants with treatment-emergent adverse events|number of participants with laboratory abnormalities (without regard to baseline abnormality)|duration of response (dor)|progression free survival rate at 55 weeks|survival rate at 55 weeks|serum concentration of bevacizumab up to 1 year|number of participants with anti-drug antibody (ada)|number of participants with neutralizing antibody (nab),pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,719.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B7391003|2014-003878-16,April 2015,May 2017,December 2017,"February 18, 2015","June 27, 2018","February 7, 2019","['southern cancer center, pc, daphne, alabama, united states southern cancer center, pc, mobile, alabama, united states southern cancer center, pc, mobile, alabama, united states beaver medical group, l.p., highland, california, united states cancer center of central connecticut, new britain, connecticut, united states cancer center of central connecticut, southington, connecticut, united states phoebe putney memorial hospital, albany, georgia, united states swedish covenant hospital, chicago, illinois, united states meritus center for clinical research, hagerstown, maryland, united states holy cross hospital resource center, silver spring, maryland, united states maryland oncology & hematology, pa, silver spring, maryland, united states holy cross hospital, hospital pharmacy, silver spring, maryland, united states holy cross hospital, silver spring, maryland, united states maryland oncology & hematology, pa, wheaton, maryland, united states st. joseph\'s regional medical center, paterson, new jersey, united states millennium oncology, houston, texas, united states millennium oncology, kingwood, texas, united states millennium oncology, shenandoah, texas, united states millennium oncology, the woodlands, texas, united states epic pharmacy, lismore, new south wales, australia the tweed hospital, tweed heads, new south wales, australia cardiac services, john flynn private hospital -, tugun, queensland, australia south coast radiology, john flynn private hospital, tugun, queensland, australia austin health - olivia newton - john cancer & wellness centre, heidelberg, victoria, australia western health, sunshine hospital, st albans, victoria, australia hospital santa izabel / santa casa de misericordia da bahia, salvador, bahia, brazil oncoclinic (clinica de oncologia e atendimento de urgencia ltda), fortaleza, ceara, brazil cot - centro oncologico do triangulo ltda, uberlandia, minas gerais, brazil liga paranaense de combate ao cancer - hospital erasto gaertner, curitiba, parana, brazil hospital bruno born (sociedade beneficencia e caridade de lajeado), lajeado, rio grande do sul, brazil oncosinos (lessa ferreira servicos oncologicos ltda), novo hamburgo, rio grande do sul, brazil hospital da cidade de passo fundo - hcpf, passo fundo, rio grande do sul, brazil irmandade da santa casa de misericordia de porto alegre - iscmpa, porto alegre, rio grande do sul, brazil irmandade da santa casa de misericordia de porto alegre - hospital santa rita, porto alegre, rio grande do sul, brazil centro de pesquisa em oncologia - uniao brasileira de educacao e assistencia, porto alegre, rio grande do sul, brazil instituto joinvillense de hematologia e oncologia ss ltda - clinica de hematologia e oncologia, joinville, santa catarina, brazil fundacao faculdade regional de medicina de sao jose do rio preto -, sao jose do rio preto, sao paulo, brazil instituto de oncologia de sorocaba - onco clinicas especializadas sc ltda, sorocaba, sao paulo, brazil instituto coi de pesquisa, educacao e gestao - coi clinicas barra da tijuca, rio de janeiro, brazil lnstituto do cancer do estado de sao paulo - octavio frias de -, sao paulo, brazil instituto de assistencia medica ao servidor publico estadual - iamspe/hspe-fmo, sao paulo, brazil complex oncological center shumen eood, shumen, bulgaria instituto clinico oncologico del sur (icos), temuco, region de la araucania, chile bradford hill centro de investigaciones clinicas, santiago, region metropolitana, chile centro internacional de estudios clinicos (ciec), santiago, region metropolitana, chile fresenius kabi chile, therapia i.v., santiago, region metropolitana, chile instituto clínico oncológico del sur (icos), temuco, región de la araucanía, chile centro de investigaciones clinicas vina del mar ltda., vina del mar, v region, chile university hospital centre ""sestre milosrdnice"", zagreb, croatia nemocnice na plesi s.r.o, nova ves pod plesi, czechia nemocnice novy jicin a.s, novy jicin, czechia lekarna agel novy jicin, novy jicin, czechia nemocnice pelhrimov p.o, radioterapeuticke oddeleni, pelhrimov, czechia lekarna oblastni nemocnice pribram, pribram, czechia centre hospitalier general de mont de marsan, mont de marsan cedex, france centre hospitalier montbeliard, montbeliard, france l\'hopital prive du confluent s.a.s., nantes cedex, france hopital d\'instruction des armees sainte anne, toulon cedex 9, france klinikum bayreuth gmbh, bayreuth, germany evangelische lungenklinik berlin, berlin, germany viereck-apotheke, berlin, germany vivantes gmbh apotheke des humboldt-klinikums, berlin, germany vivantes klinikum spandau, berlin, germany staedtisches klinikum braunschweig ggmbh apotheke, braunschweig, germany staedtisches klinikum braunschweig ggmbh institut fuer roentgendiagnostik und nuklearmedizin, braunschweig, germany staedtisches klinikum braunschweig ggmbh, braunschweig, germany fachkrankenhaus coswig gmbh, coswig, germany apotheke johannstadt sven ullrich e.k., dresden, germany klinikum esslingen gmbh, esslingen a.n., germany radiologie nuklearmedizin adickesallee, frankfurt am main, germany st. elisabethen - krankenhaus, frankfurt am main, germany sued-apotheke, frankfurt am main, germany asklepios fachkliniken muenchen gauting, gauting, germany johannes-apotheke, groebenzell, germany krankenhaus martha-maria halle-doelau ggmbh - apotheke, halle (saale), germany krankenhaus martha-maria halle-doelau ggmbh - institut fuer radiologie, halle (saale), germany krankenhaus martha-maria halle-doelau ggmbh, halle (saale), germany zytoservice deutschland gmbh, hamburg, germany katholisches marienkrankenhaus ggmbh, hamburg, germany institut fuer diagnostische und interventionelle radiologie, hannover, germany medizinische hochschule hannover zentralapotheke, hannover, germany medizinische hochschule hannover, hannover, germany universitaetsklinikum des saarlandes - klinik fuer diagnostische und interventionelle radiologie, homburg/saar, germany universitaetsklinikum des saarlandes - klinik fuer innere medizin v - pneumologie, allergologie,, homburg/saar, germany universitaetsklinikum des saarlandes, apotheke, homburg/saar, germany vincentius-diakonissen-kliniken gag karlsruhe, karlsruhe, germany vincentius-diakonissen-kliniken gag klinik fuer diagnostische und interventionelle radiologie, karlsruhe, germany vincentius-diakonissen-kliniken gag zentralapotheke, karlsruhe, germany institut fuer versorgungsforschung in der onkologie, koblenz, germany radiologisches institut koblenz, koblenz, germany sonnenschein apotheke, koblenz, germany hirsch-apotheke, leer, germany onkologie unterems, leer, germany zentrum fuer radiologie und nuklearmedizin am johannisplatz (zrn leipzig), leipzig, germany arkana apotheke ohg, leipzig, germany pois leipzig gbr, pneumologisch/onkologisch/internistisches studienzentrum, leipzig, germany onkologie moers gbr, moers, germany friedrich-ebert-krankenhaus neumuenster, neumuenster, germany university hospital of heraklion, heraklion, crete, greece univ. of athens hosp. of chest diseases of athens \'\'sotiria\'\', athens, greece general oncology hospital of kifissia ""ag. anargiroi"", athens, greece university general hospital of patras, patras, greece euromedica general clinic of thessaloniki, thessaloniki, greece european inter-balkan medical centre, thessaloniki, greece thermi clinic s.a, thessaloniki, greece gen.hospital ""g. papanikolaou"", thessaloniki, greece semmelweis egyetem klinikai pulmonologiai klinikai gyogyszertar, budapest, hungary semmelweis egyetem, pulmonologiai klinika, budapest, hungary csongrad megyei mellkasi betegsegek szakkorhaza, deszk, hungary veszprem megyei tudogyogyintezet, farkasgyepu, hungary petz aladar megyei oktato korhaz, pulmonologiai osztaly, gyor, hungary matrai gyogyintezet pulmonologiai osztaly, matrahaza, hungary jasz-nagykun-szolnok megyei hetenyi geza korhaz - rendelointezet, megyei onkologiai kozpont, szolnok, hungary tudogyogyintezet torokbalint, torokbalint, hungary zala megyei korhaz, zalaegerszeg, hungary mahatma gandhi cancer hospital and research institute, visakhapatnam, andhra pradesh, india healthcare global enterprises limited, bangalore, karnataka, india shatabdi super speciality hospital, nashik, maharashtra, india sahyadri clinical research and development center (a unit of sahayadri hospitals limited), pune, maharashtra, india sahyadri speciality hospital, pune, maharashtra, india institute of respiratory diseases, sms medical college & hospital, jaipur, rajasthan, india uoc oncologia, treviglio, bg, italy oncologia medica, fondazione poliambulanza instituto ospedaliero, brescia, bs, italy uo oncologia medica, catania, ct, italy unita di oncologia toracica, meldola, fc, italy uoc di oncologia medica, lido di camaiore, lu, italy uosd pneumologia oncologica - padiglione flaiani, roma, rm, italy s.c. oncologia medica-presidio ospedaliero sondrio, sondrio, so, italy uoc oncologia medica, legnago, vr, italy national hospital organization hirosaki national hospital, hirosaki, aomori, japan national hospital organization asahikawa medical center, asahikawa, hokkaido, japan national hospital organization himeji medical center, himeji, hyogo, japan national hospital organization mito medical center, higashi-ibaraki-gun, ibaraki, japan kanazawa university hospital, kanazawa, ishikawa, japan kanagawa cardiovascular and respiratory center, yokohama, kanagawa, japan national hospital organization mie chuo medical center, tsu, mie, japan national hospital organization sendai medical center, sendai, miyagi, japan national hospital organization tokyo national hospital, kiyose, tokyo, japan national hospital organization tokyo medical center, meguro-ku, tokyo, japan national hospital organization disaster medical center, tachikawa, tokyo, japan saiseikai fukuoka general hospital, fukuoka, japan national hospital organization kochi national hospital, kochi, japan national hospital organization oita medical center, oita, japan japanese red cross okayama hospital, okayama, japan chungbuk national university hospital, cheongju-si, chungcheongbuk-do, korea, republic of vhs medical center, seoul, gangdong-gu, korea, republic of seoul national university bundang hospital, seongnam-si, gyeonggi-do, korea, republic of ajou university hospital, suwon, gyeonggi-do, korea, republic of the catholic university of korea, seoul st.mary\'s hospital, seoul, korea, republic of nilai medical centre, nilai, negeri sembilan, malaysia mount miriam cancer hospital, tanjung bungah, penang, malaysia penang adventist hospital, penang, malaysia klinisch chemisch en hematologisch laboratorium (kchl), arnhem, netherlands rijnstate ziekenhuis, arnhem, netherlands ziekenhuis de gelderse vallei, ede, netherlands elkerliek ziekenhuis, helmond, netherlands cebu doctors\' university hospital, cebu city, cebu, philippines davao doctors hospital, davao city, davao del sur, philippines wojewodzki szpital zespolony w elblagu, elblag, poland wojewodzkie wielospecjalistyczne centrum onkologii i traumatologii im. kopernika w lodzi,, lodz, poland samodzielny publiczny zespol gruzlicy i chorob pluc w olsztynie, olsztyn, poland wielkopolskie centrum pulmonologii i torakochirurgii im.eugenii i janusza zeylandow, poznan, poland mrukmed. lekarz beata madej mruk i partner. sp. p. oddzial nr 1 w rzeszowie, rzeszow, poland samodzielny publiczny wojewodzki szpital zespolony w szczecinie szpital wojewodzki w, szczecin-zdunowo, poland wojewodzki szpital zespolony im. l. rydygiera w toruniu szpital obserwacyjno-zakazny, torun, poland centrum onkologii - instytut im. marii sklodowskiej-curie, warszawa, poland wojskowy instytut medyczny, klinika onkologii, warszawa, poland wojewodzki szpital chorob pluc im. dr alojzego pawelca, wodzislaw-slaski, poland spad imaging international s.r.l, craiova, dolj, romania sc cardio-center srl, craiova, dolj, romania sc oncolab srl, oncologie, craiova, jud dolj, romania spitalul clinic judetean de urgenta targu mures, cardiologie, targu-mures, mures, romania spitalul clinic judetean mures, radiologie si imagistica medicala, targu-mures, mures, romania spitalul clinic judetean mures, sectia clinica de oncologie medicala, targu-mures, mures, romania s.c. oncocenter oncologie clinica srl, timisoara, timis, romania medisprof, cluj napoca, romania spitalul clinic municipal, cluj-napoca, romania sc hiperdia sa, cluj-napoca, romania spitalul clinic judetean de urgenta ""sf apostol andrei"" constanta clinica oncologie medicala, constanta, romania centrul medical pozimed, sc pozitron medical investigation srl, constanta, romania s.c. centrul de oncologie sf. nectarie s.r.l., oncologie medicala, craiova, romania sc radiotherapy center cluj srl, jud cluj, romania hiperdia timisoara, cardiologie, timisoara, romania hiperdia timisoara, radiologie si imagistica medicala, timisoara, romania dr\'s grineva private clinic, sochi, krasnodar region, russian federation shi oncology dispensary #2 of health department of krasnodar region, sochi, krasnodar region, russian federation ""sahi of moscow """"moscow city oncology hospital #62 of health department of moscow"""""", p/o stepanovskoe, moscow region, russian federation ""rbhi """"kursk regional clinical oncology dispensary"""" of healthcare committee of kursk region"", kislino steading of kursk region, ryshkovskiy village council, russian federation sbhi of stavropol region ""essentuki central city hospital"", essentuki, stavropol region, russian federation federal state budgetary institution of healthcare ""clinical hospital #, lermontov, stavropol region, russian federation sbhi of stavropol region ""pyatigorsk oncology dispensary"", pyatigorsk, stavropol region, russian federation stavropol krai state budget healthcare institute ""stavropol regional oncology clinic"", stavropol, stavropol region, russian federation s.g. primushko republican clinical oncology dispensary, izhevsk, udmurt republic, russian federation sbhi of vladimir region ""regional clinical oncology dispensary"", vladimir, vladimir region, russian federation state budget healthcare institution of arkhangelsk region, arkhangelsk, russian federation evimed llc, chelyabinsk, russian federation chelyabinsk regional hospital, chelyabinsk, russian federation sbhi ""chelyabinsk regional clinical hospital"", chelyabinsk, russian federation ""sbhi """"chelyabinsk regional clinical oncology dispensary"""""", chelyabinsk, russian federation chelyabinsk regional clinical oncology dispensary, chelyabinsk, russian federation mrt-expert, llc, chelyabinsk, russian federation road clinical hospital on the station chelyabinsk of ojsc ""rzd"", chelyabinsk, russian federation sbhi ""regional clinical hospital #2"" of moh of krasnodar region, krasnodar, russian federation fsbi ""n.n.blokhin russian cancer research center"" rams, moscow, russian federation p.a.hertsen moscow oncology research institute - branch of the national medical radiological, moscow, russian federation privolzhskiy district medical center of federal biomedical agency, nizhniy novgorod, russian federation sbhi nr clinical diagnostic center, nizhniy novgorod, russian federation sbhi of nnr nizhniy novgorod regional oncology dispensary, nizhniy novgorod, russian federation sbhi of nnr nizhniy novgorod regional oncology dispensary, nizhniy novgorod, russian federation ""budgetary healthcare institution of omsk region """"clinical oncology dispensary"""""", omsk, russian federation sbei hpe ryazsmu of moh of russia based on sbi of ryazan region, ryazan, russian federation spb sbhi ""city clinical oncology dispensary"", saint petersburg, russian federation fsbi \'scientific-research oncology institute n.a. n.n.petrov\' of moh of rf, saint-petersburg, russian federation saratov scientific research institute of traumatology and orthopedics, saratov, russian federation nhi road clinical hospital at the st. saratov ii of ojsc russian railways, saratov, russian federation clinical hospital n.a. s.r. mirotvortseva of ssmu, saratov, russian federation limited liability company ""common health"", sochi, russian federation the medical oncology centre of rosebank, johannesburg, gauteng, south africa amanzimtoti oncology centre, amanzimtoti, kwa-zulu natal, south africa drs schnetler, corbett and partners inc, cape town, western cape, south africa dr lior sareli inc, cape town, western cape, south africa cape town oncology trials (pty) ltd, kraaifontein, western cape, south africa corporacio sanitaria parc tauli, sabadell, barcelona, spain hospital son llatzer, palma de mallorca, islas baleares, spain hospital universitario fundacion alcorcon, alcorcon, madrid, spain hospital universitario fundacion jimenez diaz, madrid, spain hospital 12 de octubre, madrid, spain hospital universitario la paz, servicio de oncologia, madrid, spain consorcio hospital universitario general de valencia, valencia, spain hospital arnau de vilanova, valencia, spain changhua christian hospital, changhua, taiwan chulalongkorn university, patumwan, bangkok, thailand chiangrai prachanukroh hospital, muang, chiang rai, thailand chula clinical research center, bangkok, thailand clinical research center, phramongkutklao hospital, bangkok, thailand medical oncology unit, department of medicine, phramongkutklao hospital, bangkok, thailand division of medical oncology, department of medicine, faculty of medicine siriraj hospital,, bangkok, thailand prachachuen imaging center co., ltd., bangkok, thailand oncology unit, department of medicine, faculty of medicine, naresuan university, phitsanulok, thailand baskent universitesi tip fakultesi adana hastanesi, adana, turkey cukurova universitesi tip fakultesi balcali hastanesi, adana, turkey hacettepe universitesi tip fakultesi, ankara, turkey diskapi yildirim beyazit egitim ve arastirma hastanesi, ankara, turkey ankara universitesi tip fakultesi cebeci hastanesi, ankara, turkey yildirim beyazit universitesi tip fakultesi ataturk egitim ve arastirma hastanesi, ankara, turkey yedikule gogus hastaliklari ve gogus cerrahisi, istanbul, turkey bezmialem vakif universitesi tip fakultesi hastanesi, istanbul, turkey istanbul universitesi onkoloji enstitusu, istanbul, turkey iyitem goruntuleme ve tani merkezi, istanbul, turkey istanbul universitesi cerrahpasa tip fakultesi ic hastaliklari, istanbul, turkey prof dr nuri tenekeci tani merkezi, istanbul, turkey euromed goruntuleme ve tani merkezi, istanbul, turkey ege universitesi tip fakultesi lc hastaliklari anabilim dali, izmir, turkey llc ""medical clinic ""innovacia"", chemotherapy department, lyutizh, kyiv region, ukraine ""municipal institution """"chernivtsi regional clinical oncology dispensary"""",, chernivtsi, ukraine mi \'city dnipropetrovsk multi-field clin. hospital #4 of drc\', dep.-nt of chemotherapy;, dnipropetrovsk, ukraine communal non-profit enterprise ""regional center of oncology"",, kharkiv, ukraine mi \'kryvyi rih oncology dispensary of dnipropetrovsk regional council\', kryvyi rih, ukraine lviv state oncologic regional treatment and diagnostic center, lviv, ukraine poltava reg. clinical oncology dispensary of prc, thoracic department, shei of ukr., poltava, ukraine ""rmi """"sumy reg. clin. oncology dispensary"""". oncothoracic dep.-nt. surny state univ.,, sumy, ukraine ""central city clinical hospital, city oncology center, shei """"uzhhorod national university"""", uzhhorod, ukraine vinnytsia regional clinical oncology dispensary, vinnytsia, ukraine']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/99/nct02364999/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/99/nct02364999/prot_001.pdf",https://ClinicalTrials.gov/show/NCT02364999,
430,431,NCT01271725,lux-breast 2; afatinib in her2 (human epidermal growth factor receptor)-treatment failures,,Completed,Has Results,breast neoplasms,drug: vinorelbine 25 mg/m2 weekly|drug: afatinib 40mg once daily (od)|drug: paclitaxel 80 mg/m2 weekly,percentage of participants with objective response (or) assessed by response evaluation criteria in solid tumours version (recist) 1.1|best overall response according to recist v1.1 (with confirmation)|best overall response according to recist v1.1 (regardless of confirmation)|progression free survival (pfs)|duration of objective response according to recist v1.1|percentage of patients with highest common terminology criteria for adverse events (ctcae) version 3.0 grade of 3 or higher|change from baseline to end of treatment in systolic blood pressure (sbp)|change from baseline to end of treatment in diastolic blood pressure (dbp)|number of patient with possibly clinically significant (pcs) laboratory values,boehringer ingelheim,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,74.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.98|2010-021945-29,"May 24, 2011","March 13, 2017","March 13, 2017","January 7, 2011","June 17, 2019","June 17, 2019","['queen mary hospital, hong kong, hong kong prince of wales hospital, shatin, hong kong sujan surgical cancer hospital, amravati, india tata memorial hospital, maharashtra, india curie manavata cancer centre, maharashtra, india central india cancer research institute, nagpur, india ruby hall clinic, pune, india regional cancer center, thiruvananthapuram, india university clinical center, gdansk, gdansk, poland st.auton.heal.inst.""rep.clin.onc.disp.of moh of rep. tatarstan"", kazan, russian federation clinical oncology dispensary no. 1, dept. chemotherapy, krasnodar, russian federation n.a. semashko central clinical hospital, moscow, moscow, russian federation sbih of stavropol territory ""pyatigorsk oncol. dispensary"", pyatigorsk, russian federation sbih ""samara regional clinical oncol. dispensary"", samara, samara, russian federation guz ""oncological dispesary #2"", sochi, russian federation stavropol regional clin. oncology dispensary dept. oncology, stavropol, russian federation yaroslavl regional clinical oncology hosp. dept.chemotherapy, yaroslavl, russian federation china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan national taiwan university hospital, taipei, taiwan mackay memorial hospital, taipei, taiwan koo foundation sun yet-sen cancer center, taipei, taiwan taipe veterans general hospital, taipei, taiwan north devon district hospital, barnstaple, united kingdom royal bournemouth and christchurch hospital, bournemouth, united kingdom royal devon and exeter hospital, exeter, united kingdom charing cross hospital, london, united kingdom']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/25/nct01271725/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/25/nct01271725/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01271725,breast
431,432,NCT01304524,a study of vgx-3100 dna vaccine with electroporation in patients with cervical intraepithelial neoplasia grade 2/3 or 3,HPV-003,Completed,No Results Available,cervical intraepithelial neoplasia,biological: vgx 3100|biological: placebo|device: cellectra™-5p,number of participants with histopathological regression of cervical lesions to cin 1 or less as a measure of efficacy.|number of participants with virologically-proven clearance of hpv 16 or 18 in combination with histopathological regression of cervical lesions to cin 1 or less as a secondary measure of efficacy,inovio pharmaceuticals,Female,18 Years to 55 Years   (Adult),Phase 2,167.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HPV-003,April 2011,May 2014,April 2015,"February 25, 2011",,"September 7, 2018","['phoenix, arizona, united states tucson, arizona, united states colton, california, united states la mesa, california, united states los angeles, california, united states lakewood, colorado, united states boynton beach, florida, united states fort lauderdale, florida, united states sarasota, florida, united states baltimore, maryland, united states saginaw, michigan, united states missoula, montana, united states bronx, new york, united states port jefferson, new york, united states raleigh, north carolina, united states winston-salem, north carolina, united states columbus, ohio, united states oklahoma city, oklahoma, united states eugene, oregon, united states philadelphia, pennsylvania, united states myrtle beach, south carolina, united states murray, utah, united states pleasant grove, utah, united states sandy, utah, united states richmond, virginia, united states renton, washington, united states spokane, washington, united states victoria, australia montreal, quebec, canada vancouver, canada tallinn, estonia tartu, estonia batumi, georgia tbilisi, georgia bangalore, karnataka, india jaipur, rajasthan, india kolkata, india new delhi, india pune, india seoul, korea, republic of san juan, puerto rico bloemfontein, south africa cape town, south africa']",,https://ClinicalTrials.gov/show/NCT01304524,cervic
432,433,NCT00497809,safety and efficacy study of gcsf therapy to treat patients at high risk for chemotherapy induced severe neutropenia,,Completed,No Results Available,breast cancer|neutropenia,drug: avi-014 versus filgrastim,"the primary efficacy endpoint is duration of grade 4 neutropenia (dsn), defined as anc <0.5 x 109/l during chemotherapy cycle 1.|• incidence of grade 4 neutropenia • duration of neutropenia (defined as the number of days with anc <0.5 x 109/l and <0.1 x 109/l)",avigenics,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,189.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVI-014-P02,August 2007,July 2008,July 2009,"July 9, 2007",,"May 3, 2011","['pacific cancer medical center, anaheim, california, united states california cancer center, greenbrae, california, united states ghassan al-jazayrly, md, inc., los angeles, california, united states desert hematology oncology medical group, rancho mirage, california, united states brian leberthon, md, a medical corporation, west covina, california, united states infosphere clinical research, west hills, california, united states physicians research alliance llc., debary, florida, united states southern illinois hematology/oncology, centralia, illinois, united states gabrail cancer center, canton, ohio, united states signal point clinical research center, llc, middletown, ohio, united states university of oklahoma health sciences ctr, oklaoma city, oklahoma, united states cancer care institute of carolina, aiken, south carolina, united states cancer specialists of south texas, corpus christi, texas, united states cancer outreach associates pc, abingdon, virginia, united states jawaharlal nehru cancer hospital and research centre, idgah hills, bhopal, india apollo specialty hospital, padma complex, 320 mount road, chennai, india amrita institute of medical sciences, amrita lane elamakkara, cochin, india dharamshila hospital and research centre, vasundhara enclave, delhi, india apollo hospitals educational and research foundation, jubilee hills, hyderabad, india kidwai memorial institute of oncology, dr. m.h. marigowda road, bangalore, karnataka, india mohan dai oswal cancer treatment & research foundation, g.t. road, sherpur bye pass, ludhiana, india dayanand medical college and hospital, tagore nagar, civil lines, ludhiana, india meenakshi mission hospital and research centre, lake area, melur road, madurai,, india kasturba medical college hospital, attavar, mangalore, india tata memorial hospital,, dr. e borges road, parel, mumbai, india indraprastha apollo hospital, delhi mathura road, sarita vihar, new delhi, india dharamshila cancer center, dharamshila marg, vasundhara enclave, new delhi, india regional cancer centre, igims, sheikhpura, patna, india ruby hall clinic, 40 sasoon road, pune, india king george hospital, vizag, vishakhapattanam, india irch, aiims, ansari nagar,, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00497809,breast
433,434,NCT01516736,phase iii study comparing the efficacy and safety of la-ep2006 and peg-filgrastim,PROTECT2,Completed,Has Results,chemotherapy-induced neutropenia|breast cancer,drug: la-ep2006|drug: neulasta®,mean duration of severe neutropenia (dsn) during cycle 1 of chemotherapy|incidence of febrile neutropenia (fn)|number of patients with at least one episode of fever by cycle and across all cycles|depth of anc nadir in cycle 1|number of patients with anc nadir per day in cycle 1|time to anc recovery in days in cycle 1|frequency of infections by cycle and across all cycles|mortality due to infection,sandoz|sandoz gmbh,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,308.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",LA-EP06-302,March 2012,August 2013,December 2013,"January 25, 2012","June 28, 2017","August 30, 2017","['sandoz investigational site, hot springs, arkansas, united states sandoz investigational site, jonesboro, arkansas, united states sandoz investigational site, corona, california, united states sandoz investigational site, wichita, kansas, united states sandoz investigational site, mount sterling, kentucky, united states sandoz investigational site, detroit, michigan, united states sandoz investigational site, bismarck, north dakota, united states sandoz investigational site, eugene, oregon, united states sandoz investigational site, germantown, tennessee, united states sandoz investigational site, newport news, virginia, united states sandoz investigational site, tucuman, argentina sandoz investigational site, temuco, chile sandoz investigational site, chennai, india sandoz investigational site, delhi, india sandoz investigational site, gujarat, india sandoz investigational site, hyderabad, india sandoz investigational site, karamsad, india sandoz investigational site, lucknow, india sandoz investigational site, maharashtra, india sandoz investigational site, mangalore, india sandoz investigational site, mumbai, india sandoz investigational site, pradesh, india sandoz investigational site, surat, india sandoz investigational site, vadodara, india sandoz investigational site, vellore, india sandoz investigational site, visakhapatnam, india sandoz investigational site, kelantan, malaysia sandoz investigational site, nilai, malaysia sandoz investigational site, penang, malaysia sandoz investigational site, penang, malaysia sandoz investigational site, san juan, puerto rico sandoz investigational site, san juan, puerto rico sandoz investigational site, arkhangelsk, russian federation sandoz investigational site, bashkortostan, russian federation sandoz investigational site, bryansk, russian federation sandoz investigational site, kazan, russian federation sandoz investigational site, krasnoyarsk, russian federation sandoz investigational site, moscow, russian federation sandoz investigational site, omsk, russian federation sandoz investigational site, orel, russian federation sandoz investigational site, orenburg, russian federation sandoz investigational site, rostov-na-donu, russian federation sandoz investigational site, st petersburg, russian federation sandoz investigational site, st. petersburg, russian federation sandoz investigational site, st. petersburg, russian federation sandoz investigational site, st. petersburg, russian federation sandoz investigational site, st. petersburg, russian federation sandoz investigational site, tomsk, russian federation sandoz investigational site, vladimir, russian federation sandoz investigational site, barcelona, spain sandoz investigational site, madrid, spain sandoz investigational site, santiago de compostela, spain sandoz investigational site, valencia, spain']",,https://ClinicalTrials.gov/show/NCT01516736,breast
434,435,NCT01496313,to compare the effects of two doses of vandetanib in patients with advanced medullary thyroid cancer,,"Active, not recruiting",Has Results,thyroid cancer,drug: 300mg vandetanib|drug: 150mg vandetanib,overall response rate (orr) for vandetanib 150 and 300mg with responses determined by the investigator|best objective response|duration of objective response (recist 1.1) by treatment arm|time to objective response (recist 1.1) by treatment arm|percentage change from baseline in target lesion size (recist 1.1) by treatment arm|plasma concentration of vandetanib in the bloodstream (cmax) for patients by treatment arm.,"genzyme, a sanofi company|sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 4,81.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D4200C00097|2011-004701-24|LPS14809,"August 28, 2012",April 2014,"December 31, 2022","December 21, 2011","November 27, 2015","November 1, 2021","['research site, houston, texas, united states research site, olomouc, czechia research site, praha 5, czechia research site, bangalore karnataka, india research site, vellore, india research site, beer sheva, israel research site, haifa, israel research site, jerusalem, israel research site, petach tikva, israel research site, catania, italy research site, milano, italy research site, palermo, italy research site, pisa, italy research site, roma, italy research site, siena, italy research site, torino, italy research site, groningen, netherlands research site, leiden, netherlands research site, gliwice, poland research site, warszawa, poland research site, zgierz, poland research site, saint petersburg, russian federation research site, cardiff, united kingdom research site, greater london, united kingdom research site, london, united kingdom research site, tyne & wear, united kingdom']",,https://ClinicalTrials.gov/show/NCT01496313,thyroid
435,436,NCT00268905,a dose-finding study of e7389 in combination with carboplatin in patients with solid tumors,,Completed,Has Results,cancer,drug: e7389 + carboplatin auc 5|drug: e7389 + carboplatin auc 6|drug: e7389+carboplatin auc 6,maximum tolerated dose (mtd) of eribulin mesylate of e7389 in combination with carboplatin in subjects with advanced solid tumors.|safety of eribulin mesylate in combination with carboplatin as measured by the number of subjects with treatment emergent adverse events.|percent of subjects with best overall response as measured by response evaluation criteria in solid tumors (recist) criteria.,eisai inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,64.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7389-A001-104,October 2006,November 2011,,"December 23, 2005","January 25, 2013","February 12, 2013","['new brunswick, new jersey, united states bronx, new york, united states lake success, new york, united states new york, new york, united states graz, austria salzburg, austria vienna, austria vijayawada, andhra pradesh, india new delhi, delhi, india pune, maharashtra, india melur, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT00268905,
436,437,NCT04606771,a study comparing savolitinib plus osimertinib vs savolitinib plus placebo in patients with egfrm+ and met amplified advanced nsclc,CoC,Recruiting,No Results Available,non-small cell lung cancer,drug: osimertinib + savolitinib|drug: savolitinib + placebo,"objective response rate (orr)|progression-free survival (pfs)|duration of response (dor)|tumour size assessment (tsa)|overall survival (os)|progression free survival|duration of response|tumour size assessment|total clearance in egfr mutations at 6-weeks after therapy initiation (percentage and absolute change from baseline in egfr mutation allele frequencies).|plasma concentrations of savolitinib, osimertinib and their metabolites, (m2 and m3 for savolitinib; az5104 for osimertinib)|time dependency of the pk of savolitinib, osimertinib and their metabolites, (m2 and m3 for savolitinib; az5104 for osimertinib)|aucss of savolitinib, osimertinib and their metabolites, (m2 and m3 for savolitinib; az5104 for osimertinib)|cssmax of savolitinib, osimertinib and their metabolites, (m2 and m3 for savolitinib; az5104 for osimertinib)|tssmax of savolitinib, osimertinib and their metabolites, (m2 and m3 for savolitinib; az5104 for osimertinib)|clss/f of savolitinib, osimertinib and their metabolites, (m2 and m3 for savolitinib; az5104 for osimertinib)|number and percentage of subjects with adverse events (aes) in different categories: all aes|number and percentage of subjects with adverse events (aes) in different categories: serious aes|number and percentage of subjects with adverse events (aes) in different categories: causally related aes|number and percentage of subjects with adverse events (aes) in different categories: discontinuations due to aes|number and percentage of subjects with adverse events (aes) in different categories: deaths|number of subjects with at least one treatment emergent change in laboratory parameters in albumin|number of subjects with at least one treatment emergent change in laboratory parameters in alkaline phosphatase|number of subjects with at least one treatment emergent change in laboratory parameters in alt|number of subjects with at least one treatment emergent change in laboratory parameters in amylase|number of subjects with at least one treatment emergent change in laboratory parameters in ast|number of subjects with at least one treatment emergent change in laboratory parameters in total bilirubin|number of subjects with at least one treatment emergent change in laboratory parameters in total calcium|number of subjects with at least one treatment emergent change in laboratory parameters in creatinine|number of subjects with at least one treatment emergent change in laboratory parameters in glucose|number of subjects with at least one treatment emergent change in laboratory parameters in magnesium|number of subjects with at least one treatment emergent change in laboratory parameters in sodium|number of subjects with at least one treatment emergent change in laboratory parameters in potassium|number of subjects with at least one treatment emergent change in laboratory parameters in total protein|number of subjects with at least one treatment emergent change in laboratory parameters in bun or urea|number of subjects with at least one treatment emergent change in laboratory parameters in lactate dehydrogenase|number of subjects with at least one treatment emergent change in laboratory parameters in haematocrit|number of subjects with at least one treatment emergent change in laboratory parameters in haemoglobin|number of subjects with at least one treatment emergent change in laboratory parameters in leucocyte cell count|number of subjects with at least one treatment emergent change in laboratory parameters in platelet count|number of subjects with at least one treatment emergent change in laboratory parameters in red blood cell count|number of subjects with at least one treatment emergent change in laboratory parameters in reticulocytes|number of subjects with at least one treatment emergent change in laboratory parameters in neutrophil count|number of subjects with at least one treatment emergent change in laboratory parameters in lymphocyte count|number of subjects with at least one treatment emergent change in laboratory parameters in eosinophil count",astrazeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 2,56.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D5084C00009|2020-000813-33,"September 28, 2020","February 27, 2023","February 29, 2024","October 28, 2020",,"April 27, 2022","['research site, duarte, california, united states research site, la jolla, california, united states research site, sacramento, california, united states research site, rochester, minnesota, united states research site, brooklyn, new york, united states research site, seattle, washington, united states research site, buenos aires, argentina research site, buenos aires, argentina research site, buenos aires, argentina research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, capital federal, argentina research site, ciudad autónoma de bs. as., argentina research site, la plata, argentina research site, belo horizonte, brazil research site, fortaleza, brazil research site, fortaleza, brazil research site, ibirapuera, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, são paulo, brazil research site, vitoria, brazil research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, bangalore, india research site, mumbai, india research site, rohini, india research site, daegu, korea, republic of research site, gyeongsangnam-do, korea, republic of research site, jeonnam, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, taichung city, taiwan research site, taipei 112, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, muang, thailand research site, ha noi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam']",,https://ClinicalTrials.gov/show/NCT04606771,
437,438,NCT04658862,a study of tar-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive bladder cancer (mibc) of the bladder,SunRISe-2,Recruiting,No Results Available,urinary bladder neoplasms,biological: cetrelimab|drug: tar-200|drug: cisplatin|drug: gemcitabine|radiation: conventional radiation therapy|radiation: hypo-fractioned radiation therapy,time from randomization to the first bladder intact event-free survival (bi-efs) event|metastasis-free survival (mfs)|overall survival (os)|overall response rate (orr)|number of participants with adverse events (aes) according to common terminology criteria for adverse events (ctcae)|number of participants with aes by severity according to patient-reported outcomes version of the common terminology criteria for adverse events (nci pro-ctcae)|number of participants with clinical laboratory abnormalities,"janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 3,550.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR108917|2020-002620-36|17000139BLC3001,"December 7, 2020","December 30, 2026","December 31, 2028","December 9, 2020",,"April 22, 2022","[""bladder cancer genitourinary oncology, phoenix, arizona, united states university of southern california, los angeles, california, united states university of california irvine medical center, orange, california, united states providence saint john's health center, santa monica, california, united states the urology center of colorado, denver, colorado, united states foothills urology - golden off, golden, colorado, united states uf health jacksonville, jacksonville, florida, united states winship cancer institute of emory university, atlanta, georgia, united states the university of chicago medicine, chicago, illinois, united states dupage medical group, lisle, illinois, united states johns hopkins medical institutions, baltimore, maryland, united states chesapeake urology associates, towson, maryland, united states university hospitals seidman cancer center, ann arbor, michigan, united states ellis fischel cancer center, columbia, missouri, united states adult pediatric urology & urogynecology, p.c, omaha, nebraska, united states new jersey urology llc, voorhees, new jersey, united states cardiology clinic at montefiore hutchinson complex, bronx, new york, united states roswell park comprehensive cancer center, buffalo, new york, united states winthrop university hospital, mineola, new york, united states nyu langone health, new york, new york, united states icahn school of medicine at mount sinai, new york, new york, united states columbia university medical center, herbert irving pavilion, new york, new york, united states associated medical professionals, syracuse, new york, united states duke university medical center, durham, north carolina, united states vidant urology - greenville, greenville, north carolina, united states wake forest university baptist medical center (wfubmc) - comprehensive cancer center, winston-salem, north carolina, united states ohio state university, columbus, ohio, united states oklahoma city vamc, oklahoma city, oklahoma, united states stephenson cancer center, oklahoma city, oklahoma, united states oregon urology institute, springfield, oregon, united states midlantic urology, bala-cynwyd, pennsylvania, united states thomas jefferson university, philadelphia, pennsylvania, united states allegheny, pittsburgh, pennsylvania, united states carolina urologic research center, myrtle beach, south carolina, united states urology associates, pc, nashville, tennessee, united states rio grande urology, el paso, texas, united states university of texas medical branch, league city, texas, united states virginia oncology associates, norfolk, virginia, united states spokane urology, spokane, washington, united states fundacion intecnus, bariloche, argentina hospital sirio libanes, buenos aires, argentina instituto medico especializado alexander fleming, buenos aires, argentina hospital italiano de buenos aires, ciudad autónoma de buenos aires, argentina cemaic - centro privado de especialidades medicas ambulatorias e investigacion clinica, córdoba, argentina centro urologico profesor bengio, córdoba, argentina sanatorio allende cerro, córdoba, argentina centro oncologico riojano integral (cori), la rioja, argentina centro de investigacion pergamino sa, pergamino, argentina instituto de oncologia de rosario, rosario, argentina cedic centro de investigaciones clinicas, viedma, argentina flinders medical centre, bedford park, australia royal north shore hospital, st leonards, australia krankenhaus der barmherzigen schwestern, linz, austria kh.d barmherzige bruder salzburg, salzburg, austria universitätsklinikum salzburg - landeskrankenhaus, salzburg, austria krankenhaus der barmherzigen brüder, vienna, austria medizinische universität wien, wien, austria wilhelminenspital der stadt wien, wien, austria hopital erasme, anderlecht, belgium zna middelheim, antwerpen, belgium az sint-lucas, assebroek, belgium algemeen ziekenhuis klina, brasschaat, belgium az sint-jan brugge-oostende av, brugge, belgium az groeninge, kortrijk, belgium fundacao pio xii - hospital de cancer de barretos, barretos, brazil fundação hospitalar são francisco de assis, belo horizonte, brazil hospital erasto gaertner, curitiba, brazil centro de pesquisas oncológicas - cepon, florianópolis, brazil centro regional integrado de oncologia - crio, fortaleza, brazil hospital de caridade de ijui, ijuí, brazil clinica de oncologia reichow, jardim blumenau, brazil hospital amaral carvalho, jaú, brazil liga norte riograndense contra o cancer, natal, brazil hospital das clinicas de porto alegre, porto alegre, brazil hospital são lucas - pucrs, porto alegre, brazil hospital sao rafael, salvador, brazil cepho - centro de estudos e pesquisa de hematologia e oncologia, santo andré, brazil icesp - instituto do câncer do estado de são paulo, sao paolo, brazil hospital sirio libanes, sao paulo, brazil fundação faculdade de medicina de são josé do rio preto, são josé do rio preto, brazil instituto de assistência médica ao servidor público estadual - hspe-fmo, são paulo, brazil centro oncológico do triângulo, uberlândia, brazil exdeo clinical research inc, abbotsford, british columbia, canada vancouver general hospital, vancouver, british columbia, canada the male/female health and research centre, barrie, ontario, canada william osler health system, brampton, ontario, canada university of toronto, toronto, ontario, canada mcgill university health centre, montreal, quebec, canada chu de québec -l'hôtel-dieu de québec, québec, quebec, canada centre hospitalier universitaire de sherbrooke, sherbrooke, quebec, canada chinese academy of medical sciences(cams) & peking union medical college(pumc), beijing, china peking university first hospital, beijing, china peking university third hospital, beijing, china beijing hospital, beijing, china the first hospital of jilin university, changchun, china hunan cancer hospital, changsha shi, china the third xiangya hospital of central sourth university, changsha, china general hospital of western theater command pla, chengdu shi, china west china hospital of sichuan university, chengdu, china chongqing university cancer hospital, chongqing, china first affiliated hospital of dalian medical university, dalian, china guangzhou first municipal people's hospital, guang zhou shi, china sun yat-sen university cancer center, guangzhou, china zhejiang provincial people's hospital, hangzhou, china the first affiliated hospital of nanchang university, nanchang, china nanjing drum tower hospital, nanjing, china qingdao municipal hospital, qingdao, china renji hospital, shanghai, china shengjing hospital of china medical university, shenyang, china liaoning cancer hospital & institute, shenyang, china the first affiliated hospital of wenzhou medical university, wenzhou shi, china wuhan union hospital, wuhan, china wuhan tongji hospital, tongji medical college, wuhan, china yantai yuhuangding hospital, yantai, china henan cancer hospital, zhengzhou, china kromerizska nemocnice a.s., kromeriz, czechia slezska nemocnice v opave, opava, czechia fakultni nemocnice plze, plzen-bory, czechia urocentrum praha, praha 2, czechia vseobecna fakultni nemocnice v praze, praha 2, czechia thomayerova nemocnice, praha 4, czechia fakultni nemocnice v motole, praha 5, czechia androgeos s.r.o., praha 6, czechia nemocnice na bulovce, praha 8, czechia fakultni nemocnice kralovske vinohrady, praha, czechia krajska nemocnice tomase bati, zlin, czechia hôpital côte de nacre, caen cedex 9, france clinique sainte marguerite, hyeres, france polyclinique de limoges - francois chenieux, limoges, france hôpital edouard herriot, lyon cedex 03, france institut paoli-calmettes, marseille, france institut regional du cancer de montpellier, montpellier, france chu nîmes, nimes, france hopital europeen georges-pompidou, paris, france hôpital bichat - claude bernard, paris, france chu de poitiers, poitiers, france centre hospitalier prive, saint-grégoire, france hopital foch, suresnes, france institut universitaire du cancer toulouse oncopole, toulouse cedex 9, france marien-krankenhaus gmbh bergisch gladbach, bergisch gladbach, germany urologicum duisburg, duisburg, germany universitätsklinikum düsseldorf, düesseldorf, germany waldkrankenhaus st. marien -urologische universitätsklinik, erlangen, germany agaplesion frankfurter diakonie kliniken gmbh, markus krankenhaus, frankfurt am main, germany universitatsklinikum frankfurt, frankfurt am main, germany klinikum herne - urologie, herne, germany matthias schulze - germany, markkleeberg, germany universitätsklinikum münster, münster, germany klinikum nürnberg nord - hautklinik, nürnberg, germany kliniken nordoberpfalz ag/klinikum weiden, weiden, germany alexandra general hospital of athens, athens, greece attikon university general hospital of attica, athens, greece metropolitan general a.e., holargos, greece university hospital of larissa, larissa, greece hygeia diagnostic & therapeutic center of athens, marousi, greece athens medical center, maroussi, greece metropolitan hospital, neo faliro, greece bioclinic - thessaloniki, thessaloniki, greece euromedica general clinic, thessaloniki, greece interbalkan medical center of thessaloniki, thessaloniki, greece 'papageorgiou' general hospital of thessaloniki, thessaloniki, greece anassa general clinic, volos, greece orszagos onkologiai intezet, budapest n/a, hungary magyar honvedseg egeszsegugyi kozpont, budapest, hungary bajcsy-zsilinszky kórház és rendelőintézet, budapest, hungary jahn ferenc del-pesti korhaz es rendelointezet, budapest, hungary debreceni egyetem klinikai kozpont, debrecen, hungary petz aladar megyei oktato korhaz, gyõr, hungary szabolcs-szatmar-bereg megyei korhazak es egyetemi oktatokorhaz, nyíregyháza, hungary pecsi tudomanyegyetem klinikai kozpont, pécs, hungary jasz-nagykun-szolnok megyei hetenyi geza korhaz-rendelointezet, szolnok, hungary sujan surgical cancer hospital &amp; amravati cancer foundation, amravati, india acharya tulsi regional cancer treatment research institute, bikaner, india post graduate institute of medical education & research (pgimer), chandigarh, india birla cancer centre, jaipur, india shatabdi super speciality hospital, nashik, india blk super specialty hospital, new delhi, india aakash healthcare super speciality hospital, new delhi, india rajiv gandhi cancer institute & research centre, new delhi, india indira gandhi institute of medical sciences, patna, india jehangir clinical development center pvt ltd, pune, india hillel yaffe medical center, hadera, israel rambam health care campus, haifa, israel hadassah university hospita - ein kerem, jerusalem, israel ziv medical center, safed, israel tel aviv sourasky medical center, tel aviv, israel azienda ospedaliero universitaria consorziale policlinico di bari, bari, italy azienda ospedaliero universitaria consorziale policlinico di bari, bari, italy fondazione del piemonte per i'oncologia ircc candiolo, candiolo, italy spdc villa scassi, genova, italy ospedale san martino, genova, italy ospedale s. maria della scaletta, imola, italy istituto europeo di oncologia, milano, italy ospedale san raffaele, milan, italy istituto oncologico veneto - irccs, padova, italy istituto oncologico veneto - irccs, padova, italy azienda sanitaria locale salerno - po andrea tortora di pagani, pagani, italy azienda ospedaliero universitaria pisana, pisa, italy asl napoli 2 nord-sm delle grazie hospital, pozzuoli, italy policlinico universitario agostino gemelli, roma, italy azienda ospedaliera sant andrea, roma, italy istituto nazionale tumori regina elena, rome, italy azienda ospedaliera universitaria città della salute e della scienza di torino, torino, italy ospedale di circolo e fondazione macchi, varese, italy ospedale san bortolo, vicenza, italy aso co.,ltd iizuka hospital, iizuka, japan st.marianna university hospital, kanagawa, japan nara medical university hospital, kashihara, japan saitama medical university hospital, kawagoe-shi, japan kimitsu chuo hospital, kisarazu, japan national hospital organization kumamoto medical center, kumamoto, japan nagasaki university hospital, nagasaki, japan johas osaka rosai hospital, osaka, japan sagamihara kyodo hospital, sagamihara-shi, japan tokuyama central hospital, shunan, japan toranomon hospital, tokyo, japan fujita health university hospital, toyoake, japan yamaguchi university hospital, ube, japan yokohama city university medical center, yokohama, japan inje university haeundae paik hospital, busan, korea, republic of kyungpook national university chilgok hospital, daegu, korea, republic of keimyung university dongsan hospital, daegu, korea, republic of national cancer center, goyang-si, korea, republic of gachon university gil medical center, namdong, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, seoul, korea, republic of gangnam severance hospital, seoul, korea, republic of the catholic university of korea, seoul st. mary's hospital, seoul, korea, republic of pusan national university yangsan hospital, yangsan-si, korea, republic of cryptex investigacion clinica s.a de c.v, ciudad de méxico, mexico oncologia integral satelite, ciudad de méxico, mexico consultorio privado dr jose arturo rodriguez rivera, guadalajara, mexico centro de estudio y prevencion del cancer, juchitan de zaragoza, mexico dr. marco antonio badillo santoyo, leon, mexico i can oncology center, monterrey, mexico centro de investigacion clinica chapultepec, morelia, mexico oncológico potosino, san luis potosi, mexico investigación biomedica para el desarrollo de farmacos, s.a. de c.v., zapopan, mexico the julius center - utrecht science park - stratenum, utrecht, netherlands szpital uniwersytecki nr 2 im. dr. jana biziela w bydgoszczy, bydgoszcz, poland uniwersytet medyczny w lublinie - katedra i klinika urologii i onkologii urologicznej, lublin, poland wojewódzki szpital specjalistyczny im. stefana kardynała wyszyńskiego, lublin, poland samodzielny publiczny szpital wojewodzki im. papieza jana pawla ii, siedlce, poland centrum medyczne pratia poznan, skorzewo, poland wojewodzki szpital specjalistyczny im. janusza korczaka,, słupsk, poland centralny szpital kliniczny mswia w warszawie, warszawa, poland nzoz szpital mazovia, warszawa, poland uniwersytecki szpital kliniczny, wroclaw, poland hospital garcia de orta, almada, portugal centro hospitalar e universitario de coimbra, coimbra, portugal centro hospitalar de lisboa central, lisboa, portugal h. santa maria - centro hospitalar de lisboa norte, lisboa, portugal fundação champalimaud, lisbon, portugal hospital de sao joao, porto, portugal centro hospitalar de trás os montes e alto-douro, vila real, portugal altlay regional oncology dispensary, barnaul, russian federation chelyabinsk regional clinical center of oncology and nuclear medicine, chelyabinsk, russian federation ivanovo regional oncology dispensary, ivanovo, russian federation krasnoyarsk regional oncology dispensary, krasnoyarsk, russian federation n. n. blokhin russian academy of medical sciences, moscow, russian federation hertzen oncology research institute, moscow, russian federation moscow city oncology hospital № 62, moscow, russian federation a. tsyb medical radiological research center, obninsk, russian federation bhi of omsk region clinical oncology dispensary, omsk, russian federation hospital for war veterans, rostov, russian federation ryazan state medical university named after i.p.pavlov, ryazan, russian federation city multiple-discipline hospital # 2, saint petersburg, russian federation fsbhi rscrst n.a. ac. granov a.m. of moh, saint petersburg, russian federation n.n. petrov research institute of oncology, saint petersburg, russian federation n.n. petrov research institute of oncology, saint petersburg, russian federation leningrad regional oncology dispensary, saint-petersburg, russian federation severo-zapadnyy gosudarstvennyy meditsinskiy universitet im. i. i. mechnikova, sankt-peterburg, russian federation ogarev mordovian state university, saransk, russian federation state medical institution oncological center #2 of healthcare department at krasnodar regio, sochi, russian federation multifunctional clinical medical center 'medical city', tyumen, russian federation bashkir state medical university, ufa, russian federation charlotte maxeke johannesburg academic hospital, johannesburg, south africa life wilgers hospital, pretoria, south africa hosp. univ. a coruña, a coruña, spain hosp. univ. germans trias i pujol, badalona, spain fundacion puigvert, barcelona, spain hosp. univ. vall d hebron, barcelona, spain hosp. puerta del mar, cadiz, spain hosp. univ. virgen de las nieves, granada, spain hosp. de jerez de la frontera, jerez de la frontera, spain clinica univ. de navarra, madrid, spain hosp. univ. 12 de octubre, madrid, spain hosp. univ. de la paz, madrid, spain hosp. univ. hm monteprincipe, madrid, spain hosp. virgen de la victoria, málaga, spain hosp. univ. son espases, palma de mallorca, spain corporacio sanitari parc tauli, sabadell, spain hosp. univ. infanta sofia, san sebastián de los reyes, spain hosp. univ. marques de valdecilla, santander, spain instituto valenciano de oncologia, valencia, spain hosp. clinico univ. de valencia, valencia, spain kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan national taiwan university hospital, taipei city, taiwan tri-service general hospital, taipei, taiwan chang gung memorial hospital linkou branch, taoyuan, taiwan adana baskent yuregir hospital, adana, turkey yildirim beyazit university medical faculty ankara atatürk research and training hospital, ankara, turkey ankara universitesi tip fakultesi cebeci hastanesi, ankara, turkey dokuz eylul universitesi tip fakultesi, balcova, turkey bezmialem university medical faculty, fatih, turkey medical park gaziantep hastanesi, gaziantep, turkey istanbul university cerrahpasa medical faculty, istanbul, turkey istanbul medeniyet university goztepe training and research hospital, istanbul, turkey office of ahmet cag cal, md, izmir, turkey izmir medical park hospital, izmir, turkey inonu university medical faculty, malatya, turkey erciyes univ mkd hospital, melikgazi, turkey t.c. saglik bakanligi ankara numune egitim ve arastirma hastanesi, seyhan, turkey chernihivskyi oblasnyi onkolohichnyi dyspanser, chernihiv, ukraine chernivtsi regional clinical hospital, chernivtsi, ukraine se dnipropetrovsk medical academy, dnipro, ukraine mih v.i. shapoval regional clinical centre of urology and nephrology, kharkiv, ukraine kharkiv regional clinical hospital, kharkiv, ukraine khersonsky regional oncology center, kherson, ukraine main military clinical hospital of mdu, kiev, ukraine asklepion llc, kiev, ukraine krivorizhskiy oncology dispensary, kriviy rih, ukraine oleksandrivska clinical hospital of kyiv city, infectional department #2, kyiv, ukraine kyiv city clinical hospital #3, kyiv, ukraine state institution academy of medical sciences of ukraine, kyiv, ukraine p.l. shupyk national medical academy of post-graduate education, kyiv, ukraine lviv regional clinical hospital, lviv, ukraine odeska miska klinichna likarnya no10, odessa, ukraine sumy regional clinical oncology centre, sumy, ukraine""]",,https://ClinicalTrials.gov/show/NCT04658862,bladder
438,439,NCT00440310,phase 3 trial of litx™ plus chemotherapy vs. chemotherapy only treating colorectal cancer patients with recurrent liver metastases,,Completed,Has Results,"liver metastases|colorectal neoplasms|neoplasm metastasis|neoplasm recurrence, local",drug: talaporfin sodium|procedure: percutaneous placement of device in liver metastases|device: interstitial light emitting diodes|drug: folfox4 regimen|drug: folfiri regimen,overall survival,light sciences oncology,All,"18 Years and older   (Adult, Older Adult)",Phase 3,483.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LSO-OL006,February 2007,May 2011,October 2011,"February 27, 2007","August 25, 2015","August 25, 2015","['landeskrankenhaus feldkirch, feldkirch, austria krankenhaus hietzing mit neurologischen zentrum rosenhugel, wien, austria clinical hospital mostar, internal clinic, department of gastroenterology, mostar, bosnia and herzegovina clinical centre of the university of sarajevo, institute of oncology, sarajevo, bosnia and herzegovina general hospital karlovac, karlovac, croatia clinical centre zagreb, clinical oncology, zagreb, croatia general hospital ""sveti duh"", zagreb, croatia university hospital dubrava, zagreb, croatia ostalb-klinikum aalen darmzentrum medizinische klinik i, aalen, germany helios kliniken - innere medizin und kardiologie, borna, germany katholisches krankenhaus st. johann nepomuk, erfurt, germany johann wolfgang goethe universitat, frankfurt, germany kliniken ludwigsburg bietigheim, ludwigsburg, germany bangalore institute of oncology, bangalore, karnataka, india mahavir cancer sansthan, phulwarisharif, patna, india ciigma institute of medical sciences, aurangabad, india jawaharlal nehru cancer hospital and research centre, bhopal, india searoc cancer center, s. k. soni hospital, jaipur, india shatabdi super specialty hospital, mumbai, india cancer clinic, shreevardhan complex, nagpur, india ruby hall clinic, pune, india azienda ospedaliero-universitaria riunti, ancona, italy azienda ospedaliera careggi u.o. oncologia medica, firenze, italy azienda ospedaliera universitaria padovana, padova, italy policlinico tor vergata - oncologia medica, rome, italy riga eastern hospital, latvian oncology center, riga, latvia centrum onkologii - instytut im. marii skłodowskiej -curie oddział w krakowie, kraków, poland szpital uniwersytecki cmuj, klinika chirurgii ogólnej i gastroenterologicznej, kraków, poland klinika chirurgii onkologicznej, lublin, poland zakład opieki zdrowotnej mswia z warmińsko-mazurskim centrum onkologii, olsztyn, poland klinika chirurgii ogólnej i onkologicznej, szczecin, poland centrum onkologii - instytut im. marii skłodowskiej -curie, klinika nowotworów jelita grubego, warszawa, poland szpital wojewódzki im. m. kopernika, klinika chemioterapii onkologicznej, łódź, poland fundeni clinical institute, bucharest, romania oncology institute ""ion chircuta"", cluj-napoca, romania st. spiridon university emergency hospital, iasi, romania state institution ""altay"" territorial oncological dispensary, barmaul, russian federation state healthcare institution ""sverdlovsk\' regional oncological dispensary"", ekaterinburg, russian federation main military clinical hospital named after burdenko attached to ministry of defense of russian federation, moscow, russian federation municipal cliical hospital # 33 named after ostroumov, moscow, russian federation russian oncological scientific center named after blokhin, moscow, russian federation privolzhsky district medical center, nizhny novgorod, russian federation central research institute of roentgenology and radiology, st. petersburg, russian federation scientific research institution of oncology, st. petersburg, russian federation state educational institution of high professional education ""military-medical academy named after s.m. kirov attached to ministry of defense of russia"", st. petersburg, russian federation tambov regional oncological dispensary, tambov, russian federation state healthcare institution of yaroslavl region, ""regional clinical oncological hospital"", yaroslavl, russian federation institute of oncology and radiology of serbia, belgrade, serbia military medical academy, belgrade, serbia institute of oncology, sremska kamenica, serbia karolinska university hospital, stockholm, sweden municipal institution ""cherkassy"" regional oncological dispensary of cherkassy, cherkassy, ukraine municipal multiple-discipline clinical hospital #4, dnepropetrovsk, ukraine donetsk cancer centre, donetsk, ukraine kharkov regional clinical oncology dispansery, kharkov, ukraine the central hospital of the ministry of defense, kyiv, ukraine zaporozhye medical academy for postgraduate education, zaporozhye, ukraine']",,https://ClinicalTrials.gov/show/NCT00440310,liver colon
439,440,NCT00094029,a treatment protocol for patients with gastrointestinal stromal tumor (gist) who may derive benefit from treatment with su011248,,Approved for marketing,No Results Available,gastrointestinal neoplasm,drug: sutent,,pfizer,All,"18 Years and older   (Adult, Older Adult)",,,Industry,Expanded Access,,A6181036,September 2004,October 2011,October 2011,"October 11, 2004",,"March 9, 2012","[""pfizer investigational site, duarte, california, united states pfizer investigational site, pasadena, california, united states pfizer investigational site, san francisco, california, united states pfizer investigational site, santa monica, california, united states pfizer investigational site, washington, district of columbia, united states pfizer investigational site, gainesville, florida, united states pfizer investigational site, gainsville, florida, united states pfizer investigational site, miami, florida, united states pfizer investigational site, tampa, florida, united states pfizer investigational site, niles, illinois, united states pfizer investigational site, park ridge, illinois, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, new bedford, massachusetts, united states pfizer investigational site, detroit, michigan, united states pfizer investigational site, detroit, michigan, united states pfizer investigational site, farmington hills, michigan, united states pfizer investigational site, minneapolis, minnesota, united states pfizer investigational site, rochester, minnesota, united states pfizer investigational site, creve coeur, missouri, united states pfizer investigational site, st. louis, missouri, united states pfizer investigational site, st. louis, missouri, united states pfizer investigational site, bronx, new york, united states pfizer investigational site, buffalo, new york, united states pfizer investigational site, new york, new york, united states pfizer investigational site, new york, new york, united states pfizer investigational site, durham, north carolina, united states pfizer investigational site, portland, oregon, united states pfizer investigational site, portland, oregon, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, madison, wisconsin, united states pfizer investigational site, burnos aires, argentina pfizer investigational site, camperdown, new south wales, australia pfizer investigational site, randwick, new south wales, australia pfizer investigational site, auchenflower, queensland, australia pfizer investigational site, bedford park, south australia, australia pfizer investigational site, east melbourne, victoria, australia pfizer investigational site, nedlands, western australia, australia pfizer investigational site, ashford sa, australia pfizer investigational site, auchenflower qld, australia pfizer investigational site, graz, austria pfizer investigational site, wien, austria pfizer investigational site, brussels, belgium pfizer investigational site, leuven, belgium pfizer investigational site, calgary, alberta, canada pfizer investigational site, vancouver, british columbia, canada pfizer investigational site, winnipeg, manitoba, canada pfizer investigational site, st. john's, newfoundland and labrador, canada pfizer investigational site, toronto, ontario, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, santiago, rm, chile pfizer investigational site, bogota, cundinamarca, colombia pfizer investigational site, brno, czech republic pfizer investigational site, praha 5, czech republic pfizer investigational site, aarhus c, denmark pfizer investigational site, herlev, denmark pfizer investigational site, helsinki, finland pfizer investigational site, bordeaux cedex, france pfizer investigational site, lyon, france pfizer investigational site, marseille, france pfizer investigational site, berlin, germany pfizer investigational site, duesseldorf, germany pfizer investigational site, koeln, germany pfizer investigational site, muenchen, germany pfizer investigational site, thessaloniki, greece pfizer investigational site, happy valley, hong kong pfizer investigational site, hong kong, hong kong pfizer investigational site, budapest, hungary pfizer investigational site, new delhi, delhi, india pfizer investigational site, mumbai, maharashtra, india pfizer investigational site, vellore, tamil nadu, india pfizer investigational site, tel hashomer, israel pfizer investigational site, tel-aviv, israel pfizer investigational site, aviano (pn), italy pfizer investigational site, aviano, pn, italy pfizer investigational site, bologna, italy pfizer investigational site, candiolo (to), italy pfizer investigational site, genova, italy pfizer investigational site, milano, italy pfizer investigational site, milano, italy pfizer investigational site, milano, italy pfizer investigational site, torino, italy pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, mexico, df, mexico pfizer investigational site, guadalajara, jalisco, mexico pfizer investigational site, groningen, gr, netherlands pfizer investigational site, leiden, netherlands pfizer investigational site, oslo, norway pfizer investigational site, warszawa, poland pfizer investigational site, singapore, singapore pfizer investigational site, singapore, singapore pfizer investigational site, bratislava, slovakia pfizer investigational site, oviedo, asturias, spain pfizer investigational site, l'hospitalet de llobregat, barcelona, spain pfizer investigational site, barcelona, spain pfizer investigational site, madrid, spain pfizer investigational site, sevilla, spain pfizer investigational site, valencia, spain pfizer investigational site, göteborg, sweden pfizer investigational site, lausanne, switzerland pfizer investigational site, kaohsiung hsien, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, ratchatawi, bangkok, thailand pfizer investigational site, bangkok, thailand pfizer investigational site, ankara, turkey pfizer investigational site, inciralti / izmir, turkey pfizer investigational site, istanbul, turkey pfizer investigational site, leeds, england, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, manchester, united kingdom pfizer investigational site, newcastle upon tyne, united kingdom pfizer investigational site, newcastle-upon-tyne, united kingdom pfizer investigational site, caracas, distrito capital, venezuela""]",,https://ClinicalTrials.gov/show/NCT00094029,gastric
440,441,NCT00917384,study of imc-1121b (ramucirumab) with best supportive care in participants with gastric cancer and adenocarcinoma,,Completed,Has Results,gastric cancer|adenocarcinoma,biological: ramucirumab|drug: placebo|other: best supportive care (bsc),overall survival (os)|progression-free survival (pfs)|percentage of participants who are progression-free at week 12 (pfs rate)|percentage of participants with objective response (objective response rate [orr])|duration of response (dor)|change from baseline in quality of life (qol) as measured by the european organisation for research and treatment of cancer questionnaire (eortc-qlq-c30)|number of participants with adverse events|maximum concentration (cmax) of imc-1121b|number of participants who developed antibodies against imc-1121b,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,355.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13893|2008-005964-15|CP12-0715|I4T-IE-JVBD,August 2009,July 2012,December 2015,"June 10, 2009","October 16, 2014","September 25, 2019","['imclone investigational site, bakersfield, california, united states imclone investigational site, la jolla, california, united states imclone investigational site, redlands, california, united states imclone investigational site, chicago, illinois, united states imclone investigational site, new orleans, louisiana, united states imclone investigational site, boston, massachusetts, united states imclone investigational site, omaha, nebraska, united states imclone investigational site, new york, new york, united states imclone investigational site, west reading, pennsylvania, united states imclone investigational site, providence, rhode island, united states imclone investigational site, charleston, south carolina, united states imclone investigational site, knoxville, tennessee, united states imclone investigational site, memphis, tennessee, united states imclone investigational site, houston, texas, united states imclone investigational site, buenos aires, argentina imclone investigational site, capital federal, argentina imclone investigational site, ciudad autonoma de buenos aires, argentina imclone investigational site, ciudada autonoma, argentina imclone investigational site, cordoba, argentina imclone investigational site, rosario, argentina imclone investigational site, wodonga, new south wales, australia imclone investigational site, hobart, tasmania, australia imclone investigational site, east melbourne, victoria, australia imclone investigational site, perth, western australia, australia imclone investigational site, bedford park, australia imclone investigational site, st. leonards, australia imclone investigational site, woodville, australia imclone investigational site, sarajevo, bosnia and herzegovina imclone investigational site, barretos, brazil imclone investigational site, belo horizonte, brazil imclone investigational site, belo horizonte, brazil imclone investigational site, brasilia, brazil imclone investigational site, curitiba, brazil imclone investigational site, curitiba, brazil imclone investigational site, florianopolis, brazil imclone investigational site, ijui, brazil imclone investigational site, lajeados, brazil imclone investigational site, londrina, brazil imclone investigational site, passo fundo, brazil imclone investigational site, porto alegre, brazil imclone investigational site, porto alegre, brazil imclone investigational site, porto alegre, brazil imclone investigational site, sao paulo, brazil imclone investigational site, edmonton, alberta, canada imclone investigational site, montreal, quebec, canada imclone investigational site, sherbrooke, quebec, canada imclone investigational site, concepcion, chile imclone investigational site, la serena, chile imclone investigational site, santiago, chile imclone investigational site, monteria, colombia imclone investigational site, osijek, croatia imclone investigational site, pula, croatia imclone investigational site, slavonski brod, croatia imclone investigational site, zagreb, croatia imclone investigational site, brno, czechia imclone investigational site, hradec kralove, czechia imclone investigational site, liberec, czechia imclone investigational site, nova ves pod plesi, czechia imclone investigational site, olomouc, czechia imclone investigational site, pardubice, czechia imclone investigational site, prague, czechia imclone investigational site, praha 10, czechia imclone investigational site, praha 2, czechia imclone investigational site, pribram, czechia imclone investigational site, alexandria, egypt imclone investigational site, cairo, egypt imclone investigational site, guatemala, guatemala imclone investigational site, guatemala, guatemala imclone investigational site, hyderabad, andh prad, india imclone investigational site, hyderabad, andh prad, india imclone investigational site, new delhi, delhi, india imclone investigational site, bangalore, karna, india imclone investigational site, bangalore, karna, india imclone investigational site, cochin, kerala, india imclone investigational site, thiruvananthapuram, kerala, india imclone investigational site, trivandrum, kerala, india imclone investigational site, chennai, kilpauk, india imclone investigational site, bhopal, madh prad, india imclone investigational site, indore, madh prad, india imclone investigational site, mumbai, mahara, india imclone investigational site, nashik, mahara, india imclone investigational site, pune, mahara, india imclone investigational site, chennai, tamilnadu, india imclone investigational site, chennai, tamilnadu, india imclone investigational site, kolkata, w bengal, india imclone investigational site, kolkata, w bengal, india imclone investigational site, bangalore, india imclone investigational site, chennai, india imclone investigational site, hyderabad, india imclone investigational site, hyderabad, india imclone investigational site, kolkata, india imclone investigational site, mumbai, india imclone investigational site, mumbai, india imclone investigational site, pune, india imclone investigational site, west bengal, india imclone investigational site, jakarta, indonesia imclone investigational site, jakarta, indonesia imclone investigational site, jakarta, indonesia imclone investigational site, sumatera utara, indonesia imclone investigational site, west java, indonesia imclone investigational site, aviano, italy imclone investigational site, bologna, italy imclone investigational site, brescia, italy imclone investigational site, cremona, italy imclone investigational site, lido di camaiore, italy imclone investigational site, lucca, italy imclone investigational site, meldola, italy imclone investigational site, mirano, italy imclone investigational site, noale, italy imclone investigational site, potenza, italy imclone investigational site, rimini, italy imclone investigational site, udine, italy imclone investigational site, seoul, korea, republic of imclone investigational site, seoul, korea, republic of imclone investigational site, seoul, korea, republic of imclone investigational site, seoul, korea, republic of imclone investigational site, beirut, lebanon imclone investigational site, floriana, malta imclone investigational site, floriana, malta imclone investigational site, aguascelientes, mexico imclone investigational site, christchurch, new zealand imclone investigational site, cebu city, philippines imclone investigational site, pasig city, philippines imclone investigational site, gdansk, poland imclone investigational site, krakow, poland imclone investigational site, olsztyn, poland imclone investigational site, baia mare, romania imclone investigational site, cluj napoca, romania imclone investigational site, cluj napoca, romania imclone investigational site, suceava, romania imclone investigational site, chelyabinsk, russian federation imclone investigational site, kursk, russian federation imclone investigational site, moscow, russian federation imclone investigational site, moscow, russian federation imclone investigational site, pyatigorsk, russian federation imclone investigational site, st. petersburg, russian federation imclone investigational site, st. petersburg, russian federation imclone investigational site, st. petersburg, russian federation imclone investigational site, cape town, south africa imclone investigational site, alcorcon, spain imclone investigational site, barcelona, spain imclone investigational site, barcelona, spain imclone investigational site, elche, spain imclone investigational site, madrid, spain imclone investigational site, santander, spain imclone investigational site, sevilla, spain imclone investigational site, kaohsiung, taiwan imclone investigational site, taichung county, taiwan imclone investigational site, taipei, taiwan imclone investigational site, taipei, taiwan imclone investigational site, bangkok, thailand imclone investigational site, chiang mai, thailand imclone investigational site, rajathevee district, thailand imclone investigational site, adana, turkey imclone investigational site, gaziantep, turkey imclone investigational site, istanbul, turkey imclone investigational site, izmir, turkey imclone investigational site, bebington, wirral, united kingdom imclone investigational site, london, united kingdom imclone investigational site, sutton, united kingdom imclone investigational site, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00917384,gastric kidney
441,442,NCT00925600,evaluation of new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss,,Completed,Has Results,cancer|cataract|low bone mineral density|osteopenia|osteoporosis|prostate cancer,biological: denosumab|biological: placebo,percentage of participants with lens opacification event development or progression by month 12,amgen,Male,"30 Years to 120 Years   (Adult, Older Adult)",Phase 3,769.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",20080560|2009-012076-26,"November 30, 2009","May 12, 2016","May 12, 2016","June 22, 2009","May 30, 2017","May 30, 2017","[""research site, anaheim, california, united states research site, laguna hills, california, united states research site, murrieta, california, united states research site, san diego, california, united states research site, san diego, california, united states research site, san diego, california, united states research site, san luis obispo, california, united states research site, denver, colorado, united states research site, denver, colorado, united states research site, englewood, colorado, united states research site, middlebury, connecticut, united states research site, new britain, connecticut, united states research site, trinity, florida, united states research site, coeur d'alene, idaho, united states research site, greenwood, indiana, united states research site, west des moines, iowa, united states research site, kansas city, kansas, united states research site, shreveport, louisiana, united states research site, annapolis, maryland, united states research site, baltimore, maryland, united states research site, greenbelt, maryland, united states research site, grand rapids, michigan, united states research site, sartell, minnesota, united states research site, saint louis, missouri, united states research site, missoula, montana, united states research site, omaha, nebraska, united states research site, omaha, nebraska, united states research site, berlin, new jersey, united states research site, bricktown, new jersey, united states research site, englewood, new jersey, united states research site, lawrenceville, new jersey, united states research site, mount laurel, new jersey, united states research site, albany, new york, united states research site, garden city, new york, united states research site, kingston, new york, united states research site, new york, new york, united states research site, poughkeepsie, new york, united states research site, syracuse, new york, united states research site, gastonia, north carolina, united states research site, greenville, north carolina, united states research site, cincinnati, ohio, united states research site, bala-cynwyd, pennsylvania, united states research site, lancaster, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, myrtle beach, south carolina, united states research site, knoxville, tennessee, united states research site, austin, texas, united states research site, dallas, texas, united states research site, san antonio, texas, united states research site, temple, texas, united states research site, richmond, virginia, united states research site, salem, virginia, united states research site, wahroonga, new south wales, australia research site, herston, queensland, australia research site, bentleigh east, victoria, australia research site, ringwood east, victoria, australia research site, pleven, bulgaria research site, plovdiv, bulgaria research site, sofia, bulgaria research site, kelowna, british columbia, canada research site, vancouver, british columbia, canada research site, victoria, british columbia, canada research site, victoria, british columbia, canada research site, halifax, nova scotia, canada research site, barrie, ontario, canada research site, brampton, ontario, canada research site, brantford, ontario, canada research site, burlington, ontario, canada research site, guelph, ontario, canada research site, kitchener, ontario, canada research site, london, ontario, canada research site, newmarket, ontario, canada research site, north bay, ontario, canada research site, north york, ontario, canada research site, oakville, ontario, canada research site, scarborough, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, laval, quebec, canada research site, montreal, quebec, canada research site, benesov, czechia research site, brno, czechia research site, hradec kralove, czechia research site, jindrichuv hradec, czechia research site, kromeriz, czechia research site, novy jicin, czechia research site, olomouc, czechia research site, plzen, czechia research site, praha 2, czechia research site, praha 4, czechia research site, praha 6, czechia research site, usti nad labem, czechia research site, zlin, czechia research site, lyon cédex 3, france research site, paris cedex 5, france research site, alexandroupoli, greece research site, athens, greece research site, athens, greece research site, athens, greece research site, heraklion, greece research site, larissa, greece research site, patra, greece research site, thessaloniki, greece research site, thessaloniki, greece research site, baja, hungary research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, gyor, hungary research site, miskolc, hungary research site, nyiregyhaza, hungary research site, szeged, hungary research site, ahmedabad, gujarat, india research site, bangalore, karnataka, india research site, aurangabad, maharashtra, india research site, nashik, maharashtra, india research site, ludhiana, punjab, india research site, madurai, tamil nadu, india research site, kolkata, west bengal, india research site, jelgava, latvia research site, riga, latvia research site, riga, latvia research site, distrito federal, mexico research site, distrito federal, mexico research site, christchurch, new zealand research site, takapuna, north shore city, new zealand research site, tauranga, new zealand research site, whangarei, new zealand research site, gdansk, poland research site, gdansk, poland research site, gdynia, poland research site, gdynia, poland research site, katowice, poland research site, myslowice, poland research site, opole, poland research site, poznan, poland research site, rzeszow, poland research site, siedlce, poland research site, slupsk, poland research site, szczecin, poland research site, warszawa, poland research site, warszawa, poland research site, warszawa, poland research site, wroclaw, poland research site, ivanovo, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhny novgorod, russian federation research site, rostov-na-donu, russian federation research site, bratislava, slovakia research site, kosice, slovakia research site, kosice, slovakia research site, kosice, slovakia research site, martin, slovakia research site, nitra, slovakia research site, trencin, slovakia research site, celje, slovenia research site, ljubljana, slovenia research site, slovenj gradec, slovenia research site, paarl, western cape, south africa research site, george, south africa research site, kempton park, south africa research site, port elizabeth, south africa research site, tygerberg, south africa research site, chernivtsi, ukraine research site, dnipropetrovsk, ukraine research site, kharkiv, ukraine research site, kyiv, ukraine research site, uzhgorod, ukraine research site, zaporizhzhya, ukraine""]",,https://ClinicalTrials.gov/show/NCT00925600,
442,443,NCT01154140,a clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with alk positive non squamous cancer of the lung,PROFILE 1014,Completed,Has Results,non squamous lung cancer,drug: treatment,"progression-free survival (pfs) based on irr|overall survival (os)|overall survival probability at month 12 and 18|objective response rate (orr): percentage of participants with objective response as assessed by irr|duration of response (dr) based on irr|time to tumor response (ttr) based on irr|percentage of participants with disease control at week 12 based on irr|time to progression (ttp) based on irr|time to intracranial progression (ic-ttp) based on irr|time to extracranial progression (ec-ttp) based on irr|percentage of participants with treatment emergent adverse events (aes) and serious adverse events (saes)|percentage of participants with treatment emergent treatment-related adverse events (aes) and serious adverse events (saes)|percentage of participants with adverse events (aes) according to maximum severity|plasma predose concentration (ctrough) of crizotinib and its metabolite pf-06260182|percentage of participants for each anaplastic lymphoma kinase (alk) gene fusion variants|objective response rate (orr) of anaplastic lymphoma kinase (alk) variant groups based on irr|time to deterioration (ttd) in chest pain, dyspnea or cough|change from baseline in functioning and global quality of life (qol) as assessed by the european organization for the research and treatment of cancer quality of life questionnaire core 30 (eortc-qlq-c30)|change from baseline scores in qlq-c30 symptoms as assessed by the european organization for the research and treatment of cancer quality of life questionnaire core 30 (eortc-qlq-c30)|change from baseline in lung cancer symptom scores as assessed by the european organization for the research and treatment of cancer quality of life questionnaire-lung cancer 13 (qlq- lc13)|change from baseline in general health status as assessed by euroqol 5d (eq-5d)- visual analog scale (vas)|percentage of participants with hospital admissions-healthcare resource utilization (hcru)|percentage of participants with laboratory test abnormalities by maximum severity: national cancer institute common terminology criteria for adverse event (version 4.0) grade 1 to 4 hematological test abnormalities|percentage of participants with laboratory test abnormalities by maximum severity: national cancer institute common terminology criteria for adverse event (version 4.0) grade 1 to 4 chemistry test abnormalities",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,343.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A8081014|2010-021336-33|XALCORI,"January 13, 2011","November 30, 2013","November 30, 2016","June 30, 2010","January 5, 2015","November 6, 2017","['tower cancer research foundation, beverly hills, california, united states tower hematology oncology medical group, beverly hills, california, united states cctap, fontana, california, united states loma linda university cancer center, loma linda, california, united states loma linda university cancer center (llucc)-schuman pavilion, loma linda, california, united states loma linda university medical center, loma linda, california, united states cctap, los angeles, california, united states kaiser permanente southern california, san diego, california, united states cctap, san diego, california, united states georgetown university hospital, washington, d.c., district of columbia, united states research pharmacy, georgetown university medical center, washington, d.c., district of columbia, united states lynn cancer institute center for hematology oncology, boca raton, florida, united states florida hospital, orlando, florida, united states cancer institute of florida, orlando, florida, united states investigational drug services, orlando, florida, united states georgia cancer specialists, athens, georgia, united states georgia cancer specialists, atlanta, georgia, united states georgia cancer specialists, decatur, georgia, united states georgia cancer specialists, macon, georgia, united states georgia cancer specialists, marietta, georgia, united states georgia cancer specialists, sandy springs, georgia, united states university of chicago, chicago, illinois, united states al fisher, pharm d., harvey, illinois, united states ingalls memorial hospital, harvey, illinois, united states monroe medical associates, harvey, illinois, united states monroe medical associates, tinley park, illinois, united states indiana university hospital, indianapolis, indiana, united states indiana university melvin and bren simon cancer center, indianapolis, indiana, united states lois and eskenazi hospital, indianapolis, indiana, united states monroe medical association, munster, indiana, united states the community hospital, munster, indiana, united states ochsner clinic foundation, new orleans, louisiana, united states maine center for cancer medicine, biddeford, maine, united states maine center for cancer medicine, brunswick, maine, united states maine center for cancer medicine, sanford, maine, united states maine center for cancer medicine, scarborough, maine, united states kresge eye institute, bingham farms, michigan, united states karmanos cancer institute, detroit, michigan, united states kresge eye institute, detroit, michigan, united states karmanos cancer institute at farmington hills, farmington hills, michigan, united states siteman cancer center - west county, creve coeur, missouri, united states barnes-jewish hospital, saint louis, missouri, united states washington university center for advanced medicine infusion center pharmacy, saint louis, missouri, united states siteman cancer center, saint peters, missouri, united states dartmouth hitchcock medical center, lebanon, new hampshire, united states hematology-oncology associates of northern new jersey, morristown, new jersey, united states university of new mexico cancer center, albuquerque, new mexico, united states unm eye clinic, albuquerque, new mexico, united states memorial medical center, las cruces, new mexico, united states nslij health system/monter cancer center, lake success, new york, united states north shore university hospital, manhasset, new york, united states long island jewish medical center, new hyde park, new york, united states suny upstate medical university, syracuse, new york, united states ohsu knight cancer institute, beaverton, oregon, united states ohsu knight cancer institute, gresham, oregon, united states ohsu knight cancer institute, portland, oregon, united states ohsu knight cancer institute, portland, oregon, united states oregon health and science university, portland, oregon, united states ohsu knight cancer institute, tualatin, oregon, united states fox chase cancer center, philadelphia, pennsylvania, united states vincent armenio, east providence, rhode island, united states pharma resource, east providence, rhode island, united states tennessee oncology, pllc, dickson, tennessee, united states tennessee oncology, pllc, franklin, tennessee, united states tennessee oncology, pllc, gallatin, tennessee, united states tennessee oncology, pllc, hermitage, tennessee, united states tennessee oncology, pllc, lebanon, tennessee, united states tennessee oncology, pllc, murfreesboro, tennessee, united states sarah cannon research institute, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states henry-joyce cancer clinic, nashville, tennessee, united states vanderbilt oncology pharmacy, nashville, tennessee, united states tennessee oncology, pllc, smyrna, tennessee, united states ut southwestern medical center - simmons cancer center pharmacy, dallas, texas, united states ut southwestern medical center, dallas, texas, united states ut southwestern university hospital - william p. clements, jr., dallas, texas, united states ut southwestern university hospital - zale lipshy, dallas, texas, united states university of texas md anderson cancer center, houston, texas, united states seattle cancer care alliance, seattle, washington, united states university of washington medical center, seattle, washington, united states university of wisconsin hospital and clinics, madison, wisconsin, united states macarthur cancer therapy centre, campbelltown, new south wales, australia chris o\'brien lifehouse, camperdown, new south wales, australia royal north shore hospital, st. leonards, new south wales, australia the prince charles hospital, chermside, queensland, australia the townsville hospital, douglas, queensland, australia the royal brisbane & womens hospital, herston, queensland, australia parkhaven medical center, hyde park, queensland, australia department of medical oncology, adelaide, south australia, australia peter maccallum cancer centre, department of haematology and medical oncology, east melbourne, victoria, australia peninsula & south eastern haematology and oncology group, frankston, victoria, australia klinikum wels-grieskirchen, wels, austria uz antwerpen-pneumologie, edegem, antwerp, belgium grand hopital de charleroi -site notre dame, charleroi, hainaut, belgium cliniques universitaires st luc, brussels, belgium universitair ziekenhuis brussel / medische oncologie, brussel, belgium institut jules bordet, centre des tumeurs de l\'ulb, bruxelles, belgium universitair ziekenhuis gent (u.z. gent), gent, belgium centre hospitalier universitaire de liege, liege, belgium department of pulmonary diseases az delta, roeselare, belgium instituto nacional de cancer - inca, rio de janeiro, rj, brazil associacao hospital de caridade de ijui, ijui, rs, brazil hospital sao lucas da pucrs, porto alegre, rs, brazil instituto do câncer do estado de são paulo octavio frias de oliveira - icesp, sao paulo, sp, brazil fundacao pio xii hospital de cancer de barretos, barretos, são paulo, brazil cross cancer institute, edmonton, alberta, canada qeii health sciences centre, halifax, nova scotia, canada qeii health sciences centre, halifax, nova scotia, canada r.s. mclaughlin durham regional cancer centre, oshawa, ontario, canada jewish general hospital, montreal, quebec, canada mcgill university health centre (muhc), glen site, cedars cancer centre, montreal, quebec, canada institut universitaire de cardiologie et de pneumologie de quebec (iucpq), ste-foy, quebec, canada instituto clinico oncologico del sur, temuco, cautin, chile instituto nacional del cancer, santiago, rm, chile hospital clinico universidad de chile, seccion de oncologia, independencia, santiago, rm, chile 307 hospital of pla, beijing, beijing, china oncology center, guangdong general hospital, guangzhou, guangdong, china union hospital, tongji medical college of huazhong university of science & technology/cancer center, wuhan, hubei, china no.81 hospital of the pla, nanjing, jiangsu, china oncology department, west china hospital of sichuan university, chengdu, sichuan, china cancer institute and hospital, chinese academy of medical sciences, beijing, china shanghai chest hospital/department of pulmonary medicine, shanghai, china zhongshan hospital fudan university, shanghai, china shanghai pulmonary hospital/dept. of oncology, shanghai, china helsingin yliopistollinen keskussairaala, meilahden kolmiosairaala,keuhkosairauksien poliklinikka, helsinki, finland satakunnan keskussairaala/keuhkosairauksien osasto a4, pori, finland tampereen yliopistollinen sairaala, tampere, finland hopital avicenne, bobigny cedex, france chu de caen, caen cedex, france chu grenoble, grenoble cedex, france centre oscar lambret, lille, france centre leon berard, lyon cedex 08, france aphm - hopital nord / service d\'oncologie multidisciplinaire et innovations thérapeutiques, marseille cedex 20, france hopital arnaud de villeneuve / chu de montpellier, montpellier, france hopital tenon, service de pneumologie, paris cedex 20, france nouvel hopital civil - hsu - pôle de pathologie thoracique - service de pneumologie, strasbourg, france zentralklinik bad berka gmbh, bad berka, germany charite - universitaetsmedizin berlin, campus mitte, berlin, germany thoraxklinik am universitaetsklinikum heidelberg, heidelberg, germany st.vincentius-kliniken karlsruhe, karlsruhe, germany universitätsmedizin der johannes gutenberg-universität mainz, mainz, germany kliniken maria hilf gmbh, moenchengladbach, germany pius-hospital oldenburg, oldenburg, germany hsk dr.- horst-schmidt-kliniken gmbh,, wiesbaden, germany prince of wales hospital, shatin, new territories, hong kong department of clinical oncology, queen elizabeth hospital, kowloon, hong kong the gujarat cancer & research institute (m.p shah cancer hospital),, ahmedabad,, gujarat, india tata memorial centre, tata memorial hospital,, mumbai, maharashtra, india aseptic compounding unit, dublin, ireland department of medical oncology, dublin, ireland struttura operativa complessa oncologia medica a centro di riferimento oncologico, aviano, pordenone, italy farmacia, aviano (pn), italy istituto dei tumori giovanni paolo ii, bari, italy unità operativa di oncologia medica azienda usl città di bologna, bologna, italy azienda ospedaliero-universitaria ""mater domini"", catanzaro, italy unità operativa di farmacia - campus salvatore venuta, catanzaro, italy ospedale civile azienda usl toscana nord ovest, livorno, italy unità operativa farmacia ospedaliera po di livorno, livorno, italy fondazione irccs istituto nazionale tumori, struttura complessa di medicina oncologica 1, milano, italy farmacia istituto europeo di oncologia irccs, u.o. farmacia, milano, italy istituto europeo di oncologia, milano, italy ospedale niguarda ca\'granda, divisione oncologia medica falck, milano, italy a.o.r.n. ospedale dei colli - monaldi, napoli, italy farmacia, napoli, italy azienda ospedaliera universitaria san luigi gonzaga, orbassano (to), italy s.c. farmacia ospedaliera , azienda ospedaliero universitaria san luigi gonzaga, orbassano (to), italy oncologia medica, azienda ospedaliero- universitaria di parma, parma, italy farmacia ospedaliera, perugia, italy sc oncologia medica, ospedale santa maria della misericordia, perugia, italy irccs -arcispedale s. maria nuova tecnologie avanzate e modelli assistenziali in oncologia, reggio emilia, italy istituto regina elena, struttura complessa oncologia medica a, roma, italy azienda ospedaliera san camillo forlanini-padiglione flaiani, roma, italy farmacia interna, roma, italy unita operativa, oncologia medica, istituto di medicina interna e geriatria, roma, italy aichi cancer center central hospital, nagoya, aichi, japan national cancer center hospital east, kashiwa, chiba, japan national hospital organization shikoku cancer center, matsuyama, ehime, japan national hospital organization hokkaido cancer center, sapporo, hokkaido, japan hyogo cancer center, akashi, hyogo, japan kanagawa cardiovascular and respiratory center, yokohama, kanagawa, japan tohoku university hospital, sendai, miyagi, japan okayama university hospital, okayama-city, okayama, japan kinki university hospital, osakasayama-shi, osaka, japan shizuoka cancer center, sunto-gun, shizuoka, japan national cancer center hospital, chuo-ku, tokyo, japan the cancer institute hospital of jfcr, koto-ku, tokyo, japan national hospital organization yamaguchi-ube medical center, ube-shi, yamaguchi, japan national hospital organization kyushu cancer center, fukuoka, japan kyushu university hospital respiratory medicine, fukuoka, japan seoul national university hospital, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, sungkyunkwan univ. school of medicine, seoul, korea, republic of centre hospitalier de luxembourg, luxembourg, luxembourg instituto nacional de cancerologia, mexico, d.f., mexico jeroen bosch ziekenhuis, \'s hertogenbosch, nb, netherlands vumc, amsterdam, netherlands academisch ziekenhuis maastricht / afdeling longziekten en tuberculose, maastricht, netherlands oslo universitetssykehus hf - radiumhospitalet, oslo, norway clinica anglo americana/centro de investigacion oncologia caa, san isidro, lima, peru centro hospitalar e universitario de coimbra - hospital geral, coimbra, portugal instituto português de oncologia de lisboa, prof. francisco gentil e.p.e., lisboa, portugal centro hospitalar de lisboa norte - hospital pulido valente, lisboa, portugal centro hospitalar de vila nova de gaia/espinho, e.p.e., vila nova de gaia, portugal russian oncological research center n.n. blokhin, moscow, russian federation city clinical oncology dispensary, saint-petersburg, russian federation first saint-petersburg state medical university n.a. i.p. pavlov, saint-petersburg, russian federation first saint-petersburg state medical university n.a. i.p., saint-petersburg, russian federation russian scientific center of radiology and surgical technologies, saint-petersburg, russian federation city clinical oncology dispensary, saint-petersburg, russian federation samara regional clinical oncology dispensary, samara, russian federation national university hospital, singapore, singapore national cancer centre, singapore, singapore parkway cancer centre, singapore, singapore oncocare cancer centre, singapore, singapore university of witwatersrand oncology, johannesburg, gauteng, south africa rondebosch oncology centre, rondebosch medical centre, cape town, south africa hospital general universitario de elche, elche, alicante, spain hospital universitario virgen macarena, sevilla, andalucia, spain hospital clinico universitario lozano blesa, zaragoza, aragon, spain hospital clinic i provincial de barcelona, barcelona, catalunya, spain hospital universitari vall d\'hebron, barcelona, spain hospital universitario insular de gran canaria, las palmas de gran canaria, spain hospital ramon y cajal, madrid, spain hospital doce de octubre, madrid, spain hospital universitario virgen de la victoria, malaga, spain universitaetsspital basel, basel, switzerland luzerner kantonsspital (luks), luzern, switzerland kantonsspital winterthur, winterthur, switzerland chang gung medical foundation, kaohsiung branch, kaohsiung city, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, comprehensive cancer center, taichung, taiwan chang gung medical foundation, linkou branch, taoyuan, taiwan city multiple-discipline clinical hospital #4,, dnipropetrovsk, ukraine city multiple-discipline clinical hospital #4, dnipropetrovsk, ukraine department of oncology and medical radiology, si ""dma of moh, ukraine, dnipropetrovsk, ukraine kyiv city clinical oncologic center/department of chemotherapy, kyiv, ukraine lviv state oncologic regional treatment and diagnostic center, lviv, ukraine addenbrooke\'s hospital, oncology centre, cambridge, cambridgeshire, united kingdom lister hospital, stevenage, hertfordshire, united kingdom queen elizabeth ii hospital, welwyn garden city, hertfordshire, united kingdom spire manchester hospital, manchester, lancashire, united kingdom mount vernon hospital, mount vernon cancer centre, northwood, middlesex, united kingdom nhs greater glasgow and clyde health board, beatson west of scotland cancer centre,, glasgow, scotland, united kingdom ross hall hospital, glasgow, scotland, united kingdom aberdeen royal infirmary, aberdeen, united kingdom the christie hospital nhs foundation trust, department of medical oncology, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT01154140,skin
443,444,NCT00890305,"study to evaluate the safety, tolerability and efficacy of folfox + ct-011 versus folfox alone",,Completed,No Results Available,metastatic colorectal cancer,drug: ct-011|drug: folfox,"the primary endpoint will be the median progression free survival in patients treated with ct-011 plus folfox compared to that of patients treated with folfox alone.|composite of safety, tolerability, pharmacokinetics and immunogenicity of ct-011.|anti tumor activity of the antibody.|objective response rate by recist.|progression-free survival rates.|response duration.|overall survival.|tumor and immunological markers.","medivation, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,171.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT-2008-01|2009-014593-18,May 2009,May 2012,March 2013,"April 29, 2009",,"July 8, 2015","['the cancer center of huntsville, pc, huntsville, alabama, united states university of south florida, tampa, florida, united states memorial sloan-kettering cancer center, new york, new york, united states signal point clinical research center, middletown, ohio, united states joe arrington cancer research and treatment center, lubbock, texas, united states mhat ""dr. tota venkova"", gabrovo, bulgaria interdistrict dispensary in oncology diseases with stationary-ruse, eood, ruse, bulgaria interdistrict dispensary in oncology diseases with stationary, shumen, bulgaria multiprofile hospital for active treatment ""tsaritza joanna"", sofia, bulgaria specialized hospital for active treatment for oncology, sofia, bulgaria interdistrict dispensary of oncology diseases with stationary, varna, bulgaria multiprofile hospital for active treatment ""sv. marina"", ead,, varna, bulgaria regional cancer centre, indira gandhi institute of medical sciences, sheikhpura, patna, bihar, india cancer clinic, nagpur, maharashtra, india curie manavata cancer centre, opp., nashik, maharashtra, india ruby hall clinic, pune, maharashtra, india deenanath mangeshkar hospital and research centre, pune, maharashtra, india g. kuppuswamy naidu memorial hospital, pappanaickenpalayam, coimbatore, tamilnadu, india hospital almanzor aguinaga asenjo - chiclayo, chiclayo, peru clinica ricardo palma, lima, peru hospital regional nivel iii cayetano heredia essalud piura, piura, peru ponce school of medicine/caimed center, ponce, puerto rico fundacion de investigacion de diego, santurce, puerto rico ""prof. dr. ion chiricuţă"" institute of oncology, cluj-napoca, romania clinical emergency hospital - oncology department, constanta, romania oncolab srl, no. 1, craiova, romania center of medical oncology, iasi, romania clinical hospital pelican oradea, oradea, romania no. 1 city hospital, ploiesti, romania ""sf. ioan cel nou"" clinical emergency county hospital, suceava, romania clinic of oncology - radiotherapy, tg. mures, romania']",,https://ClinicalTrials.gov/show/NCT00890305,colon
444,445,NCT01955824,a trial on clinical efficacy of 1% versus 2% lignocaine in cough suppression and pain relief in patients undergoing flexible bronchoscopy,,Completed,No Results Available,lung cancer|tuberculosis|sarcoidosis|interstitial lung disease,drug: 1% lignocaine|drug: 2% lignocaine,cough suppression (by operator and patient)|pain control,postgraduate institute of medical education and research,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,500.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Bron/Lig/Tr-1,May 2014,November 2014,November 2014,"October 8, 2013",,"December 30, 2014","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT01955824,
445,446,NCT00471146,study of gemcitabine plus ag-013736 versus gemcitabine for advanced pancreatic cancer.,,Completed,Has Results,"carcinoma, pancreatic ductal",drug: ag-013736|drug: gemcitabine|drug: placebo,"overall survival (os)|progression free survival (pfs)|percentage of participants with objective response (or)|duration of response (dr)|change from baseline in european organization for research and treatment of cancer, quality of life questionnaire core-30 (eortc qlq- c30) score|change from baseline in european organization for research and treatment of cancer quality of life questionnaire-pancreatic 26 (eortc qlq- pan26) score|change from baseline brief pain inventory-short form (bpi-sf) score|change from baseline in euro qol questionnaire- 5 dimension (eq-5d) health state profile|change from baseline in euro qol questionnaire- 5 dimension (eq-5d) vas score|population pharmacokinetic (pk) analysis for axitinib (ag-013736)",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A4061028,July 2007,January 2009,November 2010,"May 9, 2007","July 16, 2012","July 16, 2012","[""pfizer investigational site, antioch, california, united states pfizer investigational site, corona, california, united states pfizer investigational site, glendora, california, united states pfizer investigational site, la jolla, california, united states pfizer investigational site, la jolla, california, united states pfizer investigational site, laverne, california, united states pfizer investigational site, pamona, california, united states pfizer investigational site, pasadena, california, united states pfizer investigational site, pleasent hill, california, united states pfizer investigational site, pomona, california, united states pfizer investigational site, rancho cucamonga, california, united states pfizer investigational site, rancho mirage, california, united states pfizer investigational site, redlands, california, united states pfizer investigational site, san diego, california, united states pfizer investigational site, san diego, california, united states pfizer investigational site, san leandro, california, united states pfizer investigational site, west covina, california, united states pfizer investigational site, hollywood, florida, united states pfizer investigational site, pembroke pines, florida, united states pfizer investigational site, stuart, florida, united states pfizer investigational site, tampa, florida, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, augusta, georgia, united states pfizer investigational site, augusta, georgia, united states pfizer investigational site, coeur d'alene, idaho, united states pfizer investigational site, alton, illinois, united states pfizer investigational site, chicago, illinois, united states pfizer investigational site, beech grove, indiana, united states pfizer investigational site, indianapolis, indiana, united states pfizer investigational site, indianapolis, indiana, united states pfizer investigational site, jeffersonville, indiana, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, shelbyville, kentucky, united states pfizer investigational site, baton rouge, louisiana, united states pfizer investigational site, baton rouge, louisiana, united states pfizer investigational site, annapolis, maryland, united states pfizer investigational site, burlington, massachusetts, united states pfizer investigational site, peabody, massachusetts, united states pfizer investigational site, kalamazoo, michigan, united states pfizer investigational site, columbus, mississippi, united states pfizer investigational site, corinth, mississippi, united states pfizer investigational site, southaven, mississippi, united states pfizer investigational site, tupelo, mississippi, united states pfizer investigational site, st. louis, missouri, united states pfizer investigational site, billings, montana, united states pfizer investigational site, lincoln, nebraska, united states pfizer investigational site, las vegas, nevada, united states pfizer investigational site, mineola, new york, united states pfizer investigational site, syracuse, new york, united states pfizer investigational site, canton, ohio, united states pfizer investigational site, columbus, ohio, united states pfizer investigational site, sylvania, ohio, united states pfizer investigational site, portland, oregon, united states pfizer investigational site, knoxville, tennessee, united states pfizer investigational site, knoxville, tennessee, united states pfizer investigational site, knoxville, tennessee, united states pfizer investigational site, memphis, tennessee, united states pfizer investigational site, memphis, tennessee, united states pfizer investigational site, austin, texas, united states pfizer investigational site, austin, texas, united states pfizer investigational site, austin, texas, united states pfizer investigational site, austin, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, round rock, texas, united states pfizer investigational site, salt lake city, utah, united states pfizer investigational site, lynchburg, virginia, united states pfizer investigational site, everett, washington, united states pfizer investigational site, federal way, washington, united states pfizer investigational site, kennewick, washington, united states pfizer investigational site, lakewood, washington, united states pfizer investigational site, puyallup, washington, united states pfizer investigational site, tacoma, washington, united states pfizer investigational site, bahia blanca, buenos aires, argentina pfizer investigational site, la plata, buenos aires, argentina pfizer investigational site, ciudad autonoma de buenos aires, argentina pfizer investigational site, santa fe, argentina pfizer investigational site, st. leonards, new south wales, australia pfizer investigational site, wollongong, new south wales, australia pfizer investigational site, clayton, victoria, australia pfizer investigational site, east bentleigh, victoria, australia pfizer investigational site, salzburg, austria pfizer investigational site, wels, austria pfizer investigational site, wien, austria pfizer investigational site, wien, austria pfizer investigational site, wien, austria pfizer investigational site, brussel, belgium pfizer investigational site, bruxelles, belgium pfizer investigational site, bruxelles, belgium pfizer investigational site, gent, belgium pfizer investigational site, leuven, belgium pfizer investigational site, wilrijk, belgium pfizer investigational site, edmonton, alberta, canada pfizer investigational site, kelowna, british columbia, canada pfizer investigational site, victoria, british columbia, canada pfizer investigational site, winnipeg, manitoba, canada pfizer investigational site, winnipeg, manitoba, canada pfizer investigational site, moncton, new brunswick, canada pfizer investigational site, kingston, ontario, canada pfizer investigational site, kingston, ontario, canada pfizer investigational site, oshawa, ontario, canada pfizer investigational site, toronto, ontario, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, clichy cedex, france pfizer investigational site, la chaussee saint victor, france pfizer investigational site, marseille, france pfizer investigational site, montpellier cedex 02, france pfizer investigational site, paris cedex 13, france pfizer investigational site, paris, france pfizer investigational site, pessac cedex, france pfizer investigational site, rouen, france pfizer investigational site, st herblain cedex, france pfizer investigational site, berlin, germany pfizer investigational site, dresden, germany pfizer investigational site, essen, germany pfizer investigational site, greifswald, germany pfizer investigational site, magdeburg, germany pfizer investigational site, mannheim, germany pfizer investigational site, muenchen, germany pfizer investigational site, oldenburg, germany pfizer investigational site, ulm, germany pfizer investigational site, shatin, nt, hong kong pfizer investigational site, budapest, hungary pfizer investigational site, budapest, hungary pfizer investigational site, budapest, hungary pfizer investigational site, kaposvar, hungary pfizer investigational site, szentes, hungary pfizer investigational site, zalaegerszeg, hungary pfizer investigational site, ahmedabad, gujarat, india pfizer investigational site, bangalore, karnataka, india pfizer investigational site, cochin, kerala, india pfizer investigational site, andhra, pradesh, india pfizer investigational site, chennai, tamil nadu, india pfizer investigational site, dublin 24, ireland pfizer investigational site, dublin, ireland pfizer investigational site, bologna, italy pfizer investigational site, catania, italy pfizer investigational site, milano, italy pfizer investigational site, milano, italy pfizer investigational site, padova, italy pfizer investigational site, verona, italy pfizer investigational site, nagoya, aichi, japan pfizer investigational site, chiba-shi, chiba-ken, japan pfizer investigational site, chiba city, chiba, japan pfizer investigational site, kashiwa-shi, chiba, japan pfizer investigational site, fukuoka-shi, fukuoka-ken, japan pfizer investigational site, yokohama-shi, kanagawa, japan pfizer investigational site, osaka-shi, osaka-fu, japan pfizer investigational site, suntougun, shizuoka, japan pfizer investigational site, chuo-ku, tokyo, japan pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, amsterdam, noord holland, netherlands pfizer investigational site, amsterdam, netherlands pfizer investigational site, moscow, russian federation pfizer investigational site, moscow, russian federation pfizer investigational site, moscow, russian federation pfizer investigational site, omsk, russian federation pfizer investigational site, sochi, russian federation pfizer investigational site, st. petersburg, russian federation pfizer investigational site, st. petersburg, russian federation pfizer investigational site, singapore, singapore pfizer investigational site, singapore, singapore pfizer investigational site, cape town, south africa pfizer investigational site, observatory, south africa pfizer investigational site, parktown, south africa pfizer investigational site, port elizabeth, south africa pfizer investigational site, pretoria, south africa pfizer investigational site, sandton, south africa pfizer investigational site, palma de mallorca, islas baleares, spain pfizer investigational site, mostoles, madrid, spain pfizer investigational site, pamplona, navarra, spain pfizer investigational site, barcelona, spain pfizer investigational site, barcelona, spain pfizer investigational site, las palmas de gran canaria, spain pfizer investigational site, madrid, spain pfizer investigational site, malaga, spain pfizer investigational site, santa cruz de tenerife, spain pfizer investigational site, toledo, spain pfizer investigational site, lund, sweden pfizer investigational site, uppsala, sweden pfizer investigational site, winterthur, switzerland pfizer investigational site, kuei-shan jsoamg, taoyuan county, taiwan pfizer investigational site, taichung, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, whitchurch, cardiff, united kingdom pfizer investigational site, maidstone, kent, united kingdom pfizer investigational site, leicester, leicestershire, united kingdom pfizer investigational site, withington, manchester, united kingdom pfizer investigational site, northwood, middlesex, united kingdom pfizer investigational site, birmingham, united kingdom pfizer investigational site, birmingham, united kingdom pfizer investigational site, edinburgh, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, manchester, united kingdom pfizer investigational site, southhampton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00471146,pancreat
446,447,NCT00034268,"a phase 3 trial of ly900003 plus gemcitabine and cisplatin versus gemcitabine and cisplatin in patients with advanced, previously untreated non-small cell lung cancer",,Completed,No Results Available,"carcinoma, non-small-cell lung",drug: ly900003,,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6428|H7X-MC-JVAA,March 2002,,,"April 25, 2002",,"July 19, 2006","['hot springs, arkansas, united states springdale, arkansas, united states los angeles, california, united states santa rosa, california, united states denver, colorado, united states fort collins, colorado, united states wilmington, delaware, united states tucker, georgia, united states indianapolis, indiana, united states new orleans, louisiana, united states baltimore, maryland, united states detroit, michigan, united states minneapolis, minnesota, united states robbinsdale, minnesota, united states latham, new york, united states new york, new york, united states arlington, texas, united states dallas, texas, united states abingdon, virginia, united states marshfield, wisconsin, united states ciudad de buenos aires, argentina mendoza, argentina brasschaat, belgium edegem, belgium liege, belgium merksem, belgium oostende, belgium las condes, santiago, chile brest, france nice cedex 1, france paris cedex 20, france pessac cedex, france rouen cedex, france saint herblain cedex, france tours cedex, france vandoeuvre les nancy cedex, france frankfurt, hessen, germany augsburg, germany berlin, germany freiburg, germany grobhansdorf, germany hamburg, germany heidelberg, germany hofheim, germany koin, germany leipzig, germany munchen, germany neustadt/suedharz, germany trier, germany ulm, germany budapest, hungary bangalore, karnataka, india mumbai, maharashtra, india pune, maharashtra, india ludhiana, punjab, india new dehli, india rozzano, milano, italy perugia, italy pisa, italy ravenna, italy roma, italy amsterdam, netherlands arnhem, netherlands den bosch, netherlands groningen, netherlands nieuwegien, netherlands zwolle, netherlands oslo, norway otwock, mazowieckie, poland krakow-nowa huta, poland warszawa, poland wroclaw, poland bayamon, puerto rico ponce, puerto rico cluj napoca, cluj, romania moscow, russian federation overport, durban, south africa arcadia, gauteng, south africa durban, south africa parklands, south africa tygerberg, south africa oviedo, asturias, spain badalona, barcelona, spain sabadell, barcelona, spain valencia, valenica, spain barakaldo, vizcaya, spain alicante, spain barcelona, spain madrid, spain palma de mallorca, spain zaragoza, spain linkoping, sweden lund, sweden stockhlom, sweden zurich, switzerland tao-yuan, kuei-shan, taiwan taichung, taiwan, province of china, taiwan taipei, taiwan hull, east yorkshire, united kingdom london, greater london, united kingdom southampton, hampshire, united kingdom nottingham, nottinghamshire, united kingdom glasgow, scotland, united kingdom cardiff, south glamorgan, united kingdom newcastle-upon-tyne, tyneside, united kingdom']",,https://ClinicalTrials.gov/show/NCT00034268,
447,448,NCT04139317,safety and efficacy of capmatinib (inc280) plus pembrolizumab vs pembrolizumab alone in nsclc with pd-l1≥ 50%,,"Active, not recruiting",No Results Available,non-small cell lung cancer (nsclc),drug: capmatinib|biological: pembrolizumab,progression-free survival (pfs) based on local investigator assessment as per recist 1.1|objective response rate (orr) based on local investigator assessment as per recist 1.1|disease control rate (dcr) based on local investigator assessment as per recist 1.1|time-to-response (ttr) based on local investigator assessment as per recist 1.1|duration of response (dor) based on local investigator assessment as per recist 1.1|overall survival (os)|antidrug antibodies (ada) of pembrolizumab|auc of capmatinib derived from plasma capmatinib concentration|ctrough of pembrolizumab derived from serum pembrolizumab concentration|cmax of capmatinib derived from plasma capmatinib concentration|tmax of capmatinib derived from plasma capmatinib concentration|incidence of adverse events,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,76.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CINC280I12201,"January 22, 2020","January 14, 2022","February 16, 2023","October 25, 2019",,"April 26, 2022","['novartis investigative site, wollongong, new south wales, australia novartis investigative site, north adelaide, south australia, australia novartis investigative site, shepparton, victoria, australia novartis investigative site, bruxelles, belgium novartis investigative site, liege, belgium novartis investigative site, yvoir, belgium novartis investigative site, quebec, canada novartis investigative site, ostrava vitkovice, czechia novartis investigative site, lille, france novartis investigative site, strasbourg cedex, france novartis investigative site, toulouse, france novartis investigative site, berlin, germany novartis investigative site, koeln, germany novartis investigative site, athens, greece novartis investigative site, thessaloniki, greece novartis investigative site, shatin, new territories, hong kong novartis investigative site, mumbai, maharashtra, india novartis investigative site, kolkata, west bengal, india novartis investigative site, delhi, india novartis investigative site, ancona, an, italy novartis investigative site, aviano, pn, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, yokohama-city, kanagawa, japan novartis investigative site, kuching, sarawak, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, amersfoort, netherlands novartis investigative site, breda, netherlands novartis investigative site, zwolle, netherlands novartis investigative site, badalona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, barcelona, spain novartis investigative site, madrid, spain novartis investigative site, changhua, taiwan novartis investigative site, taichung, taiwan novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand']",,https://ClinicalTrials.gov/show/NCT04139317,
448,449,NCT00530764,a study of sativex® for pain relief in patients with advanced malignancy.,SPRAY,Completed,Has Results,palliative care|pain|cancer,drug: sativex low dose|drug: sativex medium dose|drug: sativex high dose,number of patients with at least 30% improvement in numerical rating scale (nrs) average pain score from baseline|change in cumulative average pain response curves|change in mean daily nrs pain score (average pain).|change in mean daily nrs pain score (worst pain).|change in sleep disruption nrs|change in brief pain inventory - short form (bpi-sf)|change in patient assessment of constipation quality of life (pac-qol)|change in patient global impression of change - pgic|change in montgomery asberg depression rating scale (madrs),"jazz pharmaceuticals|quintiles, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,360.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",GWCA0701,November 2007,January 2010,January 2010,"September 17, 2007","June 17, 2011","June 20, 2013","['cancer care center of tuscaloosa, tuscaloosa, alabama, united states desert oasis cancer center, casa grande, arizona, united states pacific coast hematology/oncology medical group, inc., fountain valley, california, united states office of dr. ronald yanagihara, gilroy, california, united states university of california san diego, la jolla, california, united states loma linda university, loma linda, california, united states florida institute of medical research, jacksonville, florida, united states clinical pharmacology services, tampa, florida, united states center of hope for cancer and blood disorders, riverdale, georgia, united states louisiana research associates, new orleans, louisiana, united states the center for clinical research - washington county hospital, hagerstown, maryland, united states capital comprehensive cancer care clinic, jefferson city, missouri, united states a & a pain institute of st. louis, st. louis, missouri, united states office of donald h. berdeaux md, great falls, montana, united states summit medical group, berkeley heights, new jersey, united states beth israel medical center, new york, new york, united states metropolitan hospital center, new york, new york, united states four seasons hospice & pallative care, flat rock, north carolina, united states center for clinical research, winston-salem, north carolina, united states gabrail cancer center, canton, ohio, united states vanderbilt-ingram cancer center, nashville, tennessee, united states lone star oncology, austin, texas, united states huntsman cancer institute, salt lake city, utah, united states jules bordet institute, bruxelles, belgium chu charleroi (hôpital civil de charleroi), charleroi, belgium uz leuven - algologisch centrum anesthesiologie, pellenberg, belgium vancouver health research center, victoria, british columbia, canada jewish general hospital, montreal, quebec, canada instituto radio-oncológico santiago (inrad), santiago, chile clínica ciudad del mar, viña del mar, chile ambulance pro lécbu bolesti, aro, benešov, czech republic ambulance pro lécbu bolesti, ceské budejovice, czech republic nemocnice ceské budejovice, ceské budejovice, czech republic fn hradec králové - klinika onkologie a radioterapie, hradec králové, czech republic nemocnice jihlava, jihlava, czech republic fn a lf up olomouc - ambulance pro lécbu bolesti, olomouc, czech republic ar klinika fn plzen -ambulance pro lécbu bolesti, plzen, czech republic fakultní nemocnice na bulovce, praha 8 - liben, czech republic aro, krajská zdravotni, k.z. a.s, nemocnice, teplice, czech republic docrates clinic, helsinki, finland centre hospitalier lyon sud, pierre-benite, france praticien hospitalier, tarbes, france rwth aachen universität, aachen, germany schmerz- und palliativzentrum göppingen, göppingen, germany st.-marien-hospital lunen, lunen, germany schmeiz - u pallielivzendium wiesbaden, wiesbaden, germany yashoda hospital, andhra pradesh, india bangalore institute of oncology, bangalore,, india cbcc- apollo hospital, gandhinagar, india apollo hospital, hyderabaad, india indo-american cancer institute and research center, hyderabaad, india bhagwaan mahaveer cancer hospital and research centre, jaipur, india chl - apollo hospitals, madhya pradesh, india jawaharlal nehru cancer hospital, madhya pradesh, india meenakshi mission hospital & research centre, madurai, india all india institute of medical sciences, new delhi, india jehangir clinical development centre pvt. ltd., pune, india deenanath mangeshkar hospital and research center, pune, india seroc cancer center, rajasthan, india regina elana cancer institute, rom, italy dir. s.c.d.u. psicologia clinica ed oncologica, turin, italy hospital aranda de la parra, leon, mexico htal ángeles de pedregal, mexico df, mexico beskidzkie centrum onkologii im. jana pawla, bielsko-biala, poland poradnia leczenia bolu, edyty jakubow, poland wojewodzki szpital specjalistyczny im. m. kopernika, gdansk, poland nzoz hospicjum milosierdzia bozego, gliwice, poland szpital uniwersytecki w krakowie, krakow, poland wielkopolskie centrum onkologii, poznan, poland niepubliczny zaklad opieki zdrowotnej, tychy, poland centrum onkologii - instytut im. m. sklodowskiej - curie, warszawa, poland spitalul judetean de urgenta ""constantin opris"", baia mare, maramures, romania spitalul judetean de urgenta braila, braila, jud. braila, romania hospice ""casa sperantei"", brasov, romania spitalul universitar de urgenta elias, bucuresti, romania s.c. ianulimed s.r.l. oncologie medicala, bucuresti, romania policnica orizont-oncologie medicala, craiova, romania district hospital dr. alexandru simionescu, hunedoara, romania centrul de oncologie medicala, iasi, romania spitalul municipal onesti, onesti, jud. bacau, romania spitalul municipal ploiesti, ploiesti, romania spitalul clinic judetean sibiu oncologie, sibiu, romania spitalul judetean de urgenta ""sf. ioan cel nou"", suceava, romania dr. pirjol & szpak inc., amanzimtoti, south africa medi clinic, bloemfontein, south africa pain clinic, cape town, south africa pretoria urology research unit, hatfield, pretoria, south africa trialtech research - embassy drive medical centre, hatfield, pretoria, south africa oncology/haematology dept research unit, kimberley, south africa eastleigh breast cancer center, lynnwood, south africa hospital virgen del mar, almeria, spain hospital universitario vall d\'hebron, barcelona, spain hospital clinic i provincial, barcelona, spain hu puerta del mar, oncologia, cadiz, spain hospital universitario de bellvitge, feixa, llarga, sn, spain hospital univ. virgen de las nieves, granada, spain hospital de la rioja, logrono, spain hospital los montalvos, salamanca, spain basingstoke & north hampshire nhs foundation trust, basingstoke, united kingdom west suffolk hospital, bury st edmunds, united kingdom fairfield general hospital, bury, lancashire, united kingdom edinburgh cancer research centre (cruk), edinburgh, united kingdom james paget hospital, gorleston on sea, norfolk, united kingdom international observatory on end of life care, lancaster, united kingdom st bartholomew\'s hospital, london, united kingdom the royal marsden nhs foundation trust, london, united kingdom marie curie hospice holme tower, penarth, united kingdom the royal marsden nhs foundation trust, sutton, united kingdom weston area health trust, weston super mare, united kingdom new cross hospital, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00530764,pain
449,450,NCT03444766,study of nivolumab for advanced cancers in india,,Completed,Has Results,non-small cell lung cancer (nsclc)|non-small-cell lung carcinoma|nonsmall cell lung cancer|kidney cancer|kidney neoplasms|renal cancer|renal neoplasms,drug: nivolumab,number of participants with treatment-related adverse events|number of participants with treatment-related select adverse events|number of participants with treatment-related serious adverse events|number of participants with adverse events leading to discontinuation,bristol-myers squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA209-887,"March 6, 2018","July 17, 2019","July 17, 2019","February 23, 2018","December 4, 2020","December 4, 2020","['local institution, bangalore, india local institution, bangalore, india local institution, bengaluru, india local institution, hyderabad, india local institution, jaipur, india local institution, kolkata, india local institution, mumbai, india local institution, new delhi, india local institution, vellore, india']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/66/nct03444766/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/66/nct03444766/prot_001.pdf",https://ClinicalTrials.gov/show/NCT03444766,kidney
450,451,NCT00038103,open-label study of exemestane with or without celecoxib in postmenopausal women with abc having progressed on tamoxifen,,Completed,Has Results,breast neoplasms,drug: exemestane|drug: celecoxib + exemestane,number of subjects with clinical benefit|number of subjects with objective response|duration of clinical benefit|duration of objective response (in subjects with cr or pr)|duration of long-term sd|time to tumor progression|time to treatment failure|survival,pfizer,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,111.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NQ8-01-02-013|A3191139,January 2002,March 2008,March 2008,"May 30, 2002","February 25, 2010","February 25, 2010","['pfizer investigational site, dallas, texas, united states pfizer investigational site, antwerpen, belgium pfizer investigational site, bruxelles, belgium pfizer investigational site, leuven, belgium pfizer investigational site, namur, belgium pfizer investigational site, wilrijk, belgium pfizer investigational site, porto alegre, rs, brazil pfizer investigational site, sao paulo, sp, brazil pfizer investigational site, sydney, nova scotia, canada pfizer investigational site, bogota, bogota . dc, colombia pfizer investigational site, cali, colombia pfizer investigational site, hyderabad, andhra pradesh, india pfizer investigational site, bangalore, karnataka, india pfizer investigational site, mumbai, maharashtra, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, mexico, distrito federal, mexico pfizer investigational site, guadalajara, jalisco, mexico pfizer investigational site, lima, peru pfizer investigational site, lima, peru pfizer investigational site, manila, philippines']",,https://ClinicalTrials.gov/show/NCT00038103,breast
451,452,NCT01360853,gemcitabine and on 01910.na in previously untreated metastatic pancreatic cancer,ONTRAC,Completed,No Results Available,metastatic pancreatic adenocarcinoma,drug: on 01910.na|drug: gemcitabine,survival|progression-free survival|tumor size|safety/tolerability|qol questionnaire|biomarkers|population pharmacokinetics|full pharmacokinetics,"onconova therapeutics, inc.|academic gi cancer consortium (agicc)",All,"18 Years and older   (Adult, Older Adult)",Phase 3,160.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-22|11PAN01,May 2011,June 2015,December 2015,"May 26, 2011",,"August 4, 2016","['ucsd moores cancer center, la jolla, california, united states desert comprehensive cancer center, palm springs, california, united states pacific cancer care, salinas, california, united states premiere oncology, santa monica, california, united states university of colorado cancer center, aurora, colorado, united states kaiser permanente colorado, denver, colorado, united states poudre valley cancer center of the rockies, fort collins, colorado, united states yale cancer center, new haven, connecticut, united states mount sinai comprehensive cancer center, miami beach, florida, united states university of hawaii cancer center, honolulu, hawaii, united states university of kansas cancer center, westwood, kansas, united states umass medical school, worcester, massachusetts, united states karmanos cancer institute, detroit, michigan, united states billings clinic cancer center, billings, montana, united states roswell park cancer institute, buffalo, new york, united states new york university langone medical center, new york, new york, united states university of rochester medical center, rochester, new york, united states university of north carolina lineberger comprehensive cancer center, chapel hill, north carolina, united states levine cancer institute, charlotte, north carolina, united states cone health cancer center, greensboro, north carolina, united states hendersonville hematology and oncology at pardee, hendersonville, north carolina, united states rex cancer center unc healthcare, raleigh, north carolina, united states st. alexis medical center-mid dakota clinic pc, bismarck, north dakota, united states university of cincinnati cancer center, cincinnati, ohio, united states kaiser permanente nw, portland, oregon, united states fox chase cancer center, philadelphia, pennsylvania, united states medical university of south carolina - hollings cancer center, charleston, south carolina, united states mcleod regional medical center, florence, south carolina, united states vanderbilt-ingram cancer center, nashville, tennessee, united states seattle cancer care alliance, seattle, washington, united states semmelweis university department of diagnostic radiology and oncotherapy, budapest, hungary semmelweis university, 3rd department of internal medicine, budapest, hungary hetenyi geza hospital 5004, szolnok, hungary, szolnok, hungary basavatarakam indo-american cancer hospital, hyderabad, andhra pradesh, india regional cancer center, thiruvananthapuram, kerala, india jaslok hospital & research centre, mumbai, maharashtra, india shatabdi superspeciality hospital, nashik, maharashtra, india ruby hall clinic, pune, maharashtra, india lifeline multispeciality hospitals, chennai, tamil nadu, india state budget medical institution of the arkhangelsk region, arkhangelsk, russian federation chelyabinsk regional clinical oncology center, chelyabinsk, russian federation state budget medical institution clinical oncology center 1, krasnodar, russian federation budget medical institution of the omsk region: clinical oncology center, omsk, russian federation state budget medical institution: leningrad regional clinical hospital, saint petersburg, russian federation state medical institution: tula regional oncology center, tula, russian federation zakarpattia regional clinical oncology center department of chemotherapy, uzhhorod, ukraine']",,https://ClinicalTrials.gov/show/NCT01360853,gastric kidney pancreat
452,453,NCT03997123,capivasertib+paclitaxel as first line treatment for patients with locally advanced or metastatic tnbc,CAPItello-290,Recruiting,No Results Available,triple negative breast neoplasms,drug: capivasertib|drug: paclitaxel|drug: placebo,"overall survival (os)|progression-free survival (pfs)|investigator assessment of pfs2|response rate (orr)|safety and tolerability of drugs by assessment of aes/saes|minimum plasma concentration(cmin), plasma concentration1-2 hours post-dose (c1-2h) and 4 hours post-dose (c4h) during months 1 and 2|eortc qlq br23(european organisation for research and treatment of cancer quality of life questionnaire breast cancer specific module)|the eortc qlq-c30 (european organisation for research and treatment of cancer quality of life questionnaire core 30 items)|duration of response (dor)|clinical benefit rate (cbr)",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,924.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3614C00001,"June 25, 2019","May 19, 2023","May 19, 2023","June 25, 2019",,"May 12, 2022","[""research site, birmingham, alabama, united states research site, tucson, arizona, united states research site, redlands, california, united states research site, west hollywood, california, united states research site, whittier, california, united states research site, whittier, california, united states research site, aurora, colorado, united states research site, new haven, connecticut, united states research site, washington, district of columbia, united states research site, fort myers, florida, united states research site, miami, florida, united states research site, miami, florida, united states research site, plantation, florida, united states research site, saint petersburg, florida, united states research site, tampa, florida, united states research site, tampa, florida, united states research site, chicago, illinois, united states research site, indianapolis, indiana, united states research site, westwood, kansas, united states research site, louisville, kentucky, united states research site, silver spring, maryland, united states research site, detroit, michigan, united states research site, rochester, minnesota, united states research site, las vegas, nevada, united states research site, las vegas, nevada, united states research site, brooklyn, new york, united states research site, greenvale, new york, united states research site, new york, new york, united states research site, nyack, new york, united states research site, rochester, new york, united states research site, cincinnati, ohio, united states research site, columbus, ohio, united states research site, oklahoma city, oklahoma, united states research site, harrisburg, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, sioux falls, south dakota, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, fort sam houston, texas, united states research site, fort worth, texas, united states research site, fort worth, texas, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, spring, texas, united states research site, salt lake city, utah, united states research site, charlottesville, virginia, united states research site, fairfax, virginia, united states research site, midlothian, virginia, united states research site, newport news, virginia, united states research site, tacoma, washington, united states research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, ciudad autonoma de buenos aire, argentina research site, ciudad autonomade buenos aires, argentina research site, córdoba, argentina research site, la plata, argentina research site, mar del plata, argentina research site, rosario, argentina research site, santa rosa, argentina research site, barretos, brazil research site, florianópolis, brazil research site, goiania, brazil research site, londrina, brazil research site, natal, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, rio de janeiro, brazil research site, santo andre, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, calgary, alberta, canada research site, victoria, british columbia, canada research site, kitchener, ontario, canada research site, mississauga, ontario, canada research site, north york, ontario, canada research site, toronto, ontario, canada research site, windsor, ontario, canada research site, montreal, quebec, canada research site, halifax, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, changsha, china research site, chengdu, china research site, chengdu, china research site, foshan, china research site, fuzhou, china research site, fuzhou, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, haikou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, jinan, china research site, kunming, china research site, lanzhou, china research site, linyi, china research site, nanchang, china research site, nanchang, china research site, nanjing, china research site, nanjing, china research site, qingdao, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, shenyang, china research site, shijiazhuang, china research site, suzhou, china research site, tianjin, china research site, urumqi, china research site, urumqi, china research site, wenzhou, china research site, wuhan, china research site, wuhan, china research site, wuhan, china research site, wuhan, china research site, wuxi, china research site, xi'an, china research site, zhengzhou, china research site, zhengzhou, china research site, zhengzhou, china research site, bogota, colombia research site, cali, colombia research site, floridablanca, colombia research site, ibague, colombia research site, medellin, colombia research site, monteria, colombia research site, valledupar, colombia research site, chomutov, czechia research site, horovice, czechia research site, hradec kralove, czechia research site, jihlava, czechia research site, liberec, czechia research site, olomouc, czechia research site, praha 10, czechia research site, praha 2, czechia research site, praha 4, czechia research site, brest cedex, france research site, lille cedex, france research site, lyon cedex 08, france research site, lyon, france research site, marseille, france research site, montpellier, france research site, nice, france research site, paris, france research site, saint herblain, france research site, toulouse cedex 9, france research site, villejuif, france research site, athens, greece research site, athens, greece research site, athens, greece research site, heraklion, greece research site, patras, greece research site, thessaloniki, greece research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, győr, hungary research site, nyíregyháza, hungary research site, szekszárd, hungary research site, veszprém, hungary research site, ahmedabad, india research site, bangalore, india research site, bangalore, india research site, bangalore, india research site, gurgaon, india research site, hyderabad, india research site, hyderabad, india research site, kolkata, india research site, kolkata, india research site, madurai, india research site, maharashtra, india research site, mumbai, india research site, mysuru, india research site, nagpur, india research site, nagpur, india research site, nasik, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, pune, india research site, bunkyo-ku, japan research site, fukuoka-shi, japan research site, hidaka-shi, japan research site, hiroshima-shi, japan research site, isehara, japan research site, kagoshima-shi, japan research site, kawasaki-shi, japan research site, kitaadachi-gun, japan research site, koto-ku, japan research site, kumamoto-shi, japan research site, matsuyama-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, ota-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shinagawa-ku, japan research site, shinjuku-ku, japan research site, sunto-gun, japan research site, takasaki-shi, japan research site, tsu-shi, japan research site, tsukuba-shi, japan research site, yokohama-shi, japan research site, busan-si, korea, republic of research site, cheonan-si, korea, republic of research site, cheongju-si, korea, republic of research site, daegu, korea, republic of research site, goyang-si, korea, republic of research site, incheon, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, kuala lumpur, malaysia research site, kuala lumpur, malaysia research site, kuching, malaysia research site, selangor, malaysia research site, aguascalientes, mexico research site, culiacan, mexico research site, estado de méxico, mexico research site, guadalajara, mexico research site, mexico city, mexico research site, mexico, mexico research site, monterrey, mexico research site, nuevo leon, mexico research site, tuxtla gutierrez, mexico research site, tuxtla gutierrez, mexico research site, arequipa, peru research site, callao, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, bacolod, philippines research site, bacolod, philippines research site, baguio city, philippines research site, baguio city, philippines research site, cagayan de oro city, philippines research site, cebu city, philippines research site, davao city, philippines research site, iloilo city, philippines research site, iloilo, philippines research site, las pinas, philippines research site, legazpi city, philippines research site, manila, philippines research site, quezon city, philippines research site, san juan, philippines research site, bydgoszcz, poland research site, grudziądz, poland research site, konin, poland research site, kościerzyna, poland research site, olsztyn, poland research site, ostrołęka, poland research site, poznan, poland research site, racibórz, poland research site, radom, poland research site, tomaszów mazowiecki, poland research site, warszawa, poland research site, wroclaw, poland research site, guimarães, portugal research site, lisboa, portugal research site, lisboa, portugal research site, lisboa, portugal research site, lisboa, portugal research site, porto, portugal research site, arkhangelsk, russian federation research site, barnaul, russian federation research site, chelyabinsk, russian federation research site, chelyabinsk, russian federation research site, kazan, russian federation research site, krasnodar, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, nizhniy novgorod, russian federation research site, nizhniy novgorod, russian federation research site, novosibirsk, russian federation research site, rostov-on-don, russian federation research site, ryazan, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, samara, russian federation research site, st.petersburg, russian federation research site, tomsk, russian federation research site, volgograd, russian federation research site, yaroslavl, russian federation research site, dammam, saudi arabia research site, jeddah, saudi arabia research site, makkah, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, bratislava, slovakia research site, bratislava, slovakia research site, košice, slovakia research site, prešov, slovakia research site, zilina, slovakia research site, johannesburg, south africa research site, johannesburg, south africa research site, johannesburg, south africa research site, pretoria, south africa research site, pretoria, south africa research site, badalona, spain research site, barcelona, spain research site, barcelona, spain research site, hospitalet dellobregat, spain research site, jaén, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, málaga, spain research site, pamplona, spain research site, sevilla, spain research site, valencia, spain research site, zaragoza, spain research site, göteborg, sweden research site, linköping, sweden research site, lund, sweden research site, stockholm, sweden research site, stockholm, sweden research site, sundsvall, sweden research site, umeå, sweden research site, uppsala, sweden research site, changhua, taiwan research site, hsinchu, taiwan research site, hualien city, taiwan research site, kaohsiung, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, tainan city, taiwan research site, tainan, taiwan research site, taipei city, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, hat yai, thailand research site, mueang, thailand research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, malatya, turkey research site, mersin, turkey research site, colchester, united kingdom research site, edinburgh, united kingdom research site, huddersfield, united kingdom research site, hull, united kingdom research site, leeds, united kingdom research site, london, united kingdom research site, london, united kingdom research site, london, united kingdom research site, maidstone, united kingdom research site, sheffield, united kingdom research site, stoke-on-trent, united kingdom research site, surrey, united kingdom research site, york, united kingdom research site, ha noi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam research site, hochiminh, vietnam""]",,https://ClinicalTrials.gov/show/NCT03997123,breast
453,454,NCT00545129,a study of tanezumab as add-on therapy to opioid medication in patients with pain due to cancer that has spread to bone,,Completed,Has Results,neoplasm metastasis|palliative care,drug: tanezumab 10 mg iv|drug: iv placebo for tanezumab,"change from baseline in daily average pain intensity numeric rating scale (nrs) score at week 6|change from baseline in daily average pain intensity numeric rating scale (nrs) score at weeks 1, 2, 4, 8, 12 and 16|change from baseline in daily worst pain intensity numeric rating scale (nrs) score at week 1, 2, 4, 6, 8, 12 and 16: baseline observation carried forward (bocf)|change from baseline in daily worst pain intensity numeric rating scale (nrs) score at week 1, 2, 4, 6, 8, 12 and 16: last observation carried forward (locf)|change from baseline in brief pain inventory-short form (bpi-sf) average pain scores at week 1, 2, 4, 6, 8, 12 and 16: bocf|change from baseline in brief pain inventory-short form (bpi-sf) average pain scores at week 1, 2, 4, 6, 8, 12 and 16: locf|change from baseline in brief pain inventory-short form (bpi-sf) worst pain scores at week 1, 2, 4, 6, 8, 12 and 16: bocf|change from baseline in brief pain inventory-short form (bpi-sf) worst pain scores weeks 1, 2, 4, 6, 8, 12 and 16: locf|percentage of participants achieving greater than or equal to (>=) 30 percent (%), >=50%, >=70% and >=90% reduction in daily average pain intensity numeric rating scale (nrs) score: bocf|percentage of participants achieving greater than or equal to (>=) 30 percent (%), >=50%, >=70% and >=90% reduction in daily average pain intensity numeric rating scale (nrs) score: locf|average daily opioid consumption|number of doses of rescue medication required per week|change from baseline in opioid-related symptom distress scale (or-sds) at weeks 2, 4, 6, 12, and 16|change from baseline in brief pain inventory (bpi) pain interference with function composite score and individual pain interference item scores of general activity, walking ability and normal work at weeks 1, 2, 4, 6, 8, 12, and 16: bocf|change from baseline in brief pain inventory (bpi) pain interference with function composite score and individual pain interference item scores at weeks 1, 2, 4, 6, 8, 12, and 16: locf|patient's global evaluation of study medication|change from baseline in patient's global assessment of disease (cancer pain) activity at weeks 1, 2, 4, 6, 8, 12, and 16: bocf|change from baseline in patient's global assessment of disease (cancer pain) activity at weeks 1, 2, 4, 6, 8, 12, and 16: locf|percentage of participants achieving improvement of >=2 points in patient's global assessment of disease (cancer pain) activity: bocf|percentage of participants achieving improvement of >=2 points in patient's global assessment of disease (cancer pain) activity: locf|number of participants with treatment-emergent adverse events (aes) or serious adverse events (saes)|number of participants with physical examination abnormalities|number of participants with abnormal neurological examination|vital sign examination: body temperature|vital sign examination: blood pressure (bp)|vital sign examination: respiratory rate|vital sign examination: heart rate|body weight of participants|number of participants with abnormal laboratory examination|number of participants with anti-drug antibodies|electrocardiogram examination|electrocardiogram examination: heart rate",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,59.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A4091003|2008-005181-31|CANCER PAIN POC,"April 29, 2009","December 24, 2011","February 7, 2012","October 17, 2007","June 18, 2021","June 18, 2021","['ucsd center for pain medicine, la jolla, california, united states ucsd medical center - thornton hospital, la jolla, california, united states ucsd moores cancer center, la jolla, california, united states indiana pain and spine clinic, south bend, indiana, united states wk river cities clinical research center, shreveport, louisiana, united states willis knighton pierremont health center, shreveport, louisiana, united states hollings cancer center, charleston, south carolina, united states medical university of south carolina, department of urology, charleston, south carolina, united states musc department of radiology, charleston, south carolina, united states musc investigational pharmacy, charleston, south carolina, united states musc urology ambulatory care, charleston, south carolina, united states huntsman cancer institute at the university of utah, salt lake city, utah, united states landeskrankenhaus graz - universitaetsklinik fuer orthopaedie und orthopaedische chirurgie, graz, austria krankenhaus der elisabethinen linz, institut fuer anaesthesiologie und intensivmedizin, linz, austria nuhr zentrum, senftenberg, austria clinic of oncology, banja luka, bosnia and herzegovina institute of oncology, university clinical center sarajevo, sarajevo, bosnia and herzegovina general hospital varazdin, varazdin, croatia institut gustave roussy, villejuif, france fovarosi onkormanyzat peterfy sandor utcai korhaz - fajdalom ambulancia, budapest, hungary fovarosi onkormanyzat jahn ferenc del-pesti korhaz - fajdalom ambulancia, budapest, hungary fejer megyei szt. gyorgy korhaz - rendelointezet/aneszteziologiai es intenziv betegellato osztaly, szekesfehervar, hungary shri siddhivinayak ganpati cancer hospital, miraj, maharashtra, india central india cancer research institute, nagpur, maharashtra, india shatabdi superspeciality hospital, nashik, maharashtra, india chhatrapati shahuji maharaj medical university, lucknow, uttar pradesh, india rajiv gandhi cancer institute and research centre,, new delhi, india severance hospital, yonsei university college of medicine, yonsei cancer center, seoul, korea, republic of samsung medical center, division of hematology-oncology, department of medicine, seoul, korea, republic of 10th department, latvian oncological centre / riga eastern clinical university hospital, riga, latvia centro de cancer del centro medico abc, mexico, distrito federal, mexico hospital nacional guillermo almenara irigoyen, lima, lima l13, peru oncocare, lima, peru niepubliczny zaklad opieki zdrowotnej, bydgoszcz, poland hospicjum im. ks. eugeniusza dutkiewicza sac w gdansku, gdansk, poland poradnia medycyny paliatywnej, hospicjum palium, poznan, poland nzoz zespol opieki domowej, wloclawek, poland fakultna nemocnica s poliklinikou f.d.roosevelta, banska bystrica, slovakia narodny onkologicky ustav, bratislava, slovakia']",,https://ClinicalTrials.gov/show/NCT00545129,
454,455,NCT02162667,efficacy and safety evaluating study of ct-p6 in her2 positive early breast cancer,,Completed,Has Results,her2-positive carcinoma of breast,drug: trastuzumab,"the percentage of patients achieving pathological complete response defined as the absence of invasion tumor cells in the breast and in axillary lymph nodes, regardless of ductal carcinoma in situ (dcis)|the percentage of patients achieving pathological complete response (pcr) of the breast regardless of dcis with positive or unknown nodal status|the percentage of patients achieving pathological complete response of the breast and axillary nodes with absence of dcis|overall response rate (orr) from local review|disease-free survival|progression-free survival|overall survival|the number of patients who had progressive disease or recurrence|maximum serum concentration after administration (cmax) in each cycle|trough serum concentration (ctrough) in each cycle","celltrion|nippon kayaku co., ltd.",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,562.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CT-P6 3.2|2013-004525-84,June 2014,"May 26, 2016",October 2018,"June 13, 2014","October 29, 2019","October 29, 2019","[""buenos aires, argentina córdoba, argentina quilmes, argentina rosario, argentina san salvador de jujuy, argentina santa rosa, argentina brest, belarus minsk, belarus minsk, belarus sarajevo, bosnia and herzegovina barretos, brazil brasilia, brazil caxias do sul, brazil curitiba, brazil goiânia, brazil ijuí, brazil jaú, brazil joaçaba, brazil lajeado, brazil natal, brazil porto alegre, brazil porto alegre, brazil porto alegre, brazil recife, brazil ribeirão preto, brazil sorocaba, brazil são paulo, brazil são paulo, brazil são paulo, brazil são paulo, brazil santiago, chile temuco, chile guayaquil, ecuador guayaquil, ecuador machala, ecuador quito, ecuador nancy, france tbilisi, georgia tbilisi, georgia tbilisi, georgia tbilisi, georgia tbilisi, georgia larissa, greece budapest, hungary debrecen, hungary bangalore, india chennai, india chennai, india delhi, india jaipur, india kolkata, india mumbai, india nashik, india nashik, india new delhi, india pune, india bari, italy pavia, italy piacenza, italy rimini, italy tokyo, japan daugavpils, latvia riga, latvia acapulco, mexico monterrey, mexico arequipa, peru arequipa, peru lima, peru trujillo, peru cebu, philippines makati, philippines manila, philippines pasig, philippines quezon city, philippines san juan city, philippines taguig, philippines gdansk, poland lodz, poland warsaw, poland lisbon, portugal brasov, romania bucharest, romania bucharest, romania cluj-napoca, romania cluj-napoca, romania suceava, romania arkhangelsk, russian federation kazan, russian federation krasnoyarsk, russian federation kursk, russian federation moscow, russian federation moscow, russian federation nizhny novgorod, russian federation novosibirsk, russian federation obninsk, russian federation omsk, russian federation samara, russian federation saransk, russian federation st. petersburg, russian federation st. petersburg, russian federation st. petersburg, russian federation st. petersburg, russian federation kragujevac, serbia cape town, south africa george, south africa johannesburg, south africa johannesburg, south africa port elizabeth, south africa pretoria, south africa sevilla, spain zaragoza, spain kaohsiung, taiwan taichung city, taiwan taipei, taiwan bangkok, thailand adana, turkey ankara, turkey ankara, turkey gaziantep, turkey cherkasy, ukraine donetsk, ukraine kharkiv, ukraine kherson, ukraine khmel'nyts'kyy, ukraine poltava, ukraine sumy, ukraine uzhhorod, ukraine vinnytsya, ukraine zaporizhzhia, ukraine""]",,https://ClinicalTrials.gov/show/NCT02162667,breast
455,456,NCT02928406,a study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract,,"Active, not recruiting",No Results Available,urinary tract cancer,drug: atezolizumab,"percentage of participants with adverse events|overall survival (os)|progression free survival (pfs) as per response evaluation criteria in solid tumors version 1.1 (recist v1.1)|pfs as per modified response evaluation criteria in solid tumors (modified recist)|percentage of participants with best overall response as assessed by recist v1.1|percentage of participants with best overall response as assessed by modified recist|percentage of participants with disease control as assessed by recist v1.1|percentage of participants with disease control as assessed by modified recist|duration of response as assessed by recist v1.1|duration of response as assessed by modified recist|change from baseline in health-related quality of life (hrqol), as assessed using european organization for research and treatment of cancer (eortc) quality-of-life questionnaire core 30 (qlq-c30) score|change from baseline in european quality of life (euroqol) group 5-dimension 5-level (eq-5d-5l) self report questionnaire health utility score",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1004.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO29983|2016-002625-11,"November 30, 2016","June 30, 2022","June 30, 2022","October 10, 2016",,"May 10, 2022","['inst. alexander fleming; oncologia, buenos aires, argentina hospital aleman, caba, argentina hospital britanico de buenos aires, ciudad autonoma buenos aires, argentina canberra hospital; medical oncology, canberra, australian capital territory, australia macquarie university hospital, macquarie park, new south wales, australia prince of wales hospital; oncology, randwick, new south wales, australia northern cancer institute, st leonards, new south wales, australia calvary mater newcastle; medical oncology, waratah, new south wales, australia icon cancer foundation, south brisbane, queensland, australia royal adelaide hospital, adelaide, south australia, australia royal hobart hospital; hematology/oncology, hobart, tasmania, australia box hill hospital, box hill, victoria, australia austin hospital olivia newton john cancer centre, heidelberg, victoria, australia medizinische universität innsbruck; universitätsklinik für urologie, innsbruck, austria ordensklinikum linz elisabethinen; abteilung für urologie und andrologie, linz, austria landeskrankenhaus salzburg; universitätsklinik für urologie und andrologie der pmu, salzburg, austria medizinische universität wien; univ.klinik für innere medizin i - abt. für onkologie, wien, austria medizinische universität wien; universitätsklinik für urologie, wien, austria uz brussel, brussel, belgium cliniques universitaires st-luc, bruxelles, belgium uz leuven gasthuisberg, leuven, belgium chu sart-tilman, liège, belgium pronutrir - suporte nutricional e quimioterapia ltda., fortaleza, ce, brazil centro integrado de oncologia de curitiba, curitiba, pr, brazil hospital sao lucas - pucrs, porto alegre, rs, brazil hospital de cancer de barretos, barretos, sp, brazil hospital sírio-libanês, sao paulo, sp, brazil hospital alemao oswaldo cruz, sao paulo, sp, brazil complex oncology center (coc)-plovidiv, plovdiv, bulgaria university multiprofile hospital for active treatment tsaritsa yoanna - isul ead, sofia, bulgaria shatod - sofia, sofia, bulgaria tom baker cancer centre-calgary, calgary, alberta, canada cross cancer institute ; dept of medical oncology, edmonton, alberta, canada queen elizabeth ii health sciences centre, halifax, nova scotia, canada royal victoria hospital, barrie, ontario, canada the ottawa hospital cancer center; general campus, ottawa, ontario, canada nanjing drum tower hospital, the affiliated hospital of nanjing university medical school, nanjing city, china clinica del country, bogota, colombia clinical hospital centre zagreb, zagreb, croatia fakultni nemocnice u sv. anny v brne, brno, czechia fakultni nemocnice kralovske vinohrady, praha, czechia fakultni thomayerova nemocnice; onkologicke oddeleni, praha, czechia aalborg universitetshospital, klinik kirurgi-kræft, onkologisk afd., aalborg, denmark aarhus universitetshospital; kræftafdelingen, aarhus n, denmark herlev hospital; afdeling for kræftbehandling, herlev, denmark rigshospitalet; onkologisk klinik, københavn ø, denmark east tallinn central hospital; clinic of internal medicine, tallinn, estonia north estonia medical centre foundation; oncology center, tallinn, estonia universitätsklinikum ""carl gustav carus""; klinik und poliklinik für urologie, dresden, germany universitätsklinikum erlangen; medizinische klinik 5; hämatologie und internistische onkologie, erlangen, germany universitätsmedizin göttingen georg-august-universität; klinik für urologie, göttingen, germany krankenhaus martha-maria halle-dölau, klinik für urologie, halle (saale), germany medizinische hochschule hannover; klinik für urologie und onkologische urologie, hannover, germany onkologische schwerpunktpraxis, heidelberg, germany universitätsklinikum schleswig-holstein / campus lübeck; klinik für urologie, lübeck, germany kliniken maria hilf gmbh, krankenhaus st. franziskus, mönchengladbach, germany klinikum rechts der isar der tu münchen; urologische klinik und poliklinik, münchen, germany universitätsklinikum münster, klinik für urologie und kinderurologie, münster, germany universitätsklinikum tübingen; klinik für urologie, tübingen, germany universitätsklinikum ulm; klinik für urologie, ulm, germany alexandras general hospital of athens; oncology department, athens, greece iaso general hospital of athens, athens, greece agioi anargyroi cancer hospital; 2nd oncology dept., kifisia, greece metropolitan hospital; 2nd oncology clinic, piraeus, greece thermi clinic; oncology clinic, thermi thessalonikis, greece euromedical general clinic of thessaloniki; oncology department, thessaloniki, greece papageorgiou general hospital; medical oncology, thessaloniki, greece honvédelmi minisztérium állami egészségügyi központ; onkológiai osztály; oncology department, budapest, hungary semmelwies university of medicine; urology dept., budapest, hungary orszagos onkologiai intezet, budapest, hungary szegedi tudomanyegyetem, aok, szent-gyorgyi albert klinikai kozpont, onkoterapias klinika, szeged, hungary jász-nagykun-szolnok megyei hetényi géza kórház; onkológiai osztály, szolnok, hungary healthcare global cancer centre; medical oncology, ahmedabad, gujarat, india tata medical centre; medical oncology, kolkata, west bengal, india artemis health institute, gurgaon, india max super speciality hospital, new delhi, india cork university hospital, cork, ireland adelaide & meath hospital, dublin, incorporating the national children\'s hospital; oncology day unit, dublin, ireland policlinico ospedaliero ss annunziata; u.o. di clinica oncologica, chieti, abruzzo, italy azienda ospedaliera universitaria federico ii, napoli, campania, italy istituto nazionale tumori irccs fondazione g. pascale; dipartimento uro-ginecologico, napoli, campania, italy az.osp s. orsola - malpighi-reparto di oncologia medica, bologna, emilia-romagna, italy irst istituto scientifico romagnolo per lo studio e cura dei tumori, sede meldola; oncologia medica, meldola, emilia-romagna, italy a.o. universitaria policlinico di modena; oncologia, modena, emilia-romagna, italy arcispedale santa maria nuova; oncologia, reggio emilia, emilia-romagna, italy a.o. universitaria s. maria della misericordia di udine; oncologia, udine, friuli-venezia giulia, italy policlinico universitario campus biomedico di roma; u.o.oncologia medica, roma, lazio, italy azienda ospedaliera san camillo forlanini; oncologia medica, roma, lazio, italy policlinico universitario ""agostino gemelli""; u.o.c. oncologia medica, roma, lazio, italy irccs istituto nazionale per la ricerca sul cancro (ist); oncologia medica a, genova, liguria, italy asst papa giovanni xxiii; oncologia medica, bergamo, lombardia, italy asst di cremona; dip. medicina - s.c. oncologia, cremona, lombardia, italy irccs istituto nazionale dei tumori (int);s.c. medicina oncologica 2, milano, lombardia, italy istituto europeo di oncologia, milano, lombardia, italy a.o. universitaria s. luigi gonzaga; oncologia medica, orbassano, piemonte, italy irccs ist. tumori giovanni paolo ii; dipartimento oncologia medica, bari, puglia, italy irccs ospedale casa sollievo della sofferenza; oncologia, san giovanni rotondo, puglia, italy a.o.u. cagliari-p.o. monserrato;u.o. oncologia, cagliari, sardegna, italy ospedale cannizzaro, oncologia, catania, sicilia, italy azienda usl8 arezzo-presidio ospedaliero 1 san donato;u.o.c. oncologia, arezzo, toscana, italy azlenda ospendaliero-universitaria pisana; c.o. oncologia 2, pisa, toscana, italy azienda ospedaliera s. maria - terni; oncologia, terni, umbria, italy irccs istituto oncologico veneto (iov); oncologia medica prima, padova, veneto, italy azienda ospedaliera di verona-policlinico g.b. rossi; oncologia medica, verona, veneto, italy hotel dieu de france; oncology, beirut, lebanon hospital of lithuanian university of health sciences kaunas clinics - endocrinology clinic, kaunas, lithuania national cancer institute, vilnius, lithuania nki/avl, amsterdam, netherlands vu medisch centrum; dept. of medical oncology, amsterdam, netherlands academ ziekenhuis groningen; medical oncology, groningen, netherlands maastricht university medical centre; medical oncology, maastricht, netherlands st. antonius locatie leidsche rijn, utrecht, netherlands centrum onkologii ziemi lubelskiej im. sw jana z dukli, i oddz. chemioterapii, lublin, poland szpital kliniczny przemienienia pańskiego uniwersytetu medycznego im. karola marcinkowskiego, poznan, poland szpital grochowski im. dr med. rafała masztaka sp. z o.o., warszawa, poland nzoz onko-dent g. l. slomian, spolka jawna, żory, poland hospital de braga; servico de oncologia medica x, braga, portugal huc; servico de urologia e transplantacao renal, coimbra, portugal hospital de santa maria; servico de oncologia medica, lisboa, portugal ipo do porto; servico de oncologia medica, porto, portugal oncopremium team srl, baia mare, romania institutul oncologic prof. dr. ion chiricuta cluj-napoca; spital de zi-parter, cluj-napoca, romania centrul de oncologie sfantul nectarie, craiova, romania centrul de radioterapie amethyst, floresti, romania oncomed srl; oncologie, timisoara, romania blokhin cancer research center; urological dept, moscow, russian federation p.a. herzen oncological inst. ; oncology, moscow, russian federation king faisal specialist hospital & research centre; oncology, riyadh, saudi arabia narodny onkologicky ustav, bratislava, slovakia hospital univ. central de asturias; servicio de oncologia, oviedo, asturias, spain hospital universitari germans trias i pujol; servicio de oncologia, badalona, barcelona, spain complejo hospitalario de althaia; servicio de oncologia, manresa, barcelona, spain corporacio sanitaria parc tauli; servicio de oncologia, sabadell, barcelona, spain hospital universitario reina sofia; servicio de oncologia, córdoba, cordoba, spain hospital universitario son espases; servicio de oncologia, palma de mallorca, islas baleares, spain complejo hospitalario universitario de santiago (chus) ; servicio de oncologia, santiago de compostela, la coruña, spain hospital universitario de canarias;servicio de oncologia, la laguna, tenerife, spain hospital de basurto; servicio de oncologia, bilbao, vizcaya, spain hospital del mar barcelona, barcelona, spain hospital univ vall d\'hebron; servicio de oncologia, barcelona, spain hospital clínic i provincial; servicio de oncología, barcelona, spain hospital de la santa creu i sant pau; servicio de oncologia, barcelona, spain hospital duran i reynals; oncologia, barcelona, spain hospital san pedro de alcantara; servicio de oncologia, caceres, spain hospital universitari de girona dr. josep trueta; servicio de oncologia, girona, spain hospital general universitario de guadalajara; servicio de oncologia, guadalajara, spain hospital lucus augusti; servicio de oncologia, lugo, spain hospital ramon y cajal; servicio de oncologia, madrid, spain hospital clinico san carlos; servicio de oncologia, madrid, spain hospital universitario 12 de octubre; servicio de oncologia, madrid, spain hospital universitario la paz; servicio de oncologia, madrid, spain hospital de madrid norte sanchinarro- centro integral oncologico clara campal; servicio de oncologia, madrid, spain hospital clinico universitario virgen de la victoria; servicio de oncologia, malaga, spain hospital general universitario j.m morales meseguer; servicio de oncologia, murcia, spain hospital de navarra; servicio de oncologia, navarra, spain complejo hospitalario de orense; servicio de oncologia, orense, spain hospital universitario virgen del rocio; servicio de oncologia, sevilla, spain complejo hospitalario de toledo- h. virgen de la salud; servicio de oncologia, toledo, spain hospital clínico universitario de valencia; servicio de oncología, valencia, spain hospital general universitario de valencia; servicio de oncologia, valencia, spain hospital la fe, valencia, spain ospedale regionale di bellinzona medizin onkologie, bellinzona, swaziland universitaetsspital basel; onkologie, basel, switzerland inselspital bern; universitätsklinik für medizinische onkologie, bern, switzerland kantonsspital graubünden medizin onkologie; onkologie und hämatologie, chur, switzerland hôpitaux universit. de genève médecine oncologie; oncologie, geneve, switzerland luzerner kantonsspital; medizinische onkologie, luzern, switzerland kantonsspital winterthur; medizinische onkologie, winterthur, switzerland national cheng kung uni hospital; dept of hematology and oncology, tainan, taiwan chang gung medical foundation-linkou, urinary oncology, taoyuan, taiwan velindre cancer centre, cardiff, united kingdom raigmore hospital; dept of radiotherapy & oncology, inverness, united kingdom leicester royal infirmary nhs trust, leicester, united kingdom barts and the london nhs trust., london, united kingdom royal marsden nhs foundation trust, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT02928406,
456,457,NCT02795988,a study of imu-131(her-vaxx) and chemotherapy compared to chemotherapy only in patients with her2 positive advanced gastric cancer,,"Active, not recruiting",No Results Available,gastrointestinal neoplasms|adenocarcinoma,biological: imu-131|drug: cisplatin and either fluorouracil (5-fu) or capecitabine or oxaliplatin and capecitabine.,safety and tolerability of imu-131 (phase 1b)|recommended phase 2 dose of imu-131 (phase 1b)|clinical efficacy of imu-131 (phase 2)|progression free survival (phase 2)|time to progression (phase 2)|disease control rate (phase 2)|objective response rate (phase 2)|duration of objective response (phase 2)|change in tumor size (phase 2)|humoral and cellular immunogenicity of imu-131(phase 2)|incidence of teae's (phase 2),imugene limited,All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IMU.ACS.001,"August 30, 2017",January 2022,February 2022,"June 10, 2016",,"January 20, 2022","[""arensia exploratory medicine llc, tbilisi, georgia city cancer center, vijayawada, andhra pradesh, india north east cancer hospital and research institute, guwahati, assam, india shetty's hospital, bengaluru, karnataka, india curie manavata cancer centre, nashik, maharashtra, india deenanath mangeshkar hospital and research centre, pune, maharashtra, india victoria hospital, bangalore, india mnj institute of oncology and regional cancer centre, hyderabad, india tata medical centre, kolkata, india hcg nchri cancer centre, nagpur, india regional cancer centre indira gandhi institute of medical sciences, patna, india arensia exploratory medicine imsp institutul oncologic, chisinau, moldova, republic of oncology institute of vojvodina, sremska kamenica, južnobanatski okrug, serbia institute for oncology and radiology of serbia - ppds, belgrade, serbia military medical academy, belgrade, serbia clinical hospital center bezanijska kosa, belgrade, serbia national cheng-kung university hospital, tainan, taiwan taipei veterans general hospital, taipei, taiwan division of medical oncology, department of medicine, prince of songkla university, songklanagarind hospital, hat yai, songkhla province, thailand national cancer institute of thailand, bangkok, thailand division of oncology, department of internal medicine, faculty of medicine, chiang mai university, chiang mai, thailand arensia exploratory medicine llc, kapitanivka, ukraine""]",,https://ClinicalTrials.gov/show/NCT02795988,gastric kidney
457,458,NCT02069704,bioequivalence study bevacizumab biosimilar (bevz92) versus bevacizumab (avastin®) in first-line treatment mcrc patients,,Completed,Has Results,metastatic colorectal cancer (mcrc),"drug: bevacizumab biosimilar (bevz92)|drug: avastin® (bevacizumab, reference product)","area under the concentration-versus-time curve (auc) at cycle 1 (auc0-336h) of bevz92 and avastin®|auc at steady state (aucss) of bevz92 and avastin®|treatment emergent adverse events (teaes) and serious adverse events (saes) reported with bevz92 and avastin®|anti-drug antibody (ada) of bevz92 and avastin®|objective response rate (orr) of bevz92 and avastin®|cmax,sd of bevz92 and avastin®|progression-free survival (pfs) of bevz92 and avastin®|cmax,ss of bevz92 and avastin®|ctrough,sd of bevz92 and avastin®|ctrough,ss of bevz92 and avastin®|elimination half-life (t1/2) of bevz92 and avastin®|elimination rate constant (kel) of bevz92 and avastin®|volume of distribution (vd) of bevz92 and avastin®",mabxience s.a|laboratorio elea phoenix s.a.|libbs farmacêutica ltda,All,"18 Years and older   (Adult, Older Adult)",Phase 1,142.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEVZ92-A-01-13,"October 29, 2014",October 2015,June 2017,"February 24, 2014","July 23, 2019","July 23, 2019","['hospital de gastroenterologia ""dr. carlos bonorino udaondo"", buenos aires, argentina instituto oncológico de rosario, rosario, argentina fundaçáo pio xii - hospital do cancer de barretos, barretos, brazil hospital caridade, ijui, brazil hospital sao lucas da pucrs, porto alegre, brazil centro de pesquisa do instituto brasileiro de controle do câncer - ibcc, são paulo, brazil hosp. a.c camargo, são paulo, brazil instituto do cancer del estado de s. paulo (iceps ), são paulo, brazil m s patel cancer centre- shree krishna hospital, karamsad, gujarat, india sri ramachandra hospital, chennai, india tata hospital, mumbai, india central india canter research institute, nagpur, india curie manavta cancer center, nashik, india regional cancer center & medical college, thiruvananthapuram, india centro oncológico clara campal, madrid, spain dnipropetrovsk city multiple-discipline clinical hospital №4, dnipropetrovsk, ukraine kharkiv regional clinical oncology center, kharkiv, ukraine danylo halytskiy lviv national medical university, lviv, ukraine']",,https://ClinicalTrials.gov/show/NCT02069704,colon
458,459,NCT00863746,a 3rd/4th line placebo-controlled trial of sorafenib in patients with predominantly non squamous non-small cell lung cancer (nsclc).,MISSION,Completed,Has Results,carcinoma|non-small-cell lung,"drug: sorafenib (nexavar, bay43-9006)|drug: placebo",overall survival|progression-free survival|disease control|objective tumor response|time to progression|mean change from baseline in european organization for research and treatment of cancer core quality of life questionnaire for palliative care (eortc qlq-c15-pal) - global health status|mean change from baseline in european organization for research and treatment of cancer core quality of life questionnaire lung cancer module (eortc qlq-lc13) - coughing subscale|mean change from baseline in european organization for research and treatment of cancer core quality of life questionnaire lung cancer module (eortc qlq-lc13) - dyspnea|mean change from baseline in euroqol-5d (eq-5d) - index score|mean change from baseline in euroqol-5d (eq-5d) - vas score,bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,703.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13266|2008-006914-62,April 2009,March 2012,April 2013,"March 18, 2009","July 30, 2013","January 19, 2015","['fayetteville, arkansas, united states stanford, california, united states philadelphia, pennsylvania, united states ramos mejía, buenos aires, argentina buenos aires, ciudad auton. de buenos aires, argentina rosario, santa fe, argentina rosario, santa fe, argentina córdoba, argentina córdoba, argentina santa fé, argentina graz, austria linz, austria wien, austria antwerpen, belgium bruxelles - brussel, belgium charleroi, belgium genk, belgium brasilia, distrito federal, brazil belo horizonte, minas gerais, brazil porto alegre, rio grande do sul, brazil porto alegre, rio grande do sul, brazil santo andré, sao paulo, brazil são josé dos campos, sao paulo, brazil são paulo, sao paulo, brazil sao paulo, brazil plovdiv, bulgaria sofia, bulgaria sofia, bulgaria varna, bulgaria varna, bulgaria montreal, quebec, canada santiago, chile santiago, chile guangzhou, guangdong, china nanjing, jiangsu, china chengdu, sichuan, china hangzhou, zhejiang, china hangzhou, zhejiang, china beijing, china beijing, china beijing, china beijing, china guangzhou, china shanghai, china shanghai, china caen, france dijon, france la roche sur yon cedex, france la tronche, france lille, france lyon cedex, france saint herblain, france tours, france heidelberg, baden-württemberg, germany karlsruhe, baden-württemberg, germany mannheim, baden-württemberg, germany ulm, baden-württemberg, germany gauting, bayern, germany münchen, bayern, germany kassel, hessen, germany köln, nordrhein-westfalen, germany großhansdorf, schleswig-holstein, germany bad berka, thüringen, germany hamburg, germany athens, greece heraklion, greece thessaloniki, greece shatin, n.t, hong kong hongkong, hong kong kowloon, hong kong budapest, hungary budapest, hungary edeleny, hungary farkasgyepu, hungary torokbalint, hungary zalaegerszeg, hungary mumbai, maharashtra, india pune, maharashtra, india kerala, india bandung, indonesia jakarta, indonesia holon, israel jerusalem, israel jerusalem, israel kfar saba, israel petach tikva, israel zrifin, israel rozzano, milano, italy monza, monza-brianza, italy orbassano, torino, italy avellino, italy genova, italy livorno, italy parma, italy perugia, italy roma, italy nagoya, aichi, japan kashiwa, chiba, japan akashi, hyogo, japan osakasayama, osaka, japan sakai, osaka, japan itabashi-ku, tokyo, japan koto-ku, tokyo, japan fukuoka, japan seoul, seoul teugbyeolsi, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of seoul, korea, republic of amsterdam, netherlands harderwijk, netherlands heerlen, netherlands helmond, netherlands nieuwegein, netherlands zwolle, netherlands lahore, punjab, pakistan karachi, sindh, pakistan callao, peru lima, peru lima, peru lima, peru lima, peru san borja, peru cebu city, philippines manila, philippines metro manila, philippines quezon city, philippines kielce, poland krakow, poland olsztyn, poland rzeszow, poland szczecin, poland warszawa, poland kazan, russian federation moscow, russian federation moscow, russian federation moscow, russian federation st. petersburg, russian federation yaroslavl, russian federation singapore, singapore singapore, singapore port elizabeth, eastern cape, south africa johannesburg, gauteng, south africa prietoria, gauteng, south africa durban, kwazulu-natal, south africa cape town, western cape, south africa cruces/barakaldo, bilbao, spain orense, ourense, spain barcelona, spain barcelona, spain lleida, spain lugo, spain madrid, spain málaga, spain sevilla, spain zamora, spain falun, sweden göteborg, sweden linköping, sweden lund, sweden stockholm, sweden kaohsiung, taiwan taichung, taiwan taichung, taiwan taipei, taiwan taoyuan, taiwan bangkok, thailand chiang mai, thailand songkhla, thailand ankara, turkey instanbul, turkey istanbul, turkey izmir, turkey kocaeli, turkey bristol, avon, united kingdom cambridge, cambridgeshire, united kingdom greater manchester, manchester, united kingdom sutton, surrey, united kingdom leeds, west yorkshire, united kingdom aberdeen, united kingdom london, united kingdom london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00863746,
459,460,NCT00813605,quilt-2.018: safety & efficacy of folfiri with amg 479 or amg 655 vs folfiri alone in kras-mutant metastatic colorectal carcinoma,,Completed,No Results Available,metastatic colorectal cancer,other: folfiri|biological: amg 655|other: placebo|biological: amg 479,"progression free survival|overall survival, objective response, duration of response, time to response|incidence of adverse events|significant laboratory abnormalities|incidence of antibody formation","nantcell, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,155.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20060579|QUILT-2.018,March 2009,January 2011,June 2012,"December 23, 2008",,"October 27, 2016","[""research site, beverly hills, california, united states research site, los angeles, california, united states research site, santa maria, california, united states research site, denver, colorado, united states research site, denver, colorado, united states research site, miami, florida, united states research site, ocala, florida, united states research site, port saint lucie, florida, united states research site, atlanta, georgia, united states research site, chicago, illinois, united states research site, joliet, illinois, united states research site, fishers, indiana, united states research site, wichita, kansas, united states research site, paducah, kentucky, united states research site, worcester, massachusetts, united states research site, lebanon, new hampshire, united states research site, hudson, new york, united states research site, new york, new york, united states research site, high point, north carolina, united states research site, columbus, ohio, united states research site, philadelphia, pennsylvania, united states research site, philadelphia, pennsylvania, united states research site, amarillo, texas, united states research site, austin, texas, united states research site, dallas, texas, united states research site, temple, texas, united states research site, tyler, texas, united states research site, roanoke, virginia, united states research site, bordeaux cedex, france research site, boulogne billancourt, france research site, lille, france research site, lyon cedex 08, france research site, new territories, hong kong research site, budapest, hungary research site, gyor, hungary research site, pecs, hungary research site, szeged, hungary research site, hyderabad, andhra pradesh, india research site, mumbai, maharashtra, india research site, nagpur, maharashtra, india research site, nashik, maharashtra, india research site, pune, maharashtra, india research site, kolkata, west bengal, india research site, bangalore, india research site, genova, italy research site, milano, italy research site, orbassano, italy research site, gdansk, poland research site, gliwice, poland research site, opole, poland research site, arkhangelsk, russian federation research site, kursk, russian federation research site, moscow, russian federation research site, obninsk, russian federation research site, saint petersburg, russian federation research site, samara, russian federation research site, st petersburg, russian federation research site, ufa, russian federation research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, barcelona, cataluã±a, spain research site, barcelona, cataluã±a, spain research site, l'hospitalet de llobregat, cataluã±a, spain research site, pamplona, navarra, spain research site, madrid, spain research site, madrid, spain""]",,https://ClinicalTrials.gov/show/NCT00813605,colon
460,461,NCT03766295,masitinib plus gemcitabine in pancreatic cancer,,Completed,No Results Available,locally advanced or metastatic pancreatic cancer,drug: masitinib|drug: gemcitabine|drug: placebo,overall survival (median)|survival rates|progression free survival,ab science,All,"18 Years and older   (Adult, Older Adult)",Phase 3,377.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AB12005,July 2014,December 2020,December 2020,"December 6, 2018",,"December 8, 2020","['hospital az sint-jan, brugge, belgium polyclinique de limoges site chenieux, limoges, france centre hospitalier de longjumeau, longjumeau, france general university hospital of patras, patras, greece sanjeevani cbcc usa cancer hospital, raipur, india omsk clinical oncology dispensary omsk, omsk, russian federation national oncology institute, bratislava, slovakia institut salah azaiez de cancerologie, bab saadoun, tunisia center of surgical innovations, kiev, ukraine']",,https://ClinicalTrials.gov/show/NCT03766295,pancreat
461,462,NCT02260544,bioequivalence study of doxorubicin hydrochloride liposome injection,,Completed,No Results Available,ovarian epithelial cancer recurrent,drug: doxorubicin hydrochloride liposome injection,pharmacokinetic ( pk ) parameter : the maximum plasma doxorubicin concentration ( cmax ) [ time frame : 2 cycles ]|pk parameter : the areas under the plasma concentration versus time curve calculated from 0 to the last measurable observation ( auc 0-t)|pk parameter : the areas under the plasma concentration versus time curve extrapolated from 0 to infinity ( auc 0-inf)|incidence of treatment-emergent adverse events ( teaes),dr. reddy's laboratories limited,Female,18 Years to 60 Years   (Adult),Phase 1,49.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,591-13,July 2014,April 2015,August 2015,"October 9, 2014",,"September 23, 2016","['city cancer center, vijaywada, andhra pradesh, india nirmal hospital pvt ltd, surat, gujarat, india srinivasam cancer care hospitals india private limited, bangalore, karnataka, india erode cancer center, erode, karnataka, india cancer clinic and nursing home & jasleen hospital, nagpur, maharahtra, india curie manavta cancer centre, nashik, maharashtra, india acharya harihar regional cancer centre, cuttack, orissa, india meenakshi mission hospital & research centre, madurai, tamil nadu, india dr. g. viswanathan speciality hospitals, trichy, tamil nadu, india bibi general hospital, hyderabad, telangana, india mnj institute of oncology & regional cancer centre, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT02260544,ovari
462,463,NCT00553410,"letrozole in preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for hormone receptor-positive, lymph node-positive, early-stage breast cancer",SOLE,Completed,Has Results,breast cancer,drug: letrozole,disease-free survival (dfs)|overall survival|distant recurrence-free interval (drfi)|breast cancer-free interval,international breast cancer study group|breast international group,Female,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,4884.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IBCSG 35-07 / BIG 1-07|2007-001370-88|CDR0000574249,August 2007,April 2018,"May 15, 2019","November 4, 2007","January 29, 2019","March 11, 2020","['dana-farber/harvard cancer center at dana-farber cancer institute, boston, massachusetts, united states faulkner hospital, boston, massachusetts, united states armidale hospital, armidale, new south wales, australia bankstown - lidcombe hospital, bankstown, new south wales, australia southern highlands cancer center, bowral, new south wales, australia concord repatriation general hospital, concord, new south wales, australia breast center, gateshead, new south wales, australia port mcquarie base hospital, port macquarie, new south wales, australia prince of wales private hospital, randwick, new south wales, australia tamworth base hospital, tamworth, new south wales, australia tweed heads hospital, tweed heads, new south wales, australia calvary mater newcastle, waratah, new south wales, australia north west regional hospital, burnie, tasmania, australia royal hobart hospital, hobart, tasmania, australia box hill hospital, box hill, victoria, australia peter maccallum cancer centre, east melbourne, victoria, australia austin health, heidelberg, victoria, australia maroondah hospital, melbourne, victoria, australia royal perth hospital, perth, western australia, australia landeskrankenhaus feldkirch, feldkirch, austria medizinische universitaet graz, graz, austria innsbruck universitaetsklinik, innsbruck, austria krankenhaus bhs linz, linz, austria allgemeines krankenhaus linz, linz, austria st. johanns-spital, salzburg, austria medical university of vienna, vienna, austria allgemeines krankenhaus - universitatskliniken, vienna, austria krankenhaus lainz, vienna, austria hanusch-krankenhaus, vienna, austria lkh villach, villach, austria klinikum kreuzschwestern wels gmbh, wels, austria ziekenhuis netwerk antwerpen middelheim, antwerpen, belgium cliniques du sud luxembourg, arlon, belgium imelda vzw, ziekenhuis, bonheiden, belgium az klina, brasschaat, belgium institut jules bordet, brussels, belgium academisch ziekenhuis der vrije universiteit brussel, brussels, belgium cliniques universitaires saint-luc, brussels, belgium centre hospitalier universitaire brugmann, brussels, belgium algemeen ziekenhuis sint-maarten - campus rooiberg, duffel, belgium universitair ziekenhuis gent, ghent, belgium hopital de jolimont, haine saint paul, belgium virga jesse hospital, hasselt, belgium centre hospitalier hutois, huy, belgium az groeninge - oncologisch centrum, kortrijk, belgium u.z. gasthuisberg, leuven, belgium centre hospitalier de l\'ardenne, libramont, belgium centre hospitalier regional de la citadelle, liege, belgium clinique saint-joseph, liege, belgium chu liege - domaine universitaire du sart tilman, liege, belgium jan palfijn hospital, merksem, belgium az damiaan, oostende, belgium clinique saint-pierre, ottignies, belgium clinique saint vincent, rocourt, belgium az nikolaas - sint-niklaas, sint-niklaas, belgium sint-elisabethziekenhuis, turnhout, belgium centre hospitalier peltzer-la tourelle, verviers, belgium hospital santiago oriente dr. luis tisne brousse, penalolen, chile fundacion arturo lopez perez, santiago, chile hospital clinico san borja arriaran, santiago, chile instituto nacional del cancer, santiago, chile iram - chile, santiago, chile hospital clinico regional de valdivia at university austral de chile, valdivia, chile hospital carlos van buren, valparaiso, chile aarhus universitetshospital - aarhus sygehus, aarhus c, denmark copenhagen county herlev university hospital, copenhagen, denmark centralsygehus esbjerg, esbjerg, denmark herning central hospital, herning, denmark hillerod hospital, hillerod, denmark naestved hospital, naestved, denmark odense university hospital, odense, denmark bornholms hospital, ronne, denmark roskilde amtssygehuset, roskilde, denmark sonderborg sygehus, sonderborg, denmark vejle sygehus, vejle, denmark viborg sygehus, viborg, denmark institut bergonie, bordeaux, france aalen breast center, aalen, germany onkologische schwerpunktpraxis bielefeld, bielefeld, germany allgemeinen krankenhaus celle kinderklinik, celle, germany klinikum deggendorf, deggendorf, germany praxis dr. wilke - onkologie am klinikum fuerth, fuerth, germany vinzenzkrankenhaus hannover ggmbh, hannover, germany henriettenstiftung krankenhaus, hannover, germany gynaekologisch-onkologische praxis hannover, hannover, germany frauenheilkunde u. geburtshilfe, ilsede, germany asklepios klinik lich, lich, germany gemeinschaftspraxis gynaekologie & geburtshilfe, mannheim, germany klinikum meiningen gmbh, meiningen, germany klinikum memmingen, memmingen, germany klinikum offenback gmbh, offenbach, germany deaconess hospital, schwabisch hall, germany johanniter kankenhaus stendal, stendal, germany srh zentralklinikum suhl gmbh, suhl, germany universitaetsklinikum tuebingen, tuebingen, germany national institute of oncology - budapest, budapest, hungary szeged university, szeged, hungary tata memorial hospital, mumbai, india centro di riferimento oncologico - aviano, aviano, italy ospedale degli infermi - asl 12, biella, italy azienda sanitaria di bolzano, bolzano, italy spedali civili di brescia, brescia, italy a. perrino hospital, brindisi, italy azienda istituti ospitalieri, cremona, italy istituto scientifico romagnolo per lo studio e la cura dei tumori, meldola, italy european institute of oncology, milan, italy fondazione salvatore maugeri, pavia, italy misericordia e dolce hospital, prato, italy ospedale civile rimini, rimini, italy ospedale di circolo e fondazione macchi, varese, italy osaka rosai hospital, sakai, osaka, japan sagara hospital, kagoshima, japan kumamoto university faculty of medical and pharmaceutical sciences, kumamoto, japan kyoto university hospital, kyoto, japan niigata cancer center hospital, niigata, japan yao municipal hospital, osaka, japan tokyo metropolitan - komagome hospital, tokyo, japan christchurch hospital, christchurch, new zealand waikato hospital, hamilton, new zealand instituto nacional de enfermedades neoplasicas, lima, peru russian academy of medical sciences cancer research center, moscow, russian federation tygerberg hospital, kapstadt, south africa sandton oncology medical research, sandton, south africa vall d\'hebron university hospital, barcelona, spain m. d. anderson international espana sa, madrid, spain hospital ramon y cajal, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital son llatzer, palma de mallorca, spain hospital sant joan de reus, reus, spain hospital universitario virgen macarena, sevilla, spain hospital de torrevieja, torrevieja, spain instituto valenciano de oncologia, valencia, spain hospital clinico universitario de valencia, valencia, spain lasarettet i boras, boras, sweden malarsjukhuset hospital, eskilstuna, sweden sahlgrenska university hospital, gothenburg, sweden lidkoping hospital, lidkoping, sweden skaraborgs hospital, skovde, sweden karolinska university hospital - huddinge, stockholm, sweden kantonsspital aarau, aarau, switzerland kantonsspital baden, baden, switzerland istituto oncologico della svizzera italiana - ospedale san giovanni, bellinzona, switzerland inselspital bern, bern, switzerland oncocare sonnenhof-klinik engeriedspital, bern, switzerland andreasklinik cham zug, cham, switzerland kantonsspital graubuenden, chur, switzerland brustzentrum thurgau at kantonsspital frauenfeld, frauenfeld, switzerland kantonsspital freiburg, freiburg, switzerland centre hospitalier universitaire vaudois, lausanne, switzerland lago maggiore oncology foundation, locarno, switzerland ospedale ""la carita"", locarno, locarno, switzerland ospedale civico, lugano, switzerland ospedale beata vergine, mendrisio, switzerland kantonsspital olten, olten, switzerland hopital regional de sion-herens-conthey, sion, switzerland tumor zentrum zetup st. gallen und chur, st. gallen, switzerland kantonsspital - st. gallen, st. gallen, switzerland regionalspital, thun, switzerland kantonsspital winterthur, winterthur, switzerland breast center, zurich, switzerland city hospital triemli, zurich, switzerland universitaetsspital zuerich, zurich, switzerland borders general hospital, melrose, england, united kingdom dumfries & galloway royal infirmary, dumfries, scotland, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/10/nct00553410/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/10/nct00553410/sap_001.pdf",https://ClinicalTrials.gov/show/NCT00553410,breast
463,464,NCT00412776,study of proxinium plus best supportive care versus best supportive care for patients with advanced head and neck cancer,,Terminated,No Results Available,"carcinoma, squamous cell of head and neck|carcinoma, squamous cell|neoplasms, squamous cell|head and neck neoplasms|mouth neoplasms|head and neck cancer",drug: proxinium,"survival|tumour response, safety and quality of life",viventia bio,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,165.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VB4-845-01-IIIA,December 2005,April 2008,April 2008,"December 18, 2006",,"December 23, 2015","['hospital italiano regional del sur, bahia blanca, argentina hospital municipal de agudos leonidas lucero, bahia blanca, argentina centro de estudio y tratamiento de las enfermedades neoplasicas (ceten), buenos aires, argentina hospital de clinicas ""jose de san martin"", buenos aires, argentina hospital nacional alejandro posadas, buenos aires, argentina hospital universitario austral, buenos aires, argentina instituto medico platense, la plata, argentina hospital italiano garibaldi, rosario, argentina hospital de câncer de barretos - fundação pio xii, barretos, brazil cettro - centro de tratamento oncológico ltda., brasilia, brazil centro regional integrado de oncologia - crio, fortaleza, brazil hospital araújo jorge, goiania - go, brazil hospital amaral carvalho, jau, brazil pro-onco centro de tratamento oncológico s/c ltda, londrina, brazil biocor - hospital de doenças cardiovasculares ltda, nova lima, brazil cecan - centro do câncer francisco cunha filho, piracicaba, brazil hospital são lucas da pucrs, porto alegre - rs, brazil irmandade santa casa de misericórdia de porto alegre, porto alegre - rs, brazil instituto ribeirãopretano de combate ao câncer, riberao preto-sp, brazil inca - instituto nacional do câncer, rio de janeiro, brazil sos vida - soluções em saúde, salvador - ba, brazil santo andré diagnósticos e tratamentos ltda, santo andre-sp, brazil grupo de pesquisas médicas, são paulo - sp, brazil hospital das clínicas - faculdade de medicina da universidade de são paulo, são paulo - sp, brazil hospital do câncer a. c. camargo, são paulo, brazil clinical hospital ""sestre milosrdnice"", zagreb, croatia clinical hospital centre zagreb, clinic for ent, department for head and neck surgery, zagreb, croatia universtity hospital for tumors, department for head and neck surgery, zagreb, croatia centre georges-francois leclerc, dijon, france clinique guillaume le conquerant, le havre, france centre régional de lutte contre le cancer val d\'aurelle, montpellier, france charité -universitätsmedizin berlin, berlin, germany medizinische hochschule hannover, hannover, germany universität heidelberg, heidelberg, germany universitätsklinikum köln, köln, germany universitätsklinikum leipzig, leipzig, germany universitätsklinikum schleswig holstein, lübeck, germany johannes gutenberg-universität, mainz, germany klinikum der philipps-universität marburg, marburg, germany universitätsklinikum tübingen, tübingen, germany fovarosi onkormanyzat uzsoki utcai korhaza, fej-nyaksebeszet, budapest, hungary orszagos onkologiai intezet, budapest, hungary debreceni egyetem oec, onkologiai tanszek, debrecen, hungary petz aladar megyei korhaz, ful-orr-gege, fej, nyak sebeszet, gyor, hungary department of medical oncology, bangalore institute of oncology, bangalore, india kidwai memorial institute of oncology, bangalore, india global hospitals, hyderabaad, india mnj institute of oncology, hyderabaad, india nizam\'s institute of medical sciences, hyderabaad, india birla cancer institute sms medical college hospital, jaipur, india sk soni hospital, jaipur, india soumya hospita, karkhana, india amrita institute of medical sciences and research centre, kochin, india netaji subash chandra bose cancer research institute, kolkata, india orchid nursing home, kolkata, india department of medical oncology dayanand medical college & hospital, ludhiana, india asian institute of oncology, s l raheja hospital, mumbai, india tata memorial hospital, mumbai, india department of medical oncology aiims, institute rotary cancer hospital, new delhi, india department of medical oncology rajiv gandhi cancer institute and research centre, new delhi, india regional cancer centre, trivandrum, india soroka university medical center, beer sheva, israel the lady davis carmel medical center, haifa, israel haddasa ein carem hospital, jerusalem, israel rabin medical center, petach tikva, israel kaplan medical center, rehovot, israel tel aviv university medical school, tel aviv, israel sheba - medical center, tel-hashomer, israel azienda ospedaliera san gerardo, monza, italy irccs policlinico san matteo, pavia, italy azienda ospedaliera pisana, pisa, italy hospital clínica del parque, chihuahua, chih., mexico centro anticanceroso de la cruz roja mexicana de mérida, merida, mexico oca hospital, monterrey n.l., mexico hospital central ""dr. ignacio morones prieto"", san luis potosi, slp, mexico hospital ""dr. angel leaño"", zapopan, jalisco, mexico swietokrzyskie centrum onkologii, kielce, poland wojewodzki szpital specjalistyczny im. l.rydygiera, krakow, poland wojewodzki szpital specjalistyczny im. mikolaja kopernika, regionalny osrodek onkologiczny, lodz, poland zaklad opieki zdrowotnej mswia z warminsko-mazurskim centrum onkologii, olsztyn, poland samodzielny publiczny zaklad opieki zdrowotnej, opolskie centrum onkologii, opole, poland wielkopolskie centrum onkologii, poznan, poland centrum onkologii instytut im. m. sklodowskiej-curie, warszawa, poland ""prof. dr. i. chiricuta"" institute of oncology medical oncology and radiotherapy ii department, cluj-napoca, romania oradea clinical county hospital department of medical oncology, oradea, romania regional oncology dispensary, astrakhan, russian federation sverdlovsk regional oncology dispensary, ekaterinburg, russian federation state medical institution kursk regional oncology dispensary out-patient department, kursk, russian federation central clinical hospital #2 after ma semashko oao ""rrw"", moscow, russian federation moscow scientific-research oncology institute after p.a. gertsen, moscow, russian federation si russian oncology scientific center after nn blokhin rams, moscow, russian federation phi oao rrw railway clinical hospital at station gorkiy, nizhniy novgorod, russian federation stavropol regional oncology center, pyatigorsk branch out-patient department, pyatigorsk, russian federation phi dorozhnaya clinical hospital at saratov ii station of pryvolzhskaya railway oao russian railways, saratov, russian federation sih leningrad regional oncology dispansery, st. petersburg, russian federation spbsih city clinical oncology dispensary, st. petersburg, russian federation tambov regional oncological dispensary surgery department, tambov, russian federation republican clinical oncological dispenser radiological therapy, ufa, russian federation state medical institution regional clinical oncology dispensary, ulyanovsk, russian federation institute for oncology and radiology of serbia, belgrade, serbia military medical academy (mma) clinic for maxillofacial surgery, belgrade, serbia teaching hospital with policlinic of f. d. roosevelt department of otorhinolaryngology and surgery, banská bystrica, slovakia oncology institute of st. elisabeth clinic of stomatology and maxillofacial surgery, bratislava, slovakia teaching hospital with policlinic bratislava 1st clinic of otorhinolaryngology, bratislava, slovakia vychodoslovensky oncologicky ustav a.s., kosice, slovakia teaching hospital with policlinic nové zámky clinic of otorhinolaryngology, nove zamky, slovakia hospital santa creu i sant pau, barcelona, spain hospital vall d\'hebron, barcelona, spain hospital 12 de octubre, madrid, spain hospital ramón y cajal, madrid, spain hospital provincial de pontevedra, pontevedra, spain hospital universitario de salamanca, salamanca, castilla y león, spain chernovtsy regional oncology center, chernivtsy, ukraine kharkov regional clinical oncology dispensary, kharkov, ukraine institute of oncology of ams of ukraine, kiev, ukraine institute of otolaryngology, kiev, ukraine volyn regional oncology dispensary, lutsk, ukraine uzhgorod national university, uzhorod, ukraine zaporozhye regional clinical oncology dispensary, zaporozhye, ukraine university hospital aintree, liverpool, united kingdom royal marsden hospital, london, united kingdom christie hospital, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00412776,skin
464,465,NCT03761225,masitinib plus docetaxel in metastatic castration-resistant prostate cancer,,Completed,No Results Available,metastatic castrate resistant prostate cancer,drug: masitinib|drug: docetaxel|drug: prednisone|drug: placebo,progression free survival|overall survival,ab science,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,714.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AB12003,September 2014,"December 15, 2020","December 15, 2020","December 3, 2018",,"June 11, 2021","[""centre hospitalier universitaire de sherbrooke, sherbrooke, canada polyclinique d'oncologie de gentilly, nancy, france sanjay gandhi post graduate institute of medical sciences, lucknow, india centro di riferimento oncologico, aviano, italy istituto europeo di oncologia, milano, italy azienda ospedaliero universitaria pisana, pisa, italy universiti malaya medical centre, kuala lumpur, malaysia clinical oncology dispensary, omsk, russian federation clinic andros llc, st. petersburg, russian federation""]",,https://ClinicalTrials.gov/show/NCT03761225,prostat
465,466,NCT00002476,radiation therapy with or without chemotherapy in treating patients with advanced head and neck cancer,,Completed,No Results Available,head and neck cancer,biological: bleomycin sulfate|drug: fluorouracil|drug: leucovorin calcium|drug: methotrexate|drug: vincristine sulfate|radiation: low-let cobalt-60 gamma ray therapy|radiation: low-let photon therapy|radiation: radiation therapy,,cancer research uk|national cancer institute (nci),All,"18 Years and older   (Adult, Older Adult)",Phase 3,,Other,Interventional,Primary Purpose: Treatment,CRC-PHASE-III-91001|CDR0000076951|UKHAN-1,January 1990,,January 2010,"June 9, 2004",,"August 2, 2013","['raj tilak, indore, india royal sussex county hospital, brighton, england, united kingdom middlesex hospital- meyerstein institute, london, england, united kingdom derriford hospital, plymouth, england, united kingdom southend general hospital, westcliff-on-sea, england, united kingdom royal victoria hospital, belfast, northern ireland, united kingdom belfast city hospital trust, belfast, northern ireland, united kingdom']",,https://ClinicalTrials.gov/show/NCT00002476,
466,467,NCT00293540,luteal vs follicular surgical oophorectomy and tamoxifen in premenopausal women with metastatic hormone receptor positive breast cancer,,Completed,Has Results,breast cancer,procedure: oophorectomy|drug: tamoxifen,overall survival,international breast cancer research foundation|breast cancer research foundation,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,249.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-0476,February 2006,February 2014,March 2015,"February 17, 2006","June 28, 2016","July 27, 2016","[""ohio state university, columbus, ohio, united states dhaka medical college hospital, dhaka, bangladesh 4th hospital of hebei medical university, shijiazhuang, hebei, china beijing hospital, beijing, china cancer institute, beijing, china choa yang capital institute, beijing, china national railroad, beijing, china peoples hospital, beijing, china qilu hospital, ji nan, china fudan university, shanghai, china nizam's institute, hyderabaad, india dr. ciptomanounkusumo general hospital, jakarta, indonesia un. mayala, kuala lumpur, malaysia national institute of oncology, rabat, morocco university college hospital, ibadan, nigeria east avenue medical center, manila, philippines jose reyes, manila, philippines philippines general hospital, manila, philippines rizal, manila, philippines vicente sotto hospital, manila, philippines hospital k, hanoi, vietnam""]",,https://ClinicalTrials.gov/show/NCT00293540,breast
467,468,NCT03056755,"study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with pik3ca mutation with advanced breast cancer who have progressed on or after prior treatments",BYLieve,"Active, not recruiting",No Results Available,breast cancer,drug: alpelisib|drug: fulvestrant|drug: letrozole|drug: goserelin|drug: leuprolide,percentage of participants who are alive without disease progression at 6 months|progression free survival (pfs) for each cohort|progression free survival (pfs) on next line treatment pfs2) for each cohort|overall response rate (orr) for each cohort|clinical benefit rate (cbr) for each cohort|duration of response (dor)|overall suvivial (os) for each cohort|percentage of participants with clinical benefit as assessed by the investigator during the extension phase,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,383.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBYL719X2402|2016-004586-67,"August 14, 2017","June 14, 2021","July 17, 2023","February 17, 2017",,"May 16, 2022","['banner md anderson cancer center, gilbert, arizona, united states mayo clinic (arizona), phoenix, arizona, united states kaiser permanente medical group kaiser permanente-moanalua m.c, anaheim, california, united states beverly hills cancer center, beverly hills, california, united states university of calif irvine medical center, orange, california, united states kaiser permanente southern california, san diego, california, united states university of california, san francisco, san francisco, california, united states yale university yale cancer center, new haven, connecticut, united states advent health cancer institute, orlando, florida, united states university of kansas cancer center, kansas city, kansas, united states university of louisville hospital/james brown cancer ctr. sc, louisville, kentucky, united states mercy medical center, baltimore, maryland, united states greater baltimore medical center cancer center, baltimore, maryland, united states massachusetts general hospital neuroendocrine unit, boston, massachusetts, united states lahey clinic, burlington, massachusetts, united states josephine ford cancer institute, detroit, michigan, united states st vincent frontier cancer center, billings, montana, united states new mexico cancer care alliance, albuquerque, new mexico, united states memorial sloane kettering cancer center, new york, new york, united states university hospitals of cleveland seidman cancer center, cleveland, ohio, united states texas oncology charles a. sammons cancer ctr, dallas, texas, united states cancer care centers of south texas hoast ccc of so. tx- san antonio(2), san antonio, texas, united states ut health san antonio, san antonio, texas, united states virginia oncology associates sc, norfolk, virginia, united states northwest medical specialists, tacoma, washington, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, rosario, sante fe, argentina novartis investigative site, la rioja, argentina novartis investigative site, leuven, belgium novartis investigative site, liege, belgium novartis investigative site, vancouver, british columbia, canada novartis investigative site, halifax, nova scotia, canada novartis investigative site, kitchener, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, temuco, araucania, chile novartis investigative site, santiago, chile novartis investigative site, santiago, chile novartis investigative site, odense c, denmark novartis investigative site, vejle, denmark novartis investigative site, nice cedex 2, alpes maritimes, france novartis investigative site, saint-cloud, hauts de seine, france novartis investigative site, bordeaux, france novartis investigative site, caen cedex, france novartis investigative site, lille cedex, france novartis investigative site, lyon cedex, france novartis investigative site, montpellier cedex 5, france novartis investigative site, saint herblain cedex, france novartis investigative site, strasbourg cedex, france novartis investigative site, toulouse cedex 9, france novartis investigative site, augsburg, germany novartis investigative site, berlin, germany novartis investigative site, dresden, germany novartis investigative site, erlangen, germany novartis investigative site, essen, germany novartis investigative site, heidelberg, germany novartis investigative site, ulm, germany novartis investigative site, delhi, india novartis investigative site, petach tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, rehovot, israel novartis investigative site, tel aviv, israel novartis investigative site, ancona, an, italy novartis investigative site, bergamo, bg, italy novartis investigative site, bologna, bo, italy novartis investigative site, genova, ge, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, roma, rm, italy novartis investigative site, napoli, italy novartis investigative site, osaka-city, osaka, japan novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, jalisco, mexico novartis investigative site, maastricht, az, netherlands novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, sevilla, andalucia, spain novartis investigative site, salamanca, castilla y leon, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, hospitalet de llobregat, catalunya, spain novartis investigative site, castellon, comunidad valenciana, spain novartis investigative site, madrid, spain novartis investigative site, tainan, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taipei, taiwan novartis investigative site, sutton, surrey, united kingdom novartis investigative site, edinburgh, united kingdom novartis investigative site, leicester, united kingdom novartis investigative site, london, united kingdom novartis investigative site, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT03056755,breast
468,469,NCT00417079,xrp6258 plus prednisone compared to mitoxantrone plus prednisone in hormone refractory metastatic prostate cancer,TROPIC,Completed,Has Results,neoplasms|prostatic neoplasms,drug: cabazitaxel (xrp6258) (rpr116258)|drug: mitoxantrone|drug: prednisone,overall survival|time to progression free survival (pfs)|overall tumor response|time to tumor progression|time to prostatic specific antigen (psa) progression|psa (prostate-specific antigen) response|time to pain progression|pain response,sanofi,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,755.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC6193,January 2007,September 2009,September 2009,"December 29, 2006","December 23, 2010","March 10, 2011","['sanofi-aventis us, bridgewater, new jersey, united states sanofi-aventis argentina, buenos aires, argentina sanofi-aventis belgium, diegem, belgium sanofi-aventis brazil, sao paulo, brazil sanofi-aventis canada, laval, quebec, canada sanofi-aventis chile, santiago, chile sanofi-aventis czech republic, praha, czech republic sanofi-aventis denmark, horsholm, denmark sanofi-aventis finland, helsinki, finland sanofi-aventis france, paris, france sanofi-aventis germany, berlin, germany sanofi-aventis hungaria, budapest, hungary sanofi-aventis india, mumbai, india sanofi-aventis italy, milano, italy sanofi-aventis south korea, seoul, korea, republic of sanofi-aventis mexico, mexico, mexico sanofi-aventis netherlands, gouda, netherlands sanofi-aventis russia, moscow, russian federation sanofi-aventis singapore, singapore, singapore sanofi-aventis slovakia, bratislava, slovakia sanofi-aventis south africa, midrand, south africa sanofi-aventis spain, barcelona, spain sanofi-aventis sweden, bromma, sweden sanofi-aventis taiwan, taipei, taiwan sanofi-aventis turkey, istanbul, turkey sanofi-aventis uk, guildford, surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00417079,prostat
469,470,NCT05152147,a study of zanidatamab in combination with chemotherapy plus or minus tislelizumab in patients with her2-positive advanced or metastatic gastric and esophageal cancers,HERIZON-GEA-01,Recruiting,No Results Available,gastric neoplasms|gastroesophageal adenocarcinoma|esophageal adenocarcinoma,drug: zanidatamab|drug: tislelizumab|drug: trastuzumab|drug: capecitabine|drug: oxaliplatin|drug: cisplatin|drug: 5-fluorouracil|diagnostic test: in situ hybridization (ish)-based companion diagnostic assay|diagnostic test: immunohistochemistry (ihc)-based companion diagnostic assay,"progression-free survival (pfs) by blinded independent central review (bicr)|overall survival|confirmed objective response rate (orr) by bicr|duration of response (dor) by bicr|pfs per investigator assessment|orr per investigator assessment|dor per investigator assessment|incidence of adverse events|incidence of clinical laboratory abnormalities|health-related quality of life (hrqol) as assessed by the european organisation for research and treatment of cancer (eortc) quality of life questionnaire (core cancer questionnaire) c30 (qlq-c30)|hrqol as assessed by the eortc quality of life questionnaire (oesophago-gastric module) og25 (qlq-og25)|hrqol as assessed by the euroqol 5-dimensions 5-levels (eq-5d-5l) questionnaire|serum concentration of zanidatamab, tislelizumab, and trastuzumab|incidence of anti-drug antibodies (adas)","zymeworks inc.|beigene, ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,714.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZWI-ZW25-301|2021-000296-36,"December 2, 2021",June 2024,July 2025,"December 9, 2021",,"May 16, 2022","['instituto de investigaciones metabólicas - idim, ciudad autónoma de buenos aires, argentina fundación centro de medicina nuclear y molecular e, córdoba, argentina centro médico privado cemaic, córdoba, argentina research site, parque patricios, argentina centro de investigación pergamino s.a., pergamino, argentina centro de investigaciones médicas tucumán, san miguel de tucumán, argentina research site, viedma, argentina border medical oncology research unit, albury, australia research site, bedford park, australia austin health, heidelberg, australia liverpool hospital, liverpool, australia fional stanley hospital, murdoch, australia imelda vzw, bonheiden, belgium cliniques universitaires saint-luc, brussels, belgium research site, brussels, belgium uz gent, gent, belgium uz leuven, leuven, belgium research site, liège, belgium research site 1, barretos, brazil research site 2, barretos, brazil research site, belo horizonte, brazil research site, brasília, brazil research site, fortaleza, brazil research site, ijuí, brazil research site 1, porto alegre, brazil research site 2, porto alegre, brazil research site 3, porto alegre, brazil research site 4, porto alegre, brazil research site, rio de janeiro, brazil research site, santo andré, brazil research site, sorocaba, brazil research site, são paulo, brazil research site, montreal, canada research site, toronto, canada corporacion de beneficencia osorno, osorno, chile centro de estudios clínicos saga spa, providencia, chile research site, providencia, chile meditek ltda, recoleta, chile sociedad oncovida s.a, santiago, chile icegclinic, santiago, chile biocinetic spa, santiago, chile sociedad de investigaciones medicas limitada, temuco, chile beijing chao-yang hospital, capital medical university, beijing, china beijing tiantan hospital, capital medical university, beijing, china beijing cancer hospital, beijing, china peking university third hospital, beijing, china beijing luhe hospital, capital medical university, beijing, china research site 1, beijing, china research site 2, beijing, china research site 3, beijing, china the first affiliated hospital of bengbu medical college, bengbu, china research site, changchun, china hunan cancer hospital, changsha, china changzhi people hospital, changzhi, china research site, changzhou, china sichuan cancer hospital & institute, chengdu, china foshan first people\'s hospital, foshan, china the first affiliated hospital of fujian medical university, fuzhou, china fujian cancer hospital, fuzhou, china the sixth affiliated hospital of sun yat-sen university, guangzhou, china research site, guangzhou, china hainan general hospital, haikou, china second affiliated hospital of zhejiang university school of medicine, hangzhou, china zhejiang cancer hospital, hangzhou, china research site 1, hangzhou, china research site 2, hangzhou, china research site, harbin, china anhui provincial cancer hospital, hefei, china the second affiliated hospital of anhui medical university, hefei, china research site, hohhot, china shandong cancer hospital, jinan, china jinan cancer hospital, jinan, china research site, jining, china research site, kunming, china the first hospital of lanzhou university, lanzhou, china gansu provincial cancer hospital, lanzhou, china the first affiliated hospital of nanchang university, nanchang, china research site, nanjing, china the affiliated hospital of qingdao university, qingdao, china fudan university affiliated zhongshan hospital, shanghai, china research site 1, shanghai, china research site 2, shanghai, china research site 3, shanghai, china research site 4, shanghai, china research site 5, shanghai, china research site, shangrao, china research site 1, shenyang, china research site 2, shenyang, china peking university shenzhen hospital, shenzhen, china research site, shenzhen, china research site, shijiazhuang, china tianjin medical university general hospital, tianjin, china tianjin medical university cancer institute & hospital, tianjin, china the tonghua central hospital, tonghua, china weihai municipal hospital, weihai, china the first affiliated hospital of wenzhou medical university, wenzhou, china union hospital tongji medical college huazhong university of science and technology, wuhan, china hubei cancer hospital, wuhan, china research site, wuxi, china first affiliated hospital of xi \'an jiaotong university, xi\'an, china research site, xi\'an, china research site, xiamen, china northern jiangsu people\'s hospital, yangzhou, china research site, yangzhou, china research site 1, zhengzhou, china research site 2, zhengzhou, china research site 3, zhengzhou, china cancer hospital affiliated to xinjiang medical university, ürümqi, china research site, hradec králové, czechia research site 1, tallinn, estonia research site 2, tallinn, estonia institut sainte catherine, avignon, france hopital jean minjoz, besançon, france edog - institut bergonie - ppds, bordeaux, france research site, dijon, france research site, grenoble, france research site, lyon, france research site, nantes, france chru de poitiers la miletrie, poitiers, france edog - centre eugene marquis centre regional de lutte contre le cancer - ppds, rennes, france chru de brest - hopital morvan, saint-priest-en-jarez, france hôpital de rangueil, toulouse, france hôpital saint antoine, villejuif, france research site 1, tbilisi, georgia research site 2, tbilisi, georgia research site 3, tbilisi, georgia research site 4, tbilisi, georgia research site, frankfurt am main, germany research site, hannover, germany research site, leipzig, germany research site, trier, germany research site, ulm, germany aretaieio hospital of athens, athens, greece attikon university general hospital, athens, greece research site, piraeus, greece bioclinic thessaloniki oncology department, thessaloniki, greece agios loucas clinic sa, thessaloniki, greece interbalkan medical center of thessaloniki oncology department, thessaloniki, greece research site 1, guatemala city, guatemala research site 2, guatemala city, guatemala research site 3, guatemala city, guatemala research site, salcaja, guatemala research site, hong kong, hong kong research site, kowloon, hong kong research site, bangalore, india research site, bhubaneswar, india research site, gurgaon, india research site, hyderabad, india research site, jaipur, india research site, nashik, india research site, new delhi, india research site, patna, india research site, pune, india research site, vijayawada, india research site 1, dublin, ireland research site 2, dublin, ireland research site, bologna, italy research site, candiolo, italy research site, genova, italy research site, meldola, italy research site 1, milano, italy research site 2, milano, italy research site 3, milano, italy research site, modena, italy research site, napoli, italy research site, reggio emilia, italy research site, roma, italy research site, torino, italy centro ricerche cliniche di verona, verona, italy research site, vicenza, italy hallym university sacred heart hospital, anyang-si, korea, republic of dong-a university hospital, busan, korea, republic of kyungpook national university chilgok hospital, daegu, korea, republic of national cancer center, goyang-si, korea, republic of gachon university gil medical center, incheon, korea, republic of cha bundang medical center, cha university, seongnam-si, korea, republic of seoul national university bundang hospital, seongnam-si, korea, republic of korea university anam hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of the catholic university of korea, seoul st. mary\'s hospital, seoul, korea, republic of kangbuk samsung hospital, seoul, korea, republic of severance hospital yonsei university health system - ppds, seoul, korea, republic of asan medical center, seoul, korea, republic of gangnam severance hospital, yonsei university health system, seoul, korea, republic of samsung medical center, seoul, korea, republic of korea university guro hospital, seoul, korea, republic of research site, george town, malaysia research site 1, kuala lumpur, malaysia research site 2, kuala lumpur, malaysia research site, kuching, malaysia research site, putrajaya, malaysia research site 1, mexico city, mexico research site 2, mexico city, mexico research site 3, mexico city, mexico research site, monterrey, mexico research site, oaxaca, mexico research site, eindhoven, netherlands research site, groningen, netherlands research site, leiden, netherlands research site, tilburg, netherlands research site, arequipa, peru research site, bellavista, peru research site, chiclayo, peru research site, jesús maría, peru research site 1, lima, peru research site 2, lima, peru research site 3, lima, peru research site 4, lima, peru research site 5, lima, peru research site, santiago de surco, peru research site 1, trujillo, peru research site 2, trujillo, peru centrum medyczne poznan - pratia - ppds, skórzewo, poland wojewodzkie wielospecjalistyczne centrum onkologii i traumatologii im. m. kopernika w lodzi, łódź, poland research site, almada, portugal research site, coimbra, portugal research site, guimarães, portugal centro hospitalar lisboa norte, e.p.e. - hospital de santa maria, lisboa, portugal research site, loures, portugal research site 1, porto, portugal research site 2, porto, portugal research site 3, porto, portugal research site 4, porto, portugal fundeni clinical institute, bucurești, romania cardiomed srl, cluj-napoca, romania prof dr i chiricuta institute of oncology - ppds, cluj-napoca, romania medisprof srl, cluj-napoca, romania onco clinic consult sa, craiova, romania oncology center sfantul nectarie, craiova, romania institutul regional de oncologie iasi, iasi, romania research site 1, belgrade, serbia research site 2, belgrade, serbia research site 3, belgrade, serbia research site 4, belgrade, serbia research site, niš, serbia research site, sremska kamenica, serbia research site 1, singapore, singapore research site 2, singapore, singapore research site, cape town, south africa research site, mogale city, south africa research site 1, pretoria, south africa research site 2, pretoria, south africa corporacio sanitaria parc tauli, sabadell, barcelona, spain complejo hospitalario de navarra, pamplona, navarra, spain hospital universitario germans trias i pujol, badalona, spain hospital universitario vall d\'hebron - ppds, barcelona, spain hospital universitari de girona dr josep trueta, girona, spain ico l\'hospitalet - hospital duran i reynals, l\'hospitalet de llobregat, spain hospital universitario ramon y cajal, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital universitario la paz - ppds, madrid, spain hospital regional universitario de malaga - hospital general, málaga, spain complejo asistencial universitario de salamanca - h. clinico, salamanca, spain hospital universitario marques de valdecilla, santander, spain hospital universitario virgen macarena, sevilla, spain hospital clinico universitario de valencia, valencia, spain hospital universitario miguel servet, zaragoza, spain china medical university hospital, taichung, taiwan chi mei medical center, tainan, taiwan mackay memorial hospital, taipei, taiwan taipei veterans general hospital, taipei, taiwan research site, bangkok noi, thailand research site 1, bangkok, thailand research site 2, bangkok, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, lak si, thailand research site 1, phitsanulok, thailand research site 2, phitsanulok, thailand research site, antalya, turkey research site, balçova, turkey research site, bursa, turkey research site, denizli, turkey research site, edirne, turkey research site, fatih, turkey research site, sur, turkey research site, tarabya, turkey research site, trabzon, turkey research site, yenimahalle, turkey research site, çankaya, turkey municipal non-profit enterprise ""city clinical hospital # 4"" of dnipro city council - ppds, dnipropetrovsk, ukraine communal non-profit enterprise regional center of oncology, kharkiv, ukraine mi kryvyi rih oncology dispensary of dnipropetrovsk regional council, kryvyi rih, ukraine medical center of limited liability company ""medical center ""verum expert"", kyiv, ukraine treatment and diagnostic center of llc specialized clinic prognosis optima, kyiv, ukraine si ""national institute of surgery and transplantology n.a. o.o. shalimov "" of nams of ukraine, kyiv, ukraine communal nonprofit enterprise kyiv city clinical oncological center, kyiv, ukraine the municipal enterprise volyn regional medical oncology centre of the volyn regional council, lutsk, ukraine municipal non-profit enterprise ""odessa regional oncology dispensary"" of odesa rc, odesa, ukraine research site, bristol, united kingdom research site, edgbaston, united kingdom research site, edinburgh, united kingdom research site, leeds, united kingdom research site 1, london, united kingdom research site 2, london, united kingdom research site 3, london, united kingdom research site, northwood, united kingdom edith cavell hospital, peterborough, united kingdom research site, sheffield, united kingdom']",,https://ClinicalTrials.gov/show/NCT05152147,gastric kidney esophag
470,471,NCT00665197,palliative radiotherapy and brachytherapy for oesophageal cancer dysphagia,,Completed,No Results Available,esophageal cancer,radiation: protracted course radiotherapy|radiation: short course radiotherapy,dysphagia relief|quality of life|treatment toxicity,international atomic energy agency,All,"18 Years to 81 Years   (Adult, Older Adult)",Phase 3,200.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E3.30.27,February 2007,February 2011,February 2011,"April 23, 2008",,"October 13, 2011","['credit valley hospital statistical centre, credit valley, ontario, canada chinese academy of medical sciences, beijing, beijing, china university of zagreb clinical hospital, zagreb, croatia tata memorial hospital, mumbai, parel, india institute of nuclear medicine and oncology, lahore, punjab, pakistan university of the witwatersrand department of radiat. oncology, johannesburg, parktown, south africa mahidol university faculty of medicine siriraj hospital, bangkok, siriraj, thailand']",,https://ClinicalTrials.gov/show/NCT00665197,esophag
471,472,NCT04177108,a study of ipatasertib in combination with atezolizumab and paclitaxel as a treatment for participants with locally advanced or metastatic triple-negative breast cancer.,,"Active, not recruiting",No Results Available,triple-negative breast cancer,drug: atezolizumab|drug: ipatasertib|drug: paclitaxel|drug: placebo for atezolizumab|drug: placebo for ipatasertib,investigator-assessed progression free survival (pfs)|overall survival (os)|percentage of participants with adverse events (aes),hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,242.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CO41101|2019-000810-12,"November 25, 2019","June 30, 2022","June 30, 2022","November 26, 2019",,"May 6, 2022","['usa mitchell cancer institute, mobile, alabama, united states highlands oncology group, springdale, arkansas, united states ucla, los angeles, california, united states kaiser permanente-scpmg; oncology research, san diego, california, united states stanford cancer center, stanford, california, united states kaiser permanente - franklin, denver, colorado, united states stamford hospital; bcc, mohr, stamford, connecticut, united states holy cross hospital, fort lauderdale, florida, united states memorial healthcare system - memorial regional hospital, hollywood, florida, united states memorial cancer institute at memorial west, pembroke pines, florida, united states winship cancer institute, atlanta, georgia, united states nancy n. and j.c. lewis cancer & research pavillion -st. josephs / candler health system-ccd prime, savannah, georgia, united states rush university, chicago, illinois, united states ochsner clinic foundation, baton rouge, louisiana, united states ochsner health system, new orleans, louisiana, united states university of maryland medical center, baltimore, maryland, united states mercy medical center, baltimore, maryland, united states medstar franklin square medical center, baltimore, maryland, united states st. joseph mercy hospital; cancer care center., ann arbor, michigan, united states henry ford health system, detroit, michigan, united states jackson oncology associates, pllc, jackson, mississippi, united states chi health saint francis; oncology, grand island, nebraska, united states dartmouth hitchcock medical center, lebanon, new hampshire, united states hackensack univ med ctr, hackensack, new jersey, united states wake forest university baptist medical center, winston-salem, north carolina, united states kaiser permanente - portland, portland, oregon, united states oregon health and science university, portland, oregon, united states charleston oncology, p .a, charleston, south carolina, united states greenville health system; cancer center, greenville, south carolina, united states the west clinic; west cancer center, germantown, tennessee, united states vanderbilt univ medical ctr, nashville, tennessee, united states fundación cenit para la investigación en neurociencias, buenos aires, argentina inst. angel roffo; haematology, buenos aires, argentina hospital britanico, ciudad autonoma bs as, argentina instituto medico rio cuarto, cordoba, argentina centro oncologico riojano integral (cori), la rioja, argentina fundacion scherbovsky, mendoza, argentina macquarie university hospital, macquarie park, new south wales, australia mid north coast cancer institute, port macquarie, new south wales, australia royal north shore hospital; department of medical oncology, st leonards, new south wales, australia calvary mater newcastle; medical oncology, waratah, new south wales, australia princess alexandra hospital, woolloongabba, queensland, australia adelaide cancer centre, kurralta park, south australia, australia monash health monash medical centre, clayton, victoria, australia peter maccallum cancer centre; medical oncology, melbourne, victoria, australia sunshine hospital; oncology research, st albans, victoria, australia st john of god hospital; bendat cancer centre, subiaco, western australia, australia tiroler landeskrankenanstalten ges.m.b.h.; abt. für gynäkologie, innsbruck, austria ordensklinikum linz barmherzige schwestern; interne 1 - hämato-onkologie, linz, austria uniklinikum salzburg, lkh; univ.klinik f. innere medizin iii der pmu, salzburg, austria medizinische universität wien; univ.klinik für innere medizin i, wien, austria az maria middelares, gent, belgium jessa zkh (campus virga jesse), hasselt, belgium hospital sao rafael - hsr, salvador, ba, brazil hospital das clinicas - ufrgs, porto alegre, rs, brazil clinica de pesquisa e centro de estudos em oncologia ginecologica e mamaria ltda, sao paulo, sp, brazil núcleo de pesquisa são camilo; oncologia clinica / quimioterapia, sao paulo, sp, brazil mhat nadezhda, sofia, bulgaria cross cancer institute ; dept of medical oncology, edmonton, alberta, canada fraser valley centre british columbia cancer agency, surrey, british columbia, canada cancer care manitoba, winnipeg, manitoba, canada royal victoria hospital, barrie, ontario, canada the ottawa hospital cancer centre, ottawa, ontario, canada mcgill university; glen site; oncology, montreal, quebec, canada jewish general hospital; research unit, montréal, quebec, canada hopital du saint sacrement, quebec city, quebec, canada clinica del country, bogota, colombia oncólogos de occidente, pereira, colombia clinica cimca, san josé, costa rica masarykův onkologický ústav; klinika komplexní onkologické péče, brno, czechia fakultni nemocnice olomouc; onkologicka klinika, olomouc, czechia herlev hospital; afdeling for kræftbehandling, herlev, denmark odense universitetshospital, onkologisk afdeling r, odense c, denmark docrates cance center, helsinki, finland kys sadesairaala; syopatautien poliklinikka, kuopio, finland vaasan keskussairaala; onkologian poliklinikka, vaasa, finland centre eugene marquis; service d\'oncologie, rennes, france agioi anargyroi cancer hospital; 2nd oncology dept., kifisia, greece euromedical general clinic of thessaloniki; oncology department, thessaloniki, greece queen mary hospital; dept of medicine, hong kong, hong kong tuen mun hospital; clinical onc, hong kong, hong kong prince of wales hospital; department of clinical onocology, shatin, hong kong sahyadri super specialty hospital hadapsar, pune, maharashtra, india shaare zedek medical center, jerusalem, israel istituto nazionale per lo studio e la cura dei tumori fondazione g. pascale, napoli, campania, italy irst istituto scientifico romagnolo per lo studio e cura dei tumori, sede meldola; oncologia medica, meldola, emilia-romagna, italy asu fc s. m. della misericordia; oncologia, udine, friuli-venezia giulia, italy asst degli spedali civili di brescia; oncologia medica, brescia, lombardia, italy asst di lecco; oncologia medica, lecco, lombardia, italy irccs istituto clinico humanitas; oncologia, rozzano, lombardia, italy ospedale civile; unita operativa di oncologia medica, livorno, toscana, italy iov - istituto oncologico veneto - irccs; oncologia medica ii, padova, veneto, italy aichi cancer center hospital, aichi, japan fukushima medical university hospital, fukushima, japan gunma prefectural cancer center, gunma, japan hiroshima university hospital, hiroshima, japan kanagawa cancer center, kanagawa, japan kumamoto shinto general hospital, kumamoto, japan okayama university hospital, okayama, japan osaka international cancer institute, osaka, japan kyungpook national university medical center, daegu, korea, republic of national cancer center, goyang-si, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of seoul st mary\'s hospital, seoul, korea, republic of investigacion oncofarmaceutica, la paz, baja california sur, mexico health pharma professional research, cdmx, mexico city (federal district), mexico christus muguerza clinica vidriera, monterrey, nuevo leon, mexico auckland city hospital, cancer and blood research, auckland, new zealand tauranga hospital, clinical trials unit; bop clinical school, tauranga, new zealand wellington regional hospital; clinical trials unit, wellington, new zealand centro medico monte carmelo, arequipa, peru instituto regional de enfermedades neoplasicas, arequipa, peru unidad de investigación oncologica; hospital nacional daniel alcides carrion, lima, peru clínica san gabriel; unidad de investigación oncológica de la clínica san gabriel, lima, peru hospital arzobispo loayza, lima, peru oncosalud sac; oncología, lima, peru instituto nacional de enfermedades neoplasicas, lima, peru clinica ricardo palma, san isidro, peru narodowy inst.onkol.im.sklodowskiej-curie panstw.inst.bad gliwice; centr.diagn.i lecz.chor.piersi, gliwice, poland szpital uniwersytecki w krakowie, oddział kliniczny kliniki onkologii, kraków, poland wielkopolskie centrum onkologii, poznan, poland narodowy instytut onkologii im. m.sklodowskiej-curie; klinika nowotworow piersi i chirurgii rekonstr, warszawa, poland instyt. centrum zdrowia matki polki; klinika chirurgii onk. chorób piersi z podod. onko klinicznej, łódź, poland hospital da luz; departamento de oncologia medica, lisboa, portugal hospital de santa maria; servico de oncologia medica, lisboa, portugal hospital beatriz angelo; departamento de oncologia, loures, portugal centro hospitalar do porto - hospital de santo antónio; oncologia, porto, portugal ipo do porto; servico de oncologia medica, porto, portugal oncology center sf. nectarie, craiova, romania arkhangelsk regional clinical oncology dispensary, arkhangelsk, arhangelsk, russian federation university сlinic of headaches, moscow, moskovskaja oblast, russian federation sbih ""moscow clinical scientific and practical center named after a.s. loginov of dhm"", moskva, moskovskaja oblast, russian federation fed state budgetary inst ""n.n. blokhin med center of oncology"" mhrf, moskva, moskovskaja oblast, russian federation fsai treatment and rehabilitation centre ministry of health; clinical research and chemotherapy., moskva, moskovskaja oblast, russian federation clinical oncology dispensary of ministry of health of tatarstan, kazan, russian federation p.a. gertsen cancer research inst. ; chemotherapy dept, moscow, russian federation limited liability company ""rc medical"", novosibirsk, russian federation s-pb clinical scientific practical center of specialized kinds of medical care (oncological), saint-petersburg, russian federation national cancer centre; medical oncology, singapore, singapore national hospital; oncotherapy dept, bloemfontein, south africa cancercare, george, south africa wits clinical research, johannesberg, south africa cancercare, port elizabeth, south africa wilgers oncology centre, pretoria, south africa hospital provincial de castellon; servicio de oncologia, castellon de la plana, castellon, spain complejo hospitalario universitario a coruña (chuac); servicio de oncologia, a coruña, la coruña, spain hospital universitario puerta de hierro; servicio de oncologia, majadahonda, madrid, spain hospital univ vall d\'hebron; servicio de oncologia, barcelona, spain hospital clínic i provincial; servicio de hematología y oncología, barcelona, spain hospital general universitario gregorio marañon; servicio de oncologia, madrid, spain hospital ramon y cajal; servicio de oncologia, madrid, spain hospital universitario clínico san carlos; servicio de oncologia, madrid, spain centro integral oncologico clara campal; servicio de oncología, madrid, spain hospital clinico universitario virgen de la victoria; servicio de oncologia, malaga, spain hospital clínico universitario de valencia; servicio de oncología, valencia, spain universitätsspital basel, basel, switzerland universitätsspital zürich gynäkologische klinik; klinik für gynäkologie, zürich, switzerland china medical university hospital; surgery, taichung, taiwan veterans general hospital; department of general surgery, taipei, taiwan national taiwan uni hospital; general surgery, taipei, taiwan chang gung memorial hosipital at linkou, taoyuan city, taiwan chulalongkorn hospital; medical oncology, bangkok, thailand rajavithi hospital; division of medical oncology, bangkok, thailand faculty of med. siriraj hosp.; med.-div. of med. oncology, bangkok, thailand maharaj nakorn chiang mai hospital; department of surgery/head neck and breast unit; clinical trial, chiang mai, thailand khonkaen hospital, khonkaen, thailand songklanagarind hospital; department of oncology, songkhla, thailand memorial ankara hastanesi, ankara, turkey medipol university mf; oncology department, istanbul, turkey hacettepe uni medical faculty hospital; oncology dept, sihhiye/ankara, turkey si institute of general&urgent surgery n/a zaytseva v.t namsu; purulent surgery department, kharkiv, kharkiv governorate, ukraine regional oncology center; department of mammology, chernigiv, ukraine chemotherapy si dnipropetrovsk ma of mohu, dnipropetrovsk, ukraine me kryviy rih oncology dispensary of dnipropetrovs\'k regional council; chemotherapy department, kryvyi rih, ukraine mi kyiv regional council kyiv regional oncological dispensary; department of mammology, kyiv, ukraine municipal institution odesa regional clinical hospital, odesa, ukraine rci sumy regional clinical oncological dispensary, sumy, ukraine beatson west of scotland cancer centre; clinical research unit - level 1, glasgow, united kingdom the royal marsden hospital, fulham, london, united kingdom nottingham university hospitals nhs trust, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT04177108,breast
472,473,NCT04154644,"performance, safety, and efficacy of a new cryotherapy device for cervical dysplasia [part ii]",CryoPop,Completed,No Results Available,cervical dysplasia,device: cryopop,efficacy of cryopop: negative pap smear and negative biopsy (if performed) on each study participant.|safety of cryopop: incidences of adverse events documented throughout the study.,jhpiego|jawaharlal nehru medical college,Female,30 Years to 49 Years   (Adult),Not Applicable,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1UH3CA189923-01,"April 9, 2019","October 31, 2021","November 30, 2021","November 6, 2019",,"January 14, 2022","['jn medical college, belgaum, karnataka, india']",,https://ClinicalTrials.gov/show/NCT04154644,cervic
473,474,NCT00866970,"safety, efficacy and pharmacokinetics of ald518 in patients with non-small cell lung cancer-related fatigue and cachexia",,Completed,No Results Available,nsclc|fatigue|cachexia,biological: ald518|biological: infusion of 0.9% saline without ald518,change in safety parameters.|time to symptomatic progressions at weeks 12 and 24,csl behring,All,"18 Years and older   (Adult, Older Adult)",Phase 2,124.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALD518-CLIN-004,September 2008,August 2009,December 2009,"March 23, 2009",,"July 9, 2020","['rivercity hospital research centre, auchenflower, queensland, australia australian clinical research organisation, kippa ring, queensland, australia royal adelaide hospital, adelaide, south australia, australia palliative care launceston general hospital, launceston, tasmania, australia cross cancer institute, edmonton, alberta, canada atlantic health sciences corporation, saint john, new brunswick, canada mcgill university, department of oncology, montreal, quebec, canada a. gvamichava national cancer centre, tbilisi, georgia union cancer prevention centre, tbilisi, georgia medulla chemotherapy and immunotherapy clinic, tbilisi, georgia indira gandhi institute of medical sciences, patna, bihar, india dr. kamakshi memorial hospital, pallikaranai, chennai, india gknm hospital, pappanaickenpalayam, coimbatore, india curie manavata cancer centre, nasik, maharashtra, india kidwai memorial institute of oncology, bangalore, india kailash cancer hospital and research centre, gujarat, india indoamerican cancer institute & research center, hyderabad, india searoc cancer centre, jaipur, india orchid nursing home, kolkata, india tata memorial hospital, mumbai, india shatabdi hospital, mumbai, india mahavir cancer sansthan, patna, india jehangir clinical development centre pvt. ltd., pune, india p3 research ltd, tauranga, new zealand oddzial chorob pluc i leczenia raka pluc, bydgoszcz, poland oddzial chemioterapii szpital morski, gdynia, poland ii oddzia chorob pluc z pododdzialem chemioterapii, krakow, poland oddzial ii chemioterapii specjalistyczny szpital, szczecin, poland professor dr. al trestioreanu institute, bucharest, romania professor dr. i chiricuta institute of oncology and radiotherapy, cluj-napoca, romania oradea clinical county hospital medical oncology department, oradea, romania county hospital sibiu medical oncology department, sibiu, romania territorial clinical oncology dispensary, krasnodar, krasnodar territory, russian federation republic oncology dispensary, ufa, republic of bashkortostan, russian federation stavropol territorial clinical, pyatigorsk, stavropol territory, russian federation city clinical hospital no. 1, novosibirsk, russian federation saint-petersburg state medical university, i.p. pavlov, saint-petersburg, russian federation st. petersburg city oncology dispensary, saint-petersburg, russian federation yaroslavl regional clinical oncology hospital, yaroslavl, russian federation institute of lung diseases and tb, belgrade, serbia clinical hospital center bezanijska kosa, belgrade, serbia clinical centre kragujevac, kragujevac, serbia institute for pulmonary diseases of vojvodina, sremska, serbia']",,https://ClinicalTrials.gov/show/NCT00866970,
474,475,NCT00066703,triptorelin with either exemestane or tamoxifen in treating premenopausal women with hormone-responsive breast cancer,TEXT,"Active, not recruiting",Has Results,breast cancer,drug: exemestane|drug: tamoxifen|drug: triptorelin,disease-free survival|breast cancer-free interval|distant recurrence-free interval|overall survival,international breast cancer study group|national cancer institute (nci)|breast international group,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,2672.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCSG 25-02 / BIG 3-02|IBCSG 25-02|BIG 3-02|NABCI IBCSG 25-02|EU-20347|2004-000168-28|CDR0000316458,"November 3, 2003","March 11, 2011",December 2025,"August 7, 2003","April 5, 2016","March 11, 2021","['roy and patricia disney family cancer center at providence saint joseph medical center, burbank, california, united states rebecca and john moores ucsd cancer center, la jolla, california, united states providence holy cross cancer center, mission hills, california, united states desert regional medical center comprehensive cancer center, palm springs, california, united states sutter cancer center at roseville medical center, roseville, california, united states sutter cancer center, sacramento, california, united states mercy general hospital, sacramento, california, united states ucsf helen diller family comprehensive cancer center, san francisco, california, united states ruby l. golleher cancer program at presbyterian intercommunity hospital, whittier, california, united states university of colorado cancer center at uc health sciences center, aurora, colorado, united states shaw regional cancer center, edwards, colorado, united states poudre valley hospital, fort collins, colorado, united states front range cancer specialists, fort collins, colorado, united states carole and ray neag comprehensive cancer center at the university of connecticut health center, farmington, connecticut, united states sibley memorial hospital, washington, district of columbia, united states walter reed army medical center, washington, district of columbia, united states mayo clinic - jacksonville, jacksonville, florida, united states northeast georgia medical center, gainesville, georgia, united states mountain states tumor institute at st. luke\'s regional medical center, boise, idaho, united states kootenai cancer center - coeur d\'alene, coeur d\'alene, idaho, united states resurrection medical center, chicago, illinois, united states university of chicago cancer research center, chicago, illinois, united states decatur memorial hospital cancer care institute, decatur, illinois, united states evanston hospital, evanston, illinois, united states ccop - carle cancer center, urbana, illinois, united states elkhart clinic, llc, elkhart, indiana, united states elkhart general hospital, elkhart, indiana, united states fort wayne medical oncology and hematology, fort wayne, indiana, united states howard community hospital, kokomo, indiana, united states center for cancer therapy at laporte hospital and health services, la porte, indiana, united states saint joseph regional medical center, mishawaka, indiana, united states ccop - northern indiana cr consortium, south bend, indiana, united states memorial hospital of south bend, south bend, indiana, united states michiana hematology-oncology, pc - south bend, south bend, indiana, united states south bend clinic, south bend, indiana, united states siouxland hematology-oncology associates, llp, sioux city, iowa, united states cancer center of kansas, pa - chanute, chanute, kansas, united states cancer center of kansas, pa - dodge city, dodge city, kansas, united states cancer center of kansas, pa - el dorado, el dorado, kansas, united states cancer center of kansas-independence, independence, kansas, united states cancer center of kansas, pa - kingman, kingman, kansas, united states lawrence memorial hospital, lawrence, kansas, united states cancer center of kansas, pa - newton, newton, kansas, united states menorah medical center, overland park, kansas, united states cancer center of kansas, pa - parsons, parsons, kansas, united states cancer center of kansas, pa - pratt, pratt, kansas, united states cancer center of kansas, pa - salina, salina, kansas, united states shawnee mission medical center, shawnee mission, kansas, united states cotton-o\'neil cancer center, topeka, kansas, united states cancer center of kansas, pa - wellington, wellington, kansas, united states associates in womens health, pa - north review, wichita, kansas, united states cancer center of kansas, pa - medical arts tower, wichita, kansas, united states cancer center of kansas, pa - wichita, wichita, kansas, united states ccop - wichita, wichita, kansas, united states via christi cancer center at via christi regional medical center, wichita, kansas, united states cancer center of kansas, pa - winfield, winfield, kansas, united states greenebaum cancer center at university of maryland medical center, baltimore, maryland, united states mercy medical center, baltimore, maryland, united states suburban hospital, bethesda, maryland, united states frederick memorial hospital regional cancer therapy center, frederick, maryland, united states tufts medical center cancer center, boston, massachusetts, united states massachusetts general hospital, boston, massachusetts, united states dana-farber/harvard cancer center at dana-farber cancer institute, boston, massachusetts, united states beth israel deaconess medical center, boston, massachusetts, united states bethke cancer center at emerson hospital, concord, massachusetts, united states addison gilbert hospital, gloucester, massachusetts, united states lowell general hospital, lowell, massachusetts, united states nsmc cancer center - peabody, peabody, massachusetts, united states midmichigan medical center - midland, midland, michigan, united states william beaumont hospital - royal oak campus, royal oak, michigan, united states lakeland regional cancer care center - st. joseph, saint joseph, michigan, united states lakeside cancer specialists, pllc, saint joseph, michigan, united states fairview ridges hospital, burnsville, minnesota, united states mercy and unity cancer center at mercy hospital, coon rapids, minnesota, united states fairview southdale hospital, edina, minnesota, united states mercy and unity cancer center at unity hospital, fridley, minnesota, united states healtheast cancer care at st. john\'s hospital, maplewood, minnesota, united states virginia piper cancer institute at abbott - northwestern hospital, minneapolis, minnesota, united states hennepin county medical center - minneapolis, minneapolis, minnesota, united states hubert h. humphrey cancer center at north memorial outpatient center, robbinsdale, minnesota, united states mayo clinic cancer center, rochester, minnesota, united states ccop - metro-minnesota, saint louis park, minnesota, united states park nicollet cancer center, saint louis park, minnesota, united states regions hospital cancer care center, saint paul, minnesota, united states united hospital, saint paul, minnesota, united states ridgeview medical center, waconia, minnesota, united states truman medical center - hospital hill, kansas city, missouri, united states saint luke\'s cancer institute at saint luke\'s hospital, kansas city, missouri, united states st. joseph medical center, kansas city, missouri, united states north kansas city hospital, kansas city, missouri, united states ccop - kansas city, kansas city, missouri, united states research medical center, kansas city, missouri, united states heartland regional medical center, saint joseph, missouri, united states saint louis university cancer center, saint louis, missouri, united states siteman cancer center at barnes-jewish hospital - saint louis, saint louis, missouri, united states saint francis cancer treatment center at saint francis memorial health center, grand island, nebraska, united states unmc eppley cancer center at the university of nebraska medical center, omaha, nebraska, united states fox chase virtua health cancer program at virtua memorial hospital marlton, marlton, new jersey, united states franklin & edith scarpa regional cancer center at south jersey healthcare, vineland, new jersey, united states fox chase virtua health cancer program at virtua west jersey, voorhees, new jersey, united states our lady of mercy medical center comprehensive cancer center, bronx, new york, united states roswell park cancer institute, buffalo, new york, united states nyu cancer institute at new york university medical center, new york, new york, united states randolph hospital, asheboro, north carolina, united states mission hospitals - memorial campus, asheville, north carolina, united states hope a women\'s cancer center, asheville, north carolina, united states moses cone regional cancer center at wesley long community hospital, greensboro, north carolina, united states pardee memorial hospital, hendersonville, north carolina, united states kinston medical specialists, kinston, north carolina, united states annie penn cancer center, reidsville, north carolina, united states aultman cancer center at aultman hospital, canton, ohio, united states metrohealth cancer care center at metrohealth medical center, cleveland, ohio, united states geisinger cancer institute at geisinger health, danville, pennsylvania, united states geisinger hazleton cancer center, hazleton, pennsylvania, united states geisinger medical group - scenery park, state college, pennsylvania, united states frank m. and dorothea henry cancer center at geisinger wyoming valley medical center, wilkes-barre, pennsylvania, united states ccop - greenville, greenville, south carolina, united states medical x-ray center, pc, sioux falls, south dakota, united states sanford cancer center at sanford usd medical center, sioux falls, south dakota, united states erlanger cancer center at erlanger hospital - baroness, chattanooga, tennessee, united states west tennessee cancer center at jackson-madison county general hospital, jackson, tennessee, united states doctor\'s hospital of laredo, laredo, texas, united states mountainview medical, berlin, vermont, united states fletcher allen health care - university health center campus, burlington, vermont, united states madigan army medical center - tacoma, tacoma, washington, united states mary babb randolph cancer center at west virginia university hospitals, morgantown, west virginia, united states langlade memorial hospital, antigo, wisconsin, united states aurora memorial hospital of burlington, burlington, wisconsin, united states oncology alliance - franklin, franklin, wisconsin, united states oncology alliance, sc - milwaukee - east, glendale, wisconsin, united states oncology alliance - kenosha south, kenosha, wisconsin, united states aurora advanced healthcare east mequon clinic, mequon, wisconsin, united states columbia-saint mary\'s hospital-ozaukee, mequon, wisconsin, united states columbia saint mary\'s water tower medical commons milwaukee, mequon, wisconsin, united states oncology alliance, sc - milwaukee - south, milwaukee, wisconsin, united states aurora health center - racine, racine, wisconsin, united states aurora health center - waukesha, waukesha, wisconsin, united states university of wisconcin cancer center at aspirus wausau hospital, wausau, wisconsin, united states oncology alliance, sc - milwaukee - west, wauwatosa, wisconsin, united states cancer therapy centre at campbelltown hospital, campbelltown, new south wales, australia coffs harbour health campus, coffs harbour, new south wales, australia lismore base hospital, lismore, new south wales, australia cancer therapy centre at liverpool hospital, liverpool, new south wales, australia tamworth base hospital, tamworth, new south wales, australia manning base hospital, taree, new south wales, australia tweed heads hospital, tweed heads, new south wales, australia newcastle mater misericordiae hospital, waratah, new south wales, australia royal brisbane and women\'s hospital, brisbane, queensland, australia flinders medical centre, bedford park, south australia, australia royal hobart hospital, hobart, tasmania, australia launceston general hospital, launceston, tasmania, australia box hill hospital, box hill, victoria, australia breast unit mercy private, east melbourne, victoria, australia peter maccallum cancer centre, east melbourne, victoria, australia st. vincent\'s hospital - melbourne, fitzroy, victoria, australia austin hospital, heidelberg, victoria, australia alfred hospital, melbourne, victoria, australia maroondah hospital, ringwood east, victoria, australia royal perth hospital, perth, western australia, australia institut jules bordet, brussels, belgium centre hospitalier hutois, huy, belgium u.z. gasthuisberg, leuven, belgium chu liege - domaine universitaire du sart tilman, liege, belgium centre hospitalier peltzer-la tourelle, verviers, belgium hospital de clinicas de porto alegre, porto alegre, rio grande do sul, brazil tom baker cancer centre - calgary, calgary, alberta, canada cross cancer institute at university of alberta, edmonton, alberta, canada doctor leon richard oncology centre, moncton, new brunswick, canada margaret and charles juravinski cancer centre, hamilton, ontario, canada trillium health centre - mississauga site, toronto, ontario, canada windsor regional cancer centre at windsor regional hospital, windsor, ontario, canada hopital charles lemoyne, greenfield park, quebec, canada allan blair cancer centre at pasqua hospital, regina, saskatchewan, canada saskatoon cancer centre at the university of saskatchewan, saskatoon, saskatchewan, canada cairo oncology center, cairo, egypt national cancer institute of egypt, cairo, egypt brustzentrum klinikum mittelbaden, baden-baden, germany klinikum deggendorf, deggendorf, germany frauenklinik des universitaetsklinikum erlangen, erlangen, germany universitaetsfrauenklinik frankfurt, frankfurt, germany universitaets-frauenklinik goettingen, göttingen, germany st. vincentius - kliniken, karlsruhe, germany universitaetsklinikum schleswig-holstein - campus luebeck, luebeck, germany universitatsklinik mainz, mainz, germany universitaetsfrauenklinik mannheim, mannheim, germany klinikum schwaebisch gmuend stauferklinik, mutlangen, germany klinikum nuernberg - klinikum nord, nuremberg, germany caritas - krankenhaus saint josef, regensburg, germany klinikum obergoeltzsch rodewisch, rodewisch, germany klinikum rosenheim, rosenheim, germany klinikum landkreis tuttlingen, tuttlingen, germany national institute of oncology, budapest, hungary tata memorial hospital, mumbai, india centro di riferimento oncologico - aviano, aviano, italy ospedali riuniti di bergamo, bergamo, italy azienda sanitaria di bolzano, bolzano, italy spedali civili di brescia, brescia, italy ospedale civile ramazzini, carpi, italy european institute of oncology, milan, italy fondazione salvatore maugeri, pavia, italy misericordia e dolce hospital, prato, italy ospedale civile rimini, rimini, italy istituto clinico humanitas, rozzano, italy policlinico universitario udine, udine, italy ospedale di circolo e fondazione macchi, varese, italy waikato hospital, hamilton, new zealand instituto nacional de enfermedades neoplasicas, lima, peru institute of oncology - ljubljana, ljubljana, slovenia sandton oncology centre, johannesburg, south africa sahlgrenska university hospital, gothenburg, sweden university hospital of linkoping, linkoping, sweden skaraborgs hospital, skovde, sweden universitaetsspital-basel, basel, switzerland oncology institute of southern switzerland, bellinzona, switzerland inselspital bern, bern, switzerland oncocare sonnenhof-klinik engeriedspital, bern, switzerland kantonsspital graubuenden, chur, switzerland onkologie-praxis zetup chur, chur, switzerland centre hospitalier universitaire vaudois, lausanne, switzerland ospedale ""la carita"", locarno, locarno, switzerland ospedale civico, lugano, switzerland ospedale beata vergine, mendrisio, switzerland kantonsspital - st. gallen, st. gallen, switzerland regionalspital, thun, switzerland universitaetsspital zuerich, zurich, switzerland addenbrooke\'s hospital, cambridge, england, united kingdom peterborough hospitals trust, peterborough, england, united kingdom south tyneside district hospital, south shields, england, united kingdom']",,https://ClinicalTrials.gov/show/NCT00066703,breast
475,476,NCT04940052,"study of efficacy and safety of dabrafenib plus trametinib in previously treated patients with locally advanced or metastatic, radio-active iodine refractory brafv600e mutation-positive differentiated thyroid cancer",,Recruiting,No Results Available,differentiated thyroid cancer,drug: dabrafenib|drug: trametinib|drug: trametinib placebo|drug: dabrafenib placebo,progression free survival|overall response rate|overall survival|duration of response|number of participants with trametinib associated serous retinopathy ocular events,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CDRB436J12301,"November 15, 2021","February 19, 2024","October 30, 2026","June 25, 2021",,"April 22, 2022","['novartis investigative site, wuhan, hubei, china novartis investigative site, chengdu, sichuan, china novartis investigative site, tianjin, tianjin, china novartis investigative site, tianjin, china novartis investigative site, mumbai, maharashtra, india novartis investigative site, seoul, seocho gu, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, kuching, sarawak, malaysia novartis investigative site, kuala lumpur, wilayah persekutuan, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, pulau pinang, malaysia novartis investigative site, tainan, taiwan novartis investigative site, taipei, taiwan novartis investigative site, istanbul, tur, turkey novartis investigative site, adana, turkey novartis investigative site, ankara, turkey novartis investigative site, ankara, turkey novartis investigative site, edirne, turkey']",,https://ClinicalTrials.gov/show/NCT04940052,thyroid
476,477,NCT01599754,adjuvant axitinib therapy of renal cell cancer in high risk patients,ATLAS,Terminated,Has Results,clear cell renal carcinoma,drug: axitinib|drug: placebo,disease free survival (dfs) as assessed by blinded independent review committee (irc)|overall survival (os)|number of participants with treatment-emergent adverse events (ae) and serious adverse events (saes)|number of participants with treatment-emergent treatment related adverse events and serious adverse events (saes)|number of participants with treatment-emergent adverse events (teaes) by severity|number of participants with laboratory abnormalities by maximum ctcae grade: hematology|number of participants with laboratory abnormalities by maximum ctcae grade: chemistry|number of participants with laboratory abnormalities: thyroid function|number of participants with laboratory abnormalities: urinalysis,"sfj pharma ltd. ii|pfizer|sfj pharmaceuticals, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,724.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AP311736,April 2012,"October 10, 2017",May 2018,"May 16, 2012","August 28, 2019","September 20, 2019","['la jolla, california, united states los angeles, california, united states palo alto, california, united states pleasant hill, california, united states denver, colorado, united states washington, district of columbia, united states ocala, florida, united states atlanta, georgia, united states annapolis, maryland, united states baltimore, maryland, united states saint paul, minnesota, united states omaha, nebraska, united states hackensack, new jersey, united states albany, new york, united states new york, new york, united states portland, oregon, united states charleston, south carolina, united states chattanooga, tennessee, united states austin, texas, united states bedford, texas, united states dallas, texas, united states houston, texas, united states san antonio, texas, united states san antonio, texas, united states norfolk, virginia, united states seattle, washington, united states beijing, china changchun, china chongqing, china dalian, china guangzhou, china hangzhou, china jinan, china nanchang, china shanghai, china suzhou, china tianjin, china wuhan, china besançon, france bordeaux cedex, france hyères, france le mans cedex 02, france lyon, france marseille cedex 5, france paris cedex 15, france rennes cedex, france saint herblain, france suresnes cedex, france vandoeuvre les nancy cedex, france hong kong, hong kong ahmeadbad, india aurangabad, india bangalore, india chennai, india hyderabad, india karamsad, india kochi, india kolkota, india lucknow, india ludhiana, india mangalore, india manipal, india mumbai, india nashik, india new delhi, india pune, india surat, india vishakhapatnam, india aichi, japan akita, japan aomori, japan chiba, japan fukuoka, japan gifu, japan hokkaido, japan hyogo, japan kagawa, japan kanagawa, japan kumamoto, japan kyoto, japan nagasaki, japan nigata, japan osaka, japan shizuoka, japan tokushima, japan tokyo, japan yamagata, japan yamaguchi,, japan busan, korea, republic of daegu, korea, republic of daejeon, korea, republic of gyeonggi, korea, republic of jeonnam, korea, republic of seoul, korea, republic of barcelona, spain leganes, spain llobregat, spain madrid, spain oviedo, spain san sebastian, spain sevilla, spain valencia, spain zaragoza, spain taichung, taiwan taipei, taiwan taoyuan, taiwan']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/54/nct01599754/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/54/nct01599754/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01599754,kidney
477,478,NCT01234311,a study of tasquinimod in men with metastatic castrate resistant prostate cancer,,Completed,No Results Available,prostate cancer,drug: tasquinimod|drug: placebo,"a phase 3 randomized, double-blind, placebo-controlled study of tasquinimod in men with metastatic castrate resistant prostate cancer",active biotech ab,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,1245.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10TASQ10,March 2011,February 2015,August 2015,"November 4, 2010",,"October 21, 2015","['tucson, arizona, united states oxnard, california, united states santa monica, california, united states santa rosa, california, united states wellington, florida, united states atlanta, georgia, united states meridian, idaho, united states melrose park, illinois, united states park ridge, illinois, united states jeffersonville, indiana, united states baltimore, maryland, united states rockville, maryland, united states boston, massachusetts, united states jefferson city, missouri, united states las vegas, nevada, united states hackensack, new jersey, united states lawrenceville, new jersey, united states buffalo, new york, united states poughkeepsie, new york, united states concord, north carolina, united states durham, north carolina, united states raleigh, north carolina, united states springfield, oregon, united states bala cynwyd, pennsylvania, united states lancaster, pennsylvania, united states pittsburgh, pennsylvania, united states myrtle beach, south carolina, united states nashville, tennessee, united states dallas, texas, united states salt lake, utah, united states fairfax, virginia, united states norfolk, virginia, united states salem, virginia, united states burien, washington, united states ciudad autonoma de buenos aires, argentina santa rosa, argentina venado tuerto, argentina camperdown, new south wales, australia coffs harbour, new south wales, australia darlinghurst, new south wales, australia tweed heads, new south wales, australia richmond, victoria, australia subiaco, western australia, australia bruxelles, belgium gent, belgium kortrijk, belgium liege, belgium botucatu, sao paulo, brazil cachoeiro de itapemirim - es, brazil curitiba, parana, brazil florianopolis, brazil juiz de fora, minas gerais, brazil mogi das cruzes, sao paulo, brazil natal, rio grande do norte, brazil passo fundo, brazil porto alegre, rs, brazil rio de janeiro, brazil salvador/ba, brazil sao paulo, brazil volta redonda - rj, brazil pleven, bulgaria plovdiv, bulgaria sofia, bulgaria varna, bulgaria kelowna, british columbia, canada victoria, british columbia, canada brantford, ontario, canada north york, ontario, canada oakville, ontario, canada santiago, chile temuco, chile vina del mar, chile beijing, china chengdu, china shanghai, china shantou, china wuhan, china bogota, colombia cali, colombia novy jicin, czech republic olomouc, czech republic praha 2, czech republic praha 5, czech republic usti nad labem, czech republic tartu, estonia angers, france cannes, france marseille, france montpellier, france paris, france pierre benite, france rennes, france suresnes, france dresden, germany hamburg, germany koln, germany mannheim, germany marburg, germany munchen, germany munster, germany nurtingen, germany tubingen, germany weiden, germany athens, greece patras, greece thessaloniki, greece pune, india beer-sheva, israel haifa, israel jerusalem, israel petach tikva, israel ramat-gan, israel tel-aviv, israel zerifin, israel cremona, italy lecco, italy meldola, italy milano, italy padova, italy ravenna, italy roma, italy torino, italy gwangju, korea, republic of seoul, korea, republic of liepaja, latvia riga, latvia beirut, lebanon bsalim, lebanon kaunas, lithuania vilnius, lithuania chihuahua, chih., mexico culiacan, sinaloa, mexico leon, gto, mexico puebla, mexico zapopan, jalisco, mexico amsterdam, netherlands groningen, netherlands leiden, netherlands nijmegen, netherlands tilburg, netherlands christchurch, new zealand nelson, new zealand palmerston north, new zealand tauranga, new zealand panama, panama arequipa, peru bialystok, poland lodz, poland myslowice, poland poznan, poland warszawa, poland wroclaw, poland baia mare, romania bucharest, romania cluj-napoca, romania craiova, romania ploiesti, romania suceava, romania timisoara, romania ekaterinburg, russian federation moscow, russian federation novosibirsk, russian federation omsk, russian federation st. petersburg, russian federation vladimir, russian federation bratislava, slovakia trencin, slovakia sevilla, andalucia, spain zaragoza, aragon, spain oviedo, asturias, spain santander, cantabria, spain sabadell, cataluna, spain alcorcon, madrid, communidad de, spain pamplona, navarra, spain barcelona, spain san sebastian de los reyes, spain valencia, spain göteborg, sweden karlstad, sweden stockholm, sweden kaohsiung, taiwan taichung, taiwan taipei, taiwan taoyuan, taiwan istanbul, turkey chernivtsi, ukraine dnipropetrovsk, ukraine donetsk, ukraine ivano-frankivsk, ukraine kharkiv, ukraine kyiv, ukraine lutsk, ukraine lviv, ukraine odesa, ukraine uzhgorod, ukraine zaporizhzhya, ukraine birmingham, united kingdom chichester, united kingdom leeds, united kingdom london, united kingdom northwood, united kingdom nottingham, united kingdom oxford, united kingdom scunthorpe, united kingdom sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01234311,prostat
478,479,NCT05319392,transcriptomic signatures in gastric adenocarcinoma,GAC,Recruiting,No Results Available,gastric adenocarcinoma,diagnostic test: observational study,transcriptome profiling of gastric adenocarcinoma|differential gene expression analysis in gastric adenocarcinoma|influence of tumor microenvironment on gene expression profile of gastric adenocarcinoma|correlation of tumor microenvironment related genes with patient's clinical features|patient risk stratification based on correlation between gene expression and overall survival,sanjay gandhi postgraduate institute of medical sciences,All,"18 Years to 80 Years   (Adult, Older Adult)",,48.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2021-240-PhD-EXP-42,"August 6, 2021","April 6, 2025","October 6, 2025","April 8, 2022",,"April 15, 2022","['sanjay gandhi postgraduate institute of medical sciences, lucknow, uttar pradesh, india']",,https://ClinicalTrials.gov/show/NCT05319392,gastric kidney
479,480,NCT02551159,phase iii open label study of medi 4736 with/without tremelimumab versus standard of care (soc) in recurrent/metastatic head and neck cancer,KESTREL,Completed,Has Results,squamous cell carcinoma of the head and neck,biological: medi4736|biological: tremelimumab|biological: medi4736+tremelimumab|biological: cetuximab|drug: 5-fluorouracil (5fu)|drug: cisplatin|drug: carboplatin,"overall survival (os) status in the pd-l1 tc/ic high subgroup - durvalumab versus standard of care (soc)|overall survival (os) median duration in the pd-l1 tc/ic high subgroup|overall survival (os) status in the pd-l1 tc/ic high subgroup - durvalumab + tremelimumab versus standard of care (soc)|percentage of patients alive at 12, 18 and 24 months in the pd-l1 tc/ic high subgroup|progression free survival (pfs) in the pd-l1 tc/ic high subgroup|objective response rate (orr) in the pd-l1 tc/ic high subgroup|duration of response (dor) in the pd-l1 tc/ic high subgroup|overall survival (os) status in the all-comers (full analysis set)|overall survival (os) median duration in the all-comers (full analysis set)|percentage of patients alive at 12, 18 and 24 months in the all-comers (full analysis set)|progression free survival (pfs) in the all-comers (full analysis set)|objective response rate (orr) in the all-comers (full analysis set)|duration of response (dor) in the all-comers (full analysis set)",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,823.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D419LC00001,"October 15, 2015","July 6, 2020","May 21, 2021","September 16, 2015","October 13, 2021","October 13, 2021","[""research site, aurora, colorado, united states research site, washington, district of columbia, united states research site, fort myers, florida, united states research site, saint petersburg, florida, united states research site, tampa, florida, united states research site, atlanta, georgia, united states research site, chicago, illinois, united states research site, baltimore, maryland, united states research site, baltimore, maryland, united states research site, boston, massachusetts, united states research site, morristown, new jersey, united states research site, new york, new york, united states research site, new york, new york, united states research site, chapel hill, north carolina, united states research site, charlotte, north carolina, united states research site, winston-salem, north carolina, united states research site, cleveland, ohio, united states research site, columbus, ohio, united states research site, nashville, tennessee, united states research site, graz, austria research site, innsbruck, austria research site, linz, austria research site, wien, austria research site, brussels, belgium research site, brussels, belgium research site, bruxelles, belgium research site, leuven, belgium research site, namur, belgium research site, barretos, brazil research site, curitiba, brazil research site, florianópolis, brazil research site, ijui, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, recife, brazil research site, rio de janeiro, brazil research site, santo andre, brazil research site, santo andré, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, calgary, alberta, canada research site, winnipeg, manitoba, canada research site, moncton, new brunswick, canada research site, halifax, nova scotia, canada research site, hamilton, ontario, canada research site, london, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, bordeaux, france research site, brest, france research site, dijon, france research site, lyon cedex 08, france research site, nice, france research site, paris, france research site, poitiers cedex, france research site, toulouse cedex, france research site, vandoeuvre les nancy, france research site, villejuif, france research site, berlin, germany research site, erlangen, germany research site, essen, germany research site, frankfurt am main, germany research site, freiburg, germany research site, hamburg, germany research site, heidelberg, germany research site, mainz, germany research site, tübingen, germany research site, würzburg, germany research site, athens, greece research site, athens, greece research site, athens, greece research site, athens, greece research site, heraklion, greece research site, thessaloniki, greece research site, bangalore, india research site, bangalore, india research site, bengaluru, india research site, gurgaon, india research site, karamsad, india research site, madurai, india research site, pune, india research site, cona, italy research site, firenze, italy research site, messina, italy research site, milano, italy research site, padova, italy research site, palermo, italy research site, salerno, italy research site, siena, italy research site, torino, italy research site, akashi-shi, japan research site, chiba-shi, japan research site, fukuoka-shi, japan research site, hirakata-shi, japan research site, isehara-shi, japan research site, kagoshima-shi, japan research site, kanazawa-shi, japan research site, kitaadachi-gun, japan research site, kobe-shi, japan research site, koto-ku, japan research site, natori-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, osakasayama, japan research site, sapporo-shi, japan research site, sapporo, japan research site, sunto-gun, japan research site, takatsuki-shi, japan research site, toyoake-shi, japan research site, yokohama-shi, japan research site, cheongju-si, korea, republic of research site, hwasun-gun, korea, republic of research site, incheon, korea, republic of research site, seo-gu, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon-si, korea, republic of research site, cebu city, philippines research site, las pinas, philippines research site, quezon city, philippines research site, białystok, poland research site, bielsko-biała, poland research site, gdańsk, poland research site, gdynia, poland research site, lublin, poland research site, poznan, poland research site, poznan, poland research site, szczecin, poland research site, warszawa, poland research site, łódź, poland research site, suceava, romania research site, arkhangelsk, russian federation research site, ekaterinburg, russian federation research site, krasnodar, russian federation research site, moscow, russian federation research site, obninsk, russian federation research site, omsk, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, sochi, russian federation research site, st.petersburg, russian federation research site, ufa, russian federation research site, bratislava, slovakia research site, kosice, slovakia research site, badajoz, spain research site, barcelona, spain research site, barcelona, spain research site, jaén, spain research site, l'hospitalet de llobregat, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, marbella, spain research site, málaga, spain research site, valencia, spain research site, zaragoza, spain research site, kaohsiung, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, hat yai, thailand research site, pathumthani, thailand research site, dnipro, ukraine research site, ivano-frankivsk, ukraine research site, kapitanivka village, ukraine research site, kharkiv region, ukraine research site, kirovohrad, ukraine research site, kryvyi rih, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, odesa, ukraine research site, sumy, ukraine research site, vinnytsia, ukraine research site, bebington, united kingdom research site, birmingham, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, sutton, united kingdom research site, taunton, united kingdom research site, ha noi, vietnam research site, hanoi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam""]","""study protocol"", https://clinicaltrials.gov/provideddocs/59/nct02551159/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/59/nct02551159/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02551159,skin
480,481,NCT00191100,"comparative study of gemcitabine,cisplatin and radiation versus cisplatin and radiation in cancer of the cervix",,Completed,Has Results,cancer of cervix,drug: gemcitabine|drug: cisplatin|radiation: brachytherapy|radiation: pelvic radiation,number of participants with progressive disease or death due to any cause at 3 years|number of participants with progressive disease or death due to disease under study at various time points|local failure rate|tumor response|number of participants who died from any cause at various time points|number of participants with progressive disease or death due to any cause at various time points,eli lilly and company,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,515.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4015|B9E-MC-JHQS,May 2002,April 2008,April 2008,"September 19, 2005","May 25, 2009","August 11, 2009","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., buenos aires, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., sarajevo, bosnia and herzegovina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mexico city, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., karachi, pakistan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lima, peru for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bangkok, thailand']",,https://ClinicalTrials.gov/show/NCT00191100,cervix
481,482,NCT03543020,radiation- induced alopecia in patients undergoing radiation therapy to the brain,,Terminated,No Results Available,alopecia; x-rays,radiation: radiation therapy to brain,to record the degree of alopecia at the conclusion of radiotherapy compared to pre- radiotherapy status with use of scalp sparing radiotherapy technique.|radiation dose range levels that causes alopecia|in vivo dosimetry values for scalp doses in modern radiotherapy treatment,fortis memorial research institute,All,"Child, Adult, Older Adult",,25.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017-008IP-20,"July 17, 2017","December 31, 2018","January 30, 2019","June 1, 2018",,"March 4, 2019","['department of radiation oncology, fortis memorial research institute, gurgaon, haryana, india']",,https://ClinicalTrials.gov/show/NCT03543020,
482,483,NCT00864331,optimization of treatment of advanced nonsmall cell lung cancer using radiotherapy and chemotherapy,,Completed,No Results Available,non small cell lung cancer,radiation: radiation|other: chemotherapy and radiotherapy|drug: chemotherapy|other: palliative radiotherapy and chemotherapy,survival|to assess the differences in toxicity of two treatment options in both stage iii (a and b) nsclc (study a) and stage iiib (wet) and stage iv nsclc (study b)|to assess the differences in health related quality of life (hrqol) of two treatment options in both study a and study b,international atomic energy agency,All,"18 Years and older   (Adult, Older Adult)",Phase 3,251.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,E33029,February 2008,November 2012,November 2012,"March 18, 2009",,"August 7, 2013","[""instituto de radiomedicine, santiago, chile affiliated hospital of ning xia medical college, department of radiation oncology, yinchuan, china university of zagreb faculty of medicine, zagreb, croatia misr oncology center (moc), cairo, egypt tata memorial centre (tmc) department of atomic energy (dae), mumbai, india general hospital kuala lumpur, institute of radiotherapy and oncology, kuala lumpur, malaysia sir paul boffa hospital, floriana, malta ministère de la santé, institut national d'oncologie sidi mohamed ben abdellah, rabat, morocco nuclear medicine oncology and radiotherapy institute, islamabad, pakistan instituto oncológico national, panama city, panama instituto nacional de enfermadades neoplasicas depto. de radioterapia, lima, peru university of witwatersrand johannesburg hospital dept of radiation oncology, johannesburg, south africa institut de la sante publique, institut national de cancer salah azaiz, tunis, tunisia""]",,https://ClinicalTrials.gov/show/NCT00864331,
483,484,NCT00034125,phase 3 study of ly353381 vs tamoxifen in women with locally advanced or metastatic breast cancer.,,Completed,No Results Available,breast neoplasms,drug: ly353381|drug: tamoxifen,,eli lilly and company,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3883|H4Z-MC-JWXD,,,,"April 24, 2002",,"July 19, 2006","['miami, florida, united states shreveport, louisiana, united states boston, massachusetts, united states nashville, tennessee, united states capital federal, buenos aires, argentina ciudad de buenos aires, argentina las condes, santiago, chile providencia, santiago, chile ahmedabab, gujarat, india mexico city, benito juarez, mexico colima, mexico']",,https://ClinicalTrials.gov/show/NCT00034125,breast
484,485,NCT00122772,crp on radiobiological and clinical studies on viral-induced cancer's response to radiotherapy,,Completed,No Results Available,cervix cancer,radiation: radiotherapy|radiation: radiotherapy/cisplatin,clinical outcome|treatment toxicity|molecular markers that will predict tumor control/resistance|whether e6 and e7 viral proteins predict cellular radiosensitivity in oxic and hypoxic conditions in vitro and tumor control/resistance in vivo|effectiveness of a questionnaire template on a computer in face-to-face interviews in a multicentre multinational study.,international atomic energy agency,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,601.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E33026,November 2005,June 2010,June 2010,"July 22, 2005",,"October 14, 2011","[""university of vienna; department of radiotherapy and radiobiology, vienna, austria rmandade de santa casa de misericordia de porto alegre; hospital santa rita, porto alegre, brazil peel regional cancer centre, mississauga, ontario, canada department of atomic energy (dae); tata memorial centre (tmc); tata, mumbai, india national cancer center, seoul, korea, republic of radiotherapy and oncology university clinic, skopje, macedonia, the former yugoslav republic of institut national d'oncologie, rabat, morocco bahawalpur institute of nuclear medicine and oncology (bino), bahawalpur, pakistan instituto nacional de enfermedades neoplásicas, lima, peru department of radiation oncology, groote schuur hospital, cape town, south africa christie hospital; nhs trust, manchester, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00122772,cervix
485,486,NCT00417209,larotaxel compared to continuous administration of 5-fu in advanced pancreatic cancer patients previously treated with a gemcitabine-containing regimen,PAPRIKA,Completed,No Results Available,pancreatic neoplasms,drug: larotaxel (xrp9881)|drug: 5-fluorouracil|drug: capecitabine,overall survival (os) defined as the time interval from the date of randomization to the date of death due to any cause|progression free survival (pfs); overall response rate (proportion of patients with confirmed recist-defined complete response (cr) or partial response (pr); clinical benefit based on the measurement of tumor related symptoms;,sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,408.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC6596|EUDRACT: 2006-003086-14,December 2006,July 2009,November 2009,"December 29, 2006",,"June 3, 2016","['sanofi-aventis administrative office, bridgewater, new jersey, united states sanofi-aventis administrative office, diegem, belgium sanofi-aventis administrative office, sao paulo, brazil sanofi-aventis administrative office, laval, quebec, canada sanofi-aventis administrative office, santiago de chile, chile sanofi-aventis administrative office, santafe de bogota, colombia sanofi-aventis administrative office, praha, czech republic sanofi-aventis administrative office, helsinki, finland sanofi-aventis administrative office, berlin, germany sanofi-aventis administrative office, budapest, hungary sanofi-aventis administrative office, mumbai, india sanofi-aventis administrative office, milan, italy sanofi-aventis administrative office, mexico, mexico sanofi-aventis administrative office, lysaker, norway sanofi-aventis administrative office, lima, peru sanofi-aventis administrative office, warszawa, poland sanofi-aventis administrative office, moscow, russian federation sanofi-aventis administrative office, brastislava, slovakia sanofi-aventis administrative office, madrid, spain sanofi-aventis administrative office, istanbul, turkey sanofi-aventis administrative office, guildford, surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00417209,pancreat
486,487,NCT03390686,"a trial to compare the efficacy, safety, pharmacokinetics and immunogenecity of hd204 to avastin® in advanced non-squamous non-small cell lung cancer patients",,Recruiting,No Results Available,lung cancer|non-small cell lung cancer,drug: bevacizumab|drug: hd204|drug: carboplatin|drug: paclitaxel,best objective response rate by 24 weeks|progression free survival|overall survival (os)|duration of response|incidence of treatment-related adverse events using ctcae v4.03|trough level [ctrough] (pharmacokinetics)|maximum plasma concentration [cmax] (pharmacokinetics)|anti-drug antibodies (immunogenecity)|neutralizing antibodies (immunogenecity),prestige biopharma limited,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SAMSON-II,"November 15, 2019",May 2022,December 2022,"January 4, 2018",,"September 8, 2021","['alexandrov cancer center, minsk, belarus mhat ""dr. tota venkova"", ad, gabrovo, bulgaria chc osijek, osijek, osijecko-baranjska, croatia ltd ""high technology hospital medcenter"", batumi, georgia institute of clinical oncology, tbilisi, georgia interbalkan hospital, thessaloníki, asklipiou 10, greece tudogyogyintezet torokbalint, törökbálint, hungary hcg manavata cancer centre, nashik, maharashtra, india riga east university hospital latvian oncology centre, riga, latvia hrpz ii, kota bharu, kelantan, malaysia asian hospital and medical center, muntinlupa, philippines magodend szpital elblaska, warszawa, poland medsi, moscow, otradnoye, russian federation ipd of vojvodina, sremska kamenica, serbia nemocnica na okraji mesta, n.o., partizánske, slovakia maharaj nakorn chiang mai, chiang mai, muang, thailand acibadem adana hospital, adana, turkey oncology dispensary, odessa, ukraine']",,https://ClinicalTrials.gov/show/NCT03390686,
487,488,NCT00418886,efficacy study comparing zd6474 in combination with pemetrexed and pemetrexed alone in 2nd line nsclc patients,ZEAL,"Active, not recruiting",Has Results,non small cell lung cancer|lung cancer,drug: vandetanib|drug: pemetrexed,progression-free survival (pfs) in the overall population|progression-free survival (pfs) in the female population|overall survival (os)|objective response rate (orr)|disease control rate (dcr)|duration of response (dor)|time to deterioration of disease-related symptoms (tds) by lung cancer symptom scale (lcss) total score|time to deterioration of disease-related symptoms (tds) by average symptom burden index (asbi) score|longitudinal analysis of lung cancer symptom scale (lcss) total score|longitudinal analysis of average symptom burden index (asbi) score,"genzyme, a sanofi company|sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 3,698.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D4200C00036|EUDRACT No. 2006-003695-35|LPS15296,January 2007,September 2008,"December 31, 2022","January 5, 2007","March 26, 2012","November 1, 2021","['research site, casa grande, arizona, united states research site, chandler, arizona, united states research site, farmington, connecticut, united states research site, stamford, connecticut, united states research site, washington, district of columbia, united states research site, orlando, florida, united states research site, gainesville, georgia, united states research site, skokie, illinois, united states research site, sioux city, iowa, united states research site, mount sterling, kentucky, united states research site, portland, maine, united states research site, baltimore, maryland, united states research site, rockville, maryland, united states research site, boston, massachusetts, united states research site, saint louis, missouri, united states research site, mineola, new york, united states research site, rochester, new york, united states research site, winston-salem, north carolina, united states research site, cincinnati, ohio, united states research site, middletown, ohio, united states research site, hilton head island, south carolina, united states research site, austin, texas, united states research site, salt lake city, utah, united states research site, avellaneda, argentina research site, buenos aires, argentina research site, ciudad de buenos aires, argentina research site, córdoba, argentina research site, la plata, argentina research site, ramos mejía, argentina research site, salta, argentina research site, santa fe, argentina research site, chermside, australia research site, fitzroy, australia research site, footscray, australia research site, heidelberg, australia research site, randwick, australia research site, st. leonards, australia research site, wodonga, australia research site, brussels (woluwé-st-lambert), belgium research site, leuven, belgium research site, liège, belgium research site, bogota, colombia research site, medellín, colombia research site, pereira, colombia research site, valledupar, colombia research site, avignon cedex 09, france research site, lyon cedex 04, france research site, paris cedex 15, france research site, pontoise cedex, france research site, strasbourg cedex, france research site, hannover, germany research site, karlsruhe, germany research site, kassel, germany research site, köln, germany research site, leipzig, germany research site, n. faliro, greece research site, patras, greece research site, thessaloniki, greece research site, hong kong, hong kong research site, ahmedabad, india research site, vellore, india research site, beer-sheeva, israel research site, haifa, israel research site, jerusalem, israel research site, kfar saba, israel research site, petach-tikva, israel research site, safed, israel research site, tel-hashomer, israel research site, zerifin, israel research site, genova, italy research site, milano, italy research site, orbassano, italy research site, roma, italy research site, s.andrea delle fratte, italy research site, aguascalientes, mexico research site, mexico, mexico research site, puebla, mexico research site, cebu city, philippines research site, manila, philippines research site, pasay city, philippines research site, quezon city, philippines research site, lisboa, portugal research site, santa maria da feira, portugal research site, setúbal, portugal research site, cape town, south africa research site, durban, south africa research site, johannesburg, south africa research site, port elizabeth, south africa research site, pretoria, south africa research site, a coruña, spain research site, lugo, spain research site, majadahonda, spain research site, mataró(barcelona), spain research site, málaga, spain research site, orense, spain research site, santiago de compostela(a coru, spain research site, vigo(pontevedra), spain research site, lund, sweden research site, sundsvall, sweden research site, umeå, sweden research site, uppsala, sweden research site, västerås, sweden research site, taipei, taiwan research site, birmingham, united kingdom research site, edinburgh, united kingdom research site, leeds, united kingdom research site, manchester, united kingdom research site, wolverhampton, united kingdom research site, caracas, venezuela research site, valencia, venezuela']",,https://ClinicalTrials.gov/show/NCT00418886,
488,489,NCT04109391,extension study to provide adjuvant treatment following neoadjuvant treatment and surgical resection in protocol tx05-03,,Completed,No Results Available,her2-positive breast cancer|early-stage breast cancer|breast cancer|breast neoplasms|stage ii breast cancer|stage iiia breast cancer,biological: tx05 (trastuzumab)|biological: herceptin (trastuzumab),rate of adverse events|immunogenicity assessments|disease-free survival|overall survival,"tanvex biopharma usa, inc.",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,338.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TX05-03E,"August 23, 2019","December 25, 2021","March 8, 2022","September 30, 2019",,"April 26, 2022","['tanvex investigational site 1003e, gomel, belarus tanvex investigational site 1006e, grodno, belarus tanvex investigational site 1008e, lesnoy, belarus tanvex investigational site 1002e, minsk, belarus tanvex investigational site 1005e, mogilev, belarus tanvex investigational site 1001e, vitebsk, belarus tanvex investigational site 4001e, temuco, chile tanvex investigational site 4002e, vina del mar, chile tanvex investigational site 5006e, batumi, georgia tanvex investigational site 5002e, batumi, georgia tanvex investigational site 5001e, tbilisi, georgia tanvex investigational site 5005e, tbilisi, georgia tanvex investigational site 5010e, tbilisi, georgia tanvex investigational site 5008e, tbilisi, georgia tanvex investigational site 6003e, budapest, hungary tanvex investigational site 7031e, nashik, maharashtra, india tanvex investigational site 7033e, ahmedabad, india tanvex investigational site 7019e, bangalore, india tanvex investigational site 7022e, belgaum, india tanvex investigational site 7045e, hyderabad, india tanvex investigational site 7036e, hyderabad, india tanvex investigational site 7006e, kolkata, india tanvex investigational site 7001e, nashik, india tanvex investigational site 7015e, pune, india tanvex investigational site 7017e, vijayawada, india tanvex investigational site 2109e, aguascalientes, mexico tanvex investigational site 2103e, monterrey, mexico tanvex investigational site 2106e, oaxaca, mexico tanvex investigational site 2110e, tequisquiapan, mexico tanvex investigational site 2108e, zapopan, mexico tanvex investigational site 1101e, arequipa, peru tanvex investigational site 1107e, arequipa, peru tanvex investigational site 1104e, chiclayo, peru tanvex investigational site 1112e, lima cercado, peru tanvex investigational site 1105e, lima, peru tanvex investigational site 1108e, san borja, peru tanvex investigational site 1102e, san isidro, peru tanvex investigational site 1109e, surquillo, peru tanvex investigational site 1103e, trujillo, peru tanvex investigational site 1211e, cebu city, philippines tanvex investigational site 1212e, davao city, philippines tanvex investigational site 1214e, makati city, philippines tanvex investigational site 1209e, quezon city, philippines tanvex investigational site 1213e, quezon city, philippines tanvex invesitgational site 1210e, santo tomas, philippines tanvex investigational site 1513e, sochi, krasnodar region, russian federation tanvex investigational site 1535e, arkhangelsk, russian federation tanvex investigational site 1531e, belgorod, russian federation tanvex investigational site 1502e, kaluga, russian federation tanvex investigational site 1505e, kislino, russian federation tanvex investigational site 1529e, krasnodar, russian federation tanvex investigational site 1512e, krasnoyarsk, russian federation tanvex investigational site 1530e, moscow, russian federation tanvex investigational site 1507e, moscow, russian federation tanvex investigational site 1511e, novosibirsk, russian federation tanvex investigational site 1503e, omsk, russian federation tanvex investigational site 1509e, omsk, russian federation tanvex investigational site 1537e, orenburg, russian federation tanvex investigational site 1526e, pesochnyy, russian federation tanvex investigational site 1510e, pushkin, russian federation tanvex investigational site 1521e, rostov-na-donu, russian federation tanvex investigational site 1516e, saint petersburg, russian federation tanvex investigational site 1524e, saint petersburg, russian federation tanvex investigational site 1525e, saint petersburg, russian federation tanvex investigational site 1506e, saint petersburg, russian federation tanvex investigational site 1501e, saint petersburg, russian federation tanvex investigational site 1523e, sankt-peterburg, russian federation tanvex investigational site 1508e, saransk, russian federation tanvex investigational site 1534e, yaroslavl, russian federation tanvex investigational site 1820e, antonivka, ukraine tanvex investigational site 1803e, chernihiv, ukraine tanvex investigational site 1808e, chernihiv, ukraine tanvex investigational site 1821e, chernivtsi, ukraine tanvex investigational site 1824e, dnipro, ukraine tanvex investigational site 1811e, kiev, ukraine tanvex investigational site 1802e, kiev, ukraine tanvex investigational site 1819e, kropyvnytskyi, ukraine tanvex investigational site 1814e, kropyvnytskyi, ukraine tanvex investigational site 1804e, kryvyi rih, ukraine tanvex investigational site 1815e, kyiv, ukraine tanvex investigational site 1809e, kyiv, ukraine tanvex investigational site 1810e, odesa, ukraine tanvex investigational site 1806e, sumy, ukraine tanvex investigational site 1822e, ternopil, ukraine tanvex investigational site 1818e, vinnytsia, ukraine tanvex investigational site 1813e, zaporizhzhya, ukraine']",,https://ClinicalTrials.gov/show/NCT04109391,breast
489,490,NCT00574275,aflibercept compared to placebo in term of efficacy in patients treated with gemcitabine for metastatic pancreatic cancer,VANILLA,Terminated,Has Results,pancreatic neoplasm,"drug: aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®)|drug: placebo|drug: gemcitabine",overall survival (os)|progression free survival (pfs) based on response evaluation criteria in solid tumors [recist] criteria|objective response rate (orr) assessed by the investigators according to recist criteria|clinical benefit|safety-number of participants with adverse events (ae)|number of participants with anti-drug antibodies,sanofi|regeneron pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,546.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EFC10547|EudraCT 2007-003476-19,December 2007,October 2009,November 2010,"December 17, 2007","September 25, 2012","June 7, 2016","['sanofi-aventis administrative office, bridgewater, new jersey, united states sanofi-aventis administrative office, buenos aires, argentina sanofi-aventis administrative office, wien, austria sanofi-aventis administrative office, diegem, belgium sanofi-aventis administrative office, sofia, bulgaria sanofi-aventis administrative office, laval, canada sanofi-aventis administrative office, santiago, chile sanofi-aventis administrative office, santafe de bogota, colombia sanofi-aventis administrative office, nikosia, cyprus sanofi-aventis administrative office, praha, czech republic sanofi-aventis administrative office, paris, france sanofi-aventis administrative office, berlin, germany sanofi-aventis administrative office, athens, greece sanofi-aventis administrative office, budapest, hungary sanofi-aventis administrative office, mumbai, india sanofi-aventis administrative office, milano, italy sanofi-aventis administrative office, mexico, mexico sanofi-aventis administrative office, warszawa, poland sanofi-aventis administrative office, puerto rico, puerto rico sanofi-aventis administrative office, bucuresti, romania sanofi-aventis administrative office, moscow, russian federation sanofi-aventis administrative office, brastislava, slovakia sanofi-aventis administrative office, barcelona, spain sanofi-aventis administrative office, geneva, switzerland']",,https://ClinicalTrials.gov/show/NCT00574275,pancreat
490,491,NCT00923702,trial of two versus three doses of human papillomavirus (hpv) vaccine in india,,Unknown status,No Results Available,cervical cancer|cervical precancerous lesions,biological: prophylactic quadrivalent hpv vaccine merck (gardasil®),"geometric mean titers of serum neutralizing antibodies to vaccine included hpv types (16/18/6/11) at 7, 12, 24, 36, 48 months.|frequency of incident and persistent hpv 16/18/6/11 infection.|frequency of infection by other non-targeted high-risk hpv types.|frequency of hpv 16/18-associated precancerous lesions and cancer.|frequency of cervical neoplasia associated with non-included hpv types.","dr r. sankaranarayanan|all india institute of medical sciences, new delhi|cancer foundation of india|christian fellowship community health centre|deutsches krebsforschungszentrum (dkfz)|gujarat cancer & research institute|jehangir clinical development centre|mnj institute of oncology & regional cancer center|rajiv gandhi centre for biotechnology|tata memorial centre rural cancer project, nargis dutt memorial cancer hospital|tata memorial centre|international agency for research on cancer",Female,"10 Years to 18 Years   (Child, Adult)",Phase 4,20000.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,BMGF48979|ISRCTN98283094|REFCTRI-2009 000137,September 2009,July 2019,July 2021,"June 18, 2009",,"September 1, 2016","['mnj institute of oncology & regional cancer center, hyderabad, andhra pradesh, india cancer foundation of india, kolkata, bengal, india gujarat cancer & research institute (gcri), ahmedabad, gujarat, india tata memorial centre rural cancer project, nargis dutt memorial cancer hospital, barshi, maharashtra, india tata memorial center, tata memorial hospital & cancer research inst, mumbai, maharashtra, india jehangir clinical development centre (jcdc) pvt. ltd., pune, maharashtra, india christian fellowship community health centre, ambilikkai, tamil nadu, india all india institute of medical sciences, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00923702,cervic
491,492,NCT00694915,study of mycobacterium w in superficial transitional cell carcinoma of bladder,STCC,Completed,No Results Available,bladder cancer,biological: mycobacterium w|biological: bcg (bacillus calmette-guerin),"recording of any clinical adverse reactions at anytime during the study for assessment of safety|recurrence rate-evaluated after 3 months by doing sonography, cystoscopy, and cytology|quality of life- the measure of an individual's sense of well-being and ability to carry out various activities|time to tumor progression -will be evaluated every 3 months for 15 months during the study period",cadila pharnmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,122.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR-60/9150,"August 28, 2008","March 31, 2014","October 7, 2015","June 11, 2008",,"August 17, 2021","['urocare hospital, rajkot, gujarat, india muljibhai patel urological hospital, nadiad, gujrat, india indira gandhi medical college, shimla, himachal pradesh, india n.r.r. hospital, bangalore, karnataka, india kasturba medical college and hospital, manipal, karnataka, india lourdes hospital, kochi, kerala, india choithram hospital and research centre, indore, madhya pradesh, india cancer hospital and research institute, gwalior, madya pradesh, india seth g s medical college & k e m hospital, parel, mumbai, india christian medical college, ludhiana, punjab, india p.b.m. hospital & a.g. of hospitals, bikaner, rajasthan, india ipgmer, s.s.k.m. hospital, kolkata, west bengal, india post graduate institute of medical education and research, chandigarh, india dr. ram manohar lohia hospital & pgimer, new delhi, india v m medical college & safdarjang hospital, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00694915,bladder
492,493,NCT00694798,study of mycobacterium w in bcg refractory superficial transitional cell carcinoma of bladder,STCC,Completed,No Results Available,bladder cancer,biological: mycobacterium w,response rate,cadila pharnmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR-80/8230,October 2008,July 2011,July 2011,"June 11, 2008",,"May 3, 2012","['aarogyam speciality hospital, ahmedabad, gujarat, india gandhi urocare, ahmedabad, gujarat, india siddhi vinayak hospital, advanced urology and orthopedic centre, ahmedabad, gujarat, india urocare hospital, rajkot, gujarat, india excel hospital, advanced laproscopy and urology centre, surat, gujarat, india desai urological & maternity hospital, vadodara, gujarat, india muljibhai patel urological hospital, nadiad, gujrat, india indira gandhi medical college, shimla, himachal pradesh, india lourdes hospital, kochi, kerala, india choithram hospital and research centre, indore, madhya pradesh, india cancer hospital and research institute, gwalior, madya pradesh, india christian medical college, ludhiana, punjab, india s.p. medical college & a. g. of hospitals, bikaner, rajasthan, india ipgmer, s.s.k.m. hospital, kolkata, west bengal, india post graduate institute of medical education and research, chandigarh, india dr. ram manohar lohia hospital & pgimer, new delhi, india v. m. medical college & safdarjang hospital, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00694798,bladder
493,494,NCT04660695,nasobiliary drain assisted eus-guided gastroenterostomies in unresectable malignant gastric outlet obstruction,PENGUIN,Completed,No Results Available,gastric outlet obstruction|gastric cancer|pancreatic cancer,device: eus-guided gastroenterostomy,technical success|early clinical success|clinical success|baseline gastric outlet obstruction score system (gooss)|early gastric outlet obstruction score system (gooss)|final gastric outlet obstruction score system (gooss)|baseline european organisation for research and treatment of cancer qol questionnaire core 30 (eortc-qlq-c30)|final european organisation for research and treatment of cancer qol questionnaire core 30 (eortc-qlq-c30)|number of participants with intraprocedure treatment-related adverse events as assessed by the asge classification|number of participants with early treatment-related adverse events as assessed by the asge classification|number of participants with delayed treatment-related adverse events as assessed by the asge classification|recurrent goo|target bowel loop diameter (mm)|total volume infused (ml)|number of patients undergoing balloon dilation|type of fluid employed,"hospital del río hortega|hospital general universitario de alicante|clinica universidad de navarra, universidad de navarra|complejo hospitalario de navarra|christian medical college, vellore, india",All,"18 Years and older   (Adult, Older Adult)",,66.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PI152-19,"August 15, 2019","May 12, 2021","May 12, 2021","December 9, 2020",,"May 14, 2021","['christian medical college, vellore, india clinica universidad de navarra, pamplona, navarra, spain complejo hospitalario de navarra, pamplona, navarra, spain hospital general universitario de alicante, alicante, spain hospital universitario río hortega, valladolid, spain']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/95/nct04660695/prot_sap_000.pdf",https://ClinicalTrials.gov/show/NCT04660695,gastric pancreat
494,495,NCT00836745,non-interventional study of indian patients with advanced renal cell cancer receiving therapy with sutent,,Completed,Has Results,renal cell carcinoma,other: non interventional,progression free survival (pfs)|percentage of participants with objective response (or)|number of participants who required management of skin and subcutaneous tissue related adverse events|number of participants who required management of other adverse events,pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",,36.0,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,A6181181,March 2009,July 2012,July 2012,"February 4, 2009","December 20, 2013","December 20, 2013","['pfizer investigational site, new delhi, delhi, india pfizer investigational site, bangalore, karnataka, india pfizer investigational site, mumbai, maharashtra, india pfizer investigational site, chandigard, punjab, india pfizer investigational site, kolkata, west bengal, india pfizer investigational site, delhi, india pfizer investigational site, jaipur, india']",,https://ClinicalTrials.gov/show/NCT00836745,kidney
495,496,NCT00021255,combination chemotherapy with or without trastuzumab in treating women with breast cancer,,Completed,Has Results,breast neoplasms,drug: doxorubicin|drug: cyclophosphamide|drug: docetaxel|drug: herceptin|drug: carboplatin,percentage of participants with disease free survival at 5 years|percentage of participants with disease free survival at 10 years|overall survival- percentage of participants who survived at 10 years,sanofi|cancer international research group (cirg),Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,3222.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAX_GMA_302|BCIRG 006,April 2001,December 2014,December 2014,"January 27, 2003","November 15, 2016","November 15, 2016","['sanofi-aventis administrative office, bridgewater, new jersey, united states sanofi-aventis administrative office, buenos aires, argentina sanofi-aventis administrative office, macquarie park, australia sanofi-aventis administrative office, vienna, austria sanofi-aventis administrative office, diegem, belgium sanofi-aventis administrative office, sarajevo, bosnia and herzegovina sanofi-aventis administrative office, sao paulo, brazil sanofi-aventis administrative office, vazrjdane region, bulgaria sanofi-aventis administrative office, québec, canada sanofi-aventis administrative office, bogota, colombia sanofi-aventis administrative office, zagreb, croatia sanofi-aventis administrative office, praha, czech republic sanofi-aventis administrative office, cairo, egypt sanofi-aventis administrative office, tallin, estonia sanofi-aventis administrative office, paris, france sanofi-aventis administrative office, frankfurt, germany sanofi-aventis administrative office, kallithea, greece sanofi-aventis administrative office, hong kong, hong kong sanofi-aventis administrative office, budapest, hungary sanofi-aventis administrative office, mumbai, india sanofi-aventis administrative office, dublin, ireland sanofi-aventis administrative office, natanya, israel sanofi-aventis administrative office, milan, italy sanofi-aventis administrative office, seoul, korea, republic of sanofi-aventis administrative office, beirut, lebanon sanofi-aventis administrative office, col. coyoacan, mexico sanofi-aventis administrative office, macquarie park, new zealand sanofi-aventis administrative office, warsaw, poland sanofi-aventis administrative office, bucuresti, romania sanofi-aventis administrative office, moscow, russian federation sanofi-aventis administrative office, bratislava, slovakia sanofi-aventis administrative office, ljubljana, slovenia sanofi-aventis administrative office, gauteng, south africa sanofi-aventis administrative office, barcelona, spain sanofi-aventis administrative office, bromma, sweden sanofi-aventis administrative office, genève, switzerland sanofi-aventis administrative office, taipei, taiwan sanofi-aventis administrative office, megrine, tunisia sanofi-aventis administrative office, istanbul, turkey sanofi-aventis administrative office, guildford surrey, united kingdom sanofi-aventis administrative office, montevideo, uruguay sanofi-aventis administrative office, caracas, venezuela']",,https://ClinicalTrials.gov/show/NCT00021255,breast
496,497,NCT00283062,adjuvant leuprolide with or without docetaxel in high risk prostate cancer after radical prostatectomy,,Completed,Has Results,prostatic neoplasms,drug: docetaxel (taxotere®) chemotherapy|drug: leuprolide acetate ( eligard®) hormonal therapy,progression-free survival (pfs) assessment - number of participants with disease progression|median overall survival (os)|median cancer-specific survival (css)|median metastasis-free survival (mfs)|to evaluate quality of life (qol) as measured using a functional assessment of cancer therapy-prostate (fact-p) questionnaire|assessment of safety and tolerability - number of participants with adverse events (ae),sanofi,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,228.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XRP6976J_3501|EudraCT # : 2004-002203-32,December 2005,December 2010,December 2010,"January 27, 2006","January 23, 2012","January 26, 2012","['sanofi-aventis administrative office, bridgewater, new jersey, united states sanofi-aventis administrative office, macquarie park, australia sanofi-aventis administrative office, vienna, austria sanofi-aventis administrative office, sao paulo, brazil sanofi-aventis administrative office, québec, canada sanofi-aventis administrative office, paris, france sanofi-aventis administrative office, frankfurt, germany sanofi-aventis administrative office, mumbai, india sanofi-aventis administrative office, natanya, israel sanofi-aventis administrative office, milan, italy sanofi-aventis administrative office, col. coyoacan, mexico sanofi-aventis administrative office, pe gouda, netherlands sanofi-aventis administrative office, warsaw, poland sanofi-aventis administrative office, moscow, russian federation sanofi-aventis administrative office, gauteng, south africa sanofi-aventis administrative office, istanbul, turkey sanofi-aventis administrative office, guildford surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00283062,prostat
497,498,NCT02303444,an observational study in differentiated thyroid cancer which is radioactive iodine (rai) refractory to assess the use of multikinase inhibitors,RIFTOS MKI,Completed,No Results Available,thyroid neoplasms,"drug: sorafenib (nexavar, bay43-9006)|drug: other multikinase inhibitors","time to symptomatic progression (ttsp) from study entry|overall survival (os) from time of study entry|progression free survival (pfs) from time of study entry|os from time of being diagnosed as radioactive iodine (rai) refractory|post-progression survival (pps) from time of symptomatic progression|os from initiation of the first multikinase inhibitor (mki)|pfs from initiation of first mki|os from initiation of any systemic treatment regimen|pfs from initiation of any systemic treatment regimen|duration of each systemic treatment regimen|response assessment to each systemic treatment regimen according to the categories ""complete response"", ""partial response"", ""stable disease"", ""clinical progression"", ""radiological progression"", and ""not evaluable at this visit""|os from initiation of sorafenib|pfs from initiation of sorafenib|daily dose of sorafenib per patient throughout the treatment period|number of adverse events during treatment with sorafenib",bayer,All,"18 Years and older   (Adult, Older Adult)",,667.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,17852|NX1401,"April 8, 2015","June 10, 2020","July 24, 2020","December 1, 2014",,"June 9, 2021","['birmingham, alabama, united states los angeles, california, united states torrance, california, united states aurora, colorado, united states washington, district of columbia, united states plantation, florida, united states atlanta, georgia, united states honolulu, hawaii, united states chicago, illinois, united states new orleans, louisiana, united states boston, massachusetts, united states ann arbor, michigan, united states bronx, new york, united states durham, north carolina, united states philadelphia, pennsylvania, united states dallas, texas, united states multiple locations, algeria multiple locations, argentina multiple locations, brazil multiple locations, egypt multiple locations, france multiple locations, germany multiple locations, greece multiple locations, india multiple locations, japan multiple locations, lebanon multiple locations, mexico multiple locations, netherlands multiple locations, philippines multiple locations, russian federation multiple locations, saudi arabia multiple locations, spain multiple locations, taiwan multiple locations, turkey']",,https://ClinicalTrials.gov/show/NCT02303444,thyroid
498,499,NCT01735175,phase iii study comparing the efficacy and safety of la-ep2006 and neulasta®,PROTECT-1,Completed,Has Results,neutropenic complications|breast neoplasms|chemotherapy-induced neutropenia|chemotherapeutic toxicity,drug: la-ep2006|drug: neulasta®,mean duration of severe neutropenia (dsn) during cycle 1 of chemotherapy|incidence of febrile neutropenia (fn)|number of patients with at least one episode of fever by cycle and across all cycles|depth of anc nadir in cycle 1|number of patients with anc nadir per day in cycle 1|time to anc recovery in days in cycle 1|frequency of infections by cycle and across all cycles|mortality due to infection,sandoz|sandoz gmbh,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,316.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",LA-EP06-301|2011-004532-58,June 2012,May 2013,February 2014,"November 28, 2012","June 15, 2017","August 7, 2017","['sandoz investigational site, ijui, brazil sandoz investigational site, lajeado, brazil sandoz investigational site, santo andre, brazil sandoz investigational site, andhra pradesh, india sandoz investigational site, delhi, india sandoz investigational site, madurai, india sandoz investigational site, maharashtra, india sandoz investigational site, maharashtra, india sandoz investigational site, maharashtra, india sandoz investigational site, mumbai, india sandoz investigational site, rajasthan, india sandoz investigational site, aguascalientes, mexico sandoz investigational site, juchitan, mexico sandoz investigational site, bucharest, romania sandoz investigational site, bucharest, romania sandoz investigational site, iasi, romania sandoz investigational site, suceava, romania sandoz investigational site, barnaul, russian federation sandoz investigational site, bashkortostan, russian federation sandoz investigational site, berdsk, russian federation sandoz investigational site, ivanovo, russian federation sandoz investigational site, kabardino, russian federation sandoz investigational site, kazan, russian federation sandoz investigational site, krasnodar, russian federation sandoz investigational site, kursk, russian federation sandoz investigational site, leningrad, russian federation sandoz investigational site, moscow, russian federation sandoz investigational site, novgorod, russian federation sandoz investigational site, oktyabrskaya, russian federation sandoz investigational site, ryazan, russian federation sandoz investigational site, st. petersburg, russian federation sandoz investigational site, tula, russian federation sandoz investigational site, cherkasy, ukraine sandoz investigational site, chernivtsi, ukraine sandoz investigational site, dnipropetrovsk, ukraine sandoz investigational site, kharkiv, ukraine sandoz investigational site, kriviy rig, ukraine sandoz investigational site, lugansk, ukraine sandoz investigational site, mariupol, ukraine sandoz investigational site, vinnytsya, ukraine sandoz investigational site, zaporizhzhia, ukraine']",,https://ClinicalTrials.gov/show/NCT01735175,breast
499,500,NCT00389441,study of ag-013736 in patients with 131i-refractory thyroid cancer,,Completed,Has Results,thyroid neoplasms,drug: ag-013736,percentage of participants with objective response (or)|progression free survival (pfs)|duration of response (dr)|overall survival (os)|change from baseline in md anderson symptom assessment inventory (mdasi) symptom severity score|change from baseline in md anderson symptom assessment inventory (mdasi) symptom interference score,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),A4061027,December 2006,September 2012,September 2012,"October 18, 2006","November 25, 2013","November 25, 2013","['pfizer investigational site, orange, california, united states pfizer investigational site, aurora, colorado, united states pfizer investigational site, tampa, florida, united states pfizer investigational site, chicago, illinois, united states pfizer investigational site, wichita, kansas, united states pfizer investigational site, witchita, kansas, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, buffalo, new york, united states pfizer investigational site, edmonton, alberta, canada pfizer investigational site, london, ontario, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, nanjing, jiangsu, china pfizer investigational site, beijing, china pfizer investigational site, shanghai, china pfizer investigational site, shanghai, china pfizer investigational site, praha 5, czech republic pfizer investigational site, vellore, tamil nadu, india pfizer investigational site, milano, italy pfizer investigational site, pisa, italy pfizer investigational site, gliwice, poland pfizer investigational site, warszawa, poland pfizer investigational site, pamplona, navarra, spain pfizer investigational site, madrid, spain pfizer investigational site, glasgow, united kingdom']",,https://ClinicalTrials.gov/show/NCT00389441,thyroid
500,501,NCT01298323,study to determine if contacting patients with mtc more frequently results in earlier detection and treatment of signs and symptoms of aes and thus a decrease in the percentage of time patients experience aes during first 12 months on vandetanib treatment,88,"Active, not recruiting",Has Results,locally advanced or metastatic medullary thyroid cancer|medullary thyroid cancer,behavioral: patient outreach|drug: vandetanib,percentage of time a patient experienced at least 1 ae of ctcae grade >=2 in first 12 months of receiving vandetanib in patients who participated in patient outreach program.,"genzyme, a sanofi company|sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 3,205.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D4200C00088|2010-023428-26|LPS14815,"February 25, 2011",April 2013,"December 31, 2022","February 17, 2011","November 24, 2014","November 1, 2021","['investigational site number 301, st leonards, australia investigational site number 401, wien, austria investigational site number 501, bruxelles, belgium investigational site number 701, porto alegre, brazil investigational site number 702, ribeirão preto, brazil investigational site number 901, sofia, bulgaria investigational site number 1001, london, canada investigational site number 1002, sherbrooke, canada investigational site number 1003, toronto, canada investigational site number 1301, beijing, china investigational site number 1302, shanghai, china investigational site number 1901, praha, czechia investigational site number 2001, odense c, denmark investigational site number 2201, helsinki, finland investigational site number 2602, essen, germany investigational site number 2603, halle, germany investigational site number 2601, würzburg, germany investigational site number 3001, athens, greece investigational site number 3501, mumbai, india investigational site number 3502, vellore, india investigational site number 4001, jerusalem, israel investigational site number 4104, napoli, italy investigational site number 4101, pisa, italy investigational site number 4102, roma, italy investigational site number 6001, seoul, korea, republic of investigational site number 5702, poznan, poland investigational site number 5703, warsaw, poland investigational site number 6201, moscow, russian federation investigational site number 6204, moscow, russian federation investigational site number 6202, obninsk, russian federation investigational site number 6203, st petersburg, russian federation investigational site number 7201, uppsala, sweden investigational site number 2802, glasgow, united kingdom investigational site number 2801, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01298323,thyroid
501,502,NCT01554397,study with intensity modulated radiation therapy with cisplatin to treat stage i-iva cervical cancer,,Unknown status,No Results Available,cervical cancer,radiation: intensity modulated radiation therapy (imrt)|drug: cisplatin,number of patients with adverse events as a measure of safety and tolerability|number of patients with acute and late adverse events as a measure of safety and tolerability|number of patients with locoregional failure as a measure of recurrence,"university of california, san diego|national cancer institute (nci)",Female,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,70.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INTERTECC|R21CA162718-01,"October 13, 2011",June 2019,June 2020,"March 15, 2012",,"February 5, 2020","[""moores uc san diego cancer center, la jolla, california, united states university of miami miller school of medicine, miami, florida, united states xijing hospital, xi'an, china university hospital hradec králové, hradec králové, czechia tata memorial hospital, parel, mumbai, india marie sklodowska cancer center, gliwice, poland king chulalongkorn hospital, bangkok, thailand""]",,https://ClinicalTrials.gov/show/NCT01554397,cervic
502,503,NCT00327444,study of the effect of intravenous ave0005 (vegf trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites,,Completed,Has Results,ovarian neoplasms|ascites,"drug: aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®)|drug: placebo",time to repeat paracentesis (trp)|area under the curve (auc) for participant assessed ascites impact measure (aim)|60-day frequency of paracentesis (fop)|plasma levels of free and vegf-bound aflibercept,sanofi|regeneron pharmaceuticals,Female,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,58.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC6125|EudraCT : 2005-005026-31|AVE0005A /3001,July 2006,October 2009,October 2009,"May 18, 2006","January 1, 2013","January 1, 2013","['sanofi-aventis administrative office, bridgewater, new jersey, united states sanofi-aventis administrative office, vienna, austria sanofi-aventis administrative office, diegem, belgium sanofi-aventis administrative office, laval, canada sanofi-aventis administrative office, budapest, hungary sanofi-aventis administrative office, mumbai, india sanofi-aventis administrative office, natanya, israel sanofi-aventis administrative office, barcelona, spain sanofi-aventis administrative office, guildford surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00327444,ovari
503,504,NCT03715205,study to evaluate the safety of pembrolizumab in participants with unresectable or metastatic melanoma or non-small cell lung cancer in india (mk-3475-593/keynote-593),,Recruiting,No Results Available,"carcinoma, non-small-cell lung|melanoma",drug: pembrolizumab,incidence of adverse events (aes)|incidence of drug-related aes|incidence of serious adverse events (saes)|incidence of drug-related saes|incidence of treatment discontinuations|incidence of events of clinical interest (ecis),merck sharp & dohme llc,All,"18 Years and older   (Adult, Older Adult)",Phase 4,150.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3475-593|MK-3475-593|KEYNOTE 593,"January 31, 2019","January 1, 2026","January 1, 2026","October 23, 2018",,"June 14, 2021","[""nizam's institute of medical sciences ( site 0011), hyderabad, andhra pradesh, india all india institute of medical sciences ( site 0012), new delhi, delhi, india indraprastha apollo hospitals ( site 0008), new delhi, delhi, india artemis health institute ( site 0007), gurgaon, haryana, india tata memorial hospital [m] ( site 0005), mumbai, maharashtra, india kokilaben ben dhirubhai ambani hosp & med res inst. ( site 0001), mumbai, maharashtra, india deenanath mangeshkar hospital and research center ( site 0009), pune, maharashtra, india rajiv gandhi cancer institute and research centre ( site 0003), delhi, india""]",,https://ClinicalTrials.gov/show/NCT03715205,skin
504,505,NCT05082311,cardiac and vascular changes in pheochromocytoma and paraganglioma,PheoCard,Completed,No Results Available,pheochromocytoma|paraganglioma|cardiovascular morbidity,other: observational study,change of systolic function indices measurement by 2d-echocardiography from baseline versus after alpha blockade and after surgery|change of systolic function indices measurement by 2d-echocardiography from baseline versus after alpha blockade and after surgery|change of systolic function index measurement by 2d-echocardiography from baseline at after alpha blockade and at after surgery|change of diastolic function index measurement by pulsed wave doppler echocardiography from baseline versus after alpha blockade and after surgery|change of diastolic function indices measurement by pulsed wave doppler echocardiography from baseline versus after alpha blockade and after surgery|change in speckle tracking echocardiographic parameters at baseline versus after alpha blockade and at after surgery|change in speckle tracking echocardiographic parameters from baseline in comparison to after alpha blockade and after surgery|change in vascular function indices by doppler ultrasonography of the brachial artery from baseline at after alpha blockade and at after surgery,sanjay gandhi postgraduate institute of medical sciences,All,"7 Years and older   (Child, Adult, Older Adult)",,55.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2018-185-Mch-EXP-4,"January 19, 2019","November 30, 2021","January 31, 2022","October 18, 2021",,"February 10, 2022","['sanjay gandhi postgraduate institute of medical sciences, lucknow, uttar pradesh, india']",,https://ClinicalTrials.gov/show/NCT05082311,brain
505,506,NCT01479283,prophylactic antibiotic regimens in tumor surgery (parity),PARITY,Completed,No Results Available,infection|bone neoplasms,drug: 24-hour prophylactic cefazolin* antibiotic regimen|drug: 5-days prophylactic cefazolin* antibiotic regimen,surgical site infections|functional outcome and quality of life|antibiotic-related complications|rate of re-operation|oncologic recurrence and/or metastases|mortality,mcmaster university|orthopedic research and education foundation|the physicians' services incorporated foundation|canadian cancer society (ccs)|canadian institutes of health research (cihr),All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,602.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",GHRT01,January 2013,March 2021,March 2021,"November 24, 2011",,"March 11, 2021","[""university of arkansas for medical sciences, little rock, arkansas, united states ronald reagan ucla medical center, los angeles, california, united states stanford university hospital and clinics, redwood city, california, united states uc davis comprehensive cancer center, sacramento, california, united states university of california san francisco medical center, san francisco, california, united states university of connecticut health center, farmington, connecticut, united states hartford hospital, hartford, connecticut, united states university of florida health shands hospital, gainesville, florida, united states emory orthopaedics and spine center, atlanta, georgia, united states holden comprehensive cancer center, iowa city, iowa, united states university of maryland medical center, baltimore, maryland, united states sinai hospital of baltimore, baltimore, maryland, united states franklin square medical center, baltimore, maryland, united states johns hopkins hospital, baltimore, maryland, united states massachusetts general hospital, boston, massachusetts, united states boston children's hospital, boston, massachusetts, united states beth israel deaconess medical center, boston, massachusetts, united states university of minnesota medical center, minneapolis, minnesota, united states saint louis university hospital, saint louis, missouri, united states dartmouth-hitchcock medical center, lebanon, new hampshire, united states albany medical center, albany, new york, united states montefiore medical center, bronx, new york, united states suny upstate university hospital, east syracuse, new york, united states memorial sloan-kettering cancer center, new york, new york, united states long island jewish medical center   northwell health, queens, new york, united states cincinnati children's hospital, cincinnati, ohio, united states the cleveland clinic - hillcrest hospital, cleveland, ohio, united states wexner medical center, columbus, ohio, united states oregon health & science university hospital, portland, oregon, united states the rothman institute at jefferson, philadelphia, pennsylvania, united states university of pittsburgh medical center, pittsburgh, pennsylvania, united states vanderbilt medical center, nashville, tennessee, united states huntsman cancer institute, salt lake city, utah, united states medical college of wisconsin - froedtert hospital, milwaukee, wisconsin, united states hospital universitario austral, pilar, buenos aires, argentina royal adelaide hospital, adelaide, south australia, australia lkh - universitätsklinikum graz, graz, austria hospital de clínicas de porto alegre, porto alegre, brazil instituto de ortopedia e traumatologia, são paulo, brazil foothills medical centre, calgary, alberta, canada vancouver general hospital, vancouver, british columbia, canada juravinski hospital and cancer centre, hamilton, ontario, canada ottawa hospital, ottawa, ontario, canada mount sinai hospital, toronto, ontario, canada maisonneuve-rosemont hospital, montreal, quebec, canada mcgill university health centre, montreal, quebec, canada hôtel-dieu de québec, québec city, quebec, canada children's cancer hospital egypt, cairo, egypt all india institute of medical sciences, new delhi, delhi, india leiden university medical center, leiden, south holland, netherlands university medical center groningen, groningen, netherlands singapore general hospital, singapore, singapore grey's hospital, pietermaritzburg, south africa hospital universitari vall d'hebron, barcelona, spain""]",,https://ClinicalTrials.gov/show/NCT01479283,
506,507,NCT00229723,iressa™ (gefitinib) with cisplatin plus radiotherapy for the treatment of previously untreated unresected late stage iii/iv non-metastatic head and neck squamous cell carcinoma,,Completed,Has Results,"neoplasms, squamous cell",drug: gefitinib (iressa)|drug: cisplatin|radiation: radiotherapy|drug: gefitinib (iressa),local disease control rate at 2 years|local disease control rate at 1 year|complete response|tumour response (complete response + partial response)|progression free survival|overall survival|safety and tolerability,astrazeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 2,224.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1839IL/0706|EudraCT number 2004-000358-21|D7919C00706,November 2004,,June 2008,"September 30, 2005","August 4, 2009","August 4, 2009","['research site, aurora, colorado, united states research site, dallas, texas, united states research site, brussels, belgium research site, gent, belgium research site, leuven, belgium research site, hradec kralove, czech republic research site, pardubice, czech republic research site, plzen, czech republic research site, berlin, germany research site, essen, germany research site, muenster, germany research site, saarbrucken, germany research site, bangalore, india research site, mumbai, india research site, new delhi, india research site, thiruvananthapuram, india research site, gliwice, poland research site, kraków, poland research site, lodz, poland research site, lublin, poland research site, warszawa, poland research site, belgrade, serbia research site, sremska kamenica, serbia research site, taipei, taiwan research site, taoynan, taiwan']",,https://ClinicalTrials.gov/show/NCT00229723,skin
507,508,NCT02500277,yield of cryoprobe vs flexible forceps pleural biopsy,COFFEE,Completed,No Results Available,pleural effusion|pleurisy|tuberculosis|metastatic malignancy,device: cryoprobe pleural biopsy first|device: flexible forceps biopsy first,yield of pleural biopsy obtained with the routine flexible thoracoscopic biopsy forceps versus that obtained with a flexible cryoprobe during semirigid thoracoscopy|biopsy size|duration of procedure|ease of biopsy vas|artifacts|tissue depth|bleeding,postgraduate institute of medical education and research,All,"12 Years to 79 Years   (Child, Adult, Older Adult)",Not Applicable,50.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NK/1815/Res/2439,January 2015,July 2018,July 2018,"July 16, 2015",,"August 31, 2018","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT02500277,skin
508,509,NCT01953913,afatinib (bibw 2992) in advanced non-small cell lung cancer patients with egfr mutation,,Completed,Has Results,"carcinoma, non-small-cell lung",drug: afatinib,percentage of participants with serious adverse events (saes)|time to symptomatic progression (ttsp)|percentage of participants with drug-related (afatinib-related) adverse events,boehringer ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,542.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.66,"September 30, 2013","July 6, 2018","July 6, 2018","October 1, 2013","August 12, 2019","August 12, 2019","[""307 hospital of pla, beijing, china beijing cancer hospital, beijing, china chinese pla general hospital, beijing, china jilin province cancer hospital, changchun, china guangdong provincial people's hospital, guangzhou, china zhejiang cancer hospital, hangzhou, china lin yi tumor hospital, linyi, china jiangsu cancer hospital, nanjing, china shanghai chest hospital, shanghai, china fudan university shanghai cancer center, shanghai, china shanghai pulmonary hospital, shanghai, china tianjin medical university cancer institute and hospital, tianjin, china queen mary hospital, hong kong, hong kong prince of wales hospital, shatin, hong kong vikram hospital, bangalore, india hcg hospital, bengaluru, india p vs hospital pvt ltd, calicut, india v s hospital, chennai, india max super speciality hospital, delhi, delhi, india global hospitals, hyderabad, india basavatarakam indo - american cancer hospital & research ins, hyderabad, india searoc cancer centre, jaipur, india b. p. poddar hospital & medial research ltd, kolkata,west bengal, india asirvatham multispeciality hospital, madurai, india curie manavata cancer centre, maharashtra, india shatabdi superspeciality hospital, maharashtra, india prince aly khan hospital, mumbai, india ruby hall clinic, pune, india national cancer centre, singapore, singapore e-da hospital, kaohsiung, taiwan nckuh, tainan, taiwan tri-service general hospital, taipei, taiwan chang-gung memorial hospital, linkou, taoyuan county, taiwan""]","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/13/nct01953913/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/13/nct01953913/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01953913,
509,510,NCT04487080,a study of amivantamab and lazertinib combination therapy versus osimertinib in locally advanced or metastatic non-small cell lung cancer,MARIPOSA,Recruiting,No Results Available,"carcinoma, non-small-cell lung",drug: amivantamab|drug: osimertinib|drug: lazertinib|drug: placebo,progression-free survival (pfs) according to recist v1.1 by blinded independent central review (bicr)|overall survival (os)|objective response rate (orr)|duration of response (dor)|progression-free survival after first subsequent therapy (pfs2)|time to symptomatic progression (ttsp)|intracranial pfs|incidence and severity of adverse events (aes)|number of participants with clinical laboratory abnormalities|number of participants with vital signs abnormalities|number of participants with physical examination abnormalities|serum concentration of amivantamab|plasma concentration of lazertinib|number of participants with anti-amivantamab antibodies|change from baseline in non-small cell lung cancer - symptom assessment questionnaire (ncslc-saq)|change from baseline in european organization of research and treatment of cancer quality of life questionnaire core 30 (eortc-qlq-c30),"janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR108856|2020-000743-31|73841937NSC3003,"September 30, 2020","April 30, 2024","March 30, 2026","July 27, 2020",,"April 27, 2022","[""arizona oncology associates, pc - hal, goodyear, arizona, united states yuma regional medical center, yuma, arizona, united states compassionate cancer care, fountain valley, california, united states city of hope long beach elm, long beach, california, united states university of california, irvine, orange, california, united states ventura county hematology oncology specialists, oxnard, california, united states palo alto medical foundation research institute, sunnyvale, california, united states rocky mountain cancer centers, lone tree, colorado, united states georgetown university hospital, washington, district of columbia, united states medstar washington hospital center, washington, district of columbia, united states university of florida, gainesville, florida, united states mayo clinic, jacksonville, florida, united states cancer specialists of north florida, jacksonville, florida, united states ocala oncology center, ocala, florida, united states moffitt cancer center, tampa, florida, united states university cancer & blood center, llc, athens, georgia, united states hawaii cancer care, honolulu, hawaii, united states illinois cancer care, peoria, illinois, united states fort wayne medical oncology and hematology, fort wayne, indiana, united states beacon medical group clinical research, south bend, indiana, united states pontchartrain cancer center, covington, louisiana, united states east jefferson general hospital, metairie, louisiana, united states center for cancer and blood disorders, bethesda, maryland, united states maryland oncology hematology, pa, columbia, maryland, united states frederick health hospital - james m stockman cancer institute, frederick, maryland, united states barbara ann karmanos cancer institute, detroit, michigan, united states henry ford hospital, detroit, michigan, united states minnesota oncology hematology, p.a., edina, minnesota, united states mayo clinic, rochester, minnesota, united states university of mississippi medical center, jackson, mississippi, united states central care cancer center, bolivar, missouri, united states washington university school of medicine, saint louis, missouri, united states comprehensive cancer centers of nevada, las vegas, nevada, united states essex oncology of north jersey, belleville, new jersey, united states astera cancer care, east brunswick, new jersey, united states summit medical group, florham park, new jersey, united states icahn school of medicine at mt. sinai, new york, new york, united states trihealth network, cincinnati, ohio, united states ohio health, columbus, ohio, united states oklahoma cancer specialists and research institute, llc, tulsa, oklahoma, united states willamette valley cancer institute and research center, eugene, oregon, united states university of pittsburgh medical center, pittsburgh, pennsylvania, united states sanford health, sioux falls, south dakota, united states baptist cancer center, bartlett, tennessee, united states sarah cannon research institute, nashville, tennessee, united states vanderbilt university medical center, nashville, tennessee, united states texas oncology p.a., austin, texas, united states mary crowley medical research center, dallas, texas, united states parkland health and hospital system, dallas, texas, united states oncology consultants - texas, houston, texas, united states utah cancer specialists, salt lake city, utah, united states virginia cancer specialists, fairfax, virginia, united states northwest medical specialties, pllc, tacoma, washington, united states instituto alexander fleming, buenos aires, argentina hospital italiano de buenos aires, c.a.b.a., argentina centro oncológico korben, ciudad autónoma de buenos aires, argentina hospital privado centro medico de cordoba, cordoba, argentina centro oncologico riojano integral (cori), la rioja, argentina clínica viedma, viedma, argentina flinders medical centre, bedford park, australia austin hospital, heidelberg, australia st george hospital, kogarah, australia cabrini medical centre, malvern, australia st john of god hospital murdoch, murdoch, australia st john of god hospital murdoch, murdoch, australia sir charles gairdner hospital, nedlands, australia westmead hospital, westmead, australia southern medical day care centre, wollongong, australia princess alexandra hospital, woolloongabba, australia cliniques universitaires saint-luc, brussel, belgium grand hôpital de charleroi, site notre dame, charleroi, belgium uz leuven, leuven, belgium clinique saint pierre, ottignies, belgium algemeen ziekenhuis delta, roeselare, belgium fundacao pio xii - hospital de cancer de barretos, barretos, brazil cetus oncologia, belo horizonte, brazil hospital evangélico de cachoeiro de itapemirim, cachoeiro de itapemirim, brazil ynova pesquisa clinica, florianopolis, brazil hospital de caridade de ijui, ijuí, brazil liga norte riograndense contra o cancer, natal, brazil upco unidade de pesquisa clinica em oncologia, pelotas, brazil santa casa de misericordia de porto alegre, porto alegre, brazil centro de pesquisa em oncologia - pucrs, porto alegre, brazil inca - instituto nacional do cancer, rio de janeiro, brazil oncoclínicas, rio de janeiro, brazil instituto d'or de pesquisa e ensino (idor), rio de janeiro, brazil núcleo de pesquisa são camilo, sao paulo, brazil ios - instituto de oncologia de sorocaba dr. gilson delgado, sorocaba, brazil instituto do cancer do estado de sao paulo icesp, são paulo, brazil fundação antônio prudente - a.c. camargo cancer center, são paulo, brazil william osler health system, brampton, ontario, canada juravinski cancer centre, hamilton, ontario, canada the ottawa hospital cancer centre, ottawa, ontario, canada sunnybrook health sciences centre, toronto, ontario, canada mcgill university health centre, montreal, quebec, canada beijing friendship hospital, capital medical university, beijing, china beijing cancer hospital, beijing, china chinese pla general hospital, beijing, china beijing chest hospital, capital medical university, beijing, china peking university international hospital, beijing, china jilin cancer hospital, changchun, china hunan cancer hospital, changsha, china the first people's hospital of changzhou, changzhou, china sichuan cancer hospital, chengdu, china west china hospital, sichuan university, chengdu, china southwest hospital, chongqing, china third military medical university daping hospital cancer center, chongqing, china the first affiliated hospital, sun yat-sen university, guang zhou, china sun yat-sen memorial hospital sun yat-sen university, guangzhou, china zhejiang cancer hospital, hang zhou, china affiliated hangzhou first people's hospital, zhejiang university school of medicine, hangzhou, china second affiliated hospital, school of medicine, zhejiang university, hangzhou, china the second affiliated hospital of zhejiang university college of medicine, hangzhou, china sir run run shaw hospital, zhejiang university school of medicine, hangzhou, china harbin medical university cancer hospital, harbin, china huizhou municipal central hospital, huizhou, china taizhou hospital of zhejiang province, linhai, china nanjing general hospital, nanjing, china nantong tumor hospital, nanjing, china ruijin hospital, shanghai jiao tong university, shanghai, china shanghai chest hospital, shanghai, china fudan university shanghai cancer center, shanghai, china shanghai east hospital, shanghai, china shanghai zhongshan hospital, shanghai, china shanghai pulmonary hospital, shanghai, china shengjing hospital of china medical university, shenyang, china tianjin medical university general hospital, tianjin, china cancer hospital of xinjiang medical university, urumchi, china the first affiliated hospital of wenzhou medical university, wenzhou, china tongji hospital of tongji medical college of huazhong university of science & technology, wuhan, china the first affiliated hospital of xi'an jiaotong university, xi'an, china yantai yuhuangding hospital, yantai, china henan cancer hospital, zhengzhou, china institut bergonié, bordeaux, france hospices civils de lyon hcl, bron, france chu de grenoble - hôpital albert michallon, la tronche, france chr hôpital calmette, lille cedex, france chu de limoges, limoges, france hopital nord, marseille cedex 20, france institut curie, paris, france hôpital tenon, paris, france chu bordeaux, pessac, france chu nantes, sain-herblain, france hia begin, saint mande, france chu bretonneau, tours, france institut gustave roussy, villejuif cedex, france zentralklinik bad berka gmbh, bad berka, germany helios klinikum emil von behring gmbh, berlin, germany universitaetsklinikum essen, essen, germany asklepios klinik gauting gmbh - asklepios fachkliniken münchen-gauting, gauting, germany lungenclinic grosshansdorf gmbh, grosshandorf, germany städtisches krankenhaus martha-maria halle-dölau ggmbh, halle (saale), germany thoraxklinik am universitätsklinikum heidelberg, heidelberg, germany onkologische schwerpunktpraxis, heilbronn, germany lungenklinik hemer, hemer, germany universitaetsklinikum koeln, koeln, germany kliniken der stadt koeln ggmbh, koeln, germany pois leipzig gbr, leipzig, germany pius-hospital oldenburg, oldenburg, germany robert-bosch-krankenhaus - klinik schillerhoehe, stuttgart, germany orszagos koranyi tbc es pulmonologiai intezet, budapest, hungary veszprém megyei tudőgyógyintézet, farkasgyepü, hungary mátrai gyógyintézet-bronchológia, gyöngyös, hungary fejer megyei szent gyorgy egyetemi oktatokorhaz, szekesfehervar, hungary markusovszky egyetemi oktatokorhaz, szombathely, hungary tudogyogyintezet torokbalint, torokbalint, hungary basavatarakam indo-american hospital, hyderabad, india tata medical center, kolkata, india tata memorial hospital, mumbai, india hcg manavta cancer centre, nasik, india noble hospital pvt ltd, pune, india soroka medical center, beersheba, israel rambam health corporation, haifa, israel hadassah medical center, jerusalem, israel meir medical center, kfar saba, israel rabin medical center, petah tikva, israel chaim sheba medical center, ramat gan, israel tel-aviv sourasky medical center, tel-aviv, israel ospedale san giuseppe moscati di avellino, avellino, italy azienda ospedaliero univ. policlinico gaspare rodolico, catania, italy istituto scientifico romagnolo per lo studio e la cura dei tumori, meldola, italy fondazione irccs ca' granda ospedale maggiore policlinico, milano, italy irccs ospedale san raffaele, milano, italy fondazione irccs istituto nazionale dei tumori, milano, italy istituto europeo di oncologia, milano, italy san gerardo hospital, monza, italy ospedale monaldi, napoli, italy aou san luigi gonzaga, orbassano, italy ospedale s. maria delle croci, ravenna, italy irccs gemelli, roma, italy istituto clinico humanitas, rozzano, italy juntendo university hospital, bunkyo-ku, japan national cancer center hospital, chuo-ku, japan national hospital organization kyushu medical center, fukuoka, japan national hospital organization himeji medical center, himeji, japan kansai medical university hospital, hirakata, japan kanazawa university hospital, kanazawa, japan national cancer center hospital east, kashiwa, japan kurume university hospital, kurume, japan matsusaka municipal hospital, matsusaka, japan niigata cancer center hospital, niigata, japan okayama university hospital, okayama, japan kindai university hospital, osaka-sayama-shi, japan national hospital organization shibukawa medical center, shibukawa, japan the cancer institute hospital of jfcr, tokyo, japan national hospital organization tokyo medical center, tokyo, japan ehime university hospital, toon, japan national hospital organization osaka toneyama medical center, toyonaka-shi, japan wakayama medical university hospital, wakayama, japan national hospital organization iwakuni clinical center, yamaguchi, japan national hospital organization yamaguchi ube medical center, yamaguchi, japan inje university haeundae paik hospital, busan, korea, republic of chungbuk national university hospital, cheongju-si, korea, republic of seoul national university bundang hospital, seongnam-si, korea, republic of kangbuk samsung hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of the catholic university of korea, seoul st. mary's hospital, seoul, korea, republic of korea university guro hospital, seoul, korea, republic of hospital pulau pinang, george town, malaysia hospital sultan ismail, johor bahru, malaysia hospital kuala lumpur, kuala lumpur, malaysia university malaya medical centre, kuala lumpur, malaysia hospital tengku ampuan afzan, kuantan, malaysia beacon hospital sdn. bhd., petaling jaya, malaysia mexico centre for clinical research, s.a. de c.v., ciudad de mexico, mexico health pharma professional research, ciudad de mexico, mexico médica sur, ciudad de mexico, mexico hospital civil de guadalajara fray antonio alcalde, guadalajara, mexico cimova, morals vargas centro de investigación sc, leon, mexico instituto nacional de cancerologia, mexico, mexico i can oncology center, monterrey, mexico oncologia integral satelite, naucalpan, mexico rijnstate ziekenhuis, arnhem, netherlands universitair medisch centrum groningen, groningen, netherlands ziekenhuis st jansdal, harderwijk, netherlands maastricht umc+, maastricht, netherlands umc radboud, nijmegen, netherlands jeroen bosch ziekenhuis, s-hertogenbosch, netherlands centrum onkologii im. prof. f. lukaszczyka, bydgoszcz, poland uniwersyteckie centrum kliniczne, gdańsk, poland szpitale pomorskie sp. z o.o., gdynia, poland warminsko-mazurskie centrum chorob pluc w olsztynie, olsztyn, poland private specialist hospitals - medpolonia, poznan, poland narodowy instytut onkologii im. marii sklodowskiej-curie - panstwowy instytut badawczy, warszawa, poland centro hospitalar lisboa norte epe - hospital pulido valente, lisboa, portugal centro hospitalar universitario do porto, epe, porto, portugal hospital cuf porto, porto, portugal instituto portugues de oncologia, porto, portugal centro hospitalar de são joão, epe, porto, portugal pan american center for oncology trials llc, rio piedras, puerto rico irkutsk regional oncology dispensary, irkutsk, russian federation state medical institution 'republican clinical oncological centre' at republic of tatarstan, kazan, russian federation moscow city oncology hospital № 62, krasnogorsk, russian federation krasnoyarsk regional oncology dispensary, krasnoyarsk, russian federation leningrad regional oncology dispensary, kuzmolovsky, russian federation moscow oncology research center n.a. blokhin, moscow, russian federation mck, moscow, russian federation central clinical hospital, moscow, russian federation city clinical hospital #1, nalchik, russian federation nizhny novgorod regional oncological dispensary, nizhniy novgorod, russian federation omsk clinical oncology dispensary, omsk, russian federation current medical technologies, saint petersburg, russian federation n.n. petrov research institute of oncology, saint petersburg, russian federation oncology medical clinics av medical group, st-petersburg, russian federation city clinical oncology dispensary, st. petersburg, russian federation tambov regional oncology clinical dispansary, tambov, russian federation tomsk cancer research institute, tomsk, russian federation bashkir state medical university, ufa, russian federation yaroslavl regional clinical oncology hospital, yaroslavl, russian federation hosp. univ. a coruña, a coruña, spain inst. cat. d'oncologia-badalona, badalona, spain hosp. de la santa creu i sant pau, barcelona, spain hosp. univ. quiron dexeus, barcelona, spain hosp. univ. vall d hebron, barcelona, spain hosp. univ. de burgos, burgos, spain institut català d'oncologia girona, girona, spain hosp. gral. univ. gregorio marañon, madrid, spain hosp. univ. 12 de octubre, madrid, spain hosp. univ. la paz, madrid, spain hosp. univ. pta. de hierro majadahonda, majadahonda, spain hosp. regional univ. de malaga, málaga, spain clinica univ. de navarra, pamplona, spain hosp. virgen del rocio, seville, spain hosp. gral. univ. valencia, valencia, spain hosp. clinico univ. lozano blesa, zaragoza, spain kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan e-da hospital, kaohsiung, taiwan chang gung medical foundation, kaohsiung, taiwan taipei medical university shuang ho hospital, new taipei, taiwan chung shan medical university hospital, taichung, taiwan china medical university hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan national taiwan university hospital, taipei city, taiwan phramongkutklao hospital and medical college, bangkok, thailand siriraj hospital, bangkok, thailand chiangrai prachanukroh hospital, chaing rai, thailand chiang mai university, chiangmai, thailand songklanagarind hospital, prince of songkla university, songkla, thailand adana city hospital, adana, turkey başkent university medical faculty adana application and research center, adana, turkey gazi university hospital, ankara, turkey ankara bilkent city hospital, ankara, turkey trakya university medical faculty, edirne, turkey istanbul universitesi cerrahpasa tip fakultesi ic hastaliklari anabilim dali medikal onkoloji bd, istanbul, turkey medipol mega university hospital, istanbul, turkey t.c. saglik bakanlıgi goztepe prof. dr. suleyman yalcın sehir hastanesi, istanbul, turkey izmir ekonomi universitesi medical park hastanesi, izmir, turkey necmettin erbakan university meram medical faculty, konya, turkey dnipropetrovsk state medical academy, dnipropetrovsk city multifield clinical hospital # 4, dnipro, ukraine municipal non-profit enterprise 'regional center of oncology', kharkiv, ukraine medical center 'ok clinic' of llc 'international institute of clinical studies', kyiv, ukraine national cancer institute, kyiv, ukraine municipal institution 'odesa clinical oncology dispensary', odesa, ukraine municipal oncology centre of uzhgorod central municipal clinical hospitlal, uzhgorod, ukraine edinburgh cancer centre western general, edinburgh, united kingdom ucl cancer institute, london, united kingdom chelsea and westminster hospital, london, united kingdom the royal marsden nhs trust, london, united kingdom christie nhs foundation trust, manchester, united kingdom nottingham university hospitals nhs trust, nottingham, united kingdom the royal marsden nhs trust, sutton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04487080,
510,511,NCT02542293,study of durvalumab with tremelimumab versus soc as 1st line therapy in metastatic non small-cell lung cancer (nsclc) (neptune).,NEPTUNE,"Active, not recruiting",No Results Available,non small cell lung carcinoma nsclc,biological: durvalumab +tremelimumab|drug: paclitaxel + carboplatin|drug: gemcitabine + cisplatin|drug: gemcitabine + carboplatin|drug: pemetrexed + cisplatin|drug: pemetrexed + carboplatin,to assess the efficacy of medi4736 + tremelimumab combination therapy compared to standard of care (soc) in terms of overall survival (os) in patients with btmb ≥ 20mut/mb|to assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of os|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of progression-free survival (pfs)|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of objective response rate (orr)|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of duration of response (dor)|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of proportion of patients alive at 12 months (os12)|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of os18|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of os24|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of proportion of patients alive and progression free at 12 months (apf12)|to further assess the efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of progression-free survival after subsequent anticancer therapy (pfs2)|to assess efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of orr in further pd-l1 defined populations|to assess efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of pfs in further pd-l1 defined populations|to assess efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of os in further pd-l1 defined populations|to further assess efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of orr|to further assess efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of pfs|to further assess efficacy of medi4736 + tremelimumab combination therapy compared to soc in terms of os|to assess the pharmacokinetics (pk) of medi4736 + tremelimumab combination therapy|to investigate the immunogenicity of medi4736 and tremelimumab,astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,953.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D419AC00003,"November 3, 2015","September 21, 2020","October 29, 2021","September 7, 2015",,"July 7, 2021","[""research site, anaheim, california, united states research site, san diego, california, united states research site, santa rosa, california, united states research site, louisville, kentucky, united states research site, florham park, new jersey, united states research site, albuquerque, new mexico, united states research site, east setauket, new york, united states research site, fresh meadows, new york, united states research site, poughkeepsie, new york, united states research site, stony brook, new york, united states research site, canton, ohio, united states research site, columbus, ohio, united states research site, zanesville, ohio, united states research site, pittsburgh, pennsylvania, united states research site, houston, texas, united states research site, berazategui, argentina research site, buenos aires, argentina research site, caba, argentina research site, córdoba, argentina research site, la rioja, argentina research site, rosario, argentina research site, san salvador de jujuy, argentina research site, santa rosa, argentina research site, barretos, brazil research site, belo horizonte, brazil research site, belo horizonte, brazil research site, fortaleza, brazil research site, ijui, brazil research site, itajai, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, plovdiv, bulgaria research site, shumen, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, vratza, bulgaria research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, temuco, chile research site, viña del mar, chile research site, beijing, china research site, changchun, china research site, chongqing, china research site, guangzhou, china research site, hangzhou, china research site, shanghai, china research site, shanghai, china research site, urumqi, china research site, wuhan, china research site, wuhan, china research site, odense c, denmark research site, oulu, finland research site, tampere, finland research site, athens, greece research site, athens, greece research site, athens, greece research site, heraklion, greece research site, holargos, athens, greece research site, ioannina, greece research site, hong kong, hong kong research site, king's park, hong kong research site, shatin, hong kong research site, ahmedabad, india research site, bangalore, india research site, bangalore, india research site, chennai, india research site, gurgaon, india research site, karamsad, india research site, new delhi, india research site, beer sheva, israel research site, jerusalem, israel research site, kfar saba, israel research site, nahariya, israel research site, petah tikva, israel research site, ramat gan, israel research site, bunkyo-ku, japan research site, fukushima-shi, japan research site, habikino-shi, japan research site, hirosaki-shi, japan research site, iizuka-shi, japan research site, iwakuni-shi, japan research site, kanazawa, japan research site, kishiwada-shi, japan research site, kobe-shi, japan research site, kurume-shi, japan research site, kyoto-shi, japan research site, mitaka-shi, japan research site, nagaoka-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, saga-shi, japan research site, sagamihara-shi, japan research site, sakai-shi, japan research site, sendai-shi, japan research site, tokushima-shi, japan research site, ube-shi, japan research site, wakayama-shi, japan research site, yokohama-shi, japan research site, yokohama-shi, japan research site, daegu, korea, republic of research site, hwasun-gun, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, kuala lumpur, malaysia research site, kuantan, malaysia research site, kuching, malaysia research site, acapulco, mexico research site, aguascalientes, mexico research site, mexico, mexico research site, monterrey, mexico research site, mérida, mexico research site, méxico, mexico research site, arequipa, peru research site, bellavista, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, baguio city, philippines research site, cebu, philippines research site, las pinas city, philippines research site, manila, philippines research site, manila, philippines research site, pasay city, philippines research site, quezon city, philippines research site, bydgoszcz, poland research site, kielce, poland research site, kraków, poland research site, mrozy, poland research site, olsztyn, poland research site, poznan, poland research site, poznań, poland research site, warszawa, poland research site, warszawa, poland research site, wodzisław śląski, poland research site, łódź, poland research site, amadora, portugal research site, lisboa, portugal research site, porto, portugal research site, porto, portugal research site, porto, portugal research site, doha, qatar research site, suceava, romania research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, omsk, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, st. petersburg, russian federation research site, dammam, saudi arabia research site, riyadh, saudi arabia research site, riyadh, saudi arabia research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, eskilstuna, sweden research site, linköping, sweden research site, stockholm, sweden research site, uppsala, sweden research site, adana, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, istanbul, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, chernivtsі, ukraine research site, dnipro, ukraine research site, ivano-frankivsk, ukraine research site, kapitanivka village, ukraine research site, kharkiv region, ukraine research site, kirovohrad, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, lviv, ukraine research site, lyutizh, ukraine research site, odesa, ukraine research site, sumy, ukraine research site, uzhhorod, ukraine research site, vinnytsia, ukraine research site, guildford, united kingdom research site, london, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, nottingham, united kingdom research site, taunton, united kingdom research site, wirral, united kingdom research site, wolverhampton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT02542293,
511,512,NCT04988295,a study of amivantamab and lazertinib in combination with platinum-based chemotherapy compared with platinum-based chemotherapy in patients with epidermal growth factor receptor (egfr)-mutated locally advanced or metastatic non- small cell lung cancer after osimertinib failure,MARIPOSA-2,Recruiting,No Results Available,"carcinoma, non-small-cell lung",drug: lazertinib|drug: amivantamab|drug: pemetrexed|drug: carboplatin,progression-free survival (pfs) according to recist v1.1 guidelines as assessed by blinded independent central review (bicr)|objective response as assessed by bicr|overall survival (os)|duration of response (dor)|time to subsequent therapy (ttst)|progression-free survival after first subsequent therapy (pfs2)|time to symptomatic progression (ttsp)|intracranial pfs|number of participants with adverse events (aes)|number of participants with clinical laboratory abnormalities|serum concentration of amivantamab|plasma concentration of lazertinib|number of participants with anti-amivantamab antibodies|non-small cell lung cancer - symptom assessment questionnaire (nsclc-saq)|european organization of research and treatment of cancer quality of life questionnaire core 30 (eortc-qlq-c30) score|patient reported outcomes measurement information system-physical function (promis-pf),"janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR109061|2021-001825-33|61186372NSC3002,"November 17, 2021","May 31, 2023","November 17, 2025","August 3, 2021",,"May 11, 2022","[""carl t. hayden veterans administration medical center, phoenix, arizona, united states city of hope, duarte, california, united states university of california san diego, la jolla, california, united states pacific shores medical group in long beach, long beach, california, united states cedars-sinai medical center, los angeles, california, united states university of california, irvine, orange, california, united states st joseph heritage healthcare, santa rosa, california, united states yale cancer center, new haven, connecticut, united states hartford hospital, plainville, connecticut, united states university of miami/sylvester cancer center, aventura, florida, united states holy cross hospital - michael and dianne bienes comprehensive cancer center, fort lauderdale, florida, united states university of florida, gainesville, florida, united states mayo clinic, jacksonville, florida, united states university cancer & blood center, llc, athens, georgia, united states pacific health research and education institute, honolulu, hawaii, united states sinai cancer care, chicago, illinois, united states cancer care specialists of central illinois, decatur, illinois, united states indiana university, indianapolis, indiana, united states east jefferson general hospital, metairie, louisiana, united states henry ford hospital, detroit, michigan, united states mayo clinic, rochester, minnesota, united states university of mississippi medical center, jackson, mississippi, united states saint louis university, saint louis, missouri, united states comprehensive cancer centers of nevada, las vegas, nevada, united states va sierra nevada health care system, reno, nevada, united states regional cancer care associates llc, east brunswick, new jersey, united states north shore-long island jewish health system, lake success, new york, united states icahn school of medicine at mt. sinai, new york, new york, united states trihealth network, cincinnati, ohio, united states oklahoma cancer specialists and research institute, llc, tulsa, oklahoma, united states providence portland medical center, portland, oregon, united states kaiser permanente northwest, portland, oregon, united states university of pittsburgh medical center, pittsburgh, pennsylvania, united states musc-hollings cancer center, charleston, south carolina, united states sanford health, sioux falls, south dakota, united states university of tennessee health sciences center, memphis, tennessee, united states baptist cancer center, memphis, tennessee, united states vanderbilt university medical center, nashville, tennessee, united states texas oncology-medical city dallas, dallas, texas, united states texas oncology-baylor charles a. sammons cancer center, dallas, texas, united states ut southwestern medical center, dallas, texas, united states oncology consultants - texas, houston, texas, united states ut md anderson cancer center, houston, texas, united states university of vermont medical center, burlington, vermont, united states university of virginia, charlottesville, virginia, united states virginia cancer specialists, fairfax, virginia, united states iadt instituto argentino de diagnostico y tratamiento, caba, argentina centro medico fleischer, caba, argentina cemic (centro de educación médica e investigaciones clínicas), caba, argentina cinme - centro de investigaciones metabolicas, ciudad autonoma de buenos aires, argentina cemaic - centro privado de especialidades medicas ambulatorias e investigacion clinica, córdoba, argentina hospital privado universitario de córdoba, córdoba, argentina hospital privado de la comunidad, mar del plata, argentina centro de investigaciones clinicas-cic-iesr, rosario, argentina clínica viedma, viedma, argentina grand hôpital de charleroi, site notre dame, charleroi, belgium uza, edegem, belgium uz gent, gent, belgium jessa ziekenhuis - campus virga jesse, hasselt, belgium uz leuven, leuven, belgium chu sart-tilman, liege, belgium clinique saint pierre, ottignies, belgium cetus oncologia, belo horizonte, brazil cionc - centro integrado de oncologia de curitiba, curitiba, brazil ynova pesquisa clinica, florianopolis, brazil fundação são francisco xavier, ipatinga, brazil upco unidade de pesquisa clinica em oncologia, pelotas, brazil hospital moinhos de vento, porto alegre, brazil hospital ernesto dornelles, porto alegre, brazil oncoclínicas, rio de janeiro, brazil instituto d'or de pesquisa e ensino (idor), rio de janeiro, brazil instituto coi, rio de janeiro, brazil núcleo de oncologia da bahia, salvador, brazil hospital sao rafael, salvador, brazil cepho - centro de estudos e pesquisa de hematologia e oncologia, santo andré, brazil ios - instituto de oncologia de sorocaba dr. gilson delgado, sorocaba, brazil hospital paulistano, são paulo, brazil bp - beneficencia portuguesa de são paulo, são paulo, brazil hospital alemão oswaldo cruz, são paulo, brazil hospital nove de julho, são paulo, brazil fundação antônio prudente - a.c. camargo cancer center, são paulo, brazil oncoclínicas, uberlândia, brazil multifunctional hospital for active treatment 'serdika', sofia, bulgaria multiprofile hospital for active treatment 'tokuda hospital sofia', sofia, bulgaria specialized hospital for active treatment in oncology, sofia, bulgaria umhat sofia med, sofia, bulgaria multiprofile hospital for active treatment 'sveta marina' ead, varna, bulgaria tom baker cancer centre, calgary, alberta, canada british columbia cancer agency, vancouver, british columbia, canada princess margaret cancer centre university health network, toronto, ontario, canada mcgill university health centre, montreal, quebec, canada cancer hospital, chinese academy of medical sciences, beijing, china peking university people's hospital, beijing, china beijing cancer hospital, beijing, china chinese pla general hospital, beijing, china beijing chest hospital, capital medical university, beijing, china hunan cancer hospital, changsha, china the first people's hospital of changzhou, changzhou, china sichuan cancer hospital, chengdu, china west china hospital, sichuan university, chengdu, china southwest hospital, chongqing, china chongqing university cancer hospital, chongqing, china the first affiliated hospital, sun yat-sen university, guang zhou, china sun yat-sen memorial hospital sun yat-sen university, guangzhou, china zhejiang cancer hospital, hang zhou, china second affiliated hospital, school of medicine, zhejiang university, hangzhou, china the second affiliated hospital of zhejiang university college of medicine, hangzhou, china sir run run shaw hospital, zhejiang university school of medicine, hangzhou, china harbin medical university cancer hospital, harbin, china the first affiliated hospital of anliui medical university, hefei, china huizhou municipal central hospital, huizhou, china taizhou hospital of zhejiang province, linhai, china affiliated hospital of north sichuan medical college, nanchong, china ruijin hospital, shanghai jiao tong university, shanghai, china fudan university shanghai cancer center, shanghai, china shanghai east hospital, shanghai, china shenzhen university general hospital, shenzhen, china cancer hospital chinese academy of medical sciences, shenzhen, china tianjin medical university general hospital, tianjin, china weifang people's hospital, weifang, china the first affiliated hospital of xi'an jiaotong university, xi'an, china yantai yuhuangding hospital, yantai, china daping hospital army characteristic medical center, yuzhong district, china henan cancer hospital, zhengzhou, china fakultni nemocnice olomouc - i.p.pavlova 6, olomouc, czechia vitkovicka nemocnice a.s., ostrava- vitkovice, czechia fakultni nemocnice plzen, plzen, czechia aarhus universitetshospital, aarhus, denmark rigshospitalet, copenhagen, denmark institut sainte catherine, avignon cedex 9, france hospices civils de lyon hcl, bron, france chu de grenoble - hôpital albert michallon, la tronche, france centre hospitalier le mans, le mans cedex 9, france chr hôpital calmette, lille, france hopital nord, marseille cedex 20, france chu de montpellier - arnaud de villeneuve, montpellier cedex 5, france institut curie, paris, france chu bordeaux, pessac, france chru hôpital de pontchaillou, rennes, france chu nantes, sain-herblain, france nouvel hopital civil - chu strasbourg, strasbourg cedex, france chu bretonneau, tours, france evangelische lungenklinik berlin, berlin, germany klinikum der johann wolfgang goethe-universität, frankfurt am main, germany asklepios klinikum harburg, hamburg, germany thoraxklinik am universitätsklinikum heidelberg, heidelberg, germany onkologische schwerpunktpraxis, heilbronn, germany vidia christliche kliniken karlsruhe/st. vincentius-kliniken, karlsruhe, germany pois sachsen gmbh ig, leipzig, germany bethanien krankenhaus, moers, germany klinikum der universität münchen, münchen, germany pius-hospital oldenburg, oldenburg, germany oncologianova gmbh, recklinghausen, germany universitaetsklinikum regensburg, regensburg, germany queen mary hospital, hong kong, hong kong health care global enterprises pvt ltd, bangalore, india artemis hospital, gurugram, india tata medical center, kolkata, india tata memorial hospital, mumbai, india kokilaben dhirubhai ambani hosp. & med. research inst, mumbai, india central india cancer research institute, nagpur, india hcg manavta cancer centre, nasik, india action cancer hospital, new delhi, india rajiv gandhi cancer institute and research centre, new delh, india noble hospital pvt ltd, pune, india bhaktivedanta hospital & research institute, thane, india soroka university medical center, beersheba, israel rambam health corporation, haifa, israel shaare zedek medical center, jerusalem, israel meir medical center, kfar saba, israel rabin medical center, petah tikva, israel chaim sheba medical center, ramat gan, israel tel-aviv sourasky medical center, tel-aviv, israel cro, irccs, istituto nazionale tumori, aviano, italy istituto scientifico romagnolo per lo studio e la cura dei tumori, meldola, italy istituto europeo di oncologia, milano, italy azienda ospedaliero-universitaria di parma, parma, italy ospedale s. maria delle croci, ravenna, italy istituto nazionale tumori regina elena, roma, italy policlinico g.b.rossi, verona, italy national hospital organization shibukawa medical center, gunma, japan kobe city medical center general hospital, hyogo, japan hyogo cancer center, hyogo, japan kanagawa cancer center, kanagawa, japan kurume university hospital, kurume, japan national hospital organization nagoya medical center, nagoya-shi, japan niigata cancer center hospital, niigata, japan osaka international cancer institute, osaka, japan shizuoka cancer center, shizuoka, japan tokyo metropolitan cancer and infectious diseases center komagome hospital, tokyo, japan the cancer institute hospital of jfcr, tokyo, japan ehime university hospital, toon, japan wakayama medical university hospital, wakayama, japan national hospital organization iwakuni clinical center, yamaguchi, japan national hospital organization yamaguchi ube medical center, yamaguchi, japan national cancer center, gyeonggi-do, korea, republic of gyeongsang national university hospital, gyeongsangnam-do, korea, republic of cha bundang medical center, cha university, seongnamsi, korea, republic of seoul national university bundang hospital, seongnam, korea, republic of korea university anam hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of the catholic university of korea, seoul st. mary's hospital, seoul, korea, republic of university malaya medical centre, kuala lumpur, malaysia hospital tengku ampuan afzan, kuantan, malaysia beacon hospital sdn. bhd., petaling jaya, malaysia subang jaya medical centre, subang jaya, malaysia mount miriam cancer hospital, tanjung bungah, malaysia hospital civil de guadalajara fray antonio alcalde, guadalajara, mexico cimova, morals vargas centro de investigación sc, leon, mexico health pharma professional research, mexico, mexico instituto nacional de cancerologia, mexico, mexico oncologia integral satelite, naucalpan, mexico nki-avl, amsterdam, amsterdam, netherlands vumc amsterdam, amsterdam, netherlands ziekenhuis st jansdal, harderwijk, netherlands erasmus mc, rotterdam, netherlands centrum onkologii im. prof. f. lukaszczyka, bydgoszcz, poland uniwersyteckie centrum kliniczne, gdansk, poland szpitale pomorskie sp. z o.o., gdynia, poland warminsko-mazurskie centrum chorob pluc w olsztynie, olsztyn, poland wielkopolskie centrum pulmonologii i torakochirurgii im. eugenii i janusza zeylandow, poznan, poland private specialist hospitals - medpolonia, poznan, poland narodowy instytut onkologii im. marii sklodowskiej-curie - panstwowy instytut badawczy, warszawa, poland centro hospitalar lisboa norte epe - hospital pulido valente, lisboa, portugal hospital beatriz angelo, loures, portugal centro hospitalar universitario do porto, epe, porto, portugal instituto portugues de oncologia, porto, portugal pan american center for oncology trials llc, rio piedras, puerto rico krasnoyarsk regional oncology dispensary, krasnoyarsk, russian federation llc vitamed, moscow, russian federation main administration for service to the diplomatic corps under the mofa of the rf, moscow, russian federation moscow city oncology hospital № 62, moskovskaya oblast', krasnogo, russian federation city clinical hospital #1, nalchik, russian federation nizhny novgorod regional oncological dispensary, nizhniy novgorod, russian federation llc, eurocityclinic, saint petersburg, russian federation n.n. petrov research institute of oncology, saint petersburg, russian federation oncology medical clinics av medical group, st-petersburg, russian federation tambov regional oncology clinical dispansary, tambov, russian federation tomsk cancer research institute, tomsk, russian federation bashkir state medical university, ufa, russian federation hosp. univ. a coruña, a coruña, spain hosp. de la santa creu i sant pau, barcelona, spain hosp. univ. quiron dexeus, barcelona, spain hosp. univ. vall d hebron, barcelona, spain hosp. clinic i provincial de barcelona, barcelona, spain hosp. univ. insular de gran canaria, las palmas de gran canaria, spain hosp. gral. univ. gregorio marañon, madrid, spain hosp. univ. fund. jimenez diaz, madrid, spain hosp. univ. 12 de octubre, madrid, spain hosp. univ. la paz, madrid, spain hosp. univ. hm sanchinarro, madrid, spain hosp. univ. pta. de hierro majadahonda, majadahonda, spain hosp. regional univ. de malaga, málaga, spain clinica univ. de navarra, pamplona, spain hosp. virgen del rocio, seville, spain hosp. gral. univ. valencia, valencia, spain hosp. univ. i politecni la fe, valencia, spain sahlgrenska universitetssjukhuset, goteborg, sweden linkoping university hospital, linkoping, sweden skanes universitetssjukhus, lund, sweden norrlands universitetssjukhus, umea, sweden akademiska sjukhuset, uppsala, sweden changhua christian hospital, changhua, taiwan kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan taipei medical university shuang ho hospital, new taipei city, taiwan chung shan medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan national cheng kung university hospital, tainan, taiwan national taiwan university hospital, taipei, taiwan adana city hospital, adana, turkey gazi university hospital, ankara, turkey memorial ankara hastanesi, ankara, turkey ankara bilkent city hospital, ankara, turkey trakya university medical faculty, edirne, turkey istanbul university cerrahpasa medical faculty, istanbul, turkey bakirkoy training and research hospital, istanbul, turkey medipol mega university hospital, istanbul, turkey acıbadem maslak hospital, istanbul, turkey goztepe prof. dr. suleyman yalcin sehir hastanesi, istanbul, turkey izmir medical park hospital, izmir, turkey queen elizabeth hospital, birmingham, united kingdom birmingham heartlands hospital, birmingham, united kingdom velindre hospital, cardiff, united kingdom edinburgh cancer centre western general, edinburgh, united kingdom royal surrey county hospital nhs trust, guildford, united kingdom barts heart centre, st. bartholomew's hospital, london, united kingdom ucl cancer institute, london, united kingdom guy's and st thomas' nhs foundation trust, london, united kingdom the royal marsden nhs trust, london, united kingdom the christie nhs foundation trust, manchester, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04988295,
512,513,NCT04538664,"a study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in participants with advanced or metastatic non-small cell lung cancer characterized by epidermal growth factor receptor (egfr) exon 20 insertions",PAPILLON,Recruiting,No Results Available,"carcinoma, non-small-cell lung",drug: amivantamab|drug: pemetrexed|drug: carboplatin,progression-free survival (pfs) according to recist v1.1 as assessed by blinded independent central review (bicr)|objective response rate (orr)|duration of response (dor)|overall survival (os)|time to subsequent therapy (tst)|progression-free survival after first subsequent therapy (pfs2)|time to symptomatic progression (ttsp)|incidence and severity of adverse events (aes)|number of participants with clinical laboratory abnormalities|number of participants with vital signs abnormalities|number of participants with physical examination abnormalities|serum concentration of amivantamab|number of participants with anti-amivantamab antibodies|european organization of research and treatment of cancer quality of life questionnaire core 30 (eortc-qlq-c30)|patient reported outcomes measurement information system-physical function (promis-pf),"janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 3,300.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR108850|2020-000633-40|61186372NSC3001,"October 13, 2020","August 31, 2022","January 31, 2025","September 4, 2020",,"April 27, 2022","[""city of hope, duarte, california, united states city of hope, duarte, california, united states compassionate cancer care, fountain valley, california, united states uc san diego moores cancer center, la jolla, california, united states university of california, irvine, orange, california, united states ucla, santa monica, california, united states university of colorado, aurora, colorado, united states georgetown university hospital, washington, district of columbia, united states mayo clinic, jacksonville, florida, united states h. lee moffitt cancer & research institute, tampa, florida, united states university cancer & blood center, llc, athens, georgia, united states hawaii cancer care, honolulu, hawaii, united states illinois cancer care, peoria, illinois, united states fort wayne medical oncology and hematology, fort wayne, indiana, united states pontchartrain cancer center, covington, louisiana, united states east jefferson general hospital, metairie, louisiana, united states center for cancer and blood disorders, bethesda, maryland, united states barbara ann karmanos cancer institute, detroit, michigan, united states henry ford hospital, detroit, michigan, united states mayo clinic, rochester, minnesota, united states university of mississippi medical center, jackson, mississippi, united states washington university medical center, saint louis, missouri, united states comprehensive cancer centers of nevada, las vegas, nevada, united states essex oncology of north jersey, belleville, new jersey, united states regional cancer care associates llc, east brunswick, new jersey, united states langone health at nyc university, nyu school of medicine, new york, new york, united states icahn school of medicine at mt. sinai, new york, new york, united states columbia university medical center, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states durham vamc, durham, north carolina, united states cleveland clinic, cleveland, ohio, united states ohio health, columbus, ohio, united states providence portland medical center, portland, oregon, united states sanford health, sioux falls, south dakota, united states vanderbilt university medical center, nashville, tennessee, united states ut southwestern medical center, dallas, texas, united states utah cancer specialists, salt lake city, utah, united states huntsman cancer institute, salt lake city, utah, united states virginia cancer specialists, fairfax, virginia, united states chris o'brien lifehouse, camperdown, australia austin hospital, heidelberg, australia st george hospital, kogarah, australia cabrini medical centre, malvern, australia sir charles gairdner hospital, nedlands, australia uz leuven, leuven, belgium algemeen ziekenhuis delta, roeselare, belgium chu ucl namur - site godinne, yvoir, belgium fundacao pio xii - hospital de cancer de barretos, barretos, brazil cetus oncologia, belo horizonte, brazil hospital evangélico de cachoeiro de itapemirim, cachoeiro de itapemirim, brazil ynova pesquisa clinica, florianopolis, brazil hospital de caridade de ijui, ijuí, brazil liga norte riograndense contra o cancer, natal, brazil upco unidade de pesquisa clinica em oncologia, pelotas, brazil santa casa de misericordia de porto alegre, porto alegre, brazil centro de pesquisa em oncologia - pucrs, porto alegre, brazil inca - instituto nacional do cancer, rio de janeiro, brazil oncoclínicas, rio de janeiro, brazil instituto d'or de pesquisa e ensino (idor), rio de janeiro, brazil núcleo de pesquisa são camilo, sao paulo, brazil ios - instituto de oncologia de sorocaba dr. gilson delgado, sorocaba, brazil instituto do cancer do estado de sao paulo icesp, são paulo, brazil fundação antônio prudente - a.c. camargo cancer center, são paulo, brazil cross cancer institute, edmonton, alberta, canada the ottawa hospital cancer centre, ottawa, ontario, canada sunnybrook health sciences centre, toronto, ontario, canada university health network, toronto, ontario, canada mcgill university health centre, montreal, quebec, canada beijing cancer hospital, beijing, china chinese pla general hospital, beijing, china beijing chest hospital, capital medical university, beijing, china peking university international hospital, beijing, china jilin cancer hospital, changchun, china hunan cancer hospital, changsha, china the first people's hospital of changzhou, changzhou, china west china hospital, sichuan university, chengdu, china chongqing university cancer hospital, chongqing, china fujian medical university union hospital, fuzhou, china the first affiliated hospital, sun yat-sen university, guang zhou, china zhejiang cancer hospital, hang zhou, china the first affiliated hospital, zhejiang university college of medicine, hangzhou, china the second affiliated hospital of zhejiang university college of medicine, hangzhou, china sir run run shaw hospital, zhejiang university school of medicine, hangzhou, china harbin medical university cancer hospital, harbin, china taizhou hospital of zhejiang province, linhai, china nanjing drum tower hospital, nanjing, china shanghai chest hospital, shanghai, china fudan university shanghai cancer center, shanghai, china shanghai zhongshan hospital, shanghai, china shanghai east hospital, shanghai, china shanghai pulmonary hospital, shanghai, china shengjing hospital of china medical university, shenyang, china cancer hospital chinese academy of medical sciences, shenzhen center, shenzhen, china tianjin medical university general hospital, tianjin, china weifang people's hospital, weifang, china tongji hospital of tongji medical college of huazhong university of science & technology, wuhan, china hospital of jiangnan university, wuxi, china the first affiliated hospital of xi'an jiaotong university, xi'an, china yantai yuhuangding hospital, yantai, china henan cancer hospital, zhengzhou, china institut bergonié, bordeaux, france hospices civils de lyon hcl, bron, france centre georges françois leclerc, dijon, france centre hospitalier le mans, le mans cedex 9, france chr hôpital calmette, lille cedex, france chu nantes - hopital nord laënnec, nantes cedex 1, france institut curie, paris, france chu bordeaux, pessac, france hia begin, saint mande, france zentralklinik bad berka gmbh, bad berka, germany evangelische lungenklinik berlin, berlin, germany asklepios klinik gauting gmbh - asklepios fachkliniken münchen-gauting, gauting, germany thoraxklinik am universitätsklinikum heidelberg, heidelberg, germany onkologische schwerpunktpraxis, heilbronn, germany lungenklinik hemer, hemer, germany universitaetsklinikum koeln, koeln, germany kliniken der stadt koeln ggmbh, koeln, germany bethanien krankenhaus, moers, germany pius-hospital oldenburg, oldenburg, germany oncologianova gmbh, recklinghausen, germany orszagos koranyi tbc es pulmonologiai intezet, budapest, hungary veszprém megyei tudőgyógyintézet, farkasgyepü, hungary mátrai gyógyintézet-bronchológia, gyöngyös, hungary fejer megyei szent gyorgy egyetemi oktatokorhaz, szekesfehervar, hungary markusovszky egyetemi oktatokorhaz, szombathely, hungary tudogyogyintezet torokbalint, torokbalint, hungary basavatarakam indo-american hospital, hyderabad, india tata medical center, kolkata, india tata memorial hospital, mumbai, india hcg manavta cancer centre, nasik, india rajiv gandhi cancer institute & research centre, new delhi, india noble hospital pvt ltd, pune, india soroka medical center, beersheba, israel shaare zedek medical center, jerusalem, israel hadassah medical center, jerusalem, israel meir medical center, kfar saba, israel rabin medical center, petah tikva, israel tel-aviv sourasky medical center, tel-aviv, israel a.o.u sant'orsola-malpighi, bologna, italy azienda ospedaliero univ. policlinico gaspare rodolico, catania, italy istituto scientifico romagnolo per lo studio e la cura dei tumori, meldola, italy fondazione irccs ca' granda ospedale maggiore policlinico, milano, italy irccs ospedale san raffaele, milano, italy fondazione irccs istituto nazionale dei tumori, milano, italy san gerardo hospital, monza, italy ospedale s. maria delle croci, ravenna, italy irccs gemelli, roma, italy istituto clinico humanitas, rozzano, italy juntendo university hospital, bunkyo-ku, japan osaka habikino medical center, habikino, japan saitama medical university international medical center, hidaka, japan national hospital organization himeji medical center, himeji, japan kansai medical university hospital, hirakata, japan hyogo cancer center, hyogo, japan kanazawa university hospital, kanazawa, japan national cancer center hospital east, kashiwa, japan kishiwada city hospital, kishiwada, japan kobe city medical center general hospital, kobe, japan kurashiki central hospital, kurashiki, japan kurume university hospital, kurume, japan matsusaka municipal hospital, matsusaka, japan national hospital organization nagoya medical center, nagoya-shi, japan aichi cancer center hospital, nagoya-shi, japan niigata cancer center hospital, niigata, japan kindai university hospital, osaka-sayama-shi, japan kitasato university hospital, sagamihara, japan hokkaido university hospital, sapporo-shi, japan iwate medical university hospital, shiwa-gun, japan shizuoka cancer center, shizuoka, japan the cancer institute hospital of jfcr, tokyo, japan ehime university hospital, toon, japan wakayama medical university hospital, wakayama, japan national hospital organization yamaguchi ube medical center, yamaguchi, japan inje university haeundae paik hospital, busan, korea, republic of national cancer center, gyeonggi-do, korea, republic of chonnam national university hwasun hospital, jeollanam-do, korea, republic of gyeongsang national university hospital, jinju, korea, republic of seoul national university bundang hospital, seongnam-si, korea, republic of korea university anam hospital, seoul, korea, republic of kangbuk samsung hospital, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of the catholic university of korea, seoul st. mary's hospital, seoul, korea, republic of hospital pulau pinang, george town, malaysia hospital sultan ismail, johor bahru, malaysia hospital kuala lumpur, kuala lumpur, malaysia university malaya medical centre, kuala lumpur, malaysia centro oncológico de chihuahua, chihuahua, mexico mexico centre for clinical research, s.a. de c.v., ciudad de mexico, mexico médica sur, ciudad de mexico, mexico instituto nacional de cancerologia, ciudad de mexico, mexico hospital civil de guadalajara fray antonio alcalde, guadalajara, mexico health pharma professional research, mexico, mexico i can oncology center, monterrey, mexico oncologia integral satelite, naucalpan, mexico centrum onkologii im. prof. f. lukaszczyka, bydgoszcz, poland uniwersyteckie centrum kliniczne, gdansk, poland szpitale pomorskie sp. z o.o., gdynia, poland warminsko-mazurskie centrum chorob pluc w olsztynie, olsztyn, poland private specialist hospitals - medpolonia, poznan, poland narodowy instytut onkologii im. marii sklodowskiej-curie - panstwowy instytut badawczy, warszawa, poland centro hospitalar e universitário de coimbra, epe, coimbra, portugal fundação champalimaud, lisboa, portugal hosp. cuf descobertas, lisboa, portugal chlc - hosp. sto antonio dos capuchos, lisboa, portugal centro hospitalar universitario do porto, epe, porto, portugal instituto portugues de oncologia, porto, portugal centro hospitalar de vila nova de gaia/espinho, e.p.e., vila nova de gaia, portugal pan american center for oncology trials llc, rio piedras, puerto rico irkutsk regional oncology dispensary, irkutsk, russian federation state medical institution 'republican clinical oncological centre' at republic of tatarstan, kazan, russian federation moscow city oncology hospital № 62, krasnogorsk, russian federation krasnoyarsk regional oncology dispensary, krasnoyarsk, russian federation leningrad regional oncology dispensary, kuzmolovsky, russian federation moscow oncology research center n.a. blokhin, moscow, russian federation mck, moscow, russian federation central clinical hospital, moscow, russian federation city clinical hospital #1, nalchik, russian federation nizhny novgorod regional oncological dispensary, nizhniy novgorod, russian federation n.n. petrov research institute of oncology, saint petersburg, russian federation leningrad regional clinical hospital, saint-petersburg, russian federation oncology medical clinics av medical group, st-petersburg, russian federation city clinical oncology dispensary, st. petersburg, russian federation tomsk cancer research institute, tomsk, russian federation bashkir state medical university, ufa, russian federation yaroslavl regional clinical oncology hospital, yaroslavl, russian federation hosp. univ. a coruña, a coruña, spain inst. cat. d'oncologia-badalona, badalona, spain hosp. de la santa creu i sant pau, barcelona, spain hosp. univ. quiron dexeus, barcelona, spain hosp. univ. vall d hebron, barcelona, spain hosp. univ. de burgos, burgos, spain hosp. gral. univ. gregorio marañon, madrid, spain hosp. univ. ramon y cajal, madrid, spain hosp. univ. 12 de octubre, madrid, spain hosp. univ. la paz, madrid, spain hosp. univ. pta. de hierro majadahonda, majadahonda, spain hosp. virgen de la victoria, málaga, spain clinica univ. de navarra, pamplona, spain hosp. virgen del rocio, seville, spain hosp. clinico univ. lozano blesa, zaragoza, spain kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan chang gung medical foundation, kaohsiung, taiwan taipei medical university shuang ho hospital, new taipei, taiwan chung shan medical university hospital, taichung, taiwan china medical university hospital, taichung, taiwan national taiwan university hospital, taipei city, taiwan phramongkutklao hospital and medical college, bangkok, thailand siriraj hospital, bangkok, thailand songklanagarind hospital, prince of songkla university, songkla, thailand adana city hospital, adana, turkey başkent university medical faculty adana application and research center, adana, turkey gazi university hospital, ankara, turkey ankara bilkent city hospital, ankara, turkey trakya university medical faculty, edirne, turkey istanbul universitesi cerrahpasa tip fakultesi ic hastaliklari anabilim dali medikal onkoloji bd, istanbul, turkey medipol mega university hospital, istanbul, turkey goztepe prof. dr. suleyman yalcin sehir hastanesi, istanbul, turkey izmir medical park hospital, izmir, turkey dnipropetrovsk state medical academy, dnipropetrovsk city multifield clinical hospital # 4, dnipro, ukraine medical center 'ok clinic' of llc 'international institute of clinical studies', kyiv, ukraine national cancer institute, kyiv, ukraine municipal institution 'odesa clinical oncology dispensary', odesa, ukraine municipal oncology centre of uzhgorod central municipal clinical hospitlal, uzhgorod, ukraine edinburgh cancer centre western general, edinburgh, united kingdom the royal marsden nhs trust, london, united kingdom nottingham university hospitals nhs trust, nottingham, united kingdom the royal marsden nhs trust, sutton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04538664,
513,514,NCT00957086,study of post-op adjuvant concurrent chemo-rt with or without nimotuzumab for head & neck cancer,,"Active, not recruiting",No Results Available,"carcinoma, squamous cell of head and neck",drug: nimotuzumab|drug: placebo,to compare the disease-free survival between patients randomized to adjuvant nimotuzumab/cisplatin/rt with the control arm|to compare the overall survival between the two arms|to assess the toxicity profile between the 2 arms,"national cancer centre, singapore|national medical research council (nmrc), singapore|innogene kalbiotech pte. ltd",All,"21 Years and older   (Adult, Older Adult)",Phase 3,710.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IHN01,"August 13, 2009","January 1, 2024","January 1, 2024","August 12, 2009",,"April 6, 2022","[""flinders medical centre, bedford park, australia peter maccallum cancer centre, melbourne, australia national institute of oncology and radiobiology, vedado, cuba alexandria university school of medicine, alexandria, egypt national cancer institute, cairo university, cairo, egypt apollo hospital bangalore, bangalore, india narayana hrudayalaya hospital (mazumdar shaw cancer institute), bangalore, india amrita institute of medical sciences, kerala, india tata memorial centre, mumbai, india christian medical college, tamil nadu, india regional cancer center trivandrum, india, trivandrum, india cipto mangunkusumo general hospital indonesia, jakarta, indonesia national cancer center korea, gyeonggi-do, korea, republic of inha university hospital, incheon, korea, republic of samsung medical center, seoul, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of pantai medical centre, kuala lumpur, kuala lumpur, malaysia mahkota medical center, melaka, malaysia university of santo tomas hospital, manila, philippines st. luke's medical center, quezon city, philippines king fahad medical city, riyadh, saudi arabia national cancer centre, singapore, singapore the oncology centre, durban, south africa gvi oncology, panorama, south africa china medical university hospital, taichung, taiwan taipei med univ hosp [tmuh], taipei, taiwan taipei veteran general hospital, taipei, taiwan national cancer institute bangkok (+chulabhorn for rt), bangkok, thailand siriraj hospital, bangkok, thailand chiang mai hospital, chiang mai, thailand""]",,https://ClinicalTrials.gov/show/NCT00957086,skin
514,515,NCT01525550,a study of the efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors,,Completed,Has Results,well-differentiated pancreatic neuroendocrine tumor,drug: sunitinib,progression-free survival (pfs): investigator assessment|progression-free survival (pfs): independent radiological review (irr) assessment|time to tumor progression (ttp): investigator assessment|overall survival (os)|percentage of participants with objective response (or): investigator assessment|duration of response (dor): investigator assessment|time to tumor response (ttr): investigator assessment|percentage of participants with objective response (or): independent radiological review (irr) assessment|duration of response (dor): independent radiological review (irr) assessment|time to tumor response (ttr): independent radiological review (irr) assessment|percentage of participants with chromogranin a (cga) response|quality of life measured by european organization for research and treatment of cancer quality of life questionnaire-c30 (eortc qlq-c30)|quality of life measured by european organization for research and treatment of cancer quality of life questionnaire-gastrointestinal related neuroendocrine tumours-21 (eortc qlq-gi net 21)|plasma concentration of soluble protein biomarker (skit)|minimum observed plasma concentration (ctrough) of sunitinib and its metabolite su012662|dose-corrected trough plasma concentration of sunitinib and its metabolite su012662|area under the curve (auc24) of sunitinib and its metabolite su012662|oral clearance (cl/f) of sunitinib and its metabolite su012662|half maximal effective concentration (ec50) of sunitinib|number of participants with treatment emergent adverse events (aes) and serious adverse events (saes)|number of participants with treatment emergent treatment-related adverse events (aes) and serious adverse events (saes)|number of participants with adverse events (aes) according to severity|number of participants with clinically significant laboratory abnormalities|number of participants with change from baseline in vital signs abnormalities|number of participants with increase from baseline in corrected qt interval (qtc)|number of participants with change from baseline in physical examinations findings|number of participants with change from baseline in body weight|number of participants with eastern co-operative oncology group performance status (ecog-ps),pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,106.0,Industry,Interventional,Masking: None (Open Label)|Primary Purpose: Other,A6181202|2011-004363-74,"June 6, 2012","March 19, 2016","July 26, 2018","February 3, 2012","May 19, 2017","July 30, 2019","['univeristy of california, orange, california, united states columbia university medical center, new york, new york, united states barwon health - university hospital geelong, geelong, victoria, australia cliniques universitaires saint-luc, gastroenterologie, bruxelles, brussels gewest, belgium china-japan friendship hospital, beijing, beijing, china 307 hospital of pla, beijing, beijing, china beijing cancer hospital, beijing, beijing, china nanjing bayi hospital, nanjing, jiangsu, china west china hospital of sichuan university, chengdu, sichuan, china fudan university shanghai cancer center, shanghai, china zhongshan hospital fudan university, shanghai, china masarykuv onkologicky ustav, brno, czechia fakultni poliklinika, praha 2, czechia vseobecna fakultni nemocnice v praze, praha 2, czechia hôpital beaujon, clichy cedex, france semmelweis egyetem/ii. sz. belgyogyaszati klinika, budapest, hungary tata memorial hospital, mumbai, maharashtra, india ieo istituto europeo di oncologia, irccs, milano, italy kyushu university hospital, fukuoka-shi, fukuoka, japan national cancer center hospital, chuo-ku, tokyo, japan oslo universitetssykehus hf, rikshospitalet, oslo, norway centrul de oncologie sf. nectarie, craiova, dolj, romania institutul clinic fundeni, centrul de gastroenterologie si hepatologie, bucuresti, romania narodny onkologicky ustav, bratislava, slovakia wits clinical research, johannesburg, gauteng, south africa hospital universitario madrid sanchinarro - centro integral oncológico clara campal (ciocc), madrid, spain']",,https://ClinicalTrials.gov/show/NCT01525550,pancreat
515,516,NCT00190840,a single arm phase 2 study of pemetrexed as 2nd-line treatment of advanced non-small cell lung cancer,,Completed,No Results Available,"carcinoma, non-small cell lung",drug: pemetrexed,response rate according to recist criteria|to assess the following time to event efficacy variables:|o duration of overall response for responding patients|o time to progressive disease|o time to treatment failure|o survival|to characterize the quantitative and qualitative toxicity of pemetrexed when used at tailored dosing in this patient population,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,186.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6685|H3E-AA-S037,September 2003,,October 2005,"September 19, 2005",,"January 26, 2007","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wollongong, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chermside, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ashford, south australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fitzroy, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hong kong, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., alexandria, egypt for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cairo, egypt for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hyderabad, andhra pradesh, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ludhiana, punjab, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chandigarh, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chennai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., goyang-si, gyeonggi-do, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oradea, bihor, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., craiova, dolj, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bucuresti, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., iasi, romania for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., eskisehir, turkey']",,https://ClinicalTrials.gov/show/NCT00190840,
516,517,NCT01459328,resource-sparing curative treatment for rectal cancer,,Unknown status,No Results Available,rectal carcinoma,radiation: radiotherapy,overall survival|biological effect and tumour biology|quality of life|health-related economics,"international atomic energy agency|centre anti cancer hopital frantz fanon|hospital a.c. camargo|credit valley hospital|instituto nacional de cancerologia, columbia|university hospital ""sestre milosrdnice""|minesterio de cienca, tecnologia y medio ambiente|v.n. cancer center gknm hospital|tata memorial hospital|dr cipto mangunkusumo general hospital|national cancer center, bratislava|university of cape town|catholic university of the sacred heart",All,"18 Years and older   (Adult, Older Adult)",Phase 3,350.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E33034,September 2009,September 2013,,"October 25, 2011",,"October 25, 2011","['centre anti-cancer, hopital franz fanon, blida, algeria hospital a.c. camargo, fundacao antonio prudente, sao paulo, brazil credit valley hospital, mississauga, ontario, canada instituto nacional de cancerologia, minesterio de salud, bogota d.c., colombia department of oncology and nuclear medicine, university hospital sestre milosrdnice, zagreb, croatia ministerio de cienca, tecnologia y medio ambiente (citma), la habana, cuba department of radiation oncology, v.n. cancer center, gknm hospital, coimbatore, india department of radiation oncology, tata memorial hospital, mumbai, india department of radiotherapy, dr. cipto mangunkusuma national general hospital, university of indonesia, jakarta, indonesia instituto di radiologia, universita cattolica del sacro cuore, roma, italy national cancer institute, bratislava, slovakia university of cape town, cape town, south africa']",,https://ClinicalTrials.gov/show/NCT01459328,
517,518,NCT00805194,lume-lung 1: bibf 1120 plus docetaxel as compared to placebo plus docetaxel in 2nd line non small cell lung cancer,,Completed,Has Results,"carcinoma, non-small-cell lung",drug: placebo plus docetaxel|drug: bibf 1120 plus docetaxel,"progression free survival (pfs) as assessed by central independent review|overall survival (key secondary endpoint)|follow-up analysis of progression free survival (pfs) as assessed by central independent review|follow-up analysis of progression free survival (pfs) as assessed by investigator|objective tumour response|duration of confirmed objective tumour response|time to confirmed objective tumour response|disease control|duration of disease control|change from baseline in tumour size|clinical improvement|quality of life (qol)|dose normalised predose plasma concentration at steady state (cpre,ss,norm) of nintedanib and of its metabolites bibf 1202 and bibf 1202 glucuronide|incidence and intensity of adverse events",boehringer ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1314.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1199.13|2007-004803-36,"December 3, 2008","November 2, 2010","November 13, 2017","December 9, 2008","December 1, 2014","December 5, 2018","['lkh-univ. hospital graz, graz, austria kh st. vinzenz, zams, int. abtlg., kufstein, austria akh d. stadt linz, pulmologie, linz, austria bobruisk inter-distict, bobruisk, belarus brest regional clinical, brest region, belarus gomel regional clinical, gomel, belarus scientific research minsk, minsk region, belarus public health inst. minsk city clinical oncology dispensary, minsk, belarus mogilov regional oncological dispensary, mogilov, belarus vitebsk regional clinical oncology dispensary, vitebsk, belarus centre hospitalier universitaire de liège, liège, belgium liège - hosp chr de la citadelle, liège, belgium multiprofile hospital for active treatment, gabrovo, bulgaria univ.multiprofile hospital ""dr. georgy stranski"" ead, pleven, pleven, bulgaria district oncology dispensary plovdiv, plovdiv, bulgaria interdistrict oncology dispensary, ruse, ruse, bulgaria district oncology dispensary shumen, shumen, bulgaria specialized hospital for active treatment in oncolcogy, sofia, bulgaria 307 hospital of pla, beijing, china jilin province cancer hospital, changchun, china first hospital of jilin university, changchun, china west china hospital, chengdu, china southwest hospital, chongqing, china first affiliated hospital of dalian medical university, dalian, china the second affiliated hospital of dalian medical university, dalian, china fujian provincial tumor hospital, fujian, china sun yat-sen university cancer center, guangzhou, china guangdong general hospital, guangzhou, china sir run run shaw hospital, hangzhou, china zhejiang cancer hospital, hangzhou, china the third affiliated hospital of harbin medical university, harbin, china the 81th hospital of pla, nanjing, china jiangsu cancer hospital, nanjing, china shanghai chest hospital, shanghai, china fudan university shanghai cancer center, shanghai, china shanghai pulmonary hospital, shanghai, china tongji hospital, tongji university, wuhan, china zhongshan hospital fudan university, xuhui area, shanghai, china clinical hospital centar sestre milosrdnice, zagreb, croatia uhc zagreb, zagreb, croatia university hospital brno, brno, czechia st. anna hospital, 2nd internal department, brno, czechia district hospital liberec, liberec, czechia institut onkologie a rehabilitace na plesi s.r.o., nova ves pod plesi, czechia district hospital pribram, oncology centrum, pribram, czechia herlev hospital, herlev, denmark odense universitetshospital, odense c, denmark hop croix rousse, pneumo, lyon, lyon cedex 4, france ins paoli-calmettes, marseille cedex 9, france hop lyon sud, pierre bénite cedex, france chu de rouen - hôpital de bois guillaume, rouen cedex, france hop nord laënnec, saint herblain cedex, france oncology institute of the loire, saint-priest en jarez, france hop civil, strasbourg cedex, france sainte anne training hospital for the armies, toulon cedex 09, france amtel hospital first clinical llc, tbilisi, georgia national centre of oncology, tbilisi, georgia chemotherapy & immunotherapy clinic \'medulla\', tbilisi, tbilisi, georgia gemeinschaftspraxis dr. brudler / dr. heinrich, augsburg, augsburg, germany zentralklinik bad berka gmbh, bad berka, germany evangelische lungenklinik berlin, berlin-buch, germany universitätsklinikum benjamin franklin, berlin, berlin, germany helios klinikum emil von behring, berlin, germany krankenhaus nordwest, frankfurt, frankfurt/main, germany klinikum frankfurt höchst gmbh, frankfurt/main, germany universitätsklinikum frankfurt, frankfurt, germany universitätsklinikum freiburg, freiburg, germany asklepios fachkliniken münchen-gauting, gauting, germany pneumologisches forschungsinstitut an der lungenclinic grosshansdorf gmbh, großhansdorf, germany krankenhaus martha-maria halle-dölau ggmbh, halle/saale, germany allgemeines krankenhaus harburg, 21075 hamburg, hamburg, germany universitätsklinikum heidelberg, heidelberg, germany klinikum kassel gmbh, kassel, germany universitätsklinikum schleswig-holstein, campus kiel, kiel, germany gemeinschaftspraxis für hämatologie und onkologie, köln, köln, germany universitätsklinikum leipzig, leipzig, germany pois leipzig gbr, leipzig, germany klinik, löwenstein, löwenstein, germany universitätsklinikum schleswig-holstein, campus kiel, lübeck, germany katholisches klinikum st. hildegardiskrankenhaus, mainz, mainz, germany universitätsmedizin der johannes gutenberg-universität mainz, mainz, germany universitätsklinik links der isar, münchen, ziemssenstr. 1, münchen, germany klinikum rechts der isar der technischen universität münchen, münchen, germany städt. krankenhaus, münchen-bogenhausen, münchen, germany pius-hospital, oldenburg, oldenburg, germany universitätsklinikum tübingen, tübingen, germany helios dr. horst schmidt kliniken wiesbaden, wiesbaden, germany evangelisches krankenhaus, witten, witten, germany athens hospital of chest diseasea ""sotiria"", athens, greece university hospital of heraklion, university pulmonology cl, heraklio, greece iaso general hospital, holargos, athens, greece papageorgiou hospital, 1st cardiological cl., thessaloniki, thessaloniki, greece general hospital of thessaloniki ""g. papanikolaou"", thessaloniki, greece vedanta institute of medical sciences, ahmedabad, india kidwai memoraial institute of oncology, bangalore, india rajalakshmi multispeciality hospital, bangalore, india jawaharlal nehru cancer hospital & research centre, bhopal, m.p., india apollo hospital, chennai, india searoc cancer center,s.k.soni hospital, jaipur, rajasthan, india birla cancer centre, jaipur, india bhagwan mahaveer cancer hospital & research center, jawahar, jaipur, india b. p .poddar hospital & medical research ltd., kolkata, west bengal, india kasturba medical college and hospital, mangalore, india tata memorial centre, mumbai, india shatabdi superspeciality hospital, nashik, india sir gangaram hospital, new delhi, india indraprastha apollo hospitals, new delhi, india rajiv gandhi cancer institute and research centre, new delhi, india jehangir hospital oncology department, pune, maharahtra, india regional cancer center, trivandrum, kerala, india city cancer centre, cancer hospital & research, vijayawada, india king george hospital, visakhapatnam, india e. wolfson medical center, holon 58100, holon, israel hadassah medical center, ein-karem, jerusalem, israel meir medical center, kfar saba, israel the chaim sheba medical center tel hashomer, tel hashomer, israel sourasky medical center, tel-aviv, israel assaf harofe medical center, zerifin, israel az. ospedaliere umberto i di ancona, ancona, italy centro di riferimento oncologico, aviano, italy policlinico s. orsola malpighi, bologna, italy fond. poliambulanza istituto, brescia, italy azienda ospedaliera careggi, firenze, italy ospedale civile, ivrea (to), italy istituto scientifico romagnolo, meldola, italy asst grande ospedale metropolitano niguarda, milano, italy azienda sanitaria ospedale s. luigi gonzaga, orbassano, italy fondazione salvatore maugeri, pavia, italy ospedale s.maria della misericordia, ao di perugia, perugia, italy gachon university gil medical center, incheon, korea, republic of vhs medical center, seoul, korea, republic of the catholic university of korea, seoul st.mary\'s hospital, seoul, korea, republic of hospital of lithuanian univ.of healthsciences kauno klinikos, kaunas, lithuania siauliu ligonine, siauliai, siauliai, lithuania vilniaus universiteto, vilnius, lithuania pulmonology center in bydgoszcz, bydgoszcz, poland regional complex hospital, elblag, poland institute of tuberculosis & pulmonology, iii. dept., olsztyn, olsztyn, poland mazowieckiego centrum, otwock, poland greater pl cent.pulmo.&thor.surg.eugenia&janusz zeyland, poznan, poland regional specialist hospital, slupsk, poland independent public hospital in suwalki, suwalki, poland specialist hospital, szczecin-zdunowo, szczecin, poland onco.cent. - instit. of maria sklodowskiej-curie, warszawa, poland ipo porto francisco gentil, epe, coimbra, portugal ipo lisboa francisco gentil, epe, lisboa, portugal chln, epe - hospital de santa maria, lisboa, portugal ipo porto francisco gentil, epe, porto, portugal centro hospitalar são joão,epe, porto, portugal chs, epe - hospital de são bernardo, setúbal, portugal centro hospitalar de vila nova de gaia, vila nova de gaia, portugal baia mare emergency county hospital, baia mare, romania spitalul clinic judetean de urgenta brasov, brasov, romania institute of oncology \'prof. dr. alexandru trestioreanu\', bucuresti, romania institutul oncologic ""prof. dr. ion chiricuta"", cluj-napoca, romania county hospital ""dr. alex simionescu"", hunedoara, romania centrul de oncologie medicala, iasi, romania emergency clinical county hospital ""sf spiridon"", iasi, iasi, romania onesti county hospital, onesti, romania emergency county hospital ""sf.loan cel nou"", suceava, romania oncomed srl, timisoara, romania sbih of arkhangelsk reg. ""arkhangelsk clin. onc. dispensary"", arkhangelsk, russian federation glpu cheliabinsky, chelyabinsk, russian federation guz irkutsk regional oncology dispensary, irkutsk, russian federation st.auton.heal.inst.""rep.clin.onc.disp.of moh of rep. tatarstan"", kazan, russian federation rbih ""kursk regional clinical oncology dispensary"", kursk, russian federation guz regional oncology dispensary, magnitogorsk, magnitogorsk, russian federation fsbi ""n.n blokhin med.res.cent.onc.""moh of rf, moscow, russian federation sbih of stavropol territory ""pyatigorsk oncol. dispensary"", pyatigorsk, russian federation guz ""regional clinical oncology dispensary"", ryazan, russian federation guz ""oncological dispesary #2"", sochi, russian federation guz leningradskaya regional clin. hospital, st. petersburg, st. petersburg, russian federation 1stpavlov st.med.univ.st.-petersburg res.inst., st. petersburg, russian federation spb sbih ""city clinical oncological dispensary"", st. petersburg, russian federation fsbi ""n.n. petrov national medical research center of oncology"" of moh of rf, st. petersburg, russian federation guz sverdlovsky regional oncology dispensary, yekaterinburg, russian federation faculty hospital trnava, trnava, slovakia gvi oncology medi clinic, cape town, south africa parklands hospital, durban, south africa wcr cmjah clinical trial site, johannesburg, south africa medical oncology centre of rosebank, johannesburg, south africa langenhoven drive oncology centre, port elizabeth, south africa pretoria academic hospital, pretoria, south africa wilgers oncology, pretoria, south africa hospital clínic de barcelona, barcelona, spain hospital universitario de elche, elche, spain hospital jerez de la frontera, jerez de la frontera-cádiz, spain hospital la princesa, madrid, spain hospital quirónsalud madrid, pozuelo de alarcon, spain fundación instituto valenciano de oncologia, valencia, spain servicio de oncologia radiotherapica, valencia, spain hospital arnau de vilanova, valencia, spain kantonsspital aarau, aarau, switzerland kantonsspital baden ag, baden, switzerland chernigiv regional oncology centre, chernigiv, ukraine bukovynsk state medical university, chernivtsi, ukraine chmelnytskyi oblasnnyi oncologichnyi tsentr, chmelnytskyi, ukraine city clinical hospital #4, dnipropetrovsk state medical academy, dnipropetrovsk, ukraine donetsk regional antitumor centre, donetsk, ukraine kharkiv medical acadamy of postgraduate education, kharkiv, ukraine kryvorizskyi regional communal clinical oncology centre, kryvyi rig, ukraine odesa regional oncological centre, odesa, ukraine ternopil regional communal clinical oncology centre, ternopil, ukraine uzhgorod national university, oncology centre, uzhgorod, ukraine vinnytsia regional clinical oncological dispensary, vinnytsia, ukraine royal bournemouth and christchurch hospital, bournemouth, united kingdom bristol haematology & onc. ctr, bristol, united kingdom broomfield hospital, chelmsford, united kingdom wythenshawe hospital, manchester, united kingdom poole hospital, poole, united kingdom']",,https://ClinicalTrials.gov/show/NCT00805194,
518,519,NCT03141021,multi-institutional registry for malignant peripheral nerve sheath tumors,,Recruiting,No Results Available,malignant peripheral nerve sheath tumors,,histologic characteristics of malignant peripheral nerve sheath tumor (mpnst)|immunohistochemical characteristics of malignant peripheral nerve sheath tumor (mpnst)|molecular characteristics of malignant peripheral nerve sheath tumor (mpnst)|radiographic characteristics of malignant peripheral nerve sheath tumor (mpnst)|treatment given to patients with malignant peripheral nerve sheath tumor (mpnst)|future genomic characterization of malignant peripheral nerve sheath tumor (mpnst),washington university school of medicine|boston's children hospital,All,"Child, Adult, Older Adult",,2000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Other,201702006,"April 28, 2017","April 28, 2027","April 28, 2027","May 4, 2017",,"May 13, 2022","['moffitt cancer center, tampa, florida, united states johns hopkins, baltimore, maryland, united states national institutes of health (nih), bethesda, maryland, united states dana farber cancer institute, boston, massachusetts, united states university of minnesota, minneapolis, minnesota, united states washington university school of medicine, saint louis, missouri, united states memorial sloan kettering cancer center, new york, new york, united states lifespan, providence, rhode island, united states mount sinai, toronto, ontario, canada global gene corporation, mumbai, india royal national orthopedic hospital, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT03141021,skin astrocyt
519,520,NCT00087711,a randomized phase 3 trial of pemetrexed and cisplatin versus gemcitabine and cisplatin in patients with locally advanced or metastatic non small cell lung cancer,,Completed,No Results Available,non small cell lung carcinoma,drug: pemetrexed|drug: gemcitabine|drug: cisplatin,overall survival|progression free survival|time to progressive disease|duration of response|time to treatment failure,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1713.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2938|H3E-MC-JMDB,July 2004,January 2007,March 2008,"July 16, 2004",,"September 12, 2019","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, sacramento, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, torrance, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, jacksonville, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, macon, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, wichita, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, lexington, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, scarborough, maine, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, duluth, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, saint louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, billings, montana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, hackensack, new jersey, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, hickory, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, portland, oregon, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, columbia, south carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, nashville, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, arlington, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, richmond, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, seattle, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, bahia blanca, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, buenos aires, argentina for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, bedford park, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, camperdown, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, chermisdie, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, fitzroy, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, hornsby, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, nedlands, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, south brisbane, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, st leonards, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, graz, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, grimmenstein, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, innsbruck, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, leoben, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, linz, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, st. poelten, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, vienna, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, wels, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, leuven, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, liege, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, florianopolis, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, porto alegre, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, rio de janeiro, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, salvador, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, sao paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, north vancouver, british columbia, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, brampton, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, toronto, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, sainte-foy, quebec, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, herlev, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, odense, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, helsinki, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, tampere, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, bordeaux, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, grenoble, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, marseille, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, montpellier, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, paris, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, saint herblain, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, strasbourg, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, vandoeuvre-les-nancy, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, mannheim, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, heraklion, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, patras, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, budapest, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, deszk, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, pecs, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, bangalore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, cochin, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, hyderabad, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, new dehli, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, pune, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, kfar saba, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, tel-aviv, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, tel-hashomer, israel for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, ancona, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, bergamo, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, bologna, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, forli, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, genova, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, livorno, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, modena, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, orbassano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, roma, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, taormina, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, goyang-si, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, ciudad obregon, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, guadalajara, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, leon, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, mexicali, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, mexico city, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, alkmaar, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, amstelveen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, amsterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, arnhem, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, den bosch, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, eindhoven, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, harderwijk, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, heerlen, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, krakow, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, lodz, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, szczecin-zdunowo, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, warszawa, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, coimbra, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, lisboa, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, porto, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, santa maria da feira, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, san juan, puerto rico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, alicante, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, badalona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, barcelona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, pamplona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, sabadell, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, santander, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, zaragoza, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, goteborg, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, lund, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, stockholm, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, niao sung hsiang, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, taichung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, tao-yuan, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, ankara, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, antalya, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, istanbul, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, izmir, turkey for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, aberdeen, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, bangor, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, chelmsford, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, fulham, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, plymouth, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) monday-friday from 9:00 am to 5:00 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician, sutton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00087711,
520,521,NCT00254891,trial of paclitaxel/carboplatin + pf-3512676 vs paclitaxel/carboplatin alone in patients with advanced non-small cell lung cancer,,Terminated,No Results Available,"carcinoma, non-small-cell lung",drug: pf-3512676 + paclitaxel + carboplatin|drug: paclitaxel + carboplatin,overall survival|overall objective response|time to tumor progression|progression free survival|duration of response|patient reported outcomes|overall safety profile,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,828.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A8501001,November 2005,July 2008,July 2008,"November 17, 2005",,"March 30, 2015","['pfizer investigational site, little rock, alaska, united states pfizer investigational site, hot springs, arkansas, united states pfizer investigational site, chula vista, california, united states pfizer investigational site, la mesa, california, united states pfizer investigational site, oceanside, california, united states pfizer investigational site, palm springs, california, united states pfizer investigational site, san diego, california, united states pfizer investigational site, san francisco, california, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, decatur, georgia, united states pfizer investigational site, fayetteville, georgia, united states pfizer investigational site, macon, georgia, united states pfizer investigational site, marietta, georgia, united states pfizer investigational site, tucker, georgia, united states pfizer investigational site, rockford, illinois, united states pfizer investigational site, jefferson, indiana, united states pfizer investigational site, new albany, indiana, united states pfizer investigational site, cedar rapids, iowa, united states pfizer investigational site, dubuque, iowa, united states pfizer investigational site, lexington, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, shelbyville, kentucky, united states pfizer investigational site, covington, louisiana, united states pfizer investigational site, gretna, louisiana, united states pfizer investigational site, lafayette, louisiana, united states pfizer investigational site, marrero, louisiana, united states pfizer investigational site, marrero, louisiana, united states pfizer investigational site, metairie, louisiana, united states pfizer investigational site, new orleans, louisiana, united states pfizer investigational site, biddeford, maine, united states pfizer investigational site, brunswick, maine, united states pfizer investigational site, scarborough, maine, united states pfizer investigational site, worcester, massachusetts, united states pfizer investigational site, allegan, michigan, united states pfizer investigational site, ann arbor, michigan, united states pfizer investigational site, ann arbor, michigan, united states pfizer investigational site, kalamazoo, michigan, united states pfizer investigational site, kalamazoo, michigan, united states pfizer investigational site, st. joseph, michigan, united states pfizer investigational site, columbus, mississippi, united states pfizer investigational site, corinth, mississippi, united states pfizer investigational site, tupelo, mississippi, united states pfizer investigational site, omaha, nebraska, united states pfizer investigational site, omaha, nebraska, united states pfizer investigational site, omaha, nebraska, united states pfizer investigational site, papillion, nebraska, united states pfizer investigational site, las vegas, nevada, united states pfizer investigational site, las vegas, nevada, united states pfizer investigational site, albuquerque, new mexico, united states pfizer investigational site, ruidoso, new mexico, united states pfizer investigational site, buffalo, new york, united states pfizer investigational site, great neck, new york, united states pfizer investigational site, asheville, north carolina, united states pfizer investigational site, brevard, north carolina, united states pfizer investigational site, lexington, north carolina, united states pfizer investigational site, winston-salem, north carolina, united states pfizer investigational site, canton, ohio, united states pfizer investigational site, dover, ohio, united states pfizer investigational site, oklahoma city, oklahoma, united states pfizer investigational site, portland, oregon, united states pfizer investigational site, langhorne, pennsylvania, united states pfizer investigational site, chattanooga, tennessee, united states pfizer investigational site, memphis, tennessee, united states pfizer investigational site, arlington, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, richardson, texas, united states pfizer investigational site, trophy club, texas, united states pfizer investigational site, bountiful, utah, united states pfizer investigational site, layton, utah, united states pfizer investigational site, murray, utah, united states pfizer investigational site, provo, utah, united states pfizer investigational site, salt lake city, utah, united states pfizer investigational site, wvc, utah, united states pfizer investigational site, burlington, vermont, united states pfizer investigational site, everett, washington, united states pfizer investigational site, kennewick, washington, united states pfizer investigational site, richland, washington, united states pfizer investigational site, madison, wisconsin, united states pfizer investigational site, albury, new south wales, australia pfizer investigational site, camperdown, new south wales, australia pfizer investigational site, randwick, new south wales, australia pfizer investigational site, pimlico, queensland, australia pfizer investigational site, townsville, queensland, australia pfizer investigational site, woolloongabba, queensland, australia pfizer investigational site, bedford park, south australia, australia pfizer investigational site, toorak gardens, south australia, australia pfizer investigational site, east melbourne, victoria, australia pfizer investigational site, east ringwood, victoria, australia pfizer investigational site, wodonga, victoria, australia pfizer investigational site, nedlands, western australia, australia pfizer investigational site, gent, belgium pfizer investigational site, liège, belgium pfizer investigational site, moncton, new brunswick, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, rimouski, quebec, canada pfizer investigational site, saskatoon, saskatchewan, canada pfizer investigational site, dalian, xigang district, liaoning, china pfizer investigational site, beijing, china pfizer investigational site, beijing, china pfizer investigational site, shanghai, china pfizer investigational site, nicosia, cyprus pfizer investigational site, nova ves pod plesi, czech republic pfizer investigational site, ostrava-poruba, czech republic pfizer investigational site, usti nad labem, czech republic pfizer investigational site, angers cedex, france pfizer investigational site, caen cedex, france pfizer investigational site, dijon, france pfizer investigational site, limoges, france pfizer investigational site, nantes cedex 2, france pfizer investigational site, paris cedex 13, france pfizer investigational site, st herblain cedex, france pfizer investigational site, strasbourg, france pfizer investigational site, toulouse cedex 9, france pfizer investigational site, vandoeuvre les nancy, france pfizer investigational site, berlin, germany pfizer investigational site, bielefeld, germany pfizer investigational site, bonn, germany pfizer investigational site, essen, germany pfizer investigational site, frankfurt, germany pfizer investigational site, karlsruhe, germany pfizer investigational site, muenchen, germany pfizer investigational site, athens, attica, greece pfizer investigational site, heraklion, crete, greece pfizer investigational site, thessaloniki, macedonia, greece pfizer investigational site, athens, greece pfizer investigational site, rio, patras, greece pfizer investigational site, pokfulam, hong kong pfizer investigational site, budapest, hungary pfizer investigational site, budapest, hungary pfizer investigational site, budapest, hungary pfizer investigational site, debrecen, hungary pfizer investigational site, bangalore, karnataka, india pfizer investigational site, kochi, kerala, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, chandigarh, punjab, india pfizer investigational site, jaipur, rajasthan, india pfizer investigational site, zerifin, israel pfizer investigational site, lido di camaiore (lu), italy pfizer investigational site, milano, italy pfizer investigational site, napoli, italy pfizer investigational site, pavia, italy pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, mexico, df, mexico pfizer investigational site, puebla, mexico pfizer investigational site, tiel, gld, netherlands pfizer investigational site, groningen, gr, netherlands pfizer investigational site, amstelveen, netherlands pfizer investigational site, den haag, netherlands pfizer investigational site, otwock, poland pfizer investigational site, wodzislaw sl., poland pfizer investigational site, faro, portugal pfizer investigational site, porto, portugal pfizer investigational site, porto, portugal pfizer investigational site, vila nova de gaia, portugal pfizer investigational site, parktown, gauteng, south africa pfizer investigational site, cape town, south africa pfizer investigational site, cape town, south africa pfizer investigational site, johannesburg, south africa pfizer investigational site, badalona, barcelona, spain pfizer investigational site, alcorcon, madrid, spain pfizer investigational site, pamplona, navarra, spain pfizer investigational site, madrid, spain pfizer investigational site, madrid, spain pfizer investigational site, santa cruz de tenerife, spain pfizer investigational site, valencia, spain pfizer investigational site, stockholm, sweden pfizer investigational site, uppsala, sweden pfizer investigational site, lausanne, switzerland pfizer investigational site, taipei, taiwan pfizer investigational site, truro, cornwall, united kingdom pfizer investigational site, exeter, devon, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, portsmouth, united kingdom pfizer investigational site, sheffield, united kingdom pfizer investigational site, surrey gu2 5xx, united kingdom pfizer investigational site, swansea, united kingdom']",,https://ClinicalTrials.gov/show/NCT00254891,
521,522,NCT01085136,lux-lung 5: afatinib plus weekly paclitaxel versus investigator's choice of single agent chemotherapy following afatinib monotherapy in non-small cell lung cancer patients failing erlotinib or gefitinib,,Completed,Has Results,"carcinoma, non-small-cell lung",drug: investigator´s choice of chemotherapy|drug: bibw 2992,progression free survival (part b)|progression free survival (part a)|overall survival (part b)|objective response (part a)|objective response (part b)|intensity and incidence of adverse events (aes) for part a & part b.,boehringer ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1154.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.42|2009-014563-39,February 2010,October 2013,January 2016,"March 11, 2010","October 3, 2014","April 4, 2017","['boehringer ingelheim investigational site, ciudad autonoma de buenos aires, argentina boehringer ingelheim investigational site, kingswood, new south wales, australia boehringer ingelheim investigational site, south brisbane, queensland, australia boehringer ingelheim investigational site, box hill, victoria, australia boehringer ingelheim investigational site, fitzroy, victoria, australia boehringer ingelheim investigational site, wodonga, victoria, australia boehringer ingelheim investigational site, salzburg, austria boehringer ingelheim investigational site, aalst, belgium boehringer ingelheim investigational site, bruxelles, belgium boehringer ingelheim investigational site, duffel, belgium boehringer ingelheim investigational site, la louvière, belgium boehringer ingelheim investigational site, liège, belgium boehringer ingelheim investigational site, middelheim, belgium boehringer ingelheim investigational site, ottignies, belgium boehringer ingelheim investigational site, porto alegre, brazil boehringer ingelheim investigational site, beijing, china boehringer ingelheim investigational site, changchun, china boehringer ingelheim investigational site, chengdu, china boehringer ingelheim investigational site, fuzhou, china boehringer ingelheim investigational site, guangzhou, china boehringer ingelheim investigational site, hangzhou, china boehringer ingelheim investigational site, nanjing, china boehringer ingelheim investigational site, shanghai, china boehringer ingelheim investigational site, helsinki, finland boehringer ingelheim investigational site, bayonne, france boehringer ingelheim investigational site, caen cedex 5, france boehringer ingelheim investigational site, dijon, france boehringer ingelheim investigational site, la tronche, france boehringer ingelheim investigational site, lyon cedex 08, france boehringer ingelheim investigational site, paris cedex 20, france boehringer ingelheim investigational site, paris, france boehringer ingelheim investigational site, saint-herblain cedex, france boehringer ingelheim investigational site, villejuif cedex, france boehringer ingelheim investigational site, berlin, germany boehringer ingelheim investigational site, essen, germany boehringer ingelheim investigational site, esslingen, germany boehringer ingelheim investigational site, gauting, germany boehringer ingelheim investigational site, hamburg, germany boehringer ingelheim investigational site, hannover, germany boehringer ingelheim investigational site, heidelberg, germany boehringer ingelheim investigational site, mainz, germany boehringer ingelheim investigational site, münster, germany boehringer ingelheim investigational site, budapest, hungary boehringer ingelheim investigational site, pecs, hungary boehringer ingelheim investigational site, törökbálint, hungary boehringer ingelheim investigational site, chennai, india boehringer ingelheim investigational site, jaipur, india boehringer ingelheim investigational site, maharashtra, india boehringer ingelheim investigational site, mumbai, india boehringer ingelheim investigational site, nashik, maharashtra, india boehringer ingelheim investigational site, kfar saba, israel boehringer ingelheim investigational site, petach tikva, israel boehringer ingelheim investigational site, tel hashomer, israel boehringer ingelheim investigational site, avellino, italy boehringer ingelheim investigational site, aviano (pn), italy boehringer ingelheim investigational site, bergamo, italy boehringer ingelheim investigational site, genova, italy boehringer ingelheim investigational site, milano, italy boehringer ingelheim investigational site, monza (mi), italy boehringer ingelheim investigational site, ravenna, italy boehringer ingelheim investigational site, roma, italy boehringer ingelheim investigational site, goyang, korea, republic of boehringer ingelheim investigational site, hwasun, korea, republic of boehringer ingelheim investigational site, seoul, korea, republic of boehringer ingelheim investigational site, distrito federal, mexico boehringer ingelheim investigational site, maastricht, netherlands boehringer ingelheim investigational site, nieuwegein, netherlands boehringer ingelheim investigational site, arequipa, peru boehringer ingelheim investigational site, la victoria, peru boehringer ingelheim investigational site, gdansk, poland boehringer ingelheim investigational site, olsztyn, poland boehringer ingelheim investigational site, otwock, poland boehringer ingelheim investigational site, warszawa, poland boehringer ingelheim investigational site, obninsk, russian federation boehringer ingelheim investigational site, st. petersburg, russian federation boehringer ingelheim investigational site, a coruña, spain boehringer ingelheim investigational site, barcelona, spain boehringer ingelheim investigational site, madrid, spain boehringer ingelheim investigational site, mataró, spain boehringer ingelheim investigational site, málaga, spain boehringer ingelheim investigational site, valencia, spain boehringer ingelheim investigational site, kaohsiung, taiwan boehringer ingelheim investigational site, taichung, taiwan boehringer ingelheim investigational site, tainan, taiwan boehringer ingelheim investigational site, taipei, taiwan boehringer ingelheim investigational site, taoyuan, taiwan boehringer ingelheim investigational site, dnipropetrovks, ukraine boehringer ingelheim investigational site, donetsk, ukraine boehringer ingelheim investigational site, kharkiv, ukraine boehringer ingelheim investigational site, kyiv, ukraine boehringer ingelheim investigational site, brighton, united kingdom boehringer ingelheim investigational site, dundee, united kingdom boehringer ingelheim investigational site, exeter, united kingdom boehringer ingelheim investigational site, london, united kingdom boehringer ingelheim investigational site, maidstone, united kingdom boehringer ingelheim investigational site, manchester, united kingdom boehringer ingelheim investigational site, sutton, surrey, united kingdom boehringer ingelheim investigational site, truro, cornwall, united kingdom']",,https://ClinicalTrials.gov/show/NCT01085136,
522,523,NCT01947608,expanded treatment protocol with ldk378 in alk(+) nsclc,,No longer available,No Results Available,non-small cell lung cancer (nsclc),drug: ldk378,,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",,,Industry,Expanded Access:Treatment IND/Protocol,,CLDK378A2402,,,,"September 20, 2013",,"November 3, 2020","[""ironwood cancer and research centers, chandler, arizona, united states banner mdacc, gilbert, arizona, united states western regional medical center, inc., goodyear, arizona, united states highlands oncology group, fayetteville, arkansas, united states city of hope national medical center, duarte, california, united states moores ucsd cancer center, la jolla, california, united states st joseph heritage healthcare, santa rosa, california, united states stanford university, stanford, california, united states eastern connecticut hematology & oncology associates, norwich, connecticut, united states advanced medical specialties, miami, florida, united states peachtree hematology/oncology consultants, atlanta, georgia, united states emory university school of medicine/winship cancer institute, atlanta, georgia, united states lurie children's hospital of chicago, chicago, illinois, united states indiana university health goshen center for cancer, goshen, indiana, united states johns hopkins bayview hospital, baltimore, maryland, united states maryland oncology hematology, p.a., rockville, maryland, united states massachusetts general hospital mass general, boston, massachusetts, united states karmanos cancer institute, detroit, michigan, united states jackson oncology associates, jackson, mississippi, united states nebraska cancer specialist/missouri valley cancer consortium, omaha, nebraska, united states hackensack university medical center, hackensack, new jersey, united states mercy clinic oklahoma communities mercy oncology, oklahoma city, oklahoma, united states fox chase cancer center, philadelphia, pennsylvania, united states tennessee cancer specialists, knoxville, tennessee, united states university of utah / huntsman cancer institute, salt lake city, utah, united states seattle cancer care alliance, seattle, washington, united states university of wisconsin, madison, wisconsin, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, buenos aires, caba, argentina novartis investigative site, córdoba, cordoba, argentina novartis investigative site, cali, valle del cauca, colombia novartis investigative site, monteria, colombia novartis investigative site, hong kong, hong kong novartis investigative site, kowloon, hong kong novartis investigative site, delhi, india novartis investigative site, amman, jordan novartis investigative site, bundang gu, gyeonggi do, korea, republic of novartis investigative site, gyeonggi do, korea, korea, republic of novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, seocho gu, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, ciudad de mexico, distrito federal, mexico novartis investigative site, mexico d f, distrito federal, mexico novartis investigative site, mexico, distrito federal, mexico novartis investigative site, taguig city, metro manila, philippines novartis investigative site, quezon city, philippines novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand""]",,https://ClinicalTrials.gov/show/NCT01947608,
523,524,NCT00943553,a randomized study of epigenetic priming using decitabine with front line induction chemotherapy compared with immediate induction chemotherapy in pediatric acute myelogenous leukemia (aml) subjects,,Withdrawn,No Results Available,acute myelogenous leukemia (aml),drug: decitabine induction chemotherapy|drug: induction chemotherapy,"primary endpoint (core component): complete remission (cr) rate as defined by international working group - 2003 criteria|secondary endpoint (core component): methylation of dna following decitabine therapy.|secondary endpoint (core component): time to platelet recovery (≥ 100,000/mm3) and time to neutrophil recovery (absolute neutrophil count [anc] ≥ 1000/mm3) following induction chemotherapy",eisai inc.,All,1 Year to 16 Years   (Child),Phase 2,0.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7373-G000-201,June 2010,August 2011,,"July 22, 2009",,"April 13, 2015","['new delhi, india']",,https://ClinicalTrials.gov/show/NCT00943553,blood
524,525,NCT01774019,preoperative biliary drainage in resectable pancreatic or periampullary cancer,,Completed,No Results Available,pancreatic carcinoma,device: wallflex™ biliary rx fully covered/uncovered stent system,"number of serious pre-operative, operative and post-operative adverse events to 120 days post randomization or to 30 days post surgery, whichever comes last|number of adverse events|time to surgery|curative intent surgery details pertaining to intraoperative assessment of resectability, surgical resection and reconstruction techniques.|amount of intraoperative blood loss and number of blood transfusions, duration of surgery|biliary obstructive symptoms assessment|improvement of liver function test (lft) levels as relative to baseline|stent placement success|stent removal success|number, type, reason, and timing of biliary re-interventions|number of hospital and icu admissions|duration of hospital and icu admissions",boston scientific corporation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,287.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,90914721|E7059,"February 20, 2013","December 13, 2021","December 13, 2021","January 23, 2013",,"February 7, 2022","[""standford university medical center, stanford, california, united states westmead hospital, westmead, new south wales, australia ulb erasme hospital, brussels, belgium beijing friendship hospital, beijing, china xijing hospital of digestive diseases fourth military medical university, xi'an, china hopital edouard herriot, lyon, france queen elizabeth hospital, kowloon, hong kong prince of wales hospital, the chinese university of hong kong, sha tin, hong kong asian institute of gastroenterology, hyderabad, india fondazione policlinico universitario agostino gemelli, rome, italy tokyo medical university, tokyo, japan""]",,https://ClinicalTrials.gov/show/NCT01774019,pancreat
525,526,NCT05215860,photographic evidence of oral precancerous lesions in current tobacco and areca nut users improves their quit rates,,Completed,No Results Available,precancerous conditions,behavioral: tobacco and areca nut cessation counselling with standard management for oral potentially malignant disorders|other: visual exposure to personal intraoral photographs of oral lesions at baseline and review,habit quit rates|size of oral lesions|oral burning sensation|colour of oral lesions|inter incisal mouth opening,"all india institute of medical sciences, new delhi",All,"Child, Adult, Older Adult",Not Applicable,200.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,IEC-616,"September 1, 2020","September 30, 2021","September 30, 2021","January 31, 2022",,"February 11, 2022","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT05215860,
526,527,NCT00102726,sb-497115 (oral thrombopoietin receptor agonist) versus placebo in adult cancer patients receiving chemotherapy,,Completed,No Results Available,thrombocytopaenia,drug: sb497115|other: placebo,"change in baseline platelet count from the first day of the second cycle of chemotherapy to the lowest count observed (nadir) during the cycle(21 days)|safety and tolerability, pharmacodynamics, changes in platelet count during cycle 1(21 days) and beyond cycle 2(21 days), population pk, and deliver intended doses of chemotherapy without thrombocytopenia related aes|safety and tolerability as indicated by physical exam, 12-lead ecgs, ophthalmologic examinations, clinical laboratory tests, clinical monitoring/observation, and ae reporting|pharmacodynamic parameters including platelet count, grade of thrombocytopenia,serum thrombopoietin, and platelet aggregation/activation during the first and second cycles of carboplatin/paclitaxel|change in platelet count from day 1 (baseline) to nadir during the first cycle and beyond the second cycle of carboplatin/paclitaxel|population pk of sb-497115, including clearance (cl/f), absorption rate constant(ka), and volume of distribution (v/f) with assessment of demographic covariates influencing sb-497115 pk|the relationship between pk of sb-497115 andrelevant safety and efficacy endpoints will be explored|dose intensity (percent of intended dose) of carboplatin/paclitaxel|carboplatin/paclitaxel-associated thrombocytopenia-related aes, as defined by nci|common terminology criteria for adverse events, ctcae v3.0, to include the number of platelet transfusions, bleeding events (hematoma), hemorrhage/bleeding,petechiae/purpura), clinical laboratory tests, and clinical observations",glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,183.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",497115/003,February 2005,February 2007,February 2007,"February 2, 2005",,"March 23, 2017","['gsk investigational site, tucson, arizona, united states gsk investigational site, jonesboro, arkansas, united states gsk investigational site, greenbrae, california, united states gsk investigational site, long beach, california, united states gsk investigational site, los angeles, california, united states gsk investigational site, los angeles, california, united states gsk investigational site, colorado springs, colorado, united states gsk investigational site, newark, delaware, united states gsk investigational site, boca raton, florida, united states gsk investigational site, hollywood, florida, united states gsk investigational site, tamarac, florida, united states gsk investigational site, savannah, georgia, united states gsk investigational site, metairie, louisiana, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, minneapolis, minnesota, united states gsk investigational site, hattiesburg, mississippi, united states gsk investigational site, tupelo, mississippi, united states gsk investigational site, las vegas, nevada, united states gsk investigational site, babylon, new york, united states gsk investigational site, new york, new york, united states gsk investigational site, durham, north carolina, united states gsk investigational site, akron, ohio, united states gsk investigational site, mayfield heights, ohio, united states gsk investigational site, toledo, ohio, united states gsk investigational site, bryan, texas, united states gsk investigational site, ogden, utah, united states gsk investigational site, salem, virginia, united states gsk investigational site, capital federal, buenos aires, argentina gsk investigational site, la plata, buenos aires, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, buenos aires, argentina gsk investigational site, buenos aires, argentina gsk investigational site, vienna, austria gsk investigational site, vienna, austria gsk investigational site, vienna, austria gsk investigational site, plovdiv, bulgaria gsk investigational site, sofia, bulgaria gsk investigational site, sofia, bulgaria gsk investigational site, sofia, bulgaria gsk investigational site, brno, czech republic gsk investigational site, praha 8, czech republic gsk investigational site, freiburg, baden-wuerttemberg, germany gsk investigational site, regensburg, bayern, germany gsk investigational site, marburg, hessen, germany gsk investigational site, hemer, nordrhein-westfalen, germany gsk investigational site, trier, rheinland-pfalz, germany gsk investigational site, grosshansdorf, schleswig-holstein, germany gsk investigational site, bad berka, thueringen, germany gsk investigational site, berlin, germany gsk investigational site, hamburg, germany gsk investigational site, budapest, hungary gsk investigational site, székesfehérvár, hungary gsk investigational site, bangalore, india gsk investigational site, hyderabad, andhra pradesh, india gsk investigational site, kolkatta, india gsk investigational site, vellore, india gsk investigational site, benevento, campania, italy gsk investigational site, roma, lazio, italy gsk investigational site, milano, lombardia, italy gsk investigational site, campobasso, molise, italy gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, merida, yucatán, mexico gsk investigational site, lima, peru gsk investigational site, olsztyn, poland gsk investigational site, poznan, poland gsk investigational site, poznan, poland gsk investigational site, szczecin, poland gsk investigational site, wroclaw, poland gsk investigational site, bucuresti, romania gsk investigational site, moscow region, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, badalona, spain gsk investigational site, barcelona, spain gsk investigational site, cordoba, spain gsk investigational site, madrid, spain gsk investigational site, santa cruz de tenerife, spain gsk investigational site, santander, spain gsk investigational site, sevilla, spain gsk investigational site, taipei, taiwan gsk investigational site, tau-yuan county, taiwan gsk investigational site, dnepropetrovsk, ukraine gsk investigational site, donetsk, ukraine gsk investigational site, kyiv, ukraine gsk investigational site, lvov, ukraine gsk investigational site, truro, cornwall, united kingdom gsk investigational site, chelmsford, essex, united kingdom gsk investigational site, colchester, united kingdom gsk investigational site, dundee, united kingdom gsk investigational site, leicester, united kingdom']",,https://ClinicalTrials.gov/show/NCT00102726,
527,528,NCT00683306,open label extension study with gefitinib (iressa™) for completing trial patients who may benefit from further treatment,,Approved for marketing,No Results Available,non small cell lung cancer (nsclc),drug: zd1839 (iressa),,astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",,,Industry,Expanded Access:Individual Patients,,D791AC00008,,,,"May 23, 2008",,"September 13, 2018","['research site, la plata, argentina research site, concord, australia research site, graz, austria research site, linz, austria research site, wien, austria research site, fortaleza, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sorocaba, brazil research site, plovdiv, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, veliko tarnovo, bulgaria research site, tallinn, estonia research site, tartu, estonia research site, budapest, hungary research site, deszk, hungary research site, mosdós, hungary research site, pécs, hungary research site, zalaegerszeg, hungary research site, hyderabad, india research site, karnataka, india research site, kolkata, india research site, mumbai, india research site, new delhi, india research site, pune, india research site, vellore, india research site, daugavpils, latvia research site, riga, latvia research site, kuala lumpur, malaysia research site, nilai, malaysia research site, penang, malaysia research site, penang, malaysia research site, penang, malaysia research site, durango, mexico research site, mexico distrito federal, mexico research site, monterrey, mexico research site, torreon, mexico research site, manila, philippines research site, pasig, philippines research site, quezon city, philippines research site, quezon city, philippines research site, bucharest, romania research site, iasi, romania research site, moscow, russian federation research site, moscow, russian federation research site, singapore, singapore research site, johannesburg, south africa research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, bangkok, thailand research site, chiang mai, thailand research site, ankara, turkey research site, istanbul, turkey research site, i̇stanbul, turkey']",,https://ClinicalTrials.gov/show/NCT00683306,
528,529,NCT05063682,the efficacy and safety of brain-targeting immune cells (egfrviii-car t cells) in treating patients with leptomeningeal disease from glioblastoma. administering patients egfrviii -car t cells may help to recognize and destroy brain tumor cells in patients,CARTREMENDOUS,"Active, not recruiting",No Results Available,"glioblastoma|glioblastoma multiforme|glioma, malignant",biological: egfrviii-specific hinge-optimized cd3 ζ-stimulatory/41bb-co-stimulatory chimeric antigen receptor autologous t-lymphocytes,"incidence of adverse events|overall survival|car (chimeric antigen receptor) t cell levels detected in tumor cyst fluid (tcf), peripheral blood (pb), and cerebrospinal fluid (csf)|endogenous t cell levels detected in tumor cyst fluid (tcf), peripheral blood (pb), and cerebrospinal fluid (csf)|cell phenotype detected in tumor cyst fluid (tcf), peripheral blood (pb), and cerebrospinal fluid (csf)|cytokine levels (procartaplex panel) in pb, tcf and csf|disease response|time to progression|car t and endogenous cells detected in tumor tissue|egfrvii (epidermal growth factor receptor) antigen expression levels in tumor tissue.","chembrain ltd|university of oulu|jyväskylä central hospital|apollo hospital, new delhi, india",All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6678EGFRvIII,"May 15, 2020",October 2023,October 2023,"October 1, 2021",,"October 1, 2021","['jyväskylä central hospital, jyväskylä, finland university of oulu, oulu, finland apollo hospital, new delhi, india']",,https://ClinicalTrials.gov/show/NCT05063682,skin astrocyt brain
529,530,NCT00532155,a study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer,VITAL,Completed,Has Results,carcinoma|non small cell lung,"drug: aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®)|drug: placebo|drug: docetaxel (taxotere®)|drug: dexamethasone (pre- and post-medication for docetaxel)",overall survival (os)|progression free survival (pfs)|overall response (or) rate as per response evaluation criteria in solid tumours (recist) criteria|health related quality of life (hrql) assessed by the lung cancer symptom scale (lcss)|health related quality of life (hrql) assessed by the average symptom burden index (asbi),sanofi|regeneron pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,913.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EFC10261|EudraCT 2007-000819-29,September 2007,January 2011,October 2011,"September 20, 2007","January 1, 2013","June 7, 2016","['sanofi-aventis administrative office, bridgewater, new jersey, united states sanofi-aventis administrative office, buenos aires, argentina sanofi-aventis australia & new zealand administrative office, macquarie park, new south wales, australia sanofi-aventis administrative office, wien, austria sanofi-aventis administrative office, sao paulo, brazil sanofi-aventis administrative office, sofia, bulgaria sanofi-aventis administrative office, laval, canada sanofi-aventis administrative office, santiago, chile sanofi-aventis administrative office, shangai, china sanofi-aventis administrative office, praha, czech republic sanofi-aventis administrative office, tallinn, estonia sanofi-aventis administrative office, helsinki, finland sanofi-aventis administrative office, paris, france sanofi-aventis administrative office, berlin, germany sanofi-aventis administrative office, athens, greece sanofi-aventis administrative office, causeway bay, hong kong sanofi-aventis administrative office, budapest, hungary sanofi-aventis administrative office, mumbai, india sanofi-aventis administrative office, milano, italy sanofi-aventis administrative office, seoul, korea, republic of sanofi-aventis administrative office, kuala lumpur, malaysia sanofi-aventis administrative office, gouda, netherlands sanofi-aventis administrative office, warszawa, poland sanofi-aventis administrative office, porto salvo, portugal sanofi-aventis administrative office, bucuresti, romania sanofi-aventis administrative office, moscow, russian federation sanofi-aventis administrative office, singapore, singapore sanofi-aventis administrative office, barcelona, spain sanofi-aventis administrative office, bromma, sweden sanofi-aventis administrative office, taipei, taiwan sanofi-aventis administraive office, istanbul, turkey sanofi-aventis admnistrative office, guildford surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00532155,
530,531,NCT00355355,a phase 3 study of talaporfin sodium and interstitial light emitting diodes treating hepatocellular carcinoma (hcc),,Completed,No Results Available,"carcinoma, hepatocellular|liver neoplasms",drug: talaporfin sodium|device: interstitial light emitting diodes|procedure: percutaneous placement of device in the liver|procedure: standard care,overall survival,light sciences oncology,All,"18 Years and older   (Adult, Older Adult)",Phase 3,208.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LSO-OL005,July 2006,September 2012,September 2012,"July 21, 2006",,"January 30, 2015","[""university hospital dubrava, zagreb, croatia tuen mun hospital, tuen mun, new territories, hong kong prince of wales hospital, dept. of clincal oncology, new territories, hong kong dr. kamakshi memorial hospital, chennai, india sms medical college, jaipur, india sanjay gandhi postgraduate institute of medical sciences, lucknow, india cancer clinic, nagpur, india shatabdi super specialty hospital, nasik, india pusan national university hospital, busan, korea, republic of seoul national university bundang hospital, gyeonggi-do, korea, republic of korea university medical center anam hospital, seoul, korea, republic of kyunghee univeristy medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of sinchon severance hospital, yonsei university, seoul, korea, republic of hospital universiti kebangsaan malaysia, kuala lumpur, malaysia university malaya medical centre, kuala lumpur, malaysia island hospital, penang, malaysia lam wah ee hospital, penang, malaysia cebu doctors university hospital, cebu city, philippines vicente sotto memorial medical center, cebu city, philippines santo tomas university hospital, manila, philippines the medical city, pasig city, philippines national kidney and transplant institute, quezon city, philippines st. luke's medical center, quezon city, philippines szpital uniwersytecki cmuj, krakow, poland centralny szpital kliniczny mswia, warsaw, poland clinical center of serbia, institute for gastroenterology and hepatology, belgrade, serbia clinical center of serbia, belgrade, serbia military medical academy, belgrade, serbia singapore general hospital, singapore, singapore national cancer centre, singapore, singapore karolinska university hospital, stockholm, sweden mahidol university, siriraj hospital, bangkok, thailand chiang mai university, chiang mai, thailand""]",,https://ClinicalTrials.gov/show/NCT00355355,liver
531,532,NCT03729453,intra-operative pancreatoscopy in patients with ipmn,,Recruiting,No Results Available,intraductal papillary mucinous neoplasm,device: spyglass,rate of detection of discontinuous (skip) lesions along the main pancreatic duct|technical success|adverse event evaluation|recurrence|comparison of visual and biopsy diagnosis|inter-observer correspondence of visual impression of ipmn,boston scientific corporation,All,"18 Years and older   (Adult, Older Adult)",,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,E7107,"March 20, 2019",June 2022,March 2027,"November 2, 2018",,"April 15, 2022","['university of colorado hospital, denver, colorado, united states indiana university health, indianapolis, indiana, united states johns hopkins hospital university, baltimore, maryland, united states the first affiliated hospital of nanjing medical university, nanjing, china asian institute of gastroenterology, hyderabad, india kansai medical university, hirakata city, osaka, japan academic medical center, amsterdam, netherlands university hospital of umea, umea, sweden']",,https://ClinicalTrials.gov/show/NCT03729453,
532,533,NCT00558636,a trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (bay43-9006) in chemonaive patients with stage iiib-iv non-small cell lung cancer (nsclc),,Terminated,Has Results,"carcinoma, non-small-cell lung",drug: sorafenib + paclitaxel + carboplatin|drug: placebo + paclitaxel + carboplatin,progression free survival|overall survival (os)|best tumor response (number of responses per category) according to response evaluation criteria in solid tumors (recist)|duration of response|change from baseline of lung cancer symptoms (lcs) score assessed at each treatment cycle (21 days per cycle) starting with cycle 2|change from baseline of health-related quality of life (hrqol) score assessed at treatment cycle 3 and cycle 5|change from baseline of health-related quality of life (hrqol) score assessed at treatment cycle 7,bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,91.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",12621,September 2007,May 2008,May 2008,"November 15, 2007","October 20, 2010","December 27, 2013","['guangzhou, guangdong, china guangzhou, guangdong, china shatin, hong kong, china nanjing, jiangsu, china hangzhou, zhejiang, china hangzhou, zhejiang, china beijing, china beijing, china beijing, china chongqing, china shanghai, china shanghai, china mumbai, maharashtra, india new- delhi, india gyeonggi-do, korea, republic of seoul, korea, republic of singapore, singapore singapore, singapore changhua, taiwan taipei, taiwan bangkok, thailand bangkok, thailand']",,https://ClinicalTrials.gov/show/NCT00558636,
533,534,NCT02383576,retrospective data collection: post study treatment anticancer therapy from imelda mo22223,,Completed,Has Results,breast cancer,other: no intervention,percentage of participants who prematurely withdrawn from maintenance therapy|percentage of participants who received further anti-cancer therapies after discontinuation of study treatment|time from last maintenance study medication start to start of further anti-cancer therapy|progression free survival (pfs)|overall survival,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",,185.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,MO29587,"April 30, 2015","January 22, 2016","January 22, 2016","March 9, 2015","April 13, 2018","April 13, 2018","['crio - centro regional integrado de oncologia, fortaleza, ce, brazil instituto nacional de cancer - inca; oncologia, rio de janeiro, rj, brazil hospital de caridade de ijui; oncologia, ijui, rs, brazil hospital das clinicas - ufrgs, porto alegre, rs, brazil hospital amaral carvalho, jau, sp, brazil faculdade de medicina do abc - fmabc; oncologia e hematologia, santo andre, sp, brazil instituto do cancer do estado de sao paulo - icesp, sao paulo, sp, brazil hospital santa marcelina;oncologia, sao paulo, sp, brazil hopital jean minjoz; oncologie, besancon, france chg de chartres hopital louis pasteur; pneumologie, chartres, france clinique sainte marguerite; oncologie medicale, hyeres, france centre bourgogne, service de radiotherapie, lille, france institut curie; oncologie medicale, paris, france hopital tenon; cancerologie medicale, paris, france clinique francheville; radiotherapie, perigueux, france institut d oncologie medical, strasbourg, france rajiv gandhi cancer inst.&research center; medical oncology, new delhi, delhi, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india università federico ii; dip. di endocrinologia ed oncologia molecolare e clinica, napoli, campania, italy uni degli studi di genova ; clinica di medicina interna ad indirizzo oncologico, genova, liguria, italy ospedale antonio perrino; oncologia medica, brindisi, puglia, italy hospital virgen de los lirios; servicio de oncologia, alcoy, alicante, spain corporacio sanitaria parc tauli; servicio de oncologia, sabadell, barcelona, spain complejo hospitalario la mancha centro;servicio oncologia, alcazar de s. juan, ciudad real, spain hospital de cruces; servicio de oncologia, barakaldo, vizcaya, spain complejo hospitalario de jaen-hospital universitario medico quirurgico; servicio de oncologia, jaen, spain hospital clinico universitario virgen de la victoria; servicio de oncologia, malaga, spain complejo hospitalario de toledo- h. virgen de la salud; servicio de oncologia, toledo, spain hospital universitario la fe; servicio de oncologia, valencia, spain gazi uni medical faculty hospital; oncology dept, ankara, turkey akdeniz university medical faculty; medical oncology department, antalya, turkey hacettepe uni medical faculty hospital; oncology dept, sıhhiye, ankara, turkey']",,https://ClinicalTrials.gov/show/NCT02383576,breast
534,535,NCT03052608,a study of lorlatinib versus crizotinib in first line treatment of patients with alk-positive nsclc,,"Active, not recruiting",Has Results,"carcinoma, non-small-cell lung",drug: lorlatinib|drug: crizotinib,"progression-free survival (pfs) based on blinded independent central review (bicr) assessment|overall survival (os)|progression-free survival (pfs) based on investigator's assessment|objective response rate (orr) - percentage of participants with objective response (or) based on bicr assessment|objective response rate (orr) - percentage of participants with objective response (or) based on investigator's assessment|intracranial objective response rate (ic-orr) - percentage of participants with intracranial objective response (ic-or) based on bicr assessment|intracranial time to progression (ic-ttp) based on bicr assessment|duration of response (dr) based on bicr assessment|intracranial duration of response (ic-dr) based on bicr assessment|time to tumor response (ttr) based on bicr assessment|intracranial time to tumor response (ic-ttr) based on bicr assessment|pfs2 based on investigator's assessment|number of participants with treatment-emergent adverse events (aes; all-causality and treatment-related)|number of participants with changes in hematology laboratory parameters from baseline maximum nci-ctcae grade lower than 3 to postbaseline maximum grade 3 or grade 4|number of participants with changes in chemistry laboratory parameters from baseline maximum nci-ctcae grade lower than 3 to postbaseline maximum grade 3 or grade 4|number of participants with changes in lipid laboratory parameters from baseline maximum nci-ctcae grade lower than 3 to postbaseline maximum grade 3 or grade 4|number of participant with vital signs and body weight data meeting pre-defined criteria|number of participant with maximum increase from baseline in electrocardiogram (ecg) data meeting pre-defined criteria|number of participants with maximum decrease from baseline greater than or equal to 20 points in left ventricular ejection fraction (lvef) percentage|change from baseline in total scores of beck depression inventory (bdi)-ii (mood assessment) across time|number of participants with suicidal ideation and suicidal behavior across time|change from baseline in global quality of life (qol), functional scales and symptoms scales as assessed by the european organization for the research and treatment of cancer quality of life questionnaire core 30 (eortc-qlq-c30) during overall treatment|change from baseline in lung cancer symptoms as assessed by the eortc quality of life questionnaire-lung cancer 13 (qlq- lc13) during overall treatment|change from baseline in health status as assessed by euroqol 5 dimension 5 level (eq-5d-5l) - visual analogue scale (vas) across time|change from baseline in health status as assessed by euroqol 5 dimension 5 level (eq-5d-5l) - index across time|time to deterioration (ttd) in participant reported pain in chest, dyspnea, or cough from qlq-lc13|number of participant with alk domain mutation in plasma circulating nucleic acid (cna) analysis at screening, cycle 2 day 1 and cycle 7 day 1|number of participant with alk fusion variant in plasma circulating nucleic acid (cna) analysis at screening, cycle 2 day 1 and cycle 7 day 1",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,296.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B7461006|2016-003315-35,"April 27, 2017","March 20, 2020","December 31, 2028","February 14, 2017","April 1, 2021","April 29, 2022","['florida cancer specialists, altamonte springs, florida, united states florida cancer specialists, brandon, florida, united states florida cancer specialists, clearwater, florida, united states florida cancer specialists, gainesville, florida, united states florida cancer specialists, largo, florida, united states florida cancer specialists, lecanto, florida, united states florida cancer specialists, orange city, florida, united states florida cancer specialists, orlando, florida, united states florida cancer specialists, saint petersburg, florida, united states florida cancer specialists, spring hill, florida, united states florida cancer specialists, tampa, florida, united states florida cancer specialists, tavares, florida, united states florida cancer specialists, the villages, florida, united states florida cancer specialists, winter park, florida, united states massachusetts eye and ear infirmary, boston, massachusetts, united states massachusetts general hospital, boston, massachusetts, united states ophthalmic consultants of boston inc, boston, massachusetts, united states the william p. beetham eye institute, joslin diabetes center, boston, massachusetts, united states university of rochester cancer center pharmacy, rochester, new york, united states university of rochester medical center, rochester, new york, united states tennessee oncology, pllc, dickson, tennessee, united states tennessee oncology, pllc, franklin, tennessee, united states tennessee oncology, pllc, gallatin, tennessee, united states tennessee oncology, pllc, hermitage, tennessee, united states tennessee oncology, pllc, lebanon, tennessee, united states tennessee oncology, pllc, murfreesboro, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states the sarah cannon research institute., nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, nashville, tennessee, united states tennessee oncology, pllc, shelbyville, tennessee, united states tennessee oncology, pllc, smyrna, tennessee, united states university of washington medical center, seattle, washington, united states centro de investigacion pergamino sa, pergamino, buenos aires, argentina centro medico austral, caba, argentina bendigo day surgery collection centre and laboratory, bendigo, victoria, australia bendigo medical imaging, bendigo hospital, bendigo, victoria, australia melbourne pathology, bendigo, victoria, australia peter maccallum cancer centre, melbourne, victoria, australia grand hopital de charleroi - site notre dame, charleroi, belgium princess margaret cancer centre, toronto, ontario, canada mcgill university health centre, montreal, quebec, canada the affiliated hospital of military medical sciences, beijing, beijing, china jilin provincial cancer hospital, changchun, jilin, china shanghai chest hospital, shanghai, shanghai, china department of respiratory,the first affiliated hospital of college of medicine, zhejiang university, hangzhou, zhejiang, china the second affiliated hospital of zhejiang university school of medicine, hangzhou, zhejiang, china zhejiang cancer hospital, hangzhou, zhejiang, china beijing cancer hospital, beijing, china guangdong general hospital, guangzhou, china fakultni nemocnice olomouc, klinika plicnich nemoci a tuberkulozy, olomouc, czechia vseobecna fakultni nemocnice v praze, praha 2, czechia hopital haut-léveque-centre françois magendie, pessac, aquitaine, france hopital de chevilly larue, chevilly larue, france centre hospitalier du mans, le mans, france institut paoli-calmettes, marseille cedex 09, france département d\'imagerie médicale, marseille cedex 20, france hôpital nord, marseille cedex 20, france service ophtalmologie, marseille cedex 20, france groupe hospitalier bichat claude bernard, ap-hp, paris, france chu de rennes hopital pontchaillou, rennes cedex 9, france chu de rennes, hopital pontchaillou, rennes cedex 9, france hopital foch, suresnes, france hopital larrey, toulouse cedex 9, france hopital pierre paul riquet, toulouse cedex 9, france hôpital larrey, toulouse cedex 9, france department d\'imagerie medicale, villejuif, france institut gustave roussy, villejuif, france uberortliche radiologische gemeinschaftspraxis dr. med. marc amler, dresden, germany technische universitat dresden , medizinische fakultat carl gustav carus, dresden, germany thoraxklinik heidelberg ggmbh, heidelberg, germany universitatsklinikum heidelberg, heidelberg, germany universitätsklinikum des saarlandes, innere medizin v, homburg - saar, germany universitätsklinikum des saarlandes, homburg - saar, germany universitatsklinikum regensburg, institut fur rontgendiagnostik, regensburg, germany universitatsklinikum regensburg, klinik und poliklinik fur innere medizin ii, regensburg, germany the university of hong kong, department of clinical oncology, hong kong, hong kong the university of hong kong, department of medicine, hong kong, hong kong tuen mun hospital, hong kong, hong kong artemis hospital, gurugram, haryana, india manipal hospital, bangalore, karnataka, india srinivasam cancer care multispeciality hospitals india pvt ltd, bangalore, karnataka, india sahyadri clinical research and development centre, pune, maharashtra, india sahyadri specialty hospital, pune, maharashtra, india aou policlinico vittorio emanuele-p.o.g. rodolico, catania, ct, italy asst monza - a.o. san gerardo, monza, mb, italy irccs ospedale san raffaele, milano, mi, italy fondazione irccs istituto nazionale dei tumori, milano, mi, italy istituto europeo di oncologia, milano, mi, italy istituto clinico humanitas, rozzano, mi, italy azienda ospedaliera di perugia - ospedale s. m. misericordia, perugia, pg, italy centro di riferimento oncologico-irccs, pordenone, pn, italy azienda ospedaliero-universitaria di parma, parma, pr, italy istituto nazionale tumori regina elena, roma, rm, italy az.osp.san camillo-forlanini, roma, rm, italy azienda ospedaliera dei colli ospedale monaldi, napoli, italy istituto nazionale tumori di napoli, napoli, italy ausl della romagna- ravenna, ravenna, italy aichi cancer center central hospital, nagoya, aichi, japan nagoya university hospital, nagoya, aichi, japan national hospital organization shikoku cancer center, matsuyama, ehime, japan kurume university hospital, kurume, fukuoka, japan national hospital organization hokkaido cancer center, sapporo, hokkaido, japan kanazawa university hospital, kanazawa, ishikawa, japan kanagawa cancer center, yokohama, kanagawa, japan sendai kousei hospital, sendai, miyagi, japan osaka international cancer institute, osaka-shi, osaka, japan kindai university hospital, osakasayama, osaka, japan shizuoka cancer center, sunto-gun, shizuoka, japan national cancer center hospital, chuo-ku, tokyo, japan national hospital organization, yamaguchi-ube medical center, ube, yamaguchi, japan the cancer institute hospital of jfcr, koto-ku, tokyo, japan niigata cancer center hospital, niigata, japan okayama university hospital, okayama, japan osaka city general hospital, osaka, japan tokushima university hospital, tokushima, japan wakayama medical university department of pulmonary medicine and oncology, wakayama, japan the catholic university of korea, st. vincents hospital, suwon, gyeonggi-do, korea, republic of seoul national university hospital, seoul, korea, republic of division of medical oncology, severance hospital, yonsei university health system, seoul, korea, republic of asan medical center, seoul, korea, republic of ulsan university hospital, ulsan, korea, republic of médicos especialistas en cancer s.c. / san peregrino., aguascalientes, mexico instituto nacional de cancerologia, distrito federal, mexico instituto nacional de enfermedades respiratorias ismael cosio villegas, distrito federal, mexico university medical center groningen, groningen, netherlands klinika onkologii i radioterapii uniwersyteckie centrum kliniczne, gdansk, poland med-polonia sp. z o.o., poznan, poland centrum medyczne dom lekarski s.a., szczecin, poland narodowy instytut onkologii im. marii sklodowskiej-curie-panstwowy instytut badawczy, warszawa, poland rbhi kursk regional clinical oncology dispensary, kislino, ryshkovsky rural council, kursk region, russian federation budgetary healthcare institution omsk region ""clinical oncological dispensary"", omsk, omsk region, russian federation lec at sbih ""saint-petersburg clinical research practical center of specialized types of, pesochniy poselok, saint-petersburg, russian federation private medical institution ""euromedservice"", pushkin, saint-petersburg, russian federation rbhi kursk regional clinical oncology dispensary, kursk, russian federation fsbi ""n.n.blokhin medical research center of oncology"", moscow, russian federation national university hospital, singapore, singapore raffles hospital, singapore, singapore institut catala d\'oncologia l\'hospitalet, l\'hospitalet de llobregat, barcelona, spain hospital universitario insular de gran canaria, las palmas de gran canaria, canarias, spain hospital universitario puerta de hierro majadahonda, majadahonda, madrid, spain complejo hospitalario de navarra, pamplona, navarra, spain hospital teresa herrera c.h.u.a.c., a coruna, spain hospital de la santa creu i sant pau, barcelona, spain hospital universitari vall d\'hebron, barcelona, spain hospital clinic i provincial de barcelona, barcelona, spain hospital de la santa creu i sant pau, barcelona, spain institut catala d\'oncologia girona, girona, spain hospital universitario ramon y cajal, madrid, spain hospital clinico san carlos, madrid, spain hospital universitario fundacion jimenez diaz, madrid, spain hospital universitario la fe, valencia, spain national taiwan university hospital, taipei, taiwan roc, taiwan chang gung memorial hospital - kaohsiung branch, kaohsiung, taiwan chung shan medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan taipei veterans general hospital, taipei, taiwan cukurova university medical faculty, adana, turkey istanbul university oncology institute, istanbul, turkey marmara univ pendik training and research hospital, istanbul, turkey ege university medical faculty, izmir, turkey the ipswich hospital nhs trust, ipswich, suffolk, united kingdom heart of england nhs foundation trust, birmingham heartlands hospital, birmingham, west midlands, united kingdom the christie nhs foundation trust, manchester, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/08/nct03052608/prot_001.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/08/nct03052608/sap_000.pdf",https://ClinicalTrials.gov/show/NCT03052608,
535,536,NCT04111029,liquid biopsy in hepatocellular carcinoma,HCCGenePanel,Recruiting,No Results Available,hepatic carcinoma malignant primary non-resectable,diagnostic test: cell free dna,comparison of exome sequencing of primary tumor tissue and cell-free dna from plasma samples|serial quantification of ctdna in plasma samples by means of real-time pcr post treatment|time to first recurrence (local or distant) diagnosed on follow up dynamic imaging.|mortality,postgraduate institute of medical education and research,All,"18 Years to 70 Years   (Adult, Older Adult)",,30.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,INT/HEP/1078,"January 16, 2020",December 2021,December 2021,"October 1, 2019",,"September 28, 2021","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT04111029,liver skin
536,537,NCT00565448,docetaxel in combination with cisplatin-5-fluorouracil for the induction treatment of nasopharyngeal carcinoma in children and adolescents,,Completed,Has Results,nasopharyngeal neoplasms|carcinoma,drug: docetaxel|drug: cisplatin|drug: 5-fluorouracil,number of participants with complete response (cr)|docetaxel area under the plasma concentration-time curve (auc) in the docetaxel/cisplatin/5-fu group|overall response (or)|overall survival (os) rate,sanofi,All,"1 Month to 21 Years   (Child, Adult)",Phase 2,75.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC10339|2007-001211-33,November 2007,March 2009,January 2012,"November 30, 2007","March 25, 2010","July 30, 2015","['investigational site number 012001, alger, algeria investigational site number 076002, rio de janeiro, brazil investigational site number 076001, sao paulo, brazil investigational site number 156005, fuzhou, china investigational site number 250001, villejuif cedex, france investigational site number 356003, ahmedabad, india investigational site number 356004, kolkata, india investigational site number 356002, thiruvananthapuram, india investigational site number 356001, vellore, india investigational site number 360001, jakarta, indonesia investigational site number 380001, milano, italy investigational site number 410001, seoul, korea, republic of investigational site number 410003, seoul, korea, republic of investigational site number 410002, seoul, korea, republic of investigational site number 484001, villahermosa, mexico investigational site number 504001, casablanca, morocco investigational site number 504002, rabat, morocco investigational site number 504003, rabat, morocco investigational site number 608002, quezon city, philippines investigational site number 764001, bangkok, thailand investigational site number 764002, chiang mai, thailand investigational site number 788002, sousse, tunisia investigational site number 788003, tunis, tunisia investigational site number 792003, abacioglu, turkey investigational site number 792001, ankara, turkey investigational site number 792002, istanbul, turkey']",,https://ClinicalTrials.gov/show/NCT00565448,brain
537,538,NCT02213263,"a study of pf-05280586 (rituximab-pfizer) or mabthera® (rituximab-eu) for the first-line treatment of patients with cd20-positive, low tumor burden, follicular lymphoma (reflections b328-06)",,Completed,Has Results,follicular lymphoma,biological: pf-05280586|biological: mabthera®,overall response rate (orr): percentage of participants with overall response (or) at week 26|number of participants with treatment-emergent adverse events (aes) and serious adverse events (saes)|number of participants with treatment related treatment-emergent adverse events (aes) and serious adverse events (saes)|number of participants with grade 3 or higher treatment-emergent adverse events (aes) as graded by national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.03|number of participants with grade 3 or higher treatment-related treatment-emergent adverse events (aes) as graded by national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.03|number of participants with clinically significant laboratory abnormalities|time to treatment failure (ttf)|progression-free survival (pfs)|percentage of participants with complete remission (cr) at week 26|duration of response (dor)|overall survival|maximum observed serum concentration (cmax) of pf-05280586 and rituximab-eu|minimum observed (trough) serum concentration (ctrough) of pf-05280586 and rituximab-eu|cluster of differentiation (cd) 19-positive b-cell counts|number of participants with positive anti-drug antibodies (adas) and neutralizing antibodies (nabs)|number of participants reporting immune-based adverse effects,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,394.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",B3281006|2014-000132-41|REFLECTIONS,"September 30, 2014","October 23, 2017","April 19, 2018","August 11, 2014","October 30, 2018","June 20, 2019","['pacific cancer medical center, inc., anaheim, california, united states the oncology institute of hope and innovation, anaheim, california, united states compassionate care research group, inc., at compassionate cancer care medical group, inc., corona, california, united states the oncology institute of hope and innovation, downey, california, united states compassionate care research group, inc., at compassionate cancer care medical group, inc., fountain valley, california, united states global cancer research institute (gcri), inc, gilroy, california, united states saint louise regional hospital radiology department (radiology only), gilroy, california, united states south valley imaging center (imaging only), gilroy, california, united states los angeles hematology oncology medical group, glendale, california, united states the oncology institute of hope and innovation, glendale, california, united states los angeles hematology oncology medical group, glendale, california, united states the oncology institute of hope and innovation, long beach, california, united states los angeles hematology oncology medical group, los angeles, california, united states los angeles hematology oncology medical group, los angeles, california, united states the oncology institute of hope and innovation, lynwood, california, united states the oncology institute of hope and innovation, montebello, california, united states comprehensive cancer center at desert regional medical center, palm springs, california, united states torrance health association dba, torrance memorial physician, network/cancer care associates, redondo beach, california, united states compassionate care research group, inc., at compassionate cancer care medical group, inc., riverside, california, united states global cancer research institute, inc., san jose, california, united states o\'connor hospital, san jose, california, united states pet imaging of san jose (imaging only), san jose, california, united states the oncology institute of hope and innovation, santa ana, california, united states torrance memorial medical center, torrance, california, united states the oncology institute of hope and innovation, whittier, california, united states innovative clinical research institute (icri), whittier, california, united states rocky mountain cancer centers, aurora, colorado, united states rocky mountain cancer centers, boulder, colorado, united states rocky mountain cancer centers, denver, colorado, united states rocky mountain cancer center-lakewood (laboratory), lakewood, colorado, united states rocky mountain cancer centers (rmcc) - lakewood - st anthony, lakewood, colorado, united states rocky mountain cancer centers, lone tree, colorado, united states rocky mountain cancer center pueblo, pueblo, colorado, united states john d. archbold memorial hospital, thomasville, georgia, united states lewis hall singletary oncology center at john d. archbold memorial hospital, thomasville, georgia, united states northwestern medicine west region, dekalb, illinois, united states cancer center,northwestern medicine, west region, geneva, illinois, united states cancer center of kansas, chanute, kansas, united states cancer center of kansas, dodge city, kansas, united states cancer center of kansas, el dorado, kansas, united states cancer center of kansas, independence, kansas, united states cancer center of kansas, kingman, kansas, united states cancer center of kansas, liberal, kansas, united states cancer center of kansas, mcpherson, kansas, united states cancer center of kansas, newton, kansas, united states the university of kansas cancer center, overland park, kansas, united states cancer center of kansas, parsons, kansas, united states cancer center of kansas, salina, kansas, united states cancer center of kansas, wellington, kansas, united states cancer center of kansas, wichita, kansas, united states cancer center of kansas, wichita, kansas, united states cancer center of kansas, winfield, kansas, united states pet/ct facility seton imaging center, baltimore, maryland, united states saint agnes hospital, baltimore, maryland, united states rcca md llc, bethesda, maryland, united states holy cross hospital resource center, silver spring, maryland, united states holy cross hospital hospital pharmacy, silver spring, maryland, united states holy cross hospital, silver spring, maryland, united states maryland oncology hematology, p.a., wheaton, maryland, united states the university of kansas cancer center, kansas city, missouri, united states the university of kansas cancer center, kansas city, missouri, united states the university of kansas cancer center, lee\'s summit, missouri, united states saint francis medical center, saint francis cancer treatment center, grand island, nebraska, united states saint francis medical center, grand island, nebraska, united states saint francis medical center, saint francis cancer treatment center, hastings, nebraska, united states comprehensive cancer centers of nevada, henderson, nevada, united states comprehensive cancer centers of nevada, henderson, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states comprehensive cancer centers of nevada, las vegas, nevada, united states brody school of medicine at east carolina university, greenville, north carolina, united states vidant medical center pharmacy, greenville, north carolina, united states vidant medical center, greenville, north carolina, united states toledo clinic cancer center - maumee, maumee, ohio, united states toledo clinic cancer center - toledo, toledo, ohio, united states toledo clinic, inc., toledo, ohio, united states willamette valley cancer institute and research center, eugene, oregon, united states university of tennessee medical center, knoxville, tennessee, united states san antonio military medical center- department of pharmacy, fort sam houston, texas, united states san antonio military medical center- department of radiology, fort sam houston, texas, united states san antonio military medical center, fort sam houston, texas, united states investigational products center (i pc), fort worth, texas, united states investigational products center (ipc), fort worth, texas, united states millennium oncology, houston, texas, united states us oncology investigational products center (ipc), irving, texas, united states millennium oncology, kingwood, texas, united states texas oncology - longview cancer center, longview, texas, united states millennium oncology, shenandoah, texas, united states millennium oncology, the woodlands, texas, united states texas oncology-tyler, tyler, texas, united states yakima valley memorial hospital/north star lodge cancer center, yakima, washington, united states krankenhaus der barmherzigen schwestern linz, linz, austria kepler universitaetsklinikum gmbh, linz, austria kepler universitaetsklinikum gmbh, linz, austria si \'republican research and practice centre of oncology and medical radiology n.a. n.n. alexandrov\', lesnoy, minsk region, belarus si \'republican research and practice centre of oncology and medical radiology n.a. n.n. alexandrov\', lesnoy, minsk region, belarus healthcare institution ""brest regional oncologic dispensary"", brest, belarus healthcare institution \'minsk city clinical oncology dispensary\', minsk, belarus si republican research and practice centre of oncology and medical radiology n.a n.n alexandrov, republic of belarus, belarus hopital erasme, brussels, belgium nuclear medicine department, brussels, belgium grand hopital de charleroi-site notre-dame, charleroi, belgium pet/ct facility: grand hopital de charleroi (ghdc) - site notre-dame, charleroi, belgium pharmacy department: grand hopital de charleroi (ghdc) - site notre-dame, charleroi, belgium pharmacy department, centre hospitalier de jolimont - lobbes, la louviere (haine-saint paul), belgium centre hospitalier de jolimont - lobbes, la louviere (haine-saint-paul), belgium radiology department, la louviere (haine-saint-paul), belgium c.h.u. ambroise pare, mons, belgium pharmacy department, chu ambroise pare, mons, belgium hospital santa izabel - setor de bioimagem, salvador, bahia, brazil hospital santa izabel / santa casa de misericordia da bahia, salvador, bahia, brazil clinica multimagem, goiania, go, brazil hospital das clinicas da universidade federal de goias \\ centro de pesquisa clinica, goiania, go, brazil centro de imagens da faculdade de medicina - inct medicina nuclear - pet/ct, belo horizonte, mg, brazil unidade funcional apoio diagnostico e terapeutica por imagem do hc/ufmg - ct scan, belo horizonte, mg, brazil hospital das clinicas universidade federal de minas gerais, belo horizonte, minas gerais, brazil central de misturas intravenosas do hospital de clinicas de porto alegre, porto alegre, rio grande do sul, brazil hospital de clinicas de porto alegre - centro de pesquisa clinica, porto alegre, rio grande do sul, brazil hospital de clinicas de porto alegre, porto alegre, rio grande do sul, brazil servico de radiologia do hospital de clinicas de porto alegre, porto alegre, rio grande do sul, brazil cdi - centro de diagnostico por imagem do hospital sao lucas da pucrs, porto alegre, rs, brazil inscer - instituto do cerebro do rio grande do sul - pucrs, porto alegre, rs, brazil uniao brasileira de educacao e assistencia (ubea) - hospital sao lucas da pucrs -, porto alegre, rs, brazil fundacao amaral carvalho / fundacao dr. amaral carvalho, jau, sao paulo, brazil fundacao amaral carvalho / fundacao dr. amaral carvalho, jau, sao paulo, brazil unidade de quimioterapia, jaú, sao paulo, brazil casa da esperanca, santo andre, sao paulo, brazil tecnolab, sao bernardo do campo, sao paulo, brazil cemedi, campinas, sp, brazil instituto radium, campinas, sp, brazil caep - centro avancado de estudos e pesquisas ltda, campinas, sp, brazil hospital e maternidade madre theodora ltda, campinas, sp, brazil cenni oncologia, campinas, sp, brazil fundacao do abc - fmabc/ faculdade de medicina abc ( cepho - centro de estudos e pesquisas de, santo andre, sp, brazil hospital bandeirantes, sao paulo, sp, brazil hospital das clinicas da faculdade de medicina da usp / fundacao faculdade de medicina mec mpas, sao paulo, sp, brazil casa de saude santa marcelina (centro de pesquisa santa marcelina), sao paulo, sp, brazil iep são lucas (pharmacy), são paulo, sp, brazil iep sao lucas - instituto de ensino e pesquisa sao lucas / hemomed - instituto de oncologia e, sao paulo, brazil fleury, sao paulo, brazil university hospital center zagreb, department of nuclear medicine and radiation protection, zagreb, croatia university hospital center zagreb, department of pathology and cytology, zagreb, croatia university hospital center zagreb, department of radiology, zagreb, croatia university hospital centre ""sestre milosrdnice"", zagreb, croatia university hospital centre zagreb, zagreb, croatia chu marseille hopital de la conception, marseille, marseille cedex 05, france ch de mulhouse, hopital emile muller, mulhouse, mulhouse cedex, france hopital duchenne chu - boulogne sur mer, boulogne sur mer, nap, france hopital duchenne chu - boulogne sur mer, boulogne sur mer, france centre hospitalier de bourg en bresse, bourg en bresse cedex, france hopital morvan-chu brest- service hematologie clinique, brest, france centre hospitalier universitaire cote de nacre, caen, france centre hospitalier du mans, le mans, france clinique de la sauvegarde, lyon, france ""ltd """"m. zodelava\'s hematology centre"""""", tbilisi, georgia ltd ""research institute of clinical medicine"", tbilisi, georgia high technology medical center, university clinic, tbilisi, georgia charite - universitaetsmedizin berlin, berlin, germany charite - universitatsmedizin berlin - campus benjamin franklin, berlin, germany charite - universitaetsmedizin berlin, campus virchow-klinikum, berlin, germany charite - universitatsmedizin berlin, campus virchow-klinikum, berlin, germany charite - universitatsmedizin berlin, berlin, germany klinikum chemnitz ggmbh - institut fuer interventionelle radiologie und neuroradiologie, chemnitz, germany klinikum chemnitz ggmbh, chemnitz, germany klinikum chemnitz ggmbh - klinik fuer nuklearmedizin, chemnitz, germany klinikum chemnitz ggmbh - zentralapotheke, chemnitz, germany universitaetsklinikum essen (aoer), essen, germany universitatsklinikum essen (aor), essen, germany dokusan gesellschaft fuer medizinische studien mbh & co. kg, herne, germany apotheke des st. anna hospital, herne, germany evk eickel, herne, germany praxis im koeln triangle, koeln, germany gemeinschaftspraxis fuer diagnostische radiologie und nuklearmedizin, mutlangen, germany kliniken ostalb, stauferklinikum schwaebisch gmuend, zentrum fuer innere medizin, mutlangen, germany stauferklinikum schwaebisch gmuend, apotheke, mutlangen, germany universitaetsmedizin rostock, rostock, germany klinikum stuttgart, klinik fuer nuklearmedizin, stuttgart, germany vinzenz von paul kliniken ggmbh, stuttgart, germany radiologie rhein-sieg, troisdorf, germany ueberoertliche berufsausuebungsgemeinschaft drs. med. helmut forstbauer, troisdorf, germany zentralapotheke, troisdorf, germany gen. hosp. of athens ""evangelismos - eye hosp.- polikliniki"", athens, greece gen. hosp. of athens ""evangelismos-eye hosp. - polikliniki"", athens, greece gen. hosp. of athens ""evangelismos-eye hosp.-polikliniki"", athens, greece gen.hosp.of athens ""evangelismos-eye hosp.-polikiliniki"", athens, greece general hospital of athens ""evangelismos - eye hosp. - polikliniki"", athens, greece bioiatriki s.a., athens, greece bioiatriki, athens, greece general hospital of athens \'laiko\', athens, greece """"""attikon"""" gen. univ. hosp"", athens, greece ""attikon\'\' gen. univ. hosp., chaidari, athens, greece magnitiki patron, patras, greece university general hospital of patras, patras, greece super scan imaging centre, surat, gujarat, india pathology department, unique hospital multispeciality & research institute, surat, gujarat, india zircon- bic imaging centre, surat, gujarat, india mangalore institute of oncology, mangalore, karanataka, india healthcare global enterprises limited, bangalore, karnataka, india kasturba medical college and hospital, manipal, karnataka, india curie manavata cancer centre, nashik, maharashtra, india department of radiology, curie manavata cancer centre, nashik, maharashtra, india department of radiology, pune, maharashtra, india jehangir clinical development centre pvt. ltd., pune, maharashtra, india ruby hall clinic, pune, maharashtra, india r.k. birla cancer center, sawai man singh hospital, jaipur, rajasthan, india apollo speciality hospital, chennai, tamilnadu, india department of radiology, chennai, tamilnadu, india global hospitals, hyderabad, telangana, india vijaya diagnostic centre, hyderabad, telangana, india n.r.s medical college and hospital, kolkata, west bengal, india spandan pet-ct unit, kolkata, west bengal, india rajiv gandhi cancer institute & research center (rgcirc), new delhi, india u.o. di ematologia e ctmo - istituti ospedalieri di cremona, cremona, cr, italy irst - irccs u. o. oncologia medica, meldola, fc, italy u.o. ematologia 1 - irccs aou san martino-ist, genova, ge, italy unita di ricerca clinica, monza, mb, italy istituto europeo di oncologia, milano, mi, italy unità semplice di medicina nucleare, latina, nap, italy clinica ematologica - a.o.u. ospedali riuniti di ancona, torrette ancona, palermo, italy az ospedaliera santa maria, terni, pg, italy medicina nucleare, reggio emilia, reggio, italy radiologia, reggio emilia, reggio, italy sc ematologia - sc ematologia - arcispedale santa maria nuova - irccs, reggio emilia, reggio, italy ""dipartimento di biotecnologie cellulari ed ematologia, universita """"sapienza"""", rome, rome rm, italy ircss a.o.u. san martino - ist - uo clinica ematologica, genova, italy sc ematologia, fondazione irccs ist nazionale dei tumori, milano, italy padiglione 1, torre delle medicine, 6 piano, parma, italy ematologia e centro trapianti - az osp. ospedali riuniti marche nord (aormn) - presidio s. salvatore, pesaro, italy u.o. ematologia universitaria - dip. di oncologia dei trapianti - aou pisana, pisa, italy policlinico universitario campus bio- medico-u.o.c. di ematologia trapianto cellule staminali, roma, italy east nagoya imaging diagnosis center, nagoya, aichi, japan nagoya daini red cross hospital, nagoya, aichi, japan akita university hospital, akita city, akita, japan chiba cancer center, chiba-shi, chiba, japan national hospital organization kyushu medical center, fukuoka-shi, fukuoka, japan national hospital organization kyushu cancer center, fukuoka-shi, fukuoka, japan kobe city medical center general hospital, kobe-city, hyogo, japan national hospital organization kanazawa medical center, kanazawa, ishikawa, japan kanazawa advanced medical center, kanazawa, ishikawa, japan showa university northern yokohama hospital, yokohama-shi, kanagawa-ken, japan kochi medical school hospital, okocho, nankoku, kochi, japan national hospital organization kumamoto medical center, kumamoto-shi, kumamoto-ken, japan uozumi clinic, kumamoto-shi, kumamoto-ken, japan sendai kousei hospital, sendai-shi, miyagi, japan national hospital organization sendai medical center, sendai-shi, miyagi, japan aizawa hospital, matsumoto-shi, nagano, japan nagano red cross hospital, nagano-shi, nagano, japan national hospital organization nagasaki medical center, omura, nagasaki, japan national hospital organization osaka minami medical center, kawachinagano, osaka, japan hanwa dai 2 senboku hospital, naka-ku sakai, osaka, japan osaka city university hospital, osaka-city, osaka, japan tokushima university hospital, tokushima-shi, tokushima, japan national hospital organization tokyo medical center, meguro-ku, tokyo, japan showa university hospital, shinagawa-ku, tokyo, japan national hospital organization disaster medical center, tachikawa, tokyo, japan yamagata university hospital, yamagata-shi, yamagata, japan fukuoka wajiro pet diagnostic imaging clinic, fukuoka, japan national hospital organization matsumoto medical center, nagano, japan musashimurayama hospital, tokyo, japan hallym university sacred heart hospital, anyang-si, gyeonggi-do, korea, republic of seoul national university bundang hospital, seongnam-si, gyeonggi-do, korea, republic of chonbuk national university hospital, jeonju-si, jeollabuk-do, korea, republic of ulsan university hospital, ulsan, korea, korea, republic of inje university busan paik hospital, busan, korea, republic of seoul national university hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of hammoud hospital, university medical center, saida, southern governate, lebanon doctors center radiology, beirut, lebanon mount lebanon hospital, beirut, lebanon middle east institute of health, el metn, lebanon ain wazein hospital, mount lebanon, lebanon grupo medico camino s.c., mexico city, distrito federal, mexico imagenus, mexico city, distrito federal, mexico isos pharmacorp, s.a. de c.v., mexico city, distrito federal, mexico vely grupo medico quirurgico, s.a. de c.v., cuautitlan izacalli, estado de mexico, mexico phylasis clinicas research s. de r.l. de c.v., cuautitlan izcalli, estado de mexico, mexico centro universitario de imagen diagnostica, radiologia e imagen del hospital universitario, monterrey, nuevo leon, mexico hospital universitario ""dr. jose eleuterio gonzalez"", monterrey, nuevo leon, mexico cirurgia y ginecobstetricia de oaxaca, s.a de c.v., oaxaca, mexico oaxaca site management organization s.c., oaxaca, mexico hospital angeles puebla, puebla, mexico cancerologia de queretaro s.c., queretaro, mexico hospital infantil teleton de oncologia, queretaro, mexico hospital san jose norte, queretaro, mexico instituto nacional de enfermedades neoplasicas, surquillo, lima, peru pet scan peru, lima, peru resocentro, lima, peru university of philippines manila-philippine general hospital, manila, metro manila, philippines st. luke\'s medical center, quezon city, philippines klinika nowotworow ukladu chlonnego centrum onkologii - instytut im. m. sklodowskiej-curie, warszawa, poland euromedic wroclawskie centrum medyczne ii, wroclaw, poland euromedic wroclawskie centrum medyczne iii, wroclaw, poland dolnoslaskie centrum transplantacji komorkowych z krajowym bankiem dawcow szpiku, wroclaw, poland euromedic wroclawskie centrum medyczne i, wroclaw, poland apteka dolnoslaskiego centrum transplantacji komorkowych z krajowym bankiem dawcow szpiku, wroclaw, poland unidade local de saude de matosinhos e.p.e. - hospital pedro hispano s.a., matosinhos, porto, portugal hospital de braga, braga, portugal hospital cuf descobertas, lisboa, portugal cimc, porto, portugal dr. campos costa clinic, porto, portugal centro hospitalar do porto-hospital de santo antonio e.p.e., porto, portugal instituto portugues de oncologia do porto francisco gentil e.p.e, porto, portugal centro hospitalar de vila nova de gaia/espinho, e.p.e., vila nova de gaia, portugal modern radiology, psc, coto laurel, puerto rico ad-vance medical research, llc, ponce, puerto rico caribe mri and ct, ponce, puerto rico policlinica de diagnostic rapid, hematologie, brasov, romania policlinica de diagnostic rapid sa, brasov, romania spitalul clinic colentina, bucuresti, romania hiperdia ritmului, bucuresti, romania affidea fundeni, bucuresti, romania affidea romania srl, bucuresti, romania spitalul clinic coltea, clinica de hematologie, bucuresti, romania institutul oncologic prof. dr. ion chiricuta, laborator radiologie si imagistica medicala, cluj-napoca, romania institutul oncologic prof. dr. ion chiricuta, sectia oncologie medicala, cluj-napoca, romania clinica de hematologie-institutul oncologic, prof. dr. ion chiricuta, cluj-napoca, romania ct clinic s.r.l., cluj-napoca, romania a.tsyb medical radiological research centre -, obninsk, kaluga region, russian federation state healthcare institution republican oncology dispensary, saransk, mordovian republic, russian federation ""sbhi of nnr """"nizhniy novgorod regional clinical hospital n.a. n.a. semashko"""""", nizhniy novgorod, nizhniy novgorod region, russian federation llc mc ""mrt-diagnostika"", nizhniy novgorod, nizhniy novgorod region, russian federation fsbi ""russian research centre of radiology and surgical technologies"" of moh of rf, saint-petersburg, pesochniy town, russian federation fsbi ""russian research centre of radiology and surgical technologies"", saint-petersburg, pesochniy town, russian federation fsbi ""russian research centre of radiology and surgical technologies, saint-petersburg, pesochniy town, russian federation fsbi \'russian research centre of radiology and surgical technologies, saint-petersburg, pesochniy town, russian federation fsbi ""russian research centre of radiology and surgical technologies n.a. a.m. granov"" of moh of rf, saint-petersburg, pesochniy, russian federation fsbi ""russian research centre of radiology and surgical technologies named after academician, saint-petersburg, pesochniy, russian federation fsbi ""russian research centre of radiology and surgical technologies, saint-petersburg, pesochniy, russian federation fsbi \'national medical oncology research centre n.a. n.n.petrov\', saint-petersburg, pos.pesochny, russian federation branch office of llc \'pet-technology\' at ufa city, ufa, republic bashkortostan, russian federation state budgetary healthcare institution ""republican clinical oncology dispensary of the ministry, ufa, republic bashkortostan, russian federation private medical institution ""euromedservice"", pushkin, saint petersburg, russian federation fsbi ""russian research centre of radiology and surgical technologies"" of moh of rf, pesochniy town, saint-petersburg, russian federation federal state-financed institution \'north-caucasian research and clinical center\', lermontov, stavropol region, russian federation sbhi of stavropol region ""pyatigorsk interdistrict oncology dispensary, pyatigorsk, stavropol region, russian federation ""state budget healthcare institution """"chelyabinsk regional clinical center of oncology, chelyabinsk, russian federation fsbsi \'n.n.blokhin russian cancer research center\' of moh of rf, moscow, russian federation russian cancer research centre them n.n. blokhin, moscow, russian federation llc ""vitamed"", moscow, russian federation sbhi of moscow city clinical hospital n.a. s.p.botkin of healthcare department of moscow, moscow, russian federation ramsay diagnostics, moscow, russian federation state budgetary institution of healthcare ""leningrad regional clinical hospital"", saint petersburg, russian federation dr. berezin medical institute, saint-petersburg, russian federation n.p. bechtereva institute of human brain of the russian academy of sciences, saint-petersburg, russian federation n.p. bechtereva institute of the human brain of the russian academy of sciences, saint-petersburg, russian federation non-state healthcare institution ""road clinical hospital of joint stock company ""russian railways"", saint-petersurg, russian federation yaroslavl state medical academy, yaroslavl, russian federation gbuz of yaroslavl region ""regional clinical hospital"", yaroslavl, russian federation niksch & partners t/a capital radiology, groenkloof, gauteng, south africa the medical oncology centre of rosebank, johannesburg, gauteng, south africa department of medical oncology, university of pretoria, steve biko academic hospitals complex, pretoria, gauteng, south africa albert alberts stem cell transplant centre, pretoria, gauteng, south africa dr jn de jong and partners t/a east rad, pretoria, gauteng, south africa niksch & partners t/a capital radiology, pretoria, gauteng, south africa drs sulman & partners specialist radiologists, rosebank, gauteng, south africa drs bloch & partners incorporated, sandton, gauteng, south africa hospital parc tauli, sabadell, barcelona, spain onkologikoa, san sebastian, guipuzcoa, spain hospital universitario sanitas la zarzuela, aravaca, madrid, spain hospital rey juan carlos, mostoles, madrid, spain hospital clinico universitario virgen de la arrixaca, el palmar, murcia, spain hospital clínico universitario virgen de la arrixaca, el palmar, murcia, spain hospital do meixoeiro complejo hospitalario universitario de vigo, vigo, pontevedra, spain complejo hospitalario universitario a coruna, a coruna, spain hospital modelo, a coruna, spain hospital del mar, barcelona, spain hospital quiron de barcelona, iec, barcelona, spain cetir, centre medic, barcelona, spain radiodiagnostic cetir - clinica del pilar, barcelona, spain hospital universitario puerta del mar, cadiz, spain hospital universitario fundacion jimenez diaz, madrid, spain hospital universitario sanitas la moraleja, madrid, spain centro cimes, malaga, spain hospital universitario virgen de la victoria, malaga, spain centro mario gallegos, malaga, spain complejo hospitalario de ourense. hematología, ourense, spain hospital universitario virgen del rocio, sevilla, spain h. quiron zaragoza, zaragoza, spain hospital de dia quiron zaragoza, zaragoza, spain universitatsspital basel, basel, switzerland inselspital bern, bern, switzerland apotheke, spital sts ag, thun, switzerland onkologiezentrum thun-berner oberland spital sts ag, thun, switzerland kantonsapotheke zuerich, zuerich, switzerland universitaetsspital zuerich, zuerich, switzerland cardiology unit,department of medicine, faculty of medicine, ramathibodi hospital,, bangkok, thailand department of radiology, ramathibodi hospital, bangkok, thailand national cancer institute, bangkok, thailand hacettepe universitesi tip fakultesi onkoloji hastanesi, ankara, turkey dr. abdurrahman yurtaslan ankara onkoloji eg. ve aras., ankara, turkey ultramar tibbi gorunteleme merkezi, ankara, turkey ultramar tibbi goruntuleme merkezi, ankara, turkey integra gurses teshis tedavi ve saglik hizmetleri a.s., ankara, turkey adnan menderes university medical faculty, aydin, turkey gaziantep universitesi sahinbey arastirma ve uygulama hastanesi, gaziantep, turkey gaziantep universitesi sahinbey arastirma ve uygulama, gaziantep, turkey bezmialem vakif universitesi tip fakultesi hastanesi, istanbul, turkey ege universitesi tip fakultesi ic hastaliklari anabilim dali, izmir, turkey ege-rad bilgisayarli tomografi ozel saglik hizmetleri ve malzemeleri tic.ltd.sti., izmir, turkey erciyes universitesi tip fakultesi nukleer tip laboratuvari, kayseri, turkey erciyes universitesi tip fakultesi radyoloji laboratuvari, kayseri, turkey erciyes universitesi tip fakultesi, kayseri, turkey inonu universitesi tip fakultesi turgut ozal tip merkezi, malatya, turkey celal bayar university medical faculty, manisa, turkey ondokuz mayis universitesi tip fakultesi, samsun, turkey ""mediks-rey international group"" llc, obukhiv district, kyiv region, ukraine ""medx-rey international group"" llc, obukhiv district, kyiv region, ukraine ""medx-ray international group"" llc, obukhiv, kyiv region, ukraine ""municipal institution """"chernivtsi regional clinical oncology center"""",, chernivtsi, ukraine mi \'city dnipropetrovsk multi-field clin. hospital #4 of drc\',, dnipropetrovsk, ukraine municipal non-profit enterprise ""regional oncology centre"", kharkiv, ukraine national cancer institute, kyiv, ukraine ""central city clinical hospital, city oncology center, shei """"uzhhorod national university"""", chair, uzhhorod, ukraine podilskyy regional oncology center, chemotherapy department, vinnytsia, ukraine municipal establishment \'zaporizhzhia regional clinical oncology dispensary\', zaporizhzhia, ukraine llc ""diaservis"", zaporizhzhia, ukraine southend university hospital nhs foundation trust, westcliff-on-sea, essex, united kingdom cobalt diagnostic imaging, cheltenham, glos., united kingdom royal united hospitals bath nhs foundation trust, bath, united kingdom barts health nhs trust, london, united kingdom positron emission tomography (pet) centre, newcastle upon tyne, united kingdom city hospitals sunderland nhs foundation trust-sunderland royal hospital, sunderland, united kingdom diagnostic imaging, sunderland, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/63/nct02213263/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/63/nct02213263/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02213263,lymphoma
538,539,NCT01147809,safety and efficacy study for solid tumor patients treated with eltrombopag,,Completed,Has Results,thrombocytopaenia,drug: eltrombopag olamine|other: placebo,"number of participants with any adverse event (ae) or serious adverse event (sae): pre-therapy, on-therapy + 30 days and post-therapy in phase i|number of participants with indicated maximum toxicity grades for the indicated hematology parameters, at anytime post-baseline in phase i|number of participants with indicated maximum toxicity grades for the indicated clinical chemistry laboratory parameters, at anytime post-baseline in phase i|number of participants with a change from baseline in creatinine of >=26.5 micromoles/liter (umol/l) in phase i|number of the participants with eastern cooperative oncology group (ecog) performance status scores at the indicated time points in phase i|number of participants with electrocardiogram (ecg) findings at anytime post-baseline in phase i|mean day 1 scheduled pre-chemotherapy platelet count evaluated across cycles 1 to 6 in phase ii|average pre-chemotherapy platelet count at the indicated time points in phase i|average within-subject central laboratory platelet count prior to scheduled chemotherapy across cycles 2 to 6 in phase i|platelet count nadir for each chemotherapy cycle in phase i|central laboratory average daily area under the curve platelet-time course across cycles 2 to 6 in phase i|number of participants with thrombocytopenia of grade 1, 2, 3 or 4 across all the chemotherapy cycles in phase i, using central laboratory platelet count|maximum duration of thrombocytopenia across cycles 2 to 6 in phase i, estimated using central laboratory platelet counts|central laboratory platelet count for time taken to reach platelet nadir for each chemotherapy cycle in phase i|time to recovery from platelet nadir for each chemotherapy cycle in phase i, estimated using central laboratory platelet counts|dose intensity of gemcitabine plus cisplatin (g+cis)/gemcitabine plus carboplatin (g+cb) and gemcitabine across chemotherapy cycles 1 to 6 in phase i|number of participants with at least one delay in their scheduled dose of chemotherapy in any cycle in phase i|number of participants with any adverse event (ae) or serious adverse event (sae): pre-therapy, on-therapy + 30 days and post-therapy in phase ii|number of participants with any bleeding and significant bleeding as assessed using the world health organization (who) bleeding scale, across cycles 1-6 in phase ii|number of participants requiring a platelet transfusion in phase ii|number of participants with at least one delay in their scheduled dose of chemotherapy in any cycle in phase ii|number of participants with any dose reduction in their scheduled dose of chemotherapy in any cycle in phase ii|dose intensity of gemcitabine plus cisplatin(g+cis)/gemcitabine plus carboplatin (g+cb) and gemcitabine across chemotherapy cycles 1-6 in phase ii|number of participants with indicated maximum toxicity grades for the indicated hematology parameters, at anytime post-baseline in phase ii|number of participants with indicated worst-case change from baseline in clinical chemistry laboratory parameters using ctcae toxicity grading, at anytime post-baseline in phase ii|number of participants with change from baseline in creatinine of >=26.5 umol/l in phase ii|number of the participants with eastern cooperative oncology group (ecog) performance status scores at the indicated time points in phase ii|number of participants with electrocardiogram (ecg) findings at cycle 1 day 4 (2 to 6 hours post-dose) in phase ii|mean day 8 scheduled pre-chemotherapy platelet counts evaluated across cycles 1 to 6 in phase ii|mean day 15 scheduled pre-chemotherapy platelet counts evaluated across cycles 1 to 6 in phase ii|mean within-subject platelet count prior to scheduled chemotherapy across cycles 1 to 6 in phase ii|platelet count nadir for each chemotherapy cycle in phase ii|average daily area under the platelet-time course across cycles 1 to 6 in phase ii|number of participants with thrombocytopenia of grade 1, 2, 3 or 4 across cycles 1 to 6 in phase ii|maximum duration of thrombocytopenia across cycles 1 to 6 in phase ii|time taken to reach platelet nadir for each chemotherapy cycle in phase ii|time to recovery from platelet nadir for each chemotherapy cycle in phase ii",glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,130.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",112765,June 2010,January 2015,March 2015,"June 22, 2010","April 18, 2016","April 18, 2016","['gsk investigational site, sedona, arizona, united states gsk investigational site, hot springs, arkansas, united states gsk investigational site, rancho cucamonga, california, united states gsk investigational site, norwich, connecticut, united states gsk investigational site, jacksonville, florida, united states gsk investigational site, new port richey, florida, united states gsk investigational site, rome, georgia, united states gsk investigational site, savannah, georgia, united states gsk investigational site, wichita, kansas, united states gsk investigational site, bethesda, maryland, united states gsk investigational site, rockville, maryland, united states gsk investigational site, columbia, missouri, united states gsk investigational site, las vegas, nevada, united states gsk investigational site, cherry hill, new jersey, united states gsk investigational site, albany, new york, united states gsk investigational site, greensboro, north carolina, united states gsk investigational site, bend, oregon, united states gsk investigational site, philadelphia, pennsylvania, united states gsk investigational site, wynnewood, pennsylvania, united states gsk investigational site, providence, rhode island, united states gsk investigational site, providence, rhode island, united states gsk investigational site, greenville, south carolina, united states gsk investigational site, arlington, texas, united states gsk investigational site, austin, texas, united states gsk investigational site, bedford, texas, united states gsk investigational site, dallas, texas, united states gsk investigational site, san antonio, texas, united states gsk investigational site, tyler, texas, united states gsk investigational site, norfolk, virginia, united states gsk investigational site, edmunds, washington, united states gsk investigational site, tacoma, washington, united states gsk investigational site, vancouver, washington, united states gsk investigational site, yakima, washington, united states gsk investigational site, charleroi, belgium gsk investigational site, leuven, belgium gsk investigational site, libramont, belgium gsk investigational site, namur, belgium gsk investigational site, edmonton, alberta, canada gsk investigational site, toronto, ontario, canada gsk investigational site, olomouc, czech republic gsk investigational site, praha 10, czech republic gsk investigational site, praha 5, czech republic gsk investigational site, helsinki, finland gsk investigational site, tampere, finland gsk investigational site, freiburg, baden-wuerttemberg, germany gsk investigational site, augsburg, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, muenchen, bayern, germany gsk investigational site, goslar, niedersachsen, germany gsk investigational site, hannover, niedersachsen, germany gsk investigational site, essen, nordrhein-westfalen, germany gsk investigational site, dresden, sachsen, germany gsk investigational site, dresden, sachsen, germany gsk investigational site, berlin, germany gsk investigational site, berlin, germany gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, heraklion, crete, greece gsk investigational site, thessaloniki, greece gsk investigational site, budapest, hungary gsk investigational site, győr, hungary gsk investigational site, kaposvár, hungary gsk investigational site, törökbálint, hungary gsk investigational site, zalaegerszeg, hungary gsk investigational site, madurai, india gsk investigational site, pune, india gsk investigational site, pune, india gsk investigational site, dublin, ireland gsk investigational site, dublin, ireland gsk investigational site, tallaght, dublin, ireland gsk investigational site, ashkelon, israel gsk investigational site, haifa, israel gsk investigational site, jerusalem, israel gsk investigational site, kfar saba, israel gsk investigational site, tel aviv, israel gsk investigational site, zrifin, israel gsk investigational site, modena, emilia-romagna, italy gsk investigational site, aviano (pn), friuli-venezia-giulia, italy gsk investigational site, milano, lombardia, italy gsk investigational site, sassari, sardegna, italy gsk investigational site, pisa, toscana, italy gsk investigational site, bialystok, poland gsk investigational site, konin, poland gsk investigational site, olsztyn, poland gsk investigational site, poznan, poland gsk investigational site, poznan, poland']",,https://ClinicalTrials.gov/show/NCT01147809,
539,540,NCT03722732,comparison of blood loss in laparoscopic vs open pancreaticoduodenectomy in patients with periampullary carcinoma,,Recruiting,No Results Available,periampullary carcinoma,procedure: pancreaticoduodenectomy,"intraoperative blood loss in ml, quantitative",govind ballabh pant hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,36.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",F.1/IEC/MAMC/63/03/18/NO325,"September 11, 2018",December 2022,March 2023,"October 29, 2018",,"August 2, 2021","['g b pant hospital, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT03722732,
540,541,NCT02492503,effectiveness of chemotherapy in metastatic or recurrent carcinoma cervix,,Unknown status,No Results Available,metastatic carcinoma to the uterine cervix|recurrent carcinoma cervix|cervix carcinoma recurrent,drug: paclitaxel and carboplatin,time to progression (length of time from start of chemotherapy to evidence of cancer progression.|response rate|overall survival|quality of life questionnaire,"all india institute of medical sciences, new delhi",Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA CX CHEMOTHERAPY,November 2013,August 2015,August 2015,"July 8, 2015",,"July 8, 2015","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT02492503,cervix fibroid
541,542,NCT00899054,safety and efficacy study of p276-00 in combination with radiation in subjects with advanced head and neck cancer,SPARK,Completed,No Results Available,squamous cell carcinoma of head and neck,drug: p276-00|radiation: external beam radiotherapy (ebrt),to determine the maximum tolerated dose (mtd) and dose limiting toxicity (ies) (dlt/s) of p276-00 in combination with radiation in subjects with recurrent and/or locally advanced squamous cell carcinoma of head and neck (scchn)|to evaluate safety and tolerability of the combination regimen of p276-00 and radiation in the study population|to analyze pharmacokinetics (pk) of p276-00 in the study population|to evaluate efficacy of the combination regimen of p276-00 and radiation in the study population|to perform exploratory analysis of biomarkers associated with use of p276-00 and radiation in the study population,piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,23.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/31/08,August 2009,January 2011,November 2012,"May 12, 2009",,"November 22, 2012","['government medical college, aurangabad, maharashtra, india curie manavata cancer center, nashik, maharashtra, india bhagwan mahawir cancer hospital & research centre, jaipur, rajasthan, india v. n. cancer centre, gknm hospital, coimbatore, tamil nadu, india meenakshi mission hospital & research centre, madurai, tamil nadu, india christian medical college, vellore, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT00899054,skin
542,543,NCT01593306,concurrent chemoradiotherapy with weekly cisplatin versus concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in locally advanced carcinoma cervix,,Unknown status,No Results Available,carcinoma cervix,"drug: paclitaxel, cisplatin|drug: cisplatin",clinical response of the disease|number of patients with adverse events,"indira gandhi medical college, shimla",Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,80.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,pragyat1805,July 2011,October 2012,February 2013,"May 8, 2012",,"May 8, 2012","['indira gandhi medical college, shimla, himachal pradesh, india']",,https://ClinicalTrials.gov/show/NCT01593306,cervix
543,544,NCT01117402,tomotherapy in postsurgery recurrent carcinoma cervix,,Unknown status,No Results Available,postsurgery recurrent carcinoma cervix,radiation: radiotherapy,"to evaluate the utility of intensity-modulated radiotherapy (imrt) in delivering dose escalated radiotherapy in postoperative recurrent cases of carcinoma cervix, in terms of local control|to study the late toxicities associated with this treatment",tata memorial hospital,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,90.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 588,December 2008,December 2013,December 2014,"May 5, 2010",,"May 5, 2010","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01117402,cervix
544,545,NCT00073385,comparative trial of pivanex and docetaxel vs docetaxel monotherapy in patients with advanced non-small cell lung cancer,,Completed,No Results Available,"carcinoma, non-small-cell lung",drug: pivanex|drug: docetaxel,,titan pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,225.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TTP-200-03-01|NSCLC Clincal Trial,September 2003,,October 2004,"November 21, 2003",,"August 30, 2005","['wilshire oncology medical group, la verne, california, united states hematology and oncology specialists, llc, new orleans, louisiana, united states montefiore medical center, department of oncology, bronx, new york, united states hemoncare, brooklyn, new york, united states gaston hematology & oncology associates, gastonia, north carolina, united states rajiv gandhi cancer institute & research center, new delhi, india regional cancer centre, thiruvananthapuram, india university of edinburgh, edinburgh cancer centre, edinburgh, united kingdom']",,https://ClinicalTrials.gov/show/NCT00073385,
545,546,NCT03367702,stereotactic body radiation therapy or intensity-modulated radiation therapy in treating patients with stage iia-b prostate cancer,,Recruiting,No Results Available,stage ii prostate adenocarcinoma,radiation: intensity-modulated radiation therapy (imrt)|radiation: stereotactic body radiation therapy (sbrt),incidence of patients-reported gastrointestinal and genitourinary toxicity|disease free survival|biochemical failure|distant metastasis|health related quality of life|incidence of adverse events (aes)|local failure|overall survival|presence of prostate imaging-reporting and data system version (piradsv) 2 = 4/5 disease|prostate cancer specific survival|regional failure,nrg oncology|national cancer institute (nci),Male,"18 Years and older   (Adult, Older Adult)",Phase 3,622.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NRG-GU005|NCI-2017-01398|U10CA180868,"November 16, 2017",December 2025,December 2030,"December 11, 2017",,"January 21, 2022","[""mobile infirmary medical center, mobile, alabama, united states lewis and faye manderson cancer center, tuscaloosa, alabama, united states arizona breast cancer specialists-gilbert, gilbert, arizona, united states arizona center for cancer care-peoria, peoria, arizona, united states arizona breast cancer specialists-scottsdale, scottsdale, arizona, united states arizona center for cancer care-surprise, surprise, arizona, united states arizona oncology associates-west orange grove, tucson, arizona, united states university of arkansas for medical sciences, little rock, arkansas, united states kaiser permanente-anaheim, anaheim, california, united states alta bates summit medical center-herrick campus, berkeley, california, united states mercy san juan medical center, carmichael, california, united states kaiser permanente dublin, dublin, california, united states fresno cancer center, fresno, california, united states marin general hospital, greenbrae, california, united states uc san diego moores cancer center, la jolla, california, united states kaiser permanente los angeles medical center, los angeles, california, united states los angeles county-usc medical center, los angeles, california, united states usc / norris comprehensive cancer center, los angeles, california, united states memorial medical center, modesto, california, united states kaiser permanente oakland-broadway, oakland, california, united states saint joseph hospital - orange, orange, california, united states stanford cancer institute palo alto, palo alto, california, united states kaiser permanente-rancho cordova cancer center, rancho cordova, california, united states rohnert park cancer center, rohnert park, california, united states the permanente medical group-roseville radiation oncology, roseville, california, united states mercy cancer center - sacramento, sacramento, california, united states sutter medical center sacramento, sacramento, california, united states university of california davis comprehensive cancer center, sacramento, california, united states salinas valley memorial, salinas, california, united states stanford cancer center south bay, san jose, california, united states kaiser permanente medical center - santa clara, santa clara, california, united states kaiser permanente cancer treatment center, south san francisco, california, united states gene upshaw memorial tahoe forest cancer center, truckee, california, united states university of colorado hospital, aurora, colorado, united states uchealth memorial hospital central, colorado springs, colorado, united states memorial hospital north, colorado springs, colorado, united states porter adventist hospital, denver, colorado, united states poudre valley hospital, fort collins, colorado, united states valley view hospital cancer center, glenwood springs, colorado, united states littleton adventist hospital, littleton, colorado, united states parker adventist hospital, parker, colorado, united states smilow cancer hospital care center - guiford, guilford, connecticut, united states yale university, new haven, connecticut, united states smilow cancer hospital care center-trumbull, trumbull, connecticut, united states smilow cancer hospital care center - waterford, waterford, connecticut, united states beebe south coastal health campus, frankford, delaware, united states helen f graham cancer center, newark, delaware, united states christiana care health system-christiana hospital, newark, delaware, united states beebe health campus, rehoboth beach, delaware, united states mount sinai comprehensive cancer center at aventura, aventura, florida, united states broward health north, deerfield beach, florida, united states broward health medical center, fort lauderdale, florida, united states genesiscare usa - key west, key west, florida, united states genesiscare usa - lakewood ranch, lakewood ranch, florida, united states mount sinai medical center, miami beach, florida, united states genesiscare usa - plantation, plantation, florida, united states grady health system, atlanta, georgia, united states emory university hospital midtown, atlanta, georgia, united states piedmont hospital, atlanta, georgia, united states emory university hospital/winship cancer institute, atlanta, georgia, united states emory saint joseph's hospital, atlanta, georgia, united states piedmont fayette hospital, fayetteville, georgia, united states lewis cancer and research pavilion at saint joseph's/candler, savannah, georgia, united states saint alphonsus cancer care center-boise, boise, idaho, united states saint alphonsus medical center-nampa, nampa, idaho, united states rush - copley medical center, aurora, illinois, united states decatur memorial hospital, decatur, illinois, united states crossroads cancer center, effingham, illinois, united states edward hines jr va hospital, hines, illinois, united states loyola university medical center, maywood, illinois, united states methodist medical center of illinois, peoria, illinois, united states osf saint francis medical center, peoria, illinois, united states memorial medical center, springfield, illinois, united states carle cancer center, urbana, illinois, united states midwestern regional medical center, zion, illinois, united states parkview hospital randallia, fort wayne, indiana, united states parkview regional medical center, fort wayne, indiana, united states franciscan health indianapolis, indianapolis, indiana, united states mercy medical center - des moines, des moines, iowa, united states university of kansas cancer center, kansas city, kansas, united states university of kansas cancer center-overland park, overland park, kansas, united states ascension via christi hospitals wichita, wichita, kansas, united states university of kentucky/markey cancer center, lexington, kentucky, united states the james graham brown cancer center at university of louisville, louisville, kentucky, united states east jefferson general hospital, metairie, louisiana, united states lsu healthcare network / metairie multi-specialty clinic, metairie, louisiana, united states tulane university health sciences center, new orleans, louisiana, united states mainehealth coastal cancer treatment center, bath, maine, united states maine medical center-bramhall campus, portland, maine, united states mainehealth cancer care center of york county, sanford, maine, united states maine medical center- scarborough campus, scarborough, maine, united states anne arundel medical center, annapolis, maryland, united states university of maryland/greenebaum cancer center, baltimore, maryland, united states saint agnes hospital, baltimore, maryland, united states walter reed national military medical center, bethesda, maryland, united states central maryland radiation oncology in howard county, columbia, maryland, united states university of maryland shore medical center at easton, easton, maryland, united states um baltimore washington medical center/tate cancer center, glen burnie, maryland, united states tidalhealth richard a henson cancer institute, ocean pines, maryland, united states tidalhealth peninsula regional, salisbury, maryland, united states massachusetts general hospital cancer center, boston, massachusetts, united states boston medical center, boston, massachusetts, united states mass general/north shore cancer center, danvers, massachusetts, united states saint joseph mercy hospital, ann arbor, michigan, united states university of michigan comprehensive cancer center, ann arbor, michigan, united states mclaren cancer institute-bay city, bay city, michigan, united states genesiscare usa - clarkston, clarkston, michigan, united states mclaren cancer institute-clarkston, clarkston, michigan, united states beaumont hospital - dearborn, dearborn, michigan, united states wayne state university/karmanos cancer institute, detroit, michigan, united states genesiscare usa - farmington hills, farmington hills, michigan, united states weisberg cancer treatment center, farmington hills, michigan, united states beaumont hospital - farmington hills, farmington hills, michigan, united states genesys hurley cancer institute, flint, michigan, united states mclaren cancer institute-flint, flint, michigan, united states spectrum health at butterworth campus, grand rapids, michigan, united states west michigan cancer center, kalamazoo, michigan, united states mclaren-greater lansing, lansing, michigan, united states sparrow hospital, lansing, michigan, united states genesiscare usa - macomb, macomb, michigan, united states genesiscare usa - madison heights, madison heights, michigan, united states mclaren cancer institute-macomb, mount clemens, michigan, united states mclaren cancer institute-northern michigan, petoskey, michigan, united states mclaren-port huron, port huron, michigan, united states william beaumont hospital-royal oak, royal oak, michigan, united states william beaumont hospital - troy, troy, michigan, united states genesiscare usa - troy, troy, michigan, united states metro health hospital, wyoming, michigan, united states sanford joe lueken cancer center, bemidji, minnesota, united states regions hospital, saint paul, minnesota, united states saint francis medical center, cape girardeau, missouri, united states southeast cancer center, cape girardeau, missouri, united states siteman cancer center at west county hospital, creve coeur, missouri, united states delbert day cancer institute at pcrmc, rolla, missouri, united states ssm health saint louis university hospital, saint louis, missouri, united states washington university school of medicine, saint louis, missouri, united states siteman cancer center-south county, saint louis, missouri, united states missouri baptist medical center, saint louis, missouri, united states siteman cancer center at saint peters hospital, saint peters, missouri, united states mercy hospital springfield, springfield, missouri, united states bozeman deaconess hospital, bozeman, montana, united states saint james community hospital and cancer treatment center, butte, montana, united states benefis healthcare- sletten cancer institute, great falls, montana, united states kalispell regional medical center, kalispell, montana, united states community medical hospital, missoula, montana, united states university of nebraska medical center, omaha, nebraska, united states exeter hospital, exeter, new hampshire, united states dartmouth hitchcock medical center, lebanon, new hampshire, united states the valley hospital-luckow pavilion, paramus, new jersey, united states capital health medical center-hopewell, pennington, new jersey, united states university of new mexico cancer center, albuquerque, new mexico, united states lovelace radiation oncology, albuquerque, new mexico, united states new mexico oncology hematology consultants, albuquerque, new mexico, united states saint peter's health partners, albany, new york, united states new york-presbyterian/brooklyn methodist hospital, brooklyn, new york, united states sands cancer center, canandaigua, new york, united states mary imogene bassett hospital, cooperstown, new york, united states garnet health medical center, middletown, new york, united states laura and isaac perlmutter cancer center at nyu langone, new york, new york, united states highland hospital, rochester, new york, united states university of rochester, rochester, new york, united states state university of new york upstate medical university, syracuse, new york, united states durham va medical center, durham, north carolina, united states duke university medical center, durham, north carolina, united states scotland memorial hospital-laurinburg cancer center, laurinburg, north carolina, united states duke raleigh hospital, raleigh, north carolina, united states nhrmc radiation oncology - supply, supply, north carolina, united states nhrmc radiation oncology - 16th street, wilmington, north carolina, united states sanford bismarck medical center, bismarck, north dakota, united states sanford roger maris cancer center, fargo, north dakota, united states cleveland clinic akron general, akron, ohio, united states uhhs-chagrin highlands medical center, beachwood, ohio, united states geauga hospital, chardon, ohio, united states the christ hospital, cincinnati, ohio, united states case western reserve university, cleveland, ohio, united states cleveland clinic cancer center/fairview hospital, cleveland, ohio, united states ohio state university comprehensive cancer center, columbus, ohio, united states riverside methodist hospital, columbus, ohio, united states mercy cancer center-elyria, elyria, ohio, united states cleveland clinic cancer center independence, independence, ohio, united states cleveland clinic cancer center mansfield, mansfield, ohio, united states hillcrest hospital cancer center, mayfield heights, ohio, united states uh seidman cancer center at lake health mentor campus, mentor, ohio, united states university hospitals portage medical center, ravenna, ohio, united states north coast cancer care, sandusky, ohio, united states promedica flower hospital, sylvania, ohio, united states uhhs-westlake medical center, westlake, ohio, united states cleveland clinic wooster family health and surgery center, wooster, ohio, united states university of oklahoma health sciences center, oklahoma city, oklahoma, united states legacy mount hood medical center, gresham, oregon, united states legacy good samaritan hospital and medical center, portland, oregon, united states lehigh valley hospital-cedar crest, allentown, pennsylvania, united states bryn mawr hospital, bryn mawr, pennsylvania, united states christiana care health system-concord health center, chadds ford, pennsylvania, united states geisinger medical center, danville, pennsylvania, united states delaware county memorial hospital, drexel hill, pennsylvania, united states fox chase cancer center - east norriton hospital outpatient center, east norriton, pennsylvania, united states fox chase cancer center buckingham, furlong, pennsylvania, united states adams cancer center, gettysburg, pennsylvania, united states penn state milton s hershey medical center, hershey, pennsylvania, united states geisinger medical oncology-lewisburg, lewisburg, pennsylvania, united states lewistown hospital, lewistown, pennsylvania, united states paoli memorial hospital, paoli, pennsylvania, united states thomas jefferson university hospital, philadelphia, pennsylvania, united states fox chase cancer center, philadelphia, pennsylvania, united states jefferson torresdale hospital, philadelphia, pennsylvania, united states temple university hospital, philadelphia, pennsylvania, united states geisinger cancer services-pottsville, pottsville, pennsylvania, united states reading hospital, west reading, pennsylvania, united states geisinger wyoming valley/henry cancer center, wilkes-barre, pennsylvania, united states asplundh cancer pavilion, willow grove, pennsylvania, united states lankenau medical center, wynnewood, pennsylvania, united states wellspan health-york cancer center, york, pennsylvania, united states prisma health cancer institute - spartanburg, boiling springs, south carolina, united states medical university of south carolina, charleston, south carolina, united states prisma health cancer institute - faris, greenville, south carolina, united states saint francis cancer center, greenville, south carolina, united states prisma health cancer institute - eastside, greenville, south carolina, united states self regional healthcare, greenwood, south carolina, united states prisma health cancer institute - greer, greer, south carolina, united states the radiation oncology center-hilton head/bluffton, hilton head island, south carolina, united states prisma health cancer institute - seneca, seneca, south carolina, united states sanford usd medical center - sioux falls, sioux falls, south dakota, united states thompson cancer survival center, knoxville, tennessee, united states texas cancer center, abilene, texas, united states texas oncology-mckinney, mckinney, texas, united states texas oncology-plano west, plano, texas, united states texas oncology cancer center sugar land, sugar land, texas, united states deke slayton cancer center, webster, texas, united states intermountain medical center, murray, utah, united states utah valley regional medical center, provo, utah, united states dixie medical center regional cancer center, saint george, utah, united states central vermont medical center/national life cancer treatment, berlin, vermont, united states university of vermont medical center, burlington, vermont, united states norris cotton cancer center-north, saint johnsbury, vermont, united states sentara cancer institute at sentara careplex hospital, hampton, virginia, united states bon secours depaul medical center, norfolk, virginia, united states sentara norfolk general hospital, norfolk, virginia, united states bon secours cancer institute at reynolds crossing, richmond, virginia, united states oncology and hematology associates of southwest virginia, roanoke, virginia, united states sentara obici hospital, suffolk, virginia, united states virginia mason medical center, seattle, washington, united states legacy salmon creek hospital, vancouver, washington, united states providence saint mary regional cancer center, walla walla, washington, united states west virginia university charleston division, charleston, west virginia, united states west virginia university healthcare, morgantown, west virginia, united states ascension saint elizabeth hospital, appleton, wisconsin, united states ascension southeast wisconsin hospital - elmbrook campus, brookfield, wisconsin, united states ascension saint francis - reiman cancer center, franklin, wisconsin, united states aurora baycare medical center, green bay, wisconsin, united states gundersen lutheran medical center, la crosse, wisconsin, united states froedtert menomonee falls hospital, menomonee falls, wisconsin, united states ascension columbia saint mary's hospital ozaukee, mequon, wisconsin, united states ascension columbia saint mary's hospital - milwaukee, milwaukee, wisconsin, united states aurora saint luke's medical center, milwaukee, wisconsin, united states medical college of wisconsin, milwaukee, wisconsin, united states zablocki veterans administration medical center, milwaukee, wisconsin, united states drexel town square health center, oak creek, wisconsin, united states ascension mercy hospital, oshkosh, wisconsin, united states vince lombardi cancer clinic - oshkosh, oshkosh, wisconsin, united states ascension all saints hospital, racine, wisconsin, united states aurora medical center in summit, summit, wisconsin, united states froedtert west bend hospital/kraemer cancer center, west bend, wisconsin, united states tom baker cancer centre, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada juravinski cancer centre at hamilton health sciences, hamilton, ontario, canada ottawa hospital and cancer center-general campus, ottawa, ontario, canada centre de sante et de services sociaux de chicoutimi, chicoutimi, quebec, canada ciusssemtl-hopital maisonneuve-rosemont, montreal, quebec, canada chum - centre hospitalier de l'universite de montreal, montreal, quebec, canada the research institute of the mcgill university health centre (muhc), montreal, quebec, canada chu de quebec-l'hotel-dieu de quebec (hdq), quebec city, quebec, canada centre hospitalier universitaire de sherbrooke-fleurimont, sherbrooke, quebec, canada allan blair cancer centre, regina, saskatchewan, canada saskatoon cancer centre, saskatoon, saskatchewan, canada pamela youde nethersole eastern hospital, chai wan, hong kong tata memorial hospital, mumbai, india beacon hospital, dublin, co dublin, ireland saint lukes hospital, dublin, co dublin, ireland kantonsspital aarau, aarau, switzerland""]",,https://ClinicalTrials.gov/show/NCT03367702,prostat gastric kidney
546,547,NCT00713427,study of the wallflex™ biliary partially-covered stent for the palliative treatment of malignant bile duct obstruction,,Completed,Has Results,biliary strictures caused by malignant neoplasms,device: wallflex™ biliary partially-covered stent,number of participants with absence of recurrent biliary obstruction|number of adverse events related to the device and/or procedure|number of participants with technical stent placement success|number of participants with occurrence of re-intervention|change in biliary obstruction symptoms|time to recurrent biliary obstruction|change in bilirubin,boston scientific corporation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ENDO-WALLFLEX-BIL-PALL-002|E7020,July 2007,May 2008,May 2008,"July 11, 2008","June 4, 2021","July 30, 2021","['ulb erasme hospital, brussels, belgium hopital edouard herriot, lyon, cedex 3, france evk krankenhaus der universitat dusseldorf, dusseldorf, germany asian institute of gastroenterology, hyderabaad, india università cattolica del sacro cuore, rome, italy academisch medisch centrum universiteit van amsterdam, amsterdam, az, netherlands']",,https://ClinicalTrials.gov/show/NCT00713427,skin biliari
547,548,NCT01615757,safety and efficacy study of ara-c at 18 gm/m2 versus 12 gm/m2 for 3 cycles each in aml consolidation,Ara-c,Unknown status,No Results Available,acute myeloid leukemia,drug: ara-c,relapse free survival at 1 yr of follow up|toxicity- haematological and non -haematological,"all india institute of medical sciences, new delhi",All,"Child, Adult, Older Adult",Phase 3,180.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AML HIDAC, AIIMS",August 2012,September 2014,September 2014,"June 11, 2012",,"September 17, 2012","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01615757,blood
548,549,NCT01265849,"efficacy and safety study of leukocyte interleukin,injection (li) to treat cancer of the oral cavity",IT-MATTERS,Unknown status,No Results Available,squamous cell carcinoma of the oral cavity|squamous cell carcinoma of the soft palate,biological: li|drug: cyclophosphamide|drug: indomethacin|dietary supplement: zinc|procedure: surgery|drug: cisplatin|radiation: radiotherapy,overall survival (os) in li + ciz + soc vs. soc|local regional control (lrc) in li + ciz + soc vs. soc|progression free survival (pfs) in li + ciz + soc vs.soc|quality of life (qol) in li + ciz + soc vs. soc,"cel-sci corporation|teva branded pharmaceutical products r&d, inc.|orient europharma co., ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,928.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CS001P3|2010-019952-35,December 2010,"May 15, 2020","April 15, 2021","December 23, 2010",,"March 19, 2021","[""simmons cancer institute at southern illinois university, springfield, illinois, united states henry ford health system henry ford hospital, detroit, michigan, united states university of cincinnati medical center, cincinnati, ohio, united states medical college of south carolina msc550, charleston, south carolina, united states va puget sound healthcare system & university of wa, seattle, washington, united states hno-klinik der medizinischen universitat graz, graz, austria n.n. alexandrov research istitute of oncology and medical radiology, lesnoy 2, minsk, belarus vitebsk regional oncology dispensary, vitebsk, belarus university clinical centre tuzla, trnovac, tuzla, bosnia and herzegovina clinical center banja luka, banja luka, bosnia and herzegovina university clinical hospital mostar, mostar, bosnia and herzegovina clinical centre university of sarejevo clinic for ent, sarajevo, bosnia and herzegovina st. josephs healthcare department of surgery, hamilton, ontario, canada centre hospitalier universitaire de sherbrooke, sherbrooke, quebec, canada chu de quebec - l'hotel dieu de quebec, quebec, canada chc osijek, osijek, croatia general hospital dr. josip bencevic, slavonski brod, croatia ch dubrava, zagreb, croatia clinical hospital center zagreb kispaticeva 12, zagreb, croatia kbc sestre milosrdnice, zagreb, croatia kbc zagreb, zagreb, croatia icl 6 avenue bourgogne cs30519, vandoeuvre les nancy, france university of debrecen medical and health scioence centre, debrecen, hajdu bihar, hungary national institute of oncology, budapest, rath gyorgy, hungary semmelweis university, budapest, hungary university of pecs institute of oncotherapy, pecs, hungary university of szeged dept of oral and maxillofacial surgery, szeged, hungary markusovsky teaching hospital, szombathely, hungary bibi general hospital and cancer centre, malkapet, andhra pradesh, india amrita institute of medical sciences, kochi, kerala, india sujan regional cancer hospital & amravati cancer foundation, amravati, maharashtra, india government medical college and hospital, aurangabad, maharashtra, india tata memorial hospital, mumbai, maharashtra, india curie manavata cancer center, mumbai, naka nashik, india searoc cancer center, jaipur, rajashlan, india v.n. cancer center g. kuppuswamy naidu memorial hospital, coimbatore, tamil nadu, india meenakshi mission hospital and research centre, madurai, tamil nadu, india regional cancer center, kerola, thiruvananthapuram, india galaxy cancer center, ghaziabad, uttar pradesh, india rambam health care campus, sha'ar ha'aliya, saint haifa, israel rabin medical center, petaẖ tiqwa, tikva, israel national tumor institute of italy, naples, italy ospedale s.g. moscati santissima annunziata, taranto, italy dept of head and neck surgery school of medical sciences univ. sains, kuantan, penang, malaysia university kabangsan medical center, kuala lumpur, malaysia wojewodzki szpital specjalistyczny im kopernika, lodz, ul paderewskiego 4, poland swietokrzyskie centrum onkologii, kielce, ul. artwinskiego 3, poland centrum onkologii im. prof. lukaszcyka, warsaw, ul. roentgena 5, poland centrum onkologi-instytut im. marie sklodowskiej-curie, warszawa, ul. roentgena 5, poland ul. m. sklodowskiej-curie 24a, bialystok, poland szpital specialistyczny im. ludwika rydgiera, krakow, poland samodzielny publiczny szpital kliniczny klinika otolarryngologii i onkologii laryngologicznej, lublin, poland weilkopolskie centrum onkologii klinika chirurgii glowy szye onkologii laryngologiczne, poznan, poland uniwersitecki szpital kliniczny klinika otolaryngologii chirugii glowy i szxyi, wroclaw, poland regional institute of oncology iasi, iasi, romania spital clinic judetean mures, targu mures, romania sverdlovsk regional cancer center, sverdlov, ekaterinberg, russian federation leningrad regional oncology center, st. petersburg, leningradskaya, russian federation kursk regional clinical oncology dispensary, kursk, russian federation blokhin cancer research center, moscow, russian federation n.n. blokhin russian cancer research center, moscow, russian federation budget institution of healthcare of omsk region clincal oncology dispensary, omsk, russian federation ryazan clinical oncology dispensary, ryazan, russian federation serbia clinic for ent and maxillofacial surgery, belgrade, pasterova 14, serbia clincal center serbia clinic for oral and maxillofacial surgery, belgrade, serbia faculty of dental medicine clinic for maxillofacial surgery, belgrade, serbia military medical academy clinic for maxillofacial surgery, belgrade, serbia clinical center nis center for oncology, nis, serbia clinic for stomatology department for maxillofacial surgery, nis, serbia clinical center vojvodina clinic for orl, novi sad, serbia clinical centre vojvodina clinic for maxillofacial surgery, novi sad, serbia hospiatl universitari vall d'hebron, barcelona, spain hospital universitario de princesa, madrid, spain hospital universitario ramon y cajal, madrid, spain complejo hospitalario univ. de santiago, santiago de compostela, spain consorsio hospital general universitario de valencia, valencia, spain national cancer institute dept of clinical oncology & radiotherapy, colombo, sri lanka oncology unit teaching hospital karapitya, galle, sri lanka kaohsiung branch chang gung memorial hospital, niaosong, kaohsiung, taiwan national cheng kung university hospital, taipei, tainan, taiwan national taiwan research hospital, chengshan, taipei, taiwan linkou branch chang gung memorial hospital, guishan, taoyuan, taiwan changua christian hospital, chang-hua, taiwan buddhist tzu chi general hospital, hualien branch, hualien city, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan shin-kong wu ho-su memorial hospital, taipei, taiwan khon kaen university dept of otolaryngology, nai- muang, thailand haceteppe university dept of otolaryngology - head and neck surgery, ankara, turkey acibadem university maslak hospital ent department, istanbul, turkey cherkasky regional oncological dyspensary dept. head and neck tumour, cherkasy, ukraine clinical diagnostic laboratory of dnepropetrovsk municipal institution city multidisciplinary clinical hospital no. 4, dnepropetrovsk, ukraine donetsk regional antitumor center, donetsk, ukraine grigoriev institute for medical radiology of national academy of medical science of ukraine dept. of remote, combined radiation and complex therapy, kharkiv, ukraine kharkiv regional clinical oncology center dept. of head and neck tumour, kharkiv, ukraine kiev city clinical oncology center of the main health care dept of kiev day hospital radiotherapy dept., kiev, ukraine kiev city clinical oncology center of the main health care dept. of the kiev day hospital, kiev, ukraine lviv state oncologyregional treatment and diagnostic ceneter, lviv, ukraine sumy regional clinical oncology dyspensary, sumy, ukraine zaporiz'ka regional clinical oncology dispensary, zaporiz'ka oblast', ukraine aintree university hospital, liverpool, united kingdom""]",,https://ClinicalTrials.gov/show/NCT01265849,skin
549,550,NCT04642469,phase iii study to determine efficacy of durvalumab in stage ii-iii non-small cell lung cancer (nsclc) after curative intent therapy.,MERMAID-2,Recruiting,No Results Available,"carcinoma, non- small cell lung",drug: durvalumab|other: placebo,"dfs in pd-l1 tc≥1% (using investigator assessments according to recist 1.1)|dfs in fas (using investigator assessments according to recist 1.1)|pfs (using local standard practice)|time to first subsequent therapy (tfst)|time to second subsequent therapy (tsst)|change from baseline in eortc qlq-c30|change from baseline in eortc qlq-lc13|time to deterioration in eortc qlq-c30|time to deterioration in eortc qlq-lc13|ihc analysis of pd-l1 tc expression and spatial distribution within the tumor microenvironment relative to efficacy outcomes (ie, dfs, os)the ventana sp263 pd-l1 immunohistochemistry (ihc) assay will be used to determine pdl1 status in all specimens.|dfs (using bicr assessments according to recist 1.1) in pd-l1 tc≥1% analysis set|dfs (using bicr assessments according to recist 1.1) in fas|os in pd-l1 tc≥1% analysis set|os in fas",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,284.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D910MC00001,"November 30, 2020","November 28, 2025","October 29, 2027","November 24, 2020",,"April 21, 2022","['research site, long beach, california, united states research site, los angeles, california, united states research site, santa rosa, california, united states research site, norwich, connecticut, united states research site, daytona beach, florida, united states research site, gainesville, florida, united states research site, miami, florida, united states research site, punta gorda, florida, united states research site, tampa, florida, united states research site, marietta, georgia, united states research site, louisville, kentucky, united states research site, baltimore, maryland, united states research site, silver spring, maryland, united states research site, detroit, michigan, united states research site, minneapolis, minnesota, united states research site, lincoln, nebraska, united states research site, albuquerque, new mexico, united states research site, bronx, new york, united states research site, new york, new york, united states research site, portland, oregon, united states research site, philadelphia, pennsylvania, united states research site, spartanburg, south carolina, united states research site, sioux falls, south dakota, united states research site, chattanooga, tennessee, united states research site, knoxville, tennessee, united states research site, nashville, tennessee, united states research site, nashville, tennessee, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, salt lake city, utah, united states research site, fairfax, virginia, united states research site, kennewick, washington, united states research site, seattle, washington, united states research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, caba, argentina research site, cipolletti, argentina research site, ciudad autonoma de buenos aire, argentina research site, rosario, argentina research site, s.c. de bariloche, argentina research site, camperdown, australia research site, melbourne, australia research site, st leonards, australia research site, aalst, belgium research site, bruxelles, belgium research site, hasselt, belgium research site, kortrijk, belgium research site, roeselare, belgium research site, barretos, brazil research site, belo horizonte, brazil research site, belo horizonte, brazil research site, cachoeiro de itapemirim, brazil research site, florianopolis, brazil research site, florianópolis, brazil research site, fortaleza, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, são paulo, brazil research site, vitoria, brazil research site, panagyurishte, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, victoria, british columbia, canada research site, saint john, new brunswick, canada research site, kingston, ontario, canada research site, london, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, brno, czechia research site, brno, czechia research site, olomouc, czechia research site, ostrava, czechia research site, praha 2, czechia research site, praha 5, czechia research site, praha 8, czechia research site, praha, czechia research site, copenhagen, denmark research site, odense c, denmark research site, marseille, france research site, pessac, france research site, st herblain, france research site, strasbourg cedex, france research site, toulouse cedex 09, france research site, villejuif cedex, france research site, esslingen, germany research site, gauting, germany research site, göttingen, germany research site, heidelberg, germany research site, köln, germany research site, muenster, germany research site, regensburg, germany research site, würzburg, germany research site, athens, greece research site, athens, greece research site, heraklion, greece research site, holargos, athens, greece research site, larissa, greece research site, thessaloniki, greece research site, hong kong, hong kong research site, hong kong, hong kong research site, hong kong, hong kong research site, jordan, hong kong research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, gyöngyös - mátraháza, hungary research site, győr, hungary research site, szolnok, hungary research site, székesfehérvár, hungary research site, törökbálint, hungary research site, bangalore, india research site, bangalore, india research site, bengaluru, india research site, kolkata, india research site, mohali, india research site, mumbai, india research site, mumbai, india research site, mumbai, india research site, nashik, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, haifa, israel research site, jerusalem, israel research site, kfar saba, israel research site, petah tikva, israel research site, ramat-gan, israel research site, meldola, italy research site, milano, italy research site, milano, italy research site, milan, italy research site, monza, italy research site, napoli, italy research site, orbassano, italy research site, peschiera del garda, italy research site, roma, italy research site, rozzano, italy research site, akashi-shi, japan research site, bunkyo-ku, japan research site, hiroshima-shi, japan research site, kashiwa, japan research site, koto-ku, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, sakai-shi, japan research site, sendai-shi, japan research site, sunto-gun, japan research site, yokohama-shi, japan research site, cheongju-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon, korea, republic of research site, culiacan, mexico research site, mexico city, mexico research site, mexico, mexico research site, mexico, mexico research site, mexico, mexico research site, monterrey, mexico research site, nuevo leon, mexico research site, torreón, mexico research site, breda, netherlands research site, maastricht, netherlands research site, zwolle, netherlands research site, bellavista, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, bydgoszcz, poland research site, gdańsk, poland research site, lublin, poland research site, poznań, poland research site, tomaszów mazowiecki, poland research site, warszawa, poland research site, wrocław, poland research site, brasov, romania research site, cluj napoca, romania research site, constanta, romania research site, floresti, romania research site, iasi, romania research site, suceava, romania research site, timisoara, romania research site, krasnoyarsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, novosibirsk, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, barcelona, spain research site, barcelona, spain research site, madrid, spain research site, málaga, spain research site, oviedo, spain research site, palma, spain research site, pamplona, spain research site, santiago de compostela, spain research site, stockholm, sweden research site, lausanne, switzerland research site, zürich, switzerland research site, chiayi, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, adana, turkey research site, ankara, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, malatya, turkey research site, birmingham, united kingdom research site, headington, united kingdom research site, leeds, united kingdom research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, surrey, united kingdom research site, hanoi, vietnam research site, ho chi minh, vietnam research site, hochiminh, vietnam']",,https://ClinicalTrials.gov/show/NCT04642469,
550,551,NCT00786838,a study to assess the potential effects of a single-dose administration of trabectedin on the qt intervals of the electrocardiogram,,Completed,Has Results,solid tumor,drug: trabectedin|drug: placebo,the difference in the change from baseline (predose on day 1) in qtc intervals trabectedin relative to placebo at 24 hour post dose by fridericia correction|the difference in the change from baseline (predose on day 1) in qtc intervals trabectedin relative to placebo at 24 hour post dose by bazett's correction|maximum plasma concentration of trabectedin (cmax)|time taken to acheive maximum plasma concentration (tmax)|number of participants with qtc interval increase from baseline (predose on day 1) greater than 30 milli seconds|number of participants with qtc interval increase from baseline (predose on day 1) greater than 60 milli seconds|number of participants with qtc interval greater than 450 milli seconds|number of participants with qtc interval greater than 480 milli seconds|number of participants with qtc interval greater than 500 milli seconds|number of participants with pr interval greater than 200 milli seconds|number of participants with qrs interval greater than 120 milli seconds|mean heart rate (beats per minute) over 24 hours postdose,"johnson & johnson pharmaceutical research & development, l.l.c.|pharmamar",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,76.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CR014917|ET743OVC1001,October 2008,December 2009,December 2009,"November 6, 2008","January 23, 2014","April 11, 2014","['miami, florida, united states charlotte, north carolina, united states philadelphia, pennsylvania, united states tacoma, washington, united states brussels, belgium edegem, belgium wilrijk, belgium lyon, france marseille, france montpellier, france villejuif, france bangalore n/a, india pune, india seoul, korea, republic of moscow n/a, russian federation moscow, russian federation st petersburg n/a, russian federation st-petersburg, russian federation sanchinarro, spain']",,https://ClinicalTrials.gov/show/NCT00786838,
551,552,NCT01438437,trial of ablation of small hepatocellular carcinomas in patients of cirrhosis,,Unknown status,No Results Available,hepatocellular carcinoma,procedure: pai|procedure: rfa,local tumor response|survival rate|number of patients with complications|change from baseline in child status at 1 year,"all india institute of medical sciences, new delhi",All,"12 Years to 70 Years   (Child, Adult, Older Adult)",Phase 4,54.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,23-16/11/2001,March 2001,August 2014,September 2015,"September 22, 2011",,"July 13, 2012","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01438437,liver
552,553,NCT04385368,phase iii study to determine the efficacy of durvalumab in combination with chemotherapy in completely resected stage ii-iii non-small cell lung cancer (nsclc),MERMAID-1,Recruiting,No Results Available,"carcinoma, non-small-cell lung",drug: durvalumab + soc chemotherapy|other: placebo + soc chemotherapy,disease free survival (dfs) in mrd+ analysis set (using investigator assessments according to recist 1.1)|dfs in fas (using investigator assessments according to recist 1.1)|dfs (using bicr assessments according to recist 1.1) in mrd+ analysis set and in fas|os in mrd+ analysis set and in fas|change from baseline in eortc qlq-lc13 score|time to deterioration in eortc qlq-lc13 score|change from baseline in eortc qlq-c30 score|time to deterioration in eortc qlq-c30 score,astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,332.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D910LC00001,"July 17, 2020","December 31, 2024","September 30, 2026","May 12, 2020",,"May 12, 2022","['research site, birmingham, alabama, united states research site, tucson, arizona, united states research site, fayetteville, arkansas, united states research site, long beach, california, united states research site, santa rosa, california, united states research site, west hollywood, california, united states research site, norwich, connecticut, united states research site, miami, florida, united states research site, tampa, florida, united states research site, atlanta, georgia, united states research site, marietta, georgia, united states research site, fort wayne, indiana, united states research site, fairway, kansas, united states research site, louisville, kentucky, united states research site, baltimore, maryland, united states research site, silver spring, maryland, united states research site, towson, maryland, united states research site, detroit, michigan, united states research site, minneapolis, minnesota, united states research site, lincoln, nebraska, united states research site, albuquerque, new mexico, united states research site, bronx, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, chapel hill, north carolina, united states research site, durham, north carolina, united states research site, cleveland, ohio, united states research site, philadelphia, pennsylvania, united states research site, spartanburg, south carolina, united states research site, sioux falls, south dakota, united states research site, knoxville, tennessee, united states research site, nashville, tennessee, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, salt lake city, utah, united states research site, salt lake city, utah, united states research site, fairfax, virginia, united states research site, kennewick, washington, united states research site, seattle, washington, united states research site, bahía blanca, argentina research site, buenos aires, argentina research site, caba, argentina research site, caba, argentina research site, cipolletti, argentina research site, ciudad autonoma de buenos aire, argentina research site, ciudad de buenos aires, argentina research site, córdoba, argentina research site, mar del plata, argentina research site, rosario, argentina research site, s.c. de bariloche, argentina research site, camperdown, australia research site, melbourne, australia research site, st leonards, australia research site, aalst, belgium research site, bruxelles, belgium research site, charleroi, belgium research site, gent, belgium research site, hasselt, belgium research site, kortrijk, belgium research site, leuven, belgium research site, roeselare, belgium research site, belo horizonte, brazil research site, blumenau, brazil research site, cachoeira de itapemirim, brazil research site, florianopolis, brazil research site, fortaleza, brazil research site, goiania, brazil research site, ibirapuera, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, vitoria, brazil research site, panagyurishte, bulgaria research site, pleven, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, sofia, bulgaria research site, varna, bulgaria research site, victoria, british columbia, canada research site, saint john, new brunswick, canada research site, kingston, ontario, canada research site, london, ontario, canada research site, ottawa, ontario, canada research site, sudbury, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, brno, czechia research site, brno, czechia research site, olomouc, czechia research site, ostrava, czechia research site, praha 2, czechia research site, praha 5, czechia research site, praha 8, czechia research site, praha, czechia research site, copenhagen, denmark research site, odense c, denmark research site, århus n, denmark research site, bordeaux, france research site, marseille, france research site, saint herblain, france research site, strasbourg cedex, france research site, toulouse, france research site, villejuif cedex, france research site, esslingen, germany research site, gauting, germany research site, göttingen, germany research site, halle, germany research site, heidelberg, germany research site, köln, germany research site, muenster, germany research site, münchen, germany research site, regensburg, germany research site, würzburg, germany research site, athens, greece research site, athens, greece research site, heraklion, greece research site, holargos, athens, greece research site, larissa, greece research site, thessaloniki, greece research site, hong kong, hong kong research site, hong kong, hong kong research site, shatin, hong kong research site, budapest, hungary research site, budapest, hungary research site, budapest, hungary research site, debrecen, hungary research site, gyöngyös - mátraháza, hungary research site, győr, hungary research site, szolnok, hungary research site, székesfehérvár, hungary research site, törökbálint, hungary research site, bangalore, india research site, bangalore, india research site, bengaluru, india research site, chandigarh, india research site, kolkata, india research site, mohali, india research site, mumbai, india research site, mumbai, india research site, mumbai, india research site, nashik, india research site, new dehli, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, beer sheva, israel research site, haifa, israel research site, jerusalem, israel research site, jerusalem, israel research site, kfar saba, israel research site, petah tikva, israel research site, ramat gan, israel research site, meldola, italy research site, milano, italy research site, milano, italy research site, milano, italy research site, monza, italy research site, napoli, italy research site, orbassano, italy research site, peschiera del garda, italy research site, roma, italy research site, rozzano, italy research site, akashi-shi, japan research site, bunkyo-ku, japan research site, hiroshima-shi, japan research site, kashiwa, japan research site, koto-ku, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sakai-shi, japan research site, sendai-shi, japan research site, sunto-gun, japan research site, yokohama-shi, japan research site, cheongju-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon-si, korea, republic of research site, culiacan, mexico research site, mexico city, mexico research site, mexico city, mexico research site, mexico, mexico research site, mexico, mexico research site, monterrey, mexico research site, nuevo leon, mexico research site, torreón, mexico research site, breda, netherlands research site, maastricht, netherlands research site, zwolle, netherlands research site, bellavista, peru research site, la libertad, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, trujillo, peru research site, bydgoszcz, poland research site, gdańsk, poland research site, lublin, poland research site, olsztyn, poland research site, poznań, poland research site, tomaszów mazowiecki, poland research site, warszawa, poland research site, wrocław, poland research site, brasov, romania research site, bucharest, romania research site, constanta, romania research site, floresti, romania research site, iasi, romania research site, timisoara, romania research site, kazan, russian federation research site, krasnodar, russian federation research site, krasnoyarsk, russian federation research site, kuzmolovsky, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, murmansk, russian federation research site, nizhny novgorod, russian federation research site, novosibirsk, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, volgograd, russian federation research site, yaroslavl, russian federation research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, barcelona, spain research site, madrid, spain research site, madrid, spain research site, málaga, spain research site, oviedo, spain research site, palma, spain research site, pamplona, spain research site, santiago de compostela (a coruña), spain research site, stockholm, sweden research site, lausanne, switzerland research site, zürich, switzerland research site, chiayi, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, taipei 112, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, tao-yuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, khon kaen, thailand research site, pathumwan, thailand research site, phisanulok, thailand research site, adana, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, antalya, turkey research site, istanbul, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, malatya, turkey research site, birmingham, united kingdom research site, headington, united kingdom research site, leeds, united kingdom research site, london, united kingdom research site, london, united kingdom research site, sutton, united kingdom research site, hanoi, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam research site, hochiminh, vietnam']",,https://ClinicalTrials.gov/show/NCT04385368,
553,554,NCT03222895,distribution of lymph node metastases in esophageal carcinoma,TIGER,Recruiting,No Results Available,esophageal neoplasms|lymph node metastases,,distribution of lymph node metastases|accuracy of preoperative diagnostics|prognostic value of different lymph node stations|distribution pattern of recurrence or metastases|number of harvested lymph nodes in patients who are treated with and without neo-adjuvant chemoradiotherapy|skip nodal metastases|ratio of nodal metastases inside and outside the radiation field|3- and 5-year overall and disease free survival,academisch medisch centrum - universiteit van amsterdam (amc-uva),All,"18 Years and older   (Adult, Older Adult)",,5000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,W17_069,"March 1, 2019","December 1, 2021","March 1, 2026","July 19, 2017",,"October 19, 2020","['md anderson cancer center, houston, texas, united states instituto nacional de câncer, rio de janeiro, brazil university of toronto, toronto, canada fudan university shanghai cancer center, shanghai, yangpu, china hospital district of helsinki and uusimaa, helsinki, finland university medical center of the johannes gutenberg university, mainz, germany university of athens, school of medicine, athens, greece university of hong kong, hong kong, hong kong tata memorial centre, mumbai, india irccs policlinico san donato, milan, italy ospedale san raffaele, milan, italy university of verona, verona, italy uonuma institute and niigata university, niigata, japan keio university school of medicine, tokyo, japan the cancer institute hospital of jfcr, tokyo, japan ziekenhuisgroep twente, almelo & hengelo, almelo, netherlands amsterdam umc, amsterdam, netherlands hospital universitario del mar, barcelona, spain karolinska institutet, stockholm, sweden']",,https://ClinicalTrials.gov/show/NCT03222895,esophag
554,555,NCT00824343,a phase ii clinical trial to study the efficacy and safety of a new drug p276-00 in treatment of recurrent and/or locally advanced head and neck cancer,MONARCH,Completed,No Results Available,squamous cell carcinoma of head and neck,drug: p276-00,"response rate|duration of response, progression free survival (pfs), time to progression (ttp), pfs at one year, overall survival (os) at one year",piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 2,86.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/21/08,September 2008,April 2011,June 2013,"January 16, 2009",,"July 10, 2013","['bharath hospital & institute of oncology, mysore, mysore, karnataka, india regional cancer centre, trivandrum, kerala, india kashyap nursing home, mumbai, maharashtra, india jaslok hospital, mumbai, mumbai, maharashtra, india central india cancer research institute,, nagpur, maharashtra, india deenanath mangeshkar hospital & research centre, pune, maharashtra, india bhagwan mahaveer cancer hospital & research centre, dept. of medical oncology, jaipur, jaipur, rajasthan, india v. n. cancer centre, gknm hospital,, coimbatore, tamilnadu, india dept. of surgical oncology, csm medical university, lucknow, lucknow, uttarpradesh, india']",,https://ClinicalTrials.gov/show/NCT00824343,skin
555,556,NCT04427072,study of capmatinib efficacy in comparison with docetaxel in previously treated participants with non-small cell lung cancer harboring met exon 14 skipping mutation,GeoMETry-III,Recruiting,No Results Available,"carcinoma, non-small-cell lung",drug: capmatinib|drug: docetaxel,"progression free survival (pfs) per blinded independent review committee (birc) using recist v1.1|overall response (orr) per recist 1.1 by birc|overall response (orr) per recist 1.1 by investigator|time to response (ttr) per recist 1.1 by birc|time to response (ttr) per recist 1.1 by investigator|duration of response (dor) per recist 1.1 by birc|duration of response (dor) per recist 1.1 by investigator|disease control rate (dcr) per recist 1.1 by birc|disease control rate (dcr) per recist 1.1 by investigator|progression free survival (pfs) per investigator using recist v1.1|overall survival (os)|percentage of patients with adverse events and serious adverse events.|plasma capmatanib concentration|change from baseline in score as per european organization for research and treatment of cancer (eortc) quality of life questionnaire (qlq)-c30|change from baseline in score as per european organization for research and treatment of cancer (eortc) quality of life lung cancer module (qlq-lc13)|change from baseline in score as per european quality of life 5-dimension 5-level (eq-5d-5l) questionnaire|overall intracranial response rate (oirr)|duration of intracranial response (doir)|time to intracranial response (ttir)|intracranial disease control rate (idcr)|time to symptom deterioration for chest pain, cough and dyspnea assessed using european organization for research and treatment of cancer (eortc) quality of life lung cancer module (qlq-lc13)|time to symptom deterioration for chest pain, cough and dyspnea assessed using european organization for research and treatment of cancer (eortc) quality of life questionnaire (qlq)-c30",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,90.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CINC280A2301,"September 25, 2020","July 14, 2023","October 21, 2024","June 11, 2020",,"February 18, 2022","['novartis investigative site, melbourne, victoria, australia novartis investigative site, leuven, belgium novartis investigative site, roeselare, belgium novartis investigative site, barretos, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sofia, bulgaria novartis investigative site, angers cedex 9, france novartis investigative site, bordeaux, france novartis investigative site, caen cedex, france novartis investigative site, clermont-ferrand, france novartis investigative site, paris, france novartis investigative site, paris, france novartis investigative site, pierre benite cedex, france novartis investigative site, rennes, france novartis investigative site, regensburg, bavaria, germany novartis investigative site, gauting, bayern, germany novartis investigative site, berlin, germany novartis investigative site, berlin, germany novartis investigative site, frankfurt, germany novartis investigative site, gottingen, germany novartis investigative site, grosshansdorf, germany novartis investigative site, koeln, germany novartis investigative site, oldenburg, germany novartis investigative site, ulm, germany novartis investigative site, torokbalint, pest, hungary novartis investigative site, budapest, hungary novartis investigative site, new delhi, delhi, india novartis investigative site, pune, maharashtra, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, bologna, bo, italy novartis investigative site, meldola, fc, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, padova, pd, italy novartis investigative site, aviano, pn, italy novartis investigative site, parma, pr, italy novartis investigative site, roma, rm, italy novartis investigative site, seoul, korea, republic of novartis investigative site, vilnius, lithuania novartis investigative site, kuantan, pahang, malaysia novartis investigative site, kuala lumpur, wilayah persekutuan, malaysia novartis investigative site, pulau pinang, malaysia novartis investigative site, nijmegen, netherlands novartis investigative site, lisboa, portugal novartis investigative site, matosinhos, portugal novartis investigative site, porto, portugal novartis investigative site, arkhangelsk, russian federation novartis investigative site, chelyabinsk, russian federation novartis investigative site, nizhniy novgorod, russian federation novartis investigative site, omsk, russian federation novartis investigative site, pushkin saint petersburg, russian federation novartis investigative site, st- petersburg, russian federation novartis investigative site, port elizabeth, western cape, south africa novartis investigative site, cape town, south africa novartis investigative site, malaga, andalucia, spain novartis investigative site, oviedo, asturias, spain novartis investigative site, hospitalet de llobregat, catalunya, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, la coruna, galicia, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, songkhla, hat yai, thailand novartis investigative site, bangkok, thailand novartis investigative site, hanoi, vietnam']",,https://ClinicalTrials.gov/show/NCT04427072,
556,557,NCT00071188,zd6474 alone or in combination with paclitaxel and carboplatin in subjects with previously untreated locally advanced or metastatic non-small cell lung cancer (nsclc),,Completed,No Results Available,"carcinoma, non-small-cell lung",drug: zd6474|drug: paclitaxel|drug: carboplatin,,"genzyme, a sanofi company|sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 2,,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D4200C00007|D4200C00007(run-in)|D4200C0007A (randomization),February 2004,October 2007,October 2007,"October 16, 2003",,"August 25, 2016","['research site, concord, california, united states research site, los angeles, california, united states research site, chicago, illinois, united states research site, boston, massachusetts, united states research site, st. louis, missouri, united states research site, providence, rhode island, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, houston, texas, united states research site, lubbock, texas, united states research site, norfolk, virginia, united states research site, seattle, washington, united states research site, helsinki, finland research site, turku, finland research site, besancon, france research site, lille, france research site, strasbourg, france research site, essen, germany research site, frankfurt, germany research site, mainz, germany research site, ulm, germany research site, pune, india research site, milano, italy research site, orbassano, italy research site, cape town, south africa research site, johannesburg, south africa research site, panorama, south africa research site, parkland, south africa research site, pretoria, south africa research site, barcelona, spain research site, madrid, spain research site, malaga, spain research site, pamplona, spain research site, chiang mai, thailand']",,https://ClinicalTrials.gov/show/NCT00071188,
557,558,NCT03706690,a study of durvalumab as consolidation therapy in non-small cell lung cancer patients,PACIFIC-5,"Active, not recruiting",No Results Available,"carcinoma, non-small-cell lung",drug: durvalumab|other: placebo,"progression-free survival (pfs) according to recist 1.1.|the efficacy of durvalumab treatment compared to placebo in terms of overall survival (os).|the efficacy of durvalumab treatment compared to placebo in terms of proportion of patients alive at 24 months (os24) from randomisation.|objective response rate (orr) assessed by bicr according to recist 1.1.|duration of response (dor) assessed by bicr according to recist 1.1.|proportion of patients alive and progression free from randomisation to second progression (pfs2) as defined by local standard clinical practice.|proportion of patients alive and progression free at 12 months from randomisation (pfs12) assessed by bicr according to recist 1.1.|proportion of patients alive and progression free at 18 months from randomisation (pfs18) assessed by bicr according to recist 1.1.|proportion of patients at time to death or distant metastasis (ttdm) assessed by bicr according to recist 1.1.|peak plasma concentration (cmax) in randomised patients|trough concentration (ctrough) in randomised patients|number of participants with treatment-related adverse events as assessed by ctcae v5.0|detection of ada neutralising antibodies titres for all randomised patients|ihc analysis of tumoural pd-l1 expression and spatial distribution within the tumour microenvironment relative to efficacy outcome os.|ihc analysis of tumoural pd-l1 expression and spatial distribution within the tumour microenvironment relative to efficacy outcome pfs.|ihc analysis of tumoural pd-l1 expression and spatial distribution within the tumour microenvironment relative to efficacy outcome orr.|number of participants with abnormal findings with physical examination|vital sign (blood pressure [bp])|vital sign (pulse rate)|vital sign (temperature)|vital sign (respiration rate)|vital sign (12-lead electrocardiogram)|change in albumin (g/l)|change in alkaline phosphatase (u/l)|change in alanine aminotransferase (u/l)|change in aspartate aminotransferase (u/l)|change in amylase (u/l)|change in bicarbonate (mmol/l)|change in calcium (mmol/l)|change in chloride (mmol/l)|change in creatinine (μmol/l)|change in gamma glutamyltransferase (u/l)|change in glucose (mmol/l)|change in lactate dehydrogenase (u/l)|change in lipase (u/l)|change in magnesium (mmol/l)|change in potassium (mmol/l)|change in sodium (mmol/l)|change in total bilirubin (μmol/l)|change in total protein (g/l)|change in tsh (miu/l)|change in t3 free (reflex) (miu/l)|change in t4 free (reflex) (miu/l)|change in urea or blood urea nitrogen, depending on the local practice (mmol/l)|change in uric acid (mmol/l)|change in absolute neutrophil count (/l)|change in absolute lymphocyte count (/l)|change in haemoglobin (g/l)|change in platelet count (/l)|change in total white blood cell count (/l)|change in activated partial thromboplastin time|change in international normalised ratio|urinalysis: change in bilirubin (μmol/l)|urinalysis: change in blood|urinalysis: change in color and apprearance|urinalysis: change in ketones (mmol/l)|urinalysis: change in ph|urinalysis: change in protein (g/l)|urinalysis: change in specific gravity",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,407.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D933YC00001,"November 27, 2018","October 14, 2022","November 29, 2024","October 16, 2018",,"April 4, 2022","['research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, bengbu, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, chengdu, china research site, chengdu, china research site, chongqing, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, linhai, china research site, nanjing, china research site, nanning, china research site, ningbo, china research site, qingdao, china research site, shanghai, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, wenzhou, china research site, wuhan, china research site, yangzhou, china research site, zhengzhou, china research site, zhengzhou, china research site, ürümqi, china research site, hong kong, hong kong research site, hongkong, hong kong research site, bangalore, india research site, bengaluru, india research site, chennai, india research site, chennai, india research site, karamsad, india research site, kolkata, india research site, nasik, india research site, vadodara, india research site, daegu, korea, republic of research site, gwangju, korea, republic of research site, seoul, korea, republic of research site, cdmx, mexico research site, culiacán, mexico research site, mexico city, mexico research site, monterrey, mexico research site, méxico, mexico research site, san luis potosí, mexico research site, bacolod, philippines research site, baguio city, philippines research site, cagayan de oro city, philippines research site, cebu, philippines research site, davao city, philippines research site, quezon city, philippines research site, quezon city, philippines research site, san juan, philippines research site, białystok, poland research site, gdańsk, poland research site, poznań, poland research site, tomaszów mazowiecki, poland research site, warszawa, poland research site, kazan, tatarstan, russian federation research site, kirov, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, murmansk, russian federation research site, novosibirsk, russian federation research site, novosibirsk, russian federation research site, obninsk, russian federation research site, saint petersburg, russian federation research site, samara, russian federation research site, saransk, russian federation research site, volgograd, russian federation research site, taichung, taiwan research site, tainan, taiwan research site, taipei city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, adana, turkey research site, ankara, turkey research site, edirne, turkey research site, istanbul, turkey research site, konya, turkey research site, malatya, turkey']",,https://ClinicalTrials.gov/show/NCT03706690,
558,559,NCT01369433,a rollover protocol to allow continued access to tivozanib (av 951) for subjects enrolled in other tivozanib protocols,,Terminated,Has Results,solid tumors,drug: tivozanib + paclitaxel|drug: tivozanib + temsirolimus|drug: tivozanib|drug: tivozanib (av-951)|drug: tivozanib + capecitabine|drug: tivo,number of subjects with adverse events (aes) and serious aes,"aveo pharmaceuticals, inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,225.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AV-951-09-901,June 2010,June 2015,October 2015,"June 9, 2011","September 1, 2020","September 1, 2020","[""translational genomics research institute (tgen), scottsdale, arizona, united states institute of urologic oncology, los angeles, california, united states stanford university, stanford, california, united states aurora, colorado, united states florida cancer specialists, fort myers, florida, united states h. lee moffitt cancer center & research institute hospital, inc, tampa, florida, united states beech grove, indiana, united states horizon oncology research, inc., lafayette, indiana, united states wichita, kansas, united states medical oncology llc, baton rouge, louisiana, united states jayne gurtler md, laura brinz md, angelo russo md and janet burroff md apmc, metairie, louisiana, united states associates in oncology/hematology, rockville, maryland, united states dana farber cancer institute, boston, massachusetts, united states grand rapids, michigan, united states tupelo, mississippi, united states nebraska methodist hospital, omaha, nebraska, united states las vegas, nevada, united states lebanon, new hampshire, united states chapel hill, north carolina, united states columbus, ohio, united states the ou cancer institute, oklahoma city, oklahoma, united states philadelphia, pennsylvania, united states sarah cannon research institute (scri), nashville, tennessee, united states austin, texas, united states coastal bend cancer center, corpus christi, texas, united states dallas, texas, united states tacoma, washington, united states hamilton, ontario, canada toronto, ontario, canada montreal, quebec, canada aveo investigational site, madurai, india aveo investigational site, mumbai, india rotterdam, netherlands aveo investigational site, krasnodar, russian federation aveo investigational site - moscow 1, moscow, russian federation aveo investigational site - moscow 2, moscow, russian federation aveo investigational site - moscow 3, moscow, russian federation aveo investigational site - moscow 4, moscow, russian federation aveo investigational site - moscow 5, moscow, russian federation aveo investigational site, obninsk, russian federation aveo investigational site, rostov, russian federation aveo investigational site, saint petersburg, russian federation stavropol', russian federation aveo investigational site, ufa, russian federation aveo investigational site, dnipropetrovsk, ukraine aveo investigational site, donetsk, ukraine aveo investigational site, kharkiv, ukraine aveo investigational site, lviv, ukraine aveo investigational site, zaporizhya, ukraine""]",,https://ClinicalTrials.gov/show/NCT01369433,
559,560,NCT00622193,dose range study of anamorelin in patients with non-small cell lung cancer,,Completed,No Results Available,"carcinoma, non-small-cell lung",drug: anamorelin hcl|drug: placebo,hand grip strength and body weight|quality of life and biomarker,"helsinn therapeutics (u.s.), inc",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,228.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ST-ANAM-207,March 2008,December 2009,December 2009,"February 22, 2008",,"April 14, 2017","[""university of arkansas for medical sciences, little rock, arkansas, united states osler medical, melbourne, florida, united states augusta oncology associates, augusta, georgia, united states south georgia medical center, valdosta, georgia, united states investigative clinical research of indiana, indianapolis, indiana, united states john hopkins university, baltimore, maryland, united states massachusetts general hospital, boston, massachusetts, united states dana farber cancer center, boston, massachusetts, united states caritas st. elizabeth's medical center, boston, massachusetts, united states beth israel deaconess medical center, boston, massachusetts, united states the west clinic, corinth, mississippi, united states the west clinic, southaven, mississippi, united states washington university school of medicine, st louis, missouri, united states duke university medical center, durham, north carolina, united states south carolina cancer specialists, hilton head island, south carolina, united states the west clinic, memphis, tennessee, united states baylor college of medicine/vamc, houston, texas, united states the methodist hospital research institute, houston, texas, united states north west medical specialties, pllc, puyallup, washington, united states regional cancer centre indira gandhi institute of medical sciences, patna, bihar, india cancer clinic 208, nagpur, maharashtra, india noble hospital, pune, maharashtra, india ruby hall clinic, pune, maharashtra, india kaushalya medical foundation trust hospital, thane, maharashtra, india searoc cancer center, jaipur, rajasthan, india jawaharlal nehru cancer hospital and research centre, bhopal, india kamakshi memorial hospital, chennai, india dharamshila cancer hospital and research center, delhi, india bhagwan mahaveer cancer hospital and resaerch center, jaipur, india birla cancer centre sms medical college hospital, jaipur, india kodlikeri memorial hospital, maharashtra, india shatabdi super speciality hospital, mumbai naka, nasik, india jaslok hospital and research centre, mumbai, india""]",,https://ClinicalTrials.gov/show/NCT00622193,
560,561,NCT01852292,study of efficacy and safety of buparlisib (bkm120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic head and neck cancer previously pre-treated with a platinum therapy,,Terminated,Has Results,head and neck squamous cell carcinoma,drug: buparlisib|drug: buparlisib matching placebo|drug: paclitaxel,"progression free survival (pfs) per investigator assessment|overall survival (os)|overall response rate (orr) as per local radiological assessment|time to response (ttr) as per local radiological assessment|disease control rate (dcr) as per local radiological assessment|duration of response (dor) as per local investigator|health-related quality of life (hrqol):time to 10% definitive deterioration in the global health status/quality of life per eortc-qlq-c30|health-related quality of life (hrqol):time to 10% definitive deterioration in the head and neck cancer symptoms scales for pain, speech problems, swallowing and sense problems per eortc-qlq-hn35|plasma concentration-time profiles of bkm120 pharmacokinetics (pk) for auc0-24 and auclast|plasma concentration-time profiles of bkm120 pharmacokinetics (pk) for cmax|plasma concentration-time profiles of bkm120 pharmacokinetics (pk) for tmax|plasma concentration-time profiles of bkm120 pharmacokinetics (pk) for cl/f",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,157.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CBKM120H2201|2013-000744-26,"October 1, 2013","March 30, 2017","March 30, 2017","May 13, 2013","June 26, 2018","July 24, 2018","['highlands oncology group, fayetteville, arkansas, united states dana farber cancer institute irb, boston, massachusetts, united states washington u school of medicine center for clinical studies sc - bkm120h2201, saint louis, missouri, united states the mount sinai hospital dept of oncology, new york, new york, united states university of n.c. at chapel hill lineberger comp. cancer ctr., chapel hill, north carolina, united states university hospitals case medical center univ. hospitals of cleveland, cleveland, ohio, united states upmc cancer centers bkm120h2201, pittsburgh, pennsylvania, united states novartis investigative site, st leonards, new south wales, australia novartis investigative site, hamilton, ontario, canada novartis investigative site, montreal, quebec, canada novartis investigative site, saint herblain cedex, france novartis investigative site, berlin, germany novartis investigative site, essen, germany novartis investigative site, hannover, germany novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, nyiregyhaza, hungary novartis investigative site, nashik, maharashtra, india novartis investigative site, dehli, new delhi, india novartis investigative site, jaipur, rajasthan, india novartis investigative site, kolkata, west bengal, india novartis investigative site, kerala, india novartis investigative site, mumbai, india novartis investigative site, dublin 4, ireland novartis investigative site, firenze, fi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, palermo, pa, italy novartis investigative site, roma, rm, italy novartis investigative site, salerno, sa, italy novartis investigative site, torino, to, italy novartis investigative site, venezia, ve, italy novartis investigative site, kashiwa, chiba, japan novartis investigative site, koto-ku, tokyo, japan novartis investigative site, minato-ku, tokyo, japan novartis investigative site, seoul, korea, korea, republic of novartis investigative site, seoul, seocho-gu, korea, republic of novartis investigative site, warszawa, poland novartis investigative site, leningrad region, russia, russian federation novartis investigative site, nizhniy novgorod, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, barcelona, catalunya, spain novartis investigative site, hospitalet de llobregat, catalunya, spain novartis investigative site, madrid, spain novartis investigative site, basel, switzerland novartis investigative site, genève, switzerland novartis investigative site, tainan, taiwan roc, taiwan novartis investigative site, kaohsiung city, taiwan novartis investigative site, taichung city, taiwan novartis investigative site, songkla, hat yai, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, glasgow, scotland, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, manchester, united kingdom']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/92/nct01852292/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/92/nct01852292/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01852292,skin
561,562,NCT04819100,a study of selpercatinib after surgery or radiation in participants with non-small cell lung cancer (nsclc),LIBRETTO-432,Recruiting,No Results Available,"carcinoma, non-small-cell lung",drug: selpercatinib|drug: placebo,event-free survival (efs)|efs|overall survival (os)|time to distant disease recurrence in the central nervous system (cns)|progression free survival on the next line of treatment (pfs2)|positive predictive value (ppv) of local lab tests compared to central lab test to detect rearranged during transfection (ret) gene fusion|mean change from baseline over time in nsclc symptoms|mean change from baseline over time in physical function,"loxo oncology, inc.|eli lilly and company",All,"18 Years and older   (Adult, Older Adult)",Phase 3,170.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",18126|J2G-MC-JZJX|2020-005191-35,"December 20, 2021","August 31, 2028","November 30, 2032","March 26, 2021",,"April 19, 2022","['ucla hematology oncology, santa monica, california, united states stockton hematology oncology medical group, stockton, california, united states ucla medical center, torrance, california, united states genesiscare, aventura, florida, united states genesiscare - boca raton, boca raton, florida, united states florida cancer specialists, fort myers, florida, united states mayo clinic in florida, jacksonville, florida, united states florida cancer specialists, saint petersburg, florida, united states beth israel deaconess medical center, boston, massachusetts, united states dana-farber cancer institute, boston, massachusetts, united states mayo clinic, rochester, minnesota, united states new york oncology hematology, p.c, clifton park, new york, united states memorial sloan kettering cancer center, new york, new york, united states sarah cannon research institute scri, nashville, tennessee, united states tennessee oncology pllc, nashville, tennessee, united states us oncology, the woodlands, texas, united states university of vermont medical center, burlington, vermont, united states border medical oncology, albury, new south wales, australia sunshine coast university hospital, birtinya, queensland, australia the townsville hospital, douglas, queensland, australia rockhampton hospital, rockhampton, queensland, australia ballarat health services, ballarat, victoria, australia bendigo health, bendigo, victoria, australia goulburn valley health, shepparton, victoria, australia south west healthcare, warrambool, victoria, australia landeskrankenhaus feldkirch, feldkirch, austria klinik floridsdorf, wien, austria cliniques universitaires saint-luc, bruxelles, brussel, belgium université catholique de louvain-namur - centre hospitalier universitaire dinant-godinne - site godinne, yvoir, namur, belgium az delta vzw, roeselare, west-vlaanderen, belgium universitair ziekenhuis antwerpen, edegem, belgium clinique saint pierre ottignies, ottignies, belgium núcleo de oncologia da bahia, salvador, bahia, brazil oncocentro bh, belo horizonte, minas gerais, brazil cot - centro oncológico do triângulo s.a., uberlândia, minas gerais, brazil multihemo servicos medicos s/a, recife, pernambuco, brazil hospital são lucas da pucrs, porto alegre, rio grande do sul, brazil instituto de educação, pesquisa e gestão em saúde, rio de janeiro, rj, brazil ibcc - instituto brasileiro de controle do câncer, são paulo, brazil centro paulista de oncologia, são paulo, brazil princess margaret hospital, toronto, ontario, canada beijing friendship hospital, beijing, beijing, china beijing cancer hospital, haidian district, beijing, china the first affiliated hospital chongqing medical university, chongqing, chongqing, china fujian provincial hospital, fuzhou, fujian, china guangdong provincial people\'s hospital, guangzhou, guangdong, china southern medical university nanfang hospital, guangzhou, guangdong, china harbin medical university cancer hospital, harbin, heilongjiang, china tongji medical college of huazhong university of science and technology, wuhan, hubei, china xiangya hospital, central south university, changsha, hunan, china hunan cancer hospital, changsha, hunan, china hunan cancer hospital, changsha, hunan, china jilin cancer hospital, changchun, jilin, china tangdu hospital of fourth military medical university of chinese people\'s liberation army, xi\'an, shaanxi, china jinan central hospital, jinan, shandong, china shanghai chest hospital, shanghai, shanghai, china zhongshan hospital, fudan university, shanghai, shanghai, china shanghai pulmonary hospital, shanghai, shanghai, china the third people\'s hospital of chengdu, chengdu, sichuan, china west china hospital of sichuan university, chengdu, sichuan, china first affiliated hosp of college of med, zhejiang university, hangzhou, zhejiang, china zhejiang cancer hospital, hangzhou, zhejiang, china beijing peking union medical college hospital, beijing, china masarykuv onkologicky ustav, brno, czech republic, czechia nemocnice agel ostrava-vitkovice a.s.-plicni oddeleni, ostrava - vitkovice, czechia fakultni nemocnice bulovka, praha 8, czechia odense universitetshospital, odense c, syd, denmark hcl-hôpital louis pradel, lyon (bron), france centre leon berard, lyon cedex 08, france assistance publique hôpitaux de marseille - hôpital nord, marseille cedex 20, france hopital cochin, paris, france chu charles nicolle in rouen, rouen cedex, france gustave roussy, villejuif cedex, france thoraxklinik-heidelberg ggmbh, heidelberg, baden-württemberg, germany asklepios fachkliniken münchen-gauting, gauting, bayern, germany lungenfachklinik immenhausen, immenhausen, hessen, germany franziskus-hospital harderberg, georgsmarienhütte, lower saxony, germany lungenclinic grosshansdorf, grosshansdorf, schleswig-holstein, germany charité-campus benjamin franklin-hematology and oncology, berlin, germany university hospital of patras, patras, achaḯa, greece agios savvas regional cancer hospital, athens, attikí, greece sotiria thoracic diseases hospital of athens, athens, attikí, greece university general hospital of heraklion, heraklion, krete, greece european interbalkan medical center, thessaloniki, thessaloníki, greece g. papanikolaou general hospital, thessaloniki, thessaloníki, greece queen elizabeth hospital, hong kong, hong kong hong kong united oncology centre, kowloon, hong kong princess margaret hospital, lai chi kok, hong kong regional cancer centre, thiruvananthapuram, kerala, india tata memorial hospital, mumbai, maharashtra, india rashtrasant tukdoji regional cancer hospital and research centre (rstrch), nagpur, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india rambam medical center, haifa, israel hadassah medical center, jerusalem, israel sheba medical center, ramat gan, israel asst grande ospedale metropolitano niguarda, milan, milano, italy istituto clinico humanitas, rozzano, milano, italy azienda ospedaliera dei colli, naples, napoli, italy azienda sanitaria ospedaliera s luigi gonzaga, orbassano, torino, italy istituto oncologico veneto irccs, padova, veneto, italy irccs ospedale oncologico di bari, bari, italy aichi cancer center hospital, nagoya, aichi, japan national cancer center hospital east, kashiwa, chiba, japan himeji medical center, himeji, hyogo, japan kanagawa cancer center, yokohama, kanagawa, japan niigata cancer center hospital, niigata-shi, niigata, japan shizuoka cancer center, nagaizumi, shizuoka, japan japanese foundation for cancer research, koto, tokyo, japan tottori university hospital, yonago, tottori, japan hiroshima university hospital, hiroshima, japan osaka international cancer institute, osaka, japan national cancer center, goyang-si, gyeonggi-do, korea, republic of seoul national university bundang hospital, seongnam-si, gyeonggi-do, korea, republic of chonnam national university hwasun hospital, hwasun-gun, jeollanam do, korea, republic of asan medical center, seoul, korea, korea, republic of korea university guro hospital, seoul, korea, korea, republic of seoul national university hospital, seoul, seoul, korea, korea, republic of kyungpook national university medical center chilgok hospital, daegu, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of samsung medical center, seoul, korea, republic of actualidad basada en la investigación del cáncer, guadalajara, jalisco, mexico oncare viaducto nápoles, delegación benito juárez, mexico city, federal district, mexico hospital universitario ""dr. jose eleuterio gonzalez"", monterrey, nuevo león, mexico avix investigación clinica, s.c., monterrey, nuevo león, mexico ziekenhuis st. jansdal, harderwijk, gelderland, netherlands universitair medisch centrum st radboud nijmegen, nijmegen, netherlands krakowski szpital specjalistyczny im. jana pawa ii, krakow, małopolskie, poland wielkopolskie centrum pulmonologii i torakochirurgii, poznan, wielkopolskie, poland uniwersyteckie centrum kliniczne, gdansk, poland narodowy instytut onkologii im. marii sklodowskiej-curie panstwowy instytut badawczy, warszawa, poland pan american center for oncology trials, rio piedras, puerto rico institutul oncologic ""prof. dr. ion chiricuta"" cluj-napoca, cluj-napoca, romania arkhangelsk clinical oncological dispensary, arkhangelsk, arkhangel\'skaya oblast\', russian federation hadassah medical ltd, moscow, russian federation national medical research center of oncology n. a. n. n. petrov, saint petersburg, russian federation eurocityclinic, saint-petersburg, russian federation parkway cancer centre, singapore, singapore tan tock seng hospital, singapore, singapore chus - hospital clinico universitario, santiago de compostela, a coruña [la coruña], spain hospital universitario puerta del mar, cádiz, andalucía, spain hospital universitario central de asturias, oviedo, asturias, spain hospital de mataró, mataró, barcelona [barcelona], spain hospital universitario virgen de la arrixaca, el palmar, murcia, spain hospital álvaro cunqueiro, vigo, pontevedra, spain hospital universitario de canarias, santa cruz de tenerife, tenerife, spain hospital general de albacete, albacete, spain hospital germans trias i pujol, badalona, spain hospital del mar, barcelona, spain hospital universitari dexeusa, barcelona, spain hospital universitari vall d\'hebron, barcelona, spain hospital clinic i provincial, barcelona, spain institut catala d\'oncologia, barcelona, spain hospital reina sofia, cordoba, spain complejo asistencial de leon, leon, spain hospital lucus augusti, lugo, spain md anderson, madrid, spain hospital universitario ramón y cajal, madrid, spain hospital clinico san carlos, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital regional universitario, malaga, spain hospital santa maria nai, ourense, spain hospital son llàtzer-oncology, palma de mallorca, spain hospital universitari sant joan de reus, reus, spain hospital universitario virgen macarena, sevilla, spain hospital universitario la fe de valencia, valencia, spain sahlgrenska universitetssjukhuset, göteborg, sweden changhua christian hospital, changhua city, changhua county, taiwan chi mei hospital - liouying branch, tainan city, tainan, taiwan kaohsiung medical university hospital, kaohsiung, taiwan chang gung memorial hospital - kaohsiung branch, kaohsiung, taiwan chung shan medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan national taiwan university cancer centre, taipei city, taiwan national taiwan university hospital, taipei city, taiwan taipei veterans general hospital, taipei, taiwan chang gung memorial hospital - linkou, taoyuan city, taiwan izmir medical park hospital, izmir, karşıyaka/i̇zmir, turkey baskent university dr. turgut noyan research and training center, adana, turkey adana sehir hastanesi, adana, turkey abdurrahman yurtaslan ankara oncology, education and research hospital, ankara, turkey ankara city hospital, ankara, turkey uludag universitesi, bursa, turkey dicle university, diyarbakir, turkey trakya university, edirne, turkey medipol mega university hospital, istanbul, turkey goztepe prof dr suleyman yalcin sehir hastanesi, istanbul, turkey ege university medicine of faculty, izmir, turkey izmir katip celebi university training and research hospital oncology, izmir, turkey memorial antalya hastanesi, kepez, turkey inonu university medical faculty oncology, malatya, turkey maslak acıbadem hstanesi, sarıyer, turkey cnpe ""regional center of oncology"", kharkiv, kharkivska oblast, ukraine communal noncommercial enterprise ""podillia regional oncology center of vinnytsia regional council"", vinnytsia, vinnytska oblast, ukraine medical center ""mriya med-service"", llc, kryvyi rig, ukraine kyiv city clinical oncological center, kyiv, ukraine communal enterprise ""odesa regional clinical hospital"", odesa, ukraine university clinic of sumy state university, sumy, ukraine medical center ""oncolife"", zaporizhya, ukraine university college hospital - london, london, greater london, united kingdom the clatterbridge cancer centre, bebbington, merseyside, united kingdom new cross hospital, wolverhampton, west midlands, united kingdom city hospital, nottingham university hospitals, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT04819100,
562,563,NCT02765503,resource sparing curative radiotherapy for locally advanced squamous cell cancer of the head and neck: the hypno trial,HYPNO,Unknown status,No Results Available,squamous cell carcinoma of the head and neck,radiation: external beam radiotherapy,primary tumor control in t and n position|treatment related late grade 2+ toxicity (ctcae 4.0)|overall survival|disease free survival|any other treatment related early and late morbidities (ctcae 4.0)|eortc qol-c30/hn-35 (optional),"international atomic energy agency|centro de lucha contra el cáncer, montevideo, uruguay|institute rotary cancer hospital, new delhi, india|tata memorial centre|bahawalpur institute of nuclear medicine and oncology, bahawalpur, pakistan|gknm hospital, tamil nadu, india|fundacion escuela de medicina nuclear, mendoza, argentina|instituto de oncología y radiobiología, havana, cuba|university of indonesia, jakarta, indonesia|st luke's medical centre, quezon city, manilla, phillippines|university of pretoria, pretoria, south africa|mahidol university, bangkok, thailand|university of maryland, college park|barretos cancer hospital, barretos, brazil",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,836.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E33035,March 2014,November 2020,November 2021,"May 6, 2016",,"August 8, 2019","[""fundacion escuela de medicina nuclear, mendoza, argentina instituto naciolal de oncologia y radiobiologia (inor), havana, cuba department of radiation oncology, v.n. cancer center, gknm hospital, coimbatore, india tata memorial centre (tmc) department of atomic energy (dae), mumbai, india institute rotary cancer hospital, new delhi, india cipto magunkusumo general hospital, university of indonesia, jakarta, indonesia bahawalpur institute of nuclear medicine and oncology (bino), bahawalpur, pakistan st luke's medical centre, quezon city, manila, philippines university of pretoria, pretoria, south africa mahidol university faculty of medicine siriraj hospital, bangkok, siriraj, thailand centro de lucha contra el cáncer, montevideo, uruguay""]",,https://ClinicalTrials.gov/show/NCT02765503,skin
563,564,NCT01449253,comparison of efficacy different treatment regimens in pulmonary hypertension secondary to lung disease and or hypoxia,,Unknown status,No Results Available,pulmonary hypertension secondary to lung disease and/or hypoxia,drug: sildenafil|drug: bosentan,echocardiogram|who functional classification|6 minute walk test|pulmonary function test|visual analog scale for dyspnea|echocardiography measuring pulmonary artery pressure|biochemical markers at 3 and 6 months|monitoring side effects of the drugs,"all india institute of medical sciences, new delhi",All,"18 Years and older   (Adult, Older Adult)",Phase 4,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,pulmonary hypertension,August 2011,July 2013,July 2013,"October 10, 2011",,"January 29, 2013","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01449253,
564,565,NCT01523587,lux-lung 8: a phase iii trial of afatinib (bibw 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy,,Completed,Has Results,"carcinoma, non-small-cell lung",drug: afatinib|drug: erlotinib,"progression-free survival, based on central independent review as determined by response evaluation criteria in solid tumours 1.1|overall survival|number of participants with objective response according to recist 1.1|number of participants with disease control according to recist 1.1|tumour shrinkage|number of participants with status change in cough, dyspnoea and pain related items over time in health related quality of life questionnaire|summary of time to deterioration in coughing, dyspnoea and pain.|change in score over time in coughing,dyspnoea and pain",boehringer ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,795.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.125|2011-002380-24,"March 5, 2012","October 21, 2013","December 27, 2017","February 1, 2012","November 21, 2014","February 15, 2019","['ironwood cancer and research centers, chandler, arizona, united states university of california, la jolla, california, united states sutter medical group, sacramento, california, united states boca raton reginl hospital-lynn cancer institute, boca raton, florida, united states memorial healthcare system, hollywood, florida, united states cancer care of north florida, pa, lake city, florida, united states illinois cancer specialists, niles, illinois, united states orchard healthcare research inc, skokie, illinois, united states university of louisville, louisville, kentucky, united states west jefferson general hospital and cancer clinic, marrero, louisiana, united states lahey clinic, burlington, massachusetts, united states commonwealth hematology-oncology, pc, lawrence, massachusetts, united states karmanos cancer institute, detroit, michigan, united states washington university school of medicine, saint louis, missouri, united states billings clinic cancer center, billings, montana, united states montefiore medical center, bronx, new york, united states montefiore medical center, bronx, new york, united states queens medical associates, fresh meadows, new york, united states suny upstate medical university, syracuse, new york, united states cleveland clinic, cleveland, ohio, united states the ohio state university wexner medical center, columbus, ohio, united states mid ohio oncology/hematology, inc, columbus, ohio, united states kaiser permanente northwest, portland, oregon, united states oncology hematology associates of norhtern pennsylvania, pc, dubois, pennsylvania, united states kimmel cancer center, philadelphia, pennsylvania, united states temple university cancer center, philadelphia, pennsylvania, united states spartanburg regional medical center, spartanburg, south carolina, united states cancer center of cookeville regional medical center, cookeville, tennessee, united states paris cancer center (pcc), texas oncology, paris, texas, united states cancer therapy and research at uthscsa, san antonio, texas, united states fletcher allen health care, burlington, vermont, united states blue ridge cancer care, christiansburg, virginia, united states virginia oncology associates, norfolk, virginia, united states instituto medico especializado alexander fleming, ciudad autonoma de bs as, argentina instituto oncologico de cordoba, cordoba, argentina clínica colombo s.a., cordoba, argentina centro oncologico de rosario, rosario, argentina centro oncologico caipo, san miguel de tucuman, argentina medical university of innsbruck, innsbruck, austria lkh leoben, leoben, austria akh d. stadt linz, pulmologie, linz, austria smz baumgartner hoehe otto wagner spital, wien, austria bc cancer agency - fraser valley centre, surrey, british columbia, canada kingston general hospital, kingston, ontario, canada the ottawa hospital, ottawa, ontario, canada royal victoria hospital, montreal, quebec, canada montreal general hospital - mcgill university health centre, montreal, quebec, canada centro oncologico antofagasta, antofagasta, chile instituto de terapias oncologicas providencia, providencia, santiago, chile centro internacional de estudios clinicos - ciec, recoleta, santiago de chile, chile orlandi oncologia, vitacura, chile beijing cancer hospital, beijing, china beijing hospital, beijing, china first hospital of jilin university, changchun, china xiangya hospital, central south university, changsha, china sun yat-sen university cancer center, guangzhou, china the 81th hospital of pla, nanjing, china jiangsu cancer hospital, nanjing, china shanghai chest hospital, shanghai, china shanghai pulmonary hospital, shanghai, china herlev hospital, herlev, denmark næstved sygehus, næstved, denmark odense universitetshospital, odense c, denmark hop d\'angers, angers, france ins bergonié, bordeaux, france hop côte de nacre, caen, france hop de chauny, chauny, france hop gabriel-montpied, clermont ferrand, france hop de creteil, pneumo, creteil, creteil, france hop le mans, le mans, france ctr oscar lambret, cancéro, lille, lille, france hop calmette, lille, france hop nord, marseille cedex 20, france ins paoli-calmettes, marseille, france hop de mulhouse, onco, mulhouse, mulhouse, france hop cochin, paris, france hop val de grâce, onco, paris, paris, france ins jean godinot, onco, reims, reims, france hop de rennes, pneumo, rennes, rennes, france hop saint quentin, onco, saint quentin, saint quentin, france hop civil, strasbourg, france hop foch, suresnes, france ins gustave roussy, villejuif, france zentralklinik bad berka gmbh, bad berka, germany ruhrlandklinik, westdeutsches lungenzentrum am universitätsklinikum essen ggmbh, essen, germany klinikum esslingen gmbh, esslingen, germany universitätsklinikum frankfurt, frankfurt am main, germany universitätsklinikum freiburg, freiburg, germany universitätsklinikum hamburg-eppendorf, hamburg, germany lungenklinik hemer, hemer, germany universitätsklinikum mannheim gmbh, mannheim, germany universitätsklinikum münster, münster, germany mathias-spital rheine, rheine, germany ""hippokratio"" hospital of athens, 2nd internal medicine clin, athens, greece general hospital of chest diseases sotiria, athens, greece university general hospital of heraklion, heraklion, greece university hospital of larisa, oncology clinic, larisa, greece general hospital of larissa, larisa, greece metropolitan hospital, oncology clinic, neo faliro, athens, greece general hospital ""g. papageorgiou"", thessaloniki, greece national koranyi tbc and pulm. internal med. clinic, budapest, hungary semmelweis university, budapest, hungary institute of chest diseases csongrad county,dpt. pulmonology, deszk, hungary pulmonology institute of veszprem county, farkasgyepu, farkasgyepü, hungary aladar petz county teaching hospital, dept. pulmonology, györ, hungary lung hospital of matra, dept. pulmonology, matrahaza, hungary josa andras korhaz, nyiregyhaza, nyiregyhaza, hungary university of pecs, 1st internal med. dept., pulmonology, pecs, hungary pest county lung hospital, department no. 3, törökbalint, hungary vikram hospital, bangalore, india v s hospital, chennai, india dr. kamakshi memorial hospital, chennai, india sri ramachandra medical college & research institute, chennai, india m.s. patel cancer hospital, karamsad, india b. p .poddar hospital & medical research ltd., kolkata, west bengal, india tata memorial hospital, mumbai, india ruby hall clinic, pune, india st james\'s hospital, dublin 8, ireland p.o. bellaria irccs istituto delle scienze neurologiche di bologna, bologna, italy asst di cremona, cremona, italy spedali riuniti di livorno, livorno, italy istituto nazionale tumori fondazione pascale, napoli, italy istituto oncologico veneto irccs, padova, italy azienda ospedaliera di parma, parma, italy azienda ospedaliera universitaria pisana, pisa, italy istituto clinico humanitas, rozzano (mi), italy ospedale san vincenzo, taormina (me), italy ospedale molinette, ao città della salute e della, torino, italy a. o. s. maria della misericordia, udine, italy chungbuk national university hospital, cheongju, korea, republic of gachon university gil medical center, incheon, korea, republic of gyeongsang national university hospital, jinju, korea, republic of seoul national university bundang hospital, seongnam, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of the catholic university of korea, seoul st.mary\'s hospital, seoul, korea, republic of the catholic university of korea, st.vincent\'s hospital, suwon, korea, republic of ulsan university hospital, ulsan, korea, republic of instituto nacional de cancerologia, mexico, mexico hospital y clínica oca s. a. de c. v., monterrey, mexico centro hemato-oncologico privado de toluca s.a. de c.v., toluca, mexico jeroen bosch ziekenhuis-hertogenbosch, \'s-hertogenbosch, netherlands rijnstate hospital, arnhem, netherlands amphia ziekenhuis, breda, netherlands catharina ziekenhuis, eindhoven, netherlands metc academisch ziekenhuis maastricht/universiteit van maastricht, maastricht, netherlands st. antonius ziekenhuis, locatie nieuwegein, nieuwegein, netherlands erasmus medisch centrum, rotterdam, netherlands chuc - centro hospitalar e universitário de coimbra, epe, coimbra, portugal chln, epe - hospital de santa maria, lisboa, portugal ipo lisboa francisco gentil, epe, lisboa, portugal ipo porto francisco gentil, epe, porto, portugal centro hospitalar são joão,epe, porto, portugal centro hospitalar de vila nova de gaia, vila nova de gaia, portugal national cancer centre, singapore, singapore johns hopkins singapore international medical centre, singapore, singapore hospital a coruña, a coruña, spain hospital vall d\'hebron, barcelona, spain hospital santa creu i sant pau, barcelona, spain hospital clínico san carlos, madrid, spain hospital la paz, madrid, spain hospital regional universitario de málaga, malaga, spain hospital virgen de la victoria, malaga, spain hospital clínico de valencia, valencia, spain hospital clínico universitario lozano blesa, zaragoza, spain chang gung memorial hospital chiayi, chiayi, taiwan buddhist tzu chi general hospital, chiayi, taiwan kaohsiung chang gung memorial hospital, kaohsiung, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan national taiwan university hospital, taipei, taiwan koo foundation sun yet-sen cancer center, taipei, taiwan taipe veterans general hospital, taipei, taiwan chang gung memorial hospital(taoyuan), taoyuan, taiwan akdeniz universitesi tip fakultesi, antalya, turkey uludag universitesi tip fakultesi, bursa, bursa, turkey dicle universitesi tip fakultesi, diyarbakir, turkey gaziantep univ. tip fakultesi tibbi onkoloji bilim dali, gaziantep, turkey kartal egitim ve arastirma hastanesi, istanbul, turkey yedikule gog. hst. eah, istanbul, turkey ege universitesi tip fakultesi tibbi onkoloji bilim dali, izmir, turkey dr.suat seren eah, izmir, turkey queen elizabeth hospital, birmingham, united kingdom royal devon and exeter hospital, exeter, united kingdom beatson west of scotland cancer centre, glasgow, united kingdom harrogate district hospital, harrogate, united kingdom royal free hospital, london, united kingdom the royal marsden hospital, london, united kingdom maidstone hospital, kent oncology centre, maidstone, united kingdom nottingham city hospital, nottingham, united kingdom scarborough hospital, scarborough, united kingdom the royal marsden hospital, sutton, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/87/nct01523587/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/87/nct01523587/sap_001.pdf",https://ClinicalTrials.gov/show/NCT01523587,
565,566,NCT02788214,helicobacter pylori genome project (hpgp),,Terminated,No Results Available,gastric cancer|non-atrophic gastritis|intestinal metaplasia,,bacterial dna sequence,"national cancer institute (nci)|new england biolabs, usa|national institute of infectious diseases, japan|national institute of genetics, japan|chiba university, japan|national institute for basic biology, japan|instituto mexicano de seguro social, mexico|universidade de lisboa, portugal|instituto de biomedicina de valencia, spain|university of bath, uk|vanderbilt university medical center, usa|karolinska institutet|university of tokyo, japan|max von pettenkofer-institute of hygiene and medical microbiology, germany|universidad de chile, chile|hosei university, japan",All,"30 Years to 70 Years   (Adult, Older Adult)",,1000.0,NIH|Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,NCI-2020-07069|16-C-N120|999916120,"July 27, 2016","May 15, 2020","May 15, 2020","June 2, 2016",,"December 19, 2020","[""white river medical center, batesville, arkansas, united states stanford university, stanford, california, united states georgia cancer center biorepository, athens, georgia, united states centers for disease control and prevention, atlanta, georgia, united states albert einstein college of medicine, bronx, new york, united states vanderbilt university medical center, nashville, tennessee, united states baylor college of medicine, houston, texas, united states université ferhat abbas, sétif, algeria hospital alemán, buenos aires, argentina dhaka medical college and hospital, dhaka, bangladesh ghent university, ghent, belgium universidade federal de minas gerais, belo horizonte, brazil ac camargo cancer center, sao paulo, brazil medical university of sofia, sofia, bulgaria tsaritsa yoanna university hospital, sofia, bulgaria university of dschang, dschang, cameroon university of alberta, edmonton, canada universidad de concepción, concepción, chile hospital hanga roa, easter island, chile pontificia universidad catolica, santiago, chile instituto nacional de cancerología, bogotá, colombia universidad del valle, cali, colombia universidad de nariño, pasto, colombia university of kinshasa, kinshasa, congo, the democratic republic of the university of mbuji mayi, mbuji-mayi, congo, the democratic republic of the universidad de costa rica, san josé, costa rica universidad autónoma de santo domingo, santo domingo, dominican republic c.h.u. pellegrin, bordeaux, france otto-von-guericke universitätsklinikum, magdeburg, germany university of cape coast, cape coast, ghana evangelismos hospital and hellenic pasteur institute, athens, greece hellenic pasteur institute, athens, greece universidad san carlos, guatemala, guatemala hospital de occidente, santa rosa de copán, honduras national university hospital, reykjavík, iceland kasturba medical college manipal, manipal, india university of indonesia, kota depok, indonesia universitas airlangga, kota surabaya, indonesia digestive disease research institute, teheran, iran, islamic republic of bar ilan university, ramat gan, israel centro di rferimento oncologico, aviano, italy nagoya city university, nagoya, japan hosei university, tokyo, japan kyorin university, tokyo, japan nippon medical school, tokyo, japan oita university, ōita, japan jordan university of science and technology, ramtha, jordan central asian cancer institute, almaty, kazakhstan tenwek hospital, bomet, kenya seoul national university bundang hospital, seongnam, korea, republic of chung-ang university hospital, seoul, korea, republic of national cancer center, seoul, korea, republic of kyrgyz state medical academy, bishkek, kyrgyzstan university of latvia, riga, latvia lithuanian university of health sciences, kaunas, lithuania university of malaya, kuala lumpur, malaysia instituto nacional de cancerología, mexico city, mexico defence services general hospital, yangon, myanmar chitwan medical college, bharatpur, nepal tribhuvan university teaching hospital, kathmandu, nepal university of calabar teaching hospital, calabar, nigeria university of nigeria teaching hospital, enugu, nigeria babcock universtiy teaching hospital, ilishan-remo, nigeria university of jos / university teaching hospital, jos, nigeria federal medical center, lagos, nigeria instituto nacional de enfermedades neoplasicas, lima, peru universidad peruana cayetano heredia, lima, peru university of lublin, publin, poland wroclaw medical center, wroclaw, poland instituto nacional de saúde dr. ricardo jorge, lisbon, portugal university of porto, porto, portugal university of puerto rico, san juan, puerto rico clinical research center of moscow, moscow, russian federation national university hospital, singapore, singapore chris hani baragwanath academic hospital, soweto, south africa hospital clinic de barcelona, barcelona, spain hospital general de granollers, barcelona, spain hospital universitari parc tauli, barcelona, spain institut d'investigació biomédica de bellvitge (idibell), barcelona, spain l'hospitalet de llobregat, barcelona, spain hospital de leon, león, spain hospital de la princesa, madrid, spain hospital general universitario gregorio marañón, madrid, spain hospital universitario de asturias, oviedo, spain complejo hospitalario de navarra, pamplona, spain hospital donostia, san sebastian, spain lozano blesa university hospital, zaragoza, spain sudan university of science and technology, khartoum, sudan karolinska institutet, stockholm, sweden university of bern, bern, switzerland university of zurich, zurich, switzerland national taiwan university hospital, taipei, taiwan istanbul university, istanbul, turkey cho ray hospital, ho chi minh city, vietnam""]",,https://ClinicalTrials.gov/show/NCT02788214,gastric
566,567,NCT00882063,study to evaluate safety and efficacy of p276-00 in subjects with refractory multiple myeloma,,Completed,No Results Available,relapsed and/or refractory multiple myeloma,drug: p276-00,to determine the maximum tolerated dose of p276-00 in subjects with relapsed and/or relapsed/refractory multiple myeloma,piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,19.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/15/07,January 2008,November 2009,May 2012,"April 16, 2009",,"November 21, 2012","['jaslok hospital & research centre, mumbai, maharashtra, india shatabdi superspeciality hospital, nasik, maharashtra, india netaji subhash chandra bose cancer research institute, kolkata, west bengal, india rajiv gandhi cancer institute and research centre, delhi, india institute rotary cancer hospital,all india institute of medical sciences(aiims), new delhi, india']",,https://ClinicalTrials.gov/show/NCT00882063,myeloma
567,568,NCT00863096,human papillomavirus screening and vaccine readiness program,,Withdrawn,No Results Available,human papilloma virus-related carcinoma,biological: gardasil,acceptability of hpv vaccine,"public health research institute, india|path",Female,18 Years to 45 Years   (Adult),,450.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GAT.1246-04-07527-GRT,June 2009,June 2010,December 2010,"March 17, 2009",,"March 3, 2011","['public health research institute, india, mysore, karnataka, india']",,https://ClinicalTrials.gov/show/NCT00863096,
568,569,NCT03561961,prostate radiotherapy comparing moderate and extreme hypo-fractionation (prime trial),PRIME,Recruiting,No Results Available,prostate adenocarcinoma,radiation: moderate hypo-fractionation|radiation: extreme hypo-fractionation,biochemical failure free survival (bffs)|acute toxicity with both treatments.|late toxicity with both treatments.|prostate cancer specific survival|overall survival|out of pocket expenditure|patient reported quality of life,tata memorial centre|tata medical center,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,464.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRIME,"May 24, 2018",March 2030,March 2035,"June 19, 2018",,"April 1, 2021","['dr vedang murthy, navi-mumbai, maharashtra, india']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/61/nct03561961/prot_sap_000.pdf",https://ClinicalTrials.gov/show/NCT03561961,prostat gastric kidney
569,570,NCT00596830,"carboplatin and paclitaxel with or without cp-751, 871 (an igf-1r inhibitor) for advanced nsclc of squamous, large cell and adenosquamous carcinoma histology",,Terminated,Has Results,"carcinoma, squamous cell|carcinoma, adenosquamous|carcinoma, large cell|carcinoma, non-small-cell lung","drug: cp-751,871 (figitumumab)|drug: carboplatin|drug: paclitaxel","overall survival (os)|progression-free survival (pfs)|percentage of participants with objective response (or)|european organization for research and treatment of cancer (eortc) quality of life questionnaire (eortc qlq-c30)|european organization for research and treatment of cancer (eortc), quality of life questionnaire-lung cancer 13 (qlq- lc13) score|euro quality of life (eq-5d)- health state profile utility score|maximum observed plasma concentration (cmax) for figitumumab|minimum observed plasma trough concentration (cmin)for figitumumab|number of participants with total anti-drug antibodies (ada)|change from baseline in serum insulin growth factor 1 (igf1) levels",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,681.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A4021016,April 2008,March 2011,September 2012,"January 17, 2008","December 3, 2013","January 13, 2014","[""pfizer investigational site, florence, alabama, united states pfizer investigational site, huntsville, alabama, united states pfizer investigational site, muscle shoals, alabama, united states pfizer investigational site, phoenix, arizona, united states pfizer investigational site, scottsdale, arizona, united states pfizer investigational site, hot springs, arkansas, united states pfizer investigational site, aurora, colorado, united states pfizer investigational site, boulder, colorado, united states pfizer investigational site, colorado springs, colorado, united states pfizer investigational site, colorado springs, colorado, united states pfizer investigational site, denver, colorado, united states pfizer investigational site, denver, colorado, united states pfizer investigational site, lakewood, colorado, united states pfizer investigational site, littleton, colorado, united states pfizer investigational site, lone tree, colorado, united states pfizer investigational site, longmont, colorado, united states pfizer investigational site, parker, colorado, united states pfizer investigational site, thornton, colorado, united states pfizer investigational site, norwalk, connecticut, united states pfizer investigational site, norwich, connecticut, united states pfizer investigational site, hudson, florida, united states pfizer investigational site, jacksonville, florida, united states pfizer investigational site, lake city, florida, united states pfizer investigational site, lake city, florida, united states pfizer investigational site, miramar beach, florida, united states pfizer investigational site, new port richey, florida, united states pfizer investigational site, orlando, florida, united states pfizer investigational site, orlando, florida, united states pfizer investigational site, pensacola, florida, united states pfizer investigational site, pensacola, florida, united states pfizer investigational site, port st. lucie, florida, united states pfizer investigational site, spring hill, florida, united states pfizer investigational site, alpharetta, georgia, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, conyers, georgia, united states pfizer investigational site, cumming, georgia, united states pfizer investigational site, decatur, georgia, united states pfizer investigational site, duluth, georgia, united states pfizer investigational site, lake spivey, georgia, united states pfizer investigational site, lawrenceville, georgia, united states pfizer investigational site, macon, georgia, united states pfizer investigational site, marietta, georgia, united states pfizer investigational site, snellville, georgia, united states pfizer investigational site, coeur d' alene, idaho, united states pfizer investigational site, arlington heights, illinois, united states pfizer investigational site, aurora, illinois, united states pfizer investigational site, chicago, illinois, united states pfizer investigational site, elk grove village, illinois, united states pfizer investigational site, galesburg, illinois, united states pfizer investigational site, winfield, illinois, united states pfizer investigational site, yorkville, illinois, united states pfizer investigational site, avon, indiana, united states pfizer investigational site, beech grove, indiana, united states pfizer investigational site, hobart, indiana, united states pfizer investigational site, hobart, indiana, united states pfizer investigational site, indianapolis, indiana, united states pfizer investigational site, indianapolis, indiana, united states pfizer investigational site, mooresville, indiana, united states pfizer investigational site, mooresville, indiana, united states pfizer investigational site, munster, indiana, united states pfizer investigational site, cedar rapids, iowa, united states pfizer investigational site, kansas city, kansas, united states pfizer investigational site, overland park, kansas, united states pfizer investigational site, shawnee mission, kansas, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, louisville, kentucky, united states pfizer investigational site, baltimore, maryland, united states pfizer investigational site, baltimore, maryland, united states pfizer investigational site, lawrence, massachusetts, united states pfizer investigational site, quincy, massachusetts, united states pfizer investigational site, stoneham, massachusetts, united states pfizer investigational site, weymouth, massachusetts, united states pfizer investigational site, worcester, massachusetts, united states pfizer investigational site, detroit, michigan, united states pfizer investigational site, farmington hills, michigan, united states pfizer investigational site, st. joseph, michigan, united states pfizer investigational site, st. louis park, minnesota, united states pfizer investigational site, columbus, mississippi, united states pfizer investigational site, corinth, mississippi, united states pfizer investigational site, oxford, mississippi, united states pfizer investigational site, southaven, mississippi, united states pfizer investigational site, tupelo, mississippi, united states pfizer investigational site, kansas city, missouri, united states pfizer investigational site, kansas city, missouri, united states pfizer investigational site, lee's summit, missouri, united states pfizer investigational site, lincoln, nebraska, united states pfizer investigational site, lincoln, nebraska, united states pfizer investigational site, lincoln, nebraska, united states pfizer investigational site, las vegas, nevada, united states pfizer investigational site, las vegas, nevada, united states pfizer investigational site, lebanon, new hampshire, united states pfizer investigational site, manchester, new hampshire, united states pfizer investigational site, lake success, new york, united states pfizer investigational site, manhasset, new york, united states pfizer investigational site, new hyde park, new york, united states pfizer investigational site, oneida, new york, united states pfizer investigational site, oswego, new york, united states pfizer investigational site, syracuse, new york, united states pfizer investigational site, syracuse, new york, united states pfizer investigational site, burlington, north carolina, united states pfizer investigational site, canton, ohio, united states pfizer investigational site, cleveland, ohio, united states pfizer investigational site, dover, ohio, united states pfizer investigational site, tulsa, oklahoma, united states pfizer investigational site, tulsa, oklahoma, united states pfizer investigational site, tulsa, oklahoma, united states pfizer investigational site, clairton, pennsylvania, united states pfizer investigational site, greensburg, pennsylvania, united states pfizer investigational site, johnstown, pennsylvania, united states pfizer investigational site, mckeesport, pennsylvania, united states pfizer investigational site, philadelphia, pennsylvania, united states pfizer investigational site, philadelphia, pennsylvania, united states pfizer investigational site, pittsburgh, pennsylvania, united states pfizer investigational site, pittsburgh, pennsylvania, united states pfizer investigational site, pittsburgh, pennsylvania, united states pfizer investigational site, radnor, pennsylvania, united states pfizer investigational site, sayre, pennsylvania, united states pfizer investigational site, wexford, pennsylvania, united states pfizer investigational site, columbia, south carolina, united states pfizer investigational site, sumter, south carolina, united states pfizer investigational site, bartlett, tennessee, united states pfizer investigational site, knoxville, tennessee, united states pfizer investigational site, knoxville, tennessee, united states pfizer investigational site, knoxville, tennessee, united states pfizer investigational site, maryville, tennessee, united states pfizer investigational site, memphis, tennessee, united states pfizer investigational site, memphis, tennessee, united states pfizer investigational site, austin, texas, united states pfizer investigational site, austin, texas, united states pfizer investigational site, austin, texas, united states pfizer investigational site, austin, texas, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, fort sam houston, texas, united states pfizer investigational site, fort worth, texas, united states pfizer investigational site, fort worth, texas, united states pfizer investigational site, grapevine, texas, united states pfizer investigational site, houston, texas, united states pfizer investigational site, irving, texas, united states pfizer investigational site, longview, texas, united states pfizer investigational site, plano, texas, united states pfizer investigational site, round rock, texas, united states pfizer investigational site, round rock, texas, united states pfizer investigational site, san antonio, texas, united states pfizer investigational site, san marcos, texas, united states pfizer investigational site, tyler, texas, united states pfizer investigational site, bountiful, utah, united states pfizer investigational site, layton, utah, united states pfizer investigational site, murray, utah, united states pfizer investigational site, provo, utah, united states pfizer investigational site, salt lake city, utah, united states pfizer investigational site, salt lake city, utah, united states pfizer investigational site, west valley city, utah, united states pfizer investigational site, arlington, virginia, united states pfizer investigational site, christiansburg, virginia, united states pfizer investigational site, fairfax, virginia, united states pfizer investigational site, gainesville, virginia, united states pfizer investigational site, leesburg, virginia, united states pfizer investigational site, roanoke, virginia, united states pfizer investigational site, salem, virginia, united states pfizer investigational site, winchester, virginia, united states pfizer investigational site, woodbridge, virginia, united states pfizer investigational site, wytheville, virginia, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, spokane valley, washington, united states pfizer investigational site, spokane, washington, united states pfizer investigational site, spokane, washington, united states pfizer investigational site, albury, new south wales, australia pfizer investigational site, port macquarie, new south wales, australia pfizer investigational site, geelong, victoria, australia pfizer investigational site, wodonga, victoria, australia pfizer investigational site, linz, austria pfizer investigational site, wien, austria pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, higienopolis, sao paulo/ brazil, brazil pfizer investigational site, sao paulo, sp, brazil pfizer investigational site, sao paulo, sp, brazil pfizer investigational site, sao paulo, sp, brazil pfizer investigational site, sofia, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, varna, bulgaria pfizer investigational site, edmonton, alberta, canada pfizer investigational site, levis, quebec, canada pfizer investigational site, nova ves pod plesi, czech republic pfizer investigational site, praha 8, czech republic pfizer investigational site, pribram i, czech republic pfizer investigational site, pribram v, czech republic pfizer investigational site, helsinki, finland pfizer investigational site, pori, finland pfizer investigational site, caen cedex 05, france pfizer investigational site, caen cedex, france pfizer investigational site, clermond-ferrand cedex 01, france pfizer investigational site, dijon, france pfizer investigational site, lyon cedex 04, france pfizer investigational site, nantes cedex 2, france pfizer investigational site, rennes cedex 9, france pfizer investigational site, saint herblain cedex, france pfizer investigational site, saint pierre la réunion cedex, france pfizer investigational site, grosshansdorf, germany pfizer investigational site, karlsruhe, germany pfizer investigational site, leipzig, germany pfizer investigational site, mainz, germany pfizer investigational site, oldenburg, germany pfizer investigational site, thessaloniki, pylaia, greece pfizer investigational site, athens, greece pfizer investigational site, athens, greece pfizer investigational site, thessaloniki, greece pfizer investigational site, kowloon, hong kong pfizer investigational site, shatin, new territories, hong kong pfizer investigational site, tuen mun, hong kong pfizer investigational site, budapest, hungary pfizer investigational site, deszk, hungary pfizer investigational site, szekesfehervar, hungary pfizer investigational site, szombathely, hungary pfizer investigational site, torokbalint, hungary pfizer investigational site, navrangpura / ahmedabad, gujarat, india pfizer investigational site, bangalore, karnataka, india pfizer investigational site, mumbai, maharashtra, india pfizer investigational site, nagpur, maharashtra, india pfizer investigational site, new delhi, india pfizer investigational site, genova, italy pfizer investigational site, orbassano (to), italy pfizer investigational site, padova, italy pfizer investigational site, roma, italy pfizer investigational site, kashiwa, chiba, japan pfizer investigational site, matsuyama-shi, ehime, japan pfizer investigational site, gifu-shi, gifu, japan pfizer investigational site, sapporo-shi, hokkaido, japan pfizer investigational site, akashi, hyogo, japan pfizer investigational site, yokohama-city, kanagawa, japan pfizer investigational site, sakai-shi, osaka-fu, japan pfizer investigational site, osaka-city, osaka, japan pfizer investigational site, osakasayama-shi, osaka, japan pfizer investigational site, chuo-ku, tokyo, japan pfizer investigational site, tokyo, japan pfizer investigational site, gyeonggi-do, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, gdansk, poland pfizer investigational site, krakow, poland pfizer investigational site, siedlce, poland pfizer investigational site, warszawa, poland pfizer investigational site, warszawa, poland pfizer investigational site, warszawa, poland pfizer investigational site, wroclaw, poland pfizer investigational site, ponce, puerto rico pfizer investigational site, moscow, russian federation pfizer investigational site, moscow, russian federation pfizer investigational site, saint-petersburg, russian federation pfizer investigational site, samara, russian federation pfizer investigational site, sochi, russian federation pfizer investigational site, st-petersburg, russian federation pfizer investigational site, st. petersburg, russian federation pfizer investigational site, nitra-zobor, slovakia pfizer investigational site, nove zamky, slovakia pfizer investigational site, poprad, slovakia pfizer investigational site, l'hospitalet de llobregat, barcelona, spain pfizer investigational site, santander, cantabria, spain pfizer investigational site, pamplona, navarra, spain pfizer investigational site, cordoba, spain pfizer investigational site, madrid, spain pfizer investigational site, valencia, spain pfizer investigational site, fribourg, switzerland pfizer investigational site, zuerich, switzerland pfizer investigational site, niao sung hsiang, kaohsiung hsien, taiwan pfizer investigational site, tainan, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, adana, turkey pfizer investigational site, ankara, turkey pfizer investigational site, dnipropetrovsk, ukraine pfizer investigational site, donetsk, ukraine pfizer investigational site, kyiv, ukraine pfizer investigational site, lviv, ukraine pfizer investigational site, sumy, ukraine""]",,https://ClinicalTrials.gov/show/NCT00596830,skin
570,571,NCT00254904,randomized trial of gemcitabine/cisplatin + pf-3512676 vs gemcitabine/cisplatin alone in patients with advanced nsclc,,Terminated,No Results Available,"carcinoma, non-small-cell lung",drug: cisplatin|drug: gemcitabine|drug: pf-3512676|drug: gemcitabine + cisplatin,overall survival|patient reported outcomes|overall safety profile|progression free survival|time to tumor progression|overall objective response|duration of response,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,839.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A8501002,November 2005,June 2008,June 2008,"November 17, 2005",,"March 30, 2015","[""pfizer investigational site, birmingham, alabama, united states pfizer investigational site, birmingham, alabama, united states pfizer investigational site, bakersfield, california, united states pfizer investigational site, st. joseph, michigan, united states pfizer investigational site, minneapolis, minnesota, united states pfizer investigational site, st. louis, missouri, united states pfizer investigational site, st. louis, missouri, united states pfizer investigational site, new york, new york, united states pfizer investigational site, spokane, washington, united states pfizer investigational site, spokane, washington, united states pfizer investigational site, innsbruck, austria pfizer investigational site, bruxelles, belgium pfizer investigational site, bruxelles, belgium pfizer investigational site, charleroi, belgium pfizer investigational site, hasselt, belgium pfizer investigational site, jette, belgium pfizer investigational site, leuven, belgium pfizer investigational site, liege, belgium pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, jau, sp, brazil pfizer investigational site, jaú, sp, brazil pfizer investigational site, jaú, sp, brazil pfizer investigational site, sao paulo, sp, brazil pfizer investigational site, são paulo, sp, brazil pfizer investigational site, são paulo, sp, brazil pfizer investigational site, toronto, ontario, canada pfizer investigational site, windsor, ontario, canada pfizer investigational site, windsor, ontario, canada pfizer investigational site, greenfield park, quebec, canada pfizer investigational site, laval, quebec, canada pfizer investigational site, levis, quebec, canada pfizer investigational site, quebec, canada pfizer investigational site, guangzhou, guangdong, china pfizer investigational site, nanjing, jiangsu, china pfizer investigational site, dalian, liaoning, china pfizer investigational site, beijing, china pfizer investigational site, beijing, china pfizer investigational site, praha 5, cz, czech republic pfizer investigational site, olomouc, czech republic pfizer investigational site, praha 8, czech republic pfizer investigational site, bielefeld, germany pfizer investigational site, karlsruhe, germany pfizer investigational site, loewenstein, germany pfizer investigational site, mannheim, germany pfizer investigational site, muenchen, germany pfizer investigational site, tuebingen, germany pfizer investigational site, kowloon, hong kong pfizer investigational site, shatin, hong kong pfizer investigational site, zalaegerszeg, külsőkórház-pózva, hungary pfizer investigational site, budapest, hungary pfizer investigational site, deszk, hungary pfizer investigational site, gyula, hungary pfizer investigational site, pecs, hungary pfizer investigational site, bangalore, karnataka, india pfizer investigational site, kochi, kerala, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, ludhiana, punjab, india pfizer investigational site, lucknow, uttar pradesh, india pfizer investigational site, new delhi, india pfizer investigational site, beer-sheva, israel pfizer investigational site, kfar saba, israel pfizer investigational site, forli', italy pfizer investigational site, milano, italy pfizer investigational site, pisa, italy pfizer investigational site, roma, italy pfizer investigational site, s.andrea delle fratte (pg), italy pfizer investigational site, gyeonggi-do, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, amsterdam, nh, netherlands pfizer investigational site, zaandam, nh, netherlands pfizer investigational site, 's-hertogenbosch, netherlands pfizer investigational site, harderwijk, netherlands pfizer investigational site, nijmegen, netherlands pfizer investigational site, gdansk, poland pfizer investigational site, lodz, poland pfizer investigational site, otwock, poland pfizer investigational site, szczecin-zdunowo, poland pfizer investigational site, warszawa, poland pfizer investigational site, warszawa, poland pfizer investigational site, warszawa, poland pfizer investigational site, wodzislaw sl., poland pfizer investigational site, coimbra, portugal pfizer investigational site, lisboa, portugal pfizer investigational site, lisboa, portugal pfizer investigational site, lisboa, portugal pfizer investigational site, porto, portugal pfizer investigational site, singapore, singapore pfizer investigational site, bratislava, slovakia pfizer investigational site, kosice, slovakia pfizer investigational site, kvetnica pri poprade, slovakia pfizer investigational site, nitra-zobor, slovakia pfizer investigational site, port elizabeth, eastern cape, south africa pfizer investigational site, cape town, south africa pfizer investigational site, port elizabeth, south africa pfizer investigational site, hospitalet de llobregat, barcelona, spain pfizer investigational site, santander, cantabria, spain pfizer investigational site, baracaldo, vizcaya, spain pfizer investigational site, alicante, spain pfizer investigational site, castellon, spain pfizer investigational site, gerona, spain pfizer investigational site, jaen, spain pfizer investigational site, taichung, taiwan pfizer investigational site, tainan, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, ankara, turkey pfizer investigational site, bornova / izmir, turkey pfizer investigational site, istanbul / ceraahpasa, turkey pfizer investigational site, bristol, avon, united kingdom pfizer investigational site, southampton, hampshire, united kingdom pfizer investigational site, sutton, surrey, united kingdom pfizer investigational site, belfast, united kingdom pfizer investigational site, dundee, united kingdom pfizer investigational site, edinburgh, united kingdom pfizer investigational site, glasgow, united kingdom pfizer investigational site, leicester, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, wolverhampton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00254904,
571,572,NCT00371566,a study of lapatinib versus placebo followed by chemoradiation in patients with locally advanced head and neck cancer,,Completed,Has Results,squamous cell carcinoma of head and neck,drug: lapatinib oral tablets|drug: placebo,"change from baseline of the apoptotic index during treatment phase|change from baseline of cell proliferation rate of the ki-67 proliferative index in tumour biopsy samples during treatment phase|overall radiological response after treatment phase in mitt population|overall radiological response after follow-up phase in mitt population|overall radiological response after treatment phase in itt population|overall radiological response after follow-up phase in itt population|number of circulating tumor cells at baseline in mitt population|number of participants with circulating tumor cells after treatment phase in mitt population|number of participants with circulating tumor cells after chemoradiotherapy phase in mitt population|number of biomarkers including erbb1, erbb2, perbb1, and perb2 at baseline and during treatment phase|number of biomarkers including tumor protein 53 and hpv during treatment phase|summary of adverse events by maximum toxicity grade started during treatment phase|summary of adverse events by maximum toxicity grade (grade 3 or higher) started during or after the chemoradiotherapy phase|comparison of overall response during treatment phase using ct/mri and pet information|comparison of overall response during follow up phase using ct/mri and pet information|summary of adverse events experienced by 15% or more subjects in either treatment group|summary of fatal/serious adverse events during or after chemoradiotherapy phase|summary of serious adverse events during or after chemoradiotherapy phase|adverse events by maximum toxicity grade 3 during or after chemoradiotherapy phase|adverse events (aes) by maximum toxicity grade 4 during or after chemoradiotherapy phase|adverse events by maximum toxicity grade 5 during or after chemoradiotherapy phase|relative change from baseline of ktrans median (1/min) after 2 - 4 weeks of treatment|relative change from baseline of kep mean (1/min) after 2 - 4 weeks of treatment|relative change from baseline of kep perfused (1/min) after 2 - 4 weeks of treatment|relative change from baseline of kep whole (1/min) after 2 - 4 weeks of treatment|relative change from baseline of ktrans mean (1/min) after 2 - 4 weeks of treatment|relative change from baseline of ktrans perfused (1/min) after 2 - 4 weeks of treatment|relative change from baseline of ktrans whole (1/min) after 2 - 4 weeks of treatment|relative change from baseline of iauc median (90) after 2 - 4 weeks of treatment|relative change from baseline of iauc mean (90) after 2 - 4 weeks of treatment|relative change from baseline of perfused iauc (90) after 2 - 4 weeks of treatment|relative change from baseline of whole iauc(90) after 2 - 4 weeks of treatment|relative change from baseline of kep median (1/min) after 2 - 4 weeks of treatment",glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,EGF104334,March 2006,December 2007,December 2007,"September 4, 2006","January 29, 2010","April 6, 2010","['gsk investigational site, caen, france gsk investigational site, montpellier cedex 5, france gsk investigational site, villejuif cedex, france gsk investigational site, athens, greece gsk investigational site, bangalore, india gsk investigational site, thiruvananthapuram, india gsk investigational site, lima, peru gsk investigational site, barcelona, spain gsk investigational site, madrid, spain']",,https://ClinicalTrials.gov/show/NCT00371566,skin
572,573,NCT03778229,osimertinib plus savolitinib in egfrm+/met+ nsclc following prior osimertinib,SAVANNAH,"Active, not recruiting",No Results Available,carcinoma,drug: osimertinib|drug: savolitinib,"objective response rate (orr) by investigator assessment in accordance with recist 1.1|objective response rate (orr) by investigator assessment in accordance with recist 1.1.|pfs by investigator assessment in accordance with recist 1.1.|overall survival by investigator assessment in accordance with recist 1.1.|duration of response by investigator assessment in accordance with recist 1.1.|percentage change in tumour size by investigator assessment in accordance with recist 1.1.|mean change from baseline in the european organisation for research and treatment of cancer (eortc) 30-item core quality-of-life questionnaire (qlq-c30), version 3 (qlq-c30 v3).|plasma concentrations of osimertinib, savolitinib and their metabolites.|prevalence of egfr mutations at 6-weeks after therapy initiation (percentage and absolute change from baseline in egfr mutation allele frequencies).|aes, saes and discontinuation rate due to aes, as characterized and graded by national cancer institute (nci) common terminology criteria for adverse event [ctcae] v5.|mean change from baseline in the european organisation for research and treatment of cancer (eortc) complementary 13-item quality-of-life questionnaire - lung cancer symptoms questionnaire (qlq-lc13).",astrazeneca|hutchison medipharma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,294.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5084C00007|2018-003012-51,"January 9, 2019","September 30, 2022","September 30, 2022","December 19, 2018",,"May 4, 2022","['research site, la jolla, california, united states research site, los angeles, california, united states research site, sacramento, california, united states research site, washington, district of columbia, united states research site, baltimore, maryland, united states research site, boston, massachusetts, united states research site, rochester, minnesota, united states research site, brooklyn, new york, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, seattle, washington, united states research site, barretos, brazil research site, curitiba, brazil research site, goiania, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, salvador, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, são paulo, brazil research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, north york, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, santiago, chile research site, santiago, chile research site, santiago, chile research site, herlev, denmark research site, næstved, denmark research site, odense c, denmark research site, vejle, denmark research site, ålborg, denmark research site, dijon, france research site, marseille cedex 20, france research site, nantes, france research site, paris cedex 5, france research site, paris, france research site, rennes, france research site, bangalore, india research site, chennai, india research site, kolkata, india research site, new delhi, india research site, avellino, italy research site, firenze, italy research site, milano, italy research site, milano, italy research site, orbassano, italy research site, padova, italy research site, parma, italy research site, perugia, italy research site, peschiera del garda, italy research site, fukuoka, japan research site, hiroshima-shi, japan research site, kanazawa-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, osakasayama, japan research site, sapporo-shi, japan research site, sunto-gun, japan research site, wakayama-shi, japan research site, yokohama-shi, japan research site, goyang-si, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, madrid, spain research site, madrid, spain research site, málaga, spain research site, san sebastian, spain research site, valencia, spain research site, zaragoza, spain research site, kaohsiung, taiwan research site, new taipei, taiwan research site, taichung city, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, ha noi, vietnam research site, ho chi minh, vietnam research site, ho chi minh, vietnam']",,https://ClinicalTrials.gov/show/NCT03778229,
573,574,NCT04078152,durvalumab long-term safety and efficacy study,WAVE,"Active, not recruiting",No Results Available,solid tumor,drug: durvalumab,number of participants with adverse events as assessed by common toxicity criteria for adverse events (ctcae v5.0)|efficacy of durvalumab in terms of overall response rate (orr) in patients who undergo retreatment with durvalumab|efficacy of durvalumab in terms of duration of response (dor) in patients who undergo retreatment with durvalumab|overall survival (os),astrazeneca|iqvia pty ltd|parexel|medidata solutions|ciscrp,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 4,163.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D910FC00001,"September 5, 2019","October 31, 2022","October 31, 2022","September 4, 2019",,"April 11, 2022","['research site, fullerton, california, united states research site, washington, district of columbia, united states research site, augusta, georgia, united states research site, baltimore, maryland, united states research site, minneapolis, minnesota, united states research site, saint louis, missouri, united states research site, mineola, new york, united states research site, chapel hill, north carolina, united states research site, huntersville, north carolina, united states research site, greenville, south carolina, united states research site, nashville, tennessee, united states research site, dallas, texas, united states research site, rosario, argentina research site, box hill, australia research site, melbourne, australia research site, brussels, belgium research site, kortrijk, belgium research site, leuven, belgium research site, florianópolis, brazil research site, ijuí, brazil research site, porto alegre, brazil research site, sao jose do rio preto, brazil research site, sofia, bulgaria research site, calgary, alberta, canada research site, toronto, ca, canada research site, newmarket, ontario, canada research site, sudbury, ontario, canada research site, santiago, chile research site, olomouc, czechia research site, brest cedex, france research site, lille, france research site, lyon cedex 08, france research site, dresden, germany research site, hannover, germany research site, holargos, athens, greece research site, budapest, hungary research site, miskolc, hungary research site, chennai, india research site, haifa, israel research site, bunkyo-ku, japan research site, fukushima-shi, japan research site, isehara-shi, japan research site, izumi-shi, japan research site, kishiwada-shi, japan research site, koto-ku, japan research site, nagaoka-shi, japan research site, nagoya-shi, japan research site, natori-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, saga-shi, japan research site, suita-shi, japan research site, sunto-gun, japan research site, tokushima-shi, japan research site, yokohama-shi, japan research site, daegu, korea, republic of research site, gwangju, korea, republic of research site, gyeongsangnam-do, korea, republic of research site, seo-gu, korea, republic of research site, seongnam-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, kuching, malaysia research site, amsterdam, netherlands research site, arnhem, netherlands research site, olsztyn, poland research site, łódź, poland research site, łódź, poland research site, craiova, romania research site, suceava, romania research site, arkhangelsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, omsk, russian federation research site, pos.pesochnyi, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, sremska kamenica, serbia research site, badalona, spain research site, barcelona, spain research site, barcelona, spain research site, barcelona, spain research site, girona, spain research site, jaén, spain research site, madrid, spain research site, madrid, spain research site, marbella, spain research site, málaga, spain research site, valencia, spain research site, bellinzona, switzerland research site, lausanne, switzerland research site, new taipei, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, bangkok, thailand research site, songkhla, thailand research site, adana, turkey research site, istanbul, turkey research site, chernivtsі, ukraine research site, ivano-frankivsk, ukraine research site, kharkiv, ukraine research site, kirovohrad, ukraine research site, kryvyi rih, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, sumy, ukraine research site, uzhhorod, ukraine research site, vinnytsia, ukraine research site, london, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, hanoi, vietnam']",,https://ClinicalTrials.gov/show/NCT04078152,
574,575,NCT05142982,radiotherapy vs observation for post chemotherapy residual mass in advanced seminoma,,Not yet recruiting,No Results Available,seminoma,radiation: radiotherapy,progression free survival(pfs)|locoregional control (lrc)|overall survival (os)|second-line salvage therapy-free survival|acute radiation toxicity|late radiation toxicity|patient-reported quality of life (qol),tata memorial centre,Male,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,74.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PROsem,"December 15, 2021","December 15, 2029","December 15, 2029","December 3, 2021",,"December 3, 2021","['tata memorial centre, mumbai, maharashtra, india dr vedang murthy, navi-mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT05142982,
575,576,NCT01950611,proteasome inhibition in acute promyelocytic leukemia,PIAPL,Unknown status,No Results Available,relapsed acute promyelocytic leukemia,drug: bortezomib,safety|efficacy,"christian medical college, vellore, india",All,"1 Year to 75 Years   (Child, Adult, Older Adult)",Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 8225 27/02/13,May 2013,May 2018,May 2018,"September 25, 2013",,"September 25, 2013","['department of haematology, christian medical college, vellore, tn, india']",,https://ClinicalTrials.gov/show/NCT01950611,blood
576,577,NCT00624143,antifungal prophylaxis in pediatric acute leukemia,,Unknown status,No Results Available,pediatric acute leukemia induction,drug: oral voriconazole and iv amphotericin b,"prevention of possible, probable or proven fungal infection.","all india institute of medical sciences, new delhi",All,up to 15 Years   (Child),Phase 3,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,antifungal prophylaxis|Dr. SAMEER BAKHSHI,February 2008,December 2009,,"February 26, 2008",,"February 26, 2008","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00624143,blood
577,578,NCT00527319,regimen for the treatment of cachexia in subjects with nsclc,VT-122,Completed,Has Results,cachexia,drug: vt-122 low dose|drug: vt-122 high dose,proportion of subjects with a positive change from baseline to week 4 in lean body mass|proportion of subjects with a positive change from baseline to week 4 in grip strength,vicus therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,37.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,VT-1 CAX-001,January 2007,August 2008,September 2008,"September 10, 2007","January 30, 2013","January 30, 2013","['first dynamic health care services, inc., waco, texas, united states rajalakshmi nursing home, bangalore, india nizam institute of medical sciences, hyderabaad, india orchid nursing home, kolkata, india shatabdi super specialty hospital, nashik, india all india institute of medical sciences, new delhi, india indraprastha apollo hospital, new delhi, india deenanath mangeshkar hospital, pune, india']",,https://ClinicalTrials.gov/show/NCT00527319,
578,579,NCT04633564,"myl-1402o compared with avastin®, in patients with stage iv nsnsclc",,Completed,Has Results,nsclc stage iv,biological: bevacizumab as myl-1402o|biological: bevacizumab as avastin,primary efficacy analysis of overall response rate ( orr) of myl-1402o as compared to avastin,mylan pharmaceuticals inc|viatris inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,671.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MYL-1402O-3001,"January 21, 2017","June 5, 2019","November 22, 2019","November 18, 2020","February 1, 2021","March 16, 2022","[""grodno clinical regional hospital, grodno, hrodzenskaya voblasts, belarus mogilev regional oncology dispensary, minsk, minskaya voblasts, belarus babruysk interregional oncological dispensary, babruysk, belarus state institution nn alexandrov republican scientific and practical centre of oncology and medical r, minsk, belarus grodno clinical regional hospital, mogilev, belarus clinical hospital mostar, mostar, bosnia and herzegovina clinical center university of sarajevo, sarajevo, bosnia and herzegovina javna zdravstvena ustanova bolnica trebinje, trebinje, bosnia and herzegovina county hospital zenica, zenica, bosnia and herzegovina complex oncology center-veliko tarnovo, veliko tarnovo, bulgaria complex oncology center - vratsa eood, vratsa, bulgaria clinical hospital centre osijek, osijek, croatia general hospital sibenik, sibenik, croatia clinical hospital center zagreb - ppds, zagreb, croatia research institute of clinical medicine, tbilisi, georgia ltd high technology medical center university clinic, tbilisi, georgia orszagos koranyi pulmonologiai intezet, budapest, hungary semmelweis egyetem, budapest, hungary debreceni egyetem klinikai kozpont, debrecen, hungary veszprem megyei tudogyogyintezet, farkasgyepü, hungary borsod-abaúj-zemplén megyei központi kórház és egyetemi oktató kórház, miskolc, hungary city cancer center, vijayawada, andhra pradesh, india mahatma gandhi medical college and hospital, visakhapatnam, andhra pradesh, india regional cancer centre indira gandhi institute of medical sciences, patna, bihar, india hcg cancer center, ahmedabad, gujarat, india shree giriraj multispeciality hospital, rajkot, gujarat, india synexus affiliate - apple hospital, surat, gujarat, india unique hospital - multispeciality & research institute, surat, gujarat, india aadhar health institute, hisar, haryana, india bgs global hospital, bangalore, karnataka, india sri venkateshwara hospital, bangalore, karnataka, india shetty's hospital, bengaluru, karnataka, india amravati cancer foundation sujan surgical and cancer hospital, amravati, maharashtra, india united ciigma institute of medical sciences pvt.ltd., aurangabad, maharashtra, india seth nandlal dhoot hospital, aurangabad, maharashtra, india government medical college, nagpur, maharashtra, india curie manavata cancer centre, nashik, maharashtra, india ruby hall clinic, pune, maharashtra, india acharya tulsi regional cancer institute and research centre, bikaner, rajasthan, india malpani multispecialty hospital, jaipur, rajasthan, india institute of respiratory diseases (chest and tb hospital), jaipur, rajasthan, india apex hospital, jaipur, rajasthan, india bhagwan mahaveer cancer hospital and research centre, jaipur, rajasthan, india rajiv gandhi government general hospital, chennai, tamil nadu, india meenakshi mission hospital and research center, madurai, tamil nadu, india shatabdi superspeciality hospital, lucknow, uttar pradesh, india chittaranjan national cancer institute, kolkata, west bengal, india kles dr prabhakar kore hospital and medical research centre, belagave, india prince aly khan hospital mumbai, mumbai, india jaslok hospital and research centre, mumbai, india sahyadri speciality hospital, pune, india kailash cancer hospital and research centre, vadodara, india ospedale felice lotti de pontedera, pontedera, italy philippine general hospital, manila, national capital region, philippines cardinal santos medical center, san juan city, national capital region, philippines med-polonia sp. z o.o., poznań, poland radomskie centrum onkologii, radom, poland medisprof srl, cluj-napoca, cluj, romania ploiesti municipal hospital, ploiesti, prahova, romania spitalul judetean de urgenta sf. pantelimon focsani, focsani, vrancea, romania elias emergency university hospital, bucharest, romania prof. dr. alexandru trestioreanu oncologic institute, bucharest, romania spitalul clinic judetean de urgenta sf. apostol andrei constanta, constanta, romania oncology center sfantul nectarie, craiova, romania arkhangelsk regional clinical oncology dispensary, arkhangelsk, russian federation chelyabinsk regional clinical oncology dispensary, chelyabinsk, russian federation kaluga regional oncology dispensary, kaluga, russian federation republican clinical oncology dispensary of ministry of healthcare of tatarstan republic, kazan, russian federation kursk regional oncology centre, kursk, russian federation vitamed, moscow, russian federation city clinical hospital #1, novosibirsk, russian federation clinical oncology dispensary, omsk, russian federation stavropol regional clinical oncology centre pyatigorsk affiliate, pyatigorsk, russian federation ryazan state medical university n.a. i.p. pavlov, ryazan, russian federation mordovia state university, saransk, russian federation research institute of phtisio-pneumology, st. petersburg, russian federation leningrad regional clinical hospital, st. petersburg, russian federation railway clinical hospital jsc rzhd, st. petersburg, russian federation clinical theoretical and practical center of specialized kinds of medical care, st. petersburg, russian federation scientific research institute of oncology n.a. n.n. petrov, st. petersburg, russian federation city clinical oncology dispensary, st. petersburg, russian federation research oncology institute of tomsk scientific center, tomsk, russian federation volgograd regional clinical oncology dispensary, volgograd, russian federation regional clinical oncology hospital, yaroslavl, russian federation hospital universitario vall d'hebrón - ppds, barcelona, spain hospital son llatzer, palma de mallorca, spain kaohsiung medical university hospital, kaohsiung, taiwan e-da hospital, kaohsiung, taiwan taichung veterans general hospital, taichung, taiwan mackay memorial hospital-taipei branch, taipei, taiwan gazi university medical faculty gazi hospital, ankara, turkey ege universitesi tip fakultesi hastanesi, izmir, turkey municipal institution city clinical hospital #4 of dnipro city council - ppds, dnipropetrovsk, ukraine municipal institution subcarpathian clinicaloncological centre, ivano-frankivsk, ukraine mi kryvyi rih oncology dispensary of dnipropetrovsk regional council, kryvyi rih, ukraine municipal non profit enterprise of sumy regional council sumy regional clinical oncology dispensary, sumy, ukraine mnpe central city clinical hospital of uzhhorod city council, uzhgorod, ukraine mi of zaporizhzhia regional council zaporizhzhia regional clinical oncology dispensary, zaporizhzhia, ukraine bach mai hospital, hanoi, vietnam national cancer hospital, hanoi, vietnam national lung hospital, hanoi, vietnam cho ray hospital, ho chi minh city, vietnam""]","""study protocol"", https://clinicaltrials.gov/provideddocs/64/nct04633564/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/64/nct04633564/sap_001.pdf",https://ClinicalTrials.gov/show/NCT04633564,
579,580,NCT01917513,prospective trial to compare the clinical efficiency of g-eye™ hd colonoscopy with standard hd colonoscopy,,Completed,Has Results,adenoma|polyps|colorectal cancer,device: g-eye™ colonoscopy|device: standard colonoscopy,"detection rate of adenomas and serrated lesions|number of polyp and adenoma detection, procedure times and safety (number of patients with adverse events.",smart medical systems ltd.,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,G-EYE 15505,May 2014,September 2016,September 2016,"August 6, 2013","January 23, 2018","January 23, 2018","['beth israel deaconess medical center, harvard medical school, boston, massachusetts, united states nyu langone medical center, new york, new york, united states herlev hospital, harlev, denmark universitätsmedizin johannes gutenberg university mainz, mainz, germany universitätsklinikum tübingen, tübingen, germany helios dr. horst schmidt kliniken (hsk), wiesbaden, germany asian institute of gastroenterology, hyderabad, india hadassah medical center, jerusalem, israel laniado hospital, netanya, israel assaf harofeh medical center, tzrifin, israel vita salute san raffaele university - scientific institute san raffaele, milan, italy maastricht university medical centre, maastricht, netherlands radboud umc, nijmegen, netherlands birmingham city university, birmingham, united kingdom russells hall hospital, dudley, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/13/nct01917513/prot_000.pdf",https://ClinicalTrials.gov/show/NCT01917513,colon
580,581,NCT00385515,efficacy of snx-1012 in the treatment of oral mucositis,,Completed,Has Results,stomatitis|oral mucositis,drug: snx-1012 (meclocycline sulfosalicylate)|drug: placebo,duration of ulcerative oral mucositis|number of participants with ulcerative oral mucositis,mucosal therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,81.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SNX-1012-CLN2-006,June 2006,May 2008,July 2008,"October 9, 2006","March 18, 2009","May 7, 2009","['desert hematology oncology medical group, rancho mirage, california, united states bridgeport hospital, bridgeport, connecticut, united states eastern connecticut hematology & oncology associates, norwich, connecticut, united states florida research cancer institute, davie, florida, united states park nicollet clinic, st louis park, minnesota, united states capitol comprehensive cancer care clinic, jefferson city, missouri, united states cancer specialists of south texas, corpus christi, texas, united states cancer outreach associates, abingdon, virginia, united states morgantown internal medicine group, morgantown, west virginia, united states vedanta institute of medical sciences, navrangpura, ahmedabad, gujarat, india jawaharlal nehru cancer hospital and research centre, post box no. 32, idgah hills, bhopal, madhya pradesh, india apollo speciality hospital, 320, mount road, teynampet, chennai, tamil nadu, india dharamshila cancer hospital and research centre,, dharamshila marg, vasundhara enclave, dehli, india apollo hospitals, jubilee hills, hyderabad, andhra pradesh, india nizams institute of medical sciences, punjagutta, hyderabad, andhra pradesh, india bhagwan mahavir cancer hospital and research centre,, jawaharlal nehru marg, jaipur, rajasthan, india s.k sony hospital, vidyadhar nagar,, sector-5 sikar road, jaipur, rajasthan, india netaji subhash chandra bose cancer hospital & research institute, 16a park lane, kolkatta, west bengal, india chittaranjan national cancer institute, 37, s.p. mukherjee rd., kolkatta, west bengal, india dayanand medical college & hospital, tagore nagar, civil lines, ludhiana, punjab, india jaslok hospital & research centre, 15-dr. g. deshmukh marg, mumbai, maharashtra, india jehangir hospital,, 32 sassoon road, pune, maharashtra, india ruby hall clinic,, 40, sassoon road, pune, maharashtra, india seth ramdas shah memorial hospital & research centre, fp-402, gokhle nagar road, shivaji nagar, pune, maharashtra, india north bengal oncology centre,, pradhan nagar, siliguri, dist- darjeeling, west bengal, india regional cancer centre, medical college campus, post bag no. 2417, trivandrum, kerala, india christian medical college & hospital, ida scuddar road, vellore, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT00385515,
581,582,NCT01339260,an efficacy and safety study of oral netupitant and palonosetron for the prevention of nausea and vomiting,,Completed,Has Results,chemotherapy-induced nausea and vomiting,drug: netupitant and palonosetron|drug: palonosetron|drug: dexamethasone,"percentage of patients with complete response (cr) defined as no emesis, no rescue medication, at cycle 1|percentage of patients with complete response (cr) defined as no emesis, no rescue medication at cycle 1",helsinn healthcare sa|parexel,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1455.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",NETU-08-18,April 2011,November 2012,,"April 20, 2011","November 26, 2014","November 26, 2014","['anniston oncology/regional medical center, anniston, alabama, united states northwest alabama cancer center, muscle shoals, alabama, united states genesis cancer centre, hot springs, arkansas, united states compassionate cancer care medical group inc, corona, california, united states compassionate cancer centre medical group, fountain valley, california, united states american institute of research, los angeles, california, united states facey medical group, mission hills, california, united states compassionate cancer care medical group, riverside, california, united states american institute of research, whittier, california, united states denver health and hospital authority, denver, colorado, united states palm beach institute of hematology and oncology, boynton beach, florida, united states baptist cancer institute, jacksonville, florida, united states deaconess clinic downtown, evansville, indiana, united states floyd memorial cancer center of indiana, new albany, indiana, united states kentucky cancer clinic, hazard, kentucky, united states the john r marsh cancer center, hagerstown, maryland, united states fallon clinic at worcester medical center, worcester, massachusetts, united states duke university medical center, durham, north carolina, united states piedmont hematology oncology associates pa, winston-salem, north carolina, united states tri-county hematology and oncolgy associates inc., massillon, ohio, united states signal point clinical research center llc, middletown, ohio, united states charleston cancer center, charleston, south carolina, united states charleston hematology oncology, charleston, south carolina, united states wellmont medical associates-oncology and hematology, bristol, tennessee, united states cancer specialists of south texas, p.a., corpus christi, texas, united states the university of texas health center, tyler, texas, united states northern utah associates hematology / oncology, ogden, utah, united states northwest medical specialties, tacoma, washington, united states instituto oncológico de córdoba - sanatorio aconcagua, cordoba, argentina hospital italiano de cordoba, córdoba, argentina clínica universitaria reina fabiola (universidad católica de córdoba), córdoba, argentina centro oncológico integral (coi), mar del plata, argentina centro oncologico de integracion regional (coir), mendoza, argentina instituto médico cer [oncology], quilmes, argentina sanatorio parque, rosario, argentina centro medico san roque, san miguel de tucuman, argentina isis clinica especializada, santa fe, argentina bobruisk interregional oncological dispensary, bobruisk, belarus brest regional oncological dispensary, brest, belarus gomel regional clinical oncological dispensary, brest, belarus minsk city clinical oncological dispensary [oncology], minsk, belarus state institution n.n. alexandrov republican scientific and practical center of oncology and medical radiology, minsk, belarus mogilev regional oncological dispensary [oncology], mogilev, belarus oxion-medicina oncológica, belo horizonte, brazil centro de pesquisas clínicas em oncologia, cachoeiro de itapemirim, brazil ipcem - centro de ciências da saúde - universidade de caxias, caxias do sul, brazil hospital araújo jorge, goiânia, brazil clinica de neoplasias do litoral, itajaã, brazil clinica de oncologia de porto alegre s s ltda, porto alegre, brazil hospital moinhos de vento, porto alegre, brazil instituto ribeirãopretano de combate ao cancer, ribeirão preto, brazil oncotrat oncologia medica ltda [oncology], rio de janeiro, brazil nucleo de oncologia da bahia, salvador bahia, brazil hospital santa cruz, são paulo, brazil casa de saude santa marcelina, são paulo, brazil shato ""sveti mina"", blagoevgrad, bulgaria mhat dr. tota venkova [oncology], gabrovo, bulgaria specialized hospital for active treatment of oncology, haskovo, bulgaria umhat """"dr. georgi stranski"""" dept. medical oncology, pleven, bulgaria umhat ""sveti georgi"" [clinic of oncology and hematology], plovdiv, bulgaria district dispensery with stationary - sofia district, sofia, bulgaria umhat ""tsaritsa yoanna - isul"" ltd.medical oncology clinic, sofia, bulgaria specialized hospital for active treatment in oncology, sofia, bulgaria specialized hospital for active treatment of onclogy diseases - sofia city, sofia, bulgaria complex oncology centre, stara zagora, bulgaria coc - veliko tarnovo dept. medical oncology, veliko tarnovo, bulgaria comprehensive cancer center - vratsa dept. of palliative care, vratsa, bulgaria županijska bolnica cakovec, cakovec, croatia klinicki bolnicki centar osijek [oncology], osijek, croatia opca bolnica pula [odjel za onklologiju], pula, croatia kbc rijeka [gastroenterology], rijeka, croatia opca bolnica varazdin [odjel za hem.onko i klin.imun.], varazdin, croatia opca bolnica zadal ulica, zadar, croatia klinički bolnički centar zagreb [oncology], zagreb, croatia klinicka bolnica [sestre milosrdnice], zagreb, croatia klinika za tumore [odjel za kemoter. i internisticku onkolog, zagreb, croatia klinik und poliklinik für onkologie und hämatologie universitatsmedizin charite mitte, berlin, germany gynäkologische arztpraxis, berlin, germany oncoresearch lerchenfeld ug, hamburg, germany schwerpktprxs gynäkolog onkologie prof. dr. diel, dr. gebert, mannheim, germany rotkreuzklinikum [münchen], münchen, germany tumorzentrum munchen sued - städtisches klinikum [hämato-, onkologie + palliativmed], münchen, germany staedtisches krankenhaus muenchen neuperlach, münchen, germany oncopro gbr dr. r. dengler, dr. a. kröber gesellschaft für klinische studien in der ambulanten hämatologie und onkologie, regensburg, germany universitätsklinikum tübingen, tübingen, germany praxis dr. g. dresemann, velen, germany onkologische gemeinschaftspraxis dr. med m. perker / pf dr. med m. sandherr, weilheim, germany semmelweis egyetem kútvölgyi klinikai tömb, budapest, hungary fővárosi önkormányzat uzsoki utcai kórház, budapest, hungary petz aladár megyei oktató kórház [onkoradiológiai oszt, győr, hungary bács-kiskun megyei önkormányzat kórháza, szegedi, kecskemet, hungary borsod-abaúj-zemplén megyei kórház és egyetemi oktató kórház, miskolc, hungary josa andras oktato korhaz [onkologiai osztaly], nyíregyháza, hungary pécsi tudományegyetem klinikai köpont, pécs, hungary jasz-nagykun-szolnok megyei hetenyi geza korhaz, szolnok, hungary hcg - multy speciality hospital, ahmedabad, india hemato-oncology clinic ahmedabad pvt ltd, ahmedabad, india sujan surgical cancer hospital and amracvati cancer foundation, amravati, india sri venkateshwara hospital [medical oncology], bangalore, india apollo speciality hospital, chennai, india dr. kamahshi memorial hospital [oncology], chennai, india bibi general hospital & cancer centre [oncology], hyderabad, india yashoda b-block hospital, hyderabad, india b.p.poddar hospital and medical research ltd, kolkata, india apollo gleneagles hospitals kolkata, kolkata, india shatabdhi superspeciality hospital, nashik, india grant medical foundation - ruby hall clinic, pune, india city cancer centre [surgical and medical oncology], vijayawada, india fondazione poliambulanza istituto ospedaliero, brescia, italy ospedale vito fazzi, asl lecce, lecce, italy presidio ospedaliero ""alessandro manzoni"", ao provincia di lecco, lecco, italy ospedale sacro cuore e don calabria - negrar, negrar, italy ospedale s.carlo di potenza [u.o. di oncologia medica], potenza, italy centro oncologico de chihuahua, chihuahua, mexico hospital de jesus, mexico, mexico centro medico quirurgico, mexico, mexico oca hospital/monterrey international research center, monterrey, mexico centro regiomontano de investigación clínica, monterrey, mexico bialostockie centrum onkologii im. m.sklodowskiej-curie, bialystok, poland wojewodzki szpital zespolony w elblagu, oddzial onkologiczny, elblag, poland niepubliczny specjalist. onkol. zaklad opieki zdrowotnej, koscierzyna, poland wojewodzki szpital specjalistyczny im. m.kopernika, lodz, poland szpital wojewodzki w lomzy im. kardynala s. wyszynskiego, lomza, poland olsztynski osrodek onkologiczny ""kopernik"", olsztyn, poland szpital rejonowy im. dr j. rostka w raciborzu, raciborz, poland wojewodzki szpital specjalistyczny im. j. korczaka, slupsk, poland centrum onkologii - instytut im. marii sklodowskiej - curie, warszawa, poland nzoz magodent - centrum medczyne ostrobramska, warszawa, poland spitalul judetean de urgenta ""dr. constantin opris"" baia-mare [oncologie medicala], baia-mare, romania spitalul universitar de urgenta elias [oncologie medicala], bucuresti, romania spitalul clinic cf nr.2 bucuresti [oncologie medicala], bucuresti, romania spitalul universitar de urgenta bucuresti, bucuresti, romania institutul oncologic ""prof. dr. alex. trestioreanu"" [sectia clinica radioterapie ii], bucuresti, romania oncolab - oncology center craiova, craiova, romania institutul regional de oncologia, iasi, romania spitalul municipal onesti [sectia oncologie medicala], onesti, romania spitalul clinic judetean mures, tg mures, romania oncomed srl, timisoara, romania guz arkhangelsk regional clinical oncological dispensary, arkhangelsk, russian federation ivanovo regional oncological dispensary [chemotherapy], ivanovo, russian federation gauz republic clinical oncology dispensary of ministry of health of republic tatarstan, kazan, russian federation gou vpo krasnoyarsk state medical university n.a. prof. v.f., krasnoyarsk, russian federation guz lipetsk regional oncology dispensary [general oncology], lipetsk, russian federation guz regional oncology dispensary #2, magnitogorsk, russian federation russian cancer research center, moscow, russian federation sbhi of moscow city oncology clinical hospital #62, moscow, russian federation mbuz city clinical hospital #1, novosibirsk, russian federation fgbu medical radiology scientific center, obninsk, russian federation guz perm regional oncology dispensary, perm, russian federation guz pyatigorsk oncology dispensary [outpatient department], pyatigorsk, russian federation gou vpo - ryazan state med. univer. n.a. i.i.pavlov based ryazan regio, ryazan, russian federation city oncology dispensary, saint petersburg, russian federation gou vpo saint-petersburg state medical university n.a. acad., saint petersburg, russian federation st. petersburg clinical oncology dispesary - 3rd gynecology d, saint petersburg, russian federation guz ""leningrad regional oncology dispensary"", saint-petersburg, russian federation guz samara regional clinical oncology dispensary, samara, russian federation fgu research institute of oncology n.a. n.n.petrov of rosmed, st. petersburg, russian federation stavropol regional clinical oncology dispensary, stavropol, russian federation gbuz - clinical oncology dispensary of moh of republic bahkortostan, ufa, russian federation guz republican clinical oncological dispensary of public, ufa, russian federation komunalnyi ""cherkaskyi oblasnyi onkolohichnyi dyspanser"" cherkaskoi oblasnoi rady, oblasnyi onkokhimioterapevtychnyi tsentr, m. cherkasy, cherkasy, ukraine komunalnyi likuvalno-profilaktychnyi zaklad ""chernigivskyi, chernigiv, ukraine chmelnytskyi regional clinical oncology centre [oncology], chmelnytskyi, ukraine komunalnyizaklad miska bahatoprofilna klinichna likarnia #4, dnipropetrovks, ukraine donetskyi oblasnyi protypukhlynnyi tsentr, donetsk, ukraine kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr, kharkiv, ukraine kyirskyi miskyi klinichnyi onkolohichnyi tsentr, kyiv, ukraine kz kor kyivskyi oblasnyi onkologichnyi dyspanser, kyiv, ukraine lvivskyi derzhavnyi onkologichnyi regionalnyi likuvalno diahnostychyi tsentr, lviv, ukraine odeska oblasna klinichna likarnia, odessa, ukraine poltavskyi oblasnyi klinichnyi onkolohichnyi dyspanser pol, poltava, ukraine zakarpatskyi oblasnyi klinichnyi onkodyspanser, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT01339260,
582,583,NCT01363479,an efficacy and safety study of oral and intravenous palonosetron for the prevention of nausea and vomiting,,Completed,Has Results,chemotherapy-induced nausea and vomiting,drug: oral palonosetron|drug: i.v. palonosetron|drug: dexamethasone,"percentage of patients with complete response (cr) defined as no emesis, no rescue medication|percentage of patients with no emesis|percentage of patients with no rescue medication",helsinn healthcare sa|parexel,All,"18 Years and older   (Adult, Older Adult)",Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PALO-10-01,July 2011,November 2012,November 2012,"June 1, 2011","November 17, 2014","September 22, 2021","['genesis cancer centre, hot springs, arkansas, united states compassionate cancer center, corona, california, united states compassionate cancer centre medical group, fountain valley, california, united states facey medical group, mission hills, california, united states compassionate cancer care medical group, riverside, california, united states signal point clinical research center, llc, middletown, ohio, united states wellmont medical associates-oncology and hematology, bristol, rhode island, united states charleston hematology oncology, charleston, south carolina, united states northern utah associates [hematology/ oncology], ogden, utah, united states centro oncológico integral (coi), mar del plata, buenos aires, argentina instituto oncológico de córdoba (ionc), cordoba, argentina clínica universitaria reina fabiola, córdoba, argentina instituto médico cer [oncology], quilmes, argentina sanatorio parque, rosario, argentina centro medico san roque, san miguel de tucuman, argentina isis clinica especializada, santa fe, argentina mhat dr. tota venkova, gabrovo, bulgaria specialized hospital for active treatement of oncology diseases - sofia district medical oncology department, sofia, bulgaria umhat ""tsaritsa yoanna - isul"" ltd.medical oncology clinic, sofia, bulgaria specialised hospital for active treatment on oncology, sofia, bulgaria district dispensery for oncology diseases with in-patient, sofia, bulgaria complex oncology centre, stara zagora, bulgaria klinicki bolnicki centar [oncology], osijek, croatia kbc rijeka, rijeka, croatia opca bolnica varazdin, varazdin, croatia kbc zagreb, zagreb, croatia klinicka bolnica [sestre milosrdnice], zagreb, croatia klinik und poliklinik für onkologie und hämatologie universitätsmedizin charité mitte, berlin, germany oncoresearch lerchenfeld ug, hamburg, germany städtisches klinikum münchen, münchen, germany staedtisches krankenhaus muenchen neuperlach, münchen, germany semmelweis egyetem kútvölgyi klinikai tömb, budapest, hungary fővárosi önkormányzat uzsoki utcai kórház, budapest, hungary petz aladár megyei oktató kórház, györ, hungary bács-kiskun megyei önkormányzat kórháza, szeged, kecskemet, hungary pécsi tudományegyetem [onkoterápiás intézet], pécs, hungary jasz-nagykun-szolnok megyei hetenyi geza korhaz, szolnok, hungary yashoda super speciality hospital, hyderabad, andhra pradesh, india sujan surgical cancer hospital and amracvati cancer foundation, pune, maharashtra, india apollo speciality hospital, chennai, tamil nadu, india sri venkateshwara hospital [medical oncology], bangalore, india chinmaya mission hospital, bangalore, india city cancer centre [surgical and medical oncology], vijayawada, india fondazione poliambulanza istituto ospedaliero, brescia, italy ospedale vito fazzi - asl lecce, lecce, italy presidio ospedaliero ""alessandro manzoni"", lecco, italy ao regionale s.carlo di potenza, potenza, italy szpital wojewodzki zespolony, elblag, poland wojewodzki szpital specjalistyczny im. m.kopernika, lodz, poland szpital wojewodzki w lomzy im. kardynala s. wyszynskiego, lomza, poland wojewodzki szpital specjalistyczny im. j. korczaka, slupsk, poland centrum onkologii - instytut im. marii sklodowskiej - curie, warszawa, poland nzoz magodent - centrum medczyne ostrobramska, warszawa, poland spitalul judetean de urgenta ""dr. constantin opris"", baia-mare, romania institutul oncologic ""prof. dr. alex. trestioreanu"", bucharest, romania institutul oncologic ""prof. dr. ion chiricuta"", cluj-napoca, romania spitalul clinic judetean de urgenta cluj (oncologie medicala), cluj-napoca, romania centrul de oncologie euroclinic, iasi, romania institutul regional de oncologie iasi, iasi, romania spitalul clinic judetean de urgenta sibiu [oncologie], sibiu, romania oncomed srl, timisoara, romania guz arkhangelsk regional clinical oncological dispensary, arkhangelsk, russian federation gou vpo krasnoyarsk state medical university n.a. prof. v.f., krasnoyarsk, russian federation guz lipetsk regional oncology dispensary [general oncology], lipetsk, russian federation guz regional oncology dispensary #2, magnitogorsk, russian federation ramn - russian cancer research center, moscow, russian federation russian oncology research center n.a. n.n. blokhin ramn, moscow, russian federation mbuz city clinical hospital #1 [oncology], novosibirsk, russian federation fgbu ""medical radiology scientific center of minzdravsotsrazvitiya rf, obninsk, russian federation ryazan state med. univer. n.a. i.i.pavlov based ryazan regio, ryazan, russian federation guz leningrad regional oncological dispensary, saint petersburg, russian federation st. petersburg clinical oncology dispesary, saint petersburg, russian federation komunalnyi likuvalno-profilaktychnyi zaklad ""chernigivskyi, chernihiv, ukraine komunalnyi zaklad miska bahatoprofilna klinichna likarnia #4, dnipropetrovsk, ukraine komunalno-klinichnyi likuvalno-profilaktychnyi zaklad, donetsk, ukraine du imr amnu [vd khemter], kharkiv, ukraine kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr, kharkiv, ukraine chmelnytskyi regional clinical oncology centre [oncology], khmelnytskyi, ukraine uzhgorod national university, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT01363479,
583,584,NCT01459757,non-interventional retrospective correlation of tumor mutational status to clinical benefit of gist patients treated with sunitinib,,Completed,No Results Available,gist,other: non-interventional,mutational status data retrospectively accessed correlated with a6181036 clinical outcomes data in gist subjects treated with sunitinib,pfizer,All,"18 Years and older   (Adult, Older Adult)",,322.0,Industry,Observational,Time Perspective: Retrospective,A6181199,October 2011,April 2013,April 2013,"October 26, 2011",,"June 19, 2013","[""city of hope, duarte, california, united states washington hospital center, washington, district of columbia, united states davis cancer pavilion and shands medical plaza, gainesville, florida, united states shands cancer hospital at the university of florida, gainesville, florida, united states shands hospital at the university of florida, gainesville, florida, united states moffitt cancer center, tampa, florida, united states brigham and women's hospital, boston, massachusetts, united states dana-farber cancer institute, boston, massachusetts, united states masonic cancer center - clinical trials office, minneapolis, minnesota, united states oregon health and science university, portland, oregon, united states seattle cancer care alliance, seattle, washington, united states university of washington, seattle, washington, united states prince of wales hospital, oncology day center, randwick, new south wales, australia ashford cancer centre research, kurralta park, south australia, australia peter maccallum cancer institute, department of medical oncology, east melbourne, victoria, australia uz leuven, leuven, belgium hopital notre-dame du centre hospitalier universitaire de montreal, montreal, quebec, canada herlev hospital, herlev, denmark helsingin yliopistollinen keskussairaala/syopatautien klinikka, helsinki, finland institut bergonie, bordeaux cedex, france centre l� b�rd, lyon cedex, france chu la timone, service d'oncologie medicale, marseille, france helios klinikum berlin-buch, klinik fuer interdisziplinaere onkologie, berlin, germany schwerpunktpraxis fuer ambulante tumortherapie, duesseldorf, germany klinikum der universitaet zu koeln, koeln, germany tata memorial centre, mumbai, maharashtra, india seoul national university hospital/department of internal medicine, seoul, korea, republic of asan medical center, department of internal medicine, seoul, korea, republic of leids universitair medisch centrum/ klinische oncologie, leiden, netherlands klinika nowotworow tkanek miekkich i kosci, warszawa, poland narodny onkologicky ustav, bratislava, slovakia hospital de la santa creu i sant pau, barcelona, spain hospital universitario virgen macarena, sevilla, spain centre hospitalier universitaire vaudois, lausanne, switzerland sarcoma unit, london, united kingdom christie hospital nhs trust, manchester, united kingdom""]",,https://ClinicalTrials.gov/show/NCT01459757,
584,585,NCT01794793,study to allow access to pasireotide for patients benefiting from pasireotide treatment in novartis-sponsored studies,,"Active, not recruiting",No Results Available,cushing's disease|acromegaly|neuroendocrine tumors|pituitary tumors|ectopic acth secreting (eas) tumors|dumping syndrome|prostate cancer|melanoma negative for braf|melanoma negative for nras,drug: pasireotide|drug: cabergoline,incidence of adverse events to evaluate long term safety data|percentage of patients with clinical benefit as assessed by the investigator,recordati group,All,"18 Years and older   (Adult, Older Adult)",Phase 4,413.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSOM230B2412,"June 10, 2013","June 9, 2023","June 9, 2023","February 20, 2013",,"November 3, 2020","['ximed research sc - som230b2412, la jolla, california, united states cedars sinai medical center cedars sinai 4, los angeles, california, united states stanford universtiy medical center stanford hospital & clinics, stanford, california, united states university of michigan comprehensive cancer center sc-2, ann arbor, michigan, united states memorial sloan-kettering cancer center sc, new york, new york, united states virginia endocrinology research sc, chesapeake, virginia, united states swedish cancer institute swedish cancer institute (sc), seattle, washington, united states recordati investigative site, caba, buenos aires, argentina recordati investigative site, mar del plata, buenos aires, argentina recordati investigative site, edegem, antwerpen, belgium recordati investigative site, brugge, belgium recordati investigative site, brussel, belgium recordati investigative site, bruxelles, belgium recordati investigative site, gent, belgium recordati investigative site, leuven, belgium recordati investigative site, liege, belgium recordati investigative site, wilrijk, belgium recordati investigative site, fortaleza, ce, brazil recordati investigative site, curitiba, pr, brazil recordati investigative site, rio de janeiro, rj, brazil recordati investigative site, porto alegre, rs, brazil recordati investigative site, joinville, sc, brazil recordati investigative site, botucatu, sp, brazil recordati investigative site, sao paulo, sp, brazil recordati investigative site, sofia, bulgaria recordati investigative site, halifax, nova scotia, canada recordati investigative site, london, ontario, canada recordati investigative site, montreal, quebec, canada recordati investigative site, montreal, quebec, canada recordati investigative site, toulouse, cedex 9, france recordati investigative site, angers cedex 09, france recordati investigative site, bron cedex, france recordati investigative site, le kremlin bicetre, france recordati investigative site, lille cedex, france recordati investigative site, marseille cedex 05, france recordati investigative site, pessac cedex, france recordati investigative site, pierre benite cedex, france recordati investigative site, berlin, germany recordati investigative site, hamburg, germany recordati investigative site, muenchen, germany recordati investigative site, muenchen, germany recordati investigative site, tübingen, germany recordati investigative site, ulm, germany recordati investigative site, wuerzburg, germany recordati investigative site, athens, gr, greece recordati investigative site, budapest, hungary recordati investigative site, bangalore, karnataka, india recordati investigative site, vellore, tamil nadu, india recordati investigative site, petach tikva, israel recordati investigative site, ancona, an, italy recordati investigative site, genova, ge, italy milano investigative site, milano, mi, italy recordati investigative site, padova, pd, italy recordati investigative site, roma, rm, italy recordati investigative site, nagoya, aichi, japan recordati investigative site, maebashi city, gunma, japan recordati investigative site, kobe-shi, hyogo, japan recordati investigative site, nankoku city, kochi, japan recordati investigative site, kyoto-city, kyoto, japan recordati investigative site, suita city, osaka, japan recordati investigative site, seoul, korea, republic of recordati investigative site, seoul, korea, republic of recordati investigative site, kuala lumpur, malaysia recordati investigative site, pulau pinang, malaysia recordati investigative site, méxico, distrito federal, mexico recordati investigative site, guadalajara, jalisco, mexico recordati investigative site, durango, mexico recordati investigative site, mexico city, mexico recordati investigative site, groningen, netherlands recordati investigative site, san isidro, lima, peru recordati investigative site, gdansk, poland recordati investigative site, poznan, poland recordati investigative site, warszawa, poland recordati investigative site, wroclaw, poland recordati investigative site, porto, portugal recordati investigative site, bucuresti, romania recordati investigative site, barnaul, russian federation recordati investigative site, moscow, russian federation recordati investigative site, saint petersburg, russian federation recordati investigative site, tyumen, russian federation recordati investigative site, alicante, comunidad valenciana, spain recordati investigative site, barcelona, spain recordati investigative site, lausanne, switzerland recordati investigative site, zuerich, switzerland recordati investigative site, taichung, taiwan recordati investigative site, bangkok, thailand recordati investigative site, bangkok, thailand recordati investigative site, songkla, thailand recordati investigative site, istanbul, tur, turkey recordati investigative site, ankara, turkey recordati investigative site, antalya, turkey recordati investigative site, istanbul, turkey recordati investigative site, izmir, turkey recordati investigative site, kocaeli, turkey']",,https://ClinicalTrials.gov/show/NCT01794793,skin brain
585,586,NCT03449602,minirigid versus conventional rigid thoracoscopy in undiagnosed pleural effusions,MICRO,Recruiting,No Results Available,pleural effusion,device: mini-thoracoscopy|device: conventional rigid thoraoscopy,diagnostic sensitivity (intention-to-treat)|diagnostic sensitivity (per protocol)|sedative and analgesic dose|pain scores by visual analog scale|diagnostic specificity|adverse effects|scope maneuverability|ease of obtaining biopsy|incision size|procedure duration|pain scores by wong baker faces pain rating scale,postgraduate institute of medical education and research,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NK/3695/Res,"March 1, 2018","September 30, 2022","September 30, 2022","February 28, 2018",,"April 26, 2022","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT03449602,
586,587,NCT02773485,chemo alone or in combination with radiation in unresectable cholangiocarcinoma,,Recruiting,No Results Available,cholangiocarcinoma,radiation: high dose radiation|drug: systemic chemotherapy,overall survival|loco-regional progression free survival|toxicity assessment|quality of life assessment of patients over a period of time|surgical resectability rates|cause specific survival,tata memorial hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,155.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMC IRB 1457,May 2015,June 2022,June 2022,"May 16, 2016",,"April 27, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02773485,biliari
587,588,NCT01362062,"study to evaluate the safety, tolerability and efficacy of tocilizumab in participants with rheumatoid arthritis (ra) who have an inadequate response to non-biologic disease modifying anti-rheumatic drugs (dmards) and/or anti-tumor necrosis factor (anti-tnf) therapy",,Completed,Has Results,rheumatoid arthritis,drug: tocilizumab,"percentage of participants with adverse events (aes) or serious aes (saes)|percentage of participants achieving a clinically meaningful improvement in disease activity score 28 (das28) (reduction of at least 1.2 units) at every visit|time required to achieve clinically meaningful improvement in das28 (reduction of at least 1.2 units)|percentage of participants achieving low disease activity (das28 less than [<] 3.2 units) at every visit|time required to achieve low disease activity (das28 <3.2 units)|percentage of participants achieving remission (das28 <2.6 units) at every visit|time taken to achieve remission (das28 <2.6 units)|percentage of participants achieving american college of rheumatology (acr) 20, acr50, acr70 and acr90 responses at every visit|change from baseline (cfb) in esr values at every visit|change from baseline in c-reactive protein (crp) levels at every visit|participant's global assessment of disease activity using vas: mean change from baseline at every visit|physician's global assessment of disease activity using vas: mean change from baseline at every visit|participant's assessment of pain using vas: mean change from baseline at every visit|health assessment questionnaire disability index (haq-di): mean change from baseline at every visit",hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",,110.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ML22835,"October 26, 2010","January 1, 2015","January 1, 2015","May 27, 2011","April 4, 2016","August 2, 2017","['sir gangaram hospital, new delhi, delhi, india healing touch city clinic, chandigarh, india excel center, guwahati, india arthritis superspeciality centre, hubli, india centre for rheumatic diseases - mumbai, mumbai, india jivdaya clinic, mumbai, india fortis hospital, noida, india']",,https://ClinicalTrials.gov/show/NCT01362062,
588,589,NCT02165215,a study of the efficacy and safety of etrolizumab treatment in maintenance of disease remission in ulcerative colitis (uc) participants who are naive to tumor necrosis factor (tnf) inhibitors,LAUREL,Completed,Has Results,"colitis, ulcerative",drug: etrolizumab|drug: placebo,"maintenance phase: percentage of participants in remission at week 62 among randomized participants with a clinical response at week 10, as determined by the mayo clinic score (mcs)|maintenance phase: percentage of participants who maintained clinical remission at week 62 among randomized participants in clinical remission at week 10, as determined by the mcs|maintenance phase: percentage of participants in clinical remission at week 62, as determined by the mcs|maintenance phase: percentage of participants in remission at week 62 among randomized participants in remission at week 10, as determined by the mcs|maintenance phase: percentage of participants with improvement from baseline in endoscopic appearance of the mucosa at week 62, as determined by the mcs endoscopic subscore|maintenance phase: percentage of participants with endoscopic remission at week 62, as determined by the mcs endoscopic subscore|maintenance phase: percentage of participants with histologic remission at week 62, as determined by the nancy histological index|maintenance phase: percentage of participants with corticosteroid-free clinical remission at week 62 among participants who were receiving corticosteroids at baseline, as determined by the mcs|maintenance phase: percentage of participants with corticosteroid-free remission at week 62 among participants who were receiving corticosteroids at baseline, as determined by the mcs|maintenance phase: change from baseline to week 62 in uc bowel movement signs and symptoms, as assessed by the ulcerative colitis patient-reported outcome signs and symptoms (uc-pro/ss) questionnaire|maintenance phase: change from baseline to week 62 in uc functional symptoms, as assessed by the uc-pro/ss questionnaire|maintenance phase: change from baseline to week 62 in health-related quality of life, as assessed by the overall score of the inflammatory bowel disease questionnaire (ibdq)|number of participants with at least one adverse event by severity, according to national cancer institute common terminology criteria for adverse events, version 4.0 (nci-ctcae v4.0)|number of participants with adverse events leading to study drug discontinuation|number of participants with serious infection-related adverse events|number of participants with infection-related adverse events by severity, according to nci-ctcae v4.0|number of participants with injection-site reactions by severity, according to nci-ctcae v4.0|number of participants with hypersensitivity reaction events by severity, according to nci-ctcae v4.0|number of participants with malignancies|number of participants with anti-therapeutic antibodies (atas) to etrolizumab|maintenance phase: etrolizumab serum trough concentration (for arms/timepoints above lloq)|maintenance phase: etrolizumab serum trough concentration (for arms/timepoints below lloq)",hoffmann-la roche,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,359.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GA29102|2013-004280-31,"August 12, 2014","April 6, 2020","April 6, 2020","June 17, 2014","June 15, 2021","August 19, 2021","[""university of california, irvine medical center, orange, california, united states clinical applications laboratories, inc., san diego, california, united states university of california at san francisco, san francisco, california, united states ventura clinical trials, ventura, california, united states peak gastroenterology associates; gastroenterology, colorado springs, colorado, united states clinical research of the rockies, lafayette, colorado, united states west central gastroenterology d/b/a gastro florida, clearwater, florida, united states imic, inc, miami beach, florida, united states regenerate clinical trials, miami, florida, united states advanced research institute, inc., trinity, florida, united states shafran gastroenterology center, winter park, florida, united states northwestern university-feinberg school of medicine; division of gastroenterology and hepatology, chicago, illinois, united states southwest gastroenterology, oak lawn, illinois, united states aquiant research, new albany, indiana, united states louisiana research center, llc, shreveport, louisiana, united states commonwealth clinical studies, brockton, massachusetts, united states henry ford health system, detroit, michigan, united states center for digestive health, troy, michigan, united states university of minnesota, minneapolis, minnesota, united states university of mississippi medical center, jackson, mississippi, united states ehrhardt clinical research, llc, belton, missouri, united states manhattan clinical research, new york, new york, united states weill cornell medical college-new york presbyterian hospital, new york, new york, united states asheville gastroenterology associates, p.a., asheville, north carolina, united states unc at chapel hill - dpt of family medicine; center for functional gi and motility disorders, chapel hill, north carolina, united states kinston medical specialists, kinston, north carolina, united states texas digestive disease consultants - dallas, dallas, texas, united states texas digestive disease consultants - southlake, southlake, texas, united states digestive health specialists of tyler, tyler, texas, united states ericksen research and development, clinton, utah, united states university of utah school of medicine, salt lake city, utah, united states mcguire research institute; gastroenterology, richmond, virginia, united states northwest gastroenterology associates, bellevue, washington, united states hospital universitario walter cantidio - ufc, fortaleza, ce, brazil centro digestivo de curitiba, curitiba, pr, brazil hospital moinhos de vento, porto alegre, rs, brazil cecip - centro de estudos clínicos do interior paulista, jaú, sp, brazil pesquisare saúde sociedade simples, santo andre, sp, brazil hospital estadual mario covas, santo andre, sp, brazil hospital sírio-libanês, sao paulo, sp, brazil hospital do servidor público estadual/hspe-sp, são paulo, sp, brazil pacific gastroenterology associates, vancouver, british columbia, canada queen elizabeth ii health sciences centre; gastroenterology research, halifax, nova scotia, canada lhsc - university hospital; movement disorders program, london, ontario, canada london health sciences centre victoria hospital; research pharmacy, london, ontario, canada mount sinai hospital, toronto, ontario, canada toronto digestive disease associates, vaughan, ontario, canada fakultni nemocnice u sv. anny v brne; i.interni kardioangiologicka klinika, brno, czechia hepato-gastroenterologie hk, s.r.o., hradec kralove, czechia nemocnice na bulovce, prague, czechia alborg universitets hospital, aalborg, denmark herlev og gentofte hospital, herlev, denmark charite universitaetsmedizin berlin - campus charite mitte, berlin, germany berufsgenossenschaftliches universitaetsklinikum bergmannsheil gmbh, bochum, germany ärztezentrum ellwangen; gemeinschaftspraxis, ellwangen, germany klinik johann wolfgang von goethe uni, frankfurt, germany medizinische hochschule hannover; klinik für gastroenterologie, hepatologie und endokrinologie, hannover, germany universitaetsklinikum jena; apotheke des uniersitätsklinikums jena, jena, germany medizinisches zentrum klinikum lueneburg, lueneburg, germany klinikum mannheim gmbh universitätsklinikum, mannheim, germany drc gyogyszervizsgalo kozpont kft, balatonfured, hungary pannónia klinika magánorvosi, budapest, hungary debreceni egyetem klinikai kozpont, debrecen, hungary pest megyei flor ferenc korhaz, kistarcsa, hungary csongrad megyei dr. bugyi istvan korhaz, szentes, hungary osmania general hospital, hyderabad, andhra pradesh, india deccan college of medical sciences and allied hospitals, hyderabad, andhra pradesh, india pushpawati singhania research institute, new delhi, delhi, india shree giriraj multispeciality hospital, rajkot, gujarat, india nirmal hospital, surat, gujarat, india k.l.e. society's dr. prabhakar kore hospital and medical research centre, belgaum, karnataka, india m. s. ramaiah medical college and hospital, bengaluru, karnataka, india midas institute of gastroenterology, nagpur, maharashtra, india dayanand medical college and hospital, ludhiana, punjab, india s. r. kalla memorial general hospital, jaipur, india kasturba medical college & hospital, mangalore, india ruby hall clinic, pune, india king edward memorial hospital research centre, pune, india assaf harofeh medical center, beer yaacov, israel bnei zion medical center; department of internal medicine b, haifa, israel shaare zedek medical center, jerusalem, israel hadassah university hospital - ein kerem, jerusalem, israel holy family hospital, nazareth, israel ospedale sandro pertini, roma, lazio, italy fondazione poliambulanza istituto ospedaliero, brescia, lombardia, italy ospedale di circolo; neuropsichiatria infantile, rho, lombardia, italy azienda ospedaliera universitaria policlinico paolo giaccone, palermo, sicilia, italy centro regiomontano de estudios clínicos roma s.c., monterrey, nuevo leon, mexico instituto de investigaciones aplicadas a la neurociencia a.c., durango, mexico phylasis clinicas research s de rl de cv, estado de méxico, mexico zespó przychodni specjalistycznych prima, warszawa, poland lexmedica osrodek badan klinicznych, wroclaw, poland fakultna nemocnica nitra, nitra, slovakia endomed, s.r.o., vranov nad topľou, slovakia dr jp wright practice, cape town, south africa emmed research, pretoria, south africa ci of src sumy rch dept of rheumatology sumy su mi, sumy, kharkiv governorate, ukraine ci of kyiv rc kyiv regional clinical hospital, kyiv, kiev governorate, ukraine lviv regional clinical hospital, lviv, kiev governorate, ukraine a.novak transcarpathian regional clinical hospital, uzhgorod, kiev governorate, ukraine odessa regional clinical hospital, odessa, ukraine m.v. sklifosovskyi poltava rch dept of gastroenterology hseiu umsa, poltava, ukraine si divisional clinical hospital of uzhgorod station of st&ba lz dep of therapy shei uzhgorod nu, uzhgorod, ukraine m.i. pyrogov vrch dept of gastroenterology m.i. pyrogov vnmu, vinnytsia, ukraine""]","""study protocol"", https://clinicaltrials.gov/provideddocs/15/nct02165215/prot_002.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/15/nct02165215/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02165215,
589,590,NCT00431236,a study of the drug casopitant for the prevention of nausea caused by cisplatin-based highly emetogenic chemotherapy,,Completed,No Results Available,"nausea and vomiting, chemotherapy-induced",drug: oral casopitant (gw679769)|drug: iv casopitant (gw679769)|drug: iv ondansetron hydrochloride|drug: oral dexamethasone,"number of participants who achieved complete response|number of participants who achieved complete response during the acute (0-24 hours) and the delayed (24-120 hours) phase following the first cycle of hec|number of participants who achieved a complete response during the overall (0-120 hours) phase following subsequent cycles of hec|maximum nausea score (to assess the severity of nausea), as assessed by a visual analogue scale (vas)|number of participants who use of anti-emetic rescue medication|number of participants with first emetic event|number of participants who received anti-emetic rescue medication|number of participants who vomited/retched|number of participants who reported significant nausea (>=25 mm on the vas)|number of participants who reported nausea (>=5 mm on the vas)|number of participants who achieved complete protection, defined as no vomiting/retching, no significant nausea and no rescue medication|number of participants who achieved total control, defined as no vomiting/retching, no nausea and no rescue medication|the impact on participants daily life activities for the first 120 hours following the first cycle of chemotherapy as assessed by the functional living index-emesis (flie) questionnaire-score|percentage of participants with impact on daily life activities for the first 120 hours following the first cycle of chemotherapy as assessed by the flie questionnaire-interpretation|participant satisfaction with the prophylactic anti-emetic regimens, as assessed by the participant satisfaction questionnaire|the willingness of participant to use the same treatment during future chemotherapy, as assessed by the participant willingness questionnaire|number of participants with nausea as assessed by a categorical scale, over the first 120 hours following hec|number of participants with adverse events (ae) and serious adverse events (sae)|number of participants with abnormalities of grade 3 and 4 in laboratory parameters (clinical chemistry and hematology)|summary of abnormal electrocardiogram findings|summary of mean systolic blood pressure (sbp) and diastolic blood pressure (dbp)|summary of mean respiratory rate|summary of mean heart rate",glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,810.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention,NKV102551,"November 6, 2006","October 9, 2007","October 9, 2007","February 5, 2007",,"August 22, 2017","['gsk investigational site, capital federal, buenos aires, argentina gsk investigational site, cordoba, córdova, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, tucuman, argentina gsk investigational site, edegem, belgium gsk investigational site, leuven, belgium gsk investigational site, liège, belgium gsk investigational site, sofia, bulgaria gsk investigational site, varna, bulgaria gsk investigational site, zagreb, croatia gsk investigational site, zagreb, croatia gsk investigational site, zagreb, croatia gsk investigational site, brno, czechia gsk investigational site, brno, czechia gsk investigational site, jihlava, czechia gsk investigational site, ostrava, czechia gsk investigational site, praha 5, czechia gsk investigational site, tabor, czechia gsk investigational site, helsinki, finland gsk investigational site, kangasala, finland gsk investigational site, turku, finland gsk investigational site, athens, greece gsk investigational site, kavala, greece gsk investigational site, papagos, athens, greece gsk investigational site, thessaloniki, greece gsk investigational site, thessaloniki, greece gsk investigational site, budapest, hungary gsk investigational site, mátraháza, hungary gsk investigational site, székesfehérvár, hungary gsk investigational site, kochi, india gsk investigational site, tirupati, india gsk investigational site, dublin, ireland gsk investigational site, tallaght, dublin, ireland gsk investigational site, wilton, cork, ireland gsk investigational site, monteforte irpino, campania, italy gsk investigational site, roma, lazio, italy gsk investigational site, roma, lazio, italy gsk investigational site, sassari, sardegna, italy gsk investigational site, pisa, toscana, italy gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, kubang kerian, malaysia gsk investigational site, penang, malaysia gsk investigational site, sarawak, malaysia gsk investigational site, islamabad, pakistan gsk investigational site, karachi, pakistan gsk investigational site, karachi, pakistan gsk investigational site, lahore, pakistan gsk investigational site, lahore, pakistan gsk investigational site, baguio city, benguet, philippines gsk investigational site, manila, philippines gsk investigational site, quezon city, philippines gsk investigational site, bialystok, poland gsk investigational site, bydgoszcz, poland gsk investigational site, krakow, poland gsk investigational site, olsztyn, poland gsk investigational site, poznan, poland gsk investigational site, poznan, poland gsk investigational site, bucuresti, romania gsk investigational site, iasi, romania gsk investigational site, timisoara, romania gsk investigational site, banska bystrica, slovakia gsk investigational site, bratislava, slovakia gsk investigational site, poprad, slovakia gsk investigational site, avila, spain gsk investigational site, badalona, spain gsk investigational site, madrid, spain gsk investigational site, murcia, spain gsk investigational site, valencia, spain gsk investigational site, taichung, taiwan gsk investigational site, taichung, taiwan gsk investigational site, taoyuan hsien, taiwan gsk investigational site, bangkok, thailand gsk investigational site, chiang mai, thailand gsk investigational site, kharkiv, ukraine gsk investigational site, kyiv, ukraine gsk investigational site, lvov, ukraine gsk investigational site, sympheropol, ukraine gsk investigational site, uzhgorod, ukraine']",,https://ClinicalTrials.gov/show/NCT00431236,
590,591,NCT03934684,study to evaluate safety tolerability & efficacy of kyprolis (carfilzomib) in relapsed or refractory multiple myeloma,,Recruiting,No Results Available,relapsed refractory multiple myeloma,drug: drug: carfilzomib + dexamethasone|drug: drug: carfilzomib + lenalidomide + dexamethasone,number of participants with treatment-emergent adverse events as assessed by ctcae v4.03|progression free survival|overall response rate|clinical benefit rate|time to response|duration of response,amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20160372,"September 16, 2019","March 23, 2023","June 26, 2025","May 2, 2019",,"February 25, 2022","['yashoda hospital, hyderabad, andhra pradesh, india apollo hospital, hyderabad, andhra pradesh, india m s ramaiah memorial hospital, bangalore, karnataka, india k l e s dr prabhakar kore hospital and medical research centre, belagavi, karnataka, india cytecare cancer hospitals, bengaluru, karnataka, india aster medcity, kochi, kerala, india government medical college, kozhikode, kerala, india tata memorial hospital, mumbai, maharashtra, india mumbai oncocare center, mumbai, maharashtra, india navsanjeevani hospital, nashik, maharashtra, india heath care group manavata cancer centre, nashik, maharashtra, india deenanath mangeshkar hospital and research centre, pune, maharashtra, india jawaharlal institute of postgraduate medical education and research, puducherry, pondicherry, india cancer institute wia, chennai, tamil nadu, india thangam cancer centre, namakkal, tamil nadu, india valentis cancer hospital, meerut, uttar pradesh, india netaji subhash chandra bose cancer research institute, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT03934684,myeloma
591,592,NCT03768960,"a study of darzalex (daratumumab) in indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent",,"Active, not recruiting",No Results Available,multiple myeloma,drug: daratumumab,incidence of treatment emergent adverse events (teae)|overall response rate (orr)|percentage of participants with very good partial response (vgpr) or better|percentage of participants with progression free survival (pfs)|time to response|change from baseline in european organization for research and treatment of cancer quality of life questionnaire (eortc qlq-c30) score|change from baseline in euroqol-5 dimensions (eq-5d-5l) score,johnson & johnson private limited,All,"18 Years and older   (Adult, Older Adult)",Phase 4,150.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR108556|54767414MMY4008,"June 10, 2019","July 25, 2022","July 25, 2022","December 7, 2018",,"April 22, 2022","['avron hospitals pvt. ltd, ahmedabad, india m s ramaiah medical college and hospital, bengaluru, india sparsh hospitals & critical care (pvt) ltd, bhubaneshwar, india apollo hospitals, bhubaneswar, india post graduate institute of medical education & research (pgimer), chandigarh, india apollo hospitals, hyderabad, india basavatarakam indo-american hospital, hyderabad, india cytecare hospitals pvt. ltd, karnataka, india tata medical center, kolkata, india shatabdi super speciality hospital, mumbai naka, india kingsway hospital, nagpur, india apex wellness hospital, nashik, india all india institute of medical sciences, new delhi, india jawaharlal institute of postgraduate medical education and research, pondicherry, india deenanath mangeshkar hospital and research centre, pune, india noble hospital pvt ltd, pune, india']",,https://ClinicalTrials.gov/show/NCT03768960,myeloma
592,593,NCT01209689,a study of tocilizumab (roactemra/actemra) in patients with ankylosing spondylitis who have had an inadequate response to previous tumor necrosis factor (tnf) antagonist therapy,,Terminated,Has Results,"spondylitis, ankylosing",drug: tocilizumab|drug: placebo,percentage of assessment in ankylosing spondylitis 20 (asas20) responders at week 12,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,113.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA22908|2009-017488-40,October 2010,December 2011,December 2011,"September 27, 2010","January 17, 2013","January 17, 2013","[""huntington beach, california, united states aventura, florida, united states miami, florida, united states orlando, florida, united states tampa, florida, united states atlanta, georgia, united states decatur, georgia, united states marietta, georgia, united states idaho falls, idaho, united states wichita, kansas, united states hagerstown, maryland, united states st. claire shores, michigan, united states freehold, new jersey, united states asheville, north carolina, united states charlotte, north carolina, united states greensboro, north carolina, united states duncansville, pennsylvania, united states austin, texas, united states houston, texas, united states heidelberg, australia hobart, australia sydney, australia woodville, australia bruxelles, belgium gent, belgium kortrijk, belgium liege, belgium yvoir, belgium cuiabá, brazil goiania, brazil sao paulo, brazil sao paulo, brazil são paulo, brazil plovdiv, bulgaria plovdiv, bulgaria sofia, bulgaria sofia, bulgaria sofia, bulgaria calgary, alberta, canada hamilton, ontario, canada kitchener, ontario, canada mississauga, ontario, canada st. catharines, ontario, canada toronto, ontario, canada toronto, ontario, canada montreal, quebec, canada quebec city, quebec, canada trois-rivières, quebec, canada st. john's, canada bruntal, czech republic hlucin, czech republic olomouc, czech republic prague, czech republic uherske hradiste, czech republic zlin, czech republic esbjerg, denmark hellerup, denmark vejle, denmark besancon, france bordeaux, france boulogne-billancourt, france creteil, france grenoble, france le kremlin bicetre, france lyon cedex 3, france montpellier, france orléans cedex 2, france paris, france paris, france rouen cedex, france strasbourg, france vandoeuvre-les-nancy, france berlin, germany berlin, germany erlangen, germany frankfurt, germany gommern, germany hamburg, germany hannover, germany heidelberg, germany herne, germany köln, germany münchen, germany regensburg, germany rostock, germany tuebingen, germany würzburg, germany bangalore, india bangalore, india jaipur, india new delhi, india secunderabad, india ferrara, italy firenze, italy monserrato, italy padova, italy pisa, italy prato, italy reggio emilia, italy roma, italy siena, italy kaunas, lithuania klaipeda, lithuania amsterdam, netherlands amsterdam, netherlands amsterdam, netherlands bydgoszcz, poland krakow, poland lublin, poland poznan, poland torun, poland warszawa, poland wroclaw, poland kosice, slovakia piestany, slovakia cape town, south africa cape town, south africa durban, south africa pinelands, south africa pretoria, south africa stellenbosch, south africa alcorcon, spain barcelona, spain córdoba, spain la coruna, spain lugo, spain madrid, spain madrid, spain madrid, spain oviedo, spain oviedo, spain sabadell, spain basingstoke, united kingdom bath, united kingdom greenock, united kingdom leeds, united kingdom london, united kingdom salford, united kingdom stoke-on-trent, united kingdom wigan, united kingdom""]",,https://ClinicalTrials.gov/show/NCT01209689,
593,594,NCT04046250,phase 2a study to evaluate suppression of methotrexate-induced mucositis by tk112690,TK112690,Completed,Has Results,mucositis,drug: tk-112690|drug: placebo tk-112690,mucositis|incidence adverse events that are related to treatment,"tosk, inc.|crystal life sciences",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",CLP-2690-0003,"May 15, 2019","October 10, 2019","March 31, 2020","August 6, 2019","June 3, 2021","June 3, 2021","['bangalore cancer, bangalore, karnataka, india karnatak cancer therapy and research institute, navanagar, karnataka, india netaji subhash chandra bose cancer hospital, kolkata, west bengal, india']","""study protocol and statistical analysis plan"", https://clinicaltrials.gov/provideddocs/50/nct04046250/prot_sap_000.pdf",https://ClinicalTrials.gov/show/NCT04046250,
594,595,NCT01646437,the international polycap study 3 (tips-3),TIPS-3,Completed,No Results Available,cardiovascular disease|fractures|cancers,drug: polycap|drug: aspirin|drug: vitamin d|drug: matching placebo,polycap primary objective|aspirin primary objective|vitamin d primary objective|combined effects of polycap and aspirin on cvd events|polycap secondary objective|aspirin secondary objective|vitamin d secondary objective|combined effects of polycap and aspirin on cvd events secondary outcome a|combined effects of polycap and aspirin on cvd events secondary outcome b,population health research institute|cadila pharnmaceuticals|wellcome trust|canadian institutes of health research (cihr)|heart and stroke foundation of ontario,All,"50 Years and older   (Adult, Older Adult)",Phase 3,7793.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",TIPS-3,June 2012,"June 30, 2020","August 30, 2021","July 20, 2012",,"September 16, 2021","[""eminence, dhaka, bangladesh hamilton health sciences, hamilton, ontario, canada fundaction oftamologica de santander (foscal), bucaramanga, colombia st. john's medical college hospital, bangalore, india harapan kita hopsital, jakarta, indonesia universiti teknologi mara (uitm), shah alam, selangor, malaysia adult medicine & medical research unit, philippine general hospital, manila, philippines pamoja tunaweza women's centre, moshi, tanzania fattouma bourguiba university hospital, monastir, tunisia""]",,https://ClinicalTrials.gov/show/NCT01646437,
595,596,NCT03110562,"bortezomib, selinexor, and dexamethasone in patients with multiple myeloma",BOSTON,"Active, not recruiting",Has Results,multiple myeloma,drug: selinexor|drug: bortezomib|drug: dexamethasone,progression-free survival (pfs) as assessed by irc|overall response rate (orr) as assessed by irc|percentage of participants with response rates|overall survival (os)|duration of response (dor) as assessed by irc|time-to-next-treatment (ttnt)|time-to-response (ttr) as assessed by irc|number of participants with grade >= 2 peripheral neuropathy events|number of participants with treatment-emergent adverse events (teaes) and serious teaes|patient-reported peripheral neuropathy measured by european organization for research and treatment of cancer (eortc) quality of life questionnaire (qlq)-cipn20 instrument,karyopharm therapeutics inc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,402.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KCP-330-023,"May 24, 2017","February 18, 2020","September 1, 2023","April 12, 2017","July 8, 2021","November 24, 2021","['boca raton clinical research (brcr) medical center, plantation, florida, united states emory university, atlanta, georgia, united states kaiser permanente hawaii, honolulu, hawaii, united states mcfarland clinic, ames, iowa, united states stormont vail health care (cotton o\'neil cancer center ), topeka, kansas, united states commonwealth hematology, danville, kentucky, united states norton cancer institute, louisville, kentucky, united states university of maryland, baltimore, maryland, united states central care cancer center, bolivar, missouri, united states the valley hospital luckow pavilion, paramus, new jersey, united states mount sinai, new york, new york, united states the cancer institute at st. francis hospital, roslyn, new york, united states novant-forsyth memorial hospital, winston-salem, north carolina, united states university of cincinnati health, cincinnati, ohio, united states southwest cancer center of oklahoma, lawton, oklahoma, united states kaiser permanente northwest or, portland, oregon, united states scor anmed health cancer center, anderson, south carolina, united states prairie lakes healthcare, watertown, south dakota, united states baylor sammons cancer center, dallas, texas, united states university of texas southwestern, dallas, texas, united states calvary mater newcastle, waratah, new south wales, australia royal brisbane and women\'s hospital, herston, queensland, australia mater misericordiae limited and mater medical research, south brisbane, queensland, australia gold coast university hospital, southport, queensland, australia royal adelaide hospital, adelaide, south australia, australia flinders medical centre, bedford park, south australia, australia st. vincent\'s hospital melbourne, fitzroy, victoria, australia the alfred hospital, melbourne, victoria, australia medical university innsbruck, department of internal medicine v (hematology and oncology), innsbruck, austria university hospital krems, department of internal medicine ii, krems, austria medical university of vienna, vienna, austria general hospital hietzing, vienna, austria wilhelminen hospital, department of internal medicine i, center for oncology & hematology, vienna, austria jules bordet institute, brussels, belgium ucl saint-luc, brussels, belgium university hospital ghent, ghent, belgium general hospital delta, roeselare, belgium st. augustinus hospital, wilrijk, belgium university multiprofile hospital for active treatment, sveti georgi clinic of clinical hematology, plovdiv, bulgaria university multiprofile hospital for active treatment, sveti ivan rilski clinic of hematology, sofia, bulgaria specialized hospital for active treatment of hematological diseases, clinic of hematology, dept. of clinical hematology, sofia, bulgaria tom baker cancer center/ alberta health services, calgary, alberta, canada cross cancer institute / university of alberta, edmonton, alberta, canada vancouver general hospital, vancouver, british columbia, canada queen elizabeth ii health sciences center, halifax, nova scotia, canada north east cancer centre sudbury, sudbury, ontario, canada princess margaret cancer research, toronto, ontario, canada maisonneuve-rosemont hospital, montreal, quebec, canada royal victoria hospital / mcgill university, montreal, quebec, canada l\'hôtel-dieu de québec, quebec city, quebec, canada saskatchewan cancer agency-allan blair cancer centre, regina, saskatchewan, canada saskatoon cancer center, saskatoon, saskatchewan, canada general university hospital in prague, praha 2, prague, czechia university hopsital brno, brno, czechia university hospital hradec kralove, hradec kralove, czechia university hospital olomouc, olomouc, czechia university hospital ostrava, dept. of hematooncology, ostrava, czechia university hospital kralovske vinohrady, clinic of internal hematology, prague, czechia necker children\'s hospital, department of adult hematology, paris, ile de france, france hospital center departmental la roche-sur-yon, la roche-sur-yon, france claude huriez hospital, lille, france south lyon hospital center, lyon, france brabois adults hospital, university hospital center of nancy, nancy, france nantes university hospital center, nantes, france saint-louis hospital, paris, france miletrie hospital, university hospital center of poitiers, poitiers, france university hospital freiburg, department of internal medicine i, freiburg, baden-wuerttemberg, germany klinikum leverkusen ggmbh medizinisxhe klinik 3, leverkusen, north rhine westfalia, germany group practice for hematology and oncology, dresden, saxony, germany alexandra general hospital, therapeutic clinic, athens, greece general hospital of athens ""evangelismos"", department of hematology and lymphoma, athens, greece university general hospital of patra, pátra, greece theageneion cancer hospital, hematology department, thessaloníki, greece semmelweis university, 1st department of internal medicine, budapest, hungary integrated szent istvan and szent laszlo hospital, department of hematology and stem cell transplantation, budapest, hungary semmelweis university, 3rd department of internal medicine, budapest, hungary kaposi mor teaching hospital, 2nd department of internal medicine, kaposvar, hungary medical center of the university of pecs, department of hematology, pecs, hungary regional cancer centre, patna, bihar, india regional cancer centre, thiruvananthapuram, kerala, india prince aly khan hospital, mumbai, maharashta, india jaslok hospital and research centre, mumbai, maharashta, india bhaktivedanta hospital, thane, maharashtra, india ims & sum hospital, bhubaneswar, odisha, india postgraduate institute of medical education & research (pgimer), chandigarh, punjab, india dayanand medical college & hospital, ludhiana, punjab, india cancer institute, chennai, tamil nadu, india srm institute of medical sciences, chennai, tamil nadu, india saveetha medical college hospital, chennai, tamil nadu, india g. kuppuswamy naidu hospital, coimbatore, tamil nadu, india asviratham speciality hospital, madurai, tamil nadu, india meenakshi mission hospital, madurai, tamil nadu, india yashoda hospital, hyderabad, telengana, india king george\'s medical university, lucknow, uttar pradesh, india netaji subhash chandra bose cancer research institute, kolkata, west bengal, india nil ratan sircar (nrs) medical college, kolkata, west bengal, india tata memorial centre, kolkata, west bengal, india rajiv gandhi cancer hospital, new delhi, india barzilai medical center, ashkelon, israel rambam health care campus, haifa, israel hadassah medical center, jerusalem, israel rabin medical center, petaẖ tiqwa, israel hospital santa maria of terni, terni, umbria, italy azienda ospedaliero-universitaria ospedali riuniti, ancona, italy asst papa giovanni xxiii, bergamo, italy polyclinic s. orsola-malpighi, department of hematology, oncology and laboratory medicine, operative unit of hematology - cavo, bologna, italy university hospital careggi, department of hematology, florence, italy university hospital san martino, ircca, dept. of integrative cancer therapies, operative unit of clinical hematology, genoa, italy hospital niguerda ca granda, department of hematology and oncology, hematology unit, milan, italy umberto i polyclinic of rome, department of cellular biotechnology and hematology, hematology center, rome, italy university hospital san giovanni battista of turin, turin, italy jan biziel university hospital #2 in bydgoszcz, department of hematology, bydgoszcz, poland independent public healthcare facility municipal hospital group in chorzow, department of hematology, chorzow, poland university hospital in krakow, teaching unit of the hematology department, krakow, poland independent public teaching hospital no.1 in lublin, department of hematology-oncology and bone marrow transplantation, lublin, poland st. john of dukla oncology center of lublin, department of hematology, lublin, poland military institute of medicine, department of internal medicine and hematology, warsaw, poland nicolaus copernicus memorial provincial specialist hospital in lodz, department of hematology, łódź, poland hyperclnical medlife pdr vulturului brasov, hematology department, braşov, romania colentina clinical hospital, department of hematology, bucharest, romania bucharest university emergency hospital, department of hematology, bucharest, romania s.p. botkin city clinical hospital, moscow, russian federation n.a. semashko central clinical hospital #2 under ojsc russian railways, moscow, russian federation first i.p. pavlov state medical university of st. petersburg, saint petersburg, russian federation v.a. almazov north-west federal medical research center, chemotherapy of oncohematology diseases and bone marrow transplantation department #1, saint petersburg, russian federation clinical center of serbia, clinic of hematology, belgrade, serbia institute of oncology and radiology of serbia, clinic of medical oncology, belgrade, serbia clinical center kragujevac, clinic of hematology, kragujevac, serbia clinical center nis, clinic of hematology and clinical immunology, nis, serbia clinical center of vojvodina, clinic of hematology, novi sad, serbia university hospital of the canary islands, la laguna, santa cruz de tenerife, spain catalan institute of oncology (ico) badalona, badalona, spain university hospital of vall d\'hebron, barcelona, spain university hospital infanta leonor, department of hematology, madrid, spain university clinical hospital of salamanca, department of hematology, salamanca, spain university hospital virgen del rocio (huvr), seville, spain cherkasy regional oncology center, regional treatment and diagnostic hematology center, department of hematology, cherkasy, ukraine city clinical hospital no.4 of dnipro city council, city hematology center, dnipropetrovsk, ukraine bmt kiev center, kiev, ukraine kiev cancer institute, kiev, ukraine institute of blood pathology and transfusion medicine, department of hematology with laboratory group, lviv, ukraine vinnytsia m.i. pyrohov regional clinical hospital, department of hematology, vinnytsia, ukraine o.f. herbachevskyi regional clinical hospital, hematology department with intensive therapy wards, zhytomyr, ukraine belfast heatlh & social care trust belfast city hospital, belfast, northern ireland, united kingdom nhs tayside ninewells hospital, dundee, scotland, united kingdom cardiff & vale university health board university hospital of wales, cardiff, wales, united kingdom university hospitals birmingham nhs foundation trust queen elizabeth hospital, birmingham, united kingdom the leeds teaching hospitals nhs trust st. james university hospital, leeds, united kingdom university hospitals of leicester nhs trust royal leicester infirmary, leicester, united kingdom royal liverpool & broadgreen university hospital nhs trust royal liverpool university hospital, liverpool, united kingdom london north west healthcare nhs trust northwick park hospital, london, united kingdom university college london, london, united kingdom king\'s college hospital nhs foundation trust, london, united kingdom imperial college healthcare nhs trust hammersmith hospital, london, united kingdom the christie nhs foundation trust, manchester, united kingdom freeman hospital, newcastle upon tyne, united kingdom the royal wolverhampton nhs trust new cross hospital, wolverhampton, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/62/nct03110562/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/62/nct03110562/sap_001.pdf",https://ClinicalTrials.gov/show/NCT03110562,myeloma
596,597,NCT05317416,study with elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma after transplant,MagnetisMM-7,Recruiting,No Results Available,multiple myeloma,drug: elranatamab|drug: lenalidomide,minimal residual disease negativity rate|progression free survival|overall minimal residual disease negativity rate|duration of minimal residual disease negativity|sustained minimal residual disease negativity rate|complete response rate|duration of complete response|overall survival|frequency of adverse events|frequency of laboratory abnormalities|pre-dose concentrations of elranatamab|post-dose concentrations of elranatamab|incidence and titers of anti-drug antibody and neutralizing antibody against elranatamab|health-related quality of life by european organization for research and treatment of cancer quality of life questionnaire - core 30|health-related quality of life by european organization for research and treatment of cancer quality of life questionnaire - myeloma 20,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,366.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C1071007|2021-006052-14,"March 25, 2022","June 14, 2027","June 14, 2027","April 7, 2022",,"May 16, 2022","[""juravinski cancer center, hamilton, ontario, canada helsinki university hospital - comprehensive cancer center (hyks - syöpäkeskus), helsinki, uusimaa, finland fortis memorial research institute, gurugram, haryana, india artemis hospital, gurugram, haryana, india rajiv gandhi cancer institute and research centre, delhi, india sheba medical center, ramat gan, hamerkaz, israel gachon university gil medical center, namdong-gu, incheon-gwangyeoksi [incheon], korea, republic of chonnam national university hwasun hospital, hwasun gun, jeonranamdo, korea, republic of seoul national university bundang hospital, seongnam, kyǒnggi-do, korea, republic of pusan national university hospital, busan, pusan-kwangyǒkshi, korea, republic of seoul national university hospital, seoul, seoul-teukbyeolsi [seoul], korea, republic of samsung medical center, seoul, seoul-teukbyeolsi [seoul], korea, republic of the catholic univ. of korea seoul st. mary's hospital(seoul st. mary's hospital), seoul, seoul-teukbyeolsi [seoul], korea, republic of the catholic univ. of korea seoul st. mary's hospital, seoul, seoul-teukbyeolsi [seoul], korea, republic of kyungpook national university, daegu, taegu-kwangyǒkshi, korea, republic of kyungpook national university hospital, jung-gu, taegu-kwangyǒkshi, korea, republic of centrum medyczne pratia poznań, skorzewo, wielkopolskie, poland pratia onkologia katowice, katowice, śląskie, poland china medical university hospital, taichung, taiwan national taiwan university hospital, taipei, taiwan medipol mega universite hastanesi, i̇stanbul, i̇̇stanbul, turkey sisli florence nightingale hastanesi, i̇stanbul, i̇̇stanbul, turkey özel anadolu sağlık merkezi, kocaeli, turkey""]",,https://ClinicalTrials.gov/show/NCT05317416,myeloma
597,598,NCT00452569,efficacy and safety study of 3 thalidomide doses for the treatment of relapsed refractory multiple myeloma,OPTIMUM,Completed,No Results Available,multiple myeloma,drug: thalidomide|drug: dexamethasone,"the evaluation of independent review committee-documented time to progression (ttp).|response rate (cr + pr), according to the ebmt criteria|response duration|clinical benefit as measured by ecog performance status, transfusion requirement and grade ≥3 infections (assessed by the national cancer institute common toxicity criteria)|progression-free survival (pfs)|overall survival (os)|composite of disease progression and death (recurrent time(s) from randomisation to disease progression and/or death)|quality of life as determined by the european organisation for research and treatment of cancer quality of life questionnaire c30 (eortc qlq-c30)|adverse events (aes)|assessment of peripheral neuropathy|vital signs and physical examination|clinical laboratory tests",celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 3,499.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THA PH INT 2005 CL001,"February 1, 2006","December 1, 2008","January 1, 2009","March 27, 2007",,"November 18, 2019","['clinic of haematology, university multiprofiled hospital for active treatment ""g. stranski"", pleven, bulgaria clinic of haematology, university multiprofiled hospital for active treatment, plovdiv, bulgaria university of multiprofiled hospital for active treatment ""alexandrovska"" - sofia, sofia, bulgaria military medical academy/dept haematology and oncology, sofia, bulgaria national center of haematology & transfusiology, sofia, bulgaria clinic of haematology, multiprofiled hospital for active treatment ""sveta marina"", varna, bulgaria klinicki bolnicki centar rijeka interna klinika, rijeka, croatia klinika bolnica split - klinika za unutarnje bolesti, split, croatia kbc zagreb - klinika za unutarnje bolesti, zagreb, croatia klinicka bolnica ""dubrava"" klinika za unutarnje bolesti, zagreb, croatia klinicka bolnica ""sestre milosrdnice"" klinika za unutarnje bolesti, zagreb, croatia klinicka bolnica merkur - klinika za unutarnje bolesti, zagreb, croatia interni hemato-onkologicka klinika, brno, czechia hematologicka klinika, fakultni nemocnice hradec kralove, hradec kralove, czechia onkologicke centrum j.g. mendela, novi jicin, czechia interni klinika, oddeleni hematoonkologie, olomouc, czechia hematologicka klinika, fakultni nemocnice kralovske vinohrady srobarova, prague 10, czechia interni klinika, oddeleni hematoonkologie, prague 2, czechia chru de lille - hopital claude huriez, lille, france chu de nancy - hopital brabois, nancy cedex, france hematologie - chu purpan place du dr. baylac, toulouse, france charite, universitatsmedizin berlin, campus robert-rossle klinik, berlin, germany med. klinik i/university bonn, bonn, germany medizinische klinik und poliklinik i/carl-gustav-carus university, dresden, germany hematology, oncology & clinical immunology/heinrich-heine-university, duesseldorf, germany abt. haematologie - onkologie/ allg. krankenhaus, hamburg, germany allgemeinse krankenhaus st. georg hamatologische abteilung, hamburg, germany medizinische klinik abteilung innere v/universitatsklinikum, heidelberg, germany universitat schleswig holstein ii med. klinik, kiel, germany universitaetsklinik - klinik fur innere medizin, koeln, germany medizinische klinik und poliklinik iii/klinikum der universitaet muenchen, muenchen, germany innere medizin university hospital, muenster, germany abteilung haematologie - univeresitaetsklinikum, saale, germany robert-bosch-krankenhaus gmbh, stuttgart, stuttgart, germany universitaetsklinik - abteilung innere medizin iii, ulm, germany med. klinik ii/klinikum of the julius-maximilians-university, wuerzburg, germany national medical centre dpt haematology, budapest, hungary petz aladar megyei oktato korhaz, ii. belgyogyaszat, gyor, hungary pandy kalman megyei korhaz, megyei onkologiai centrum, gyula, hungary szent-gyorgyi albert university ii clinic of internal medicine, szeged, hungary nizam\'s institute of medical sciences, department of medical oncology, hyderabaad, india department of medical oncology, amrita institute of medical sciences, kerala, india orchid nursing home, kolkata, india department of medical oncology, dayanand medical college dmch, ludhiana, india department of medical oncology/tata memorial hospital, mumbai, india department of medical oncology, s.l. raheja hospital, mumbai, india department of medical oncology, jaslok hospital and research centre, mumbai, india department of medical oncology, deenanath mangeshkar hospital, pune, india department of medical oncology/regional cancer centre, trivandrum, india instituto di ematologia e oncologia medica, bologna, italy dipartimento medicina ed oncologia sperimentale - divisione universitaria di ematologia azienda ospedaliera s. giovanni battista, torino, italy department of internal medicine - baguio general hospital & medical center, baguio city, philippines chong hua hospital, cebu city, philippines doctors clinic makati medical center, makati city, philippines university of sto tomas hospital, manila city, philippines doctors clinic - national kidney & transplant institute, quezon city, philippines st. luke\'s medical center, quezon city, philippines spsk, klinika hematologii akademii medycznej, bialystok, poland klinika hematologii akademii medycznej w gdanskuul, gdansk, poland katedra i klinika hematologii i transplantacji szpiku - slaska akademia medyczna, katowice, poland swietokrzyskie centrum onkologii spzoz poradnia hematologii, kielce, poland klinika hematologii uniwersytetu medycznego, lodz, poland klinika chorob wewnetrznych i hemagologii, warszawa, poland katedra i klinika hematologii, onkologii i chorob wewnetrznych, warszawa, poland instytut hematologii i transfuzjologii - klinika hematologiczna, warszawa, poland centrum onkologii-instytut im. marii sklodowskiej-curie, warszawa, poland klinika hematologii nowotworow krwi i transplantacji - szpiku akademii medycznej, wroclaw, poland hospital da universidade de coimbra - servico de hematologia clinica, coimbra, portugal instituto portugues de oncologia, lisboa, portugal hospital geral de santo antonio - servico de hematologia clinica, porto, portugal institute of hematology, clinical centre of serbia, belgrade, serbia clinic for hematology, clinical centre nis, nis, serbia clinic for hematology, clinical centre novi sad, novisad, serbia department of internal medicine, national cancer institute, bratilslava, slovakia hematology department university hospital, bratilslava, slovakia hematology department, university hospital pjs, kosice, slovakia university of free state, faculty of health science, dept of hematology & cell biology, bloemfontein, south africa tygerberg hospital, university of stellenbosch, department of haematology, cape town, south africa department of haematology, uct medical school, cape town, south africa chris hani baragwanath hospital, clinical haematology unit, johannesburg, south africa medical oncology centre of rosebank, johannesburg, south africa johannesburg hospital, department of medical oncology, parktown, south africa oncology research unit heartlands hospital, birmingham, united kingdom clinical haematology, guy\'s hospital, london, united kingdom haematology department - king\'s college hospital, london, united kingdom department of haematology-oncology, the royal marsden nhs foundation trust, surrey, united kingdom']",,https://ClinicalTrials.gov/show/NCT00452569,myeloma
598,599,NCT00911859,a study to compare cnto 328 (anti-il-6 monoclonal antibody) and velcade-melphalan-prednisone (vmp) with vmp alone in previously untreated multiple myeloma patients,,Completed,Has Results,multiple myeloma,drug: siltuximab11 mg/kg|drug: siltuximab 8.3 mg/kg or 11 mg/kg|drug: velcade (bortezomib)|drug: melphalan|drug: prednisone,"percentage of participants who achieved complete response (cr) - european group for blood and marrow transplantation (ebmt) criteria|percentage of participants who achieved overall response ie, complete response (cr) or partial response (pr) - european group for blood and marrow transplantation (ebmt) criteria|percentage of participants who achieved stringent complete response (scr) - international myeloma working group (imwg) criteria|progression-free survival (pfs)|1-year progression-free survival (pfs) rate|duration of response (dor)|1-year survival rate|overall survival|change from baseline to cycle 9 in global health status/quality of life subscale of the european organization for research and treatment of cancer quality of life questionnaire core 30 (eortc qlq c30)","janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,118.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR015901|CNTO328MMY2001|2008-007157-12,June 2009,April 2013,April 2013,"June 2, 2009","November 18, 2014","November 18, 2014","['boston, massachusetts, united states chapel hill, north carolina, united states philadelphia, pennsylvania, united states houston, texas, united states adelaide, australia melbourne, australia bordeaux cedex, france montpellier, france strasbourg, france ahmedabad, india calicut, india hyderabad n/a, india jaipur, india mumbai, india afula, israel haifa, israel jerusalem, israel petah tikva, israel ramat-gan, israel seoul, korea, republic of bialystok, poland chorzów, poland gdynia, poland lodz, poland wroclaw, poland baia mare, romania brasov, romania iasi, romania arkhangelsk, russian federation moscow n/a, russian federation nizhni novgorod, russian federation st. petersburg, russian federation singapore, singapore barcelona, spain madrid, spain murcia n/a, spain salamanca, spain']",,https://ClinicalTrials.gov/show/NCT00911859,myeloma
599,600,NCT00776165,safety and efficacy trial of recombinant human granulocyte colony stimulating factor (gcsf),,Completed,No Results Available,chemotherapy-induced neutropenia,biological: recombinant human gcsf (shantha biotechnics limited)|biological: neupogen,"percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°c or developing a temperature of > 38°c twice in a 12-hour period and absolute neutrophil count < 0.5 x 10e9/l on the same day of the fever or the day after.|percentage of patients developing adverse events and/ or changes in laboratory values.|incidence of neutropenia defined as absolute neutrophil count < 0.5 x 10e9/l not associated with fever|incidence of need for iv anti-infectives and days of admission, as a result of neutropenia",shantha biotechnics limited,All,"18 Years and older   (Adult, Older Adult)",Phase 3,126.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SBL/GCSF/N/2007/0100,October 2007,July 2009,September 2009,"October 21, 2008",,"February 3, 2010","[""indo american cancer institute and research centre, hyderabad, andhra pradesh, india nizam's institute of medical sciences, hyderabad, andhra pradesh, india vedanta institute of medical sciences, ahmedabad, gujrat, india lakeshore hospital and research center, cochin, kerala, india regional cancer centre, trivandrum, kerala, india seth ramdas shah memorial hospital, pune, maharashtra, india sms medical college and hospital, jaipur, rajasthan, india""]",,https://ClinicalTrials.gov/show/NCT00776165,
600,601,NCT05020236,magnetismm-5: study of elranatamab (pf-06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed/refractory multiple myeloma,MAGNETISMM-5,Recruiting,No Results Available,multiple myeloma,drug: elranatamab|drug: daratumumab|drug: pomalidomide|drug: dexamethasone,part 1 safety lead-in: incidence of dose limiting toxicities|part 2 randomized: progression free survival per international myeloma working group criteria|part 1 safety lead-in: progression free survival per international myeloma working group criteria|overall survival|objective response rate per international myeloma working group criteria|duration of response per international myeloma working group criteria|time to response per international myeloma working group criteria|complete response rate per international myeloma working group criteria|duration of complete response per international myeloma working group criteria|minimal residual disease negativity rate per international myeloma working group criteria|sustained minimal residual disease negativity rate per international myeloma working group criteria|progression free survival on next-line treatment per international myeloma working group criteria|frequency of treatment-emergent adverse events|frequency of abnormal laboratory results|rate of grade ≥2 cytokine release syndrome|elranatamab pharmacokinetics by pre- and post-dose concentrations|elranatamab immunogenicity by anti-drug antibodies against elranatamab|daratumumab pharmacokinetics by pre-dose concentrations|health-related quality of life by european organization for research and treatment of cancer quality of life questionnaire - core 30|health-related quality of life by european organization for research and treatment of cancer quality of life questionnaire - myeloma 20,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,581.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,C1071005|2021-000044-22|MAGNETISMM-5,"October 4, 2021","November 25, 2024","January 26, 2026","August 25, 2021",,"May 9, 2022","[""queen elizabeth ii health science centre, halifax, nova scotia, canada princess margaret cancer centre, toronto, ontario, canada helsinki university hospital - comprehensive cancer center (hyks - syöpäkeskus), helsinki, finland oulun yliopistollinen sairaala, oulu, finland evangelismos general hospital of athens, athens, attikí, greece evangelismos hospital, athens, attikí, greece alexandra general hospital of athens, athens, attikí, greece rajiv gandhi cancer institute & research centre, new delhi, delhi, india rajiv gandhi cancer institute and research centre, new delhi, delhi, india artemis hospital, gurugram, haryana, india hamamatsu university hospital, hamamatsu, shizuoka, japan shizuoka cancer center, sunto-gun, shizuoka, japan national hospital organization okayama medical center, okayama, japan national hospital organization okayama medical center, okayama, japan seoul national university bundang hospital, seongnam-si, gyeonggi-do, korea, republic of chonnam national university hwasun hospital, hwasun-gun, jeonranamdo, korea, republic of seoul national university hospital, seoul, seoul-teukbyeolsi [seoul], korea, republic of samsung medical center, seoul, seoul-teukbyeolsi [seoul], korea, republic of the catholic univ. of korea seoul st. mary's hospital, seoul, seoul-teukbyeolsi [seoul], korea, republic of gachon university gil medical center, incheon, korea, republic of uniwersyteckie centrum kliniczne, gdansk, poland pratia onkologia katowice, katowice, poland centrum medyczne pratia poznan, skorzewo, poland instituto catalan de oncologia - hospital duran i reynals, l'hospitalet del llobregat, barcelona [barcelona], spain hospital universitari de girona doctor josep trueta, girona, girona [gerona], spain hospital universitari vall d'hebron, barcelona, spain instituto catalán de oncología. hospital universitario dr. josep trueta, gerona, spain hospital universitari de girona doctor josep trueta, girona, spain hospital universitario la princesa, madrid, spain hospital universitario madrid sanchinarro, madrid, spain hospital universitario virgen del rocio, sevilla, spain hospital universitario y politecnico la fe, valencia, spain södra älvsborg sjukhus, borås, sweden sahlgrenska universitetssjukhuset, göteborg, sweden universitetssjukhuset örebro, örebro, örebro län [se-18], sweden national cheng-kung uni. hosp., tainan, taiwan national taiwan university hospital, taipei, taiwan sisli florence nightingale hastanesi, i̇stanbul / şişli, i̇̇stanbul, turkey medipol mega universite hastanesi, i̇stanbul, i̇̇stanbul, turkey acibadem universitesi atakent hastanesi, istanbul, i̇̇stanbul, turkey dr. abdurrahman yurtaslan ankara onkoloji egitim ve arastırma hastanesi, ankara, turkey aydın adnan menderes universitesi hastanesi, aydin, turkey gaziantep universitesi sahinbey arastirma ve uygulama hastanesi, gaziantep, turkey özel anadolu sağlık merkezi, kocaeli, turkey""]",,https://ClinicalTrials.gov/show/NCT05020236,myeloma
601,602,NCT00315757,study of mapatumumab in combination with bortezomib (velcade) and bortezomib alone in subjects with relapsed or refractory multiple myeloma,,Completed,No Results Available,multiple myeloma,biological: mapatumumab|drug: bortezomib,"to evaluate disease response to mapatumumab in combination with bortezomib and bortezomib alone|to evaluate the safety, including the frequency and severity of adverse events and laboratory abnormalities, of mapatumumab in combination with bortezomib and bortezomib alone throughout the study period",human genome sciences inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,105.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HGS1012-C1055,May 2006,October 2010,October 2010,"April 19, 2006",,"August 8, 2013","[""mayo clinic arizona, scottsdale, arizona, united states scripps clinic medical group, inc., la jolla, california, united states cancer and blood disorders center, lecanto, florida, united states university of chicago, chicago, illinois, united states center for cancer and blood disorders, bethesda, maryland, united states capitol comprehensive cancer care clinic, jefferson city, missouri, united states nebraska methodist cancer center, omaha, nebraska, united states roswell park cancer institute, buffalo, new york, united states department of haematology, royal north shore hospital, st leonards, new south wales, australia institute of medical & veterinary science, adelaide, south australia, australia peter maccallum cancer centre, east melbourne, victoria, australia clinical haematology & bmt, alfred hospital, melbourne, victoria, australia tom baker cancer center, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada ottawa health research institute - general campus, ottawa, ontario, canada notre dame centre hospitalier de l'universite de montreal, montreal, quebec, canada bharath hospital & institute of oncology, mysore, karnataka, india bangalore institute of oncology, bangalore, india all india institute of medical sciences, new delhi, india rajiv gandhi cancer institute & research center, new delhi, india""]",,https://ClinicalTrials.gov/show/NCT00315757,myeloma
602,603,NCT00101998,study of alvimopan drug for treatment of constipation due to prescription pain medication,,Completed,No Results Available,constipation|bowel dysfunction,drug: alvimopan|drug: placebo,"change in weekly scbm frequency. a scbm is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.|additional measures of bowel movement (bm) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.",cubist pharmaceuticals llc|glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,233.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3753-009|767905/008,"October 1, 2003","May 1, 2006","May 1, 2006","January 19, 2005",,"August 30, 2017","[""gsk investigational site, tucson, arizona, united states gsk investigational site, hot springs, arkansas, united states gsk investigational site, duarte, california, united states gsk investigational site, fountain valley, california, united states gsk investigational site, fresno, california, united states gsk investigational site, la verne, california, united states gsk investigational site, los angeles, california, united states gsk investigational site, los gatos, california, united states gsk investigational site, modesto, california, united states gsk investigational site, sacramento, california, united states gsk investigational site, san diego, california, united states gsk investigational site, san diego, california, united states gsk investigational site, santa monica, california, united states gsk investigational site, denver, colorado, united states gsk investigational site, washington, d.c., district of columbia, united states gsk investigational site, washington, d.c., district of columbia, united states gsk investigational site, gainesville, florida, united states gsk investigational site, inverness, florida, united states gsk investigational site, lecanto, florida, united states gsk investigational site, miami shores, florida, united states gsk investigational site, new port richey, florida, united states gsk investigational site, new port richey, florida, united states gsk investigational site, ocala, florida, united states gsk investigational site, palm harbor, florida, united states gsk investigational site, stuart, florida, united states gsk investigational site, tampa, florida, united states gsk investigational site, titusville, florida, united states gsk investigational site, decatur, georgia, united states gsk investigational site, chicago, illinois, united states gsk investigational site, west des moines, iowa, united states gsk investigational site, hutchinson, kansas, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, baltimore, maryland, united states gsk investigational site, bethesda, maryland, united states gsk investigational site, boston, massachusetts, united states gsk investigational site, boston, massachusetts, united states gsk investigational site, worcester, massachusetts, united states gsk investigational site, ann arbor, michigan, united states gsk investigational site, flint, michigan, united states gsk investigational site, saint louis park, minnesota, united states gsk investigational site, kansas city, missouri, united states gsk investigational site, saint louis, missouri, united states gsk investigational site, reno, nevada, united states gsk investigational site, albuquerque, new mexico, united states gsk investigational site, bethpage, new york, united states gsk investigational site, huntington station, new york, united states gsk investigational site, jamaica, new york, united states gsk investigational site, chapel hill, north carolina, united states gsk investigational site, charlotte, north carolina, united states gsk investigational site, durham, north carolina, united states gsk investigational site, hendersonville, north carolina, united states gsk investigational site, raleigh, north carolina, united states gsk investigational site, winston-salem, north carolina, united states gsk investigational site, bismarck, north dakota, united states gsk investigational site, bismarck, north dakota, united states gsk investigational site, canton, ohio, united states gsk investigational site, middletown, ohio, united states gsk investigational site, portland, oregon, united states gsk investigational site, nashville, tennessee, united states gsk investigational site, amarillo, texas, united states gsk investigational site, houston, texas, united states gsk investigational site, webster, texas, united states gsk investigational site, norfolk, virginia, united states gsk investigational site, portsmouth, virginia, united states gsk investigational site, richmond, virginia, united states gsk investigational site, richmond, virginia, united states gsk investigational site, tacoma, washington, united states gsk investigational site, milwaukee, wisconsin, united states gsk investigational site, capital federal, buenos aires, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, st leonards, new south wales, australia gsk investigational site, redcliffe, queensland, australia gsk investigational site, south brisbane, queensland, australia gsk investigational site, daw park, south australia, australia gsk investigational site, malvern, victoria, australia gsk investigational site, winnipeg, manitoba, canada gsk investigational site, saint john's, newfoundland and labrador, canada gsk investigational site, kitchener, ontario, canada gsk investigational site, london, ontario, canada gsk investigational site, north bay, ontario, canada gsk investigational site, oshawa, ontario, canada gsk investigational site, sudbury, ontario, canada gsk investigational site, bonaventure, quebec, canada gsk investigational site, chandler, quebec, canada gsk investigational site, levis, quebec, canada gsk investigational site, montreal, quebec, canada gsk investigational site, sherbrooke, quebec, canada gsk investigational site, quebec, canada gsk investigational site, brno, czechia gsk investigational site, brno, czechia gsk investigational site, plzen, czechia gsk investigational site, praha 10, czechia gsk investigational site, helsinki, finland gsk investigational site, bordeaux cedex, france gsk investigational site, vandoeuvre-les-nancy, france gsk investigational site, villejuif cedex, france gsk investigational site, goettingen, niedersachsen, germany gsk investigational site, goslar, niedersachsen, germany gsk investigational site, kwun tong, hong kong gsk investigational site, pokfulam, hong kong gsk investigational site, shatin, hong kong gsk investigational site, budapest, hungary gsk investigational site, budapest, hungary gsk investigational site, miskolc, hungary gsk investigational site, zalaegerszeg-pozva, hungary gsk investigational site, bangalore, india gsk investigational site, caserta, campania, italy gsk investigational site, napoli, campania, italy gsk investigational site, forlì, emilia-romagna, italy gsk investigational site, rimini, emilia-romagna, italy gsk investigational site, genova, liguria, italy gsk investigational site, milano, lombardia, italy gsk investigational site, pavia, lombardia, italy gsk investigational site, busca (cn), piemonte, italy gsk investigational site, novara, piemonte, italy gsk investigational site, catania, sicilia, italy gsk investigational site, firenze, toscana, italy gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, leeuwarden, netherlands gsk investigational site, dunedin, new zealand gsk investigational site, hastings, new zealand gsk investigational site, wellington, new zealand gsk investigational site, lahore, pakistan gsk investigational site, lima, peru gsk investigational site, lima, peru gsk investigational site, manila, philippines gsk investigational site, bialystok, poland gsk investigational site, olsztyn, poland gsk investigational site, otwock, poland gsk investigational site, poznan, poland gsk investigational site, lisboa, portugal gsk investigational site, lisboa, portugal gsk investigational site, lisboa, portugal gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, st'petersburg, russian federation gsk investigational site, durban, kwazulu- natal, south africa gsk investigational site, groenkloof, pretoria, south africa gsk investigational site, houghton, johannesburg, south africa gsk investigational site, kenilworth, cape town, south africa gsk investigational site, alcorcon, spain gsk investigational site, barcelona, spain gsk investigational site, barcelona, spain gsk investigational site, cordoba, spain gsk investigational site, granada, spain gsk investigational site, jaén, spain gsk investigational site, madrid, spain gsk investigational site, sabadell / barcelona, spain gsk investigational site, serra / valencia, spain gsk investigational site, sevilla, spain gsk investigational site, soria, spain gsk investigational site, valencia, spain gsk investigational site, taipei, taiwan gsk investigational site, chiang mai, thailand gsk investigational site, london, united kingdom gsk investigational site, newcastle-upon-tyne, united kingdom gsk investigational site, nottingham, united kingdom gsk investigational site, sheffield, united kingdom gsk investigational site, surrey, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00101998,
603,604,NCT00774930,an efficacy and safety study of somatuline depot (lanreotide) injection to treat carcinoid syndrome,ELECT,Completed,Has Results,carcinoid syndrome,drug: lanreotide|drug: placebo,"percentage of days with subcutaneous octreotide as rescue medication|average frequency of diarrhoea events (per day) based on subject diary records.|average frequency of flushing events (per day) based on subject diary records.|percentage of days of use of other rescue medication|proportion of subjects who rolled over into the iol phase before completing the db phase of the study|changes from baseline in ""global health status/quality of life (qol)"" score (based on items 29 and 30 of the european organisation for the research and treatment of cancer quality of life questionnaire [eortc-qlq] c30)|changes from baseline in ""gastrointestinal (g.i). symptoms"" subscore (based on items q34, q35, q36, q37 and q38 of eortc g.i. neuroendocrine tumour [net] 21]|changes from baseline in qol in ""endocrine symptoms"" subscore (assessed based on items q31, q32 and q33 using eortc qlq-g.i.net-21 questionnaires)|absolute changes from baseline in biochemical markers (plasma chromogranin a [cga])|absolute changes from baseline in biochemical markers (urinary 5-hydroxyindoleacetic acid [5-hiaa])",ipsen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,115.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2-55-52030-730|TR321|2010-019066-92,May 2009,May 2013,December 2015,"October 17, 2008","February 9, 2016","November 5, 2020","['va greater los angeles health care system, los angeles, california, united states david geffen school of medicine at ucla, los angeles, california, united states stanford cancer center, stanford, california, united states cedars sinai outpatient cancer center, west hollywood, california, united states kentuckiana cancer institute, louisville, kentucky, united states louisiana state university health science center, kenner, louisiana, united states university of michigan, ann arbor, michigan, united states university of mississippi medical center, jackson, mississippi, united states university of new mexico cancer care center, albuquerque, new mexico, united states providence portland medical center, portland, oregon, united states oregon health science university, portland, oregon, united states penn state milton s. hershey medical center, hershey, pennsylvania, united states university of pennsylvania, philadelphia, pennsylvania, united states upmc liver cancer center, pittsburgh, pennsylvania, united states eastern virginia medical school, norfolk, virginia, united states froedtert & medical college of wisconsin, milwaukee, wisconsin, united states biocancer - centro de pesquisa e tratamento do câncer, belo horizonte, brazil hospital lifecenter, belo horizonte, brazil oxion medicina oncológica, belo horizonte, brazil hospital universitário de brasilia, brasilia, brazil hospital erasto gaertner, curitiba, brazil irmandade da santa casa de misericórdia de porto alegre, porto alegre, brazil hospital de base de são josé do rio preto, são josé do rio preto, brazil vfn onkologicka klinika, prague, czechia sir gangaram hospital, delhi, india indo-american cancer institute & research centre, hyderabad, india omega hospitals, hyderabad, india santokaba durlabhji memorial hospital and research institute, jaipur, india bhagwan mahaveer cancer hospital and research centre, jaipur, india shatabdi super speciality hospital, mumbai, india tata memorial hospital, mumbai, india paul stradins clinical university hospital, riga, latvia klinika endokrynologii, diabetologii i leczenia izotopami, wrocław, poland non-federal institution of healthcare ""central clinical hospital # 1 of the llc ""russian railways (rzd)"", moscow, russian federation russian academy of medical sciences ""russian oncological research centre named after n.n. blokhin rams"", moscow, russian federation federal institution of healthcare ""leningradsky regional oncological dispensary"", saint-petersburg, russian federation clinic of endocrinology, diabetes and metabolic diseases, clinical center of serbia, belgrade, serbia oncology institute of vojvodina, sremska kamenica, sremska kamenica, serbia rondebosch oncology unit, cape town, south africa groote schuur hospital, cape town, south africa westridge medical centre, durban, south africa gvi oncology clinical trial unit, port elizabeth, south africa erciyes university medical faculty, kayseri, turkey cherkassy regional oncology dispensary, cherkassy, ukraine chernivtsi regional oncology center, chernivtsi, ukraine oncology and medical radiology chair of dnepropetrovsk state medical academy, dnepropetrovsk, ukraine regional anticancer center, department of oncoproctology, donetsk, ukraine municipal clinical hospital #2, proctology department, kharkiv, ukraine kyiv city oncological hospital, thoracic department, kyiv, ukraine medical centre ""mriya"", kyiv, ukraine national cancer institute, kyiv, ukraine odessa regional clinical hospital, odessa, ukraine uzhgorods\'ka tsentral\'na mis\'ka klinichna likarnya, mis\'kyy onkologichnyy tsentr, uzhgorod, ukraine vinnytsya regional clinical oncological center, vinnytsya state medical university, vinnytsya, ukraine']",,https://ClinicalTrials.gov/show/NCT00774930,
604,605,NCT00263484,higher frequency zoledronic acid in the treatment of multiple myeloma,dtZ,Completed,No Results Available,multiple myeloma,drug: dexamethasone|drug: thalidomide|drug: zoledronic acid,1. to determine response rates (rr) and disease progression rates in all mm patients treated with dtz regimen.|to assess overall survival (os) in all patients treated with dtz regimen.|assessment of incidence of skeletal related events (sres).|assessment of percent change in renal function in all patients.,"gleneagles hospital|singapore general hospital|national cancer centre, singapore|tan tock seng hospital|seoul national university hospital|asan medical center|samsung medical center|chonnam national university hospital|christian medical college, vellore, india|tata memorial hospital",All,"21 Years and older   (Adult, Older Adult)",Phase 2,56.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SQMM01(dtZ),December 2005,October 2008,October 2010,"December 8, 2005",,"July 21, 2011","['christian medical college, vellore, tamil nadu, india tata memorial hospital, mumbai, india chonnam national university hwasun hospital, kwangju, korea, republic of seoul national university hospital, seoul, korea, republic of samsung medical center, seoul, south korea, seoul, korea, republic of asan medical center, university of ulsan, south korea, seoul, korea, republic of singapore general hospital, singapore, singapore national cancer centre, singapore, singapore, singapore gleneagles hospital, singapore, singapore, singapore tan tock seng hospital, singapore, singapore, singapore']",,https://ClinicalTrials.gov/show/NCT00263484,myeloma
605,606,NCT00110110,combination chemotherapy and cyclosporine followed by focal therapy for bilateral retinoblastoma,,"Active, not recruiting",No Results Available,retinoblastoma,biological: filgrastim|drug: carboplatin|drug: cyclosporine|drug: etoposide|drug: vincristine sulfate|procedure: cryosurgery|procedure: laser therapy,"comparing efficacy of study treatment with historic world data, in terms of increasing the proportion of eyes that remains relapse-free while avoiding external beam radiation and/or enucleation|toxicity during treatment",the hospital for sick children|terry fox foundation,All,"Child, Adult, Older Adult",Phase 2,71.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1000005587|HFSC-OCRN-RB-2003|CDR0000422340,June 2004,"April 20, 2016","December 31, 2022","May 4, 2005",,"May 4, 2022","[""children's and women's hospital of british columbia, vancouver, british columbia, canada hospital for sick children, toronto, ontario, canada montreal children's hospital at mcgill university health center, montreal, quebec, canada hospital san juan de dios, santiago, chile sankara nethralaya super specialty clinic, chennai, india kandang kerbau women's and children's hospital, singapore, singapore""]",,https://ClinicalTrials.gov/show/NCT00110110,
606,607,NCT00652613,study of 3-dimensional conformal radiotherapy (3d-crt) versus intensity modulated radiotherapy (imrt) for head and neck squamous cell carcinoma (hnscc),,Unknown status,No Results Available,squamous cell carcinoma of the head and neck,radiation: 3 dimensional radiation therapy|radiation: intensity modulated radiation therapy,"major salivary gland sparing by 3-d crt vis-à-vis imrt. assess adequacy of target volume coverage|determine the pattern of local and loco-regional recurrence|disease free survival (dfs) and overall survival (oas)|quality of life 3. dose to oar|assess the reduction in dose with imrt to the normal larynx and normal pharyngeal constrictors in oropharyngeal cancers, uninvolved oral mucosa and auditory apparatus",tata memorial hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H&N_3DCRT_IMRT07,August 2005,March 2008,August 2009,"April 4, 2008",,"April 11, 2008","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00652613,skin
607,608,NCT00691236,evaluation of zoledronic acid as a single agent or as an adjuvant to chemotherapy in high grade osteosarcoma,ZOL,Unknown status,No Results Available,osteosarcoma,drug: zoledronic acid|drug: standard chemotherapy,histological response disease free interval,tata memorial hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,382,May 2008,May 2013,August 2013,"June 5, 2008",,"June 23, 2011","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00691236,sarcoma
608,609,NCT00689195,pilot study of curcumin formulation and ashwagandha extract in advanced osteosarcoma,OSCAT,Unknown status,No Results Available,osteosarcoma,dietary supplement: curcumin powder|dietary supplement: ashwagandha extract,"response, toxicity, disease progression|quality of life",tata memorial hospital|pharmanza herbals pvt limited (phpl),All,"8 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,381,May 2008,June 2013,June 2013,"June 3, 2008",,"June 23, 2011","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT00689195,sarcoma
609,610,NCT02830230,"""performance of hpv dna test in presence of co-infection with common rtis""",,Unknown status,No Results Available,cervical inflammation and human papilloma virus performance,"drug: tab cefixime,tab azithromycin",difference in the number of participants diagnosed with hpv infections before and after treating clinical cervicitis,tata memorial hospital,Female,30 Years to 50 Years   (Adult),Not Applicable,508.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,1671 RTIs And HPVDNA Test,July 2016,December 2017,July 2018,"July 12, 2016",,"July 12, 2016","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02830230,cervic
610,611,NCT03237637,comparative study to evaluate the effectiveness of atenolol and propranolol in the treatment of infantile hemangiomas,,Unknown status,No Results Available,infantile hemangioma,drug: oral propranolol|drug: oral atenolol,mean difference in number of patients achieving complete clinical clearance of lesion (pga score of 5) in the two groups|mean difference in number of days required to achieve complete clinical clearance of lesion (pga score of 5) in the two groups|mean difference in hemangioma activity score in the two groups|frequency of adverse effects (minor and serious) in the two groups|mean difference in hif-1α levels before and after treatment in group a and group b,postgraduate institute of medical education and research,All,up to 12 Months   (Child),Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INT/IEC/2017/322,"March 24, 2017",December 2018,December 2018,"August 2, 2017",,"August 28, 2018","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT03237637,
611,612,NCT02281019,spyglass amea registry,,Completed,No Results Available,biliary stricture|biliary obstruction due to common bile duct stone|periampullary tumor|hemobilia,procedure: ercp (endoscopic retrograde cholangiopancreatography)|device: spyglass dvs and spyglass digital simple (ds),procedural success for indeterminate strictures or undefined filling defects|procedural success for biliary stone cases|procedural success for other indications|evaluation of serious adverse events (saes) related to the spyglass devices and/or the spyglass procedure|impact of spyglass procedure on suspected diagnosis based on prior ercp|evaluation of impact of use of antibiotics on incidence of saes related to the device and/or procedure.|for patients undergoing spybite biopsy: correlation between number of biopsies and conclusive histopathology of spybite biopsies.|for patients undergoing stone management: number of spyglass procedures needed to reach stone clearance.|for patients undergoing stone management: correlation between stone size and ability to reach stone clearance in one spyglass session.|for patients undergoing stone management: incidence of visualization of stones not suspected during previous ercp.,boston scientific corporation,All,"18 Years and older   (Adult, Older Adult)",,526.0,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,90947376,"November 15, 2014",September 2016,"October 18, 2016","November 2, 2014",,"July 10, 2019","[""royal brisbane and women's hospital, herston, queensland, australia royal adelaide hospital, adelaide, australia royal prince alfred hospital, newtown, australia prince of wales hospital, shatin, hong kong apollo gleneagles hospitals kolkata, kolkata, west bengal, india postgraduate institute of medical education & research, chandigarh, india medanta -the medicity institute of digestive & hepatobiliary sciences, gurgaon, india asian institute of gastroenterology, hyderabad, india baldota institute of digestive sciences, parel, india teikyo university mizonokuchi hospital, kawasaki, japan kinki university school of medicine, osaka-sayama, japan tokyo medical university, tokyo, japan soon chun hyang university bucheon hospital, bucheon, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of civil hospital- karachi, karachi, pakistan king khalid university hospital, riyadh, saudi arabia changi general hospital pte ltd., singapore, singapore netcare unitas hospital, centurion, south africa king chulalongkorn memorial hospital, bangkok, thailand""]",,https://ClinicalTrials.gov/show/NCT02281019,biliari
612,613,NCT02239120,dabigatran etexilate for secondary stroke prevention in patients with embolic stroke of undetermined source (re-spect esus),,Completed,Has Results,stroke|secondary prevention,drug: optional asa as comedication|drug: placebo to asa|drug: placebo to optional asa as comedication|drug: placebo to dabigatran etexilate|drug: asa 100 mg|drug: dabigatran etexilate,"adjudicated recurrent stroke|first major bleed (adjudicated)|adjudicated ischaemic stroke|adjudicated composite of non-fatal stroke, non-fatal myocardial infarction, or cardiovascular death|disabling stroke|all-cause death|adjudicated intracranial hemorrhage|adjudicated fatal bleed|adjudicated life-threatening bleed|any bleed (investigator-reported)",boehringer ingelheim,All,"18 Years to 150 Years   (Adult, Older Adult)",Phase 3,5390.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",1160.189|2013-003444-24,"November 27, 2014","August 14, 2018","August 14, 2018","September 12, 2014","September 6, 2019","September 6, 2019","['bronislava shafran, md pc, phoenix, arizona, united states westside medical associates of los angeles, beverly hills, california, united states triwest research associates, llc, el cajon, california, united states university of california, fresno, california, united states glendale adventist medical center, glendale, california, united states collaborative neuroscience network, llc (cns), long beach, california, united states kaiser permanente los angeles medical center, los angeles, california, united states university of california los angeles, los angeles, california, united states huntington hospital, pasadena, california, united states university of california, san diego, california, united states university of california, san francisco, california, united states university of colorado denver, aurora, colorado, united states colorado neurological institute, englewood, colorado, united states university of colorado denver, fort collins, colorado, united states st. mary\'s hospital and regional medical center, grand junction, colorado, united states hartford hospital, hartford, connecticut, united states jem research institute, atlantis, florida, united states boca raton regional hospital, boca raton, florida, united states tenet florida physician services, boynton beach, florida, united states nova clinical research, llc, bradenton, florida, united states broward health north, deerfield beach, florida, united states center for advanced research excellence, hialeah, florida, united states bruce w. carter, miami va healthcare system, miami, florida, united states university of miami, miami, florida, united states bay neurological institute, panama city, florida, united states carol l pappas, md phd pa, saint petersburg, florida, united states university of south florida, tampa, florida, united states vero beach neurology and research institute, vero beach, florida, united states palm beach neuroscience institute, west palm beach, florida, united states augusta university, augusta, georgia, united states wellstar medical group - neurosurgery, marietta, georgia, united states the queen\'s medical center, honolulu, hawaii, united states saint alphonsus medical center-neurology, boise, idaho, united states northwest heart clinical research, llc, arlington heights, illinois, united states northwestern university, chicago, illinois, united states rush university medical center, chicago, illinois, united states university of chicago, chicago, illinois, united states medicoricium, llc, fairview heights, illinois, united states osf saint francis medical center, peoria, illinois, united states quincy physicians and surgeons clinic, s.c., quincy, illinois, united states southern illinois university school of medicine, springfield, illinois, united states community clinical research center, anderson, indiana, united states ruan neurology clinic and research center, des moines, iowa, united states associates in neurology, psc, lexington, kentucky, united states university of louisville, louisville, kentucky, united states alexandria cardiology clinic, alexandria, louisiana, united states culicchia neurological clinic, marrero, louisiana, united states tulane university hospital and clinic, new orleans, louisiana, united states ochsner medical center, new orleans, louisiana, united states anne arundel medical center, annapolis, maryland, united states johns hopkins hospital, baltimore, maryland, united states massachusetts general hospital, boston, massachusetts, united states beth israel deaconess medical center, boston, massachusetts, united states newton-wellesley hospital, newton, massachusetts, united states henry ford health system, detroit, michigan, united states mclaren flint, flint, michigan, united states mercy health saint mary\'s, grand rapids, michigan, united states spectrum health medical center, grand rapids, michigan, united states sparrow clinical research institute, lansing, michigan, united states st. joseph mercy oakland, pontiac, michigan, united states the duluth clinic dba essentia health duluth clinic, duluth, minnesota, united states abbott northwestern hospital, radiology department, minneapolis, minnesota, united states healthpartners neuroscience center, saint paul, minnesota, united states jackson heart clinic, p.a., jackson, mississippi, united states boone hospital center, columbia, missouri, united states university of missouri health system, columbia, missouri, united states ssm health st. clare hospital, fenton, missouri, united states saint luke\'s hospital of kansas city, kansas city, missouri, united states saint louis university, saint louis, missouri, united states st. louis heart and vascular, p.c., saint louis, missouri, united states the nebraska medical center, omaha, nebraska, united states renown institute for neurosciences, reno, nevada, united states nyc health + hospitals/coney island, brooklyn, new york, united states new york presbyterian hudson valley hospital, cortlandt manor, new york, united states uhs wilson medical center,office of clin trials, johnson city, new york, united states north shore university hospital, manhasset, new york, united states winthrop university hospital, mineola, new york, united states mount sinai beth israel, new york, new york, united states novant health neurology specialists, charlotte, north carolina, united states duke clinic 1l, durham, north carolina, united states cone health system, greensboro, north carolina, united states novant health neurology hickory, hickory, north carolina, united states wake forest university health sciences, winston-salem, north carolina, united states altru health system, grand forks, north dakota, united states the ohio state university wexner medical center, columbus, ohio, united states holzer clinic llc, gallipolis, ohio, united states advanced neurology associates, youngstown, ohio, united states oregon health and sciences university, portland, oregon, united states veterans affairs portland health care system, portland, oregon, united states sacred heart medical center at riverbend, springfield, oregon, united states penn state milton s. hershey medical center, hershey, pennsylvania, united states thomas jefferson university, philadelphia, pennsylvania, united states temple university hospital, philadelphia, pennsylvania, united states abington neurological associates, willow grove, pennsylvania, united states rhode island hospital, providence, rhode island, united states greenville memorial hospital, greenville, south carolina, united states methodist university hospital, memphis, tennessee, united states centennial heart cardiovascular consultants, llc, nashville, tennessee, united states saint thomas health, nashville, tennessee, united states seton medical center austin, austin, texas, united states houston methodist hospital, houston, texas, united states bhupesh dihenia, m.d.,p.a., lubbock, texas, united states university of vermont, burlington, vermont, united states virginia commonwealth university, richmond, virginia, united states carilion riverside, roanoke, virginia, united states virginia mason medical center, seattle, washington, united states swedish neuroscience institute, seattle, washington, united states marshall university, huntington, west virginia, united states aurora baycare medical center, green bay, wisconsin, united states university of wisconsin, madison, wisconsin, united states stat research, caba, argentina fundación favaloro, caba, argentina hospital italiano de buenos aires, caba, argentina instituto médico damic s.r.l., cordoba, argentina clinica coronel suarez sa, coronel suarez, argentina hospital privado de comunidad, mar del plata, argentina royal prince alfred hospital, camperdown, new south wales, australia st vincent\'s hospital sydney, darlinghurst, new south wales, australia kanwal medical complex, kanwal, new south wales, australia john hunter hospital, new lambton, new south wales, australia royal north shore hospital, st leonards, new south wales, australia sunshine coast university hospital, birtinya, queensland, australia royal brisbane and women\'s hospital, herston, queensland, australia royal adelaide hospital, adelaide, south australia, australia calvary north adelaide hospital, adelaide, south australia, australia box hill hospital, box hill, victoria, australia austin health, heidelberg, victoria, australia royal melbourne hospital, parkville, victoria, australia alfred health, victoria, australia lkh-univ. hospital graz, graz, austria medical university of innsbruck, innsbruck, austria kepler univ. klinikum linz, linz, austria kepler univ. klinikum linz, linz, austria kh d. barmherzigen brüder linz, neurologie, linz, austria universitätsklinikum tulln, abteilung für neurologie, tulln, austria hosp.hietzing with neuro.centr rosenhuegel,ii neuro.dep,wien, vienna, austria wilhelminenspital, wien, austria aalst - hosp onze-lieve-vrouw, aalst, belgium arlon - hosp sud luxembourg - vivalia, arlon, belgium az sint-jan brugge, brugge, belgium brussels-univ brugmann -horta, brussel, belgium brussels - hosp europe (ste-elisabeth), brussel, belgium brussels - univ saint-luc, bruxelles, belgium univ uz gent, gent, belgium kortrijk - hosp az groeninge kennedylaan, kortrijk, belgium uz leuven, leuven, belgium liège - hosp st-joseph, liège, belgium roeselare - hosp az delta, roeselare, belgium rumst - hosp az heilige familie, rumst, belgium sint-truiden - hosp st-trudo (st-jozef), sint-truiden, belgium wilrijk - hosp gza (st-augustinus), wilrijk, belgium yvoir - univ ucl de mont-godinne, yvoir, belgium hospital clinicas de botucatu, botucatu, brazil instituto de medicina flumignano, curitiba, brazil clinica neurologica e neurocirurgica de joinvile, joinvile, brazil hospital de clínicas de porto alegre, porto alegre, brazil h.c.da fac. de medicina de ribeirao preto, ribeirao preto, brazil hospital quinta d¿or, rio de janeiro, brazil foothills medical centre, calgary, alberta, canada university of alberta hospital (university of alberta), edmonton, alberta, canada grey nuns hospital, edmonton, alberta, canada prairie mountain health, brandon, manitoba, canada hopital notre-dame du chum, montreal, migration data, canada jewish general hospital, montreal, migration data, canada saint john regional hospital, saint john, new brunswick, canada eastern health (mun), st. john\'s, newfoundland and labrador, canada victoria hospital (lhsc), london, ontario, canada st. michael\'s hospital, toronto, ontario, canada toronto western hospital, toronto, ontario, canada csss de chicoutimi, chicoutimi, quebec, canada hopital charles - lemoyne, greenfield park, quebec, canada montreal general hospital - mcgill university health centre, montreal, quebec, canada chus fleurimont, sherbrooke, quebec, canada st jerome medical research inc., st-jerome, quebec, canada chu de quebec-universite laval research centre, quebec, canada clínica alemana de santiago s.a., santiago, chile clínica dávila, santiago, chile clinica alemana de temuco, temuco, chile beijing tiantan hospital affiliated to cap med university, beijing, china peking university third hospital, beijing, china first hospital of jilin university, changchun, china first affiliated hospital of guangzhou medical university, guangzhou, china first affiliated hospital of guangzhou university of tcm, guangzhou, china the first affiliated hospital of jinan university, guangzhou, china the affiliated hospital of guizhou medical university, guiyang, china 2nd affiliated hosp zhejiang university college of medical, hangzhou, china zhejiang hospital, hangzhou, china the affiliated hospital of hangzhou normal university, hangzhou, china zhejiang university school of medicine sir run run shaw hospital, hangzhou, china jinlin central hospital, jilin, china the second affiliated hospital to nanchang university, nanchang, china nanjing drum tower hospital, nanjing, china zhongda hospital southeast university, nanjing, china qingdao municipal hospital, qingdao, china the affiliated hospital of medicalcollege qingdao university, qingdao, china huashan hospital, fudan university, shanghai, china tongji hospital, tongji university, shanghai, china general hospital of shenyang military region, shenyang, china first affiliated hospital of xiamen university, xiamen, china affiliated hospital, xuzhou medical college, xuzhou, china servicios médicos muñoz solano, bogotá, colombia sociedad de cirugia de bogota hospital de san josé, bogotá, colombia fundación valle del lili, cali, colombia fundación cardiovascular de colombia, floridablanca, colombia general hospital varazdin, varazdin, croatia clin.hosp.centre zagreb,cerebrovascul.disease w/ intens.care, zagreb, croatia university hospital center zagreb, zagreb, croatia univ. hosp. sisters of mercy, neurology clinic, zagreb, zagreb, croatia cerebrovascular site, private prac., brno, brno, czechia hospital jihlava, jihlava, czechia university hospital olomouc, olomouc, czechia cerebrovascular site, ostrava, ostrava, czechia cerebrovascular site, ostrava, ostrava, czechia hospital homolka, prague, prague 5, czechia university hospital motol, praha 5, czechia east estonia central hospital, neurology dept, ahtme, ahtme, estonia west tallinn central hospital, neurology dept., tallinn, estonia north estonia medical centre foundation, tallin, tallinn, estonia tartu university hospital, tartu, estonia hop pays d\'aix, aix en provence, france hop de bayonne, bayonne, france hop jean minjoz, besançon, france hop pellegrin, bordeaux, france hop de la cavale blanche, brest, france hop pierre wertheimer, bron, france hop côte de nacre, caen, france hop grenoble, neuro, grenoble, grenoble, france hop roger salengro, lille, france hop mercy, metz, france hop paris saint-joseph, paris, france ghu paris psychiatrie et neurosciences, paris, france hop purpan, toulouse, france klinikum altenburger land gmbh, altenburg, germany neurologische klinik gmbh, bad neustadt, bad neustadt, germany vivantes netzwerk für gesundheit gmbh, berlin, germany evangelisches klinikum bethel ggmbh, bielefeld, germany berufsgenossenschaftliches universitätsklinikum bergmannsheil ggmbh, bochum, germany st. josef- und st. elisabeth-hospital ggmbh, bochum, germany gesundheit nord ggmbh   klinikverbund bremen, bremen, germany klinikum bremerhaven, bremen, germany krankenhäuser buchholz und winsen ggmbh, buchholz, germany allgemeines krankenhaus, celle, celle, germany klinikum chemnitz ggmbh, chemnitz, germany klinikum coburg ggmbh, coburg, germany klinikzentrum mitte, dortmund, dortmund, germany städtisches klinikum dresden, dresden, germany universitätsklinikum carl gustav carus dresden, dresden, germany universitätsklinikum düsseldorf, düsseldorf, germany marien-hospital, düsseldorf, düsseldorf, germany universitätsklinikum erlangen, erlangen, germany alfried krupp krankenhaus essen, essen, germany universitätsklinikum essen aör, essen, germany universitätsklinikum frankfurt, frankfurt am main, germany klinikum frankfurt höchst gmbh, frankfurt, germany klinikum friedrichshafen, friedrichshafen, germany klinikum fulda gag, fulda, germany evangelische klinik gelsenkirchen, gelsenkirchen, germany srh wald-klinikum gera gmbh, gera, germany universitätsklinikum gießen und marburg gmbh, gießen, germany universitätsmedizin greifswald, greifswald, germany bezirkskrankenhaus, günzburg, günzburg, germany asklepios klinik st. georg, hamburg, germany universitätsklinikum hamburg-eppendorf, hamburg, germany asklepios klinik harburg, hamburg, germany asklepios klinik wandsbek, hamburg, germany asklepios klinik barmbek, hamburg, germany asklepios klinik altona, hamburg, germany klinikum hanau gmbh, hanau, germany medizinische hochschule hannover, hannover, germany universitätsklinikum heidelberg, heidelberg, germany slk-kliniken heilbronn gmbh, heilbronn, germany klinikum idar-oberstein, idar-oberstein, germany universitätsklinikum jena, jena, germany universitätsklinikum schleswig-holstein, campus kiel, kiel, germany universitätsklinikum köln (aör), köln, germany universitätsklinikum leipzig, leipzig, germany klinikum der stadt ludwigshafen am rhein ggmbh, ludwigshafen, germany universitätsklinikum magdeburg aör, magdeburg, germany universitätsmedizin der johannes gutenberg-universität mainz, mainz, germany universitätsklinikum gießen und marburg gmbh, marburg, germany elblandklinikum meißen, meißen, germany johannes wesling klinikum, minden, germany kliniken maria hilf gmbh, moenchengladbach, germany ökumenisches hainich klinikum ggmbh, mühlhausen, germany klinikum der universität münchen - campus großhadern, münchen, germany klinikum rechts der isar der technischen universität münchen, münchen, germany universitätsklinikum münster, münster, germany klinikum nürnberg, nürnberg, germany sana klinikum offenbach gmbh, offenbach, germany klinikum osnabrück gmbh, osnabrück, germany universitätsklinikum regensburg, regensburg, germany nordwest-krankenhaus sanderbusch ggmbh, sande, germany kreisklinikum siegen gmbh, siegen, germany bürgerhospital, stuttgart, stuttgart, germany nervenklinik teupitz, teupitz, teupitz, germany krankenhaus der barmherzigen brüder trier, trier, germany universitätsklinikum tübingen, tübingen, germany rku - universitäts- und rehabilitationskliniken ulm ggmbh, ulm, germany sophien- und hufeland-klinikum ggmbh, weimar, germany helios dr. horst schmidt kliniken wiesbaden, wiesbaden, germany universitätsklinikum würzburg, würzburg, germany univ.hosp. of alexandroupolis, alexandroupolis, greece gen.hosp.of ath.evangelismos, athens, greece attikon university hospital, athens, greece gen.univ. hosp. of herakleion, herakleion, greece general university hospital of larissa, larissa, greece univ. gen. hosp. of patras, patras, greece univ.gen.hosp. of thessaloniki, thessaloniki, greece prince of wales hospital, hong kong, hong kong pamela youde nethersole eastern hospital, hong kong, hong kong queen mary hospital, hong kong, hong kong semmelweis university, budapest, hungary national instit.of neurosciences,neurology dept,budapest, budapest, hungary univ. debrecen medical health science center, neurology dept, debrecen, hungary pest megyei flor ferenc hospital, kistarcsa, hungary cru hungary ltd, private practice, miskolc, miskolc, hungary univ. of pecs clinic for neurology, pecs, hungary st. johns medical college and hospital, bangalore, india post graduate institute of medical education and research, chandigarh, india lalitha super specialities hospital, guntur, india nizam\'s institute of medical sciences, hyderabad, india shree krishna hospital and research centre, karamsad, india caritas hospital, kottayam, india mangala hospital and mangala kidney foundation, mangalore, india ltmmc & gh medical college,, mumbai, india magnum heart institute, nashik, india all india institute of medical sciences, new delhi, india sahyadri speciality hospital, pune, india hillel yaffe medical center, hadera, hadera, israel wolfson medical center, holon, israel the chaim sheba medical center tel hashomer, tel hashomer, ramat gan, israel sourasky medical center, telaviv, israel osp. ss filippo nicola, avezzano, italy policlinico s. orsola malpighi, bologna, italy a.o. spedali civili di brescia, brescia, italy azienda ospedaliero universitaria di ferrara, cona (fe), italy policlinico san martino, genova, italy a.o.u.policlinico g.martino, messina, italy fondazione centro san raffaele del monte tabor, milano, italy istituto auxologico italiano, milano, italy nuovo ospedale civile s. agostino-estense, modena, italy azienda ospedaliera universitaria di padova, padova, italy ospedale s.maria della misericordia, ao di perugia, perugia, italy osp. guglielmo da saliceto ausl di piacenza, piacenza, italy ospedale santa corona azienda sanitaria locale n.2 savonese, pietra ligure, italy università degli studi campus bio-medico, roma, italy a.o. san camillo forlanini, roma, italy umberto i pol. di roma-università di roma la sapienza, roma, italy azienda ospedaliera sant\'andrea-università di roma la sapienza, roma, italy a.o.u. senese policlinico santa maria alle scotte, siena, italy ospedale molinette, ao città della salute e della, torino, italy ospedale maria vittoria, torino, italy ospedale s. maria di ca\' foncello azienda ulss9 treviso, treviso, italy a. o. ospedale circolo fond. macchi, varese, italy ospedale policlinico g.b. rossi (borgo roma) di verona, verona, italy chubu rosai hospital, aichi, nagoya, japan national hospital organization toyohashi medical center, aichi, toyohashi, japan toyota memorial hospital, aichi, toyota, japan reserch institute for brain and blood vessels akita, akita, akita, japan juntendo university urayasu hospital, chiba, urayasu, japan go neurosurgical clinic, fukuoka, chikushi-gun, japan fukuoka university chikushi hospital, fukuoka, chikushino, japan national hospital organization kyushu medical center, fukuoka, fukuoka, japan fukuoka wajiro hospital, fukuoka, fukuoka, japan fukuoka university hospital, fukuoka, fukuoka, japan fukuoka tokushukai medical center, fukuoka, kasuga, japan steel memorial yawata hospital, fukuoka, kitakyushu, japan japan community health care organization kyushu hospital, fukuoka, kitakyushu, japan st. mary\'s hospital, fukuoka, kurume, japan shin koga hospital, fukuoka, kurume, japan fukuoka shin mizumaki hospital, fukuoka, onga, japan social insurance tagawa hospital, fukuoka, tagawa, japan shin yukuhashi hospital, fukuoka, yukuhashi, japan fujita general hospital, fukushima, date-gun, japan shinseikai masu memorial hospital, fukushima, nihonmatsu, japan asahi university hospital, gifu, gifu, japan japanese red cross takayama hospital, gifu, takayama, japan mihara memorial hospital, gunma, isesaki, japan maebashi red cross hospital, gunma, maebashi, japan medical corporation suiseikai suiseikai kajikawa hospital, hiroshima, hiroshima, japan araki neurosurgical hospital, hiroshima, hiroshima, japan hiroshima prefectural hospital, hiroshima, hiroshima, japan sapporo shiroishi memorial hospital, hokkaido, sapporo, japan nakamura memorial hospital, hokkaido, sapporo, japan kobe city medical center general hospital, hyogo, kobe, japan ja toride medical center, ibaraki, toride, japan tsukuba medical center hospital, ibaraki, tsukuba, japan iwate medical university hospital, iwate, morioka, japan kagoshima city hospital, kagoshima, kagoshima, japan national hospital organization kagoshima medical center, kagoshima, kagoshima, japan shonan kamakura general hospital, kanagawa, kamakura, japan saiseikai kumamoto hospital, kumamoto, kumamoto, japan japanese red cross kumamoto hospital, kumamoto, kumamoto, japan kumamoto city hospital, kumamoto, kumamoto, japan uji-tokushukai medical center, kyoto, uji, japan national hospital organization sendai medical center, miyagi, sendai, japan south miyagi medical center, miyagi, shibata-gun, japan ina central hospital, nagano, ina, japan nagano municipal hospital, nagano, naganoi, japan nagasaki university hospital, nagasaki, nagasaki, japan nozaki tokushukai hospital, osaka, daito, japan higashiosaka city medical center, osaka, higashiosaka, japan wakakusa daiichi hospital, osaka, higashiosaka, japan rinku general medical center, osaka, izumisano, japan kishiwada tokushukai hospital, osaka, kishiwada, japan yagi neurosurgical hospital, osaka, osaka, japan tominaga hospital, osaka, osaka, japan osaka university hospital, osaka, suita, japan tmg asaka medical center, saitama, asaka, japan saitama medical university international medical center, saitama, hidaka, japan sainokuni higashiomiya medical center, saitama, saitama, japan saitama municipal hospital, saitama, saitama, japan nippon medical school hospital, tokyo, bunkyo-ku, japan tokyo metropolitan geriatric hospital, tokyo, itabashi-ku, japan kyorin university hospital, tokyo, mitaka, japan tokyo women\'s medical university hospital, tokyo, shinjuku-ku, japan saiseikai wakayama hospital, wakayama, wakayama, japan yamagata city hospital saiseikan, yamagata, yamagata, japan hallym university sacred heart hospital, anyang, korea, republic of dong-a university hospital, busan, korea, republic of kyungpook national univ. hosp, daegu, korea, republic of chungnam national university hospital, daejoen, korea, republic of inje university ilsan paik hospital, goyang, korea, republic of chonnam national university hospital, gwangju, korea, republic of chosun university hospital, gwangju, korea, republic of seoul national university bundang hospital, seongnam, korea, republic of severance hospital, seoul, korea, republic of asan medical center, seoul, korea, republic of the catholic university of korea, seoul st.mary\'s hospital, seoul, korea, republic of chung-ang university hospital, seoul, korea, republic of korea university guro hospital, seoul, korea, republic of kangdong sacred heart hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of smg-snu boramae medical center, seoul, korea, republic of ajou university hospital, suwon, korea, republic of sarawak general hospital, kuching, malaysia hospital seberang jaya, pulau pinang, malaysia hospital sultanah nur zahirah, terengganu, malaysia hospital general de culiacán ""dr. bernardo j. gastellum"", culiacán, mexico hospital general ""dr. miguel silva"", morelia, mexico hospital angeles del pedregal, méxico, d.f., mexico hospital universitario dr jose eleuterio gonzalez, nuevo leon, mexico h. central dr ignacio m. p., san luis potosi, mexico auckland city hospital, grafton / auckland, new zealand north shore hospital, takapuna, takpuna auckland, new zealand wellington hospital, wellington, new zealand instituto nacional de ciencias neurológicas, barrios altos, peru hospital nacional guillermo almenara irigoyen, la victoria, peru pi house sp. z o.o., gdansk, gdansk, poland spec.hosp.of dr. wladyslaw bieganski in grudziadz, grudziadz, poland univ.clin.centr gibinski of silesian med,neurol.dep,katowice, katowice, poland university hospital in krakow, krakow, poland center of clinical neurology, private prac, krakow, krakow, poland clin.research center,leszek szczepanski,private prac.,lublin, lublin, poland medicome sp. z o.o., oswiecim, poland specialist holy spirit hospital, neurology dept,sandomierz, sandomierz, poland public central clinical hosp,neurology clinic,warsaw, warsaw, poland military institute of medicine neurology clinic, warsaw, warsaw, poland hospital garcia de orta, epe, almada, portugal hospital fernando fonseca, epe, amadora, portugal hospital de braga - centro clínico académico (2ca), braga, portugal chuc - centro hospitalar e universitário de coimbra, epe, coimbra, portugal chlc, epe - hospital de são josé, lisboa, portugal chlo, epe - hospital egas moniz, lisboa, portugal chuln, epe - hospital de santa maria, lisboa, portugal hospital beatriz ângelo, loures, portugal uslm, epe - hospital pedro hispano, matosinhos, portugal h. santo antónio - centro hospitalar do porto, porto, portugal centro hospitalar são joão,epe, porto, portugal centro hospitalar de entre o douro e vouga, e.p.e. - hospital de são sebastião, santa maria da feira, portugal interreg. clinical & diagnostic center, neurol. dept., kazan, kazan, russian federation reg.clin.hosp#1 na s.v.ochapovskiy,neurology#1 dep,krasnodar, krasnodar, russian federation city clin.emergency hosp of kursk, neurology department no.2, kursk, russian federation clin.hosp#2,na.semashko,russ.railways,restorative med&rehab., moscow, russian federation cityclin.hosp na i.v.davydovsky of dept of healthcare moscow, moscow, russian federation research&clini cent neuropsychiatry dep. healthcare,moscow, moscow, russian federation city clin.hosp#1na n.i.pirogov,dept of healthcare of moscow, moscow, russian federation ltd liabilitycom.cityneurologic cntr sibneiromed,novosibirsk, novosibirsk, russian federation saratov state med.univ na v.i.razumovsky,facultytherapy clin, saratov, russian federation reg.state instit.of healthc.smolensk reg.clin.hosp,neurology, smolensk, russian federation research inst. of emerg. med., vascul. center,st. petersburg, st. petersburg, russian federation military medical academy n.a. c. m. kirov, st. petersburg, st. petersburg, russian federation sverdlovsk reg.clin.hosp.no.1, yekaterinburg, russian federation clinical center of serbia, belgrade, serbia special hosp.for cerebrovascul.disease,\'sveti sava,belgrade, belgrade, serbia clinical centre nis, nis, serbia clinical center of vojvodina, novi sad, serbia national university hospital, singapore, singapore singapore general hospital, singapore, singapore national neuroscience institute, singapore, singapore faculty hospital l. pasteura, kosice, kosice, slovakia faculty hospital nitra, nitra, slovakia instit.f.applicative research in med.rehab.dobrna, dobrna, slovenia cardial d.o.o., specialist out-patient unit, ljubljana, ljubljana, slovenia univ. medical center maribor, maribor, slovenia university of pretoria, pretoria, south africa dr. moodley and dr. sarvan, tongaat, south africa hospital general universitario de albacete, albacete, spain hospital del mar, barcelona, spain hospital santa creu i sant pau, barcelona, spain hospital vall d\'hebron, barcelona, spain hospital universitari de girona doctor josep trueta, girona, spain hospital arnau de vilanova, lleida, spain hospital la princesa, madrid, spain hospital general universitario gregorio marañón, madrid, spain hospital ramón y cajal, madrid, spain hospital clínico san carlos, madrid, spain hospital la paz, madrid, spain hospital son espases, palma de mallorca, spain complejo hospitalario de navarra, pamplona, spain hospital universitario donostia, san sebastian, spain hospital clínico de santiago, santiago de compostela, spain hospital virgen del rocío, sevilla, spain hospital universitari joan xxiii, tarragona, spain hospital mútua terrassa, tarrasa (barcelona), spain hospital clínico de valencia, valencia, spain hospital clínico universitario de valladolid, valladolid, spain sahlgrenska us, göteborg, göteborg, sweden sahlgrenska universitetssjukhuset, östra, göteborg, sweden skaraborgs sjukhus, skövde, sweden karolinska univ. sjukhuset, stockholm, sweden karolinska univ. sjukhuset, stockholm, sweden danderyds sjukhus, stockholm, sweden canton hospital aarau, neurology dept., stroke center, aarau, switzerland university hospital basel, basel, switzerland univ. hospital bern, neurology dept, stroke center, bern, switzerland chuv - centre hospitalier universitaire vaudois, lausanne, switzerland regional hospital lugano,neurocenter of southern switzerland, lugano, switzerland kantonsspital st.gallen, st. gallen, switzerland university hosp. zürich, dept. of neurology, stroke center, zürich, switzerland chang-hua christian hospital, changhua, taiwan kaohsiung chang gung memorial hospital, kaohsiung, taiwan kaohsiung medical university chung-ho memorial hospital, kaohsiung, taiwan china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan chi mei medical center, tainan,, taiwan nckuh, tainan, taiwan national taiwan university hospital, taipei, taiwan mackay memorial hospital, taipei, taiwan cheng hsin general hospital, taipei, taiwan taipe veterans general hospital, taipei, taiwan tri-service general hospital, taipei, taiwan chang gung memorial hospital(taoyuan), taoyuan, taiwan chulalongkorn university, bangkok, thailand ramathibodi hospital, bangkok, thailand siriraj hospital, bangkok, thailand lampang hospital, lampang, thailand ankara universitesi tip fakultesi, ankara, turkey hacettepe universitesi tip fakultesi noroloji a.b.d., ankara, turkey gazi universitesi tip fakultesi, ankara, turkey eskisehir osmangazi universitesi tip fakultesi, eskisehir, turkey bezmialem vakif universitesi tip fakultesi hastanesi, istanbul, turkey istanbul universitesi istanbul tip fakultesi noroloji a.b.d., istanbul, turkey istanbul universitesi cerrahpasa tip fakultesi, istanbul, turkey bakırkoy dr. sadi konuk egitim ve arastirma hastanesi, istanbul, turkey bakirkoy prof. dr. mazhar osman ruh sagligi ve sinir hastaliklari, istanbul, turkey sisli hamidiye etfal egitim ve arastirma hastanesi, istanbul, turkey marmara universitesi pendik egitim ve arastirma hastanesi, istanbul, turkey dokuz eylul universitesi tip fakultesi noroloji a.b.d., izmir, turkey ondokuz mayis universitesi tip fakultesi, samsun, turkey namik kemal universitesi tip fakultesi, tekirdag, turkey bukovinian med.univ.chernivtsi reg.psychiatric hosp,neurolog, chernivtsi, ukraine city clinical hospital no. 7, kharkov, kharkiv, ukraine instit.of neurol,psychiatry&narcol,vascul. malformations dep, kharkiv, ukraine instit.of gerontology na d.f.chebotarev,brain vascular path., kyiv, ukraine lviv regional clinical hospital, lviv, lviv, ukraine ternopil state med.univ.na gorbachevskiy,neurology dept n3, ternopil, ukraine vinnitsia reg.psychoneurol.hosp.na yushchenko,dept.n3,neurol, vinnitsia, ukraine zhytomyr reg.clinhosp na gerbachevskiy regcouncil,neurol.dep, zhytomyr, ukraine']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/20/nct02239120/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/20/nct02239120/prot_001.pdf",https://ClinicalTrials.gov/show/NCT02239120,
613,614,NCT03975205,"to study the concentration level of, doxil, and doxorubicin at various time frames",Doxil,Unknown status,No Results Available,lymphoma leukemia,drug: doxorubicin,bioavailability of doxil versus doxorubicin,sutphin drugs|bharath charitable cancer hospital and institute,All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,500.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Global CRO Doxil,"July 1, 2019","October 31, 2019","December 31, 2019","June 5, 2019",,"June 5, 2019","['bharat cancer hospital, surat, gujarat, india']",,https://ClinicalTrials.gov/show/NCT03975205,lymphoma blood
614,615,NCT01191138,gastric emptying after infracolic or supracolic gastrojejunostomy following pancreaticoduodenectomy,,Completed,No Results Available,postprocedural gastric stasis,procedure: infracolic gastrojejunal anastamosis|procedure: supracolic gastrojejunal anastamosis,gastric emptying assessed clinically and correlated objectively with liquid and solid emptying of radionucleotide|correlation of pancreatic duct leak with gastric emptying,"asian institute of gastroenterology, india|kk nuclear scan",All,"Child, Adult, Older Adult",Not Applicable,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AIG-GIS-20090,January 2009,February 2012,March 2012,"August 30, 2010",,"June 20, 2012","['asian institute of gastroenterology, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT01191138,gastric
615,616,NCT00631371,study comparing bevacizumab + temsirolimus vs. bevacizumab + interferon-alfa in advanced renal cell carcinoma subjects,INTORACT,Completed,Has Results,renal cell carcinoma,drug: bevacizumab|drug: temsirolimus|drug: interferon-alfa 9mu,progression-free survival (pfs): independent-assessment|progression-free survival (pfs): investigator-assessment|percentage of participants with objective response (complete response/partial response): independent-assessment|overall survival (os),pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,791.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3066K1-3311|B1771006|2007-003793-26,April 2008,April 2012,April 2015,"March 7, 2008","June 4, 2013","April 27, 2016","['hematology oncology services of arkansas, little rock, arkansas, united states south county hematology/oncology, chula vista, california, united states cancer center oncology medical group, la mesa, california, united states ucla medical center, los angeles, california, united states ucla, los angeles, california, united states ucla, los angeles, california, united states north county oncology medical clinic, oceanside, california, united states medical oncology associates - sd, san diego, california, united states sharp memorial hospital investigational pharmacy, san diego, california, united states sharp rees-stealy, san diego, california, united states california pacific medical center, san francisco, california, united states pacific hematology/oncology associates, san francisco, california, united states san francisco oncology associates, san francisco, california, united states cohen & hufford md\'s inc, san francisco, california, united states the jones clinic, pc, new albany, mississippi, united states the cleveland clinic, cleveland, ohio, united states edmond oncology center, edmond, oklahoma, united states ou medical center, oklahoma city, oklahoma, united states ou physician\'s building, oklahoma city, oklahoma, united states university of oklahoma, oklahoma city, oklahoma, united states the jones clinic, pc, germantown, tennessee, united states the vanderbilt clinic, nashville, tennessee, united states university of washington medical center, seattle, washington, united states virginia mason medical center, seattle, washington, united states seattle cancer care alliance, seattle, washington, united states centro oncológico rosario, rosario, santa fé, argentina centro medico san roque, san miguel de tucuman, tucuman, argentina isis clinica especializado, santa fe, argentina mater adult hospital, south brisbane, queensland, australia royal adelaide hospital, adelaide, south australia, australia ashford cancer center research, kurralta park, south australia, australia cancer care sa, kurralta park, australia mater private hospital, south brisbane, australia zna middelheim, antwerpen, belgium universitair ziekenhuis gent, gent, belgium jessa ziekenhuis - campus virga jessa, hasselt, belgium cliniques universitaires de mont-godinne ucl, mont-godinne, belgium centro goiano de oncologia, goiania, go, brazil centro goiano de oncologia - cgo, goiania, go, brazil procura - centro goiano de pesquisa clínica ltda, goiania, go, brazil clínica de oncologia de porto alegre sociedade simples ltda, porto alegre, rio grande do sul, brazil instituto nacional de cancer - inca, rio de janeiro, rj, brazil associaçao hospital de caridade ijui, ijui, rs, brazil hospital de clinicas de porto alegre, porto alegre, rs, brazil clinica de oncologia de porto alegre - sociedade simples ltda., porto alegre, rs, brazil fundação pio xii - hospital de câncer de barretos, barretos, sao paulo, brazil instituto de oncologia de piracicaba s/s ltda, piracicaba, sp, brazil instituto do cancer do estado de sao paulo octavio frias de oliveira - icesp, sao paulo, sp, brazil irmandade da santa casa de misericordia de porto alegre, porto alegre, brazil instituto nacional do cancer - inca, rio de janeiro, brazil odette cancer centre, sunnybrook health sciences centre, toronto, ontario, canada centre de sante et de services sociaux de rimouski - neigette, rimouski, quebec, canada instituto nacional del cancer, santiago, region metropolitana / chile, chile fundacion arturo lopez perez, santiago, chile instituto clinico oncologico del sur, santiago, chile oncologos del occidente s.a, pereira, risaralda, colombia oblastni nemocnice jicin a s, jicin, ceska republika, czech republic masarykuv onkologicky ustav, brno, czech republic fakultni nemocnice olomouc, olomouc, czech republic krajska zdravotni, a.s., usti nad labem, czech republic centre jean perrin, clermont-ferrand, france clinique sainte marguerite, hyères, france hopital andre mignot, le chesnay, france centre médical oncogard, nimes, france chu de poitiers, poitiers cedex, france chu de rouen, rouen cedex, france centre rené gauducheau, saint-herblain-nantes, france hopital foch, suresnes, france institut gustave roussy, villejuif cedex, france vivantes klinikum am urban, neztwerk fuer gesundheit gmbh, berlin, germany universitaetsklinikum hamburg eppendorf, hamburg, germany klinikum region hannover, krankenhaus siloah, hannover, germany tu muenchen, rechts der isar, muenchen, germany pamela youde nethersole eastern hospital, chai wan, hong kong prince of wales hospital, hong kong, hong kong queen mary hospital, hong kong, hong kong orszagos onkologiai intezet, budapest, hungary uzsoki utcai korhaz, budapest, hungary petz aladar megyei oktato korhaz, gyor, hungary josa andras oktato korhaz nonprofit kft., nyiregyhaza, hungary szegedi tudomanyegyetem, urologiai klinika, szeged, hungary veszprem megyei csolnoky ferenc, veszprem, hungary vedanta institute of medical sciences, ahmedabad, gujarat, india healthcare global enterprises limited, bangalore, karnataka, india lakeshore hospital & research center limited, kochi, kerala, india jawaharlal nehru cancer hospital, department of medical oncology, bhopal, madhya pradesh, india tata memorial center, mumbai, maharashtra, india tata memorial centre, navi mumbai, maharashtra, india jehangir hospital, pune, maharashtra, india searoc cancer centre, jaipur, rajasthan, india apollo hospital, chennai, tamil nadu, india regional cancer centre, kerela, trivandrum, india divisione di urologia, azienda ospedaliera policlinico consorziale di bari, bari, italy sezione di oncologia medica centro di ricerca clinica, chieti, italy unità operativa di oncologia, azienda ospedaliera policlinico di modena, modena, italy farmacia del comitato etico provinciale di modena, modena, italy struttura complessa di oncologia medica ospedale santa maria della misericordia, perugia, italy ifo- istituti fisioterapici ospitalieri, roma, italy azienda ospedaliera s. maria, terni, italy samsung medical center, seoul, korea, korea, republic of yonsei university health system-severance hospital, seoul, korea, republic of university malaya medical centre, kuala lumpur, malaysia hospital aranda de la parra, leon, guanajuato, mexico spaarne ziekenhuis, hoofddorp, netherlands uniwersyteckie centrum kliniczne, gdansk, poland szpital specjalistyczny im. l. rydygiera sp. z o.o., krakow, poland centrum onkologii ziemi lubelskiej im. sw jana z dukli, lublin, poland szpital kliniczny przemienienia panskiego um im. karola marcinkowskiego w poznaniu, poznan, poland centrum onkologii, instytut im. m. sklodowskiej-curie, warszawa, poland centrum medyczne ostrobramska nzoz ""magodent"", warszawa, poland wojskowy instytut medyczny, pracownia badan cynnosciowych ukladu oddechowego, klinika chorob wewnetr, warszawa, poland wojskowy intsytut medyczny, zaklad diagnostyki laboratoryjnej csk mon, warszawa, poland wojskowy intsytut medyczny, zaklad medycyny nuklearnej csk mon, warszawa, poland hospital de san joao, porto, portugal hospital de são joão, porto, portugal medical radiology research center of the minzdravsotsrazvitiya of russia, obninsk, kaluga region, russian federation leningrad regional oncology dispensary, saint-petersburg, leningradskaya oblast, russian federation republican clinical oncology dispensary of minzdrav of tatarstan republic, kazan, russian federation chair of radiology and radiotherapy, moscow, russian federation n.n. blokhin russian cancer research center, department of clinical pharmacology and chemotherapy, moscow, russian federation n.n. blokhin russian cancer research center, department of urology, moscow, russian federation moscow scientific research oncology institute p.a. herzen, moscow, russian federation privolzhskiy district medical center of federal biomedical agency, nizhni novgorod, russian federation scientific research institute of oncology n.n. petrov, pesochny, saint-petersburg, russian federation city hospital no.26, saint-petersburg, russian federation city pokrovskaya hospital, saint-petersburg, russian federation clinical center of serbia, belgrade, serbia institute for oncology and radiology of serbia, belgrade, serbia military medical academy, belgrade, serbia national cancer centre singapore, singapore, singapore fakultna nemocnica s poliklinikou f d roosevelta, banska bystrica, slovakia oddelenie funkcnej diagnostiky, banska bystrica, slovakia klinika pneumologie a ftiziologie fnsp lfuk, bratislava, slovakia fakultna nemocnica s poliklinikou akad l derera, bratislava, slovakia klinica nuklcarncj mediciny, martin, slovakia klinika nuklearnej mediciny jlf uk a martinskej fakultnej nemocnice, martin, slovakia klinika tuberkulozy a plucnych chorob uk jlf a martinskej fakultnej nemocince, martin, slovakia nemocnica s poliklinikou skalica, skalica, slovakia kk med, s.r.o., zilina, slovakia medivasa s.r.o., zilina, slovakia nemocnica s poliklinikou zilina, zilina, slovakia gvi oncology trial unit, kraaifontein, cape town, south africa westridge medical centre, mayville, durban, south africa pretoria urology hospital, hatfield, pretoria, south africa panorama medical centre, panorama, cape town, western cape, south africa university of the witwatersrand oncology, parktown, south africa langenhoven drive oncology centre, port elizabeth, south africa dr. fourie & voges, pretoria, south africa institut catala doncologia, l\'hospitalet de llobregat, barcelona, spain hospital universitario marques de valdecilla, santander, cantabria, spain hospital sant creu i sant pau, barcelona, spain hospital del mar de barcelona, barcelona, spain hospital de madrid norte-sanchinarro, madrid, spain instituto valenciano de oncología, valencia, spain veterans general hospital-taipei, taipei, roc, taiwan tri-service general hospital, neihu, tapei, taiwan china medical university hospital, taichung, taiwan national taiwan university hospital, taipei toc, taiwan division of oncology, tao yuan, taiwan universitet, kafedra onkologyy, chenivtsi, ukraine a.p romodanov itstitut nejrohirurhii, chernovtsi, ukraine uchbobo-naukovyi likuvalnyi kompleks ddmu im. m.gor\'kogo, donetsk, ukraine donetskyy oblasyy protypukhlynnyy tsenter, donetsk, ukraine donetske obl. clinico-teritorial\'ne medichne ob\'yednannya, donetsk, ukraine ""state institution """"institute for occupational health of the, kiev, ukraine r.e.kavetsky institute of experimental pathology, oncology and radiobiology nas of ukraine,laborator, kiev, ukraine a.p romodanov itstitut nejrohirurhii, kiyv, ukraine oblasnyy onkologychnyy dispanser, onkourologichne viddilennya, ivano-frankivskiy derzhavniy medichni, medychna vul., ivano-frankivsk, ukraine southampton general hospital, southampton, hampshire, united kingdom christie hospital, withington, manchester, united kingdom university of leeds, leeds, north yorkshire, united kingdom guy\'s hospital, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00631371,kidney
616,617,NCT01304849,use of interim pet scan to modify therapy in advanced hodgkin's lymphoma in order to improve outcomes,,Completed,No Results Available,hodgkin's lymphoma,drug: escalated beacopp,efficacy of interim pet guided therapy strategy interms of efs in advanced hl|toxicity of escalated beacopp,cancer institute wia,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,50.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIA-HL-1,January 2011,September 2013,September 2013,"February 28, 2011",,"February 4, 2015","['department of medical oncology, cancer institute (wia), adyar, chennai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT01304849,lymphoma
617,618,NCT04538547,randomized trial to evaluate accelerated radiotherapy in locally advanced carcinoma of nasopharynx,EARN,Recruiting,No Results Available,"carcinoma, nasopharyngeal",radiation: accelerated radiotherapy|radiation: non accelerated radiotherapy,to compare acute treatment related toxicity between the two study groups|to compare overall response rates between the two study group,postgraduate institute of medical education and research|indian council of medical research,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,120.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IEC-02/2019-1122,"September 16, 2019",September 2022,September 2022,"September 4, 2020",,"September 4, 2020","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT04538547,brain
618,619,NCT05068076,"role of perfluorobutane in lesion detection, targeting and response assessment for ablation of hcc",,Completed,No Results Available,hepatocellular carcinoma|microwave ablation,drug: perfluorobutane,comparison of treatment response two hours post procedure with perfluorobutane with routine cect/cemri done at 1 month post procedure using modified recist criteria for hcc.|targeting of lesions (fulfilling ceus lirads 4/5 criteria) in the kupffer phase for ablation,"institute of liver and biliary sciences, india",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,21.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ILBS-HCC-04,"October 1, 2021","December 16, 2021","December 16, 2021","October 5, 2021",,"December 21, 2021","['institute of liver & biliary sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT05068076,liver
619,620,NCT04443049,to study the effects of addition of mebendazole to lenvatinib in cirrhotics with advanced hepatocellular carcinoma.,,Recruiting,No Results Available,hepatocellular carcinoma|liver cirrhosis,drug: lenvatinib|drug: mebendazole|other: placebo,overall survival in both groups|death|progressive disease requiring change of therapy in both groups|progressive disease requiring quitting therapy in both groups|therapy related adverse effects in both groups|worsening of performance status in both groups|decompensation of underlying cirrhosis in both groups,"institute of liver and biliary sciences, india",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,170.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILBS-Cirrhosis-32,"July 10, 2020","June 19, 2022","June 19, 2022","June 23, 2020",,"October 5, 2021","['institute of liver & biliary sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT04443049,liver
620,621,NCT03338647,sbrt or tace for advanced hcc,,Recruiting,No Results Available,hepatocellular carcinoma,drug: deb|radiation: sbrt,"progression (total of local, intra- and extrahepatic)|response|local control of treated tumor|intrahepatic failure|extrahepatic failure|overall survival|treatment related toxicity|cost-benefit",university of aarhus|international atomic energy agency,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,180.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UAarhus HCC,"October 26, 2017","December 31, 2023","December 31, 2023","November 9, 2017",,"December 2, 2021","['medanta, delhi, nct, india']",,https://ClinicalTrials.gov/show/NCT03338647,liver
621,622,NCT04250064,a study of low dose bevacizumab with conventional radiotherapy alone in diffuse intrinsic pontine glioma,LoBULarDIPG,Recruiting,No Results Available,dipg,drug: bevacizumab injection|radiation: ultra-low-dose rt,overall survival|progression-free survival|adverse events|steroid use|pattern of relapse|overall survival|compliance|inconvenience rates|quality of life scores,tata memorial centre,All,"3 Years to 18 Years   (Child, Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3201,"February 4, 2020",February 2023,February 2023,"January 31, 2020",,"May 4, 2022","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT04250064,
622,623,NCT04474964,focal radiotherapy plus low dose craniospinal irradiation followed by adjuvant chemotherapy in wnt medulloblastoma.,FOR-WNT2,Recruiting,No Results Available,"medulloblastoma, wnt-activated",radiation: low dose craniospinal irradiation plus focal radiotherapy,relapse-free survival will be analysed using using the product-limit method of kaplan-meier and compared using the log-rank test.|overall survival of participants will be analysed using the product-limit method of kaplan-meier and compared using the log-rank test.|neuro-cognitive function of participants will be analysed longitudinally over time using linear regression model with time-test for trend|growth hormone levels of participants will be analysed longitudinally over time using linear regression model with time-test for trend.|thyroid function levels of participants will be analysed longitudinally over time using linear regression model with time-test for trend.|cortisol levels of participants will be analysed longitudinally over time using linear regression model with time-test for trend.|sex hormone levels of participants will be analysed longitudinally over time using linear regression model with time-test for trend.|pure tone audiometry of participants will be analysed longitudinally over time using linear regression model with time-test for trend.,tata memorial centre,All,3 Years to 16 Years   (Child),Not Applicable,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3468,"August 13, 2020",July 2030,July 2030,"July 17, 2020",,"October 6, 2021","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT04474964,brain
623,624,NCT02041793,laparoscopic cystogastrostomy versus endoscopic cystogastrostomy,,Completed,No Results Available,pancreatic pseudocyst,procedure: laparoscopic cystogastrostomy|procedure: endoscopic cystogastrostomy,resolution of pseudocyst|adverse events|cost per patient|recurrence rate of pseudocyst,"all india institute of medical sciences, new delhi|indian council of medical research",All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICMR-PP 5/10,May 2010,April 2015,November 2015,"January 22, 2014",,"July 2, 2017","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT02041793,pancreat
624,625,NCT04712929,candida associated cytokines in oral leukoplakia,,Completed,No Results Available,oral leukoplakia,other: fluconazole,oral burning sensation|clinical size of lesion|pro- inflammatory cytokines|erythema of oral lesion|thickness of oral lesion|candida positivity|phospholipase activity of candida in oral leukoplakia|secreted aspartyl proteinase activity of candidain oral leukoplakia|biofilm formation|antifungal sensitivity|histopathology|malignant transformation,"all india institute of medical sciences, new delhi",All,"18 Years to 100 Years   (Adult, Older Adult)",,90.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,A-634,"November 1, 2018","February 15, 2020","March 30, 2020","January 19, 2021",,"January 20, 2021","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT04712929,
625,626,NCT02160600,dual energy ct vs standard triple phase ct-a randomised control trial,,Completed,No Results Available,renal cell carcinoma|renal cysts|transitional cell carcinoma|aml,other: standard multiphase ct|other: split bolus dual energy ct,appropriateness of the treatment recieved,"all india institute of medical sciences, new delhi",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,124.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,IESC/T-457/29.11.2013,April 2014,December 2016,December 2016,"June 10, 2014",,"April 27, 2017","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT02160600,kidney
626,627,NCT04251845,evaluation of effect of topical melatonin in treatment of oral leukoplakia,,Unknown status,No Results Available,oral leukoplakia,dietary supplement: topical melatonin|other: placebo,change in the size of the lesion.|degree of dysplasia|expression of immunopositivity of ki67 cells in the lesion.,postgraduate institute of dental sciences rohtak,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Shubhangi OMR,"February 1, 2020","August 30, 2020","September 30, 2020","February 5, 2020",,"February 5, 2020","['post graduate institute of dental sciences, rohtak, haryana, india']",,https://ClinicalTrials.gov/show/NCT04251845,
627,628,NCT02259647,sorafenib plus vitamin k1 versus sorafenib in advanced hepatocellular carcinoma,,Completed,No Results Available,hepatocellular carcinoma,drug: sorafenib 400mg twice daily + intravenous infusion ofvit k1|drug: sorafenib 400 mg twice daily + intravenousinfusion of placebo,overall survival|objective response rate (orr) of tumour based on mrecist (response evaluation criteria in solid tumors ) criteria|disease control rate (dcr) of tumour based on mrecist (response evaluation criteria in solid tumors ) criteria|biochemical response - improvement in tumor biomarker level|safety,"institute of liver and biliary sciences, india",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ILBS-HCC-02,"October 1, 2014","October 31, 2015","October 31, 2015","October 8, 2014",,"October 28, 2019","['institute of liver & biliary sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT02259647,liver
628,629,NCT02240771,transarterial chemotherapy compared with oral chemotherapy in the treatment of advanced hepatocellular carcinoma,,Unknown status,No Results Available,hepatocellular carcinoma,procedure: transarterial chemotherapy|drug: oral chemotherapy,survival rate-|tumor response,"all india institute of medical sciences, new delhi|indian council of medical research",All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,124.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAC-HCC,January 2006,December 2014,March 2015,"September 16, 2014",,"September 16, 2014","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT02240771,liver
629,630,NCT02155452,fluorescence and glioma heterogeneity,ALAglioma,Completed,No Results Available,malignant gliomas,procedure: ala,degree of fluorescence|high throughput proteomic screening of tissue samples,tata memorial hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",,25.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,TMC- ACTREC IRB project no 139,May 2014,July 2019,July 2019,"June 4, 2014",,"May 6, 2022","['advanced centre for treatment, research & education in cancer (actrec), navi mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02155452,skin brain
630,631,NCT01438450,oral chemotherapy versus supportive therapy in the treatment of unresectable hepatocellular carcinoma,OTCHCC,Unknown status,No Results Available,hepatocellular carcinoma,drug: oral|other: supportive,survival|tumour response|number of patients with side effects|quality of life|change from baseline in child status at 1 year,"all india institute of medical sciences, new delhi",All,"12 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,74.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICMR- D.O No.5/8/7/26/99-ECD-1,October 2007,August 2013,September 2014,"September 22, 2011",,"July 13, 2012","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT01438450,liver
631,632,NCT00889018,trial comparing two carboplatin doses in groups c and d intraocular retinoblastoma,,Unknown status,No Results Available,intraocular retinoblastoma,drug: carboplatin,"ocular salvage rates in two randomly divided groups of group c and d retinoblastomas, treated with primary chemotherapy protocol using 560mg/m2 carboplatin and 750mg/m2 carboplatin respectively|to evaluate the response of subtenon carboplatin injections in cases of group c and d retinoblastomas that fail to respond to primary chemotherapy and local treatment","all india institute of medical sciences, new delhi|council of scientific and industrial research, india",All,"Child, Adult, Older Adult",Not Applicable,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",RACHNAMEEL,April 2009,April 2012,April 2012,"April 28, 2009",,"February 9, 2012","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00889018,
632,633,NCT02583282,a study to compare the efficacy and safety of intrapleural doxycycline versus iodopovidone for performing pleurodesis in malignant pleural effusion,,"Active, not recruiting",No Results Available,malignant pleural effusion,other: doxycycline|other: iodopovidine,complete success|partial success|failed pleurodesis|time to pleurodesis,postgraduate institute of medical education and research,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",INT/IEC/2015/232,"August 1, 2015","December 31, 2020","August 31, 2021","October 22, 2015",,"March 23, 2021","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT02583282,skin
633,634,NCT00522405,randomized control trial (rct) of transarterial chemoembolization (tace) versus tace and oral drug therapy in the treatment of unresectable hepatocellular carcinoma,,Unknown status,No Results Available,hepatocellular carcinoma,procedure: tace,"survival rate- calculated from the start of tace|a) tumor response on dual phase cect b) patient tolerance c) childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the childs' scorescore <6- childs'a, 7-9 childs'b and >10 childs'c","all india institute of medical sciences, new delhi|indian council of medical research",All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A-39/29.1.2007|ICMR No-5/8/7/26/99-ECD-I,October 2007,August 2014,October 2014,"August 29, 2007",,"July 16, 2012","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00522405,liver
634,635,NCT01143584,efficacy of rapid escalation of cabergoline in comparison to conventional dosing in prolactin secreting macroadenomas.,,Unknown status,No Results Available,macroprolactinoma,drug: cabergoline|drug: cabergoline,normoprolactinemia|duration for resolution of hypogonadism,postgraduate institute of medical education and research,All,"Child, Adult, Older Adult",Not Applicable,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,prlcab2020,May 2010,December 2011,March 2012,"June 14, 2010",,"June 14, 2010","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT01143584,
635,636,NCT01630954,a comparison of single versus double evacuation for treatment of hydatidiform mole,,Unknown status,No Results Available,hydatidiform mole,procedure: suction and evacuation,"proportion of patents diagnosed as gtn following treatment in each group|maternal complications,|time interval of normalization of hcg|duration of hospital stay",nilratan sircar medical college,Female,"15 Years to 45 Years   (Child, Adult)",Phase 4,120.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-Chaudhuri,June 2012,December 2018,June 2019,"June 28, 2012",,"March 23, 2016","['dr snehamay chaudhuri, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT01630954,
636,637,NCT00430664,a comparative study of the safety and efficacy of face talc slurry and iodopovidone for pleurodesis,,Unknown status,No Results Available,malignant pleural effusions|recurrent pleural effusions|primary spontaneous pneumothorax|secondary spontaneous pneumothorax,procedure: pleurodesis with either talc or iodopovidone,success|failure|death|pain by vas|time to pleurodesis|others,postgraduate institute of medical education and research,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7134-PG-1Tg-05/5469-71,January 2006,,December 2007,"February 2, 2007",,"February 2, 2007","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT00430664,skin
637,638,NCT01142869,an observational study to evaluate the safety and efficacy of cetuximab in combination with platinum-based chemotherapy in the first-line treatment of recurrent or metastatic squamous cell carcinoma of head and neck,,Terminated,No Results Available,"carcinoma, squamous cell",drug: cetuximab,to obtain further safety information on the use of cetuximab in combination with platinum-based chemotherapy in patients with recurrent/metastatic scchn.|to obtain clinical effectiveness information of cetuximab in combination with platinum based chemotherapy in patients with recurrent/ metastatic scchn.,"merck kgaa, darmstadt, germany|merck ltd., india",All,"Child, Adult, Older Adult",,133.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,EMR 062202-514,"December 31, 2009","July 31, 2013","August 5, 2014","June 11, 2010",,"May 8, 2017","[""ambaa hospitals, hyderabad, andhra pradesh, india indo- american cancer institute & research centre, hyderabad, andhra pradesh, india nvs ramakrishna's clinic, hyderabad, andhra pradesh, india dr. nikhil's clinic, secunderabad, andhra pradesh, india swarna sai hospital, secunderabad, andhra pradesh, india sparsh hospital, orissa, bhubaneswar, india all india institute of medical sciences, new delhi, delhi, india wellness consultants clinic, surat, gujarat, india global health pvt ltd, gurgaon, haryana, india the cancer clinic, kochin, kerala, india dr. t. p. sahoo's clinic, bhopal, madhya pradesh, india bnd onco centre, mumbai, maharashtra, india s.l.raheja hospital, mumbai, maharashtra, india s m karandikar's clinic, pune, maharashtra, india ruby hall clinic, pune, maharashtra, india galaxy care laproscopic institute, pune, maharashtra, india neigrihms, shillong, meghalaya, india grace nursing home, aizwal, mizoram, india cancer clinic, jaipur, rajasthan, india sms hospital, jaipur, rajasthan, india bhagwan mahaveer cancer hospital, jaipur, rajasthan, india j.k.cancer institute, kanpur, uttar pradesh, india annapurna medical and cancer relief society, lucknow, uttar pradesh, india dr. vineet's clinic, new delhi, uttar pradesh, india smh-curie cancer centre, shanti mukand hospital, new delhi, uttar pradesh, india apollo gleneagles cancer hospital, kolkata, west bengal, india b.r. singh hospital, kolkatta, west bengal, india sunil gupta's clinic, delhi, india""]",,https://ClinicalTrials.gov/show/NCT01142869,skin
638,639,NCT05193006,assessment of histologic prognostic factors in peritoneal malignant mesothelioma,,Recruiting,No Results Available,peritoneal malignant mesothelioma,other: no intervention,assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma,hospices civils de lyon,All,"18 Years to 80 Years   (Adult, Older Adult)",,300.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,69HCL21_1120,"December 28, 2021","July 15, 2022","January 1, 2023","January 14, 2022",,"January 14, 2022","['uz gent, gent, belgium university hospital of lyon, pierre-bénite, france institut f. pathologie und neuropathologie, tübingen, germany zydus hospitals, ahmedabad, india the norwegian radium hospital, oslo, norway fundação champalimaud, lisboa, portugal']",,https://ClinicalTrials.gov/show/NCT05193006,skin
639,640,NCT02625389,evaluation of lipiodol® ultra fluid in association with surgical glues during vascular embolization.,In-Live,Unknown status,No Results Available,congenital hemangioma|hemangioendothelioma|angiosarcoma|arteriovenous malformation,drug: lipiodol® ultra fluid with surgical glues,adverse drug reactions during any session of embolization|adverse drug reactions up to one month follow-up|adverse events up to one month follow-up|obliteration rate,guerbet,All,"18 Years and older   (Adult, Older Adult)",Phase 4,125.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LUF-44-001|CTRI/2017/05/008607|EUPAS15045,"November 29, 2017",September 2020,October 2020,"December 9, 2015",,"February 19, 2020","['division of peripheral vascular & endovascular sciences, medanta-the medicity hospital, gurgaon, haryana, india christian medical college hospital, vellore, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT02625389,sarcoma
640,641,NCT03974893,"dietary intake, sarcopenic obesity, and other treatment-related outcomes in indian children with acute lymphoblastic leukemia",TATA,Unknown status,No Results Available,sarcopenic obesity,other: vegetarian diet,incidence of sarcopenic obesity|association of a vegetarian diet and sarcopenic obesity,columbia university|tata memorial hospital,All,5 Years to 15 Years   (Child),,50.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAR8814,"April 18, 2019",November 2021,December 2021,"June 5, 2019",,"June 6, 2019","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03974893,
641,642,NCT02964858,radiation dose optimization in diffuse large b- cell lymphoma.,DOBL,Recruiting,No Results Available,nonhodgkin lymphoma,radiation: standard arm|radiation: experimental arm,event free survival|local control rate|overall survival|overall response rate|late toxicity|acute toxicity|quality of life scores,tata memorial hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,840.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Project No-1627,November 2016,November 2022,June 2023,"November 16, 2016",,"February 23, 2017","['tata memorial hospital, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT02964858,lymphoma
642,643,NCT03847428,assess efficacy and safety of durvalumab alone or combined with bevacizumab in high risk of recurrence hcc patients after curative treatment,EMERALD-2,"Active, not recruiting",No Results Available,hepatocellular carcinoma,drug: durvalumab|drug: bevacizumab|other: placebo,recurrence-free survival (rfs) for arm a vs arm c|recurrence-free survival (rfs) arm b vs arm c|overall survival (os) for arm a vs arm c and arm b vs arm c|recurrence-free survival at 24 months (rfs24) and 36 months (rfs36) for arm a vs arm c and arm b vs arm c|time to recurrence (ttr) for arm a vs arm c and arm b vs arm c|time from randomization to recurrence/progression on next therapy (rfs2/pfs2) for arm a vs arm c and arm b vs arm c,astrazeneca,All,"18 Years to 150 Years   (Adult, Older Adult)",Phase 3,877.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D910DC00001|2018-004105-85,"April 29, 2019","June 5, 2023","May 31, 2024","February 20, 2019",,"May 5, 2022","[""research site, birmingham, alabama, united states research site, mobile, alabama, united states research site, phoenix, arizona, united states research site, costa mesa, california, united states research site, la jolla, california, united states research site, long beach, california, united states research site, orange, california, united states research site, sacramento, california, united states research site, washington, district of columbia, united states research site, miami, florida, united states research site, tampa, florida, united states research site, honolulu, hawaii, united states research site, chicago, illinois, united states research site, westwood, kansas, united states research site, louisville, kentucky, united states research site, shreveport, louisiana, united states research site, detroit, michigan, united states research site, grand rapids, michigan, united states research site, rochester, minnesota, united states research site, omaha, nebraska, united states research site, new brunswick, new jersey, united states research site, albuquerque, new mexico, united states research site, new york, new york, united states research site, stony brook, new york, united states research site, durham, north carolina, united states research site, winston-salem, north carolina, united states research site, cleveland, ohio, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, spartanburg, south carolina, united states research site, knoxville, tennessee, united states research site, memphis, tennessee, united states research site, dallas, texas, united states research site, madison, wisconsin, united states research site, kogarah, australia research site, melbourne, australia research site, nedlands, australia research site, westmead, australia research site, innsbruck, austria research site, linz, austria research site, st. pölten, austria research site, florianópolis, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, santa maria, brazil research site, santo andre, brazil research site, são josé do rio preto, brazil research site, vitória, brazil research site, hamilton, ontario, canada research site, kingston, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, quebec, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, bengbu, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, hangzhou, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, hohhot, china research site, nanjing, china research site, nanjing, china research site, ningbo, china research site, shanghai, china research site, tianjin, china research site, urumqi, china research site, wuhan, china research site, xi'an, china research site, zhengzhou, china research site, alexandria, egypt research site, assiut, egypt research site, cairo, egypt research site, cairo, egypt research site, cairo, egypt research site, dakahlia, egypt research site, new cairo, egypt research site, shebeen el kom, egypt research site, amiens cedex 1, france research site, angers cedex 9, france research site, besançon, france research site, clichy, france research site, dijon cedex, france research site, nantes, france research site, nice, france research site, paris cedex 12, france research site, pessac, france research site, toulouse cedex 9, france research site, tours cedex 9, france research site, berlin, germany research site, bonn, germany research site, chemnitz, germany research site, freiburg, germany research site, heidelberg, germany research site, köln, germany research site, leipzig, germany research site, lübeck, germany research site, münchen, germany research site, tuebingen, germany research site, hong kong, hong kong research site, hong kong, hong kong research site, hongkong, hong kong research site, kwai chung, hong kong research site, shatin, hong kong research site, bangalore, india research site, bangalore, india research site, hyderabad, india research site, kolkata, india research site, mumbai, india research site, new delhi, india research site, new delhi, india research site, new delhi, india research site, bologna, italy research site, milano, italy research site, milano, italy research site, napoli, italy research site, roma, italy research site, tricase, lecce, italy research site, verona, italy research site, bunkyo-ku, japan research site, fukuoka-shi, japan research site, gifu-shi, japan research site, hiroshima-shi, japan research site, koto-ku, japan research site, kumamoto-shi, japan research site, kurume-shi, japan research site, kyoto-shi, japan research site, kyoto-shi, japan research site, matsuyama-shi, japan research site, mitaka-shi, japan research site, musashino-shi, japan research site, nagasaki-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sapporo-shi, japan research site, sapporo-shi, japan research site, sendai-shi, japan research site, shinagawa-ku, japan research site, shinjuku-ku, japan research site, shinjuku-ku, japan research site, shiwa-gun, japan research site, takasaki-shi, japan research site, tsu-shi, japan research site, wakayama-shi, japan research site, yokohama-shi, japan research site, yokohama-shi, japan research site, busan, korea, republic of research site, daegu, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, lima, peru research site, lima, peru research site, lima, peru research site, lima, peru research site, san isidro, peru research site, manila, philippines research site, muntinlupa city, philippines research site, pasig city, philippines research site, bydgoszcz, poland research site, gdańsk, poland research site, poznan, poland research site, warszawa, poland research site, ponce, puerto rico research site, barnaul, russian federation research site, ekaterinburg, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, obninsk, russian federation research site, saint petersburg, russian federation research site, saint-petersburg, russian federation research site, saint-petersburg, russian federation research site, singapore, singapore research site, singapore, singapore research site, singapore, singapore research site, changhua, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan research site, yunlin, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, pathumthani, thailand research site, ankara, turkey research site, ankara, turkey research site, istanbul, turkey research site, izmir, turkey research site, malatya, turkey research site, hanoi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam research site, hochiminh, vietnam""]",,https://ClinicalTrials.gov/show/NCT03847428,liver
643,644,NCT01901666,assessment of gh-igf-1 axis in children with chronic myelogenous leukemia (cml) in remission,,Unknown status,No Results Available,chronic myelogenous leukemia|short stature,drug: growth hormone,"to know whether patients of cml who are faltering on growth after imatinib therapy are gh deficient or having gh resistance by performing gh provocation tests and igf-1 generation test.|to administer growth hormone therapy to children with cml on imatinib in remission having gh deficiency and to measure igf-1 levels, gain in height and height velocity on gh therapy.",postgraduate institute of medical education and research,All,"Child, Adult, Older Adult",Phase 4,20.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,GH-IGF-1 AXIS AND CML,January 2013,June 2014,December 2014,"July 17, 2013",,"July 17, 2013","['pgimer, chandigarh, india']",,https://ClinicalTrials.gov/show/NCT01901666,blood
644,645,NCT01266811,a phase 3 study of siltuximab or placebo in combination with velcade and dexamethasone in patients with relapsed or refractory multiple myeloma,,Withdrawn,No Results Available,multiple myeloma,"drug: placebo, velcade and dexamethasone|biological: siltuximab, velcade and dexamethasone","progression-free survival (pfs)|overall survival|overall response rate|siltuximab pharmacokinetic evaluations (cmin, cmax) to provide information on the pharmacokinetic profile of siltuximab|dexamethasone pharmacokinetic evaluations (cmin, auc[t1-t2]) from approx. 30 patients from each treatment arm to provide information on the pharmacokinetic profile of dexamethasone|number of adverse events as a measure of safety and tolerability","centocor, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR017743|CNTO328MMY3001,July 2011,April 2014,December 2014,"December 24, 2010",,"January 28, 2013","['iowa city, iowa, united states boston, massachusetts, united states toledo, ohio, united states willow grove, pennsylvania, united states milwaukee, wisconsin, united states adelaide, australia camperdown, australia heidelberg, australia parkville, australia prahran, australia edegem, belgium liège, belgium turnhout, belgium yvoir, belgium plovdiv n/a, bulgaria sofia, bulgaria varna, bulgaria toronto, canada hradec kralove, czech republic liberec, czech republic praha 2, czech republic praha, czech republic gandhinagar guiarat, india hwasun gun, korea, republic of seoul, korea, republic of apeldoorn, netherlands deventer, netherlands zwolle, netherlands christchurch, new zealand grafton, new zealand nz 9 takapuna auckland, new zealand palmerston north, new zealand brzozow, poland gdansk, poland lodz, poland opole, poland wroclaw, poland ankara, turkey bursa, turkey edirne, turkey cherkassy, ukraine dnepropetrovsk, ukraine kharkov, ukraine khmelnitskiy, ukraine kiev, ukraine odessa, ukraine simferopol, ukraine vinnitsa, ukraine nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT01266811,myeloma
645,646,NCT00810680,study of efficacy and safety of valproic acid in chronic lymphocytic leukemia (cll),,Unknown status,No Results Available,chronic lymphocytic leukemia,drug: valproic acid,best clinical response as defined by nciwg criteria for cll|hematological toxicity (graded according to nciwg criteria for cll)|non- hematological toxicity (graded according to nci common toxicity criteria),"all india institute of medical sciences, new delhi",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRCH-VAL-01,September 2008,March 2009,March 2009,"December 18, 2008",,"December 18, 2008","['all india institute of medical sciences, new delhi, delhi, india']",,https://ClinicalTrials.gov/show/NCT00810680,blood
646,647,NCT01721876,"volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy (polo-aml-2)",,Completed,Has Results,"leukemia, myeloid, acute",drug: placebo|drug: volasertib|drug: cytarabine,objective response (or)|overall survival (os)|event-free survival (efs)|relapse-free survival (rfs),boehringer ingelheim,All,65 Years and older   (Older Adult),Phase 3,666.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1230.14|2012-002487-27,"January 29, 2013","August 12, 2014","May 28, 2021","November 6, 2012","November 19, 2021","November 19, 2021","['university of california, los angeles, california, united states st. luke\'s hospital association of duluth, inc., duluth, minnesota, united states henry-joyce cancer clinic, nashville, tennessee, united states the university of texas md anderson cancer center, houston, texas, united states fundacion coir, mendoza, argentina hospital central de salud zenón santillan, san miguel de tucumán, argentina lkh-univ. hospital graz, graz, austria lkh leoben, leoben, austria hospital hietzing, wien, austria az sint-jan brugge, brugge, belgium brussels - univ saint-luc, bruxelles, belgium haine-st-paul - hosp jolimont, haine-saint-paul, belgium jessa ziekenhuis - campus virga jesse, hasselt, belgium uz leuven, leuven, belgium centre hospitalier universitaire de liège, liège, belgium roeselare - hosp az delta, roeselare, belgium yvoir - univ ucl de mont-godinne, yvoir, belgium hospital doutor amaral carvalho, jau, brazil hospital mãe de deus, porto alegre, brazil h.c.da fac. de medicina de ribeirao preto, ribeirao preto, brazil university of alberta hospital (university of alberta), edmonton, alberta, canada vancouver general hospital, vancouver, british columbia, canada maisonneuve-rosemont hospital, montreal, migration data, canada princess margaret cancer centre, toronto, ontario, canada montreal general hospital - mcgill university health centre, montreal, quebec, canada hospital hradec kralove, hradec kralove, czechia university hospital plzen, plzen-lochotin, plzen - lochotin, czechia univ. hospital kralovske vinohrady, praha 10, czechia meilahden sairaala, helsinki, finland tyks, sisätautien klinikka, turku, finland hop amiens-picardie sud, amiens, france hop côte de nacre, caen, france hop michallon, la tronche, france hop andré mignot, le chesnay, france hop dupuytren 1, limoges cedex 1, france ins paoli-calmettes, marseille, france hop nantes, hémato, nantes, nantes, france hop saint-antoine, paris cedex 12, france hop haut-lévêque, pessac, france hop lyon sud, pierre bénite, france hop pontchaillou, rennes cedex 9, france ins universitaire du cancer, toulouse, france universitätsklinikum augsburg, augsburg, germany med. klinik m.s. hämatologie und onkologie, berlin, germany städtisches klinikum braunschweig ggmbh, braunschweig, germany universitätsklinikum erlangen, erlangen, germany ruhrlandklinik, westdeutsches lungenzentrum am universitätsklinikum essen ggmbh, essen, germany universitätsklinikum frankfurt, frankfurt/main, germany universitätsmedizin göttingen, georg-august-universität, göttingen, germany martin-luther-universität halle-wittenberg, halle (saale), germany universitätsklinikum hamburg-eppendorf, hamburg, germany medizinische hochschule hannover, hannover, germany universitätsklinikum heidelberg, heidelberg, germany universitätsklinikum schleswig-holstein, campus kiel, kiel, germany universitätsmedizin der johannes gutenberg-universität mainz, mainz, germany universitätsklinikum gießen und marburg gmbh, marburg, germany klinikum rechts der isar der technischen universität münchen, münchen, germany universitätsklinikum münster, münster, germany universitätsklinikum regensburg, regensburg, germany robert-bosch-krankenhaus gmbh, stuttgart, germany universitätsklinikum ulm, ulm, germany schwarzwald-baar klinikum, villingen-schwenningen, germany general hospital of athens ""g. gennimatas"", athens, greece general hospital of athens ""laiko"", athens, greece univ. gen. hosp. of ioannina, ioannina, greece university of patras medical school, patras, greece general hospital of thessaloniki ""g. papanikolaou"", thessaloniki, greece semmelweis university, budapest, hungary petz aldar hospital, 2nd dept. of internal med., haematology, gyor, hungary univ. of szeged, 2nd dept. of internal med., haematology, szeged, hungary st. john medical college and hospital, bangalore, india tata memorial hospital, mumbai, india a.o. spedali civili di brescia, brescia, italy asst grande ospedale metropolitano niguarda, milano, italy ao città della salute e della, torino, italy national hospital organization nagoya medical center, aichi, nagoya, japan japanese red cross nagoya daini hospital, aichi, nagoya, japan akita university hospital, akita, akita, japan university of fukui hospital, fukui, yoshida-gun, japan kyushu university hospital, fukuoka, fukuoka, japan kobe university hospital, hyogo, kobe, japan tokai university hospital, kanagawa, isehara, japan yokohama city university medical center, kanagawa, yokohama, japan tohoku university hospital, miyagi, sendai, japan nagasaki university hospital, nagasaki, nagasaki, japan kurashiki central hospital, okayama, kurashiki, japan okayama university hospital, okayama, okayama, japan osaka city university hospital, osaka, osaka, japan national cancer center hospital, tokyo, chuo-ku, japan ntt medical center tokyo, tokyo, sinagawa-ku, japan chonnam national university hwasun hospital, hwasun, korea, republic of the catholic university of korea, seoul st.mary\'s hospital, seoul, korea, republic of seoul national university hospital, seoul, korea, republic of severance hospital, seoul, korea, republic of samsung medical center, seoul, korea, republic of asan medical center, seoul, korea, republic of hospital universitario dr jose eleuterio gonzalez, monterrey, mexico amsterdam umc locatie vumc, amsterdam, netherlands haukeland universitetssykehus, bergen, norway sykehuset østfold kalnes, grålum, norway reg. specialist hospital of m. kopernik, dept. haematology, lodz, poland city hospital torun, department of hematology, torun, poland chuln, epe - hospital de santa maria, lisboa, portugal centro hospitalar universitário do porto, epe - hospital de santo antónio, porto, portugal ipo porto francisco gentil, epe, porto, portugal centro hospitalar universitário são joão,epe, porto, portugal regional clinical hospital \'the badge of honor order\', irkutsk, russian federation fsbi ""n.n blokhin med.res.cent.onc.""moh of rf, moscow, russian federation nizhniy novgorod reg. clinical hospital, dept. haematology, nizhniy novgorod, russian federation leningrad reg. clin. hosp., oncohematology department no. 2, st. petersburg, russian federation netcare pretoria east hospital, moreleta park, pretoria, south africa hospital germans trias i pujol, badalona, spain hospital santa creu i sant pau, barcelona, spain hospital vall d\'hebron, barcelona, spain hospital clínic de barcelona, barcelona, spain hospital universitario 12 de octubre, madrid, spain hospital la paz, madrid, spain hospital universitario de salamanca, salamanca, spain hospital politècnic la fe, valencia, spain chang-hua christian hospital, changhua, taiwan national taiwan university hospital, taipei, taiwan mackay memorial hospital, taipei, taiwan']",,https://ClinicalTrials.gov/show/NCT01721876,blood
647,648,NCT03062436,to study the impact of stopping therapy in patients of cml with molecular remission,,Unknown status,No Results Available,chronic myeloid leukemia|treatment free remission,other: stopping the standard drug therpy|diagnostic test: quantitative bcrabl recording every month for first 6 months,disease recurrence,"command hospital, india",All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,27.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFMRC 4714/2016,"August 1, 2017","December 31, 2019",December 2020,"February 23, 2017",,"July 23, 2019","['command hospital, pune, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT03062436,blood
648,649,NCT01394861,endoscopic submucosal dissection (esd)- master slave robotic system - human study,ESD,Completed,No Results Available,endoscopic submucosal dissection,device: esd using master slave robotic system,ease of the procedure|completeness of the procedure|immediate procedure related complications|delayed procedure related complications,"asian institute of gastroenterology, india|nanyang technological university",All,25 Years to 60 Years   (Adult),Early Phase 1,3.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AIG-GI2011-04,June 2011,July 2011,October 2011,"July 15, 2011",,"March 6, 2012","['asian institute of gastroenterology, hyderabad, telangana, india']",,https://ClinicalTrials.gov/show/NCT01394861,
649,650,NCT04411641,nonrelapsing secondary progressive multiple sclerosis (nrspms) study of bruton's tyrosine kinase (btk) inhibitor tolebrutinib (sar442168),HERCULES,Recruiting,No Results Available,secondary progressive multiple sclerosis,drug: tolebrutinib|drug: placebo to match tolebrutinib,6-month confirmed disability progression (cdp)|3-months change in t25-fw and 9-hpt|3-month cdp|new and enlarging t2 hyperintense lesions by mri|time to onset of confirmed disability improvement (cdi)|brain volume loss (bvl)|change in cognitive function|change in multiple sclerosis quality of life-54 (msqol-54)|safety and tolerability|population pharmacokinetics|change in plasma neurofilament light chain (nfl)|changes in serum immunoglobulin level|change in lymphocyte phenotype subsets|change in serum chitinase-3 like protein 1 (chi3l1),sanofi,All,18 Years to 60 Years   (Adult),Phase 3,1290.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC16645|U1111-1246-7768,"September 24, 2020",August 2024,August 2024,"June 2, 2020",,"May 12, 2022","[""investigational site number :8400013, birmingham, alabama, united states investigational site number :8400089, phoenix, arizona, united states investigational site number :8400070, arcadia, california, united states investigational site number :8400101, la jolla, california, united states investigational site number :8400045, long beach, california, united states investigational site number :8400143, los angeles, california, united states investigational site number :8400137, san francisco, california, united states investigational site number :8400088, torrance, california, united states investigational site number :8400059, west hollywood, california, united states investigational site number :8400128, basalt, colorado, united states investigational site number :8400012, denver, colorado, united states investigational site number :8400025, fort collins, colorado, united states investigational site number :8400029, boca raton, florida, united states investigational site number :8400004, maitland, florida, united states investigational site number :8400027, naples, florida, united states investigational site number :8400001, tampa, florida, united states investigational site number :8400006, tampa, florida, united states investigational site number :8400003, savannah, georgia, united states investigational site number :8400011, northbrook, illinois, united states investigational site number :8400023, kansas city, kansas, united states investigational site number :8400110, lexington, kentucky, united states investigational site number :8400072, boston, massachusetts, united states investigational site number :8400014, worcester, massachusetts, united states investigational site number :8400046, detroit, michigan, united states investigational site number :8400033, owosso, michigan, united states investigational site number :8400051, minneapolis, minnesota, united states investigational site number :8400111, rochester, minnesota, united states investigational site number :8400019, saint louis, missouri, united states investigational site number :8400117, las vegas, nevada, united states investigational site number :8400104, teaneck, new jersey, united states investigational site number :8400032, albuquerque, new mexico, united states investigational site number :8400038, new york, new york, united states investigational site number :8400042, stony brook, new york, united states investigational site number :8400005, raleigh, north carolina, united states investigational site number :8400126, fargo, north dakota, united states investigational site number :8400083, cleveland, ohio, united states investigational site number :8400125, cleveland, ohio, united states investigational site number :8400147, columbus, ohio, united states investigational site number :8400002, dayton, ohio, united states investigational site number :8400010, westerville, ohio, united states investigational site number :8400020, portland, oregon, united states investigational site number :8400142, philadelphia, pennsylvania, united states investigational site number :8400016, philadelphia, pennsylvania, united states investigational site number :8400069, greer, south carolina, united states investigational site number :8400024, greer, south carolina, united states investigational site number :8400087, cordova, tennessee, united states investigational site number :8400035, franklin, tennessee, united states investigational site number :8400136, houston, texas, united states investigational site number :8400036, san antonio, texas, united states investigational site number :8400130, burlington, vermont, united states investigational site number :8400028, milwaukee, wisconsin, united states investigational site number :0320002, capital federal, buenos aires, argentina investigational site number :0320001, caba, ciudad de buenos aires, argentina investigational site number :0320005, san miguel de tucuman, tucumán, argentina investigational site number :0320007, buenos aires, argentina investigational site number :0320006, córdoba, argentina investigational site number :0360003, woolloongabba, queensland, australia investigational site number :0360002, kent town, south australia, australia investigational site number :0360004, hobart, tasmania, australia investigational site number :0360001, fitzroy, victoria, australia investigational site number :0360006, heidelberg west, victoria, australia investigational site number :0400003, innsbruck, austria investigational site number :0400001, linz, austria investigational site number :0400004, linz, austria investigational site number :0400002, wien, austria investigational site number :1120004, vitebsk, belarus investigational site number :1120005, vitebsk, belarus investigational site number :0560007, bruxelles, belgium investigational site number :0560003, edegem, belgium investigational site number :0560006, leuven, belgium investigational site number :0560008, liège, belgium investigational site number :0560002, mons, belgium investigational site number :0560001, pelt, belgium investigational site number :1000002, pleven, bulgaria investigational site number :1000005, plovdiv, bulgaria investigational site number :1000004, sofia, bulgaria investigational site number :1000008, sofia, bulgaria investigational site number :1000001, sofia, bulgaria investigational site number :1000006, sofia, bulgaria investigational site number :1000009, sofia, bulgaria investigational site number :1240017, burnaby, british columbia, canada investigational site number :1240011, halifax, nova scotia, canada investigational site number :1240003, ottawa, ontario, canada investigational site number :1240008, toronto, ontario, canada investigational site number :1240006, gatineau, quebec, canada investigational site number :1240005, greenfield park, quebec, canada investigational site number :1240004, montreal, quebec, canada investigational site number :1240015, montreal, quebec, canada investigational site number :1240007, sherbrooke, quebec, canada investigational site number :1240021, quebec, canada investigational site number :1560006, beijing, china investigational site number :1560012, beijing, china investigational site number :1560021, beijing, china investigational site number :1560003, beijing, china investigational site number :1560009, beijing, china investigational site number :1560004, changchun, china investigational site number :1560015, changsha, china investigational site number :1560005, chengdu, china investigational site number :1560019, chongqing, china investigational site number :1560035, fuzhou, china investigational site number :1560001, guangzhou, china investigational site number :1560007, hangzhou, china investigational site number :1560014, shijiazhuang, china investigational site number :1560008, taiyuan, china investigational site number :1560017, xi'an, china investigational site number :2030002, brno, czechia investigational site number :2030004, hradec kralove, czechia investigational site number :2030001, jihlava, czechia investigational site number :2030010, ostrava - poruba, czechia investigational site number :2030005, praha 2, czechia investigational site number :2030003, teplice, czechia investigational site number :2080001, esbjerg, denmark investigational site number :2080005, holstebro, denmark investigational site number :2080004, odense, denmark investigational site number :2460003, helsinki, finland investigational site number :2460001, tampere, finland investigational site number :2460002, turku, finland investigational site number :2500011, bron, france investigational site number :2500005, clermont ferrand, france investigational site number :2500015, gonesse, france investigational site number :2500009, lille, france investigational site number :2500006, montpellier, france investigational site number :2500008, nancy, france investigational site number :2500010, nantes, france investigational site number :2500017, nimes, france investigational site number :2500016, paris, france investigational site number :2500014, paris, france investigational site number :2500007, paris, france investigational site number :2500003, rennes, france investigational site number :2500001, strasbourg, france investigational site number :2500012, toulouse, france investigational site number :2760005, bayreuth, germany investigational site number :2760009, berlin, germany investigational site number :2760001, dresden, germany investigational site number :2760012, essen, germany investigational site number :2760002, gießen, germany investigational site number :2760010, halle (saale), germany investigational site number :2760006, hannover, germany investigational site number :2760008, münster, germany investigational site number :2760004, rostock, germany investigational site number :2760011, ulm, germany investigational site number :3000001, athens, greece investigational site number :3000006, athens, greece investigational site number :3000002, athens, greece investigational site number :3000007, athens, greece investigational site number :3000004, larissa, greece investigational site number :3000003, thessaloniki, greece investigational site number :3000005, thessaloniki, greece investigational site number :3480008, budapest, hungary investigational site number :3480004, budapest, hungary investigational site number :3480007, budapest, hungary investigational site number :3480002, pécs, hungary investigational site number :3480001, szeged, hungary investigational site number :3480006, tatabánya, hungary investigational site number :3560007, gurgaon, india investigational site number :3560003, gurgaon, india investigational site number :3560005, india, india investigational site number :3560004, mangaluru, india investigational site number :3560006, new delhi, india investigational site number :3560002, new delhi, india investigational site number :3760002, ashkelon, israel investigational site number :3760003, haifa, israel investigational site number :3760008, jerusalem, israel investigational site number :3760001, tel hashomer, israel investigational site number :3760004, zefat, israel investigational site number :3800011, bergamo, italy investigational site number :3800007, cagliari, italy investigational site number :3800012, firenze, italy investigational site number :3800016, firenze, italy investigational site number :3800014, genova, italy investigational site number :3800013, l'aquila, italy investigational site number :3800004, milano, italy investigational site number :3800001, milano, italy investigational site number :3800010, milano, italy investigational site number :3800008, pavia, italy investigational site number :3800005, roma, italy investigational site number :3800009, roma, italy investigational site number :3920016, chiba-shi, chiba, japan investigational site number :3920022, morioka-shi, iwate, japan investigational site number :3920011, kyoto-shi, kyoto, japan investigational site number :3920020, sendai-shi, miyagi, japan investigational site number :3920005, niigata-shi, niigata, japan investigational site number :3920004, moriguchi-shi, osaka, japan investigational site number :3920001, osaka-shi, osaka, japan investigational site number :3920018, kawagoe-shi, saitama, japan investigational site number :3920003, kodaira-shi, tokyo, japan investigational site number :3920010, ota-ku, tokyo, japan investigational site number :3920023, sagamihara-shi, japan investigational site number :4400003, kaunas, lithuania investigational site number :4400002, klaipeda, lithuania investigational site number :4400001, vilnius, lithuania investigational site number :5280001, amsterdam, netherlands investigational site number :5280003, breda, netherlands investigational site number :5280006, groningen, netherlands investigational site number :5280002, sittard-geleen, netherlands investigational site number :5780003, bergen, norway investigational site number :5780002, namsos, norway investigational site number :5780001, oslo, norway investigational site number :6160003, bydgoszcz, kujawsko-pomorskie, poland investigational site number :6160001, lodz, lódzkie, poland investigational site number :6160005, warszawa, mazowieckie, poland investigational site number :6160006, warszawa, mazowieckie, poland investigational site number :6160002, katowice, slaskie, poland investigational site number :6160007, katowice, slaskie, poland investigational site number :6160004, katowice, slaskie, poland investigational site number :6160008, plewiska, wielkopolskie, poland investigational site number :6160012, lublin, poland investigational site number :6160011, zabrze, poland investigational site number :6200001, braga, portugal investigational site number :6200011, lisboa, portugal investigational site number :6200007, lisboa, portugal investigational site number :6200006, lisboa, portugal investigational site number :6200002, matosinhos, portugal investigational site number :6200010, porto, portugal investigational site number :6420008, bucuresti, romania investigational site number :6420004, campulung, romania investigational site number :6420006, cluj-napoca, romania investigational site number :6420003, constanta, romania investigational site number :6420013, oradea, romania investigational site number :6420005, sibiu, romania investigational site number :6420001, targu mures, romania investigational site number :6420002, timisoara, romania investigational site number :6430018, barnaul, russian federation investigational site number :6430023, ekaterinburg, russian federation investigational site number :6430025, kaliningrad, russian federation investigational site number :6430003, kazan, russian federation investigational site number :6430022, kemerovo, russian federation investigational site number :6430017, kirov, russian federation investigational site number :6430024, krasnoyarsk, russian federation investigational site number :6430020, moscow, russian federation investigational site number :6430002, moscow, russian federation investigational site number :6430013, moscow, russian federation investigational site number :6430001, moscow, russian federation investigational site number :6430008, moscow, russian federation investigational site number :6430021, nizhny novgorod, russian federation investigational site number :6430006, nizhny novgorod, russian federation investigational site number :6430005, novosibirsk, russian federation investigational site number :6430026, perm, russian federation investigational site number :6430007, pyatigorsk, russian federation investigational site number :6430016, rostov-on-don, russian federation investigational site number :6430004, saint-petersburg, russian federation investigational site number :6430009, samara, russian federation investigational site number :6430019, saransk, russian federation investigational site number :6430014, smolensk, russian federation investigational site number :6430011, st-petersburg, russian federation investigational site number :6430012, tyumen, russian federation investigational site number :6430010, ufa, russian federation investigational site number :7240007, sevilla, andalucia, spain investigational site number :7240013, barcelona, barcelona [barcelona], spain investigational site number :7240016, barcelona, barcelona [barcelona], spain investigational site number :7240015, lleida / lleida, catalunya [cataluña], spain investigational site number :7240014, salt, girona [gerona], spain investigational site number :7240004, majadahonda, madrid, spain investigational site number :7240001, pozuelo de alarcón, madrid, spain investigational site number :7240012, donostia, pais vasco, spain investigational site number :7240008, córdoba, spain investigational site number :7240005, madrid, spain investigational site number :7240002, madrid, spain investigational site number :7240003, madrid, spain investigational site number :7240010, murcia, spain investigational site number :7240009, málaga, spain investigational site number :7240011, valencia, spain investigational site number :7920005, eskisehir, turkey investigational site number :7920010, hatay, turkey investigational site number :7920002, istanbul, turkey investigational site number :7920009, istanbul, turkey investigational site number :7920007, istanbul, turkey investigational site number :7920006, istanbul, turkey investigational site number :7920003, istanbul, turkey investigational site number :7920013, izmir, turkey investigational site number :7920001, izmit, turkey investigational site number :7920011, kuttahta, turkey investigational site number :7920012, mersin, turkey investigational site number :7920008, trabzon, turkey investigational site number :8040008, chernivtsi, ukraine investigational site number :8040016, chernivtsi, ukraine investigational site number :8040003, dnipro, ukraine investigational site number :8040010, ivano-frankivsk, ukraine investigational site number :8040007, kharkiv, ukraine investigational site number :8040011, kharkiv, ukraine investigational site number :8040012, kharkiv, ukraine investigational site number :8040013, kyiv, ukraine investigational site number :8040005, lutsk, ukraine investigational site number :8040009, lviv, ukraine investigational site number :8040004, lviv, ukraine investigational site number :8040002, odesa, ukraine investigational site number :8040006, vinnytsia, ukraine investigational site number :8040014, zhytormyr, ukraine investigational site number :8260003, exeter, devon, united kingdom investigational site number :8260008, plymouth, devon, united kingdom investigational site number :8260018, london, london, city of, united kingdom investigational site number :8260010, swansea, neath port talbot, united kingdom investigational site number :8260012, nottingham, nottinghamshire, united kingdom investigational site number :8260013, oxford, oxfordshire, united kingdom investigational site number :8260009, bristol, united kingdom investigational site number :8260001, cardiff, united kingdom investigational site number :8260014, newcastle upon tyne, united kingdom investigational site number :8260019, salford, united kingdom investigational site number :8260005, tooting, london, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04411641,
650,651,NCT01514188,preliminary efficacy and safety of inno-206 compared to doxorubicin in advanced soft tissue sarcoma,,Unknown status,No Results Available,metastatic soft tissue sarcoma|locally advanced soft tissue sarcoma|unresectable soft tissue sarcoma,drug: inno-206|drug: doxorubicin,progression-free survival|overall survival|progression-free survival at 4 and 6 months|objective overall response rate (orr)|safety measures.,cytrx,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2,105.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INNO-206-P2-STS-01,December 2011,December 2013,April 2014,"January 23, 2012",,"September 13, 2013","['sarcoma oncology center, santa monica, california, united states stanford university, stanford, california, united states university of iowa, iowa city, iowa, united states pennsylvania hematology oncology associates, philadelphia, pennsylvania, united states ctrc institute for drug development, university of texas, san antonio, texas, united states royal north shore, st. leonards, new south wales, australia epworth healthcare clinical trials and research centre, richmond, victoria, australia border medical oncology, wodonga, victoria, australia royal hobart hospital, hobart, australia royal perth hospital, perth, australia mount medical centre, perth, australia the crown princess mary cancer centre westmead, sydney, australia state health centre oncology department, budapest, hungary hemato oncology clinic, vedanta institute of medical science, navrangpura, ahmedaba, india delhi state cancer institute, dilshad garden, delhi, india hemato oncology clinic, vedanta institute of medical science, navrangpura ahmedabad, gujarat, india m.s. ramaiah medical college and hospitals, bangalore, karnataka, india curie manavata cancer centre, nashik, maharashtra, india delhi state cancer institute, pune, maharashtra, india jehangir clinical development centre pvt ltd, pune, maharashtra, india noble hospital clinical research department 1st floor, hadapsar, pune maharashtra, india christian medical college, vellore, tami nadu, india tata memorial hospital, department of medical oncology, mumbai, india oncological institute ""prof. dr. i. chiricuta"", cluj-napoca, cluj-napoca, county cluj, romania clinical county hospital mures, medical oncology department, targu-mures, county mures, romania spitalul judetean de urgenta ""dr. constantin opris"" baia-mare, sectia oncologie, baia-mare, judet maramures, romania medisprof srl, cluj-napoca, romania state healthcare institution ""republican clinical oncological center of the ministry of health of republic of tatarstan"", kazan, republic of tatarstan, russian federation blokhin cancer research center, moscow, russian federation municipal institution ""chernivtsi regional clinical oncologic dispensary"",, chernivtsi, ukraine municipal institution ""dnipropetrovsk city multi-field clinical hospital #4"" of dnipropetrovsk regional councel, dnipropetrovsk, ukraine state institution ""institute of medical radiology named after s.p.grygoryev of national academy of medical sciences of ukraine"",, kharliv, ukraine lviv state oncological regional treatment - diagnostics center, chemotherapy department, lviv, ukraine vinnytsya regional clinical oncologic dispensary, surgical department, vinnytsya, ukraine']",,https://ClinicalTrials.gov/show/NCT01514188,sarcoma
651,652,NCT01168791,study of palifosfamide-tris in combination with doxorubicin in patients with front-line metastatic soft tissue sarcoma,PICASSO III,Completed,No Results Available,soft tissue sarcoma,drug: doxorubicin in combination with palifosfamide-tris|drug: doxorubicin in combination with placebo,"progression free survival followed by overall survival|quality of life, as assessed by eortc qlq-c30 and eq-5d questionnaires|safety and tolerability as evaluated using ctcae v 4.0",alaunos therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,447.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IPM3001,July 2010,March 2013,March 2013,"July 23, 2010",,"July 18, 2013","['birmingham, alabama, united states arizona oncology associates, phoenix, arizona, united states scottsdale, arizona, united states arizona cancer center, tucson, arizona, united states university of arkansas for medical sciences, little rock, arkansas, united states university of california, los angeles, los angeles, california, united states los angeles, california, united states university of california, irvine, orange, california, united states pomona, california, united states sarcoma oncology center, santa monica, california, united states university of colorado cancer center, aurora, colorado, united states rocky mountain cancer centers, denver, colorado, united states medical oncology hematology consultants, newark, delaware, united states medstar research institute, washington, district of columbia, united states washington, district of columbia, united states jacksonville, florida, united states orlando, florida, united states moffitt cancer center, tampa, florida, united states palm beach cancer institute, west palm beach, florida, united states emory, atlanta, georgia, united states medical college of georgia, augusta, georgia, united states kootenai cancer center, post falls, idaho, united states chicago, illinois, united states park ridge, illinois, united states indiana university simon cancer center, indiannapolis, indiana, united states university of iowa hospital and clinics, iowa city, iowa, united states kansas city cancer center, overland park, kansas, united states new orleans, louisiana, united states lsu health sciences center, feist-weiller cancer center, shreveport, louisiana, united states baltimore, maryland, united states dana-farber cancer institute, boston, massachusetts, united states ann arbor, michigan, united states mayo clinic, rochester, minnesota, united states st.louis university, st. louis, missouri, united states washington university school of medicine, st. louis, missouri, united states las vegas, nevada, united states hackensack, new jersey, united states morristown, new jersey, united states saint barnabas, west orange, new jersey, united states albuquerque, new mexico, united states bronx, new york, united states mount sinai school of medicine, new york, new york, united states columbia university medical center, new york, new york, united states university of rochester, rochester, new york, united states university of north carolina, chapel hill, north carolina, united states durham, north carolina, united states raleigh, north carolina, united states wake forest university health sciences, winston-salem, north carolina, united states summa health system, akron, ohio, united states uc cancer institute, cinncinnati, ohio, united states cleveland clinic, cleveland, ohio, united states the ohio state university medical center, columbus, ohio, united states cancer care associates, tulsa, oklahoma, united states oregon health and science university, portland, oregon, united states bethelehem, pennsylvania, united states fox chase cancer center, philadelphia, pennsylvania, united states pennsylvania oncology/hematology associates, philadelphia, pennsylvania, united states university of pittsburgh, pittsburg, pennsylvania, united states providence, rhode island, united states charleston, south carolina, united states cancer centers of the carolinas, greenville, south carolina, united states memphis, tennessee, united states nashville, tennessee, united states texas oncology, bedford, texas, united states texas oncology - medical city dallas, dallas, texas, united states cancer therapy and research center, san antonio, texas, united states utah cancer specialists, salt lake city, utah, united states burlington, vermont, united states virginia cancer specialists, fairfax, virginia, united states university of washington/seattle cancer care alliance, seattle, washington, united states bellin cancer center, green bay, wisconsin, united states university of wisconsin, madison, wisconsin, united states milwaukee, wisconsin, united states ciudad de buenos aires, argentina cordoba, argentina ramos mejia, argentina instituto caici, rosario, argentina sante fe, argentina north adelaide oncology, adelaide, australia royal adelaide hospital, adelaide, australia camperdown, australia east melbourne, australia the canberra hospital, garran, australia garran, australia kurralta park, australia nedlands, australia prince of wales hospital, randwick, australia princess alexandra hospital, woolloongabba, australia antwerp, belgium bruxelles, belgium leuven, belgium liege, belgium institution name: hospital de câncer de barretos - fundação pioxii, barretos, brazil belo horizonte, brazil santa casa da misericórdia de curitiba, curitiba, brazil florianopolis, brazil jau, brazil hospital da cidade de passo fundo, passo fundo, brazil hospital das clínicas de porto alegre, porto alegre, brazil irmandade da santa casa de misericórdia de porto alegre, porto alegre, brazil centro de oncologia da bahia, salvador, brazil sao paulo, brazil calgary, alberta, canada cross cancer institute, edmonton, alberta, canada mount sinai hospital, toronto, ontario, canada jewish general hospital, montreal, quebec, canada mcgill university, montreal, quebec, canada santiago, chile instituto clínico oncológico del sur, temuco, chile vina del mar, chile bogota, colombia medellin, colombia monteria, colombia angers, france bordeaux, france institut paoli calmettes, marseilles, france marseille, france montpellier, france nice, france paris, france toulouse, france villejuif, france helios klinikum berlin buch, bad sarrow, germany hannover, germany universitätsklinikum köln, koln, germany mannheim, germany tuebingen university hospital, tuebingen, germany guatemala, guatemala jaipur, india mumbai, india nasik, india pune, india secunderabad, india haifa, israel shaare zedek medical center, jerusalem, israel jerusalem, israel petach tikva, israel ramat gan, israel ramat-gan, israel tel aviv, israel candiolo, italy humanitas cancer center, rozzana, italy ospedale gradenigo oncology, torino, italy centro hemato oncologico paitilla, panama, panama medical and research center, panama, panama wojewodzkie centrum onkologii, gdansk, poland gilwice, poland centrum onkologii instytut, warszawa, poland bucharest, romania cluj napoca, romania craiova, romania moscow, russian federation obninsk, russian federation st. petersburg, russian federation yaroslavl, russian federation singapore, singapore badalona, spain madrid, spain hospital universitario puerta de hierro, majadahonda, spain valencia, spain the royal marsden nhs foundation trust sarcoma, london, united kingdom christie hospital nhs foundation trust, manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT01168791,sarcoma
652,653,NCT00943072,vascular endothelial growth factor (vegf) trap-eye: investigation of efficacy and safety in central retinal vein occlusion (crvo),,Completed,Has Results,macular edema secondary to central retinal vein occlusion,biological: vegf trap-eye 2.0mg|drug: sham,"percentage of participants who gained at least 15 letters in bcva at week 24 as measured by etdrs letter score|change from baseline in bcva as measured by etdrs letter score at week 24 - last observation carried forward (locf)|change from baseline in central retinal thickness (crt) at week 24 - locf|percentage of participants progressing to any of the following: anterior segment neovascularization, new vessels of the disc (nvd) or new vessels elsewhere (nve) during the first 24 weeks|change from baseline in the nei vfq-25 in total score at week 24 (locf)",regeneron pharmaceuticals|bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,189.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VGFT-OD-0819,July 2009,October 2010,April 2012,"July 21, 2009","May 27, 2013","May 27, 2013","['phoenix, arizona, united states phoenix, arizona, united states tucson, arizona, united states arcadia, california, united states beverly hills, california, united states la jolla, california, united states mountain view, california, united states oakland, california, united states sacramento, california, united states torrance, california, united states new london, connecticut, united states altamonte springs, florida, united states fort lauderdale, florida, united states fort myers, florida, united states fort myers, florida, united states miami, florida, united states palm beach gardens, florida, united states winter haven, florida, united states augusta, georgia, united states chicago, illinois, united states wichita, kansas, united states baltimore, maryland, united states hagerstown, maryland, united states towson, maryland, united states boston, massachusetts, united states grand rapids, michigan, united states jackson, michigan, united states lincoln, nebraska, united states las vegas, nevada, united states northfield, new jersey, united states toms river, new jersey, united states rochester, new york, united states winston-salem, north carolina, united states cleveland, ohio, united states oklahoma city, oklahoma, united states portland, oregon, united states salem, oregon, united states kingston, pennsylvania, united states pittsburgh, pennsylvania, united states west columbia, south carolina, united states rapid city, south dakota, united states nashville, tennessee, united states abilene, texas, united states ft worth, texas, united states houston, texas, united states san antonio, texas, united states vancouver, british columbia, canada victoria, british columbia, canada halifax, nova scotia, canada london, ontario, canada mississauga, ontario, canada toronto, ontario, canada medellin, antioquia, colombia bogota, colombia hyderabad, a.p., india bangalore, karnataka, india kolkata, west bengal, india kfar-saba, israel petah tikva, israel rehovot, israel tel aviv, israel']",,https://ClinicalTrials.gov/show/NCT00943072,
653,654,NCT00610272,optimization of radiotherapy in treatment of painful bone metastasis,bone mets,Completed,No Results Available,pain|bone metastasis,radiation: radiotherapy,pain relief (response rate) at 4 weeks|onset and duration of pain relief in responders|toxicity|quality of life|rates of pathological fractures and spinal cord compression,international atomic energy agency,All,"18 Years and older   (Adult, Older Adult)",Phase 3,650.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E33028,January 2008,April 2012,August 2012,"February 7, 2008",,"August 7, 2013","['centre pierre et marie curie, centre hospitalier universitaire mustapha (chu), alger, algeria irmandade de santa casa de misericordia de porto alegre, porto alegre, brazil misr oncology center (moc), cairo, egypt tata memorial hospital, mumbai, india institute of oncology, university of vilinius, vilnius, lithuania institute of radiotherapy and oncology, skopje, macedonia, the former yugoslav republic of instituto nacional de cancerología (incan), ciudad de mexico, mexico institute of oncology and radiology, belgrade, serbia hospital clinic universidad de barcelona, barcelona, spain hospital son dureta, palma de mallorca, spain institut national de cancer salah azaiz, tunis, tunisia mount vernon cancer centre, northwood, united kingdom']",,https://ClinicalTrials.gov/show/NCT00610272,pain
654,655,NCT02703064,furocyst - poly cystic ovary syndrome study,,Completed,No Results Available,pcos,dietary supplement: furocyst,reduction in overian volume & number of overian cysts|restoration of normal menstrual cycle,chemical resources,Female,18 Years to 45 Years   (Adult),Not Applicable,107.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Protocol No. CR-PCOS/1-15,"March 26, 2015",July 2017,July 2017,"March 9, 2016",,"September 15, 2017","[""dept of obs & gynae, king george's medical university, lucknow, up, india, lucknow, uttar pradesh, india""]",,https://ClinicalTrials.gov/show/NCT02703064,ovari
655,656,NCT00699517,a study of ave8062 in advanced-stage soft tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies,,Completed,No Results Available,sarcoma,drug: ombrabulin (ave8062)|drug: placebo,progression free survival|overall survival|response rate|safety profile,sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,355.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC10145|EudraCT 2007-003592-39,June 2008,April 2013,April 2013,"June 18, 2008",,"December 21, 2015","['investigational site number 840004, santa monica, california, united states investigational site number 840003, orlando, florida, united states investigational site number 840005, maywood, illinois, united states investigational site number 840002, newark, new jersey, united states investigational site number 840007, philadelphia, pennsylvania, united states investigational site number 840001, san antonio, texas, united states investigational site number 056001, bruxelles, belgium investigational site number 056004, haine-saint-paul, belgium investigational site number 056005, liège, belgium investigational site number 076007, belo horizonte, brazil investigational site number 076008, goiania, brazil investigational site number 076003, ijui, brazil investigational site number 076004, jau, brazil investigational site number 076006, novo hamburgo, brazil investigational site number 076002, porto alegre, brazil investigational site number 076005, porto alegre, brazil investigational site number 076009, rio de janeiro, brazil investigational site number 250008, bordeaux, france investigational site number 250002, dijon, france investigational site number 250004, lille, france investigational site number 250001, lyon cedex 03, france investigational site number 250010, marseille, france investigational site number 250006, montpellier cedex, france investigational site number 250007, nice cedex 02, france investigational site number 250005, rennes, france investigational site number 250003, saint cloud, france investigational site number 250012, saint priest en jarez, france investigational site number 250009, saint-herblain, france investigational site number 348001, budapest, hungary investigational site number 348002, debrecen, hungary investigational site number 356005, bangalore, india investigational site number 356003, hyderabad, india investigational site number 356004, new delhi, india investigational site number 380001, aviano, italy investigational site number 380003, milano, italy investigational site number 380004, milano, italy investigational site number 380002, rozzano, italy investigational site number 891001, belgrade, serbia investigational site number 891002, sremska kamenica, serbia investigational site number 724004, barcelona, spain investigational site number 724001, madrid, spain investigational site number 724003, pamplona, spain investigational site number 826001, bebington, united kingdom investigational site number 826003, bristol, united kingdom investigational site number 826002, newcastle upon tyne, united kingdom']",,https://ClinicalTrials.gov/show/NCT00699517,sarcoma
656,657,NCT03778957,a global study to evaluate transarterial chemoembolization (tace) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma,EMERALD-1,"Active, not recruiting",No Results Available,hepatocellular carcinoma,drug: durvalumab|drug: bevacizumab|other: placebo|procedure: transarterial chemoembolization (tace),progression free survival (pfs) for arm b vs arm c|progression free survival (pfs) for arm a vs arm c|overall survival (os)|health status/quality of life measured by european organization for research and treatment of cancer (eortc) 30-item core quality of life questionnaire (qlq-c30)|disease-related symptoms measured by european organization for research and treatment of cancer (eortc) 18-item hepatocellular cancer health-related quality of life questionnaire (qlq-hcc18),astrazeneca,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 3,724.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D933GC00001|2018-002134-20,"November 30, 2018","September 19, 2022","August 19, 2024","December 19, 2018",,"April 14, 2022","[""research site, mobile, alabama, united states research site, phoenix, arizona, united states research site, tucson, arizona, united states research site, costa mesa, california, united states research site, la jolla, california, united states research site, orange, california, united states research site, aurora, colorado, united states research site, washington, district of columbia, united states research site, jacksonville, florida, united states research site, miami, florida, united states research site, miami, florida, united states research site, honolulu, hawaii, united states research site, chicago, illinois, united states research site, indianapolis, indiana, united states research site, westwood, kansas, united states research site, shreveport, louisiana, united states research site, boston, massachusetts, united states research site, boston, massachusetts, united states research site, detroit, michigan, united states research site, rochester, minnesota, united states research site, saint louis, missouri, united states research site, omaha, nebraska, united states research site, stony brook, new york, united states research site, charlotte, north carolina, united states research site, durham, north carolina, united states research site, winston-salem, north carolina, united states research site, cleveland, ohio, united states research site, portland, oregon, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, sioux falls, south dakota, united states research site, knoxville, tennessee, united states research site, memphis, tennessee, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, morgantown, west virginia, united states research site, milwaukee, wisconsin, united states research site, benowa, australia research site, box hill, australia research site, camperdown, australia research site, clayton, australia research site, herston, australia research site, liverpool, australia research site, melbourne, australia research site, barretos, brazil research site, florianópolis, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, santa maria, brazil research site, sao paulo, brazil research site, são josé do rio preto, brazil research site, vitória, brazil research site, hamilton, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, fuzhou, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, guangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, nanchang, china research site, nanjing, china research site, nanjing, china research site, nantong, china research site, neijiang, china research site, shanghai, china research site, shanghai, china research site, shenyang, china research site, shenzhen, china research site, tianjin, china research site, wuhan, china research site, wuhan, china research site, xi'an, china research site, zhengzhou, china research site, zhuhai, china research site, bobigny, france research site, clichy, france research site, grenoble cedex 9, france research site, montpellier cedex 5, france research site, nice cedex 3, france research site, paris cedex 13, france research site, pessac, france research site, poitiers, france research site, toulouse cedex 9, france research site, vandoeuvre les nancy, france research site, hong kong, hong kong research site, shatin, hong kong research site, bangalore, india research site, bengaluru, india research site, hyderabad, india research site, kolkata, india research site, kolkata, india research site, madurai, india research site, mumbai, india research site, nasik, india research site, pune, india research site, surat, india research site, vijayawada, india research site, vishakhapatnam, india research site, arezzo, italy research site, brescia, italy research site, milano, italy research site, milano, italy research site, pisa, italy research site, bunkyo-ku, japan research site, chiba-shi, japan research site, chuo-ku, japan research site, fukuoka-shi, japan research site, hiroshima-shi, japan research site, kurume-shi, japan research site, musashino-shi, japan research site, nagoya-shi, japan research site, okayama, japan research site, osaka-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sapporo-shi, japan research site, shiwa-gun, japan research site, tsu-shi, japan research site, yokohama-shi, japan research site, busan, korea, republic of research site, daegu, korea, republic of research site, goyang-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, alc. cuauhtémoc, mexico research site, culiacan, mexico research site, guadalajara, mexico research site, mexico, distrito federal+52 55, mexico research site, mexico, mexico research site, monterrey, mexico research site, monterrey, mexico research site, mérida, mexico research site, tuxtla gutierrez, mexico research site, barnaul, russian federation research site, ekaterinburg, russian federation research site, kazan, russian federation research site, moscow, russian federation research site, novosibirsk, russian federation research site, obninsk, russian federation research site, sankt-peterburg, russian federation research site, st. petersburg, russian federation research site, bukit merah, singapore research site, córdoba, spain research site, madrid, spain research site, pamplona, spain research site, san sebastián(guipuzcoa), spain research site, kaohsiung, taiwan research site, liou ying township, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan research site, yunlin, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, phisanulok, thailand research site, hanoi, vietnam research site, hanoi, vietnam research site, ho chi minh city, vietnam research site, ho chi minh, vietnam""]",,https://ClinicalTrials.gov/show/NCT03778957,liver
657,658,NCT03225586,prospective urban rural epidemiology study,PURE,Recruiting,No Results Available,"cardiovascular diseases|risk factor, cardiovascular|health behavior|environmental exposure|lung diseases|cancer|injuries|renal disease|communicable disease",,incident cardiovascular disease|incident cancer|incident copd|incident asthma|pneumonia|respiratory outcomes|all cause hospitalizations|kidney disease|all cause and cause specific mortality|incident diabetes|obesity|hypertension|incident injuries,population health research institute|canadian institutes of health research (cihr)|heart and stroke foundation of ontario,All,"35 Years to 70 Years   (Adult, Older Adult)",,200000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PURE,"January 1, 2002","December 31, 2030","December 31, 2030","July 21, 2017",,"June 19, 2020","[""estudios clinicos latinoamerica ecla, rosario, santa fe, argentina independent university, bangladesh, dhaka, bangladesh dante pazzanese institute of cardiology, são paulo, brazil simon fraser university, vancouver, british columbia, canada population health research institute, hamilton, ontario, canada university of ottawa, ottawa, ontario, canada université laval institut universitaire de cardiologie et de pneumologie de québec, quebec city, quebec, canada universidad de la frontera, temuco, chile state key laboratory of cardiovascular disease, fuwai hospital, beijing, china fundacion oftalmologica de santander - foscal, floridablanca, santander, colombia st john's research institute, bangalore, karnataka, india health action by people, thiruvananthapuram, kerala, india eternal heart care centre and research institute, jaipur, rajasthan, india madras diabetes research foundation, chennai, tamil nadu, india post graduate institute of medical education and research (pgimer), chandigarh, india isfahan university of medical sciences, isfahan, iran, islamic republic of research institute of cardiology & internal diseases, almaty, kazakhstan kyrgyz society of cardiology, national center of cardiology and internal disease, bishkek, kyrgyzstan universiti teknologi mara, ucsi universiti, kuala lumpur, malaysia university kebangsaan malaysia, kuala lumpur, malaysia aga khan university, karachi, pakistan birzeit university, birzeit, ramallah, palestinian territory, occupied universidad peruana cayetano heredia, lima, peru university of philippines, section of adult medicine & medical research unit, manila, philippines wroclaw medical university & department of internal medicine, wrocław, poland research institute for complex issues of cardiovascular diseases, kemerovo, russian federation king saud university, riyadh, saudi arabia school of public health, university of the western cape, bellville, south africa north-west university, potchefstroom, south africa sahlgrenska university hospital/östra hospital, göteborg, sweden pamoja tunaweza women center, moshi, tanzania istanbul medeniyet university, i̇stanbul, turkey dubai medical university, dubai, united arab emirates university of zimbabwe college of health sciences, harare, zimbabwe""]",,https://ClinicalTrials.gov/show/NCT03225586,
658,659,NCT04142398,incidence of hpv infection and hpv-associated disease in screening indian men who have sex with hiv-positive men,,Not yet recruiting,No Results Available,hiv infection|human papillomavirus infection|human papillomavirus-related carcinoma,other: cytology specimen collection procedure|procedure: high resolution anoscopy with biopsy|other: laboratory biomarker analysis|procedure: medical examination|procedure: physical examination|other: questionnaire administration,"prevalence of hpv-associated high-grade anal intraepithelial neoplasia (hgain)|prevalence of premalignant lesions of the penis|prevalence and incidence of human papillomavirus (hpv)|the proportion of men with hgain at baseline according to presence and absence of hpv infection (types 6, 11, 16, and/or 18).|the proportion of men with premalignant lesions of the penis at baseline according to reported number of sex partners in the last 6 months|the proportion of men with hgain at baseline according to reported number of sex partners in the last 6 months|the proportion of men with premalignant lesions of the penis at baseline according cd4+ level.|the proportion of men with hgain at baseline according cd4+ level.|the proportion of men with premalignant lesions of the penis at baseline according to presence and absence of hpv infection (types 6, 11, 16, and/or 18).",aids malignancy consortium|national cancer institute (nci),Male,"18 Years and older   (Adult, Older Adult)",,246.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,AMC-094|NCI-2016-01347|R21CA167653|UM1CA121947,"April 30, 2022","December 31, 2024","December 31, 2024","October 29, 2019",,"February 17, 2022","['ucsf medical center-parnassus, san francisco, california, united states tata memorial hospital, mumbai, india udaan trust, mumbai, india']",,https://ClinicalTrials.gov/show/NCT04142398,
659,660,NCT03299244,head-to-head study of etelcalcetide and cinacalcet in asian hemodialysis patients with secondary hyperparathyroidism (shpt),,Completed,Has Results,secondary hyperparathyroidism|chronic kidney disease,drug: etelcalcetide|drug: cinacalcet,percentage of participants with > 30% reduction from baseline in mean predialysis intact parathyroid hormone during the efficacy assessment phase - non-inferiority analysis|percentage of participants with > 50% reduction from baseline in mean predialysis ipth during the efficacy assessment phase|percentage of participants with > 30% reduction from baseline in mean predialysis ipth during the efficacy assessment phase - superiority analysis|percent change from baseline in mean predialysis corrected calcium during the efficacy assessment phase|percentage of participants with mean predialysis serum phosphorus ≤ 4.5 mg/dl during the efficacy assessment phase,amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,637.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20150238,"May 15, 2018","April 8, 2020","April 8, 2020","October 3, 2017","April 30, 2021","April 30, 2021","['research site, beijing, beijing, china research site, lanzhou, gansu, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, guangzhou, guangdong, china research site, shenzhen, guangdong, china research site, zhanjiang, guangdong, china research site, nanning, guangxi, china research site, nanning, guangxi, china research site, zhengzhou, henan, china research site, zhengzhou, henan, china research site, wuhan, hubei, china research site, wuhan, hubei, china research site, wuhan, hubei, china research site, changsha, hunan, china research site, changsha, hunan, china research site, changzhou, jiangsu, china research site, nanjing, jiangsu, china research site, nanjing, jiangsu, china research site, wuxi, jiangsu, china research site, changchun, jilin, china research site, changchun, jilin, china research site, dalian, liaoning, china research site, dalian, liaoning, china research site, dalian, liaoning, china research site, shenyang, liaoning, china research site, shenyang, liaoning, china research site, xian, shaanxi, china research site, qingdao, shandong, china research site, shanghai, shanghai, china research site, shanghai, shanghai, china research site, shanghai, shanghai, china research site, shanghai, shanghai, china research site, taiyuan, shanxi, china research site, chengdu, sichuan, china research site, chengdu, sichuan, china research site, tianjin, tianjin, china research site, tianjin, tianjin, china research site, urumqi, xinjiang, china research site, hangzhou, zhejiang, china research site, hangzhou, zhejiang, china research site, hong kong, hong kong research site, kowloon, hong kong research site, new territories, hong kong research site, new delhi, delhi, india research site, new delhi, delhi, india research site, new delhi, delhi, india research site, new delhi, delhi, india research site, ahmedabad, gujarat, india research site, nadiad, gujarat, india research site, belagavi, karnataka, india research site, mysuru, karnataka, india research site, kozhikode, kerala, india research site, kozhikode, kerala, india research site, chandigarh, punjab, india research site, chennai, tamil nadu, india research site, lucknow, uttar pradesh, india research site, dehradun, uttaranchal, india research site, wardha, india research site, busan, korea, republic of research site, busan, korea, republic of research site, daegu, korea, republic of research site, gumi-si, gyeongsangbuk-do, korea, republic of research site, guri-si, gyeonggi-do, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, ipoh, perak, malaysia research site, george town, pinang, malaysia research site, kuching, sarawak, malaysia research site, batu caves, selangor (incl. putrajaya), malaysia research site, changhua, taiwan research site, kaohsiung, taiwan research site, keelung, taiwan research site, new taipei, taiwan research site, taichung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan']","""study protocol"", https://clinicaltrials.gov/provideddocs/44/nct03299244/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/44/nct03299244/sap_001.pdf",https://ClinicalTrials.gov/show/NCT03299244,thyroid kidney
660,661,NCT03633708,a study of etelcalcetide in pediatric subjects with secondary hyperparathyroidism and chronic kidney disease on hemodialysis,,Recruiting,No Results Available,secondary hyperparathyroidism|chronic kidney disease,drug: etelcalcetide,proportion of participants with ≥ 30% reduction from baseline in intact parathyroid hormone (ipth) level during the efficacy assessment phase (eap)|maximum serum concentration (cmax) of etelcalcetide|minimum serum concentration (cmin) of etelcalcetide|incidence of adverse events|frequency of hypocalcemia|number of participants with corrected serum calcium levels at any time during the study|number of participants with serum phosphorous levels below normal for age|number of participants with predialysis ipth levels below normal|change from baseline in systolic blood pressure|change from baseline in diastolic blood pressure|change from baseline in heart rate|change in tanner stage|change in height|change in weight|achievement of ≥ 30% reduction in ipth from baseline on two consecutive visits|mean change from baseline in predialysis ipth|percentage change from baseline in predialysis ipth|percentage change from baseline in corrected total serum calcium|percentage change from baseline in corrected total serum phosphorous,amgen,All,"up to 18 Years   (Child, Adult)",Phase 3,56.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140315|2017-002411-34,"April 29, 2019","January 31, 2023","January 31, 2023","August 16, 2018",,"March 31, 2022","['childrens hospital of los angeles, los angeles, california, united states childrens hospital colorado, aurora, colorado, united states childrens mercy hospital, kansas city, missouri, united states mount sinai kidney center - b1 renal treatment, new york, new york, united states cincinnati childrens hospital medical center, cincinnati, ohio, united states cleveland clinic, cleveland, ohio, united states the childrens hospital at oklahoma university medical center, oklahoma city, oklahoma, united states childrens hospital of philadelphia, philadelphia, pennsylvania, united states childrens medical center dallas, dallas, texas, united states primary childrens hospital outpatient services, salt lake city, utah, united states hospital italiano, ciudad autonoma de buenos aires, buenos aires, argentina fresenius escobar, escobar, buenos aires, argentina centro infantil del rinon, san miguel de tucuman, tucuman, argentina fortis flt lt rajan dhall hospital, new delhi, delhi, india all india institute of medical sciences, new delhi, delhi, india sir ganga ram hospital, new delhi, delhi, india manipal hospital, bangalore, karnataka, india kles dr prabhakar kore hospital and medical research centre, belagavi, karnataka, india nrs medical college and hospital, kolkata, west bengal, india seoul national university hospital, seoul, korea, republic of pusan national university yangsan hospital, yangsan-si, gyeongsangnam-do, korea, republic of hospital raja perempuan zainab ii, kota bharu, kelantan, malaysia hospital tuanku jaafar, seremban, negri sembilan, malaysia hospital wanita dan kanak-kanak kuala lumpur, kuala lumpur, wilayah persekutuan, malaysia sbhi pediatrics city clinical hospital of saint vladimir, moscow, russian federation municipal children hospital 1, saint petersburg, russian federation state budgetary healthcare institution samara regional clinical hospital na v d seredavin, samara, russian federation national university hospital, singapore, singapore kaohsiung veterans general hospital, kaohsiung, taiwan national cheng kung university hospital, tainan, taiwan national taiwan university hospital, taipei, taiwan linkou chang gung memorial hospital, taoyuan, taiwan hacettepe universitesi tip fakultesi ihsan dogramaci cocuk hastanesi, ankara, turkey baskent universitesi ankara hastanesi, ankara, turkey gazi universitesi tip fakultesi, ankara, turkey istanbul universitesi cerrahpasa tip fakultesi, istanbul, turkey ege universitesi tip fakultesi, izmir, turkey erciyes universitesi tip fakultesi mustafa eraslan ve fevzi mercan cocuk hastanesi, kayseri, turkey national childrens specializated hospital okhmatdit, kyiv, ukraine']",,https://ClinicalTrials.gov/show/NCT03633708,thyroid kidney
661,662,NCT01480479,phase iii study of rindopepimut/gm-csf in patients with newly diagnosed glioblastoma,ACT IV,Completed,No Results Available,glioblastoma|small cell glioblastoma|giant cell glioblastoma|gliosarcoma|glioblastoma with oligodendroglial component,drug: rindopepimut (cdx-110) with gm-csf|drug: temozolomide|drug: klh,overall survival|progression-free survival|safety and tolerability,celldex therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,745.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CDX110-04,November 2011,November 2016,November 2016,"November 29, 2011",,"January 16, 2018","['university of alabama at birmingham, birmingham, alabama, united states university of south alabama mitchell cancer institute, mobile, alabama, united states barrow neurological institute at st. joseph\'s hospital and medical center, phoenix, arizona, united states university of arizona health network, tucson, arizona, united states university of arkansas for medical sciences, little rock, arkansas, united states city of hope cancer center, duarte, california, united states uc san diego moores cancer center, la jolla, california, united states usc norris comprehensive cancer center, los angeles, california, united states chao family comprehensive cancer center, orange, california, united states kaiser permanente, redwood city medical center, redwood city, california, united states university of california, davis, sacramento, california, united states university of california, san francisco, san francisco, california, united states stanford cancer institute, stanford university, stanford, california, united states hartford hospital, hartford, connecticut, united states yale university medical center, new haven, connecticut, united states christiana care health services, newark, delaware, united states university of florida, gainesville, florida, united states mount sinai medical center, comprehensive cancer center, miami beach, florida, united states md anderson cancer center orlando, orlando, florida, united states tampa general hospital, tampa, florida, united states atlanta cancer care, atlanta, georgia, united states winship cancer institute, emory university school of medicine, atlanta, georgia, united states georgia regents university, augusta, georgia, united states kaiser permanente hawaii moanalua medical center, honolulu, hawaii, united states northwestern university robert h. lurie comprehensive cancer center, chicago, illinois, united states rush university medical center, chicago, illinois, united states university of chicago, chicago, illinois, united states north shore university health system, evanston, illinois, united states loyola university medical center, maywood, illinois, united states covenant clinic / iowa spine and brain institute, waterloo, iowa, united states university of kentucky, lexington, kentucky, united states norton cancer institute, louisville, kentucky, united states mary bird perkins cancer center, baton rouge, louisiana, united states lsu health sciences center, feist-weiller cancer center, shreveport, louisiana, united states anne arundel medical center, annapolis, maryland, united states johns hopkins university school of medicine, baltimore, maryland, united states center for cancer and blood disorders, pc, bethesda, maryland, united states dana-farber cancer institute and mass general hospital, boston, massachusetts, united states dana-farber cancer institute, boston, massachusetts, united states university of massachusetts memorial medical center, worcester, massachusetts, united states university of michigan health system, ann arbor, michigan, united states edward w. sparrow hospital association - sparrow regional cancer center, lansing, michigan, united states st. mary\'s of michigan medical center/field neurosciences institute, saginaw, michigan, united states allina health, abbott northwestern hospital, john nasseff neuroscience institute, minneapolis, minnesota, united states ellis fischel cancer center, columbia, missouri, united states washington university in st. louis, saint louis, missouri, united states southeast nebraska cancer center, lincoln, nebraska, united states dartmouth hitchcock medical center, lebanon, new hampshire, united states new jersey neuroscience institute, jfk medical center, edison, new jersey, united states john theurer cancer center at hackensack university medical center, hackensack, new jersey, united states monmouth medical center, long branch, new jersey, united states dent neurosciences research institute, amherst, new york, united states montefiore medical center, bronx, new york, united states new york methodist hospital, brooklyn, new york, united states the long island brain tumor center at neurology surgery, p.c., great neck, new york, united states north shore university hospital, manhasset, new york, united states columbia university medical center - the neurologic institute of new york, new york, new york, united states weill cornell medical college, new york, new york, united states university of rochester medical center, rochester, new york, united states suny upstate medical university, syracuse, new york, united states brain and spine surgeons of new york, white plains, new york, united states the preston robert tisch brain tumor center at duke university medical center, durham, north carolina, united states wake forest baptist health, winston-salem, north carolina, united states university of cincinnati cancer institute, cincinnati, ohio, united states university hospitals, case medical center (cleveland), cleveland, ohio, united states cleveland clinic foundation, cleveland, ohio, united states ohio state university, columbus, ohio, united states providence portland medical center, oncology & hematology care, portland, oregon, united states pacific neurosurgical, portland, oregon, united states lehigh valley physician group-hematology-oncology associates, allentown, pennsylvania, united states university of pennsylvania, philadelphia, pennsylvania, united states temple university hospital, philadelphia, pennsylvania, united states west penn. allegheny health system, pittsburgh, pennsylvania, united states university of pittsburgh cancer institute, pittsburgh, pennsylvania, united states medical university of south carolina - department of neuroscience, charleston, south carolina, united states university of tennessee medical center - knoxville, knoxville, tennessee, united states sarah cannon research institute, nashville, tennessee, united states vanderbilt-ingram cancer center, nashville, tennessee, united states texas oncology midtwon, austin, texas, united states baylor research institute, dallas, texas, united states the methodist neurological institute, houston, texas, united states university of utah department of neurosurgery, salt lake city, utah, united states fletcher allen health care, burlington, vermont, united states university of virginia healthcare system, charlottesville, virginia, united states swedish neuroscience institute, seattle, washington, united states university of washington medical center, seattle, washington, united states university of wisconsin paul p carbone comprehensive cancer center, madison, wisconsin, united states medical college of wisconsin, milwaukee, wisconsin, united states prince of wales hospital, randwick, new south wales, australia royal north shore hospital, st leonards, new south wales, australia the crown princess mary cancer centre, westmead hospital, westmead, new south wales, australia royal brisbane and women\'s hospital, herston, queensland, australia mater adult hospital, mater misericordiae health services brisbane limited, south brisbane, queensland, australia royal adelaide hospital, adelaide, south australia, australia calvary north adelaide hospital, north adelaide, south australia, australia royal hobart hospital, hobart, tasmania, australia launceston general hospital, launceston, tasmania, australia monash medical centre, clayton, victoria, australia austin health, heidelberg, victoria, australia epworth healthcare, richmond, victoria, australia sir charles gairdner hospital, nedlands, western australia, australia liverpool hospital, liverpool, australia medical university innsbruck, dept of neurology, anichstrabe 35, innsbruck, austria medizinische universität wien, innere medizin i, onkologie, vienna, austria universitair ziekenhuis antwerpen, edegem, antwerp, belgium zna middelheim, antwerpen, belgium ghent university hospital, ghent, belgium hospital mae de deus-centro de pesquisa em oncologia clinica, porto alegre, rio grande do sul, brazil centro de pesquisas clinicas da fundação dr amaral carvalho, jaú, são paulo, brazil fundação faculdade regional de medicina de de são josé do rio preto - hospital de base, são josé do rio preto, são paulo, brazil instituto nacional do cancer (inca), rio de janeiro, brazil hospital albert einstein, sao paulo, brazil instituto do câncer do estado de são paulo - icesp, são paulo, brazil real e benemerita associação portuguesa de beneficiência/ hospital são josé, são paulo, brazil hospital a c camargo, são paulo, brazil foothills hospital medical centre, calgary, alberta, canada british columbia cancer agency, vancouver clinic, vancouver, british columbia, canada bc cancer agency - vancouver island centre, victoria, british columbia, canada university of manitoba-cancer care manitoba, winnipeg, manitoba, canada qeii health sciences centre, halifax, nova scotia, canada juravinski cancer centre, hamilton, ontario, canada london regional cancer program, london health sciences centre, london, ontario, canada ottawa hospital, regional cancer centre, ottawa, ontario, canada sunnybrook health sciences centre, toronto, ontario, canada centre hospitalier de l\'universite de montreal (chum) - hopital notre-dame, montreal, quebec, canada montreal neurological institute and hospital, montreal, quebec, canada chus hôpital fleurimont, shenbrooke, quebec, canada chuq l\'hotel dieu de qujebec, quebec, canada fundacion santa fe, bogota, bogota d.c, colombia hospital ceske budejovice, ceske budejovice, czechia umiversity hospital (fakultni nemocnice), prague, czechia hospital na homolce, prague, czechia multiscan s.r.o., praha 5, czechia masaryk´s hospital usti nad labem, usti nad labem, czechia institut de cancerologie de i\'quest-paul papin, angers, france institute bergonie, bordeaux, france centre leon berard de lyon, lyon, france icm val d\'aurel montpellier, montpellier, france institut de cancerologie de l\'quest-center rane gauducheau, nantes, france service de neurologie-gh, paris, france centre eugene marquis, rennes, france institut de cancerologie de l\'ouest-center rene gauducheau, st herblain, france institut gustave roussy, villejuif, france klinik und poliklinik fur neurologie der universitat regensburg, regensburg, bavaria, germany strahlenklinik universitatsklinikum erlangen, erlangen, germany dr. senchkenbergisches institut fur neuroonkologie, frankfurt, germany university hospital hamburg kopf und neurozentrum, hamburg, germany universitaetsklinikum heidelberg, neurologische klinik, im neuenheimer feld 672, heidelberg, germany university medical centre, kiel, germany universitaetsklinikum muenster, muenster, germany lmu munich, munich, germany nna, athens, attiki, greece ""hygeia"" hospital, marousi, district of attica, greece országos onkológiai intézet sugárterápiás osztály, budapest, hungary debreceni egyetem orvos- és egészségtudományi centrum onkológiai intézet, debrecen, hungary borsod-abaúj-zemplén megyei kórház és egyetemi oktató kórház, sugárterápiás osztály, miskolc, hungary pécsi tudományegyetem általános orvostudományi kar, pécs, hungary szegedi tudományegyetem onkoterápiás klinika, szeged, hungary vas megyei markusovszky lajos általános rehabilitációs és gyógyfürdő kórház, egyetemi oktatókórház nonprofit zrt, szombathely, hungary city cancer centre, vijayawada, vijayawada, andhra pradesh, india hcg - bangalore institute of oncology, bangalore, bengaluru, karnataka, india amrita institute of medical sciences and research centre, kochi, kochi, kerala, india sree chitra tirunal institute for medical sciences & technology, thiruvananthapuram, thiruvananthapuram, kerala, india marathwada regional cancer centre and research institute - government, aurangabad, maharashtra, india kokilaben dhirubhai ambani hospital and medical research institute, andheri-west, mumbai, india tata memorial hospital , mumbai, parel, mumbai, india indraprastha apollo hospital, new delhi, jasola viha, new delhi, india sahyadri hospitals limited, erandauame, pune, india dr. rai memorial medical centre, chennai, chennai, tamil nadu, india hcg shanti mukand hospital - curie cancer centre, delhi, delhi, india soroka university m.c., beer-sheva, israel rambam health care campus, haifa, israel hadassah medical center, jerusalem, israel sheba medical center, tel hashomer, israel tel-aviv sourasky medical center, tel-aviv, israel uo oncologie medica dipartimento oncologico, bologna, italy fondazione irccs instituto neurologico carlo besta, milano, italy sacred heart catholic university, rome, italy universita e ao citta delia scienza, universita di torino, torino, italy grupo médico camino s.c., mexico, d.f, mexico hospital civil de guadalajara ""fray antonio alcalde"", guadalajara, jalisco, mexico ensayos clínicos y medicina de alta especialidad, s.c., culiacán, sinaloa, mexico servicios medicos de investigacion clinica sc, durango, mexico hospital central ""ignacio morones prieto"", san luis potosí, mexico medisch centrum haaglanden, the hague, zuid holland, netherlands vumc, amsterdam, netherlands radboud university nijmegen medical center, nijmegen, netherlands christchurch hospital, christchurch central, christchurch, new zealand palmerston north hospital, roslyn, palmerston north, new zealand waikato hospital, regional cancer centre, hamilton, waikato district, new zealand waikato hospital, regional cancer center, hamilton, waikato distric, new zealand hospital almanzor aguinaga asenjo, chiclayo, peru instituto oncologico miraflores, lima, peru clinica anglo americana, lima, peru clinica ricardo palma, lima, peru oncosalud, lima, peru institut catala d oncologia, lahospitalet de lubregat, catalonia, spain dra. sonia del barco berron, ico girona avda,, franca, girona, spain hospital clinic, barcelona, spain ico badalona-hospital germans trias i pujol, barcelonia, spain hospital 12 de octubre, madrid, spain kantonsspital aarau medizinische onkologie tellstrasse, aarau, ag, switzerland chuv, centre hospitalier universitaire vaudois, lausanne, vd, switzerland oncology institute of southern switzerland (iosi), bellinzona, switzerland inselspital, universitatsspital bern, universitatsklinik fur medizinische onkologie, freiburgstrasse, bern, switzerland hopitaux universitaires de geneve-hug-centre d\'oncologie, geneva, switzerland brain tumor center, university hospital zurich, zurich, switzerland national cheng kung university hospital, tainan city, bei district, taiwan kaohsiung chang gung memorial hospital, kaohsiung, taiwan chang gung memorial hospital linkou branch, taichung, taiwan taichung veterans general hospital, taichung, taiwan chi mei medical center, tainan city - yongkang district, taiwan tri-service general hospital, taipei city - neihu district, taiwan siriraj hospital, bangkoknoi, bangkok, thailand king chulalongkorn memorial hospital, patumwan, bankok, thailand maharaj nakorn chiang mai hospital, amphoe muang, chiang mai, thailand songkhlanagarind hospital, hat yai, songkla, thailand royal marsden nhs foundation trust, sutton, surrey, united kingdom the bristol haematology and oncology centre, bristol, united kingdom edinburgh cancer centre western general hospital, edinburgh, united kingdom beatson west of scotland cancer centrel, glasgow, united kingdom guy\'s and st thomas\' nhs, westminister bridge road, london, united kingdom nottingham city hospital, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT01480479,astrocyt sarcoma
662,663,NCT02744131,ocp vs metformin for improvement in clinical symptoms and metabolic markers in indian pcos women,OCP,Unknown status,No Results Available,polycystic ovary syndrome,drug: oral contraceptive pill combination of ethyl estradiol and cyproterone acetate|drug: metformin 1500mgs per day,improvements in menstrual cycle in women with polycystic ovary syndrome.|improvement in hirsutism|improvement in acne score|weight loss following treatment|reduction in total testosterones|reduction in serum fasting insulin|improvements in lipid profile|improvement in glucose tolerance,"kar clinic & hospital pvt. ltd.|all india institute of medical sciences, new delhi|nova ivi fertility, new delhi|dr patil's fertility & endoscopy clinic, bangalore|shreyas hospital & sushrut assisted conception clinic, kolhapur|university of messina",Female,"16 Years to 40 Years   (Child, Adult)",Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OCP-MET-2016,May 2016,September 2018,December 2019,"April 20, 2016",,"February 5, 2018","['kar clinic and hospital pvt ltd, bhubaneswar, odisha, india']",,https://ClinicalTrials.gov/show/NCT02744131,ovari
663,664,NCT05113030,impact of pcos on periodontal status of adolescent and adult age group women,,Not yet recruiting,No Results Available,polycystic ovary syndrome|gingival inflammation,other: periodontal status of female patients with pcos (newly diagnosed) of adolescent age group will be assessed|other: periodontal status of female patients with pcos (newly diagnosed) of adult age group will be assessed,"bleeding on probing(bop),|probing pocket depth(ppd), in both the groups.|serum hscrp levels( high sensitivity c reactive proteins)",postgraduate institute of dental sciences rohtak,Female,"11 Years to 40 Years   (Child, Adult)",,100.0,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,swati PCOS perio,November 2021,March 2022,June 2022,"November 9, 2021",,"November 9, 2021","['post graduate institute of dental sciences, rohtak, haryana, india']",,https://ClinicalTrials.gov/show/NCT05113030,ovari
664,665,NCT03579303,homoeopathy and yoga in the treatment of menstrual disorders in females with polycystic ovarian syndrome,,Unknown status,No Results Available,menstrual disorders|polycystic ovary syndrome,other: homoeopathic remedies,to assess if the interventions can facilitate regular menstrual cycle.|to assess reduction in hyperandrogenism,fr muller homoeopathic medical college,Female,18 Years to 36 Years   (Adult),Not Applicable,84.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AJP123,October 2018,"April 15, 2021","October 15, 2021","July 6, 2018",,"July 9, 2018","['fr muller homoeopathic medical college, mangalore, karnataka, india']","""study protocol, statistical analysis plan, and informed consent form"", https://clinicaltrials.gov/provideddocs/03/nct03579303/prot_sap_icf_000.pdf",https://ClinicalTrials.gov/show/NCT03579303,ovari
665,666,NCT05021861,evaluation of periodontal status and hscrp levels in females with pcos on cpa/ee combination drug regimen,,Not yet recruiting,No Results Available,periodontitis|polycystic ovary syndrome|gingivitis,"drug: cyproterone acetate, ethinyl estradiol drug combination|diagnostic test: female patients with pcos|diagnostic test: control group",bleeding on probing|pocket depth|hscrp levels,postgraduate institute of dental sciences rohtak,Female,"15 Years to 40 Years   (Child, Adult)",,150.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,RidhimaPerio,November 2021,"July 31, 2022","September 30, 2022","August 26, 2021",,"November 15, 2021","['post graduate institute of dental science, rohtak, haryana, india']",,https://ClinicalTrials.gov/show/NCT05021861,ovari
666,667,NCT00761280,efficacy and safety of ap 12009 in patients with recurrent or refractory anaplastic astrocytoma or secondary glioblastoma,SAPPHIRE,Terminated,Has Results,anaplastic astrocytoma|glioblastoma,drug: trabedersen|drug: temozolomide|device: drug delivery system for administration of ap 12009|procedure: placement of drug delivery system|drug: carmustine|drug: lomustine,"survival rate at 24 months in the intent-to-treat population - percentage of participants (descriptive analysis, only)|survival at 24 months in the intent-to-treat population - number of participants|survival rate at 12, 18, and 21 months in the intent-to-treat population - percentage of participants (descriptive analysis, only)|survival at 12, 18, and 21 months in the intent-to-treat population - number of participants|median overall survival (days) from randomization in the intent-to-treat population (descriptive analysis, only)|response category by independent review in the intent-to-treat population - number of participants|overall response rate (cr+pr) by independent review in the intent-to-treat population - percentage of participants (descriptive analysis, only)|tumor control rate (cr+pr+sd) by independent review in the intent-to-treat population - percentage of participants (descriptive analysis, only)|median duration of response (days) by independent review (descriptive analysis, only)|disease progression at 10, 12, 14, 16, 18, 21, and 24 months by independent review in the intent-to-treat population - number of participants|disease progression rate at 10, 12, 14, 16, 18, 21, and 24 months by independent review in the intent-to-treat population - percentage of participants (descriptive analysis, only)|median time to progression (days) by independent review for the intent-to-treat population (descriptive analysis, only)",isarna therapeutics gmbh,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,27.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP 12009-G005,December 2008,February 2012,June 2012,"September 29, 2008","August 22, 2014","November 14, 2014","[""nj neuroscience institute; jfk medical center, edison, new jersey, united states winthrop university hospital, mineola, new york, united states university of rochester medical center, rochester, new york, united states hospital británico, ciudad autónoma de buenos aires, argentina fleni, ciudad autónoma de buenos aires, argentina sanatorio allende, córdoba, argentina universitätsklinik innsbruck, abteilung für neurologie, innsbruck, austria akh wien, klinik für neurochirurgie, wien, austria hospital de câncer de barretos, barretos / sp, brazil centro goiano de oncologia (cgo), goiania, brazil hospital sao vicente de paulo, passo fundo, brazil hospital de clínicas de porto alegre, porto alegre, brazil hospital sao lucas da pucrs, porto alegre, brazil hospital do servidor público estadual, sao paulo, brazil ecogene-21 centre d'études cliniques, chicoutimi, quebec, canada foothills medical centre, calgary, canada montreal neurological institute and hospital, montreal, canada la timone university hospital, marseille, france klinik und poliklinik für neurochirurgie, frankfurt/m., germany universitätsklinikum freiburg, freiburg, germany neurochirurgische klinik an der universität ulm am bezirkskrankenhaus günzburg, günzburg, germany universitätklinikum hamburg-eppendorf, klinik für neurochirurgie, hamburg, germany medizinische hochschule hannover neurochirurgische klinik, hannover, germany universitätsklinik heidelberg neurologische klinik, heidelberg, germany universitätsklinikum leipzig, neurochirurgische klinik, leipzig, germany otto-von-guericke-universität, klinik für neurochirurgie, magdeburg, germany klinik und poliklinik für neurochirurgie, münster, germany klinik und poliklinik für neurologie, regensburg, germany szegedi tudományegyetem szent-györgyi albert klinikai központ, szeged, hungary manipal hospital & manipal institute for neurological disorders, bangalore, india nimhans, bangalore, india bgs global hospital, bangalore, india postgraduate institute of medical education & research (pgimer), chandigarh, india apollo speciality hospitals, chennai, india amrita institute of medical sciences research center, cochin, india care hospitals, hyderabaad, india amri hospitals, kolkata, india sgpgi of medical sciences, lucknow, india advanced centre for treatment research and education in cancer (actrec), mumbai, india all india institute of medical sciences (aiims), new delhi, india sctimst, dept. of neurosurgery, thiruvananthapuram, india severance hospital, yonsei university college of medicine, seoul, korea, republic of kangnam st. mary's hospital, seoul, korea, republic of asan medical center, seoul, korea, republic of hospital san javier, guadalajara, mexico hospital general de mexico, mexico city, mexico medica sur, mexico city, mexico wojskowy szpital kliniczny, klinika neurochirurgii, bydgoszcz, poland akademickie centrum kliniczne, gdańsk, poland samodzielny publiczny szpital kliniczny nr 4, klinika neurochirurgii i neurochirurgii dziecięcej, lublin, poland kliniczny oddzial neurochirurgii sum w sosnowcu wojewódzki szpital specjalistyczny nr 5, sosnowiec, poland centrum onkologii - instytut im. marii sklodowskiej-curie, warszawa, poland sp zoz uniwersytecki szpital kliniczny nr 1, klinika neurochirurgii, łódź, poland chelyabinsk city hospital #3; department of neurosurgery, chelyabinsk, russian federation state institution russian oncology research center n.n. blokhin, moscow, russian federation samara region clinical hospital m.i. kalinin, samara, russian federation russian scientific research neurosurgical institute a.l. polenov, st. petersburg, russian federation military medical academy, neurosurgery dept, st. petersburg, russian federation hospital de cruces, baracaldo, spain hospital universitario vall d'hebron, barcelona, spain hospital doce de octubre, madrid, spain hospital universitario marqués de valdecilla, santander, spain hospital universitario virgen del rocío, sevilla, spain china medical university hospital, taichung, taiwan taichung veterans general hospital, taichung, taiwan tri-service general hospital, taipei city, taiwan edinburgh centre for neuro-oncology, western general hospital, edinburgh, united kingdom the national hospital for neurology and neurosurgery, london, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00761280,astrocyt
667,668,NCT02866786,"the effects of ocp and metformin on clinical, hormonal, metabolic and ultrasonographic characteristics in pcos",,Completed,No Results Available,polycystic ovary syndrome,drug: metformin|drug: ethinyl estradiol and cyproterone acetate,"improvement in menstrual cycle pattern|change in abdominal fat as measured by waist circumference in centimeter|change in weight as measured in kg|improvement in hirsutism measured by modified ferriman and gallwey scores|improvement in glucose tolerance (measured by of fasting plasma glucose and 2-hour post prandial plasma glucose)|change in waist-to-hip ratio|change in body mass index (kg/m2)|lipid profile (cholesterol, ldl, hdl and triglyceride) improvement|change in blood level of luteinizing hormone [lh] (miu/ml)|change in blood level of follicle stimulating hormone [fsh] (miu/ml)|change in blood level of testosterone (nmol/l)|change in blood level of sex hormone binding globulin (shbg) (ng/ml)|change in free androgen index (fai)|change in dehydroepiandrosterone sulfate (dheas) level (microgram/dl)|changes in fasting serum insulin levels (miu/l)|homeostatic model assessment of insulin resistance (homa-ir)|ovarian stromal artery pulsatility index|ovarian stromal artery resistivity index|chang in ovarian follicle number by ultrasonography (usg)|change in ovarian follicle diameter (in mm) by usg|change in ovarian volume (in cc) by usg|change in endometrial thickness (in mm)|change in ovarian stromal/total area ratio (s/a)",s.c.b. medical college and hospital,Female,18 Years to 35 Years   (Adult),Phase 4,101.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OG/2016/13,"August 15, 2016","April 20, 2017","August 1, 2017","August 15, 2016",,"April 20, 2018","['department of obstetrics & gynecology, cuttack, odisha, india']",,https://ClinicalTrials.gov/show/NCT02866786,ovari
668,669,NCT00431561,phase iib clinical trial with tgf-β2 antisense compound ap 12009 for recurrent or refractory high-grade glioma,,Completed,No Results Available,glioblastoma|anaplastic astrocytoma,drug: ap 12009 10 µm|drug: ap 12009 80 µm|drug: temozolomide or pcv|device: drug delivery system for administration of ap 12009|procedure: placement of drug delivery system,overall response rate of two ap 12009 dose groups and control group assessed by the evaluation of tumor size on brain mri scans|overall survival|response rates|progression-free survival|time to progression|time to response|best of all response rates assessed by survival status and variation of tumor size on brain mri|change of quality of life and karnofsky performance status (kps)|best of all response rates|safety and tolerability,isarna therapeutics gmbh,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,141.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP 12009-G004,April 2003,March 2009,March 2009,"February 6, 2007",,"December 3, 2013","['universitätsklinik innsbruck; abteilung für neurochirurgie, innsbruck, austria landes-nervenklinik wagner-jauregg, linz, austria kaiser franz josef spital, abteilung für neurologie, wien, austria sarajishvili institute of clinical neurology and neurosurgery, tbilisi, georgia medizinische klinik und poliklinik mit schwerpunkt onkologie und hämatologie, charité campus mitte, berlin, germany klinik und poliklinik für neurologie, cottbus, germany universitätsklinikum carl gustav carus an der technischen universität dresden, dresden, germany universitätsklinikum gießen, neurochirurgische universitätsklinik, gießen, germany universitätsklinikum kiel, klinik für neurochirurgie, kiel, germany universitätsklinikum leipzig, klinik und poliklinik für neurochirurgie, leipzig, germany universitätsklinik magdeburg, klinik für neurochirurgie, magdeburg, germany universitätskliniken mainz, neurochirurgische klinik und poliklinik, mainz, germany universitätsklinikum münster, klinik und poliklinik für neurochirurgie, münster, germany klinikum und poliklinik für neurologie, universität regensburg, regensburg, germany klinikum saarbrücken, neurochirurgie, saarbrücken, germany neurologische universitätsklinik tübingen, tübingen, germany department of neurosurgery, amrita institute of medical sciences & research centre, cochin, kerala, india sree chitra tirunal institute for medical sciences & technology, department of neurosurgery, trivandrum, kerala, india manipal hospital; manipal institute for neurological disorders, bangalore, india department of neurosurgery, national institute of mental health and neurosciences, bangalore, india department of medical oncology, nizam\'s institute of medical sciences, hyderabad, india department of neurosurgery, ltmg hospital & ltm medical college, mumbai, india department of neurosurgery, neurosciences center, new dehli, india department of neurological sciences, christian medical college & hospital, vellore, india soroka medical center, neurosurgery department, beer sheva, israel rambam medical center, neurosurgery department, haifa, israel rabin medical center, neurosurgery department, petach tikva, israel sverdlovsk regional oncological clinic, ekaterinburg, russian federation republican clinical hospital of ministry of health of tatarstan republic, kazan, russian federation burdenko neurosurgery research institute, moscow, russian federation omsk state medical academy; state educational institution of higher professional education, omsk, russian federation state institution of healthcare, samara regional clinical hospital in the name of m.i. kalinin, samara, russian federation polenov neurosurgery research institute, st. petersburg, russian federation military medical academy named after i.s.m. kirov, neurosurgery department, st. petersburg, russian federation medical center ""xxi century"", st. petersburg, russian federation tcheliabinsk regional clinical hospital; state medical institution for prophylaxis and treatment, tcheliabinsk, russian federation']",,https://ClinicalTrials.gov/show/NCT00431561,astrocyt
669,670,NCT01838122,prevalence of hba1c in women with pcos,WHI,Unknown status,No Results Available,polycystic ovarian syndrome|pelvic endometriosis|insulin resistance|non-insulin dependent diabetes mellitus|tubal obstruction,,prevalence of hba1c in both arms of the cohort of subjects,southern cross fertility centre,Female,"15 Years to 40 Years   (Child, Adult)",,300.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HbA1C-PCOS|PCOS-IR,April 2013,September 2013,November 2013,"April 23, 2013",,"April 23, 2013","['southern cross fertility centre, mumbai, maharashtra, india']",,https://ClinicalTrials.gov/show/NCT01838122,ovari
670,671,NCT03196115,biomarker for hyaline fibromatosis syndrome (biohfs),BioHFS,"Active, not recruiting",No Results Available,hyalinosis|hyaline membrane disease|juvenile hyaline fibromatosis|fibromatosis hyalinica multiplex juvenilis|skin and connective tissue diseases,,sequencing of the hyaline fibromatosis syndrome related gene|the hyaline fibromatosis syndrome specific biomarker candidates finding,centogene gmbh rostock,All,"2 Months and older   (Child, Adult, Older Adult)",,1000.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,BHFS 06-2018,"August 20, 2018",June 2021,June 2021,"June 22, 2017",,"May 13, 2021","['centogene ag, rostock, germany nirman navi mumbai institute of research in mental and neurological handicap/pediatric geneticist, mumbai, india lady ridgeway hospital for children, colombo 8, sri lanka']",,https://ClinicalTrials.gov/show/NCT03196115,skin
671,672,NCT04335227,yoga therapy and aerobic exercise on anti-mullerian hormone in young women with polycystic ovary syndrome,,Not yet recruiting,No Results Available,polycystic ovary syndrome|anti-mullerian hormone deficiency|female infertility endocrine,other: structured yoga therapy program|other: aerobic exercise training program|other: combined yoga and aerobic training program|other: nutritional management,serum anti-mullerian hormone concentration|antral follicle count|serum follicle-stimulating hormone concentration|serum luteinizing hormone concentration|serum testosterone concentration|serum prolactin concentration|serum thyroid-stimulating hormone concentration|serum dehydroepiandrosterone sulfate concentration|serum insulin fasting concentration|serum glucose fasting concentration|homeostatic model assessment for insulin resistance|concentration of lipid profiles in serum,maharishi markendeswar university (deemed to be university),Female,18 Years to 30 Years   (Adult),Not Applicable,128.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MMDU/IEC/141E,"November 14, 2021","March 12, 2023","April 14, 2023","April 6, 2020",,"August 24, 2021","['maharishi markandeshwar hospital, mullana, ambala, haryana, india maharishi markandeshwar medical college & hospital, kumarhatti, solan, himachal pradesh, india']",,https://ClinicalTrials.gov/show/NCT04335227,ovari
672,673,NCT00517712,single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia,IAPLSG04,Unknown status,No Results Available,acute promyelocytic leukemia,drug: single agent arsenic trioxide,measure complete hematological remission rate|measure complete molecular remission rate|measure duration of response|document early and late toxicities|measure relapse rates|measure treatment related mortality,"christian medical college, vellore, india|ministry of science and technology, india",All,"Child, Adult, Older Adult",Phase 2|Phase 3,400.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IAPLSG2004|BT/PR4460/Med/14/531/2003,June 2004,,July 2009,"August 17, 2007",,"August 17, 2007","['kidwai memorial institute of oncology, bangalore, karnataka, india st. johns hospital, bangalore, karnataka, india regional cancer center, trivandrum, kerala, india prince aly khan hospital, mumbai, maharastra, india kem hospital, mumbai, maharastra, india tata memorial hospital, mumbai, maharastra, india sahyadri speciality hospital, pune, maharastra, india netaji subhash chandra bose cancer research institute, kolkata, west bengal, india institute rotary cancer hospital, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00517712,blood
673,674,NCT01014208,ofatumumab versus rituximab salvage chemoimmunotherapy followed by autologous stem cell transplant in relapsed or refractory diffuse large b cell lymphoma,ORCHARRD,Completed,Has Results,"lymphoma, large-cell, diffuse",drug: ofatumumab + dhap|drug: rituximab + dhap,progression-free survival as assessed by independent reviewers|number of participants with overall response (or) and complete response (cr) after salvage chemoimmunotherapy|number of participants with overall response (or) and complete response (cr) three months after autologous stem cell transplant|event-free survival|overall survival (os)|number of participants with the ability to mobilize at least 2 million cluster of differentiation (cd)34+ cells per kilogram from peripheral blood|number of participants completing autologous stem cell transplant (asct)|change from baseline in functional assessment of cancer therapy-general (fact-g) during treatment|change from baseline in the functional assessment of cancer therapy lymphoma trial outcome index (fact-lym toi) total score during treatment|time to neutrophil and platelet recovery after each cycle of salvage chemotherapy|time to engraftment after high-dose therapy (hdt)/asct,glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,447.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,110928,March 2010,February 2014,November 2014,"November 16, 2009","October 16, 2014","August 7, 2015","['gsk investigational site, sacramento, california, united states gsk investigational site, new haven, connecticut, united states gsk investigational site, chicago, illinois, united states gsk investigational site, chicago, illinois, united states gsk investigational site, westwood, kansas, united states gsk investigational site, jackson, mississippi, united states gsk investigational site, new york, new york, united states gsk investigational site, syracuse, new york, united states gsk investigational site, chaple hill, north carolina, united states gsk investigational site, philadelphia, pennsylvania, united states gsk investigational site, providence, rhode island, united states gsk investigational site, charleston, south carolina, united states gsk investigational site, greenville, south carolina, united states gsk investigational site, nashville, tennessee, united states gsk investigational site, san antonio, texas, united states gsk investigational site, seattle, washington, united states gsk investigational site, capital federal, buenos aires, argentina gsk investigational site, ciudad autonoma de buenos aires, buenos aires, argentina gsk investigational site, la plata, buenos aires, argentina gsk investigational site, graz, austria gsk investigational site, innsbruck, austria gsk investigational site, linz, austria gsk investigational site, linz, austria gsk investigational site, salzburg, austria gsk investigational site, wien, austria gsk investigational site, wien, austria gsk investigational site, brugge, belgium gsk investigational site, bruxelles, belgium gsk investigational site, gent, belgium gsk investigational site, hasselt, belgium gsk investigational site, leuven, belgium gsk investigational site, yvoir, belgium gsk investigational site, fuzhou, fujian, china gsk investigational site, guangzhou, guangdong, china gsk investigational site, guangzhou, guangdong, china gsk investigational site, guangzhou, guangdong, china gsk investigational site, nanjing, jiangsu, china gsk investigational site, jianan, shandong, china gsk investigational site, hangzhou, zhejiang, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, chengdu, china gsk investigational site, jiang su province, china gsk investigational site, shanghai, china gsk investigational site, shanghai, china gsk investigational site, tianjin, china gsk investigational site, brno, czech republic gsk investigational site, hradec kralove, czech republic gsk investigational site, aarhus, denmark gsk investigational site, koebenhavn, denmark gsk investigational site, tallinn, estonia gsk investigational site, tartu, estonia gsk investigational site, helsinki, finland gsk investigational site, oulu, finland gsk investigational site, tampere, finland gsk investigational site, ulm, baden-wuerttemberg, germany gsk investigational site, aachen, nordrhein-westfalen, germany gsk investigational site, muenster, nordrhein-westfalen, germany gsk investigational site, berlin, germany gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, budapest, hungary gsk investigational site, budapest, hungary gsk investigational site, debrecen, hungary gsk investigational site, győr, hungary gsk investigational site, kaposvár, hungary gsk investigational site, szeged, hungary gsk investigational site, szombathely, hungary gsk investigational site, ludhiana, india gsk investigational site, pune, india gsk investigational site, vellore, india gsk investigational site, dublin, ireland gsk investigational site, galway, ireland gsk investigational site, james street, ireland gsk investigational site, petach-tikva, israel gsk investigational site, ramat gan, israel gsk investigational site, aichi, japan gsk investigational site, akita, japan gsk investigational site, fukuoka, japan gsk investigational site, hokkaido, japan gsk investigational site, hyogo, japan gsk investigational site, ibaraki, japan gsk investigational site, kanagawa, japan gsk investigational site, kanagawa, japan gsk investigational site, kyoto, japan gsk investigational site, miyagi, japan gsk investigational site, nagano, japan gsk investigational site, nagasaki, japan gsk investigational site, okayama, japan gsk investigational site, osaka, japan gsk investigational site, tochigi, japan gsk investigational site, tokushima, japan gsk investigational site, tokyo, japan gsk investigational site, tokyo, japan gsk investigational site, tokyo, japan gsk investigational site, tokyo, japan gsk investigational site, jellanamdo, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, amersfoort, netherlands gsk investigational site, amsterdam, netherlands gsk investigational site, amsterdam, netherlands gsk investigational site, amsterdam, netherlands gsk investigational site, den haag, netherlands gsk investigational site, enschede, netherlands gsk investigational site, groningen, netherlands gsk investigational site, hoofddorp, netherlands gsk investigational site, leiden, netherlands gsk investigational site, maastricht, netherlands gsk investigational site, nieuwegein, netherlands gsk investigational site, nijmegen, netherlands gsk investigational site, rotterdam, netherlands gsk investigational site, rotterdam, netherlands gsk investigational site, rotterdam, netherlands gsk investigational site, sittard-geleen, netherlands gsk investigational site, utrecht, netherlands gsk investigational site, zwolle, netherlands gsk investigational site, oslo, norway gsk investigational site, chorzow, poland gsk investigational site, gdansk, poland gsk investigational site, poznan, poland gsk investigational site, warszawa, poland gsk investigational site, warszawa, poland gsk investigational site, wroclaw, poland gsk investigational site, moscow, russian federation gsk investigational site, st-petersburg, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, singapore, singapore gsk investigational site, barcelona, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, madrid, spain gsk investigational site, majadahonda (madrid), spain gsk investigational site, murcia, spain gsk investigational site, pamplona, spain gsk investigational site, pozuelo de alarcón/madrid, spain gsk investigational site, salamanca, spain gsk investigational site, göteborg, sweden gsk investigational site, lund, sweden gsk investigational site, stockholm, sweden gsk investigational site, uppsala, sweden gsk investigational site, bangkok, thailand gsk investigational site, bangkok, thailand gsk investigational site, bangkok, thailand gsk investigational site, birmingham, united kingdom gsk investigational site, blackpool, united kingdom gsk investigational site, bristol, united kingdom gsk investigational site, cambridge, united kingdom gsk investigational site, cheltenham, united kingdom gsk investigational site, edinburgh, united kingdom gsk investigational site, glasgow, united kingdom gsk investigational site, headington, oxford, united kingdom gsk investigational site, leeds, united kingdom gsk investigational site, liverpool, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, london, united kingdom gsk investigational site, manchester, united kingdom gsk investigational site, manchester, united kingdom gsk investigational site, newcastle upon tyne, united kingdom gsk investigational site, northwood, united kingdom gsk investigational site, nottingham, united kingdom gsk investigational site, sheffield, united kingdom gsk investigational site, southampton, united kingdom gsk investigational site, whitchurch, cardiff, united kingdom gsk investigational site, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01014208,lymphoma
674,675,NCT05301842,evaluate durvalumab and tremelimumab +/- lenvatinib in combination with tace in patients with locoregional hcc,EMERALD-3,Recruiting,No Results Available,hepatocellular carcinoma,drug: tremelimumab|drug: durvalumab|procedure: transarterial chemoembolization (tace)|drug: lenvatinib,progression free survival (pfs) for arm a vs arm c|progression free survival (pfs) for arm b vs arm c|overall survival (os) for arm a vs arm c|overall survival (os) for arm b vs arm c,astrazeneca,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,525.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,D910VC00001|2021-003822-54,"March 28, 2022","October 30, 2025","January 29, 2027","March 31, 2022",,"May 11, 2022","[""research site, birmingham, alabama, united states research site, commack, new york, united states research site, memphis, tennessee, united states research site, barretos, brazil research site, brasilia, brazil research site, niterói, brazil research site, porto alegre, brazil research site, santa maria, brazil research site, santo andre, brazil research site, são paulo, brazil research site, vitória, brazil research site, toronto, ca, canada research site, halifax, nova scotia, canada research site, kingston, ontario, canada research site, ottawa, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, beijing, china research site, beijing, china research site, beijing, china research site, changsha, china research site, chengdu, china research site, fuzhou, china research site, fuzhou, china research site, guangzhou, china research site, guangzhou, china research site, haikou, china research site, hangzhou, china research site, harbin, china research site, lanzhou, china research site, lishui, china research site, nanjing, china research site, nantong, china research site, neijiang, china research site, shanghai, china research site, suzhou, china research site, tianjin, china research site, urumqi, china research site, wuhan, china research site, xi'an, china research site, zhengzhou, china research site, zhuhai, china research site, dresden, germany research site, hamburg, germany research site, heidelberg, germany research site, kiel, germany research site, ahmedabad, india research site, ahmedabad, india research site, anand, india research site, bangalore, india research site, bangalore, india research site, gurugram, india research site, jaipur, india research site, kolkata, india research site, new delhi, india research site, new delhi, india research site, arezzo, italy research site, firenze, italy research site, milano, italy research site, milano, italy research site, rozzano, italy research site, tricase (lecce), italy research site, chuo-ku, japan research site, fukuoka-shi, japan research site, kashihara-shi, japan research site, morioka-shi, japan research site, osaka-shi, japan research site, osakasayama-shi, japan research site, sapporo-shi, japan research site, busan, korea, republic of research site, goyang-si, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, george town, malaysia research site, kuala lumpur, malaysia research site, kuching, malaysia research site, selangor, malaysia research site, makati, philippines research site, manila, philippines research site, pasig city, philippines research site, moscow, russian federation research site, moscow, russian federation research site, barcelona, spain research site, barcelona, spain research site, cordoba, spain research site, madrid, spain research site, madrid, spain research site, oviedo, spain research site, san sebastian, spain research site, taichung, taiwan research site, taichung, taiwan research site, tainan city, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, bangkok, thailand research site, chiang mai, thailand research site, hat yai, thailand research site, khon kaen, thailand research site, phisanulok, thailand""]",,https://ClinicalTrials.gov/show/NCT05301842,liver
675,676,NCT02778295,biomarker for patients with fabry disease (biofabry),BioFabry,"Active, not recruiting",No Results Available,angiokeratomas|chronic kidney disease|ocular abnormalities|hearing loss,,sequencing of the fabry disease related gene|the fabry disease specific biomarker candidates finding,centogene gmbh rostock,All,"2 Months and older   (Child, Adult, Older Adult)",,1000.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,BFA 06-2018,"August 20, 2018",June 2021,June 2021,"May 19, 2016",,"May 13, 2021","['centogene gmbh, rostock, germany nirman-university of mumbai-institute of research in mental and neurological handicap, mumbai, india lady ridgeway hospital for children, colombo 8, sri lanka']",,https://ClinicalTrials.gov/show/NCT02778295,kidney
676,677,NCT00677716,dose confirmation study of cotara for the treatment of glioblastoma multiforme at first relapse,,Completed,No Results Available,glioblastoma multiforme,drug: 131i-chtnt-1/b mab (cotara),"to confirm the safety and tolerability of the maximum tolerated dose|to estimate overall survival, progression free survival and proportion of patients alive at six months after treatment.",peregrine pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,41.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PPHM 0503,July 2007,September 2011,November 2011,"May 14, 2008",,"April 24, 2014","['barrow neurological institute, phoenix, arizona, united states university of pennsylvania, department of neurosurgery, philadelphia, pennsylvania, united states medical university of south carolina, charleston,, south carolina, united states amrita institute of medical sciences and research center,, cochin, kerala, india manipal institute for neurological disorders,, bangalore, india department of neurosurgery jaslok hospital and research centre, mumbai, india all india instutite of medical sciences, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00677716,astrocyt
677,678,NCT01922102,efficacy and safety of ranibizumab 0.5 vs verteporfin pdt in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia,Brilliance,Completed,Has Results,visual impairment due to choroidal neovascularization (cnv) secondary to pathologic myopia (pm),drug: ranibizumab 0.5mg|drug: ranibizumab 0.5 mg|drug: verteporfin pdt,"change from baseline bcva to the average level of bcva over all monthly assessments from month 1 to month 3|change from baseline bcva to the average level of bcva over all monthly assessments from month 1 to month 6|the average change in bcva score from baseline to month 1 through month 12|mean change from baseline in visual acuity over time|categorized bcva changes at months 3, 6 and 12 compared with baseline for the study eye|mean change from baseline over time in central sub-field thickness (csft)|number of patients with cnv leakage (center involvement) in the study eye at baseline and month 12|nei-vfq-25 - change from baseline to month 3, 6 and 12|number of ranibizumab injections received in the study eye for the ranibizumab groups",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,457.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRFB002F2302,"September 11, 2013","September 14, 2016","September 14, 2016","August 14, 2013","June 24, 2019","June 24, 2019","[""novartis investigative site, beijing, beijing, china novartis investigative site, beijing, beijing, china novartis investigative site, chongqing, chongqing, china novartis investigative site, shantou, guangdong, china novartis investigative site, harbin, heilongjiang, china novartis investigative site, wuhan, hubei, china novartis investigative site, wuhan, hubei, china novartis investigative site, changsha, hunan, china novartis investigative site, changsha, hunan, china novartis investigative site, nanjing, jiangsu, china novartis investigative site, nanjing, jiangsu, china novartis investigative site, wu xi, jiangsu, china novartis investigative site, nanchang, jiangxi, china novartis investigative site, qingdao, shandong, china novartis investigative site, xi'an, shanxi, china novartis investigative site, chengdu, sichuan, china novartis investigative site, tianjin, tianjin, china novartis investigative site, tianjin, tianjin, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, wenzhou, zhejiang, china novartis investigative site, beijing, china novartis investigative site, beijing, china novartis investigative site, beijing, china novartis investigative site, chongqing, china novartis investigative site, shanghai, china novartis investigative site, shanghai, china novartis investigative site, shanghai, china novartis investigative site, hongkong, hong kong novartis investigative site, chandigarh, haryana, india novartis investigative site, bangalore, karnataka, india novartis investigative site, vanchiyoor, kerala, india novartis investigative site, bhubaneswar, orissa, india novartis investigative site, chennai, tamil nadu, india novartis investigative site, chennai, tamil nadu, india novartis investigative site, coimbatore, tamil nadu, india novartis investigative site, hyderabad, telangana, india novartis investigative site, angamaly, india novartis investigative site, new delhi, india novartis investigative site, pusan, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, manila, metro manila, philippines novartis investigative site, manila, metro manila, philippines novartis investigative site, khon kaen, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, chiang mai, thailand novartis investigative site, nakornphathom, thailand""]",,https://ClinicalTrials.gov/show/NCT01922102,brain
678,679,NCT03994627,olaratumab (ly3012207) patient access for soft tissue sarcoma,,Available,No Results Available,soft tissue sarcoma,drug: olaratumab,,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",,,Industry,Expanded Access:Individual Patients,,17468|I5B-MC-Y001,,,,"June 21, 2019",,"May 5, 2022","[""ironwood cancer & research centers, glendale, arizona, united states marin specialty care, inc, greenbrae, california, united states the angeles clinic & research institute, los angeles, california, united states kaiser permanente los angeles medical center, los angeles, california, united states kaiser permanente west los angeles, los angeles, california, united states kaiser permanente moreno valley, moreno valley, california, united states university of colorado health hospital, aurora, colorado, united states uchealth cancer center, fort collins, colorado, united states baptist md anderson cancer center, jacksonville, florida, united states mayo clinic in florida, jacksonville, florida, united states ocala oncology, p.a., ocala, florida, united states florida cancer specialists, orlando, florida, united states orlando health uf health cancer center, orlando, florida, united states florida cancer specialists, sarasota, florida, united states oncology-hematology associates of west broward, tamarac, florida, united states northside hospital, athens, georgia, united states tift regional health system anita stewart oncology center, tifton, georgia, united states beacon cancer care, coeur d'alene, idaho, united states rush university medical center, chicago, illinois, united states illinois cancercare, peoria, illinois, united states james graham brown cancer center, louisville, kentucky, united states hematology oncology clinic, baton rouge, louisiana, united states alton ochsner medical center, new orleans, louisiana, united states university of maryland, baltimore, baltimore, maryland, united states skccc at johns hopkins, baltimore, maryland, united states baltimore washington health services, glen burnie, maryland, united states university of massachusetts medical center, worcester, massachusetts, united states henry ford macomb hospital, clinton township, michigan, united states cancer & hematology centers of western michigan, grand rapids, michigan, united states st. luke's hospital of duluth, duluth, minnesota, united states masonic cancer center, university, minneapolis, minnesota, united states jackson oncology associates, pllc, jackson, mississippi, united states university of mississippi medical center, jackson, mississippi, united states county oncologist, inc., saint louis, missouri, united states cooper hospital university medical center, camden, new jersey, united states regional cancer care associates, llc, east brunswick, new jersey, united states hudson valley cancer center, fishkill, new york, united states suny upstate medical university, syracuse, new york, united states suny upstate medical university, syracuse, new york, united states east carolina school of medicine, greenville, north carolina, united states aultman medical group hematology & oncology, canton, ohio, united states university of cincinnati cancer institute, cincinnati, ohio, united states cleveland clinic foundation, cleveland, ohio, united states the james cancer hospital, columbus, ohio, united states upmc hillman cancer center, greenville, pennsylvania, united states steward sharon regional cancer center, hermitage, pennsylvania, united states upmc hillman cancer center, new castle, pennsylvania, united states abramson cancer center at pennsylvania hospital, philadelphia, pennsylvania, united states the west clinic, germantown, tennessee, united states tennessee oncology pllc, hixson, tennessee, united states uvahs emily couric clin cancer ctr, charlottesville, virginia, united states kaiser permanente of wa, olympia, washington, united states harrison healthpartners hematology, poulsbo, washington, united states seattle integrative cancer center, renton, washington, united states mon health medical center, morgantown, west virginia, united states ssm health cancer care center, madison, wisconsin, united states west allis memorial hospital, west allis, wisconsin, united states ordensklinikum linz gmbh elisabethinen, linz, oberösterreich, austria kepler universitätsklinikum gmbh, med campus iii, linz, oberösterreich, austria clion - clínica de oncologia, salvador, bahia, brazil instituto londrina de radioterapia, londrina, paraná, brazil chum, montreal, quebec, canada allan blair cancer centre, regina, saskatchewan, canada allan blair cancer centre, regina, saskatchewan, canada szabolcs-szatmar-bereg m-i korhazak es egyetemi oktatokorhaz, nyiregyhaza, szabolcs-szatmar-bereg, hungary national institute of oncology, budapest, hungary healthcare global enterprises limited (hcg), bangalore, karnataka, india istituto oncologico veneto irccs, padova, veneto, italy irccs - aou di bologna, bologna, italy ospedale santa chiara di trento, trento, italy inha university hospital, incheon, incheon-gwangyeoksi [incheon], korea, republic of gachon university gil hospital, namdong-gu, incheon, korea, republic of seoul national university bundang hospital, seongnam, kyǒnggi-do, korea, republic of pusan national university hospital, busan, pusan-kwangyǒkshi, korea, republic of wonkwang university hospital, iksan-si, jeonlabuk-do, korea, republic of hospital universitario de canarias, tenerife, la laguna, spain hospital de navarra, pamplona, navarra, spain clínica mompia, cantabria, santa cruz de bezana, spain hospital universitari vall d'hebron, barcelona, spain cl. universitaria navarra, madrid, spain centro oncológico md anderson, madrid, spain hospital clinico san carlos, madrid, spain hospital madrid norte sanchinarro, madrid, spain gerencia de asistencia sanitaria de segovia_hospital general de segovia, segovia, spain hospital universitario virgen del rocio, sevilla, spain hospital universitario virgen del rocio, sevilla, spain fundación instituto valenciano de oncología, valencia, spain hospital universitario la fe de valencia, valencia, spain china medical university hospital, taichung, taiwan the christie, manchester, greater manchester, united kingdom ninewells hospital, dundee, scotland, united kingdom queen elizabeth hospital, nhs foundation trust, birmingham, united kingdom cambridge university hospitals nhs foundation trust, cambridge, united kingdom""]",,https://ClinicalTrials.gov/show/NCT03994627,sarcoma
679,680,NCT00824265,ofatumumab added to fludarabine-cyclophosphamide vs fludarabine-cyclophosphamide combination in relapsed subjects with chronic lymphocytic leukemia,,Completed,Has Results,"leukaemia, lymphocytic, chronic",drug: ofc infusion|drug: fc infusion,"progression-free survival (pfs), as assessed by the independent review committee (irc)|overall survival (os)|time to response, as assessed by the irc|duration of response (dor), as assessed by the irc|time to progression, as assessed by the irc|time to next therapy|number of participants with improvement in eastern cooperative oncology group (ecog) performance status|number of participants with no b-symptoms or at least one b-symptoms over the time|percentage of participants with the best overall response (or), as assessed by the irc|percentage of participants with the best or, as assessed by the investigator|number of participants who were negative for minimal residual disease (mrd) assessed by irc|number of participants who were negative for mrd assessed by investigator|number of participants with any adverse event (ae) or serious adverse event (sae)|number of participants with a human anti-human antibody (haha) positive result at indicated time points|number of participants with autoimmune hemolytic anaemia (aiha)|number of participants with drug related infections reported as aes and saes of maximum severity of grade 3 or higher|number of participants with at least one grade 3/grade 4 myelosuppression adverse events|number of participants who received no transfusion or at least one transfusion during the study|mean level of immunoglobulin (ig) antibodies iga, igg, and igm|change from baseline in cluster of differentiation (cd) cell counts, cd5+ and cd19+|change from baseline in cell counts, cd5- cd19+|prognostic and biological markers correlating with clinical response|changes in patient reported outcome (pro) measures and scores for european organization for research and treatment of cancer quality of life questionnaire, chronic lymphocytic leukaemia 16 item module (eortc qlq-cll 16)|change from baseline in patient reported outcome (pro) as assessed by euroqol five-dimension (eq-5d) score at indicated visit|change from baseline in the european organization for the research and treatment of cancer quality of life questionnaire core 30 (eortc qlq-c30) score|mean of health change questionnaire (hcq)|mean area under the time-concentration curve (auc) curve over the dosing interval (auc[0-tau]) of ofatumumab|maximum concentration (cmax) and observed drug concentration prior to the next dose (ctrough) of ofatumumab|time of occurrence of cmax (tmax) of ofatumumab",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,365.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,110913,"March 12, 2009","December 17, 2014","October 25, 2017","January 16, 2009","July 25, 2016","June 18, 2020","[""novartis investigative site, boca raton, florida, united states novartis investigative site, chicago, illinois, united states novartis investigative site, clinton, maryland, united states novartis investigative site, kansas city, missouri, united states novartis investigative site, saint louis, missouri, united states novartis investigative site, memphis, tennessee, united states novartis investigative site, brasilia, goiás, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigational site, porto alegre, brazil novartis investigative site, rio de janeiro, brazil novartis investigation site, rio de janeiro, brazil novartis investigative site, rio de janeiro, brazil novartis investigational site, sao paulo, brazil novartis investigative site, pleven, bulgaria novartis investigative site, plovdiv, bulgaria novartis investigative site, sofia, bulgaria novartis investigational site, sofia, bulgaria novartis investigational site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, varna, bulgaria novartis investigative site, new westminster, british columbia, canada novartis investigative site, kitchener, ontario, canada novartis investigative site, newmarket, ontario, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, greenfield park, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, sherbrooke, quebec, canada novartis investigative site, saskatoon, saskatchewan, canada novartis investigative site, karlsruhe, baden-wuerttemberg, germany novartis investigative site, stuttgart, baden-wuerttemberg, germany novartis investigative site, stuttgart, baden-wuerttemberg, germany novartis investigative site, villingen-schwenningen, baden-wuerttemberg, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, frankfurt, hessen, germany novartis investigative site, kassel, hessen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, lehrte, niedersachsen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, moenchengladbach-rheydt, nordrhein-westfalen, germany novartis investigative site, muenster, nordrhein-westfalen, germany novartis investigative site, saarbruecken, saarland, germany novartis investigative site, dresden, sachsen, germany novartis investigational site, hamburg, germany novartis investigational site, lubeck, germany novartis investigative site, athens,, greece novartis investigative site, athens, greece novartis investigative site, thessaloniki, greece novartis investigative site, thessaloniki, greece novartis investigative site, bangalore, india novartis investigative site, mumbai, india novartis investigative site, mumbai, india novartis investigative site, new delhi, india novartis investigative site, pune, india novartis investigative site, vadodara, india novartis investigative site, potenza, basilicata, italy novartis investigative site, roma, lazio, italy novartis investigative site, roma, lazio, italy novartis investigative site, genova, liguria, italy novartis investigative site, pavia, lombardia, italy novartis investigative site, ascoli piceno, marche, italy novartis investigative site, alessandria, piemonte, italy novartis investigative site, novara, piemonte, italy novartis investigative site, catania, sicilia, italy novartis investigative site, palermo, sicilia, italy novartis investigative site, guadalajara, jalisco, mexico novartis investigative site, monterrey, nuevo león, mexico novartis investigative site, monterrey, nuevo león, mexico novartis investigative site, mexico city, mexico novartis investigative site, amersfoort, netherlands novartis investigative site, den haag, netherlands novartis investigative site, nijmegen, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, bialystok, poland novartis investigative site, chorzow, poland novartis investigative site, krakow, poland novartis investigative site, lodz, poland novartis investigative site, opole, poland novartis investigative site, slupsk, poland novartis investigative site, szczecin, poland novartis investigative site, warszawa, poland novartis investigative site, warszawa, poland novartis investigative site, warszawa, poland novartis investigative site, wroclaw, poland novartis investigative site, bucharest, romania novartis investigative site, bucharest, romania iasi, romania novartis investigative site, iasi, romania novartis investigative site, kazan, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, novosibirsk, russian federation novartis investigative site, st'petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, barcelona, spain novartis investigative site, barcelona, spain novartis investigative site, barcelona, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, salamanca, spain novartis investigative site, sevilla, spain novartis investigative site, taichung, taiwan novartis investigative site, taipei city, taiwan novartis investigative site, taipei, taiwan novartis investigational site, taipei, taiwan novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, cherkasy, ukraine novartis investigative site, dnipropetrovsk, ukraine novartis investigative site, kharkiv, ukraine novartis investigative site, khmelnytskyi, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, lviv, ukraine novartis investigative site, makiivka, ukraine novartis investigational site, simferopil, ukraine novartis investigative site, vinnitsa, ukraine novartis investigational site, zhytomyr, ukraine novartis investigative site, birmingham, united kingdom novartis investigative site, bradford, united kingdom novartis investigative site, burton on trent, united kingdom novartis investigative site, cottingham, united kingdom novartis investigative site, dudley, united kingdom novartis investigative site, glasgow, united kingdom novartis investigative site, leicester, united kingdom novartis investigative site, london, united kingdom novartis investigative site, manchester, united kingdom novartis investigative site, sutton, united kingdom novartis investigative site, swindon, united kingdom novartis investigative site, truro, united kingdom novartis investigative site, uxbridge, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00824265,
680,681,NCT04529772,a combination of acalabrutinib with r-chop in subjects with previously untreated non-gcb dlbcl (ace-ly-312),ESCALADE,Recruiting,No Results Available,diffuse large b-cell lymphoma,drug: acalabrutinib|drug: placebo|drug: prednisone|drug: rituximab|drug: cyclophosphamide|drug: vincristine|drug: doxorubicin,progression-free survival (pfs) per the lugano classification for nhl in arm a compared to arm b|investigator-assessed event-free survival (efs) for nhl in arm a compared to arm b|overall survival in arm a compared to arm b|percentage of participants who achieved a complete response (cr) per 2014 lugano classification at the end of study treatment,acerta pharma bv|astrazeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,600.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D8227C00001,"October 8, 2020","August 31, 2026","August 31, 2026","August 28, 2020",,"May 11, 2022","[""research site, tucson, arizona, united states research site, orange, california, united states research site, aurora, colorado, united states research site, denver, colorado, united states research site, norwich, connecticut, united states research site, fort myers, florida, united states research site, miami, florida, united states research site, saint petersburg, florida, united states research site, tallahassee, florida, united states research site, west palm beach, florida, united states research site, fort wayne, indiana, united states research site, des moines, iowa, united states research site, wichita, kansas, united states research site, louisville, kentucky, united states research site, new orleans, louisiana, united states research site, grand rapids, michigan, united states research site, duluth, minnesota, united states research site, kansas city, missouri, united states research site, saint louis, missouri, united states research site, billings, montana, united states research site, omaha, nebraska, united states research site, albany, new york, united states research site, new york, new york, united states research site, new york, new york, united states research site, stony brook, new york, united states research site, eugene, oregon, united states research site, portland, oregon, united states research site, portland, oregon, united states research site, pittsburgh, pennsylvania, united states research site, chattanooga, tennessee, united states research site, nashville, tennessee, united states research site, fort sam houston, texas, united states research site, fort worth, texas, united states research site, lubbock, texas, united states research site, salem, virginia, united states research site, adelaide, australia research site, camperdown, australia research site, clayton, australia research site, darlinghurst, australia research site, heidelberg, australia research site, hobart, australia research site, kogarah, australia research site, liverpool, australia research site, murdoch, australia research site, nedlands, australia research site, south brisbane, australia research site, westmead, australia research site, graz, austria research site, krems, austria research site, linz, austria research site, salzburg, austria research site, wels, austria research site, antwerpen, belgium research site, brugge, belgium research site, brugge, belgium research site, gent, belgium research site, curitiba, brazil research site, florianopolis, brazil research site, goiania, brazil research site, passo fundo, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, ribeirão preto, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são paulo, brazil research site, vancouver, british columbia, canada research site, toronto, ca, canada research site, winnipeg, manitoba, canada research site, st. john's, newfoundland and labrador, canada research site, london, ontario, canada research site, toronto, ontario, canada research site, lévis, quebec, canada research site, montreal, quebec, canada research site, montreal, quebec, canada research site, ottawa, canada research site, quebec, canada research site, changchun, china research site, chengdu, china research site, guangzhou, china research site, haidian district, china research site, hangzhou, china research site, hangzhou, china research site, harbin, china research site, luoyang, china research site, nanchang, china research site, nanjing, china research site, nanning, china research site, shanghai, china research site, shijiazhuang, china research site, suzhou, china research site, tianjin, china research site, wuhan, china research site, xiamen, china research site, xuhui district, china research site, zhengzhou, china research site, brno, czechia research site, hradec kralove, czechia research site, ostrava - poruba, czechia research site, plzen, czechia research site, praha 10, czechia research site, praha 2, czechia research site, bordeaux, france research site, brest, france research site, caen cedex 9, france research site, dijon, france research site, limoges, france research site, lyon, france research site, marseille cedex 5, france research site, montpellier, france research site, nantes, france research site, paris, france research site, pessac, france research site, pierre benite, france research site, rennes cedex 9, france research site, toulouse, france research site, bamberg, germany research site, berlin, germany research site, bremen, germany research site, dresden, germany research site, hamburg, germany research site, homburg, germany research site, mutlangen, germany research site, münster, germany research site, neumünster, germany research site, bangalore, india research site, bangalore, india research site, kochi, india research site, mumbai, india research site, nashik, india research site, nashik, india research site, nashik, india research site, pune, india research site, afula, israel research site, beer sheba, israel research site, haifa, israel research site, haifa, israel research site, holon, israel research site, jerusalem, israel research site, jerusalem, israel research site, petah tikva, israel research site, ramat gan, israel research site, tel aviv, israel research site, zerifin, israel research site, bari, italy research site, bergamo, italy research site, bologna, italy research site, firenze, italy research site, genova, italy research site, meldola, italy research site, milano, italy research site, milan, italy research site, novara, italy research site, palermo, italy research site, pavia, italy research site, pisa, italy research site, ravenna, italy research site, reggio emilia, italy research site, roma, italy research site, roma, italy research site, rozzano, italy research site, siena, italy research site, torino, italy research site, tricase (lecce), italy research site, venezia, italy research site, chiba-shi, japan research site, chuo-ku, japan research site, fukuoka-shi, japan research site, itabashi-ku, japan research site, kahoku-gun, japan research site, kashiwa, japan research site, kobe-shi, japan research site, koto-ku, japan research site, kumamoto-shi, japan research site, matsuyama-shi, japan research site, nagasaki-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, nagoya-shi, japan research site, niigata-shi, japan research site, okayama-shi, japan research site, osaka-shi, japan research site, sapporo-shi, japan research site, shimotsuke-shi, japan research site, tsu-shi, japan research site, busan, korea, republic of research site, busan, korea, republic of research site, goyang-si, korea, republic of research site, jeonjusi deokjingu, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, suwon-si, korea, republic of research site, ulsan, korea, republic of research site, chihuahua, mexico research site, hermosillo, mexico research site, monterrey, mexico research site, kraków, poland research site, poznan, poland research site, warszawa, poland research site, wrocław, poland research site, łódź, poland research site, braga, portugal research site, lisboa, portugal research site, lisboa, portugal research site, lisbon, portugal research site, matosinhos, portugal research site, porto, portugal research site, porto, portugal research site, vila nova de gaia, portugal research site, chelyabinsk, russian federation research site, kazan, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, petrozavodsk, russian federation research site, saint petersburg, russian federation research site, st. petersburg, russian federation research site, alcalá de henares, spain research site, barcelona, spain research site, barcelona, spain research site, barcelona, spain research site, gijón, spain research site, l'hospitalet de llobregat, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, palma, spain research site, pamplona, spain research site, pozuelo de alarcón, spain research site, salamanca, spain research site, sevilla, spain research site, valencia, spain research site, valencia, spain research site, kaohsiung, taiwan research site, tainan, taiwan research site, tainan, taiwan research site, taipei 112, taiwan research site, taipei, taiwan research site, taipei, taiwan research site, taoyuan city, taiwan research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, balcova, turkey research site, edirne, turkey research site, izmir, turkey research site, kayseri, turkey research site, mersin, turkey research site, samsun, turkey research site, trabzon, turkey research site, cherkasy, ukraine research site, ivano-frankivsk, ukraine research site, khmelnytskyi, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, kyiv, ukraine research site, lviv, ukraine research site, mykolayiv, ukraine research site, zaporizhzhia, ukraine""]",,https://ClinicalTrials.gov/show/NCT04529772,lymphoma
681,682,NCT01915303,study of the efficacy and safety of pasireotide s.c. +/- cabergoline in patients with cushing's disease,,Terminated,Has Results,cushings disease,drug: pasireotide with or without cabergoline,"percentage of responders with mean urinary free cortisol (mufc) ≤ 1.0xuln collected or imputed at week 35|mean urinary free cortisol (mufc) at scheduled visits|percentage of responders with mean urinary free cortisol (mufc) ≤ 1.0xuln|percentage of participants who attain mufc ≤ 1.0 x uln or have at least 50% reduction from baseline in mufc|duration (weeks) of controlled or partially controlled response|plasma adrenocorticotropic hormone (acth)|serum cortisol levels|sitting systolic blood pressure at week 35|sitting diastolic blood pressure at week 35|body weight at week 35|body mass index at week 35|waist circumference at week 35|ldl, hdl and total cholesterol at week 35|mean scores of cushing qol standardized score at week 17 and 35|mean scores of sf-12v2 domain scores at week 17 and 35|number of participants with improvement in clinical symptom of hypercortisolism from baseline - facial rubor|number of participants with improvement in clinical symptom of hypercortisolism from baseline - hirsutism|number of participants with improvement in clinical symptom of hypercortisolism from baseline - striae|number of participants with improvement in clinical symptom of hypercortisolism from baseline - supraclavicular fat pad|number of participants with improvement in clinical symptom of hypercortisolism from baseline - dorsal fat pad|number of participants with shift from mild to severe in clinical signs of hypercortisolism|number of patients with shift from standing easily to not being able to stand",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,68.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSOM230B2411,"March 6, 2014","September 5, 2016","September 4, 2019","August 2, 2013","September 18, 2020","September 18, 2020","['university of alabama at birmingham the kirklin clinic, birmingham, alabama, united states oregon health and science university som230b2411, portland, oregon, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, gent, belgium novartis investigative site, leuven, belgium novartis investigative site, curitiba, pr, brazil novartis investigative site, rio de janeiro, rj, brazil novartis investigative site, porto alegre, rs, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, bogota, cundinamarca, colombia novartis investigative site, vandoeuvre cedex, france novartis investigative site, erlangen, germany novartis investigative site, athens, greece novartis investigative site, thessaloniki, greece novartis investigative site, budapest, hungary novartis investigative site, budapest, hungary novartis investigative site, vellore, tamil nadu, india novartis investigative site, chandigarh, india novartis investigative site, new delhi, india novartis investigative site, napoli, italy novartis investigative site, wilayah persekutuan, malaysia novartis investigative site, méxico, distrito federal, mexico novartis investigative site, durango, mexico novartis investigative site, rotterdam, netherlands novartis investigative site, malaga, andalucia, spain novartis investigative site, alzira, comunidad valenciana, spain novartis investigative site, istanbul, tur, turkey novartis investigative site, izmir, turkey novartis investigative site, pendik / istanbul, turkey']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/03/nct01915303/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/03/nct01915303/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01915303,
682,683,NCT00748189,ofatumumab + chlorambucil vs chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia,COMPLEMENT 1,Terminated,Has Results,"leukaemia, lymphocytic, chronic","drug: chlorambucil, tablets|drug: ofatumumab (gsk1841157) infusion","progression-free survival (pfs), as assessed by the independent review committee (irc)|number of participants with the best overall response (or), as assessed by the irc|number of participants who were negative for minimal residual disease (mrd)|overall survival|time to response, as assessed by the irc|duration of response (dor), as assessed by the irc|time to progression, as assessed by the irc|time to next therapy|number of participants with improvement in ecog performance status of 0 or 1|number of participants with improvement in constitutional symptoms (cs)|number of participants with a human anti-human antibody (haha) positive result|cmax and ctrough of ofatumumab|total plasma clearance (cl) of ofatumumab|auc(0-tau) of ofatumumab|volume of distribution at steady state (vss) of ofatumumab|plasma half life (t1/2) of ofatumumab|dose-normalized cmax of chlorambucil and phenylacetic acid mustard (paam)|dose-normalized auc(0-6) and auc(0-inf) of chlorambucil and dose-normalized auc(0-6) of phenylacetic acid mustard (paam)|change from baseline in health related quality of life (hrqol)|number of participants with any adverse event (ae) or serious adverse event (sae)|number of participants with aes and saes of maximum severity of grade 3 or higher|number of participants with at least one grade 3/grade 4 myelosuppression (anemia, neutropenia, and thrombocytopenia)|number of participants with autoimmune hemolytic anaemia (aiha) disease|number of participants who received no transfusion or at least one transfusion during the study|mean change from baseline in the immunoglobulin (ig) antibodies iga, igg, and igm",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,447.0,Industry,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,OMB110911,"December 22, 2008","March 20, 2013","May 17, 2018","September 8, 2008","March 26, 2014","June 25, 2019","[""novartis investigative site, sedona, arizona, united states novartis investigative site, tucson, arizona, united states novartis investigative site, murrieta, california, united states novartis investigative site, aurora, colorado, united states novartis investigative site, denver, colorado, united states novartis investigative site, boca raton, florida, united states novartis investigative site, new port richey, florida, united states novartis investigative site, ocala, florida, united states novartis investigative site, ocoee, florida, united states novartis investigative site, marietta, georgia, united states novartis investigative site, chicago, illinois, united states novartis investigative site, indianapolis, indiana, united states novartis investigative site, lee's summit, missouri, united states novartis investigative site, raleigh, north carolina, united states novartis investigative site, abilene, texas, united states novartis investigative site, arlington, texas, united states novartis investigative site, austin, texas, united states novartis investigative site, dallas, texas, united states novartis investigative site, dallas, texas, united states novartis investigative site, fort worth, texas, united states novartis investigative site, midland, texas, united states novartis investigative site, odessa, texas, united states novartis investigative site, san antonio, texas, united states novartis investigative site, san antonio, texas, united states novartis investigative site, tyler, texas, united states novartis investigative site, waco, texas, united states novartis investigative site, webster, texas, united states novartis investigative site, seattle, washington, united states novartis investigative site, vancouver, washington, united states novartis investigative site, yakima, washington, united states novartis investigative site, brugge, belgium novartis investigative site, bruxelles, belgium novartis investigative site, gent, belgium novartis investigative site, haine-saint-paul, belgium novartis investigative site, leuven, belgium novartis investigative site, porto alegre, rio de janeiro, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, toronto, ontario, canada novartis investigative site, montreal, quebec, canada novartis investigative site, sherbrooke, quebec, canada novartis investigative site, brno, czechia novartis investigative site, hradec kralove, czechia novartis investigative site, praha 10, czechia novartis investigative site, creteil, france novartis investigative site, pierre benite, france novartis investigative site, karlsruhe, baden-wuerttemberg, germany novartis investigative site, mannheim, baden-wuerttemberg, germany novartis investigative site, stuttgart, baden-wuerttemberg, germany novartis investigative site, ulm, baden-wuerttemberg, germany novartis investigative site, erlangen, bayern, germany novartis investigative site, muenchen, bayern, germany novartis investigative site, regensburg, bayern, germany novartis investigative site, wuerzburg, bayern, germany novartis investigative site, frankfurt, hessen, germany novartis investigative site, kassel, hessen, germany novartis investigative site, hannover, niedersachsen, germany novartis investigative site, lehrte, niedersachsen, germany novartis investigative site, essen, nordrhein-westfalen, germany novartis investigative site, koeln, nordrhein-westfalen, germany novartis investigative site, moenchengladbach-rheydt, nordrhein-westfalen, germany novartis investigative site, muenster, nordrhein-westfalen, germany novartis investigative site, saarbruecken, saarland, germany novartis investigative site, athens,, greece novartis investigative site, thessaloniki, greece novartis investigative site, thessaloniki, greece novartis investigative site, ahmedabad, india novartis investigative site, bangalore, india novartis investigative site, mumbai, india novartis investigative site, mumbai, india novartis investigative site, new delhi, india novartis investigative site, pune, india novartis investigative site, cork, ireland novartis investigative site, dublin, ireland novartis investigative site, galway, ireland novartis investigative site, james street, ireland novartis investigative site, limerick, ireland novartis investigative site, tullamore, ireland novartis investigative site, waterford, ireland novartis investigative site, potenza, basilicata, italy novartis investigative site, napoli, campania, italy novartis investigative site, albano laziale (roma), lazio, italy novartis investigative site, genova, liguria, italy novartis investigative site, brescia, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, milano, lombardia, italy novartis investigative site, ascoli piceno, marche, italy novartis investigative site, novara, piemonte, italy novartis investigative site, bari, puglia, italy novartis investigative site, palermo, sicilia, italy novartis investigative site, venezia - mestre, veneto, italy novartis investigative site, vicenza, veneto, italy novartis investigative site, udine, italy novartis investigative site, amersfoort, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, den haag, netherlands novartis investigative site, groningen, netherlands novartis investigative site, nijmegen, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, bialystok, poland novartis investigative site, chorzow, poland novartis investigative site, lodz, poland novartis investigative site, slupsk, poland novartis investigative site, warszawa, poland novartis investigative site, wroclaw, poland novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, novosibirsk, russian federation novartis investigative site, st'petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, barcelona, spain novartis investigative site, barcelona, spain novartis investigative site, hospitalet de llobregat (barcelona), spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, salamanca, spain novartis investigative site, valencia, spain novartis investigative site, lulea, sweden novartis investigative site, stockholm, sweden novartis investigative site, uppsala, sweden novartis investigative site, plymouth, devon, united kingdom novartis investigative site, taunton, somerset, united kingdom novartis investigative site, sunderland, tyne, united kingdom novartis investigative site, bath, united kingdom novartis investigative site, belfast, united kingdom novartis investigative site, birmingham, united kingdom novartis investigative site, bournemouth, united kingdom novartis investigative site, bradford, united kingdom novartis investigative site, cambridge, united kingdom novartis investigative site, canterbury, kent, united kingdom novartis investigative site, carshalton, united kingdom novartis investigative site, cornwall, united kingdom novartis investigative site, dudley, united kingdom novartis investigative site, exeter, united kingdom novartis investigative site, glasgow, united kingdom novartis investigative site, leeds, united kingdom novartis investigative site, liverpool, united kingdom novartis investigative site, london, united kingdom novartis investigative site, london, united kingdom novartis investigative site, manchester, united kingdom novartis investigative site, milton keynes, united kingdom novartis investigative site, newcastle-upon-tyne, united kingdom novartis investigative site, norwich, united kingdom novartis investigative site, oxford, united kingdom novartis investigative site, peterborough, united kingdom novartis investigative site, rhyl, denbighshire, united kingdom novartis investigative site, salford, united kingdom novartis investigative site, stoke on trent, united kingdom novartis investigative site, swindon, united kingdom novartis investigative site, uxbridge, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00748189,
683,684,NCT00018954,chemotherapy in treating patients with acute lymphoblastic leukemia and diffuse non-hodgkin's lymphoma,,Completed,No Results Available,leukemia|lymphoma,drug: asparaginase|drug: cyclophosphamide|drug: cytarabine|drug: daunorubicin hydrochloride|drug: doxorubicin hydrochloride|drug: etoposide|drug: ifosfamide|drug: mercaptopurine|drug: methotrexate|drug: prednisone|drug: vincristine sulfate|procedure: conventional surgery|radiation: radiation therapy,,national institutes of health clinical center (cc)|national cancer institute (nci),All,"Child, Adult, Older Adult",Phase 2,,NIH,Interventional,Primary Purpose: Treatment,CDR0000077227|NCI-92-C-0030|NCI-T91-0259N|OH92-C-0030,October 1992,,October 2002,"June 12, 2003",,"February 20, 2012","['warren grant magnuson clinical center - nci clinical studies support, bethesda, maryland, united states national cancer institute of egypt, cairo, egypt kidwai memorial institute of oncology, bangalore, india cancer institute (w.i.a.), madras, india tata memorial centre, mumbai, india']",,https://ClinicalTrials.gov/show/NCT00018954,lymphoma blood
684,685,NCT02629692,safety and anti-leukemic activity of vodobatinib (k0706) for treatment refractory/intolerant cml failing ≥3 prior cml therapies,,Recruiting,No Results Available,healthy (for part a)|chronic myeloid leukemia (for part b and c),drug: vodobatinib (k0706) capsules,to determine the maximum tolerated dose (mtd) as determined by frequency of dose limiting toxicities|incidence and severity of treatment emergent aes as assessed by ctcae v4.03|for cml subjects in cp at study entry|for cml subjects in ap at study entry|for cml subjects in bp at study entry|pharmacokinetic profile of k0706 - cmax [the maximum (peak) observed drug concentration after dose administration]|pharmacokinetic profile of vodobatinib (k0706) - tmax [the time to reach maximum (peak) drug concentration after dose administration]|pharmacokinetic profile of vodobatinib (k0706) - cmin [ minimum observed drug concentration after dose administration]|in subjects with cml- cp:proportion of subjects achieving complete hematological response as assessed by complete blood count of peripheral blood sample|in subjects with cml- cp:proportion of subjects achieving complete cytogenetic response as assessed by conventional karyotyping of bone marrow aspirate|in subjects with cml- cp:proportion of subjects achieving major molecular response as assessed by bcr-abl transcript levels (bcr-abl1 ratio of ≤ 0.1%) in peripheral blood using pcr (polymerase chain reaction)|in subjects with cml-ap & bp: proportion of subjects achieving complete cytogenetic response as assessed by conventional karyotyping of bone marrow aspirate|in subjects with cml-ap & bp: proportion of subjects achieving partial cytogenetic response (pcyr) as assessed by conventional karyotyping of bone marrow aspirate|in subjects with cml-ap & bp: proportion of subjects achieving major molecular response as assessed by bcr-abl transcript levels (bcr-abl1 ratio of ≤ 0.1%) in peripheral blood using pcr (polymerase chain reaction)|time to major cytogenetic response (mcyr): time to mcyr is the time from first dose to first mcyr (0-35% ph+ metaphases) ; computed only for subjects who achieved mcyr|time to major molecular response : time to mmr is the time from first dose to first mmr (bcr-abl1 ratio of ≤ 0.1%) computed only for subjects who achieved mmr|in all subjects progression free survival (pfs)|in all subjects overall survival (os)|incidence and severity of treatment emergent aes as assessed by ctcae v5.0,sun pharma advanced research company limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,303.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLR_15_03 V 12 Amendment 12,"April 25, 2017",August 2022,August 2026,"December 14, 2015",,"April 28, 2022","['the oncology institute of hope and innovation, innovative clinical research institute, downey, california, united states ucla hematologic malignancy program, los angeles, california, united states university of southern california, los angeles, california, united states mayo clinic, jacksonville, florida, united states board of regents of the university system of georgia, augusta, georgia, united states iu simon cancer center, indianapolis, indiana, united states indiana blood marro transplant, indianapolis, indiana, united states hackensack university medical center, hackensack, new jersey, united states memorial sloan kettering cancer center - main, new york, new york, united states new york medical college, valhalla, new york, united states east carolina university, greenville, north carolina, united states baylor university medical center, dallas, texas, united states md anderson cancer center, houston, texas, united states huntsman cancer institute university of utah, salt lake city, utah, united states zna stuivenberg, antwerpen, belgium cliniques universitaires saint-luc, bruxelles, belgium uz leuven, leuven, belgium institut paoli calmettes, marseille cedex 9, bouches-du-rhône, france institut bergonié, bordeaux cedex, gironde, france chu de limoges - hôpital dupuytren, limoges cedex, haute vienne, france chu rennes - hopital pontchaillou, rennes cedex 9, ille et vilaine, france chu de nantes - hotel dieu, nantes cedex 1, loire atlantique, france chu angers - hôpital hôtel dieu, angers, maine et loire, france chu de nancy - hôpital de brabois adultes, vandœuvre-lès-nancy, meurthe et moselle, france hopital claude huriez - chru lille, lille cedex, nord, france hôpital saint-louis, paris cedex 10, paris, france centre léon bérard, lyon cedex 08, rhone, france centre hospitalier lyon sud, pierre-bénite, rhone, france hôpital avicenne, bobigny cedex, seine saint denis, france chu amiens - hopital sud, salouel, somme, france chu poitiers - hôpital la milétrie, poitiers, vienne, france semmelweis egyetem, budapest, hungary debreceni egyetem, debrecen, hungary szszb megyei korhazak es egyetemi oktatokorhaz, nyiregyhaza, hungary pecsi tudomanyegyetem, pecs, hungary prince aly khan hospital, mumbai, maharashtra, india tata memorial hospital, mumbai, maharashtra, india sahyadri specialty hospital, pune, maharashtra, india meenakshi mission hospital & research centre, madurai, tamilnadu, india chittaranjan national cancer institute, kolkata, west bengal, india tata medical centre, kolkata, west bengal, india istituto scientifico romagnolo per lo studio e la cura dei tumori, meldola, forli - cesena, italy azienda socio sanitaria territoriale di monza (presidio san gerardo), monza, milano, italy azienda ospedaliera universitaria ""policlinico - vittorio emanuele"" (presidio ferrarotto alessi), catania, italy azienda ospedaliera universitaria careggi, firenze, italy fondazione irccs ca\' granda ospedale maggiore policlinico, milano, italy azienda socio sanitaria territoriale niguarda (grande ospedale metropolitano niguarda), milano, italy ospedale sant\'eugenio, roma, italy azienda ospedaliera universitaria policlinico umberto i - università di roma la sapienza, roma, italy the catholic university of korea, seoul st. mary\'s hospital, seoul, gyeonggi-do, korea, republic of the catholic university of korea, seoul st. mary\'s hospital, seoul, gyeonggi-do, korea, republic of uijeongbu eulji medical center, eulji university, gyeonggi-do, korea, republic of spitalul clinic colentina, bucuresti, romania spitalul clinic coltea, bucuresti, romania institutul oncologic ""prof. dr. ion chiricuta"" cluj-napoca, cluj-napoca, romania spitalul clinic municipal filantropia craiova, craiova, romania spitalul clinic judetean de urgenta targu mures, târgu mureș, romania singapore general hospital, singapore, singapore ico badalona - hospital universitari germans trias i pujol, badalona, barcelona, spain hospital universitari vall d\'hebron, barcelona, spain ico girona - hospital universitari de girona dr josep trueta, girona, spain hospital universitario ramon y cajal, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital universitario la paz, madrid, spain hospital clinico universitario virgen de la victoria, málaga, spain hospital universitario de salamanca, salamanca, spain hospital universitario virgen macarena, sevilla, spain hospital universitario virgen del rocio, sevilla, spain king\'s college hospital, london, greater london, united kingdom hammersmith hospital, london, greater london, united kingdom']",,https://ClinicalTrials.gov/show/NCT02629692,blood
685,686,NCT02944682,household air pollution and health: a multi-country lpg intervention trial,HAPIN,"Active, not recruiting",No Results Available,"infant, low birth weight",other: liquefied petroleum gas (lpg) cookstove,birth weight|incidence of hapin severe pneumonia|length-for-age z-score|blood pressure|maternal blood pressure|change in fetal growth|preterm birth|gestational age at birth|change in child development|brachial artery reactivity testing (bart)|carotid intima-media thickness (cimt)|adult respiratory health and well-being|short form 36 survey|severe pneumonia,"emory university|national institutes of health (nih)|national heart, lung, and blood institute (nhlbi)|bill and melinda gates foundation|berkeley air monitoring group|colorado state university|global alliance for clean cookstoves|global lpg partnership|harvard university|johns hopkins university|london school of hygiene and tropical medicine|asociacion benefica prisma|sri ramachandra university|universidad del valle, guatemala|universidad peruana cayetano heredia|university of georgia|washington university school of medicine|university of rwanda|eagle research center|university of oxford",All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,3640.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB00089799|1UM1HL134590-01,"April 16, 2018","October 1, 2021","June 30, 2022","October 26, 2016",,"April 8, 2022","['universidad del valle de guatemala, guatemala, guatemala sri ramachandra institute of higher education and research, chennai, tamil nadu, india puno global non-communicable disease research site, school of medicine, johns hopkins university, puno, peru rwanda research site, london school of hygiene and tropical medicine, kigali, rwanda']","""statistical analysis plan: birthweight (intention-to-treat and exposure-response)"", https://clinicaltrials.gov/provideddocs/82/nct02944682/sap_000.pdf|""statistical analysis plan: stunting (intention-to-treat)"", https://clinicaltrials.gov/provideddocs/82/nct02944682/sap_002.pdf|""informed consent form"", https://clinicaltrials.gov/provideddocs/82/nct02944682/icf_001.pdf",https://ClinicalTrials.gov/show/NCT02944682,
686,687,NCT00777036,a phase ii study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (cml) or with ph+ leukemias resistant or intolerant to imatinib,,"Active, not recruiting",Has Results,leukemia,drug: dasatinib,major cytogenetic response (mcyr) rate|complete hematologic response (chr) rate|complete cytogenetic response (ccyr) rate|major cytogenetic response (mcyr) rate in cohort 2|complete hematologic response (chr) rate in cohorts 1 and 3|rate of best cytogenetic response|time to major cytogenetic response (mcyr)|duration of major cytogenetic response (mcyr)|time to complete cytogenetic response (ccyr)|duration of complete cytogenetic response (ccyr)|progression-free survival (pfs) rate at 2 years|time to complete hematologic response (chr)|duration of complete hemotologic response (chr)|disease-free survival rate at 2 years|overall survival (os) rate at 2 years|major molecular response (mmr) rate|complete molecular response (cmr) rate|major cytogenetic response (mcyr) rate up to 2 years|complete cytogenetic response (ccyr) rate up to 2 years|major molecular response (mmr) rate up to 2 years|complete molecular response (cmr) rate up to 2 years,bristol-myers squibb,All,"up to 18 Years   (Child, Adult)",Phase 2,145.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA180-226|2008-002260-33,"March 20, 2009","September 1, 2016","December 16, 2022","October 22, 2008","January 5, 2018","May 5, 2022","[""local institution, birmingham, alabama, united states phoenix children's hospital, phoenix, arizona, united states jonathan jaques children's cancer center, long beach, california, united states jonathan jaques children's cancer center, long beach, california, united states children's hospital of orange county, orange, california, united states children's hospital, aurora, colorado, united states children's healthcare of atlanta - egleston, atlanta, georgia, united states children's hospital of chicago, chicago, illinois, united states local institution - 0072, chicago, illinois, united states local institution, chicago, illinois, united states dana faber cancer institute, boston, massachusetts, united states dana farber cancer institute., boston, massachusetts, united states stephen d. hassenfeld children's center, new york, new york, united states local institution - 0061, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states memorial sloan kettering nassau, new york, new york, united states oregon health & sci univ, portland, oregon, united states oregon health & sci univ, portland, oregon, united states children's hospital of philadelphia, philadelphia, pennsylvania, united states children's hospital of pittsburgh, pittsburgh, pennsylvania, united states md anderson cancer center, houston, texas, united states texas children's cancer center, houston, texas, united states seattle children's, seattle, washington, united states local institution, bunos aires, buenos aires, argentina hospital nacional profesor alejandro posadas, el palomar, buenos aires, argentina local institution, cordoba, argentina local institution, randwick, new south wales, australia local institution, westmead, new south wales, australia local institution, sth brisbane, queensland, australia local institution, north adelaide, south australia, australia local institution, parkville, victoria, australia local institution, curitiba, parana, brazil local institution, porto alegre, rio grande do sul, brazil local institution, campinas, brazil local institution, sao paulo, brazil local institution, sao paulo, brazil alberta children's hospital, calgary, alberta, canada stollery children's hospital, edmonton, alberta, canada bc children's hospital, vancouver, british columbia, canada iwk health centre, halifax, nova scotia, canada children's hospital of eastern ontario, ottawa, ontario, canada the hospital for sick children, toronto, ontario, canada chu ste-justine, montreal, quebec, canada local institution, lyon, france local institution, nantes, france local institution, paris cedex 12, france local institution, paris, france local institution, paris, france local institution, poitiers, france local institution, frankfurt, germany local institution, hannover, germany local institution - 0089, navrangpura, ahmedabad, gujarat, india local institution, navrangpura, ahmedabad, gujarat, india local institution, bangalore, karnataka, india local institution, mumbai, maharashtra, india local institution, pune, maharashtra, india local institution, madurai, tamil nadu, india local institution, vellore, tamilnadu, india local institution, kolkatta, india local institution, mumbai, india local institution, trivandrum, india local institution, bologna, italy local institution, monza (mb), italy local institution, roma, italy local institution, roma, italy local institution, torino, italy local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, df, distrito federal, mexico local institution, mexico d.f., distrito federal, mexico local institution, mexico, d. f., distrito federal, mexico local institution, mexico, distrito federal, mexico hospital civil de guadalajara - nuevo dr. juan i. menchaca, guadalajara, jalisco, mexico local institution, monterrey, n.l., nuevo leon, mexico local institution, monterrey, nuevo leon, mexico local institution, rotterdam, netherlands local institution - 0099, utrecht, netherlands local institution, bucharest, romania local institution, moscow, russian federation local institution, moscow, russian federation local institution, saint-petersburg, russian federation local institution, singapore, singapore local institution, bloemfontein, free state, south africa local institution, pretoria, gauteng, south africa local institution, cape town, western cape, south africa local institution, tygerberg, western cape, south africa local institution, barcelona, spain local institution, barcelona, spain local institution, madrid, spain local institution, madrid, spain local institution, malaga, spain local institution, valencia, spain local institution, valencia, spain local institution, glasgow, central, united kingdom local institution, sutton, surrey, united kingdom local institution, birmingham, west midlands, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00777036,blood
687,688,NCT00802841,randomized phase lll study of imatinib dose optimization vs nilotinib in cml patients with suboptimal response to imatinib,LASOR,Completed,Has Results,chronic myelogenous leukemia,drug: nilotinib|drug: imatinib,percentage of participants with complete cytogenetic response (ccyr)|percentage of participants with major molecular response (mmr)|percentage of participants with ccyr|time to ccyr|duration of ccyr|progression-free survival (pfs)|event-free survival (efs)|overall survival (os),novartis pharmaceuticals|novartis,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,191.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAMN107A2404|2008-007054-35,May 2009,July 2014,July 2014,"December 5, 2008","November 16, 2015","November 16, 2015","['novartis investigative site, caba, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, la plata, buenos aires, argentina novartis investigative site, rio negro, viedma, argentina novartis investigative site, belo horizonte, mg, brazil novartis investigative site, cuiaba, mg, brazil novartis investigative site, curitiba, pr, brazil novartis investigative site, londrina, pr, brazil novartis investigative site, rio de janeiro, rj, brazil novartis investigative site, rio de janeiro, rj, brazil novartis investigative site, porto alegre, rs, brazil novartis investigative site, florianopolis, sc, brazil novartis investigative site, campinas, sp, brazil novartis investigative site, jaú, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, são paulo, sp, brazil novartis investigative site, são paulo, sp, brazil novartis investigative site, são paulo, sp, brazil novartis investigative site, nanjing, jiangsu, china novartis investigative site, chengdu, sichuan, china novartis investigative site, tianjin, tianjin, china novartis investigative site, beijing, china novartis investigative site, fuzhou, china novartis investigative site, shanghai, china novartis investigative site, bogota, cundinamarca, colombia novartis investigative site, monteria, colombia novartis investigative site, berlin, germany novartis investigative site, guatemala city, guatemala novartis investigative site, hyderabad, andhra pradesh, india novartis investigative site, bangalore, karnataka, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, ahmedabad, india novartis investigative site, mumbai 400 020, india novartis investigative site, mumbai, india novartis investigative site, new delhi, india novartis investigative site, mexico, distrito federal, mexico novartis investigative site, méxico, distrito federal, mexico novartis investigative site, méxico, distrito federal, mexico novartis investigative site, méxico, distrito federal, mexico novartis investigative site, zapopan, jalisco, mexico novartis investigative site, monterrey, nuevo león, mexico novartis investigative site, panama city, panamá, panama novartis investigative site, kraków, poland novartis investigative site, wroclaw, poland novartis investigative site, ekaterinburg, russian federation novartis investigative site, krasnoyarsk, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, n.novgorod, russian federation novartis investigative site, perm, russian federation novartis investigative site, rostov-on-don, russian federation novartis investigative site, saint-petersburg, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, volgograd, russian federation novartis investigative site, caracas, distrito capital, venezuela novartis investigative site, maracaibo, estado zulia, venezuela']",,https://ClinicalTrials.gov/show/NCT00802841,blood
688,689,NCT01254188,safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients,ENESTxtnd,Completed,Has Results,chronic myeloid leukemia,drug: nilotinib,"the percentage of patients achieving mmr by 12 months|time to molecular response at 24 months|duration of major molecular response|complete cytogenetic response|percentage of participants estimated to maintain their first ccyr for 6, 12, 18, and 24 months after the first ccyr was achieved as determined by kaplan meier estimatation.|overall survival|kaplan-meier estimates of progression-free survival|kaplan-meier estimates of failure-free survival",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,421.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAMN107E2401,April 2011,November 2014,November 2014,"December 6, 2010","March 3, 2016","March 3, 2016","[""novartis investigative site, alger, bouzareah, algeria novartis investigative site, oran, algeria novartis investigative site, caba, buenos aires, argentina novartis investigative site, paraná, entre rios, argentina novartis investigative site, buenos aires, argentina novartis investigative site, canberra, australian capital territory, australia novartis investigative site, concord nsw, new south wales, australia novartis investigative site, gosford, new south wales, australia novartis investigative site, kingswood, new south wales, australia novartis investigative site, kogarah, new south wales, australia novartis investigative site, liverpool, new south wales, australia novartis investigative site, st. leonards, new south wales, australia novartis investigative site, westmead, new south wales, australia novartis investigative site, douglas, queensland, australia novartis investigative site, woolloongabba, queensland, australia novartis investigative site, adelaide, south australia, australia novartis investigative site, bedford park, south australia, australia novartis investigative site, hobart, tasmania, australia novartis investigative site, box hill, victoria, australia novartis investigative site, clayton, victoria, australia novartis investigative site, fitzroy, victoria, australia novartis investigative site, heidelberg, victoria, australia novartis investigative site, parkville, victoria, australia novartis investigative site, wodonga, victoria, australia novartis investigative site, nedlands, western australia, australia novartis investigative site, perth, western australia, australia novartis investigative site, salvador, ba, brazil novartis investigative site, goiania, go, brazil novartis investigative site, curitiba, pr, brazil novartis investigative site, porto alegre, rs, brazil novartis investigative site, edmonton, alberta, canada novartis investigative site, vancouver, british columbia, canada novartis investigative site, vancouver, british columbia, canada novartis investigative site, moncton, new brunswick, canada novartis investigative site, saint john, new brunswick, canada novartis investigative site, st. john's, newfoundland and labrador, canada novartis investigative site, halifax, nova scotia, canada novartis investigative site, barrie, ontario, canada novartis investigative site, brampton, ontario, canada novartis investigative site, hamilton, ontario, canada novartis investigative site, london, ontario, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, weston, ontario, canada novartis investigative site, windsor, ontario, canada novartis investigative site, montreal, quebec, canada novartis investigative site, québec, quebec, canada novartis investigative site, saskatoon, saskatchewan, canada novartis investigative site, alexandria, egypt novartis investigative site, cairo, egypt novartis investigative site, cairo, egypt novartis investigative site, mansoura, egypt novartis investigative site, tamil nadu, chennai, india novartis investigative site, pune, maharashtra, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, jerusalem, israel novartis investigative site, petach tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, beirut, lebanon novartis investigative site, saida, lebanon novartis investigative site, pulau pinang, malaysia novartis investigative site, selangor, malaysia novartis investigative site, hermosillo, sonora, mexico novartis investigative site, san luis potosi, mexico novartis investigative site, muscat, oman novartis investigative site, arkhangelsk, russia, russian federation novartis investigative site, novosibirsk, russia, russian federation novartis investigative site, perm, russia, russian federation novartis investigative site, ryazan, russia, russian federation novartis investigative site, st petersburg, russia, russian federation novartis investigative site, tumen, russia, russian federation novartis investigative site, ekaterinburg, russian federation novartis investigative site, irkutsk, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, nizhnii novgorod, russian federation novartis investigative site, rostov-on-don, russian federation novartis investigative site, rostov-on-don, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, st-petersburg, russian federation novartis investigative site, tula, russian federation novartis investigative site, dammam, saudi arabia novartis investigative site, jeddah, saudi arabia novartis investigative site, jeddah, saudi arabia novartis investigative site, riyadh, saudi arabia novartis investigative site, riyadh, saudi arabia novartis investigative site, soweto, gauteng, south africa novartis investigative site, bloemfontein, south africa novartis investigative site, observatory, south africa novartis investigative site, parktown, south africa novartis investigative site, pretoria, south africa novartis investigative site, taipei, taiwan, roc, taiwan novartis investigative site, lin-kou, taiwan novartis investigative site, niaosong township, taiwan novartis investigative site, taichung, taiwan novartis investigative site, chiang mai, thailand novartis investigative site, muang, thailand novartis investigative site, sousse, tunisie, tunisia novartis investigative site, tunis, tunisia novartis investigative site, dubai, united arab emirates""]",,https://ClinicalTrials.gov/show/NCT01254188,blood
689,690,NCT01303237,a post marketing surveillance study to assess the safety and efficacy of cetuximab plus radiotherapy in locally advanced squamous cell carcinoma of the head and neck,PMS LAD SCCHN,Terminated,No Results Available,unresectable locally advanced squamous cell carcinoma of head and neck|la scchn,drug: cetuximab + rt,number of patients with serious adverse reactions|response rate|progression free survival|duration of locoregional disease control|overall survival|management of skin conditions due to treatment protocol,"merck kgaa, darmstadt, germany|merck ltd., india",All,"Child, Adult, Older Adult",,88.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,EMR062202-539,"February 28, 2011","June 30, 2013","August 5, 2014","February 24, 2011",,"June 9, 2017","[""omega hospital, hyderabad, andhra pradesh, india shanti chandra family clinic, hyderabad, andhra pradesh, india swarna sai hospital, hyderabad, andhra pradesh, india dr. nikhil's clinic, secunderabad, andhra pradesh, india arogya multispeciality clinic, mangalore, bangalore, india aastha oncology associates, ahmedabad, gujarat, india navneet memorial centre, ahmedabad, gujarat, india meharbai tata memorial hospital, bistupur, jamshedpur, india dr. t. p. sahoo's clinic, bhopal, madhya pradesh, india ruby hall clinic, pune, maharashtra, india dr s m karandikar hospital, pune, maharashtra, india dwidal nursing home, pune, maharashtra, india regional cancer center, sheikpura, patna, india grecian superspeciality hospital, mohali, punjab, india harmony health care, mohali, punjab, india bhagwan mahaveer cancer hospital & research center, jaipur, rajasthan, india sms hospital, jaipur, rajasthan, india cancer care centre, jaipur, rajasthan, india balaji clinic & general hospital, jaipur, rajasthan, india royal cancer institute and research centre, kanpur, uttar pradesh, india smh curie cancer centre, new delhi, uttar pradesh, india bengal oncology, kolkata, west bengal, india apollo gleneagles cancer hospital, kolkata, west bengal, india oncologist & palliative care specialist clinic, kolkata, west bengal, india dr. meenu's clinic, delhi, india""]",,https://ClinicalTrials.gov/show/NCT01303237,skin
690,691,NCT00019409,radiation therapy to the head or intrathecal chemotherapy plus high dose cytarabine in preventing cns disease in children with acute lymphoblastic leukemia,,Withdrawn,No Results Available,leukemia,drug: asparaginase|drug: cyclophosphamide|drug: cytarabine|drug: daunorubicin hydrochloride|drug: mercaptopurine|drug: methotrexate|drug: prednisone|drug: therapeutic hydrocortisone|drug: vincristine sulfate|radiation: radiation therapy,,national institutes of health clinical center (cc)|national cancer institute (nci),All,"1 Year to 20 Years   (Child, Adult)",Phase 3,0.0,NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,999998007|98-C-N007|MCP943|NCI-0H98-C-N007|CDR0000066120,October 1999,,July 2001,"February 27, 2004",,"March 23, 2012","['pediatric oncology branch, bethesda, maryland, united states texas tech university health sciences center school of medicine, amarillo, texas, united states kidwai memorial institute of oncology, bangalore, india cancer institute (w.i.a.), madras, india tata memorial centre, mumbai, india all-india institute of medical sciences, new delhi, india']",,https://ClinicalTrials.gov/show/NCT00019409,blood
691,692,NCT00206219,head and neck phase iii iressa versus methotrexate refractory: iressa versus methotrexate (imex),,Completed,No Results Available,squamous cell carcinoma of the head and neck,drug: gefitinib|drug: methotrexate,"compare zd1839 versus methotrexate in overall survival|compare zd1839 versus methotrexate in symptom improvement, tumor response, safety and tolerability and quality of life - assessed throughout the study.",astrazeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,477.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1839IL/0704|EudraCT no.2004-002662-38,November 2003,September 2007,September 2007,"September 21, 2005",,"January 27, 2011","[""research site, birmingham, alabama, united states research site, tucson, arizona, united states research site, palm springs, california, united states research site, aurora, colorado, united states research site, new haven, connecticut, united states research site, norwalk, connecticut, united states research site, miami, florida, united states research site, orlando, florida, united states research site, ormand beach, florida, united states research site, savannah, georgia, united states research site, chicago, illinois, united states research site, des moines, iowa, united states research site, louisville, kentucky, united states research site, baton rouge, louisiana, united states research site, waterville, maine, united states research site, bethesda, maryland, united states research site, detroit, michigan, united states research site, omaha, nebraska, united states research site, hackensack, new jersey, united states research site, brooklyn, new york, united states research site, new york, new york, united states research site, oklahoma city, oklahoma, united states research site, philadelphia, pennsylvania, united states research site, norfolk, virginia, united states research site, olympia, washington, united states research site, milwaukee, wisconsin, united states research site, capital federal, buenos aires, argentina research site, el palomar, buenos aires, argentina research site, salta, argentina research site, santa fe, argentina research site, westmead, new south wales, australia research site, brussels (woluwé-st-lambert), belgium research site, brussels, belgium research site, edegem, belgium research site, gent, belgium research site, haine-saint-paul, belgium research site, goiânia, go, brazil research site, rio de janeiro, rj, brazil research site, são paulo, sp, brazil research site, vancouver, british columbia, canada research site, winnipeg, manitoba, canada research site, halifax, nova scotia, canada research site, london, ontario, canada research site, windsor, ontario, canada research site, montreal, quebec, canada research site, zagreb, croatia research site, brno, czech republic research site, ostrava - poruba, czech republic research site, ostrava, czech republic research site, praha 2, czech republic research site, praha 5, czech republic research site, praha 8, czech republic research site, tallinn, estonia research site, tartu, estonia research site, thessaloniki, greece research site, kochi, kerala, india research site, thiruvananthapuram, kerala, india research site, bhopal, madhya pradesh, india research site, pune, maharashtra, india research site, ansari nagar, new dehli, india research site, jaipur, rajasthan, india research site, kolkatta, west bengal, india research site, new dehli, india research site, petach tikva, israel research site, tel-hashomer, israel research site, bologna, italy research site, cuneo, italy research site, forli', italy research site, genova, italy research site, milano, italy research site, napoli, italy research site, roma, italy research site, torino, italy research site, riga, latvia research site, klaipeda, lithuania research site, vilnius, lithuania research site, nilai, malaysia research site, petaling jaya, malaysia research site, amsterdam, netherlands research site, maastricht, netherlands research site, nijmegen, netherlands research site, utrecht, netherlands research site, oslo, norway research site, krasnogorsk, russian federation research site, moscow, russian federation research site, st.petersburg, russian federation research site, zaloska, ljubljana, slovenia research site, ljubljana, slovenia research site, bloemfontein, south africa research site, cape town, south africa research site, durban, south africa research site, johannesburg, south africa research site, pretoria, south africa research site, tygerberg, south africa research site, santiago de compostela, a coruña, spain research site, leganés, madrid, spain research site, baracaldo, vizcaya, spain research site, granada, spain research site, madrid, spain research site, pontevedra, spain research site, santander, spain research site, valencia, spain research site, vitoria, álava, spain research site, göteborg, sweden research site, malmö, sweden research site, stockholm, sweden research site, bangkok, thailand research site, chiang mai, thailand research site, leeds, united kingdom research site, london, united kingdom""]",,https://ClinicalTrials.gov/show/NCT00206219,skin
692,693,NCT00375219,homoharringtonine (omacetaxine mepesuccinate) in treating patients with chronic myeloid leukemia (cml) with the t315i bcr-abl gene mutation,,Completed,Has Results,chronic myeloid leukemia,drug: omacetaxine mepesuccinate,percentage of participants achieving an overall hematologic response by subpopulation and total population|percentage of participants achieving a major cytogenetic response by subpopulation and total population|number of participants with treatment-emergent adverse events (teaes) by subpopulation and total|percentage of participants in each cytogenetic response category representing the degree of suppression of the philadelphia chromosome (ph+)|percentage of participants with major molecular response (mmr) representing the degree of suppression of bcr-abl transcript levels using the housekeeping gene gus|percentage of participants with major molecular response (mmr) representing the degree of suppression of bcr-abl transcript levels using the housekeeping gene abl|percentage of participants in each hematologic response category|percentage of participants with extramedullary disease (emd) at baseline achieving a clinical response|percentage of participants with the largest percentage reduction from baseline of t315i mutated bcr-abl|number of treatment cycles needed to achieve best hematologic response|number of treatment cycles needed to achieve best cytogenetic response|kaplan-meier estimates for time to onset of best hematologic response|kaplan-meier estimates for time to onset of best cytogenetic response|kaplan-meier estimates for duration of best hematologic response|kaplan-meier estimates for duration of best cytogenetic response|kaplan-meier estimates for time to disease progression|kaplan-meier estimates for overall survival,"teva branded pharmaceutical products r&d, inc.|cephalon|chemgenex pharmaceuticals",All,"18 Years and older   (Adult, Older Adult)",Phase 2,103.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CGX-635-CML-202|2006-000176-32,"September 20, 2006","March 23, 2010","June 28, 2013","September 12, 2006","June 3, 2014","November 15, 2021","['teva investigational site 003, los angeles, california, united states teva investigational site 007, jacksonville, florida, united states teva investigational site 006, atlanta, georgia, united states teva investigational site 008, beech grove, indiana, united states teva investigational site 011, baltimore, maryland, united states teva investigational site 004, boston, massachusetts, united states teva investigational site 002, bronx, new york, united states teva investigational site 005, buffalo, new york, united states teva investigational site 010, philadelphia, pennsylvania, united states teva investigational site 001, houston, texas, united states teva investigational site 013, montreal, canada teva investigational site 009, toronto, canada teva investigational site 029, bordeaux, france teva investigational site 021, le chesnay cedex, france teva investigational site 022, lille, france teva investigational site 020, lyon cedex 03, france teva investigational site 024, nice, france teva investigational site 028, paris, france teva investigational site 023, poitiers cedex, france teva investigational site 027, strasbourg, france teva investigational site 025, toulouse, france teva investigational site 026, vandoeuvre-les-nancy cedex, france teva investigational site 031, berlin, germany teva investigational site 030, mannheim, germany teva investigational site 050, budapest, hungary teva investigational site 071, hyderabad, india teva investigational site 070, mumbai, india teva investigational site 090, bologna, italy teva investigational site 060, gdansk, poland teva investigational site 061, warszawa, poland teva investigational site 080, singapore, singapore teva investigational site 040, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00375219,blood
693,694,NCT00755755,pgl4001 versus placebo in uterine myomas,PEARLI,Completed,Has Results,uterine myomas,drug: pgl4001 (ulipristal) and iron|drug: pgl4001 matching placebo and iron,co-primary endpoint: percentage of subjects with reduction in uterine bleeding defined as a pictorial blood-loss assessment chart (pbac) score <75 at end-of-treatment visit (week 13)|co-primary endpoint: percent change in total myoma volume assessed by magnetic resonance imaging (mri) from screening to end of treatment visit (week 13 visit),preglem sa,Female,18 Years to 50 Years   (Adult),Phase 3,241.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PGL07-021,October 2008,March 2010,August 2010,"September 19, 2008","November 16, 2012","December 13, 2012","['gynekologicko-porodnicka klinika fn brno, brno, czech republic mediva, praha, czech republic gynekologicko-porodnicka klinika 1.lf uk a vfn, praha, czech republic gynekologicko-porodnicka klinika uk 2.lf a fn, praha, czech republic rethy-pal hospital-clinic bekescsaba, department of obstetrics and gynecology, bekescsaba, hungary saint stephen hospital of budapest,department of obstetrics, gynecology and gynecological oncology, budapest, hungary fovarosi bajcsy-zsilinszky hospital, department of obstetrics and gynecology, budapest, hungary saint george hospital of fejer county, department of obstetrics and gynecology, szekesfehervar, hungary dr. bugyi istvan hospital, department of obstetrics and gynecology, szentes, hungary saint borbala hospital of komarom-esztergom county, department of obstetrics and gynecology, tatabanya, hungary dr. jilla hospital, aurangabad, india m. s. ramaiah medical college and memorial hospital, bangalore, india divakars speciality hospital, bangalore, india sri ramachandra medical college and research institute, chennai, india om women\'s hospital, nagpur, india nagpur test tube baby centre, nagpur, india central medical sanador, bucharest, romania departamentul de obstretica ginecologie si nou nascuti, bucharest, romania sectia obstretica-ginecologie spitalul clinic dr. ioan cantacuzino, bucharest, romania centrul medical euromed, departementul de obstetrica/ginecologie, bucuresti, romania spitalul clinic de obstetrica ginecologie oradea, oradea, romania spitalul clinic judetean de urgenta, sectia de obstetrica ginecologie i, targu mures, romania northern state medical university, arkhangelsk, russian federation kursk state medical university, kursk, russian federation oao ""medical company idk"", samara, russian federation american medical clinic, st. petersburg, russian federation saint-petersburg city alexandrovsky hospital, st.petersburg, russian federation military medical academy n.a.s.m kirov, chair of obstetrics and gynecology, st.petersburg, russian federation medical research institute (mri), st.petersburg, russian federation russian scientific research center of radiology and surgical technologies, st.petersburg, russian federation scientific research institute of obstetrics and gynecology n.a. d.o.ott of rams, st.petersburg, russian federation donetsk national medical university, department of obstetrics, gynecology and perinatology fpe, donetsk, ukraine city clinical hospital n9, kiev, ukraine institute of pediatrics, obstetrics and gynecology, department of endocrine gynecology, kiev, ukraine kiev maternity hospital no.2, kiev, ukraine state enterprise ""institute of pediatrics, obstetrics and gynecology of ams of ukraine, kyiv, ukraine lviv national medical university named after danylo halytskyy, lviv, ukraine medical sanitory centre vat ""motor sich"" gynecology department, zaporizhzhya, ukraine']",,https://ClinicalTrials.gov/show/NCT00755755,fibroid
694,695,NCT04576156,a study comparing imetelstat versus best available therapy for the treatment of intermediate-2 or high-risk myelofibrosis (mf) who have not responded to janus kinase (jak)-inhibitor treatment,,Recruiting,No Results Available,myelofibrosis,drug: imetelstat|drug: best available therapy (bat),"overall survival|symptom response rate|progression-free survival|spleen response rate|complete remission (cr), partial remission (pr), clinical improvement (ci), spleen response, symptoms response, and anemia response per modified 2013 iwg-mrt criteria|reduction in the degree of bone marrow fibrosis|number of participants with adverse events|assessment of cmax|european organization for research and treatment of cancer quality-of-life-questionnaire-core-30 (eortc qlq-c30) scores|euroqol-eq-5d (eq-5d-5l) questionnaire scores|assessment of auc",geron corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,320.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MYF3001|2020-003288-24,"April 12, 2021","May 1, 2024","May 1, 2024","October 6, 2020",,"April 19, 2022","['university of california-san diego/moores ucsd cancer center, la jolla, california, united states ucla david geffen school of medicine, los angeles, california, united states brcr medical center inc, plantation, florida, united states university of south florida, tampa, florida, united states icahn school of medicine at mount sinai, new york, new york, united states weill cornell medical college, new york, new york, united states duke, durham, north carolina, united states gabrail cancer center, canton, ohio, united states prairie lakes health care system, inc., watertown, south dakota, united states the university of texas md, houston, texas, united states northwest medical specialties pllc, tacoma, washington, united states hospital aleman, ciudad de buenos aires, buenos aires, argentina hospital universitario austral, pilar, buenos aires, argentina sanatorio de la mujer, rosario, santa fe, argentina fundaleu, buenos aires, argentina sanatorio allende, córdoba, argentina royal north shore hospital, st leonards, new south wales, australia royal brisbane and women\'s hospital, herston, queensland, australia royal hobart hospital, hobart, tasmania, australia epworth healthcare, richmond, victoria, australia krankenhaus der elisabethinen, linz, oberösterreich, austria uz antwerpen, edegem, antwerpen, belgium centre hospitalier de jolimont, haine-saint-paul, hainaut, belgium zna - campus middelheim, antwerpen, belgium zna stuyvenberg antwerpen, antwerpen, belgium az klina, antwerpen, belgium universitair ziekenhuis brussel - myeloom centrum brussel (mcb), jette, belgium centro de oncologia leonardo da vinci, fortaleza, ceará, brazil hospital das clínicas ufg, goiânia, goiás, brazil hospital erasto gaertner, curitiba, paraná, brazil hospital de clinicas de porto alegre - ufrgs, porto alegre, rio grande do sul, brazil centro gaucho integrado de oncologia, hematologia, ensino e pesquisa ltda, porto alegre, rio grande do sul, brazil cepon centro de pesquisas oncologicas sc, florianópolis, brazil instituto de educação, pesquisa e gestão em saúde, são paulo, brazil hospital israelita albert einstein, são paulo, brazil hospital a.c.camargo cancer center - clinical oncology, são paulo, brazil umhat ""dr. georgi stranski"", pleven, bulgaria umbal sveti georgi, plovdiv, bulgaria specialized hospital for active therapy of hematological dis, sofia, bulgaria oncologos del occidente s.a, pereira, risaralda, colombia hospital pablo tobon uribe, antioquia, colombia centro medico imbanaco de cali s.a., cali, colombia foscal, floridablanca-santander, colombia aarhus university hospital - hematology, aarhus, denmark odense university hospital - hematology, odense, denmark institut de cancérologie du gard - hematologie clinique, nimes cedex 09, gard, france chu bretonneau, tours, indre-et-loire, france chu de nantes - hã©matologie c, nantes, loire-atlantique, france centre hospitalier lyon, pierre-benite, rhône-alpes, france centre hospitalier du mans - cancérologie médicale, le mans, sarthe, france hopital avicenne - hã©matologie clinique, bobigny, seine-saint-denis, france chru brest - hôpital morvan, brest cedex, france chu - hã´pital saint louis - centre d\'investigations cliniq, paris, france hopital cochin - aphp hôpitaux universitaires paris centre, paris, île-de-france, france chru brest - hôpital morvan, georgia, georgia multi profile clinic consilium, georgia, georgia ltd israeli-georgian medical r, tbilisi, georgia m.zodelava hematology center l, tbilisi, georgia j.s.c.""k.eristavi national cen, tbilisi, georgia ltd ""medinvest"" institute of h, tbilisi, georgia universitätsk+b4:o4linikum tüb, tübingen, baden-württemberg, germany universitätsklinikum carl gust, dresden, hamburg, germany university hospital rwth aache, aachen, nordrhein-westfalen, germany universitaetsklinik und polikl, halle (saale), sachsen-anhalt, germany universitätsklinikum leipzig aör, leipzig, sachsen, germany universitätsklinikum schleswig, kiel, schleswig-holstein, germany klinikum kempten-oberallgaeu g, kempten, germany semmelweis egyetem - iii. sz., budapest, hungary dél-pesti centrumkórház ország, budapest, hungary szabolcs-szatmár-bereg megyei önkormányzat jósa andrás, nyíregyháza, hungary fejer megyei szent gyorgy egye, székesfehérvár, hungary all india institute of medical sciences, dept. of hematology, new delhi (all india institute of medical sciences), new delhi, delhi, india sir ganga ram hospital, new delhi, delhi, india nirmal hospital - hematology, surat, gujarat, india st. john\'s medical college hospital, bangalore, karnataka, india fortis hospital 154/9, bengaluru, karnataka, india fortis memorial research institute, gurgaon, new delhi, india all india institute of medical sciences, bhubaneswar, orissa, india nilratan sircar medical college, kolkata, west bengal, india deenanath mangeshkar hospital & research center, pune, india sahyadri specialty hospital, pune, india assuta ashdod university hospi, ashdod, hadarom, israel barzilai medical center, ashkelon, hadarom, israel kaplan medical center, rehovot, hamerkaz, israel shamir medical center (assaf harofeh), zerifin, hamerkaz, israel western galilee hospital - nahariya, nahariya, hazafon, israel tel aviv sourasky medical cent, tel aviv, tel-aviv, israel hadassah medical organization, jerusalem, yerushalayim, israel bnai zion medical center, haifa, israel carmel mc, haifa, israel arcispedale s.anna - ematologi, cona, ferrara, italy istituto clinico humanitas roz, rozzano, milano, italy aou san luigi gonzaga, orbassano, torino, italy po civile ss.antonio e biagio, alessandria, italy a.o.di bologna policl.s.orsola, bologna, italy presidio ospedaliero garibaldi, catania, italy aou careggi, firenze, italy clinica ematologica, univ. deg, genova, italy irccs irst, meldola, italy ospedale san raffaele, milano, italy asst grande ospedale metropoli, milano, italy azienda ospedaliera san gerard, monza, italy aou federico ii, napoli, italy ospedale civile s.maria delle, ravenna, italy azienda ospedaliera bianchi-me, reggio calabria, italy ausl di rimini ospedale inferm, rimini, italy asl roma 2 - po ""s. eugenio"", roma, italy policlinico universitario agostino gemelli, roma, italy ospedale s.bortolo, aulss n.6, vicenza, italy kyungpook national university, daegu, daegu gwang\'yeogsi [taegu-kwan], korea, republic of seoul national university hospital - department of internal, seoul, seoul teugbyeolsi [seoul-t\'ukp, korea, republic of pusan national university hospital - hematology and oncology, busan, korea, republic of the catholic university of korea, seongdong, korea, republic of severance hospital, yonsei uni, seoul, korea, republic of hospital pulau pinang, georgetown, pulau pinang, malaysia sarawak general hospital, kuching, sarawak, malaysia hospital ampang, ampang, selangor, malaysia hospital raja perempuan zainab ii, kelantan, malaysia wojewodzki szpital specjalistyczny im. janusza korczaka w sl, slupsk, pomorskie, poland ars medical sp. z o.o., piła, wielkopolskie, poland centrum medyczne pratia poznan, skorzewo, wielkopolskie, poland pratia onkologia katowice, katowice, śląskie, poland cca-braga. centro clínico académico - hospital braga, braga, portugal chuc - centro hospitalar e uni, coimbra, portugal instituto português de oncologia de lisboa, lisboa, portugal centro clinico fundacao champalimaud, lisboa, portugal h. são francisco xavier-centro, lisboa, portugal h. santa maria. centro hospita, lisboa, portugal moscow city hospital n.a. botkin, moscow, moska, russian federation moniki - oncology, moscow, moskovskaya oblast\', russian federation moscow city hospital n.a. botkin, moscow, moskva, russian federation novosibirsk state medical univ, novosibirsk, novosibirskaya oblast\', russian federation gou vpo saratov state medical university n.a. v.i. razumovsk, saratov, saratovskaya oblast\', russian federation llc ""interleykin"", pyatigorsk, stavropol\'skiy kray, russian federation tula regional clinical hospital, tula, tul\'skaya oblast\', russian federation clinical oncological dispensar, omsk, russian federation fgu ""russian research institute, saint petersburg, russian federation saint-petersburg state medical, saint petersburg, russian federation v.a. almazov national medical, saint-petersburg, russian federation national university cancer institute (ncis), singapore, central singapore, singapore singapore general hospital, singapore, central singapore, singapore institut català d\'oncologia-ho, badalona, barcelona, spain c.s. parc tauli, sabadell, barcelona, spain hospital universitario de gran, las palmas de gran canaria, canarias, spain h.u. ribera de alzira, alzira, valencia, spain h.g.u. alicante, alicante, spain h. san pedro de alcántara, cáceres, spain ico-hospital universitari de g, girona, spain hospital universitario virgen, granada, spain hospital universitario fundaci, madrid, spain hospital u. 12 octubre, madrid, spain h.u. la paz, madrid, spain h.u.v. de la victoria, málaga, spain complejo asistencial universit, salamanca, spain hospital universitario doctor, valencia, spain h. quirón zaragoza, zaragoza, spain universitaetsspital zuerich, zurich, switzerland chang gung medical foundation, chiayi city, chiayi, taiwan china medical university hospital, taichung city, taiwan taipei veterans general hospital, taipei, taiwan tri-service general hospital, taipei, taiwan ankara university medical facu, ankara, turkey istanbul üniversitesi cerrahpaşa, istanbul, turkey marmara university pendik training and research hospital, istanbul, turkey ege universitesi tip fakultesi, izmir, turkey maidstone hospital, maidstone, kent, united kingdom st bartholomew\'s hospital, london, united kingdom guys and st thomas\' hospital, london, united kingdom oxford university hospitals, oxford, united kingdom']",,https://ClinicalTrials.gov/show/NCT04576156,
695,696,NCT04297254,a study to assess the safety and efficacy of lenvatinib as first-line treatment in participants with unresectable hcc,,Recruiting,No Results Available,"carcinoma, hepatocellular",drug: lenvatinib,percentage of participants with grade 3 or higher treatment-emergent adverse events (teaes)|number of participants with serious adverse events (saes)|number of participants with grades 1 and 2 treatment-emergent adverse events (teaes)|objective response rate (orr)|progression-free survival (pfs)|percentage of participants requiring dose modifications (dose interruptions or dose reductions)|time to first dose reduction,eisai pharmaceuticals india pvt. ltd|eisai inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7080-M091-511,"February 4, 2021","August 27, 2022","August 27, 2022","March 5, 2020",,"February 23, 2022","[""sri venkateshwara hospital, bangalore, karnataka, india tata memorial hospital, mumbai, maharashtra, india hcg manavata cancer centre, nashik, maharashtra, india shatabdi hospital, nashik, maharashtra, india lmmf's deenanath mangeshkar hospital & research center, pune, maharashtra, india noble hospital, pune, maharashtra, india somani hospital, jaipur, rajasthan, india meenakshi mission hospital, madurai, tamil nadu, india apollo gleneagles hospital limited, kolkata, west bengal, india""]",,https://ClinicalTrials.gov/show/NCT04297254,liver
696,697,NCT03677596,a study of two inotuzumab ozogamicin doses in relapsed/ refractory acute lymphoblastic leukemia transplant eligible patients,,"Active, not recruiting",No Results Available,leukemia|precursor b-cell lymphoblastic leukemia-lymphoma|acute lymphoblastic leukemia,drug: inotuzumab ozogamicin-dose level 2|drug: inotuzumab ozogamicin-dose level 1,"percentage of participants with hematologic remission (complete remission [cr]/complete remission with incomplete hematologic recovery [cri])|rate of veno-occlusive disease (vod)|frequency of adverse events|minimal residual disease (mrd) negativity|duration of remission (dor) for participants who achieved cr/cri|progression free survival (pfs)|overall survival (os)|rate of hematopoietic stem cell transplantation (hsct)|post hsct relapse|post hsct mortality|post hsct non relapse mortality|post hsct relapse related mortality|pharmacokinetics, cmax|percentage of patients with positive anti-drug antibody response|percentage of patients with laboratory abnormalities (nci ctcae grade)|pharmacokinetics, ctrough|pharmacokinetics, clearance|pharmacokinetics, area under the curve (auc)",pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,103.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1931030|2018-001557-27,"July 1, 2019","September 14, 2022","September 22, 2023","September 19, 2018",,"March 11, 2022","[""keck hospital of usc-norris comprehensive cancer center (hc3), los angeles, california, united states keck hospital of usc, los angeles, california, united states lac+usc medical center, los angeles, california, united states usc/norris comprehensive cancer center, los angeles, california, united states rush university medical center, chicago, illinois, united states university of maryland- greenebaum comprehensive cancer center, baltimore, maryland, united states seattle cancer care alliance, seattle, washington, united states university of washington medical center, seattle, washington, united states debreceni egyetem klinikai központ, orvosi kepalkotó klinika, radiológia, debrecen, hungary debreceni egyetem klinikai központ, pathológiai lntézet, debrecen, hungary szabolcs-szatmar bereg megyei korhazak es egyetemi oktatokorhaz, josa andras korhaz, hematologia, nyiregyhaza, hungary artemis hospital, gurugram, haryana, india sahyadri clinical research and development centre, pune, maharashtra, india sahyadri super speciality hospital, pune, maharashtra, india sahyadri super speciality hospital nagar road, pune, maharashtra, india sahyadri super speciality hospital, pune, maharashtra, india christian medical college, vellore, tamil nadu, india klinika hematologii i transplantologii, uniwersyteckie centrum kliniczne, gdansk, poland instytut hematologii i transfuzjologii, warsaw, poland uniwersytecki szpital kliniczny im. jana mikulicza - radeckiego we wroclawiu, wroclaw, poland apteka centralna, wroclaw, poland national university hospital, singapore, singapore pharmacy @ ncis, national university hospital, singapore, singapore raffles hospital, singapore, singapore raffles radiology, singapore, singapore hospital universitario central de asturias, oviedo, asturias, spain hospital universitari vall d'hebron, barcelona, spain hospital general universitario gregorio maranon, madrid, spain hospital universitario ramon y cajal, madrid, spain hospital universitario virgen del rocio, sevilla, spain hospital clinico universitario de valencia, valencia, spain hospital universitari i politecnic la fe, valencia, spain changhua christian hospital, changhua, taiwan clinical research pharmacy, changhua christian hospital, changhua, taiwan national taiwan university hospital, taipei, taiwan anadolu health center hospital, gebze, istanbul, turkey dr. abdurrahman yurtaslan ankara oncology training and research hospital clinical research center, ankara, turkey dr. abdurrahman yurtaslan ankara oncology training and research hospital hematology department, ankara, turkey ankara university faculty of medicine cebeci hospital hematology department, ankara, turkey private medstar antalya hosp. hematology and stem cell transplantation center, antalya, turkey marmara university pendik training and research hospital hematology unit, istanbul, turkey ege university medical faculty, izmir, turkey dokuz eylul university medical faculty, izmir, turkey medicalpark izmir hospital, izmir, turkey erciyes universitesi tip fakultesi hastaneleri, kayseri, turkey ondokuz mayis university faculty of medicine hospital, samsun, turkey""]",,https://ClinicalTrials.gov/show/NCT03677596,lymphoma blood
697,698,NCT03452137,a study of atezolizumab (anti-pd-l1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck,,"Active, not recruiting",No Results Available,locally advanced squamous cell carcinoma of the head and neck (scchn),drug: atezolizumab|drug: placebo,investigator-assessed event free survival (efs)|overall survival (os) after randomization|independent review facility-assessed event free survival (irf-assessed efs)|change from baseline in physical function and quality of life global health status/quality of life scales of the european organization for research and treatment of cancer (eortc) quality of life questionnaire|percentage of participants with adverse events|serum concentration of atezolizumab|incidence of ada response to atezolizumab,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,406.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WO40242|2017-003302-40,"April 3, 2018","September 3, 2023","July 3, 2026","March 2, 2018",,"March 2, 2022","[""city of hope national medical center, duarte, california, united states university of california san diego medical center; moores cancer center, la jolla, california, united states ucla hematology/oncology, santa monica, california, united states miami cancer institute of baptist health, inc., miami, florida, united states woodlands medical specialists, p.a., pensacola, florida, united states winship cancer institute of emory university, atlanta, georgia, united states northwest georgia oncology centers, a service of wellstar cobb hospital, marietta, georgia, united states cancer center of kansas, wichita, kansas, united states dana-farber cancer institute, boston, massachusetts, united states billings clinic research center, billings, montana, united states cleveland clinic; taussig cancer institute, cleveland, ohio, united states blue ridge cancer care, roanoke, virginia, united states st george hospital, kogarah, new south wales, australia adelaide cancer centre, kurralta park, south australia, australia peter maccallum cancer center, east melbourne, victoria, australia sir charles gairdner hospital, nedlands, western australia, australia clinique ste-elisabeth, namur, belgium santa casa de misericordia de salvador, salvador, ba, brazil hospital do cancer de pernambuco - hcp, recife, pe, brazil instituto nacional de cancer - inca; oncologia, rio de janeiro, rj, brazil hospital sao lucas - pucrs, porto alegre, rs, brazil hospital nossa senhora da conceicao, porto alegre, rs, brazil faculdade de medicina do abc - fmabc, santo andre, sp, brazil instituto do cancer do estado de sao paulo - icesp, sao paulo, sp, brazil cross cancer institute, edmonton, alberta, canada cancer care manitoba, winnipeg, manitoba, canada london health sciences centre, london, ontario, canada beijing cancer hospital, beijing, china west china hospital, sichuan university, chengdu, china fujian cancer hospital, fuzhou, china the second affiliated hospital of zhejiang university school of medicine, hangzhou city, china fudan university shanghai cancer center, shanghai city, china shanghai ninth people's hospital affiliated to shanghai jiao tong university school of medicine, shanghai, china shanghai east hospital, shanghai, china tianjin medical university general hospital, tianjin, china union hospital tongji medical college huazhong university of science and technology, wuhan city, china zhejiang cancer hospital, zhejiang, china institut sainte catherine, avignon, france centre georges francois leclerc, dijon, france centre leon berard; département d'hématologie et d'oncologie, lyon, france hopital timone adultes; oncologie medicale et usp, marseille, france icm; radiotherapie, montpellier cedex 5, france hopital tenon; oncologie radiotherapie, paris, france chu bordeaux, pessac, france hôpitaux d'instruction des armees begin, st mande, france gustave roussy cancer campus; radiotherapie, villejuif cedex, france universitätsklinikum bonn; med. klinik und poliklinik iii; hämatologie, onkologie und rheumatologie, bonn, germany universitätsklinikum freiburg, klinik für strahlenheilkunde, freiburg, germany klinikum d. uni. münchen; campus großhadern; klinik und poliklinik f. strahlenthera. und radioonko, münchen, germany universitätsmedizin rostock, klinik und poliklinik für strahlentherapie; zentrum für radiologie, rostock, germany orszagos onkologial intezet; onkologiai osztaly x, budapest, hungary uzsoki utcai korhaz, budapest, hungary pécsi tudományegyetem; klinikai központ onkoterápiás intézet, pécs, hungary medanta-the medicity, gurgaon, haryana, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india istituto nazionale tumori fondazione g. pascale; s.c. oncol. medica testa-collo e sarcoma, napoli, campania, italy ospedale umberto i asl di ravenna presidio ospedaliero di lugo, lugo, emilia-romagna, italy irst istituto scientifico romagnolo per lo studio e cura dei tumori, sede meldola; oncologia medica, meldola, emilia-romagna, italy policlinico umberto i di roma; dip. scienze radiologiche, oncologiche, anatomopatologiche, roma, lazio, italy ospedale civile; servizio oncologia, savona, liguria, italy spedali civili di brescia, brescia, lombardia, italy fondazione irccs istituto nazionale dei tumori;s.s. trattamento medicotumori dellatesta e delcollo, milano, lombardia, italy asst santi paolo e carlo; unita operativa di oncologia medica, milano, lombardia, italy istituto clinico humanitas;u.o. oncologia medica ed ematologia, rozzano, lombardia, italy azienda ospedaliero-universitaria careggi; sod radioterapia, firenze, toscana, italy iov - istituto oncologico veneto irccs, padova, veneto, italy aichi cancer center hospital, aichi, japan national cancer center hospital east, chiba, japan national hospital organization kyushu cancer center, fukuoka, japan hokkaido university hospital, hokkaido, japan kobe university hospital, hyogo, japan miyagi cancer center, miyagi, japan okayama university hospital, okayama, japan osaka international cancer institute, osaka, japan shizuoka cancer center, shizuoka, japan national cancer center hospital, tokyo, japan the jikei university hospital, tokyo, japan tokyo medical and dental university hospital, tokyo, japan the cancer institute hospital of jfcr, tokyo, japan tokyo medical university hospital, tokyo, japan seoul national university bundang hospital, seongnam-si, korea, republic of seoul national university hospital, seoul, korea, republic of asan medical center, seoul, korea, republic of samsung medical center, seoul, korea, republic of uniwersyteckie centrum kliniczne; klinika onkologii i radioterapii, gdańsk, poland narodowy inst.onkol.im.sklodowskiej-curie panstw.inst.bad gliwice; iii klin. radioter. i chemioter., gliwice, poland narodowy inst.onkologii im.sklodowskiej-curie panstw.inst.bad; klinika nowotworów głowy i szyi, warszawa, poland ipo de coimbra; servico de oncologia medica, coimbra, portugal hospital de santa maria; servico de oncologia medica, lisboa, portugal ipo do porto; servico de oncologia medica, porto, portugal moscow city oncology hospital #62, moscovskaya oblast, moskovskaja oblast, russian federation main military clinical hospital named after n.n. burdenko, moscow, moskovskaja oblast, russian federation first msmu n.a. sechenov univercity hospital 1; plastic surgery, moskva, moskovskaja oblast, russian federation fsai treatment and rehabilitation centre ministry of health; clinical research and chemotherapy., moskva, moskovskaja oblast, russian federation sverdlovsk regional oncology dispensary; chemotherapy, ekaterinburg, russian federation krasnoyarsk regional oncology dispensary n.a. krizhanovsky; chemotherapy, krasnoyarsk, russian federation p.a. herzen oncological inst. ; oncology, moscow, russian federation novosibirsk regional oncological dispancer, novosibirsk, russian federation bhi of omsk region clinical oncology dispensary, omsk, russian federation s-pb clinical scientific practical center of specialized kinds of medical care (oncological), saint-petersburg, russian federation tomsk scientific research institute of oncology so ramn, pad; pathological, tomsk, russian federation tygerberg hospital; oncology dept, cape town, south africa gvi oncology outeniqua unit; gvi oncology outeniqua unit, george, south africa the oncology centre; haematology - radiation oncology, mayville, south africa steve biko academic hospital; oncology, pretoria, south africa hospital universitari germans trias i pujol; servicio de oncologia, badalona, barcelona, spain insititut catala d'oncologia, hospitalet de llobregat, barcelona, spain hospital clínic i provincial; servicio de hematología y oncología, barcelona, spain hospital general universitario gregorio marañon; servicio de oncologia, madrid, spain hospital clinico universitario de salamanca; servicio de oncologia, salamanca, spain hospital univ. nuestra señora de valme; servicio de oncologia, sevilla, spain hospital universitario la fe; servicio de oncologia, valencia, spain china medical university hospital;oncology and hematology office critical care center, 14h, taichung, taiwan taichung veterans general hospital; radiation oncology, taichung, taiwan national cheng kung university hospital; oncology, tainan, taiwan division of hematology and oncology, taipei veterans general hospital, taipei, taiwan national taiwan university hospital; oncology, zhongzheng dist., taiwan ramathibodi hospital; dept of med.-div. of med. onc, bangkok, thailand faculty of med. siriraj hosp.; med.-div. of med. oncology, bangkok, thailand songklanagarind hospital; department of oncology, songkhla, thailand hacettepe universitesi tip fakultesi hastanesi; ic hastaliklari anabiim dali, ankara, turkey dr. abdurrahman yurtarslan oncology hospital; 2nd oncology clinic, ankara, turkey gazi university medical faculty, oncology hospital, ankara, turkey medikal park izmir hospital, karşıyaka, turkey municipal noncommercial institution regional center of oncology, kharkiv, kharkiv governorate, ukraine vinnytsya regional clinical oncology dispensary, vinnytsya, podolia governorate, ukraine ivano-frankivsk regional oncology center, ivano-frankivsk, ukraine kyiv city clinical oncological center, day hospital department for oncological patients, kiev, ukraine me kryviy rih oncology dispensary of dnipropetrovs'k regional council; chemotherapy department, kryvyi rih, ukraine lviv state oncology regional treatment and diagnostic centre; department of hemotherapy, lviv, ukraine rci sumy regional clinical oncological dispensary, sumy, ukraine aberdeen royal infirmary; medical oncology dept, aberdeen, united kingdom velindre cancer centre, cardiff, united kingdom the royal marsden hospital, fulham, london, united kingdom derriford hospital, plymouth, united kingdom royal marsden nhs foundation trust, sutton, united kingdom""]",,https://ClinicalTrials.gov/show/NCT03452137,skin
698,699,NCT02747043,study to assess if abp798 is safe & effective in treating non hodgkin lymphoma compared to rituximab,JASMINE,Completed,Has Results,"lymphoma, non-hodgkin",biological: abp 798|biological: rituximab,percentage of participants who responded (overall response rate - orr) by week 28 based on independent central assessment of disease|percentage of participants who responded (overall response rate - orr) at week 12 based on independent central assessment of disease|pharmacokinetic serum concentrations by visit|percentage of participants with complete depletion of clusters of differentiation 19-positive (cd19+) cell count from baseline to day 8|total immunoglobulin g (igg) results by visit|total immunoglobulin m (igm) results by visit|participants with treatment-emergent adverse events|percentage of participants with treatment-emergent adverse events of interest (aeois)|number of participants who developed anti-drug antibodies|participants' progression-free survival (pfs) status based on the independent central assessment of disease|percentage of participants who survived -- overall survival (os),amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,256.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20130109|2013-005542-11,"May 25, 2016","June 28, 2019","June 28, 2019","April 21, 2016","August 18, 2020","August 18, 2020","[""research site, encinitas, california, united states research site, mount sterling, kentucky, united states research site, billings, montana, united states research site, zanesville, ohio, united states research site, roanoke, virginia, united states research site, gosford, new south wales, australia research site, frankston, victoria, australia research site, perth, western australia, australia research site, plovdiv, bulgaria research site, stara zagora, bulgaria research site, windsor, ontario, canada research site, medellin, antioquia, colombia research site, bogota, cundinamarca, colombia research site, praha 5, praha, czechia research site, ostrava - poruba, severomoravsky kraj, czechia research site, bordeaux cedex, aquitaine, france research site, clermont ferrand, auvergne, france research site, cesson-sevigne, bretagne, france research site, boulogne sur mer, nord pas-de-calais, france research site, la rochelle, poitou-charentes, france research site, poitiers cedex, poitou-charentes, france research site, batumi, georgia research site, tbilisi, georgia research site, tbilisi, georgia research site, tbilisi, georgia research site, freiburg, baden-wuerttemberg, germany research site, augsburg, bayern, germany research site, würzburg, bayern, germany research site, kassel, hessen, germany research site, münster, nordrhein-westfalen, germany research site, leipzig, sachsen, germany research site, flensburg, schleswig-holstein, germany research site, athens, attica, greece research site, athens, attica, greece research site, patra, peloponnese, greece research site, surat, gujarat, india research site, vadodara, gujarat, india research site, bangalore, karnataka, india research site, mangalore, karnataka, india research site, nashik, maharashtra, india research site, pune, maharashtra, india research site, bikaner, rajasthan, india research site, be'er ya'akov, rehoboth, israel research site, san giovanni rotondo, foggia, italy research site, bergamo, lombardia, italy research site, pesaro, pesaro e urbino, italy research site, aviano, pordenone, italy research site, candiolo, torino, italy research site, brescia, italy research site, milano, italy research site, milano, italy research site, padova, italy research site, parma, italy research site, ravenna, italy research site, rimini, italy research site, terni, italy research site, chiba-city, chiba, japan research site, fukuoka-shi, fukuoka, japan research site, maebashi-city, gunma, japan research site, kobe-city, hyogo, japan research site, tsu, mie, japan research site, utsunomiya city, tochigi, japan research site, tachikawa-city, tokyo, japan research site, tokyo, japan research site, seoul, gyeonggi-do, korea, republic of research site, seoul, gyeonggi-do, korea, republic of research site, busan, gyeongsangnam-do, korea, republic of research site, jinju-si, gyeongsangnam-do, korea, republic of research site, daegu, korea, republic of research site, daegu, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, ulsan, korea, republic of research site, mexico city, distrito federal, mexico research site, chihuahua, mexico research site, legnica, dolnoslaskie, poland research site, toruń, kujawsko-pomorskie, poland research site, kraków, malopolskie, poland research site, gdańsk, pomorskie, poland research site, targu-mures, mures, romania research site, targu-mures, mures, romania research site, timisoara, timis, romania research site, bucuresti, romania research site, sabadell, barcelona, spain research site, córdoba, cordoba, spain research site, majadahonda, madrid, spain research site, la laguna tenerife, santa cruz de tenerife, spain research site, barcelona, spain research site, caceres, spain research site, cadiz, spain research site, madrid, spain research site, salamanca, spain research site, kyiv, kiev, ukraine research site, kyiv, kiev, ukraine research site, uzhgorod, transcarpathia, ukraine research site, chernivtsi, ukraine research site, dnipropetrovsk, ukraine""]","""study protocol"", https://clinicaltrials.gov/provideddocs/43/nct02747043/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/43/nct02747043/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02747043,lymphoma
699,700,NCT05239507,oreios international study,OREIOS,Recruiting,No Results Available,hepatocellular carcinoma,,"to describe the os rate in patients with unresectable hcc including estimates of survival rates at 6, 12, and 18 months and at 2 years|to describe the management patterns in patients with unresectable hcc|to describe the demographic and clinical characteristics of patients with unresectable hcc",astrazeneca,All,"Child, Adult, Older Adult",,1440.0,Industry,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,D419CR00025,"February 1, 2022","August 31, 2022","August 31, 2022","February 15, 2022",,"May 10, 2022","['research site, alexandira, egypt research site, cairo, egypt research site, menufia, egypt research site, faridabad, india research site, howrah, india research site, kolkata, india research site, kolkata, india research site, mumbai, india research site, new delhi, india research site, new delhi, india research site, chelyabinsk, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, saint petersburg, russian federation research site, makkah, saudi arabia']",,https://ClinicalTrials.gov/show/NCT05239507,liver
700,701,NCT01031069,evaluation of safety and immunogenicity of a human papillomavirus (hpv) vaccine in human immunodeficiency virus (hiv) infected females,,Completed,Has Results,"infections, papillomavirus|papillomavirus vaccines","biological: gsk biologicals' hpv vaccine 580299|biological: merck's human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine (gardasil)","number of human immunodeficiency virus positive subjects (hiv+) with any and grade 3 solicited local symptoms|number of hiv+ subjects with any, grade 3 and related solicited general symptoms|number of hiv+ subjects with any, grade 3 and related unsolicited adverse events (aes)|number of hiv+ subjects with serious adverse events (saes)|number of hiv+ subjects with medically significant conditions (mscs)|number of hiv+ subjects with potential immune-mediated diseases (pimds)|number of hiv+ subjects reporting pregnancies and outcomes of reported pregnancies|number of hiv+ subjects with haematological and biochemical parameter abnormalities|cluster of differentiation 4 (cd4+) cell count in hiv+ subjects at month 7|hiv viral load (vl) in hiv+ subjects at month 7|number of hiv+ subjects by world health organization (who) hiv clinical staging|pseudovirion-based neutralization assay (pbna) titers of anti-hpv-16/18 antibodies in hiv+ subjects, based on adapted according-to-protocol (atp) cohort for immunogenicity|pseudovirion-based neutralization assay (pbna) titers of anti-hpv-16/18 antibodies in hiv+ subjects, based on total vaccinated cohort (tvc)|number of hiv- subjects with any and grade 3 solicited local symptoms|number of hiv- subjects with any, grade 3 and related solicited general symptoms|number of hiv- subjects with unsolicited adverse events (aes)|number of hiv- subjects with serious adverse events (saes)|number of hiv- subjects with medically significant conditions (mscs)|number of hiv- subjects with potential immune-mediated disease (pimds)|number of subjects reporting pregnancies and outcomes of reported pregnancies|number of subjects with relevant abnormalities in alanine aminotransferase, basophils, creatinine and eosinophils parameters|number of subjects with relevant abnormalities in haematocrit, haemoglobin, lymphocytes and monocytes parameters|number of subjects with relevant abnormalities in neutrophils, platelets, red blood cells and white blood cells parameters|number of subjects with saes|number of subjects with medically significant conditions (mscs)|number of subjects with potential immune-mediated diseases (pimds)|cluster of differentiation 4 (cd4+) cell count in hiv+ subjects at months 12, 18 and 24|hiv viral load (vl) in hiv+ subjects at months 12, 18 and 24|number of hiv+ subjects by who hiv clinical staging|pseudovirion-based neutralization assay (pbna) titers of anti-hpv-16/18 antibodies in hiv- subjects, based on tvc|anti-hpv-16 and anti-hpv-18 antibody concentrations by enzyme-linked immunosorbent assay (elisa) in serum|anti-hpv-16 and anti-hpv-18 antibody concentrations by elisa in cervicovaginal secretion (cvs)|frequency of specific b-cells for hpv-16/18 antigens|frequency of cluster of differentiation 4/8 [cd4+/cd8+] t-cell response",glaxosmithkline,Female,"15 Years to 25 Years   (Child, Adult)",Phase 4,873.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",109823|2013-003429-28,"October 26, 2010","January 13, 2016","April 19, 2017","December 14, 2009","July 24, 2019","July 21, 2020","['gsk investigational site, porto alegre, rio grande do sul, brazil gsk investigational site, ribeirão preto, são paulo, brazil gsk investigational site, campinas, brazil gsk investigational site, rio de janeiro, brazil gsk investigational site, são paulo, brazil gsk investigational site, kohtla-järve, estonia gsk investigational site, tallinn, estonia gsk investigational site, chennai, india gsk investigational site, kolkata, india gsk investigational site, mumbai, india gsk investigational site, pune, india gsk investigational site, bangkok, thailand gsk investigational site, bangkok, thailand gsk investigational site, chiangmai, thailand gsk investigational site, khon kaen, thailand']",,https://ClinicalTrials.gov/show/NCT01031069,
701,702,NCT00502307,"a study of tivozanib (av-951), an oral vegf receptor tyrosine kinase inhibitor, in the treatment of renal cell carcinoma",,Completed,Has Results,"carcinoma, renal cell",drug: tivozanib (av-951)|drug: placebo comparator,number of subjects with adverse events (aes)/serious aes (saes)|objective response [complete response (cr) + partial response (pr)] rate at 16 week open-label period (all treated population)|percentage of randomly assigned subjects remaining progression free at 12 weeks following random assignment to tivozanib (av-951) or placebo|number of subjects with progression free-survival (pfs) after random assignment (randomized sub-set only) (at 12 weeks post randomization )|overall progression-free survival (from start of treatment)|time to peak plasma concentration (tmax) of tivozanib in a subset of subjects|maximum observed serum concentration during a dosing interval at steady state (cmax)|area under the serum concentration versus time curve from zero to the last quantifiable sampling point [auc(0→24)],"aveo pharmaceuticals, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,272.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AV-951-07-201,October 2007,August 2010,August 2010,"July 17, 2007","September 1, 2020","September 1, 2020","['vellore, tamil nadu, india kolkata, india mumbai, india new delhi, india pune, india astrakhan, russian federation ioshkar-ola, russian federation kazan, russian federation moscow, russian federation moscow, russian federation moscow, russian federation novgorod, russian federation obninsk, russian federation pyatigorsk, russian federation rostove-on-don, russian federation sochi, russian federation st. petersburg, russian federation tomsk, russian federation ufa, russian federation cherkassy, ukraine dnepropetrovsk, ukraine donetsk, ukraine kharkov, ukraine lviv, ukraine uzhgorod, ukraine zaporizzhya, ukraine']",,https://ClinicalTrials.gov/show/NCT00502307,kidney
702,703,NCT05043090,"savolitinib plus durvalumab versus sunitinib and durvalumab monotherapy in met-driven, unresectable and locally advanced or metastatic prcc",SAMETA,Recruiting,No Results Available,papillary renal cell carcinoma,drug: savolitinib|drug: durvalumab|drug: sunitinib,"progression-free survival (pfs) /savolitinib plus durvalumab relative to sunitinib|overall survival (os) /savolitinib plus durvalumab relative to sunitinib|objective response rate (orr) / savolitinib plus durvalumab relative to sunitinib|duration of response (dor) / savolitinib plus durvalumab relative to sunitinib|disease control rate (dcr) at 24 and 48 weeks /savolitinib plus durvalumab relative to sunitinib|time from randomisation to second progression or death (pfs2) /savolitinib plus durvalumab relative to sunitinib|assessment of patient-reported symptoms, functioning, and hrqol /savolitinib plus durvalumab relative to sunitinib|objective response rate (orr) / savolitinib plus durvalumab relative to durvalumab monotherapy|duration of response (dor) / savolitinib plus durvalumab relative to durvalumab monotherapy|progression-free survival (pfs) /savolitinib plus durvalumab relative to durvalumab monotherapy|evaluation of the pk of savolitinib pre-dose|evaluation of the pk of savolitinib post-dose|evaluation of the pk of durvalumab pre-dose|evaluation of the pk of durvalumab / cmax (maximum plasma concentration)",astrazeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,220.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5086C00001|2021-000336-55,"October 28, 2021","March 28, 2024","June 9, 2025","September 13, 2021",,"April 20, 2022","['research site, whittier, california, united states research site, gurnee, illinois, united states research site, boston, massachusetts, united states research site, new york, new york, united states research site, syracuse, new york, united states research site, bahía blanca, argentina research site, buenos aires, argentina research site, caba, argentina research site, cordoba, argentina research site, la plata, argentina research site, rosario, argentina research site, san miguel de tucuman, argentina research site, box hill, australia research site, macquarie university, australia research site, malvern, australia research site, st leonards, australia research site, belo horizonte, brazil research site, brasilia, brazil research site, cachoeiro de itapemirim, brazil research site, criciuma, brazil research site, curitiba, brazil research site, florianopolis, brazil research site, fortaleza, brazil research site, natal, brazil research site, pelotas, brazil research site, porto alegre, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, salvador, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, são jose do rio preto, brazil research site, săo paulo, brazil research site, vitoria, brazil research site, calgary, alberta, canada research site, montreal, quebec, canada research site, providencia, chile research site, santiago, chile research site, santiago, chile research site, temuco, chile research site, brno, czechia research site, hradec kralove, czechia research site, olomouc, czechia research site, praha 10, czechia research site, praha 5, czechia research site, praha 8, czechia research site, praha, czechia research site, bordeaux, france research site, nice, france research site, toulouse, france research site, villejuif, france research site, hamburg, germany research site, hannover, germany research site, münchen, germany research site, tübingen, germany research site, ulm, germany research site, hong kong, hong kong research site, shatin, hong kong research site, bangalore, india research site, belagavi, india research site, jaipur, india research site, kolkata, india research site, mumbai, india research site, mysore, india research site, nashik, india research site, ashdod, israel research site, haifa, israel research site, jerusalem, israel research site, jerusalem, israel research site, petah tikva, israel research site, rehovot, israel research site, safed, israel research site, tel-aviv, israel research site, arezzo, italy research site, avellino, italy research site, bari, italy research site, firenze, italy research site, meldola, italy research site, milano, italy research site, milan, italy research site, padova, italy research site, reggio emilia, italy research site, tricase (lecce), italy research site, verona, italy research site, daejeon, korea, republic of research site, goyang-si, korea, republic of research site, incheon, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, aguascalientes, mexico research site, cancún, mexico research site, monterrey, mexico research site, méxico, mexico research site, queretaro, mexico research site, toluca de lerdo, mexico research site, amsterdam, netherlands research site, arnhem, netherlands research site, rotterdam, netherlands research site, gdansk, poland research site, gdynia, poland research site, kraków, poland research site, otwock, poland research site, poznan, poland research site, warsaw, poland research site, baia mare, romania research site, cluj napoca, romania research site, cluj-napoca, romania research site, constanta, romania research site, craiova, romania research site, craiova, romania research site, iasi, romania research site, arkhangelsk, russian federation research site, ekaterinburg, russian federation research site, krasnoyarsk, russian federation research site, kursk, russian federation research site, kuzmolovskiy, russian federation research site, moscow, russian federation research site, moscow, russian federation research site, omsk, russian federation research site, ryazan, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, st-petersburg, russian federation research site, singapore, singapore research site, barcelona, spain research site, barcelona, spain research site, barcelona, spain research site, cordoba, spain research site, coruña, spain research site, madrid, spain research site, madrid, spain research site, madrid, spain research site, majadahonda, spain research site, málaga, spain research site, pamplona, spain research site, sabadell, spain research site, sevilla, spain research site, valencia, spain research site, kaohsiung city, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, adana, turkey research site, ankara, turkey research site, ankara, turkey research site, ankara, turkey research site, edirne, turkey research site, istanbul, turkey research site, istanbul, turkey research site, istanbul, turkey research site, izmir, turkey research site, karsiyaka, turkey research site, kazımkarabekir, turkey research site, chernivtsі, ukraine research site, dnipropetrovsk, ukraine research site, ivano-frankivsk, ukraine research site, kharkiv, ukraine research site, kyiv, ukraine research site, poltava, ukraine research site, zaporizhzhia, ukraine research site, zaporizhzhia, ukraine research site, leicester, united kingdom research site, london, united kingdom research site, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT05043090,kidney
703,704,NCT00312845,study of velcade and rituximab in patients with relapsed or refractory b-cell non-hodgkin's lymphoma,,Completed,Has Results,non-hodgkin's lymphoma,drug: bortezomib + rituximab|drug: rituximab,progression free survival|overall response rate,"millennium pharmaceuticals, inc.|johnson & johnson pharmaceutical research & development, l.l.c.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,676.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26866138-LYM-3001,March 2006,June 2010,July 2010,"April 11, 2006","July 26, 2011","June 25, 2012","['east alabama medical center, opelika,, alabama, united states central hematology oncology medical group, inc, alhambra, california, united states comprehensive blood and cancer center, bakersfield, california, united states providence saint joseph medical center, burbank, california, united states st. jude heritage medical group, fullerton, california, united states wilshire oncology medical group, inc., la verne, california, united states pacific shores medical group, long beach, california, united states university of southern california, los angeles, california, united states university of california, los angeles, los angeles, california, united states north valley hematology oncology, mission hills, california, united states university of california, irvine medical center, orange, california, united states ventura county hematology-oncology specialists, oxnard, california, united states cancer care associates medical group, inc., redondo beach, california, united states central coast medical oncology corporation, santa maria, california, united states norwalk medical group, norwalk, connecticut, united states hematology oncology pc, stamford, connecticut, united states integrated community oncology network, jacksonville, florida, united states innovative clinical research of south florida, miami, florida, united states palm beach cancer institute, west palm beach, florida, united states emory univeersity ,winship cancer institute, atlanta, georgia, united states suburban hematology-oncology associates, lawrenceville, georgia, united states northwest georgia oncology centers, p.c., marietta, georgia, united states north idaho cancer center, coeur d alene, idaho, united states investigative clinical research of indiana, indianapolis, indiana, united states siouxland hematolgoy-oncology associates, sioux city, iowa, united states kansas city cancer center, llc, kansas city, kansas, united states louisville oncology, louisville, kentucky, united states hematology & oncology specialists, metairie, louisiana, united states sinai hospital, baltimore, maryland, united states hattiesburg clinic, hattesburg, missouri, united states southeastern medical oncology center, goldsboro, north carolina, united states oregon health & science university, portland, oregon, united states lancaster cancer center, ltd., lancaster, pennsylvania, united states the western pennsylvania hospital, pittsburg, pennsylvania, united states south carolina oncology associates, pa, columbia, south carolina, united states south carolina oncology associates, columbia, south carolina, united states vanderbilt university, nashville, tennessee, united states the center for cancer and blood disorders, fort worth, texas, united states oncology consultants, houston, texas, united states south texas oncology and hematology, san antonio, texas, united states medical college of wisconsin milwaukee, milwaukee, wisconsin, united states higa san martin, la plata - buenos aires, argentina hospital professor rodolfo rossi, la plata - buenos aires, argentina centro oncologico integracion regional, mendoza, argentina princess alexandra hospital, woolloongabba, queensland, australia royal adelaide hospital, adelaide, south australia, australia peter maccallum cancer institute, east melbourne, victoria, australia alfred hospital, melbourne, victoria, australia royal melbourne hospital, parkville, victoria, australia fremantle hospital, fremantle, western australia, australia ulb erasme, anderlecht, belgium az stuivenberg, antwerpen, belgium az sint jan, brugge, belgium institute j. bordet, bruxelles, belgium clinique notre dame, charleroi, belgium uz antwerpen - universitair ziekenhuis antwerpen, edegem, belgium uz gent - universitair ziekenhuis gent, gent, belgium virga jesse ziekenhuis, dienst hematologie, hasselt, belgium chr la citadelle, liege, belgium chu sart tilman, liege, belgium heilig hart roeselare, roeselare, belgium servico de oncologia do hospital sao lucas da puc do rio grande do sul, porto alegre, rio grande do sul, brazil instituto nacional de cancer, rio de janeiro, brazil hospital brigadeiro, sao paulo, brazil faculdade de medicina do abc, sao paulo, brazil toronto sunnybrook regional cancer centre, toronto, ontario, canada university health network - princess margaret hospital, toronto, ontario, canada juravinski cancer centre, hamilton, canada west china hospital of sichuan, chengdu, sichuan, china cancer hospital (institute), cams&pumc, beijing, china beijing cancer hospital, beijing, china peking university people\'s hospital, beijing, china affiliated hospital of the academy of military medical sciences, beijing, china cancer center, sun yat-sen university, guangzhou, china peking university third hospital, haidian district beijing, china ruijin hospital, shanghai, china cancer hospital - fudan university, shanghai, china bank of cyprus oncology centre, nikosia, cyprus fakultni nemocnice brno, brno, czech republic fakultni nemocnice hradec kralove, hradec kralove, czech republic fakultni nemocnice olomouc, olomouc, czech republic vseobecna fakultni nemocnice, praha, czech republic paijat - hameen keskussairaala, lahti, finland satakunnan keskussairaala, pori, finland institut bergonie, bordeaux, france clinique victor hugo, le mans, france hopital claude huriez, lille, france centre léon bérard, lyon, france hopital hotel dieu, nantes, france service des maladies due sang - hopital haut leveque, pessac, france centre hospitalier lyon sud, pierre benite, france onkologische schwerpunktpraxis, herrsching, germany universitatsklinikum munster - klinik fur innere medizin, munster, germany praxis für hämetologie und oncologie, würzburg, germany laiko general hospital of athens - 1st internist clinic - hematology department, athens, greece university general hospital attikon - 2nd department of internal medicine - propedeutic & research institute, athens, greece university hospital of patras - department of internal medicine - hematology division, rio patras, greece debreceni egyetem, orvos- es egeszsegtudomanyl centrum, iii. belgyogyaszati klinika, debrecen, hungary petz aladar county hospital, gyor, hungary szegedi tudomanyegyetem, ii belgyaszati klinika, szeged, hungary institution manipal hospital, bangalore, india postgraduate institute of medical education and research, chandigarh, india apollo speciality hospital, chennai, india nizam\'s institute of medical sciences, hyderabaad, india sms medical college hospital, jaipur, india apollo hospitals, hyderabad apollo hospital complex, jubilee hills, india shirdi saibaba cancer hospital, karnataka, india department of medical oncology - regional cancer centre, kerala, india regional cancer centre, kerala, india tata memorial centre, mumbai, india soroka medical center, beer sheva, israel rambam medical center, haifa, israel hadassah medical center, jerusalem, israel rabin medical center, petah tikva, israel sorraski tel aviv medical center, tel aviv, israel sheba medical center, tel hashomer, israel azienda ospedaliero universitaria di bologna, bologna, italy universita degli studi di perugia, perugia, italy azienda ospedallera universitaria policlinico tor vergata, roma, italy azienda sanitaria ospedaliera molinette s. giovanni battista, torino, italy lung cancer center - national cancer center, gyeonggi-do, korea, republic of samsung medical center - division of hematology-oncology, department of medicine, ilmon-dong, kangnam-ku, seoul, korea, republic of hematology-oncology clinic, center for specific organs cancer - national cancer center, ilsandong-gu, goyang-si, and gyeonggi-do, korea, republic of samsung medical center - department of internal medicine, ilwon dong, kangnam-ku, seoul, korea, republic of severance hospital, yonsei university college of medicine, seoul, korea, republic of asan medical center, seoul, korea, republic of instituto nacional de ciencias medicas y nutricion salvador zubiran, delagacion tlalpan, mexico instituto nacional de cancerologia incan, delagacion tlalpan, mexico hospital universitario dr. jose eleuterio gonzalez uanl, monterrey, nuevo leon, mexico canterbury health laboratories, christchurch, new zealand klinika hematologii instytut chorob wewnetrznych, gdansk, poland klinika hematologii cmuj, krakow, poland klinika hematologii - uniwersytetu medycznego, lodz, poland klinika hematologii i transplantologii szpiku am, lublin, poland wojskowy instytut medyczny - klinika hematologii, warsawa, poland instytut hematologii i transfuzjologii, warszawa, poland klinika hematologii am, warszawa, poland klinika nowotworow ukladu chlonnego, warszawa, poland katedra i klinika hematologii, nowotworow krwi i transplantacji szpiku, wroclaw, poland servico de hematologia - hospital de dia - hospital da universidade de coimbra, coimbra, portugal instituto portugues de oncologia de lisboa francisco gentil, e.p.e. - departmento de hematologia, lisboa, portugal hospital de dia de hematologia - hospital de santa maria e.p.e., lisboa, portugal serviço de onco-hematologia, instituto português de oncologia do porto franscisco gentil, epe, porto, portugal san juan va medical center, san juan, puerto rico spitalul clinic de urgenta, brasov, romania institutul clinic fundeni clinica de hematologie, bucuresti, romania spitalul universitar de urgenta hematologie, bucuresti, romania spitalul clinic judetean de urgenta ""sf. spiridon, clinica hematologie, iasi, romania spitalul clinic judetean de urgenta mures, targu mures, romania arkhangelsk region clinical hospital, arghangelsk, russian federation altay regional oncology dispensary, barnaul, russian federation belgorod regional oncology center, belgorod, russian federation cheliabinsk regional oncology dispensary, cheliabinsk, russian federation ekaterinburg city clinical hospital #7, ekaterinburg, russian federation 1st republican clinical hospital of udmurtia, izhevsk, russian federation cancer research center, moscow, russian federation s.p. botkin moscow city clinical hospital, moscow, russian federation moscow region clinical research institute, moscow, russian federation semashko central clinical hospital #2, moscow, russian federation city oncology hospital #62, moscow, russian federation nizhniy novgorod region clinical hospital, nizhniy novgorod, russian federation novosibirsk state regional clinical hospital, novosibirsk, russian federation novosibirsk state medical university, novosibirsk, russian federation medical scientifical radiology center, obninsk, russian federation republikan hospital named after v.a. baranov, petrozavodsk, russian federation saint petersburg pavlov state medical university, saint petersburg, russian federation saratov state medical university, saratov, russian federation st. petersburg clinical research institute of hematology and transfusiology, st. petersburg, russian federation st. petersburg city hospital #31, st. petersburg, russian federation tomsk research oncology institute, tomsk, russian federation republican clinical hospital of bashkorkostan, ufa, russian federation fn f.d. roosevelt - oddelenie hematologie, banska bysterica, slovakia fakultna nemocnica l. pasteura - klinika hematologie a onkohematologie, kosice, slovakia vychodoslovensky onkologicky ustave, a.s., kosice, slovakia martinska fn, klinika hematologie a transfuziologie, martin, slovakia gvi oncology clinical trial unit, panorama, cape town, south africa mary potter oncology centre - little company of mary hospital, groenkloof, pretoria, south africa chris hani baragwanath hospital, johannesburg, south africa east cape oncology centre - st. georges hospital, port elizabeth, south africa hospital durans i reynals - institut catala d\'oncologia, barcelona, spain hospital germans trias i pujol institut catala d\'oncologia, barcelona, spain hospital universitario la paz, madrid, spain hospital universitario de salamanca, salamanca, spain onkologiska kliniken universitetssjukhuset, lund, sweden centrum for hematologi karolinska university hospital, stockholm, sweden hematologiska kliniken m54 karolinska university hospital, stockholm, sweden king chulalongkorn memorial hospital, bangkok, thailand ramathibodi hospital, mahidol university, bangkok, thailand siriraj hospital, mahidol university, bangkok, thailand maharaj nakorn chiang mai hospital, chiang mai university, chiang mai, thailand cherkassy regional oncology dispensary, cherkassy, ukraine dnepropetrovsk regional clinical oncology dispensary, dnepropetrovsk, ukraine institute for emergency and urgent medical assistance named after v.k. gusak of ams of ukraine, donetsk, ukraine khmelnitskiy regional hopsital, khmelnitsky, ukraine kiev center of marrow transplantaion, kiev, ukraine krivoy rog oncology dispensary, krivoy rog, ukraine institute of blood pathology and transfusional medicine of ams of ukraine, lviv clinical hospital #5, lviv, ukraine ukrainian medical stomatological academy, poltava regional dispensary, poltava, ukraine crimean republic clinical oncology dispensary, simferopol, ukraine zhitomir gerbachevsky regional clinical hospital, zhitomir, ukraine aberdeen royal infirmary - department of haematology, aberdeen, united kingdom addenbrooke\'s hospital - department of haematology, cambridge, united kingdom university hospital of wales, cardiff, united kingdom guy\'s & st. thomas hospital, london, united kingdom derriford hospital - department of haematology, plymouth, united kingdom taunton & somerset hospital, taunton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00312845,lymphoma
704,705,NCT00088530,"bbr 2778 for relapsed, aggressive non-hodgkin's lymphoma (nhl)",,Completed,Has Results,"lymphoma, non-hodgkin","drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|drug: vinorelbine, oxalplatin, ifosfasmide, etoposide, mitoxatrone, gemcitabine or rituximab",complete response (cr) and complete response unconfirmed (cru)|progression-free survival (pfs)|overall survival|overall response rate (orr) lasting at least 4 months,cti biopharma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,140.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PIX301,July 2004,February 2010,July 2010,"July 29, 2004","June 1, 2017","February 5, 2020","['robert a. moss, m.d., facp, inc., fountain valley, california, united states ucla medical center, los angeles, california, united states watson clinic for cancer care and research, lakeland, florida, united states rush university medical center, chicago, illinois, united states new mexico oncology/hematology, albuquerque, new mexico, united states suny upstate medical university, syracuse, new york, united states duke university medical center, durham, north carolina, united states northwest kaiser permanente, portland, oregon, united states northern utah hematology oncology, p.c., ogden, utah, united states clinica modelo s.a., parana, entre rios, argentina instituto de investigaciones clinicas, rosario, santa fe, argentina centro oncologico rosario, rosario, santa fe, argentina fundaleu - fundacion para combatir le leucernia, buenos aires, argentina hospital universitario austral, buenos aires, argentina academia nacional de medicina, caba, argentina hospital privado centro medico de cordoba s.a., cordoba, argentina isis clinica especializada, santa fe, argentina university gernal hospital for active treatment ""alexandrovska"" - clinic of hematology, sofia, bulgaria national centre for hemotransfusion, sofia, bulgaria university general hospital for active treatment ""st. marina"" clinic of hematology, varna, bulgaria hospital cima san jose, escazu, costa rica hospital oncologico de solca, capilla mauta, guayaquil, ecuador hospital carlos andrade marin oncologia, quito,, pinchincha, ecuador hospital solca quito, quito, ecuador tartu university clinics, hematology oncology clinic, tartu, estonia institute bergonie, bordeaux, france centre hospitalier lyo sud, service d\'hematologie et d\'oncologie, pierre-benite, france hopitaux universitaires de strabourg - hopital de hautepierre, strasbourg, france staedtische kliniken hoechst, frankfurt, he, germany charite, campus benjamin franklin, berlin, germany universitatklinik des saarlandes, innere medzin i, hamburg, germany westpfalzklinikum kaiserslautern, kaiserslautern, germany klinikum der universitaet zu koeln, koeln, germany kliniken maria hilf gmbh, moenchengladbach, germany mutterhaus der borromaeerinne, trier, germany szent laszlo korhaz, budapest, hungary petz aladar megyei okato korhaz, gyor, hungary bekes megyei pandy kalman korhaz, gyula, hungary kaposi mor megyei korhaz, kaposvar, hungary pecsi tudomanyegyetem, pecs, hungary szegedi tudomanyegyetem szent-gyorgyi albert orvos-es gyogy ii, szeged, hungary indo-american cancer institute & research center, hyderabaad, andhprad, india nizam\'s institute of medical sciences, panjagutta, hyderabad, india manipal hospital, bangalore, karnataka, india shirdi sai baba cancer hospital, k.m.c. manipal, manipala, karna, india regional cancer center, thiruvananthapuram, kerla, india bhagwan mahaveer cancer hospital & research center, jaipur, rajasthan, india m.s. ramaiah medical college, bangalore, india tata memorial hospital, mumbai, india policlinico s. orsola, instituto di ematologia, bologna, italy ospedale oncologico ""a. businco"", cagliari, italy ospedale s. martino, genova, italy universita degli studi perugia policlinico monteluce, perugia, italy azienda ospedaliera pisana ""santa chiara"", pisa, italy azienda ospedaliera pisanan ""santana chiara"", pisa, italy ospedale oncolgoico regionale della basilicata, rionero in vulture, italy ospedale s. eugenio, roma, italy universita la sapienza, roma, italy ospedale casa sollievo della sofferenza, san giovanni rotondo, italy policlinico s. maria alle scotte, siena, italy presidio san giuseppe moscati, taranto, italy ospedale civile, udine, italy fundacion centro de investigacion, medellin, columbia, mexico medical solutions, guatimala, guatemala, mexico complejo hospitalario ""arnulfo arias madrid, panama, panama hospital edgardo rebagliati martins, lima, peru onococenter, san borja, peru klinika hematologii, onkologii i chorob wewnetrznych, gdansk, poland brasov counthy hospital, brasov, romania colentina clinical hospital hem dept, bucharest, romania fundei clinical institute, bucharest, romania prof. dr. ian chiricuta, institute of oncology, radiotheraphy, cluj napoca, romania institutul oncologic ""ion chiricuta"" oncologie medicala, cluj-napoca, romania mures county clinical hospital, targu mures, romania state medical institution altai territorial oncological center, barnaul, russian federation state medical institution replubican oncological center, bashkortostan, russian federation state therapeutical & prophlatic institution: cheylabinsk regional oncological center, chelyabinsk, russian federation state medical institution, irkutsk, russian federation state medical institution: clinical oncological center, krasnodar, russian federation russian oncological research center n.a. n.n. blokhin, moscow, russian federation state institution: hematological research center under the russian academy of medical sciences, moscow, russian federation state institution: moscow regional research clinical institute n.a. m.f., moscow, russian federation semashko central clinical hospital, moscow, russian federation medical radiological research center under the russian academey of medical sciences, obninsk, russian federation research insitute of hematology and blood transfusion, st. petersburg, russian federation st. petersburg pavlov state medical clinic of intensive care & bone marrow transplantation, st. petersburg, russian federation st. petersburg state medical univ. n.a. i.p. pavlov, st. petersburg, russian federation st. petersburg state medical institution: municipal hospital #31, st. petersburg, russian federation central research rontgenological and radiological institute, st. petersburg, russian federation state research institution: research institute of oncology, st. petersburg, russian federation institute of clinical radiology of the research center for radiation medicine under the uams, kyiv, ukraine kyiv bone marrow transplantation, kyiv, ukraine institute of blood pathology & transfusion medicine under the uams, lviv, ukraine zhtomyr o.f. gerbachevsky regional hospital, zhytomyr, ukraine beatson oncology centre, western infirmary, glasgow, united kingdom st. georges hospital, london, united kingdom weston park hospital, sheffield, united kingdom hospital maciel, montevideo, uruguay hospital policial de montevideo, poblado montevideo chico, uruguay']",,https://ClinicalTrials.gov/show/NCT00088530,lymphoma
705,706,NCT03298451,study of durvalumab and tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma,HIMALAYA,Recruiting,No Results Available,hepatocellular carcinoma,drug: durvalumab|drug: tremelimumab (regimen 1)|drug: tremelimumab (regimen 2)|drug: sorafenib|drug: durvalumab (regimen 1)|drug: durvalumab (regimen 2),overall survival (os)|time to progression (ttp)|progression-free survival (pfs)|objective response rate (orr)|disease control rate (dcr)|duration of response (dor),astrazeneca,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,1504.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D419CC00002,"October 11, 2017","August 27, 2021","August 27, 2024","October 2, 2017",,"April 29, 2022","['research site, los angeles, california, united states research site, orange, california, united states research site, san francisco, california, united states research site, washington, district of columbia, united states research site, fort myers, florida, united states research site, jacksonville, florida, united states research site, westwood, kansas, united states research site, baltimore, maryland, united states research site, ann arbor, michigan, united states research site, rochester, minnesota, united states research site, new york, new york, united states research site, charlotte, north carolina, united states research site, portland, oregon, united states research site, pittsburgh, pennsylvania, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, dallas, texas, united states research site, houston, texas, united states research site, houston, texas, united states research site, murray, utah, united states research site, barretos, brazil research site, curitiba, brazil research site, florianopolis, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, sao paulo, brazil research site, sao paulo, brazil research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, hamilton, ontario, canada research site, kingston, ontario, canada research site, london, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, quebec city, quebec, canada research site, sherbrooke, quebec, canada research site, beijing, china research site, beijing, china research site, changchun, china research site, changsha, china research site, chengdu, china research site, dalian, china research site, fuzhou, china research site, guangzhou, china research site, hangzhou, china research site, harbin, china research site, hefei, china research site, nanchang, china research site, nanjing, china research site, nanning, china research site, neijiang, china research site, shanghai, china research site, suzhou, china research site, wuhan, china research site, xian, china research site, yibin, china research site, zhengzhou, china research site, clichy, france research site, lile, france research site, lyon, france research site, marseille, france research site, montpellier, france research site, nancy, france research site, nantes, france research site, nice, france research site, pessac, france research site, poitiers, france research site, reims, france research site, rouen, france research site, saint-etienne, france research site, toulouse, france research site, villejuif, france research site, aachen, germany research site, essen, germany research site, hannover, germany research site, heidelberg, germany research site, koeln, germany research site, leipzig, germany research site, mainz, germany research site, muenchen, germany research site, tuebingen, germany research site, ulm, germany research site, hong kong, hong kong research site, bangalore, india research site, bhubneshwar, india research site, chennai, india research site, chennai, india research site, hubli, india research site, hyderabad, india research site, kanpur, india research site, karmsad, india research site, ludhiana, india research site, mumbai, india research site, mumbai, india research site, nashik, india research site, new delhi, india research site, benevento, italy research site, meldola, italy research site, milano, italy research site, napoli, italy research site, perugia, italy research site, pisa, italy research site, roma, italy research site, rozzano (mi), italy research site, bunkyoku, japan research site, chiba, japan research site, fukuoka, japan research site, hiroshima, japan research site, iizuka, japan research site, kanazawa, japan research site, kotoku, japan research site, kumamoto, japan research site, kurume, japan research site, matsuyama, japan research site, mitakashi, japan research site, musashino, japan research site, nagoya, japan research site, ogaki, japan research site, okayama, japan research site, osaka sayama, japan research site, osaka, japan research site, osaka, japan research site, saga, japan research site, sapporo, japan research site, shiwa, japan research site, suntogun, japan research site, tsu, japan research site, yokohama, japan research site, ilsan, gyeonggi-do, korea, republic of research site, seongnam-si, gyeonggi-do, korea, republic of research site, busan, korea, republic of research site, daegu, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, seoul, korea, republic of research site, moscow, russian federation research site, moscow, russian federation research site, murmansk, russian federation research site, nizhniy novgorod, russian federation research site, novosibirsk, russian federation research site, obninsk, russian federation research site, omsk, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, saint petersburg, russian federation research site, ufa, russian federation research site, barcelona, spain research site, madrid, spain research site, oviedo, spain research site, pamplona madrid, spain research site, santander, spain research site, chiayi, taiwan research site, kaohsiung, taiwan research site, taichung, taiwan research site, tainan, taiwan research site, tainan, taiwan research site, taipei, taiwan research site, taoyuan, taiwan research site, bangkok, thailand research site, bangkok, thailand research site, chang mai, thailand research site, khon kaen, thailand research site, phitsanulok, thailand research site, songkhla, thailand research site, dnipro, ukraine research site, ivanofrankivsk, ukraine research site, kharkiv, ukraine research site, kropyvnitskyi, ukraine research site, kyiv, ukraine research site, lviv, ukraine research site, odesa, ukraine research site, uzhgorod, ukraine research site, hanoi, vietnam research site, hochiminh, vietnam']",,https://ClinicalTrials.gov/show/NCT03298451,liver
706,707,NCT00332202,prelude:study to investigate the prevention of relapse in lymphoma using daily enzastaurin,,Completed,Has Results,non hodgkin lymphoma,drug: enzastaurin|drug: placebo,"overall disease-free survival|disease free survival at 2 years|event-free survival|event-free survival at 2 years|overall survival|number of participants with treatment-emergent adverse events|quality of life: change from baseline in functional assessment of cancer therapy - lymphoma (fact-lym) score|change from baseline in euroqol-5d (eq-5d) score|translational research: dfs participants with diffuse large b-cell lymphoma (dlbcl) germinal-center b-cells (gcb) versus non-germinal-center b-cells|translational research: dfs of participants with diffuse large b-cell lymphoma (dlbcl) protein kinase c-β2 (pkc-β2) expression|pharmacokinetics: average steady-state concentration (cavg,ss) for total analyte",eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,758.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",9823|H6Q-MC-JCBJ|PRELUDE,June 2006,April 2013,July 2013,"June 1, 2006","September 10, 2018","September 10, 2018","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., anchorage, alaska, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., los angeles, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., orlando, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chicago, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bloomington, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., indianapolis, indiana, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., iowa city, iowa, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lexington, kentucky, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., boston, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., robbinsdale, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rochester, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbia, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., durham, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tulsa, oklahoma, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pittsburgh, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., houston, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., the woodlands, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., salt lake city, utah, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., everett, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seattle, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vancouver, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madison, wisconsin, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., garran, australian capital territory, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gosford, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., casuarina, northern territory, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., woolloongabba, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heidelberg, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., prahran, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nedlands, western australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brugge, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brussels, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gent, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., leuven, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., roeselare, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., belo horizonte, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., campinas, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., goiania, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rio de janeiro, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., são paulo, brazil for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edmonton, alberta, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vancouver, british columbia, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hamilton, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toronto, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., montreal, quebec, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., regina, saskatchewan, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., beijing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chengdu, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guang zhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hangzhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nanjing, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shanghai, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., suzhou, china for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brno, czechia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., olomouc, czechia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., prague, czechia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., herlev, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., odense, denmark for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., helsinki, finland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., avignon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bayonne, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., la roche sur yon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., le mans, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nantes, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nice, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nimes, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pessac, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rennes, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vandoeuvre les nancy, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., berlin, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chemnitz, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., erlangen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., frankfurt, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., giessen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hamburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., homburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kassel, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mainz, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., muenchen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., haidari/athens, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., thessaloniki, greece for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., budapest, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., miskolc, hungary for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pune, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., secunderabad, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., trivandrum, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aviano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bergamo, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bologna, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., milano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pisa, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., reggio emilia, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rome, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vicenza, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aichi, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., fukuoka, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., gunma, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kanagawa, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kyoto, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mie, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., miyagi, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nagasaki, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., okayama, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., shiga, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tokyo, japan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., daegu, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., goyang-si, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hwasun-gun, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seoul, korea, republic of for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., col. florida, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guadalajara, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mexico city, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., monterrey, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san luis potosi, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toluca, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lublin, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., olsztyn, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poznan, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., warsaw, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wroclaw, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., coimbra, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lisbon, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa maria da feira, portugal for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san juan, puerto rico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hospitalet llobregat, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oviedo, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., salamanca, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santander, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toledo, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., valencia, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., zaragoza, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lund, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., umea, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., uppsala, sweden for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., changhua, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chiayi city, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kaohsiung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liouying/tainan, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., neihu taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taichung, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tainan, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., taipei, taiwan for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., plymouth, devon, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brighton, east sussex, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., maidstone, kent, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aberdeen, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., glasgow, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00332202,lymphoma
707,708,NCT00532259,ct-011 mab in dlbcl patients following asct,,Completed,Has Results,"lymphoma, large cell, diffuse|lymphoma, mixed cell, diffuse|primary mediastinal large b-cell lymphoma",drug: ct-011,progression-free survival|overall survival,curetech ltd,All,"18 Years and older   (Adult, Older Adult)",Phase 2,72.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT-2007-01,October 2007,August 2011,August 2011,"September 20, 2007","September 12, 2014","September 12, 2014","['moores ucsd cancer center, la jolla,, california, united states scripps cancer center, san diego, california, united states northside hospital, atlanta,, georgia, united states emory university-winship cancer institute, atlanta, georgia, united states northwestestern memorial hospital, chicago, illinois, united states rush university medical center, chicago, illinois, united states the university of chicago, chicago, illinois, united states dana-farber cancer institute, boston, massachusetts, united states university of michigan, ann arbor, michigan, united states karmanos cancer institute, detroit, michigan, united states university of north carolina, chapel hill, north carolina, united states duke university medical center, durham, north carolina, united states case western reserve university, cleveland, ohio, united states ohio state university, colombus, ohio, united states temple university, philadelphia, pennsylvania, united states the university of pittsburgh medical center, pittsburgh, pennsylvania, united states cancer center of the carolinas, greenville, south carolina, united states sarah cannon research institute, nashville, tennessee, united states baylor sammons cancer center, dallas,, texas, united states m.d. anderson cancer center, houston, texas, united states jaslok hospital and research centre, mumbai, maharashtra, india deenanath mangeshkar hospital and research centre, pune, maharashtra, india gujarat cancer and research institute, ahmedabad, india rajiv gandhi cancer institute and research centre, delhi, india rambam medical center, haifa, israel hadassah medical organization, jerusalem, israel chaim sheba medical center, tel hashomaer, ramat gan, israel']",,https://ClinicalTrials.gov/show/NCT00532259,lymphoma
708,709,NCT01030783,a study to compare tivozanib (av-951) to sorafenib in subjects with advanced renal cell carcinoma,TIVO-1,Completed,Has Results,advanced renal cell carcinoma,drug: tivozanib (av-951)|drug: sorafenib,progression-free survival (pfs) of subjects with advanced renal cell cancer (rcc) randomized to treatment with tivozanib or sorafenib|overall survival (os) of subjects randomized to treatment with tivozanib or sorafenib|objective response rate (orr) of subjects randomized to treatment with tivozanib or sorafenib|duration of response (dr) of subjects randomized to treatment with tivozanib or sorafenib|safety and tolerability of tivozanib and sorafenib|to compare kidney-specific symptoms and health outcome measurements in subjects randomized to treatment with tivozanib or sorafenib|pharmacokinetics (serum concentrations) of tivozanib,"aveo pharmaceuticals, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,517.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AV-951-09-301,December 2009,July 2012,June 2013,"December 11, 2009","October 28, 2019","October 28, 2019","['site 185, los angeles, california, united states site 180, gainesville, florida, united states site 184, orlando, florida, united states site 182, minneapolis, minnesota, united states site 186, new york, new york, united states site 187, dallas, texas, united states site 102, sante fe, argentina site 403, plovdiv, bulgaria site 404, sofia, bulgaria site 400, sofia, bulgaria site 401, varna, bulgaria site 402, veliko tarnovo, bulgaria site 110, montréal, quebec, canada site 121, la reina, santiago de chile, chile site 122, santiago, chile site 123, temuco, chile site 411, prague 8, czechia site 130, marseille, france site 133, saint herblain cedex, france site 423, budapest, hungary site 421, kaposvár, hungary site 422, pécs, hungary site 424, szombathely, hungary site 157, hyderabad, andhra pradesh, india site 190, patna, bihar, india site 156, ahmedabad, gujarat, india site 151, nashik, maharashtra, india site 153, pune, maharashtra, india site 159, pune, maharashtra, india site 191, jaipur, rajasthan, india site 155, jaipur, rajasthan, india site 152, vellore, tamil nadu, india site 158, lucknow, uttar pradesh, india site 150, kolkata, west bengal, india site 154, delhi, india site 160, arezzo, italy site 161, pavia, italy site 162, roma, italy site 432, bialystok, poland site 434, bydgoszcz, poland site 431, gdansk, poland site 435, olsztyn, poland site 433, poznan, poland site 430, warsaw, poland site 436, warsaw, poland site 444, brasov, romania site 441, bucharest, romania site 440, bucharest, romania site 443, bucharest, romania site 442, timisoara, romania site 459, ufa, republic of bashkortostan, russian federation site 451, chelyabinsk, russian federation site 455, ekaterinburg, russian federation site 468, ioshkar ola, russian federation site 452, kazan, russian federation site 454, moscow, russian federation site 453, moscow, russian federation site 458, moscow, russian federation site 460, moscow, russian federation site 461, moscow, russian federation site 462, moscow, russian federation site 450, nizhny novgorod, russian federation site 456, obninsk, russian federation site 467, omsk, russian federation site 463, pyatigorsk, russian federation site 457, rostov-on-don, russian federation site 466, st. petersburg, russian federation site 465, st. petersburg, russian federation site 464, yaroslavi, russian federation site 480, belgrade, serbia site 481, belgrade, serbia site 482, belgrade, serbia site 483, nis, serbia site 484, sremska kamenica, serbia site 491, chernihiv, ukraine site 492, dniproperovsk, ukraine site 498, dnipropetrovsk, ukraine site 493, donetsk, ukraine site 496, donetsk, ukraine site 490, ivano-frankivsk, ukraine site 494, kharkiv, ukraine site 497, uzhhorod, ukraine site 495, zaporizhia, ukraine site 170, cambridge, united kingdom site 173, ipswich, united kingdom site 172, leicester, united kingdom']",,https://ClinicalTrials.gov/show/NCT01030783,kidney
709,710,NCT01076010,an extension treatment protocol for subjects who have participated in a study of tivozanib versus sorafenib in kidney carcinoma (protocol av-951-09-301).,,Completed,Has Results,advanced renal cell carcinoma,drug: tivozanib|drug: sorafenib,number of days subjects received treatment in each treatment arm|number of cycles subjects received treatment in each treatment arm|total dose administered to subjects in each treatment arm (mg)|average daily dose administered to subjects in each treatment arm|relative dose intensity (rdi) of treatment administered to subjects in each treatment arm|number of subjects with adverse events|number of subjects with objective response rate (orr) who continued treatment with tivozanib or sorafenib and who received tivozanib after failure of sorafenib|duration of response (dr)|progression-free survival (pfs)|overall survival (os),"aveo pharmaceuticals, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,277.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AV-951-09-902|2009-015987-32,March 2010,July 2014,July 2014,"February 25, 2010","October 5, 2020","October 5, 2020","['site 185, los angeles, california, united states site 184, orlando, florida, united states site 182, minneapolis, minnesota, united states site 186, new york, new york, united states site 187, dallas, texas, united states site 403, plovdiv, bulgaria site 404, sofia, bulgaria site 400, sofia, bulgaria site 401, varna, bulgaria site 402, veliko tarnovo, bulgaria site 110, montréal, quebec, canada site 122, santiago, chile site 123, temuco, chile site 411, prague 8, czechia site 133, saint herblain cedex, france site 423, budapest, hungary site 421, kaposvár, hungary site 422, pécs, hungary site 156, ahmedabad, gujarat, india site 151, nashik, maharashtra, india site 153, pune, maharashtra, india site 191, jaipur, rajasthan, india site 152, vellore, tamil nadu, india site 158, lucknow, uttar pradesh, india site 150, kolkata, west bengal, india site 154, delhi, india site 160, arezzo, italy site 161, pavia, italy site 162, roma, italy site 432, bialystok, poland site 434, bydgoszcz, poland site 431, gdansk, poland site 435, olsztyn, poland site 433, poznan, poland site 430, warsaw, poland site 436, warsaw, poland site 444, brasov, romania site 441, bucharest, romania site 440, bucharest, romania site 443, bucharest, romania site 442, timisoara, romania site 459, ufa, republic of bashkortostan, russian federation site 451, chelyabinsk, russian federation site 455, ekaterinburg, russian federation site 452, kazan, russian federation site 454, moscow, russian federation site 453, moscow, russian federation site 458, moscow, russian federation site 460, moscow, russian federation site 461, moscow, russian federation site 462, moscow, russian federation site 450, nizhny novgorod, russian federation site 456, obninsk, russian federation site 467, omsk, russian federation site 463, pyatigorsk, russian federation site 457, rostov-on don, russian federation site 466, st. petersburg, russian federation site 465, st. petersburg, russian federation site 464, yaroslavl, russian federation site 480, belgrade, serbia site 481, belgrade, serbia site 482, belgrade, serbia site 483, nis, serbia site 484, sremska kamenica, serbia site 491, chernihiv, ukraine site 498, dniproperovsk, ukraine site 492, dniproperovsk, ukraine site 493, donetsk, ukraine site 496, donetsk, ukraine site 490, ivano-frankivsk, ukraine site 494, kharkiv, ukraine site 497, uzhhorod, ukraine site 495, zaporizhia, ukraine site 170, cambridge, united kingdom site 172, leicester, united kingdom']",,https://ClinicalTrials.gov/show/NCT01076010,kidney
710,711,NCT01307397,a study of vemurafenib in participants with metastatic melanoma,,Completed,Has Results,malignant melanoma,drug: vemurafenib,"percentage of participants experiencing any grade 3 or 4 adverse events (aes) as determined by national cancer institute-common toxicity criteria for adverse events (nci-ctcae) version 4.0|percentage of participants with at least 1 ae leading to study drug interruption or drug discontinuation|percentage of participants with aes of special interest|mean cumulative dose of vemurafenib|duration of vemurafenib treatment|mean total vemurafenib dose per day|dose intensity of vemurafenib|percentage of participants with improvement in eastern cooperative group (ecog) performance status|percentage of participants who received any concomitant medications|percentage of participants with best overall response (bor) of confirmed complete response (cr) or partial response (pr), as per response evaluation criteria in solid tumors version 1.1 (recist v1.1)|duration of response|time to response|percentage of participants with pd assessed according to recist v1.1 or death|progression free survival (pfs)|percentage of participants who died|overall survival (os)",hoffmann-la roche,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,3219.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO25515|2010-023526-21,"March 1, 2011","February 24, 2016","February 24, 2016","March 2, 2011","December 18, 2017","December 18, 2017","['university ""mother theresa"" hospital center; oncology department, tirana, albania hospital britanico; oncologia, buenos aires, argentina fundación cidea, buenos aires, argentina inst. alexander fleming; oncologia, buenos aires, argentina melanoma institute australia, north sydney, new south wales, australia newcastle mater misericordiae hospital; oncology, waratah, new south wales, australia westmead hospital, westmead, new south wales, australia border medical oncology, wodonga, new south wales, australia greenslopes private hospital; gallipoli research centre, greenslopes, queensland, australia the townsville hospital; townsville cancer centre, townsville, queensland, australia princess alexandra hospital woolloongabba; clinical hematology and medical oncology, woolloongabba, queensland, australia royal adelaide hospital; oncology, adelaide, south australia, australia geelong hospital; geelong cardiology practice, geelong, victoria, australia peter maccallum cancer centre; medical oncology, melbourne, victoria, australia alfred hospital, melbourne, victoria, australia sir charles gairdner hospital, nedlands, western australia, australia landeskrankenhaus feldkirch; abteilung für innere medizin, feldkirch, austria lkh graz; abteilung für allgemeine dermatologie, graz, austria lkh innsbruck; universitätsklinik für dermatologie, innsbruck, austria krankenhaus der elisabethinen linz; abteilung für dermatologie, linz, austria lkh salzburg - univ. klinikum salzburg; iii. medizinische abt., salzburg, austria lkh salzburg; universitätsklinik für dermatologie, salzburg, austria landesklinikum st. pölten, st. pölten, austria medizinische universität wien; univ.klinik für dermatologie, wien, austria uz brussel, brussel, belgium cliniques universitaires st-luc, bruxelles, belgium sint augustinus wilrijk, wilrijk, belgium university clinical center of the republic of srpska, banja luka, bosnia and herzegovina clinic of oncology, university clinical center sarajevo, sarajevo, bosnia and herzegovina instituto nacional de cancer - inca; pesquisa clinica, rio de janeiro, rj, brazil hospital das clinicas - ufrgs, porto alegre, rs, brazil instituto do cancer do estado de sao paulo - icesp, sao paulo, sp, brazil hospital a. c. camargo; oncologia, sao paulo, sp, brazil hospital sao jose, são paulo, sp, brazil district oncology dispensary; department for oncology and dermatology, plovdiv, bulgaria national specialized hospital for active oncology treatment; dermatology clinic, sofia, bulgaria cross cancer institute ; dept of medical oncology, edmonton, alberta, canada lion\'s gate hospital, north vancouver, british columbia, canada british columbia cancer agency (bcca) - vancouver cancer centre, vancouver, british columbia, canada st. boniface general hospital; medicine, winnipeg, manitoba, canada qeii hsc; oncology, halifax, nova scotia, canada hamilton health sciences - juravinski cancer centre, hamilton, ontario, canada london regional cancer centre, london, ontario, canada the ottawa hospital; division of infectious diseases, ottawa, ontario, canada sunnybrook health sciences centre, toronto, ontario, canada university health network; princess margaret hospital; medical oncology dept, toronto, ontario, canada mcgill university; sir mortimer b davis jewish general hospital; oncology, montreal, quebec, canada chuq - hopital hotel dieu de quebec; oncology, quebec city, quebec, canada centro javeriano de oncología, bogota, colombia fundacion santa fe de bogotá, bogota, colombia clínica imbanaco; oncology, cali, colombia hospital pablo tobon uribe, medellin-antioquia, colombia clinical hospital sisters of mercy, zagreb, croatia masarykův onkologický ústav; klinika komplexní onkologické péče, brno, czechia university hospital; oncology and radiotherapy, hradec kralove, czechia fakultni nemocnice olomouc; onkologicka klinika, olomouc, czechia faculty hospital; dialysis unit, ostrava, czechia 1 lekarska fakulta uni karlovy; 3 interni klinika, labor. pro endokrinologii a metabolismus, praha, czechia faculty hospital kralovske vinohrady; oncology, praha, czechia aarhus universitetshospital; kræftafdelingen, aarhus c, denmark herlev hospital; onkologisk afdeling, herlev, denmark odense universitetshospital, onkologisk afdeling r, odense, denmark hospital regional vicente corral moscoso, servicio de oncología, cuenca, ecuador hospital abel gilbert ponton; oncology, guayaquil, ecuador hospital solca portoviejo; oncologia, portoviejo, ecuador east tallinn central hospital; clinic of internal medicine, tallinn, estonia north estonia medical centre foundation; oncology center, tallinn, estonia tartu university hospital; clinic of hematology and oncology, tartu, estonia helsinki university central hospital; dept of oncology, helsinki, finland tampere university hospital; dept of oncology, tampere, finland turku uni central hospital; oncology clinics, turku, finland uniklinik rwth aachen; klinik für dermatologie und allergologie - hautklinik, aachen, germany klinikum augsburg süd; klinik für dermatologie und allergologie, augsburg, germany campus benjamin franklin charitécentrum 14 med.klinik f.hämatologie u.onkologie, berlin, germany st. josef-hospital klinik f. dermatologie u. allergologie, bochum, germany elbekliniken buxtehude; klinik für dermatologie, buxtehude, germany drk-krankenhaus; hautklinik, chemnitz, germany universitätsklinikum ""carl gustav carus""; medizinische klinik und poliklinik i, dresden, germany universitätsklinikum düsseldorf; hautklinik, düsseldorf, germany helios klinikum erfurt, klinik für hautkrankheiten und allergologie, erfurt, germany universitätsklinikum erlangen; hautklinik, erlangen, germany universitätsklinikum essen, essen, germany klinik johann wolfgang von goethe uni; klinik fuer allgemein- und viszeralchirurgie, frankfurt, germany uniklinikum freiburg dermatol, freiburg, germany srh wald-klinikum gera; klinik für hautkrankheiten und allergologie, gera, germany universitätsmedizin göttingen georg-august-universität zentrum dermatologie, göttingen, germany universitätsklinikum hamburg-eppendorf zentrum f.innere medizin klinik f.dermatologie, hamburg, germany medizinische hochschule; hautklinik linden, hannover, germany uni-hautklinik, heidelberg, germany klinikum am gesundbrunnen; tumorzentrum, heilbronn, germany universitätsklinikum jena; klinik für hautkrankheiten, jena, germany klinikum kassel; hautklinik, kassel, germany uni-klinikum campus kiel klinik f.dermatologie tagesklinik f.dermatologie, kiel, germany klinik der uni zu köln; klinik & poliklinik fuer dermatologie & venerologie, köln, germany universitätsklinikum leipzig klinik f.dermatologie venerologie u.allergologie, leipzig, germany klinikum d.stadt ludwigshafen hautklinik, ludwigshafen, germany universitätsklinikum schleswig-holstein; campus lübeck, lübeck, germany universitätsklinikum magdeburg; hautklinik; klinik für dermatologie und venerologie, magdeburg, germany johannes gutenberg unis-klinik; dept for dermatology, mainz, germany klinikum mannheim klinik fuer dermatologie, venerologie und allergologie, mannheim, germany universitätsklinikum marburg klinik f. dermatologie, marburg, germany johannes-wesling-klinikum minden; onkologische ambulanz / tagesklinik, minden, germany klinikum der lmu münchen; klinik und poliklinik für dermatologie und allergologie, münchen, germany staedtisches krankenhaus muenchen-schwabing, haematologie & onkolgie, münchen, germany universitätsklinikum münster, münster, germany fachklinik hornheide; internistische onkologie, münster, germany klinikum nürnberg nord; hautklinik; klinik für dermatologie, nürnberg, germany klinikum dorothea ch.erxleben; klinik für dermatologie und allergologie, quedlinburg, germany klinikum vest gmbh knappschaftskrankenhaus abt.haut- allergie- venen- und umwelterkrankungen, recklinghausen, germany universitätsklinikum regensburg; klinik und poliklinik für dermatologie, regensburg, germany universitaets-hautklinik tuebingen, tübingen, germany wilhelm fresenius klinik; klinik f. dermatologie u. allergologie, wiesbaden, germany helios klinikum barmen zentrum dermatologie allergologie und umweltmedizin, wuppertal, germany universitätsklinikum würzburg; klinik und poliklinik für dermatologie venerologie u. allergologie, würzburg, germany laiko general hospital; 1st pathological clinic, athens, greece hospital hygeia; 1st oncology dept., athens, greece univ general hosp heraklion; medical oncology, heraklion, greece metropolitan hospital; dept. of oncology, piraeus, greece semmelweis egyetem; bor-, nemikortani es boronkologiai klinika, budapest, hungary orszagos onkologiai intezet; b belgyogyaszati osztaly, budapest, hungary debreceni egyetem oec; borgyogyaszati klinika, debrecen, hungary pecsi tudomanyegyetem aok; borgyogyaszati klinika, pecs, hungary szegedi tud.egyetem szent-gyorgyi albert klin.kozp., szeged, hungary rajiv gandhi cancer inst.&research center; medical oncology, new delhi, delhi, india tata memorial hospital; dept of medical oncology, mumbai, maharashtra, india curie manavata cancer centre, nashik, maharashtra, india basavatarakam indo-american cancer hospital & research institute, hyderabad, india chhatrapati shahuji maharaj medical university; department of oncology, lucknow, india regional cancer centre; dept of oncology, trivandrum, india christian med clg & hspt, vellore, india cork uni hospital; oncology dept, cork, ireland st vincent\'s uni hospital; medical oncology, dublin, ireland mater misericordiae uni hospital; oncology, dublin, ireland mater private hospital, dublin, ireland st james\' hospital; cancer clinical trials office, dublin, ireland galway uni hospital; oncology dept, galway, ireland university hospital limerick - oncology, limerick, ireland waterford regional hospital; department of medical oncology, waterford, ireland soroka medical center; oncology dept, beer sheva, israel ranbam health care campus; oncology - hafia, hafia, israel hadassah ein karem hospital; oncology dept, jerusalem, israel chaim sheba medical center; oncology dept, ramat gan, israel istituto nazionale tumori fondazione g. pascale, napoli, campania, italy irst istituto scientifico romagnolo per lo studio e cura dei tumori, sede meldola; oncologia medica, meldola, emilia-romagna, italy a.o. universitaria policlinico di modena; oncologia, modena, emilia-romagna, italy ao santa maria nuova; u.o. day hospital di oncologi, reggio emilia, emilia-romagna, italy a.o. universitaria s. maria della misericordia di udine; oncologia, udine, friuli-venezia giulia, italy istituto dermopatico dell\'immacolata (idi)-irccs; iv divisione oncologica e dermatologia oncologica, roma, lazio, italy ifo - istituto regina elena; oncologia medica, roma, lazio, italy irccs istituto nazionale per la ricerca sul cancro (ist); oncologia medica a, genova, liguria, italy asst papa giovanni xxiii; oncologia medica, bergamo, lombardia, italy az. osp. spedali civili; divisione di oncologia - iii medicina, brescia, lombardia, italy irccs ospedale san raffaele;oncologia medica, milano, lombardia, italy irccs istituto nazionale dei tumori (int);s.c. medicina oncologica 2, milano, lombardia, italy irccs istituto europeo di oncologia (ieo); oncologia medica, milano, lombardia, italy policlinico le molinette; clinica dermatologica, torino, piemonte, italy istituto tumori giovanni paolo ii ircss; ospedale oncologico bari, bari, puglia, italy policlinico p. giaccone; istituto di oncologia, clinica medica 1, palermo, sicilia, italy azienda ospedaliero-universitaria careggi;s.c. oncologia medica 1, firenze, toscana, italy azienda ospedaliera s. chiara; dip di onc,trapianti e delle nuove tecnologie in medicina, pisa, toscana, italy a.o.u. senese policlinico santa maria alle scotte, siena, toscana, italy azienda ospedaliera s. maria - terni; oncologia, terni, umbria, italy irccs istituto oncologico veneto (iov); oncologia medica seconda, padova, veneto, italy samsung medical center, seoul, korea, republic of seoul st mary\'s hospital, seoul, korea, republic of seoul national university hosp; dept internal med hem onc, seoul, korea, republic of yonsei university severance hospital; medical oncology, seoul, korea, republic of asan medical center., seoul, korea, republic of daugavpils regional hospital, daugavpils, latvia rigas austrumu kliniska universitates slimnica, latvijas onkologijas centrs, riga, latvia klaipeda university hospital, klaipeda, lithuania vilnius university hospital santariskiu clinic, hematology, oncology and tranfusion medicine center, vilnius, lithuania university clinic for radiotherapy and oncology skopje; department of skin malignancies, skopje, macedonia, the former yugoslav republic of fundación rodolfo padilla padilla, a.c.; oncology, leon, mexico inst. nacional de cancerologia; investigacion clinica, mexico city, mexico hospital general de méxico; unidad de oncologia, mexico df, mexico antoni van leeuwenhoek ziekenhuis; inwendige geneeskunde, amsterdam, netherlands vu medisch centrum; dept. of medical oncology, amsterdam, netherlands tergooiziekenhuizen, blaricum, netherlands amphia ziekenhuis, breda, netherlands academ ziekenhuis groningen; medical oncology, groningen, netherlands academisch ziekenhuis leiden; clinical oncology, leiden, netherlands academish ziekenhuis maastricht (azm); inwendige geneeskunde, maastricht, netherlands umc st radboud; interne oncologie; medical oncology department, nijmegen, netherlands erasmus mc, rotterdam, netherlands universitair medisch centrum utrecht; inwendige geneeskunde afd., utrecht, netherlands haukeland universitetshospital; onkologisk avd., bergen, norway the norvegian radium hospital montebello; dept of oncology, oslo, norway hospital nacional carlos alberto seguin escobedo-essalud; oncology & haemathology, arequipa, peru instituto nacional de enfermedades neoplasicas, lima, peru szpital uniwersytecki w krakowie, oddział kliniczny kliniki onkologii, krakow, poland zoz mswia z warminsko-mazurskim centrum onkologii;wojska polskiego 37, olsztyn, poland nzoz med.-polonia sp. z o.o., poznań, poland centrum onkologii- instytut; im. m.skłodowskiej-curie, warszawa, poland ipo de lisboa; servico de oncologia medica, lisboa, portugal ipo do porto; servico de oncologia medica, porto, portugal institut of oncology al. trestioreanu bucharest; oncology, bucuresti, romania medisprof srl, cluj-napoca, romania s.c. life search s.r.l; medical oncology clinic, timisoara, romania fsbi ""scientific research institute of oncology named after n.n.petrov"" ministry of health of rf, st petersburg, leningrad, russian federation regional clinical oncology dispensary, krasnodar, russian federation russian cancer research center, moscow, russian federation moscow city oncology hospital #62 of moscow healthcare department, moscow, russian federation st. petersburg oncology & gynecology; city clinical oncology dispensary, saint-petersburg, russian federation stavropol clinical oncology dispansary, stavropol, russian federation bashkirian republican clinical oncology dispensary, ufa, russian federation institute for oncology and radiology of serbia; medical oncology, belgrade, serbia clinical center bezanijska kosa; oncology, belgrade, serbia onkologicky ustav sv. alzbety; oddelenie ambulantnej chemoterapie, bratislava, slovakia narodny onkologicky ustav; oddelenie klinickej onkologie e, bratislava, slovakia poko poprad; department of oncology, poprad, slovakia institute of oncology ljubljana, ljubljana, slovenia universitas annex, university of the free state; clinical oncology, bloemfontein, south africa cape town oncology trials, cape town, south africa cancercare, cape town, south africa medical oncology centre of rosebank; oncology, johannesburg, south africa steve biko academic hospital; oncology, pretoria, south africa sandton oncology centre, sandton, south africa hospital univ. central de asturias; servicio de oncologia, oviedo, asturias, spain hospital universitario marques de valdecilla; servicio de oncologia, santander, cantabria, spain hospital universitario son espases, palma de mallorca, islas baleares, spain hospital universitario materno infantil de gran canaria; servicio de oncologia, las palmas de gran canaria, las palmas, spain hospital universitario de santa lucía; servicio de oncología médica, cartagena (murcia), murcia, spain clinica universitaria de navarra; servicio de oncologia, pamplona, navarra, spain hospital xeral cíes; servicio de oncologia, vigo, pontevedra, spain hospital universitario de canarias (huc), la laguna (tenerife), tenerife, spain hospital de cruces; servicio de oncologia, barakaldo, vizcaya, spain hospital univ vall d\'hebron; servicio de oncologia, barcelona, spain hospital clínic i provincial; servicio de hematología y oncología, barcelona, spain hospital universitari germans trias i pujol; servicio de oncologia, barcelona, spain hospital reina sofia, cordoba, spain hospital universitario virgen de las nieves; servicio de oncologia, granada, spain complejo hospitalario universitario a coruña (chuac, materno infantil), oncología, la coruña, spain complejo asistencial universitario de leon; servicio de oncologia, leon, spain hospital ramon y cajal; servicio de oncologia, madrid, spain hospital universitario clínico san carlos; servicio de oncologia, madrid, spain hospital universitario 12 de octubre; servicio de oncologia, madrid, spain hospital universitario la paz; servicio de oncologia, madrid, spain hospital clinico universitario virgen de la victoria; servicio de oncologia, malaga, spain hospital regional universitario carlos haya; servicio de oncologia, malaga, spain hospital clinico universitario de salamanca; servicio de oncologia, salamanca, spain hospital universitario virgen macarena; servicio de oncologia, sevilla, spain hospital general universitario de valencia; servicio de oncologia, valencia, spain instituto valenciano oncologia; oncologia medica, valencia, spain hospital universitario miguel servet; servicio oncologia, zaragoza, spain sahlgrenska universitetssjukhuset; onkology, gothenburg, sweden skånes onkologiska klinik, universitetssjukhuset, lund, sweden karolinska universitetssjukhuset, solna, stockholm, sweden norrlands universitetssjukhus; onkologkliniken, umeå, sweden akademiska sjukhuset, onkologkliniken, uppsala, sweden universitaetsspital basel; onkologie, basel, switzerland inselspital bern; medizinische onkologie, bern, switzerland kantonsspital graubünden;onkologie und hämatologie, chur, switzerland chuv; departement d\'oncologie, lausanne, switzerland kantonsspital st. gallen; onkologie/hämatologie, st. gallen, switzerland universitätsspital zürich; dermatologische klinik, zürich, switzerland adana baskent university hospital; medical oncology, adana, turkey cukurova uni faculty of medicine; medical oncology, adana, turkey ankara uni , ibn-i sina hospital; oncology dept, ankara, turkey gazi uni medical faculty hospital; oncology dept, ankara, turkey akdeniz university school of medicine; general surgery, antalya, turkey ege university medical faculty; medical oncology department, bornova, i̇zmi̇r, turkey gaziantep university medical faculty, medical oncology department, gaziantep, turkey kartal training and research hospital;medical oncology department, istanbul, turkey istanbul uni cerrahpasa medical faculty hospital; medical oncology, istanbul, turkey american hospital, medical oncology department, istanbul, turkey dokuz eylul uni ; medical oncology, izmir, turkey hacettepe uni medical faculty hospital; oncology dept, sıhhiye, ankara, turkey addenbrookes nhs trust; oncology clinical trials unit, cambridge, united kingdom beatson west of scotland cancer centre, glasgow, united kingdom royal surrey county hospital; st. lukes cancer centre, guildford, united kingdom st james university hospital, leeds, united kingdom royal marsden hospital, london, united kingdom christie hospital; breast cancer research office, manchester, united kingdom northern centre for cancer care freeman hospital; sir bobby robson cancer trials research centre, newcastle upon tyne, united kingdom mount vernon hospital; centre for cancer treatment, northwood, united kingdom nottingham university hospitals city campus, nottingham, united kingdom churchill hospital; oxford cancer and haematology centre, oxford, united kingdom southampton general hospital; medical oncology, southampton, united kingdom singleton hospital; oncology, swansea, united kingdom']",,https://ClinicalTrials.gov/show/NCT01307397,skin
711,712,NCT00858871,first line hepato cellular carcinoma (hcc),BRISK FL,Completed,No Results Available,hepato cellular carcinoma (hcc),drug: brivanib|drug: placebo|drug: sorafenib,"to compare the overall survival of brivanib versus sorafenib in subjects with advanced hcc who have not received prior systemic treatment|to compare the time to progression (ttp) (investigator assessed using modified recist criteria for hcc|to compare the investigator assessed objective response rate (orr) and disease control rate (dcr) using modified recist criteria for hcc|to determine duration of response, duration of disease control, and time to response (ttr)|to assess the safety profile of brivanib and sorafenib|to explore pk and exposure-response in the study population|to compare time to symptomatic progression|to compare health-related quality of life",bristol-myers squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1714.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CA182-033|EUDRACT # 2008-003533-24,May 2009,June 2012,September 2013,"March 10, 2009",,"October 17, 2016","['mayo clinic arizona, scottsdale, arizona, united states univ of ark for med sci, little rock, arkansas, united states agajanian institute of hematology and oncology, downey, california, united states sharp clinical oncology research, san diego, california, united states va ct healthcare system, west haven, connecticut, united states medical specialists of palm beaches, lake worth, florida, united states james graham brown cancer center, louisville, kentucky, united states 3912 taubman center, ann arbor, michigan, united states karmanos cancer institute, detroit, michigan, united states thomas jefferson univ., philadelphia, pennsylvania, united states mcguire dvamc, richmond, virginia, united states university of wisconsin, madison, wisconsin, united states local institution, caba, buenos aires, argentina local institution, capital federal, buenos aires, argentina local institution, rosario, santa fe, argentina local institution, buenos aires, argentina local institution, camperdown, new south wales, australia local institution, concord, new south wales, australia local institution, westmead nsw, new south wales, australia local institution, parkville, victoria, australia local institution, prahan, victoria, australia local institution, liege, belgium local institution, salvador - ba, bahia, brazil local institution, salvador, bahia, brazil local institution, fortaleza, ceara, brazil local institution, goiania, goias, brazil local institution, divinopolis, minas gerais, brazil local institution, curitiba, parana, brazil local institution, porto alegre, rio grande do sul, brazil local institution, porto alegre, rio grande do sul, brazil local institution, porto alegre, rio grande do sul, brazil local institution, barretos, sao paulo, brazil local institution, jau, sao paulo, brazil local institution, sao paulo, brazil local institution, calgary, alberta, canada local institution, vancouver, british columbia, canada local institution, london, ontario, canada local institution, montreal, quebec, canada local institution, beijing, beijing, china local institution, beijing, beijing, china local institution, beijing, beijing, china local institution, chongqing, chongqing, china local institution, guangzhou, guangdong, china local institution, guanzhou, guangdong, china local institution, nanning, guangxi, china local institution, wuhan, hubei, china local institution, changsha, hunan, china local institution, changzhou, jiangsu, china local institution, nanjing, jiangsu, china local institution, nanjing, jiangsu, china local institution, nanjing, jiangsu, china local institution, suzhou, jiangsu, china local institution, dalian, liaoning, china local institution, xi an, shaanxi, china local institution, shanghai, shanghai, china local institution, chengdu, sichuan, china local institution, hangzhou, zhejiang, china local institution, brno, czech republic local institution, prague 5, czech republic local institution, praha 2, czech republic local institution, bordeaux, france local institution, clichy cedex, france local institution, creteil cedex, france local institution, grenoble cedex 09, france local institution, lille, france local institution, lyon cedex 04, france local institution, marseille cedex 05, france local institution, marseille cedex 9, france local institution, paris, france local institution, paris, france local institution, paris, france local institution, rennes, france local institution, vandoeuvre cedex, france local institution, berlin, germany local institution, halle, germany local institution, hamburg, germany local institution, magdeburg, germany local institution, ulm, germany local institution, hong kong, hong kong local institution, shatin, hong kong local institution, hyderabad, andhra pradesh, india local institution, kochi, kerala, india local institution, trivandrum, kerala, india local institution, pune, maharashtra, india local institution, ahmedabad, india local institution, chennai, india local institution, coimbatore, india local institution, hyderabad, india local institution, kolkata, india local institution, kolkata, india local institution, mumbai, india local institution, mumbai, india local institution, new delhi, india local institution, milano, italy local institution, milano, italy local institution, napoli, italy local institution, pisa, italy local institution, roma, italy local institution, torrette -ancona, italy local institution, kashiwa-shi, chiba, japan local institution, sapporo-shi, hokkaido, japan local institution, kanazawa-shi, ishikawa, japan local institution, kawasaki-shi, kanagawa, japan local institution, yokohama, kanagawa, japan local institution, tsu-shi, mie, japan local institution, okayama-shi, okayama, japan local institution, higashinari-ku, osaka, japan local institution, osaka-sayama city, osaka, japan local institution, osaka-shi, osaka, japan local institution, osaka-shi, osaka, japan local institution, osaka-shi, osaka, japan local institution, sunto-gun, shizuoka, japan local institution, chuo-ku, tokyo, japan local institution, minato-ku, tokyo, japan local institution, musashino-shi, tokyo, japan local institution, shimonoseki-shi, yamaguchi, japan local institution, nishinomiya-shi, japan local institution, busan, korea, republic of local institution, daegu, korea, republic of local institution, gyeonggi-do, korea, republic of local institution, kyunggi-do, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, d.f., distrito federal, mexico local institution, d.f., distrito federal, mexico local institution, mexico city, distrito federal, mexico local institution, tlalpan, distrito federal, mexico local institution, monterrey, nuevo leon, mexico local institution, aguascalientes, mexico local institution, distrito federal, mexico local institution, gdansk, poland local institution, gliwice, poland local institution, krakow, poland local institution, warszawa, poland local institution, san juan, puerto rico local institution, moscow, russian federation local institution, moscow, russian federation local institution, moscow, russian federation local institution, moscow, russian federation local institution, pretoria, gauteng, south africa local institution, durban, kwa zulu natal, south africa local institution, cape town, western cape, south africa local institution, observatory, cape town, western cape, south africa local institution, rondebosch, western cape, south africa local institution, santiago de compostela, a coruna, spain local institution, alicante, spain local institution, barcelona, spain local institution, stockholm, sweden local institution, uppsala, sweden local institution, changhua, taiwan local institution, kaohsiung, taiwan local institution, taichung, taiwan local institution, tainan r.o.c., taiwan local institution, taipei, taiwan local institution, taipei, taiwan local institution, taoyuan, taiwan local institution, bangkok, thailand local institution, bangkok, thailand local institution, ankara, turkey local institution, antalya, turkey local institution, istanbul, turkey local institution, izmir, turkey local institution, kayseri, turkey local institution, bristol, avon, united kingdom local institution, london, greater london, united kingdom local institution, london, greater london, united kingdom local institution, london, greater london, united kingdom local institution, manchester, greater manchester, united kingdom local institution, birmingham, west midlands, united kingdom local institution, leeds, yorkshire, united kingdom']",,https://ClinicalTrials.gov/show/NCT00858871,liver
712,713,NCT00334282,safety and efficacy of gw786034 (pazopanib) in metastatic renal cell carcinoma,,Completed,Has Results,"carcinoma, renal cell",drug: pazopanib|drug: placebo,"progression-free survival|overall survival|overall response|participants with complete response, partial response, or 6 months of stable disease|duration of response|time to response as assessed by an independent review committee (irc) and the investigator|adjusted mean change from baseline in the european organization for research and treatment of cancer quality of life (qol) questionnaire core 30 (eortc qlq c-30) score at weeks 6, 12, 18, 24, and 48|adjusted mean change from baseline in the index score of the eq-5d (euroqol [quality of life]-5d) questionnaire at weeks 6, 12, 18, 24, and 48|adjusted mean change from baseline in the visual analog scale (vas) score of the eq-5d (euroqol [quality of life]-5d) questionnaire at weeks 6, 12, 18, 24, and 48|plasma pazopanib concentrations before dosing and at 2, 4, and 8 hours after dosing on day 1 and week 3|baseline expression levels of the indicated target proteins in pazopanib- and placebo-treated participants",glaxosmithkline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,435.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VEG105192,April 2006,May 2008,December 2014,"June 7, 2006","August 2, 2010","February 5, 2016","['gsk investigational site, capital federal, buenos aires, argentina gsk investigational site, cordoba, córdova, argentina gsk investigational site, córdoba, córdova, argentina gsk investigational site, rosario, santa fe, argentina gsk investigational site, quilmes, argentina gsk investigational site, tucuman, argentina gsk investigational site, st leonards, new south wales, australia gsk investigational site, waratah, new south wales, australia gsk investigational site, hobart, tasmania, australia gsk investigational site, heidelberg, victoria, australia gsk investigational site, wodonga, victoria, australia gsk investigational site, salzburg, austria gsk investigational site, vienna, austria gsk investigational site, vienna, austria gsk investigational site, vienna, austria gsk investigational site, belo horizonte, minas gerais, brazil gsk investigational site, porto alegre, rio grande do sul, brazil gsk investigational site, jaú, são paulo, brazil gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, santiago, región metro de santiago, chile gsk investigational site, viña del mar, valparaíso, chile gsk investigational site, beijing, china gsk investigational site, beijing, china gsk investigational site, brno, czech republic gsk investigational site, chomutov, czech republic gsk investigational site, ostrava - poruba, czech republic gsk investigational site, praha 2, czech republic gsk investigational site, tallinn, estonia gsk investigational site, tartu, estonia gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, athens, greece gsk investigational site, patra, greece gsk investigational site, thessaloniki, greece gsk investigational site, hong kong, hong kong gsk investigational site, kowloon, hong kong gsk investigational site, tuen mun, new territories, hong kong gsk investigational site, bangalore, india gsk investigational site, hyderabad, india gsk investigational site, mumbai, india gsk investigational site, pune, india gsk investigational site, trivandrum, india gsk investigational site, galway, ireland gsk investigational site, tallaght, dublin, ireland gsk investigational site, roma, lazio, italy gsk investigational site, roma, lazio, italy gsk investigational site, casalpusterlengo (lo), lombardia, italy gsk investigational site, crema, lombardia, italy gsk investigational site, milano, lombardia, italy gsk investigational site, rozzano (mi), lombardia, italy gsk investigational site, orbassano (to), piemonte, italy gsk investigational site, seoul, korea, republic of gsk investigational site, seoul, korea, republic of gsk investigational site, songpa-gu, seoul, korea, republic of gsk investigational site, riga, latvia gsk investigational site, kaunas, lithuania gsk investigational site, klaipeda, lithuania gsk investigational site, vilnius, lithuania gsk investigational site, guadalajara, jalisco, mexico gsk investigational site, merida, yucatán, mexico gsk investigational site, mexico city, mexico gsk investigational site, christchurch, new zealand gsk investigational site, newtown, wellington, new zealand gsk investigational site, palmerston north, new zealand gsk investigational site, islamabad, pakistan gsk investigational site, karachi, pakistan gsk investigational site, lahore, pakistan gsk investigational site, gdansk, poland gsk investigational site, krakow, poland gsk investigational site, kraków, poland gsk investigational site, olsztyn, poland gsk investigational site, olsztyn, poland gsk investigational site, poznan, poland gsk investigational site, warszawa, poland gsk investigational site, chelyabinsk, russian federation gsk investigational site, kazan, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, moscow, russian federation gsk investigational site, omsk, russian federation gsk investigational site, samara, russian federation gsk investigational site, st. petersburg, russian federation gsk investigational site, voronezh, russian federation gsk investigational site, yaroslavl, russian federation gsk investigational site, bratislava, slovakia gsk investigational site, sfax, tunisia gsk investigational site, sousse, tunisia gsk investigational site, tunis, tunisia gsk investigational site, tunis, tunisia gsk investigational site, donetsk, ukraine gsk investigational site, kharkiv, ukraine gsk investigational site, kyiv, ukraine gsk investigational site, lviv, ukraine gsk investigational site, zaporizhzhya, ukraine gsk investigational site, exeter, devon, united kingdom gsk investigational site, manchester, lancashire, united kingdom gsk investigational site, bebington, wirral, united kingdom gsk investigational site, belfast, united kingdom gsk investigational site, swansea, united kingdom']",,https://ClinicalTrials.gov/show/NCT00334282,kidney
713,714,NCT00130897,treatment use study with sunitinib (su011248) for patients with cytokine-refractory metastatic renal cell carcinoma,,Approved for marketing,No Results Available,"carcinoma, renal cell",drug: sutent,,pfizer,All,"18 Years and older   (Adult, Older Adult)",,,Industry,Expanded Access,,A6181037,July 2005,November 2011,November 2011,"August 16, 2005",,"March 9, 2012","[""pfizer investigational site, scottsdale, arizona, united states pfizer investigational site, san francisco, california, united states pfizer investigational site, san francisco, california, united states pfizer investigational site, aurora, colorado, united states pfizer investigational site, norwalk, connecticut, united states pfizer investigational site, miami, florida, united states pfizer investigational site, ocala, florida, united states pfizer investigational site, tampa, florida, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, maywood, illinois, united states pfizer investigational site, indianapolis, indiana, united states pfizer investigational site, council bluffs, iowa, united states pfizer investigational site, covington, louisiana, united states pfizer investigational site, gretna, louisiana, united states pfizer investigational site, marrero, louisiana, united states pfizer investigational site, metairie, louisiana, united states pfizer investigational site, metairie, louisiana, united states pfizer investigational site, new orleans, louisiana, united states pfizer investigational site, baltimore, maryland, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, detroit, michigan, united states pfizer investigational site, minneapolis, minnesota, united states pfizer investigational site, southaven, mississippi, united states pfizer investigational site, tupelo, mississippi, united states pfizer investigational site, columbia, missouri, united states pfizer investigational site, columbia, missouri, united states pfizer investigational site, omaha, nebraska, united states pfizer investigational site, bronx, new york, united states pfizer investigational site, new york, new york, united states pfizer investigational site, new york, new york, united states pfizer investigational site, durham, north carolina, united states pfizer investigational site, cleveland, ohio, united states pfizer investigational site, norman, oklahoma, united states pfizer investigational site, oklahoma city, oklahoma, united states pfizer investigational site, oklahoma city, oklahoma, united states pfizer investigational site, oklahoma city, oklahoma, united states pfizer investigational site, oklahoma city, oklahoma, united states pfizer investigational site, tulsa, oklahoma, united states pfizer investigational site, tulsa, oklahoma, united states pfizer investigational site, portland, oregon, united states pfizer investigational site, portland, oregon, united states pfizer investigational site, hershey, pennsylvania, united states pfizer investigational site, memphis, tennessee, united states pfizer investigational site, memphis, tennessee, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, salt lake city, utah, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, seattle, washington, united states pfizer investigational site, madison, wisconsin, united states pfizer investigational site, buenos aires, argentina pfizer investigational site, buenos aires, argentina pfizer investigational site, buenos aires, argentina pfizer investigational site, randwick, new south wales, australia pfizer investigational site, st leonards, new south wales, australia pfizer investigational site, westmead, new south wales, australia pfizer investigational site, south brisbane, queensland, australia pfizer investigational site, elizabeth vale, south australia, australia pfizer investigational site, woodville south, south australia, australia pfizer investigational site, east melbourne, victoria, australia pfizer investigational site, heidelburg, victoria, australia pfizer investigational site, perth, western australia, australia pfizer investigational site, innsbruck, austria pfizer investigational site, wien, austria pfizer investigational site, bruxelles, belgium pfizer investigational site, bruxelles, belgium pfizer investigational site, gent, belgium pfizer investigational site, leuven, belgium pfizer investigational site, liege, belgium pfizer investigational site, wilrijk, belgium pfizer investigational site, sarajevo, bosnia and herzegovina pfizer investigational site, salvador, ba, brazil pfizer investigational site, belo horizonte, mg, brazil pfizer investigational site, porto alegre, rio grande do sul, brazil pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, rio de janeiro, rj, brazil pfizer investigational site, porto alegre, rs, brazil pfizer investigational site, jau, sp, brazil pfizer investigational site, jaú, sp, brazil pfizer investigational site, jaú, sp, brazil pfizer investigational site, são paulo, sp, brazil pfizer investigational site, são paulo, sp, brazil pfizer investigational site, são paulo, sp, brazil pfizer investigational site, sofia, bulgaria pfizer investigational site, sofia, bulgaria pfizer investigational site, calgary, alberta, canada pfizer investigational site, edmonton, alberta, canada pfizer investigational site, kelowna, british columbia, canada pfizer investigational site, vancouver, british columbia, canada pfizer investigational site, victoria, british columbia, canada pfizer investigational site, winnipeg, manitoba, canada pfizer investigational site, winnnipeg, manitoba, canada pfizer investigational site, st. john's, newfoundland and labrador, canada pfizer investigational site, halifax, nova scotia, canada pfizer investigational site, halifax, nova scotia, canada pfizer investigational site, london, ontario, canada pfizer investigational site, toronto, ontario, canada pfizer investigational site, toronto, ontario, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, montreal, quebec, canada pfizer investigational site, quebec, canada pfizer investigational site, santiago, rm, chile pfizer investigational site, bogotá, cundinamarca, colombia pfizer investigational site, cali, colombia pfizer investigational site, rijeka, croatia pfizer investigational site, split, croatia pfizer investigational site, brno, czech republic pfizer investigational site, hradec kralove, czech republic pfizer investigational site, praha 5, czech republic pfizer investigational site, praha 8, czech republic pfizer investigational site, guayaquil, guayas, ecuador pfizer investigational site, quito, pichincha, ecuador pfizer investigational site, cairo, egypt pfizer investigational site, giza, egypt pfizer investigational site, turku, finland pfizer investigational site, lyon, cedex 08, france pfizer investigational site, saint herblain, cedex, france pfizer investigational site, strasbourg, cedex, france pfizer investigational site, bordeaux, france pfizer investigational site, clermont ferand, france pfizer investigational site, marseille cedex 9, france pfizer investigational site, marseille, france pfizer investigational site, montpellier, france pfizer investigational site, paris cedex 13, france pfizer investigational site, paris, france pfizer investigational site, reims, france pfizer investigational site, rennes, france pfizer investigational site, tours, france pfizer investigational site, vandoeuvre les nancy, france pfizer investigational site, aachen, germany pfizer investigational site, berlin, germany pfizer investigational site, dresden, germany pfizer investigational site, essen, germany pfizer investigational site, frankfurt, germany pfizer investigational site, freiburg, germany pfizer investigational site, hamburg, germany pfizer investigational site, hannover, germany pfizer investigational site, homburg/saar, germany pfizer investigational site, jena, germany pfizer investigational site, kassel, germany pfizer investigational site, muenchen, germany pfizer investigational site, nuernberg, germany pfizer investigational site, rostock, germany pfizer investigational site, ulm, germany pfizer investigational site, athens, attiki, greece pfizer investigational site, athens, greece pfizer investigational site, patras, greece pfizer investigational site, thessaloniki, greece pfizer investigational site, hong hong, hong kong pfizer investigational site, budapest, hungary pfizer investigational site, new delhi, delhi, india pfizer investigational site, pune, maharashtra, india pfizer investigational site, parel, mumbai, india pfizer investigational site, jaipur, rajasthan, india pfizer investigational site, new delhi, india pfizer investigational site, dublin 24, ireland pfizer investigational site, dublin, ireland pfizer investigational site, jerusalem, israel pfizer investigational site, tel hashomer, israel pfizer investigational site, bergamo, italy pfizer investigational site, brescia, italy pfizer investigational site, cattolica (rn), italy pfizer investigational site, cuneo, italy pfizer investigational site, legnago, vr, italy pfizer investigational site, modena, italy pfizer investigational site, napoli, italy pfizer investigational site, padova, italy pfizer investigational site, parma, italy pfizer investigational site, pavia, italy pfizer investigational site, perugia, italy pfizer investigational site, pordenone, italy pfizer investigational site, rimini, italy pfizer investigational site, roma, italy pfizer investigational site, roma, italy pfizer investigational site, roma, italy pfizer investigational site, torino, italy pfizer investigational site, seoul, korea, republic of pfizer investigational site, seoul, korea, republic of pfizer investigational site, beirut, lebanon pfizer investigational site, petaling jaya, selangor, malaysia pfizer investigational site, kuala lumpur, malaysia pfizer investigational site, mexico, df, mexico pfizer investigational site, mexico, df, mexico pfizer investigational site, toluca, estado de mexico, mexico pfizer investigational site, guadalajara, jalisco, mexico pfizer investigational site, merida, yucatan, mexico pfizer investigational site, chihuahua, mexico pfizer investigational site, puebla, mexico pfizer investigational site, groningen, gr, netherlands pfizer investigational site, amsterdam, nh, netherlands pfizer investigational site, amsterdam, netherlands pfizer investigational site, rotterdam, netherlands pfizer investigational site, oslo, norway pfizer investigational site, ciudad de panama, panama pfizer investigational site, panama, panama pfizer investigational site, lima, peru pfizer investigational site, lima, peru pfizer investigational site, quezon city, philippines pfizer investigational site, quezon city, philippines pfizer investigational site, gdansk, poland pfizer investigational site, lodz, poland pfizer investigational site, poznan, poland pfizer investigational site, warszawa, poland pfizer investigational site, wroclaw, poland pfizer investigational site, lisboa, portugal pfizer investigational site, porto, portugal pfizer investigational site, bucuresti, romania pfizer investigational site, cluj-napoca, romania pfizer investigational site, obninsk, kaluga region, russian federation pfizer investigational site, chelyabinsk, russian federation pfizer investigational site, moscow, russian federation pfizer investigational site, belgrade, serbia pfizer investigational site, singapore, singapore pfizer investigational site, bratislava, slovakia pfizer investigational site, zilina, slovakia pfizer investigational site, ljubljana, slovenia pfizer investigational site, oviedo, asturias, spain pfizer investigational site, l'hospitalet del llobregat, barcelona, spain pfizer investigational site, pamplona, navarra, spain pfizer investigational site, baracaldo, vizcaya, spain pfizer investigational site, barcelona, spain pfizer investigational site, barcelona, spain pfizer investigational site, la coruña, spain pfizer investigational site, madrid, spain pfizer investigational site, madrid, spain pfizer investigational site, madrid, spain pfizer investigational site, salamanca, spain pfizer investigational site, sevilla, spain pfizer investigational site, valencia, spain pfizer investigational site, göteborg, sweden pfizer investigational site, lund, sweden pfizer investigational site, stockholm, sweden pfizer investigational site, umeå, sweden pfizer investigational site, basel, switzerland pfizer investigational site, bellinzona, switzerland pfizer investigational site, bern, switzerland pfizer investigational site, biel, switzerland pfizer investigational site, ch-4058 basel, switzerland pfizer investigational site, ch-4101 bruderholz, switzerland pfizer investigational site, ch-4410 liesthal, switzerland pfizer investigational site, chur, switzerland pfizer investigational site, genève 14, switzerland pfizer investigational site, taipei, taiwan pfizer investigational site, taipei, taiwan pfizer investigational site, taoyun, taiwan pfizer investigational site, bangkok, thailand pfizer investigational site, bangkok, thailand pfizer investigational site, istanbul, capa, turkey pfizer investigational site, istanbul, cerrahpasa, turkey pfizer investigational site, whitchurch, cardiff, united kingdom pfizer investigational site, london, se1 9rt, united kingdom pfizer investigational site, sutton, surrey, united kingdom pfizer investigational site, leeds, west yorkshire, united kingdom pfizer investigational site, belfast, united kingdom pfizer investigational site, birmingham, united kingdom pfizer investigational site, birmingham, united kingdom pfizer investigational site, bristol, united kingdom pfizer investigational site, cottingham, united kingdom pfizer investigational site, edinburgh, united kingdom pfizer investigational site, guildford, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, london, united kingdom pfizer investigational site, manchester, united kingdom pfizer investigational site, northwood, united kingdom pfizer investigational site, nottingham, united kingdom pfizer investigational site, sheffield, united kingdom pfizer investigational site, southampton, united kingdom pfizer investigational site, swansea, united kingdom pfizer investigational site, caracas, distrito capital, venezuela pfizer investigational site, caracas, estado miranda, venezuela""]",,https://ClinicalTrials.gov/show/NCT00130897,kidney
714,715,NCT00562965,study comparing inotuzumab ozogamicin in combination with rituximab versus defined investigator's choice in follicular non-hodgkin's lymphoma (nhl),,Terminated,Has Results,"lymphoma, follicular",drug: inotuzumab ozogamicin|drug: rituximab|drug: cyclophosphamide|drug: vincristine|drug: prednisone/prednisolone|drug: mitoxantrone|drug: fludarabine|drug: dexamethasone,"progression-free survival (pfs)|percentage of participants with objective response (or)|overall survival probability at months 6, 12 and 24|pharmacokinetics of inotuzumab ozogamicin in combination with rituximab",pfizer|ucb pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,29.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,3129K4-3301|B1931006|2007-000219-27,November 2007,April 2011,April 2011,"November 26, 2007","January 9, 2018","January 9, 2018","['facey medical group, mission hills, california, united states deaconess clinic, evansville, indiana, united states the harry & jeanette weinberg cancer inst at franklin square, baltimore, maryland, united states newland medical associates, novi, michigan, united states newland medical associates, pc, southfield, michigan, united states park nicollet frauenshuh cancer center, saint louis park, minnesota, united states hematology and oncology associates, columbus, mississippi, united states hematology and oncology associates, corinth, mississippi, united states hematology and oncology associates at bridgepoint, tupelo, mississippi, united states hackensack university medical center, hackensack, new jersey, united states the cancer center at hackensack university medical center, hackensack, new jersey, united states hematology oncology associates of northern new jersy, morristown, new jersey, united states advanced oncology associates, armonk, new york, united states avi einzing, md, bronx, new york, united states advanced oncology associates, new rochelle, new york, united states marc zimmerman, md, pomona, new york, united states wenatchee valley medical center, wenatchee, washington, united states centro de transplantes de medula osea de rosario, cetramor, rosario, santa fe, argentina universitair ziekenhuis gent, gent, belgium oncologisch centrum gza - location st. augustinus, wilrijk, belgium hopital charles lemoyne, greenfield park, quebec, canada jewish general hospital, montreal, quebec, canada chus-hopital fleurimont, sherbrooke, quebec, canada c.h.a. enfant-jesus, quebec, canada prince of wales hospital, shatin, new territories, hong kong queen mary hospital, hong kong, hong kong jehangir clinical development centre, pune, maharashtra, india mmf joshi hospital and ratna memorial hospital, pune, maharashtra, india b. p. poddar hospital and medical research ltd., kolkata, west bengal, india divisione di ematologia - fondazione irccs policlinico san matteo, pavia, italy yonsei university health system-severance hospital, seoul, korea, republic of hospital universitario de nuevo leon, monterrey, nuevo leon, mexico instytut hematologii i transfuzjologii, warszawa, poland hospitais da universidade de coimbra, coimbra, portugal moscow regional research clinical institute named after vladimirsky, moscow, russian federation wits donald gordon clinical trial site, johannesburg, gauteng, south africa hospital universitario puerta de hierro, majadahonda, madrid, spain hospital santa creu i sant pau, barcelona, spain hospital de la princesa, madrid, spain']",,https://ClinicalTrials.gov/show/NCT00562965,lymphoma
715,716,NCT01587144,safety and efficacy study of lucanthone when used in combination with temozolomide(tmz) and radiation to treat glioblastoma multiforme(gbm),,Terminated,No Results Available,glioblastoma multiforme,drug: lucanthone|drug: temozolomide (tmz)|radiation: radiation|drug: placebo,progression free survival|objective response rate (orr)|overall survival|safety profile of lucanthone,"spectrum pharmaceuticals, inc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,18.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SPI-LUC-11-01,"June 19, 2012","April 15, 2013","April 15, 2013","April 30, 2012",,"October 19, 2021","['ucsd moores cancer center, la jolla, california, united states uci medical center, orange, california, united states dent neurologic institute, amherst, new york, united states fairview hospital moll cancer center/cleveland clinic, cleveland, ohio, united states cleveland clinic, cleveland, ohio, united states hillcrest hospital hirsh cancer center/cleveland clinic, mayfield, ohio, united states gujarat cancer research institute, ahmedabad, gujarat, india jaslok hospital & research centre, mumbai, maharashtra, india bhagwan mahaveer cancer hospital & reseach centre, jaipur, rajasthan, india chittaranjan national cancer institute, kolkata, west bengal, india']",,https://ClinicalTrials.gov/show/NCT01587144,astrocyt
716,717,NCT02180217,safety and efficacy of lci699 for the treatment of patients with cushing's disease,,Completed,Has Results,cushings disease,drug: osilodrostat|drug: lci699 matching placebo,"percentage of primary efficacy responder at week 34 by randomized treatment and strata|percentage of secondary efficacy responder at week 24 (key secondary endpoint)|time-to-loss of control of mean urinary free cortisol (mufc) by randomized treatment group|complete response rate (crr)|actual change from baseline in mufc|actual change from baseline in cardiovascular-related parameter associated with cushing's disease: fasting glucose|actual change from baseline in cardiovascular-related parameter associated with cushing's disease: hemoglobin a1c (hba1c)|actual change from baseline in cardiovascular-related parameter associated with cushing's disease: cholesterol, ldl cholesterol, hdl cholesterol & triglyceride|actual change from baseline in cardiovascular-related parameter associated with cushing's disease: sitting systolic blood pressure (sbp) & sitting diastolic blood pressure (dbp)|actual change from baseline in cardiovascular-related parameter associated with cushing's disease: weight|actual change from baseline in cardiovascular-related parameter associated with cushing's disease: body mass index (bmi)|actual change from baseline in cardiovascular-related parameter associated with cushing's disease: waist circumference|actual change from baseline in patient-reported outcomes (cushing's health-related quality of life (qol)) - total score|actual change from baseline in patient-reported outcomes: beck depression inventory-ii (bdi-ii)|actual change in patient-reported outcomes: eq-5d-5l utility index|actual change in patient-reported outcomes: eq-5d-5l vascular analog scale (vas)|change from baseline in the physical features of cushing's disease by photography|change from baseline in bone mineral density - all participants|time-to-escape|lci699 exposures|percentage of participants with complete response rate (crr)|percentage of participants with partial response rate (prr)|percentage of participants with overall response rate (orr)",novartis pharmaceuticals|novartis,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,137.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLCI699C2301|2013-004766-34,"October 6, 2014","February 21, 2018","December 4, 2019","July 2, 2014","June 16, 2020","January 6, 2021","['university of colorado hospital sc - lci699c2301, aurora, colorado, united states emory university school of medicine g2304 - c2301, atlanta, georgia, united states northwestern university sc - lci699c2301, chicago, illinois, united states the johns hopkins university school of medicine johns hopkins university, baltimore, maryland, united states massachusetts general hospital neuroendocrine unit, boston, massachusetts, united states university of michigan comprehensive cancer center, ann arbor, michigan, united states mount sinai school of medicine sc - lci699c2301, new york, new york, united states columbia university medical center new york presbyterian sc - lci699c2301, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states oregon health and science university sc lci699c2301, portland, oregon, united states university of pennsylvania clinical studies unit unniv sc, philadelphia, pennsylvania, united states medical college of wisconsin mcw 2, milwaukee, wisconsin, united states novartis investigative site, caba, buenos aires, argentina novartis investigative site, caba, buenos aires, argentina novartis investigative site, wien, austria novartis investigative site, sofia, bulgaria novartis investigative site, edmonton, alberta, canada novartis investigative site, halifax, nova scotia, canada novartis investigative site, montreal, quebec, canada novartis investigative site, sherbrooke, quebec, canada novartis investigative site, beijing, beijing, china novartis investigative site, chengdu, sichuan, china novartis investigative site, beijing, china novartis investigative site, cali, colombia novartis investigative site, le kremlin bicetre, france novartis investigative site, lille cedex, france novartis investigative site, marseille, france novartis investigative site, paris, france novartis investigative site, pessac cedex, france novartis investigative site, erlangen, germany novartis investigative site, muenchen, germany novartis investigative site, bangalore, karnataka, india novartis investigative site, chandigarh, punjab, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, new delhi, india novartis investigative site, ancona, an, italy novartis investigative site, genova, ge, italy novartis investigative site, messina, me, italy novartis investigative site, milano, mi, italy novartis investigative site, padova, pd, italy novartis investigative site, pisa, pi, italy novartis investigative site, napoli, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, fukuoka city, fukuoka, japan novartis investigative site, kobe-shi, hyogo, japan novartis investigative site, nishinomiya, hyogo, japan novartis investigative site, yokohama, kanagawa, japan novartis investigative site, bunkyo-ku, tokyo, japan novartis investigative site, shinjuku-ku, tokyo, japan novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, rotterdam, netherlands novartis investigative site, moscow, russian federation novartis investigative site, sevilla, andalucia, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, songkla, thailand novartis investigative site, istanbul, tur, turkey novartis investigative site, sheffield, south yorkshire, united kingdom']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/17/nct02180217/sap_002.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/17/nct02180217/prot_003.pdf",https://ClinicalTrials.gov/show/NCT02180217,
717,718,NCT04524273,myasthenia gravis inebilizumab trial,MINT,Recruiting,No Results Available,myasthenia gravis,drug: inebilizumab|drug: iv placebo,"change from baseline in myasthenia gravis activities of daily living (mg-adl) profile score.|change in quantitative myasthenia gravis (qmg) scores.|proportion of subjects with both (1) ≥ 3-point improvement in mg-adl and (2) no use of rescue therapy.|change in mg-adl at week 26 in the achr-ab+ population. (achr-ab+ only)|time to first exacerbation.|change in myasthenia gravis composite (mgc) score.|change in myasthenia gravis quality of life-15, revised (mgqol-15r) score.|change in patient global impression of change (pgic) score.|number of participants with treatment-emergent adverse events (teaes), adverse events of special interest (aesis), and treatment-emergent serious adverse events (tesaes) during the randomized controlled period and open-label period.",viela bio (acquired by horizon therapeutics),All,"18 Years and older   (Adult, Older Adult)",Phase 3,270.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VIB0551.P3.S1,"August 30, 2020","June 30, 2023","December 28, 2024","August 24, 2020",,"April 11, 2022","[""viela bio investigative site - 1010, scottsdale, arizona, united states viela bio investigative site - 1015, orange, california, united states viela bio investigative site - 1013, aurora, colorado, united states viela bio investigative site - 1002, new haven, connecticut, united states viela bio investigative site - 1005, tampa, florida, united states viela bio investigative site - 1016, augusta, georgia, united states viela bio investigative site - 1012, kansas city, kansas, united states viela bio investigative site - 1011, minneapolis, minnesota, united states viela bio investigative site - 1020, great neck, new york, united states viela bio investigative site - 1007, new york, new york, united states viela bio investigative site - 1018, charlotte, north carolina, united states viela bio investigative site - 1001, cincinnati, ohio, united states viela bio investigative site - 1009, columbus, ohio, united states viela bio investigative site - 1008, pittsburgh, pennsylvania, united states viela bio investigative site - 1019, austin, texas, united states viela bio investigative site - 1003, houston, texas, united states viela bio investigative site - 1014, san antonio, texas, united states viela bio investigative site - 1017, salt lake city, utah, united states viela bio investigative site - 1004, burlington, vermont, united states viela bio investigative site - 1006, richmond, virginia, united states vielabio investigative site - 2002, buenos aires, argentina viela bio investigative site - 2001, buenos aires, argentina viela bio investigative site - 5203, grodno, belarus viela bio investigative site - 5202, minsk, belarus viela bio investigative site - 5204, minsk, belarus viela bio investigative site - 5201, vitebsk, belarus vielabio investigative site - 2201, porto alegre, brazil vielabio investigative site - 2203, porto alegre, brazil vielabio investigative site - 2207, ribeirão preto, brazil vielabio investigative site - 2206, san paolo, brazil viela bio investigative site - 1102, toronto, ontario, canada viela bio investigative site - 1101, montréal, quebec, canada viela bio investigative site - 1103, montréal, quebec, canada viela bio investigative site - 1104, west vancouver, canada viela bio investigative site - 4007, beijing, china viela bio investigative site - 4005, guiyang, china viela bio investigative site - 4006, shanghai, china viela bio investigative site - 4008, suzhou, china viela bio investigative site - 4004, tianjin, china viela bio investigative site - 5602, aarhus, denmark viela bio investigative site - 5601, copenhagen, denmark viela bio investigative site - 3003, lille cedex, france viela bio investigative site - 3001, nice cedex 01, france viela bio investigative site - 3002, strasbourg, france vielabio investigative site - 3101, essen, germany viela bio investigative site - 4113, nagpur, maharashtra, india viela bio investigative site - 4111, vellore, tamil nadu, india viela bio investigative site - 4112, hyderabad, telangana, india viela bio investigative site - 4104, bangalore, india viela bio investigative site - 4105, lucknow, india viela bio investigative site - 4103, manipala, india viela bio investigative site - 4107, nagpur, india viela bio investigative site - 4102, nashik, india viela bio investigative site - 4108, pune, india viela bio investigative site - 4109, pune, india viela bio investigative site - 4101, surat, india viela bio investigative site - 5701, jerusalem, israel viela bio investigative site - 5702, tel aviv, israel viela bio investigative site - 3204, milano, italy viela bio investigative site - 3203, milano, italy viela bio investigative site - 3201, pavia, italy viela bio investigative site - 3202, rome, italy viela bio investigative site - 4402, chiba, japan viela bio investigative site - 4401, hanamaki, japan vielabio investigative site - 4408, hokkaido, japan vielabio investigative site - 4407, morioka-shi, japan viela bio investigative site - 4404, saitama, japan viela bio investigative site - 4202, seoul, korea, republic of viela bio investigative site - 4203, seoul, korea, republic of viela bio investigative site - 4201, seoul, korea, republic of viela bio investigative site - 3301, kraków, poland viela bio investigative site - 5303, barnaul, russian federation viela bio investigative site - 5302, nizhny novgorod, russian federation viela bio investigative site - 5304, novosibirsk, russian federation viela bio investigative site - 5311, rostov-on-don, russian federation viela bio investigative site - 5309, rostov-on-don, russian federation viela bio investigative site - 5308, saint petersburg, russian federation viela bio investigative site - 5305, samara, russian federation viela bio investigative site - 5306, smolensk, russian federation viela bio investigative site - 5301, tomsk, russian federation viela bio investigative site - 5312, ufa, russian federation viela bio investigative site - 3403, badalona, spain viela bio investigative site - 3402, barcelona, spain viela bio investigative site - 3404, córdoba, spain viela bio investigative site - 3401, madrid, spain viela bio investigative site - 4601, changhua, taiwan viela bio investigative site - 4605, kaohsiung city, taiwan viela bio investigative site - 4606, tainan, taiwan viela bio investigative site - 4604, taipei, taiwan viela bio investigative site - 4603, taipei, taiwan viela bio investigative site - 4602, taoyuan city, taiwan viela bio investigative site - 5103, dnipro, ukraine viela bio investigative site - 5105, ivano-frankivs'k, ukraine viela bio investigative site - 5104, lutsk, ukraine viela bio investigative site - 5101, lviv, ukraine viela bio investigative site - 5106, vinnytsia, ukraine""]",,https://ClinicalTrials.gov/show/NCT04524273,
718,719,NCT01374906,efficacy and safety of pasireotide administered monthly in patients with cushing's disease,,Completed,Has Results,cushing's disease,drug: pasireotide lar|drug: som230 lar 30 mg|drug: som230 lar 10 mg,"percentage participants that attained a mufc ≤ 1.0 x uln at month 7 regardless of dose titration|percentage of participants that attained a mufc ≤ 1.0 x uln at month 7 and had not had a dose increase at month 4|actual change in mean urinary free cortisol (mufc) from baseline|percentage change in mean urinary free cortisol (mufc) from baseline|percentage of patients who attain mufc ≤ 1.0 x uln|percentage of patients who attain mufc ≤1.0 x uln or have at least 50 % reduction from baseline in mufc|percentage of patients who are controlled responders (mufc ≤ 1.0 xuln) on at least 4 of the 7 mufc assessments by month 7 & on at least 7 of the 12 mufc assessments by month 12.|percentage of patients with uncontrolled response at month 7 & month 12 within the subset of patients who had uncontrolled response at a) months 1 and 2; b) months 1, 2, and 3|percent of participants attaining a mufc ≤ 1.0 x uln or at least a 50% reduction in mufc from baseline at indicated time points|percent of participants attaining a duration of controlled or partially controlled response at indicated time points|percentage change from baseline on plasma adrenocorticotropic hormone (acth) over time|percentage change from baseline on serum cortisol over time|actual change from baseline in clinical signs over time: blood pressure|actual change from baseline in clinical signs over time: body mass index (bmi)|actual change from baseline in clinical signs over time: weight|actual change from baseline in clinical signs over time: body composition: region|actual change from baseline in clinical signs over time: waist circumference|actual change from baseline in clinical signs over time: cholesterol & triglycerides|percentage change from baseline in clinical signs over time|percentage of participants having a favorable shift from baseline in clinical signs|percentage of participants that attained a mean urinary free cortisol (mufc) <= 1.0 x upper limit of normal (uln) at month 7 regardless of dose up-titration at month 4.|percentage of patients that attain a reduction of at least 50% in mufc from baseline|percent of participants attaining a time to first achievement of at least a 50% reduction in mufc from baseline at indicated time points|percent of participants with a duration of at least 50% reduction in mufc from baseline at indicated time points|pharmacokinetic (pk) parameter: ctrough|pharmacokinetic (pk) parameter: cmax|actual change in standardized score of cushing's disease hrqol (cushingqol) score from baseline|actual change in sf-12v2 score from baseline - mental component summary|actual change in sf-12v2 score from baseline - physical component summary",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CSOM230G2304|2009-011128-70,"November 4, 2011","December 21, 2016","December 21, 2016","June 16, 2011","April 11, 2018","May 22, 2018","['clintrico, phoenix, arizona, united states university of california at los angeles ucla tiverton, los angeles, california, united states harbor-ucla medical center la biomed, torrance, california, united states emory university school of medicine/winship cancer institute g2304 - c2301, atlanta, georgia, united states pituitary center, division of endocrinology sc, baltimore, maryland, united states university of michigan comprehensive cancer center sc-2, ann arbor, michigan, united states mount sinai school of medicine mt. sinai medical center, new york, new york, united states oregon health & sciences university deptoforegonhealth&sciences(2), portland, oregon, united states university of pennsylvania - clinical studies unit unniv sc, philadelphia, pennsylvania, united states vanderbilt university medical center csom230g2304, nashville, tennessee, united states swedish medical center swedish, seattle, washington, united states medical college of wisconsin mcw 2, milwaukee, wisconsin, united states novartis investigative site, buenos aires, argentina novartis investigative site, cordoba, argentina novartis investigative site, edegem, antwerpen, belgium novartis investigative site, jette, brussel, belgium novartis investigative site, bruxelles, belgium novartis investigative site, gent, belgium novartis investigative site, leuven, belgium novartis investigative site, fortaleza, ce, brazil novartis investigative site, rio de janeiro, rj, brazil novartis investigative site, ribeirao preto, sp, brazil novartis investigative site, são paulo, sp, brazil novartis investigative site, halifax, nova scotia, canada novartis investigative site, montreal, quebec, canada novartis investigative site, sherbrooke, quebec, canada novartis investigative site, beijing, beijing, china novartis investigative site, chengdu, sichuan, china novartis investigative site, shanghai, china novartis investigative site, shanghai, china novartis investigative site, besancon cedex, france novartis investigative site, caen cedex9, france novartis investigative site, le kremlin bicetre, france novartis investigative site, lille cedex, france novartis investigative site, marseille cédex 5, france novartis investigative site, pessac cedex, france novartis investigative site, berlin, germany novartis investigative site, erlangen, germany novartis investigative site, germering, germany novartis investigative site, wurzburg, germany novartis investigative site, mumbai, maharashtra, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, new delhi, india novartis investigative site, petach tikva, israel novartis investigative site, ancona, an, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, padova, pd, italy novartis investigative site, napoli, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, fukuoka city, fukuoka, japan novartis investigative site, maebashi city, gunma, japan novartis investigative site, sapporo-city, hokkaido, japan novartis investigative site, kobe-city, hyogo, japan novartis investigative site, nankoku-city, kochi, japan novartis investigative site, kyoto-city, kyoto, japan novartis investigative site, suita-city, osaka, japan novartis investigative site, bunkyo-ku, tokyo, japan novartis investigative site, minato-ku, tokyo, japan novartis investigative site, shinjuku-ku, tokyo, japan novartis investigative site, osaka, japan novartis investigative site, rotterdam, netherlands novartis investigative site, jesus maria, lima, peru novartis investigative site, miraflores, lima, peru novartis investigative site, gdansk, poland novartis investigative site, poznan, poland novartis investigative site, warszawa, poland novartis investigative site, wroclaw, poland novartis investigative site, moscow, russian federation novartis investigative site, st.- petersburg, russian federation novartis investigative site, sevilla, andalucia, spain novartis investigative site, alzira, comunidad valenciana, spain novartis investigative site, barcelona, spain novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, diskapi / ankara, ankara, turkey novartis investigative site, istanbul, tur, turkey novartis investigative site, izmir, turkey novartis investigative site, salford, manchester, united kingdom novartis investigative site, norwich, united kingdom novartis investigative site, sheffield, united kingdom novartis investigative site, southampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01374906,
719,720,NCT04930536,acalabrutinib study in indian patients with chronic lymphocytic leukaemia & relapsed and refractory mantle cell lymphoma,,Recruiting,No Results Available,chronic lymphocytic leukemia and relapsed and refractory mantle cell lymphoma,drug: acalabrutinib capsule,to assess the safety of acalabrutinib capsules in indian adult patients with chronic lymphocytic leukaemia and relapsed and refractory mantle cell lymphoma|to assess the efficacy of acalabrutinib capsules in indian adult patients with chronic lymphocytic leukaemia and relapsed and refractory mantle cell lymphoma|patient reported outcome,astrazeneca,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8220C00022,"July 14, 2021","October 3, 2022","October 3, 2022","June 18, 2021",,"May 10, 2022","['research site, ahmedabad, india research site, bangalore, india research site, bangalore, india research site, bengaluru, india research site, chandigarh, india research site, gurugram, india research site, guwahati, india research site, hyderabad, india research site, hyderabad, india research site, kochi, india research site, kolkata, india research site, ludhiana, india research site, mumbai, india research site, mumbai, india research site, new delhi, india']",,https://ClinicalTrials.gov/show/NCT04930536,lymphoma blood
720,721,NCT00295815,enzastaurin versus lomustine in glioblastoma,,Completed,No Results Available,glioblastoma,drug: enzastaurin|drug: lomustine,the primary objective is to compare enzastaurin versus lomustine in patients who for the second time have brain cancer (specifically intracranial glioblastoma) to see what effect the drugs have on keeping the disease from progressing (worsening).|to measure survival to see how the tumor responded to the therapy and how long the response lasted using mri (a scanning technique).|to measure changes in patient's ability to care for themselves (this will be determined through a standard survey).|to measure changes from baseline and a neurologic exam.|to review all bad reactions reported by the patient and detected in blood tests.|to review the effect of the cancer on the patient's ability to care for themselves and on their general health status.|to determine through blood tests how long the medication is in the patient's body.|to review through testing of tumor and blood samples to see if there are reasons why some patients responded to the drugs better than other patients.,eli lilly and company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,397.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9817|H6Q-MC-JCBF,January 2006,August 2007,May 2014,"February 24, 2006",,"September 12, 2019","['for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., phoenix, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tucson, arizona, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., berkeley, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., los angeles, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san francisco, california, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., aurora, colorado, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., newark, delaware, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tampa, florida, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., atlanta, georgia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., honolulu, hawaii, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., chicago, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., peoria, illinois, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., iowa city, iowa, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., kansas city, kansas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., baltimore, maryland, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bethesda, maryland, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., boston, massachusetts, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., detroit, michigan, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., minneapolis, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rochester, minnesota, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbia, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., saint louis, missouri, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., omaha, nebraska, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., las vegas, nevada, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lebanon, new hampshire, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., albuquerque, new mexico, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., santa fe, new mexico, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., buffalo, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new york, new york, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., winston-salem, north carolina, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., columbus, ohio, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., pittsburgh, pennsylvania, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., memphis, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nashville, tennessee, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dallas, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., houston, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lubbock, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., san antonio, texas, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., salt lake city, utah, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., charlottesville, virginia, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., seattle, washington, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madison, wisconsin, united states for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liverpool, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., st leonards, new south wales, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., auchenflower, queensland, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heidelberg, victoria, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nedlands, western australia, australia for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., graz, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., innsbruck, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., linz, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., wien, austria for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., brussels, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., leuven, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., liège, belgium for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., london, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ottawa, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toronto, ontario, canada for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lyon, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., marseille, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., nancy, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., paris, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., poitiers, france for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bonn, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., dresden, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., freiburg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., heidelberg, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., münchen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tübingen, germany for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mumbai, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., new delhi, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., vellore, india for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bologna, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., milano, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., napoli, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., roma, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., torino, italy for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., ciudad obregon, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., guadalajara, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., mexico city, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., monterrey, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tijuana, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., tlalpan, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., toluca, mexico for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., amsterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., den haag, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., maastricht, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., rotterdam, netherlands for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., lublin, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., warsaw, poland for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., badalona, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., hospitalet llobregat, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., madrid, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., oviedo, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., valencia, spain for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., bristol, avon, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., cambridge, cambridgeshire, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., edinburgh, scotland, united kingdom for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician., glasgow, scotland, united kingdom']",,https://ClinicalTrials.gov/show/NCT00295815,astrocyt
721,722,NCT03476655,clinical outcomes of chronic lymphocytic leukemia (ccl) and mantle cell lymphoma (mcl) participants treated with ibrutinib: a medical chart review from india,,Completed,No Results Available,"leukemia, lymphocytic, chronic, b-cell|lymphoma, mantle-cell",drug: ibrutinib,overall response rate (orr)|time to progression (ttp)|percentage of participants with complete response (cr)|percentage of participants with partial response (pr)|percentage of participants with stable disease (sd)|percentage of participants with progressive disease (pd)|median time to response with ibrutinib|change from baseline in hemoglobin levels|change from baseline in platelet counts|number of participants with response to ibrutinib by prior lines of therapy|number of participants with hematological and non-hematological adverse drug reactions (adr),johnson & johnson private limited,All,"18 Years and older   (Adult, Older Adult)",,40.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CR108441|54179060LYM4007,"April 28, 2018","May 14, 2019","May 31, 2019","March 26, 2018",,"August 7, 2020","['apollo hospitals international limited, ahmedabad, india healthcare global (hcg) hospital, bangalore, india fortis memorial research institute, gurgaon, india basavatarakam indo-american hospital, hyderabad, india bhagwan mahaveer hospital & research centre, jaipur, india tata medical center, kolkata, india all india institute of medical sciences, new delhi, india yashoda hematology clinic, pune, india']",,https://ClinicalTrials.gov/show/NCT03476655,lymphoma blood
722,723,NCT03190330,a study to assess safety of imbruvicatm in indian participants with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion,,"Active, not recruiting",No Results Available,"leukemia, lymphocytic, chronic, b-cell|lymphoma, mantle-cell",drug: ibrutinib 420 mg|drug: ibrutinib 560 mg,number of participants with adverse events as a measure of safety and tolerability,johnson & johnson private limited,All,"18 Years and older   (Adult, Older Adult)",Phase 4,75.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CR108316|54179060LYM4005,"June 26, 2019","April 9, 2022","April 21, 2023","June 16, 2017",,"May 5, 2022","['avron hospitals pvt. ltd, ahmedabad, india post graduate institute of medical education & research (pgimer), chandigarh, india basavatarakam indo-american hospital, hyderabad, india bhagwan mahaveer cancer hospital & research centre, jaipur, india cytecare hospitals pvt. ltd, karnataka, india apollo multispeciality hospital ltd, kolkata, india tata medical center, kolkata, india jawaharlal institute of postgraduate medical education and research, pondicherry, india deenanath mangeshkar hospital and research centre, pune, india noble hospital pvt ltd, pune, india regional cancer centre, thiruvananthapuram, india christian medical college, vellore, india']",,https://ClinicalTrials.gov/show/NCT03190330,lymphoma blood
723,724,NCT04964908,"study to understand clinical characteristics, treatment pathway in chronic lymphocytic leukemia",CREEK,Recruiting,No Results Available,chronic lymphocytic leukemia,,to describe the clinical characteristics for with chronic lymphocytic leukemia (cll) patients|calculation of epidemiological measure(s) of interest|to describe disease characteristics|recording the treatment patterns|subsequent lines of therapies,astrazeneca,All,"Child, Adult, Older Adult",,1333.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,D8220R00031,"November 7, 2021","September 30, 2022","September 30, 2022","July 16, 2021",,"April 20, 2022","['research site, argentina, argentina research site, cairo, egypt research site, ahmedabad, india research site, bangalore, india research site, faridabad, india research site, hitech, india research site, new delhi, india research site, shibpur, india research site, kuwait, kuwait research site, riyadh, saudi arabia research site, adana, turkey research site, ankara, turkey research site, izmir, turkey research site, samsun, turkey']",,https://ClinicalTrials.gov/show/NCT04964908,blood
724,725,NCT02085408,clofarabine or daunorubicin hydrochloride and cytarabine followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia,,"Active, not recruiting",No Results Available,acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome|adult acute megakaryoblastic leukemia (m7)|adult acute minimally differentiated myeloid leukemia (m0)|adult acute monoblastic leukemia (m5a)|adult acute monocytic leukemia (m5b)|adult acute myeloblastic leukemia with maturation (m2)|adult acute myeloblastic leukemia without maturation (m1)|adult acute myeloid leukemia with 11q23 (mll) abnormalities|adult acute myeloid leukemia with del(5q)|adult acute myeloid leukemia with inv(16)(p13;q22)|adult acute myeloid leukemia with t(16;16)(p13;q22)|adult acute myeloid leukemia with t(8;21)(q22;q22)|adult acute myelomonocytic leukemia (m4)|adult erythroleukemia (m6a)|adult pure erythroid leukemia (m6b)|secondary acute myeloid leukemia|untreated adult acute myeloid leukemia,drug: clofarabine|drug: daunorubicin hydrochloride|other: clinical observation|drug: cytarabine|drug: decitabine|other: laboratory biomarker analysis|procedure: quality-of-life assessment|other: questionnaire administration,"overall survival|mortality rate|induction complete response rates|disease-free survival (dfs)|epidemiological factors, measured using the acute leukemia epidemiology and survival in ecog (alese) questionnaire|change in the functional assessment of cancer therapy (fact)-leukemia-specific (leu) trial outcome index (toi) score|change in the functional assessment of chronic illness therapy (facit)-fatigue score",eastern cooperative oncology group|national cancer institute (nci),All,"60 Years and older   (Adult, Older Adult)",Phase 3,727.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E2906|NCI-2011-01992|CDR0000659585|ECOG-E2906|U10CA021115,"December 28, 2010","March 15, 2021",October 2024,"March 12, 2014",,"February 25, 2021","[""university of alabama at birmingham, birmingham, alabama, united states mayo clinic in arizona, scottsdale, arizona, united states arizona cancer center at university medical center north, tucson, arizona, united states university of arizona health sciences center, tucson, arizona, united states the medical center of aurora, aurora, colorado, united states boulder community hospital, boulder, colorado, united states penrose-saint francis healthcare, colorado springs, colorado, united states saint anthony central hospital, denver, colorado, united states porter adventist hospital, denver, colorado, united states exempla saint joseph hospital, denver, colorado, united states presbyterian - saint lukes medical center - health one, denver, colorado, united states rose medical center, denver, colorado, united states colorado cancer research program ccop, denver, colorado, united states swedish medical center, englewood, colorado, united states north colorado medical center, greeley, colorado, united states littleton adventist hospital, littleton, colorado, united states sky ridge medical center, lone tree, colorado, united states longmont united hospital, longmont, colorado, united states mckee medical center, loveland, colorado, united states parker adventist hospital, parker, colorado, united states saint mary corwin medical center, pueblo, colorado, united states north suburban medical center, thornton, colorado, united states exempla lutheran medical center, wheat ridge, colorado, united states saint francis hospital and medical center, hartford, connecticut, united states the hospital of central connecticut, new britain, connecticut, united states beebe medical center, lewes, delaware, united states christiana care health system-christiana hospital, newark, delaware, united states university of florida, gainesville, florida, united states mayo clinic in florida, jacksonville, florida, united states florida hospital, orlando, florida, united states piedmont hospital, atlanta, georgia, united states atlanta regional ccop, atlanta, georgia, united states northside hospital, atlanta, georgia, united states saint joseph's hospital of atlanta, atlanta, georgia, united states georgia regents university, augusta, georgia, united states well star cobb hospital, austell, georgia, united states john b amos cancer center, columbus, georgia, united states dekalb medical center, decatur, georgia, united states piedmont fayette hospital, fayetteville, georgia, united states gwinnett medical center, lawrenceville, georgia, united states wellstar kennestone hospital, marietta, georgia, united states southern regional medical center, riverdale, georgia, united states harbin clinic medical oncology and clinical research, rome, georgia, united states kapiolani medical center at pali momi, 'aiea, hawaii, united states oncare hawaii inc - kapiolani medical center at pali momi, 'aiea, hawaii, united states oncare hawaii inc-pob ii, honolulu, hawaii, united states queen's medical center, honolulu, hawaii, united states straub clinic and hospital, honolulu, hawaii, united states university of hawaii, honolulu, hawaii, united states oncare hawaii-liliha, honolulu, hawaii, united states kuakini medical center, honolulu, hawaii, united states oncare hawaii inc-kuakini, honolulu, hawaii, united states kapiolani medical center for women and children, honolulu, hawaii, united states castle medical center, kailua, hawaii, united states wilcox memorial hospital and kauai medical clinic, lihue, hawaii, united states saint alphonsus regional medical center, boise, idaho, united states saint anthony's health, alton, illinois, united states illinois cancercare-bloomington, bloomington, illinois, united states saint joseph medical center, bloomington, illinois, united states graham hospital association, canton, illinois, united states illinois cancercare-canton, canton, illinois, united states illinois cancercare-carthage, carthage, illinois, united states memorial hospital, carthage, illinois, united states mount sinai hospital medical center, chicago, illinois, united states hematology and oncology associates, chicago, illinois, united states northwestern university, chicago, illinois, united states university of illinois, chicago, illinois, united states decatur memorial hospital, decatur, illinois, united states eureka hospital, eureka, illinois, united states illinois cancercare-eureka, eureka, illinois, united states illinois cancercare galesburg, galesburg, illinois, united states western illinois cancer treatment center, galesburg, illinois, united states illinois cancercare-havana, havana, illinois, united states mason district hospital, havana, illinois, united states hematology oncology associates of illinois-highland park, highland park, illinois, united states hinsdale hematology oncology associates incorporated, hinsdale, illinois, united states presence saint mary's hospital, kankakee, illinois, united states illinois cancercare-kewanee clinic, kewanee, illinois, united states north shore hematology oncology, libertyville, illinois, united states illinois cancercare-macomb, macomb, illinois, united states mcdonough district hospital, macomb, illinois, united states loyola university medical center, maywood, illinois, united states holy family medical center, monmouth, illinois, united states illinois cancercare-monmouth, monmouth, illinois, united states illinois cancer specialists-niles, niles, illinois, united states bromenn regional medical center, normal, illinois, united states community cancer center foundation, normal, illinois, united states illinois cancercare-community cancer center, normal, illinois, united states illinois cancercare-ottawa clinic, ottawa, illinois, united states ottawa regional hospital and healthcare center, ottawa, illinois, united states pekin cancer treatment center, pekin, illinois, united states illinois cancercare-pekin, pekin, illinois, united states methodist medical center of illinois, peoria, illinois, united states proctor hospital, peoria, illinois, united states illinois cancercare-peoria, peoria, illinois, united states illinois oncology research association ccop, peoria, illinois, united states osf saint francis medical center, peoria, illinois, united states illinois cancercare-peru, peru, illinois, united states illinois valley hospital, peru, illinois, united states illinois cancercare-princeton, princeton, illinois, united states perry memorial hospital, princeton, illinois, united states swedish american hospital, rockford, illinois, united states hematology oncology associates of illinois - skokie, skokie, illinois, united states illinois cancercare-spring valley, spring valley, illinois, united states memorial medical center, springfield, illinois, united states saint francis hospital and health centers, beech grove, indiana, united states fort wayne medical oncology and hematology inc - state boulevard, fort wayne, indiana, united states franciscan st. francis health, indianapolis, indiana, united states reid hospital and health care services, richmond, indiana, united states mcfarland clinic, ames, iowa, united states siouxland hematology oncology associates, sioux city, iowa, united states mercy medical center-sioux city, sioux city, iowa, united states saint luke's regional medical center, sioux city, iowa, united states university of kentucky, lexington, kentucky, united states norton health care pavilion - downtown, louisville, kentucky, united states ochsner clinic foundation-baton rouge, baton rouge, louisiana, united states ochsner baptist medical center, new orleans, louisiana, united states ochsner clinic foundation, new orleans, louisiana, united states harold alfond center for cancer care, augusta, maine, united states eastern maine medical center, bangor, maine, united states johns hopkins university, baltimore, maryland, united states walter reed national military medical center, bethesda, maryland, united states union hospital of cecil county, elkton, maryland, united states tufts medical center, boston, massachusetts, united states beth israel deaconess medical center, boston, massachusetts, united states caritas saint elizabeth's medical center, brighton, massachusetts, united states baystate medical center, springfield, massachusetts, united states saint joseph mercy hospital, ann arbor, michigan, united states michigan cancer research consortium community clinical oncology program, ann arbor, michigan, united states bronson battle creek, battle creek, michigan, united states mecosta county medical center, big rapids, michigan, united states oakwood hospital, dearborn, michigan, united states wayne state university, detroit, michigan, united states saint john hospital and medical center, detroit, michigan, united states hurley medical center, flint, michigan, united states genesys hurley cancer institute, flint, michigan, united states genesys regional medical center-west flint campus, flint, michigan, united states genesys regional medical center, grand blanc, michigan, united states grand rapids clinical oncology program, grand rapids, michigan, united states saint mary's health care, grand rapids, michigan, united states spectrum health at butterworth campus, grand rapids, michigan, united states allegiance health, jackson, michigan, united states borgess medical center, kalamazoo, michigan, united states bronson methodist hospital, kalamazoo, michigan, united states west michigan cancer center, kalamazoo, michigan, united states sparrow hospital, lansing, michigan, united states saint mary mercy hospital, livonia, michigan, united states mercy health partners-mercy campus, muskegon, michigan, united states saint joseph mercy oakland, pontiac, michigan, united states saint joseph mercy port huron, port huron, michigan, united states spectrum health reed city hospital, reed city, michigan, united states saint mary's of michigan, saginaw, michigan, united states providence hospital, southfield, michigan, united states munson medical center, traverse city, michigan, united states saint john macomb-oakland hospital, warren, michigan, united states sanford clinic north-bemidgi, bemidji, minnesota, united states essentia health saint joseph's medical center, brainerd, minnesota, united states essentia health duluth clinic ccop, duluth, minnesota, united states essentia health saint mary's medical center, duluth, minnesota, united states miller-dwan hospital, duluth, minnesota, united states lake region healthcare corporation-cancer care, fergus falls, minnesota, united states mayo clinic, rochester, minnesota, united states university of mississippi medical center, jackson, mississippi, united states saint francis medical center, cape girardeau, missouri, united states saint louis cancer and breast institute-south city, saint louis, missouri, united states saint louis university hospital, saint louis, missouri, united states washington university school of medicine, saint louis, missouri, united states saint john's mercy medical center, saint louis, missouri, united states saint louis-cape girardeau ccop, saint louis, missouri, united states montana cancer consortium ccop, billings, montana, united states saint vincent healthcare, billings, montana, united states hematology-oncology centers of the northern rockies pc, billings, montana, united states billings clinic, billings, montana, united states bozeman deaconess cancer center, bozeman, montana, united states bozeman deaconess hospital, bozeman, montana, united states saint james community hospital and cancer treatment center, butte, montana, united states benefis healthcare- sletten cancer institute, great falls, montana, united states great falls clinic, great falls, montana, united states northern montana hospital, havre, montana, united states saint peter's community hospital, helena, montana, united states glacier oncology pllc, kalispell, montana, united states kalispell medical oncology, kalispell, montana, united states kalispell regional medical center, kalispell, montana, united states montana cancer specialists, missoula, montana, united states saint patrick hospital - community hospital, missoula, montana, united states nevada cancer research foundation ccop, las vegas, nevada, united states cooper hospital university medical center, camden, new jersey, united states winthrop university hospital, mineola, new york, united states memorial sloan kettering cancer center, new york, new york, united states university of rochester, rochester, new york, united states park ridge hospital breast health center, hendersonville, north carolina, united states kinston medical specialists pa, kinston, north carolina, united states roger maris cancer center, fargo, north dakota, united states sanford clinic north-fargo, fargo, north dakota, united states sanford medical center-fargo, fargo, north dakota, united states summa akron city hospital, akron, ohio, united states akron general medical center, akron, ohio, united states summa barberton hospital, barberton, ohio, united states aultman health foundation, canton, ohio, united states the jewish hospital, cincinnati, ohio, united states case western reserve university, cleveland, ohio, united states grandview hospital, dayton, ohio, united states good samaritan hospital - dayton, dayton, ohio, united states miami valley hospital, dayton, ohio, united states samaritan north health center, dayton, ohio, united states dayton ccop, dayton, ohio, united states blanchard valley hospital, findlay, ohio, united states atrium medical center-middletown regional hospital, franklin, ohio, united states wayne hospital, greenville, ohio, united states kettering medical center, kettering, ohio, united states saint rita's medical center, lima, ohio, united states upper valley medical center, troy, ohio, united states clinton memorial hospital, wilmington, ohio, united states greene memorial hospital, xenia, ohio, united states university of oklahoma health sciences center, oklahoma city, oklahoma, united states clackamas radiation oncology center, clackamas, oregon, united states providence milwaukie hospital, milwaukie, oregon, united states providence newberg medical center, newberg, oregon, united states providence willamette falls medical center, oregon city, oregon, united states providence portland medical center, portland, oregon, united states columbia river oncology program, portland, oregon, united states providence saint vincent medical center, portland, oregon, united states lehigh valley hospital, allentown, pennsylvania, united states lehigh valley hospital - muhlenberg, bethlehem, pennsylvania, united states geisinger medical center, danville, pennsylvania, united states geisinger medical center-cancer center hazelton, hazleton, pennsylvania, united states penn state milton s hershey medical center, hershey, pennsylvania, united states lewistown hospital, lewistown, pennsylvania, united states abramson cancer center of the university of pennsylvania, philadelphia, pennsylvania, united states fox chase cancer center, philadelphia, pennsylvania, united states geisinger medical group, state college, pennsylvania, united states mount nittany medical center, state college, pennsylvania, united states geisinger wyoming valley, wilkes-barre, pennsylvania, united states york hospital, york, pennsylvania, united states anmed health cancer center, anderson, south carolina, united states saint francis hospital, greenville, south carolina, united states carolina blood and cancer care associates pa-lancaster, lancaster, south carolina, united states carolina blood and cancer care associates pa, rock hill, south carolina, united states spartanburg regional medical center, spartanburg, south carolina, united states upstate carolina ccop, spartanburg, south carolina, united states sanford cancer center-oncology clinic, sioux falls, south dakota, united states medical x-ray center, sioux falls, south dakota, united states sanford usd medical center - sioux falls, sioux falls, south dakota, united states erlanger medical center, chattanooga, tennessee, united states jackson-madison county general hospital, jackson, tennessee, united states vanderbilt-ingram cancer center, nashville, tennessee, united states peacehealth southwest medical center, vancouver, washington, united states northwest cancer specialists, vancouver, washington, united states west virginia university charleston, charleston, west virginia, united states west virginia university, morgantown, west virginia, united states green bay oncology at saint vincent hospital, green bay, wisconsin, united states saint vincent hospital, green bay, wisconsin, united states green bay oncology limited at saint mary's hospital, green bay, wisconsin, united states saint mary's hospital, green bay, wisconsin, united states gundersen lutheran, la crosse, wisconsin, united states university of wisconsin hospital and clinics, madison, wisconsin, united states holy family memorial hospital, manitowoc, wisconsin, united states bay area medical center, marinette, wisconsin, united states froedtert and the medical college of wisconsin, milwaukee, wisconsin, united states d n greenwald center, mukwonago, wisconsin, united states oconomowoc memorial hospital-prohealth care inc, oconomowoc, wisconsin, united states saint nicholas hospital, sheboygan, wisconsin, united states waukesha memorial hospital - prohealth care, waukesha, wisconsin, united states aurora cancer care-milwaukee west, wauwatosa, wisconsin, united states rocky mountain oncology, casper, wyoming, united states welch cancer center, sheridan, wyoming, united states mayo clinic methodist hospital, nagpur, india rambam medical center, haifa, israel shaare zedek medical center, jerusalem, israel""]",,https://ClinicalTrials.gov/show/NCT02085408,blood
725,726,NCT01903733,bosutinib treatment extension study only for subjects with chronic myeloid leukemia (cml) who have previously participated in bosutinib studies b1871006 or b1871008,,Completed,Has Results,chronic myeloid leukemia,drug: bosutinib,number of participants with treatment-emergent adverse events (aes) and serious adverse events (saes) based on national cancer institute common terminology criteria for aes (nci ctcae) (version 3.0)|number of participants with grade 3 or 4 treatment-emergent adverse events (aes) based on national cancer institute common terminology criteria for aes (nci ctcae) (version 3.0)|number of participants with treatment-emergent treatment related adverse events (aes) based on national cancer institute common terminology criteria for aes (nci ctcae) (version 3.0)|number of participants with laboratory test abnormalities based on national cancer institute common terminology criteria for aes (nci ctcae) (version 4.03)|number of participants with adverse events as reason for treatment discontinuation|number of participants with diarrhea after switch from bosutinib clinical formulation to bosutinib commercial formulation|number of participants with breakpoint cluster region abelson protooncogene (bcr-abl) mutations present at time of bosutinib treatment discontinuation|overall survival (os) rate at year 10|plasma steady-state trough concentrations (ctrough) of bosutinib|kaplan-meier estimate of probability of maintaining major cytogenetic response (mcyr) at year 10: b1871006 participants|kaplan-meier estimate of probability of maintaining complete cytogenetic response (ccyr) at year 10: b1871006 participants|kaplan-meier estimate of probability of maintaining complete hematologic response (chr) at year 10: b1871006 participants|cumulative incidence of progression/death events at year 10: b1871006 participants|cumulative incidence of rate of transformation to accelerated phase (ap) or blast phase (bp) at year 10: b1871006 participants,pfizer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,281.0,Industry,Interventional,Masking: None (Open Label),B1871040|2013-000691-15,"August 28, 2013","June 5, 2020","June 5, 2020","July 19, 2013","August 17, 2021","August 17, 2021","['orlando health, inc, orlando, florida, united states emory university hospital, atlanta, georgia, united states the emory clinic, atlanta, georgia, united states winship cancer institute, emory university, atlanta, georgia, united states northside hospital inc., - gcs/northside, atlanta, georgia, united states northside hospital, inc. - central research department, atlanta, georgia, united states indiana blood and marrow transplantation, indianapolis, indiana, united states siouxland hematology-oncology associates, llp, sioux city, iowa, united states rcca md,llc, bethesda, maryland, united states hudson valley hematology and oncology associates, hawthorne, new york, united states penn state milton s. hershey medical center, hershey, pennsylvania, united states the university of texas md anderson cancer center, houston, texas, united states the university of texas, md anderson cancer center, houston, texas, united states instituto medico especializado alexander fleming, cd. autonoma de buenos aires, buenos aires, argentina hospital italiano de la plata, la plata, buenos aires, argentina hospital dr. jose ramon vidal, corrientes, argentina royal brisbane & women\'s hospital, herston, queensland, australia royal adelaide hospital, adelaide, south australia, australia ghdc (grand hopital de charleroi), charleroi, belgium universidade estadual de campinas / centro de hematologia e hemoterapia, campinas, sp, brazil faculdade de medicina do abc - centro de estudos e pesquisa em hematologia e oncologia (cepho), santo andre, sp, brazil alberta health services - department of medical oncology - cross cancer institute, edmonton, alberta, canada vancouver general hospital, vancouver, british columbia, canada princess margaret cancer centre, toronto, ontario, canada sir mortimer b. davis-jewish general hospital, montreal, quebec, canada instituto oncologico, clinica renaca, renaca, v region, chile instituto oncologico, renaca, v region, chile peking union medical college hospital, beijing, beijing, china the first affiliated hospital of college of medicine, zhejiang university, hangzhou, zhejiang, china chinese people\'s liberation army general hospital, beijing, china ruijin hospital- shanghai jiaotong university school of medicine, shanghai, china blood disease hospital, chinese academy of medical science & peking union medical college, tianjin, china fundacion santa fe de bogota, bogota, cundinamarca, colombia helsingin yliopistollinen keskussairaala, hematologian poliklinikka, helsinki, finland chu de caen, caen cedex 9, france chu hotel dieu - service hematologie, nantes cedex 1, france chu de poitiers, poitiers cedex, france chu poitiers, poitiers, france strasbourg oncologie liberale -centre de radiotherapie, clinique ste anne, strasbourg, france pamela youde nethersole eastern hospital, chai wan, hong kong department of medicine & therapeutics, prince of wales hospital, shatin, new territories, hong kong egyesitett szent istvan es szent laszlo korhaz-rendelointezet, budapest, hungary somogy megyei kaposi mor oktato korhaz, belgyogyaszati osztaly, kaposvar, hungary christian medical college. vellore, vellore, tamil nadu, india a.o.u. policlinico s.orsola malpighi, bologna, bo, italy asst monza - ospedale san gerardo, monza, monza and brianza, italy a.o.u. san luigi gonzaga di orbassano, orbassano, to, italy ospedale s. eugenio - uoc ematologia, roma, italy toyohashi municipal hospital, toyohashi, aichi, japan akita university hospital, akita city, akita, japan national hospital organization kyushu cancer center, fukuoka-shi, fukuoka, japan kanazawa university hospital, kanazawa-shi, ishikawa, japan kindai university hospital, osakasayama-city, osaka, japan osaka university hospital, suita-city, osaka, japan hamamatsu university school of medicine university hospital, hamamatsu-shi, shizuoka, japan tokyo metropolitan cancer and infectious diseases center komagome hospital, tokyo, japan the catholic university of korea, seoul st. mary\'s hospital, seoul, korea, republic of riga east clinical university hospital, riga, latvia vu university medical center, amsterdam, netherlands university medical center groningen, department of hematology, groningen, netherlands unidad de investigacion de hematologia - hospital nacional edgardo rebagliati martins, lima, peru uniwersyteckie centrum kliniczne, gdansk, poland uniwersyteckie centrum kliniczne, gdańsk, poland sp zoz szpital uniwersytecki w krakowie, krakow, poland samodzielny publiczny szpital kliniczny nr 1 w lublinie, lublin, poland state budgetary institution of healthcare of sverdlovsk region, ekaterinburg, sverdlovsk region, russian federation federal state-funded institution national research center of hematology of the ministry of, moscow, russian federation state budgetary institution of rostov region - rostov regional clinical hospital, rostov-on-don, russian federation state budgetary educational institution of higher professional education, rostov-on-don, russian federation state budgetary institution of healthcare - leningrad regional clinical hospital, saint petersburg, russian federation clinic ""institute of pediatric oncology, hematology and transplantation n.a. r.m. gorbachova"", saint petersburg, russian federation federal state budgetary institution ""federal almazov medical research centre"", saint petersburg, russian federation state budgetary institution of healthcare samara regional clinical hospital n.a. v.d. seredavin, samara, russian federation singapore general hospital, singapore, singapore wits clinical research-chris hani baragwanath hospital, soweto, gauteng, south africa hospital clinic barcelona, barcelona, spain hospital universitario la princesa, madrid, spain hospital universitario la paz, madrid, spain hospital universitario madrid sanchinarro, centro integral oncologico clara campal, madrid, spain hospital virgen de la salud, toledo, spain hospital clinico universitario de valencia (chuv), valencia, spain division of hematology, department of medicine, faculty of medicine, siriraj hospital,, bangkok, thailand gaziantep universitesi tip fakultesi sahinbey uygulama ve arastirma hastanesi, gaziantep, sehit kamil, turkey hacettepe universitesi tip fakultesi, ankara, turkey municipal institution ""cherkasy regional oncology dispensary"", cherkasy, ukraine mi ""dnipropetrovsk city multi-field clinical hospital #4"" of drc hematology center, dnipropetrovsk, ukraine state institution ""national research center for radiation medicine of the national academy of, kyiv, ukraine kyiv city clinical hospital #9, si ""institute of hematology and transfusiology of nams of ukraine"", kyiv, ukraine state institution ""institute of blood pathology and transfusion medicine of, lviv, ukraine freeman hospital, newcastle upon tyne, united kingdom nottingham university hospitals nhs trust, nottinhgam, united kingdom']","""study protocol"", https://clinicaltrials.gov/provideddocs/33/nct01903733/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/33/nct01903733/sap_001.pdf",https://ClinicalTrials.gov/show/NCT01903733,blood
726,727,NCT00462943,open label study of subcutaneous homoharringtonine (omacetaxine mepesuccinate) in patients with advanced cml,,Completed,Has Results,chronic myeloid leukemia,drug: omacetaxine mepesuccinate,percentage of participants achieving an overall hematologic response by subpopulation and total population|percentage of participants achieving a major cytogenetic response by subpopulation and total population|number of participants with treatment-emergent adverse events (teaes) by subpopulation and total|percentage of participants in each cytogenetic response category representing the degree of suppression of the philadelphia chromosome (ph+)|percentage of participants with major molecular response (mmr) representing the degree of suppression of bcr-abl transcript levels using the housekeeping gene gus|percentage of participants with major molecular response (mmr) representing the degree of suppression of bcr-abl transcript levels using the housekeeping gene abl|percentage of participants in each hematologic response category|percentage of participants with extramedullary disease (emd) at baseline achieving a clinical response|percentage of participants with the largest percentage reduction from baseline of t315i mutated bcr-abl|number of treatment cycles needed to achieve best hematologic response|number of treatment cycles needed to achieve best cytogenetic response|kaplan-meier estimates for time to onset of best hematologic response|kaplan-meier estimates for time to onset of best cytogenetic response|kaplan-meier estimates for duration of best hematologic response|kaplan-meier estimates for duration of best cytogenetic response|kaplan-meier estimates for time to disease progression|kaplan-meier estimates for overall survival,"teva branded pharmaceutical products r&d, inc.|cephalon|chemgenex pharmaceuticals",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CGX-635-CML-203|2007-001286-15,"March 7, 2007","August 4, 2009","June 27, 2013","April 19, 2007","June 30, 2014","December 28, 2021","['teva investigational site 303, los angeles, california, united states teva investigational site 308, beech grove, indiana, united states teva investigational site 311, baltimore, maryland, united states teva investigational site 302, bronx, new york, united states teva investigational site 305, buffalo, new york, united states teva investigational site 310, philadelphia, pennsylvania, united states teva investigational site 301, houston, texas, united states teva investigational site 314, seattle, washington, united states teva investigational site 313, montreal, canada teva investigational site 309, toronto, canada teva investigational site 329, bordeaux, france teva investigational site 321, le chesnay cedex, france teva investigational site 322, lille, france teva investigational site 320, lyon cedex 03, france teva investigational site 324, nice, france teva investigational site 328, paris, france teva investigational site 323, poitiers cedex, france teva investigational site 327, strasbourg, france teva investigational site 325, toulouse, france teva investigational site 331, berlin, germany teva investigational site 330, mannheim, germany teva investigational site 350, budapest, hungary teva investigational site 371, hyderabad, india teva investigational site 370, mumbai, india teva investigational site 390, bologna, italy teva investigational site 360, gdansk, poland teva investigational site 361, warszawa, poland teva investigational site 380, singapore, singapore teva investigational site 340, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00462943,blood
727,728,NCT01701232,safety and efficacy study of bcd-020 in therapy of indolent non-hodgkin's lymphoma,,Completed,No Results Available,follicular non-hodgkin's lymphoma|nodal marginal zone lymphoma|splenic marginal zone lymphoma,biological: rituximab,"overall response rate|cd20-positive cells count|cmax|auc(0-168)|complete response rate|frequency of aes/saes grade 3-4 (ctcae v.4.03)|levels of binding and neutralizing antibodies to rituximab|auc(0-1176), auc(0-inf)",biocad,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,174.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIORIX (BCD-020-3),September 2011,January 2017,January 2017,"October 5, 2012",,"November 6, 2017","['instituto nacional de cancerología, bogotá, colombia fundación reina isabel, cali, colombia hospital pablo tobon uribe, medellín, colombia hcg multi specialty hospitals, ahmedabad, india department of medical oncology, navneet memorial hospital, ""sushrusha"", ahmedabad, india sujan surgicals, amaravati, india hcg bangalore institute of oncology, bangalore, india department of medicine (haemotology), st.john\'s medical college hospital, bangalore, india narayana hrudayalaya hospitals, bangalore, india srinivasam cancer care hospital, bangalore, india all india institute of medical sciences (aiims), bhubaneswar, india acharya tulasi regional cancer treatment and research centre, bikaner, india g.kuppuswamy naidu memorial hospital, coimbatore, india medical oncology department, the karnatak cancer therapy and research institute, hubli, india bibi general hospital & cancer center, hyderabad, india department of medical oncology, basavatarakam indo-american cancer hospital and research institute, hyderabad, india omega hospitals, hyderabad, india nilratan siracar medical college & hospital, kolkata, india king george medical university, lucknow, india department of radiation oncology, meenakshi mission hospital & research centre, madurai, india manas super speciality hospital, nashik, india city cancer center, vijayawada, india arkhangelsk district clinical oncology dispensary, arkhangelsk, russian federation city hospital n8, barnaul, russian federation municipal institution ""central city hospital № 7"", ekaterinburg, russian federation public health facility ""irkutsk regional oncology center"", irkutsk, russian federation ivanovo regional oncology center, ivanovo, russian federation state health care institution ""republican clinical cancer center,"" the ministry of health of the udmurt republic, izhevsk, russian federation public health facility ""kemerovo regional hospital"", kemerovo, russian federation clinical oncology dispensary n1, krasnodar, russian federation public health facility ""kursk regional cancer center,"" health committee of kursk region, kursk, russian federation public health facility ""lipetsk regional oncology center"", lipetsk, russian federation n.n. burdenko general military clinical hospital, moscow, russian federation russian medical academy of post-graduate education, ministry of health and social development of the russian federation, moscow, russian federation research center for hematology mhsd rf, moscow, russian federation official body of the health of the city of moscow ""moscow city clinical hospital named after s. p. botkin"", moscow, russian federation medical radiological research center, ministry of health and social development of the russian federation, obninsk, russian federation regional government health care ""oryol regional hospital"", oryol, russian federation perm region oncology dispensary, perm, russian federation v.a. baranov republican hospital of ministry of health republic karelia, petrozavodsk, russian federation pyatigorsk oncology center, pyatigorsk, russian federation russian research institute of hematology and transfusiology federal state institution of federal medical and biological agency, saint petersburg, russian federation st. petersburg state health care institution ""alexander city hospital"", saint petersburg, russian federation saint petersburg city clinical oncology center, saint petersburg, russian federation saint petersburg pavlov state medical university, saint petersburg, russian federation v.a. almazov federal center for heart, blood and endocrinology, ministry of health and social development of the russian federation, saint petersburg, russian federation the federal government military educational institution of higher education, ""military medical academy named after sm kirov\'s\' ministry of defense"", saint petersurg, russian federation provincial health official body ""smolensk regional clinical oncological dispensary"", smolensk, russian federation oncology dispensary 2, sochi, russian federation n.n.petrov oncology research center, st.petersburg, russian federation russian scientific center of radiology and surgery technologies, st.petersburg, russian federation tambov regional oncology center, tambov, russian federation municipal health ""clinical hospital № 5"" togliatti, togliatti, russian federation tula regional hospital, tula, russian federation public health care setting of the tyumen region ""regional oncology center"", tyumen, russian federation state health care institution republican clinical hospital named after g. g. kuvatova, ufa, russian federation republican clinical oncology dispensary of ministry of health republic bashkortostan, ufa, russian federation volgograd district oncology dispensary №1, volgograd, russian federation medi-clinic vereeniging, vereeniging, south africa khmel\'nyts\'kyy regional hospital, hematology department, khmel\'nyts\'kyy, ukraine national cancer institute of ukraine, oncohematology department, kiev, ukraine state institution ""institute of blood pathology and transfusion medicine ams of ukraine"", hematology department, l\'viv, ukraine']",,https://ClinicalTrials.gov/show/NCT01701232,lymphoma
728,729,NCT02268045,study of rtxm83 plus chop chemotherapy versus a rituximab plus chop therapy in patients with non hodgkin's lymphoma,,Completed,Has Results,diffuse large b-cell lymphoma,biological: rtxm83|biological: mabthera,response rate (rr) achieved after cycle 6 with rtxm83 plus chop compared to the rr obtained with mabthera® plus chop (r-chop) in patients with dlbcl|auc 0-∞ (h μg/ml) at cycle 1 of rtxm83 and mabthera®|auc 0-∞ (h μg/ml) at cycle 6 of rtxm83 and mabthera®|cmax (μg/ml) at cycle 1 of rtxm83 and mabthera®|cmax (μg/ml) at cycle 6 of rtxm83 and mabthera®|percentage change from baseline in pharmacodynamic (pd) markers (cd19+ and cd20+ cells) blood counts of rtxm83 and mabthera®|comparable safety profile in both treatment arms|comparable immunogenicity profile between rtxm83 and mabthera®|event free survival (efs) in rtxm83 arm and mabthera® arm,mabxience s.a|pisa® farmacéutica|laboratorios de productos éticos c.e.i.s.a.|laboratorio elea phoenix s.a.|tecnoquimicas s.a|innogene kalbiotech pte. ltd|libbs farmacêutica ltda|key oncologics (pty) ltd|nanolek llc|actoverco,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,272.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RTXM83-AC-01-11,May 2013,May 2016,July 2017,"October 20, 2014","September 26, 2019","September 26, 2019","['hosp. interzonal ""r"" carrillo, ciudadela, bariloche, argentina clinica radiologica del sur, cipolletti, río negro, argentina clinica viedma, viedma, río negro, argentina hospital britanico, buenos aires, argentina hospital gral. de agudos donación francisco santojanni, buenos aires, argentina instituto roffo, buenos aires, argentina centro oncologico riojano integral (cori), cordoba, argentina hospital nacional de clinicas, cordoba, argentina hospital privado de cordoba, cordoba, argentina sanatorio allende, cordoba, argentina ctr. oncologico de rosario, rosario, argentina inst. cardiovascular rosario, rosario, argentina instituto de hematología y medicina clínica dr. rubén dávoli, rosario, argentina sanatorio parque, rosario, argentina fundación ars médica, san salvador de jujuy, argentina hospital j. b. iturraspe, santa fe, argentina hospital angel padilla, tucumán, argentina hospital clinicas porto alegre, pôrto alegre, rio grande do sul, brazil hospital de caridade de ijuí, ijuí, rs, brazil hospital da cidade de passo fundo, passo fundo, rs, brazil hospital são lucas da pucrs, porto alegre, rs, brazil hospital santa marcelina, itaquera, sao paulo, brazil hospital amaral carvalho jaú, jaú, sp, brazil hospital das clínicas da faculdade de medicina de ribeirão preto da universidade de são paulo-hcfmrp, ribeirão preto, sp, brazil cepho - centro de estudos e pesquisas de hematologia e oncologia / faculdade de medicina do abc, santo andré, sp, brazil fundação antônio prudente - ac camargo câncer center, sao paulo, sp, brazil hospital das clinicas-ufmg, belo horizonte, brazil unicamp-univ zeferino vaz, campinas, brazil hospital uniao oeste paranaense de estudos e comabte ao cancer (uopeccan), cascavel, brazil hospital erasto gaertner cepep, curitiba, brazil hospital das clínicas da universidade federal de goiás, goiânia, brazil santa casa de porto alegre, porto alegre, brazil hospital universitário clemente fraga filho - ufrj, rio de janeiro, brazil instituto coi de educação e pesquisa, rio de janeiro, brazil instituto est. de hematologia arthur de siqueira cavalcanti, rio de janeiro, brazil monte tabor - hospital são rafael, salvador, brazil centro de pesquisa do instituto brasileiro de controle do câncer - ibcc, sao paulo, brazil hospital clinica faculdade medicina usp, sao paulo, brazil hospital de base de são josé, são josé do rio prêto, brazil inst. nacional de cancerologia, bogotá, colombia fundación valle de lili, cali, colombia hospital pablo tobon uribe, medellin, colombia srinivasam cancer care hospital, bangalore, india cancer institute, chennai, india rajiv gandhi cancer institute and research centre, delhi, india bibi general hospital&canc ct, hyderabad, india birla cancer center - sms hospital, jaipur, india health point multi-specialty hospital, kolkata, india institute of hematology and transfusion medicine, kolkata, india netaji subhash chandra bose cancer research institute, kolkata, india acharya tulsi regional cancer treatment and research institute, madurai, india guru hospital, madurai, india meenakshi mission hospital, madurai, india kailash cancer hospital and research centre, vadodara, india dr. hasan sadikin hospital, bandung, indonesia dharmais n. c. center, jakarta, indonesia imam khomeini complex hospital - cancer institute, tehrān, iran, islamic republic of hospital sultanah aminah, johor bahru, malaysia university malaya medical centre - ummc, kuala lumpur, malaysia mount miriam cancer hospital, pulau pinang, malaysia hospital pulau pinang, pulau pinang, malaysia insituto nacional de cancerología, mexico city, mexico instituto privado de hematologia e investigaciona clinica, asunción, paraguay cebu doctors university hospital, cebu, philippines perpetual succour hospital, cebu, philippines davao doctors hospital, davao, philippines national kidney and transplant institute, quezon city, philippines veterans memorial medical center, quezon city, philippines arkhangelsk clinical oncology dispensary, arkhangelsk, russian federation kursk regional clinical oncology dispensary, kursk, russian federation n.n. blokhin russian cancer research cente, moscow, russian federation national medical surgical center n.a. n.i. pirogov, moscow, russian federation murmansk regional oncology dispensary, murmansk, russian federation state budgetary healthcare institution of stavropol region ""pyatigorsk oncology center"", pyatigorsk, russian federation rostov scientific research oncology institute, rostov-na-donu, russian federation russian research center for radiology and surgical technologies, saint-petersburg, russian federation saint-petersburg state budgetary institution ""city clinical oncology dispensary"", saint-petersburg, russian federation scientific research institute of oncology n.a. n.n. petrov, saint-petersburg, russian federation oncology center # 2, sochi, russian federation komi republican oncology dispensary, syktyvkar, russian federation state healthcare institution of tula region ""tula regional clinical hospital"", tula, russian federation republican clinical oncology dispensary, ufa, russian federation volgograd regional clinical oncology center, volgograd, russian federation rainbow oncology centre, amanzimtoti, south africa tygerberg academic hosp, cape town, south africa gvi oncology, port elizabeth, south africa chris hani baragwanath hospital, soweto, south africa']",,https://ClinicalTrials.gov/show/NCT02268045,lymphoma
729,730,NCT02227251,selinexor (kpt-330) in patients with relapsed/refractory diffuse large b-cell lymphoma (dlbcl),,Recruiting,No Results Available,diffuse large b-cell lymphoma,drug: selinexor,part 1: overall response rate (orr)|part 2: overall response rate (orr) based on lugano criteria|part 1: duration of response (dor)|part 1: disease control rate (dcr)|part 1: number of participants with treatment-emergent adverse events (teaes)|part 1: number of participants with eastern cooperative oncology group (ecog) performance status|part 2: duration of response (dor)|part 2: disease control rate (dcr)|part 2: overall response rate (orr) based on modified lugano criteria|part 2: number of participants with treatment-emergent adverse events|part 2: number of participants with eastern cooperative oncology group (ecog) performance status,karyopharm therapeutics inc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,244.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KCP-330-009|2014-001977-15,November 2014,August 2022,December 2024,"August 28, 2014",,"May 9, 2022","['uacc arizona, tucson, arizona, united states university of california san francisco, san francisco, california, united states university of california los angeles (ucla), santa monica, california, united states boca raton cancer research medical center, plantation, florida, united states university of chicago, chicago, illinois, united states robert h. lurie comprehensive cancer center/northwestern university, chicago, illinois, united states norton cancer institute, louisville, kentucky, united states dana farber cancer institute, boston, massachusetts, united states tufts medical center, boston, massachusetts, united states lahey clinic, burlington, massachusetts, united states university of massachusetts medical school, worcester, massachusetts, united states john theurer cancer center at hackensack university medical center, hackensack, new jersey, united states clinical research alliance, lake success, new york, united states new york presbyterian hospital/ cornell medical college, new york, new york, united states stony brook university hospital, stony brook, new york, united states gabrail cancer center, canton, ohio, united states cleveland clinic foundation, cleveland, ohio, united states university hospitals seidman cancer center, cleveland, ohio, united states university of oklahoma, oklahoma city, oklahoma, united states greenville hospital system, greenville, south carolina, united states md anderson, houston, texas, united states swedish cancer institute, seattle, washington, united states virginia mason hospital & medical center, seattle, washington, united states st. vincent\'s hospital sydney, darlinghurst, new south wales, australia liverpool hospital, ingham institute of medical research, liverpool, new south wales, australia calvary mater newcastle hospital, waratah, new south wales, australia icon cancer care, south brisbane, queensland, australia royal adelaide hospital, adelaide, south australia, australia ashford cancer centre, kurralta park, south australia, australia monash medical centre, clayton, victoria, australia epworth hospital, east melbourne, victoria, australia st. vincent\'s melbourne, fitzroy, victoria, australia the alfred hospital, melbourne, victoria, australia fiona stanley hospital, murdoch, western australia, australia medical university of graz, graz, austria medizinische universität innsbruck für innere medizin, innsbruck, austria lkh leoben department for haemato-oncology, leoben, austria akh linz innere med iii - zentrum für hämatologie und med. onkologie, linz, austria krankenhaus barmherzigen schwestern linz, linz, austria krankenhaus der elisabethinen linz gmbh, linz, austria uni. klinik für innere medizin iii universitätsklinikum der pmu lkh salzburg, salzburg, austria medical university of vienna (muw) department of medicine i, vienna, austria univ. general hospital hietzing, vienna, austria ziekenhuis netwerk antwerpen, antwerpen, belgium az sint-jan, bruges, belgium institut jules bordet, brussels, belgium cliniques universitaires saint-luc, brussels, belgium uz gent, gent, belgium ch jolimont, la louviere, belgium az delta, roeselare, belgium h-hartziekenhuis roeselare-menen, roeselare, belgium university hospital for active treatment dr. georgi stranski, pleven, bulgaria university multiprofile hospital for active treatment sveti ivan rilski ead, sofia, bulgaria specialized hospital for active treatment of haematological diseases ead, sofia, bulgaria princess margaret cancer centre, toronto, ontario, canada sir mortimer b davis jewish general hospital/mcgill university, montreal, quebec, canada chu lyon sud, pierre-bénite, lyon, france university hospital brest, brest, france centre hospitalier universitaire henri mondor, créteil, france unite hemopathies lymphoides chu henri mondor, créteil, france chu dijon-bourgogne - hematologie clinique, dijon, france hospitalier de la rochelle-ré-aunis, la rochelle, france chru de lille - hopital claude-huriez, lille, france marseille institute of cancer - institut j. paoli and i. calmettes, marseille, france chu montpellier, montpellier, france hostpial saint louis - circo (centre d\'investigations et de recherche clinique en oncologie), paris, france hôpital necker service d\'hématologie adult, paris, france pitié-salpêtrière hospital, paris, france centre henri becquerel, rouen, france uniklinik aachen klinik für hämatologie, onkologie, hämostaseologie und stammzelltransplantation, aachen, germany helios klinikum bad saarow, bad saarow, germany charite universitatsmedizin berlin (benjamin franklin campus), berlin, germany charite universitatsmedizin berlin (virchow campus), berlin, germany ev. diakonie-krankenhaus ggmbh, bremen, germany gemeinschaftspraxis haematologie and onkologie-dresden, dresden, germany martin-luther-university halle-wittenberg department of oncology, halle, germany medizinische hochschule, hannover, germany universität heidelberg medizinische klinik v hämatologie, onkologie und rheumatologie, heidelberg, germany klinikum kempten klinik für innere medizin iii - hämatologie, onkologie und palliativmedizin, koln, germany klinikum leverkusen, leverkusen, germany klinikum ludwigshafen, ludwigshafen, germany rotkreuzklinikum münchen, muenchen, germany klinikum nürnberg nord, nuernberg, germany haematology department and hct unit g.papanicolaou hospital, exochi, thessaloniki, greece hematology clinic,general hospital of athens,g. gennimatos, athens, greece national & kapodistrian university of athens, laiko general hospital, athens, greece hematology department laiko general hospital, athens, greece second depth of internal medicine, attiko university hospital, athens, greece national & kapodistrian university of athens, attiko university hospital, chaidari, greece department of clinical hematology ,university hospital ioannina, ioánnina, greece university of patras medical school, patras, greece semmelweis egyetem általános orvosi kar, budapest, hungary országos onkológiai intézet ""a"" belgyógyászati onkológiai osztály, budapest, hungary semmelweis university department of medicine and oncology, budapest, hungary dekk belgyogyaszati klinika hematologia, debrecen, hungary somogy megyei kaposi mór oktató kórház, kaposvár, hungary pécsi tudományegyetem, áok, i. számú belgyógyászati klinika, pécs, hungary veszprém megyei csolnoky ferenc kórház, veszprém, hungary csolnoky ferenc hospital, veszprém, hungary regional cancer centre, igims, patna, bihar, india srm institutes for medical science, vadapalani, chennai, india rajiv gandhi cancer hospital, new delhi, delhi, india regional cancer centre, thiruvananthapuram, kerala, india prince aly khan hospital, mumbai, maharashtra, india jaslok hospital and research centre, mumbai, maharashtra, india deenanath mangeshkar hospital, pune, maharashtra, india institute of medical sciences & sum hospital, bhubaneswar, odisha, india dayanand medical college and hospital, ludhiāna, punjab, india cancer institute (wia), chennai, tamil nadu, india saveetha medical college hospital, chennai, tamil nadu, india g. kuppu swamy naidu hospital, coimbatore, tamil nadu, india meenakshi mission hospital & research centre, madurai, tamil nadu, india king george\'s medical university (kgmu), lucknow, uttar pradesh, india nil ratan sircar medical college and hospital, kolkata, west bengal, india netaji subhas chandra bose cancer research hospital, kolkata, west bengal, india tata memorial centre, kolkata, west bengal, india netaji subhas chandra bose cancer research institute, kolkata, west bengal, india irch, all india institute of medical sciences, delhi, india dr. b.r.a. institute rotary cancer hospital all india institute of medical sciences, new delhi, india hematology-soroka, beer sheva, israel rambam healthcare campus, haifa, israel wolfson mc, holon, israel hadassah medical center, jerusalem, israel rabin medical center, petach tikva, israel assuta medical center, tel aviv, israel tlv sorasky medical center, tel aviv, israel sheba medical center, tel hashomer, israel instituto di ematologia seragnoli pad 8 universita di bologna, bologna, italy sodc ematologica ,aou careggi, florence, italy aou maggiore della carità scdu ematologia, florence, italy hematology-oncology & stem cell transplantation unit, national cancer institute, fondazione \'g. pascale\', irccs, naples, italy scdu ematologia, division of hematology, dept. of translational medicine, universita del piemonte orientale, novara, italy fondazione policlinico universitario a. gemelli, rome, italy azienda ospedaliero-universitaria senese, siena, italy città della salute e della scienza di torino, torino, italy vumc (vrije universiteit amsterdam), amsterdam, netherlands lumc (leidse universitair medisch centrum), leiden, netherlands north shore hospital, auckland, new zealand christchurch hospital, christchurch, new zealand uniwersytecki szpital kliniczny im. jana mikulicza, wrocław, radeckiego, poland szpitale wojewódzkie w gdyni, gdyńskie centrum onkologii, gdynia, poland mcm (małopolskie centrum medyczne), krakow, poland wojewodzki szpital specjalistyczny w legnicy, legnica, poland samodzielny publiczny szpital kliniczny nr 1 w lublinie, lublin, poland hematology department st john\'s cancer centre, lublin, poland samodzielny publiczny zakład opieki zdrowotnej ministerstwa, olsztyn, poland instytut hematologii i transfuzjologii, warszawa, poland centrum onkologii- insytut im. marii skłodowskiej-curie klinika nowotworow ukladu chlonnego, warszawa, poland maria sklodowska curie national research institute, warszawa, poland memorial provincial specialist hospital in lodz, łódź, poland institut za onkologiju i radiologiju srbije, belgrade, serbia klinicko bolnick centar zemun odeljenje hematologije, belgrade, serbia klinički centar srbije klinika za hematologiju, belgrade, serbia kliničko bolnički centar zvezdara, belgrade, serbia klinički centar niš klinika za hematologiju, nis, serbia institut za onkologiju vojvodine, sremska kamenica, serbia hospitla universitari germans trias i pujol - ico, badalona, spain hospital university vall d\'hebron, barcelona, spain hospital clinic i provincial de barcelona, barcelona, spain hospital universitario la paz, madrid, spain hospital de son llàtzer, palma de mallorca, spain clínica universidad de navarra, pamplona, spain hospital universitario de salamanca, salamanca, spain hospital universitario virgen del rocio, sevilla, spain gloucestershire royal hospital, gloucester, gloucestershire, united kingdom southampton university hospital, southampton, hampshire, united kingdom royal marsden hospital, sutton, london, united kingdom northwick park hospital, harrow, middlesex, united kingdom leeds teaching hospitals nhs trust, leeds, yorkshire, united kingdom addenbrooke\'s hospital cambridge, cambridge, united kingdom royal liverpool university hospital, liverpool, united kingdom the clatterbridge cancer centre nhs foundation trust, liverpool, united kingdom king\'s college hospital, london, united kingdom princess royal university hospital (pruh), london, united kingdom guy\'s and st thomas\' nhs foundation trust, london, united kingdom the christie nhs foundation trust, manchester, united kingdom oxford university hospitals nhs trust oxford cancer and haematology centre, churchill hospital, oxford, united kingdom derriford hospital, plymouth, united kingdom']",,https://ClinicalTrials.gov/show/NCT02227251,lymphoma
730,731,NCT01206764,a trial of everolimis in patients with advanced renal cell carcinoma.,,Completed,Has Results,renal cell carcinoma,drug: rad001,pfs (progression-free survival)|disease control rate (stable disease [sd] + partial response [pr] + complete response [cr]);|objective response rate (orr; where orr = cr + pr)|duration of response (dor)|overall survival,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 4,143.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRAD001LIC01,"November 11, 2009","June 6, 2017","July 1, 2017","September 22, 2010","June 24, 2019","June 24, 2019","['novartis investigative site, alger, algeria novartis investigative site, oran, algeria novartis investigative site, alexandria, egypt novartis investigative site, cairo, egypt novartis investigative site, mansoura, egypt novartis investigative site, indore, madhya pradesh, india novartis investigative site, pune, maharashtra, india novartis investigative site, amman, jordan novartis investigative site, ashrafieh, lebanon novartis investigative site, moscow, russian federation novartis investigative site, samara, russian federation novartis investigative site, riyadh, saudi arabia novartis investigative site, cape town, south africa novartis investigative site, cape town, south africa novartis investigative site, durban, south africa novartis investigative site, parktown, south africa novartis investigative site, songkhla, hat yai, thailand novartis investigative site, bangkok, thailand novartis investigative site, chiang mai, thailand novartis investigative site, tunis, tunisie, tunisia novartis investigative site, ariana, tunisia novartis investigative site, sousse, tunisia']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/64/nct01206764/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/64/nct01206764/prot_001.pdf",https://ClinicalTrials.gov/show/NCT01206764,kidney
731,732,NCT00683969,a study to assess the effect of cellcept (mycophenolate mofetil) and reduced corticosteroids in controlling symptoms of myasthenia gravis,,Completed,No Results Available,"myasthenia gravis, generalized",drug: mycophenolate mofetil (cellcept)|drug: placebo,"proportion of subjects reaching responder status|time to start of response|mean and median prednisone dose and cholinesterase inhibitor dose|adverse events, lab parameters, vital signs",hoffmann-la roche|aspreva pharmaceuticals,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WX17798,August 2004,,May 2007,"May 26, 2008",,"May 26, 2008","['sun city, arizona, united states sacramento, california, united states miami, florida, united states kansas city, kansas, united states rochester, new york, united states chapel hill, north carolina, united states columbus, ohio, united states upland, pennsylvania, united states dallas, texas, united states galveston, texas, united states edmonton, alberta, canada london, ontario, canada belgrade, former serbia and montenegro bordeaux cedex, france nice, france düsseldorf, germany münchen, germany regensburg, germany tübingen, germany hyderabad, india mumbai, india new delhi, india jerusalem, israel milano, italy roma, italy san donato milanese, italy mexico city, mexico mexico city, mexico mexico city, mexico leiden, netherlands maastricht, netherlands rotterdam, netherlands kazan, russian federation moscow, russian federation nizhniy novgorad, russian federation barcelona, spain madrid, spain kharkov, ukraine kiev, ukraine zaporozhye, ukraine liverpool, united kingdom oxford, united kingdom salford, united kingdom']",,https://ClinicalTrials.gov/show/NCT00683969,
732,733,NCT01419665,"gp2013 in the treatment of patients with previously untreated, advanced stage follicular lymphoma (assist_fl)",ASSIST_FL,Completed,Has Results,follicular lymphoma,biological: gp2013|biological: rituximab,"overall response rate (orr)|to evaluate the complete response (cr) rate during the combination treatment period|to evaluate the partial response (pr) rate during the combination treatment period|to evaluate the progression free survival (pfs) with up to 3 years of follow-up post randomization|to evaluate the overall survival (os) with up to 3 years of follow-up post randomization, as assessed by the number of deaths|to evaluate the incidence of immunogenicity (ada formation) against gp2013 and mabthera (rituximab)|to evaluate a pk marker following the treatment with gp2013-chemotherapy and mabthera-chemotherapy (c max)|to evaluate a pk marker following the treatment with gp2013-chemotherapy and mabthera-chemotherapy (c trough)|to evaluate a pd marker (peripheral cd19+ b-cell counts) following the treatment with gp2013 + chemotherapy amd mabthera- chemotherapy",sandoz|novartis pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,629.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GP13-301|2010-019522-13,"December 1, 2011","July 10, 2015","January 22, 2018","August 18, 2011","May 14, 2021","May 14, 2021","['investigative site, la plata, argentina investigative site, rosario, argentina investigative site, san miguel de tucuman, argentina investigative site, adelaide, australia investigative site, ballarat, australia investigative site, epping, australia investigative site, footscray, australia investigative site, wodonga, australia investigative site, graz, austria investigative site, wien, austria investigative site, barretos, brazil investigator site, barretos, brazil investigative site, botucatu, brazil investigative site, campinas, brazil investigative site, curitiba, brazil investigative site, florianopolis, brazil investigative site, fortaleza, brazil investigative site, goiania, brazil investigative site, jau, brazil investigative site, passo fundo, brazil investigative site, porto alegre, brazil investigative site, rio de janeiro, brazil investigative site, santo andre, brazil investigative site, sao paulo, brazil investigative site, sorocaba, brazil investigative site, pleven, bulgaria investigative site, plovdiv, bulgaria investigative site, ruse, bulgaria investigative site, sofia, bulgaria investigative site, varna, bulgaria investigative site, medellin, colombia investigative site, monteria, colombia investigative site, colmar, france investigative site, nimes, france investigative site, strasbourg, france investigative site, bad saarow, germany investigative site, koblenz, germany investigative site, athens, greece investigative site, ioannina, greece investigative site, larissa, greece investigative site, patras, greece investigative site, györ, hungary investigative site, kaposvar, hungary investigative site, ahmedabad, india india, amritsar, india investigative site, aurangabad, india investigative site, bangalore, india investigative site, chennai, india investigative site, hyderabad, india investigative site, kolkata, india investigtive site, kolkata, india investigative site, madurai, india investigative site, mumbai, india investigative site, nashik, india investigative site, new delhi, india investigative site, pune, india investigative site, surat, india investigative site, trivandrum, india investigative site, vellore, india investigative site, dublin, ireland investigative site, limerick, ireland investigative site, waterford, ireland investigative site, ashkelon, israel investigative site, nahariya, israel investigative site, bari, italy investigative site, firenze, italy investigative site, meldola, italy investigative site, milano, italy investigative site, palermo, italy investigative site, pavia, italy investigative site, pescara, italy investigative site, piacenza, italy investigative site, ravenna, italy investigative site, reggio calabria, italy investigative site, varese, italy investigative site, aomori, japan investigative site, fukuoka, japan investigative site, gifu, japan investigative site, kagoshima, japan investigative site, kitakyushu, japan investigative site, kobe, japan investigative site, komaki, japan investigative site, matsuyama, japan investigative site, ogaki, japan investigative site, okayama, japan invstigative site, omura, japan investigative site, saga, japan investigative site, tachikawa, japan investigative site, ōtake, japan investigative site, alor setar, malaysia investigative site, ampang, malaysia investigative site, george town, malaysia investigative site, ipoh, malaysia investigative site, johor bahru, malaysia investigative site, klang, malaysia investigative site, kuala lumpur, malaysia investigative site, kuching, malaysia investigative site, melaka, malaysia investigative site, pulau pinang, malaysia investigative site, subang jaya, malaysia investigative site, amsterdam, netherlands investigative site, delft, netherlands investigative site, gouda, netherlands investigative site, heerlen, netherlands investigative site, rotterdam, netherlands investigative site, schiedam, netherlands investigative site, sittard, netherlands investigative site, zwolle, netherlands investigative site, lima, peru investigative site, brzozow, poland investigative site, bydgoszcz, poland investigative site, chorzow, poland investigative site, krakow, poland investigative site, lublin, poland investigative site, warszawa, poland investigative site, braga, portugal investigative site, coimbra, portugal investigative site, lisboa, portugal investigative site, porto, portugal investigative site, brasov, romania investigative site, bucharest, romania investigative site, cluj-napoca, romania investigative site, iasi, romania investigative site, timisoara, romania investigative site, arkhangelsk, russian federation investigative site, chelyabinsk, russian federation investigative site, krasnodar, russian federation investigative site, kursk, russian federation investigative site, moscow, russian federation investigative site, nizhniy novgorod, russian federation investigative site, rostov-on -don, russian federation investigative site, st. petersburg, russian federation investigative site, cape town, south africa investigative site, george, south africa investigative site, johannesburg, south africa investigative site, port elizabeth, south africa investigative site, pretoria, south africa investigative site, barcelona, spain investigative site, madrid, spain investigative site, oviedo, spain investigative site, san sebastian, spain investigative site, sevilla, spain investigative site, zaragoza, spain investigative site, cherkasy, ukraine investigative site, dnipropetrovsk, ukraine investigative site, donetsk, ukraine investigative site, ivano-frankivsk, ukraine investigative site, kharkiv, ukraine investigative site, kyiv, ukraine investigative site, lviv, ukraine investigative site, eastbourne, united kingdom investigative site, london, united kingdom investigative site, worthing, united kingdom']",,https://ClinicalTrials.gov/show/NCT01419665,lymphoma
733,734,NCT00835419,efficacy study of p276-00 in subjects of malignant melanoma positive for cyclin d1 expression,ENVER,Completed,No Results Available,melanoma,drug: p276-00,"progression free survival rate at day 168|overall survival rate at 1 year, objective response rate,duration of response",piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 2,12.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/27/08,May 2009,April 2011,November 2012,"February 3, 2009",,"December 4, 2012","['university of newcastle, school of medicine and public health, newcastle, new south wales, australia mater adult hospital raymond tce south brisbane, qld 4101, brisbane, australia peninsula oncology centre, frankston, australia john fawkner cancer trial centre, victoria, australia curie manavata cancer center, nasik, maharashtra, india chhatrapati shahuji maharaj medical university, lucknow, uttar pradesh, india christchurch oncology research unit, oncology service, christchurch hospital, riccarton avenue, private bag 4710, christchurch,, christchurch, new zealand']",,https://ClinicalTrials.gov/show/NCT00835419,skin
734,735,NCT04266301,"study of efficacy and safety of mbg453 in combination with azacitidine in subjects with intermediate, high or very high risk myelodysplastic syndrome (mds) as per ipss-r, or chronic myelomonocytic leukemia-2 (cmml-2)",STIMULUS-MDS2,"Active, not recruiting",No Results Available,"myelodysplastic syndromes|leukemia, myelomonocytic, chronic",drug: mbg453|drug: azacitidine|drug: placebo,"overall survival|key secondary endpoint 1: time to definitive deterioration of fatigue using functional assessment of cancer therapy (facit)-fatigue score|key secondary endpoint 2: red blood cell transfusion-free intervals|key secondary endpoint: percent of subjects with at least 3 point confirmed improvement from baseline in facit-fatigue scoresscore|key secondary endpoint 4: percent of subjects with at least 10 point confirmed improvement from baseline in physical functioning using european or ganization for research and treatment of cancer's core quality of life questionnaire (eortc qlq-c30)|key secondary endpoint 5: percent of subjects with at least 10 point confirmed improvement from baseline in emotional functioning using eortc-qlq-c30|percentage of subjects with either cr, or mcr, or pr, or hi in each treatment arm according to international working group for mds (iwg-mds) as per investigator assessment|percentage of subjects with sd in each treatment arm according to international working group for mds (iwg-mds) as per investigator assessment|progression free survival (pfs)|leukemia-free survival|number of transfusion dependent subjects at baseline who become red blood cells/platelets transfusion independent after randomization|percentage of transfusion dependent subjects at baseline who become red blood cells/platelets transfusion independent after randomization|pharmacokinetics of mbg453 (parameter cmax)|pharmacokinetics of mbg453 (parameter auc)|anti-drug antibody (ada) prevalence at baseline and ada incidence on-treatment|change from baseline in the european quality of life (euroqol) - 5 dimensions, 5 level questionnaire (eq-5d-5l) score over time|change from baseline in the european quality of life (euroqol) - 5 dimensions, 5 level questionnaire (eq-5d-5l) visual analogue scale over time|change from baseline to c12d1 of global health status/quality of life scores using european organization for research and treatment of cancer's core quality of life questionnaire (eortc-qlq-c30)",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,530.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CMBG453B12301|2019-002089-11,"June 8, 2020","January 15, 2027","January 15, 2027","February 12, 2020",,"April 26, 2022","['yuma regional cancer center, yuma, arizona, united states university of california at los angeles, los angeles, california, united states yale university school of medicine smilow cancer hospital, new haven, connecticut, united states mayo clinic jacksonville, jacksonville, florida, united states university of miami, miami, florida, united states northwestern university div of hematology/oncology, chicago, illinois, united states massachusetts general hospital, boston, massachusetts, united states hackensack university medical center sc, hackensack, new jersey, united states weill cornell medicine newyork presbyterian hospital, new york, new york, united states university of rochester medical center dept.ofuniv.rochester/jpwilmot, rochester, new york, united states university of virginia university of virginia, charlottesville, virginia, united states novartis investigative site, pilar, buenos aires, argentina novartis investigative site, woolloongabba, queensland, australia novartis investigative site, clayton, victoria, australia novartis investigative site, perth, western australia, australia novartis investigative site, graz, austria novartis investigative site, innsbruck, austria novartis investigative site, linz, austria novartis investigative site, brasschaat, belgium novartis investigative site, roeselare, belgium novartis investigative site, florianopolis, sc, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, sao paulo, sp, brazil novartis investigative site, calgary, alberta, canada novartis investigative site, toronto, ontario, canada novartis investigative site, vina del mar, valparaiso, chile novartis investigative site, guangzhou, guangdong, china novartis investigative site, guangzhou, guangdong, china novartis investigative site, shenzhen, guangdong, china novartis investigative site, wuhan, hubei, china novartis investigative site, wuhan, hubei, china novartis investigative site, suzhou, jiangsu, china novartis investigative site, chang chun, jilin, china novartis investigative site, tianjin, tianjin, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, beijing, china novartis investigative site, beijing, china novartis investigative site, chengdu, china novartis investigative site, jinan, china novartis investigative site, shanghai, china novartis investigative site, shanghai, china novartis investigative site, tianjin, china novartis investigative site, rionegro, antioquia, colombia novartis investigative site, bogota, colombia novartis investigative site, praha 2, czech republic, czechia novartis investigative site, hradec kralove, cze, czechia novartis investigative site, brno - bohunice, czechia novartis investigative site, praha, czechia novartis investigative site, helsinki, finland novartis investigative site, kuopio, finland novartis investigative site, grenoble, france novartis investigative site, lille cedex, france novartis investigative site, paris cedex 10, france novartis investigative site, toulouse, france novartis investigative site, tours, france novartis investigative site, vandoeuvre les nancy, france novartis investigative site, velbert, north rhine-westphalia, germany novartis investigative site, dresden, sachsen, germany novartis investigative site, augsburg, germany novartis investigative site, duesseldorf, germany novartis investigative site, frankfurt, germany novartis investigative site, greifswald, germany novartis investigative site, jena, germany novartis investigative site, kiel, germany novartis investigative site, ulm, germany novartis investigative site, alexandroupolis, evros, greece novartis investigative site, patras, greece novartis investigative site, ahmedabad, gujrat, india novartis investigative site, faridabad, haryana, india novartis investigative site, madurai, tamil nadu, india novartis investigative site, kolkata, west bengal, india novartis investigative site, kolkata, west bengal, india novartis investigative site, delhi, india novartis investigative site, afula, israel novartis investigative site, tel aviv, israel novartis investigative site, bologna, bo, italy novartis investigative site, catania, ct, italy novartis investigative site, firenze, fi, italy novartis investigative site, genova, ge, italy novartis investigative site, milano, mi, italy novartis investigative site, rozzano, mi, italy novartis investigative site, reggio calabria, rc, italy novartis investigative site, roma, rm, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, kashiwa, chiba, japan novartis investigative site, fukuoka city, fukuoka, japan novartis investigative site, sapporo, hokkaido, japan novartis investigative site, isehara, kanagawa, japan novartis investigative site, sendai city, miyagi, japan novartis investigative site, nagasaki-city, nagasaki, japan novartis investigative site, osaka sayama, osaka, japan novartis investigative site, bunkyo-ku, tokyo, japan novartis investigative site, osaka, japan novartis investigative site, yamagata, japan novartis investigative site, seoul, seocho gu, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, beirut, lebanon novartis investigative site, vilnius, lithuania novartis investigative site, kuching, sarawak, malaysia novartis investigative site, kuala lumpur, malaysia novartis investigative site, pulau pinang, malaysia novartis investigative site, selangor, malaysia novartis investigative site, mexico, distrito federal, mexico novartis investigative site, satelite, edo mexico, mexico novartis investigative site, morelia, michoacan, mexico novartis investigative site, estado de mexico, mexico novartis investigative site, groningen, netherlands novartis investigative site, muscat, oman novartis investigative site, lisboa, portugal novartis investigative site, porto, portugal novartis investigative site, sain petersburg, russian federation novartis investigative site, st petersburg, russian federation novartis investigative site, riyadh, saudi arabia novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, sevilla, andalucia, spain novartis investigative site, oviedo, asturias, spain novartis investigative site, salamanca, castilla y leon, spain novartis investigative site, badalona, catalunya, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, valencia, comunidad valenciana, spain novartis investigative site, madrid, spain novartis investigative site, bern, switzerland novartis investigative site, zürich, switzerland novartis investigative site, hualien city, hualien, taiwan novartis investigative site, kaohsiung city, taiwan novartis investigative site, liouying township, taiwan novartis investigative site, taichung, taiwan novartis investigative site, taipei, taiwan novartis investigative site, taoyuan, taiwan novartis investigative site, songkhla, hat yai, thailand novartis investigative site, khon kaen, tha, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, chiang mai, thailand novartis investigative site, ankara, turkey novartis investigative site, edirne, turkey novartis investigative site, istanbul, turkey novartis investigative site, izmir, turkey novartis investigative site, samsun, turkey novartis investigative site, portsmouth, hants, united kingdom novartis investigative site, edinburgh, united kingdom novartis investigative site, manchester, united kingdom novartis investigative site, nottingham, united kingdom']",,https://ClinicalTrials.gov/show/NCT04266301,blood
735,736,NCT00843050,a phase ii study to evaluate efficacy and safety of p276-00 in relapsed and/or refractory mantle cell lymphoma,,Terminated,Has Results,mantle cell lymphoma,drug: p276-00,best overall objective response rate|duration of response|time to progression,piramal enterprises limited,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P276-00/23/08,November 2009,February 2011,August 2012,"February 13, 2009","July 27, 2012","July 27, 2012","['division of hematology/oncology, department of internal medicine, mayo clinic, phoenix, arizona, phoenix, arizona, united states division of hematology/oncology, department of internal medicine, mayo clinic, arizona, scottsdale, arizona, united states college of medicine, mayo clinic, rochester, minnesota, united states hackensack university medical center, hackensack, new jersey, united states gabrail cancer center research, canton, ohio, united states gabrail cancer center research, dover, ohio, united states vanderbilt university medical center, nashville, tennessee, united states cancer care centers of south texas, new braunfels, texas, united states cancer care centers of south texas, san antonio, texas, united states huntsman cancer institute, 2000 circle of hope, room 2145, salt lake city, utah, united states seattle cancer care alliance, seattle, washington, united states department of medicine, university of washington, seattle, washington, united states dept of hematology/oncology, university of wisconsin- madison, madison, wisconsin, united states institute rotary cancer hospital, all india institute of medical sciences, new delhi, delhi, india st. johns medical college & hospital, bangalore, karnataka, india malabar institute of medical sciences, calicut, kerala, india jaslok hospital and research centre, mumbai, maharashtra, india tata memorial hospital, mumbai, maharashtra, india cancer care clinic and hospital, nagpur, maharashtra, india meenakshi mission hospital and research centre, madurai, tamil nadu, india']",,https://ClinicalTrials.gov/show/NCT00843050,lymphoma
736,737,NCT04057040,hepcidin mimetic in patients with polycythemia vera (revive),,"Active, not recruiting",No Results Available,polycythemia vera,drug: ptg-300|drug: placebo,"proportion of responders during the blinded randomized withdrawal period (week 29 to week 41).|change in rate of phlebotomy events between week 17 through week 29 (inclusive; 12 weeks) compared to each subject's historical rate.|change in rate of phlebotomy events between week 1 through week 29 (inclusive; 28 weeks) compared to each subject's historical rate.|proportion of subjects achieving a response at week 29, with response defined as having achieved the absence of ""phlebotomy eligibility"" during the efficacy evaluation phase beginning at week 17 and continuing to week 29.|proportion of subjects with reduction in the rate of phlebotomy events beginning at the week 17 visit and continuing to week 29 (12 weeks) compared to each subject's historical rate.","protagonist therapeutics, inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PTG-300-04,"October 1, 2019","October 15, 2025","January 1, 2026","August 14, 2019",,"April 14, 2022","['mayo clinic - mayo clinic hospital, phoenix, arizona, united states marin cancer care, greenbrae, california, united states stanford university, palo alto, california, united states moffitt cancer center, tampa, florida, united states university of kansas, westwood, kansas, united states pontchartrain cancer care, covington, louisiana, united states center for cancer and blood disorders, bethesda, maryland, united states university of michigan, ann arbor, michigan, united states karmanos cancer center, detroit, michigan, united states mount sinai, new york, new york, united states new york presbyterian hospital - weill cornell medical center, new york, new york, united states cleveland clinic - taussig cancer center, cleveland, ohio, united states mary crowley cancer research center, dallas, texas, united states the university of texas md anderson cancer center, houston, texas, united states sahyadri super specialty hospital, pune, maharashtra, india all india institute of medical sciences, rishikesh, uttarakhand, india']",,https://ClinicalTrials.gov/show/NCT04057040,blood
737,738,NCT00722137,"study of the combination of rituximab, cyclophosphamide, doxorubicin, velcade, and prednisone or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed mantle cell lymphoma",,Completed,Has Results,mantle cell lymphoma,drug: rituximab 375 mg/m^2|drug: cyclophosphamide 750 mg/m^2|drug: doxorubicin 50 mg/m^2|drug: velcade 1.3 mg/m^2|drug: prednisone 100 mg/m^2|drug: vincristine 1.4 mg/m^2,progression free survival (pfs)|time to progression (ttp)|duration of response|time to next anti-lymphoma treatment (ttnt)|treatment-free interval (tfi)|overall response rate (orr)|overall complete response (cr + cru)|overall survival (os)|18-month survival|overall survival (os) in long term follow-up period|number of participants experiencing an adverse event (ae),"millennium pharmaceuticals, inc.|johnson & johnson pharmaceutical research & development, l.l.c.|takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 3,487.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26866138-LYM-3002|26866138-LYM-3002CTIL|2007-005669-37|0970313683|U1111-1195-3827,"May 1, 2008","January 1, 2014","June 17, 2017","July 25, 2008","November 17, 2014","July 12, 2018","['st. francis hosptial and medical center, hartford, connecticut, united states center for cancer care at goshen hospital, goshen, indiana, united states sinai hospital, baltimore, maryland, united states capitol comp. cancer center, jefferson city, missouri, united states nebraska cancer specialists, omaha, nebraska, united states hematology-oncology associates of northern nj, morristown, new jersey, united states legacy pharma research, bismarck, north dakota, united states division of hematology and oncology vanderbilt university, nashville, tennessee, united states cancer outreach associates, pc, abingdon, virginia, united states st.johanns spital/landeskrankenhaus salzburg, salzburg, austria allgemeines krankenhaus der stadt wien, wien, austria az stuivenberg oncologie/ hematologie, antwerpen, belgium az st jan av, brugge, belgium uz brussel department medical oncology, brussels, belgium uza hematologie, 1e verdiep, edegem, belgium universitair ziekenhuis gent - uz gent, hematologie, 9k12ie 9de verdiep- polikliniek hematologie, gent, belgium uz leuven gasthuisberg hematologie, leuven, belgium c.h.r. citadelle, liege, belgium centre hospitalier universitaire, liege, belgium ucl de mont-godinne, yvoir, belgium centro de hematologia e hemoterapia - unicamp, campinas, brazil fundacao hospital amaral carvalho, jau, brazil hospital nossa senhora da conceicao, porto alegre, brazil hospital sao lucas puc-rs, porto alegre, brazil inca - instituto nacional do cancêr, rio de janeiro, brazil centro de estudos de hematologia e oncologia da fmabc, sao paulo, brazil fundacao pio xii - hospital de cancer de barretos, sao paulo, brazil hospital ac camargo, sao paulo, brazil hospital alemao oswaldo cruz, sao paulo, brazil hospital das clínicas da faculdade de medicina da usp, sao paulo, brazil santa casa de misericórida de são paulo, sao paulo, brazil cross cancer institute, edmonton, alberta, canada university health network, princess margaret hospital, toronto, ontario, canada hospital clinico universidad catolica de chile, santiago, chile hospital del salvador, santiago, chile instituto nacional del cancer, santiago, chile sun yat-sen university cancer center, guangzhou, guangdong, china west china hospital, sichuan university, chengdu, sichuan, china zhejiang university first hospital, hangzhou, zhejiang, china beijing cancer hospital, beijing, china cancer institute & cancer hospital, cams&pumc, beijing, china peking university third hospital, beijing, china cancer hospital, fudan university, shanghai, china ruijin hospital, shanghai, china tianjin medical university cancer hospital and institute, tianjin, china clinica reina sofia, bogota, colombia hospital pablo tobon uribe, medellin, colombia hospital universitario san vicente de paul, medellin, colombia interni hematoonkoligicka klinika, brno, czechia interni klinika - oddeleni klin. hematologie fakultni nemocnice hradec kralove, hradec kralove, czechia oddeleni klinicke hematologie, fakultni nemocnice kralovske vinohrady, praha, czechia vivantes klinikum neukölln klinik für innere medizin hämatologie und onkologie, berlin, germany vivantes klinikum spandau klinik für innere medizin - hämatologie, onkologie und gastroenterologie, berlin, germany städt. kliniken frankfurt-hoechst med. klinik ii - hämatologie und onkologie, frankfurt, germany tumorklinik sanafontis alpine gmbh, freiburg, germany wilhelm-anton-hospital goch ggmbh klinik für hämatologie und internistische onkologie, goch, germany klinikum lippe-lemgo med. klinik ii - hämatologie und onkologie, lemgo, germany johannes-gutenberg-universität mainz iii. med. klinik, mainz, germany mutterhaus der borromäerinnen med. klinik i, trier, germany schwarzwald-baar-kliniken innere med. ii, villingen, germany debreceni egyetem orvos- es egeszsegtudomanyi centrum, iii. sz. belgyogyaszati klinika, debrecen, hungary petz aladár kórház, ii. belgyógyászat, győr, hungary kaposi mor megyei korhaz, belgyogyaszat, kaposvar, hungary apollo hospital and research foundation, apollo hospitals, hyderabad 500033, andhra pradesh, india sir ganga ram hospital, new delhi- 110060, delhi, india kidwai memorial institute of oncology, bangalore 560 029, karnataka, india regional cancer centre, medical oncology, thiruvananthapuram, kerala-695011, india jehangir hospital, pune-411002, maharashtra, india apollo speciality hospital, chennai, chennai-600035, tamil nadu, india netaji subash chanda bose cancer research institute, kolkata- 700016, west bengal, india rambam medical center-hematology department, haifa, israel hadassah medical center - hematology department, jerusalem, israel rabin medical center, beilinson campus, petach tiqva, israel sheba medical center, ramat-gan, israel kaplan medical center - hematology institute, rechovot, israel azienda ospedaliera universitaria di bologna policlinico s.orsola-malpighi dipartimento di ematologia e scienze oncologiche ""l. e a. seragnoli"", bologna, italy spedali civili di brescia, brescia, italy dipartimento di oncologia ed ematologia università di modena e reggio emilia, modena, italy azienda ospedaliera universitaria policlinico tor vergata dipartimento di medicina u.o.c. ematologia, roma, italy azienda ospedaliera san giovanni battista ""molinette"" struttura complessa ematologia 2, torino, italy university malaya medical centre, kuala lumpur, malaysia gleneagles medical centre, pulau pinang, malaysia hopital du 20 aout 1953, casablanca, morocco centre d\'oncologie al azhar, rabat, morocco institut national d\'oncologie, rabat, morocco national kidney and transplant institute, quezon city, philippines st lukes medical center, quezon city, philippines szpital morski im. pck w gdyni gdynskie centrum onkologii oddzial chemioterapii, gdynia, poland klinika hematologii uniwersytetu medycznego w lodzi, lodz, poland ""katedra i klinika hematologii i chorob rozrostowych ukladu krwiotworczego, poznan, poland klinika hematologii nowotworow krwi i transplantacji szpiku akademii medycznej we wroclawiu, wroclaw, poland hospital sao marcos, braga, portugal hospitais da universidade de coimbra, coimbra, portugal hospital de santa maria, lisboa, portugal instituto portugues de oncologia, porto, portugal spitalul judetean de urgenta ""dr. constantin opris"", hematologie, baia mare, romania institutul clinic fundeni, hematologie, bucuresti, romania spitalul clinic coltea, clinica hematologie, bucuresti, romania spitalul clinic universitar de urgenta bucuresti, hematologie, bucuresti, romania spitalul clinic judetean de urgenta ""sf. spiridon"" iasi, oncologie medicala, iasi, romania arkhangelsk regional clinical hospital, arkhangelsk, russian federation belgorod regional oncology center, belgorod, russian federation chelyabinsk regional oncology center, chelyabinsk, russian federation sverdlovsk regional oncology dispensary, ekaterinburg, russian federation 1st republican clinical hospital of udmurtia, izhevsk, russian federation cancer research center rams - n.n. blokhin - academy of medical science, moscow, russian federation hematology scientific center, moscow, russian federation moscow regional clinical research institute, moscow, russian federation s.p. botkin moscow city clinical hospital, moscow, russian federation nizhniy novgorod region clinical hospital, nizhniy novgorod, russian federation medical scientific radiology - center, obninsk, russian federation omsk regional oncology dispensary, omsk, russian federation medical sanitary unit # 1, perm, russian federation republikan hospital named after v.a/ baranov, petrozavodsk, russian federation rostov research institute of oncology, rostov-on-don, russian federation city clinical oncology dispensary, st petersburg, russian federation central res. inst. of roentgen-radiology, st-petersburg, russian federation pavlov state medical univercity, st-petersburg, russian federation leningrad region clinical hospital, st. petersburg, russian federation st.-petersburg clinical research institute of hematology and transfusiology, st. petersburg, russian federation national cancer centre, singapore, singapore singapore general hospital - hematology, singapore, singapore chris hani baragwanath hospital, johannesburg, gauteng, south africa medical oncology center of rosebank, johannesburg, gauteng, south africa university of the witwatersrand oncology, johannesburg, gauteng, south africa pretoria academic hospital-dr. savage road, 3rd floor radiotherapy building, prinshof, pretoria, gauteng, south africa dr ai pirjol & dr wm szpak inc., durban, kwazulu natal, south africa hospital universitario germans trias i pujol, badalona, barcelona, spain hospital clinic i provincial de barcelona, barcelona, spain hospital de la princesa, madrid, spain hospital universitario 12 de octubre, madrid, spain hospital clinico universitario salamanca, salamanca, spain chang gung memorial hospital, linkou, tao-yuan, taiwan king chulalongkorn memorial hospital, bangkok, thailand ramathibodi hospital, bangkok, thailand siriraj hospital-hematology unit, bangkok, thailand maharaj nakorn chiang mai hospital - faculty of medicine, chiang mai, thailand hôpital farhat hached, sousse, tunisia centre national de greffe de moelle osseuse, tunis, tunisia hôpital aziza othmana, tunis, tunisia institut salah azaiz, tunis, tunisia hacettepe university medical faculty, ankara, turkey dokuz eylul university med. fac., izmir, turkey cherkassy regional oncology center, dept. of hematology, cherkassy, ukraine dnepropetrovsk city clinical hospital #4, regional hematology center, dnepropetrovsk, ukraine institute of urgent and recovery surgery named after v.k.gusaka of ams of ukraine, haematology dept., donetsk, ukraine khmelnitskiy regional hospital, hematology department, khmelnitsky, ukraine national cancer institute, department of chemotherapy of hemoblastosis, kiev, ukraine institute of blood pathology and transfusion medicine, lviv clinical hospital #5, hematology dept., lviv, ukraine crimean republic clinical oncology dispensary, haematology department, simferopol, ukraine']","""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/37/nct00722137/sap_000.pdf|""study protocol"", https://clinicaltrials.gov/provideddocs/37/nct00722137/prot_001.pdf",https://ClinicalTrials.gov/show/NCT00722137,lymphoma
738,739,NCT00481247,a phase iii study of dasatinib vs imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia,DASISION,Completed,Has Results,"myeloid leukemia, chronic",drug: dasatinib|drug: imatinib,number of participants with best confirmed complete cytogenetic response (cccyr) within 12 months|percentage of participants remaining in confirmed complete cytogenetic response (cccyr)|percentage of participants with major molecular response (mmr) at any time|time to confirmed complete cytogenic response (cccyr) overall|time to major molecular response (mmr) overall|percentage of participants with progression-free survival (pfs)|percentage of participants with overall survival (os),bristol-myers squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,547.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA180-056|2006-005712-27,September 2007,December 2009,December 2015,"June 1, 2007","March 15, 2011","February 15, 2017","['molecular md, portland, oregon, united states local institution, capital federal, buenos aires, argentina local institution, capital federal, buenos aires, argentina local institution, buenos aires, argentina local institution, waratah, new south wales, australia local institution, brisbane, queensland, australia local institution, greenslopes, queensland, australia local institution, perth, western australia, australia local institution, innsbruck, austria local institution, wien, austria local institution, brugge, belgium local institution, bruxelles, belgium local institution, curitiba, parana, brazil local institution, campinas, sao paulo, brazil local institution, jau, sao paulo, brazil local institution, rio de janeiro, brazil local institution, sao paulo, brazil local institution, sao paulo, brazil local institution, santiago, metropolitana, chile local institution, beijing, beijing, china local institution, fuzhou, fujian, china local institution, shanghai, shanghai, china local institution, tianjin, tianjin, china local institution, colombia, bogota, colombia local institution, bogota, colombia local institution, brno, czech republic local institution, hradec kralove, czech republic local institution, olomouc, czech republic local institution, prague 2, czech republic local institution, aarhus, denmark local institution, nantes, cedex 1, france local institution, brest cedex 02, france local institution, lille cedex, france local institution, limoges, france local institution, montpellier cedex, france local institution, paris cedex 10, france local institution, paris, france local institution, pierre benite cedex, france local institution, poitiers cedex, france local institution, rennes, france local institution, strasbourg cedex, france local institution, toulouse cedex 09, france local institution, vandoeuvre les nancy, france local institution, berlin, germany local institution, rostock, germany local institution, tuebingen, germany local institution, ulm, germany local institution, thessaloniki, greece local institution, budapest, hungary local institution, debrecen, hungary local institution, vellore, tamilnadu, india local institution, ahmedabad, india local institution, cochin, india local institution, mumbai, india local institution, mumbai, india local institution, mumbai, india local institution, trivandrum, india local institution, bologna, italy local institution, catania, italy local institution, monza (mb), italy local institution, orbassano (to), italy local institution, pavia, italy local institution, roma, italy local institution, roma, italy local institution, nagoya, aichi, japan local institution, kamogawa-shi, chiba, japan local institution, fukuoka-shi, fukuoka, japan local institution, morioka-shi, iwate, japan local institution, kagoshima-shi, kagoshima, japan local institution, yokohama, kanagawa, japan local institution, kyoto-shi, kyoto, japan local institution, sendai, miyagi, japan local institution, okayama-shi, okayama, japan local institution, osaka-shi, osaka, japan local institution, bunkyo-ku, tokyo, japan local institution, shinagawa-ku, tokyo, japan local institution, seoul, korea, republic of local institution, seoul, korea, republic of local institution, mexico d.f., distrito federal, mexico local institution, mexico, d. f., distrito federal, mexico local institution, mexico, distrito federal, mexico local institution, monterrey, nuevo leon, mexico local institution, culiacan, sinaloa, mexico local institution, groningen, netherlands local institution, nijmegen, netherlands local institution, arequipa, peru local institution, lima, peru local institution, lima, peru local institution, chorzow, poland local institution, krakow, poland local institution, lodz, poland local institution, poznan, poland local institution, warsaw, poland local institution, moscow, russian federation local institution, rostov-on-don, russian federation local institution, st.petersburg, russian federation local institution, singapore, singapore local institution, a coruna, spain local institution, barcelona, spain local institution, barcelona, spain local institution, barcelona, spain local institution, madrid, spain local institution, madrid, spain local institution, malaga, spain local institution, oviedo, spain local institution, salamanca, spain local institution, valencia, spain local institution, ankara, turkey local institution, kayseri, turkey']",,https://ClinicalTrials.gov/show/NCT00481247,blood
739,740,NCT00391066,"lumiliximab with fludarabine, cyclophosphamide, and rituximab (fcr) versus fcr alone in subjects with relapsed chronic lymphocytic leukemia (cll)",LUCID,Terminated,No Results Available,chronic lymphocytic leukemia,drug: fcr + lumiliximab|drug: fcr,"complete response (cr) rate|time to event variables (progression free survival, duration of response, time to next therapy, time to progression and overall survival)|response variables",biogen,All,"18 Years and older   (Adult, Older Adult)",Phase 2,627.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,152CL201,November 2006,July 2010,December 2010,"October 23, 2006",,"October 2, 2015","['research site, scottsdale, arizona, united states research site, alhambra, california, united states research site, burbank, california, united states research site, fullerton, california, united states research site, la jolla, california, united states research site, long beach, california, united states research site, los angeles, california, united states research site, northridge, california, united states research site, oxnard, california, united states research site, pomona, california, united states research site, redondo beach, california, united states research site, sacramento, california, united states research site, santa maria, california, united states research site, fort myers, florida, united states research site, atlanta, georgia, united states research site, marietta, georgia, united states research site, chicago, illinois, united states research site, maywood, illinois, united states research site, indianapolis, indiana, united states research site, overland park, kansas, united states research site, shreveport, louisiana, united states research site, boston, massachusetts, united states research site, detroit, michigan, united states research site, st. joseph, michigan, united states research site, ypsilant,, michigan, united states research site, minneapolis, minnesota, united states research site, columbia, missouri, united states research site, st. louis, missouri, united states research site, billings, montana, united states research site, omaha, nebraska, united states research site, hackensack, new jersey, united states research site, morristown, new jersey, united states research site, chapel hill, north carolina, united states research site, raleigh, north carolina, united states research site, columbus, ohio, united states research site, kettering, ohio, united states research site, philadelphia, pennsylvania, united states research site, pittsburgh, pennsylvania, united states research site, greenville, south carolina, united states research site, nashville, tennessee, united states research site, austin, texas, united states research site, bedford, texas, united states research site, dallas, texas, united states research site, fort worth, texas, united states research site, fredericksburg, texas, united states research site, houston, texas, united states research site, san antonio, texas, united states research site, norfolk, virginia, united states research site, roanoke, virginia, united states research site, kennewick, washington, united states research site, spokane, washington, united states research site, st. louis, washington, united states research site, yakima, washington, united states research site, cordoba, argentina research site, mendoza, argentina research site, darlinghurst, new south wales, australia research site, gosford, new south wales, australia research site, st. leonards, new south wales, australia research site, waratah, new south wales, australia research site, westmead, new south wales, australia research site, greenslopes, queensland, australia research site, herston, queensland, australia research site, south brisbane, queensland, australia research site, woolloongabba, queensland, australia research site, adelaide, south australia, australia research site, adelaide, south australia, australia research site, ashford, south australia, australia research site, woodville, south australia, australia research site, box hill, victoria, australia research site, clayton, victoria, australia research site, clayton, victoria, australia research site, east melbourne, victoria, australia research site, fitzroy, victoria, australia research site, freemantle, western australia, australia research site, nedlands, western australia, australia research site, perth, western australia, australia research site, melbourne, australia research site, graz, austria research site, innsbruck, austria research site, salzburg, austria research site, wien, austria research site, antwerpen, belgium research site, brugge, belgium research site, bruxelles, belgium research site, edegem, belgium research site, ghent, belgium research site, herestraat, belgium research site, yvoir, belgium research site, goiania - go, brazil research site, porto alegre, brazil research site, rio de janeiro, brazil research site, santo andre, brazil research site, sao paulo, brazil research site, calgary, alberta, canada research site, edmonton, alberta, canada research site, halifax, nova scotia, canada research site, london, ontario, canada research site, toronto, ontario, canada research site, montreal, quebec, canada research site, hamilton, canada research site, quebec city, canada research site, brno, czech republic research site, hradec kralove, czech republic research site, prague, czech republic research site, angers, france research site, bordeaux, france research site, le mans, france research site, lille, france research site, limoges, france research site, nantes, france research site, nice, france research site, pessac, france research site, rennes, france research site, rouen, france research site, tours, france research site, augsburg, germany research site, dessau, germany research site, frankfurt, germany research site, greifswald, germany research site, kiel, germany research site, wurzburg, germany research site, athens, greece research site, herakleion, greece research site, ahmedabad, india research site, bangalore, india research site, delhi, india research site, mumbai, india research site, nashik, india research site, new delhi, india research site, pune, india research site, trivandrum, india research site, ashkelon, israel research site, haifa, israel research site, jerusalem, israel research site, petach tikva, israel research site, ramat gan, israel research site, rehovo, israel research site, milano, italy research site, novara, italy research site, roma, italy research site, rome, italy research site, rozzano, italy research site, verona, italy research site, klaipeda, lithuania research site, auckland, new zealand research site, christchurch, new zealand research site, hamilton, new zealand research site, palmerston north, new zealand research site, wellington, new zealand research site, bialystok, poland research site, gdansk, poland research site, katowice, poland research site, krakow, poland research site, lodz, poland research site, szczecin, poland research site, warszawa, poland research site, almada, portugal research site, braga, portugal research site, coimbra, portugal research site, lisbon, portugal research site, porto, portugal research site, viseu, portugal research site, brasov, romania research site, bucharest, romania research site, iasi, romania research site, ekaterinburg, russian federation research site, nizhniy novgorod, russian federation research site, obninsk, russian federation research site, ryazan, russian federation research site, samara, russian federation research site, saratov, russian federation research site, st. peterburg, russian federation research site, st. petersburg, russian federation research site, banska bystrica, slovakia research site, bratislava, slovakia research site, martin, slovakia research site, madrid, spain research site, murcia, spain research site, palma de mallorca, spain research site, salamanca, spain research site, toledo, spain research site, zaragoza, spain research site, bath, united kingdom research site, belfast, united kingdom research site, birmingham, united kingdom research site, bournemouth, united kingdom research site, edinburgh, united kingdom research site, glasgow, united kingdom research site, leeds, united kingdom research site, london, united kingdom research site, manchester, united kingdom research site, plymouth, united kingdom research site, surrey, united kingdom research site, taunton, united kingdom']",,https://ClinicalTrials.gov/show/NCT00391066,blood
740,741,NCT02060383,study of management of pasireotide-induced hyperglycemia in adult patients with cushing's disease or acromegaly,,Completed,Has Results,cushing's disease|acromegaly,drug: pasireotide s.c.|drug: sitagliptin|drug: liraglutide|drug: insulin|drug: pasireotide lar|drug: metformin,change in hba1c from randomization to approximately 16 weeks|change in hba1c from randomization (r) over time per randomized arm|change in fpg (fasting plasma glucose) from randomization until end of core phase|percentage of participants in the incretin-based arm who required anti-diabetic rescue therapy with insulin|absolute change in hba1c from baseline to end of core phase|absolute change in fpg from baseline to end of core phase|percentage of participants with ≤ 0.3% hba1c increase to end of core phase,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 4,249.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CSOM230B2219|2012-002916-16,"May 23, 2014","February 5, 2018","March 26, 2018","February 12, 2014","May 29, 2019","May 29, 2019","['diabetes and endocrine associates la mesa location, multiple locations, california, united states la biomedical research at harbor ucla medical center sc - som230b2219, torrance, california, united states coastal metabolic research centre sc, ventura, california, united states east coast institute for research east coast inst. for res(ecir), jacksonville, florida, united states washington university sc - som230b2411, saint louis, missouri, united states great falls clinic, great falls, montana, united states robert wood johnson medical school - rutgers sc, new brunswick, new jersey, united states the mount sinai hospital sc, new york, new york, united states columbia university medical center new york presbyterian neuroendocrine unit, new york, new york, united states lenox hill hospital/manhattan eye, ear and throat hospital sc, new york, new york, united states allegheny endocrinology associates sc, pittsburgh, pennsylvania, united states vanderbilt clinical trials center som230b2219, nashville, tennessee, united states baylor college of medicine ben taub general hosp., houston, texas, united states virginia endocrinology research sc-2, chesapeake, virginia, united states swedish medical center dept.ofseattle neuroscience(2), seattle, washington, united states novartis investigative site, leuven, belgium novartis investigative site, wilrijk, belgium novartis investigative site, rio de janeiro, rj, brazil novartis investigative site, porto alegre, rs, brazil novartis investigative site, joinville, sc, brazil novartis investigative site, são paulo, sp, brazil novartis investigative site, beijing, beijing, china novartis investigative site, guangzhou, guangdong, china novartis investigative site, chengdu, sichuan, china novartis investigative site, aalborg, denmark novartis investigative site, aarhus, denmark novartis investigative site, herlev, denmark novartis investigative site, odense c, denmark novartis investigative site, erlangen, germany novartis investigative site, freiburg, germany novartis investigative site, oldenburg, germany novartis investigative site, bangalore, karnataka, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, san isidro, lima, peru novartis investigative site, warszawa, poland novartis investigative site, wroclaw, poland novartis investigative site, saint petersburg, russian federation novartis investigative site, bangkok, thailand novartis investigative site, bangkok, thailand novartis investigative site, songkla, thailand novartis investigative site, altunizade, turkey novartis investigative site, ankara, turkey novartis investigative site, antalya, turkey']","""study protocol"", https://clinicaltrials.gov/provideddocs/83/nct02060383/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/83/nct02060383/sap_001.pdf",https://ClinicalTrials.gov/show/NCT02060383,
741,742,NCT00574873,compare bosutinib to imatinib in subjects with newly diagnosed chronic phase philadelphia chromosome positive cml,,Completed,Has Results,chronic myeloid leukemia,drug: bosutinib|drug: imatinib,percentage of participants with complete cytogenetic response (ccyr) at year 1|percentage of participants with major molecular response (mmr) at year 1|kaplan-meier estimate of probability of retaining ccyr at 192 weeks|kaplan-meier estimate of probability of retaining complete hematologic response (chr) at 192 weeks|kaplan-meier estimate of probability of retaining derived mmr at 144 weeks|cumulative incidence of on-treatment transformation to accelerated phase (ap) or blast phase (bp) at 192 weeks,pfizer|wyeth is now a wholly owned subsidiary of pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,502.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3160A4-3000|B1871008|2007-003780-50,"February 5, 2008","August 31, 2010","May 27, 2015","December 17, 2007","November 4, 2012","January 8, 2019","['pacific cancer medical center inc, anaheim, california, united states tower cancer research foundation (tcrf), beverly hills, california, united states robert a moss, md, facp, inc, fountain valley, california, united states ucsd medical center-thornton, la jolla, california, united states ucsd moores cancer center, la jolla, california, united states ucsd medical center-hillcrest, san diego, california, united states stanford hospital and clinics investigational drug services, stanford, california, united states stanford hospitals and clinics, stanford, california, united states stanford university medical center, stanford, california, united states cancer care centers of florida, hudson, florida, united states cancer care centers of florida, new port richey, florida, united states pasco pinellas cancer center, new port richey, florida, united states orlando health, inc., orlando, florida, united states pasco pinellas cancer center, tarpon springs, florida, united states northside hospital, inc. - gcs/annex, atlanta, georgia, united states indiana blood and marrow transplantation research franciscan st. francis health center inc., indianapolis, indiana, united states indiana blood and marrow transplantation research, indianapolis, indiana, united states siouxland hematology-oncology associates, llp, sioux city, iowa, united states cancer center of kansas, salinas, kansas, united states cancer center of kansas, wichita, kansas, united states kentucky cancer clinic, hazard, kentucky, united states center for cancer and blood disorders, bethesda, maryland, united states josephine ford cancer - downriver, brownstown, michigan, united states henry ford medical center- fairlane, dearborn, michigan, united states henry ford hospital, detroit, michigan, united states henry ford hospital - west bloomfield, detroit, michigan, united states regional cancer care associates, cherry hill, new jersey, united states study supplies: regional cancer care associates, cherry hill, new jersey, united states somerset hematology oncology associates, somerville, new jersey, united states san juan oncology associates, farmington, new mexico, united states associates in oncology and hematology, chattanooga, tennessee, united states the university of texas m.d. anderson cancer center, houston, texas, united states hospital italiano de la plata, la plata, buenos aires, argentina hospital privado de cordoba, cordoba, prov. de cordoba, argentina centro de investigaciones oncologicas, bahia blanca, provincia buenos aires, argentina instituto medico especializado alexander fleming, buenos aires, argentina cliniques universitaires saint luc, brussels, belgium c.h.r.st. - r. fabiola (n-d), charleroi, belgium university hospital gent - department of hematology, gent, belgium centre hospitalier de jolimont - lobbes, la louviere, belgium chu de charleroi - hopital civil marie curie, lodelinsart, belgium h.-hartziekenhuis roeselare-menen, roeselare, belgium centro de hematologia e hemoterapia da unicamp, campinas/ sp, brazil vancouver general hospital, vancouver, british columbia, canada university health network, princess margaret hospital, toronto, ontario, canada hopital maisonneuve rosemont, montreal, quebec, canada instituto oncologico del sur, temuco, chile instituto oncologico, vina del mar, chile ruiging hospital affiliated to shanghai jiaotong university school of medicine, shanghai, p.r. china, china peking union medical college hospital of chinese academy of medical sciences, beijing, china the chinese pla general hospital, beijing, china the hematology hospital of chinese academy of medical science, tianjin, china fundacion santa fe de bogota, bogota, cundinamarca, colombia fundacion cardiovascular de colombia, floridablanca, santander, colombia ciosad centro de investigaciones oncologicas, bogota, colombia institut bergonie, bordeaux, france chu caen - cote de nacre, caen, france centre hospitalier de versailles hopital andre mignot, le chesnay cedex, france hopital edouard herriot, lyon, france hopital hotel dieu, nantes, france hospital archet 1, nice cedex 3, france centre d\'investigation clinique- cic inserm802, poitiers, france chu de poitiers, poitiers, france clinique sainte anne, strasbourg, france hopitaux universitaires de strasbourg - hopital civil, strasbourg, france charite university medical center - campus virchow klinikum, berlin, germany universitätsklinikum carl gustav carus, dresden, germany univeristatsklinikum hamburg-eppendorf, hamburg, germany universitaetsklinikum leipzig zentrum fur innere medizin, leipzig, germany iii. medizinische klinik, universitaetsklinikum mannheim ggmbh, mannheim, germany iii. medizinischen klinik und poliklinik des klinikums rechts der isar der tu-munchen, muenchen, germany prince of wales hospital, shatin n.t., hong kong egyesitett szent istvan es szent laszlo korhaz-rendelointezet, budapest, hungary petz aladar megyei oktato korhaz, gyor, hungary kaposi mor oktato korhaz, belgyogyaszati osztaly, kaposvar, hungary josa andras hospital, nyiregyhaza, hungary tata memorial center, tata memorial hospital, mumbai, maharashtra, india advanced centre for treatment, research and education in cancer, mumbai, maharashtra, india jehangir clinical development centre,, pune, maharashtra, india birla cancer centre, jaipur, rajasthan, india searoc cancer center, soni manipal hospital, jaipur, rajasthan, india azienda ospedaliera san gerardo, monza, lombardia, italy azienda ospedaliera universitaria san luigi gonzaga, orbassano, torino, italy ospedale ferrarotto - divisione di ematologia, catania, italy dipartimento di ematologia ospedale santo eugenio, roma, italy toyohashi municipal hospital, toyohashi, aichi, japan akita university hospital, akita city, akita, japan national hospital organization kyushu cancer center, fukuoka-shi, fukuoka, japan kanazawa university hospital, kanazawa, ishikawa, japan tohoku univesity hospital, sendai, miyagi, japan kinki university school of medicine, osakasayama, osaka, japan jikei university hospital daisan, komae-shi, tokyo, japan japanese red cross nagoya first hospital, aichi, japan aichi cancer center hospital, aichi, japan chiba university hospital, chiba, japan tokai university hospital, kanagawa, japan nagasaki university hospital, nagasaki, japan niigata university medical and dental hospital, niigata, japan osaka university hospital, osaka, japan hamamatsu medical university hospital faculty of medicine, shizuoka, japan tokyo metropolitan cancer & infectious disease centre komagome hp, tokyo, japan the catholic university of korea, seoul st. mary\'s hospital/division of hematology, seoul, korea, republic of riga centre of haematology, riga, latvia hematology, oncology & transfusion medicine center, vilnius, lithuania centro medico de las americas, merida, mexico uniwersyteckie centrum kliniczne, gdansk, poland samodzielny publiczny szpital kliniczny im. a. mieleckiego slaskiego uniwersytetu medycznego, katowice, poland sp zoz szpital uniwersytecki w krakowie, krakow, poland wojewodzki szpital specjalistyczny im. m. kopernika, lodz, poland samodzielny publiczny szpital kliniczny nr 1 w lublinie, lublin, poland guz komi republican oncology center, syktyvkar, komi republic, russian federation regional state budgetary healthcare institution ""barnaul city hospital #8"", barnaul, russian federation sverdlovsk regional clinical hospital #1, ekaterinburg, russian federation central city hospital #7, ekaterinburg, russian federation kirov research institute of hematology and blood transfusion of, kirov, russian federation federal state budget institution hematology scientific center of minzdravsotsrazvitiya of russia, moscow, russian federation state novosibirsk regional clinical hospital, novosibirsk, russian federation perm territory state budgetary healthcare inst, perm, russian federation republican hospital na baranov, petrozavodsk, russian federation rostov regional clinical hospital, rostov-on-don, russian federation rostov state medical university of the minzdravsotsrazvitiya of russia, rostov-on-don, russian federation leningrad regional clinical hospital, saint petersburg, russian federation st-petersburg pavlov\'s state medical university, saint petersburg, russian federation st-petersburg state medical university, saint petersburg, russian federation samara regional clinical hospital m.i. kalinin, samara, russian federation st-petersburg pavlov\'s state medical university, st. petersburg, russian federation yaroslavl region state budgetary healthcare institution regional clinical hospital, yaroslavl, russian federation singapore general hospital, singapore, singapore university witwatersrand and oncology, johannesburg, south africa johannesburg hospital, department of medical oncology, parktown, south africa clinical haematology unit - department of medicine, soweto, south africa department of cardiology, chris hani baragwanath hospital, soweto, south africa department of radiology, chris hani baragwanath hospital, soweto, south africa hospital universitari clinic de barcelona, barcelona, spain hospital de la princesa, madrid, spain hospital universitario la paz, madrid, spain hospital de madrid norte-sanchinarro centro integral oncologico, madrid, spain complejo hospitalario de toledo- servicio de hematologia., toledo, spain hospital clinico universitario de valencia (chuv), valencia, spain changhua christian hospital, changhua city, taiwan national taiwan university hospital, taipei toc, taiwan division of hematology, department of medicine, bangkoknoi, bangkok, thailand hacettepe universitesi tip fakultesi, ankara, sihhiye, turkey ankara universitesi tip fakultesi cebeci hastanesi, ankara, turkey gaziantep universitesi tip fakultesi, gaziantep, turkey cherkaskiy oblasniy onkologichniy dispanser, cherkassy, ukraine clinical assocation of emergency care, dnipropetrovsk, ukraine clinical diagnostic laboratory of komunalnyj zaklad, dnipropetrovsk, ukraine komunalnyj zaklad ""dnipropetrovska miska bagatoprofilna klinichna likarnja #4"", dnipropetrovsk, ukraine instytut nevidkladnoi ta vidnovnoi hirurgii im. p.k. husaka namn ukrainy, viddilennja hematologii, donetsk, ukraine oleksandrovska clinical hospital cardiological rehabilitation department, kiev, ukraine miska klinichna likarnja # 9, kyev, ukraine institut klinichnoi radiologii du ""natsionalnyj naukovyj centr radiacijnoi medicini namn ukraini"", kyiv, ukraine institut klinichnoi radiologii naukovogo centru radiacijnoi medicini namn ukraini, kyiv, ukraine institut klinichnoi radiologii naukovogo, kyiv, ukraine ultrasaund educational and diagnostic center, lviv, ukraine instutut patologii krovi to transfuziynoi medicinu amn ukraini, lviv, ukraine polyclinic of 5th municipal hospital, lviv, ukraine 3rd floor centre for clinical haematology, nottingham, east midlands, united kingdom the park hospital, nottingham, east midlands, united kingdom hammersmith hospital clinical trial units, hammersmith, london, united kingdom good hope hospital, birmingham, west midlands, united kingdom birmingham heartlands hospital, birmingham, west midlands, united kingdom department of haematology - level 3, bexley wing, leeds, west yorkshire, united kingdom department of haematology, london, united kingdom hammersmith hospital, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT00574873,blood
742,743,NCT02038036,ruxolitinib efficacy and safety in patients with hu resistant or intolerant polycythemia vera vs best available therapy.,RESPONSE-2,Completed,Has Results,polycythemia vera,drug: best available therapy|drug: ruxolitinib,"number of participants achieving hematocrit (hct) control at week 28|number of participants achieving a complete hematological remission at week 28|number of participants achieving a hematocrit (hct) control at week 52 and week 80|number of participants achieving a complete hematological remission at week 52 and week 80|number of participants with phlebotomies over time|change from baseline in hematocrit (hct) at each visit|change from baseline in hematocrit (hct) at each scheduled visit after crossover in participants randomized to bat who cross over to ruxolitinib|spleen length by visit|change from baseline in eastern cooperative oncology group (ecog) performance status to week 28|number of participants achieving a partial remission based on the european leukemia net (eln) and international working group for myelofibrosis research and treatment (iwg-mrt) criteria at week 28|number of participants who achieved partial remission based on the european leukemia net (eln) and international working group for myelofibrosis research and treatment (iwg-mrt) criteria at week 52 and week 80|number of participants achieving a hematocrit (hct) control at week 104, week 156, week 208 and week 260.|number of participants achieving a complete hematological remission at week 104, week 156, week 208 and week 260|number of participants who achieved partial remission based on the european leukemia net (eln) and international working group for myelofibrosis research and treatment (iwg-mrt) criteria at week 104, week 156, week 208 and week 260.|number of participants with transformation free survival events|number of participants with overall survival (os) events|change from baseline in myeloproliferative neoplasm symptom assessment form total symptom score (mpn-saf tss)|change from baseline in total scores of mpn-saf by visit in patients from bat group who cross over to ruxolitinib after crossover|change from baseline in score as per european quality of life 5-dimension 5-level (eq-5d-5l) questionnaire|change from baseline in eq-5d-5l vas, by visit in patients from bat group who cross over to ruxolitinib after crossover|change from baseline in work productivity and activity impairment (wpai) questionnaire|change from baseline in work productivity and activity impairment questionnaire (wpai), by visit in patients from bat group who cross over to ruxolitinib after crossover|patient global impression of change (pgic)|summary of patient global impression of change (pgic), by visit in patients from bat group who cross over to ruxolitinib after crossover|number of participants developing thrombosis",novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,149.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CINC424B2401,"March 25, 2014","September 29, 2015","April 7, 2020","January 16, 2014","July 20, 2021","July 20, 2021","['novartis investigative site, herston, queensland, australia novartis investigative site, antwerpen, belgium novartis investigative site, leuven, belgium novartis investigative site, toronto, ontario, canada novartis investigative site, bayonne, bayonne cedex, france novartis investigative site, bordeaux, france novartis investigative site, brest, france novartis investigative site, lille cedex, france novartis investigative site, nice cedex, france novartis investigative site, paris, france novartis investigative site, toulouse, france novartis investigative site, mannheim, baden-wuerttemberg, germany novartis investigative site, augsburg, germany novartis investigative site, dresden, germany novartis investigative site, jena, germany novartis investigative site, leipzig, germany novartis investigative site, magdeburg, germany novartis investigative site, mainz, germany novartis investigative site, minden, germany novartis investigative site, ulm, germany novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, kaposvar, hungary novartis investigative site, mumbai, maharashtra, india novartis investigative site, vellore, tamil nadu, india novartis investigative site, nahariya, israel novartis investigative site, netanya, israel novartis investigative site, tel aviv, israel novartis investigative site, bologna, bo, italy novartis investigative site, firenze, fi, italy novartis investigative site, roma, lazio, italy novartis investigative site, milano, mi, italy novartis investigative site, pavia, pv, italy novartis investigative site, torino, to, italy novartis investigative site, varese, va, italy novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, malaga, andalucia, spain novartis investigative site, salamanca, castilla y leon, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, alicante, comunidad valenciana, spain novartis investigative site, la coruna, galicia, spain novartis investigative site, las palmas de gran canaria, las palmas de g.c, spain novartis investigative site, pamplona, navarra, spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, izmir, turkey novartis investigative site, talas / kayseri, turkey']",,https://ClinicalTrials.gov/show/NCT02038036,blood
743,744,NCT01232556,a study of inotuzumab ozogamicin plus rituximab for relapsed/refractory aggressive non-hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy,,Terminated,Has Results,"lymphoma, non-hodgkin",drug: inotuzumab ozogamicin|drug: rituximab|drug: rituximab + gemcitabine|drug: rituximab +bendamustine,"overall survival|percentage of participants with a treatment emergent adverse event (teae) (safety population)|progression-free survival (pfs)|percentage of participants with a best overall response of cr or partial response (pr) per nci international response criteria for nhl|percentage of participants with a best overall response of cr, unconfirmed cr (uncr), pr, or unconfirmed pr (unpr) per nci international response criteria for nhl|duration of response|health status as assessed by the european quality of life 5 dimension (eq-5d) questionnaire|health related quality of life as assessed by the functional assessment of cancer therapy for lymphoma (fact-lym) questionnaire",pfizer|ucb pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,338.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1931008|3129K5-3303|2010-020147-12,"April 4, 2011","March 28, 2014","March 28, 2014","November 2, 2010","August 21, 2018","January 8, 2019","['disney family cancer center at providence st joseph medical center, burbank, california, united states providence st joseph medical center, burbank, california, united states hematology-oncology medical group of fresno inc, fresno, california, united states ronald reagan ucla medical center drug information center department of pharmaceutical services, los angeles, california, united states clinical research unit, los angeles, california, united states peter morton medical plaza, los angeles, california, united states ronald reagan ucla medical center, los angeles, california, united states sansum clinic, santa barbara, california, united states ucla santa monica hematology oncology, santa monica, california, united states sansum clinic, solvang, california, united states howard university hospital, washington, district of columbia, united states mount sinai comprehensive cancer center at aventura, aventura, florida, united states university cancer institute, boynton beach, florida, united states 21st century oncology of jacksonville, llc, fernandina beach, florida, united states davis cancer pavilion and shands medical plaza, gainesville, florida, united states shands cancer hospital at the university of florida, gainesville, florida, united states uf health davis cancer pavillion and shands med plaza, gainesville, florida, united states uf health shands cancer hospital, gainesville, florida, united states shands hospital at the university of florida, gainesville, florida, united states uf health shands hospital, gainesville, florida, united states 21st century oncology of jacksonville, llc, jacksonville, florida, united states 21st century oncology of jacksonville, llc, jacksonville, florida, united states baptist cancer institute, jacksonville, florida, united states baptist medical center, jacksonville, florida, united states 21st century oncology of jacksonville, llc, jacksonville, florida, united states 21st century oncology of jacksonville, inc., jacksonville, florida, united states medical specialists of the palm beaches, lake worth, florida, united states mount sinai comprehensive cancer center, miami beach, florida, united states mount sinai medical center, miami beach, florida, united states advanced medical specialties, miami, florida, united states mercy hospital, miami, florida, united states mercy research institute, miami, florida, united states 21st century oncology of jacksonville, llc, orange park, florida, united states georgia regents medical cancer pharmacy, augusta, georgia, united states georgia regents university, augusta, georgia, united states kootenai cancer center, coeur d\'alene, idaho, united states kootenai cancer center, post falls, idaho, united states decatur memorial hospital (dmh), decatur, illinois, united states floyd memorial cancer center of indiana, new albany, indiana, united states university of kansas medical center, kansas city, kansas, united states university of kansas cancer center and medical pavilion, westwood, kansas, united states university of kentucky a.b. chandler medical center, lexington, kentucky, united states university of kentucky markey cancer center, lexington, kentucky, united states tulane university hospital and clinic, new orleans, louisiana, united states barbara ann karmanos cancer institute, detroit, michigan, united states barbara ann karmanos cancer institute at farmington hills, farmington hills, michigan, united states park nicollet frauenshuh cancer center, saint louis park, minnesota, united states barnes-jewish hospital, saint louis, missouri, united states washington university in st louis, saint louis, missouri, united states washington university school of medicine, saint louis, missouri, united states washington university, saint louis, missouri, united states barnes-jewish st. peters, saint peters, missouri, united states southeast nebraska hematology & oncology consultants, p.c. d/b/a southeast nebraska cancer center, lincoln, nebraska, united states beth israel medical center;, new york, new york, united states beth israel comprehensive cancer center, new york, new york, united states st luke\'s- roosevelt hospital center, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states stony brook university medical center, the cancer center, stony brook, new york, united states stony brook university medical center, stony brook, new york, united states university hospital, cincinnati, ohio, united states west chester hospital medical building, west chester, ohio, united states ou medical center presbyterian professional building, oklahoma city, oklahoma, united states ou medical center presbyterian tower, oklahoma city, oklahoma, united states peggy and charles stephenson cancer center (chemo & infusion), oklahoma city, oklahoma, united states peggy and charles stephenson cancer center (clinic location), oklahoma city, oklahoma, united states good samaritan hospital corvallis, corvallis, oregon, united states good samaritan hospital, corvallis, corvallis, oregon, united states samaritan ambulatory infusion services, corvallis, oregon, united states samaritan pacific coast hospital, newport, oregon, united states penn state milton s. hershey medical center, hershey, pennsylvania, united states guthrie clinic, ltd., sayre, pennsylvania, united states robert packer hospital, sayre, pennsylvania, united states thompson oncology group, knoxville, tennessee, united states thompson oncology group, knoxville, tennessee, united states thompson oncology group, maryville, tennessee, united states thompson oncology group, sevierville, tennessee, united states university hospital - st. paul, dallas, texas, united states university hospital - zale lipshy, dallas, texas, united states baylor university medical center, dallas, texas, united states baylor: charles a. sammons cancer center, dallas, texas, united states simmons comprehensive cancer center, dallas, texas, united states the university of texas md anderson cancer center, houston, texas, united states universitaire ziekenhuizen leuven, leuven, vlaams brabant, belgium institut jules bordet, bruxelles, belgium grand hopital de charleroi, charleroi, belgium h.-hartziekenhuis roeselare-menen, roeselare, belgium st augustinus ziekenhuis, wilrijk, belgium cliniques universitaires ucl de mont-godinne,, yvoir, belgium umbal sveti georgi, klinika po hematologia, plovdiv, bulgaria sbal na hematologichnichni zabolyavania,cth sofia, sofia, bulgaria spetsializirana bolnitsa za aktivno lechenie na hematologichni zabolyavania, cth sofia, sofia, bulgaria tom baker cancer centre, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada sunnybrook health sciences centre, toronto, ontario, canada centre hospitalier universitaire de sherbrooke (chus), hopital fleurimont, sherbrooke, quebec, canada university hospital zagreb, zagreb, croatia university hospital dubrava department of internal medicine division of hematology, zagreb, croatia fakultni nemocnice kralovske vinohrady, praha 10, czech republic, czechia fakultni nemocnice brno, brno, czechia département pharmacie, marseille, bouches-du-rhône, france institut paoli calmettes, marseille, cedex 09, france hospital universitaire andre mignot, le chesnay cedex, yvelines, france hopital andre mignot, le chesnay, yvelines, france centre leon berard, lyon, france chu saint eloi, montpellier, france hopital du haut leveque, pessac, france centre henri becquerel, rouen, france universitaetsklinikum aachen, aachen, germany sozialstiftung bamberg, bamberg, germany charite campus benjamin franklin, berlin, germany charite campus virchow-klinikum, berlin, germany universitaetsklinikum mainz, mainz, germany tu muenchen iii. medizinische klinik, muenchen, germany universitaetsklinik ulm, ulm, germany egyesitett szent istvan es szent laszlo korhaz /, budapest, hungary deoec, belgyogyaszati intezet, debrechen, hungary somongy megyei kaposi mor okato korhaz/ belgyogyaszati osztaly, kaposvar, hungary kodlikeri memorial hospital, aurangabad, maharashtra, india sahyadri clinical research and development center, pune, maharashtra, india oec record management company pvt. ltd.,, pune, maharashtra, india sahyadri speciality hospital, pune, maharashtra, india bon secours hospital, cork, ireland nagoya daini red cross hospital, nagoya, aichi, japan national cancer center hospital east, kashiwa, chiba, japan ehime university hospital, toon-shi, ehime, japan gunma university hospital, maebashi-city, gunma, japan tohoku university hospital, sendai, miyagi, japan matsushita memorial hospital, moriguchi, osaka, japan shizuoka cancer center, sunto-gun, shizuoka, japan national cancer center hospital, chuo-ku, tokyo, japan cancer institute hospital, japanese foundation for cancer research, koto-ku, tokyo, japan akita university hospital, akita, japan national kyushu cancer center, fukuoka, japan tokai university hospital, kanagawa, japan university hospital, kyoto prefectural university of medicine, kyoto, japan klaipeda seamen\'s hospital, public institution, department of oncology, klaipeda, lithuania instituto biomédico de investigación a.c., aguascalientes, aguascalientes. mexico, mexico niepubliczny zaklad opieki zdrowotnej avi diagnostyka obrazowa, warszawa, poland klinika nowotworow ukladu chlonnego, warszawa, poland advanced infusion services, catano, puerto rico hospital espanol auxilio mutuo de puerto rico inc, san juan, puerto rico federal state budgetary institution hematology scientific centre of ministry of, moscow, russian federation moscow state healthcare institution city clinical hospital s.p. botkin, moscow, russian federation institute of pediatric hematology and transplantology r.m.gorbacheva, saint-petersburg, russian federation national university hospital, singapore, singapore singapore general hospital, singapore, singapore narodny onkologicky ustav, bratislava, slovakia hospital virgen del rocio, sevilla, andalucia, spain hospital universitario de salamanca, salamanca, castille and lion, spain hospital clinic de barcelona, barcelona, spain hospital clinic universitari de barcelona, barcelona, spain institut catala d\'oncologia-l\'hospitalet, l\'hospitalet de llobregat (bcn), spain hospital universitario de canarias, la laguna (tenerife), spain hospital de la princesa, madrid, spain universitetssjukhuset, linkoping, sweden skanes universitetssjukhus i lund, lund, sweden chang gung medical foundation - linkou branch, kuei-shan hsiang, taoyuan county, taiwan taichung veterans general hospital, taichung, taiwan national taiwan university hospital, department of internal medicine, taipei, taiwan taipei veterans general hospital, taipei, taiwan hematology division department of medicine faculty of medicine siriraj hospital mahidol university, bangkoknoi, bangkok, thailand chiang mai university, chiang mai, thailand regional treatment and diagnostic hematology center communal establishment, cherkasy, ukraine department of oncology and medical radiology of state institution, dnipropetrovsk, ukraine si""research center for radiation medicine of nams of ukraine"", kyiv, ukraine barts cancer centre dept haemato-oncology st. bartholomew\'s hospital barts health nhs trust, london, united kingdom chemotherapy preparative unit st. bartholomew\'s hospital, london, united kingdom department of medical oncology st. bartholomew\'s hospital, london, united kingdom the christie nhs foundation trust - christie hospital, manchester, united kingdom department of clinical pathology newcastle upon tyne hospitals nhs foundation trust royal victoria i, newcastle upon tyne, united kingdom department of clinical biochemistry newcastle upon tyne hospitals, newcastle upon tyne, united kingdom northern centre for cancer care, newcastle upon tyne, united kingdom nottingham university hospital, nottingham, united kingdom pathology department nottingham university hospital - city hospital campus, nottingham, united kingdom pharmacy nottingham university hospital - city hospital campus, nottingham, united kingdom local laboratory nottingham university hospital - city hospital campus, nottingham, united kingdom new cross hospital, wolverhampton, united kingdom']",,https://ClinicalTrials.gov/show/NCT01232556,lymphoma
744,745,NCT01039376,ofatumumab maintenance treatment vs no further treatment in relapsed cll responding to induction therapy,PROLONG,Terminated,Has Results,"leukaemia, lymphocytic, chronic",biological: ofatumumab|other: observation,"progression-free survival, as assessed by the investigator|progression-free survival, as assessed by the independent review committee (irc)|overall survival|number of participants with improvement in response from baseline|time to next therapy|progression-free survival after next-line therapy|time to progression after next-line therapy|change from baseline (bl) in the european organization for research and treatment of cancer quality of life questionnaire, chronic lymphocytic leukaemia 16 item module (eortc qlq-cll 16)|change from baseline in the european organization for the research and treatment of cancer quality of life questionnaire core 30 (eortc qlq-c30) score|change from baseline in the quality of life status as assessed by the euroqol-5d (eq-5d) scale|number of participants with an improvement in eastern cooperative oncology group (ecog) performance status at the indicated time points|number of participants with the indicated constitutional or b-symptoms at the indicated time points|number of participants with grade 3 and above adverse event of infection|number of participants with any adverse event (ae) or serious adverse event (sae)|number of participants with a grade 3 or grade 4 myelosuppression (anemia, neutropenia, or thrombocytopenia) at indicated time points|number of participants who received at least one transfusion during the study|number of participants diagnosed with autoimmune hemolytic anemia (aiha)|number of participants with a positive anti-ofatumumab antibody (human anti-human antibody; haha) result|mean change from baseline in the immunoglobulin (ig) antibodies iga, igg, and igm at indicated time points|number of participants who were positive and negative for minimal residual disease (mrd) at any visit|change from baseline in cluster of differentiation (cd) cd5+cd19+ and cd5-cd19+ cell counts at the indicated time points|summary of covariates to compute cox proportional hazards regression model for relationship between investigator assessed progression-free survival and the indicated prognostic markers|cmax and ctrough of ofatumumab|total plasma clearance (cl) of ofatumumab|auc(0-tau) of ofatumumab|vss of ofatumumab|plasma half-life (t1/2) of ofatumumab",novartis pharmaceuticals|novartis,All,"Child, Adult, Older Adult",Phase 3,480.0,Industry,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,112517|COMB157C2301,"May 6, 2010","February 20, 2017","June 26, 2018","December 25, 2009","April 21, 2015","July 30, 2019","[""novartis investigative site, gilbert, arizona, united states novartis investigative site, tucson, arizona, united states novartis investigative site, tucson, arizona, united states novartis investigative site, jonesboro, arkansas, united states novartis investigative site, berkeley, california, united states novartis investigative site, la verne, california, united states novartis investigative site, sacramento, california, united states novartis investigative site, sacramento, california, united states novartis investigative site, san pablo, california, united states novartis investigative site, hartford, connecticut, united states novartis investigative site, gainesville, florida, united states novartis investigative site, lake worth, florida, united states novartis investigative site, orlando, florida, united states novartis investigative site, pembroke pines, florida, united states novartis investigative site, west palm beach, florida, united states novartis investigative site, macon, georgia, united states novartis investigative site, savannah, georgia, united states novartis investigative site, post falls, idaho, united states novartis investigative site, indianapolis, indiana, united states novartis investigative site, iowa city, iowa, united states novartis investigative site, westwood, kansas, united states novartis investigative site, metairie, louisiana, united states novartis investigative site, cumberland, maryland, united states novartis investigative site, hagerstown, maryland, united states novartis investigative site, worcester, massachusetts, united states novartis investigative site, detroit, michigan, united states novartis investigative site, saint louis, missouri, united states novartis investigative site, springfield, missouri, united states novartis investigative site, henderson, nevada, united states novartis investigative site, new brunswick, new jersey, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, albuquerque, new mexico, united states novartis investigative site, mineola, new york, united states novartis investigative site, rochester, new york, united states novartis investigative site, chapel hill, north carolina, united states novartis investigative site, durham, north carolina, united states novartis investigative site, philadelphia, pennsylvania, united states novartis investigative site, greenville, south carolina, united states novartis investigative site, chattanooga, tennessee, united states novartis investigative site, knoxville, tennessee, united states novartis investigative site, memphis, tennessee, united states novartis investigative site, orem, utah, united states novartis investigative site, salt lake city, utah, united states novartis investigative site, capital federal, buenos aires, argentina novartis investigative site, ciudad autonoma de buenos aires, buenos aires, argentina novartis investigative site, derqui, pilar, buenos aires, argentina novartis investigative site, la plata, buenos aires, argentina novartis investigative site, rosario, santa fe, argentina novartis investigative site, ciudad autonoma de buenos aires, argentina novartis investigative site, darlinghurst, new south wales, australia novartis investigative site, randwick, new south wales, australia novartis investigative site, clayton, victoria, australia novartis investigative site, east melbourne, victoria, australia novartis investigative site, parkville, victoria, australia novartis investigative site, antwerpen, belgium novartis investigative site, antwerpen, belgium novartis investigative site, brugge, belgium novartis investigative site, brussels, belgium novartis investigative site, gent, belgium novartis investigative site, hasselt, belgium novartis investigative site, roeselare, belgium novartis investigative site, wilrijk, belgium novartis investigative site, salvador, bahía, brazil novartis investigative site, goiania - go, goiás, brazil novartis investigative site, porto alegre, rio grande do sul, brazil novartis investigative site, barretos, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, sao paulo, são paulo, brazil novartis investigative site, calgary, alberta, canada novartis investigative site, kitchener, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, montreal, quebec, canada novartis investigative site, montreal, quebec, canada novartis investigative site, sherbrooke, quebec, canada novartis investigative site, saskatoon, saskatchewan, canada novartis investigative site, brno, czechia novartis investigative site, hradec kralove, czechia novartis investigative site, olomouc, czechia novartis investigative site, pelhrimov, czechia novartis investigative site, praha 10, czechia novartis investigative site, herlev, denmark novartis investigative site, kobenhavn, denmark novartis investigative site, roskilde, denmark novartis investigative site, helsinki, finland novartis investigative site, jyvaskyla, finland novartis investigative site, pori, finland novartis investigative site, tampere, finland novartis investigative site, turku, finland novartis investigative site, blois cedex, france novartis investigative site, caen cedex 5, france novartis investigative site, clermont-ferrand cedex 1, france novartis investigative site, dijon, france novartis investigative site, lille cedex, france novartis investigative site, marseille cedex 9, france novartis investigative site, mulhouse, france novartis investigative site, pessac cedex, france novartis investigative site, saint pierre cedex, france novartis investigative site, strasbourg cedex, france novartis investigative site, toulouse cedex 9, france novartis investigative site, vandoeuvre-les-nancy, france novartis investigative site, athens,, greece novartis investigative site, athens, greece novartis investigative site, piraeus, greece novartis investigative site, thessaloniki, greece novartis investigative site, thessaloniki, greece novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, kecskemet, hungary novartis investigative site, szeged, hungary novartis investigative site, ahmedabad, india novartis investigative site, mumbai, india novartis investigative site, mumbai, india novartis investigative site, pune, india novartis investigative site, afula, israel novartis investigative site, haifa, israel novartis investigative site, haifa, israel novartis investigative site, jerusalem, israel novartis investigative site, jerusalem, israel novartis investigative site, kfar saba, israel novartis investigative site, nahariya, israel novartis investigative site, petach-tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, rehovot, israel novartis investigative site, tel-aviv, israel novartis investigative site, zrifin, israel novartis investigative site, modena, emilia-romagna, italy novartis investigative site, piacenza, emilia-romagna, italy novartis investigative site, roma, lazio, italy novartis investigative site, novara, piemonte, italy novartis investigative site, torino, piemonte, italy novartis investigative site, pisa, toscana, italy novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, amersfoort, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, amsterdam, netherlands novartis investigative site, blaricum, netherlands novartis investigative site, breda, netherlands novartis investigative site, den bosch, netherlands novartis investigative site, den haag, netherlands novartis investigative site, deventer, netherlands novartis investigative site, dordrecht, netherlands novartis investigative site, enschede, netherlands novartis investigative site, groningen, netherlands novartis investigative site, hoofddorp, netherlands novartis investigative site, leiden, netherlands novartis investigative site, maastricht, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, rotterdam, netherlands novartis investigative site, sittard-geleen, netherlands novartis investigative site, tilburg, netherlands novartis investigative site, oslo, norway novartis investigative site, bialystok, poland novartis investigative site, chorzow, poland novartis investigative site, slupsk, poland novartis investigative site, szczecin, poland novartis investigative site, warszawa, poland novartis investigative site, warszawa, poland novartis investigative site, warszawa, poland novartis investigative site, wroclaw, poland novartis investigative site, wroclaw, poland novartis investigative site, san juan, puerto rico novartis investigative site, kazan, russian federation novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, novosibirsk, russian federation novartis investigative site, penza, russian federation novartis investigative site, st'petersburg, russian federation novartis investigative site, st'petersburg, russian federation novartis investigative site, st. petersburg, russian federation novartis investigative site, volgograd, russian federation novartis investigative site, hospitalet de llobregat (barcelona), spain novartis investigative site, madrid, spain novartis investigative site, madrid, spain novartis investigative site, salamanca, spain novartis investigative site, sevilla, spain novartis investigative site, toledo, spain novartis investigative site, zaragoza, spain novartis investigative site, goteborg, sweden novartis investigative site, linkoping, sweden novartis investigative site, lulea, sweden novartis investigative site, orebro, sweden novartis investigative site, stockholm, sweden novartis investigative site, uppsala, sweden novartis investigative site, ankara, turkey novartis investigative site, ankara, turkey novartis investigative site, istanbul, turkey novartis investigative site, izmir, turkey novartis investigative site, izmir, turkey novartis investigative site, cherkasy, ukraine novartis investigative site, dnipropetrovsk, ukraine novartis investigative site, kharkiv, ukraine novartis investigative site, khmelnytskyi, ukraine novartis investigative site, kyiv, ukraine novartis investigative site, lviv, ukraine novartis investigative site, makiivka, ukraine novartis investigative site, vinnitsa, ukraine novartis investigative site, zhytomyr, ukraine""]","""study protocol"", https://clinicaltrials.gov/provideddocs/76/nct01039376/prot_000.pdf|""statistical analysis plan"", https://clinicaltrials.gov/provideddocs/76/nct01039376/sap_002.pdf",https://ClinicalTrials.gov/show/NCT01039376,
745,746,NCT01602952,philadelphia chromosome positive cml patients without optimal response or tolerance to bcr-abl tki,,Completed,No Results Available,"leukemia|leukemia, myeloid|leukemia, myelogenous, chronic, bcr-abl positive|philadelphia chromosome|hematologic diseases",drug: radotinib,to investigate the maximum tolerated dose(phase 1)|rate of complete hematologic response(chr)(phase 2)|to investigate the dose limiting toxicity(phase 1)|rate of complete cytogenetic response(ccyr)(phase 2)|adverse events(phase 1& phase 2)|progression-free survival or pfs,"il-yang pharm. co., ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,85.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IY5511A1201,July 2008,October 2012,"July 13, 2018","May 21, 2012",,"August 29, 2018","[""local institution, mumbai, maharashtra, india local institution, mumbai, mazagaon, india local institution, daegu, buk-gu, korea, republic of local institution, jeonju, deokjin-gu, korea, republic of local institution, ulsan, dong-gu, korea, republic of local institution, anyang-si, dongan-gu, korea, republic of local institution, hwasun, hwasun-eup, korea, republic of local institution, seoul, jongro-ku, korea, republic of local institution, busan, seo-gu, korea, republic of seoul st. mary's hospital, seoul, seocho-gu, korea, republic of local institution, suwon, yeongtong-gu, korea, republic of local institution, bangkok, phyathai, thailand""]",,https://ClinicalTrials.gov/show/NCT01602952,blood
746,747,NCT02829775,a study of continued treatment among participants who have responded to peginterferon alfa-2a (pegasys®) or recombinant interferon alfa-2a (roferon-a®) in prior clinical studies,,Completed,Has Results,chronic myelogenous leukemia|malignant melanoma|renal cell carcinoma,drug: pegylated interferon alfa-2a|drug: recombinant interferon alfa 2a,number of participants with serious adverse events (saes)|number of participants with overall tumor response,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,9.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NO17754|2004-002093-30,January 2004,January 2008,January 2008,"July 12, 2016","November 17, 2016","January 9, 2017","['sofia, bulgaria halifax, nova scotia, canada lucknow, india moscow, russian federation moscow, russian federation kosice, slovakia durban, south africa valencia, spain']",,https://ClinicalTrials.gov/show/NCT02829775,skin blood
747,748,NCT03180268,observation or radiation therapy in treating patients with newly diagnosed grade ii meningioma that has been completely removed by surgery,,Recruiting,No Results Available,grade ii meningioma|intracranial meningioma,other: clinical observation|radiation: radiation therapy,progression-free survival (pfs)|overall survival (os)|5 year overall survival (os)|disease-specific survival (dss)|3 year disease-specific survival (dss)|5 year disease-specific survival (dss)|3 year progression-free survival (pfs)|5 year progression-free survival (pfs)|neurocognitive function (ncf)|patient reported outcomes (pro) as assessed by mdasi-bt|assessment of phh3 mitotic index|incidence of adverse events as measured by the national cancer institute common terminology criteria for adverse events (ctcae) version 4 (exclusive of alopecia),nrg oncology|national cancer institute (nci),All,"18 Years and older   (Adult, Older Adult)",Phase 3,148.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NRG-BN003|NCI-2016-01619|U10CA180868,"June 14, 2017","June 15, 2027","August 31, 2027","June 8, 2017",,"January 18, 2022","[""university of alabama at birmingham cancer center, birmingham, alabama, united states saint joseph's hospital and medical center, phoenix, arizona, united states mayo clinic hospital in arizona, phoenix, arizona, united states mayo clinic in arizona, scottsdale, arizona, united states university of arizona cancer center-orange grove campus, tucson, arizona, united states banner university medical center - tucson, tucson, arizona, united states university of arizona cancer center-north campus, tucson, arizona, united states kaiser permanente-anaheim, anaheim, california, united states sutter cancer centers radiation oncology services-auburn, auburn, california, united states kaiser permanente dublin, dublin, california, united states kaiser permanente los angeles medical center, los angeles, california, united states los angeles county-usc medical center, los angeles, california, united states usc / norris comprehensive cancer center, los angeles, california, united states memorial medical center, modesto, california, united states kaiser permanente oakland-broadway, oakland, california, united states uc irvine health/chao family comprehensive cancer center, orange, california, united states stanford cancer institute palo alto, palo alto, california, united states kaiser permanente-rancho cordova cancer center, rancho cordova, california, united states rohnert park cancer center, rohnert park, california, united states sutter cancer centers radiation oncology services-roseville, roseville, california, united states the permanente medical group-roseville radiation oncology, roseville, california, united states sutter medical center sacramento, sacramento, california, united states south sacramento cancer center, sacramento, california, united states kaiser permanente medical center - santa clara, santa clara, california, united states kaiser permanente cancer treatment center, south san francisco, california, united states sutter solano medical center/cancer center, vallejo, california, united states hartford hospital, hartford, connecticut, united states yale university, new haven, connecticut, united states helen f graham cancer center, newark, delaware, united states christiana care health system-christiana hospital, newark, delaware, united states beebe health campus, rehoboth beach, delaware, united states tidalhealth nanticoke / allen cancer center, seaford, delaware, united states boca raton regional hospital, boca raton, florida, united states um sylvester comprehensive cancer center at coral gables, coral gables, florida, united states um sylvester comprehensive cancer center at deerfield beach, deerfield beach, florida, united states baptist md anderson cancer center, jacksonville, florida, united states university of miami miller school of medicine-sylvester cancer center, miami, florida, united states miami cancer institute, miami, florida, united states adventhealth orlando, orlando, florida, united states adventhealth east orlando, orlando, florida, united states moffitt cancer center, tampa, florida, united states grady health system, atlanta, georgia, united states emory proton therapy center, atlanta, georgia, united states piedmont hospital, atlanta, georgia, united states emory university hospital/winship cancer institute, atlanta, georgia, united states emory saint joseph's hospital, atlanta, georgia, united states northside hospital, atlanta, georgia, united states northside hospital-forsyth, cumming, georgia, united states piedmont fayette hospital, fayetteville, georgia, united states piedmont newnan hospital, newnan, georgia, united states piedmont henry hospital, stockbridge, georgia, united states queen's medical center, honolulu, hawaii, united states the cancer center of hawaii-liliha, honolulu, hawaii, united states northwestern university, chicago, illinois, united states rush university medical center, chicago, illinois, united states university of illinois, chicago, illinois, united states decatur memorial hospital, decatur, illinois, united states northshore university healthsystem-evanston hospital, evanston, illinois, united states northwestern medicine cancer center delnor, geneva, illinois, united states northshore university healthsystem-glenbrook hospital, glenview, illinois, united states northshore university healthsystem-highland park hospital, highland park, illinois, united states loyola university medical center, maywood, illinois, united states northwestern medicine cancer center warrenville, warrenville, illinois, united states indiana university/melvin and bren simon cancer center, indianapolis, indiana, united states iu health methodist hospital, indianapolis, indiana, united states iowa methodist medical center, des moines, iowa, united states university of iowa/holden comprehensive cancer center, iowa city, iowa, united states university of kansas cancer center, kansas city, kansas, united states university of kansas cancer center-overland park, overland park, kansas, united states university of kentucky/markey cancer center, lexington, kentucky, united states mainehealth coastal cancer treatment center, bath, maine, united states maine medical center-bramhall campus, portland, maine, united states mainehealth cancer care center of york county, sanford, maine, united states maine medical center- scarborough campus, scarborough, maine, united states maryland proton treatment center, baltimore, maryland, united states university of maryland/greenebaum cancer center, baltimore, maryland, united states tufts medical center, boston, massachusetts, united states saint joseph mercy hospital, ann arbor, michigan, united states university of michigan comprehensive cancer center, ann arbor, michigan, united states saint joseph mercy chelsea, chelsea, michigan, united states henry ford macomb hospital-clinton township, clinton township, michigan, united states henry ford hospital, detroit, michigan, united states ascension saint john hospital, detroit, michigan, united states saint mary mercy hospital, livonia, michigan, united states ascension saint mary's hospital, saginaw, michigan, united states saint john macomb-oakland hospital, warren, michigan, united states henry ford west bloomfield hospital, west bloomfield, michigan, united states essentia health cancer center, duluth, minnesota, united states miller-dwan hospital, duluth, minnesota, united states mayo clinic in rochester, rochester, minnesota, united states park nicollet clinic - saint louis park, saint louis park, minnesota, united states regions hospital, saint paul, minnesota, united states university of mississippi medical center, jackson, mississippi, united states university of missouri - ellis fischel, columbia, missouri, united states siteman cancer center at west county hospital, creve coeur, missouri, united states washington university school of medicine, saint louis, missouri, united states siteman cancer center-south county, saint louis, missouri, united states siteman cancer center at saint peters hospital, saint peters, missouri, united states benefis healthcare- sletten cancer institute, great falls, montana, united states kalispell regional medical center, kalispell, montana, united states university of nebraska medical center, omaha, nebraska, united states dartmouth hitchcock medical center, lebanon, new hampshire, united states memorial sloan kettering basking ridge, basking ridge, new jersey, united states memorial sloan kettering monmouth, middletown, new jersey, united states memorial sloan kettering bergen, montvale, new jersey, united states rutgers cancer institute of new jersey, new brunswick, new jersey, united states rutgers new jersey medical school, newark, new jersey, united states capital health medical center-hopewell, pennington, new jersey, united states procure proton therapy center-somerset, somerset, new jersey, united states robert wood johnson university hospital somerset, somerville, new jersey, united states university of new mexico cancer center, albuquerque, new mexico, united states new york-presbyterian/brooklyn methodist hospital, brooklyn, new york, united states memorial sloan kettering commack, commack, new york, united states the new york hospital medical center of queens, flushing, new york, united states memorial sloan kettering westchester, harrison, new york, united states nyp/columbia university medical center/herbert irving comprehensive cancer center, new york, new york, united states memorial sloan kettering cancer center, new york, new york, united states nyp/weill cornell medical center, new york, new york, united states university of rochester, rochester, new york, united states memorial sloan kettering nassau, uniondale, new york, united states unc lineberger comprehensive cancer center, chapel hill, north carolina, united states case western reserve university, cleveland, ohio, united states cleveland clinic foundation, cleveland, ohio, united states ohio state university comprehensive cancer center, columbus, ohio, united states mercy cancer center-elyria, elyria, ohio, united states uh seidman cancer center at lake health mentor campus, mentor, ohio, united states promedica flower hospital, sylvania, ohio, united states uhhs-westlake medical center, westlake, ohio, united states university of oklahoma health sciences center, oklahoma city, oklahoma, united states legacy mount hood medical center, gresham, oregon, united states legacy good samaritan hospital and medical center, portland, oregon, united states saint luke's university hospital-bethlehem campus, bethlehem, pennsylvania, united states christiana care health system-concord health center, chadds ford, pennsylvania, united states geisinger medical center, danville, pennsylvania, united states geisinger medical oncology-lewisburg, lewisburg, pennsylvania, united states lewistown hospital, lewistown, pennsylvania, united states thomas jefferson university hospital, philadelphia, pennsylvania, united states fox chase cancer center, philadelphia, pennsylvania, united states temple university hospital, philadelphia, pennsylvania, united states geisinger cancer services-pottsville, pottsville, pennsylvania, united states geisinger wyoming valley/henry cancer center, wilkes-barre, pennsylvania, united states lankenau medical center, wynnewood, pennsylvania, united states prisma health cancer institute - spartanburg, boiling springs, south carolina, united states medical university of south carolina, charleston, south carolina, united states prisma health cancer institute - faris, greenville, south carolina, united states prisma health cancer institute - eastside, greenville, south carolina, united states prisma health cancer institute - greer, greer, south carolina, united states prisma health cancer institute - seneca, seneca, south carolina, united states vanderbilt university/ingram cancer center, nashville, tennessee, united states ut southwestern/simmons cancer center-dallas, dallas, texas, united states m d anderson cancer center, houston, texas, united states university of texas health science center at san antonio, san antonio, texas, united states american fork hospital / huntsman intermountain cancer center, american fork, utah, united states intermountain medical center, murray, utah, united states utah valley regional medical center, provo, utah, united states riverton hospital, riverton, utah, united states lds hospital, salt lake city, utah, united states norris cotton cancer center-north, saint johnsbury, vermont, united states virginia commonwealth university/massey cancer center, richmond, virginia, united states university of washington medical center - montlake, seattle, washington, united states legacy salmon creek hospital, vancouver, washington, united states marshfield medical center-ec cancer center, eau claire, wisconsin, united states university of wisconsin hospital and clinics, madison, wisconsin, united states marshfield medical center-marshfield, marshfield, wisconsin, united states froedtert menomonee falls hospital, menomonee falls, wisconsin, united states medical college of wisconsin, milwaukee, wisconsin, united states marshfield clinic-minocqua center, minocqua, wisconsin, united states marshfield clinic stevens point center, stevens point, wisconsin, united states diagnostic and treatment center, weston, wisconsin, united states tom baker cancer centre, calgary, alberta, canada cross cancer institute, edmonton, alberta, canada juravinski cancer centre at hamilton health sciences, hamilton, ontario, canada london regional cancer program, london, ontario, canada university health network-princess margaret hospital, toronto, ontario, canada chum - centre hospitalier de l'universite de montreal, montreal, quebec, canada the research institute of the mcgill university health centre (muhc), montreal, quebec, canada allan blair cancer centre, regina, saskatchewan, canada tata memorial hospital, mumbai, india hokkaido university hospital, sapporo, hokkaido, japan iwate medical university hospital, shiwa-gun, iwate, japan keio university, shinjuku-ku, tokyo, japan hiroshima university hospital, hiroshima city, japan saitama medical university international medical center, saitama, japan national cancer center hospital, tokyo, japan king faisal specialist hospital and research centre, riyadh, saudi arabia""]",,https://ClinicalTrials.gov/show/NCT03180268,brain
748,749,NCT02654340,biomarkers for tuberous sclerosis complex (biotusccom),TuScCom,"Active, not recruiting",No Results Available,hypomelanotic macules|facial angiofibroma|shagreen patches|ungual fibromas|cortical dysplasia|cardiac rhabdomyoma|lymphangioleiomyomatosis|renal angiomyolipoma|subependymal giant cell astrocytoma,,"identification of tsc biomarker/s|exploring the clinical robustness, specificity, and longterm variability of tsc biomarker/s",centogene gmbh rostock,All,"2 Years to 50 Years   (Child, Adult)",,1000.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,TSC 08-2018,"August 1, 2018","December 30, 2023","December 30, 2023","January 13, 2016",,"March 24, 2022","['university hospital center mother teresa, tirana, albania department of pediatrics, alexandria university children\'s hospital, alexandria, egypt departmnet of molecular and medical genetics, tbilisi state medical university, tbilisi, georgia department of pediatric genetics, amrita institute of medical sciences & research centre, cochin, kerala, india rare diseases coordinating centre, vilnius university hospital santaros klinikos, vilnius, lithuania departmnet of pediatric gastroenterology and hepatology, the children\'s hospital and institute of child health, lahore, pakistan emergency hospital for children ""louis turcanu"", timişoara, romania lady ridgeway hospital for children, colombo, sri lanka']",,https://ClinicalTrials.gov/show/NCT02654340,astrocyt brain
749,750,NCT01933945,"outcomes of hcc (hepatocellular carcinoma) patients treated with tace (transarterial chemoembolization) and early, not early or not at all followed by sorafenib",OPTIMIS,Completed,No Results Available,"carcinoma, hepatocellular","procedure: tace (transarterial chemoembolization)|drug: sorafenib (nexavar, bay43-9006)",overall survival (os)|overall survival from initial tace|progression-free survival (pfs) from initial tace|time to progression (ttp) from initial tace|tumor response according to mrecist criteria|duration of tace treatment|number of patients with teaes (treatment emergent adverse events)|tace unsuitability|time to tace non-eligibility|deterioration of liver dysfunction|os from initiation of sorafenib|pfs from initiation of sorafenib|tumor status at different visits response according to mrecist|duration of sorafenib treatment|ttp from initiation of sorafenib,bayer,All,"Child, Adult, Older Adult",,1676.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,16560|NX1301,"October 28, 2013","July 22, 2017","November 10, 2017","September 2, 2013",,"November 6, 2018","['multiple locations, austria multiple locations, brazil multiple locations, canada multiple locations, china multiple locations, czechia multiple locations, denmark multiple locations, egypt multiple locations, france multiple locations, greece multiple locations, hong kong multiple locations, hungary multiple locations, india multiple locations, indonesia multiple locations, israel multiple locations, japan multiple locations, kazakhstan multiple locations, korea, republic of multiple locations, mexico multiple locations, netherlands multiple locations, pakistan multiple locations, poland multiple locations, russian federation multiple locations, singapore multiple locations, slovakia multiple locations, spain multiple locations, sweden multiple locations, switzerland multiple locations, taiwan multiple locations, thailand multiple locations, turkey multiple locations, vietnam']",,https://ClinicalTrials.gov/show/NCT01933945,liver
750,751,NCT00812175,global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib,GIDEON,Completed,No Results Available,"carcinoma, hepatocellular","drug: sorafenib (nexavar, bay43-9006)","the safety of nexavar in all patients with unresectable hcc who are candidates for systemic therapy and in whom a decision to treat with nexavar has been made under real-life practice conditions|efficacy [overall survival (os), progression-free survival (pfs), time to progression (ttp), response rate (rr), stable disease(sd) rate] by the response evaluation criteria in solid tumor (recist) criteria of nexavar|the duration of therapy with nexavar in a variety of settings according to patient characteristics and other variables|to evaluate the methods of patient evaluation, diagnosis and follow up|to evaluate the co-morbidities in patients with unresectable hcc and their influence on treatment and outcome|to evaluate the practice patterns of the physicians involved in the care of patients with hcc under real-life conditions|reports of adverse events",bayer,All,"18 Years and older   (Adult, Older Adult)",,3371.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,13414|NX0802,January 2009,April 2012,April 2012,"December 22, 2008",,"October 17, 2016","['many locations, alabama, united states many locations, arizona, united states many locations, arkansas, united states many locations, california, united states many locations, colorado, united states many locations, connecticut, united states many locations, florida, united states many locations, georgia, united states many locations, hawaii, united states many locations, illinois, united states many locations, indiana, united states many locations, iowa, united states many locations, kansas, united states many locations, kentucky, united states many locations, louisiana, united states many locations, maryland, united states many locations, massachusetts, united states many locations, michigan, united states many locations, minnesota, united states many locations, missouri, united states many locations, nebraska, united states many locations, nevada, united states many locations, new hampshire, united states many locations, new jersey, united states many locations, new york, united states many locations, north carolina, united states many locations, ohio, united states many locations, oklahoma, united states many locations, oregon, united states many locations, pennsylvania, united states many locations, south carolina, united states many locations, tennessee, united states many locations, texas, united states many locations, utah, united states many locations, virginia, united states many locations, washington, united states many locations, wisconsin, united states many locations, canada many locations, china many locations, colombia many locations, croatia many locations, czech republic many locations, finland many locations, france many locations, greece many locations, hong kong many locations, hungary many locations, india many locations, indonesia many locations, israel many locations, italy many locations, japan many locations, kazakhstan many locations, korea, republic of many locations, libyan arab jamahiriya many locations, malaysia many locations, mexico many locations, norway many locations, pakistan many locations, philippines many locations, portugal many locations, qatar many locations, romania many locations, russian federation many locations, singapore many locations, slovakia many locations, spain many locations, sweden many locations, syrian arab republic many locations, thailand many locations, ukraine many locations, united arab emirates many locations, uruguay many locations, venezuela many locations, vietnam']",,https://ClinicalTrials.gov/show/NCT00812175,liver
751,752,NCT00335738,"vincristine, carboplatin, and etoposide or observation only in treating patients who have undergone surgery for newly diagnosed retinoblastoma",,Completed,Has Results,intraocular retinoblastoma,drug: liposomal vincristine sulfate|drug: carboplatin|drug: etoposide,event-free survival (efs)|overall survival (os)|toxicity as assessed by the national cancer institute common terminology criteria for adverse events version 4.0|pathological features present at diagnosis - posterior uveal invasion (pvi)|pathological features present at diagnosis - tumor involving the optic nerve posterior to the lamina cribrosa (lc) as an independent finding|pathological features present at diagnosis - scleral invasion (si)|pathological features present at diagnosis - anterior chamber seeding (acs)|pathological features present at diagnosis - iris infiltration (ii)|pathological features present at diagnosis - ciliary body infiltration (cbi),children's oncology group|national cancer institute (nci),All,up to 6 Years   (Child),Phase 3,331.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARET0332|NCI-2009-00423|CDR0000483043|U10CA098543|COG-ARET0332,December 2005,September 2011,"September 30, 2020","June 12, 2006","April 17, 2018","February 18, 2021","[""university of alabama at birmingham, birmingham, alabama, united states university of arizona health sciences center, tucson, arizona, united states children's oncology group, arcadia, california, united states southern california permanente medical group, downey, california, united states children's hospital los angeles, los angeles, california, united states rady children's hospital - san diego, san diego, california, united states university of california san francisco medical center-parnassus, san francisco, california, united states children's hospital colorado, aurora, colorado, united states children's national medical center, washington, district of columbia, united states lombardi comprehensive cancer center at georgetown university, washington, district of columbia, united states university of miami miller school of medicine-sylvester cancer center, miami, florida, united states university of illinois, chicago, illinois, united states childrens memorial hospital, chicago, illinois, united states university of iowa hospitals and clinics, iowa city, iowa, united states university of kentucky, lexington, kentucky, united states kosair children's hospital, louisville, kentucky, united states maine children's cancer program, scarborough, maine, united states johns hopkins university, baltimore, maryland, united states massachusetts general hospital cancer center, boston, massachusetts, united states dana-farber cancer institute, boston, massachusetts, united states wayne state university, detroit, michigan, united states university of minnesota medical center-fairview, minneapolis, minnesota, united states mayo clinic, rochester, minnesota, united states the childrens mercy hospital, kansas city, missouri, united states washington university school of medicine, saint louis, missouri, united states children's hospital and medical center of omaha, omaha, nebraska, united states university of new mexico cancer center, albuquerque, new mexico, united states brooklyn hospital center, brooklyn, new york, united states carolinas medical center, charlotte, north carolina, united states duke university medical center, durham, north carolina, united states cincinnati children's hospital medical center, cincinnati, ohio, united states rainbow babies and childrens hospital, cleveland, ohio, united states cleveland clinic foundation, cleveland, ohio, united states nationwide children's hospital, columbus, ohio, united states the children's medical center of dayton, dayton, ohio, united states lehigh valley hospital - muhlenberg, bethlehem, pennsylvania, united states children's hospital of philadelphia, philadelphia, pennsylvania, united states vanderbilt-ingram cancer center, nashville, tennessee, united states cook children's medical center, fort worth, texas, united states baylor college of medicine, houston, texas, united states m d anderson cancer center, houston, texas, united states covenant children's hospital, lubbock, texas, united states university of texas health science center at san antonio, san antonio, texas, united states scott and white memorial hospital, temple, texas, united states primary children's medical center, salt lake city, utah, united states childrens hospital-king's daughters, norfolk, virginia, united states marshfield clinic, marshfield, wisconsin, united states midwest children's cancer center, milwaukee, wisconsin, united states royal brisbane and women's hospital, herston, queensland, australia royal children's hospital, parkville, victoria, australia princess margaret hospital for children, perth, western australia, australia cancercare manitoba, winnipeg, manitoba, canada hospital sainte-justine, montreal, quebec, canada l v prasad eye institute, hyderabad, india starship children's hospital, grafton, auckland, new zealand christchurch hospital, christchurch, new zealand""]",,https://ClinicalTrials.gov/show/NCT00335738,
752,753,NCT01450449,short course vs. standard course radiotherapy in elderly and/or frail patients with glioblastoma multiforme,,Completed,No Results Available,glioblastoma multiforme,radiation: radiotherapy,overall survival|progression-free survival|quality of life,international atomic energy agency|fundación escuela de medicina nuclear|n.n. alexandrov national cancer centre of belarus|hospital a.c. camargo|irmandade santa casa de misericórdia de porto alegre|instituto de radiomedicina (iram)|postgraduate institute of medical education and research|dr cipto mangunkusumo general hospital|maria sklodowska-curie national research institute of oncology|chiang mai university|salah azaïz cancer institute|wilson roa professional corporation|cancer trials ireland|ege university|high technology medical center,All,"50 Years and older   (Adult, Older Adult)",Phase 3,115.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E33033,February 2009,December 2013,November 2014,"October 12, 2011",,"March 24, 2015","['fundacion escuela de medicina nuclear, mendoza, argentina n.n. alexandrov national cancer centre of belarus, minsk, belarus irmandade de santa casa de misericordia de porto alegre, porto alegre, brazil hospital ""a.c. camargo"", fundacao ""antonio prudente"", sao paulo, brazil wilson roa professional corporation, edmonton, canada instituto de radiomedicina (iram), santiago, chile regionaalhailga, tallinn, estonia high technology medical center, university clinic, tbilisi, georgia postgraduate institute of medical education and research (pgimer), chandigarh, india cipto magunkusumo general hospital, university of indonesia, jakarta, indonesia icorg the all ireland cooperative oncology, dublin, ireland marie curie- sklodowska institute of oncology, warsaw, poland division of therapeutic radiology and oncology, faculty of medicine, chiang mai university, chiang mai, thailand institut national de cancer salah aziz, ministere de la sante publique, tunis, tunisia ege university hospital, izmir, turkey']",,https://ClinicalTrials.gov/show/NCT01450449,astrocyt
753,754,NCT02386800,cinc424a2x01b rollover protocol,,Recruiting,No Results Available,primary myelofibrosis|chronic idiopathic myelofibrosis|post polycythemia vera myelofibrosis|post essential thrombocythaemia myelofibrosis|steroid refractory graft versus host disease,"drug: ruxolitinib tablets or oral pediatric formulation, panobinostat capsules|drug: ruxolitinib tablets or oral pediatric formulation",number of participants with adverse events as a measure of safety and tolerability|to evaluate clinical benefit as assessed by the investigator,novartis pharmaceuticals|novartis,All,"1 Month and older   (Child, Adult, Older Adult)",Phase 4,356.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CINC424A2X01B|2014-003527-22,"March 5, 2015","September 16, 2027","September 16, 2027","March 12, 2015",,"March 31, 2022","['novartis investigative site, darlinghurst, new south wales, australia novartis investigative site, st leonards, new south wales, australia novartis investigative site, herston, queensland, australia novartis investigative site, wooloongabba, queensland, australia novartis investigative site, bedford park, south australia, australia novartis investigative site, box hill, victoria, australia novartis investigative site, clayton, victoria, australia novartis investigative site, franston, victoria, australia novartis investigative site, perth, western australia, australia novartis investigative site, antwerpen, belgium novartis investigative site, brugge, belgium novartis investigative site, leuven, belgium novartis investigative site, liege, belgium novartis investigative site, pleven, bulgaria novartis investigative site, plovdiv, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, sofia, bulgaria novartis investigative site, santiago, rm, chile novartis investigative site, vina del mar, valparaiso, chile novartis investigative site, santiago, chile novartis investigative site, beijing, beijing, china novartis investigative site, hangzhou, zhejiang, china novartis investigative site, copenhagen, denmark novartis investigative site, paris cedex 10, france novartis investigative site, aachen, germany novartis investigative site, dresden, germany novartis investigative site, dresden, germany novartis investigative site, hamburg, germany novartis investigative site, magdeburg, germany novartis investigative site, mainz, germany novartis investigative site, ulm, germany novartis investigative site, goudi-athens, gr, greece novartis investigative site, patras, greece novartis investigative site, budapest, hungary novartis investigative site, debrecen, hungary novartis investigative site, kaposvar, hungary novartis investigative site, kecskemet, hungary novartis investigative site, szeged, hungary novartis investigative site, szombathely, hungary novartis investigative site, pune, maharashtra, india novartis investigative site, afula, israel novartis investigative site, jerusalem, israel novartis investigative site, bari, ba, italy novartis investigative site, bologna, bo, italy novartis investigative site, brescia, bs, italy novartis investigative site, san giovanni rotondo, fg, italy novartis investigative site, firenze, fi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, milano, mi, italy novartis investigative site, rozzano, mi, italy novartis investigative site, palermo, pa, italy novartis investigative site, palermo, pa, italy novartis investigative site, pavia, pv, italy novartis investigative site, reggio calabria, rc, italy novartis investigative site, roma, rm, italy novartis investigative site, roma, rm, italy novartis investigative site, orbassano, to, italy novartis investigative site, varese, va, italy novartis investigative site, napoli, italy novartis investigative site, nagoya, aichi, japan novartis investigative site, fukuoka city, fukuoka, japan novartis investigative site, isehara, kanagawa, japan novartis investigative site, suita city, osaka, japan novartis investigative site, bunkyo ku, tokyo, japan novartis investigative site, osaka, japan novartis investigative site, seoul, seocho gu, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, beirut, lebanon novartis investigative site, monterrey, nuevo leon, mexico novartis investigative site, gliwice, slaskie, poland novartis investigative site, wroclaw, poland novartis investigative site, lisboa, portugal novartis investigative site, lisboa, portugal novartis investigative site, moscow, russian federation novartis investigative site, moscow, russian federation novartis investigative site, petrozavodsk, russian federation novartis investigative site, sain petersburg, russian federation novartis investigative site, bratislava, slovakia novartis investigative site, soweto, gauteng, south africa novartis investigative site, cape town, western province, south africa novartis investigative site, pretoria, south africa novartis investigative site, pretoria, south africa novartis investigative site, salamanca, castilla y leon, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, pamplona, navarra, spain novartis investigative site, huddinge, sweden novartis investigative site, lulea, sweden novartis investigative site, lund, sweden novartis investigative site, uddevalla, sweden novartis investigative site, bangkok, bangkoknoi, thailand novartis investigative site, bangkok, thailand novartis investigative site, ankara, sihhiye, turkey novartis investigative site, istanbul, turkey novartis investigative site, izmir, turkey novartis investigative site, talas / kayseri, turkey']",,https://ClinicalTrials.gov/show/NCT02386800,blood
754,755,NCT00068952,study of iv edotecarin vs temozolomide or carmustine (bcnu) or lomustine (ccnu) in patients with glioblastoma multiforme,,Completed,No Results Available,glioblastoma,drug: edotecarin|drug: temozolomide|drug: carmustine (bcnu)|drug: lomustine (ccnu),to compare the overall survival associated with edotecarin versus that associated with temozolomide or bcnu or ccnu for the treatment of patients with gbm at first relapse previously treated with alkylator-based (neo)adjuvant therapy|to assess measures of tumor control to evaluate measures of clinical benefit to assess the safety profile of edotecarin to assess the pk profile of edotecarin and the potential for drug interactions between anticonvulsants and edotecarin,pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,118.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EDOAGL-8725-001|A5921009,August 2003,,March 2006,"September 16, 2003",,"April 1, 2008","['pfizer investigational site, phoenix, arizona, united states pfizer investigational site, little rock, arkansas, united states pfizer investigational site, new haven, connecticut, united states pfizer investigational site, orlando, florida, united states pfizer investigational site, atlanta, georgia, united states pfizer investigational site, chicago, illinois, united states pfizer investigational site, evanston, illinois, united states pfizer investigational site, edgewood, kentucky, united states pfizer investigational site, edgweood, kentucky, united states pfizer investigational site, lexington, kentucky, united states pfizer investigational site, boston, massachusetts, united states pfizer investigational site, lebanon, new hampshire, united states pfizer investigational site, edison, new jersey, united states pfizer investigational site, summit, new jersey, united states pfizer investigational site, cincinnati, ohio, united states pfizer investigational site, philadelphia, pennsylvania, united states pfizer investigational site, pittsburgh, pennsylvania, united states pfizer investigational site, dallas, texas, united states pfizer investigational site, charlottesville, virginia, united states pfizer investigational site, st. leonards, new south wales, australia pfizer investigational site, east bentleigh, victoria, australia pfizer investigational site, clayton, australia pfizer investigational site, graz, austria pfizer investigational site, wien, austria pfizer investigational site, calgary, alberta, canada pfizer investigational site, vancouver, british columbia, canada pfizer investigational site, winnipeg, manitoba, canada pfizer investigational site, moncton, new brunswick, canada pfizer investigational site, halifax, nova scotia, canada pfizer investigational site, hamilton, ontario, canada pfizer investigational site, ottawa, ontario, canada pfizer investigational site, toronto, ontario, canada pfizer investigational site, split, croatia pfizer investigational site, zagreb, croatia pfizer investigational site, hradec kralove, czech republic pfizer investigational site, praha 5, czech republic pfizer investigational site, lyon, france pfizer investigational site, nantes st. herblain, france pfizer investigational site, berlin, germany pfizer investigational site, mainz, germany pfizer investigational site, regensburg, germany pfizer investigational site, tuebingen, germany pfizer investigational site, bangalore, india pfizer investigational site, bologna, italy pfizer investigational site, padova, italy pfizer investigational site, moscow, russian federation pfizer investigational site, cape town, south africa pfizer investigational site, pretoria, south africa pfizer investigational site, badalona, spain pfizer investigational site, hospitalet de llobregat, spain pfizer investigational site, oviedo, spain pfizer investigational site']",,https://ClinicalTrials.gov/show/NCT00068952,astrocyt
755,756,NCT02562443,controlled study of rigosertib versus physician's choice of treatment in mds patients after failure of an hma,INSPIRE,"Active, not recruiting",No Results Available,myelodysplastic syndrome|mds|refractory anemia with excess blasts|raeb,drug: rigosertib|drug: any approved or standard-of-care therapy|drug: best supportive care (bsc),"overall survival of all randomized patients and overall survival of patients scored as ipss-r very high risk.|overall survival of patients with monosomy 7 chromosomal aberrations.|overall survival of patients with trisomy 8 chromosomal aberrations.|percent of patients with response according to 2006 iwg criteria.|scores of quality of life questionnaire.|percent of patients with bone marrow blast response rate according to 2006 iwg criteria.|percent of patients with hematologic improvement (hi) (erythroid, platelet and neutrophil responses) according to 2006 iwg criteria.","onconova therapeutics, inc.",All,"18 Years to 81 Years   (Adult, Older Adult)",Phase 3,360.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Onconova 04-30|2015-001476-22,"December 2, 2015","October 17, 2020","December 31, 2021","September 29, 2015",,"June 14, 2021","['uc san diego moores cancer center, la jolla, california, united states usc norris comprehensive cancer center, los angeles, california, united states ucla medical center, los angeles, california, united states cancer specialists of north florida, fleming island, florida, united states uf health shands cancer hospital, gainesville, florida, united states mid florida hematology and oncology centers, orange city, florida, united states advanced research institute, inc, saint petersburg, florida, united states rush university medical center, chicago, illinois, united states university of illinois cancer center, chicago, illinois, united states loyola university chicago at loyola university medical center, maywood, illinois, united states indiana university health hospital, indianapolis, indiana, united states the university of kansas cancer center, westwood, kansas, united states tulane medical center, new orleans, louisiana, united states university of maryland greenebaum cancer center, baltimore, maryland, united states tufts medical center, boston, massachusetts, united states university of minnesota physicians bone marrow transplant clinic, minneapolis, minnesota, united states mayo clinic, rochester, minnesota, united states john theurer cancer center at hackensack university medical center, hackensack, new jersey, united states rutgers cancer institute of new jersey, new brunswick, new jersey, united states the valley hospital, ridgewood, new jersey, united states mount sinai school of medicine, new york, new york, united states columbia university medical center, new york, new york, united states new york medical college, valhalla, new york, united states hospital of the university of pennsylvania, philadelphia, pennsylvania, united states albert einstein medical center, cancer center, philadelphia, pennsylvania, united states greenville health system (ghs) cancer institute, greenville, south carolina, united states ut southwestern medical center, dallas, texas, united states md anderson cancer center, houston, texas, united states emily couric clinical cancer center, charlottesville, virginia, united states seattle cancer care alliance (scca), seattle, washington, united states university of wisconsin clinical science center, madison, wisconsin, united states marshfield clinic - marshfield center, marshfield, wisconsin, united states icon cancer care icon south brisbane, south brisbane, queensland, australia royal hobart hospital, hobart, tasmania, australia monash health, monash medical centre, melbourne, victoria, australia hospital of the elisabethinen linz gmbh, linz, austria salzburg university hospital, salzburg, austria hanusch hospital, vienna, austria antwerp hospital network stuivenberg, antwerp, belgium university hospital ghent, ghent, belgium university hospital leuven, campus gasthuisberg, leuven, belgium chu ucl namur - site godinne, yvoir, belgium cancercare manitoba, winnipeg, manitoba, canada sunnybrook research institute, toronto, ontario, canada princess margaret cancer centre, toronto, ontario, canada jewish general hospital, montreal, quebec, canada klinički bolnički centar osijek, osijek, croatia clinical hospital merkur, zagreb, croatia klinički bolnicki centar sestre milosrdnice, zagreb, croatia klinički bolnički centar zagreb, zagreb, croatia university hospital brno, brno, czechia university hospital hradec kralove, hradec kralove, czechia university hospital ostrava, department of hematooncology, ostrava poruba, czechia general university hospital, prague 2, czechia institute of hematology and blood transfusion, prague 2, czechia north estonia medical centre, tallinn, estonia tartu university hospital, tartu, estonia chd vendée, la roche sur yon cedex 9, france hôpital claude huriez, chru lille, lille cedex, france institut paoli-calmettes, marseille, france hôpital l\'archet 1, nice cedex 3, france institut de cancérologie du gard, nimes cedex 9, france hôpital saint louis, paris cedex 10, france centre hospitalier lyon-sud, pierre-bénite, france hôpital civil, strasbourg, strasbourg cedex, france chru tours hôspital bretonneau, tours, france universitätsklinikum carl gustav carus, dresden, germany marien hospital düsseldorf, düsseldorf, germany universitätsklinikum frankfurt am main, frankfurt, germany semmelweis university medical school, budapest, hungary somogy county kaposi mór teaching hospital, kaposvár, hungary jósa andrás teaching hospital, nyíregyháza, hungary university of pécs 1st department of internal medicine, pécs, hungary hemato oncology clinic pvt. ltd, ahmedabad, gujarat, india st. john\'s medical college hospital, bangalore, karnataka, india tata memorial hospital, mumbai, maharashtra, india jaslok hospital and research center, mumbai, maharashtra, india sahyadri clinical research and development center, pune, maharashtra, india christian medical college, vellore, tamil nadu, india institute of hematology and transfusion medicine, kolkata, west bengal, india cork university hospital, cork, ireland adelaide and meath hospital, incorporating the national children\'s hospital, dublin, ireland university hospital waterford, waterford, ireland ha\'emek medical center, \'afula, israel soroka university medical center, beer sheva, israel rambam medical center, haifa, israel hadassah medical center, jerusalem, israel kaplan medical center, rehovot, israel sourasky medical center, tel aviv, israel the chaim sheba medical center, tel hashomer, israel polyclinic s. orsola-malpighi, bologna, italy azienda ospedaliera spedali civili, brescia, italy azienda ospedaliero universitaria careggi, firenze, italy azienda ospedaliero-universitaria maggiore della carità, novara, italy a.o.u. pisana, divisione di ematologia - university hospital of pisa, pisa, italy policlinico universitario tor vergata, roma, italy ospedale s. eugenio - s. eugenio hospital, roma, italy azienda ospedaliera santa maria di terni, terni, italy cittá della salute e della scienza di torino, torino, italy kokura memorial hospital, kitakyushu, fukuoka, japan chugoku central hospital of the mutual aid association of public school teachers, fukuyama, hiroshima, japan sapporo medical university hospital, sapporo, hokkaido, japan kanazawa university hospital, kanazawa, ishikawa, japan yokohama city university hospital, yokohama-shi, kanagawa, japan shimane university hospital, izumo, shimane, japan japanese red cross medical center, shibuya, tokyo, japan akita university hospital, akita, japan tokyo metropolitan cancer and infectious diseases center komagome hospital, bunkyo-ku, japan national hospital organization kyushu cancer center, fukuoka-shi, japan kagoshima university hospital, kagoshima, japan tokai central hospital of the mutual aid association of public school teachers, kakamigahara, japan saitama medical center, kawagoe, japan kobe city hospital organization kobe city medical center general hospital, kobe, japan national hospital organization kumamoto medical center, kumamoto, japan japanese red cross kyoto daini hospital, kyoto, japan nagasaki university hospital, nagasaki, japan japanese red cross nagoya daini hospital, nagoya-shi, japan niigata university medical and dental hospital, niigata, japan oita prefectural hospital, oita, japan national hospital organization okayama medical center, okayama, japan kindai university hospital, osakasayama-shi, japan hokkaido university hospital, sapporo-shi, japan tohoku university hospital, sendai-shi, japan ntt medical center tokyo, shinagawa-ku, japan tokyo medical university hospital, shinjuku-ku, japan dokkyo medical university hospital, tochigi, japan tokushima university hospital, tokushima, japan yamagata university hospital, yamagata, japan saiseikai yokohamashi nanbu hospital, yokohama-shi, japan university of fukui hospital, yoshida, japan independent public healthcare facility university hospital in cracow, clinical department of hematology, kraków, poland independent public health care facility of the ministry of internal affairs with warmia and mazury oncology centre in olsztyn, olsztyn, poland ludwik rydygier provinicial hospital in suwalki, department of clinical oncology and hematology, suwalki, poland mtz clinical research sp. z o.o., warsaw, poland independent public university hospital no. 1 in wroclaw, department of hematology, blood cancers and bone marrow, wroclaw, poland state autonomous healthcare institution of kemerovo region ""kemerovo regional clinical hospital n.a. s.v. belyaev"",, kemerovo, russian federation state budgetary healthcare institution of moscow city, moscow, russian federation fsbi ""russian scientific research hematology and tranfusiology institute of the federal biomedical agency"", saint petersburg, russian federation hospital son llàtzer, palma de mallorca, balearic islands, spain hospital duran i reynals - instituto catalán de oncología, hospitalet de llobregat, barcelona, spain hospital universitario vall d\'hebron, barcelona, spain hospital universitari germans trias i pujol, barcelona, spain hospital universitario gregorio marañón, madrid, spain fundación jiménez díaz, madrid, spain hospital universitario virgen de la victoria, málaga, spain hospital universitario salamanca, salamanca, spain hospital universitari i politècnic la fe, valencia, spain karolinska university hospital, stockholm, huddinge, sweden skåne university hospital, department of hematology, lund, sweden uppsala university hospital, uppsala, sweden linköping university hospital, linköping, östergötland, sweden university hospital and university of bern; inselspital bern, bern, switzerland university hospital zurich, zurich, switzerland royal bournemouth hospital, bournemouth, dorset, united kingdom aberdeen royal infirmary, aberdeen, scotland, united kingdom the royal liverpool university hospital, liverpool, united kingdom st bartholomew\'s hospital, barts health nhs trust, london, united kingdom king\'s college hospital nhs foundation trust, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT02562443,
756,757,NCT01024036,a study to evaluate the efficacy and safety of cnto328 plus best supportive care in multicentric castleman's disease,,Completed,Has Results,multicentric castleman's disease,drug: siltuximab|drug: placebo|drug: best supportive care (bsc),percentage of participants who achieved durable tumor and symptomatic response - by independent radiology review|median duration of tumor and symptomatic response - by independent radiology review|percentage of participants who achieved complete response (cr) + partial response (pr) (tumor response rate) - by independent radiology review|median duration of tumor response - by independent radiology review|time to treatment failure|percentage of participants who achieved greater than or equal to (>=) 15 gram per liter (g/l) hemoglobin at week 13 (hemoglobin response rate)|percentage of participants who achieved >= 20 g/l hemoglobin at week 13 (hemoglobin response rate)|percentage of participants who discontinued corticosteroids|6-year survival rate|median time required to achieve >=1 point decrease in the multicentric castleman's disease symptom scale (mcd-ss) score from baseline|median time required to achieve >=3-point increase in functional assessment of chronic illness therapy-fatigue (facit-f) scores from baseline|median time required to achieve >=5-point increase in the short-form-36 (sf-36) physical component summary (pcs) scores from baseline,"janssen research & development, llc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,79.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR016705|CNTO328MCD2001|2009-012380-34,"March 18, 2010","March 25, 2013","February 24, 2017","December 2, 2009","August 20, 2014","March 21, 2018","['little rock, arkansas, united states los angeles, california, united states tampa, florida, united states boston, massachusetts, united states lansing, michigan, united states rochester, minnesota, united states chapel hill, north carolina, united states greenville, south carolina, united states houston, texas, united states salt lake city, utah, united states seattle, washington, united states east melbourne, australia brussels, belgium leuven, belgium brasilia, brazil porto alegre, brazil rio de janeiro, brazil sao paulo, brazil toronto, canada beijing, china chengdu, china guangzhou, china hangzhou, china shanghai, china cairo, egypt clermont ferrand, france grenoble cedex 1, france lille cedex, france montpellier, france paris, france rennes, france tours cedex 9, france vandoeuvre les nancy, france berlin, germany mainz, germany münchen, germany sha tin, hong kong budapest, hungary hyderabad n/a, india pune, india petach tikva, israel ramat gan, israel seoul, korea, republic of pandan, malaysia rotterdam, netherlands auckland, new zealand oslo, norway kazan, russian federation moscow, russian federation saint-petersburg, russian federation st.-petersburg, russian federation singapore, singapore barcelona, spain madrid, spain taipei, taiwan london, united kingdom manchester, united kingdom']",,https://ClinicalTrials.gov/show/NCT01024036,
757,758,NCT04971226,a study of oral asciminib versus other tkis in adult patients with newly diagnosed ph+ cml-cp,,Recruiting,No Results Available,chronic myeloid leukemia (cml) philadelphia chromosome positive,drug: imatinib|drug: nilotinib|drug: bosutinib|drug: dasatinib|drug: asciminib,major molecular response (mmr) at week 48|major molecular response at week 96|time to discontinuation of study treatment due to adverse events (ttdae)|major molecular response at scheduled data collection time points|major molecular response by scheduled data collection time points|mr4.0 at scheduled data collection time points|mr4.5 at all scheduled data collection time points|mr4.0 by scheduled data collection time points|mr4.5 by all scheduled data collection time points|complete hematological response (chr) at all scheduled data collection time points|complete hematological response (chr) by all scheduled data collection time points|complete cytogenic response (ccyr) at week 48 & week 96|complete cytogenic response (ccyr) by week 48 & week 96|duration of mmr|duration of mr4.0|duration of mr4.5|time to first mmr|time to first mr4.0|time to first mr4.5|time to treatment failure (ttf)|failure free survival (ffs)|event free survival (efs)|progression free survival (pfs)|overall survival (os)|trough plasma concentrations.|pharmacokinetics (pk) of asciminib: cmax|pk of asciminib: tmax|pk of asciminib: auctau and auclast|pk of asciminib: cl/f|change from baseline in overall scores and individual scales of the eortc qlq-c30|change from baseline in overall scores and individual scales of the eortc qlq-cml24,novartis pharmaceuticals|novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,402.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CABL001J12301|2021-000678-27,"October 6, 2021","September 27, 2024","November 24, 2028","July 21, 2021",,"May 11, 2022","['rocky mountain cancer centers, denver, colorado, united states florida cancer specialists dept of oncology (2), fort myers, florida, united states florida cancer specialists, fort myers, florida, united states florida cancer specialists panhandle, tallahassee, florida, united states florida cancer specialists, west palm beach, florida, united states illinois cancer care p.c. il cancer specialists, peoria, illinois, united states university of kentucky, lexington, kentucky, united states oncology hematology care inc, cincinnati, ohio, united states williamette cancer center, eugene, oregon, united states avera cancer avera cancer institute, sioux falls, south dakota, united states chattanooga oncology and hematology associates pc tennessee oncology chattanooga, chattanooga, tennessee, united states texas oncology texas onc - amarillo, dallas, texas, united states texas oncology-baylor uso, dallas, texas, united states texas oncology p a austin, dallas, texas, united states us oncology p a, tyler, texas, united states virginia cancer specialists, gainesville, virginia, united states virginia oncology associates, norfolk, virginia, united states novartis investigative site, kingswood, new south wales, australia novartis investigative site, port macquarie, new south wales, australia novartis investigative site, woolloongabba, queensland, australia novartis investigative site, linz, upper austria, austria novartis investigative site, wien, austria novartis investigative site, leuven, belgium novartis investigative site, hamilton, ontario, canada novartis investigative site, ottawa, ontario, canada novartis investigative site, toronto, ontario, canada novartis investigative site, guangzhou, guangdong, china novartis investigative site, shenzhen, guangdong, china novartis investigative site, wuhan, hubei, china novartis investigative site, nantong, jiangsu, china novartis investigative site, chengdu, sichuan, china novartis investigative site, tianjin, tianjin, china novartis investigative site, brno bohunice, czech republic, czechia novartis investigative site, ostrava poruba, czech republic, czechia novartis investigative site, hradec kralove, cze, czechia novartis investigative site, aarhus, denmark novartis investigative site, helsinki, finland novartis investigative site, bordeaux, france novartis investigative site, lyon cedex, france novartis investigative site, nantes cedex 1, france novartis investigative site, paris cedex 10, france novartis investigative site, mannheim, baden-wuerttemberg, germany novartis investigative site, aachen, germany novartis investigative site, berlin, germany novartis investigative site, frankfurt, germany novartis investigative site, jena, germany novartis investigative site, luebeck, germany novartis investigative site, debrecen, hungary novartis investigative site, kaposvar, hungary novartis investigative site, kecskemet, hungary novartis investigative site, delhi, india novartis investigative site, petah tikva, israel novartis investigative site, ramat gan, israel novartis investigative site, tel aviv, israel novartis investigative site, bologna, bo, italy novartis investigative site, verona, vr, italy novartis investigative site, toyoake city, aichi, japan novartis investigative site, fukushima city, fukushima, japan novartis investigative site, suita city, osaka, japan novartis investigative site, sunto gun, shizuoka, japan novartis investigative site, shimotsuke, tochigi, japan novartis investigative site, akita, japan novartis investigative site, yamagata, japan novartis investigative site, uijeongbu si, gyeonggi do, korea, republic of novartis investigative site, seoul, seocho gu, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, seoul, korea, republic of novartis investigative site, kuantan, pahang, malaysia novartis investigative site, subang jaya, selangor, malaysia novartis investigative site, pulau pinang, malaysia novartis investigative site, selangor, malaysia novartis investigative site, bergen, norway novartis investigative site, oslo, norway novartis investigative site, trondheim, norway novartis investigative site, moscow, russian federation novartis investigative site, saint petersburg, russian federation novartis investigative site, singapore, singapore novartis investigative site, singapore, singapore novartis investigative site, bratislava, slovak republic, slovakia novartis investigative site, kosice, slovak republic, slovakia novartis investigative site, granada, andalucia, spain novartis investigative site, barcelona, catalunya, spain novartis investigative site, el palmar, murcia, spain novartis investigative site, pamplona, navarra, spain novartis investigative site, madrid, spain novartis investigative site, goteborg, sweden novartis investigative site, stockholm, sweden novartis investigative site, bellinzona, switzerland novartis investigative site, taichung, taiwan novartis investigative site, london, united kingdom']",,https://ClinicalTrials.gov/show/NCT04971226,blood
758,759,NCT04182204,"a study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin compared to rituximab, gemcitabine and oxaliplatin alone in participants with relapsed or refractory diffuse large b-cell lymphoma",POLARGO,Recruiting,No Results Available,diffuse large b-cell lymphoma,drug: polatuzumab vedotin|drug: rituximab|drug: gemcitabine|drug: oxaliplatin,stage 1: percentage of participants with adverse events (aes)|stage 2: overall survival (os)|stage 1: percentage of participants with peripheral neuropathy|stage 1: percentage of participants with polatuzumab vedotin dose interruptions and dose reductions|stage 1: polatuzumab vedotin dose intensity|stage 1: percentage of participants with anti-drug antibodies (adas) to polatuzumab vedotin at baseline|stage 1: percentage of participants with anti-drug antibodies (adas) to polatuzumab vedotin post-baseline|stage 1: percentage of participants with complete response (cr)|stage 1: percentage of participants with objective response (or)|stage 1: best overall response (bor)|stage 1: progression free survival (pfs)|stage 1: overall survival (os)|stage 1: event free survival (efs)|stage 2: percentage of participants with objective response (or)|stage 2: percentage of participants with complete response (cr)|stage 2: best overall response (bor)|stage 2: progression free survival (pfs)|stage 2: duration of response (dor)|stage 2: event free survival (efs)|stage 2: change from baseline in european organisation for research and treatment of cancer (eortc) quality-of-life questionnaire core 30 (qlq-c30) score|stage 2: time to deterioration in physical functioning and fatigue|stage 2: change from baseline in functional assessment of cancer therapy-lymphoma (fact-lym) total score|stage 2: time to progression in lymphoma symptoms according to fact-lym subscale|stage 2: change from baseline in peripheral neuropathy according to fact/gog-ntx-12 subscale score|stage 2: percentage of participants with adverse events (aes)|stage 2: percentage of participants with polatuzumab vedotin dose interruptions and dose reductions|stage 2: polatuzumab vedotin dose intensity|stage 2: percentage of participants with peripheral neuropathy|stage 2: percentage of participants with anti-drug antibodies (adas) to polatuzumab vedotin at baseline|stage 2: percentage of participants with anti-drug antibodies (adas) to polatuzumab vedotin post-baseline,hoffmann-la roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,216.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO40598|2018-003727-10,"February 7, 2020","July 18, 2023","July 18, 2023","December 2, 2019",,"May 9, 2022","[""memorial regional hospital, hollywood, florida, united states cancer specialists; north florida ;jacksonville (ac skinner pkwy), jacksonville, florida, united states memorial cancer institute at memorial west, pembroke pines, florida, united states oncology hematology associates - springfield, springfield, missouri, united states nebraska cancer specialists; oncology hematology west, pc, omaha, nebraska, united states mskcc at basking ridge, basking ridge, new jersey, united states memorial sloan kettering - monmouth, middletown, new jersey, united states memorial sloan kettering cancer center at bergen, montvale, new jersey, united states mskcc @ commack, commack, new york, united states the cancer institute at st francis hospital, east hills, new york, united states memorial sloan kettering cancer center at westchester, harrison, new york, united states memorial sloan-kettering cancer center, new york, new york, united states memorial sloan kettering nassau, uniondale, new york, united states baptist memorial hospital, memphis, tennessee, united states millennium research & clinical development, houston, texas, united states hospital sao rafael - hsr, salvador, ba, brazil liga norte riograndense contra o câncer, natal, rn, brazil hospital das clinicas - ufrgs, porto alegre, rs, brazil hospital das clinicas - fmusp, sao paulo, sp, brazil london health sciences centre, london, ontario, canada niagara health systems - st. catherines general site; niagara health system-st. catharines site, st. catharines, ontario, canada mcgill university health centre - glen site, montreal, quebec, canada centre hospitalier regional de trois-rivieres, trois-rivieres, quebec, canada hu nan provincial cancer hospital, changsha, china west china hospital - sichuan university, chengdu city, china cancer center, sun yat-sen university of medical sciences; department of medical oncology, guangzhou, china zhujiang hospital, southern medical university, guangzhou, china the 1st affiliated hospital of nanchang unversity, nanchang, china guangxi cancer hospital of guangxi medical university, nanning, china institute of hematology and hospital of blood disease, tianjin city, china union hospital tongji medical college huazhong university of science and technology, wuhan city, china first affiliated hospital of medical college of xi'an jiaotong university, xi'an, china helsinki university central hospital; dept of oncology, helsinki, finland kuopio uni hospital; oncology dept, kuopio, finland oulu university hospital; oncology, oulu, finland tampere university hospital; dept of oncology, tampere, finland hopital henri mondor; 51 av mal lattre de tassigny, creteil, france chu de nîmes - hôpital carémeau, nimes, france centre henri becquerel; service hématologie, rouen, france icans, strasbourg, france hopital bretonneau; hematologie therapie cellulaire, tours cedex, france universitätsklinikum ulm; medizinische uni-klinik iii abt. innere medizin iii hämatologie u. onkolo., ulm, germany laiko general hospital; hematology clinic, athens, greece attiko hospital; haematology clinic, athens, greece all india institute of medical sciences ,institute rotary cancer hospital; department of oncology, new delhi, india cork university hospital, cork, ireland st james' hospital; cancer clinical trials office, dublin, ireland azienda ospedaliero-universitaria policlinico di modena ematologia, modena, emilia-romagna, italy az. osp. uni ria policlinico tor vergata; unita di ematologia, roma, lazio, italy osp. san raffaele; dip. di oncoematologia, milano, lombardia, italy arnas garibaldi; ematologia, catania, sicilia, italy usl 4 di prato - nuovo ospeale di prato, prato, toscana, italy ematologia/immunologia clinica azienda ospedaliera policlinico di padova, padova, veneto, italy pusan national university hospital, busan, korea, republic of chungnam national university hospital, daejeon, korea, republic of seoul national university bundang hospital, seongnam-si, korea, republic of severance hospital, yonsei university health system, seoul, korea, republic of health pharma professional research, cdmx, mexico city (federal district), mexico instituto nacional de cancerologia; oncology, distrito federal, mexico hospital de especialidades centro medico nacional la raza; haematology, mexico city, mexico hospital universitari germans trias i pujol; servicio de hematologia, badalona, barcelona, spain hospital universitario de canarias;servicio de hematologia, la laguna, tenerife, spain hospital univ. 12 de octubre; servicio de hematologia, madrid, spain hospital clinico universitario de salamanca;servicio de hematologia, salamanca, spain hospital universitario dr. peset; servicio de hematologia, valencia, spain akademiska sjukhuset, onkologkliniken, uppsala, sweden sakarya universitesi egitim ve arastirma hastanesi, adapazari/sakarya, turkey abdurrahman yurtarslan onkoloji training and research hospital, ankara, turkey akdeniz uni school of medicine; hematology, antalya, turkey istanbul uni istanbul medical faculty, istanbul, turkey istanbul university cerrahpasa medical faculty; hematology department, istanbul, turkey kocaeli universitesi tip fakultesi, kocaeli, turkey amerikan hastanesi onkoloji birimi teşvikiye, nişantaşı, turkey beatson west of scotland cancer centre, glasgow, united kingdom kings college hospital, london, united kingdom nottingham city hospital; dept of haematology, nottingham, united kingdom""]",,https://ClinicalTrials.gov/show/NCT04182204,lymphoma
759,760,NCT00261846,study evaluating ski-606 (bosutinib) in philadelphia chromosome positive leukemias,,Completed,Has Results,chronic myeloid leukemia,drug: bosutinib,"number of participants with dose limiting toxicity (dlt)|maximum tolerated dose (mtd)|maximum observed plasma concentration (cmax) - part 1|time to reach maximum observed plasma concentration (tmax) - part 1|plasma decay half-life (t1/2) - part 1|area under the curve from time zero to last quantifiable concentration [auc(0-48)] - part 1|area under the concentration-time curve (auc) - part 1|apparent oral clearance (cl/f) - part 1|apparent volume of distribution (vz/f) - part 1|maximum observed plasma concentration at steady state (cmax,ss) - part 1|time to reach maximum observed plasma concentration at steady state (tmax,ss) - part 1|plasma decay half-life at steady state (t1/2,ss) - part 1|area under the concentration-time curve at steady state (aucss) - part 1|apparent oral clearance at steady state (cl/f,ss) - part 1|accumulation ratio (r)|percentage of participants with mcyr at week 24 in chronic phase second-line imatinib resistant cml population - part 2|percentage of participants with major cytogenetic response (mcyr) - part 1|phosphorylation inhibition of breakpoint cluster region-abelson kinase (bcr-abl) - part 1|phosphorylation inhibition of crk like (crkl) protein at baseline - part 1|percent change from baseline in phosphorylation inhibition of crk like protein (crkl) at day 1, 8 and 15 - part 1|percentage of participants with major cytogenetic response (mcyr) in chronic phase second-line and chronic phase third-line cml population - part 2|kaplan-meier estimate of retaining an attained/maintained major cytogenetic response (mcyr) at year 5 in chronic phase second-line cml - part 2|time to achieve major cytogenetic response (mcyr) in chronic phase second-line cml for responders only - part 2|kaplan-meier estimate of maintaining complete hematologic response (chr) at year 4 (cp3l and adv) or year 5 (cp2l) - part 2|duration of complete hematologic response (chr) - part 2|time to achieve complete hematologic response (chr) for responders only - part 2|cumulative incidence of progression/death - part 2|progression free survival (pfs) - part 2|kaplan-meier estimate of overall survival (os) - part 2|overall survival (os) - part 2|percentage of participants with confirmed complete hematologic response (chr) - part 2|percentage of participants with overall hematologic response (ohr) by week 48 in advanced leukemia population - part 2|percentage of participants with treatment-emergent adverse events (aes) or serious adverse events (saes)|duration of potentially clinically important (pci) adverse events (aes)|percentage of participants with change from baseline in laboratory tests results|percentage of participants with on-treatment pci change from baseline in electrocardiogram (ecg) findings|number of participants with change from baseline in findings of chest x-ray|number of participants who received concomitant medications for management of adverse events (aes)|number of participants with change from baseline in eastern cooperative oncology group performance status (ecog-ps)|percentage of participants with change from baseline in physical examinations and vital signs|percentage of participants with change from baseline in physical examinations and vital signs and number of participants with pci values",pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,571.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"3160A4-200|B1871006, 3160A4-200-WW|2005-004230-40|B1871006","January 18, 2006","September 25, 2009","August 6, 2015","December 5, 2005","March 12, 2013","July 27, 2017","['city of hope national medical center, duarte, california, united states healthone presbyterian, denver, colorado, united states rocky mountain cancer centers, denver, colorado, united states georgetown university hospital, washington, d.c., district of columbia, united states emory clinic, atlanta, georgia, united states emory university hospital, atlanta, georgia, united states winship cancer institute, atlanta, georgia, united states oncology specialists, s.c., niles, illinois, united states indiana blood and marrow transplantation, indianapolis, indiana, united states lsu health sciences center, shreveport, louisiana, united states university of maryland medical center, baltimore, maryland, united states university of maryland, baltimore, maryland, united states roswell park cancer institute, buffalo, new york, united states hudson valley hematology and oncology associates, hawthorne, new york, united states westchester oncology hematology group, p.c., hawthorne, new york, united states westchester oncology hematology, group, p.c., hawthorne, new york, united states new york presbyterian hospital, new york, new york, united states new york presbyterian hospital, new york, new york, united states university of rochester cancer center pharmacy, rochester, new york, united states university of rochester medical center strong memorial hospital - james p. wilmot cancer center, rochester, new york, united states university of rochester medical center, rochester, new york, united states university of rochester-james p. wilmot cancer center, rochester, new york, united states university of rochester, rochester, new york, united states westchester medical center, valhalla, new york, united states penn state milton s hershey medical center, hershey, pennsylvania, united states md anderson cancer center, houston, texas, united states the university of texas md anderson cancer center, houston, texas, united states the university of texas, houston, texas, united states virginia commonwealth university, richmond, virginia, united states hospital italiano de la plata, la plata, provincia de buenos aires, argentina hospital britanico, buenos aires, argentina academia nacional de medicina-instituto de investigaciones hematologicas, buenos aires, argentina instituto medico especializado alexander fleming, buenos aires, argentina clinica del sol, ciudad autonoma de buenos aires, argentina centro medico s.a., corrientes, argentina hospital jose ramon vidal, corrientes, argentina hospital universitario austral, pcia de buenos aires, argentina royal adelaide hospital, adelaide, south australia, australia institute of medical and veterinary science, adelaide, australia department of clinical haematology and bone marrow transplantation, melbourne, australia royal brisbane and women\'s hospital, queensland, australia haematology and oncology clinics of australia, queensland, australia klinikum kreuzschwestern wels, wels, austria hospital brigadeiro da secretaria de estado da saude de sao paulo, jardim paulista, sao paulo/sp - brazil, brazil centro de estudos da disciplina dr hematologia da faculdade de medicine do abc, santo andre, sp - brazil, brazil hospital das clinicas da faculdade de medicina da universidade de sao paulo, sao paulo, sp brazil, brazil hospital de clinicas - universidade federal do parana, curitiba, pr, brazil cross cancer institute, edmonton, alberta, canada bc cancer agency - cancer centre for the southern interior, kelowna, british columbia, canada cancercare manitoba, winnipeg, manitoba, canada university health network princess margaret hospital, toronto, ontario, canada sir mortimer b. davis, jewish general hospital, montreal, quebec, canada instituto clinico oncologico del sur, temuco, chile the first hospital affiliated to the medical school of zhejiang university, zhejiang, p.r china, china peking union medical college hospital of chinese academy of medical sciences, beijing, p.r. china, china the department of hematology, the chinese pla general hospital, beijing, p.r. china, china the hematology hospital of chinese academy of medical sciences, tianjin, p.r. china, china the department of hematology, ruijin hospital affiliated to school of medicine of shanghai jiaotong, shanghai, china hospital pablo tobon uribe, medellin, antioquia, colombia fundacion santa fe de bogota, bogota, cundinamarca, colombia biomedicum helsinki, helsinki, finland universitaet mainz, mainz, rp, germany university hospital carl gustav carus, dresden, germany universitaetsklinikum hamburg - eppendorf, hamburg, germany universitaetsklinikum hamburg-eppendorf, hamburg, germany universitaetsklinikum magdeburg a. oe. r., magdeburg, germany iii medizinische klinik und poliklinik, mainz, germany klinikum der johann gutenberg universitaet mainz, mainz, germany universitaet mainz iii. medizinische klinik abteilung fuer haematologie, mainz, germany universitaetsklinikum mainz, mainz, germany iii. medizinische klinik, mannheim, germany pamela youde nethersole eastern hosp., chai wan, hong kong queen mary hospital, hong kong, hong kong fovarosi onkormanyzat egyesitett szent istvan es szent laszlo, budapest, hungary christian medical college, vellore, tamil nadu, india university of bologna, bologna, province of bologna, italy azienda ospedaliero - universitaria san luigi gonzaga, orbassano, torino, italy aou-s.orsola-malpighi - universita degli studi di bologna, bologna, italy azienda ospedaliera san gerardo, monza, italy the catholic university of korea, seoul st. mary hospital, seoul, korea, republic of dept. of hematology, seoul, korea, republic of hospital universitario ""dr. jose eleuterio gonzalez"", nuevo leon, mexico centro oncologico estatal issemym, toluca estado de mexico, mexico vu university medical center, amsterdam, netherlands university medical center groningen, groningen, netherlands umcg - pharmacy, groningen, netherlands universitair medisch centrum groningen, groningen, netherlands vumc, the netherlands, netherlands avd. for blodsykdommer, trondheim, norge, norway hospital nacional edgardo rebagliati martins, lima, peru state healthcare institution, sverdlovsk regional clinical hospital, ekaterinburg, russian federation kirov research institute of hematology and blood transfusion of roszdrav hematology clinic, kirov, russian federation hematological research centre of rams, moscow, russian federation moscow regional clinical research institute named after m.f vladimirsky, moscow, russian federation rostov state medical university of roszdrav, rostov-on don, russian federation saint petersburg state medical university hematology department, saint petersburg, russian federation singapore general hospital, singapore, singapore university of the free state, bloemfontein, south africa university of cape town, cape town, south africa johannesburg hospital, parktown, south africa clinical haematology unit, soweto, south africa hospital clinic de barcelona (hospital clinic i provincial), barcelona, catalonia, spain hospital universitari clinic de barcelona, barcelona, catalonia, spain hospital universitario la princesa, madrid, spain hospital clinico universitario de valencia (chuv), valencia, spain akademiska university hospital, uppsala, sweden national taiwan university hospital - section of hematology-oncology, taipei 100, taiwan northern centre for cancer care - the newcastle upon tyne hospitals - nhs foundation trust, newcastle upon tyne, north east england, united kingdom school of clinical and laboratory sciences, university upon tyne, north east england, united kingdom hammersmith hospital, london, united kingdom clinical research facility, newcastle upon tyne, north east england, united kingdom']",,https://ClinicalTrials.gov/show/NCT00261846,blood
